<SEC-DOCUMENT>0000950170-25-064436.txt : 20250506
<SEC-HEADER>0000950170-25-064436.hdr.sgml : 20250506
<ACCEPTANCE-DATETIME>20250506160534
ACCESSION NUMBER:		0000950170-25-064436
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		74
CONFORMED PERIOD OF REPORT:	20250331
FILED AS OF DATE:		20250506
DATE AS OF CHANGE:		20250506

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Day One Biopharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001845337
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				832415215
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40431
		FILM NUMBER:		25917200

	BUSINESS ADDRESS:	
		STREET 1:		2000 SIERRA POINT PARKWAY, SUITE 501
		CITY:			BRISBANE
		STATE:			CA
		ZIP:			94005
		BUSINESS PHONE:		650 484-0899

	MAIL ADDRESS:	
		STREET 1:		2000 SIERRA POINT PARKWAY, SUITE 501
		CITY:			BRISBANE
		STATE:			CA
		ZIP:			94005

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Day One Biopharmaceuticals Holding Co LLC
		DATE OF NAME CHANGE:	20210209
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>dawn-20250331.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2025-05-06T14:07:58.1137+00:00 -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:dawn="http://www.dayonebio.com/20250331" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2024" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:srt="http://fasb.org/srt/2024" xmlns:utr="http://www.xbrl.org/2009/utr">
 <head>
  <title>10-Q</title>
  <meta http-equiv="Content-Type" content="text/html"/>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;position:relative;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_48d683d5-1b1c-45ac-9f94-523d199d6b60" name="dei:CurrentFiscalYearEndDate" contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b">--12-31</ix:nonNumeric><ix:nonNumeric id="F_e6f4cab5-8aec-450e-8766-eb81987b6f5f" name="dei:DocumentFiscalPeriodFocus" contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b">Q1</ix:nonNumeric><ix:nonNumeric id="F_98157962-cc3f-4ca8-950f-f51468f6a1a6" name="dei:AmendmentFlag" contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b" format="ixt:fixed-false">false</ix:nonNumeric><ix:nonNumeric id="F_6832b236-bceb-42b9-ad8d-15689755f2d4" name="dei:EntityCentralIndexKey" contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b">0001845337</ix:nonNumeric><ix:nonFraction id="F_2822a515-be27-4a7e-b4e8-a1d6dcb822ad" name="us-gaap:CommitmentsAndContingencies" contextRef="C_b103f351-0eb2-495b-85c1-5630e54c751c" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_e884c67c-98c2-4dc5-85ba-d3ff1ddf6d72" name="us-gaap:CommitmentsAndContingencies" contextRef="C_1b7733fe-22fe-416b-a33e-e8b388655156" unitRef="U_USD" xsi:nil="true"></ix:nonFraction></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="dawn-20250331.xsd"/></ix:references><ix:resources><xbrli:context id="C_80830bed-79cc-4012-a094-ef9b93307718"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dawn:PRV-RelatedObligationPaymentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_80a0754a-565e-4050-8b95-677c6495d268"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8186e570-f43c-44d8-af7f-4d4d7125520a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-03-31</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_81949730-fa21-4927-8bb8-150b98f7b91f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_827ac41e-d0d2-4df1-8321-6fb95701054e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8387ea00-db0a-45ff-8cd7-7258098914d9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_88ef0d56-c34a-4726-8307-009388d0ca1d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dawn:MabcareLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_89780293-cea0-4538-b7bb-9bfd5ea8a319"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8a694c05-0437-4c75-8ae6-45e4b83604d0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">dawn:ConcentrationOfCreditRiskAndOtherRisksAndUncertaintiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">dawn:OneCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8b0fbd15-0039-4354-9bc0-e49520f5e256"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8bbef5b6-cf7a-452a-9829-28292e282f79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_910c0420-f57a-418a-8295-ee1ffb7bd08a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dawn:TwoThousandAndTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_92096138-dcf7-4329-ae91-d02c48ac8ed0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">dawn:BrisbaneCaliforniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_94ce4acc-2f61-45fc-9674-ab4c0d8f85f3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_966510c1-eaf6-4a1c-9fae-2da70fcc6537"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dawn:ViractaLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9be30ffd-c276-4ccc-8f21-4e37e3595dc7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dawn:AgreementAxis">dawn:TwoThousandTwentyFourPrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-08-01</xbrli:startDate><xbrli:endDate>2024-08-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9c3764ad-c7bb-4bf4-a68b-e200db91be51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dawn:PRV-RelatedObligationPaymentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9cc6beef-2bd0-4841-8e97-5da5102095a3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9cfff08d-a5d3-4ed4-8454-95741093c5c8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">dawn:CommonSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9e37dcd2-0722-43fd-aedf-af23527c98ee"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dawn:TwoThousandAndTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9ece43fe-da8e-4bfb-aa46-983f40858774"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dawn:TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-31</xbrli:startDate><xbrli:endDate>2021-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a0ee4c82-d202-4563-aeeb-4840f5b9e70e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a308fa2a-9dd8-441a-aaa4-31aac0a1a5eb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a320baa6-cd53-4730-8cba-58584c6ac43a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a356b3ae-e91c-4aa9-82fb-80206cb22503"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dawn:LicenseAgreementWithIpsenPharmaSasMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">dawn:NoncurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a3c664ec-2577-4bad-ba57-d70b9f3e5a3e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a48de969-8ddc-4b3b-a6a7-5c2b29ae4e05"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a49147be-0409-42b0-a2d6-250d7ea0c7b6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a9d09cb0-58f1-4b18-b47f-7276b7057656"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ab5b8469-0456-4d89-a289-b75cc0f4a77c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">dawn:BrisbaneCaliforniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ac5f563a-6d18-4f41-8866-bd417f95f7f7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">dawn:CommonSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ac9ee8d9-bca6-4fd2-9709-df26868eb7bf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_af8109ab-99db-4170-9328-c13fd756a885"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">dawn:CommonSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_afbd7133-30d1-4e7e-80d8-66c0f4c8b5c1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dawn:UnvestedCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_afcca245-4cb7-422b-8748-147e3421ebb4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b0966c50-b1d4-43dc-abb7-4c4d573ddf0b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b103f351-0eb2-495b-85c1-5630e54c751c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b18881d4-5741-464f-8b09-c6e20048b1ff"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dawn:TakedaAssetAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dawn:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-16</xbrli:startDate><xbrli:endDate>2019-12-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b2b75b00-4621-44ed-bdf4-f92f43226a4c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b5d41f12-6166-4c3e-a249-6ff0239c1d95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b5f6c9ab-25d5-4e70-992c-f10381920bf2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b77b4a90-bf68-4a05-8f01-62a9520247e8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ba36f1f4-7ce5-434c-b80f-2bcb5a767c07"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ba5b769f-138e-4a96-8876-aa121d01b3cc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ba809785-9e5e-4537-b8ed-aa9a95f5018c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">dawn:MarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bcf4433c-d298-4d36-a850-dfba1a092198"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bf59d3f6-5cf9-4cca-852c-63e292df8618"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dawn:TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c2dd807f-0b0a-4c78-a0c1-eae1f3ef85f9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dawn:TwoThousandAndTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c5d9f2d2-fe53-4440-9bbe-b118d81d16cc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-05-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c5ebd5f2-8017-4e7b-b087-5114b6fdabe3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">us-gaap:PurchaseCommitmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ca787bd4-a367-40e2-8820-37c26a26c233"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dawn:ViractaLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-04</xbrli:startDate><xbrli:endDate>2024-03-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ca7ef576-0ffb-4b1b-9387-f848fc7d1ea5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dawn:LicenseAgreementWithIpsenPharmaSasMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cb883bf9-9846-4518-bf47-5d7e85524d73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dawn:TwoThousandAndTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dawn:PerformanceStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cbc72dd7-8c81-4d68-9f7a-1b1c2d90b6a0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cc903eab-f003-453f-ad1c-4dd61852d801"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dawn:TakedaAssetAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-26</xbrli:startDate><xbrli:endDate>2021-05-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cd3e5fd3-74ef-469d-8938-ed22cb45f3fd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dawn:LicenseAgreementWithIpsenPharmaSasMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ce9b7ba8-66b0-4fb8-95da-9540fc395eeb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">dawn:UnvestedCommonSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cfe0c0d8-2e22-409b-b482-35888c79dbfa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d33c859c-b7aa-4b79-9a88-d16340c5fe28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dawn:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dawn:TakedaAssetAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-26</xbrli:startDate><xbrli:endDate>2021-05-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d9880916-1c46-4df1-82f9-7cfa90e42ed8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dawn:UnvestedCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_dce557e4-9275-4019-bfcf-ce698a8400c6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_dcf6712c-475d-4506-9554-ded223b0331a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dawn:TwoThousandAndTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_de732af7-5533-4ee5-aaa0-722119902a1a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_dea27b68-18b7-4c73-9c27-b5c829ef0241"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e6665180-612b-4fba-adce-73d240ace7bb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e9b4d1c1-00d7-4c4a-8ead-1b510859ed98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dawn:TakedaAssetAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-16</xbrli:startDate><xbrli:endDate>2019-12-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ebb60e12-8f30-4b8b-a830-3f64f4c2ba34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dawn:AgreementAxis">dawn:ResearchAndDevelopmentAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ebe52b1a-a4be-4f4e-a3d1-d3bb26eaa194"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ee47eb20-6b00-401a-8f3b-4c791e30712a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ee6e19da-95ec-456c-abbd-e2850974503c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ef0986cb-13e6-4f2b-818c-1d5b4469876d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">dawn:CommonSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ef89ab97-3fce-42e2-a82b-c2a5c9189a28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dawn:SprintBioscienceAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f17c501c-d230-47ae-bbff-603a48bd4de4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f1827e81-e977-406d-8a9b-6f880a33cdfe"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f30f7047-2b1e-4315-95a7-8a873401a0b3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dawn:TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f31a84ee-cbb2-48fa-a085-f699999cd961"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">dawn:TwoCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">dawn:ConcentrationOfCreditRiskAndOtherRisksAndUncertaintiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f34d98de-c249-4523-b50b-c9af86c79722"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dawn:AgreementAxis">dawn:SalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fd1aa0b8-3528-4b28-9293-cf863f031981"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">dawn:LeaseForCorporateOfficeFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fd702879-0dc1-44c9-85ec-00d54500225b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ffb4c57e-cb92-46fd-9286-ea36197252e3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">dawn:PreFundedWarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dawn:AgreementAxis">dawn:TwoThousandTwentyFourPrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ffe0f1b7-fa8f-4028-beb7-7b994de8b4b7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dawn:TwoThousandAndTwentyOneStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_01058ddf-79d2-4e72-962f-17fe256a6f09"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dawn:TwoThousandAndTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_01bb969c-6b26-4ada-840e-3e6660f4d113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_02cfe4b1-bd5d-4fbb-95f7-4ee6c0f9824a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_09d1a768-c6f7-4724-958d-e37516f230d8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dawn:AgreementAxis">dawn:ResearchAndDevelopmentAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0a5c3519-45df-4f60-a8a7-7437f71f7bfb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0bf779c8-a9a8-4ba9-bbb1-898f93f339e4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0cc93ae0-4f9d-48ec-aec0-c24fe1944b49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0d1e25ff-1b51-4a66-aafb-97dc40b3998f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dawn:TwoThousandAndTwentyTwoEquityInducementPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0ddc2569-0696-4885-b32d-8451ee567481"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0eee3e9c-c51c-4e38-bfea-aebbe8a2a4a1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0fd32f25-7d1d-46c5-938d-d9b0e3f9dfaa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1012909a-67d0-4f8d-9538-ec497e5c24af"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dawn:PrvPressureReliefValveMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dawn:ViractaLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_10416dad-c8fd-476e-89d5-ae0a83b9440c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1129e786-4666-4dce-88b0-ece78eb6efc6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dawn:AgreementAxis">dawn:InvestmentAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_13a2630f-ef56-4f08-840c-b986a80c28b9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dawn:TwoThousandAndTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1438aa38-1e5a-4af2-922f-a3f067944262"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">dawn:TwoCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">dawn:ConcentrationOfCreditRiskAndOtherRisksAndUncertaintiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_145e429b-05a9-4c43-8d23-41fa26213179"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_14897498-6682-45a8-b5bc-6360e09cde1d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dawn:AgreementAxis">us-gaap:IndemnificationGuaranteeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_172d1f62-d597-4e9e-a3d0-7f8bd3d31541"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dawn:TwoThousandAndTwentyOneStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_18678d79-8e7d-4c54-8b85-ba5704b25f78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dawn:AgreementAxis">dawn:InvestmentAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_190b79d3-0ec2-457e-b743-7f9aaa10d94b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">us-gaap:PurchaseCommitmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_19ecbc75-781d-4703-b1ec-88b78ffef3f7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1b7733fe-22fe-416b-a33e-e8b388655156"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1bd10525-22f6-4072-ab95-5fd14d1f9842"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dawn:LicenseAgreementWithIpsenPharmaSasMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-23</xbrli:startDate><xbrli:endDate>2024-07-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1ce17a75-0fd7-4298-bfc0-f235a473361b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_21176c5a-4a94-4c88-9e64-63ebfc46b526"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_21c9ec3b-26c7-4a87-b2d1-3f695174dd3f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_22370d4f-2229-4fea-b11d-aaa9611c4ebe"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_22c0360b-da7f-497c-9e18-47a5bdec0579"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_23977cdf-3070-48c6-b19d-11d5afb96e9a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dawn:LicenseAgreementMilestonePaymentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_24aa28dd-3f08-4c12-b95e-d974f2524368"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">dawn:ConcentrationOfCreditRiskAndOtherRisksAndUncertaintiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">dawn:OneCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_27899ba1-a824-4fc6-ac6a-83ca5fb4f9b5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dawn:TwoThousandAndTwentyOneStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2896a425-ea56-4272-8792-62ad898655c5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dawn:AgreementAxis">dawn:CommonSharesPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2a107001-c05d-46f0-ab44-70e8338ecfcf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2a98f92e-aa86-4a5c-aad4-edb5374ed00b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dawn:TwoThousandAndTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dawn:PerformanceStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2d38634e-b453-46b0-9ce4-c47fae6625de"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dawn:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2e6bdcde-a879-4a55-aaf6-c92b45ed690a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dawn:AgreementAxis">us-gaap:IndemnificationGuaranteeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2f4d68d5-969e-46de-b564-f0c6755d1515"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_30fad386-55b9-45a7-8945-04e8a03f752e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dawn:TwoThousandAndTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_310c50ba-37a3-430e-bd89-9a82d7460226"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dawn:TwoThousandAndTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_342128b9-4127-453a-8974-3c82ca357e86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">dawn:SharesCommittedUnderESPPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3488a8c4-e12f-41ec-89c7-dac4e84ea67e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dawn:MerckLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_359c3fbb-d10c-4741-807c-98dd361851e9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3844ba24-08c1-421c-b49d-4740f7e0d572"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_388de2bd-eeb7-4fa1-87a1-3cdac91fa91d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">dawn:AtTheMarketMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3aa48c9e-64e5-48ce-b002-f58764db64d0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">dawn:UnvestedCommonSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3ab621ae-436f-433d-9df2-8c8bce28b89e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">dawn:IndividualCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">dawn:ConcentrationOfCreditRiskAndOtherRisksAndUncertaintiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3b0aca41-c2bf-46f8-b765-42580bbf6433"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3b446226-328f-479e-b281-6a7fd0379692"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dawn:MabcareLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3b4a9bf0-9117-492a-a8d5-7f4450cbd994"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3b67e9fd-7c04-48f2-969e-4f1fa6b5693c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3c025e0b-f004-497c-8763-6a8406223ff4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3c61836b-73ea-4fb6-bc25-ae73f9f94d9d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dawn:ViractaLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3e17f855-9bc9-4474-9b6f-1728c5807a4b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3ef9f2ba-6c3d-4611-94f4-9657c80e0ee2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dawn:UnvestedCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_414a2ccf-e2e3-4dea-882d-8f99a0bcc263"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_429b0413-0de5-4e2b-b3ca-8e5807492a3e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dawn:SprintBioscienceAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_43327af5-1891-4b55-b0a6-4f7ba631a198"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dawn:DetailsAxis">dawn:IncrementalSharesReservedForFutureIssuanceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dawn:TwoThousandAndTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-31</xbrli:startDate><xbrli:endDate>2021-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_451cb9d2-19ad-4b9a-87a0-770cffddb183"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_46800e87-c56c-4f8c-b6af-964b831f2ace"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dawn:TwoThousandAndTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-31</xbrli:startDate><xbrli:endDate>2021-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_491e1be7-189f-4d71-b2f9-eac0bf60040c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dawn:PrvPressureReliefValveMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dawn:ViractaLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_494cf197-0008-4f30-9715-0a6b5cf186d6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dawn:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_494ea4ad-935d-45a3-a172-b60cd7e73582"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4a5ebb63-8e69-4e8d-bc72-3ec0c91774e6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dawn:LicenseAgreementWithIpsenPharmaSasMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-23</xbrli:startDate><xbrli:endDate>2024-07-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4a61c31c-c9f6-4c86-9285-1639c02fc666"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">dawn:SharesCommittedUnderESPPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4b6fd4af-8d4f-4f7d-b960-b6ac6218c53a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">dawn:CommonSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4ba97ac7-abe6-41af-8f29-b34dd24231c3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4c2bf0b9-0d5c-4b03-b0a7-3c3a06954490"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4f40a47c-f03a-48ad-8dc7-1d9331ced26a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">dawn:MarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4f6e2663-8d98-4973-a359-76163a03ea8a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">dawn:MarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4f8d1d22-bf0a-41bc-b883-13763363dd92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4fbcd2d8-640a-4a12-888c-5b1b8885e9aa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5399640b-8a12-4325-9bb5-9eaa7ac09323"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5459b1fe-9af9-4c02-891b-a32f266837c2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_56ac395d-44a1-4679-8062-efee79181688"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">dawn:CommonSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5a86561f-8ff9-4f61-acd4-e523f9c716bf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dawn:TwoThousandAndTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5b86a378-9cda-47eb-8a66-30562f03c4e4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5c990fe2-3f39-456d-8159-af4c23323a1d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dawn:LicenseAgreementWithIpsenPharmaSasMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-07-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5cceec90-fafe-4db7-b0a1-8211d20a03b7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dawn:LicenseAgreementMilestonePaymentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5d08cb7b-c76a-4de6-8dca-2d248eef4467"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">us-gaap:PurchaseCommitmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5f6d6e0e-3d98-4fa4-8a41-68a23cdaa376"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_60b37620-bd42-435a-8868-27168e7b2da5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_60b4b3d3-4a6b-45de-b852-487c0414710f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dawn:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6180a865-9d79-4110-bb9f-16515c37344b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">dawn:NetProductRevenueAndAccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">dawn:ConcentrationOfCreditRiskAndOtherRisksAndUncertaintiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">dawn:OtherIndividualCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_63138494-78aa-453f-87e2-d7692e2526f2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dawn:AgreementAxis">dawn:TwoThousandTwentyFourPrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6687375b-114a-46c2-aae2-63bb21248fa4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dawn:PreFundedWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dawn:AgreementAxis">dawn:TwoThousandTwentyFourPrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-08-01</xbrli:startDate><xbrli:endDate>2024-08-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_68539f11-26b8-4c60-96db-44201518557b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6aaeb9ec-3a51-423c-ad71-3fa489ff189c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">dawn:LeaseForCorporateOfficeFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6ad97ba9-d866-451d-a09a-4e4e40d00691"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dawn:ViractaLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-23</xbrli:startDate><xbrli:endDate>2024-04-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6b43dd28-89c1-4746-bb60-edcdf09081e0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dawn:TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6bcd3432-198e-484b-9415-19fc999fd457"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6c0cbe2c-a995-47f4-a87e-6d13cd05d122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dawn:LicenseAgreementWithIpsenPharmaSasMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-23</xbrli:startDate><xbrli:endDate>2024-07-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6d1be359-db5b-4358-8204-bf1ab5d70c18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6e1b373b-8302-46c1-aa4e-7f2da1ba09e1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6efcf18f-0833-44b1-8d9a-6ebe85307a08"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">dawn:CurrentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dawn:LicenseAgreementWithIpsenPharmaSasMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_709f7aa4-e121-4df0-b0d0-a36cdf0a83fe"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_749941a2-d394-4f48-bd13-a62ecd76cd82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_74bf62ce-416a-4686-8cdc-9e58e09531b6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dawn:PrvPressureReliefValveMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dawn:ViractaLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-05-29</xbrli:startDate><xbrli:endDate>2024-05-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_76de7769-5c35-42b4-83aa-9ca4c0b858aa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">dawn:IndividualCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">dawn:ConcentrationOfCreditRiskAndOtherRisksAndUncertaintiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_78dfe459-4b7a-4e97-aa42-abf96dae2d9e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7902fa1d-00a4-4ae2-802d-20016ff59f3d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7a2a1b79-4a52-4f59-8224-b2b1f9654b55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">dawn:MarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7a724b91-c619-4f16-b0fa-87eb52d80cd1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dawn:AgreementAxis">dawn:TwoThousandTwentyFourPrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-08-01</xbrli:startDate><xbrli:endDate>2024-08-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7aae3619-1673-4b07-91a5-706dabc13942"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dawn:TwoThousandAndTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dawn:PerformanceStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7d91f4bf-04a0-434b-a91a-e1fd4c41cbe1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7f6b13fb-87e4-41c9-982f-9121e8dc50ce"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7f944cae-458f-4eb0-b171-e53812c6128e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001845337</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dawn:TwoThousandAndTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="U_pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="U_UnitedStatesOfAmericaDollarsShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="U_sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:unit id="U_shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="U_Segment"><xbrli:measure>dawn:Segment</xbrli:measure></xbrli:unit><xbrli:unit id="U_USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="FNT_60f2d66a-bd18-4379-ab25-550bcb317590" fromRefs="F_e7bc9a6d-21f3-4425-a0f4-b8ddd2c8a2f5 F_a38f27e3-eb4b-4eb4-814a-963ea523b1df"/></ix:resources></ix:header></div>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="border-top:2.25pt double;padding-top:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">f</span></p><p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:17pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">UNITED STATES</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:17pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SECURITIES AND EXCHANGE COMMISSION</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:17pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">WASHINGTON, D.C. 20549</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:39.2%;padding-bottom:1pt;font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:39.204%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:17pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FORM </span><span style="font-size:17pt;font-family:Times New Roman;"><ix:nonNumeric id="F_71359b49-12e7-4d1e-80fa-983392b1c335" contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b" name="dei:DocumentType"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:17pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10-Q</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:17pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:39.2%;padding-bottom:1pt;font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:39.204%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Mark One)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:11pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5960062d-fdb4-4a0e-abfc-50572638669d" contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b" name="dei:DocumentQuarterlyReport" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the quarterly period ended </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2f6e3da0-afc6-4f2c-8015-e4daa7fec05f" contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 31, </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fd5082b4-5fd7-4bf0-8c80-8a9e27dffe0f" contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b" name="dei:DocumentFiscalYearFocus"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2025</span></ix:nonNumeric></span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">OR</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:11pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7991f431-73f4-4a7c-b963-3c8fdb4252e9" contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b" name="dei:DocumentTransitionReport" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the transition period from </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">                    </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">                   </span></p><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Commission File Number: </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f9a69a21-7771-457d-88b0-17dfa1e7fde4" contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b" name="dei:EntityFileNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">001-40431</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:39.2%;padding-bottom:1pt;font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:39.204%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:23pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d2a72bcc-f368-456e-b4fe-ce0b5ff14b55" contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b" name="dei:EntityRegistrantName"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:23pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">DAY ONE BIOPHARMACEUTICALS, INC.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:23pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Exact Name of Registrant as Specified in its Charter)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:39.2%;padding-bottom:1pt;font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:39.204%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:50%;box-sizing:content-box;"/>
     <td style="width:50%;box-sizing:content-box;"/>
    </tr>
    <tr style="word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_f849259d-cfe0-4c03-9d07-e11847bd6d58" contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_ed1ac380-8598-4925-9ef0-26147011eb12" contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b" name="dei:EntityTaxIdentificationNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">83-2415215</span></ix:nonNumeric></span></p></td>
    </tr>
    <tr style="height:7pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(State or other jurisdiction of</span></p><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">incorporation or organization)</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(I.R.S. Employer<br/>Identification No.)</span></p></td>
    </tr>
    <tr style="height:12.25pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
    <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_0c7687a0-8a61-4463-888f-36e5d689497a" contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b" name="dei:EntityAddressAddressLine1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">1800 Sierra Point Parkway</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:9pt;"><ix:nonNumeric id="F_65d4a2e9-af68-4244-ab82-10458b032fa7" contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b" name="dei:EntityAddressAddressLine2"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Suite 200</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_6931060f-7d07-4711-97f1-91a7de0be76b" contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b" name="dei:EntityAddressCityOrTown"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Brisbane</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:9pt;"><ix:nonNumeric id="F_c5af7fa3-5e16-477f-bee9-fde1ebeef573" contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b" name="dei:EntityAddressStateOrProvince"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">CA</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_57028f4d-7eaf-40cd-8daa-71293e271cf8" contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b" name="dei:EntityAddressPostalZipCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">94005</span></ix:nonNumeric></span></p></td>
    </tr>
    <tr style="height:7pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Address of principal executive offices)</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Zip Code)</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e4392354-914b-4cae-bf79-68a68caefa4a" contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b" name="dei:CityAreaCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">650</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9a253445-9ef1-41c3-966f-766a4543cb7e" contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b" name="dei:LocalPhoneNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">484-0899</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Registrant&#8217;s telephone number, including area code)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">N/A</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Former name, former address and former fiscal year, if changed since last report)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:39.2%;padding-bottom:1pt;font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:39.204%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:33.333%;box-sizing:content-box;"/>
     <td style="width:33.333%;box-sizing:content-box;"/>
     <td style="width:33.333%;box-sizing:content-box;"/>
    </tr>
    <tr style="word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Title of each class</span></p><p style="border-top:1pt solid;padding-top:1pt;font-size:7pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Trading Symbol</span></p><p style="border-top:1pt solid;padding-top:1pt;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Name of each exchange on which registered</span></p><p style="border-top:1pt solid;padding-top:1pt;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
    <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_fa8740e2-b3d8-466b-8d86-f6a5d15eb16d" contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b" name="dei:Security12bTitle"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Common Stock, par value $0.0001 per share</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_cb410d86-a4aa-47b2-9fde-792d441a6d24" contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b" name="dei:TradingSymbol"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">DAWN</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_f68d4b7e-b816-4821-a9eb-bc7a8205f0d0" contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Nasdaq Global Select Market</span></ix:nonNumeric></span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9d9a2414-6df6-4458-8562-5f2ad2ce6423" contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b" name="dei:EntityCurrentReportingStatus"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">   &#9746;     No &#9744;</span></p><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).  </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fe870b4a-7a00-4fbc-bc5f-91f8a43b0d45" contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b" name="dei:EntityInteractiveDataCurrent"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">    &#9746;  No    &#9744;</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:18.24%;box-sizing:content-box;"/>
     <td style="width:54%;box-sizing:content-box;"/>
     <td style="width:25.84%;box-sizing:content-box;"/>
     <td style="width:1.92%;box-sizing:content-box;"/>
    </tr>
    <tr style="word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;"><ix:nonNumeric id="F_74dbe06c-4bc9-4800-b4f1-73d4a90704f6" contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Large accelerated filer</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9746;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accelerated filer</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9744;</span></p></td>
    </tr>
    <tr style="height:5.75pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
    <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-accelerated filer</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9744;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Smaller reporting company</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;"><ix:nonNumeric id="F_4e407aca-49b8-4d89-bd0b-539d3bc2c6ce" contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b" name="dei:EntitySmallBusiness" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
    </tr>
    <tr style="height:5.75pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
    <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Emerging growth company</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;"><ix:nonNumeric id="F_82b2d1a9-0a34-4771-a937-a05363a5ae82" contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  &#9744;</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes  &#9744;    No  </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_051d15c2-244a-4f1e-9ea6-41b6e0582d59" contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b" name="dei:EntityShellCompany" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of May 1, 2025, the registrant had </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fd7db2d7-ed5c-46ed-b4d7-d560d16b91ff" contextRef="C_c5d9f2d2-fe53-4440-9bbe-b118d81d16cc" name="dei:EntityCommonStockSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">101,362,468</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock, $0.0001 par value per share, outstanding.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:2.25pt double;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, and section 27A of the Securities Act of 1933, as amended, or the Securities Act. All statements contained in this Quarterly Report other than statements of historical fact, including statements regarding our future results of operations and financial position, business strategy, market size, potential growth opportunities, nonclinical and clinical development activities, efficacy and safety profile of OJEMDA&#153; (tovorafenib) and our product candidates, potential therapeutic benefits and economic value of OJEMDA and our product candidates, our ability to market and sell OJEMDA while maintaining full compliance with applicable federal and state laws, rules and regulations, use of net proceeds from our public offerings, our ability to maintain and recognize the benefits of certain designations received by products and product candidates, the timing and results of nonclinical studies and clinical trials, commercial collaboration with third parties, and our ability to recognize milestone and royalty payments from commercialization agreements, the potential impact of global business or macroeconomic conditions, including as a result of inflation, changing interest rates, cybersecurity incidents, significant political or regulatory developments or changes in trade policy, including tariffs or shifting priorities within the U.S. Food and Drug Administration, and global regional conflicts on our operations and the receipt and timing of potential regulatory designations, approvals and commercialization of product candidates, are forward-looking statements. The words &#8220;believe,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; &#8220;potentially,&#8221; &#8220;estimate,&#8221; &#8220;continue,&#8221; &#8220;anticipate,&#8221; &#8220;predict,&#8221; &#8220;target,&#8221; &#8220;intend,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;should,&#8221; &#8220;project,&#8221; &#8220;plan,&#8221; &#8220;expect,&#8221; and other similar expressions that convey uncertainty of future events or outcomes are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including those described in Part II, Item 1A, &#8220;Risk Factors&#8221; and elsewhere in this Quarterly Report. Moreover, we operate in a very competitive and rapidly changing environment, and new risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this Quarterly Report may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur. We undertake no obligation to update publicly any forward-looking statements for any reason after the date of this report to conform these statements to actual results or to changes in our expectations, except as required by law. You should read this Quarterly Report with the understanding that our actual future results, levels of activity, performance and events and circumstances may be materially different from what we expect.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Unless the context indicates otherwise, as used in this Quarterly Report on Form 10-Q, the terms &#8220;Day One,&#8221; &#8220;the Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221; refer to Day One Biopharmaceuticals, Inc., a Delaware corporation unless otherwise noted. &#8220;Day One&#8221; and all product and product candidate names are our common law trademarks. This Quarterly Report contains additional trade names, trademarks and service marks of other companies, which are the property of their respective owners. We do not intend our use or display of other companies&#8217; trade names, trademarks or service marks to imply a relationship with, or endorsement or sponsorship of us by, these other companies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:9.84%;box-sizing:content-box;"/>
     <td style="width:83%;box-sizing:content-box;"/>
     <td style="width:7.16%;box-sizing:content-box;"/>
    </tr>
    <tr style="word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Page</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">PART I.</span></p></td>
     <td style="padding-top:0in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#tx180355_1"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">FINANCIAL INFORMATION</span></a></p></td>
     <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 1.</span></p></td>
     <td style="padding-top:0in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#tx180355_2"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Interim Condensed Financial Statements (Unaudited)</span></a></p></td>
     <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#tx180355_3"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Condensed Balance Sheets</span></a></p></td>
     <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#tx180355_4"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Condensed Statements of Operations</span></a></p></td>
     <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#condensed_consolidated_socl"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Condensed Statements of Comprehensive Loss</span></a></p></td>
     <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#tx180355_6"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Condensed Statements of Stockholders&#8217; Equity</span></a></p></td>
     <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#tx180355_7"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Condensed Statements of Cash Flows</span></a></p></td>
     <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#tx180355_8"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Notes to Condensed Financial Statements</span></a></p></td>
     <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 2.</span></p></td>
     <td style="padding-top:0in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#tx180355_9"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td>
     <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 3.</span></p></td>
     <td style="padding-top:0in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#tx180355_10"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td>
     <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">34</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 4.</span></p></td>
     <td style="padding-top:0in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#tx180355_11"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Controls and Procedures</span></a></p></td>
     <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">34</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">PART II.</span></p></td>
     <td style="padding-top:0in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#part_ii_other_information"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">OTHER INFORMATION</span></a></p></td>
     <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">35</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 1.</span></p></td>
     <td style="padding-top:0in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1_legal_proeedings"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Legal Proceedings</span></a></p></td>
     <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">35</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 1A.</span></p></td>
     <td style="padding-top:0in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1a_risk_factors"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Risk Factors</span></a></p></td>
     <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">35</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 2.</span></p></td>
     <td style="padding-top:0in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#tx180355_15"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Unregistered Sales of Equity Securities, Use of Proceeds, and Issuer Purchases of Equity Securities</span></a></p></td>
     <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">94</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 3.</span></p></td>
     <td style="padding-top:0in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#tx180355_16"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Defaults Upon Senior Securities</span></a></p></td>
     <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">94</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 4.</span></p></td>
     <td style="padding-top:0in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#tx180355_17"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Mine Safety Disclosures</span></a></p></td>
     <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">94</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 5.</span></p></td>
     <td style="padding-top:0in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#tx180355_18"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Other Information</span></a></p></td>
     <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">94</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 6.</span></p></td>
     <td style="padding-top:0in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#tx180355_19"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Exhibits</span></a></p></td>
     <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">96</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#tx180355_20"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Signatures</span></a></p></td>
     <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">97</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="tx180355_1"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PART I-FINANCIAL INFORMATION</span><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="tx180355_2"><span id="tx180355_3"></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">D</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ay One Biopharmaceuticals, Inc.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Condensed Balance Sheets</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(in thousands, except share amounts)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(unaudited)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:63.753%;box-sizing:content-box;"/>
     <td style="width:1.74%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:14.383%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.74%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:14.383%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">March 31,<br/>2025</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,<br/>2024</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Assets</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current assets:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash and cash equivalents</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_05892d23-f80f-4fee-845c-2a236580e192" contextRef="C_b103f351-0eb2-495b-85c1-5630e54c751c" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">33,358</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8b9704fc-af31-4285-ae31-719eced41ae9" contextRef="C_1b7733fe-22fe-416b-a33e-e8b388655156" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">124,968</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Short-term investments</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_eb07b6ad-8a26-434f-a2ca-3073b2403484" contextRef="C_b103f351-0eb2-495b-85c1-5630e54c751c" name="us-gaap:ShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">439,662</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ddae1e7e-6ca7-47f8-abee-acb363d880ff" contextRef="C_1b7733fe-22fe-416b-a33e-e8b388655156" name="us-gaap:ShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">406,752</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accounts receivable, net</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_75f6a68b-2927-4ea7-9182-4e19dfccc3b0" contextRef="C_b103f351-0eb2-495b-85c1-5630e54c751c" name="us-gaap:ReceivablesNetCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,054</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_03a547c2-3392-47a6-a8ed-ec6b14bfaa86" contextRef="C_1b7733fe-22fe-416b-a33e-e8b388655156" name="us-gaap:ReceivablesNetCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,876</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inventory</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_eae29e2d-0684-40ef-93fc-9882440bbc87" contextRef="C_b103f351-0eb2-495b-85c1-5630e54c751c" name="us-gaap:InventoryNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,565</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c3cb119f-c020-4f27-8018-0b60e6194bb6" contextRef="C_1b7733fe-22fe-416b-a33e-e8b388655156" name="us-gaap:InventoryNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,321</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid expenses and other current assets</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9f2ec791-50b1-4625-ba3b-b8a8373b7a53" contextRef="C_b103f351-0eb2-495b-85c1-5630e54c751c" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,012</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8dd1bb82-1d8b-4c52-996c-d9e2374b14fc" contextRef="C_1b7733fe-22fe-416b-a33e-e8b388655156" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,413</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:2.773%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total current assets</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_59a559b0-6510-45bd-ba48-a7416f2b1734" contextRef="C_b103f351-0eb2-495b-85c1-5630e54c751c" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">508,651</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0506ec50-8323-47cd-9547-8bad5401182a" contextRef="C_1b7733fe-22fe-416b-a33e-e8b388655156" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">562,330</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Property and equipment, net</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a646628b-3595-49a4-931a-124c1eac3b6b" contextRef="C_b103f351-0eb2-495b-85c1-5630e54c751c" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,508</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8c9ca39f-28fa-40f6-b422-f3ba66136e89" contextRef="C_1b7733fe-22fe-416b-a33e-e8b388655156" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,285</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease right-of-use asset</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e898ed53-4f5c-41fa-8b8c-be121b22e462" contextRef="C_b103f351-0eb2-495b-85c1-5630e54c751c" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,577</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2123452c-13b5-472d-b0e2-108ffb9f5c11" contextRef="C_1b7733fe-22fe-416b-a33e-e8b388655156" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,422</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Intangible assets, net</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_866d7c67-5ac1-4cd5-b886-fe8787abf42c" contextRef="C_b103f351-0eb2-495b-85c1-5630e54c751c" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,405</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d6a45aeb-3351-4c2d-9f94-9ccb17ac12f1" contextRef="C_1b7733fe-22fe-416b-a33e-e8b388655156" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,630</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deposits and other long-term assets</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_42aca274-19c5-4556-8274-43e9ffc07b3a" contextRef="C_b103f351-0eb2-495b-85c1-5630e54c751c" name="dawn:DepositsAndOtherLongtermAssetsNonCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">215</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d1722279-3084-4a8e-80c3-2c65b7ddd4b1" contextRef="C_1b7733fe-22fe-416b-a33e-e8b388655156" name="dawn:DepositsAndOtherLongtermAssetsNonCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">121</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:2.773%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total assets</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_954d8997-94ea-4fc4-ba39-0a68e8c58729" contextRef="C_b103f351-0eb2-495b-85c1-5630e54c751c" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">534,356</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9903decd-b640-435e-b291-dc111c78ba7a" contextRef="C_1b7733fe-22fe-416b-a33e-e8b388655156" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">582,788</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Liabilities and stockholders&#8217; equity</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current liabilities:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accounts payable</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4a2abc04-a31a-4c04-a742-cac012d19356" contextRef="C_b103f351-0eb2-495b-85c1-5630e54c751c" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,540</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_71039b44-e57b-4eae-a24e-9938a848ab79" contextRef="C_1b7733fe-22fe-416b-a33e-e8b388655156" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,262</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued expenses and other current liabilities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1a9a4e80-4bb8-4f32-bba5-7874440cb44e" contextRef="C_b103f351-0eb2-495b-85c1-5630e54c751c" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">43,641</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_44fa4675-5efc-406c-96ba-5d6a735fb4f0" contextRef="C_1b7733fe-22fe-416b-a33e-e8b388655156" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">68,625</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current portion of deferred revenue</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4a8cecbe-3229-4f38-8617-1e124a355248" contextRef="C_b103f351-0eb2-495b-85c1-5630e54c751c" name="us-gaap:DeferredRevenueCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,636</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e9a492d2-38cc-49dd-9024-6f43f282d0e2" contextRef="C_1b7733fe-22fe-416b-a33e-e8b388655156" name="us-gaap:DeferredRevenueCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,554</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current portion of operating lease liabilities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6cca5915-ffb6-4676-83dd-46babde6c612" contextRef="C_b103f351-0eb2-495b-85c1-5630e54c751c" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">62</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f00767bd-3abf-4fb2-9b85-1160588a8f40" contextRef="C_1b7733fe-22fe-416b-a33e-e8b388655156" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:2.773%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total current liabilities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ff91b70b-1035-4b7b-849a-124e5d34540e" contextRef="C_b103f351-0eb2-495b-85c1-5630e54c751c" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">47,879</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9644b5fd-4267-4ca7-a017-54bd0ee57655" contextRef="C_1b7733fe-22fe-416b-a33e-e8b388655156" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">73,451</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Long-term portion of deferred revenue</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_13c9d680-c460-4331-91bb-e45a94e8b1a8" contextRef="C_b103f351-0eb2-495b-85c1-5630e54c751c" name="us-gaap:DeferredRevenueNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,350</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5a687350-abc1-48d5-888b-52a4936ff645" contextRef="C_1b7733fe-22fe-416b-a33e-e8b388655156" name="us-gaap:DeferredRevenueNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,233</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Long-term portion of operating lease liabilities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c7bde89e-e36b-493d-9d4e-e1043221e2fc" contextRef="C_b103f351-0eb2-495b-85c1-5630e54c751c" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,854</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7e37ec9e-8bb5-4450-914e-b2a63a3822b7" contextRef="C_1b7733fe-22fe-416b-a33e-e8b388655156" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,592</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other long-term liability</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f144e392-ce33-4abc-80a3-3dea69ddb750" contextRef="C_b103f351-0eb2-495b-85c1-5630e54c751c" name="us-gaap:OtherLiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">761</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_99bb3812-658a-4787-b343-77ae0a0d53aa" contextRef="C_1b7733fe-22fe-416b-a33e-e8b388655156" name="us-gaap:OtherLiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">761</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:2.773%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total liabilities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d56f5e8a-1f32-41cb-a2e0-d2f4304e99c1" contextRef="C_b103f351-0eb2-495b-85c1-5630e54c751c" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">54,844</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_06390701-f47a-4fbf-b4ef-d057d7610fb4" contextRef="C_1b7733fe-22fe-416b-a33e-e8b388655156" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">80,037</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;"><span style="-sec-ix-hidden:F_2822a515-be27-4a7e-b4e8-a1d6dcb822ad;"><span style="-sec-ix-hidden:F_e884c67c-98c2-4dc5-85ba-d3ff1ddf6d72;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commitments and contingencies (Note 7)</span></span></span></span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stockholders&#8217; equity:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">Common stock, $</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_07300589-19c5-4ab9-8b35-27e1cd6512a7" contextRef="C_b103f351-0eb2-495b-85c1-5630e54c751c" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="4" format="ixt:num-dot-decimal"><ix:nonFraction id="F_bde21e23-5130-496d-a184-8ff984bb5b26" contextRef="C_1b7733fe-22fe-416b-a33e-e8b388655156" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="4" format="ixt:num-dot-decimal">0.0001</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">&#160;par value; </span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e6204760-e1e2-4320-9e15-8544a8c2ca03" contextRef="C_b103f351-0eb2-495b-85c1-5630e54c751c" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_b29f0c11-ff87-492f-81c3-932b4eb56345" contextRef="C_1b7733fe-22fe-416b-a33e-e8b388655156" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">500,000,000</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">&#160;shares authorized as of March 31, 2025 and December 31, 2024; </span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4d7f4d84-7180-4930-a696-b83e390d51d7" contextRef="C_b103f351-0eb2-495b-85c1-5630e54c751c" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_b637289b-6d54-4500-9444-4e09668fcbe3" contextRef="C_b103f351-0eb2-495b-85c1-5630e54c751c" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">101,353,781</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">&#160;and </span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_79d656d4-b482-49a2-ac01-45bbc920d553" contextRef="C_1b7733fe-22fe-416b-a33e-e8b388655156" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_3fd79347-ac49-4a26-8e15-e1abdfe222cd" contextRef="C_1b7733fe-22fe-416b-a33e-e8b388655156" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">101,116,162</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">&#160;shares issued and outstanding as of March 31, 2025 and December 31, 2024, respectively</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2b50aaf5-d6a6-435e-a395-b65ffc7bae18" contextRef="C_b103f351-0eb2-495b-85c1-5630e54c751c" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_39388701-944e-42b3-b64d-d18e54631351" contextRef="C_1b7733fe-22fe-416b-a33e-e8b388655156" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Additional paid-in-capital</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_53ad2141-2e65-4305-b9ba-5507f92c9f2b" contextRef="C_b103f351-0eb2-495b-85c1-5630e54c751c" name="us-gaap:AdditionalPaidInCapital" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,069,631</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_892c25aa-9b94-4510-a6cb-bef6839d441d" contextRef="C_1b7733fe-22fe-416b-a33e-e8b388655156" name="us-gaap:AdditionalPaidInCapital" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,056,738</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accumulated other comprehensive income</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_746494c7-dac3-4406-a76f-0ad3f1ecb512" contextRef="C_b103f351-0eb2-495b-85c1-5630e54c751c" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">52</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bbe71ebb-71cd-4762-b3c4-2188bcc4fd90" contextRef="C_1b7733fe-22fe-416b-a33e-e8b388655156" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">84</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accumulated deficit</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a5353292-5c12-47cd-97fd-d8567219864a" contextRef="C_b103f351-0eb2-495b-85c1-5630e54c751c" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">590,077</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_69931125-12e4-4033-8b6e-3557fd8afb3b" contextRef="C_1b7733fe-22fe-416b-a33e-e8b388655156" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">554,081</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:2.773%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total stockholders&#8217; equity</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f8bcc9a3-c02b-4a90-aeca-9f33802b8aa8" contextRef="C_b103f351-0eb2-495b-85c1-5630e54c751c" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">479,512</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3494ac32-e41d-46a2-a156-62f683f4b054" contextRef="C_1b7733fe-22fe-416b-a33e-e8b388655156" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">502,751</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:2.773%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total liabilities and stockholders' equity</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a183b31d-5806-4d15-9b48-189ab8203a71" contextRef="C_b103f351-0eb2-495b-85c1-5630e54c751c" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">534,356</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5c0f6927-dc0f-4706-86cd-7f21a53b625e" contextRef="C_1b7733fe-22fe-416b-a33e-e8b388655156" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">582,788</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">See accompanying notes to the condensed financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4</span><span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="tx180355_4"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Day One Biopharmaceuticals, Inc.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Condensed Statements of Operations</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in thousands, except share and per share amounts)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(unaudited)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:51.11%;box-sizing:content-box;"/>
     <td style="width:2.36%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:20.084%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:2.36%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:20.084%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended<br/>March 31,</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Revenue:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Product revenue, net</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_85050965-7319-43f5-b18b-93c00134526f" contextRef="C_b5f6c9ab-25d5-4e70-992c-f10381920bf2" name="us-gaap:Revenues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">30,503</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9f5e2684-a34e-49a4-8d72-78e3ccf0f899" contextRef="C_749941a2-d394-4f48-bd13-a62ecd76cd82" name="us-gaap:Revenues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">License revenue</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_12d40946-793c-427e-bb14-87478ff5b689" contextRef="C_7902fa1d-00a4-4ae2-802d-20016ff59f3d" name="us-gaap:Revenues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">258</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b9618f86-7053-4ee2-b2b0-3ba4a49cf3d7" contextRef="C_8bbef5b6-cf7a-452a-9829-28292e282f79" name="us-gaap:Revenues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total revenues</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f85cfbe8-6ece-4879-83df-8c65c261f11a" contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b" name="us-gaap:Revenues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">30,761</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7c165b2a-65b3-4812-ad6b-e90c128a315e" contextRef="C_0fd32f25-7d1d-46c5-938d-d9b0e3f9dfaa" name="us-gaap:Revenues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cost and operating expenses:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cost of product revenue</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b2dba719-411f-4052-8bfb-389c451ebf5a" contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b" name="dawn:CostOfProductRevenue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,884</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_24b7c733-3c58-4d9d-ac75-89b3daaf3b3f" contextRef="C_0fd32f25-7d1d-46c5-938d-d9b0e3f9dfaa" name="dawn:CostOfProductRevenue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_308c170b-6447-49e7-bed7-8d025d37eed2" contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">39,619</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f11f6130-1173-45c8-989e-2f91fd41f758" contextRef="C_0fd32f25-7d1d-46c5-938d-d9b0e3f9dfaa" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">40,210</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Selling, general and administrative</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2a2f9861-5eff-41e8-b5c3-a24dfb6bd29b" contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">29,325</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8c1dc444-d46f-41d1-ae82-0bfd6186e0c2" contextRef="C_0fd32f25-7d1d-46c5-938d-d9b0e3f9dfaa" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">26,557</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total cost and operating expenses</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1fc10f39-922d-4603-b593-b17937e2eaff" contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">71,828</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_962c3746-6170-43ed-a879-a195517f2214" contextRef="C_0fd32f25-7d1d-46c5-938d-d9b0e3f9dfaa" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">66,767</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Loss from operations</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2cf5f8e8-5717-4cf3-8201-826a3d041e0b" contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">41,067</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8f73a89e-c86c-4954-8e65-1da805b42c71" contextRef="C_0fd32f25-7d1d-46c5-938d-d9b0e3f9dfaa" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">66,767</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-operating income:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Investment income, net</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a51e496f-07bf-473f-bef6-1c6cb5d727a8" contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b" name="us-gaap:InvestmentIncomeNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,094</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_066a4e3c-04ca-46b3-a55a-d0962f42854a" contextRef="C_0fd32f25-7d1d-46c5-938d-d9b0e3f9dfaa" name="us-gaap:InvestmentIncomeNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,365</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other expense, net</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5a1e3662-3152-4820-bcde-94ce1d795623" contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">23</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_30972918-5fd3-46c9-8725-508f97e5bca1" contextRef="C_0fd32f25-7d1d-46c5-938d-d9b0e3f9dfaa" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">10</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total non-operating income, net</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7bb7ba68-d382-4d59-befd-c84669e95f99" contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,071</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_19352ba3-e94d-403c-b14f-043dffcd90c0" contextRef="C_0fd32f25-7d1d-46c5-938d-d9b0e3f9dfaa" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,355</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Loss before income taxes</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d0946080-f83f-4ec1-8103-d32d4f8129af" contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b" name="us-gaap:IncomeLossAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">35,996</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5bf0d181-3951-469e-a6eb-cb797fee192b" contextRef="C_0fd32f25-7d1d-46c5-938d-d9b0e3f9dfaa" name="us-gaap:IncomeLossAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">62,412</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Income tax benefit (expense)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d8fb95ed-ed4c-4ded-a726-5343fa46e8f4" contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_da9ef3dc-b8d9-4e1f-8036-838356a19507" contextRef="C_0fd32f25-7d1d-46c5-938d-d9b0e3f9dfaa" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b0dd88bd-0334-4306-8873-0d0f01c681c1" contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">35,996</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1fbba0f1-11cc-4c91-be85-7b8e3017efa7" contextRef="C_0fd32f25-7d1d-46c5-938d-d9b0e3f9dfaa" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">62,412</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss per share - basic</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3ffe07c1-316b-4622-a79d-73d3d82ddb7c" contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">0.35</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_09780e53-f1e2-40c1-b503-dcfba7e3daf4" contextRef="C_0fd32f25-7d1d-46c5-938d-d9b0e3f9dfaa" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">0.72</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss per share - diluted</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f25fb7e5-e7b1-46ac-8f26-a15d5da73f53" contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">0.35</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c261b4d6-b02e-4224-951a-38fefe85906b" contextRef="C_0fd32f25-7d1d-46c5-938d-d9b0e3f9dfaa" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">0.72</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average number of common shares used in net loss per share - basic</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9a3f449a-0fcc-4de8-a354-c1b8e665a156" contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">102,710,382</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_49c18272-e4c0-4357-8755-ccfbed6c613d" contextRef="C_0fd32f25-7d1d-46c5-938d-d9b0e3f9dfaa" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">86,679,282</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average number of common shares used in net loss per share - diluted</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_99eb882e-688c-4974-88f9-1d5b690128c5" contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">102,710,382</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b16ddf80-df44-4164-b373-e81f046b7b53" contextRef="C_0fd32f25-7d1d-46c5-938d-d9b0e3f9dfaa" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">86,679,282</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">See accompanying notes to the condensed financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="condensed_consolidated_socl"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Day One Biopharmaceuticals, Inc.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Condensed Statements of Comprehensive Loss</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in thousands)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(unaudited)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:48.099%;box-sizing:content-box;"/>
     <td style="width:2.501%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:21.449%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:2.501%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:21.449%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended<br/>March 31,</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_35bb620a-13eb-489b-ba2e-e58420095b22" contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">35,996</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_01e11454-bd8d-4511-9a83-a0dec3843427" contextRef="C_0fd32f25-7d1d-46c5-938d-d9b0e3f9dfaa" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">62,412</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other comprehensive loss:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:0.92%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unrealized loss on available-for-sale securities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b7353c95-dd99-479e-92b1-1486a9e5f0b8" contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">136</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5b90b3fd-8617-421a-95ba-40d1d9c9634c" contextRef="C_0fd32f25-7d1d-46c5-938d-d9b0e3f9dfaa" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">14</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total comprehensive loss</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_81dee589-5e66-4754-813c-a36a9c1ed5d2" contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">36,132</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_95deac4d-5491-4f75-aa5c-08c1c00e62c2" contextRef="C_0fd32f25-7d1d-46c5-938d-d9b0e3f9dfaa" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">62,426</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">See accompanying notes to the condensed financial statements.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="tx180355_6"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Day One Biopharmaceuticals, Inc.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Condensed Statements of Stockholders&#8217; Equity</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(in thousands, except share amounts)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(unaudited)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:23.52%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:9.88%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:9.64%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:9.64%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:9.64%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:9.64%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:10.04%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Common Shares</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Additional</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Accumulated Other</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Accumulated</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total Stockholders'</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Shares</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amount</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Paid-In Capital</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Comprehensive Income (Loss)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Deficit</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Equity</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Balance at December 31, 2024</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3b93e06c-aa6a-4db6-9281-7aed6c1eab45" contextRef="C_9cfff08d-a5d3-4ed4-8454-95741093c5c8" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">101,116,162</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_416edd78-5cc5-41ae-a17f-76c38ed64acb" contextRef="C_9cfff08d-a5d3-4ed4-8454-95741093c5c8" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c69fe68b-f450-4955-a6da-0bd7587c9904" contextRef="C_3844ba24-08c1-421c-b49d-4740f7e0d572" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,056,738</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7f8360d8-3811-468d-840e-3d000e7754a7" contextRef="C_827ac41e-d0d2-4df1-8321-6fb95701054e" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">84</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c4bb9d8d-e3e6-4d99-898b-10a50fa4b041" contextRef="C_02cfe4b1-bd5d-4fbb-95f7-4ee6c0f9824a" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">554,081</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_35901308-18ae-43be-b5de-96f8c64f71ea" contextRef="C_1b7733fe-22fe-416b-a33e-e8b388655156" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">502,751</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuance of common stock upon release of restricted stock units</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ab1c24c6-88e5-4ff1-82b5-7ffc9db4b00b" contextRef="C_ef0986cb-13e6-4f2b-818c-1d5b4469876d" name="dawn:IssuanceOfCommonStockUponReleaseOfRestrictedStockUnits" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">238,354</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;word-break:break-word;">
     <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unvested common stock forfeiture</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_98c36d37-856a-4bd6-9323-652a9a1bc6ef" contextRef="C_ef0986cb-13e6-4f2b-818c-1d5b4469876d" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" unitRef="U_shares" decimals="0" sign="-" format="ixt:num-dot-decimal">735</ix:nonFraction></span></p></td>
     <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#ffffff;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#ffffff;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Share-based compensation expenses</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cff4609d-4765-4715-9017-725f56ccd567" contextRef="C_ee47eb20-6b00-401a-8f3b-4c791e30712a" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,893</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1db65d77-7d46-4ea4-bd7f-315046c66c25" contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,893</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unrealized loss on available-for-sale securities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_217e78af-522d-40d3-b8d1-da2e4d963618" contextRef="C_ee6e19da-95ec-456c-abbd-e2850974503c" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">136</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5532ed49-7b0a-4c23-bdae-afac514fbea9" contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">136</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2e35e8a4-7580-4880-94dc-b3f3c203dd96" contextRef="C_3b4a9bf0-9117-492a-a8d5-7f4450cbd994" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">35,996</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_542159c7-7e63-4766-9533-7c237bc55a45" contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">35,996</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Balance at March 31, 2025</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_eb9b7f8d-b8ff-44ca-854f-ebdbdc6397bc" contextRef="C_4b6fd4af-8d4f-4f7d-b960-b6ac6218c53a" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">101,353,781</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ea6a85d4-31ad-4789-b9af-0c9ba499bad7" contextRef="C_4b6fd4af-8d4f-4f7d-b960-b6ac6218c53a" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ea484ccd-318d-4fff-9617-535bbf7137ac" contextRef="C_60b37620-bd42-435a-8868-27168e7b2da5" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,069,631</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_67548d1b-a65f-45b9-a698-9606406c38b4" contextRef="C_94ce4acc-2f61-45fc-9674-ab4c0d8f85f3" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">52</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_525d4254-a26c-4015-96c1-75c3f2683d44" contextRef="C_78dfe459-4b7a-4e97-aa42-abf96dae2d9e" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">590,077</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5835950c-93ec-47fe-87d9-83868645829b" contextRef="C_b103f351-0eb2-495b-85c1-5630e54c751c" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">479,512</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">See accompanying notes to the condensed financial statements.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Day One Biopharmaceuticals, Inc.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Condensed Statements of Stockholders&#8217; Equity</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(in thousands, except share amounts)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(unaudited)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:22.049%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:10.124%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:9.884%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:9.884%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:9.884%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:9.884%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:10.284%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Common Shares</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Additional</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Accumulated Other</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Accumulated</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total Stockholders'</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Shares</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amount</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Paid-In Capital</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Comprehensive Income (Loss)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Deficit</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Equity</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Balance at December 31, 2023</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_10e08763-8e37-410a-b012-3ce67b0ef675" contextRef="C_ac5f563a-6d18-4f41-8866-bd417f95f7f7" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">87,227,132</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ff7f54c0-8229-416f-b3e1-003c5237b8db" contextRef="C_ac5f563a-6d18-4f41-8866-bd417f95f7f7" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4ae1528d-fc7f-4b68-a341-b72f72b32e0a" contextRef="C_21c9ec3b-26c7-4a87-b2d1-3f695174dd3f" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">805,107</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d4f3fa11-48f3-48e7-ba89-ac2c4533da5e" contextRef="C_01bb969c-6b26-4ada-840e-3e6660f4d113" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3479542b-a1e9-491b-869d-8061c9614ba9" contextRef="C_6e1b373b-8302-46c1-aa4e-7f2da1ba09e1" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">458,585</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ffc3b164-b7ae-4190-8bc9-0bcbb7585035" contextRef="C_ba36f1f4-7ce5-434c-b80f-2bcb5a767c07" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">346,540</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuance of common stock upon exercise of stock options</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4c68dbff-2838-41b4-8018-6b48a883cf59" contextRef="C_56ac395d-44a1-4679-8062-efee79181688" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">4,862</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_69d52458-849a-4fe2-8fe6-4590d8b407c5" contextRef="C_22370d4f-2229-4fea-b11d-aaa9611c4ebe" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">48</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b69611e9-fb21-475e-aea3-afe89421f24d" contextRef="C_0fd32f25-7d1d-46c5-938d-d9b0e3f9dfaa" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">48</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuance of common stock upon release of restricted stock units</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a4f94902-c32f-4cf7-80ce-7938dfb7f38b" contextRef="C_56ac395d-44a1-4679-8062-efee79181688" name="dawn:IssuanceOfCommonStockUponReleaseOfRestrictedStockUnits" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">157,724</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unvested common stock forfeiture</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8b8ddf3d-a6cc-4f13-ad4c-694f6a0c24a0" contextRef="C_56ac395d-44a1-4679-8062-efee79181688" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" unitRef="U_shares" decimals="0" sign="-" format="ixt:num-dot-decimal">12,555</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Share-based compensation expenses</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fced9535-3784-4799-9592-35949343ce53" contextRef="C_22370d4f-2229-4fea-b11d-aaa9611c4ebe" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,644</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ad607df5-8f9b-4c36-b48e-8ad7f7bcf767" contextRef="C_0fd32f25-7d1d-46c5-938d-d9b0e3f9dfaa" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,644</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unrealized loss on available-for-sale securities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_61d99163-9f1a-41ae-a52b-2e0d67443dec" contextRef="C_6d1be359-db5b-4358-8204-bf1ab5d70c18" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">14</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3923c26c-9d10-4b24-a360-00f910dbcbc9" contextRef="C_0fd32f25-7d1d-46c5-938d-d9b0e3f9dfaa" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">14</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_728b41d4-5e94-4528-9b06-4ec6b27a9431" contextRef="C_80a0754a-565e-4050-8b95-677c6495d268" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">62,412</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_384317bf-d506-4c81-9114-18014a8cc71d" contextRef="C_0fd32f25-7d1d-46c5-938d-d9b0e3f9dfaa" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">62,412</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Balance at March 31, 2024</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e665be3b-5330-42e4-b9fa-b1201b0cea81" contextRef="C_af8109ab-99db-4170-9328-c13fd756a885" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">87,377,163</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_415e3d2f-4f3b-4183-b606-f66c3c3e696d" contextRef="C_af8109ab-99db-4170-9328-c13fd756a885" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_acc32a59-7636-43b2-beae-7543e0e0d2c5" contextRef="C_ac9ee8d9-bca6-4fd2-9709-df26868eb7bf" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">817,799</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_41e974b3-bac2-46b9-8e30-44e99c318c6b" contextRef="C_22c0360b-da7f-497c-9e18-47a5bdec0579" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">5</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d4e3f64c-b221-46d8-bdd1-56cb3a8b9b76" contextRef="C_5b86a378-9cda-47eb-8a66-30562f03c4e4" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">520,997</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5c641216-3840-47c4-b9f3-565e67fca857" contextRef="C_4ba97ac7-abe6-41af-8f29-b34dd24231c3" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">296,806</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">See accompanying notes to the condensed financial statements.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="tx180355_7"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Day One Biopharmaceuticals, Inc.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Condensed Statements of Cash Flows</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(in thousands)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(unaudited)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:71.834%;box-sizing:content-box;"/>
     <td style="width:1.36%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:10.842%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.12%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:10.842%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended<br/>March 31,</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Cash flows from operating activities:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_267c33ce-7d9c-4487-b9b1-bc217470b99a" contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">35,996</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a8b672e7-ec09-4f41-8f8f-00f1a2eb0e46" contextRef="C_0fd32f25-7d1d-46c5-938d-d9b0e3f9dfaa" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">62,412</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Adjustments to reconcile net loss to net cash used in operating activities:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Share-based compensation expense</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b6545f19-f4a1-4621-9528-30d22593e4ac" contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,861</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2498ff81-3476-4f79-acd0-88f6477129c7" contextRef="C_0fd32f25-7d1d-46c5-938d-d9b0e3f9dfaa" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,644</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Depreciation expense</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_967cd8b4-0729-4bea-97b1-f14390fc6518" contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b" name="us-gaap:DepreciationDepletionAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">94</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6121ee80-b591-4087-8346-098f16ee866a" contextRef="C_0fd32f25-7d1d-46c5-938d-d9b0e3f9dfaa" name="us-gaap:DepreciationDepletionAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">23</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accretion of discounts on short-term investments, net</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d55fd735-e219-4f91-a588-3011fb0f865f" contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,250</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_211c1ba9-32f1-497c-843f-0ba9f1a076b3" contextRef="C_0fd32f25-7d1d-46c5-938d-d9b0e3f9dfaa" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,292</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Amortization of intangible assets</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5a7326ec-623f-4d33-9f26-069bf3b6c873" contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b" name="us-gaap:AmortizationOfIntangibleAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">725</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_26277fd1-0704-43e3-8120-84637128cde5" contextRef="C_0fd32f25-7d1d-46c5-938d-d9b0e3f9dfaa" name="us-gaap:AmortizationOfIntangibleAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Amortization of operating right-of-use asset</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f45f00dd-c92a-4ab7-88d0-edc84988302f" contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">75</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_05b5050c-7ed1-490f-acc8-1413ed2ebff1" contextRef="C_0fd32f25-7d1d-46c5-938d-d9b0e3f9dfaa" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">93</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Changes in operating assets and liabilities:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accounts receivable, net</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b77b23a9-2e49-4022-9397-be04ef0fa3b3" contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b" name="us-gaap:IncreaseDecreaseInAccountsReceivable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,178</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a9a520f0-bf85-46b7-9a7b-3aba71fc2866" contextRef="C_0fd32f25-7d1d-46c5-938d-d9b0e3f9dfaa" name="us-gaap:IncreaseDecreaseInAccountsReceivable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inventory</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_aff03aa7-0f6e-4d84-b256-e495e7260959" contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b" name="us-gaap:IncreaseDecreaseInInventoriesAndOtherOperatingAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">212</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_38265443-974a-4592-9f44-336d4484b2a8" contextRef="C_0fd32f25-7d1d-46c5-938d-d9b0e3f9dfaa" name="us-gaap:IncreaseDecreaseInInventoriesAndOtherOperatingAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid expenses and other current assets</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ebf2958e-09c7-4c2f-89a9-24d6bb9ae887" contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">606</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f143a285-16d6-4965-9d60-7adbd85d6788" contextRef="C_0fd32f25-7d1d-46c5-938d-d9b0e3f9dfaa" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">837</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deposits and other long-term assets</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6851b91d-b8c4-483a-a100-651ce701955a" contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b" name="us-gaap:IncreaseDecreaseInDepositOtherAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">94</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_12232f1d-967c-47ad-a293-568daca3ff7b" contextRef="C_0fd32f25-7d1d-46c5-938d-d9b0e3f9dfaa" name="us-gaap:IncreaseDecreaseInDepositOtherAssets" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">47</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accounts payable</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e12a6d4a-74d9-4271-998e-6e9dc0cf9ed2" contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">722</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a6878b11-c74b-4d3c-997e-b05bc729a415" contextRef="C_0fd32f25-7d1d-46c5-938d-d9b0e3f9dfaa" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,204</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued expenses and other current liabilities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3710633f-9689-4346-b4ef-bee0dc570a3f" contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b" name="dawn:IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">26,984</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a806cb74-f5a9-4782-897a-3bdaa1f1a2eb" contextRef="C_0fd32f25-7d1d-46c5-938d-d9b0e3f9dfaa" name="dawn:IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,765</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred revenue</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e1975174-1f77-4b8f-8760-b185e9477d19" contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b" name="us-gaap:IncreaseDecreaseInDeferredRevenue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">199</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_65f7d098-f4f6-465d-a545-e6478098c441" contextRef="C_0fd32f25-7d1d-46c5-938d-d9b0e3f9dfaa" name="us-gaap:IncreaseDecreaseInDeferredRevenue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease liability</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2f06ace4-e289-4e77-ac92-0d636baccfdc" contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">91</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b1d30144-5a67-4570-93ce-1a3000e72b11" contextRef="C_0fd32f25-7d1d-46c5-938d-d9b0e3f9dfaa" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">108</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:30pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5.56%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash used in operating activities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b7d4e41a-9bc0-4ca0-acbe-0f851f0fed55" contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">58,997</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_65fe17e6-5bdd-4e1e-a2a8-3c0fbac25733" contextRef="C_0fd32f25-7d1d-46c5-938d-d9b0e3f9dfaa" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">49,729</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Cash flows from investing activities:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash paid for purchase of short-term investments</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0d5e7751-30d1-4baa-9e5a-6bf222867a0f" contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b" name="us-gaap:PaymentsToAcquireShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">189,796</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bb71d88d-b0f5-4bdc-9f10-8decd1641d92" contextRef="C_0fd32f25-7d1d-46c5-938d-d9b0e3f9dfaa" name="us-gaap:PaymentsToAcquireShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">47,162</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Proceeds from maturity of short-term investments</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6f66e746-d1f2-46c5-a16c-fd1a9885ffac" contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b" name="us-gaap:ProceedsFromSaleOfShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">161,000</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e041ef13-7f9b-444b-9e27-dc05eaa6d72e" contextRef="C_0fd32f25-7d1d-46c5-938d-d9b0e3f9dfaa" name="us-gaap:ProceedsFromSaleOfShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">136,450</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash paid for acquired intangible assets</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2e6b0891-5b1b-46ca-9273-465e9beb7903" contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b" name="us-gaap:PaymentsToAcquireIntangibleAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,500</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9fb4fd9c-5e36-4fb0-ba02-44d11b66c20f" contextRef="C_0fd32f25-7d1d-46c5-938d-d9b0e3f9dfaa" name="us-gaap:PaymentsToAcquireIntangibleAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash paid for purchase of property and equipment</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e70a3346-7d6d-4868-b364-7eb367b65088" contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">317</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ab1866b6-1aae-43db-b367-3a6e3c23ae68" contextRef="C_0fd32f25-7d1d-46c5-938d-d9b0e3f9dfaa" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:30pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5.56%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash (used in) provided by investing activities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f79d4a3c-2258-4e56-b441-a049aabc6d37" contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">32,613</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fd05487b-eef7-4dec-a70a-e4078d35a302" contextRef="C_0fd32f25-7d1d-46c5-938d-d9b0e3f9dfaa" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">89,288</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Cash flows from financing activities:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Proceeds from issuance of common stock upon stock option exercises</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_699f5caf-9c08-4cce-a9ee-69da3818d0f6" contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_feb6e485-9a44-4ebc-b5d2-a8601492d6e8" contextRef="C_0fd32f25-7d1d-46c5-938d-d9b0e3f9dfaa" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">48</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:30pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5.56%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash provided by financing activities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_df61ad46-88d1-4ae0-bcfd-d8910b61df59" contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dc890493-53d4-4a9b-a1ff-ffae1be3aa21" contextRef="C_0fd32f25-7d1d-46c5-938d-d9b0e3f9dfaa" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">48</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net (decrease) increase in cash and cash equivalents</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_af5798f3-c683-4958-9690-b5052bc175a7" contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">91,610</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4584b921-b232-4922-b059-303b21d5ebe1" contextRef="C_0fd32f25-7d1d-46c5-938d-d9b0e3f9dfaa" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">39,607</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;word-break:break-word;">
     <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash and cash equivalents, beginning of period</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9be8e831-794f-4419-8e45-d45149dc765e" contextRef="C_1b7733fe-22fe-416b-a33e-e8b388655156" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">124,968</ix:nonFraction></span></p></td>
     <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#ffffff;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2cc87b42-3224-462b-b6d8-d390881356d8" contextRef="C_ba36f1f4-7ce5-434c-b80f-2bcb5a767c07" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">230,784</ix:nonFraction></span></p></td>
     <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash and cash equivalents, end of period</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_156f3ad7-6f1b-4c7b-ab7e-97aecf506966" contextRef="C_b103f351-0eb2-495b-85c1-5630e54c751c" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">33,358</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_13b33463-8e4a-4e2a-87de-6717488d35b4" contextRef="C_4ba97ac7-abe6-41af-8f29-b34dd24231c3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">270,391</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Supplemental disclosures of noncash activities:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash not yet paid for acquired intangible asset</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_954b59ed-f56f-41ce-8ad6-51bcaf6bbc00" contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,000</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_54e427ee-0bbf-4657-bb92-effee4e33177" contextRef="C_0fd32f25-7d1d-46c5-938d-d9b0e3f9dfaa" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Right-of-use asset obtained in exchange for new operating lease liabilities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_83839d54-7f56-42aa-a6a9-ae401ddc2c2a" contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">230</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f962f9e5-83a4-4044-b590-f60b15023872" contextRef="C_0fd32f25-7d1d-46c5-938d-d9b0e3f9dfaa" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">See accompanying notes to the condensed financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="tx180355_8"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Day One Biopharmaceuticals, Inc.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notes to the Condensed Financial Statements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_20ea2eb4-b8b3-49b2-b4a6-1e1b42d33731" contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" escape="true"><div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Description of Business and Organization </span></div></div><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Organization and Business</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Day One Biopharmaceuticals, Inc. is a commercial-stage company focused on advancing medicines for childhood and adult diseases with equal intensity. The Company was founded in November 2018 and is headquartered in Brisbane, CA.</span></p></ix:nonNumeric></div><div><ix:nonNumeric id="F_45f6c985-3bb0-409b-845d-3c3cfd8df0e8" contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b" name="us-gaap:SignificantAccountingPoliciesTextBlock" escape="true" continuedAt="F_45f6c985-3bb0-409b-845d-3c3cfd8df0e8_1"><div class="item-list-element-wrapper" style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Summary of Significant Accounting Policies </span></div></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8502d0db-a2ad-4d3f-af5b-1fc09376a6c3" contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" escape="true"><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Basis of Presentation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States, or U.S. GAAP, for interim financial information and Article 10 of Regulation S-X of the Securities and Exchange Commission, or SEC, and should be read in conjunction with the Company's financial statements and notes thereto contained in the Company's Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on February 25, 2025. The condensed financial statements presented in this Quarterly Report on Form 10-Q are unaudited; however, in the opinion of management, such financial statements reflect all adjustments, consisting solely of normal recurring adjustments, necessary for a fair presentation of the results for the interim periods presented.</span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in Accounting Standards Codification, or ASC, and Accounting Standards Updates, or ASU, of the Financial Accounting Standards Board, or FASB.</span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Certain prior period amounts in the Notes to the Condensed Financial Statements have been reclassified to conform to the current period's presentation. These reclassifications did not affect the prior period's total assets, liabilities, stockholders' equity, net loss or cash flows. Specifically, the reclassifications separately present accrued rebates and accrued federal and state taxes within Note 4.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_30c7b7a6-1731-48ec-ba1a-5a9fddba4b23" contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b" name="us-gaap:UseOfEstimates" escape="true"><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Use of Estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The preparation of condensed financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and disclosure of contingent assets and liabilities at the date of the condensed financial statements, and the reported amounts of expenses during the reporting period. Estimates and assumptions made in the accompanying condensed financial statements include, but are not limited to, accruals for research and development expenses, variable consideration and other relevant inputs impacting the gross and net revenue recognition, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the valuation of share-based awards, and the valuation of deferred tax assets. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable. Actual results may differ from those estimates or assumptions.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7e5e5987-f4b6-471d-8bd9-91c233c2647c" contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" escape="true"><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Segments</span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Operating segments are defined as components of an entity about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business in one operating segment.</span></p></ix:nonNumeric></div><div><ix:nonNumeric id="F_b37d1975-dac4-436c-b6ae-f91b4a634954" contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b" name="us-gaap:ConcentrationRiskCreditRisk" escape="true" continuedAt="F_b37d1975-dac4-436c-b6ae-f91b4a634954_1"><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Concentration of Credit Risk and Other Risks and Uncertainties</span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Financial instruments that subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents, short-term investments, and accounts receivable. Amounts on deposit may at times exceed federally insured limits. The Company is exposed to credit risk in the event of default by the financial institutions holding its cash, cash equivalents and short-term investments that are recorded on its balance sheet. Per policy, the Company mitigates its risk by investing in high-grade instruments and limiting the concentration in any one non-United States government or government backed issuer, which limits its exposure. The Company has not experienced any losses on its cash, cash equivalents and short-term investments.
</span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the three months ended March 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, two individual customers accounted for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c44b83ca-cf4e-4d70-ade2-b67813163973" contextRef="C_3ab621ae-436f-433d-9df2-8c8bce28b89e" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">98.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of total net product revenue, with these individual customers representing </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_570c7b4b-0c52-42ce-a3d4-5fcb2177a18f" contextRef="C_8a694c05-0437-4c75-8ae6-45e4b83604d0" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">64.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_97b70f04-b829-402c-824a-f97cd036285b" contextRef="C_1438aa38-1e5a-4af2-922f-a3f067944262" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">34.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the Company's total net product revenue. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, two customers accounted for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ba728a66-7985-44ac-a41d-370eade6ed5f" contextRef="C_76de7769-5c35-42b4-83aa-9ca4c0b858aa" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">96.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the accounts receivable balance, with these individual customers representing </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_19528bdd-38c3-4398-8903-36000df3f63c" contextRef="C_24aa28dd-3f08-4c12-b95e-d974f2524368" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">72.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_87bd2291-4a30-4087-89ab-e53e915b4ad3" contextRef="C_f31a84ee-cbb2-48fa-a085-f699999cd961" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">23.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the accounts receivable balance. No other individual customers account for more than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dbf8aa7c-ff0e-47c6-83ae-5a21cedabe50" contextRef="C_6180a865-9d79-4110-bb9f-16515c37344b" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">10.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of net product revenue or accounts receivable. The Company monitors the financial condition of its customers so that it can appropriately respond to changes in their creditworthiness. To date, the Company has not experienced any losses with respect to the collection of its accounts receivable.</span></p></ix:nonNumeric></div></ix:nonNumeric></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_45f6c985-3bb0-409b-845d-3c3cfd8df0e8_1"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_b37d1975-dac4-436c-b6ae-f91b4a634954_1"><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is subject to certain risks and uncertainties and believes that changes in any of the following areas could have a material adverse effect on the Company's future financial position or results of its operations: ability to obtain future financing; regulatory requirements for approval and market acceptance of, and reimbursement for, product candidates; performance of third-party clinical research organizations and manufacturers upon which the Company relies; development of sales channels; protection of the Company&#8217;s intellectual property; litigation or claims against the Company based on intellectual property, patent, product, regulatory or other factors; changes to the market landscape; and the Company&#8217;s ability to attract and retain employees necessary to support its growth.
</span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is dependent on third-party manufacturers to supply products for commercial and research and development activities in its programs. In particular, the Company relies and expects to continue to rely on a small number of manufacturers to supply it with its requirements for the active pharmaceutical ingredients and formulated drugs related to these programs. These programs could be adversely affected by a significant interruption in the supply of active pharmaceutical ingredients and formulated drugs.</span></p></ix:continuation></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1055abc8-5105-414e-81b5-7fd6bb7ab37c" contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" escape="true"><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Recently Issued Accounting Pronouncements</span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740) &#8211; Improvements to Income Tax Disclosures, which enhances the transparency and decision usefulness of income tax disclosures by requiring disclosure of disaggregated income taxes paid, prescribes standard categories for the components of the effective tax rate reconciliation, and modifies other income tax-related disclosures. The ASU is effective for fiscal years beginning after December 15, 2024 and allows for adoption on a prospective basis, with a retrospective option. The Company is currently evaluating the effect of this update on its financial statement disclosures.</span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2024, the FASB issued ASU No. 2024-03, Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures, which requires disclosure, in the notes to financial statements, of specified information about certain costs and expenses at each interim and annual reporting period. The ASU is effective for fiscal years beginning after December 15, 2026 and allows for adoption on a prospective basis, with a retrospective option. Early adoption is permitted. The Company is currently evaluating the effect of this update on its financial statement disclosures.</span></p></ix:nonNumeric></div></ix:continuation></div><div><ix:nonNumeric id="F_9c3f78aa-cd37-4661-affe-9c0d6f7471b5" contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b" name="us-gaap:FairValueDisclosuresTextBlock" escape="true" continuedAt="F_9c3f78aa-cd37-4661-affe-9c0d6f7471b5_1"><div class="item-list-element-wrapper" style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Recurring Fair Value Measurements </span></div></div><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a41b4c2e-0a13-47ea-93e5-efa43f98ca55" contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" escape="true"><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table sets forth the Company&#8217;s financial instruments as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 31, 2025 and December 31, 2024, which are measured at fair value on a recurring basis by level within the fair value hierarchy (in thousands):</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:36.214%;box-sizing:content-box;"/>
         <td style="width:1.2%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.745000000000001%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.2%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.745000000000001%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.2%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.745000000000001%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.2%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.745000000000001%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">March 31, 2025</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 1</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 3</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Financial assets:</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_51edd0e3-aaf5-4218-8e84-15a8d88633a6" contextRef="C_a48de969-8ddc-4b3b-a6a7-5c2b29ae4e05" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,146</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8dc30d4f-43ab-4234-9c20-72d17c7319a9" contextRef="C_494ea4ad-935d-45a3-a172-b60cd7e73582" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d2987544-5a35-4324-926b-aea62ccd519a" contextRef="C_5399640b-8a12-4325-9bb5-9eaa7ac09323" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5af2fb38-8018-4ade-b37a-39d8ea5d2b75" contextRef="C_de732af7-5533-4ee5-aaa0-722119902a1a" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,146</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. treasury securities</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e16b4d5f-c5b9-4ca2-88f6-f185a05a427c" contextRef="C_4c2bf0b9-0d5c-4b03-b0a7-3c3a06954490" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_43d69cae-cb9f-4bff-9cfd-d6311d534feb" contextRef="C_a49147be-0409-42b0-a2d6-250d7ea0c7b6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">345,377</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3cd3ca72-7f26-4650-ad81-6e63d0cc08fe" contextRef="C_bcf4433c-d298-4d36-a850-dfba1a092198" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bcef674c-54b0-4541-9846-315bd378bd8f" contextRef="C_709f7aa4-e121-4df0-b0d0-a36cdf0a83fe" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">345,377</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. government agency securities</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6855971f-8c44-4827-8a5f-39ca1f5ba8a7" contextRef="C_81949730-fa21-4927-8bb8-150b98f7b91f" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9ff045de-110e-4909-82b9-79a7f9e7cde4" contextRef="C_359c3fbb-d10c-4741-807c-98dd361851e9" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">94,285</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_02fa2387-9d0d-4e18-8445-a999766d124f" contextRef="C_10416dad-c8fd-476e-89d5-ae0a83b9440c" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_41efaf01-4653-4f91-af83-a4d153c50738" contextRef="C_3b67e9fd-7c04-48f2-969e-4f1fa6b5693c" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">94,285</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total assets measured at fair value</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_957d3591-e6be-496f-9596-e681db1d1837" contextRef="C_5459b1fe-9af9-4c02-891b-a32f266837c2" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,146</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ce8614ca-db90-4baa-8210-9a6acc451882" contextRef="C_21176c5a-4a94-4c88-9e64-63ebfc46b526" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">439,662</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7da4f03a-150f-4b94-8985-949c3be6d4d8" contextRef="C_1ce17a75-0fd7-4298-bfc0-f235a473361b" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1967d11a-5c49-4a8f-b027-4505e2209977" contextRef="C_3e17f855-9bc9-4474-9b6f-1728c5807a4b" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">451,808</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:36.295%;box-sizing:content-box;"/>
         <td style="width:1.2%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.725%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.2%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.725%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.2%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.725%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.2%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.725%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 1</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 3</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Financial assets:</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e2d372fd-9168-4426-b769-bbca7d38f0b4" contextRef="C_a3c664ec-2577-4bad-ba57-d70b9f3e5a3e" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,728</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_98b3ba31-6778-4886-ac8f-ff69ee81041f" contextRef="C_0a5c3519-45df-4f60-a8a7-7437f71f7bfb" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8ae5d7b6-4089-44fb-a427-c1b33df3cca3" contextRef="C_0cc93ae0-4f9d-48ec-aec0-c24fe1944b49" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3495400c-c42a-4132-acd2-0e25ae728bbd" contextRef="C_dea27b68-18b7-4c73-9c27-b5c829ef0241" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,728</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. treasury securities</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_632bb6f1-a640-4043-ab15-5673703a9440" contextRef="C_7f6b13fb-87e4-41c9-982f-9121e8dc50ce" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_387d6a0c-f135-4d5c-a961-f522f530124b" contextRef="C_e6665180-612b-4fba-adce-73d240ace7bb" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">311,487</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0a826a85-58d6-4249-bbff-c29826aaec5c" contextRef="C_dce557e4-9275-4019-bfcf-ce698a8400c6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_97e1fde9-0fd1-435e-ba4b-061f8263aaac" contextRef="C_4f8d1d22-bf0a-41bc-b883-13763363dd92" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">311,487</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. government agency securities</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_348e7bdc-dcad-43e2-873a-72864f0e9ba6" contextRef="C_a9d09cb0-58f1-4b18-b47f-7276b7057656" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6b9f7c28-ebe8-422c-a259-4d6e955d8830" contextRef="C_5f6d6e0e-3d98-4fa4-8a41-68a23cdaa376" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">183,375</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8cd4c46c-2cb0-4c62-a3d9-41151ba2b05e" contextRef="C_0bf779c8-a9a8-4ba9-bbb1-898f93f339e4" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5a9d4092-95dd-4633-9fda-43f99ca7578e" contextRef="C_a0ee4c82-d202-4563-aeeb-4840f5b9e70e" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">183,375</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total assets measured at fair value</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4b0b021c-5e1b-4d36-a4b0-57d3275e8944" contextRef="C_a320baa6-cd53-4730-8cba-58584c6ac43a" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,728</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_899de0f5-c8e8-4392-af39-930b20c0aad7" contextRef="C_19ecbc75-781d-4703-b1ec-88b78ffef3f7" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">494,862</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ff402c68-2995-4915-8ed1-8e8a1a392f59" contextRef="C_b5d41f12-6166-4c3e-a249-6ff0239c1d95" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5e178641-286e-4313-9878-cc2c4694a2b3" contextRef="C_4fbcd2d8-640a-4a12-888c-5b1b8885e9aa" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">511,590</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company's money market funds are classified as Level 1 because they are measured using observable inputs from active markets for identical assets.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company's U.S. treasury securities and U.S. government agency securities are classified as Level 2 because they are measured with inputs that are either directly or indirectly observable for the asset which include quoted prices for similar assets in active markets and quoted prices for identical or similar assets in markets that are not active.</span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There were no assets or liabilities classified as Level 3 as of March 31, 2025 and December 31, 2024.</span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b5cbe40c-876b-4d18-a834-ed4b8057e02f" contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen"><ix:nonFraction id="F_d2e6006b-7d84-4d19-a8de-68df65ef6d6d" contextRef="C_8b0fbd15-0039-4354-9bc0-e49520f5e256" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> transfers between Level 1, Level 2 or Level 3 categories during the periods presented.</span></p></ix:nonNumeric></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_9c3f78aa-cd37-4661-affe-9c0d6f7471b5_1"><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9cb77509-6d02-4c11-8d8a-80f191961df2" contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" escape="true"><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following tables summarize the estimated fair value of the Company's cash equivalents, available-for-sale securities classified as short-term investments, and associated unrealized gains and losses (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:41.6%;box-sizing:content-box;"/>
         <td style="width:1.1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:11.5%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:11.5%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:11.5%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:11.5%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">March 31, 2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortized Cost</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized Gains</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized Losses</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Estimated Fair Value</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash equivalents:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7c9b005a-31b1-4303-aa82-22d74d9b32b0" contextRef="C_b77b4a90-bf68-4a05-8f01-62a9520247e8" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,146</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_945d2381-3842-4315-a928-05559582f521" contextRef="C_b77b4a90-bf68-4a05-8f01-62a9520247e8" name="dawn:CashEquivalentsUnrealizedGains" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_284bfba2-3839-43c7-8e50-e300f92b87b7" contextRef="C_b77b4a90-bf68-4a05-8f01-62a9520247e8" name="dawn:CashEquivalentsUnrealizedLosses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b17bdfe2-93e1-4fe5-9cbe-8abeccf9d98a" contextRef="C_b77b4a90-bf68-4a05-8f01-62a9520247e8" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,146</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total cash equivalents</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a5a20148-abea-442a-9a9a-3e0f0e042057" contextRef="C_a308fa2a-9dd8-441a-aaa4-31aac0a1a5eb" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,146</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9c44b5e3-dc50-474e-b715-4622276d6be2" contextRef="C_a308fa2a-9dd8-441a-aaa4-31aac0a1a5eb" name="dawn:CashEquivalentsUnrealizedGains" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b400c7f8-abd5-4de1-81c5-c7e778cb8173" contextRef="C_a308fa2a-9dd8-441a-aaa4-31aac0a1a5eb" name="dawn:CashEquivalentsUnrealizedLosses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_47fbb381-d033-4040-aa65-09ccc9f90fd2" contextRef="C_a308fa2a-9dd8-441a-aaa4-31aac0a1a5eb" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,146</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Short-term investments</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. government agency securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_329b405e-1244-45c5-b5c0-7550323eb01c" contextRef="C_cbc72dd7-8c81-4d68-9f7a-1b1c2d90b6a0" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">94,297</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9f57fbdd-0735-452e-9243-a03ef94c6928" contextRef="C_68539f11-26b8-4c60-96db-44201518557b" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ec0bbf22-7d26-4c36-b5fe-abff913efcb5" contextRef="C_68539f11-26b8-4c60-96db-44201518557b" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b1f63ada-91c0-4f41-a849-61e18e1d67e0" contextRef="C_cbc72dd7-8c81-4d68-9f7a-1b1c2d90b6a0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">94,285</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. treasury securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b5f192b6-aaa0-4b3f-953d-d3e353ddeba0" contextRef="C_3c025e0b-f004-497c-8763-6a8406223ff4" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">345,418</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4d834299-d6c7-4cac-8474-c98c28a8b337" contextRef="C_cfe0c0d8-2e22-409b-b482-35888c79dbfa" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f59228b7-20a3-48ff-8b17-d8bfb6551e99" contextRef="C_cfe0c0d8-2e22-409b-b482-35888c79dbfa" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">48</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_eb7403e2-a650-43a9-88bc-7bf0c8798984" contextRef="C_3c025e0b-f004-497c-8763-6a8406223ff4" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">345,377</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total short-term investments</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8a0cdc85-dc2a-4c76-8073-b67903b3738b" contextRef="C_7a2a1b79-4a52-4f59-8224-b2b1f9654b55" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">439,715</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0bd10917-0259-49ed-a2c7-0e16a3420363" contextRef="C_ba809785-9e5e-4537-b8ed-aa9a95f5018c" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_19d0f00d-808a-4855-bd0b-0e8c077544df" contextRef="C_ba809785-9e5e-4537-b8ed-aa9a95f5018c" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">60</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_603b34f2-a841-4cb8-945b-c4139c5ac26e" contextRef="C_7a2a1b79-4a52-4f59-8224-b2b1f9654b55" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">439,662</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:41.6%;box-sizing:content-box;"/>
         <td style="width:1.1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:11.5%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:11.5%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:11.5%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:11.5%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortized Cost</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized Gains</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized Losses</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Estimated Fair Value</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash equivalents:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_83b47e59-aa06-4158-982d-2d8249637a07" contextRef="C_3b0aca41-c2bf-46f8-b765-42580bbf6433" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,728</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d63c3164-f879-46d4-a66a-c522f19fe585" contextRef="C_3b0aca41-c2bf-46f8-b765-42580bbf6433" name="dawn:CashEquivalentsUnrealizedGains" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_067c2246-de42-4c19-b59c-d688a98e138d" contextRef="C_3b0aca41-c2bf-46f8-b765-42580bbf6433" name="dawn:CashEquivalentsUnrealizedLosses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_55402a75-52e3-45cb-bfe9-fdb1e9b5f775" contextRef="C_3b0aca41-c2bf-46f8-b765-42580bbf6433" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,728</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. government agency securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d29ce536-bfa2-4d7f-b3c1-14ff421e3ade" contextRef="C_ebe52b1a-a4be-4f4e-a3d1-d3bb26eaa194" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">75,163</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bff94360-6c15-444b-a487-af9e348767dc" contextRef="C_ebe52b1a-a4be-4f4e-a3d1-d3bb26eaa194" name="dawn:CashEquivalentsUnrealizedGains" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a10122dc-cfaf-4801-a5e3-13eb7de02ec8" contextRef="C_ebe52b1a-a4be-4f4e-a3d1-d3bb26eaa194" name="dawn:CashEquivalentsUnrealizedLosses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_361d6bc1-868a-46f0-9ce7-91a1e387e0f0" contextRef="C_ebe52b1a-a4be-4f4e-a3d1-d3bb26eaa194" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">75,163</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. treasury securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fbd362d4-bbc0-488f-b7c3-33fda9be5a01" contextRef="C_451cb9d2-19ad-4b9a-87a0-770cffddb183" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,947</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_aa955f6b-33c6-49dd-8582-afed5fa7e6a9" contextRef="C_451cb9d2-19ad-4b9a-87a0-770cffddb183" name="dawn:CashEquivalentsUnrealizedGains" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_91c29798-df3a-4314-b50e-3dadcb095236" contextRef="C_451cb9d2-19ad-4b9a-87a0-770cffddb183" name="dawn:CashEquivalentsUnrealizedLosses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_32227377-01b7-4c0a-abc8-021f1c7f423d" contextRef="C_451cb9d2-19ad-4b9a-87a0-770cffddb183" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,947</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total cash equivalents</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bd7c3b5c-777e-4b68-bd87-7607e484cb74" contextRef="C_0eee3e9c-c51c-4e38-bfea-aebbe8a2a4a1" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">104,838</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_02ece62d-69af-4c2e-a634-6b9dc8c93379" contextRef="C_0eee3e9c-c51c-4e38-bfea-aebbe8a2a4a1" name="dawn:CashEquivalentsUnrealizedGains" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_88cd65b3-032e-4d87-8555-41987a6acc7d" contextRef="C_0eee3e9c-c51c-4e38-bfea-aebbe8a2a4a1" name="dawn:CashEquivalentsUnrealizedLosses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_368a7267-3194-4703-836c-00d72831cfe4" contextRef="C_0eee3e9c-c51c-4e38-bfea-aebbe8a2a4a1" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">104,838</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;text-indent:5pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Short-term investments</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. government agency securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_72122798-998d-4590-a17c-124f05e229e1" contextRef="C_ebe52b1a-a4be-4f4e-a3d1-d3bb26eaa194" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">108,210</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9a421caf-3312-4a1a-90d3-a981542e980e" contextRef="C_afcca245-4cb7-422b-8748-147e3421ebb4" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6e4a95f6-e61b-4898-9357-ee8166b0b78a" contextRef="C_afcca245-4cb7-422b-8748-147e3421ebb4" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b2209374-f491-4e90-ac01-6e8137ac9ae9" contextRef="C_ebe52b1a-a4be-4f4e-a3d1-d3bb26eaa194" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">108,212</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. treasury securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_07877ad6-9596-4caa-a841-c3a4b974d0e5" contextRef="C_451cb9d2-19ad-4b9a-87a0-770cffddb183" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">298,457</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e70cc5ce-bd55-496f-8bbf-bffb25000a4f" contextRef="C_414a2ccf-e2e3-4dea-882d-8f99a0bcc263" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">85</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5ef6642a-0061-4003-b091-4134e38fe29d" contextRef="C_414a2ccf-e2e3-4dea-882d-8f99a0bcc263" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5785368b-c09e-4694-8d50-f2973cae0722" contextRef="C_451cb9d2-19ad-4b9a-87a0-770cffddb183" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">298,540</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total short-term investments</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9df01d23-5a38-4ada-a6d3-f14a38a38d35" contextRef="C_4f40a47c-f03a-48ad-8dc7-1d9331ced26a" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">406,667</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d456144a-edfa-42c6-9263-2238d4e047ad" contextRef="C_4f6e2663-8d98-4973-a359-76163a03ea8a" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">98</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2b245e60-9bf3-458a-bde6-6dc77289ca08" contextRef="C_4f6e2663-8d98-4973-a359-76163a03ea8a" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_56793866-b642-4cd1-8e9a-b1cadbf56477" contextRef="C_4f40a47c-f03a-48ad-8dc7-1d9331ced26a" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">406,752</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div><div style="font-size:11pt;font-family:'Calibri',sans-serif;"><ix:nonNumeric id="F_f42047de-cf1d-4eac-9939-ef4791e1b9b0" contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b" name="dawn:ScheduleOfMaturitiesForAvailableForSaleSecuritiesTableTextBlock" escape="true"><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the maturities of our cash equivalents and available-for-sale securities (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:53.261%;box-sizing:content-box;"/>
         <td style="width:1.761%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:19.607999999999997%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.761%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:19.607999999999997%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">March 31, 2025</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortized Cost</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Mature in one year or less</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2e079bb6-b35b-48b3-8171-a0da2f932b30" contextRef="C_b103f351-0eb2-495b-85c1-5630e54c751c" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">451,861</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a2b0849b-89d7-4069-bb0c-5cf5d310d19c" contextRef="C_b103f351-0eb2-495b-85c1-5630e54c751c" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">451,808</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_022e1a4c-a3c6-4260-83a5-93fc4b5b0246" contextRef="C_b103f351-0eb2-495b-85c1-5630e54c751c" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">451,861</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7f50af9a-2b60-460d-9b77-299cd5c18e27" contextRef="C_b103f351-0eb2-495b-85c1-5630e54c751c" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">451,808</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:53.261%;box-sizing:content-box;"/>
         <td style="width:1.761%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:19.607999999999997%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.761%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:19.607999999999997%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortized Cost</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Mature in one year or less</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_459a2599-1558-47bd-831a-7d9701c60dd5" contextRef="C_1b7733fe-22fe-416b-a33e-e8b388655156" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">511,505</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e34d38bb-03f5-47c6-9982-e0c4ce7500e8" contextRef="C_1b7733fe-22fe-416b-a33e-e8b388655156" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">511,590</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7affcaa1-d0c4-42ba-b2e2-832f03af3ceb" contextRef="C_1b7733fe-22fe-416b-a33e-e8b388655156" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">511,505</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_032bd089-7adf-4458-bedf-e755b2c9cea3" contextRef="C_1b7733fe-22fe-416b-a33e-e8b388655156" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">511,590</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company regularly reviews the changes to the rating of its securities and monitors the surrounding economic conditions to assess the risk of expected credit losses. As of March 31, 2025 and December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, there were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_73777bf9-a0ca-4be0-95ea-151e7dd1d3f6" contextRef="C_b103f351-0eb2-495b-85c1-5630e54c751c" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen"><ix:nonFraction id="F_95663651-fbe2-4d5f-8e89-d834330e5c36" contextRef="C_1b7733fe-22fe-416b-a33e-e8b388655156" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> securities that were in an unrealized loss position for more than 12 months. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the unrealized losses on the Company&#8217;s short-term investments were primarily caused by interest rate increases. The Company does not expect the issuers to settle any security at a price less than the amortized cost basis of the investment with the contractual cash flows of these investments guaranteed by the issuer. No allowance for credit losses has been recorded since it is not more-likely-than-not that the Company will be required to sell the investments before recovery of their amortized cost basis.</span></p></ix:continuation></div><div><ix:nonNumeric id="F_9ed4494a-75fb-49e3-b10b-aed2d3b1d0e4" contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" escape="true" continuedAt="F_9ed4494a-75fb-49e3-b10b-aed2d3b1d0e4_1"><div class="item-list-element-wrapper" style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">4.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Balance Sheet Items </span></div></div><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Prepaid Expenses and Other Current Assets</span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0eee9bc9-531b-41af-bc7a-4f75679411bb" contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b" name="dawn:ScheduleOfPrepaidAndOtherCurrentAssetstableTextBlockTableTextBlock" escape="true"><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prepaid expenses and other current assets consisted of the following (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:76.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:66.967%;box-sizing:content-box;"/>
         <td style="width:1.62%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.897%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.62%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.897%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">March 31,<br/>2025</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,<br/>2024</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid research and development expenses</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d984e44b-c396-44d9-978a-a65d09b415db" contextRef="C_b103f351-0eb2-495b-85c1-5630e54c751c" name="dawn:PrepaidResearchAndDevelopmentExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,733</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_00972291-3c80-4282-9d4f-0c17eb990f33" contextRef="C_1b7733fe-22fe-416b-a33e-e8b388655156" name="dawn:PrepaidResearchAndDevelopmentExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,216</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid insurance</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e2a98ba2-82cc-44a5-817a-b0655e9c5a97" contextRef="C_b103f351-0eb2-495b-85c1-5630e54c751c" name="us-gaap:PrepaidInsurance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">305</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_43dde408-dd3b-4fc2-845a-1787052e43b8" contextRef="C_1b7733fe-22fe-416b-a33e-e8b388655156" name="us-gaap:PrepaidInsurance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">830</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other prepaid expenses and other assets</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_61a06455-16c5-4f4d-9cf8-240df09fd384" contextRef="C_b103f351-0eb2-495b-85c1-5630e54c751c" name="us-gaap:OtherPrepaidExpenseCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,974</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0f0756d1-75b6-4e92-8ce2-fd53bc78ab6c" contextRef="C_1b7733fe-22fe-416b-a33e-e8b388655156" name="us-gaap:OtherPrepaidExpenseCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,367</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total prepaid expenses and other current assets</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2d9b2a53-29dd-48a2-b333-b8e6ae68a08a" contextRef="C_b103f351-0eb2-495b-85c1-5630e54c751c" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,012</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4e2e0296-08fa-47d3-9d5b-1aa4b625f70c" contextRef="C_1b7733fe-22fe-416b-a33e-e8b388655156" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,413</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div></ix:nonNumeric></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div><ix:continuation id="F_9ed4494a-75fb-49e3-b10b-aed2d3b1d0e4_1"><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Accrued Expenses and Other Current Liabilities</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1be0e3e7-cc23-4ee7-979d-d596213428b0" contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" escape="true" continuedAt="F_1be0e3e7-cc23-4ee7-979d-d596213428b0_1"><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accrued expenses and other current liabilities consisted of the following (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:76.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:68.84%;box-sizing:content-box;"/>
         <td style="width:1.26%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.32%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.26%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.32%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">March 31,<br/>2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,<br/>2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued research and development expenses</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fb20fe33-f2bb-4ab0-ad42-289f5e77c644" contextRef="C_b103f351-0eb2-495b-85c1-5630e54c751c" name="dawn:AccruedLicenseAgreementUpfrontPayment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,457</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1e2de41d-0b0b-4edc-a3b8-4f7c8d00e8fc" contextRef="C_1b7733fe-22fe-416b-a33e-e8b388655156" name="dawn:AccruedLicenseAgreementUpfrontPayment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,760</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued rebates</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2d98c760-afaa-454a-a45b-334c1e89214e" contextRef="C_b103f351-0eb2-495b-85c1-5630e54c751c" name="dawn:AccruedRebates" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,008</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d712f54f-eed3-4916-bc75-5572c0d1d6e2" contextRef="C_1b7733fe-22fe-416b-a33e-e8b388655156" name="dawn:AccruedRebates" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,518</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued federal and state taxes</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c7725163-7466-4638-a592-529df2c9782e" contextRef="C_b103f351-0eb2-495b-85c1-5630e54c751c" name="dawn:AccruedFederalAndStateTaxPayments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,966</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ebfef2f5-e4c9-42d5-bc1f-4678c0003573" contextRef="C_1b7733fe-22fe-416b-a33e-e8b388655156" name="dawn:AccruedFederalAndStateTaxPayments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,966</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued professional service expenses</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bcce9027-0c36-4b63-94d6-0c1f5726a65e" contextRef="C_b103f351-0eb2-495b-85c1-5630e54c751c" name="us-gaap:AccruedProfessionalFeesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,943</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_965fbf13-e292-4953-9162-d6f8806a952e" contextRef="C_1b7733fe-22fe-416b-a33e-e8b388655156" name="us-gaap:AccruedProfessionalFeesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,758</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued payroll related expenses</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1fa1782f-2cf0-459b-93a4-c81c8c4ad212" contextRef="C_b103f351-0eb2-495b-85c1-5630e54c751c" name="dawn:AccruedPayrollRelatedExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,202</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4070a4b9-2089-44b6-b4d5-67190974de85" contextRef="C_1b7733fe-22fe-416b-a33e-e8b388655156" name="dawn:AccruedPayrollRelatedExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,943</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued milestone payment</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8f08c72e-17f5-47ac-bfb3-e0b70743d2c7" contextRef="C_b103f351-0eb2-495b-85c1-5630e54c751c" name="dawn:AccruedMilestonePayment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,000</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7cd7a541-d15c-4d87-9b16-e4362daa2f15" contextRef="C_1b7733fe-22fe-416b-a33e-e8b388655156" name="dawn:AccruedMilestonePayment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,000</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2dd6841d-dc06-4993-be17-01d440693d52" contextRef="C_b103f351-0eb2-495b-85c1-5630e54c751c" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,065</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bb6d480c-b1ed-4cfe-9f24-73ce70088230" contextRef="C_1b7733fe-22fe-416b-a33e-e8b388655156" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,680</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total accrued expenses and other current liabilities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f601b69e-1b2c-4fd3-90f0-c73df0e3346b" contextRef="C_b103f351-0eb2-495b-85c1-5630e54c751c" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">43,641</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_80bbb80e-acae-49f5-bba1-6fae46ff49e1" contextRef="C_1b7733fe-22fe-416b-a33e-e8b388655156" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">68,625</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div></ix:continuation></div><div><ix:continuation id="F_1be0e3e7-cc23-4ee7-979d-d596213428b0_1"></ix:continuation></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e2f0cf4d-f16b-419c-b9f3-43cd01d2a047" contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b" name="us-gaap:IntangibleAssetsDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5. Intangible Assets</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9ec26968-af5e-4f07-a60f-efa7e4a5e8b3" contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Intangible assets, net consisted of the following:</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:68.84%;box-sizing:content-box;"/>
         <td style="width:1.26%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.32%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.26%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.32%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">March 31,<br/>2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,<br/>2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Intangible assets with finite lives:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">License agreement milestone payments</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0db8151d-adda-41eb-86e7-1a299c172d17" contextRef="C_23977cdf-3070-48c6-b19d-11d5afb96e9a" name="us-gaap:FiniteLivedIntangibleAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,500</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2b5cdb4b-0ff5-41e2-83e3-5cd6834533fa" contextRef="C_5cceec90-fafe-4db7-b0a1-8211d20a03b7" name="us-gaap:FiniteLivedIntangibleAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,000</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">PRV-related obligation payment</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d93e8cf3-3872-47ad-8487-ba3cfa90261e" contextRef="C_80830bed-79cc-4012-a094-ef9b93307718" name="us-gaap:FiniteLivedIntangibleAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,100</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_689659d5-a15c-4067-be6f-2e244ce865c7" contextRef="C_9c3764ad-c7bb-4bf4-a68b-e200db91be51" name="us-gaap:FiniteLivedIntangibleAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,100</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Intangible assets, gross</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d0080482-9dcc-45e7-8031-97d72f0201f6" contextRef="C_b103f351-0eb2-495b-85c1-5630e54c751c" name="us-gaap:FiniteLivedIntangibleAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">22,600</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1ab4dbd1-9573-4643-a1ed-db72f51f1aca" contextRef="C_1b7733fe-22fe-416b-a33e-e8b388655156" name="us-gaap:FiniteLivedIntangibleAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,100</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less accumulated amortization</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_702c533f-55b2-4f3b-94bb-d4609980eae3" contextRef="C_b103f351-0eb2-495b-85c1-5630e54c751c" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,195</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4d537071-d543-4827-af1c-8b408fdf9799" contextRef="C_1b7733fe-22fe-416b-a33e-e8b388655156" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,470</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Intangible assets, net</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7f104227-6cc9-4960-ac3b-1451c009bf10" contextRef="C_b103f351-0eb2-495b-85c1-5630e54c751c" name="us-gaap:FiniteLivedIntangibleAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,405</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_13846300-1835-49b3-9c0d-36f04ce3cb82" contextRef="C_1b7733fe-22fe-416b-a33e-e8b388655156" name="us-gaap:FiniteLivedIntangibleAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,630</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company incurred amortization expense of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_40423762-5e75-4766-8965-4cc4f8da66a3" contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b" name="us-gaap:AmortizationOfIntangibleAssets" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three months ended March 31, 2025.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c69429e9-a946-4adf-a32d-e3897e5a74f1" contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The estimated aggregate amortization expense for amortizable, finite-lived intangible assets as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 31, 2025 is as follows:</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:70.56%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:27.439999999999998%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ending December 31,</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Estimated<br/>Amortization<br/>Expense</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2025 (Remaining)</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_89279f8e-7f2c-4930-9aaf-42b7c3aa9d4f" contextRef="C_b103f351-0eb2-495b-85c1-5630e54c751c" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,385</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2026</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ce3534ff-5904-4e75-b149-4841cc5e5914" contextRef="C_b103f351-0eb2-495b-85c1-5630e54c751c" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,180</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2027</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_807763b5-37ad-4e21-a4bd-90c8d3ed6914" contextRef="C_b103f351-0eb2-495b-85c1-5630e54c751c" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,180</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2028</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_38dc264a-7683-4830-8ad1-3eed6fdd5882" contextRef="C_b103f351-0eb2-495b-85c1-5630e54c751c" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,180</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2029</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b0ff28db-af69-41e7-ad99-8bd6c10f9728" contextRef="C_b103f351-0eb2-495b-85c1-5630e54c751c" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,180</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Thereafter</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_40040eb0-4ebb-4e34-9761-a88299ed7bb2" contextRef="C_b103f351-0eb2-495b-85c1-5630e54c751c" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,300</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total future expected amortization expense</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_03465e73-f62d-4925-b7cd-020ebd631764" contextRef="C_b103f351-0eb2-495b-85c1-5630e54c751c" name="us-gaap:FiniteLivedIntangibleAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,405</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div><ix:nonNumeric id="F_79d29752-12c2-4b8d-9e41-21c880df84b8" contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" escape="true" continuedAt="F_79d29752-12c2-4b8d-9e41-21c880df84b8_1"><div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">6.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Significant Agreements</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Takeda asset purchase agreement</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On December 16, 2019, a subsidiary of the Company entered into an asset purchase agreement, or the Takeda Asset Agreement, with Millennium Pharmaceuticals, Inc., a related party and an affiliate of Takeda Pharmaceutical Company Limited, or Takeda. Effective December 31, 2021, the subsidiary was merged with and into the Company, with the Company being the surviving corporation and assuming the subsidiary&#8217;s obligations under the Takeda Asset Agreement. Pursuant to the Takeda Asset Agreement, the Company purchased certain technology rights and know-how related to TAK-580 (which is now OJEMDA&#153; (tovorafenib)) that provides a new approach for treating patients with primary brain tumors or brain metastases of solid tumors. The Company also received clinical inventory supplies to use in the Company's research and development activities of such RAF-inhibitor and an assigned investigator clinical trial agreement. Takeda also assigned to the Company its exclusive license agreement, or the Viracta License Agreement, with Viracta. Takeda also granted the Company a worldwide, sublicensable exclusive license under specified patents and know-how and non-exclusive license under other patents and know-how generated by Takeda under the Takeda Asset Agreement. The Company also granted Takeda a grant back license, as defined in the Takeda Asset Agreement, which is terminable either automatically or by the Company in the event Takeda does not achieve specified development milestones within the applicable timeframes set forth under the Takeda Asset Agreement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div><ix:continuation id="F_79d29752-12c2-4b8d-9e41-21c880df84b8_1" continuedAt="F_79d29752-12c2-4b8d-9e41-21c880df84b8_2"><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This grant back license to Takeda was terminated at the time of conversion of the Company from an LLC to a corporation in connection with the Millennium Stock Exchange Agreement.</span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The term of the Takeda Asset Agreement will expire on a country-by-country basis upon expiration of all assigned patent rights and all licensed patent rights in such country. Takeda can terminate the Takeda Asset Agreement in the event of the Company's bankruptcy. In the event of termination of the Takeda Asset Agreement by Takeda as a result of the Company's cessation of development or bankruptcy, all assigned patents, know-how and contracts (other than the Viracta License Agreement) will be assigned back to Takeda and Takeda will obtain a reversion license under patents and know-how generated to exploit all such terminated products.</span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In consideration for the sale and assignment of assets and the grant of the license under the Takeda Asset Agreement, the Company made an upfront payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0a7da810-9f23-4814-8318-3f4beb38cfd9" contextRef="C_e9b4d1c1-00d7-4c4a-8ead-1b510859ed98" name="dawn:UpfrontOfCashPayment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in cash and issued </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bd5a1bc6-b37a-4fb8-8c56-5a1ca5ebf106" contextRef="C_b18881d4-5741-464f-8b09-c6e20048b1ff" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">9,857,143</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Series A redeemable convertible preferred stock in the Company&#8217;s subsidiary in December 2019. The fair value of issued shares was estimated as $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_111196fd-05d8-40bd-8733-e3d852307667" contextRef="C_b18881d4-5741-464f-8b09-c6e20048b1ff" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">9.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, based on the price paid by other investors for issued shares in the Series A financing of the Company&#8217;s subsidiary. Based on the terms of the Millennium Stock Exchange Agreement, Takeda exchanged the </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a36fb902-95dd-4cee-ba9e-11c128f145fa" contextRef="C_d33c859c-b7aa-4b79-9a88-d16340c5fe28" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">9,857,143</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Series A redeemable convertible preferred stock of the Company&#8217;s subsidiary for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0518ac3f-868c-4375-b875-904309f404c3" contextRef="C_cc903eab-f003-453f-ad1c-4dd61852d801" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">6,470,382</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of the Company's common stock upon the effectiveness of the conversion of the Company from an LLC to a corporation, on May 26, 2021.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">License agreement with Viracta</span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On December 16, 2019, a subsidiary of the Company amended and restated the Viracta License Agreement that was assigned pursuant to the Takeda Asset Agreement. Effective December 31, 2021, the subsidiary was merged with and into the Company, with the Company being the surviving corporation and assuming the subsidiary&#8217;s obligations under Viracta License Agreement. Under the Viracta License Agreement, the Company received a worldwide exclusive license under specified patent rights and know-how to develop, use, manufacture, and commercialize products containing compounds binding the RAF protein family.</span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The term of the Viracta License Agreement will expire on a licensed product-by-licensed product and country-by-country basis upon the expiration of the Company&#8217;s obligation to pay royalties to Viracta with respect to such product in such country. The Company has the right to terminate the Viracta License Agreement with respect to any or all of the licensed products at will upon a specified notice period.</span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company paid $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0d8d51a4-0c5e-4258-acfa-db4fa4e3b2a7" contextRef="C_3c61836b-73ea-4fb6-bc25-ae73f9f94d9d" name="dawn:UpfrontOfCashPayment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million upfront in cash to Viracta in December 2019, which was recorded as research and development expenses as the technology does not have an alternative future use.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On March 4, 2024, the Company entered into an amendment to the Viracta License Agreement. As part of the amendment, the Company made a one-time payment in March 2024 to Viracta of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c08d998e-3979-47bd-9d84-52db10bb19bc" contextRef="C_ca787bd4-a367-40e2-8820-37c26a26c233" name="dawn:UpfrontPayment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, which was recorded as research and development expenses during the year ended December 31, 2024, in exchange for reduced future payment obligations ranging from the mid-teens to the high single-digit percentage related to the future sale or use of the rare pediatric disease priority review voucher, or PRV, received.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On April 23, 2024, the FDA approved OJEMDA (a tablet formulation and powder solution formulation of tovorafenib) for the treatment of patients 6 months of age and older with relapsed or refractory pLGG harboring a BRAF fusion or rearrangement, or BRAF V600 mutation. The indication was approved under accelerated approval based on response rate and duration of response. With the approval, the Company received a rare pediatric disease PRV from the FDA. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company made a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e6c3b2e3-ae19-419e-ba03-51f5d23fe7e7" contextRef="C_6ad97ba9-d866-451d-a09a-4e4e40d00691" name="dawn:PaymentOfMilestones" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">9.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million milestone payment to Viracta in May 2024 for the achievement of this milestone. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_52c76b70-49f2-4f37-b743-74aa909de48c" contextRef="C_966510c1-eaf6-4a1c-9fae-2da70fcc6537" name="dawn:PaymentOfMilestones" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">9.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million milestone was accounted for as a </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">finite-lived intangible asset and will be amortized over the life of the underlying asset. Related amortization expense will be recorded as cost of product revenue in the Company&#8217;s statements of operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On May 29, 2024, the Company sold its rare pediatric disease PRV for $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_24db83aa-cb53-46b9-ad4a-77d1b690a651" contextRef="C_74bf62ce-416a-4686-8cdc-9e58e09531b6" name="us-gaap:ProceedsFromSaleOfProductiveAssets" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">108.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million to an undisclosed buyer. As part of the transaction, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ba46d8ba-f8a3-4c9f-87e8-3dd3fd764d24" contextRef="C_74bf62ce-416a-4686-8cdc-9e58e09531b6" name="dawn:PaymentToObligationOfLicenseAgreement" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">8.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of the total consideration received from the sale of the rare pediatric disease PRV was paid to Viracta to fully satisfy PRV-related obligations under the Viracta License Agreement and was capitalized as a finite-lived intangible asset, which will be amortized on a straight-line basis over its estimated useful life. The gross proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_503e67f9-84b3-41b8-8dfd-6e3c7b6ed6b2" contextRef="C_1012909a-67d0-4f8d-9538-ec497e5c24af" name="us-gaap:ProceedsFromSaleOfProductiveAssets" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">108.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million were recorded as a gain from sale of priority review voucher in the accompanying statements of operations during the year ended December 31, 2024. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the unamortized finite-lived intangible asset was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c1ae3286-648d-4f7b-9cb1-e9c38564e31f" contextRef="C_491e1be7-189f-4d71-b2f9-eac0bf60040c" name="us-gaap:FiniteLivedIntangibleAssetsNet" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">7.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. Related amortization expense will be recorded as cost of product revenue in the Company&#8217;s statements of operations.</span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On December 3, 2024, Viracta assigned the Viracta License Agreement to XOMA (US) LLC, or XOMA, pursuant to a Royalty Purchase Agreement dated March 22, 2021, between Viracta and XOMA, whereby Viracta sold its right, title, and interest in and to the Viracta License Agreement to XOMA. The Company has agreed to the assignment and novation of the Viracta License Agreement to XOMA as successor party, now referred to as the XOMA License Agreement. In connection with such assignment, the parties also agreed to assign all rights, title and interest in related intellectual property. No material terms of the XOMA License Agreement have been amended or modified in relation to the same.</span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:continuation></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div><ix:continuation id="F_79d29752-12c2-4b8d-9e41-21c880df84b8_2" continuedAt="F_79d29752-12c2-4b8d-9e41-21c880df84b8_3"><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On March 27, 2025, Ipsen Pharma SAS received validation of its completed submission of the Marketing Authorization Application to the European Medicines Agency, or EMA, for tovorafenib for the treatment of patients with relapsed or refractory pLGG. As a result, the Company paid $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_62392313-0cc2-434d-a91f-e76f33605fad" contextRef="C_ca7ef576-0ffb-4b1b-9387-f848fc7d1ea5" name="dawn:PaymentOfMilestones" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">4.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million to XOMA for the achievement of this milestone in March 2025.</span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of March 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company could be required to make additional milestone payments of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_87626e68-36a9-4d55-9444-a166c0dbb91d" contextRef="C_3c61836b-73ea-4fb6-bc25-ae73f9f94d9d" name="dawn:PaymentOfMilestones" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">36.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million upon achievement of specified development and regulatory milestones for each licensed product in two indications, with milestones payable for the second indication upon achievement of a specified milestone event being lower than milestones payable for the first indication. Commencing with the first commercial sale of OJEMDA in a country, the Company is obligated to pay tiered royalties ranging in the mid-single-digit percentages on net sales of licensed products. The obligation to pay royalties will end on a country-by-country and licensed product-by-licensed product basis commencing on the first commercial sale in a country and continuing until the later of: (i) the expiration of the last valid claim of the XOMA licensed patents, jointly owned collaboration patents or specified patents owned by the Company covering the use or sale of such product in such country, (ii) the expiration of the last statutory exclusivity pertaining to such product in such country or (iii) the tenth anniversary of the first commercial sale of such product in such country.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">License agreement with Merck KGaA, Darmstadt, Germany</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On February 10, 2021, a subsidiary of the Company entered into a license agreement, or the MRKDG License Agreement, with Merck KGaA, Darmstadt, Germany, a pharmaceutical corporation located in Darmstadt, Germany. Effective December 31, 2021, the subsidiary was merged with and into the Company, with the Company being the surviving corporation and assuming the subsidiary&#8217;s obligations under the MRKDG License Agreement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the MRKDG License Agreement, Merck KGaA, Darmstadt, Germany granted to the Company an exclusive worldwide license, with the right to grant sublicenses through multiple tiers, under specified patent rights and know-how for the Company to research, develop, manufacture and commercialize products containing and comprising the pimasertib and MSC2015103B compounds. The Company also received clinical inventory supplies to use in its research and development activities. The Company's exclusive license grant is subject to a non-exclusive license granted by Merck KGaA, Darmstadt, Germany&#8217;s affiliate to a cancer research organization and Merck KGaA, Darmstadt, Germany retains the right to conduct, directly or indirectly, certain ongoing clinical studies relating to pimasertib. Under the MRKDG License Agreement, the Company has obligations to use commercially reasonable efforts to develop and commercialize at least two licensed products in at least two specified major market countries by the year 2029.</span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The term of the MRKDG License Agreement will expire on a licensed product-by-licensed product and country-by-country basis upon the expiration of the Company's obligation to pay royalties to the licensor with respect to such licensed product in such country and will expire in its entirety upon the expiration of all of the Company's payment obligations with respect to all licensed products and all countries under the MRKDG License Agreement.</span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In consideration for the rights granted under the MRKDG License Agreement and clinical supplies, the Company made an upfront payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_430e9dac-23a4-4ccc-86dd-533af793f825" contextRef="C_3488a8c4-e12f-41ec-89c7-dac4e84ea67e" name="dawn:UpfrontPayment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">8.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in March 2021, which was recorded as research and development expenses, as the technology does not have an alternative future use and supplies are used for research activities. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company could be required to make additional payments of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_08b600b5-4a53-41df-929a-4bb6cd9caf6b" contextRef="C_3488a8c4-e12f-41ec-89c7-dac4e84ea67e" name="dawn:MilestonePaymentsNotYetPaid" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">364.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million based upon the achievement of specified development, regulatory, and commercial milestones, as well a high, single-digit royalty percentage on future net sales of licensed products, if any. Milestones and royalties are contingent upon future events and will be recorded when the milestones are achieved and when payments are due.</span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2023, the Company discontinued its monotherapy substudy due to a limited duration of response in this rare patient population despite observing responses with a generally well tolerated therapy. In July 2024, the Company decided to close the program as the Company determined that the benefit/risk profile, as well as the market opportunity, did not justify the significant investment required to continue the trial despite observing some clinical responses.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research collaboration and license agreement with Sprint Bioscience AB</span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On August 15, 2023, the Company entered into a research collaboration and license agreement, or the Sprint License Agreement, with Sprint Bioscience AB, or Sprint, a Swedish corporation located in Huddinge, Sweden. Under the Sprint License Agreement, Sprint granted to the Company an exclusive, worldwide license, with the right to grant sublicenses through multiple tiers, to research, develop, and commercialize pharmaceutical products and to engage in research aimed at discovery, optimization and development of an inhibitor targeting Vaccinia Related Kinase 1, or VRK1.</span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The term of the Sprint License Agreement will expire on a licensed product and country basis upon the expiration of the royalty term with respect to such licensed product and such country, unless terminated earlier. The Company has the right to terminate the Sprint License Agreement in its entirety, or on a licensed product-by-licensed product basis, at will upon a specified notice period.</span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company paid $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_40752c42-9d6e-4d17-a9d9-117664fbdb80" contextRef="C_ef89ab97-3fce-42e2-a82b-c2a5c9189a28" name="dawn:UpfrontPayment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million upfront in cash to Sprint in September 2023, which was recorded as research and development expenses as the technology does not have an alternative future use. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the Company could be</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:continuation></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">15</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div><ix:continuation id="F_79d29752-12c2-4b8d-9e41-21c880df84b8_3" continuedAt="F_79d29752-12c2-4b8d-9e41-21c880df84b8_4"><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">required </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to make milestone payments of up to </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c5e26be0-f1cb-457c-a2c3-ebba6942e8f9" contextRef="C_429b0413-0de5-4e2b-b3ca-8e5807492a3e" name="dawn:MilestonePaymentsNotYetPaid" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">309.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million based upon achievement of specified development, regulatory, and commercial milestones for each licensed product, as well as tiered royalties ranging in the single-digit percentages on future net sales of licensed products, if any. Milestones and royalties are contingent upon future events and will be recorded when the milestones are achieved and when payments are due.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">License agreement with MabCare Therapeutics</span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On June 17, 2024, the Company entered into a license agreement, or the MabCare License Agreement, with MabCare Therapeutics, or MabCare, a pharmaceutical corporation located in Shanghai, China. Under the MabCare License Agreement, MabCare granted to the Company an exclusive worldwide license, excluding Greater China, with the right to grant sublicenses through multiple tiers, under specified patent rights and know-how for the Company to develop, manufacture and commercialize DAY301 (formerly MTX-13), a novel Antibody Drug Conjugate, or ADC, targeting protein-tyrosine kinase 7, or PTK7. The Company will also receive clinical inventory supplies to use in its research and development activities. Under the MabCare License Agreement, the Company has obligations to use commercially reasonable efforts to develop, obtain regulatory approval for, and commercialize at least one licensed product in one indication in each of the United States, Japan, and three European countries.</span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The term of the MabCare License Agreement will expire in its entirety upon the expiration of the last to expire royalty term with respect to all licensed products in the Company's territory, unless terminated earlier. Following the expiration of the royalty term for a licensed product in a country, the license granted to the Company shall become non-exclusive, fully paid-up, royalty-free, perpetual, and irrevocable for such licensed product in such country. Upon the expiration of the term, the license granted to the Company shall become non-exclusive, transferable, sublicensable, fully paid, royalty free, perpetual, and irrevocable in its entirety.</span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In consideration for the rights granted under the MabCare License Agreement, the Company made a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a2023928-0802-4585-9be8-d7511700a427" contextRef="C_3b446226-328f-479e-b281-6a7fd0379692" name="dawn:UpfrontPayment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">55.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million upfront payment in July 2024. The upfront payment was recorded as research and development expenses, as the technology and supplies licensed do not have an alternative future use. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company could be required to make additional payments of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bf9354ea-a37d-4d65-bc3b-307939d46621" contextRef="C_88ef0d56-c34a-4726-8307-009388d0ca1d" name="dawn:MilestonePaymentsNotYetPaid" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1,132.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million based upon the achievement of specified development, regulatory, and commercial success-based milestones plus low-to-mid single-digit royalties on net sales outside of Greater China. Milestones and royalties are contingent upon future events and will be recorded when the milestones are achieved and when payments are due. In January 2025, the Company cleared the first cohort (a single-patient accelerated titration cohort) in the Phase 1a portion of the DAY301 Phase 1a/b clinical trial. The Company made a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5b5fcb4a-97f2-410b-8d9d-81ca2349c756" contextRef="C_88ef0d56-c34a-4726-8307-009388d0ca1d" name="dawn:PaymentOfMilestones" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">20.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million milestone payment to MabCare in January 2025 for the achievement of this milestone.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">License agreement with Ipsen Pharma SAS</span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On July 23, 2024, the Company entered into the Ipsen License Agreement, pursuant to which, the Company licensed to Ipsen, on an exclusive basis, the right to commercialize tovorafenib in all territories outside the United States and agreed to provide certain research and development and manufacturing services. Ipsen shall have the right to grant sublicenses to third-parties.</span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the terms of the Ipsen License Agreement, (i) Ipsen paid the Company an upfront license fee in the amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f524b1b6-c1da-4d21-b37d-4c2655eeae62" contextRef="C_6c0cbe2c-a995-47f4-a87e-6d13cd05d122" name="dawn:UpfrontPayment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">70.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in August 2024 and (ii) the Investor, a fully-owned United States affiliate of Ipsen, purchased </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_00da296b-8a26-4cf8-a47c-162bd4222ece" contextRef="C_4a5ebb63-8e69-4e8d-bc72-3ec0c91774e6" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">2,341,495</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">shares of the Company&#8217;s common stock in a private placement for $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3b1282c4-588f-4974-9cc1-bb9c573f3e87" contextRef="C_1bd10525-22f6-4072-ab95-5fd14d1f9842" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">40.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, at a price per share representing a </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7d77c138-d6ee-4522-b06c-e20f1795557a" contextRef="C_4a5ebb63-8e69-4e8d-bc72-3ec0c91774e6" name="dawn:VolumeWeightedAveragePrice" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">17.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% premium to the VWAP of the Company&#8217;s common stock as traded on The Nasdaq Stock Market LLC for the ten consecutive trading days prior to and including the date of the Revenue Release, and the ten consecutive trading days following the Revenue Release, in accordance with the terms set forth in an investment agreement by and between the Company and the Investor dated July 23, 2024.</span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of March 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company is also eligible to receive up to approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f43a628d-6cfd-4b8b-b150-ecce32278bbd" contextRef="C_cd3e5fd3-74ef-469d-8938-ed22cb45f3fd" name="dawn:MilestonePaymentsNotYetReceived" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">350.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in additional commercial launch and sales-based milestone payments based on exchange rates as of the reporting date. The Company is also entitled to tiered, double-digit royalty payments starting at mid-teens percentage of annual net sales of tovorafenib, subject to customary adjustments specified in the Ipsen License Agreement. The royalty payment obligations under the Ipsen License Agreement expire on a country-by-country basis no earlier than ten years following the first commercial sale of tovorafenib in the applicable country.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, the Ipsen License Agreement provides that the Company will supply to Ipsen, and Ipsen will purchase from the Company, all required quantities of tovorafenib for all territories outside the United States in accordance with a supply agreement to be entered into by and between the Company and Ipsen, or the Ipsen Supply Agreement. The Company determined that the cost-plus rate to be charged for the supply of tovorafenib does not represent a material right. Ipsen has the right to request a manufacturing technology transfer of the then-current manufacturing process of tovorafenib under the Ipsen License Agreement, and such consent shall not be unreasonably withheld, such that upon completion of the manufacturing technology transfer, Ipsen or a third-party would be solely responsible for the manufacture of tovorafenib for all territories outside the United States.</span></p></ix:continuation></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">16</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_79d29752-12c2-4b8d-9e41-21c880df84b8_4"><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Following the two-year anniversary of July 23, 2024, the effective date of the Ipsen License Agreement, Ipsen may terminate the Ipsen License Agreement for convenience with six months&#8217; prior written notice or for certain other specified reasons. The Company may terminate the Ipsen License Agreement if Ipsen or any of its affiliates challenge the validity of any patents controlled by the Company that are licensed under the Ipsen License Agreement. Both Ipsen and the Company may terminate the Ipsen License Agreement (i) for material breach by the other party and a failure to cure such breach within the time period specified in the Ipsen License Agreement or (ii) the other party&#8217;s bankruptcy event.</span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company evaluated the Ipsen License Agreement under Accounting Standards Codification, or ASC, 606 and concluded that Ipsen represents a customer in the transaction. The Company identified two distinct performance obligations for licenses to intellectual property in the form of the exclusive license to </span><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">commercialize tovorafenib outside the United States for both (i) relapsed or </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">refractory and (ii) front-line pLGG;</span><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and three distinct research and development performance obligations related to tovorafenib for completion of (i) the pivotal Phase 2 relapsed or refractory pLGG trial, or FIREFLY-1, (ii) the pivotal Phase 3 front-line pLGG trial, or FIREFLY-2, and (iii) the European Union, or EU, companion diagnostic for pLGG. Both the FIREFLY-1 and FIREFLY-2 trials related to pLGG pertain to later-stage intellectual property and only involve validating the efficacy of tovorafenib with respect to each distinct designation and are not expected to significantly modify or customize the licensed intellectual property. The FIREFLY-1 and FIREFLY-2 trials, and EU companion diagnostic research and development services related to pLGG could be performed by a third-party. The Company determined that the promise of the manufacturing technology transfer is a customer option that does not represent a material right given the value of the services is not material and fulfillment of this promise is ancillary to the main transaction. Accordingly, the manufacturing technology transfer is not a performance obligation at the outset of the arrangement.</span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Upon execution of the Ipsen License Agreement, the transaction price was determined to be $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_481055df-085a-449f-aa84-6903eff89a86" contextRef="C_1bd10525-22f6-4072-ab95-5fd14d1f9842" name="dawn:TransactionPrice" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">78.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, representing the aggregate of the upfront license fee of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b1d6690e-72b2-4c9d-894d-48bcc2313228" contextRef="C_6c0cbe2c-a995-47f4-a87e-6d13cd05d122" name="dawn:UpfrontPayment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">70.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and the premium paid by Ipsen on its equity investment in the Company of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_df8e1e1d-1038-4cc6-9ef9-c7528172b778" contextRef="C_5c990fe2-3f39-456d-8159-af4c23323a1d" name="us-gaap:EquityMethodInvestmentUnderlyingEquityInNetAssets" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">7.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(the excess of the value of the shares of the Company issued to Ipsen), representing additional consideration from Ipsen for the rights under the Ipsen License Agreement. Commercial launch milestones related to first commercial sale(s) in certain territories, sales-based milestones and royalties on net sales upon commercialization by Ipsen were excluded from the transaction price and will be recognized when the related sales occur as they were determined to predominantly relate to the intellectual property and, therefore, have been excluded from the transaction price in accordance with the sales-based royalty exception.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company allocated the transaction price to the performance obligations based on their relative standalone selling price. The Company developed the estimated stand-alone selling price for each license using discounted cash flow models. In developing this estimate, the Company applied judgment in the determination of the assumptions relating to forecasted future revenues, the discount rate, and the probability of success. The stand-alone selling price for each of the research and development services was estimated based on the Company&#8217;s forecasted costs to be incurred to fulfill the obligations plus a reasonable margin. The portion of the transaction price allocable to the</span><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> relapsed or </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">refractory and front-line pLGG</span><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">licenses to intellectual property was recognized as license revenue at the point in time in which Ipsen had the right to use the license/know-how, which occurred during the year ended December 31, 2024. The portion of the transaction price allocable to the </span><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">relapsed or </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">refractory, front-line and companion diagnostic research and development services performance obligations will be recognized over time as the services are delivered based on costs incurred relative to the total estimated cost to deliver the services. During the three months ended March 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_11261d9b-8025-4883-8ea7-e374eef3e624" contextRef="C_cd3e5fd3-74ef-469d-8938-ed22cb45f3fd" name="dawn:LicenseRevenue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of license revenue was recognized with $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e44ea41a-981b-4ddd-b24a-7ef274831d26" contextRef="C_6efcf18f-0833-44b1-8d9a-6ebe85307a08" name="us-gaap:DeferredRevenueCurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ef7331c2-d9c9-40c0-b5e2-83ae2af3f4c5" contextRef="C_a356b3ae-e91c-4aa9-82fb-80206cb22503" name="us-gaap:DeferredRevenueNoncurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of the undelivered services included in current and non-current deferred revenue, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:continuation></div><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div><ix:nonNumeric id="F_7567309d-adc0-4135-9719-4b604c1cb212" contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" escape="true" continuedAt="F_7567309d-adc0-4135-9719-4b604c1cb212_1"><div class="item-list-element-wrapper" style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">7.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Commitments and Contingencies </span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Leases</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In April 2022, the Company entered into a lease agreement for approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0671d7f7-0891-4b7c-8aec-19870e8aa1f6" contextRef="C_ab5b8469-0456-4d89-a289-b75cc0f4a77c" name="us-gaap:AreaOfLand" unitRef="U_sqft" decimals="0" format="ixt:num-dot-decimal">12,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> square feet of general use office space in Brisbane, California. The agreement was determined to be a lease since the right to control the use of the identified asset was conveyed to the Company for a period of time in exchange for consideration. The lease commenced in May 2022 and expired in November 2024. The Company was obligated to pay monthly rent expense and its pro rata share of the landlord's operating expenses which include utilities, common area maintenance expenses, and property taxes. Such expenses were a non-lease component and a variable consideration and included in the Company's operating expenses as incurred. The Company concluded that this lease was an operating lease.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">17</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div><ix:continuation id="F_7567309d-adc0-4135-9719-4b604c1cb212_1" continuedAt="F_7567309d-adc0-4135-9719-4b604c1cb212_2"><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In June 2024, the Company entered into a lease agreement for approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_41903056-cc9b-4879-8453-3bba2a503167" contextRef="C_92096138-dcf7-4329-ae91-d02c48ac8ed0" name="us-gaap:AreaOfLand" unitRef="U_sqft" decimals="0" format="ixt:num-dot-decimal">19,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> square feet of general use office space in Brisbane, California. The agreement was determined to be a lease since the right to control the use of the identified asset was conveyed to the Company for a period of time in exchange for consideration. The term of the lease is approximately </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a91a534f-e6ac-48ea-937c-7127eefc4ad0" contextRef="C_2f4d68d5-969e-46de-b564-f0c6755d1515" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7.4</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years and commenced in August 2024. There is no option to extend the lease term nor is there an option to terminate the lease term prior to its expiration. The Company is obligated to pay monthly rent expense and its pro rata share of the landlord's operating expenses which include utilities, common area maintenance expenses, and property taxes. Such expenses are a non-lease component and a variable consideration and included in the Company's operating expenses as incurred. The Company concluded that this lease is an operating lease. The total payments for base rent over the term of the lease is approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d39a7e7b-4cc8-4867-a19b-1ef1e20bdfe8" contextRef="C_8186e570-f43c-44d8-af7f-4d4d7125520a" name="us-gaap:OperatingLeasePayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">4.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. Upon execution of the agreement, the Company paid a security deposit of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_35b90c71-26ef-4cc6-b5ea-bf15c3d2d68a" contextRef="C_92096138-dcf7-4329-ae91-d02c48ac8ed0" name="us-gaap:SecurityDeposit" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">86,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> classified as deposits and other long-term assets on the condensed balance sheet.</span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company determined the lease incremental borrowing rate, or IBR, based on the information available at the applicable lease commencement date as the Company&#8217;s leases do not provide an implicit rate. The IBR is determined by using the rate of interest that the Company would pay to borrow on a collateralized basis an amount equal to the lease payments for a similar term and in a similar economic environment where the asset is located. As of March 31, 2025, the weighted-average remaining lease term and weighted-average discount rate were </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0249cd5b-c46e-465a-8450-a07352885b21" contextRef="C_b103f351-0eb2-495b-85c1-5630e54c751c" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6.5</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f107ca95-0a53-4cb7-99fd-d734ad87f589" contextRef="C_b103f351-0eb2-495b-85c1-5630e54c751c" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">12.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively.</span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s leases do not require any contingent rental payments, impose financial restrictions, or contain any residual value guarantees.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Lease expense of right-of-use assets is recognized on a straight-line basis over the applicable lease term. Lease expense was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6462f02c-4851-4211-9357-5503fdf7a805" contextRef="C_fd1aa0b8-3528-4b28-9293-cf863f031981" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal"><ix:nonFraction id="F_27b4e436-a277-46d4-9326-e6087c2547f6" contextRef="C_6aaeb9ec-3a51-423c-ad71-3fa489ff189c" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.1</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for the three months ended March 31, 2025 and 2024. There was no cash paid for amounts included in the measurement of operating lease liabilities for the three months ended March 31, 2025. Cash paid for amounts included in the measurement of operating lease liabilities was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cdcf7b2b-9408-4ebb-8e57-dac721b49846" contextRef="C_6aaeb9ec-3a51-423c-ad71-3fa489ff189c" name="us-gaap:OperatingLeasePayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for the three months ended March 31, 2024. Variable payments expensed during the three months ended March 31, 2025 and 2024 were immaterial.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f8c7f8a8-02e4-4fed-9842-699f43034870" contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" escape="true"><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 31, 2025, the future lease obligations were as follows (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:81.82%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:16.18%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ending December 31,</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2025 (Remaining)</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b1d44225-c7ee-49ab-aeed-a1e2d1c37c94" contextRef="C_b103f351-0eb2-495b-85c1-5630e54c751c" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">404</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2026</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dd90d6ce-e292-40d6-a811-c6c0b31769af" contextRef="C_b103f351-0eb2-495b-85c1-5630e54c751c" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">527</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2027</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c5de17f6-3a57-4931-9d73-c18bdec2b486" contextRef="C_b103f351-0eb2-495b-85c1-5630e54c751c" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">543</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2028</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_15efd895-6b1d-4b37-b1af-619a0d250569" contextRef="C_b103f351-0eb2-495b-85c1-5630e54c751c" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">492</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2029</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3107678d-4b88-4e86-a4de-5a1debf13060" contextRef="C_b103f351-0eb2-495b-85c1-5630e54c751c" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">711</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Thereafter</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_62a577ab-cfd0-4f2a-a4cb-c642bdd18445" contextRef="C_b103f351-0eb2-495b-85c1-5630e54c751c" name="dawn:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,981</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total future minimum lease payments</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5b1c7cbb-3db4-4444-99f2-bbaf584ab47c" contextRef="C_b103f351-0eb2-495b-85c1-5630e54c751c" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,658</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: imputed interest</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8e4a4539-128e-48b5-9cf6-f5df8c1eb0b0" contextRef="C_b103f351-0eb2-495b-85c1-5630e54c751c" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,742</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Present value of operating lease liabilities</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_64ac51b0-01fb-4353-a797-fbad50733f37" contextRef="C_b103f351-0eb2-495b-85c1-5630e54c751c" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,916</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: current portion of operating lease liabilities</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9bcdcc05-1995-4e2d-b876-3abe4eab6912" contextRef="C_b103f351-0eb2-495b-85c1-5630e54c751c" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">62</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Long-term portion of operating lease liabilities</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8f73b4c1-20a3-4290-ba29-3a67e159c3b6" contextRef="C_b103f351-0eb2-495b-85c1-5630e54c751c" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,854</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and Development Agreements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company enters into contracts in the normal course of business with clinical research organizations, contract manufacturing organizations, and other third-party vendors for clinical trial, manufacturing, testing, and other research and development activities. These contracts generally provide for termination on notice, with the exception of one vendor where certain costs are non-cancellable after the approval of the project. As of March 31, 2025 and December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, there were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8abe0082-ae9b-4829-a58b-e1e35b6abe27" contextRef="C_09d1a768-c6f7-4724-958d-e37516f230d8" name="us-gaap:LossContingencyAccrualAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen"><ix:nonFraction id="F_1751673a-f8a3-405e-bb88-fffc4fbc8f02" contextRef="C_ebb60e12-8f30-4b8b-a830-3f64f4c2ba34" name="us-gaap:LossContingencyAccrualAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> amounts accrued related to termination and cancellation charges as these are not probable.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">License Agreements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company entered into license agreements, as disclosed in Note 6, with various parties under which it is obligated to make contingent and non-contingent payments.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Purchase Commitments</span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To support product needs for OJEMDA, the Company entered into a manufacturing and supply agreement with Quotient Sciences - Philadelphia, LLC in July 2023 that requires the Company to meet minimum purchase obligations on an annual basis. The remaining amount of future minimum purchase obligations under the manufacturing and supply agreement over the next five years is approximately </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ef4d9a6d-017b-4a6b-8fad-167c853564fe" contextRef="C_190b79d3-0ec2-457e-b743-7f9aaa10d94b" name="us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">12.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, in aggregate, as of March 31, 2025. For the three months ended March 31, 2025 and 2024, the Company made purchases of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_62d88a31-6d8f-40b4-8ffa-b9d6f05f1ea6" contextRef="C_5d08cb7b-c76a-4de6-8dca-2d248eef4467" name="dawn:PurchasesUnderThePurchaseObligation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_594d0f22-aa68-4f7f-8191-c2e8131f45f9" contextRef="C_c5ebd5f2-8017-4e7b-b087-5114b6fdabe3" name="dawn:PurchasesUnderThePurchaseObligation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively, under the purchase obligation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Legal Proceedings</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company, from time to time, may be party to litigation, claims and assessments arising in the ordinary course of business. The Company accrues liabilities for such matters when it is probable that future expenditures will be made and such</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:continuation></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">18</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_7567309d-adc0-4135-9719-4b604c1cb212_2"><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">expenditures can be reasonably estimated. The Company is not subject to any material legal proceedings, and to the best of its knowledge, no material legal proceedings are currently pending or threatened.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Indemnification Agreements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and provide for indemnification for certain liabilities. The exposure under these agreements is unknown because it involves claims that may be made against it in the future but have not yet been made. To date, the Company has not paid any claims or been required to defend any action related to its indemnification obligations. However, the Company may record charges in the future as a result of these indemnification obligations. The Company also has indemnification obligations to its directors and executive officers for specified events or occurrences, subject to some limits, while they are serving at its request in such capacities. There have been no claims to date, and the Company believes the fair value of these indemnification agreements is minimal. Accordingly, the Company had </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c6bf0bc0-9b0c-4305-9917-2a45b5cc4761" contextRef="C_2e6bdcde-a879-4a55-aaf6-c92b45ed690a" name="us-gaap:LossContingencyAccrualAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen"><ix:nonFraction id="F_e1329753-44dd-42e1-b08d-dba2adee4645" contextRef="C_14897498-6682-45a8-b5bc-6360e09cde1d" name="us-gaap:LossContingencyAccrualAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t recorded any liabilities for these agreements as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 31, 2025 and December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p></ix:continuation></div><div><ix:nonNumeric id="F_f4375883-f708-4c9a-b463-7fd6df3b82f4" contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" escape="true" continuedAt="F_f4375883-f708-4c9a-b463-7fd6df3b82f4_1"><div class="item-list-element-wrapper" style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">8.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Common Stock </span></div></div><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to its certificate of incorporation, the Company is authorized to issue </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_23f10c48-6f13-472c-9755-31a17eb0715b" contextRef="C_2896a425-ea56-4272-8792-62ad898655c5" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" scale="6" decimals="-5" format="ixt:num-dot-decimal">500.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million shares of common stock at a par value of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d3ef6aa7-2ef0-4d2e-b71f-99d43c9270ea" contextRef="C_2896a425-ea56-4272-8792-62ad898655c5" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">0.0001</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 31, 2025, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_26f00029-172d-4a28-b302-441612aa7370" contextRef="C_b103f351-0eb2-495b-85c1-5630e54c751c" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_988188e4-a5ed-4842-b19f-3eed0542334e" contextRef="C_b103f351-0eb2-495b-85c1-5630e54c751c" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">101,353,781</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock were issued and outstanding.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_df498bab-49a3-42f3-aa32-73387aea7fcd" contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b" name="dawn:ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock" escape="true"><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has reserved shares of common stock for future issuances as follows:</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:69.66%;box-sizing:content-box;"/>
         <td style="width:2.62%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:25.72%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">March 31,<br/>2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common stock options issued and outstanding</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_306c7289-8074-45bb-b699-da34bac29beb" contextRef="C_145e429b-05a9-4c43-8d23-41fa26213179" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">14,055,674</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common stock available for future grants</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2d741296-38e1-44ca-bee8-85835f663e12" contextRef="C_0ddc2569-0696-4885-b32d-8451ee567481" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">5,393,445</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common stock available for ESPP</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1f81d0b0-c4a2-4c03-82bb-b3058c8a0520" contextRef="C_2d38634e-b453-46b0-9ce4-c47fae6625de" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">3,448,112</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restricted stock units issued and outstanding</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_656dd46c-f53f-46ca-a7ae-f50329a1e402" contextRef="C_f1827e81-e977-406d-8a9b-6f880a33cdfe" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">2,856,820</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Pre-funded warrants</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0f2be637-fc7a-492d-a474-4e7ae298c542" contextRef="C_494cf197-0008-4f30-9715-0a6b5cf186d6" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,517,241</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ef098990-0822-4174-adb7-4aa4dc65e1a3" contextRef="C_b103f351-0eb2-495b-85c1-5630e54c751c" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">27,271,292</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">2024 Private Placement</span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In July 2024, the Company entered into a securities purchase agreement with certain institutional and accredited investors, or the PIPE Investors, pursuant to which the Company agreed to sell and issue to the PIPE Investors in a private placement, or the Private Placement, an </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">aggregate of (i) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_47489efe-6523-480b-bf83-201f3fb6853a" contextRef="C_63138494-78aa-453f-87e2-d7692e2526f2" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">10,551,718</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of the Company&#8217;s common stock, par value $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6ba03abc-79d1-44cd-b4a6-25fee8a43f8d" contextRef="C_f17c501c-d230-47ae-bbff-603a48bd4de4" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="4" format="ixt:num-dot-decimal">0.0001</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, at a purchase price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_763358c5-8e4d-4478-81b0-1b63d0142521" contextRef="C_f17c501c-d230-47ae-bbff-603a48bd4de4" name="us-gaap:SharePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">14.50</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share and (ii) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_aa7c39a5-0497-49a2-8de3-7cb1017443bb" contextRef="C_60b4b3d3-4a6b-45de-b852-487c0414710f" name="us-gaap:ClassOfWarrantOrRightOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,517,241</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> pre-funded warrants, or the Pre-Funded Warrants, to purchase up to an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e6603764-18ad-49d8-82c5-0f57cc909e7e" contextRef="C_f17c501c-d230-47ae-bbff-603a48bd4de4" name="us-gaap:ClassOfWarrantOrRightOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,517,241</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of the Company's common stock</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, or the Warrant Shares,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> at a purchase price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5cf35e4b-72a6-4b26-9546-6ce0dc904d6c" contextRef="C_60b4b3d3-4a6b-45de-b852-487c0414710f" name="us-gaap:SharePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="4" format="ixt:num-dot-decimal">14.4999</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per Pre-Funded Warrant. Each Pre-Funded Warrant has an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c23aaaa2-45f6-4520-be70-5005093ae588" contextRef="C_60b4b3d3-4a6b-45de-b852-487c0414710f" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="4" format="ixt:num-dot-decimal">0.0001</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per Warrant Share.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Pre-Funded Warrants are exercisable at any time after their original issuance at the option of each holder, in such holder&#8217;s discretion, by (i) payment in full in immediately available funds for the number of shares of common stock purchased upon such exercise or (ii) a cashless exercise, in which case the holder would receive upon such exercise the net number of shares of common stock determined according to the formula set forth in the Pre-Funded Warrant. A holder will not be entitled to exercise any portion of any Pre-Funded Warrant if the holder&#8217;s ownership of the Company&#8217;s common stock would exceed </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2d135658-0136-4a89-8a61-92a440e72091" contextRef="C_ffb4c57e-cb92-46fd-9286-ea36197252e3" name="us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">9.99</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% following such exercise.</span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the event of certain fundamental transactions, the holders of the Pre-Funded Warrants will be entitled to receive upon exercise of the Pre-Funded Warrants the kind of amounts of securities, cash or other property that the holders would have received had they exercised the Pre-Funded Warrants immediately prior to such fundamental transaction without regard to any limitations on exercise contained in the Pre-Funded Warrants.</span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Pre-Funded Warrants were classified as a component of permanent stockholders&#8217; equity within additional paid-in capital and were recorded at the issuance date using a relative fair value allocation method. The Pre-Funded Warrants are equity classified because they (i) are freestanding financial instruments that are legally detachable and separately exercisable from the equity instruments, (ii) are immediately exercisable, (iii) do not embody an obligation for the Company to repurchase its shares, (iv) permit the holders to receive a fixed number of shares of common stock upon exercise, (v) are indexed to the Company&#8217;s common stock and (vi) meet the equity classification criteria. In addition, such Pre-Funded Warrants do not provide any guarantee of value or return. The Company valued the Pre-Funded Warrants at issuance, concluding that their sales price approximated their fair value, and allocated net proceeds from the Private Placement proportionately to the Company's common stock and Pre-Funded Warrants.</span></p></ix:nonNumeric></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">19</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_f4375883-f708-4c9a-b463-7fd6df3b82f4_1"><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Private Placement closed on August 1, 2024 and the Company received net proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cf86c4b1-1382-4031-b9d5-5d6665a142a1" contextRef="C_7a724b91-c619-4f16-b0fa-87eb52d80cd1" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">166.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, after deducting placement agent fees, offering costs, and other expenses, of which $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ed9cb9f5-f525-41c7-b698-4e96538a6c4b" contextRef="C_9be30ffd-c276-4ccc-8f21-4e37e3595dc7" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">145.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million was allocated to the common stock and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_60d86044-748f-47af-ae1f-e3304faa0db5" contextRef="C_6687375b-114a-46c2-aae2-63bb21248fa4" name="us-gaap:ProceedsFromIssuanceOfWarrants" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">20.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million was allocated to the Pre-Funded Warrants. The net proceeds were recorded as a component of additional paid-in capital.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Investment agreement with Ipsen Biopharmaceuticals, Inc.</span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In July 2024, the Company entered into the Ipsen License Agreement, pursuant to which, the Company licensed to Ipsen, on an exclusive basis, the right to commercialize tovorafenib in all territories outside the United States and agreed to provide certain research and development and manufacturing services. Under the terms of the Ipsen License Agreement, (i)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Ipsen paid the Company an upfront license fee in the amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0ee93ab3-570c-49a9-8cf4-09c1c103d0cb" contextRef="C_18678d79-8e7d-4c54-8b85-ba5704b25f78" name="dawn:UpfrontLicenseFee" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">70.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in August 2024 and (ii) the Investor, a fully-owned United States affiliate of Ipsen, purchased </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d8ce56f2-5851-4b52-9902-8b4fbf6bbd27" contextRef="C_18678d79-8e7d-4c54-8b85-ba5704b25f78" name="dawn:CommonStockSharesPurchased" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">2,341,495</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of the Company&#8217;s common stock in a private placement for $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_aeae08e9-8dc5-4ab9-a3a1-4d41b821f0e6" contextRef="C_1129e786-4666-4dce-88b0-ece78eb6efc6" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">40.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, at a price per share representing a </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0b418f0b-2483-4b77-bbbf-2643e3a11c2f" contextRef="C_18678d79-8e7d-4c54-8b85-ba5704b25f78" name="dawn:WeightedAveragePriceOfCompanysCommonStock" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">17.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% premium to the VWAP of the Company&#8217;s common stock as traded on The Nasdaq Stock Market LLC for the ten consecutive trading days prior to and including the date of the Revenue Release, and the ten consecutive trading days following the Revenue Release, in accordance with the terms set forth in an investment agreement by and between the Company and the Investor dated July 23, 2024. The Company valued the shares at issuance at $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a9fbb6b3-52d0-46bd-b20d-4a66c14518a4" contextRef="C_18678d79-8e7d-4c54-8b85-ba5704b25f78" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">32.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, concluding that the Company's common stock price as traded on The Nasdaq Stock Market LLC on the closing date of the transaction approximated fair value, which was recorded as a component of additional paid-in capital.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">At-The-Market Offering</span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has entered into an equity distribution agreement, or the Equity Distribution Agreement, with Piper Sandler &amp; Co. and JonesTrading Institutional Services LLC, as sales agents, relating to the issuance and sale of shares of the Company&#8217;s common stock for an aggregate offering price of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c94488ae-3af3-40c7-a485-94fc22363f42" contextRef="C_f34d98de-c249-4523-b50b-c9af86c79722" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">250.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million under an at-the-market offering program, or the ATM. The Company has no obligation to sell any shares and could at any time suspend solicitations and offers under the ATM. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_13419e56-cc84-40a6-a583-503888385ce2" contextRef="C_388de2bd-eeb7-4fa1-87a1-3cdac91fa91d" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="0" format="ixt-sec:numwordsen">No</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of the Company&#8217;s common stock have been sold under the ATM as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p></ix:continuation></div><div><ix:nonNumeric id="F_ac184c94-590e-4277-b7e0-e314b9e5f5ba" contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" escape="true" continuedAt="F_ac184c94-590e-4277-b7e0-e314b9e5f5ba_1"><div class="item-list-element-wrapper" style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">9.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Share-based Compensation</span></div></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_cd7e9c25-28a9-4d40-946c-03d929b26586" contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" escape="true"><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Share-based compensation expense recorded in the accompanying condensed statements of operations is as follows (in thousands):</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:65.92%;box-sizing:content-box;"/>
         <td style="width:1.6%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.64%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.6%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.64%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.6%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended<br/>March 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development expense</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c2c28270-fddc-4d29-a556-fb12d04dac7e" contextRef="C_7d91f4bf-04a0-434b-a91a-e1fd4c41cbe1" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,251</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b8e0906e-c12e-495a-982e-bf2cf4b16ca8" contextRef="C_6bcd3432-198e-484b-9415-19fc999fd457" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,653</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Selling, general and administrative expense</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6b91d740-51d8-44da-98d2-fb180be5e382" contextRef="C_2a107001-c05d-46f0-ab44-70e8338ecfcf" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,610</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_07235f28-ac47-4092-bec5-d5edfee15841" contextRef="C_b2b75b00-4621-44ed-bdf4-f92f43226a4c" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,991</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total share-based compensation expense</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_408ced96-7c69-480c-b1f1-0b895c434da2" contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,861</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_804903f9-3196-4d29-a98d-5dd5e5cc5e39" contextRef="C_0fd32f25-7d1d-46c5-938d-d9b0e3f9dfaa" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,644</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">2022 Equity Inducement Plan</span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In October 2022, the Company's board of directors approved the 2022 Equity Inducement Plan, or the 2022 Plan. The 2022 Plan provides for the grant of non-statutory stock options and restricted stock units. The number of shares of common stock reserved for issuance under the 2022 Plan is </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9bebbbbf-bed1-4dad-93c6-6cc615c13c9d" contextRef="C_0d1e25ff-1b51-4a66-aafb-97dc40b3998f" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,000,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">2021 Equity Incentive Plan</span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In May 2021, in connection with the IPO, the board of directors and stockholders approved the 2021 Equity Incentive Plan, or the 2021 Plan, which became effective on the day before the date of the effectiveness of the IPO. The 2021 Plan provides for the grant of incentive stock options, non-statutory stock options, stock appreciation rights, awards of restricted stock, restricted stock units and other share-based awards. The number of shares of common stock reserved for issuance under the 2021 Plan is equal to the sum of: (x) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6bd58c8b-a8fc-4167-a5ed-cbb47d2d06bc" contextRef="C_01058ddf-79d2-4e72-962f-17fe256a6f09" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">6,369,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock; plus (y) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_261a4ab6-603b-4b43-8f4d-5f8ac7377c18" contextRef="C_46800e87-c56c-4f8c-b6af-964b831f2ace" name="us-gaap:ConversionOfStockSharesIssued1" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">4,719,605</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock issued in respect of the conversion of incentive shares that were subject to vesting immediately prior to the effectiveness of the registration statement for the IPO that expire, terminate or are otherwise surrendered, canceled, forfeited or repurchased by us at their original issuance price pursuant to a contractual repurchase right. The number of shares available for grant and issuance under the 2021 Plan will be automatically increased on the first day of each fiscal year, beginning with the fiscal year commencing on January 1, 2021 and continuing for each fiscal year until, and including, the fiscal year commencing on January 1, 2031, by the lesser of (a) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_eea0a91d-ea44-44e2-9bd5-3492fe3ecafb" contextRef="C_43327af5-1891-4b55-b0a6-4f7ba631a198" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the number of shares of all classes of the Company&#8217;s common stock, plus the total number of shares of Company common stock issuable upon conversion of any preferred stock or exercise of any warrants to acquire shares of Company common stock for a nominal exercise price issued and outstanding on each December 31 immediately prior to the date of increase or (b) such number of shares determined by the board of directors.</span></p></ix:nonNumeric></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">20</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div><ix:continuation id="F_ac184c94-590e-4277-b7e0-e314b9e5f5ba_1" continuedAt="F_ac184c94-590e-4277-b7e0-e314b9e5f5ba_2"><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stock Options</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_edb97fe5-97b9-48aa-9b9e-641c4f93d97a" contextRef="C_910c0420-f57a-418a-8295-ee1ffb7bd08a" name="us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" escape="true"><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table provides a summary of stock option activity during the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three months ended March 31, 2025.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:39.088%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.322%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.34%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:11.722000000000001%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.322%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.34%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:11.862%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Options</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-Average<br/>Exercise Price<br/>Per Share</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-Average<br/>Remaining <br/>Contractual Term</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Aggregate <br/>Intrinsic Value<br/>(in thousands)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding at December 31, 2024</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d96cf084-8d83-423a-8100-21862cbe63fc" contextRef="C_dcf6712c-475d-4506-9554-ded223b0331a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">12,127,435</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9f278333-2080-40fb-ba1b-a4b09973168c" contextRef="C_dcf6712c-475d-4506-9554-ded223b0331a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">16.50</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_05981031-2743-48ff-9ec1-b11b54b8b01a" contextRef="C_910c0420-f57a-418a-8295-ee1ffb7bd08a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">2,132,000</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7ce9a9d8-fa6e-410c-bf51-35a938a3b9c8" contextRef="C_910c0420-f57a-418a-8295-ee1ffb7bd08a" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">11.86</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercised</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_11f1988c-13c3-44b1-a9cb-d5a3fab1afd3" contextRef="C_910c0420-f57a-418a-8295-ee1ffb7bd08a" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6aff3823-d0df-48b8-80b7-f28971a29da4" contextRef="C_910c0420-f57a-418a-8295-ee1ffb7bd08a" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_436c447d-abfa-4a13-9aca-9a0ef82486cc" contextRef="C_910c0420-f57a-418a-8295-ee1ffb7bd08a" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forfeiture</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_edb08972-534b-4530-b462-b902ca381d52" contextRef="C_910c0420-f57a-418a-8295-ee1ffb7bd08a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">203,761</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6d3fcfef-0c60-4731-bc56-4832fb7f8a81" contextRef="C_910c0420-f57a-418a-8295-ee1ffb7bd08a" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">15.87</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding at March 31, 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7d90d9ee-9a20-4639-b4a9-0e9564fd4431" contextRef="C_13a2630f-ef56-4f08-840c-b986a80c28b9" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">14,055,674</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b2c31ee6-9e2d-49eb-b726-fd9dd5546e65" contextRef="C_13a2630f-ef56-4f08-840c-b986a80c28b9" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">15.81</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_1b1476d8-1826-42a0-b8b8-24d6a034ac0c" contextRef="C_910c0420-f57a-418a-8295-ee1ffb7bd08a" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.6</span></ix:nonNumeric></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3138fdba-3ecb-4c78-b7d6-bf23fd17b07a" contextRef="C_13a2630f-ef56-4f08-840c-b986a80c28b9" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="3" decimals="-2" format="ixt:num-dot-decimal">27.0</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Vested and expected to vest at March 31, 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8be841a1-9738-416e-bcf5-fd07e153f374" contextRef="C_910c0420-f57a-418a-8295-ee1ffb7bd08a" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">14,055,674</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3d0162aa-47b1-450a-ab7c-78b38a14ab41" contextRef="C_13a2630f-ef56-4f08-840c-b986a80c28b9" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">15.81</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_bdc99b59-8421-4382-9f27-21709f681eda" contextRef="C_910c0420-f57a-418a-8295-ee1ffb7bd08a" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.6</span></ix:nonNumeric></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4a428053-fdfd-448a-9d82-f19c728f56c2" contextRef="C_13a2630f-ef56-4f08-840c-b986a80c28b9" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" unitRef="U_USD" scale="3" decimals="-2" format="ixt:num-dot-decimal">27.0</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercisable at March 31, 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4face764-886c-461f-ab2c-8d60c48da6b7" contextRef="C_13a2630f-ef56-4f08-840c-b986a80c28b9" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">8,362,276</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3670ded4-3741-47a8-83bc-96841a57aba3" contextRef="C_13a2630f-ef56-4f08-840c-b986a80c28b9" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">16.58</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_decdfb17-f3d8-4201-aa44-6c03e0d8db3e" contextRef="C_910c0420-f57a-418a-8295-ee1ffb7bd08a" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.8</span></ix:nonNumeric></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_75f6322b-edf9-47a1-b66f-3ac4cdbee77d" contextRef="C_13a2630f-ef56-4f08-840c-b986a80c28b9" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" unitRef="U_USD" scale="3" decimals="-2" format="ixt:num-dot-decimal">18.6</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Aggregate intrinsic value represents the difference between the estimated fair value of the underlying common stock and the exercise price of outstanding, in-the-money options. There were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_638a09cf-b1ed-4c18-89ac-a51ad2a04393" contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> options exercised during the three months ended March 31, 2025. The total intrinsic value of options exercised during the three months ended March 31, 2024 was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_683c9d1f-f88c-48c3-85b7-57ea6567a342" contextRef="C_c2dd807f-0b0a-4c78-a0c1-eae1f3ef85f9" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The total fair value of options that vested during the three months ended March 31, 2025 and 2024 was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_32673d9f-aa0f-4222-8cf5-a21fd95e23d9" contextRef="C_13a2630f-ef56-4f08-840c-b986a80c28b9" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">8.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_06e1fbd9-ce87-44ad-a4d2-1282213643ba" contextRef="C_7f944cae-458f-4eb0-b171-e53812c6128e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">7.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively. The weighted-average grant date fair value of options granted during the three months ended March 31, 2025 and 2024 was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_00cdbcbd-b417-4665-8c00-fb8c46caccb0" contextRef="C_cb883bf9-9846-4518-bf47-5d7e85524d73" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">7.73</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9c42ce77-2328-4e09-bfc5-2f4219205ba7" contextRef="C_2a98f92e-aa86-4a5c-aad4-edb5374ed00b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">9.31</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, respectively.</span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Unrecognized share-based compensation for stock options as of March 31, 2025 was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e496d29f-55e4-4f5a-b712-ecea69b901a1" contextRef="C_7aae3619-1673-4b07-91a5-706dabc13942" name="dawn:UnamortizedStockBasedCompensationForStockOptions" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">52.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, which is expected to be recognized over a weighted-average period of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_24ea5e55-66d3-46b9-91f7-baa8fbdfe1c4" contextRef="C_cb883bf9-9846-4518-bf47-5d7e85524d73" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.5</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years.</span></p><div style="font-size:11pt;font-family:'Calibri',sans-serif;"><ix:nonNumeric id="F_9020f117-7ffa-4b07-93cf-1288c35921ce" contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b" name="dawn:ScheduleOfStockOptionsAssumptionsTableTextBlock" escape="true"><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company used the Black-Scholes option pricing model to estimate the fair value of stock option awards granted with the following assumptions:</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:41.608%;box-sizing:content-box;"/>
         <td style="width:3.001%;box-sizing:content-box;"/>
         <td style="width:26.565%;box-sizing:content-box;"/>
         <td style="width:2.26%;box-sizing:content-box;"/>
         <td style="width:26.565%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended<br/>March 31,</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected term (in years)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_81c3115d-376d-4731-82ba-d44a302bfcd4" contextRef="C_9e37dcd2-0722-43fd-aedf-af23527c98ee" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.69 </span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">- </span><span><ix:nonNumeric id="F_08722941-cfbc-4c32-bf37-a4e5dd22e1d9" contextRef="C_30fad386-55b9-45a7-8945-04e8a03f752e" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.70</span></ix:nonNumeric></span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_6dfb5887-8b67-4695-ba0a-194a7760c9ac" contextRef="C_5a86561f-8ff9-4f61-acd4-e523f9c716bf" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.77</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;- </span><span><ix:nonNumeric id="F_d7a6dd76-a386-400f-a46f-e67d76f694fe" contextRef="C_310c50ba-37a3-430e-bd89-9a82d7460226" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.74</span></ix:nonNumeric></span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected volatility</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5370be91-e5bd-4f1c-8e6a-b25aaffe9e03" contextRef="C_9e37dcd2-0722-43fd-aedf-af23527c98ee" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">68.30</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9a7461f2-a249-4902-a704-cf301ad8be9c" contextRef="C_30fad386-55b9-45a7-8945-04e8a03f752e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">69.13</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ebfb3a65-7ed9-48e9-a0d4-a45069905975" contextRef="C_5a86561f-8ff9-4f61-acd4-e523f9c716bf" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">68.27</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5604a5b7-2ba8-4a4a-9e47-0691a919e564" contextRef="C_310c50ba-37a3-430e-bd89-9a82d7460226" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">70.57</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Risk-free interest rate</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0ed52d3b-aecc-4280-947a-c65144551fb2" contextRef="C_9e37dcd2-0722-43fd-aedf-af23527c98ee" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">3.99</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d5f64d06-8d38-4594-8d42-6cefa31e6b4b" contextRef="C_30fad386-55b9-45a7-8945-04e8a03f752e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">4.48</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f5c3d57a-6588-4746-a44a-ada289391dd5" contextRef="C_5a86561f-8ff9-4f61-acd4-e523f9c716bf" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">3.90</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_648e1f2d-0fa8-470a-af5c-efb439719970" contextRef="C_310c50ba-37a3-430e-bd89-9a82d7460226" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">4.31</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected dividend yield</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_01569e7f-2fcc-4e08-8e92-d30a9aa01c8e" contextRef="C_910c0420-f57a-418a-8295-ee1ffb7bd08a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_57463d82-9c4c-4b74-83b3-f644c2abea48" contextRef="C_c2dd807f-0b0a-4c78-a0c1-eae1f3ef85f9" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        </tr>
       </table></ix:nonNumeric></div><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Restricted Stock Units</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_febb0fd8-ec3f-448d-8a98-4b89457d66aa" contextRef="C_910c0420-f57a-418a-8295-ee1ffb7bd08a" name="us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" escape="true"><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table provides a summary of restricted stock units activity under the 2021 Plan during the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three months ended March 31, 2025:</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:66.98%;box-sizing:content-box;"/>
         <td style="width:1.16%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:13.36%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.62%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.88%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of<br/>Shares</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted Average<br/>Grant Date Fair Value<br/>Per Share</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unvested restricted stock units at December 31, 2024</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7df6d044-d70f-4ca7-907a-e1c3852b4f85" contextRef="C_27899ba1-a824-4fc6-ac6a-83ca5fb4f9b5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,774,287</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_86bceefa-34b5-449e-91db-b01ea0576780" contextRef="C_27899ba1-a824-4fc6-ac6a-83ca5fb4f9b5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">15.58</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_86aa0f62-67a8-45f3-8d6b-8754caaa1295" contextRef="C_172d1f62-d597-4e9e-a3d0-7f8bd3d31541" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,393,000</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fea9aa74-a2de-4456-a5ad-22ca085cc940" contextRef="C_172d1f62-d597-4e9e-a3d0-7f8bd3d31541" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">11.86</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Vested</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a31000c1-d8f3-4543-a39a-f62018d25e28" contextRef="C_172d1f62-d597-4e9e-a3d0-7f8bd3d31541" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">247,041</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_46d02cbd-03fe-4925-9242-95edfa27ad14" contextRef="C_172d1f62-d597-4e9e-a3d0-7f8bd3d31541" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">14.73</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forfeiture</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b2ba6629-c338-4bc5-a534-3e99076a7a88" contextRef="C_172d1f62-d597-4e9e-a3d0-7f8bd3d31541" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">63,426</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b7b1ec11-ed5f-4767-a6db-6e500adc82f5" contextRef="C_172d1f62-d597-4e9e-a3d0-7f8bd3d31541" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">14.14</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unvested restricted stock units at March 31, 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c073f266-65d9-4813-9051-2ed2cd8b6a63" contextRef="C_ffe0f1b7-fa8f-4028-beb7-7b994de8b4b7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">2,856,820</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e0f27f00-99fc-4846-a2eb-e3d0ac4210f1" contextRef="C_ffe0f1b7-fa8f-4028-beb7-7b994de8b4b7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">13.88</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Unamortized share-based compensation for restricted stock units as of March 31, 2025 was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0fc7fe20-cd58-400d-9f82-1ac036cfa51d" contextRef="C_fd702879-0dc1-44c9-85ec-00d54500225b" name="dawn:UnamortizedStockBasedCompensationForStockOptions" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">37.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, which is expected to be recognized over a weighted-average period of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_be20a77a-46a6-4d83-9c5a-f5f692e70a03" contextRef="C_b0966c50-b1d4-43dc-abb7-4c4d573ddf0b" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.9</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Restricted Stock Awards</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_dc67d8fe-4c27-4d74-b1fa-881a03b34d57" contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b" name="us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock" escape="true"><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table provides a summary of the unvested common stock awards activity during the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three months ended March 31, 2025.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:66.98%;box-sizing:content-box;"/>
         <td style="width:1.16%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:13.36%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.62%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.88%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of<br/>Shares</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted Average<br/>Grant Date Fair Value<br/>Per Share</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unvested common stock as of December 31, 2024</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2600f399-79b9-4f09-9bf4-99b3821641d6" contextRef="C_3ef9f2ba-6c3d-4611-94f4-9657c80e0ee2" name="dawn:ShareBasedCompensationByShareBasedPaymentArrangementEquityInstrumentsOtherThanOptionsOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">82,281</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_45737355-b46b-4025-8e2c-5c21afc218d9" contextRef="C_3ef9f2ba-6c3d-4611-94f4-9657c80e0ee2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">16.00</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Vested</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_afadc249-e738-4274-b1e6-2d33b51da8cc" contextRef="C_d9880916-1c46-4df1-82f9-7cfa90e42ed8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">66,752</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_580a9157-1d03-4977-b725-5fbd5fdefcc8" contextRef="C_d9880916-1c46-4df1-82f9-7cfa90e42ed8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">16.00</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forfeiture</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a46d2e8e-be76-4268-81fa-8ca08899b2e9" contextRef="C_d9880916-1c46-4df1-82f9-7cfa90e42ed8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">735</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fed4643b-823e-4816-af1b-32a4287f14f2" contextRef="C_d9880916-1c46-4df1-82f9-7cfa90e42ed8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">16.00</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unvested common stock as of March 31, 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3f68ff4e-49c2-4d96-b4f2-94c38b7497d2" contextRef="C_afbd7133-30d1-4e7e-80d8-66c0f4c8b5c1" name="dawn:ShareBasedCompensationByShareBasedPaymentArrangementEquityInstrumentsOtherThanOptionsOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">14,794</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_55fdbda3-337d-41c2-8496-512f0962178e" contextRef="C_afbd7133-30d1-4e7e-80d8-66c0f4c8b5c1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">16.00</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div></ix:continuation></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">21</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_ac184c94-590e-4277-b7e0-e314b9e5f5ba_2"><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Unamortized share-based compensation for restricted stock awards as of March 31, 2025 was approximately </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0f45d8bc-cbfd-4425-b5c5-d5dd77fadcad" contextRef="C_afbd7133-30d1-4e7e-80d8-66c0f4c8b5c1" name="dawn:UnamortizedStockBasedCompensationForStockOptions" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">15,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, which is expected to be recognized over a weighted-average period of less than one year.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">2021 Employee Stock Purchase Plan</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In May 2021, the board of directors adopted and the stockholders approved the 2021 Employee Stock Purchase Plan, or the ESPP, which became effective on May 26, 2021. A total of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_613f63be-d862-40f8-9a03-604e44dcfbfe" contextRef="C_bf59d3f6-5cf9-4cca-852c-63e292df8618" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">603,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock were initially reserved for issuance under the ESPP. The number of shares of the common stock reserved for issuance under the ESPP will automatically increase on the first day of each fiscal year, beginning with the fiscal year commencing on January 1, 2021 and continuing for each fiscal year until, and including, the fiscal year commencing on January 1, 2031, by the lesser of: (a) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3eb74b7e-4886-48d7-be5d-72ad4985baf3" contextRef="C_9ece43fe-da8e-4bfb-aa46-983f40858774" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the total number of outstanding shares of common stock of the Company (on an as converted basis outstanding on the immediately preceding December 31 (rounded down to the nearest whole share)) and (b) an amount determined by the board of directors. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ae94f1dd-48dd-48d8-ae7a-8c231f52b31f" contextRef="C_f30f7047-2b1e-4315-95a7-8a873401a0b3" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">407,629</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares have been issued under the ESPP as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 31, 2025. The Company recognized compensation expense related to the ESPP of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fe3b2385-7cd2-4605-89bd-32789433088e" contextRef="C_f30f7047-2b1e-4315-95a7-8a873401a0b3" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal"><ix:nonFraction id="F_a6d25e54-451d-4885-96c1-91f5ea629318" contextRef="C_6b43dd28-89c1-4746-bb60-edcdf09081e0" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.2</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for each of the three months ended March 31, 2025 and 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p></ix:continuation></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_260d7941-4683-487c-afcd-cd7f71309700" contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b" name="us-gaap:IncomeTaxDisclosureTextBlock" escape="true"><div class="item-list-element-wrapper" style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">10.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Income Taxes</span></div></div><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_01cf5331-c97a-4c45-bcad-83e83bb19bc6" contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen"><ix:nonFraction id="F_8cf50d33-db2d-45ec-a1c8-b18afd115e43" contextRef="C_0fd32f25-7d1d-46c5-938d-d9b0e3f9dfaa" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t record an income tax provision for the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three months ended March 31, 2025 and 2024 as it generated tax losses during each of the periods.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A valuation allowance is established when it is more likely than not that some portion or all of a deferred tax asset will not be realized. The realization of deferred tax assets depends on the generation of future taxable income during the period in which related temporary differences become deductible. The Company continues to establish a valuation allowance against the full amount of its net deferred tax assets since it is more likely than not that benefits will not be realized, including those benefits created in the current year. This assessment is based on the Company's historical cumulative losses, which provide strong objective evidence that cannot be overcome with projections of income, as well as the fact the Company expects continuing losses in the future.</span></p></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div><ix:nonNumeric id="F_cd190b48-44e3-4058-9cbf-10a1f1966382" contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b" name="us-gaap:EarningsPerShareTextBlock" escape="true"><div class="item-list-element-wrapper" style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">11.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Net Loss Per Share </span></div></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_403c9985-20b1-49a6-977c-b58fcb322c81" contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" escape="true"><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basic and diluted net loss per share attributable to common stockholders is calculated as follows (in thousands except share and per share amounts):</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:55.28%;box-sizing:content-box;"/>
         <td style="width:1.92%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:18.439999999999998%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.92%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:18.439999999999998%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended<br/>March 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="border-top:0.5pt solid #000000;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="border-top:0.5pt solid #000000;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss - basic and diluted</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_29c4c747-9eed-43b0-8b84-1aa72374cae1" contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">35,996</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_89978c8e-0233-4727-853f-951ab97cb6eb" contextRef="C_0fd32f25-7d1d-46c5-938d-d9b0e3f9dfaa" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">62,412</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss per share, basic and diluted</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f205c988-a611-4285-b1ba-c025213e5e4c" contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_4fcaf1b4-b13f-4c60-a7ee-6376a6b6edc3" contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">0.35</ix:nonFraction></ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_162132c3-37f0-475e-a40a-5947f82536b1" contextRef="C_0fd32f25-7d1d-46c5-938d-d9b0e3f9dfaa" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_b5de2b7c-9c7a-4d0f-8003-79729fcd6c64" contextRef="C_0fd32f25-7d1d-46c5-938d-d9b0e3f9dfaa" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">0.72</ix:nonFraction></ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average number of common shares used in computing net loss per share, basic and diluted</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dae78655-b457-40b0-98ee-cf7f9b6ee18e" contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_d4d24c2c-0d2e-4196-9340-6b2efeff63c5" contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">102,710,382</ix:nonFraction></ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_32d27fa8-d857-4da1-8c69-00a94f963fea" contextRef="C_0fd32f25-7d1d-46c5-938d-d9b0e3f9dfaa" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_1b1c86c2-4863-4229-aba6-87a2b4a07489" contextRef="C_0fd32f25-7d1d-46c5-938d-d9b0e3f9dfaa" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">86,679,282</ix:nonFraction></ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span><ix:nonNumeric id="F_5ff50c6d-2e7c-4261-8783-6aa733283d75" contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" escape="true" continuedAt="F_5ff50c6d-2e7c-4261-8783-6aa733283d75_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following outstanding potentially dilutive securities have been excluded from the calculation of diluted net loss per share, as their effect is anti-dilutive:</span></ix:nonNumeric></span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_5ff50c6d-2e7c-4261-8783-6aa733283d75_1" continuedAt="F_5ff50c6d-2e7c-4261-8783-6aa733283d75_2">
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:66.967%;box-sizing:content-box;"/>
         <td style="width:1.16%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:13.357%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.16%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:13.357%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of March 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="border-top:0.5pt solid #000000;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="border-top:0.5pt solid #000000;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock options</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d7d69373-2668-4802-a673-27de76d0d73e" contextRef="C_ba5b769f-138e-4a96-8876-aa121d01b3cc" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">14,055,674</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e7129b53-b7a7-446f-b468-3b5928ff0b39" contextRef="C_89780293-cea0-4538-b7bb-9bfd5ea8a319" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">12,404,090</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unvested common shares</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_316bb835-8c61-4cec-97ec-46eb2d2578d1" contextRef="C_ce9b7ba8-66b0-4fb8-95da-9540fc395eeb" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">14,794</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_94bb63a4-ca28-4c63-8c52-1d9f8aa24134" contextRef="C_3aa48c9e-64e5-48ce-b002-f58764db64d0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">543,239</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restricted stock units</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2033911f-5777-4e4c-ae49-8a91dfc5388f" contextRef="C_8387ea00-db0a-45ff-8cd7-7258098914d9" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">2,856,820</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1ba18590-5afa-4533-93ac-ed954d507a49" contextRef="C_9cc6beef-2bd0-4841-8e97-5da5102095a3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">2,243,998</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Shares committed under ESPP</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_da6e2763-bd93-4aac-9a5f-c358b0509868" contextRef="C_4a61c31c-c9f6-4c86-9285-1639c02fc666" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">108,717</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ecc9a0fc-a1f0-4e55-86e5-2daa75db6fea" contextRef="C_342128b9-4127-453a-8974-3c82ca357e86" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">100,753</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7c058de1-d167-4f1d-9420-50354337396f" contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">17,036,005</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_81a6a0d3-712d-4eba-b8c0-25ce49730fc8" contextRef="C_0fd32f25-7d1d-46c5-938d-d9b0e3f9dfaa" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">15,292,080</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:continuation></div></ix:nonNumeric></div><div><ix:continuation id="F_5ff50c6d-2e7c-4261-8783-6aa733283d75_2"></ix:continuation></div><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_04560c55-8160-47f6-ac0f-db3a3da2fef9" contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b" name="us-gaap:DefinedContributionPlanTextBlock" escape="true"><div class="item-list-element-wrapper" style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">12.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Defined Contribution Plan</span></div></div><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company maintains an employee savings plan pursuant to Section 401(k) of the Internal Revenue Code. All employees are eligible to participate provided that they meet the requirements of the plan. For each of the three months ended March 31, 2025 and 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company made matching contributions of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cbc92a61-a042-4108-bd24-50232f4cc343" contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b" name="dawn:DefinedContributionPlanEmployerMatchingContribution" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4c7a9e3d-efcb-4e2a-81aa-abe3fe0684ee" contextRef="C_0fd32f25-7d1d-46c5-938d-d9b0e3f9dfaa" name="dawn:DefinedContributionPlanEmployerMatchingContribution" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively.</span></p></ix:nonNumeric></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">22</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7953a92d-7f57-479f-9913-29fdfc1e934c" contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b" name="us-gaap:SegmentReportingDisclosureTextBlock" escape="true"><div class="item-list-element-wrapper" style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">13.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Segment Reporting</span></div></div><p style="text-indent:4.173%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company views its operations and manages its business in </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5f1881aa-ec16-47f0-8431-0930fed21bb0" contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b" name="us-gaap:NumberOfOperatingSegments" unitRef="U_Segment" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> operating and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_106641bf-392a-439f-a74f-3d69a9b04c97" contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b" name="us-gaap:NumberOfReportableSegments" unitRef="U_Segment" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> reportable segment, which includes all activities related to the identification, development and commercialization of medicines for childhood and adult diseases with equal intensity. The determination of a single operating segment is consistent with the consolidated financial information regularly provided to the Company&#8217;s chief operating decision maker, or CODM. The Company&#8217;s CODM is its Chief Executive Officer, who reviews and evaluates net loss for purposes of assessing performance, making operating decisions, allocating resources, and planning and forecasting for future periods. Our CODM does not evaluate the operating segment using asset or liability information. The operating segment derives all net product revenues from the sales of OJEMDA in the United States through contractual arrangements with its specialty pharmacy and specialty distributor customers. All the Company&#8217;s assets are located in the United States.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1570f557-5635-491a-acb0-89e798625859" contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" escape="true"><p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to the significant expense categories included within net loss presented on the Company's condensed statements of operations, see below for disaggregated amounts that comprise research and development expenses:</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:66.993%;box-sizing:content-box;"/>
         <td style="width:1.62%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.883000000000001%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.62%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.883000000000001%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended<br/>March 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">External costs:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Third-party CRO, CMO and other third-party clinical trial costs (1)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a38f27e3-eb4b-4eb4-814a-963ea523b1df" contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b" name="dawn:Third-PartyCROCMOAndOtherThird-PartyClinicalTrialCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,821</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e7bc9a6d-21f3-4425-a0f4-b8ddd2c8a2f5" contextRef="C_0fd32f25-7d1d-46c5-938d-d9b0e3f9dfaa" name="dawn:Third-PartyCROCMOAndOtherThird-PartyClinicalTrialCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,546</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">License agreement related payments</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_74fc83ab-f8dd-49ed-a6b3-359a7dc79fec" contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b" name="dawn:LicenseAgreementRelatedPayments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,000</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4df9da7b-c2b6-4fdf-bf84-4991ae86a62f" contextRef="C_0fd32f25-7d1d-46c5-938d-d9b0e3f9dfaa" name="dawn:LicenseAgreementRelatedPayments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,000</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other research and development costs</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_45d09d44-4a94-430e-a610-feec2ba4e21c" contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b" name="us-gaap:OtherResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,021</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f88d3733-d976-4726-8508-ea1def957279" contextRef="C_0fd32f25-7d1d-46c5-938d-d9b0e3f9dfaa" name="us-gaap:OtherResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,167</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Internal costs:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Employee related expenses</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b353f1cc-a14c-4910-b4c2-36ca758f9a68" contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b" name="dawn:EmployeeRelatedExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,777</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_77f46c6a-f712-4c4f-9e21-63c7be7825dd" contextRef="C_0fd32f25-7d1d-46c5-938d-d9b0e3f9dfaa" name="dawn:EmployeeRelatedExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,497</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total research and development expenses</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c6586fc6-c034-4e77-aaf9-6227bb506b37" contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">39,619</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8fec429e-3f3c-4f94-ba4f-8409c33f43f1" contextRef="C_0fd32f25-7d1d-46c5-938d-d9b0e3f9dfaa" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">40,210</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1) </span><ix:footnote id="FNT_60f2d66a-bd18-4379-ab25-550bcb317590" xml:lang="en-US"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Costs incurred under agreements with third-party CROs, CMOs, and other third parties that conduct clinical activities on the Company's behalf.</span></ix:footnote></p></ix:nonNumeric></div></ix:nonNumeric></div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="tx180355_9"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">You should read the following discussion and analysis of our financial condition and results of operations together with our consolidated financial statements and related notes, our interim condensed financial statements and related notes, and other financial information appearing in our Annual Report on Form 10-K for the year ended December 31, 2024, or our Annual Report, and this Quarterly Report on Form 10-Q. Some of the information contained in this discussion and analysis includes forward-looking statements that involve risks and uncertainties. As a result of many factors, including those factors set forth in the &#8220;Risk Factors&#8221; in this Quarterly Report on Form 10-Q, our actual results could differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Overview</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Day One Biopharmaceuticals, Inc. is a commercial-stage company focused on advancing first- or best-in-class medicines for childhood and adult diseases with equal intensity. We were founded to address the lack of new therapies resulting from the traditional drug development model, which has left children with cancer and their families waiting too long for new treatments.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At Day One, we aim to identify and develop breakthrough medicines with the goal of improving the outcomes and life trajectories of patients of any age facing serious diseases &#8212; starting from Day One. Our &#8220;search &amp; development&#8221; strategy enables us to find, acquire, and develop potential best- or first-in-class programs with the goal of introducing new medicines that will make a real difference in the treatment of children and adults with cancer.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our first commercial product, tovorafenib, is an oral, brain-penetrant, highly selective type II rapidly accelerated fibrosarcoma, or RAF, kinase inhibitor. Tovorafenib was granted breakthrough therapy designation by the U.S. Food and Drug Administration, or the FDA, in August 2020 for the treatment of relapsed or refractory low-grade glioma, or pLGG, based on initial results from a Phase 1 trial which showed evidence of rapid anti-tumor activity and durable responses in patients with pLGG. Pediatric low-grade glioma is the most common brain tumor diagnosed in children. While new targeted therapeutic options have recently become available for patients with pLGG, there is no consensual standard of care and a vast majority of patients with pLGG do not yet have access to approved therapies. Tovorafenib received orphan drug designation for the treatment of malignant glioma from the FDA in September 2020 and from the EU Commission for the treatment of glioma in May 2021. Additionally, the FDA granted rare pediatric disease designation to tovorafenib for treatment of low-grade gliomas, or LGGs, harboring an activating RAF alteration in July 2021.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On April 23, 2024, we announced that the FDA approved OJEMDA&#153; (tovorafenib) for the treatment of patients 6 months of age and older with relapsed or refractory pLGG harboring a BRAF fusion or rearrangement, or BRAF V600 mutation. The indication was approved under accelerated approval based on response rate and duration of response. With the approval, we received a rare</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">23</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">pediatric disease priority review voucher, or PRV, from the FDA. We have commenced the commercial launch of OJEMDA in the United States. OJEMDA is the only systemic therapy for pLGG that offers once-weekly dosing, with or without food, as a tablet or oral suspension.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The accelerated approval of OJEMDA is based on data from the Company&#8217;s pivotal open-label Phase 2 trial, or FIREFLY-1, which enrolled a total of 137 relapsed or refractory BRAF-altered pLGG patients across two study arms. Arm 1, which accrued 77 patients, was used for the efficacy analyses. Arm 2 provided additional safety data from an incremental 60 patients and was initiated to enable access to OJEMDA once Arm 1 had fully accrued. Details of this trial were presented in November 2023 at the Society for Neuro-Oncology meeting through two oral plenary presentations and in parallel through a publication in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Nature Medicine</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The approval of OJEMDA was based, in part, on the major efficacy outcome measure of overall response rate, or ORR, defined as the proportion of patients with complete response, partial response, or PR, or minor response, or MR, by independent review based on Response Assessment in Pediatric Neuro-Oncology Low-Grade Glioma, or RAPNO LGG.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> In Arm 1, data from the 76 RAPNO LGG evaluable patients include:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#149;  A best ORR of 51% (95% CI: 40 - 63), which included 28% PRs and 11% MRs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#149;  The ORR for OJEMDA was 52% among the 64 patients with BRAF fusions or rearrangements and 50% for the 		    12 patients with a BRAF V600 mutation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#149;  The ORR was 49% among the 45 patients who had received a prior MAPK-targeted therapy, and 55% among the 		    31 patients who had not received a prior MAPK-targeted therapy.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#149;  As of the June 5, 2023 data cutoff, the median duration of response by RAPNO LGG was 13.8 months (95% CI: 11.3, not 		   estimable). In addition, 66% of patients remained on study and continue on treatment as of the cutoff date.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#149;  The median time to response, following initiation of treatment, with OJEMDA was 5.3 months (range 1.6 months, 11.2 		    months).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#149;  Based on RANO LGG criteria, the ORR was 53% [95% CI: (41, 64)].</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The safety of OJEMDA was evaluated in 137 patients with relapsed or refractory pLGG, with the majority of adverse events being Grade 1 or Grade 2. The most common side effects were rash, hair color changes, tiredness, viral infection, vomiting, headache, fever, dry skin, constipation, nausea, acne and upper respiratory tract infection.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We initiated a pivotal Phase 3 trial, or FIREFLY-2, evaluating tovorafenib as a front-line therapy in patients ages 6 months to 25 years with pLGG in June 2022. The first patient was dosed in FIREFLY-2 in March 2023. To date, patients continue to enroll in the United States, Canada, Europe, Australia and Asia, with approximately 118 sites activated. In June 2024, we announced the following changes to our FIREFLY-2 trial: the primary endpoint of objective response rate will be assessed according to the RAPNO-LGG criteria, key secondary endpoints of progression free survival and duration of response will be assessed according to RAPNO-LGG criteria, new patients will be initiated on a starting dose of 380 mg/m</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/dose once weekly, and the addition of a once-monthly carboplatin regime as a fourth standard of care option for arm 2. We expect to complete enrollment of FIREFLY-2 in the first half of 2026.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In July 2024, we entered into the Ipsen License Agreement, pursuant to which, we licensed to Ipsen, on an exclusive basis, the right to commercialize tovorafenib in all territories outside the United States and agreed to provide certain research and development and manufacturing services.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the terms of the Ipsen License Agreement, (i) Ipsen paid us an upfront license fee in the amount of $70.8 million in August 2024 and (ii) Ipsen Biopharmaceuticals, Inc., or the Investor, a fully-owned Affiliate of Ipsen, purchased 2,341,495 shares of our common stock in a private placement for $40.0 million, at a price per share representing a 17.0% premium to the volume weighted average price, or VWAP, of our common stock as traded on The Nasdaq Stock Market LLC for the ten consecutive trading days prior to and including the date of our public release of U.S. GAAP revenue for the quarter ended June 30, 2024 on July 30, 2024, or the Revenue Release, and the ten consecutive trading days following the Revenue Release, in accordance with the terms set forth in an investment agreement by and between us and the Investor dated July 23, 2024.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are also eligible to receive up to approximately $350.0 million in additional commercial launch and sales-based milestone payments based on exchange rates as of the reporting date. We are also entitled tiered, double-digit royalty payments starting at mid-teens percentage of annual net sales of tovorafenib, subject to customary adjustments specified in the Ipsen License Agreement. The royalty payment obligations under the Ipsen License Agreement expire on a country-by-country basis no earlier than ten years following the first commercial sale of tovorafenib in the applicable country.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On March 27, 2025, Ipsen Pharma SAS received validation of its completed submission of the Marketing Authorization Application to the EMA for tovorafenib for the treatment of patients with relapsed or refractory pLGG.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">24</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In August 2023, we entered into a research collaboration and license agreement, or the Sprint License Agreement, with Sprint Bioscience AB, or Sprint, a Swedish corporation located in Huddinge, Sweden. Under the Sprint License Agreement, Sprint granted to us an exclusive, worldwide license, with the right to grant sublicenses through multiple tiers, to research, develop, and commercialize pharmaceutical products and to engage in research aimed at discovery, optimization and development of an inhibitor targeting Vaccinia Related Kinase 1, or VRK1. VRK1 is a novel target involved in the regulation of cell division and DNA damage repair. Over-expression of VRK1 is linked to poor prognosis in a variety of adult and pediatric cancers, and VRK1 has been identified as a synthetic lethal target in tumors where expression of its paralog, VRK2, is lost. Silencing of VRK2 expression via promoter methylation has been noted in most high-grade gliomas and high-risk neuroblastomas, providing a concrete approach for selecting patients with tumors sensitive to VRK1 inhibition. Preclinical research activities to advance the VRK1 inhibitor program are ongoing.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In June 2024, we entered into a license agreement, or the MabCare License Agreement, with MabCare Therapeutics, or MabCare, a pharmaceutical corporation located in Shanghai, China. Under the MabCare License Agreement, MabCare granted to us an exclusive worldwide license, excluding Greater China, with the right to grant sublicenses through multiple tiers, under specified patent rights and know-how for the Company to develop, manufacture and commercialize DAY301 (formerly MTX-13 or CB-002). DAY301 is a novel Antibody Drug Conjugate, or ADC, targeting protein-tyrosine kinase 7, or PTK7.  In pre-clinical studies, DAY301 showed antitumor activity in a wide range of solid tumors. DAY301 targets PTK7, a highly-conserved, catalytically inactive transmembrane protein that is overexpressed in multiple adult cancers, including esophageal, ovarian, lung, and endometrial cancer, as well as pediatric cancers such as neuroblastoma, rhabdomyosarcoma and osteosarcoma. In April 2024, the FDA cleared the investigational new drug application for DAY301. In January 2025, we cleared the first cohort (a single-patient accelerated titration cohort) in the Phase 1a portion of the DAY301 Phase 1a/b clinical trial.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We believe our business development capabilities combined with our extensive experience in oncology drug development and deep ties within the research and patient advocacy communities, particularly within the pediatric setting, positions us to be a leader in identifying, acquiring and developing therapies for patients of all ages. We hold exclusive rights to develop tovorafenib and the VRK1 inhibitor program for all therapeutic areas worldwide and DAY301 for all therapeutic areas worldwide, excluding Greater China, subject to certain milestone and royalty payments. Further, we hold exclusive rights to commercialize tovorafenib in the United States subject to royalty payments. Pursuant to the Ipsen License Agreement, we licensed to Ipsen, on an exclusive basis, the right to commercialize tovorafenib outside of the United States, in exchange for certain milestone and royalty payments.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes our product and product candidate pipeline.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img14486971_0.jpg" alt="img14486971_0.jpg" style="width:623px;height:354px;"/></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Significant Agreements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Takeda asset purchase agreement</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On December 16, 2019, our subsidiary entered into an asset purchase agreement, or the Takeda Asset Agreement, with Millennium Pharmaceuticals, Inc., a related party and an affiliate of Takeda Pharmaceutical Company Limited, or Takeda. Effective December 31, 2021, the subsidiary was merged with and into our company, with our company being the surviving corporation and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">25</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">assuming the subsidiary&#8217;s obligations under the Takeda Asset Agreement. Pursuant to the Takeda Asset Agreement, we purchased certain technology rights and know-how related to TAK-580 (which is now OJEMDA) that provides a new approach for treating patients with primary brain tumors or brain metastases of solid tumors. Takeda also assigned us its exclusive license agreement, or the Viracta License Agreement, with Viracta. Takeda also granted us a worldwide, sublicensable exclusive license under specified patents and know-how and non-exclusive license under other patents and know-how generated by Takeda under the Takeda Asset Agreement. We also granted Takeda a grant back license, as defined in the Takeda Asset Agreement, which is terminable either automatically or by us in the event Takeda does not achieve specified development milestones within the applicable timeframes set forth under the Takeda Asset Agreement. This grant back license to Takeda was terminated at the time of conversion of the Company from an LLC to a corporation in connection with the Millennium Stock Exchange Agreement.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The term of the Takeda Asset Agreement will expire on a country-by-country basis upon expiration of all assigned patent rights and all licensed patent rights in such country. Takeda can terminate the Takeda Asset Agreement in the event of our bankruptcy. In the event of termination of the Takeda Asset Agreement by Takeda as a result of our cessation of development or bankruptcy, all assigned patents, know-how and contracts (other than the Viracta License Agreement) will be assigned back to Takeda and Takeda will obtain a reversion license under patents and know-how generated to exploit all such terminated products.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In consideration for the sale and assignment of assets and the grant of the license under the Takeda Asset Agreement, we made an upfront payment of $1.0 million in cash and issued 9,857,143 shares of our Series A redeemable convertible preferred stock in our subsidiary in December 2019. Based on the terms of the Millennium Stock Exchange Agreement, Takeda exchanged the 9,857,143 shares of Series A redeemable convertible preferred stock of our subsidiary for 6,470,382 shares of our common stock upon the effectiveness of the conversion of the Company from an LLC to a corporation, on May 26, 2021.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">License agreement with Viracta</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On December 16, 2019, our subsidiary amended and restated the Viracta License Agreement that was assigned pursuant to the Takeda Asset Agreement. Effective December 31, 2021, our subsidiary was merged with and into our company, with our company being the surviving corporation and assuming our subsidiary&#8217;s obligations under Viracta License Agreement. Under the Viracta License Agreement, we received a worldwide exclusive license under specified patent rights and know-how to develop, use, manufacture, and commercialize products containing compounds binding the RAF protein family. We paid $2.0 million upfront in cash to Viracta in December 2019.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The term of the Viracta License Agreement will expire on a licensed product-by-licensed product and country-by-country basis upon the expiration of our obligation to pay royalties to Viracta with respect to such product in such country. We have the right to terminate the Viracta License Agreement with respect to any or all of the licensed products at will upon a specified notice period.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On March 4, 2024, we entered into an amendment to the Viracta License Agreement. As part of the amendment, we made a one-time payment in March 2024 to Viracta of $5.0 million in exchange for reduced future payment obligations related to the future sale or use of the rare pediatric disease PRV received.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On April 23, 2024, the FDA approved OJEMDA (a tablet formulation and powder solution formulation of tovorafenib) for the treatment of patients 6 months of age and older with relapsed or refractory pLGG harboring a BRAF fusion or rearrangement, or BRAF V600 mutation. The indication was approved under accelerated approval based on response rate and duration of response. With the approval, we received a rare pediatric disease PRV from the FDA. We made a $9.0 million milestone payment to Viracta in May 2024 for the achievement of this milestone.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On May 29, 2024, we sold our rare pediatric disease PRV for $108.0 million to an undisclosed buyer. As part of the transaction, $8.1 million of the total consideration received from the sale of the rare pediatric disease PRV was paid to Viracta to fully satisfy PRV-related obligations under the Viracta License Agreement.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On December 3, 2024, Viracta assigned the Viracta License Agreement to XOMA (US) LLC, or XOMA, pursuant to a Royalty Purchase Agreement dated March 22, 2021, between Viracta and XOMA, whereby Viracta sold its right, title, and interest in and to the Viracta License Agreement to XOMA. We have agreed to the assignment and novation of the Viracta License Agreement to XOMA as successor party, now referred to as the XOMA License Agreement. No material terms of the XOMA License Agreement have been amended or modified in relation to the same.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On March 27, 2025, Ipsen Pharma SAS received validation of its completed submission of the Marketing Authorization Application to the EMA for tovorafenib for the treatment of patients with relapsed or refractory pLGG. As a result, we paid $4.0 million to XOMA for the achievement of this milestone in March 2025.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of March 31, 2025, we could be required to make additional milestone payments of up to $36.0 million upon achievement of specified development and regulatory milestones for each licensed product in two indications. Commencing with the first commercial sale of OJEMDA in a country, we are obligated to pay tiered royalties ranging in the mid-single-digit percentages on net sales of licensed products. The obligation to pay royalties will end on a country-by-country and licensed product-by-licensed product basis commencing on the first commercial sale in a country and continuing until the later of: (i) the expiration of the last valid claim of the XOMA licensed patents, jointly owned collaboration patents or specified patents owned by us covering the use or sale of such product</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">26</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in such country, (ii) the expiration of the last statutory exclusivity pertaining to such product in such country or (iii) the tenth anniversary of the first commercial sale of such product in such country.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">License agreement with Merck KGaA, Darmstadt, Germany</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On February 10, 2021, our subsidiary entered into a license agreement, or the MRKDG License Agreement, with Merck KGaA, Darmstadt, Germany, a pharmaceutical corporation located in Darmstadt, Germany. Effective December 31, 2021, the subsidiary was merged with and into our company, with our company being the surviving corporation and assuming the subsidiary&#8217;s obligations under the MRKDG License Agreement. Under the MRKDG License Agreement, Merck KGaA, Darmstadt, Germany granted to us an exclusive worldwide license, with the right to grant sublicenses through multiple tiers, under specified patent rights and know-how for us to research, develop, manufacture and commercialize products containing and comprising the pimasertib and MSC2015103B compounds. Under the MRKDG License Agreement, we have obligations to use commercially reasonable efforts to develop and commercialize at least two licensed products in at least two specified major market countries by the year 2029.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The term of the MRKDG License Agreement will expire on a licensed product-by-licensed product and country-by-country basis upon the expiration of our obligation to pay royalties to the licensor with respect to such licensed product in such country and will expire in its entirety upon the expiration of all of our payment obligations with respect to all licensed products and all countries under the MRKDG License Agreement.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In consideration for the rights granted under the MRKDG License Agreement and clinical supplies, we made an upfront payment of $8.0 million in March 2021. As of March 31, 2025, we could be required to make additional payments of up to $364.5 million based upon the achievement of specified development, regulatory, and commercial milestones, as well a high, single-digit royalty percentage on future net sales of licensed products, if any.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2023, we discontinued our monotherapy substudy due to a limited duration of response in this rare patient population despite observing responses with a generally well tolerated therapy. In July 2024, we decided to close the program because we determined that the benefit/risk profile, as well as the market opportunity, did not justify the significant investment required to continue the trial despite observing some clinical responses.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research collaboration and license agreement with Sprint Bioscience AB</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On August 15, 2023, we entered into the Sprint License Agreement. Under the Sprint License Agreement, Sprint granted to us an exclusive, worldwide license, with the right to grant sublicenses through multiple tiers, to research, develop, and commercialize pharmaceutical products and to engage in research aimed at discovery, optimization and development of an inhibitor targeting VRK1.</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The term of the Sprint License Agreement will expire on a licensed product and country basis upon the expiration of the royalty term with respect to such licensed product and such country, unless terminated earlier. We have the right to terminate the Sprint License Agreement in its entirety, or on a licensed product-by-licensed product basis, at will upon a specified notice period.</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We paid $3.0 million upfront in cash to Sprint in September 2023. As of March 31, 2025, we could be required to make milestone payments of up to $309.0 million based upon achievement of specified development, regulatory, and commercial milestones for each licensed product, as well as tiered royalties ranging in the single-digit percentages on future net sales of licensed products, if any.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">License agreement with MabCare Therapeutics</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On June 17, 2024, we entered into the MabCare License Agreement. Under the MabCare License Agreement, MabCare granted to us an exclusive worldwide license, excluding Greater China, with the right to grant sublicenses through multiple tiers, under specified patent rights and know-how for us to develop, manufacture and commercialize DAY301, a novel ADC targeting PTK7. Under the MabCare License Agreement, we have obligations to use commercially reasonable efforts to develop, obtain regulatory approval for, and commercialize at least one licensed product in one indication in each of the United States, Japan, and three European countries.</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The term of the MabCare License Agreement will expire in its entirety upon the expiration of the last to expire royalty term with respect to all licensed products in our territory, unless terminated earlier. Following the expiration of the royalty term for a licensed product in a country, the license granted to us shall become non-exclusive, fully paid-up, royalty-free, perpetual, and irrevocable for such licensed product in such country. Upon the expiration of the term, the license granted to us shall become non-exclusive, transferable, sublicensable, fully paid, royalty free, perpetual, and irrevocable in its entirety.</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In consideration for the rights granted under the MabCare License Agreement, we made an upfront payment of $55.0 million in July 2024. As of March 31, 2025, we could be required to make additional payments of $1,132.0 million based upon the achievement of specified development, regulatory, and commercial success-based milestones plus low-to-mid single-digit royalties on net sales outside of Greater China.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">27</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">License agreement with Ipsen Pharma SAS</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On July 23, 2024, we entered into the Ipsen License Agreement, pursuant to which, we licensed to Ipsen, on an exclusive basis, the right to commercialize tovorafenib in all territories outside the United States and agreed to provide certain research and development and manufacturing services. Ipsen shall have the right to grant sublicenses to third-parties.</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the terms of the Ipsen License Agreement, (i) Ipsen paid us an upfront license fee in the amount of $70.8 million in August 2024 and (ii) the Investor, a fully-owned United States affiliate of Ipsen, purchased 2,341,495 shares of our common stock in a private placement for $40.0 million, at a price per share representing a 17.0% premium to the VWAP of our common stock as traded on The Nasdaq Stock Market LLC for the ten consecutive trading days prior to and including the date of the Revenue Release, and the ten consecutive trading days following the Revenue Release, in accordance with the terms set forth in an investment agreement by and between us and the Investor dated July 23, 2024.</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of March 31, 2025, we are also eligible to receive up to approximately $350.0 million in additional commercial launch and sales-based milestone payments based on exchange rates as of the reporting date. We are also entitled to tiered, double-digit royalty payments starting at mid-teens percentage of annual net sales of tovorafenib, subject to customary adjustments specified in the Ipsen License Agreement. The royalty payment obligations under the Ipsen License Agreement expire on a country-by-country basis no earlier than ten years following the first commercial sale of tovorafenib in the applicable country.</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, the Ipsen License Agreement provides that we will supply to Ipsen, and Ipsen will purchase from us, all required quantities of tovorafenib for all territories outside the United States in accordance with a supply agreement to be entered into by and between us and Ipsen, or the Ipsen Supply Agreement.</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Following the two-year anniversary of July 23, 2024, the effective date of the Ipsen License Agreement, Ipsen may terminate the Ipsen License Agreement for convenience with six months&#8217; prior written notice or for certain other specified reasons. We may terminate the Ipsen License Agreement if Ipsen or any of its affiliates challenge the validity of any patents controlled by us that are licensed under the Ipsen License Agreement. Both we and Ipsen may terminate the Ipsen License Agreement (i) for material breach by the other party and a failure to cure such breach within the time period specified in the Ipsen License Agreement or (ii) the other party&#8217;s bankruptcy event.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Components of Results of Operations</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Revenue</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Product revenue, net</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In April 2024, the FDA approved OJEMDA for the treatment of patients 6 months of age and older with relapsed or refractory pLGG harboring a BRAF fusion or rearrangement, or BRAF V600 mutation. We record product revenue net of estimated discounts, chargebacks, rebates, specialty distributor fees, copay assistance, and product returns.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">License revenue</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In July 2024, we entered into the Ipsen License Agreement, pursuant to which, we licensed to Ipsen, on an exclusive basis, the right to commercialize tovorafenib in all territories outside the United States and agreed to provide certain research and development and manufacturing services. The portion of the transaction price allocated to the licenses was recognized as revenue upon delivery of the licenses in the year ended of December 31, 2024. The transaction price allocated to the research and development services is being recognized over time as services are delivered.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Operating expenses</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cost of product revenue</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cost of product revenue includes the cost of inventory sold, amortization expense of intangible assets and third-party royalties payable on our net product revenue. Cost of goods sold may also include costs related to excess or obsolete inventory adjustment charges, abnormal costs, unabsorbed manufacturing and overhead costs, and manufacturing variances. We expect to use inventory previously expensed to research and development by the third quarter of 2025, and accordingly, we expect our cost of product revenue of OJEMDA to increase as a percentage of product revenue in future periods as we produce and sell inventory that reflects the full cost of manufacturing the product.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and development expenses</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development expenses consist primarily of external and internal expenses incurred for our research activities, including our discovery and in-licensing undertakings, and the development of our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">28</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">External expenses include:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.5760267799665257%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">costs incurred under agreements with third-party contract research organizations, or CROs, contract manufacturing organizations, or CMOs, and other third parties that conduct clinical activities on our behalf;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.5760267799665257%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">costs associated with acquiring technology and intellectual property licenses that have no alternative future uses; and </span></div></div><div class="item-list-element-wrapper" style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.5760267799665257%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">other business operational costs, such as rent, facilities and maintenance, travel and information technology, incurred related to research and development activities, but are not allocable to a specific product or product candidate. </span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Internal expenses include:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.5760267799665257%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">employee-related costs, including salaries, bonuses, benefits and share-based compensation expense, for our research and development personnel.</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expense research and development expenses as incurred. We track external costs by program, which currently consist of expenses for our tovorafenib, pimasertib, DAY301, and the VRK1 inhibitor program. We do not track indirect costs on a program specific basis because these costs are deployed across multiple programs and, as such, are not separately classified.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development activities are central to our business model. We expect that our research and development expenses will increase for the foreseeable future as we continue to implement our business strategy; advance our product candidates through clinical trials and conduct larger clinical trials; expand our research and development efforts; and identify, acquire and develop additional product candidates, particularly as more of our product candidates move into clinical development and later stages of clinical development.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The successful development of our drug candidates is uncertain and subject to a number of risks. We cannot guarantee that results of clinical trials will be favorable or sufficient to support marketing authorizations for any of our product development programs. We could decide to abandon development or be required to spend considerable resources not otherwise contemplated. For additional discussion regarding the risks and uncertainties regarding our research and development programs, please refer to Part II, Item 1A &#8220;Risk Factors&#8221; in this Quarterly Report on Form 10-Q.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Selling, general and administrative expenses</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Selling, general and administrative expenses consist primarily of employee-related costs, professional services and other operational costs. Employee-related costs include salaries, bonuses, benefits and share-based compensation expense for our selling, general and administrative personnel. Professional service expenses include legal fees; professional fees for accounting, marketing, human resources, business development, and other consulting services. Other operational costs include expenses for rent and facilities maintenance, travel, insurance and information technology.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect that our selling, general and administrative expenses will increase for the foreseeable future as we anticipate an increase in our personnel headcount to support the expansion of our corporate and commercial activities and continued expenses associated with being a public company, including costs related to compliance with the requirements of the Nasdaq Global Select Market, or Nasdaq, and the Securities and Exchange Commission, or the SEC; and investor and public relations costs.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">29</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Results of operations</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Comparison of three months ended March 31, 2025 and 2024</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes our results of operations for the three months ended March 31, 2025 and 2024 (unaudited):</span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:45.04%;box-sizing:content-box;"/>
     <td style="width:1.36%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:10.38%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.36%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:10.38%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.36%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:10.26%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:10.860000000000001%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended<br/>March 31,</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">$ Change</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">% Change</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Revenue:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Product revenue, net</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30,503</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30,503</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">*</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">License revenue</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">258</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">258</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">*</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total revenues</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30,761</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30,761</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">*</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Cost and operating expenses:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cost of product revenue</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,884</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,884</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">*</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">39,619</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">40,210</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(591</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(1.5</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Selling, general and administrative</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29,325</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26,557</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,768</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.4</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total cost and operating expenses</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">71,828</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">66,767</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,061</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.6</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Loss from operations</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(41,067</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(66,767</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25,700</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(38.5</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Non-operating income:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Investment income, net</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,094</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,365</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">729</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16.7</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other expense, net</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(23</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(10</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(13</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">*</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total non-operating income, net</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,071</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,355</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">716</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16.4</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Loss before income taxes</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(35,996</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(62,412</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26,416</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(42.3</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Income tax benefit (expense)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">*</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(35,996</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(62,412</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26,416</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(42.3</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
    </tr>
   </table><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">* Amount and/or percentage not meaningful</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Product revenue, net</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the three months ended March 31, 2025, we recorded net product revenue of $30.5 million from sales of OJEMDA in the United States.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">License revenue</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the three months ended March 31, 2025, we recorded license revenue of $0.3 million related to the Ipsen License Agreement.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cost of product revenue</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the three months ended March 31, 2025, we recorded cost of product revenue of $2.9 million related to sales of OJEMDA in the United States.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and development expenses</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development expenses decreased $0.6 million, from $40.2 million for the three months ended March 31, 2024 to $39.6 million for the three months ended March 31, 2025. Third-party expenses increased by $1.3 million due primarily to an increase in clinical trial and manufacturing activities associated with DAY301 and personnel related expenses decreased by $0.7 million driven by changes in headcount. Additionally, license related payments decreased by $1.0 million due to a $4.0 million milestone payment related to the XOMA License Agreement in the three months ended March 31, 2025 compared to a $5.0 million amendment payment related to the Viracta License Agreement in the three months ended March 31, 2024.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">30</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes our external and internal research and development expenses for the three months ended March 31, 2025 and 2024:</span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:66.993%;box-sizing:content-box;"/>
     <td style="width:1.62%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:12.883000000000001%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.62%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:12.883000000000001%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended<br/>March 31,</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">External costs:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Third-party CRO, CMO and other third-party clinical trial costs (1)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,821</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,546</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">XOMA License Agreement milestone payment</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,000</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Viracta License Agreement amendment payment</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,000</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other research and development costs</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,021</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,167</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Internal costs:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Employee related expenses</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,777</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,497</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total research and development expenses</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">39,619</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">40,210</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Third-party CRO, CMO and other clinical trial costs for the tovorafenib, pimasertib, DAY301, and the VRK1 inhibitor programs were $16.5 million, $0.4 million, $2.2 million, and $1.7 million, respectively, for three months ended March 31, 2025 compared to $16.7 million, $1.0 million, $0.0 million, and $1.8 million, respectively, for the three months ended March 31, 2024. </span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Selling, general and administrative expenses</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Selling, general and administrative expenses increased $2.7 million, from $26.6 million for the three months ended March 31, 2024 to $29.3 million for the three months ended March 31, 2025. The increase in selling, general and administrative expenses was primarily due to an increase of $2.0 million in personnel related expenses driven by headcount growth, an increase of $1.0 million in professional services driven by commercial launch activities, and a decrease of $0.2 million in other selling, general and administrative costs.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income tax benefit</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We did not record an income tax provision for the three months ended March 31, 2025 and 2024 as we generated tax losses during these periods.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Liquidity and Capital Resources</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Sources of liquidity</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In July 2024, we entered into a securities purchase agreement with certain institutional and accredited investors, or the PIPE Investors, pursuant to which we agreed to sell and issue to the PIPE Investors in a private placement, or the Private Placement, an aggregate of (i) 10,551,718 shares of our common stock at a purchase price of $14.50 per share and (ii) 1,517,241 pre-funded warrants, or the Pre-Funded Warrants, to purchase up to an aggregate of 1,517,241 shares of our common stock, or the Warrant Shares, at a purchase price of $14.4999 per Pre-Funded Warrant. Each Pre-Funded Warrant has an exercise price of $0.0001 per Warrant Share. The Pre-Funded Warrants are exercisable at any time after their original issuance and will not expire. The Private Placement closed on August 1, 2024 and we received net proceeds of $166.5 million, after deducting placement agent fees, offering costs and other expenses, of which $145.6 million was allocated to the common stock and $20.9 million was allocated to the Pre-Funded Warrants. The net proceeds were recorded as a component of additional paid-in capital.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In July 2024, we entered into the Ipsen License Agreement, pursuant to which, we licensed to Ipsen, on an exclusive basis, the right to commercialize tovorafenib in all territories outside the United States and agreed to provide certain research and development and manufacturing services. Under the terms of the Ipsen License Agreement, (i) Ipsen paid us an upfront license fee in the amount of $70.8 million in August 2024 and (ii) the Investor, a fully-owned United States affiliate of Ipsen, purchased 2,341,495 shares of our common stock in a private placement for $40.0 million, at a price per share representing a 17.0% premium to the VWAP of our common stock as traded on The Nasdaq Stock Market LLC for the ten consecutive trading days prior to and including the date of the Revenue Release, and the ten consecutive trading days following the Revenue Release, in accordance with the terms set forth in an investment agreement by and between we and the Investor dated July 23, 2024. We valued the shares at issuance at $32.6 million, concluding that our Company's common stock price as traded on The Nasdaq Stock Market LLC on the closing date of the transaction approximated fair value, which was then recorded as a component of additional paid-in capital.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have entered into an equity distribution agreement, or the Equity Distribution Agreement, with Piper Sandler &amp; Co. and JonesTrading Institutional Services LLC, as sales agents, relating to the issuance and sale of shares of our common stock for an aggregate offering price of up to $250.0 million under an at-the-market offering program, or the ATM. No shares of our common stock have been sold under the ATM as of March 31, 2025.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">31</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of March 31, 2025, we had an accumulated deficit of $590.1 million and $473.0 million in cash, cash equivalents and short-term investments. We believe our cash, cash equivalents and short-term investments will be sufficient to satisfy our capital requirements through at least twelve months after the date that this Quarterly Report is filed.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our primary use of cash is to fund operating expenses, which consist of research and development expenditures and selling, general and administrative expenditures. Cash used to fund operating expenses is impacted by the timing of when we pay these expenses, as reflected in the change in our outstanding accounts payable and accrued expenses. Our material cash requirements include the following contractual and other obligations.
</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Leases</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have an operating lease obligation for office space. As of March 31, 2025, we had fixed lease payment obligations of approximately $0.4 million payable, within 12 months.
</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Contract Research Organizations and Contract Manufacturing Organizations</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have entered into contracts in the normal course of business with CROs, CMOs, and other third-party vendors for clinical trial, manufacturing, testing, and other research and development activities. These contracts generally provide for termination on notice, with the exception of one vendor where certain costs are non-cancellable after the approval of the project. As of March 31, 2025, there were no amounts accrued related to termination and cancellation charges as these are not probable.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">License Agreements</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under our license agreements, we have payment obligations that are contingent upon future events such as our achievement of specified development, regulatory and commercial milestones and are required to make royalty payments in connection with the sale of products developed under those agreements. The amount and timing of milestone obligations are unknown or uncertain as we are unable to estimate the timing or likelihood of achieving the milestone events. Additionally, the amount of royalty payments are based upon future product sales, which we are unable to predict with certainty. These potential obligations are further described in Note 6 to the financial statements.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cash flows</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes our sources and uses of cash for the periods presented:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:66.967%;box-sizing:content-box;"/>
     <td style="width:1.62%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:12.897%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.62%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:12.897%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended<br/>March 31,</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash used in operating activities</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(58,997</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(49,729</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash (used in) provided by investing activities</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(32,613</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">89,288</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash provided by financing activities</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">48</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net (decrease) increase in cash and cash equivalents</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(91,610</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">39,607</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Operating activities</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Net cash used in operating activities for the three months ended March 31, 2025 was $59.0 million consisting of our net loss of $36.0 million and changes in net operating assets and liabilities of $32.5 million, which were offset by non-cash charges of $9.5 million. Changes in operating assets and liabilities were primarily related to a decrease in accrued expenses and other current liabilities of $27.0 million, an increase in accounts receivable of $4.2 million, a decrease in accounts payable of $0.7 million, an increase in prepaid expenses and other current assets of $0.6 million, an increase in inventory of $0.2 million, and an increase in deposits and other long-term assets of $0.1 million. This was partially offset by an increase in deferred revenue of $0.2 million and an increase in operating lease liability of $0.1 million. Non-cash charges consisted primarily of accretion of discounts on short-term investments of $4.3 million partially offset by share-based compensation expense of $12.9 million, amortization of intangible assets of $0.7 million, depreciation expense of $0.1 million, and amortization of operating right-of-use asset of $0.1 million.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Net cash used in operating activities for the three months ended March 31, 2024 was $49.7 million, consisting of our net loss of $62.4 million, non-cash charges of $11.5 million and net changes in operating assets and liabilities of $1.2 million. Non-cash charges are primarily related to share-based compensation expense of $12.6 million, which was partially offset by accretion of discounts on short-term investments of $1.3 million. Net changes in operating assets and liabilities are primarily related to an increase in accounts payable of $2.2 million and a decrease in prepaid expenses and other current assets of $0.8 million, which were partially offset by a decrease in accrued expenses and other current liabilities of $1.8 million and a decrease in operating lease liabilities of $0.1 million.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Investing activities</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Net cash used in investing activities for the three months ended March 31, 2025 was $32.6 million attributable to the purchase of short-term investments of $189.8 million, acquisition of intangible assets of $3.5 million, and the purchase of property and equipment of $0.3 million. This was partially offset by the proceeds from maturity of short-term investments of $161.0 million.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">32</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Net cash provided by investing activities for the three months ended March 31, 2024 was $89.3 million related to the proceeds from the maturity of short-term investments of $136.5 million, partially offset by the purchase of short-term investments of $47.2 million.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Financing activities</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There were no cash flow activities provided by or used in financing activities during the three months ended March 31, 2025.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash provided by financing activities for the three months ended March 31, 2024 was $48,000 related to net proceeds from the issuance of common stock upon stock option exercises.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Funding requirements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Since our inception, we have incurred significant operating losses. We expect to continue to incur significant expenses and increasing operating losses for the foreseeable future in connection with our ongoing activities. As of March 31, 2025, we had $473.0 million in cash and cash equivalents and short-term investments. We believe our cash, cash equivalents and short-term investments will be sufficient to satisfy our capital requirements at least twelve months after the date that this Quarterly Report is filed.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If our cash, cash equivalents and short-term investments are not sufficient to meet capital needs until such time that we can generate substantial revenue, we expect to finance our cash needs through a combination of equity offerings, debt financings, collaborations, strategic alliances and marketing, distribution or licensing arrangements. Adequate additional funds may not be available to us on acceptable terms, or at all. If we are unable to raise capital when needed or on attractive terms, we may be required to delay, limit, reduce or terminate our research, product development programs or any future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To the extent that we raise additional capital through the sale of equity or convertible debt securities, stockholder ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect stockholder rights as a common stockholder. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making acquisitions or capital expenditures or declaring dividends.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our ability to raise additional funds may be adversely impacted by potential worsening global economic conditions, and disruptions to and volatility in the credit and financial markets in the United States and worldwide resulting from inflation, changing interest rates, significant political, trade or regulatory developments, global regional conflicts, public health epidemics, or otherwise. Because of the numerous risks and uncertainties associated with product development, we cannot predict the timing or amount of increased expenses and cannot assure that we will ever be profitable or generate positive cash flow from operating activities.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Critical accounting policies and use of estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our management&#8217;s discussion and analysis of financial condition and results of operations is based on our condensed financial statements, which have been prepared in accordance with U.S. GAAP. The preparation of condensed financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. We base our estimates on historical experience, known trends and events and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates under different assumptions or conditions.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">While our significant accounting policies are described in more detail in the Notes to our Condensed Financial Statements appearing within Item 2 of this Quarterly Report, we believe that the following accounting policies are the most critical to the judgments and estimates used in the preparation of our condensed financial statements.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Accrued research and development expense</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We record accrued liabilities for estimated costs of our clinical trials conducted by third-party service providers. We record the estimated costs of the clinical trials as research and development expense based upon the estimated amount of services provided but not yet invoiced. We accrue for these costs based on factors such as estimates of the work completed and in accordance with terms established with our third-party service providers under the service agreements.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We make payments in connection with the clinical trials under contracts with CROs who conduct and manage our clinical trials. The financial terms of these contracts are subject to negotiation, which vary by contract and may result in payments that do not match</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">33</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the periods over which materials or services are provided. Generally, these agreements set forth the scope of work to be performed at a fixed fee, unit price or on a time and materials basis. We accrue costs for clinical trial activities performed by CROs based upon the estimated amount of work completed on each trial. For clinical trials, the significant factors used in estimating accruals include the number of patients enrolled, the activities to be performed for each patient, the number of active clinical sites and the duration for which the patients will be enrolled in the trial. We monitor patient enrollment levels and related activities to the extent possible through internal reviews, correspondence with CROs and review of contractual terms. We base our estimates on the best information available at the time.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we do not identify costs that have begun to be incurred or if we under- or over-estimate the level of services performed or the costs of these services, actual expenses could differ from our estimates. To date, we have not experienced any material differences between accrued costs and actual costs incurred. However, due to the nature of estimates, we cannot assure that we will not make changes to our estimates in the future as we become aware of additional information about the status or conduct of our clinical trials.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">New Accounting Pronouncements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Refer to Note 2 of the Notes to our Financial Statements included elsewhere in this Quarterly Report on Form 10-Q for a summary of recently issued and adopted accounting pronouncements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="tx180355_10"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 3. Quantitative and Qualitative Disclosures About Market Risk.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There were no material changes to our market risks from those described in Part II Item 7A. Quantitative and qualitative disclosures about market risk of our 2024 Form 10-K.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="tx180355_11"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 4. Controls and Procedures.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Evaluation of Disclosure Controls and Procedures</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of March 31, 2025, management, with the participation of our Principal Executive Officer and Principal Financial Officer, performed an evaluation of the effectiveness of our disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act. Our disclosure controls and procedures are designed to ensure that information required to be disclosed in the reports we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC&#8217;s rules and forms, and that such information is accumulated and communicated to our management, including the Principal Executive Officer and the Principal Financial Officer, to allow timely decisions regarding required disclosures. Any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objective and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on this evaluation, our Principal Executive Officer and Principal Financial Officer concluded that, as of March 31, 2025, our disclosure controls and procedures were effective at a reasonable assurance level.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Changes in Internal Control over Financial Reporting</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There were no changes in our internal control over financial reporting that occurred during the three months ended March 31, 2025 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">34</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="part_ii_other_information"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PART II-OTHE</span><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">R</span><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> INFORMATION</span><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_1_legal_proeedings"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Legal Proceedings.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time, we may be involved in legal proceedings arising in the ordinary course of our business. We are not presently a party to any legal proceedings that, in the opinion of management, would have a material adverse effect on our business. Regardless of outcome, litigation can have an adverse impact on us due to defense and settlement costs, diversion of management resources, negative publicity and reputational harm, and other factors.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_1a_risk_factors"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1A</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Risk Factors.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Investing in our common stock involves a high degree of risk. Before making your decision to invest in shares of our common stock, you should carefully consider the risks and uncertainties described below, together with the other information contained in this quarterly report, including our financial statements and the related notes and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.&#8221; The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties that we are unaware of, or that we currently believe are not material, may also become important factors that affect us. We cannot assure you that any of the events discussed below will not occur. These events could have a material and adverse impact on our business, financial condition, results of operations and prospects. If that were to happen, the trading price of our common stock could decline, and you could lose all or part of your investment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Summary of Risk Factors</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our business is subject to several risks and uncertainties, including those immediately following this summary. Some of these risks are:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are a commercial stage biopharmaceutical company with a limited operating history in the initial stages of the commercialization of our product, OJEMDA, which may make it difficult for investors to evaluate our current business and likelihood of success and viability. </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have incurred significant net losses since our inception. We expect to incur continued losses for the foreseeable future and may never achieve or maintain profitability.</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our near-term revenues are highly dependent on the successful commercialization of OJEMDA, which received marketing approval in April 2024 from the FDA for the treatment of patients 6 months of age and older with relapsed or refractory pLGG harboring a BRAF fusion or rearrangement, or BRAF V600 mutation. To the extent that OJEMDA is not commercially successful, our business, financial condition and results of operations would be materially and adversely affected and the price of our common stock would decline. </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our ability to generate revenue and achieve profitability depends significantly on our ability to achieve several objectives relating to the discovery or identification, development and commercialization of OJEMDA and our product candidates. </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may require additional capital to finance our operations and achieve our goals. If we are unable to raise capital when needed or on terms acceptable to us, we may be forced to delay, reduce or eliminate our research or product development programs, any future commercialization efforts or other operations. </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Clinical trials are very expensive, time-consuming and difficult to design and implement, and involve uncertain outcomes. Furthermore, results of earlier preclinical studies and clinical trials may not be predictive of results of future preclinical studies or clinical trials. OJEMDA and our product candidates may not have favorable results in later clinical trials, if any, or receive marketing authorization. If we fail to demonstrate the safety and effectiveness of our product candidates, our reputation may be harmed and our business will suffer.</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may rely on data from investigator-initiated studies, as we did for the Phase 1 clinical trial, and we do not control the trial operations or reporting of the results of such trials. </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The development and commercialization of pharmaceutical products are subject to extensive regulation, and we may not obtain marketing authorizations for DAY301, the VRK1 inhibitor program or any future product candidates, on a timely basis or at all. </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The manufacture of pharmaceutical products, including OJEMDA and our product candidates, including DAY301 and the VRK1 inhibitor program, is complex. Our third-party manufacturers may encounter difficulties in production, which could delay or entirely halt their ability to supply our product candidates for clinical trials or, if approved, our products for commercial sale. </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our future success depends on our ability to retain our executive officers and key employees and to attract, retain and motivate qualified personnel and manage our human capital. </span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">35</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We will need to grow the size and capabilities of our organization, and we may experience difficulties in managing this growth.</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we are unable to obtain and maintain patent protection or other necessary rights for our products and technology, or if the scope of the patent protection obtained is not sufficiently broad or our rights under our patents (owned, co-owned or licensed) is not sufficiently broad, our competitors could develop and commercialize products and technology similar or identical to ours, and our ability to successfully commercialize our products and technology may be adversely affected.</span></div></div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Our Financial Position</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We are a commercial-stage biopharmaceutical company with a limited operating history in the initial stages of the commercialization our product OJEMDA, which may make it difficult for investors to evaluate our current business and likelihood of success and viability.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are a commercial-stage biopharmaceutical company with a limited operating history upon which you can evaluate our business and prospects. Investment in drug development is a highly speculative undertaking and involves a substantial degree of risk. We commenced operations in 2018, and, to date, we have devoted substantially all of our resources to identifying, acquiring and developing OJEMDA and our product candidates, including DAY 301, which we licensed from MabCare Therapeutics in June 2024, building our pipeline, organizing and staffing our company, business planning, building a commercial organization, establishing and maintaining our intellectual property portfolio, establishing arrangements with third parties for the manufacture of our product candidates, raising capital and providing selling, general and administrative support for these operations.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of March 31, 2025, we have generated approximately $87.7 million of net revenue from product sales of OJEMDA and we have financed our operations primarily through the sale and issuance of redeemable convertible preferred shares, the completion of our initial public offering, or IPO, and follow-on public offerings of our common stock.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are continuing to transition from a company with a research and development focus to a company capable of supporting commercial activities and we may not be successful in such transition. We are still at the early stages of demonstrating our ability to manufacture at commercial scale, or arrange for a third party to do so on our behalf, or conduct sales, marketing and distribution activities necessary for successful product commercialization. As a result, it may be more difficult for you to accurately predict our likelihood of success and viability than it could be if we had a longer operating history.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, we may encounter unforeseen expenses, difficulties, complications, delays and other known and unknown factors and risks frequently experienced by biopharmaceutical companies in rapidly evolving fields and with recently approved therapies. If we do not adequately address these risks and difficulties or successfully make a commercial transition, our business will suffer.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We have incurred significant net losses since our inception. We expect to incur continued losses for the foreseeable future and may never achieve or maintain profitability.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have incurred significant net losses in each reporting period since our inception, and as of March 31, 2025, we have generated approximately $87.7 million of revenue from product sales of OJEMDA. We have financed our operations principally through the sale and issuance of redeemable convertible preferred shares, the completion of our initial public offering, or IPO, and follow-on public offerings of our common stock. For the three months ended March 31, 2025 and 2024 we reported a net loss of $36.0 million and $62.4 million, respectively. We had an accumulated deficit of $590.1 million as of March 31, 2025. We expect to incur increasing levels of operating losses for the foreseeable future, particularly as we advance tovorafenib, DAY301 and the VRK1 inhibitor program through clinical development. Our prior losses, combined with expected future losses, have had, and will continue to have, an adverse effect on our stockholders&#8217; equity and working capital. We expect our research and development expenses to significantly increase in connection with our additional planned clinical trials for our product and product candidates, including our ongoing pivotal Phase 3 FIREFLY-2 trial of tovorafenib as a potential front-line therapy in pLGG, our post-marketing commitments and requirements for OJEMDA, our Phase 1a/b trial of DAY301 targeting PTK7 and development of and subsequent Investigational New Drug Applications, or INDs, for any future product candidates we may choose to pursue. In October 2023, the U.S. Food and Drug Administration, or FDA, accepted our New Drug Applications, or NDAs, and granted priority review for OJEMDA as a monotherapy in relapsed or refractory pLGG. On April 23, 2024, the FDA approved the NDAs for OJEMDA for use in the treatment of patients 6 months of age and older with relapsed or refractory pLGG harboring a BRAF fusion or rearrangement, or BRAF V600 mutation. We will incur significant sales, marketing and outsourced manufacturing expenses in connection with the commercialization of OJEMDA, or our product candidates, including DAY301 and the VRK1 inhibitor program, if marketing authorization is received. We have also incurred, and will continue to incur, additional costs associated with operating as a public company.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As a result, we expect to continue to incur significant and increasing net losses for the foreseeable future. Because of the numerous risks and uncertainties associated with developing pharmaceutical products, we are unable to predict the extent of any future losses or when we will become profitable, if at all. Even if we do become profitable, we may not be able to sustain or increase our profitability on a quarterly or annual basis. In addition, we expect our financial condition and operating results to fluctuate significantly from</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">36</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">quarter-to-quarter and year-to-year due to a variety of factors, many of which are beyond our control. Accordingly, you should not rely upon the results of any quarterly or annual periods as indications of future operating performance.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our near-term revenues are highly dependent on the successful commercialization of OJEMDA, which received marketing approval in April 2024 from the FDA for the treatment of patients 6 months of age and older with relapsed or refractory pLGG harboring a BRAF fusion or rearrangement, or BRAF V600 mutation. To the extent that OJEMDA is not commercially successful, our business, financial condition and results of operations would be materially and adversely affected and the price of our common stock would decline.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our future success is highly dependent on our ability to timely complete successful clinical trials, obtain marketing authorization for, and then successfully commercialize, OJEMDA and our product candidates. OJEMDA is our only drug that has been approved for sale and it has only been approved for the treatment of patients 6 months of age and older with relapsed or refractory pLGG harboring a BRAF fusion or rearrangement, or BRAF V600 mutation. Prior to OJEMDA, we have not, as an organization, launched or commercialized a product, and there is no guarantee that we will be able to do so successfully with OJEMDA. There are numerous examples of unsuccessful product launches and failures to meet high expectations of market potential. We are focusing a significant portion of our activities and resources on OJEMDA, and we believe our near-term revenues are highly dependent on, and a meaningful portion of the value of our company relates to, our ability to successfully commercialize OJEMDA in the United States. If the launch or commercialization of OJEMDA is unsuccessful or perceived as disappointing, our stock price could decline significantly and the long-term success of the product and our company could be harmed.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The success of OJEMDA will depend on several factors, including the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">making arrangements with third-party manufacturers, or establishing manufacturing capabilities, for both clinical and commercial supplies of OJEMDA and ensuring a resilient, effective supply chain that produces supply that outpaces demand;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">implementing marketing, pricing and reimbursement strategies, as well as adequate demand forecasts for supply and sales planning;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">establishing sales, marketing and distribution capabilities for OJEMDA, whether alone or in collaboration with others in a market where promotional sales approaches are rapidly moving to digital platforms and access of sales representatives to major institutions remains uncertain;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">acceptance of OJEMDA by patients, physicians, the medical community and third-party payors underpinned by adequate health economic data and a meaningful value proposition;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">obtaining and maintaining third-party payor coverage and adequate reimbursement in both public and private payor spaces across multiple countries;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">effectively competing with other therapies, including those that have not yet entered the market;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">effectively competing with other companies in the pharmaceutical and biotechnology industries, which are characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary and novel products and product candidates;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">obtaining appropriate support from patient advocacy organizations;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">effectively shaping the market in the early years following launch to help providers understand a new way of thinking about treating relevant patients;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">whether our patents will be sufficient to prevent generic competition for OJEMDA after our orphan drug exclusivity expires;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the successful completion of any required or committed post-marketing studies and available funding to perform any such post-marketing requirements or post-marketing commitments;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">maintaining a continued acceptable safety profile of the products following approval.   </span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Many of these factors are beyond our control, and if we cannot address any of them in a timely manner or at all, we could experience significant delays or an inability to successfully commercialize OJEMDA and our product candidates, which would materially harm our business.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our ability to generate revenue and achieve profitability depends significantly on our ability to achieve several objectives relating to the development and commercialization of OJEMDA and our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our business depends entirely on the successful commercialization of OJEMDA and development of our product candidates. We are early in our development efforts for other indications, and our product tovorafenib is currently in a pivotal Phase 3 clinical trial as a</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">37</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">potential front-line therapy in pLGG. Our product candidates, DAY301 and the VRK1 inhibitor program, are in earlier stages of development and are not approved for sale in any jurisdiction. There can be no assurance that tovorafenib, DAY301, the VRK1 inhibitor program or any future product candidates we develop, if any, will achieve success in their ongoing clinical trials or obtain marketing authorization.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our ability to generate future revenue at the levels or timing we expect and achieve profitability depends on several factors, including, but not limited to, our ability to:</span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">successfully market and sell OJEMDA while maintaining full compliance with applicable federal and state laws, rules and regulations;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">complete a successful pivotal Phase 3 FIREFLY-2 trial with tovorafenib that achieves a competitive, clinically meaningful and generally well-tolerated target product profile for the front-line treatment of pLGG;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">complete a successful Phase 1a/b trial of DAY301;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">initiate and successfully complete all safety, pharmacokinetic and other studies required to support Ipsen to obtain foreign marketing authorization for OJEMDA as a treatment for patients with pLGGs; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">initiate and complete additional, successful late-stage clinical trials that meet their clinical endpoints; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">obtain favorable results from our clinical trials and apply for and obtain marketing authorizations for DAY301 and the VRK1 inhibitor program from applicable regulatory authorities, including NDAs from the FDA, and maintaining such approvals; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">establish licenses, collaborations or strategic partnerships that allow for the commercialization of OJEMDA and our product candidates and/or may increase the value of our programs; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">successfully commercialize OJEMDA, DAY301, the VRK1 inhibitor program and any future product candidates we may develop, if approved, by building and maintaining a sales force and/or entering into collaborations with third parties; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">satisfy any post-marketing requirements imposed by, or post-marketing commitments made to, applicable regulatory authorities; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">demonstrate an acceptable safety profile of our product and our product candidates, including DAY301 and the VRK1 inhibitor program, and continue to maintain a continued acceptable safety profile following marketing authorization, if any;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">identify, assess and develop new product candidates; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">establish and maintain patent and trade secret protection, statutory exclusivities and other intellectual property protections for our products;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">obtain, maintain, protect and defend our intellectual property portfolio, including any necessary licenses from third parties;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">address any competing therapies and technological and market developments; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">achieve market acceptance of our product candidates, including DAY301 and the VRK1 inhibitor program, if approved, with patients, the medical community and third-party payors, both in the United States and internationally; and </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">attract, hire and retain qualified personnel and management. </span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To become and remain profitable, we must succeed in developing and commercializing products that generate significant revenue. This will require us to be successful in a range of challenging activities, including completing clinical trials for OJEMDA and our product candidates, acquiring additional product candidates, establishing arrangements with third parties for the manufacture of clinical supplies of our product candidates, obtaining marketing authorization for our product candidates, obtaining and retaining patents, trade secrets, statutory exclusivities, and other intellectual property protections and marketing and selling products for which we may obtain marketing authorization, if any. We are in the early stages of most of these activities. We may never succeed in these activities and, even if we do, may never generate revenues that are significant enough to achieve profitability.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In cases where we are successful in obtaining marketing authorizations to market one or more of our product candidates, our revenue will be dependent, in part, upon the size of the markets in the territories for which we gain marketing authorizations, the pricing for the product, the duration of treatment with our product, the adoption of our product in treatment guidelines and by prescribers, the ability to obtain coverage and reimbursement and whether we own the commercial rights for that territory. If the number of our addressable patients is not as significant as we estimate, the approved indication is narrower than expected or the treatment population is narrowed by competition, physician choice, payor decisions or treatment guidelines, we may not generate significant revenue from sales of such products, even if approved.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we decide to, or are required by the FDA or regulatory authorities in other jurisdictions to, perform studies or clinical trials in addition to those currently expected, or to modify ongoing or planned clinical trials, or if there are any delays in establishing</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">38</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">appropriate manufacturing arrangements for, in initiating or completing our current and planned clinical trials for or in the development of, any of our product candidates, our expenses could increase significantly and profitability could be further delayed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our failure to become and remain profitable could depress the value of our company and could impair our ability to raise capital, expand our business, maintain our research and development efforts, diversify our product offerings or even continue our operations. A decline in the value of our company could also cause you to lose all or part of your investment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may require additional capital to finance our operations and achieve our goals. If we are unable to raise capital when needed or on terms acceptable to us, we may be forced to delay, reduce or eliminate our research or product development programs, any future commercialization efforts or other operations.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Developing pharmaceutical products, including conducting preclinical studies and clinical trials, is a very time-consuming, expensive and uncertain process that takes years to complete. Our operations have consumed substantial amounts of cash since inception, and we expect our expenses to increase in connection with our ongoing activities, particularly as we commercialize our product, OJEMDA, and advance product candidates, DAY301 and the VRK1 inhibitor program, and any future product candidates through clinical development. We expect increased expenses as we continue our research and development, initiate additional clinical trials, seek to expand our product pipeline, seek marketing authorization for our programs and future product candidates, if any, and invest in our organization. In addition, we expect to incur significant expenses related to the product manufacturing, marketing, sales and distribution of OJEMDA and, if we obtain marketing authorization, for our product candidates including DAY301 and the VRK1 inhibitor program. Furthermore, we have incurred and will continue to incur additional costs associated with operating as a public company, such as acquiring and retaining experienced personnel, developing new information technology systems and other costs associated with being a public company. Also, we expect to experience ongoing and additional costs related to preparing and filing patent applications, maintaining our intellectual property and potentially expanding our office facilities. Accordingly, we will need to obtain additional funding in connection with our continuing operations.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We had $473.0 million in cash, cash equivalents and short-term investments as of  March 31, 2025. Based on our cash, cash equivalents and short-term investments, as of March 31, 2025, we estimate that our current liquidity will be sufficient to satisfy our capital requirements at least twelve months after the date that this Quarterly Report is filed. We have based this estimate on assumptions that may prove to be wrong, and we could use our capital resources sooner than we currently expect. Changes beyond our control may occur that would cause us to use our available capital before that time, including changes in and progress of our drug development activities and changes in regulation. Our future capital requirements will depend on many factors, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the progress, timing and results of preclinical studies and clinical trials for our current or any future product candidates; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the extent to which we develop, in-license or acquire other pipeline product candidates or technologies; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the number and development requirements of current or future product candidates that we may pursue, and other indications for our current product candidates that we may pursue; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs, timing and outcome of obtaining marketing authorization for our current or future product candidates or the modification of ongoing or planned clinical trials;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the successful development of and marketing authorization for any complementary or companion diagnostics that may be useful to or necessary for the commercialization of OJEMDA and our product candidates;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the scope and costs of making arrangements with third-party manufacturers, or establishing manufacturing capabilities, for both clinical and commercial supplies of our current or future product candidates; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs involved in growing our organization to the size needed to allow for the research, development and potential commercialization of our current or future product candidates; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to the extent we pursue strategic collaborations, including collaborations to commercialize OJEMDA, DAY301, the VRK1 inhibitor program or any of our future pipeline products and product candidates, if any, our ability to establish and maintain collaborations on favorable terms, if at all, as well as the timing and amount of any milestone or royalty payments we are required to make or are eligible to receive under such collaborations or our current licenses; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the cost associated with commercializing any approved products and product candidates, including establishing sales, marketing, market access and distribution capabilities; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the cost associated with completing any post-marketing studies or trials requested or required by the FDA or other regulatory authorities, including for OJEMDA; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the revenue, if any, received from commercial sales of OJEMDA, DAY301, the VRK1 inhibitor program or any of our future product candidates, if approved, or any other future pipeline product candidates that receive marketing authorization; </span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">39</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims that we may become subject to, including any litigation costs and the outcome of such litigation; and </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs associated with potential product liability claims, including the costs associated with obtaining insurance against such claims and with defending against such claims. </span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may require additional capital to complete our planned clinical development programs for our current product candidates to obtain marketing authorization, and we anticipate needing to raise additional capital to complete the development of our product candidates. Our ability to raise additional funds will depend on financial, economic and market conditions and other factors, over which we may have no or limited control. If adequate funds are not available on commercially acceptable terms when needed, we may be forced to delay, reduce or terminate the development or commercialization of all or part of our research programs or products and product candidates or we may be unable to take advantage of future business opportunities. Furthermore, any additional capital-raising efforts may divert our team&#8217;s attention from their day-to-day activities, which may adversely affect our business, including our ability to develop and commercialize our current and future product candidates, if approved. Changing circumstances, some of which may be beyond our control, could cause us to consume capital significantly faster than we currently anticipate, and we may need to seek additional funds sooner than planned.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may be required to obtain further funding through public or private equity financings, debt financings, collaborative agreements, licensing arrangements or other sources of financing, which may dilute our stockholders or restrict our operating activities. We do not have any committed external source of funds. We have entered into an equity distribution agreement, or the Equity Distribution Agreement, with Piper Sandler &amp; Co. and JonesTrading Institutional Services LLC, as sales agents, relating to the issuance and sale of shares of our common stock for an aggregate offering price of up to $250.0 million under an at-the-market offering program, or the ATM. No shares of our common stock have been sold under the ATM as of March 31, 2025. To the extent that we raise additional capital through the sale of equity or convertible debt securities, including pursuant to the ATM, each investor&#8217;s ownership interests will be diluted, and the terms may include liquidation or other preferences that adversely affect each investor&#8217;s rights as a stockholder. Debt financing may result in imposition of debt covenants, increased fixed payment obligations or other restrictions that may affect our business. If we raise additional funds through upfront payments or milestone payments pursuant to strategic collaborations with third parties, we may have to relinquish valuable rights to our product candidates or grant licenses on terms that are not favorable to us. Our ability to raise additional funds may be adversely impacted by potential worsening global economic conditions and disruptions to, and volatility in, the credit and financial markets in the United States and worldwide resulting from inflation, changes in interest rates, significant political, trade or regulatory developments, global regional conflicts, public health epidemics or otherwise.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our failure to raise capital as and when needed or on acceptable terms would have a negative impact on our financial condition and our ability to pursue our business strategy, and we may have to delay, reduce the scope of, suspend or eliminate one or more of our research or drug development programs, clinical trials or future commercialization efforts.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Development and Commercialization of OJEMDA and our Product Candidates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Clinical trials are very expensive, time-consuming and difficult to design and implement, and involve uncertain outcomes. Furthermore, results of earlier preclinical studies and clinical trials may not be predictive of results of future preclinical studies or clinical trials. OJEMDA and our product candidates may not have favorable results in later clinical trials, if any, and not all of our product candidates will receive marketing authorization. If we fail to demonstrate the safety and effectiveness of our product candidates, our reputation may be harmed and our business will suffer.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The risk of failure for our product candidates is high. It is impossible to predict when or if our product candidates will prove effective or safe in humans or if our product candidates will receive marketing authorization. To obtain the requisite marketing authorizations to market and sell our product candidates, we must demonstrate through extensive preclinical studies and clinical trials that our product candidates are safe and effective in humans for use in each target indication. Clinical testing is expensive and can take many years to complete, and the outcome is inherently uncertain. Failure can occur at any time during the clinical trial process.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, the results of preclinical studies and earlier clinical trials may not be predictive of the results of later-stage preclinical studies or clinical trials. We have limited clinical data for our product candidates. Products and product candidates in later stages of clinical trials may fail to show similar or desired safety and efficacy traits despite having progressed through preclinical and earlier stage clinical trials.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In some instances, there can be significant variability in safety or efficacy results between different clinical trials of the same product or product candidate due to numerous factors, including changes in clinical trial procedures set forth in protocols, differences in the size and type of the patient populations, adherence to the dosing regimen and other clinical trial protocols and the rate of discontinuation among clinical trial participants.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">40</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we fail to produce positive results in our planned clinical trials of any of our product candidates, the development timeline and marketing authorization and commercialization prospects for our product candidates, and, correspondingly, our business and financial prospects, would be materially and adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">OJEMDA has only been studied in a limited number of patients. Following commercial launch, OJEMDA is now available to a much larger number of patients, and we do not know whether the results of OJEMDA&#8217;s use in such larger number of patients will be consistent with the results from our clinical studies.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">OJEMDA has been administered only to a limited number of patients in clinical studies. While the FDA granted accelerated approval of OJEMDA based on the data included in the NDAs, we do not know whether the real-world safety and effectiveness of the product will be consistent with the safety and effectiveness profile seen in the clinical studies. New data relating to OJEMDA, including from adverse events reports and our post-marketing commitments in the United States, and from other ongoing clinical studies, may result in changes to the product label and may adversely affect sales, or result in withdrawal of OJEMDA from the market. If any of these actions were to occur, it could result in significant expense and delay and/or limit our ability to generate future sales revenues in line with our expectations.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may rely on data from investigator-initiated studies, as we did for the Phase 1 clinical trial, and we do not control the trial operations or reporting of the results of such trials.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time, we may rely on certain clinical data from investigator-sponsored clinical studies, and we do not control the trial operations or reporting of the results of such trials. This was the case for the initial Phase 1 study for our product, OJEMDA, which was run as an investigator-initiated, multi-center trial in patients with relapsed or refractory pLGG that is being conducted by the Dana Farber Cancer Institute in collaboration with the Pacific Pediatric Neuro-Oncology Consortium, or PNOC. The last data reported from that trial was in January 2023. It is possible that additional data, when reported, will not demonstrate similar results. We have no control over the timing of such clinical data announcements. Our pivotal Phase 2 FIREFLY-1 trial OJEMDA is a Day One-sponsored trial. In addition, in later-stage clinical trials, we will likely be subject to more rigorous statistical analyses than in completed earlier stage clinical trials. A number of companies in the pharmaceutical industry have suffered significant setbacks in later-stage clinical trials due to lack of efficacy or adverse safety profiles, notwithstanding promising results in earlier trials, and we cannot be certain that we will not face similar setbacks. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing authorization for their product candidates.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Furthermore, we do not control the design or administration of investigator-sponsored trials, nor the submission or approval of any IND or foreign equivalent required to conduct these trials, and the investigator-sponsored trials could, depending on the actions of such third parties, jeopardize the validity of the clinical data generated, identify significant concerns with respect to our product candidates that could impact our findings or clinical trials and adversely affect our ability to obtain marketing authorization from the FDA or other applicable regulatory authorities. To the extent the results of this or other investigator-sponsored trials are inconsistent with, or different from, the results of our planned company-sponsored trials or raise concerns regarding our product candidates, the FDA or a foreign regulatory authority may question the results of the company-sponsored trial or subject such results to greater scrutiny than it otherwise would. In these circumstances, the FDA or such foreign regulatory authorities may require us to obtain and submit additional clinical data, which could delay clinical development or marketing authorization of our product candidates. While investigator-sponsored trials could be useful to inform our own clinical development efforts, we do not control the data or timing of data releases for investigator-sponsored trials, and there is no guarantee that we will be able to use the data from these trials to form the basis for marketing authorization of our product candidates.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our compassionate use programs could subject us to additional risks, including delays in our clinical trial programs, impacts to our supply capabilities, or adverse publicity.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Some patients receive access to investigational drugs outside of clinical trials through compassionate use programs, which refer to expanded access or right-to-try programs. These patients generally have life-threatening illnesses for which there are no alternative therapies or they have exhausted all other available treatment options. There are a number of risks that we may face as a result of our compassionate use programs. For example, the risk for serious adverse events in this patient population is high, which, if those adverse events are determined to be drug-related, could have a negative impact on the safety profile of our drug candidates and/or cause significant regulatory delays, result in an inability to obtain regulatory approvals or successfully commercialize our drug candidates and/or materially harm our business. Additionally, if we were to provide patients with any of our drug candidates under a compassionate use program, our supply capabilities may limit the number of patients who are able to enroll in the program.  It also may become challenging to enroll patients in randomized trials if product candidates are being supplied to patients under expanded access programs.  These factors may result in the need to restructure or pause any compassionate use program in order to enroll sufficient numbers of patients in our clinical trials required for marketing authorization and successful commercialization of our drug</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">41</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">candidates. If we were to restructure or pause our compassionate use programs, we could face adverse publicity or disruptions related to current or potential participants in our programs.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our clinical trials may be suspended, delayed or fail to adequately demonstrate the safety and effectiveness of OJEMDA and our product candidates, which would prevent or delay development, marketing authorization and commercialization.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Before obtaining marketing authorization from the FDA or comparable foreign regulatory authorities for the sale of OJEMDA and our product candidates, we must demonstrate through lengthy, complex and expensive clinical trials that our product candidates are both safe and effective for use in each target indication. Clinical testing is expensive, difficult to design and implement, can take many years to complete and its ultimate outcome is uncertain. Failure can occur at any time during the clinical trial processes and for any number of reasons, and, because our product candidates are in earlier stages of development, there is a high risk of failure and we may never succeed in developing marketable products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may experience numerous challenges and unforeseen events during, or as a result of, clinical trials that could delay or prevent receipt of marketing authorization or our ability to successfully commercialize OJEMDA or our product candidates, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the FDA or other regulators refusing to permit our clinical studies to proceed or placing studies on hold before or after the studies begin;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a failure to demonstrate that the dose for a product candidate has been optimized;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">failure of our product candidates in clinical trials to demonstrate important functional, quality, or patient-reported outcomes;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">changes in the competitive landscape causing clinical trial enrollment challenges or preventing or delaying marketing authorization in one or several subsets studied in our programs, including in relapsed or front-line pLGG;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">receipt of feedback from regulatory authorities that requires us to modify the design of our clinical trials; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">negative or inconclusive clinical trial results that may require us to conduct additional clinical trials or abandon certain research and/or drug development programs; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the number of patients required for clinical trials being larger than anticipated, enrollment in these clinical trials being slower than anticipated or participants dropping out of these clinical trials at a higher rate than anticipated;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">unanticipated delays in our preclinical studies or clinical trials;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">third-party contractors failing to comply with regulatory requirements, including Good Clinical Practice, or GCP, regulations, or meet their contractual obligations to us in a timely manner, or at all; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the suspension or termination of our clinical trials for various reasons, including non-compliance with regulatory requirements or a finding that our product candidates have undesirable side effects or other unexpected characteristics or risks; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the cost of clinical trials of our product candidates being greater than anticipated; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the supply or quality of our product candidates or other materials necessary to conduct clinical trials of our product candidates being insufficient or inadequate;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">failure of our clinical trials to demonstrate the safety or effectiveness of our product candidates;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">regulators revising the requirements for approving our product candidates; and </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">receipt of feedback from regulatory authorities that would require us to include data from additional patients or longer term efficacy and safety data.</span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may also face unanticipated regulatory hurdles in our drug development program that may require additional data generation or delay our existing or planned trials and the timing of applications for marketing authorization. For instance, we may make formulation or manufacturing changes to our product candidates, in which case we may need to conduct additional preclinical studies to bridge our modified product candidates to earlier versions. Additionally, the FDA may determine that it has questions or concerns about our trials and may not permit our proposed clinical studies to move forward by imposing a partial or full clinical hold.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, we, the FDA or an institutional review board, or IRB, may suspend our clinical trials at any time if it appears that we or our collaborators are failing to conduct a trial in accordance with regulatory requirements, including GCP regulations, that we are exposing participants to unacceptable health risks or if the FDA finds deficiencies in our INDs or the conduct of these trials. Therefore, we cannot predict with any certainty the schedule for commencement and completion of future clinical trials.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may also conduct clinical trials in foreign countries, which presents additional risks that may delay completion of our clinical trials. These risks include the failure of enrolled patients in foreign countries to adhere to clinical protocol as a result of differences in healthcare services or cultural customs, managing additional administrative burdens associated with foreign regulatory schemes, as</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">42</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">well as political and economic risks relevant to such foreign countries. Further, data from trials conducted outside of the United States may be subject to additional scrutiny by the FDA, which may require that additional U.S. data be generated.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Because some of our product candidates are targeted towards the pediatric population, we may face additional hurdles and be subjected to greater scrutiny by regulatory agencies. Trials involving pediatric populations can be difficult to conduct, can be quite costly and, like other clinical trials, may not yield the anticipated results. In addition, pediatric studies are more dependent on a smaller number of specialized clinical trial sites, which in turn can limit site availability and make the trials more expensive to conduct. In addition, as interest in pediatric indications grows as a result of the Research to Accelerate Cures and Equity (RACE) for Children Act and other market forces, trial recruitment may become even more difficult due to competition for eligible patients. Moreover, it may be challenging to ensure that pediatric or adolescent patients adhere to clinical trial protocols. Our inability to enroll a sufficient number of pediatric patients for our clinical trial could result in significant delays, require us to abandon one or more clinical trials altogether, impact our ability to raise additional capital and delay or prevent our ability to obtain necessary marketing authorizations for any drug product candidate.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We cannot predict the outcome of our clinical trials, nor can we guarantee that the data we generate from our clinical trials will be acceptable to regulatory authorities so as to support marketing authorization.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The outcome of clinical trials is uncertain, and, because our product candidates are in earlier stages of development, there is a significant risk of failure. If we complete our clinical trials but the results of our clinical trials are inconclusive or only modestly positive, if there are safety concerns or serious adverse events associated with our product candidates or if our clinical trials are delayed or require unplanned changes, we may:</span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">incur additional, unplanned drug development and/or commercialization costs;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">be delayed in obtaining or unable to obtain marketing authorization;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">be required to perform additional clinical trials to support approval;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">obtain approval for indications or patient populations that are not as broad as intended or desired or may have contraindications, limitations of use or other restrictions that affect the market for the product;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">obtain marketing authorization with labeling that includes safety warnings, a risk evaluation and mitigation strategy, or REMS, and/or other restrictions on distribution or use that could affect market access;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">be subject to additional post-marketing testing requirements or commitments;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">have regulatory authorities withdraw, or suspend, their approval of the drug or impose post-marketing safety labeling changes or a REMS;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">be subject to civil or criminal investigations and litigation; or</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">experience damage to our reputation. </span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we experience delays in the commencement or completion of our clinical trials, or if we terminate a clinical trial prior to completion, the commercial prospects of our product candidates could be negatively impacted, and our ability to generate revenues from our product candidates may be delayed or eliminated entirely.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and receive compensation in connection with such services. Under certain circumstances, we may be required to report some of these relationships to the FDA or comparable foreign regulatory authorities. The FDA or a comparable foreign regulatory authority may conclude that a financial relationship between us and a principal investigator has created a conflict of interest or has affected the conduct or interpretation of the study. The FDA or a comparable foreign regulatory authority may therefore question the integrity of the data generated at the applicable clinical trial site and the utility of the clinical trial itself may be jeopardized. This could result in a delay in approval, or rejection, of our marketing applications by the FDA or comparable foreign regulatory authority, as the case may be, and may ultimately lead to the denial of marketing authorization of one or more of our product candidates.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we experience delays or difficulties in enrolling patients in our ongoing or planned clinical trials, we may be delayed in or prevented from obtaining necessary marketing authorization for any or all of our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may not be able to initiate or continue our ongoing or planned clinical trials for our product candidates if we are unable to identify and enroll a sufficient number of eligible patients to participate in these trials as required by the FDA or comparable foreign regulatory authorities. In our OJEMDA program, we utilize genomic profiling of patients&#8217; tumors to identify suitable patients for recruitment into our clinical trials. We cannot be certain (i) how many patients will have the requisite alterations for inclusion in our clinical trials, (ii) that the number of patients enrolled in each program will suffice for marketing authorization or (iii) whether each specific BRAF mutation targeted will be included in the approved drug labeling. If our strategies for patient identification and enrollment prove</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">43</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">unsuccessful, we may have difficulty enrolling or maintaining patients appropriate for our product candidates. Patient enrollment is also affected by other factors, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">severity of the disease under investigation; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to recruit clinical trial investigators of appropriate competencies and experience; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the incidence and prevalence of our target indications; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clinicians&#8217; and patients&#8217; awareness of, and perceptions as to, the potential advantages and risks of our product candidates in relation to other available therapies, including any new drugs that may be approved for the indications we are investigating;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the availability and capacity of clinical researchers to conduct our clinical trials;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the availability, expertise and selection of contract research organizations, or CROs, to manage operations related to clinical trial enrollment;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">competing studies or trials with similar eligibility criteria; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any invasive procedures that may be required to enroll patients and to obtain evidence of the product candidate&#8217;s performance during the clinical trial; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">availability and efficacy of approved medications for the disease under investigation;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ongoing shortages of chemotherapy standard of care, which may be used in the control arm of certain of our clinical trials, including FIREFLY-2; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">eligibility criteria defined in the protocol for the trial in question; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the size and nature of the patient population required for analysis of the trial&#8217;s primary endpoints; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">efforts to facilitate timely enrollment in clinical trials; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">whether we are subject to a partial or full clinical hold on any of our clinical trials; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">reluctance of physicians or patient advocacy organizations to encourage patient participation in clinical trials; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the ability to monitor patients adequately during and after treatment; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to obtain and maintain patient consents; and </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">proximity and availability of clinical trial sites for prospective patients. </span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, the conditions for which we currently plan to evaluate our product candidates are orphan or rare diseases with limited patient pools from which to draw for clinical trials. The eligibility criteria of our clinical trials, once established, will further limit the pool of available trial participants. Further, some of our competitors currently have ongoing clinical trials for product candidates that would treat the same patients as our clinical product candidates, and patients who would otherwise be eligible for our clinical trials may instead enroll in clinical trials of our competitors&#8217; product candidates. Moreover, if any of our competitors receive FDA approval for a product, it may limit our ability to enroll patients in our clinical trials if they decide to seek treatment with an approved product. For example, in March 2023, Novartis received approval for dabrafenib in combination with trametinib, which could in the future limit our ability to enroll patients whose tumors harbor V600E mutations in clinical trials for OJEMDA.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our inability to enroll and maintain a sufficient number of patients for our clinical trials would result in significant delays or may require us to abandon one or more clinical trials or clinical programs altogether. There may be competing trials, as well as the limited bandwidth of pediatric oncology institutions for running trials, which can lead to the prioritization of certain trials, resulting in delays in our clinical trials. In addition, because our product candidates are initially targeted to pediatric populations, we may face additional challenges. For example, parents may be reluctant to enroll their children in our clinical trials or may decide to withdraw their children from our clinical trials to pursue other therapies.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Preliminary, interim, initial and topline data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">  </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time, we may publicly disclose preliminary, interim or topline data from our clinical trials. These updates are based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data related to the particular study. Additionally, interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Therefore, positive interim or initial results in any ongoing clinical trial may not be predictive of such</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">44</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">results in the completed study. Initial or topline data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate or product and our company in general. For example, our FIREFLY-1 clinical trial was designed to use the Response Assessment for Neuro-Oncology &#8211; High Grade Glioma, or RANO-HGG, to measure the primary endpoint of overall response rate, or ORR, in alignment with the FDA, with ORR using Response Assessment for Pediatric Neuro-Oncology &#8211; Low-Grade Glioma, or RAPNO-LGG, as a secondary endpoint. Following discussions with the FDA and the March 2023 approval of dabrafenib, in combination with trametinib in BRAF V600E pLGG, we initially structured the primary endpoint in our FIREFLY-2/LOGGIC trial to be assessed using the Response Assessment for Neuro-Oncology Low-Grade Glioma, or RANO-LGG, and have included RANO-LGG as an exploratory endpoint in FIREFLY-1. Following further feedback from the FDA during review of the NDAs for OJEMDA, in June 2024 we updated the structure of the primary endpoint in our FIREFLY-2/LOGGIC trial to be assessed using the Response Assessment in Pediatric Neuro-Oncology Low-Grade Glioma, or RAPNO-LGG, criteria.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and you or others may not agree with what we determine is the material or otherwise appropriate information to include in our disclosure, and any information we determine not to disclose may ultimately be deemed significant with respect to future decisions, conclusions, views, activities or otherwise regarding a particular drug, drug candidate or our business. If the topline data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, our product candidates may be harmed, which could harm our business, operating results, prospects or financial condition.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We face substantial competition which may result in others discovering, developing or commercializing products before or more successfully than we do.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The pharmaceutical and biotechnology industries are characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary and novel products and product candidates. Our competitors have developed, are developing or may develop products, product candidates and processes competitive with our product candidates. Any products or product candidates that we successfully develop and commercialize, including OJEMDA, may compete with existing therapies and new therapies that may become available in the future. We believe that a significant number of competing product candidates are currently under development, and may become commercially available in the future, for the treatment of conditions for which we are developing, or may in the future develop, product candidates. In addition, our product candidates may need to compete with drugs that are prescribed off-label to treat the indications for which we seek approval. This may make it difficult for us to replace existing therapies with our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We also compete with these organizations to recruit and retain qualified scientific, management and sales and commercial and marketing personnel, which could negatively affect our level of expertise and our ability to execute our business plan. We will also face competition in establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In particular, there is intense competition in the field of oncology. We have competitors both in the United States and internationally, including major multinational pharmaceutical companies, established biotechnology companies, specialty pharmaceutical companies, emerging and start-up companies, universities and other research institutions.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect to face competition from existing products and products in development for each of our programs. Drug discovery efforts focused on V600 mutations have led to clinical success in some cancers. Three BRAF inhibitors have been approved by the FDA for the treatment of tumors containing V600E or V600K mutations. These first-generation BRAF inhibitors, known more generally as Type I RAF inhibitors, are vemurafenib, marketed as Zelboraf</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.03pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> by Genentech; dabrafenib, marketed as Tafinlar</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.03pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> by Novartis; and encorafenib, marketed as Braftovi</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.03pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> by Pfizer. Dabrafenib, in combination with trametinib, marketed as Mekinist&#174; by Novartis, has been approved for the treatment of adult and pediatric patients &#8805; 6 years of age with unresectable or metastatic solid tumors with BRAF V600E mutation who have progressed following prior treatment and have no satisfactory alternative treatment options. This includes BRAF V600E pLGG, a subset of the greater RAF-altered pLGG clinical scope of the OJEMDA development program. We believe that current data indicates that the BRAF V600E subset represents 10%-20% of BRAF-altered pLGG, but additional epidemiologic data may emerge as more patients are profiled. Further, dabrafenib, in combination with trametinib, was granted full approval in the BRAF V600E pLGG indication in March 2023 to include the treatment of pediatric patients 1 year of age and older with low-grade glioma, or LGG, with a BRAF V600E mutation who require initial systemic therapy.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Five MEK inhibitors have been approved by the FDA. Three have been approved for the treatment of tumors containing BRAF V600E or V600K mutations, including cobimetinib, marketed as Cotellic</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.03pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> by Genentech; trametinib, marketed as Mekinist</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.03pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> by Novartis; and binimetinib, marketed as Mektovi</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.03pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> by Pfizer. Two have been approved for the treatment of pediatric patients, 2 years of</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">45</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">age and older, with neurofibromatosis type 1, or NF1, who have symptomatic plexiform neurofibromas not amenable to complete resection, including selumetinib, marketed as Koselugo&#174; by AstraZeneca and mirdametinib, marketed as Gomekli&#174; by SpringWorks. While MEK inhibitors as monotherapy have been shown to be active in BRAF altered pLGG (both BRAF V600E mutant pLGG and BRAF fusion-driven pLGG), no MEK inhibitors have been approved by the FDA as a monotherapy for the treatment of patients with pLGG.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There are a number of next-generation BRAF inhibitors in clinical development. BeiGene has two next-generation BRAF programs: Lifirafenib (BGB-283), which is currently in a Phase 1/2 trial in combination with mirdametinib, and BGB-3245 which is currently in a single agent in Phase 1 dose escalation study as well as in combination studies with mirdametinib and panitumumab. Fore Biotherapeutics (formerly NovellusDx) is developing the RAF dimer breaker plixorafenib (formerly FORE8394 or PLX-8394) in a Phase 2 trial in combination with cobicistat in patients with cancers harboring BRAF alterations. Black Diamond Therapeutics have the next-generation BRAF inhibitor BDTX-4933 in Phase 1 clinical trials in adult solid tumors (KRAS-mutant NSCLC and solid tumors with RAF/RAS-mutations). Jazz Pharmaceuticals and Redx have announced that the pan-RAF inhibitor JZP815 has entered clinical development in a Phase 1 trial. Erasca recently announced that it has entered into an exclusive worldwide license agreement with Novartis for naporafenib, a pan-RAF inhibitor with a potential first-in-class and best-in-class profile in NRAS mutant melanoma and other RAS/MAPK pathway-driven tumors. Naporafenib, in combination with trametinib, is being studied in a Phase 3 clinical trial in patients with NRAS-mutant melanoma. Nested Therapeutics has advanced NST-628, a pan-RAF/MEK &#8220;molecular glue&#8221; into a Phase 1 clinical trial. Pfizer&#8217;s PF-07799933 (ARRY-440) is a brain-penetrant BRAF-selective monomer/dimer inhibitor that spares ARAF and CRAF, and is currently being evaluated in a phase 1 trial in adults with solid tumors.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">With regard to the treatment of pLGG, some MEK inhibitors, some type I RAF inhibitors, and other targeted therapies have been studied, or are being studied, in academic investigator-initiated clinical trials, and in some regions may be being used in an off-label manner. The off-label use of these agents may represent competition for OJEMDA if it is approved and enters the market.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the MabCare License Agreement, we have the exclusive right to develop, manufacture and commercialize DAY301, a novel ADC targeting PTK7, worldwide, excluding Greater China. In January 2025, we cleared the first cohort (a single-patient accelerated titration cohort) in the Phase 1a portion of the DAY301 Phase 1a/b clinical trial. There are a few ADCs targeting PTK7 in development. In February 2024, Profound Bio dosed its first patient in a Phase 1/2 Clinical Trial of PRO1107, a PTK7-targetted ADC with an auristatin payload. Profound Bio was acquired by Genmab A/S in May of 2024 and the program was renamed to GEN1107. Eli Lilly and Company anticipates an IND submission in 2025 for LY4175408, a PTK-7 targeted ADC with an exatecan payload.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Many of our competitors, either alone or with their collaborators, have significantly greater financial resources, established presence in the market and expertise in research and development, manufacturing, preclinical and clinical testing, obtaining marketing authorizations and reimbursement and marketing approved products than we do.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Large pharmaceutical and biotechnology companies, in particular, have extensive experience in clinical testing, obtaining marketing authorizations, recruiting patients and manufacturing biotechnology product candidates. These companies also have significantly greater research, marketing and sales capabilities than we do and may also have product candidates that have been approved or are in late stages of development, and collaborative arrangements in our target markets with leading companies and research institutions. Established pharmaceutical and biotechnology companies may also invest heavily to accelerate discovery and development of novel compounds or to in-license novel compounds that could make the product candidates that we develop obsolete. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies, as well as in acquiring technologies complementary to, or necessary for, our programs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As a result of all of these factors, our competitors may succeed in obtaining approval from the FDA or comparable foreign regulatory authorities or in discovering, developing and commercializing product candidates in our field before we do, which could result in our competitors establishing a strong market position before we are able to enter the market with a particular product or product candidate or could make our development more complicated.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our potential commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient, have a broader label, are marketed more effectively, are more widely reimbursed or are less expensive than OJEMDA or our product candidates. Even if the product candidates we develop achieve marketing authorization, they may be priced at a significant premium over competitive products if any have been approved by then, resulting in reduced competitiveness. Technological advances or products developed by our competitors may render our technologies or product candidates obsolete, less competitive or not economical. If we are unable to compete effectively, our opportunity to generate future revenue from the sale of the product candidates we may develop, if approved, could be adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">46</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Safety risks or other side effects associated with OJEMDA, DAY301, the VRK1 inhibitor program or any future products and product candidates we may develop could delay or preclude approval, cause us to suspend or discontinue clinical trials or abandon further development, limit the use of an approved product or result in significant negative consequences following marketing authorization, if any.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As is the case with pharmaceuticals generally, we have observed side effects and adverse events associated with our product, OJEMDA, and our product candidates. The most common side effects (adverse events) observed to date with OJEMDA included maculopapular rash, anemia, headache, elevation in blood creatinine phosphokinase, or CPK, nausea, skin and hair discoloration and fatigue.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Results of our ongoing and planned clinical trials could reveal a high and unacceptable severity and prevalence of side effects or unexpected characteristics. These side effects or unexpected characteristics may be subject to regulatory reporting requirements before and/or after approval. Undesirable side effects caused by OJEMDA or our product candidates could result in the delay, suspension or termination of clinical trials by us or regulatory authorities for a number of reasons. Furthermore, clinical trials by their nature utilize a sample of the potential patient population. With a limited number of subjects and limited duration of exposure, rare and severe side effects of OJEMDA or our product candidates or those of our competitors may only be uncovered with a significantly larger number of patients exposed to the drug.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, patients treated with OJEMDA and our product candidates have undergone, or may also be undergoing, medical, surgical, radiation and chemotherapy treatments, which can cause side effects or adverse events that are unrelated to OJEMDA or our product candidates but may still impact the success of our clinical trials. The inclusion of critically ill patients in our clinical trials may result in deaths or other adverse medical events due to other therapies or medications that such patients may be using or due to the gravity of such patients&#8217; illnesses. For example, it is expected that some of the patients to be enrolled in our future clinical trials will die or experience major clinical events either during the course of our clinical trials or after participating in such trials for non-treatment related reasons, which could impact development of OJEMDA, DAY301, the VRK1 inhibitor program or our other product candidates. If we elect or are required to delay, suspend or terminate any clinical trial, the commercial prospects of OJEMDA and our product candidates will be harmed and our ability to generate product revenues from such product or product candidate will be delayed or eliminated. Serious adverse events, or SAEs, observed in clinical trials could hinder or prevent market acceptance of any approved products or reduce the duration of time that physicians expect to use our product in particular patients. Any of these occurrences may significantly harm our business, prospects, financial condition and results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Moreover, if OJEMDA or our product candidates are associated with undesirable side effects in clinical trials or have characteristics that are unexpected, we may elect to abandon or limit their development to more narrow uses or subpopulations in which the undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective, which may limit the commercial expectations for our product candidates, if approved. We may also be required to modify our study plans based on findings in our clinical trials. Such side effects could also affect patient recruitment or the ability of enrolled patients to complete the trial. Many drugs that initially showed promise in early-stage testing have later been found to cause side effects that prevented further development. In addition, regulatory authorities may draw different conclusions, require additional testing to confirm these determinations, require more restrictive labeling or deny marketing authorization of the product candidate.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">It is possible that, as we test OJEMDA or our product candidates in larger, longer and more extensive clinical trials, including with different dosing regimens, or as the use of our product candidates becomes more widespread following any marketing authorization, illnesses, injuries, discomforts and other adverse events that were observed, did not occur or went undetected in earlier trials, will be reported by patients. If such side effects become known later in development or upon approval, if any, such findings may significantly harm our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If any of our product candidates receive marketing authorization, and we or others later identify undesirable side effects caused by treatment with such drug, a number of potentially significant negative consequences could result, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">regulatory authorities may withdraw approval of the drug; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may be required to recall a product or change the way the drug is administered to patients; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">regulatory authorities may require additional warnings in the labeling, such as a contraindication or a boxed warning, or issue safety alerts, Dear Healthcare Provider letters, press releases or other communications containing warnings or other safety information about the product;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may be required to implement a REMS or create a medication guide outlining the risks of such side effects for distribution to patients; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">regulatory authorities may impose additional restrictions on the marketing or promotion of the particular product or the manufacturing processes for the product or any component thereof; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we could be sued and held liable for harm caused to patients; </span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">47</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may be subject to regulatory investigations and government enforcement actions; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the drug could become less competitive; and </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our reputation may suffer. </span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any of these events could prevent us from achieving or maintaining market authorization or acceptance of our product candidates, if approved, and could significantly harm our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may expend our limited resources to pursue a particular product or product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Because we have limited financial and managerial resources, we focus on research programs and products and product candidates that we identify for specific indications. As a result, we may forego or delay pursuit of opportunities with other product candidates or for other indications that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs and products and product candidates for specific indications may not yield any commercially viable products. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The market opportunities for any products and product candidates we develop, if approved, may be limited to certain smaller patient subsets and may be smaller than we estimate them to be.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On April 23, 2024, the FDA approved the NDAs for the treatment of patients 6 months of age and older with relapsed or refractory pLGG harboring a BRAF fusion or rearrangement, or BRAF V600 mutation. We have commenced the commercial launch of OJEMDA in the United States. There is no guarantee that OJEMDA or our product candidates will be approved for the front-line setting, and prior to any such approvals we may have to conduct additional clinical trials that may be costly, time-consuming and subject to risk.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">   </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our projections of both the number of people who have the cancers we are targeting, as well as the subset of people with these cancers in a position to receive a particular line of therapy and who have the potential to benefit from treatment with OJEMDA and our product candidates, are based on our beliefs and estimates. For example, pLGG is a rare disease, and our projections of both the number of people who have this disease, as well as the subset of people with pLGG who have the potential to benefit from treatment with OJEMDA and our product candidates, are based on estimates. These estimates have been derived from a variety of sources, including scientific literature, surveys of clinics, patient foundations and market research. These estimates may prove to be incorrect. Additionally, new studies or information may change the estimated incidence or prevalence of the cancers that we are targeting, which could affect our eligibility for orphan designation for certain indications. The potentially addressable patient population for OJEMDA and our product candidates may be limited or may not be amenable to treatment with OJEMDA and our product candidates. Consequently, even if our product candidates are approved, the number of patients that may be eligible for treatment with our product candidates may turn out to be much lower than expected. Even if we obtain significant market share for our products, if the potential target populations are small, we may never achieve profitability without obtaining marketing authorization for additional indications, if at all.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our clinical development activities are primarily focused on the development of targeted therapeutics for patients with genomically-defined cancers, which is a rapidly evolving area of science, and the approach we are taking to discover and develop drugs is novel and may never lead to additional approved or marketable products.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The discovery and development of targeted therapeutics for patients with genomically-defined cancers is an emerging field, and the scientific discoveries that form the basis for our efforts to discover, identify and develop product candidates are relatively new. The scientific evidence to support the feasibility of developing product candidates based on these discoveries is both preliminary and limited. Although we believe, based on our products and product candidates&#8217; preclinical trial results and our clinical work, that the genomic alterations targeted by our programs are oncogenic drivers, clinical results may not confirm this hypothesis or may only confirm it for certain alterations or certain tumor types. The patient populations for OJEMDA and our product candidates are limited to those with specific target alterations and may not be completely defined but are substantially smaller than the general treated cancer population. In some cases, the target patient populations may not be completely defined. We will need to screen and identify appropriate patients with the targeted alterations. Successful identification of patients is dependent on several factors, including achieving certainty as to how specific alterations respond to OJEMDA and our product candidates and the ability to identify such alterations. Furthermore, even if we are successful in identifying patients, we cannot be certain that the resulting patient populations for each mutation will be large enough to allow us to successfully obtain approval for each mutation type and successfully commercialize OJEMDA and our product candidates and achieve profitability. In addition, even if our approach is successful in</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">48</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">showing clinical benefit for RAF-driven cancers for our OJEMDA program, we may never successfully identify additional oncogenic alterations sensitive to OJEMDA in other MAPK-driven tumors. Therefore, we do not know if our approach of treating patients with genomically-defined cancers will be successful, and if our approach is unsuccessful, our business will suffer.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">OJEMDA and our product candidates, including DAY301 and the VRK1 inhibitor program, may not achieve adequate market acceptance among physicians, healthcare professionals, patients or their families, healthcare payors and others in the medical community necessary for commercial success.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our product, OJEMDA, and product candidates, including DAY301 and the VRK1 inhibitor program, if approved, may not achieve adequate market acceptance among physicians, healthcare professionals, patients or their families, healthcare payors and others in the medical community necessary for commercial success globally. The degree of market acceptance of any of our approved product candidates will depend on a number of factors, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the efficacy, durability and safety profile as demonstrated in clinical trials compared to alternative treatments, in addition to functional, quality or patient-reported outcomes; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the timing of market introduction of the product candidate and of any competitive products; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the clinical indications for which a product candidate is approved; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">restrictions on the use of product candidates in the labeling approved by regulatory authorities, such as boxed warnings or contraindications in labeling, or REMS, which may not be required of alternative treatments and competitor products; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the potential and perceived advantages of OJEMDA and our product candidates over alternative treatments; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the cost of treatment in relation to alternative treatments and the cost/benefit ratios of each; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the availability of coverage and adequate reimbursement by third-party payors, including government authorities, and timing of relevant formulary decision-making resulting in this coverage and reimbursement; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">relative convenience and ease of administration in relation to competition; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the willingness of the target patient population (which may include willingness of our pediatric patients&#8217; parents) to try new therapies and undergo required diagnostic screening to determine treatment eligibility and of physicians to prescribe these therapies and diagnostic tests; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the effectiveness of sales and marketing efforts and market access; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">unfavorable publicity relating to our product candidates; and </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the approval of other new therapies for the same indications.</span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If our product candidates are approved but do not achieve an adequate level of acceptance by physicians, hospitals, healthcare payors and patients, we may not generate or derive sufficient revenue from that product candidate and our financial results could be negatively impacted. With respect to OJEMDA specifically, successful commercialization globally will depend on negotiations with, and coverage, reimbursement, selection and/or acquisition decisions by, third-party payors, which we cannot predict.  These decisions in turn may depend on value assessments conducted by various entities (e.g., formulary committees, such as pharmacy and therapeutics committees, healthcare systems and pharmacies, among others) that consider various factors (including the price of OJEMDA)&#8212;the outcomes of which we cannot predict.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Any products and product candidates we develop may become subject to unfavorable third-party coverage and reimbursement practices, as well as price restrictions.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The availability and extent of coverage and adequate reimbursement by third-party payors, including government health administration authorities, private health coverage insurers, managed care organizations and other third-party payors is essential for most patients to be able to afford expensive treatments. Sales of any of our products, including OJEMDA, and our product candidates, including DAY301 and the VRK1 inhibitor program, should it receive marketing authorization, will depend substantially, both in the United States and internationally, on the extent to which the costs of such products and product candidates will be covered and reimbursed by third-party payors, as patients who are prescribed medicine for the treatment of their condition generally rely on third-party payors to reimburse all or part of the costs associated with their prescription drugs. Further, coverage and adequate reimbursement from governmental healthcare programs, such as Medicare and Medicaid, and commercial payors is critical to new product acceptance. If reimbursement is not available, or is available only to limited levels, we may not be able to successfully commercialize OJEMDA and product candidates. Even if coverage is provided, the approved reimbursement amount may not be high enough to allow us to establish or maintain pricing sufficient to realize an adequate return on our investment. Coverage and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">49</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">reimbursement may impact the demand for, or the price of, any product or product candidate for which we obtain marketing authorization.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There is significant uncertainty related to third-party payor coverage and reimbursement of newly approved products, particularly pediatric products. The payor mix for pediatric products in the United States is a fragmented combination of state-specific Medicaid policies and a broad universe of private insurance companies. There is no consistent policy or leading payor to inform other price-setting entities. Public and private payor policies are expected to be critical to our ability to achieve broad payment coverage. Further, to the extent one or more of our products obtain coverage by one third-party payor, that does not assure that other payors will also provide coverage for the product. As a result, the coverage determination process is often time-consuming and costly. This process will require us to provide scientific and clinical support for the use of our products to each third-party payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As federal and state governments implement additional health care cost containment measures, including measures to lower prescription drug pricing, we cannot be sure that our products, if approved, will be covered by private or public payors, and if covered, whether the reimbursement will be adequate or competitive with other marketed products. These and other actions by federal and state governments and health plans may put additional downward pressure on pharmaceutical pricing and health care costs, which could negatively impact coverage and reimbursement for our products (if approved), our revenue and our ability to compete with other marketed products and to recoup the costs of our research and development.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Increasingly, third-party payors are requiring that drug companies provide them with predetermined discounts from list prices and are generally challenging the prices for medical products, including by examining the medical necessity and reviewing the cost effectiveness of medical product candidates. There may be especially significant delays in obtaining coverage and reimbursement for newly approved drugs. Third-party payors may limit coverage to specific products on an approved list, known as a formulary, which might not include all FDA-approved drugs for a particular indication. We plan to conduct pharmaco-economic studies to demonstrate the medical necessity and cost-effectiveness of our products, which may be costly. Nonetheless, our products and product candidates may not be considered medically necessary or cost-effective. Moreover, third-party payor coverage decisions may depend upon clinical and economic standards that disfavor new drug products when more established or lower cost therapeutic alternatives are already available or subsequently become available. We cannot be sure that coverage and reimbursement will be available for any product that we commercialize and, if reimbursement is available, what the level of reimbursement will be.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, complementary and companion diagnostic tests require coverage and reimbursement separate and apart from the coverage and reimbursement for related pharmaceutical or biological products. Similar challenges to obtaining coverage and reimbursement, applicable to pharmaceutical or biological products, will apply to companion diagnostics. Additionally, if any companion diagnostic provider is unable to obtain reimbursement or is inadequately reimbursed, that may limit the availability of such companion diagnostic, which would negatively impact prescriptions for our product candidates, if approved.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Outside the United States, the commercialization of therapeutics is generally subject to extensive governmental price controls and other market regulations. We believe the increasing emphasis on cost containment initiatives in Europe, Canada and other countries has and will continue to put pressure on the pricing and usage of therapeutics such as our product candidates. In many countries, particularly the countries of the European Union, or EU, medicinal product prices are subject to varying price control mechanisms as part of national health systems. In these countries, pricing negotiations with governmental authorities can take considerable time after a product receives marketing authorization. To obtain reimbursement or pricing approval in some countries, we may be required to conduct a clinical trial that compares the cost-effectiveness of our product candidate to other available therapies. In general, product prices under such systems are substantially lower than in the United States. Other countries allow companies to fix their own prices for products but monitor and control company profits. Additional foreign price controls or other changes in pricing regulation could restrict the amount that we are able to charge for our product candidates. Accordingly, in markets outside the United States, the reimbursement for our products may be reduced compared with the United States and may be insufficient to generate commercially reasonable revenue and profits.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Coverage policies and third-party payor reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which we receive marketing authorization, less favorable coverage policies and reimbursement rates may be implemented in the future.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we are unable to establish or sustain coverage and adequate reimbursement for any products from third-party payors, the adoption of those products and sales revenue will be adversely affected, which, in turn, could adversely affect the ability to market or sell those product, if approved.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our business entails a significant risk of product liability and if we are unable to obtain sufficient insurance coverage such inability could have an adverse effect on our business and financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our business exposes us to significant product liability risks inherent in the development, testing, manufacturing and commercialization of OJEMDA and any future products and marketing of therapeutic treatments. Product liability claims could delay or prevent completion of our development programs. If we succeed in marketing products, such claims could result in an FDA or other</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">50</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">regulatory authority investigation of the safety and effectiveness of our products, our manufacturing processes and facilities or our marketing programs. The FDA or other regulatory authority investigations could potentially lead to a recall of our products or more serious enforcement action, limitations on the approved indications for which they may be used or suspension or withdrawal of approvals. Regardless of the merits or eventual outcome, liability claims may also result in decreased demand for our products, injury to our reputation, costs to defend the related litigation, a diversion of management&#8217;s time, our resources and substantial monetary awards to trial participants or patients. We currently have product liability insurance that we believe is appropriate for our stage of development and may need to obtain higher levels prior to advancing our product candidates into clinical trials or marketing any of our product candidates, if approved. Any insurance we have or may obtain may not provide sufficient coverage against potential liabilities. Furthermore, clinical trial and product liability insurance is becoming increasingly expensive. As a result, we may be unable to obtain sufficient insurance at a reasonable cost to protect us against losses caused by product liability claims that could have an adverse effect on our business and financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Government Regulation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The development and commercialization of pharmaceutical products are subject to extensive regulation, and we may not obtain marketing authorizations for DAY301, the VRK1 inhibitor program or any future product candidates, on a timely basis or at all.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The clinical development, manufacturing, labeling, packaging, storage, recordkeeping, advertising, promotion, export, import, marketing, distribution, adverse event reporting, including the submission of safety and other post-marketing information and reports, and other possible activities relating to OJEMDA, DAY301 and the VRK1 inhibitor program, currently our only product and product candidates in planned or ongoing clinical trials, as well as any other product candidate that we may develop in the future, are subject to extensive regulation. Marketing authorization of drugs in the United States requires the submission of an NDA to the FDA. An NDA must be supported by extensive clinical and preclinical data, as well as extensive information regarding pharmacology, chemistry, manufacturing and controls. We are not permitted to market any product candidate in the United States until we obtain approval from the FDA of the NDA for that product.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA may refer any application we submit to an advisory committee. An advisory committee is a panel of independent experts, including clinicians and other scientific experts, which reviews, evaluates and provides advice and recommendations to the FDA as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FDA approval of an NDA is not guaranteed, and the review and approval process is an expensive and uncertain process over which the FDA has substantial discretion.  The FDA approval process may also take several years. The timelines for the FDA review and approval process may be delayed as a result of future organizational changes and/or staffing reductions. The number and types of preclinical studies and clinical trials that will be required for NDA approval vary depending on the product candidate, the disease or the condition that the product candidate is designed to treat and the regulations applicable to any particular product candidate. Of the large number of drugs in development in the United States, only a small percentage will successfully complete the FDA marketing authorization process and will be commercialized. On April 23, 2024, the FDA approved the NDAs for the treatment of patients 6 months of age and older with relapsed or refractory pLGG harboring a BRAF fusion or rearrangement, or BRAF V600 mutation. In connection with its approval of OJEMDA, the FDA may impose restrictions, post-marketing requirements or post-marketing commitments that may limit our ability to commercialize OJEMDA or any other product. If we fail to comply with FDA-mandated requirements or if the results of certain required post-marketing studies are negative, the FDA could withdraw approval, add warnings or narrow approved indications, which could affect the commercial success of our products.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, we may experience delays or rejections based upon additional government regulation from future legislation or administrative action, or changes in regulatory authority policy during the period of product development, clinical trials and the review process. For example, in May 2022, the Oncology Center of Excellence within the FDA advanced Project Optimus, an initiative to reform the dose optimization and dose selection paradigm in oncology drug development to emphasize selection of an optimal dose, which is a dose or doses that maximizes not only the efficacy of a drug but the safety and tolerability as well. This shift from the prior approach, which generally determined the maximum tolerated dose, may require sponsors to spend additional time and resources to further explore a product candidate&#8217;s dose-response relationship to facilitate optimum dose selection in a target population. Other recent Oncology Center of Excellence initiatives have included Project FrontRunner, a new initiative with a goal of developing a framework for identifying candidate drugs for initial clinical development in the earlier advanced setting rather than for treatment of patients who have received numerous prior lines of therapies or have exhausted available treatment options.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Clinical trial failure may result from a multitude of factors, including flaws in trial design, dose selection, placebo effect, patient enrollment criteria, data integrity challenges or failure to demonstrate favorable safety or efficacy traits. Failure in clinical trials can occur at any stage. Companies in the pharmaceutical industry frequently suffer setbacks in the advancement of clinical trials due to lack of efficacy or adverse safety profiles, notwithstanding promising results in earlier trials. Based upon negative or inconclusive results, we may decide, or regulators may require us, to conduct additional clinical trials or preclinical studies. In addition, data obtained from clinical trials are susceptible to varying interpretations, and regulators may not interpret our data as favorably as we do,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">51</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">which may further delay, limit or prevent marketing authorization. On the basis of our clinical trials, the FDA could delay, limit or deny approval of a product candidate for many reasons, including because the FDA may:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">not deem our product candidate to be safe and effective; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">determine that the product candidate does not have an acceptable benefit-risk profile; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">determine in the case of an NDA seeking accelerated approval that the NDA does not provide evidence that the product candidate represents a meaningful advantage over available therapies and, therefore, may deny approval; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">determine that ORR as the primary endpoint, complemented by key secondary endpoints, is insufficient to reliably define clinical benefit;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">not agree that the data collected from preclinical studies and clinical trials are acceptable or sufficient to support the submission of an NDA or other submission or to obtain marketing authorization, and may impose requirements for additional preclinical studies or clinical trials; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">determine that adverse events experienced by participants in our clinical trials represent an unacceptable level of risk;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">determine that the population studied in the clinical trial may not be sufficiently broad or representative to assure safety in the full population for which we seek approval;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">not accept clinical data from trials, which are conducted at clinical facilities or in countries where the standard of care is potentially different from that of the United States; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">disagree regarding the formulation, labeling and/or the specifications; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">not approve the manufacturing processes associated with our product candidate or may determine that a manufacturing facility does not have an acceptable compliance status; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">change approval policies or adopt new regulations; or </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">not file a submission due to, among other reasons, the content or formatting of the submission. </span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have not yet obtained FDA approval for our product candidates, DAY301 and the VRK1 inhibitor program. While the FDA approved the NDAs for the treatment of patients 6 months of age and older with relapsed or refractory pLGG harboring a BRAF fusion or rearrangement, or BRAF V600 mutation, there is no assurance that we will receive similar approval for OJEMDA from comparable regulatory authorities in foreign jurisdictions, which may limit our addressable market and could adversely affect our business, prospects, financial condition and results of operations.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we seek to utilize any of the FDA&#8217;s expedited programs, the FDA may not find our product candidates to be eligible for these programs and, if granted, these programs may not lead to faster development, regulatory review or approval of our product candidates.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA has several expedited programs, including Fast Track, Priority Review, Breakthrough Therapy and Accelerated Approval, which are authorized by the Federal Food, Drug and Cosmetic Act, or FD&amp;C Act, and implemented pursuant to FDA regulations and guidance. None of these programs change the standard for FDA approval of a pharmaceutical product. We still must demonstrate substantial evidence of effectiveness and an acceptable safety profile to obtain marketing authorization.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may seek to avail ourselves of one or more of the FDA&#8217;s expedited programs. For example, we may seek Fast Track designation for one or more of our product candidates.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA may grant a Fast Track designation to a drug that is intended for the treatment of a serious or life-threatening condition and nonclinical or clinical data demonstrates the potential to address unmet medical needs for this condition. The FDA has broad discretion whether to grant this designation, so even if we believe a particular product candidate is eligible for this designation, we cannot assure you that the FDA would decide to grant it. The FDA may withdraw Fast Track designation if it believes that the designation is no longer supported by data from our clinical development program.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have applied for and have been granted breakthrough therapy designation for tovorafenib in patients with advanced pLGG, and we may apply for breakthrough therapy designation for other product candidates or indications in the future.  The FDA may designate a drug candidate as a potential breakthrough therapy if the drug candidate is intended, alone or in combination with one or more other drugs or drug candidates, to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the drug candidate may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints.  For drug candidates that have been designated as breakthrough therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens. Drug candidates designated as breakthrough therapies by the FDA are also eligible for priority</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">52</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">review if supported by clinical data at the time of the submission of the NDA.  The FDA may withdraw breakthrough therapy designations if it determines that the criteria for the designation is no longer met.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may seek priority review of one or more of our other applications for marketing authorization, or we may receive priority review as part of other designations we may seek for one or more of our other product candidates. The FDA may grant priority review to an application if an application is for a drug that treats a serious condition and, if approved, would provide a significant improvement in safety or effectiveness. The FDA may also grant priority review to supplements that propose a labeling change pursuant to a report on a pediatric study under Section 505A of the FD&amp;C Act. Additionally, the FDA may grant priority review to any application or supplement for a drug submitted with a PRV. We cannot assure you that the FDA would decide to grant priority review of any of our product candidates.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if we do receive Fast Track designation, breakthrough therapy designation or priority review for any of our product candidates, we may not experience expedited development, review or faster action on our applications for marketing authorization compared to products without such designations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The accelerated approval pathway may be unavailable or, if available, may not lead to faster development, regulatory review or marketing authorization, and the use of the accelerated approval pathway does not necessarily increase the likelihood that our product candidates will receive marketing authorization.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the FDA&#8217;s Accelerated Approval Program, and subject to the conditions set forth in Section 506(c) of the FD&amp;C Act and FDA regulations, the FDA may approve a product for a serious or life-threatening disease or condition based on a determination that the product has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity or prevalence of the condition and the availability or lack of alternative treatments. The FDA generally reserves the use of accelerated approvals for situations in which the product candidate at issue provides a meaningful therapeutic benefit over existing treatments.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may seek accelerated approval for one or more of our product candidates on the basis of a surrogate endpoint that we believe is reasonably likely to predict clinical benefit, such as ORR. The FDA may not agree with our conclusion that an endpoint we select is reasonably likely to predict clinical benefit, and thus the FDA may not agree that accelerated approval is appropriate based on that endpoint (even if the results on that endpoint are statistically significant), which could delay or preclude accelerated approval.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Products granted accelerated approval are subject to certain post-marketing requirements, which typically include a requirement to conduct one or more post-approval studies to confirm the clinical benefit of the product, which must be completed with due diligence. By the time of approval of the product, the FDA must set forth the conditions for the post-marketing studies which may include specific conditions and deadlines relating to the study protocol, enrollment targets, target completion date and other milestones. The FDA generally expects&#8212;and may require, as appropriate&#8212;the confirmatory study or studies to be underway at the time of the accelerated approval or within a specific time frame following approval. The FDA may disagree with our proposed clinical study designs for post-marketing confirmatory studies, and may require study conditions that are unfavorable to us, which could delay approval or lead to the withdrawal of a product approved under the accelerated approval pathway.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, FDA regulations require that sponsors of products granted accelerated approval submit during the pre-approval review period copies of all promotional materials intended to be used within 120 days following marketing approval. After 120 days following marketing approval, unless otherwise informed by the FDA, the sponsor must submit all promotional materials at least 30 days prior to use.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The accelerated approval pathway has come under scrutiny within the FDA, by Congress and by other stakeholders. The FDA has put increased focus on ensuring that confirmatory studies are conducted with diligence and, ultimately, that such studies confirm the benefit. For example, the FDA has convened its Oncologic Drugs Advisory Committee to review what the FDA has called "dangling" or "delinquent" accelerated approvals where confirmatory studies have not been completed or where results did not confirm benefit. In addition, in 2021, the Oncology Center of Excellence announced Project Confirm, which is an initiative to promote the transparency of outcomes related to accelerated approvals for oncology indications and provide a framework to foster discussion, research and innovation in approval and post-marketing processes, with the goal to enhance the balance of access and verification of benefit for therapies available to patients with cancer and hematologic malignancies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Finally, Congress recently passed the Food and Drug Omnibus Reform Act of 2022, or FDORA, which implemented key reforms to the FDA&#8217;s authorities with respect to accelerated approval, including strengthening requirements around post-approval studies, codifying procedures for withdrawal of a product approved under the expedited approval pathway and establishing an intra-agency Accelerated Approval Council to address accelerated approval policy.  FDORA also added the failure to conduct post-approval studies with due diligence or to submit timely progress reports on such studies to the list of prohibited acts under the FD&amp;C Act, which means that any such failures, whether they result from our actions or the actions of third parties, could provide the basis for enforcement actions to be brought against us, which may be costly to defend or we may be unsuccessful in our defense.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">53</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA also has the authority to withdraw products approved under the accelerated approval pathway using expedited withdrawal procedures. Circumstances that may lead to such withdrawal include:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the failure to conduct any required post-approval study of a product candidate with due diligence, including with respect to conditions specified by the FDA;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a study required to verify and describe the predicted clinical benefit of a product candidate fails to verify and describe such benefit; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">other evidence demonstrates that the product candidate is not shown to be safe or effective under the conditions of use; or </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the sponsor's dissemination of false or misleading promotional materials relating to the relevant product candidate.</span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If any of our competitors were to receive full approval for an indication for which we are seeking accelerated approval before we receive accelerated approval, the indication we are seeking may no longer qualify as a condition for which there is an unmet medical need, and accelerated approval of our product candidate would be more difficult or may not occur at all.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may not be able to obtain or maintain orphan drug designation or exclusivity for our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have obtained orphan drug designation in the United States and in the EU for use of tovorafenib in treating malignant glioma and glioma, respectively. We may seek orphan drug designation for tovorafenib in additional geographies or indications, or for DAY301, the VRK1 inhibitor program or any product candidates we may develop in the future. Regulatory authorities in some jurisdictions, including the United States, may designate drugs for relatively small patient populations as &#8220;orphan drugs.&#8221; Under the Orphan Drug Act, the FDA may designate a drug as an orphan drug if it is intended to treat a rare disease or condition, which is generally defined as a patient population of fewer than 200,000 individuals in the United States, or if the disease or condition affects more than 200,000 individuals in the United States and there is no reasonable expectation that the cost of developing and making available the drug for such disease or condition will be recovered from sales of the product in the United States.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Generally, if a product candidate with a U.S. orphan drug designation subsequently receives the first marketing authorization for the drug for the indication for which it has such designation, the product is entitled to a period of marketing exclusivity, which precludes the FDA from approving another marketing application for the same drug for the same indication for a period of seven years. Orphan drug exclusivity in the United States may be lost if the FDA determines that the request for designation was materially defective or the drug in fact was ineligible for orphan-drug designation at the time the request for designation was submitted, or if the manufacturer is unable to assure a sufficient quantity of the drug to meet the needs of patients with the rare disease or condition.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA may approve a subsequent application to market the same drug for the same indication during the exclusivity period in certain circumstances, such as if the subsequent product demonstrates clinical superiority (i.e., the subsequent product is safer, more effective or makes a major contribution to patient care) over the product with orphan exclusivity. Competitors, however, may receive approval of different products for the same indication for which the orphan product has exclusivity, or obtain approval for the same product but for a different indication than that for which the orphan product has exclusivity. Orphan drug designation also entitles a party to financial incentives, such as opportunities for grant funding towards clinical trial costs, tax advantages and user-fee waivers.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the EU, if a medicinal product is granted marketing authorization as an orphan medicinal product, it benefits from a period of orphan market exclusivity during which the European Medicines Agency, or EMA, or a national regulator may not accept a marketing authorization application for a similar medicinal product in the same orphan indication. The applicable period of orphan exclusivity is ten years in the EU, but this can be reduced to six years if a drug no longer meets the criteria for orphan drug designation.  The EMA or a national regulator may accept an application and grant a marketing authorization for a similar medicinal product for the orphan indication during the exclusivity period if the similar product is safer, more effective or otherwise clinically superior to the orphan product.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We cannot assure you that any future application for orphan drug designation with respect to any other product candidate will be granted. If we are unable to obtain orphan drug designation with respect to other product candidates in the United States or other jurisdictions, we will not be eligible to obtain the period of market exclusivity that could result from orphan drug designation or be afforded the other incentives associated with orphan drug designation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Moreover, a recent Eleventh Circuit decision in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Catalyst Pharmaceuticals, Inc. vs. FDA</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> regarding interpretation of the Orphan Drug Act exclusivity provisions as applied to drugs approved for orphan indications narrower than the drug&#8217;s orphan designation has the potential to significantly broaden the scope of orphan drug exclusivity for such products. Specifically, the Eleventh Circuit held that orphan drug exclusivity precludes the FDA from approving another marketing application for the same drug for the same orphan-designated disease or condition for a period of seven years. Although the FDA has announced that it will not apply the Catalyst decision beyond the facts at issue in that case, Catalyst could serve as a precedent for future challenges to the FDA&#8217;s orphan drug-related decisions, and, accordingly, could fundamentally change how companies rely on, or seek to work around, orphan drug exclusivity in the United States. Legislation has also been introduced that may reverse the Catalyst decision, but such legislation has not yet been passed.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">54</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We must comply with certain legal requirements and FDA policies, and may seek incentives under certain laws, relating to the development of drugs for pediatric patients, including the Pediatric Research Equity Act and the Best Pharmaceuticals for Children Act.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Pediatric Research Equity Act, as amended, or PREA, requires that certain NDAs, Biologics License Applications, or BLAs, and NDA/BLA supplements contain assessment reports regarding the safety and efficacy of the product for the claimed indications in all relevant pediatric subpopulations to support dosing and administration for each pediatric subpopulation for which the product has been assessed to be safe and effective. In addition, PREA requires a molecularly targeted pediatric cancer investigation for an original NDA or BLA for a new active ingredient if the product candidate is intended to treat an adult cancer and is directed at a molecular target that the FDA determines to be substantially relevant to the growth or progression of a pediatric cancer, which may be different than the claimed adult cancer indication. PREA requires these pediatric studies be conducted using appropriate formulations for each age group that is studied, and an applicant must seek approval of any pediatric formulations that are used.  The FDA may grant deferrals of PREA requirements or full or partial waivers. Unless otherwise required by regulation, PREA does not apply to a drug for an indication for which orphan designation has been granted, except that PREA will apply to an original NDA or BLA that is subject to the molecularly targeted pediatric cancer investigation requirement. Even if we are deemed exempt from PREA requirements for one application, any of our other applications may be subject to PREA requirements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the Best Pharmaceuticals for Children Act, or the BPCA, the FDA can grant pediatric exclusivity to a sponsor that conducts pediatric studies requested by the FDA in a document called a Written Request. We may seek pediatric exclusivity for one or more of our product candidates under the BPCA, although we may not be granted such exclusivity.  Pediatric exclusivity, if granted, adds six months to the end of certain unexpired statutory exclusivity periods and may also extend unexpired patent terms, depending on whether the application is an NDA or BLA. Whether this six-month extension is granted depends on the voluntary completion of pediatric studies in accordance with and in response to a Written Request for such studies, the submission of the study reports to the FDA within the timeframe required by the BPCA and the FDA&#8217;s acceptance of the study reports.  The FDA has indicated a strong preference to issue Written Requests only for studies that are in addition to and/or different from pediatric studies required under PREA (if applicable).</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In general, pediatric drug development is an area that recently has been, and may continue to be, subject to evolving statutory requirements and regulatory standards, so some uncertainty exists with respect to expectations for pediatric drug development generally.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may seek a rare pediatric disease designation for one or more of our product candidates under the FDA&#8217;s Rare Pediatric Disease Priority Review Voucher Program. Even if we were to obtain marketing authorization for a product with a rare pediatric disease designation, the Rare Pediatric Disease Priority Review Voucher Program may no longer be in effect at the time of such approval or we might not be able to capture the value of the Rare Pediatric Disease Priority Review Voucher Program.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">OJEMDA was granted rare pediatric designation by the FDA in May 2021 for the treatment of LGGs harboring an activating RAF alteration that disproportionately affects children. We submitted the OJEMDA NDAs as a rare pediatric designation marketing application, and the FDA conditionally designated the marketing application as a &#8220;rare pediatric disease product application&#8221; pending the final determination at the time of approval or licensure on whether the application meets all of the eligibility criteria set forth in section 529(a)(4) of the FD&amp;C Act. On April 23, 2024, the FDA approved the NDAs for the treatment of patients 6 months of age and older with relapsed or refractory pLGG harboring a BRAF fusion or rearrangement, or BRAF V600 mutation, and in connection with the accelerated approval, Day One received a rare pediatric disease PRV.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Congress authorized the FDA to award PRVs to sponsors of certain rare pediatric disease product applications that meet the specified criteria. These vouchers are designed to encourage development of new drug and biological products for prevention and treatment of certain rare pediatric diseases.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Specifically, under this program, a sponsor who receives an approval for a drug or biologic for a &#8220;rare pediatric disease&#8221; may qualify for a voucher that can be redeemed to receive a priority review of a subsequent marketing application for a different product. The sponsor of a rare pediatric disease drug product receiving a PRV may transfer (including by sale) the voucher to another sponsor. On May 29, 2024, we entered into an asset purchase agreement, pursuant to which we agreed to sell our rare pediatric disease PRV to an undisclosed buyer for gross proceeds of $108.0 million. Following the sale, we are no longer eligible to take advantage of the incentives under the rare pediatric disease PRV, including priority review of a subsequent marketing application. The voucher may be further transferred any number of times before the voucher is used, as long as the sponsor making the transfer has not yet submitted the application. Although the voucher can be sold or transferred to third parties, there is no guarantee that we will be able to receive such voucher in the future for any of our current or future product candidates or that we will realize any value if we receive and were to sell any such voucher.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the purposes of this program, a rare pediatric disease is a (i) serious or life-threatening disease in which the serious or life-threatening manifestations primarily affect individuals aged from birth to 18 years, including age groups often called neonates, infants,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">55</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">children, and adolescents; and (ii) rare disease or condition within the meaning of the Orphan Drug Act. The FDA may determine that an application for one or more of our product candidates does not meet the eligibility criteria for a PRV upon approval.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Moreover, under the current statutory sunset provisions, the FDA generally may not award rare pediatric disease PRVs after December 20, 2024. However, if the sponsor has received rare pediatric disease designation for a drug no later than September 30, 2024, the FDA may award a rare pediatric disease PRV if the drug is approved by September 30, 2026.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we or a business partner are unable to successfully develop, validate, obtain marketing authorization for and commercialize any companion diagnostic tests that are deemed necessary for the use of any of our product candidates, or experience significant delays in doing so, we may not be able to obtain marketing authorization for, or realize the full commercial potential of, one or more of our product candidates.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Diagnostic tests can be useful in identifying patients who are most likely to benefit from a particular therapeutic drug product, among other potential uses.  If a regulatory authority determines that an in vitro diagnostic test is necessary for the safe and effective use of a corresponding therapeutic product, that test is referred to as a &#8220;companion diagnostic.&#8221;  Diagnostics that are not essential for the safe and effective use of a therapeutic product but that may aid in the benefit-risk decision-making about the use of the therapeutic product (such as to identify a subset of the indicated patient population for the therapeutic product that may respond particularly well) are typically referred to as &#8220;complementary diagnostics.&#8221;  In the future, we may evaluate opportunities to develop, either by ourselves or with collaborators, companion or complementary diagnostic tests for our product candidates for certain indications.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If a companion diagnostic is needed for a therapeutic product, the companion diagnostic is generally developed in conjunction with the clinical program for an associated therapeutic product. To date, the FDA has required premarket approval of the vast majority of companion diagnostics for cancer therapies. Generally, when a companion diagnostic is essential to the safe and effective use of a drug product, the FDA generally requires that the companion diagnostic be approved before or concurrent with approval of the therapeutic product and before such product can be commercialized (except in limited circumstances). Where a companion diagnostic must be used to identify patients who are likely to benefit from the therapeutic product, the therapeutic product&#8217;s labeling typically limits the use of the therapeutic product to only those patients who express the specific genetic alteration or other biomarker that the companion diagnostic was developed to detect. By contrast, complementary diagnostics are not typically referenced in the indications for the therapeutic product (i.e., the therapeutic product is not limited to use in biomarker positive patients) but the complementary diagnostic may be described in other areas of the therapeutic product labeling, such as when describing clinical study results for biomarker positive and negative patient subpopulations. While a complementary diagnostic is also typically developed in conjunction with the clinical program for an associated therapeutic product, the FDA may not require that the complementary diagnostic be approved before or concurrent with approval of the therapeutic product.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Development of a companion or complementary diagnostic could include additional meetings with regulatory authorities, such as a pre-submission meeting and the requirement to comply with the FDA&#8217;s investigational device exemption regulations for clinical studies involving the diagnostic. In the case of an investigational diagnostic that is designated as &#8220;significant risk device,&#8221; approval of an investigational device exemption application by an IRB and the FDA is required before such diagnostic may be used in conjunction with the clinical trials for a corresponding product candidate.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To be successful in developing, validating, obtaining approval of and commercializing a companion or complementary diagnostic, we or our collaborators will need to address a number of scientific, technical, regulatory and logistical challenges. We have no prior experience with medical device or diagnostic test development. If we choose to develop and seek FDA approval for companion diagnostic tests on our own, we will require additional personnel. We may rely on third parties for the design, development, testing, validation and manufacture of companion diagnostic tests for our therapeutic product candidates that require companion diagnostic tests or would benefit from complementary diagnostics, the application for and receipt of any required marketing authorizations and the commercial supply of these diagnostics. If these parties are unable to successfully develop companion diagnostics for these therapeutic product candidates, or experience delays in doing so, we may be unable to enroll enough patients for our current and planned clinical trials, the development of these therapeutic product candidates may be adversely affected, these therapeutic product candidates may not obtain marketing authorization and we may not realize the full commercial potential of any of these therapeutics that obtain marketing authorization. For any product candidate for which a companion diagnostic is necessary to select patients who may benefit from use of the product candidate, any failure to successfully develop a companion diagnostic may cause or contribute to delayed enrollment of our clinical trials, and may prevent us from initiating a pivotal trial. In addition, the commercial success of any of our product candidates that require a companion diagnostic will be tied to and dependent upon the receipt of required marketing authorizations and the continued ability of such third parties to make the companion diagnostic commercially available to us on reasonable terms in the relevant geographies. There is no guarantee that physicians will adopt any particular companion diagnostic, be willing to understand how to use it, how to obtain reimbursement for it or how to explain it to patients or dedicate staff to using it. Any failure to do so could materially harm our business, results of operations and financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">56</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">For each product and product candidate for which marketing authorization is granted, including OJEMDA, the terms of approvals, ongoing regulation of our products or other post-approval restrictions may limit how we manufacture and market our products and compliance with such requirements may involve substantial resources, which could materially impair our ability to generate revenue in line with our expectations.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For each product and product candidate for which marketing authorization is granted, including OJEMDA, an approved product and the marketing authorization holder are subject to ongoing regulation by the FDA, the EMA and other regulators.  Regulators may impose post-marketing requirements and elicit post-marketing commitments, which may be onerous and subject us to ongoing review and extensive regulation. For example, the FDA or EMA may request or require post-marketing clinical studies, enhanced pharmacovigilance programs, additional reporting requirements and other obligations at the time of approval or after approval. The FDA also may impose a REMS under Section 505-1 of the FD&amp;C Act in order to ensure that the benefits of our product candidates outweigh their risks. Additionally, either at the time or approval or after approval, the FDA could invoke its authority under Section 505(o) of the FD&amp;C Act and require costly post-marketing safety studies, including clinical trials, and/or epidemiologic surveillance to monitor the safety of our approved products in order to assess a known risk related to the product, assess signals of serious risks related to the product or identify an unexpected serious risk when available data indicates the potential for a serious risk.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, any product candidates for which we receive accelerated approval from the FDA are required to undergo one or more clinical trials to confirm the clinical benefit of the product. If confirmatory studies fail to meet their efficacy endpoints, the FDA may withdraw approval of the product pursuant to expedited withdrawal authorities. There is no assurance that any such product will successfully advance through its confirmatory clinical trial(s). Therefore, even if a product candidate receives accelerated approval from the FDA, such approval may be withdrawn at a later date.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We must also comply with requirements concerning advertising and promotion for any of our product candidates for which we obtain marketing authorization. Further, there are additional requirements regarding promotional communications if our products are approved through the accelerated approval pathway. Promotional communications with respect to prescription drugs are subject to a variety of legal and regulatory restrictions and must be consistent with the information in the product&#8217;s approved labeling. Thus, we will not be able to promote any products we develop for indications or uses for which they are not approved.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, manufacturers of approved products and those manufacturers&#8217; facilities are required to ensure that quality control and manufacturing procedures conform to current good manufacturing practices, or cGMPs, which include requirements relating to quality control and quality assurance as well as the corresponding maintenance of records and documentation and reporting requirements. We and our CMOs could be subject to periodic inspections by the FDA to monitor and ensure compliance with cGMPs, including pre-approval inspections of any manufacturing facilities proposed to commercially manufacture our product candidates, the success of which would be required prior to a commercial product launch. Accordingly, assuming we obtain marketing authorization for one or more of our product candidates, we and our CMOs will continue to expend time, money and effort in all areas of regulatory compliance, including manufacturing, production, testing, product surveillance and quality assurance.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we are not able to comply with all of our post-approval regulatory requirements, we could have the marketing authorizations for our products withdrawn by regulatory authorities and our ability to market any future products could be limited, which could adversely affect our ability to achieve or sustain profitability. In addition, the cost of compliance with post-approval regulations may have a negative effect on our operating results and financial condition.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Any product for which we obtain marketing authorization, including OJEMDA, will be subject to ongoing enforcement of post-marketing requirements by regulatory agencies, and we could be subject to substantial penalties, including withdrawal of our product from the market, if we fail to comply with all regulatory requirements or if we experience unanticipated problems with our products, when and if any of them are approved.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any product for which we obtain marketing authorization, such as OJEMDA, along with the manufacturing processes, post-approval clinical data, labeling, advertising and promotional activities for such product, will be subject to continual requirements of and review by the FDA, the EMA and other regulatory authorities. These requirements include, but are not limited to, restrictions governing promotion of an approved product, submissions of safety and other post-marketing information and reports, registration and listing requirements, cGMP requirements relating to manufacturing, quality control, quality assurance and corresponding maintenance of records and documents and requirements regarding drug distribution and the distribution of samples to physicians and recordkeeping.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA and other federal and state agencies, including the Department of Justice, closely regulate compliance with all requirements governing prescription drug products, including requirements pertaining to marketing and promotion of drugs in accordance with the provisions of the approved labeling and manufacturing of products in accordance with cGMP requirements. For example, the FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant liability. Violations of such requirements may lead to investigations alleging violations of the FD&amp;C Act and other statutes, including the False Claims Act and other federal and state healthcare fraud and abuse laws as well as state consumer protection laws. Our failure to comply with all regulatory requirements, and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">57</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">later discovery of previously unknown adverse events or other problems with our products, manufacturers or manufacturing processes, may yield various results, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">litigation involving patients taking our products; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">restrictions on such products, manufacturers or manufacturing processes; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">restrictions on the labeling or marketing of a product; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">restrictions on product distribution or use; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">requirements to conduct post-marketing studies or clinical trials; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">warning or untitled letters; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">withdrawal of the products from the market; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">refusal to approve pending applications or supplements to approved applications that we submit; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">voluntary or mandatory recall of products; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">fines, restitution or disgorgement of profits or revenues; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">suspension or withdrawal of marketing authorizations; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">damage to relationships with any potential collaborators; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">unfavorable media coverage and damage to our reputation; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">refusal to permit the import or export of our products; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">product seizure; or </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">injunctions or the imposition of civil or criminal penalties. </span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Non-compliance by us or any future collaborator with regulatory requirements, including safety monitoring or pharmacovigilance, and with requirements related to the development of products for the pediatric population can also result in significant financial penalties. Further, if any of these actions were to occur, we may have to discontinue the commercialization of our product, OJEMDA, and product candidates, limit our sales and marketing efforts, conduct further post-approval studies and/or discontinue or change any other ongoing clinical studies, which in turn could result in significant expense and delay and/or limit our ability to generate sales revenues.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our failure to obtain marketing authorization in foreign jurisdictions would prevent OJEMDA and our product candidates from being marketed in those jurisdictions, and any approval we are granted for our product candidates in the United States would not assure approval of product candidates in foreign jurisdictions.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In order to market and sell our products in any jurisdiction outside the United States, we must obtain separate marketing authorizations and comply with numerous and varying regulatory requirements. The approval procedure varies among countries and can involve additional testing and/or product release specifications. The time required to obtain approval may differ substantially from that required to obtain FDA approval. The marketing authorization process outside the United States generally includes all of the risks associated with obtaining FDA approval. In addition, in many countries outside the United States, it is required that the product be approved for reimbursement before the product can be approved for sale in that country. We may not obtain approvals from regulatory authorities outside the United States on a timely basis, if at all. Approval by the FDA or EMA does not ensure approval by regulatory authorities in other countries or jurisdictions, and approval by one regulatory authority outside the United States does not ensure approval by regulatory authorities in other countries or jurisdictions or by the FDA. We may not be able to submit and receive approval for marketing authorizations in other foreign jurisdictions and may not receive necessary approvals to commercialize our products in any market.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our current and future relationships with customers and third-party payors may be subject to applicable anti-kickback, fraud and abuse, transparency, health privacy and other healthcare laws and regulations, which could expose us to significant penalties, including criminal, civil and administrative penalties, contractual damages, reputational harm and diminished profits and future earnings.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Healthcare providers, including physicians, and third-party payors will play a primary role in the recommendation and prescription of any product candidates for which we obtain marketing authorization. Our current and future arrangements with healthcare providers, third-party payors and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we research, as well as market, sell and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">58</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">distribute, any products for which we obtain marketing authorization. Restrictions under applicable federal and state healthcare laws and regulations that may be applicable to our business include the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the federal Anti-Kickback Statute prohibits, among other things, persons and entities from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made under a federal healthcare program such as Medicare and Medicaid; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the federal civil false claims laws, including the False Claims Act, which can be enforced by civil whistleblower or qui tam actions on behalf of the government, and criminal false claims laws and the civil monetary penalties law, prohibit individuals or entities from, among other things, knowingly presenting, or causing to be presented false or fraudulent claims for payment by a federal government program, or making a false statement or record material to payment of a false claim or avoiding, decreasing or concealing an obligation to pay money to the federal government; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, prohibits, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, regardless of the payor (e.g. public or private), and knowingly and willfully falsifying, concealing or covering up by any trick or device a material fact or making any materially false, fictitious or fraudulent statements in connection with the delivery of, or payment for, healthcare benefits, items or services relating to healthcare matters; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH, and their implementing regulations, impose requirements on certain covered healthcare providers, health plans and healthcare clearinghouses, as well as their respective business associates and their subcontractors that perform services for them that involve the use, or disclosure of, individually identifiable health information, relating to the privacy, security and transmission of such individually identifiable health information; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the federal transparency requirements under the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, collectively referred to as the ACA, require certain manufacturers of drugs, devices, biologics and medical supplies to annually report to the Centers for Medicare &amp; Medicaid Services, or CMS, information related to payments and other transfers of value provided to teaching hospitals, as well as ownership and investment interests held by physicians, defined to include doctors, dentists, optometrists, podiatrists and chiropractors, as well as ownership and investment interests held by physicians and their immediate family members. Since January 1, 2021, manufacturers are required to collect information regarding payments and transfers of value to physician assistants, nurse practitioners, clinical nurse specialists, anesthesiologist assistants, certified nurse anesthetists and certified nurse-midwives for reporting in the following year. The reported information is made available on a public website; and </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">analogous state laws and regulations such as state anti-kickback and false claims laws and analogous non-U.S. fraud and abuse laws and regulations, may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by state payors and non-governmental third-party payors, including private insurers. Some state laws require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance regulations promulgated by the federal government and may require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers, marketing expenditures or drug pricing, including price increases. Certain state and local laws require the registration of pharmaceutical sales representatives. Certain state and non-U.S. laws, many of which differ from each other in significant ways and often are not preempted by HIPAA, also govern the privacy and security of health information in some circumstances, thus complicating compliance efforts. </span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Efforts to ensure that our internal business processes and business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices do not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment, exclusion from government funded healthcare programs, such as Medicare and Medicaid and other federal healthcare programs, contractual damages, reputational harm, diminished profits and future earnings, additional integrity reporting and oversight obligations and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations. If any of the physicians or other healthcare providers or entities with whom we expect to do business is found to be not in compliance with applicable laws, they may be subject to significant criminal, civil and administrative sanctions, including exclusions from government funded healthcare programs, which could have a material adverse effect on our business, reputation, results of operations, financial condition and prospects. Although compliance programs can mitigate the risk of investigation and prosecution for violations of these laws, the risks cannot be entirely eliminated. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management&#8217;s attention from the operation of our business.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">59</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Existing, recently enacted and future legislation may increase the difficulty and cost for us to obtain marketing authorization of and commercialize our product candidates and decrease the prices we may obtain.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the United States and some foreign jurisdictions, there have been a number of legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing authorization of our product candidates, restrict or regulate post-approval activities and affect our ability to profitably sell any products for which we obtain marketing authorization.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For example, in March 2010, the ACA was signed into law. The ACA is a sweeping law intended to broaden access to health insurance, reduce or constrain the growth of healthcare spending, enhance remedies against fraud and abuse, add new transparency requirements for the healthcare and health insurance industries, impose new taxes and fees on the health industry and impose additional health policy reforms.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Among the provisions of the ACA of importance to our potential product candidates are the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">annual fees and taxes on manufacturers of certain branded prescription drugs; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">an annual, nondeductible fee on any entity that manufactures or imports specified branded prescription drugs and biologic products; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a Medicare Part D coverage gap discount program, in which manufacturers must now agree to offer 70% point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#8217;s outpatient drugs to be covered under Medicare Part D; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program and extended the rebate program to individuals enrolled in Medicaid managed care organizations; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">expansion of healthcare fraud and abuse laws, including the False Claims Act and the federal Anti-Kickback Statute, new government investigative powers and enhanced penalties for noncompliance; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">extension of manufacturers&#8217; Medicaid rebate liability; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">expansion of eligibility criteria for Medicaid programs; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">expansion of the entities eligible for discounts under the Public Health Service pharmaceutical pricing program; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">requirements to report financial arrangements with physicians, as defined by such law, and teaching hospitals; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a requirement to annually report drug samples that manufacturers and distributors provide to physicians; and </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a Patient-Centered Outcomes Research Institute to oversee, identify priorities in and conduct comparative clinical effectiveness research, along with funding for such research. </span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There have been executive, judicial and Congressional challenges to repeal or replace certain aspects of the ACA, including measures taken during the first Trump administration. While Congress has not passed comprehensive repeal legislation, it has enacted laws that modify certain provisions of the ACA such as removing penalties, since January 1, 2019, for not complying with the ACA&#8217;s individual mandate to carry health insurance, eliminating the implementation of certain ACA-mandated fees and increasing the point-of-sale discount that is owed by pharmaceutical manufacturers who participate in Medicare Part D. In addition, there have been legal challenges to the constitutionality of the ACA and certain requirements such as the individual mandate. Although these challenges have been unsuccessful to date, there may be other efforts to challenge the individual mandate or to challenge, repeal or replace the ACA. It is unclear how any pending or future litigation and the healthcare reform measures of the current presidential administration and Congress will impact the ACA and our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, other legislative changes have been proposed and adopted since the ACA was enacted. On August 2, 2011, the Budget Control Act of 2011 was signed into law, which, among other things, created the Joint Select Committee on Deficit Reduction to recommend to Congress proposals for spending reductions. The Joint Select Committee did not achieve a targeted deficit reduction, triggering the legislation&#8217;s automatic reduction to several government programs. These changes include aggregate reductions to Medicare payments to providers of up to 2% per fiscal year, which began in 2013, and due to subsequent legislative amendments to the statute, will remain in effect through 2030, with the exception of a temporary suspension from May 1, 2020 through December 31, 2021 due to the COVID-19 pandemic, unless additional Congressional action is taken. In January 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, reduced Medicare payments to several providers and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. These laws may result in additional reductions in Medicare and other healthcare funding.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">60</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, there has been heightened governmental scrutiny recently over the manner in which drug manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs and reform government program reimbursement methodologies for drug products. At the federal level, recent presidential administrations were focused on drug pricing and have used several means to propose or implement drug pricing reform, including through federal budget proposals, executive orders and policy initiatives. For example, on September 9, 2021, the Biden administration published a wide-ranging list of policy proposals to lower prescription drug prices, including by allowing Medicare to negotiate prices and disincentivizing price increases, and to support market changes that strengthen supply chains, promote biosimilars and generic drugs and increase price transparency. These initiatives recently culminated in the enactment of the Inflation Reduction Act, or IRA, in August 2022, which will, among other things, allow the U.S. Department of Health and Human Services, or HHS, to negotiate the price of certain drugs and biologics that CMS reimburses under Medicare Part B and Part D. The IRA&#8217;s negotiation program will apply to high-expenditure single-source drugs that have been approved for at least 7 years (11 years for biologics), among other negotiation selection criteria. One statutory exemption from the negotiation program is for a drug that has only a single orphan drug designation and is approved only for an indication or indications within the scope of such designation. The negotiated prices, which for the first round of selected drugs announced August 29, 2023 will become effective in 2026, will be capped at a statutorily-determined ceiling price. The IRA also penalizes drug manufacturers that increase prices of Medicare Part B and Part D drugs at a rate greater than the rate of inflation. In addition, the law eliminates the &#8220;donut hole&#8221; under Medicare Part D beginning in 2025 by significantly lowering the beneficiary maximum out-of-pocket cost and requiring manufacturers to subsidize, through a newly established manufacturer discount program, 10% of Part D enrollees&#8217; prescription costs for brand drugs below the out-of-pocket maximum, and 20% once the out-of-pocket maximum has been reached.  The IRA permits the Secretary of HHS to implement many of these provisions through guidance, as opposed to regulation, for the initial years. Manufacturers that fail to comply with the IRA may be subject to various penalties, including civil monetary penalties. The IRA also extends enhanced subsidies for individuals purchasing health insurance coverage in ACA marketplaces through plan year 2025. These IRA provisions began taking effect progressively starting in 2023, although the drug negotiation provisions of the IRA are currently the subject of legal challenges. In addition, the Secretary of the HHS recently proposed testing three new models for pricing efficiency, including one that develops payment methods for drugs approved under accelerated approval, in consultation with the FDA, to encourage timely confirmatory trial completion and improve access to post-market safety and efficacy data with the goal of reducing Medicare spending on drugs that have no confirmed clinical benefit. Further, at the state level, individual states have increasingly introduced and passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including: restricting price, reimbursement, discounts, product access and marketing; imposing drug price and cost disclosure and transparency requirements; permitting importation from other countries; and encouraging bulk purchasing.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect that additional state and federal healthcare reform measures, including potentially significant additional changes to current drug pricing and reimbursement structures, will be adopted in the future. Current and future reform measures may result in more rigorous coverage criteria and in additional downward pressure on the prices that we receive for any approved product. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate future revenue in line with our expectations, attain profitability or commercialize OJEMDA and our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Legislative and regulatory proposals have been made to expand post-approval requirements and restrict sales and promotional activities for pharmaceutical products. We cannot be sure whether additional legislative changes will be enacted, or whether the FDA regulations, guidance or interpretations will be changed, or what the impact of such changes on the marketing authorizations of our product candidates, if any, may be. In addition, increased scrutiny by the U.S. Congress of the FDA&#8217;s approval process may significantly delay or prevent marketing authorization, as well as subject us to more stringent product labeling and post-marketing testing and other requirements.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, in June 2024, the U.S. Supreme Court reversed its longstanding approach under the Chevron doctrine, which provided for judicial deference to regulatory agencies, including the FDA. As a result of this decision, we cannot be sure whether there will be increased challenges to existing agency regulations or how lower courts will apply the decision in the context of other regulatory schemes without more specific guidance from the U.S. Supreme Court. For example, this decision may result in more companies bringing lawsuits against the FDA to challenge longstanding decisions and policies of the FDA, which could undermine the FDA&#8217;s authority, lead to uncertainties in the industry, and disrupt the FDA&#8217;s normal operations, which could impact the timely review of any regulatory filings or applications we submit to the FDA. We cannot predict the full impact of this decision, future judicial challenges brought against the FDA, or the nature or extent of government regulation that may arise from future legislation or administrative action.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Governments outside of the United States tend to impose strict price controls, which may adversely affect our future revenues.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In some countries, including Canada and certain member states of the EU, the pricing of prescription pharmaceuticals is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after the receipt of marketing authorization for a product. To obtain reimbursement or pricing approval in some countries, we may be required to conduct a clinical trial that compares the cost-effectiveness of our product candidates to other available therapies. If reimbursement</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">61</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">of our products is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, our business could be harmed. Political, economic and regulatory developments, including the imposition of new or additional tariffs or other trade barriers, may further complicate pricing negotiations, and pricing negotiations may continue after reimbursement has been obtained. Reference pricing used by various EU member states, and parallel trade, such as arbitrage between low-priced and high-priced member states, can further reduce prices. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any products, if approved in those countries. Publication of discounts by third-party payors or authorities may lead to further pressure on the prices or reimbursement levels within the country of publication or other countries.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Laws and regulations governing any international operations we may have in the future may preclude us from developing, manufacturing and selling certain product candidates and products outside of the United States and require us to develop and implement costly compliance programs.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we expand our operations outside of the United States, we must dedicate additional resources to comply with numerous laws and regulations in each jurisdiction in which we plan to operate. The Foreign Corrupt Practices Act, or FCPA, prohibits certain U.S. individuals and entities and their party agents from paying, offering, authorizing payment or offering anything of value, directly or indirectly, to any foreign official, political party or candidate for the purpose of influencing any act or decision of such third party in order to assist the individual or business in obtaining or retaining business or gaining an improper advantage. The FCPA also obligates companies whose securities are listed in the United States to comply with certain accounting provisions requiring the company to maintain books and records that accurately and fairly reflect all transactions of the company, including international subsidiaries, and to devise and maintain an adequate system of internal accounting controls for international operations.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Compliance with the FCPA is expensive and difficult, particularly in countries where corruption is a recognized problem. In addition, the FCPA presents particular challenges in the pharmaceutical industry, because, in many countries, hospitals are operated by the government, and doctors and other hospital employees are considered foreign officials and therefore our interactions with these individuals are subject to regulation under the FCPA.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Various laws, regulations and executive orders also restrict the use and dissemination outside of the United States, or the sharing with certain non-U.S. nationals, of information classified for national security purposes, as well as certain products and technical data relating to those products. We are also subject to U.S. laws and regulations governing export controls, as well as economic sanctions and embargoes on certain countries and persons. If we expand our presence outside of the United States, it will require us to dedicate additional resources to comply with these laws, and these laws may preclude us from developing, manufacturing or selling certain product candidates and products outside of the United States, which could limit our growth potential and increase our development costs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The failure to comply with laws governing international business practices may result in substantial civil and criminal penalties and suspension or debarment from government contracting. The U.S. Securities and Exchange Commission, or the SEC, also may suspend or bar issuers from trading securities on U.S. exchanges for violations of the FCPA&#8217;s accounting provisions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Disruptions at the FDA may slow the time necessary for new products to be reviewed and/or approved, which would adversely affect our business. There is substantial uncertainty regarding new initiatives and how these might impact the FDA, its implementation of laws, regulations, policies and guidance and its personnel. Similar initiatives may also be directed toward other government agencies. These initiatives could prevent, limit or delay development and regulatory approval of our product candidates, which would adversely affect our business.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Disruptions at the FDA may slow the time necessary for new products to be reviewed and/or approved, which would adversely affect our business. Changes in FDA staffing could result in delays in the FDA&#8217;s responsiveness or in its ability to review submissions or applications, issue regulations or guidance, or implement or enforce regulatory requirements in a timely fashion or at all. If any legislation, executive orders, or lapses in agency funding impose constraints on the FDA&#8217;s ability to engage in oversight and implementation activities in the normal course, our business may be negatively impacted.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Similar consequences would also result in the event of another significant shutdown of the federal government. For example, in 2024, the U.S. government was on the verge of a shutdown and has previously shut down several times, and certain regulatory agencies, such as the FDA, had to furlough critical employees and stop critical activities. If a prolonged government shutdown occurs, or if geopolitical or global health concerns prevent the FDA from conducting their regular inspections, reviews, or other regulatory activities, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Further, future government shutdowns or delays could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FDA-regulated industries, such as ours, face uncertainty with regard to the regulatory environment we will face as we proceed with research, development and commercialization. Some of these efforts have manifested to date in the form of personnel measures that could impact the FDA&#8217;s ability to hire and retain key personnel, which could result in delays or limitations on our ability to obtain</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">62</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">guidance from the FDA on our product candidates in development or obtain the requisite regulatory approvals in the future. There remains general uncertainty regarding future activities. New executive orders, regulations, policies or guidance could be issued or promulgated that adversely affect us or creates a more challenging or costly environment to pursue the development of new therapeutic products. Alternatively, state governments may attempt to address or react to changes at the federal level with changes to their own regulatory frameworks in a manner that is adverse to our operations. If we become negatively impacted by future governmental orders, regulations, policies or guidance, there could be a material adverse effect on us and our business.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could harm our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We and our third-party contractors are subject to numerous foreign, federal, state and local environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our operations involve the use of hazardous and flammable materials, including chemicals and biological materials. Our operations also produce hazardous waste products. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources, including any available insurance. We could also be held liable for unexpected safety events that could happen in our business offices.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, our leasing and operation of real property may subject us to liability pursuant to certain of these laws or regulations. Under existing U.S. environmental laws and regulations, current or previous owners or operators of real property and entities that disposed or arranged for the disposal of hazardous substances may be held strictly, jointly and severally liable for the cost of investigating or remediating contamination caused by hazardous substance releases, even if they did not know of and were not responsible for the releases.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We could incur significant costs and liabilities which may adversely affect our financial condition and operating results for failure to comply with such laws and regulations, including, among other things, civil or criminal fines and penalties, property damage and personal injury claims, costs associated with upgrades to our facilities or changes to our operating procedures or injunctions limiting or altering our operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Although we maintain liability insurance to cover us for costs and expenses we may incur due to injuries to our employees, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of biological, hazardous or radioactive materials.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations, which are becoming increasingly more stringent, may impair our research, development or production efforts. Our failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We are subject to certain U.S. and foreign anti-corruption, anti-money laundering, export control, sanctions and other trade laws and regulations. We can face serious consequences for violations.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">U.S. and foreign anti-corruption, anti-money laundering, export control, sanctions and other trade laws and regulations prohibit, among other things, companies and their employees, agents, CROs, CMOs, legal counsel, accountants, consultants, contractors and other partners from authorizing, promising, offering, providing, soliciting, or receiving directly or indirectly, corrupt or improper payments or anything else of value to or from recipients in the public or private sector. Violations of these laws can result in substantial criminal fines and civil penalties, imprisonment, the loss of trade privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm and other consequences. We have direct or indirect interactions with officials and employees of government agencies or government-affiliated hospitals, universities and other organizations. We also expect our non-U.S. activities to increase over time. We expect to rely on third parties for research, preclinical studies and clinical trials and/or to obtain necessary permits, licenses, patent registrations and other marketing authorizations. We can be held liable for the corrupt or other illegal activities of our personnel, agents or partners, even if we do not explicitly authorize or have prior knowledge of such activities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any violations of the laws and regulations described above may result in substantial civil and criminal fines and penalties, imprisonment, the loss of export or import privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm and other consequences.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">63</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We are developing our current product candidates, and may continue to develop future product candidates, in combination with other therapies, which would expose us to additional risks.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are developing our current product candidates in combination with one or more currently approved cancer therapies or therapies in development. Even if our current or future product candidates, including DAY301 and the VRK1 inhibitor program, receive marketing authorization or are commercialized for use in combination with other existing therapies, we would continue to be subject to the risks that the FDA or comparable foreign regulatory authorities could revoke approval of the therapy used in combination with any of our product candidates, or safety, efficacy, manufacturing or supply issues could arise with these existing therapies. In addition, it is possible that existing therapies with which our product candidates are approved for use could themselves fall out of favor or be relegated to later lines of treatment. This could result in the need to identify other combination therapies for our product candidates or our own products being removed from the market or being less successful commercially.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may also evaluate our current product candidates in combination with one or more other cancer therapies that have not yet been approved for marketing by the FDA or comparable foreign regulatory authorities. We will not be able to market and sell any product candidate in combination with any such unapproved cancer therapies that do not ultimately obtain marketing authorization.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If the FDA or comparable foreign regulatory authorities do not approve or withdraw their approval of these other therapies, or if safety, efficacy, commercial adoption, manufacturing or supply issues arise with the therapies we choose to evaluate in combination with any of our current or future product candidates, we may be unable to obtain approval of or successfully market any one or all of the current or future product candidates we develop. Additionally, if the third-party providers of therapies or therapies in development used in combination with our current or future product candidates are unable to produce sufficient quantities for clinical trials or for commercialization of our current or future product candidates, or if the cost of combination therapies are prohibitive, our development and commercialization efforts would be impaired, which would have an adverse effect on our business, financial condition, results of operations and growth prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We have limited experience as a commercial company and the sales, marketing, and distribution of OJEMDA or any future approved products may be unsuccessful or less successful than anticipated.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We recently began commercializing our first product, OJEMDA, in the United States. As a company, we had no prior experience commercializing a product. The success of our commercialization efforts for OJEMDA and any future approved products is difficult to predict and subject to the effective execution of our business plan, including, among other things, the continued development of our internal sales, marketing, and distribution capabilities and our ability to navigate the significant expenses and risks involved with the development and management of such capabilities.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For example, we have completed hiring in areas to support commercialization, including in sales management, sales representatives, marketing, access and reimbursement, sales support, and distribution. There are significant expenses and risks involved with establishing our own sales, marketing, and distribution capabilities, including our ability to hire, retain, and appropriately incentivize qualified individuals, provide adequate training to sales and marketing personnel, and effectively manage geographically dispersed sales and marketing teams to generate sufficient demand. Any failure or delay in the development of these capabilities could delay or negatively affect the success of our commercialization efforts and our business. For example, the commercialization of OJEMDA may not develop as planned or anticipated, which may require us to, among others, adjust or amend our business plan and incur significant expenses.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Alternatively, we may license certain rights with respect to our products or product candidates to collaborators and rely on the assistance and guidance of those collaborators. We may also seek collaborations to secure marketing authorizations and commercialize our products outside of the United States. We cannot assure that any collaboration(s) will result in short-term or long-term benefit to the company. If we choose to collaborate, either globally or on a territory-by-territory basis, with third parties that have direct sales forces and established distribution systems, either to augment our own sales force and distribution systems or in lieu of our own sales force and distribution systems, we will be required to negotiate and enter into arrangements with such third parties relating to the proposed collaboration and such arrangements may prove to be less profitable than commercializing the product on our own. If we are unable to build our own distribution and marketing capabilities or to find suitable partners for the commercialization of our products and product candidates, we may not generate substantial revenues, if any, from them or be able to reach or sustain profitability.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Given our lack of experience commercializing products, we do not have a track record of successfully executing on the commercialization of an approved product. If we are unsuccessful in accomplishing our objectives and executing on our business plan, or if the commercialization of OJEMDA or any future approved products does not develop as planned, we may require significant additional capital and financial resources, we may not become profitable, and we may not be able to compete against more established companies in our industry.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">64</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Our Reliance on Third Parties</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We rely, and intend to continue to rely, on third parties to conduct our clinical trials and perform some of our research and potential preclinical studies. If these third parties do not satisfactorily carry out their contractual duties, fail to comply with applicable regulatory requirements or do not meet expected deadlines, our development programs may be delayed or subject to increased costs or we may be unable to obtain marketing authorization, each of which may have an adverse effect on our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We do not have the ability to independently conduct all aspects of our clinical trials ourselves. As a result, we are dependent on third parties to conduct our ongoing and planned clinical trials of tovorafenib, DAY301, the VRK1 inhibitor program and any preclinical studies and clinical trials of any future products and product candidates. The timing of the initiation and completion of these trials will therefore be partially controlled by such third parties and may result in delays to our development programs. Since such third parties partially control the progress of these trials, they may also publish the data related to these trials prior to obtaining or without our approval for doing so. Specifically, we expect CROs, independent clinical investigators and consultants to play a significant role in the conduct of these trials and the subsequent collection and analysis of data. For example, in addition to the Phase 1 clinical trial run by Dana Farber Cancer Institute in collaboration with PNOC, the Children&#8217;s Oncology Group, a National Cancer Institute-supported clinical trials group and the world&#8217;s largest organization devoted exclusively to childhood and adolescent cancer research, is developing a group-wide clinical trial of tovorafenib in relapsed Langerhans cell histiocytosis. However, these investigators, CROs and other third parties are not our employees, and we will not be able to control all aspects of their activities. Nevertheless, we are responsible for ensuring that each clinical trial is conducted in accordance with the applicable protocol and legal, regulatory and scientific standards, and our reliance on the investigators, CROs and other third parties does not relieve us of our regulatory responsibilities. We and our CROs are required to comply with GCP requirements, which are regulations and guidelines enforced by the FDA for products and product candidates in clinical development. Regulatory authorities enforce these GCP requirements through periodic inspections of trial sponsors, clinical trial investigators and clinical trial sites. If we or any of our CROs or clinical trial sites fail to comply with applicable GCP requirements, the data generated in our clinical trials may be deemed unreliable, and the FDA may require us to perform additional clinical trials before approving our marketing applications. We cannot assure you that, upon inspection, the FDA will determine that our clinical trials comply with GCPs. In addition, our clinical trials must be conducted with products and product candidates produced under cGMP regulations. Our failure or the failure of third parties on whom we rely to comply with these regulations may require us to stop and/or repeat clinical trials, which would delay the marketing authorization process.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There is no guarantee that any such CROs, clinical trial investigators or other third parties on which we rely will devote adequate time and resources to our development activities or perform as contractually required. In addition, these third parties may be subject to supply chain or inflationary pressures that limit their ability to achieve anticipated timelines or result a greater cost to us. For example, we are aware of a shortage of non-human primates available for preclinical studies and although that is not expected to impact our current business if we begin new product development programs we could be subject to longer development times or difficulty completing necessary research. If any of these third parties fail to meet expected deadlines, adhere to our clinical protocols or meet regulatory requirements, otherwise perform in a substandard manner or terminate their engagements with us, the timelines for our development programs may be extended or delayed or our development activities may be suspended or terminated. If our clinical trial site terminates for any reason, we may experience the loss of follow-up information on subjects enrolled in such clinical trial unless we are able to transfer those subjects to another qualified clinical trial site, which may be difficult or impossible.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, with respect to investigator-sponsored trials that may be conducted, we would not control the design or conduct of these trials, and it is possible that the FDA will not view these investigator-sponsored trials as providing adequate support for future clinical trials or market approval, whether controlled by us or third parties, for any one or more reasons, including elements of the design or execution of the trials or safety concerns or other trial results. We expect that such arrangements will provide us certain information rights with respect to the investigator-sponsored trials, including access to and the ability to use and reference the data, including for our own regulatory submissions, resulting from the investigator-sponsored trials. However, we would not have control over the timing and reporting of the data from investigator-sponsored trials, nor would we own the data from the investigator-sponsored trials. If we are unable to confirm or replicate the results from the investigator-sponsored trials or if negative results are obtained, we would likely be further delayed or prevented from advancing further clinical development. Further, if investigators or institutions breach their obligations with respect to the clinical development of OJEMDA or our product candidates, or if the data proves to be inadequate compared to the firsthand knowledge we might have gained had the investigator-sponsored trials been sponsored and conducted by us, then our ability to design and conduct any future clinical trials ourselves may be adversely affected. The investigators may design clinical trials with clinical endpoints that are more difficult to achieve, or in other ways that increase the risk of negative clinical trial results compared to clinical trials that we may design on our own. Negative results in investigator-sponsored clinical trials could have a material adverse effect on our efforts to obtain marketing authorization for our product candidates and the public perception of our product candidates. Additionally, the FDA may disagree with the sufficiency of our right of reference to the preclinical, manufacturing or clinical data generated by these investigator-sponsored trials, or our interpretation of preclinical, manufacturing or clinical data from these investigator-sponsored trials. If so, the FDA may require us to obtain and submit additional preclinical, manufacturing or clinical data.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">65</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Furthermore, these third parties may also have relationships with other entities, some of which may be our competitors for whom they may also be conducting clinical trials or other pharmaceutical product development activities that could harm our competitive position. If these third parties do not successfully carry out their contractual duties, meet expected deadlines or conduct our clinical trials in accordance with regulatory requirements or our stated protocols, we will not be able to obtain, or may be delayed in obtaining, marketing authorizations for OJEMDA, DAY301, the VRK1 inhibitor program or any future product candidates and will not be able to, or may be delayed in our efforts to, successfully commercialize our products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The manufacture of pharmaceutical products, including OJEMDA and our product candidates including DAY301 and the VRK1 inhibitor program, is complex. Our third-party manufacturers may encounter difficulties in production, which could delay or entirely halt their ability to supply our product candidates for clinical trials or, if approved, for commercial sale.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We do not have any manufacturing facilities, and we currently contract with certain third-party manufacturers in China. We rely, and expect to continue to rely, on third parties for the manufacture of OJEMDA and our product candidates for clinical testing, product development purposes, to support regulatory application submissions, as well as for commercial manufacture of our product candidates. In addition, we expect to contract with analytical laboratories for release and stability testing of OJEMDA and our product candidates. This reliance on third parties increases the risk that we will not have sufficient quantities of OJEMDA or our product candidates or products or such quantities at an acceptable cost or quality, which could delay, prevent or impair our development or commercialization efforts and cause the FDA to withdraw certain designations, including orphan drug designation. For example, we cannot be sure to what extent the supply chain issues caused by geopolitical uncertainty, the imposition of new or additional tariffs or other trade barriers, and public health epidemics, may impact our ability to procure sufficient supplies for the development of OJEMDA and our product candidates and what, if any, impact that may have on our facilities and operations in the region, including but not limited to a decrease or disruption of production, increased costs of production or other interruptions in our supply chain.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, any disruption in production or inability of our manufacturers, specifically in China, to produce adequate quantities to meet our needs, whether as a result of a natural disaster or other causes, could impair our ability to operate our business on a day-to-day basis and to continue our development of OJEMDA and our product candidates. Furthermore, since these manufacturers are located in China, we are exposed to the possibility of product supply disruption and increased costs in the event of economic sanctions, changes in the policies of the United States or Chinese governments, political unrest or unstable economic conditions in China. In April 2025, the U.S. presidential administration announced extensive tariffs on goods imported from China, where certain of our third-party manufacturers are located. We believe we currently have sufficient API inventory for commercial and clinical use and do not anticipate any near-term impact to our sales or clinical programs, we expect these tariffs to increase the cost of our API in the future, which would negatively impact our business, financial condition and results of operations. In addition, legislation has been introduced in Congress to limit certain U.S. biotechnology companies from using equipment or services produced or provided by select Chinese biotechnology companies, including those affiliated with the manufacture of our API, Wuxi STA, and others in Congress have advocated for the use of existing executive branch authorities to limit those Chinese service providers&#8217; ability to engage in business in the United States. We cannot predict what actions may ultimately be taken with respect to trade relations between the United States and China or other countries, what products and services may be subject to such actions or what actions may be taken by the other countries in retaliation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any of these matters could materially adversely affect our business, financial condition and results of operations. In addition, disruptions in logistics routes and transportation capabilities could disrupt our supply chain. And, if we experience unexpected spikes in demand over time, we risk running out of our necessary supplies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We entered into a manufacturing and supply agreement with Quotient for drug manufacturing of OJEMDA and a packaging agreement with Sharp Corporation, or Sharp, for the packaging and serialization of OJEMDA. Supply chain issues, such as those related to certain packaging material, may negatively impact our ability to package and deliver OJEMDA and our product candidates if not managed effectively. Moreover, if any of our existing or future contract manufacturers or suppliers fail to perform satisfactorily, it could delay development or regulatory approval of our drug candidates or commercialization of our drugs, which could negatively impact our results of operations and business.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may be unable to enter into additional agreements with third-party manufacturers or suppliers or do so on favorable terms. Our anticipated reliance on a limited number of third party-manufacturers or suppliers exposes us to the following risks:</span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">reliance on the third party for regulatory, compliance and quality assurance; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">reliance on the third party for product development, analytical testing and data generation to support regulatory applications; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">operations of our third-party manufacturers or suppliers could be disrupted by conditions unrelated to our business or operations, including the bankruptcy of the manufacturer or supplier, the issuance of an FDA Form 483 notice or warning letter or other enforcement action by the FDA or other regulatory authority; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the possible breach of the manufacturing agreement by the third party; </span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">66</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the possible misappropriation of our proprietary information, including our trade secrets and know-how; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the possible termination or nonrenewal of the agreement by the third party at a time that is costly or inconvenient for us; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">carrier disruptions or increased costs that are beyond our control; and </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">failure to deliver our drugs under specified storage conditions and in a timely manner. </span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Third-party manufacturers may not be able to comply with cGMP regulations or similar regulatory requirements outside of the United States. If the FDA determines that our CMOs are not in compliance with FDA laws and regulations, including those governing cGMPs, the FDA may not approve an NDA until the deficiencies are corrected or we replace the manufacturer in our application with a manufacturer that is in compliance. Moreover, our failure, or the failure of our third-party manufacturers and suppliers, to comply with applicable regulations could result in sanctions being imposed on us, including clinical holds, fines, injunctions, civil penalties, seizures or recalls of product candidates or products, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of our products. In addition, approved products and the facilities at which they are manufactured are required to maintain ongoing compliance with extensive FDA requirements and the requirements of other similar agencies, including ensuring that quality control and manufacturing procedures conform to cGMP requirements. As such, our CMOs are subject to continual review and periodic inspections to assess compliance with cGMPs. Furthermore, although we do not have day-to-day control over the operations of our CMOs, we are responsible for ensuring compliance with applicable laws and regulations, including cGMPs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, our third-party manufacturers and suppliers are subject to numerous environmental, health and safety laws and regulations, including those governing the handling, use, storage, treatment and disposal of waste products, and failure to comply with such laws and regulations could result in significant costs associated with civil or criminal fines and penalties for such third parties. Based on the severity of regulatory actions that may be brought against these third parties in the future, our clinical or commercial supply of drug and packaging and other services could be interrupted or limited, which could harm our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">OJEMDA and our product candidates and any products that we may develop may compete with other product candidates and products for access to manufacturing facilities. As a result, we may not obtain access to these facilities on a priority basis or at all. There are a limited number of manufacturers that operate under cGMP regulations and that might be capable of manufacturing for us.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As we prepare for later-stage clinical trials and commercialization of OJEMDA, we will need to take steps to increase the scale of production of OJEMDA and our product candidates. Other than for our product OJEMDA, we have not yet scaled up the manufacturing process for any of our product candidates and may need to scale further to support future supply needs for any of our product candidates. Third-party manufacturers may be unable to successfully increase the manufacturing capacity for any of our product candidates in a timely or cost-effective manner, or at all. In addition, quality issues may arise during scale-up or commercial activities. For example, if microbial, viral or other contaminations are discovered in our product candidates or in the manufacturing facilities in which our product candidates are made, such manufacturing facilities may need to be closed for an extended period of time to investigate and remedy the contamination.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any performance failure on the part of our existing or future manufacturers could delay clinical development or marketing authorization. If our current CMOs for clinical testing cannot perform as agreed, we may be required to replace such CMOs. Although we believe that there are several potential alternative manufacturers who could manufacture OJEMDA or our product candidates, we may incur added costs and delays in identifying and qualifying any such replacement manufacturer or be able to reach agreement with any alternative manufacturer. Further, our third-party manufacturers may experience manufacturing or shipping difficulties due to resource constraints or as a result of natural disasters, labor disputes, unstable political environments or public health epidemics. If our current third-party manufacturers cannot perform as agreed, we may be required to replace such manufacturers and we may be unable to replace them on a timely basis or at all.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our current and anticipated future dependence upon others for the manufacture of OJEMDA or our product candidates may adversely affect our future profit margins and our ability to commercialize any products that obtain marketing authorization on a timely and competitive basis.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We rely on a limited number of suppliers for raw materials and any disruptions arising from our sole suppliers could result in delays in our clinical trials or otherwise adversely affect our business and results of operations.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We rely on a limited number of suppliers, some of whom are our sole source for certain materials, and some of whom are based in foreign jurisdictions.  Our small number of suppliers involves a number of additional risks, including risks related to supplier capacity constraints, component availability, price increases, timely delivery, component quality, failure of a key supplier to remain in business and adjust to market conditions, including inflation and changes in interest rates, significant political, trade or regulatory developments, including the implementation of tariffs by the United States, China, and other governments, natural disasters, fire, regional geopolitical conflicts, acts of terrorism, pandemics, or other catastrophic events. Further, in the case of materials for which we have a sole supplier, even if we are able to replace any raw materials or other materials with an alternative, such alternatives may cost more, result in lower yields or not be as suitable for our purposes. In addition, some of the materials that we use to manufacture</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">67</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">OJEMDA and our product candidates are complex materials, which may be more difficult to substitute. Therefore, any disruptions arising from our sole suppliers could result in delays and additional regulatory submissions, which may adversely affect our business and results of operations.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our existing License Agreement with Ipsen is important to our business. If Ipsen fails to fulfill its contract obligations, or if any of the Ipsen License Agreement is terminated, our ability to commercialize OJEMDA in territories outside the United States may be delayed or prevented and we may never receive milestone payments or future royalties under the License Agreement.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In July 2024, we entered into the Ipsen License Agreement, pursuant to which we licensed to Ipsen, on an exclusive basis, the right to commercialize tovorafenib in all territories outside the United States and agreed to provide certain research and development and manufacturing services. Ipsen shall have the right to grant sublicenses to third -parties. A significant portion of our future revenue and cash resources may be derived from the Ipsen License Agreement, or other similar agreements into which we may enter in the future.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the Ipsen License Agreement, we are eligible to receive up to approximately $350.0 million in additional commercial launch and sales-based milestone payments based on exchange rates as of the reporting date, as well as tiered, double-digit royalty payments starting at mid-teens percentage of annual net sales of tovorafenib, subject to customary adjustments.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the terms of the Ipsen License Agreement, Ipsen will have significant discretion in determining the efforts and resources that they will apply to their marketing efforts and their management of the ex-U.S. regulatory activities and they may not perform their obligations as expected. Disputes may arise between Ipsen and us that result in the delay or termination of the research, development or commercialization of our products or product candidates or that result in costly litigation or arbitration that diverts management attention and resources. Furthermore, they may have changes in their strategic focus or available funding, or experience external factors, such as an acquisition, may divert resources or create competing priorities. Any of these events would have a material adverse effect on our business, financial condition and results of operations.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Ipsen License Agreement may be terminated by either party for material breach or bankruptcy. In addition, Ipsen may terminate the Ipsen License Agreement after the second anniversary of the effective date for convenience with six months&#8217; prior written notice or for certain other specified reasons.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If the Ipsen License Agreement is terminated, then, depending on the event:</span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our cash expenditures could increase significantly if it is necessary for us to hire additional employees and allocate internal resources to the commercialization or other activities that were previously shared by Ipsen;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we would bear all of the risks and costs related to the further commercialization and development activities that were previously the subject of the Ipsen License Agreement;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in order to fund further commercialization activities, we may need to seek out and establish  alternative strategic collaborations with third-party partners, which may not be possible; or</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may not be able to do so on terms which are acceptable to us, in which case it may be necessary for us to limit the size or scope of one or more of our programs or increase our expenditures and seek additional funding by other means.</span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any of these events would have a material adverse effect on our business, financial condition and results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may enter into collaborations with third parties for the development and commercialization of our product candidates. If those collaborations are not successful, we may not be able to capitalize on the market potential of our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may seek third-party collaborators for the development and commercialization of our product candidates on a select basis, such as our collaboration with Ipsen with respect to commercialization of tovorafenib in all territories outside the United States. Our likely collaborators for any future collaboration arrangements include large and mid-size pharmaceutical companies, regional and national pharmaceutical companies and biotechnology companies. We face significant competition in seeking appropriate collaborators. Our ability to reach a definitive agreement for a future collaboration will depend, among other things, upon our assessment of the future collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#8217;s evaluation of a number of factors.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we do enter into any additional arrangements with any third parties, we will likely have limited control over the amount and timing of resources that our future collaborators dedicate to the development or commercialization of our product candidates. Our ability to generate revenues from these arrangements will depend on our future collaborators&#8217; abilities and efforts to successfully perform the functions assigned to them in these arrangements. Collaborations with future collaborators involving our product candidates would pose numerous risks to us, including the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">collaborators have significant discretion in determining the efforts and resources that they will apply to these collaborations and may not perform their obligations as expected; </span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">68</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">collaborators may de-emphasize or not pursue development and commercialization of our product candidates or may elect not to continue or renew development or commercialization programs based on clinical trial results, changes in the collaborator's strategic focus, including as a result of a sale or disposition of a business unit or development function, or available funding or external factors such as an acquisition that diverts resources or creates competing priorities; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our product candidates if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a collaborator with marketing and distribution rights to multiple products may not commit sufficient resources to the marketing and distribution of our product relative to other products;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">collaborators may reassign manufacturing responsibilities to themselves or a new CMO, which would require that any new manufacturing facility also comply with cGMPs. The FDA or another regulator could decide to conduct an inspection of any new manufacturing facility and a material noncompliance could delay the launch of commercial manufacturing at such facility;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">collaborators may not properly obtain, maintain, defend or enforce our intellectual property rights or may use our proprietary information and intellectual property in such a way as to invite litigation or other intellectual property related proceedings that could jeopardize or invalidate our proprietary information and intellectual property or expose us to potential litigation or other intellectual property related proceedings; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">disputes may arise between the collaborators and us that result in the delay or termination of the research, development or commercialization of our product candidates or that result in costly litigation or arbitration that diverts management attention and resources; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">collaborations may be terminated and, if terminated, may result in a need for additional capital to pursue further development or commercialization of the applicable products or product candidates; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">collaboration agreements may not lead to development or commercialization of our product candidates in the most efficient manner or at all; and </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">if a future collaborator of ours were to be involved in a business combination, the continued pursuit and emphasis on our product development or commercialization program could be delayed, diminished or terminated. </span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we establish additional collaborations in the future, all of the risks relating to product development, marketing authorization and commercialization described herein would also apply to the activities of any such future collaborators.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The loss of any large customer, or any cancellation or delay of a significant purchase by a large customer, could reduce our net sales and harm our operating results.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have received a substantial portion of our revenue from a limited number of customers. For example, for the three months ended March 31, 2025, two individual customers accounted for 98.4% of our total net product revenue, with these individual customers representing 64.4% and 34.0% of total net product revenue. As of March 31, 2025, two customers accounted for 96.2% of the accounts receivable balance, with these individual customers representing 72.4% and 23.8% of the accounts receivable balance.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We cannot provide any assurances that we will retain our current customers or groups of customers, that they will maintain their current or forecasted demand for our products, or that we will be able to attract and retain additional customers in the future. If for any reason we were to lose our ability to sell to a specific group or class of customers, we could experience a significant reduction in revenue or loss of market share, which would adversely impact our operating results.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Employee Matters and Our Operations</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our future success depends on our ability to retain our executive officers and key employees and to attract, retain and motivate qualified personnel and manage our human capital.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our ability to compete in the highly competitive biotechnology and pharmaceutical industries depends upon our ability to attract, motivate and retain highly qualified managerial, scientific, medical and commercial personnel. We are highly dependent on the development and management expertise of Jeremy Bender, Ph.D., M.B.A., our Chief Executive Officer, as well as the other members of our management team, other key employees and advisors. We currently do not maintain key person insurance on these individuals. Although we have entered into employment agreements with our executive officers, each of them may terminate their employment with us at any time.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">69</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our industry has experienced a high rate of turnover in recent years. Our ability to compete in the highly competitive pharmaceuticals industry depends upon our ability to attract, retain and motivate highly skilled and experienced personnel with scientific, clinical, regulatory, manufacturing, quality, commercial and management skills and experience.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We largely conduct our operations in the greater San Francisco Bay Area, a region that is home to other pharmaceutical companies as well as many academic and research institutions, resulting in fierce competition for qualified personnel. We may not be able to attract or retain qualified personnel in the future due to the intense competition for a limited number of qualified personnel among pharmaceutical companies. Many of the other pharmaceutical companies against which we compete have greater financial and other resources, different risk profiles and a longer history in the industry than we do. Our competitors may provide higher compensation, more diverse opportunities and/or better opportunities for career advancement. In addition, as our business changes, key personnel may not want to work for a larger, commercial enterprise. Any or all of these competing factors may limit our ability to continue to attract and retain high quality personnel, which could negatively affect our ability to successfully develop and commercialize OJEMDA or our product candidates and to grow our business and operations as currently contemplated. We have adopted a greater level of flexibility in our recruiting practices to attract and hire candidates outside of the San Francisco Bay Area, which is intended to increase retention but could have a negative impact on employee engagement, resulting in greater employee turnover.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We will need to grow the size and capabilities of our organization, and we may experience difficulties in managing this growth.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We had 181 full-time employees as of March 31, 2025. We expect significant growth in the number of our employees and the scope of our operations, particularly in the areas of clinical development, clinical operations, manufacturing, regulatory affairs, sales, marketing and distribution. To manage our anticipated future growth, we must continue to implement and improve our managerial, operational and financial systems, expand our facilities and continue to recruit and train additional qualified personnel. Due to our limited financial resources and the limited experience of our management team in managing a company with such anticipated growth and with developing sales, marketing and distribution infrastructure, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel. The expansion of our operations may lead to significant costs and may divert our management and business development resources.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, we currently rely, and for the foreseeable future will continue to rely, in substantial part on certain third-party contract organizations, advisors and consultants to provide certain services, including assuming substantial responsibilities for the conduct of our clinical trials and the manufacture of OJEMDA, DAY301, the VRK1 inhibitor program or any future product candidates. We cannot assure you that the services of such third-party contract organizations, advisors and consultants will continue to be available to us on a timely basis when needed, or that we can find qualified replacements. In addition, if we are unable to effectively manage our outsourced activities or if the quality or accuracy of the services provided by our vendors or consultants is compromised for any reason, our clinical trials may be extended, delayed or terminated, and we may not be able to obtain marketing authorization of DAY301, the VRK1 inhibitor program or any future product candidates or otherwise advance our business. We cannot assure you that we will be able to properly manage our existing vendors or consultants or find other competent outside vendors and consultants on economically reasonable terms, or at all.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we are not able to effectively manage growth and expand our organization, we may not be able to successfully implement the tasks necessary to further develop and commercialize OJEMDA, DAY301, the VRK1 inhibitor program, our other pipeline product candidates or any future product candidates and, accordingly, may not achieve our research, development and commercialization goals.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our employees, clinical trial investigators, CROs, CMOs, consultants, vendors and any future commercial partners may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements and insider trading.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are exposed to the risk of fraud or other misconduct by our employees and third parties that we rely on, including, clinical trial investigators, CROs, CMOs, consultants, vendors and any future commercial partners. Misconduct by these parties could include intentional, reckless and/or negligent conduct or disclosure of unauthorized activities to us that violates: (i) FDA regulations or those of comparable foreign regulatory authorities, including those laws that require the reporting of true, complete and accurate information, (ii) manufacturing (e.g., cGMP) and clinical practice (e.g., GCP) standards, (iii) federal and state health and data privacy, security, fraud and abuse, government price reporting, transparency reporting requirements and other healthcare laws and regulations in the United States and abroad, (iv) sexual harassment and other workplace misconduct, or (v) laws that require the true, complete and accurate reporting of financial information or data. In particular, research, sales, marketing and business arrangements in our industry are subject to a wide variety of laws and regulations that are intended to prevent fraud, misconduct, kickbacks and other abusive practices. Such misconduct could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and cause serious harm to our reputation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have adopted a code of conduct applicable to all of our employees, as well as a disclosure program and other applicable policies and procedures, but it is not always possible to identify and deter employee misconduct, and the precautions we take to detect and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">70</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, with respect to third parties, third parties are not our employees, and except for remedies available to us under our agreements, we have limited ability to control resources that any such third party will devote to our preclinical studies or our clinical trials. The third parties we rely on for these services may also have relationships with other entities, some of which may be our competitors, for whom they may also be conducting drug development activities, which could affect their performance on our behalf. Our reliance on third parties for drug development activities means that we will have less direct control over the conduct, timing and completion of studies and the management of data generated from such studies. Nonetheless, we remain responsible for ensuring that our studies and trials are conducted in accordance with applicable protocol, legal and regulatory requirements and scientific standards. In other words, our reliance on third parties does not relieve us of our regulatory responsibilities. For example, we will remain responsible for ensuring that each of our clinical trials is conducted in accordance with the investigational plan and relevant protocols and that any such trial complies with GCP standards. If we or any of our CROs or any clinical trial sites fail to comply with applicable GCP requirements, the clinical data generated in those trials may be deemed unreliable. This may cause the FDA or other comparable foreign regulatory authorities to require us to perform additional clinical trials before approving our marketing applications. If any of the third parties we rely on violates federal or state fraud and abuse or false claims laws and regulations or healthcare privacy and security laws, or other laws, actions may be instituted against us.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If any actions based on our conduct, our employees&#8217; conduct or third-party conduct are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment, exclusion from government funded healthcare programs, such as Medicare, Medicaid and other federal healthcare programs, injunctions, private actions brought by individual whistleblowers in the name of the government, debarment or refusal to allow us to enter into government contracts, contractual damages, reputational harm, diminished profits and future earnings, additional integrity reporting and oversight obligations and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, there are risks that the third parties we rely on could become disqualified, debarred, suspended or otherwise penalized by the FDA or other comparable foreign regulatory authorities for violations of applicable regulatory requirements, in which case we may need to engage a substitute and may not be able to use some or all of the data produced by such contractors in support of our marketing applications.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If our security measures are compromised, or our information technology systems or those of our CROs, CMOs, vendors, contractors, consultants or other third-party partners fail or suffer security breaches, cyber-attacks, loss or leakage of data or other disruptions, this could result in a material disruption of our development programs, compromise sensitive information related to our business or other personal information or prevent us from accessing critical information, potentially exposing us to liability, harm our reputation or otherwise adversely affecting our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the ordinary course of business, we may collect, process, store and transmit proprietary, confidential and sensitive information (including intellectual property, trade secrets, proprietary business information, personal information and protected health information). It is critical that we do so in a secure manner to maintain the confidentiality, integrity and availability of such information. We depend on information technology and telecommunications systems for significant elements of our operations and we utilize, and expect to expand, a number of enterprise software systems that affect a broad range of business processes and functional areas, including, for example, systems handling human resources, financial reporting and controls, customer relationship management, regulatory compliance and other infrastructure operations. We face a number of risks relative to protecting this critical information, including loss of access risk, inappropriate use or disclosure, inappropriate modification and the risk of our being unable to adequately monitor, audit and modify our controls over our critical information. These risks extend to the third parties with whom we work, as we rely on a number of third parties to operate our critical business systems and process confidential, proprietary and sensitive information.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Despite the implementation of security measures, given the size, complexity and increasing amounts of proprietary, confidential and sensitive information maintained by our internal information technology systems and those of our CROs, CMOs, vendors, contractors, consultants and other third-party partners are potentially vulnerable to breakdown, service interruptions, system malfunction, accidents by our personnel or third-party partners, natural disasters, terrorism, global pandemics, war and telecommunication and electrical failures, as well as security breaches from inadvertent or intentional actions by our personnel or those of our CROs, CMOs, vendors, contractors, consultants, business partners and/or other third-party partners, or from cyber-attacks by malicious third parties (including through viruses, worms, malicious code, malware, ransomware, distributed denial-of-service attacks, social engineering and other means to affect service reliability and the confidentiality, integrity and availability of information), which may compromise our system infrastructure, or that of our CROs, CMOs, vendors, contractors, consultants and other third-party partners, or lead to data leakage.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">71</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The risk of a security breach or disruption, particularly through cyber-attacks or cyber intrusion, including by computer hackers, viruses, foreign governments and cyber terrorists, has generally increased as the number, intensity and sophistication of attempted attacks and intrusions from around the world have increased. We may not be able to anticipate all types of security threats, nor may we be able to implement preventive measures effective against all such security threats. The techniques used by cyber criminals change frequently, may not be recognized until launched and can originate from a wide variety of sources, including outside groups such as external service providers, organized crime affiliates, terrorist organizations or hostile foreign governments or agencies. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or those of our CROs, CMOs, vendors, contractors, consultants and other third-party partners, or inappropriate disclosure of confidential, sensitive or proprietary information, we could incur liability and reputational damage and the further development and commercialization of OJEMDA, DAY301, the VRK1 inhibitor program or any future product candidates could be delayed. Any breach, loss or compromise of proprietary, confidential or sensitive information may also subject us to civil fines and penalties, including under HIPAA, and other relevant state and federal privacy laws in the United States.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The costs related to significant security breaches or disruptions could be material and exceed the limits of the cybersecurity insurance we maintain against such risks. If the information technology systems of our CROs, CMOs, vendors, contractors, consultants and other third-party partners become subject to disruptions or security breaches, we may have insufficient recourse against such third parties and we may have to expend significant resources to mitigate the impact of such an event, and to develop and implement protections to prevent future events of this nature from occurring.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We cannot assure you that our data protection efforts and our investment in information technology will prevent significant breakdowns, data leakages, breaches in our systems, or those of our CROs, CMOs, vendors, contractors, consultants and other third-party partners, or other cyber incidents that could have a material adverse effect upon our reputation, business, operations or financial condition. For example, if such an event were to occur and cause interruptions in our operations, or those of our third-party CROs, CMOs, vendors and other contractors and consultants, it could result in a material disruption of our programs and the development of OJEMDA or our product candidates could be delayed. In addition, the loss of clinical trial data for OJEMDA, DAY301, the VRK1 inhibitor program or any other product candidates could result in delays in our marketing authorization efforts and significantly increase our costs to recover or reproduce the data. Furthermore, significant disruptions of our internal information technology systems or those of our third-party CROs, CMOs, vendors and other contractors and consultants, or security breaches could result in the loss, misappropriation and/or unauthorized access, use or disclosure of, or the prevention of access to, confidential information (including trade secrets or other intellectual property, proprietary business information and personal information), which could result in financial, legal, business and reputational harm to us. If the information technology systems of our CROs, CMOs, vendors, contractors, consultants and other third-party partners become subject to disruptions or security incidents, we may have insufficient recourse against such third parties and we may have to expend significant resources to mitigate the impact of such an event, and to develop and implement protections to prevent future events of this nature from occurring.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any event that leads to unauthorized access, use or disclosure of personal information, including personal information regarding our clinical trial subjects or personnel, could harm our reputation directly, compel us to comply with federal and/or state breach notification laws and foreign law equivalents, subject us to mandatory corrective action and otherwise subject us to liability under laws and regulations that protect the privacy and security of personal information, which could result in significant legal and financial exposure and reputational damages that could potentially have an adverse effect on our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may have contractual and other legal obligations to notify relevant stakeholders of security breaches. Most jurisdictions have enacted laws requiring companies to notify individuals, regulatory authorities and others of security breaches involving certain types of data. Such mandatory disclosures are costly, could lead to negative publicity, may cause our customers to lose confidence in the effectiveness of our security measures and require us to expend significant capital and other resources to respond to and/or alleviate problems caused by the actual or perceived security breach.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The costs to respond to a security breach and/or to mitigate any security vulnerabilities that may be identified could be significant, our efforts to address these issues may not be successful and these issues could result in interruptions, delays, negative publicity, loss of customer trust or diminished use of our products, as well as other harms to our business and our competitive position. Remediation of any potential security breach may involve significant time, resources and expenses. Any security breach may result in regulatory inquiries, litigation or other investigations, and can affect our financial and operational condition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Unauthorized access to our systems, networks or physical facilities could result in litigation with our customers or other relevant stakeholders. These proceedings could force us to spend money in defense or settlement, divert management&#8217;s time and attention, increase our costs of doing business or adversely affect our reputation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">While we maintain cybersecurity insurance coverage, we may not have adequate insurance coverage for security incidents or breaches, including fines, judgments, settlements, penalties, costs, attorney fees and other impacts that arise out of incidents or breaches. The successful assertion of one or more large claims against us that exceeds our available insurance coverage, or results in changes to insurance policies (including premium increases or the imposition of large deductible or co-insurance requirements), could have an adverse effect on our business. In addition, we cannot be sure that our existing insurance coverage and coverage for errors and omissions will continue to be available on acceptable terms or that our insurers will not deny coverage as to any future claim. Our</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">72</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">risks are likely to increase as we continue to expand, grow our customer base and process, store and transmit increasingly large amounts of proprietary and sensitive data.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We are subject to stringent and changing laws, regulations and standards, and contractual obligations related to privacy, data protection and data security. The actual or perceived failure to comply with such obligations could lead to government enforcement actions (which could include civil or criminal penalties), fines and sanctions, private litigation and/or adverse publicity and could negatively affect our operating results and business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We and third parties who we work with are or may become subject to numerous domestic and foreign data protection laws and regulations (i.e., laws and regulations that address privacy and data security), the scopes of which are changing, subject to differing applications and interpretations, and may be inconsistent among states, countries, or conflict with other requirements. We are or may become subject to the terms of contractual obligations related to privacy, data protection and data security. The actual or perceived failure by us or related third parties to comply with such obligations could increase our compliance and operational costs, expose us to regulatory scrutiny, actions, fines and penalties, result in reputational harm, lead to a loss of customers, result in litigation and liability and otherwise cause a material adverse effect on our business, financial condition and results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the United States, numerous federal and state laws and regulations, including health information privacy and security laws, data breach notification laws, health information privacy laws and consumer protection laws that govern the collection, use, disclosure and protection of health-related and other personal information could apply to our operations or the operations of our collaborators. In addition, we may obtain protected health information from third parties (including research institutions from which we obtain clinical trial data) that are subject to privacy and security requirements under HIPAA, as amended by HITECH. Depending on the facts and circumstances, we could be subject to civil and criminal penalties if we obtain, use or disclose individually identifiable health information maintained by a HIPAA-covered entity in a manner that is not authorized or permitted by HIPAA.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Over a third of U.S. states have adopted comprehensive privacy and security laws and regulations, which govern the privacy, processing and protection of personal information, including certain specific requirements and laws with respect to health-related information. For example, Washington state has passed the My Health My Data Act, which is focused on the collection of consumer health data, which has a broader scope than HIPAA and includes a private right of action.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In California, the CCPA, grants individual privacy rights for California consumers and places increased privacy and data security obligations on entities handling personal information of consumers or households. The CCPA is enforced by the California Privacy Protection Agency, or the CPPA. The CCPA gives California residents expanded privacy rights, including the right to request correction, access and deletion of their personal information, the right to opt out of certain personal information sharing, and the right to receive detailed information about how their personal information is processed, including by California residents&#8217; employers, and provides for civil penalties and a private right of action for data breaches that is expected to increase data breach litigation.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are also subject to foreign data protection laws, including the General Data Protection Regulation, or GDPR, which applies to personal information (including health-related data) obtained from individuals in the European Economic Area, or the EEA (as well as substantially similar laws that govern the collection of data from individuals in the UK and Switzerland). The GDPR imposes strict obligations on businesses, including requiring changes to informed consent practices and more detailed notices for clinical trial subjects and investigators, requiring limitations on data processing, establishing a legal basis for processing personal information, notification of data processing obligations, notification of security incidents to appropriate data protection authorities or data subjects, protecting the security and confidentiality of the personal information, and establishing means for data subjects to exercise rights in relation to their personal information. The GDPR subjects noncompliant companies to fines of up to the greater of 20 million Euros (17.5 million GBP in the UK) or 4% of their global annual revenues, potential bans on processing of personal information (including clinical trials), and private litigation. To the extent applicable, the GDPR will increase our responsibility and liability in relation to personal information that we process, and we may be required to put in place additional mechanisms and expend additional time and resources to ensure compliance with the EU data protection rules. Changes in international legislations may add additional complexity, variation in requirements, restrictions and potential legal risk, require additional investment in resources for compliance programs, could impact strategies and availability of previously useful data, and could result in increased compliance costs and/or changes in business practices and policies. In addition, supervisory authorities in the EEA, Switzerland, and the UK have enforced data protection legislation inconsistently, which may result in us having to spend additional resources in order to comply with rules and guidance applicable only in certain, local jurisdictions.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, European data protection laws generally prohibit the transfer of personal information to countries outside of the EEA, UK and Switzerland, such as the United States, which are not considered by their relevant authorities to provide an adequate level of data protection. Switzerland has adopted similar restrictions. Although there are legal mechanisms to allow for the transfer of personal information from the EEA, UK, and Switzerland to the United States and other countries, they are or may become subject to legal challenges that, if successful, could invalidate these mechanisms, restrict our ability to process personal information of Europeans outside of Europe and adversely impact our business. If we cannot implement a valid compliance mechanism for cross-border data transfers, we may face increased exposure to regulatory actions, substantial fines, and injunctions against processing or transferring</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">73</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">personal data from Europe or other foreign jurisdictions. In the EU and other markets, potential new rules and restrictions on the flow of data across borders could increase the cost and complexity of doing business in those regions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, further to the UK&#8217;s exit from the EU on January 31, 2020, the GDPR ceased to apply in the UK at the end of the transition period on December 31, 2020. However, as of January 1, 2021, the United Kingdom&#8217;s European Union (Withdrawal) Act 2018 incorporated the GDPR (as it existed on December 31, 2020 but subject to certain UK-specific amendments) into UK law, referred to as the UK GDPR. The UK GDPR and the UK Data Protection Act 2018 set out the UK&#8217;s data protection regime, which is independent from but aligned to the EU&#8217;s data protection regime. Non-compliance with the UK GDPR may result in monetary penalties of up to &#163;17.5 million or 4% of worldwide revenue, whichever is higher. With respect to transfers of personal data from the EU to the United Kingdom, on June 28, 2021 the European Commission issued an adequacy decision in respect of the UK&#8217;s data protection framework, enabling data transfers from EU member states to the UK to continue without requiring organizations to put in place contractual or other measures in order to lawfully transfer personal data between the territories. While it is intended to last for at least four years, the European Commission may unilaterally revoke the adequacy decision at any point, and if this occurs it could lead to additional costs and increase our overall risk exposure.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other countries, including China, Brazil, Australia and Japan, for example, have adopted certain legal requirements for local storage and processing of data and cross-border transfers of personal information, any and all of which could increase the cost and complexity of conducting preclinical testing and clinical trials or delivering our future products, if any, and operating our business. These obligations may be interpreted and applied in a manner that is inconsistent from one jurisdiction to another and may conflict with other requirements or our practices.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are or may become subject to the terms of external and internal privacy and security policies, representations, certifications and publications related to privacy and security.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Compliance with domestic and foreign privacy, data security and data protection laws, regulations and contractual and other obligations could require us to take on more onerous obligations in our contracts, restrict our ability to collect, use and disclose data, or in some cases, impact our ability to operate in certain jurisdictions. The actual or perceived failure to comply with domestic and foreign privacy, data privacy and data protection laws and regulations could result in government enforcement actions (which could include civil, criminal and administrative penalties), private litigation and/or adverse publicity and could negatively affect our operating results and business. Moreover, clinical trial subjects about whom we or our potential collaborators obtain information, as well as the providers who share this information with us, may contractually limit our ability to use and disclose the information. Claims that we have violated individuals&#8217; privacy rights, failed to comply with privacy, data security and data protection laws or breached our contractual obligations, even if we are not found liable, could be expensive and time consuming to defend and could result in adverse publicity that could harm our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Investors&#8217; expectations of our performance relating to environmental, social and governance factors may impose additional costs and expose us to new risks.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There is continued focus from certain regulators, investors, employees, users and other stakeholders concerning corporate responsibility, specifically related to ESG matters both in the United States and internationally. Some investors may use these non-financial performance factors to guide their investment strategies and, in some cases, may choose not to invest in us if they believe our policies and actions relating to corporate responsibility are inadequate. We may face reputational damage in the event that we do not meet the ESG standards set by various constituencies.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, ESG initiatives, goals or commitments could be difficult to achieve or costly to implement. If our competitors&#8217; corporate social responsibility performance is perceived to be better than ours, potential or current investors may elect to invest with our competitors instead. Moreover, California recently adopted two new climate-related bills, which require companies doing business in California that meet certain revenue thresholds to publicly disclose certain greenhouse gas emissions data and climate-related financial risk reports, and compliance with such requirements could require significant effort and resources. Additionally, in March 2024, the SEC enacted comprehensive climate change disclosure rules, although the SEC has since issued an order to stay the rules pending the completion of judicial review of multiple petitions challenging the rules. Our business may face increased scrutiny related to these activities and our related disclosures, including from the investment community, and our failure to achieve progress or manage the dynamic public sentiment and legal landscape in these areas on a timely basis, or at all, could adversely affect our reputation, business, and financial performance.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We or the third parties upon whom we depend may be adversely affected by natural disasters and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our current operations are primarily located in the San Francisco Bay Area. Any unplanned event, such as earthquake, flood, fire, explosion, extreme weather conditions, medical epidemic or pandemic, power shortage, telecommunication failure or other natural or man-made accident or incident that results in our being unable to fully utilize our facilities, or the manufacturing facilities of our third-party contract manufacturers, may have a material and adverse effect on our ability to operate our business, particularly on a daily</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">74</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">basis, and have significant negative consequences on our financial and operating conditions. In addition, the long-term effects of climate change on general economic conditions and the pharmaceutical industry in particular are unclear, and may heighten or intensify existing risk of natural disasters. Loss of access to these facilities may result in increased costs, delays in the development of OJEMDA or our product candidates or interruption of our business operations, and have a material adverse effect on our business, financial condition, results of operations and prospects. If a natural disaster, power outage or other event occurred that prevented us from using all or a significant portion of our headquarters, that damaged critical infrastructure such as our research facilities or the manufacturing facilities of our third-party contract manufacturers, or that otherwise disrupted operations, it may be difficult or, in certain cases, impossible, for us to continue our business for a substantial period of time. The disaster recovery and business continuity plans we have in place may prove inadequate in the event of a serious disaster or similar event. We may incur substantial expenses as a result of the limited nature of our disaster recovery and business continuity plans, which could have a material adverse effect on our business. As part of our risk management policy, we maintain insurance coverage at levels that we believe are appropriate for our business. However, in the event of an accident or incident at these facilities, we cannot assure you that the amounts of insurance will be sufficient to satisfy any damages and losses. If our facilities, or the manufacturing facilities of our third-party contract manufacturers, are unable to operate because of an accident or incident or for any other reason, even for a short period of time, any or all of our research and development programs may be harmed. Any business interruption could have a material and adverse effect on our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Changes in tax laws or regulations that are applied adversely to us may have a material adverse effect on our business, cash flow, financial condition or results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">New income, sales, use or other tax laws, statutes, rules, regulations or ordinances could be enacted at any time, which could adversely affect our business operations and financial performance. Further, existing tax laws, statutes, rules, regulations or ordinances could be interpreted, changed, modified or applied adversely to us. For example, the Tax Cuts and Jobs Act of 2017, or the Tax Cuts and Jobs Act, enacted many significant changes to the U.S. tax laws. For example, for tax years beginning on or after January 1, 2022, the Tax Cuts and Jobs Act requires taxpayers to capitalize and amortize, rather than deduct, R&amp;D expenses. R&amp;D expenses are amortizable over five years for research performed in the United States and 15 years for research performed outside the United States. Although there are legislative proposals to repeal or defer the capitalization requirement to later years, there can be no assurance that the provision will be repealed or otherwise modified.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Effective for transactions occurring on or after January 1, 2023, the Inflation Reduction Act imposed a new one percent excise tax on certain repurchases of stock by publicly traded U.S. domestic corporations. The excise tax is imposed on the repurchasing corporation itself, not its shareholders from which shares are repurchased. For purposes of calculating the base excise tax, repurchasing corporations are permitted to net the fair market value of certain new stock issuances against the fair market value of stock repurchases during the same taxable year. Certain repurchases are not counted in the base of the excise tax.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Future changes in corporate tax rates, the realization of net deferred tax assets relating to our operations, the taxation of foreign earnings, and the deductibility of expenses under the Tax Cuts and Jobs Act, or future reform legislation could have a material impact on the value of our deferred tax assets, could result in significant one-time charges, and could increase our future U.S. tax expense.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have incurred substantial losses during our history and do not expect to become profitable in the near future, and we may never achieve profitability. U.S. federal net operating losses generated in tax years beginning after December 31, 2017, will not expire and may be carried forward indefinitely but the deductibility of such federal net operating losses is limited to 80% of current year taxable income (without regard to certain deductions).</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, both our current and our future unused losses and other tax attributes may be subject to limitation under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, or the Code, if we undergo, or have undergone, an &#8220;ownership change,&#8221; generally defined as a greater than 50 percentage point change (by value) in our equity ownership by certain stockholders over a three-year period. During the year ended December 31, 2024, the Company has completed a Section 382 study to determine whether an ownership change per the provisions of Section 382 of the Internal Revenue Code, as well as similar state provisions, has occurred. The study found that one of our predecessor companies experienced an ownership change on June 16, 2022 and that the tax attributes that it generated are subject to a change pursuant to Section 382; however, based on the study all of these attributes are fully available for use as of December 31, 2023. The Company&#8217;s current year utilization of net operating losses and income tax credits is not impacted by the provisions of Section 382 or 383. As a result, if we undergo an ownership change (or if we previously underwent such an ownership change), our ability to use our pre-change net operating loss carryforwards and other pre-change tax attributes (such as research tax credits) to offset our post-change income or taxes may be limited. Similar provisions of state tax law may also apply to limit our use of accumulated state tax attributes. In addition, at the state level, there may be periods during which the use of net operating losses is suspended or otherwise limited, which could accelerate or permanently increase state taxes owed. As a result, even if we attain profitability, we may be unable to use all or a material portion of our net operating losses and other tax attributes, which could adversely affect our future cash flows.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">75</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We have engaged, and will continue to engage, in strategic transactions that could impact our liquidity, increase our expenses and present significant distractions to our management.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have engaged in strategic transactions, for instance, with affiliates of Takeda Pharmaceutical Company Limited, Viracta Therapeutics, Inc., Merck KGaA, Darmstadt, Germany, MabCare, and Ipsen, and from time to time, we may consider further strategic transactions, such as acquisitions of companies, businesses or assets and out-licensing or in-licensing of products, product candidates (such as DAY301 and the VRK1 inhibitor program) or technologies. Additional potential transactions that we may consider include a variety of different business arrangements, including spin-offs, strategic partnerships, joint ventures, restructurings, divestitures, business combinations and investments. Any such transaction may require us to incur non-recurring or other charges, may increase our near term or long-term expenditures and may pose significant integration challenges or disrupt our management or business, which could adversely affect our operations and financial results. For example, these transactions may entail numerous operational and financial risks, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">exposure to unknown liabilities; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">disruption of our business and diversion of our management&#8217;s time and attention in order to develop acquired products, product candidates or technologies; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">incurrence of substantial debt or dilutive issuances of equity securities to pay for acquisitions; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">higher than expected acquisition and integration costs; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">write-downs of assets or goodwill or impairment charges; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">increased amortization expenses; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">difficulty and cost in combining the operations, systems and personnel of any acquired businesses with our operations, systems and personnel; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">impairment of relationships with key suppliers or customers of any acquired businesses due to changes in management and ownership; and </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">inability to retain key employees of any acquired businesses. </span></div></div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Our Intellectual Property</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we are unable to obtain and maintain patent protection or other necessary rights for our products and technology, or if the scope of the patent protection obtained is not sufficiently broad or our rights under our patents (owned, co-owned or licensed) is not sufficiently broad, our competitors could develop and commercialize products and technology similar or identical to ours, and our ability to successfully commercialize our products and technology may be adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our commercial success depends in part on our ability to obtain and maintain proprietary or intellectual property protection in the United States and other countries for OJEMDA and our current product candidates and future products, as well as our core technologies, including our manufacturing know-how. We strive to protect and enhance the proprietary technology, inventions and improvements that are commercially important to the development of our business by seeking, maintaining and defending our intellectual property, whether developed internally or licensed from third parties. We also rely on trade secrets, know-how, continuing technological innovation and in-licensing opportunities to develop, strengthen and maintain our proprietary position in the field of cancer drug development. Additionally, we intend to rely on regulatory protection afforded through rare drug designations, data exclusivity and market exclusivity as well as patent term extensions, where available.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions and has in recent years been the subject of much litigation. The degree of patent protection we require to successfully compete in the marketplace may be unavailable or severely limited in some cases and may not adequately protect our rights or permit us to gain or keep any competitive advantage. We cannot provide any assurances that any of our own or licensed patent applications will mature into issued patents, and cannot provide any assurances that any such patents, if issued, will include claims with a scope sufficient to protect OJEMDA and our current and future product candidates or otherwise provide any competitive advantage. Additionally, patents can be enforced only in those jurisdictions in which the patent has issued. Furthermore, patents have a limited lifespan. In the United States, the natural expiration of a patent is generally 20 years after its first nonprovisional U.S. filing. The natural expiration of a patent outside of the United States varies in accordance with provisions of applicable local law, but is generally 20 years from the earliest local filing date. Various extensions may be available; however, the life of a patent, and the protection it affords, is limited. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Moreover, our exclusive licenses may be subject to field restrictions and retained rights, which may adversely impact our competitive position. See &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8212;Significant Agreements.&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">76</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our licensed patent portfolio may not provide us with adequate and continuing patent protection sufficient to exclude others from commercializing products similar to OJEMDA and our product candidates, including generic versions of such products. In addition, the patent portfolio licensed to us is, or may be, licensed to third parties outside our licensed field, and such third parties may have certain enforcement rights. Thus, patents licensed to us could be put at risk of being invalidated or interpreted narrowly in litigation filed by or against another licensee or in administrative proceedings brought by or against another licensee in response to such litigation or for other reasons.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other parties have developed technologies that may be related or competitive to our own and such parties may have filed or may file patent applications, or may have received or may receive patents, claiming inventions that may overlap or conflict with those claimed in our own patent applications or issued patents. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and in other jurisdictions are typically not published until 18 months after filing, or in some cases not at all. Therefore, we cannot know with certainty whether the inventors of our patents and applications were the first to make the inventions claimed in those patents or pending patent applications, or that they were the first to file for patent protection of such inventions. Further, we cannot assure you that all of the potentially relevant prior art relating to our patents and patent applications has been found. If such prior art exists, it can invalidate a patent or prevent a patent from issuing from a pending patent application. As a result, the issuance, scope, validity and commercial value of our patent rights cannot be predicted with any certainty. Further, if the breadth or strength of protection provided by our patents and patent applications is threatened, regardless of the outcome, it could dissuade companies from collaborating with us to license, develop or commercialize OJEMDA or our current or future product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, the patent prosecution process is expensive and time-consuming, and we or our licensors may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. In addition, the scope of the claims initially submitted for examination may be significantly narrowed by the time they issue, if at all. It is also possible that we or our licensors will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. We cannot provide any assurances that we will be able to pursue or obtain additional patent protection based on our research and development efforts, or that any such patents or other intellectual property we generate will provide any competitive advantage. Moreover, we do not have the right to control the preparation, filing and prosecution of patent applications, or to control the maintenance of the patents, covering technology that we license from third parties. Therefore, these patents and applications may not be filed, prosecuted or maintained in a manner consistent with the best interests of our business.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, recent reforms and changes at government agencies of the United States and those of non-U.S. jurisdictions could increase the delays, uncertainties and costs surrounding the prosecution of our patent applications, and the maintenance, enforcement, or defense of our issued patents. For example, the ability of the USPTO and other applicable patent authorities to properly administer their functions is highly dependent on the levels of funding available to the agency and their ability to retain personnel and fill key leadership appointments, among various factors. Termination of employees or delays in replacing or hiring for positions could significantly impact the ability of the USPTO and other applicable patent authorities to fulfill their functions and could greatly impact our ability to timely and adequately prosecute or maintain our patent applications, and our ability to timely and adequately maintain, enforce, or defend our issued patents.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if we acquire patent protection that we expect should enable us to maintain competitive advantage, the issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability. Third parties, including competitors, may challenge the inventorship, scope, validity or enforceability thereof, which may result in such patents being narrowed, invalidated or held unenforceable. If issued, our patents may be challenged in patent offices in the United States and abroad, or in court. For example, we may be subject to a third-party submission of prior art to the U.S. Patent and Trademark Office, or USPTO, challenging the validity of one or more claims of our patents, once issued. Such submissions may also be made prior to a patent&#8217;s issuance, precluding the granting of a patent based on one of our patent applications. We may become involved in opposition, reexamination, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">inter partes</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> review, post-grant review, derivation, interference or similar proceedings in the United States or abroad challenging the claims of our patents, once issued. Furthermore, patents may be challenged in court, once issued. Competitors may claim that they invented the inventions claimed in such patents or patent applications prior to the inventors of our patents, or may have filed patent applications before the inventors of our patents did. A competitor may also claim that we are infringing its patents and that we therefore cannot practice our technology as claimed under our patent applications and patents, if issued. As a result, one or more claims of our patents may be narrowed or invalidated. In litigation, a competitor could claim that our patents, if issued, are not valid for a number of reasons. If a court agrees, we would lose our rights to those challenged patents.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if they are unchallenged, our patents and pending patent applications, if issued, may not provide us with any meaningful protection or prevent competitors from designing around our patent claims to circumvent our patents by developing similar or alternative technologies or therapeutics in a non-infringing manner. For example, even if we have a valid and enforceable patent, we may not be able to exclude others from practicing our invention if the other party can show that they used the invention in commerce before our filing date or the other party benefits from a compulsory license. If the patent protection provided by the patents and patent applications we hold or pursue with respect to OJEMDA or our product candidates is not sufficiently broad to impede such competition, our ability to successfully commercialize OJEMDA or our product candidates could be negatively affected, which would harm our business. Certain regulatory exclusivities may be available, however, the scope of such regulatory exclusivities is subject to</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">77</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">change and may not provide us with adequate and continuing protection sufficient to exclude others from commercializing products similar to OJEMDA and our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If the scope of any patent protection we obtain is not sufficiently broad, or if we lose any of our patent protection, our ability to prevent our competitors from commercializing similar or identical products or product candidates would be adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The patent position of biopharmaceutical companies generally is highly uncertain, involves complex legal and factual questions and has been the subject of much litigation in recent years. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. Our pending and future patent applications and those of our licensors may not result in patents being issued which protect our product candidates or which effectively prevent others from commercializing competitive product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Moreover, the coverage claimed in a patent application can be significantly reduced before the patent is issued, and its scope can be reinterpreted after issuance. Even if patent applications we own or in-license in the future issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors or other third parties from competing with us or otherwise provide us with any competitive advantage. Any patents that we own or in-license may be challenged or circumvented by third parties or may be narrowed or invalidated as a result of challenges by third parties. Consequently, we do not know whether our product candidates will be protectable or remain protected by valid and enforceable patents. Our competitors or other third parties may be able to circumvent our patents or the patents of our licensors by developing similar or alternative technologies or products in a non-infringing manner which could materially adversely affect our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our patents or the patents of our licensors may be challenged in the courts or patent offices in the United States and abroad. We may be subject to a third-party pre-issuance submission of prior art to the USPTO, or become involved in opposition, derivation, revocation, reexamination, post-grant review and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">inter partes</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> review, or other similar proceedings challenging our owned patent rights. An adverse determination in any such submission, proceeding or litigation could jeopardize patent term adjustment or otherwise reduce patent term, reduce the scope of or invalidate or render unenforceable, our patent rights, or allow third parties to commercialize our product candidates and compete directly with us, without payment to us. Moreover, our patents or the patents of our licensors may become subject to post-grant challenge proceedings, such as oppositions in a foreign patent office, that challenge our priority of invention or other features of patentability with respect to our patents and patent applications and those of our licensors. Such challenges may result in loss of patent rights, loss of exclusivity or in patent claims being narrowed, invalidated or held unenforceable, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our product candidates. Such proceedings also may result in substantial cost and require significant time from our scientists and management, even if the eventual outcome is favorable to us. In addition, if the breadth or strength of protection provided by our patents and patent applications or the patents and patent applications of our licensors is threatened, regardless of the outcome, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Furthermore, the issuance of a patent does not give us the right to practice the patented invention. Third parties may have blocking patents that could prevent us from marketing our own patented product and practicing our own patented technology.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Intellectual property rights do not necessarily address all potential threats to our competitive advantage.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations, and may not adequately protect our business or permit us to maintain our competitive advantage. For example:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">others may be able to develop products that are similar to OJEMDA and our product candidates but that are not covered by the claims of the patents that we own or license; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we or our licensors or collaborators might not have been the first to make the inventions covered by the issued patents or patent application that we own or license; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we or our licensors or collaborators might not have been the first to file patent applications covering certain of our inventions; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual property rights; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">it is possible that the pending patent applications we own or license will not lead to issued patents; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">issued patents that we own or license may be held invalid or unenforceable, as a result of legal challenges by our competitors; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our competitors might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may not develop additional proprietary technologies that are patentable; </span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">78</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the patents of others may have an adverse effect on our business; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may fail to adequately protect and police our trademarks and trade secrets; and </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may choose not to file a patent in order to maintain certain trade secrets or know-how, and a third party may subsequently file a patent covering such intellectual property. </span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Should any of these events occur, it could significantly harm our business, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our commercial success depends significantly on our ability to operate without infringing the patents and other proprietary rights of third parties. Claims by third parties that we infringe their proprietary rights may result in liability for damages or prevent or delay our developmental and commercialization efforts.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our commercial success depends in part on avoiding infringement of the patents and proprietary rights of third parties. However, our research, development and commercialization activities may be subject to claims that we infringe or otherwise violate patents or other intellectual property rights owned or controlled by third parties. Other entities may have or obtain patents or proprietary rights that could limit our ability to make, use, sell, offer for sale or import our product candidates and products that may be approved in the future, or impair our competitive position. There is a substantial amount of litigation, both within and outside the United States, involving patent and other intellectual property rights in the biopharmaceutical industry, including patent infringement lawsuits, oppositions, reexaminations, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">inter partes</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> review proceedings and post grant review proceedings before the USPTO and/or corresponding foreign patent offices. Numerous third-party U.S. and foreign issued patents and pending patent applications exist in the fields in which we are developing product candidates. There may be third-party patents or patent applications with claims to materials, formulations, methods of manufacture or methods for treatment related to the use or manufacture of our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There may also be patent applications that, if issued as patents, could be asserted against us. Patent applications in the United States and elsewhere are typically published approximately 18 months after the earliest filing for which priority is claimed, with such earliest filing date being commonly referred to as the priority date. Certain U.S. patent applications that will not be filed outside the United States can remain confidential until patents issue. Therefore, patent applications covering our product candidates could have been filed by third parties without our knowledge. Additionally, pending patent applications that have been published can, subject to certain limitations, be later amended in a manner that could cover our product candidates and their uses or manufacturing processes. The scope of a patent claim is determined by an interpretation of the law, the written disclosure in a patent and the patent&#8217;s prosecution history and can involve other factors such as expert opinion. Our interpretation of the relevance or the scope of claims in a patent or a pending application may be incorrect, which may negatively impact our ability to market our product candidates. Further, we may incorrectly determine that our product candidates and their uses and manufacturing processes are not covered by a third-party patent or may incorrectly predict whether a third-party&#8217;s pending patent application will issue with claims of relevant scope. Our determination of the expiration date of any patent in the United States or abroad that we consider relevant may be incorrect, which may negatively impact our ability to develop and market our product candidates. Third-party intellectual property right holders may also actively bring infringement or other intellectual property-related claims against us, even if we have received patent protection for our product candidates and the relevant uses and processes.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As the biopharmaceutical industry expands and more patents are issued, the risk increases that our product candidates may be subject to claims of infringement of the patent rights of third parties. Because patent applications are maintained as confidential for a certain period of time, until the relevant application is published, we may be unaware of third-party patents that may be infringed by commercialization of any of our product candidates, and we cannot be certain that we were the first to file a patent application related to a product candidate or technology. Moreover, because patent applications can take many years to issue, there may be currently pending patent applications that may later result in issued patents that our product candidates may infringe. In addition, identification of third-party patent rights that may be relevant to our technology is difficult because patent searching is imperfect due to differences in terminology among patents, incomplete databases and the difficulty in assessing the meaning of patent claims. There is also no assurance that there is not prior art of which we are aware, but which we do not believe is relevant to our business, which may, nonetheless, ultimately be found to limit our ability to make, use, sell, offer for sale or import our products that may be approved in the future, or impair our competitive position. In addition, third parties may obtain patents in the future and claim that use of our technologies infringes upon these patents. Any claims of patent infringement asserted by third parties would be time consuming and could:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">result in costly litigation that may cause negative publicity; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">divert the time and attention of our technical personnel and management; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">cause development delays; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">prevent us from commercializing OJEMDA or any of our product candidates until the asserted patent expires or is held finally invalid or not infringed in a court of law; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">require us to develop non-infringing technology, which may not be possible on a cost-effective basis; </span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">79</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">subject us to significant liability to third parties; or </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">require us to enter into royalty or licensing agreements, which may not be available on commercially reasonable terms, or at all, or which might be non-exclusive, which could result in our competitors gaining access to the same technology. </span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Although no third party has asserted a claim of patent infringement against us as of March 31, 2025, others may hold proprietary rights that could prevent OJEMDA or our product candidates from being marketed. It is possible that a third-party may assert a claim of patent infringement directed at OJEMDA or our product candidates. Any patent-related legal action against us claiming damages and seeking to enjoin commercial activities relating to OJEMDA or our product candidates, treatment indications, or processes could subject us to significant liability for damages, including treble damages if we were determined to willfully infringe, and require us to obtain a license to manufacture or market OJEMDA or our product candidates. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. We may also in the future pursue invalidity proceedings with respect to third-party patents. The outcome following legal assertions of invalidity is unpredictable. Additionally, we may be subject to claims of patent infringement during those proceedings, and delays caused by the federal agencies may increase the time period that we are subject to such claims.  For example, administrative changes, including reduced personnel and budgets experienced by the Patent and Trial Appeal Board, could further delay our ability to timely challenge any such patents. We cannot predict whether we would prevail in any such actions or that any license required under any of these patents would be made available on commercially acceptable terms, if at all. Moreover, even if we or our current and/or future strategic partners were able to obtain a license, the rights may be nonexclusive, which could result in our competitors gaining access to the same intellectual property. In addition, we cannot be certain that we could redesign OJEMDA, our product candidates, treatment indications, or processes to avoid infringement, if necessary. Accordingly, an adverse determination in a judicial or administrative proceeding, or the failure to obtain necessary licenses, could prevent us from developing and commercializing our product candidates, which could harm our business, financial condition and operating results. In addition, intellectual property litigation, regardless of its outcome, may cause negative publicity and could prohibit us from marketing or otherwise commercializing OJEMDA or our product candidates and technology.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Parties making claims against us may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation or administrative proceedings, there is a risk that some of our confidential information could be compromised by disclosure. In addition, any uncertainties resulting from the initiation and continuation of any litigation could have a material adverse effect on our ability to raise additional funds or otherwise have a material adverse effect on our business, results of operations, financial condition and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Some of our current product candidates and research programs are licensed from third parties. If these license agreements are terminated or interpreted to narrow our rights, our ability to advance OJEMDA and our current product candidates or develop new product candidates based on these technologies will be materially adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We now depend on, at least in part, Viracta Therapeutics, Inc., Takeda Pharmaceutical Company Limited, Dana Farber Cancer Institute, Millennium Pharmaceuticals, Inc., Merck KGaA, Darmstadt, Germany, MabCare, and Ipsen and will continue to depend on Viracta Therapeutics, Inc., Takeda Pharmaceutical Company Limited, Dana Farber Cancer Institute, Millennium Pharmaceuticals, Inc. and Merck KGaA, Darmstadt, Germany, MabCare, and Ipsen and on licenses and sublicenses from other third parties, as well as potentially on other strategic relationships with third parties, for the research, development, manufacturing and commercialization of OJEMDA and our current product candidates. If any of our licenses or relationships or any in-licenses on which our licenses are based are terminated or breached, we may:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">lose our rights to develop and market OJEMDA or our current product candidates; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">lose patent or trade secret protection for OJEMDA or our current product candidates; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">experience significant delays in the development or commercialization of OJEMDA or our current product candidates; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">not be able to obtain any other licenses on acceptable terms, if at all; or </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">incur liability for damages. </span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, even if not terminated or breached, our intellectual property licenses or sublicenses may be subject to disagreements over contract interpretation which could narrow the scope of our rights to the relevant intellectual property or technology or increase our financial or other obligations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we experience any of the foregoing, it could have a materially adverse effect on our business and could force us to cease operations which could cause you to lose all of your investment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">80</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we breach our license agreements, it could have a material adverse effect on our commercialization efforts for OJEMDA and our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we breach any of the agreements under which we license the use, development and commercialization rights to OJEMDA and our product candidates or technology from third parties, we could lose license rights that are important to our business. Or if we fail to comply with our obligations in the agreements under which we license intellectual property rights from third parties or otherwise experience disruptions to our business relationships with our licensors, we could lose license rights that are important to our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">OJEMDA and our current lead product candidates are protected by, among other intellectual property rights, patents and patent applications we co-own and exclusively in-license from Viracta Therapeutics, Inc. (f/k/a Sunesis Pharmaceuticals, Inc.). OJEMDA and our current lead product candidates and pipeline and our anticipated near-term pipeline may include technologies licensed from other third parties, including, for example, Merck KGaA, Darmstadt, Germany. Further, pursuant to the MabCare License Agreement, we have the exclusive right to develop, manufacture and commercialize DAY301 worldwide, excluding Greater China.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the license agreements, we are subject to various obligations, including diligence obligations such as development and commercialization obligations, as well as potential royalty payments and other obligations. If we fail to comply with any of these obligations or otherwise breach our license agreements, our licensors may have the right to terminate the applicable license in whole or in part. Generally, the loss of any one of our current licenses, or any other license we may acquire in the future, could harm our business, prospects, financial condition and results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Licensing of intellectual property is of critical importance to our business and involves complex legal, business and scientific issues. Disputes may arise between us and our licensors regarding intellectual property subject to a license agreement, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the scope of rights granted under the license agreement and other interpretation-related issues; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">whether and the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our right to sublicense patent and other intellectual property rights to third parties under collaborative development relationships; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our diligence obligations with respect to the use of the licensed technology in relation to our development and commercialization of OJEMDA and our product candidates, and what activities satisfy those diligence obligations; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the priority of invention of patented technology; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our partners; and </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">whether and the extent to which inventors are able to contest the assignment of their rights to our licensors. </span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on acceptable terms or at all, we may be unable to successfully develop and successfully commercialize OJEMDA and the affected product candidates. In addition, if disputes arise as to ownership of licensed intellectual property, our ability to pursue or enforce the licensed patent rights may be jeopardized. If we or our licensors fail to adequately protect this intellectual property, our ability to commercialize our products could suffer.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, the agreements under which we license intellectual property or technology from third parties, including our licenses with Viracta Therapeutics, Inc., Takeda Pharmaceutical Company Limited, Dana Farber Cancer Institute, Millennium Pharmaceuticals, Inc., Merck KGaA, Darmstadt, Germany, MabCare, and Ipsen are complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology, or increase what we believe to be our financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business, financial condition, results of operations, and prospects. Moreover, if disputes over intellectual property that we license prevent or impair our ability to maintain our licensing arrangements on commercially acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates, which could have a material adverse effect on our business, financial conditions, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In spite of our best efforts, our licensors might conclude that we materially breached our license agreements and might therefore terminate the license agreements, thereby removing our ability to develop and commercialize products and technology covered by these license agreements. If these in-licenses are terminated, or if the underlying patents fail to provide the intended exclusivity, competitors would have the freedom to seek marketing authorization of, and to market, products identical to ours. This could have a material adverse effect on our competitive position, business, financial conditions, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">While we cannot currently determine the amount of the royalty obligations we would be required to pay on sales of future products, if any, the amounts may be significant. The amount of our future royalty obligations will depend on the technology and intellectual</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">81</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">property we use in products that we successfully develop and commercialize, if any. Therefore, even if we successfully develop and commercialize products, we may be unable to achieve or maintain profitability.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">In the future, we may need to obtain additional licenses of third-party technology that may not be available to us or are available only on commercially unreasonable terms, and which may cause us to operate our business in a more costly or otherwise adverse manner that was not anticipated.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We seek to expand our product candidate pipeline in part by in-licensing the rights to key technologies. The future growth of our business will depend in part on our ability to in-license or otherwise acquire the rights to additional product candidates or technologies. We cannot assure you that we will be able to in-license or acquire the rights to any product candidates or technologies from third parties on acceptable terms or at all.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other companies and academic institutions may also have filed or are planning to file patent applications potentially relevant to our business. From time to time, in order to avoid infringing these third-party patents, we may be required to license technology from third parties to further develop or commercialize our existing or future product candidates. Should we be required to obtain licenses to any third-party technology, including any such patents required to manufacture, use or sell our existing or future product candidates, such licenses may not be available to us on commercially reasonable terms, or at all. The inability to obtain any third-party license required to develop or commercialize any of our existing or future product candidates could cause us to abandon any related efforts, which could seriously harm our business and operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The in-licensing and acquisition of these technologies is a competitive area, and a number of more established companies are also pursuing strategies to license or acquire product candidates or technologies that we may consider attractive. These established companies may have a competitive advantage over us due to their size, cash resources and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to license rights to us. Furthermore, we may be unable to identify suitable product candidates or technologies within our area of focus. If we are unable to successfully obtain rights to suitable product candidates or technologies, our business, financial condition and prospects could suffer.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may be involved in lawsuits to protect or enforce our own patents or our licensors&#8217; patents, which could be expensive, time consuming and unsuccessful. Further, our own issued patents or our licensors&#8217; patents could be found invalid or unenforceable if challenged in court.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Competitors may infringe our intellectual property rights. To prevent infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time-consuming. In addition, in a patent infringement proceeding, a court may decide that a patent we own or in-license is not valid, is unenforceable and/or is not infringed. If we or any of our collaborators were to initiate legal proceedings against a third-party to enforce a patent directed at OJEMDA or one of our product candidates, the defendant could counterclaim that our patent or the patent of our licensors is invalid and/or unenforceable in whole or in part. In patent litigation in the United States, defendant counterclaims alleging invalidity and/or unenforceability are commonplace. Grounds for a validity challenge include an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, lack of sufficient written description, non-enablement or obviousness-type double patenting. Grounds for an unenforceability assertion could include an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO or made a misleading statement during prosecution.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Third parties may also raise similar invalidity claims before the USPTO or patent offices abroad, even outside the context of litigation. Such mechanisms include re-examination, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">inter partes </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">review proceedings, post grant review proceedings, derivation proceedings and equivalent proceedings in foreign jurisdictions (e.g., opposition proceedings). The outcome following legal assertions of invalidity and/or unenforceability is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which we, our licensors and the patent examiners are unaware during prosecution. There is also no assurance that there is not prior art of which we are aware, but which we do not believe affects the validity or enforceability of a claim in our patents and patent applications or the patents and patent applications of our licensors, which may, nonetheless, ultimately be found to affect the validity or enforceability of a claim. If a third party were to prevail on a legal assertion of invalidity or unenforceability, we would lose at least part, and perhaps all, of the patent protection on our technology, or any product candidates that we may develop. Such a loss of patent protection would have a material adverse impact on our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, if the breadth or strength of protection provided by our patents and patent applications or the patents and patent applications of our licensors is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if resolved in our favor, litigation or other legal proceedings relating to our intellectual property rights may cause us to incur significant expenses, and could distract our technical and management personnel from their normal responsibilities. Such litigation or proceedings could substantially increase our operating costs and reduce the resources available for development activities or any future sales, marketing or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">82</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">proceedings adequately. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could compromise our ability to compete in the marketplace.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation or other legal proceedings relating to our intellectual property rights, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation or other proceedings.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Intellectual property litigation may lead to unfavorable publicity that harms our reputation and causes the market price of our common shares to decline.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the course of any intellectual property litigation, there could be public announcements of the initiation of the litigation as well as results of hearings, rulings on motions and other interim proceedings or developments in the litigation. If securities analysts or investors regard these announcements as negative, the perceived value of our existing product candidates, approved products, programs or intellectual property could be diminished. Accordingly, the market price of shares of our common stock may decline. Such announcements could also harm our reputation or the market for our product candidates, which could have a material adverse effect on our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Derivation proceedings may be necessary to determine priority of inventions, and an unfavorable outcome may require us to cease using the related technology or to attempt to license rights from the prevailing party.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Derivation proceedings provoked by third parties or brought by us or declared by the USPTO may be necessary to determine the priority of inventions with respect to our patents or patent applications or those of our licensors. An unfavorable outcome could require us to cease using the related technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms. Our defense of derivation proceedings may fail and, even if successful, may result in substantial costs and distract our management and other employees from their regular responsibilities. In addition, the uncertainties associated with such proceedings could have a material adverse effect on our ability to raise the funds necessary to continue our clinical trials, continue our development programs, license necessary technology from third parties or enter into development or manufacturing partnerships that would help us bring our product candidates to market.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Because of the expense and uncertainty of litigation, we may not be in a position to enforce our intellectual property rights against third parties.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Because of the expense and uncertainty of litigation, we may conclude that even if a third party is infringing our issued patent, any patents that may be issued as a result of our pending or future patent applications or other intellectual property rights, the risk-adjusted cost of bringing and enforcing such a claim or action may be too high or not in the best interest of our company or our stockholders, or it may be otherwise impractical or undesirable to enforce our intellectual property against some third parties. Our competitors or other third parties may be able to sustain the costs of complex patent litigation or proceedings more effectively than we can because of their greater financial resources and more mature and developed intellectual property portfolios. In such cases, we may decide that the more prudent course of action is to simply monitor the situation or initiate or seek some other non-litigious action or solution. In addition, the uncertainties associated with litigation could compromise our ability to raise the funds necessary to continue our product development, in-license needed technology or enter into development partnerships that would help us bring OJEMDA and our product candidates to market.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Recent patent reform legislation could increase the uncertainties and costs surrounding the prosecution of our patent applications and/or those of our licensors and the enforcement or defense of our issued patents and/or those of our licensors.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On September 16, 2011, the Leahy-Smith America Invents Act, or the Leahy-Smith Act, was signed into law. The Leahy-Smith Act includes a number of significant changes to U.S. patent law. These include provisions that affect the way patent applications will be prosecuted and may also affect patent litigation. In particular, under the Leahy-Smith Act, the United States transitioned in March 2013 to a &#8220;first inventor to file&#8221; system in which, assuming that other requirements of patentability are met, the first inventor to file a patent application will be entitled to the patent regardless of whether a third-party was first to invent the claimed invention. A third-party that files a patent application in the USPTO after March 2013 but before us could therefore be awarded a patent covering an invention of ours even if we had made the invention before it was made by such third-party. This will require us to be cognizant going forward of the time from invention to filing of a patent application. Furthermore, our ability to obtain and maintain valid and enforceable patents depends on whether the differences between our technology and the prior art allow our technology to be patentable over the prior art. Since patent applications in the United States and most other countries are confidential for a period of time after filing or until issuance, we may not be certain that we or our licensors are the first to either (1) file any patent application related to our product candidates or (2) invent any of the inventions claimed in the patents or patent applications.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">83</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Leahy-Smith Act also includes a number of significant changes that affect the way patent applications will be prosecuted and also may affect patent litigation. These include allowing third-party submission of prior art to the USPTO during patent prosecution and additional procedures to attack the validity of a patent by USPTO administered post-grant proceedings, including post-grant review, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">inter partes</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> review and derivation proceedings. An adverse determination in any such submission or proceeding could reduce the scope or enforceability of, or invalidate, our patent rights, which could adversely affect our competitive position.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary standard in United States federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action. Accordingly, a third party may attempt to use the USPTO procedures to invalidate our patent claims that would not have been invalidated if first challenged by the third party as a defendant in a district court action. Thus, the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and/or those of our licensors and the enforcement or defense of our issued patents or those of our licensors, all of which could have a material adverse effect on our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Changes in U.S. patent law, or laws in other countries, could diminish the value of patents in general, thereby impairing our ability to protect OJEMDA and our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As is the case with other pharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biopharmaceutical industry involves a high degree of technological and legal complexity. Therefore, obtaining and enforcing biopharmaceutical patents is costly, time consuming and inherently uncertain. Changes in either the patent laws or in the interpretations of patent laws in the United States and other countries may diminish the value of our intellectual property and may increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of issued patents. We cannot predict the breadth of claims that may be allowed or enforced with respect to our patents or third-party patents. In addition, the U.S. Congress or other foreign legislative bodies may pass patent reform legislation that is unfavorable to us.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For example, the U.S. Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by the U.S. Congress, the U.S. federal courts, the USPTO or similar authorities in foreign jurisdictions, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patent and the patents we might obtain or license in the future.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, starting from June 1, 2023, European applications have the option, upon grant of a patent, of becoming a Unitary Patent which will be subject to the jurisdiction of the Unitary Patent Court, or the UPC.  This will be a significant change in European patent practice. As the UPC is a new court system, there is limited precedent for the court, increasing the uncertainty of any litigation.  Patents granted before the implementation of the UPC will have the option of opting out of the jurisdiction of the UPC and remaining as national patents in the UPC countries. Patents that remain under the jurisdiction of the UPC may be potentially vulnerable to a single UPC-based revocation challenge that, if successful, could invalidate the patent in all countries who are signatories to the UPC. We cannot predict with certainty the long-term effects of the new unitary patent system.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We and/or our licensors may be subject to claims that former employees, collaborators or other third parties have an interest in our patents or other intellectual property as an inventor or co-inventor. In addition, we cannot assure you that all inventors have been or will be identified by us and/or by our collaborators despite diligent effort. The failure to name the proper inventors on a patent application can result in the patents issuing thereon being unenforceable. Inventorship disputes may arise from conflicting views regarding the contributions of different individuals named as inventors, the effects of foreign laws where foreign nationals are involved in the development of the subject matter of the patent, conflicting obligations of third parties involved in developing our product candidates or as a result of questions regarding co-ownership of potential joint inventions. Litigation may be necessary to resolve these and other claims challenging inventorship and/or ownership. Alternatively, or additionally, we may enter into agreements to clarify the scope of our rights in such intellectual property. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a material adverse effect on our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our licensors may have relied on third-party consultants or collaborators such that our licensors are not the sole and exclusive owners of the patents we in-licensed. If other third parties have ownership rights or other rights to our in-licensed patents, they may be able to license such patents to our competitors, and our competitors could market competing products. This could have a material adverse effect on our competitive position, business, financial conditions, results of operations, and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">84</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, while it is our policy to require our employees and contractors who may be involved in the conception or development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who, in fact, conceives or develops intellectual property that we regard as our own. The assignment of intellectual property rights may not be self-executing, or the assignment agreements may be breached, and we may be forced to bring claims against third parties, or defend claims that they may bring against us, to determine the ownership of what we regard as our intellectual property. Such claims could have a material adverse effect on our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Patents have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest U.S. non-provisional filing date. Various extensions may be available, but the life of a patent, and the protection it affords, is limited. Even if patents covering our product candidates are obtained, once the patent life has expired, we may be open to competition from competitive products. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we do not obtain patent term extension for OJEMDA and product candidates, our business may be materially harmed.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Depending upon the timing, duration and specifics of FDA marketing authorization of our product and product candidates, one or more of our U.S. patents or those of our licensors may be eligible for limited patent term restoration under the Drug Price Competition and Patent Term Restoration Act of 1984, or the Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent restoration term of up to five years as compensation for patent term lost during product development and the FDA regulatory review process. A maximum of one patent may be extended per FDA approved product as compensation for the patent term lost during the FDA regulatory review process. A patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval and only those claims covering such approved drug product, a method for using it or a method for manufacturing it may be extended. Patent term extension may also be available in certain foreign countries upon marketing authorization of our product candidates. However, we may not be granted an extension because of, for example, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents or otherwise failing to satisfy applicable requirements. Additionally, administrative changes at the USPTO or other applicable patent authorities, such as reduced hiring and/or funding, may result in delays in issuance of a patent or in accrual of patent term extension, thereby reducing the amount of patent term extension that could otherwise be received. Administrative changes (e.g., at the FDA or USPTO) may also lead to delays in review and analysis of regulatory submissions or requests for patent term extension, which could result in a patent term extension not being timely granted (e.g., before the expiration of the patent) and there may be no patent eligible for extension. Moreover, the applicable time period or the scope of patent protection afforded could be less than we request. If we are unable to obtain patent term extension or restoration or the term of any such extension is less than we request, our competitors may obtain approval of competing products following our patent expiration, and our revenue could be reduced, possibly materially. Further, if this occurs, our competitors may take advantage of our investment in development and trials by referencing our clinical and preclinical data and may launch their product earlier than might otherwise be the case.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may not be able to protect our intellectual property rights throughout the world.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Although we have pending patent applications in the United States and other countries, filing, prosecuting and defending patents in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in the United States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we have patent protection, but enforcement is not as strong as that in the United States. These products may compete with our product candidates, and our patents, the patents of our licensors or other intellectual property rights may not be effective or sufficient to prevent them from competing.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of many foreign countries do not favor the enforcement of patents and other intellectual property protection, which could make it difficult for us to stop the infringement of our patents or our licensors&#8217; patents or marketing of competing products in violation of our proprietary rights. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents or the patents of our licensors at risk of being invalidated or interpreted narrowly and our patent applications or the patent applications of our licensors at</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">85</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Many countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent. If we are forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired, and our business, financial condition, results of operations and prospects may be adversely affected.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, trade barriers and unexpected changes in tariffs, including tariffs that have been or may in the future be imposed by the United States or other countries, could impact our intellectual property rights in unpredictable ways. For example, trade barriers and changes in tariffs may require us to change our supply chain and move our current or future production to countries with more favorable trade agreements but less favorable or no intellectual property rights protection. The United States and other countries may also take protectionist or retaliatory measures in response to the changes in tariffs, leading to a plethora of unpredictable consequences that could weaken our intellectual property rights throughout the world.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Obtaining and maintaining our patent protection depends on compliance with various procedural, documentary, fee payment and other requirements imposed by regulations and governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on patents and/or applications will be due to the USPTO and various foreign patent offices at various points over the lifetime of our patents and/or applications and those of our licensors. We have systems in place to remind us to pay these fees, and we rely on our outside patent annuity service to pay these fees when due. Additionally, the USPTO and various foreign patent offices require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. We employ reputable law firms and other professionals to help us comply, and in many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with rules applicable to the particular jurisdiction. However, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. If such an event were to occur, it could have a material adverse effect on our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We intend to use registered or unregistered trademarks or trade names to brand and market ourselves and our products. Our trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names, which we need to build name recognition among potential partners or customers in our markets of interest. At times, competitors may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement claims brought by owners of other registered trademarks or trademarks that incorporate variations of our registered or unregistered trademarks or trade names. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively, and our business may be adversely affected. Our efforts to enforce or protect our proprietary rights related to trademarks, trade secrets, domain names, copyrights or other intellectual property may be ineffective and could result in substantial costs and diversion of resources and could adversely affect our financial condition or results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We rely in part on the protection of our trade secrets, including unpatented know-how, technology and other proprietary information, to maintain our competitive position. Although we have taken steps to protect our trade secrets and unpatented know-how, including entering into confidentiality agreements with third parties, and confidential information and inventions agreements with employees, consultants and advisors, we cannot provide any assurances that all such agreements have been duly executed, and any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Moreover, third parties may still obtain this information or may come upon this or similar information independently, and we would have no right to prevent them from using that technology or information to compete with us. If any of these events occurs or if we otherwise lose protection for our trade secrets, the value of this information may be greatly reduced, and our competitive position</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">86</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">would be harmed. If we do not apply for patent protection prior to such publication or if we cannot otherwise maintain the confidentiality of our proprietary technology and other confidential information, then our ability to obtain patent protection or to protect our trade secret information may be jeopardized.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may be subject to claims that we or our employees have wrongfully used or disclosed alleged confidential information or trade secrets.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have entered into or may enter in the future into non-disclosure and confidentiality agreements to protect the proprietary positions of third parties, such as outside scientific collaborators, CROs, third-party manufacturers, consultants, advisors, potential partners and other third parties. We may become subject to litigation where a third party asserts that we or our employees inadvertently or otherwise breached the agreements and used or disclosed trade secrets or other information proprietary to the third parties. Defense of such matters, regardless of their merit, could involve substantial litigation expense and be a substantial diversion of employee resources from our business. We cannot predict whether we would prevail in any such actions. Moreover, intellectual property litigation, regardless of its outcome, may cause negative publicity and could prohibit us from marketing or otherwise successfully commercializing OJEMDA and our product candidates and technology. Failure to defend against any such claim could subject us to significant liability for monetary damages or prevent or delay our developmental and commercialization efforts, which could adversely affect our business. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to our management team and other employees.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Parties making claims against us may be able to sustain the costs of complex intellectual property litigation more effectively than we can because they have substantially greater resources. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure. In addition, any uncertainties resulting from the initiation and continuation of any litigation could have a material adverse effect on our ability to raise additional funds or otherwise have a material adverse effect on our business, operating results, financial condition and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may be subject to claims that we have wrongfully hired an employee from a competitor or that we or our employees have wrongfully used or disclosed alleged confidential information or trade secrets of their former employers.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As is common in the biopharmaceutical industry, in addition to our employees, we engage the services of consultants to assist us in the development of OJEMDA and our product candidates. Many of these consultants, and many of our employees, were previously employed at, or may have previously provided or may be currently providing consulting services to, other pharmaceutical companies including our competitors or potential competitors. We may become subject to claims that we, our employees or a consultant inadvertently or otherwise used or disclosed trade secrets or other information proprietary to their former employers or their former or current clients. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel, which could adversely affect our business. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to our management team and other employees.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The patent protection and patent prosecution for OJEMDA and some of our product candidates may be dependent on third parties.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">While we normally seek to obtain the right to control prosecution, maintenance and enforcement of the patents relating to OJEMDA and our product candidates, there may be times when the filing and prosecution activities for patents and patent applications relating to OJEMDA and our product candidates are controlled by our licensors or collaboration partners. If any of our licensors or collaboration partners fail to prosecute, maintain and enforce such patents and patent applications in a manner consistent with the best interests of our business, including by payment of all applicable fees for patents covering OJEMDA and our product candidates, we could lose our rights to the intellectual property or our exclusivity with respect to those rights, our ability to develop and commercialize OJEMDA and those product candidates may be adversely affected and we may not be able to prevent competitors from making, using and selling competing products. In addition, even where we have the right to control patent prosecution of patents and patent applications we have licensed from third parties, we may still be adversely affected or prejudiced by actions or inactions of our licensors and their counsel that took place prior to the date upon which we assumed control over patent prosecution.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Currently, our intellectual property protection includes patents and patent applications that we have in-licensed from, among others, Viracta Therapeutics, Inc., Takeda Pharmaceutical Company Limited, Merck KGaA, Darmstadt, Germany, MabCare, and Ipsen. Our exclusive and non-exclusive licenses may be subject to certain retained rights, which may adversely impact our competitive position. We do not control the prosecution and maintenance of several of the licensed patent portfolios; thus, we cannot assure you that the licensed patent families will be prepared, filed, prosecuted, or maintained in a manner consistent with the best interests of our business. See &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8212;Significant Agreements.&#8221; Our licensed patent portfolio may not provide us with adequate and continuing patent protection sufficient to exclude others from commercializing products similar to OJEMDA and our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">87</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Intellectual property discovered through government funded programs may be subject to federal regulations such as &#8220;march-in&#8221; rights, certain reporting requirements and a preference for U.S.-based companies. Compliance with such regulations may limit our exclusive rights and limit our ability to contract with non-U.S. manufacturers.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Some of our own issued patents or pending patent applications may have been generated through the use of U.S. government funding, and we may acquire or license in the future intellectual property rights that have been generated through the use of U.S. government funding or grants. Pursuant to the Bayh-Dole Act of 1980, the U.S. government has certain rights in inventions developed with government funding. These U.S. government rights include a non-exclusive, non-transferable, irrevocable worldwide license to use inventions for any governmental purpose. In addition, the U.S. government has the right, under certain limited circumstances, to require us to grant exclusive, partially exclusive or non-exclusive licenses to any of these inventions to a third party if it determines that: (1) adequate steps have not been taken to commercialize the invention; (2) government action is necessary to meet public health or safety needs; or (3) government action is necessary to meet requirements for public use under federal regulations (also referred to as &#8220;march-in rights&#8221;). If the U.S. government exercised its march-in rights in our existing or future intellectual property rights that are generated through the use of U.S. government funding or grants, we could be forced to license or sublicense intellectual property developed by us or that we license on terms unfavorable to us, and there can be no assurance that we would receive compensation from the U.S. government for the exercise of such rights. The U.S. government also has the right to take title to these inventions if the grant recipient fails to disclose the invention to the government or fails to file an application to register the intellectual property within specified time limits. Intellectual property generated under a government funded program is also subject to certain reporting requirements, compliance with which may require us to expend substantial resources. In addition, the U.S. government requires that any products embodying any of these inventions or produced through the use of any of these inventions be manufactured substantially in the United States. This preference for U.S. industry may be waived by the federal agency that provided the funding if the owner or assignee of the intellectual property can show that reasonable but unsuccessful efforts have been made to grant licenses on similar terms to potential licensees that would be likely to manufacture substantially in the United States or that under the circumstances domestic manufacture is not commercially feasible. This preference for U.S. industry may limit our ability to contract with non-U.S. product manufacturers for products covered by such intellectual property.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Geo-political actions in the United States and in foreign countries could increase the uncertainties and costs surrounding the prosecution or maintenance of our patent applications or those of any current or future licensors and the maintenance, enforcement or defense of our issued patents or those of any current or future licensors.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Certain geo-political actions in the United States or other countries may increase the uncertainties and costs related to the prosecution or maintenance of our patent applications, or those of our current or future licensors. For example, the United States and foreign government actions related to Russia&#8217;s invasion of Ukraine may limit or prevent filing, prosecution and maintenance of patent applications in Russia. Government actions may also prevent maintenance of issued patents in Russia. These actions could result in abandonment or lapse of our patents or patent applications, resulting in partial or complete loss of patent rights in Russia. If such an event were to occur, it could have a material adverse effect on our business. In addition, a decree was adopted by the Russian government in March 2022, allowing Russian companies and individuals to exploit inventions owned by patentees that have citizenship or nationality in, are registered in, or have predominately primary place of business or profit-making activities in the United States and other countries that Russia has deemed unfriendly without consent or compensation. Consequently, we would not be able to prevent third parties from practicing our inventions in Russia or from selling or importing products made using our inventions in and into Russia.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Our Common Stock</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">An active and liquid trading market for our common stock may never be sustained. As a result, you may not be able to resell your shares of common stock at or above the purchase price.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">An active trading market for our common stock may never be sustained. The market value of our common stock may decrease from the purchase price. As a result of these and other factors, you may be unable to resell your shares of our common stock at or above the purchase price. The lack of an active market may impair your ability to sell your shares at the time you wish to sell them or at a price that you consider reasonable. The lack of an active market may also reduce the fair market value of your shares.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Furthermore, an inactive market may also impair our ability to raise capital by selling shares of our common stock and may impair our ability to enter into strategic collaborations or acquire companies or products by using our shares of common stock as consideration.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our quarterly operating results may fluctuate significantly or may fall below the expectations of investors or securities analysts, each of which may cause our stock price to fluctuate or decline.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect our operating results to be subject to quarterly fluctuations. Our operating results will be affected by numerous factors, including:</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">88</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to generate revenue from the sales of our product, OJEMDA;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">timing and variations in the level of expense related to the current or future development of our programs; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">timing and status of enrollment for our clinical trials;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">results of clinical trials, or the addition or termination of clinical trials or funding support by us or potential future partners; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our execution of any collaboration, licensing or similar arrangements, and the timing of payments we may make or receive under potential future arrangements or the termination or modification of any such potential future arrangements; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any intellectual property infringement, misappropriation or violation lawsuit or opposition, interference or cancellation proceeding in which we may become involved;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">additions and departures of key personnel;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">strategic decisions by us or our competitors, such as acquisitions, divestitures, spin-offs, joint ventures, strategic investments or changes in business strategy;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">if a product candidate we develop receives marketing authorization, the timing and terms of such approval and market acceptance and demand for such product;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the timing and cost to establish a sales, marketing and distribution infrastructure to commercialize any products for which we may obtain marketing authorization and intend to commercialize on our own or jointly with future collaborators;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">regulatory developments affecting current or future product candidates or products, if any, or those of our competitors;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the amount of expense or gain associated with the change in value of the success payments and contingent consideration;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">changes in general market and economic conditions, such as due to rising interest rates, inflation, significant political or trade regulatory developments or changes in trade policy, global regional conflicts and public health epidemics;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">business development activities, such as additional program in-licensing, which could result in up-front payments or increased development expenses; and</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">cybersecurity incidents. </span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If our quarterly operating results fall below the expectations of investors or securities analysts, the price of our common stock could decline substantially. Furthermore, any quarterly fluctuations in our operating results may, in turn, cause the price of our common stock to fluctuate substantially. We believe that quarterly comparisons of our financial results are not necessarily meaningful and should not be relied upon as an indication of our future performance.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The market price of our common stock is likely to be highly volatile, which could result in substantial losses for purchasers of our common stock.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The market price of our common stock is likely to continue to be highly volatile and subject to wide fluctuations in response to various factors, some of which we cannot control. As a result of this volatility, you may not be able to sell your shares of common stock at or above the price paid. The market price for our common stock may be influenced by many factors, including the other risks described in this &#8220;Risk Factors&#8221; section and the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the success of our commercialization efforts for our product, OJEMDA;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">results of preclinical studies or clinical trials by us or those of our competitors or by existing or future collaborators or licensing partners; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the timing and enrollment status of our clinical trials; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">changes in the development status of our product candidates, including variations in the level of expense related to the development of our programs or funding support by us or by existing or future collaborators or licensing partners; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">regulatory or legal developments in the United States and other countries, especially changes in laws or regulations applicable to our business; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the success of competitive products or technologies; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">introductions and announcements of new product candidates by us, our future collaboration partners, or our competitors, and the timing of these introductions or announcements; </span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">89</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">actions taken by regulatory agencies with respect to our product candidates, clinical studies, manufacturing process or sales and marketing terms; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our execution of any collaboration, licensing or similar arrangements, and the timing of payments we may make or receive under existing or future arrangements or the termination or modification of any such existing or future arrangements; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">actual or anticipated variations in our financial results or those of companies that are perceived to be similar to us; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the success of our efforts to acquire or in-license additional technologies or product candidates; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">announced or completed significant acquisitions, strategic collaborations, joint ventures or capital commitments by us or our competitors; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">developments or disputes concerning our intellectual property and proprietary rights; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the recruitment or departure of key personnel; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">changes in the structure of healthcare payment systems; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">actual or anticipated changes in earnings estimates or changes in stock market analyst recommendations regarding our common stock, other comparable companies or our industry generally; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our failure or the failure of our competitors to meet analysts&#8217; projections or guidance that we or our competitors may give to the market; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">speculation in the press or investment community; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">share price and fluctuations of trading volume of our common stock;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the impact of interest rate increases on the overall stock market and the market for biopharmaceutical company stocks;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">fluctuations in the valuation of companies perceived by investors to be comparable to us; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">sales of shares of our common stock by us, insiders or our stockholders; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability or inability to raise additional capital and the terms on which we raise it; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the concentrated ownership of our common stock; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">changes in accounting principles; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">natural disasters and other calamities;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">general economic, industry and market conditions, including inflation, changes in interest rates and significant political or regulatory developments or changes in trade policy, many of which are beyond our control;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">other events or factors, including those resulting from global pandemics, such as the COVID-19 pandemic, or war, incidents of terrorism or responses to these events, including global regional conflicts; and</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">cybersecurity incidents.</span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, the stock market in general, and the markets for pharmaceutical, biopharmaceutical and biotechnology stocks in particular, have experienced extreme price and volume fluctuations, including as a result of the COVID-19 pandemic, increase in inflation and changes in interest rates, as well as disruptions to the supply chain, that have been often unrelated or disproportionate to the operating performance of the issuer. Furthermore, the trading price of our common stock may be adversely affected by third parties trying to drive down the market price. Short sellers and others, some of whom post anonymously on social media, may be positioned to profit if our stock declines and their activities can negatively affect our stock price. These broad market and industry factors may seriously harm the market price of our common stock, regardless of our actual operating performance. The realization of any of the above risks or any of a broad range of other risks, including those described in this &#8220;Risk Factors&#8221; section, could have a dramatic and adverse impact on the market price of our common stock.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the past, securities class action litigation has often been brought against public companies following declines in the market price of their securities. This risk is especially relevant for biopharmaceutical companies, which have experienced significant stock price volatility in recent years. If we face such litigation, it could result in substantial costs and a diversion of management&#8217;s attention and our resources, which could harm our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">90</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We do not currently intend to pay dividends on our common stock and, consequently, our stockholders&#8217; ability to achieve a return on their investment will depend on appreciation of the value of our common stock.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have never declared or paid cash dividends on our common stock. We currently intend to retain all available funds and any future earnings to support operations and to finance the growth and development of our business. We do not intend to declare or pay any cash dividends on our capital stock in the foreseeable future. As a result, any investment return on our common stock will depend upon increases in the value for our common stock, which is not certain.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">A sale of a substantial number of shares of our common stock may cause the price of our common stock to decline.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sales of a substantial number of shares of our common stock in the public market could occur at any time. If our stockholders sell, or the market perceives that our stockholders intend to sell, substantial amounts of our common stock in the public market, the market price of our common stock could decline significantly.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The holders of an aggregate of 8,502,776 shares of our outstanding common stock as of March 31, 2025 will have rights, subject to some conditions, to require us to file registration statements covering their shares or to include their shares in registration statements that we may file for ourselves or our stockholders. We also have registered shares of common stock that we may issue under our equity incentive plans. These shares are freely tradeable in the public market upon issuance.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We cannot predict what effect, if any, sales of our shares in the public market or the availability of shares for sale will have on the market price of our common stock. However, future sales of substantial amounts of our common stock in the public market, including shares issued upon exercise of our outstanding options or vesting of outstanding restricted stock unit awards, or the perception that such sales may occur, could adversely affect the market price of our common stock.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We also expect that significant additional capital may be needed in the future to continue our planned operations. To raise capital, we may sell common stock, convertible securities or other equity securities in one or more transactions at prices and in a manner we determine from time to time. To the extent that additional capital is raised through the sale and issuance of shares or other securities convertible into shares, our stockholders will be diluted. These sales, or the perception in the market that the holders of a large number of shares intend to sell shares, could reduce the market price of our common stock.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our principal stockholders and management own a significant percentage of our stock and will be able to exert significant control over matters subject to stockholder approval.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on the beneficial ownership of our common stock as of March 31, 2025, our executive officers, directors, holders of 5% or more of our capital stock and their respective affiliates beneficially owned 39.7% of our voting stock. The voting power of this group may increase to the extent they convert shares of non-voting common stock they hold into common stock. As a result, these stockholders, if acting together, will continue to have significant influence over the outcome of corporate actions requiring stockholder approval, including the election of directors, amendment of our organizational documents, any merger, consolidation or sale of all or substantially all of our assets and any other significant corporate transaction. The interests of these stockholders may not be the same as or may even conflict with your interests. For example, these stockholders could delay or prevent a change of control of our company, even if such a change of control would benefit our other stockholders, which could deprive our stockholders of an opportunity to receive a premium for their common stock as part of a sale of our company or our assets and might affect the prevailing market price of our common stock.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Anti-takeover provisions in our charter documents and under Delaware law could prevent or delay an acquisition of us, which may be beneficial to our stockholders, and may prevent attempts by our stockholders to replace or remove our current management.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our restated certificate of incorporation and our amended and restated bylaws contain provisions that could delay or prevent a change in control of our company. These provisions could also make it difficult for stockholders to elect directors who are not nominated by current members of our board of directors or take other corporate actions, including effecting changes in our management. These provisions:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">establish a classified board of directors so that not all members of our board are elected at one time; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">permit only the board of directors to establish the number of directors and fill vacancies on the board; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provide that directors may only be removed &#8220;for cause&#8221; and only with the approval of two-thirds of our stockholders; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">require super-majority voting to amend some provisions in our restated certificate of incorporation and restated bylaws; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">authorize the issuance of &#8220;blank check&#8221; preferred stock that our board could use to implement a stockholder rights plan; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">eliminate the ability of our stockholders to call special meetings of stockholders; </span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">91</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">prohibit stockholder action by written consent, which requires all stockholder actions to be taken at a meeting of our stockholders; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">prohibit cumulative voting; and </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">establish advance notice requirements for nominations for election to our board or for proposing matters that can be acted upon by stockholders at annual stockholder meetings. </span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, Section 203 of the Delaware General Corporation Law, or DGCL, may discourage, delay or prevent a change in control of our company. Section 203 imposes certain restrictions on mergers, business combinations and other transactions between us and holders of 15% or more of our common stock.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The exclusive forum provision in our organizational documents may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or any of our directors, officers or other employees, or the underwriters of any offering giving rise to such claim, which may discourage lawsuits with respect to such claims.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our restated certificate of incorporation provides that, to the fullest extent permitted by law, the Court of Chancery of the State of Delaware is the exclusive forum for: any derivative action or proceeding brought on our behalf; any action asserting a breach of fiduciary duty; any action asserting a claim against us arising pursuant to the DGCL, our restated certificate of incorporation or our amended and restated bylaws; or any action asserting a claim against us that is governed by the internal affairs doctrine. This exclusive forum provision does not apply to suits brought to enforce a duty or liability created by the Securities Exchange Act of 1934, as amended, or the Exchange Act. It could apply, however, to a suit that falls within one or more of the categories enumerated in the exclusive forum provision.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This choice of forum provision may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or any of our directors, officers, or other employees, or the underwriters of any offering giving rise to such claims, which may discourage lawsuits with respect to such claims. Alternatively, if a court were to find the choice of forum provisions contained in our restated certificate of incorporation to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could harm our business, results of operations and financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 22 of the Securities Act of 1933, as amended, or the Securities Act, creates concurrent jurisdiction for federal and state courts over all claims brought to enforce any duty or liability created by the Securities Act or the rules and regulations thereunder. Our amended and restated bylaws provide that the federal district courts of the United States of America will, to the fullest extent permitted by law, be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act, or a Federal Forum Provision, including for all causes of action asserted against any defendant named in such complaint. For the avoidance of doubt, this provision is intended to benefit and may be enforced by us, our officers and directors, the underwriters to any offering giving rise to such complaint and any other professional entity whose profession gives authority to a statement made by that person or entity and who has prepared or certified any part of the documents underlying the offering. Our decision to adopt a Federal Forum Provision followed a decision by the Supreme Court of the State of Delaware holding that such provisions are facially valid under Delaware law. While federal or state courts may not follow the holding of the Delaware Supreme Court or may determine that the Federal Forum Provision should be enforced in a particular case, application of the Federal Forum Provision means that suits brought by our stockholders to enforce any duty or liability created by the Securities Act must be brought in federal court and cannot be brought in state court, and our stockholders cannot waive compliance with the federal securities laws and the rules and regulations thereunder.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 27 of the Exchange Act creates exclusive federal jurisdiction over all claims brought to enforce any duty or liability created by the Exchange Act or the rules and regulations thereunder. In addition, neither the exclusive forum provision nor the Federal Forum Provision applies to suits brought to enforce any duty or liability created by the Exchange Act. Accordingly, actions by our stockholders to enforce any duty or liability created by the Exchange Act or the rules and regulations thereunder must be brought in federal court, and our stockholders cannot waive compliance with the federal securities laws and the rules and regulations thereunder.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any person or entity purchasing or otherwise acquiring or holding any interest in any of our securities shall be deemed to have notice of and consented to our exclusive forum provisions, including the Federal Forum Provision. These provisions may limit a stockholders&#8217; ability to bring a claim and may result in increased costs for a stockholder to bring such a claim, in a judicial forum of their choosing for disputes with us or our directors, officers, or other employees, or the underwriters of any offering giving rise to such claim, which may discourage lawsuits against us and our directors, officers, and other employees.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If securities or industry analysts do not publish research or reports about our business, or if they issue an adverse or misleading opinion regarding our company, our common stock price and trading volume could decline.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The trading market for our common stock is influenced by the research and reports that industry or securities analysts publish about us or our business. We do not have any control over the analysts, or the content and opinions included in their reports. If any of the analysts who cover us issue an adverse or misleading opinion regarding us, our business model, our intellectual property or our stock</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">92</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">performance, or if our preclinical studies and future clinical trials and operating results fail to meet the expectations of analysts, our stock price would likely decline. If one or more of such analysts cease coverage of us or fail to publish reports on us regularly, we could lose visibility in the financial markets, which in turn could cause a decline in our stock price or trading volume.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">General Risk Factors</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We incur increased costs as a result of operating as a public company, and our management will be required to devote substantial time to new compliance initiatives and corporate governance practices.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As a public company, we incur significant legal, accounting and other expenses that we did not incur as a private company. The Sarbanes-Oxley Act, the Dodd-Frank Wall Street Reform and Consumer Protection Act, the listing requirements of the Nasdaq Global Select Market, or Nasdaq, and other applicable securities rules and regulations impose various requirements on public companies, including establishment and maintenance of effective disclosure and financial controls and corporate governance practices. Our management and other personnel will need to devote a substantial amount of time to these compliance initiatives. Moreover, we expect these rules and regulations to substantially increase our legal and financial compliance costs and to make some activities more time consuming and costly. For example, we expect that these rules and regulations may make it more difficult and more expensive for us to obtain director and officer liability insurance and we may be required to incur substantial costs to maintain sufficient coverage. We cannot predict or estimate the amount or timing of additional costs we may incur to respond to these requirements. The impact of these requirements could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors, our board committees or as executive officers. The increased costs may require us to reduce costs in other areas of our business or increase the prices of our products once commercialized. Moreover, these rules and regulations are often subject to varying interpretations, in many cases due to their lack of specificity, and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we fail to maintain proper and effective internal controls over financial reporting our ability to produce accurate and timely financial statements could be impaired.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to Section 404 of the Sarbanes-Oxley Act, our management is required to report upon the effectiveness of our internal control over financial reporting and our independent registered public accounting firm is required to attest to the effectiveness of our internal control over financial reporting in our annual reports on Form 10-K. The rules governing the standards that must be met for our management and our independent registered public accounting firm to assess our internal control over financial reporting are complex and require significant documentation, testing, and possible remediation. In connection with our and our independent registered public accounting firm&#8217;s evaluations of our internal control over financial reporting, we will need to continue to dedicate internal resources, potentially engage outside consultants and adopt a detailed work plan to assess and document the adequacy of internal control over financial reporting, continue steps to improve control processes as appropriate, validate through testing that controls are functioning as documented and implement a continuous reporting and improvement process for internal control over financial reporting. This process will be time-consuming, costly and complicated.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any failure to maintain internal control over financial reporting, including any failure to implement required new or improved controls, or difficulties encountered in their implementation, could severely inhibit our ability to accurately report our financial condition, results of operations or cash flows. If we or our independent registered public accounting firm are unable to conclude that our internal control over financial reporting is effective, or if our independent registered public accounting firm determines we have a material weakness or significant deficiency in our internal control over financial reporting, investors may lose confidence in the accuracy and completeness of our financial reports, the market price of our common stock could decline, and we could be subject to sanctions or investigations by Nasdaq, the SEC or other regulatory authorities. Failure to remedy any material weakness in our internal control over financial reporting, or to implement or maintain other effective control systems required of public companies, could also restrict our future access to the capital markets.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are subject to the periodic reporting requirements of the Exchange Act. We designed our disclosure controls and procedures to reasonably assure that information we must disclose in reports we file or submit under the Exchange Act is accumulated and communicated to management, and recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC. We believe that any disclosure controls and procedures or internal controls and procedures, no matter how well-conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. For example, our directors or executive officers could inadvertently fail to disclose a new relationship or arrangement causing us to fail to make any related party transaction disclosures. Additionally, controls can be</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">93</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">circumvented by the individual acts of some persons, by collusion of two or more people or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our control system, misstatements due to error or fraud may occur and not be detected. In addition, we do not have a formal risk management program for identifying and addressing risks to our business in other areas.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may be subject to securities litigation, which is expensive and could divert management attention.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The market price of our common stock may be volatile. The stock market in general, and Nasdaq and biopharmaceutical companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. In the past, companies that have experienced volatility in the market price of their stock have been subject to securities class action litigation. We may be the target of this type of litigation in the future. Securities litigation against us could result in substantial costs and divert our management&#8217;s attention from other business concerns, which could seriously harm our business.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Unfavorable global economic conditions could adversely affect our business, financial condition, stock price and results of operations.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our results of operations could be adversely affected by general conditions in the global economy and in the global financial markets. The global economy, including credit and financial markets, has recently experienced extreme volatility and disruptions, including severely diminished liquidity and credit availability, volatile interest rates and increasing inflation, declines in consumer confidence, declines in economic growth, increases in unemployment rates, changes in tariffs and trade policy and uncertainty about economic stability. A severe or prolonged economic downturn or recession and a continued increase in inflation rates or interest rates could result in a variety of risks to our business, including weakened demand for OJEMDA and our ability to raise additional capital when needed on acceptable terms, if at all. Likewise, the capital and credit markets may be adversely affected by global regional conflicts, and the possibility of wider or additional global conflicts, global sanctions imposed in response thereto or an energy crisis. A weak or declining economy also could strain our suppliers, possibly resulting in supply disruption. We cannot anticipate all of the ways in which the foregoing, and the current economic climate and financial market conditions generally, could adversely impact our business. Furthermore, our stock price may decline due in part to the volatility of the stock market and any general economic downturn.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, our business and operations may be impacted by the political instability and military hostilities in multiple geographies including Ukraine, the Middle East and the tensions between China and Taiwan.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="tx180355_15"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 2. Unregistered Sales of Equity Securities, Use of Proceeds and Issuer Purchases of Equity Securities.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Unregistered Sales of Equity Securities</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">None.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Use of Proceeds</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">None.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Issuer Purchases of Equity Securities</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">None.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="tx180355_16"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 3. Defaults Upon Senior Securities.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">None.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="tx180355_17"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 4. Mine Safety Disclosures.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Not applicable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="tx180355_18"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 5. Other Information.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Insider Trading Policies and Arrangements</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Company&#8217;s directors and Section 16 officers (as defined in Rule 16a-1(f) under the Exchange Act) are only permitted to trade in the Company&#8217;s securities pursuant to a prearranged trading plan intended to satisfy the affirmative defense of Rule 10b5-1(c)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">94</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">under </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the Exchange Act, or a Rule 10b5-1 Plan. During the three months ended March 31, 2025, one of the Company&#8217;s Section 16 officers adopted a new </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a08815c4-c959-4bb7-a54c-dcaa0bf7c6cc" contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-false"><ix:nonNumeric id="F_76229d00-facf-4577-9c80-7b4f0c32a399" contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false"><ix:nonNumeric id="F_6c5aae11-6941-4d7b-affb-106f426213be" contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-false"><ix:nonNumeric id="F_b2a71166-3338-4d09-8c8e-6ebd68f20322" contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b" name="ecd:NonRule10b51ArrTrmntdFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Rule 10b5-1 Plan</span></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Merendino Rule 10b5-1 Plan (as defined below) was entered into during an open trading window in accordance with the Company&#8217;s Insider Trading Policy and Trading Plan Policy.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On February 28, 2025, Lauren Merendino, our Chief Commercial Officer, entered into a pre-arranged written stock sale plan in accordance with Rule 10b5-1, or the Merendino Rule 10b5-1 Plan, under the Exchange Act for the sale of shares of our common stock. The Merendino Rule 10b5-1 Plan was entered into during an open trading window in accordance with our policies regarding transactions in our securities and is intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act. The Merendino Rule 10b5-1 Plan provides for the potential sale of shares of our common stock, including upon the vesting and settlement of restricted stock units/vesting and exercise of stock options, so long as the market price of our common stock is higher than certain minimum threshold prices specified in the Merendino Rule 10b5-1 Plan, between May 30, 2025 and March 31, 2026. The aggregate number of shares of common stock that will be available for sale under the Merendino Rule 10b5-1 Plan is not yet determinable because the shares available will be net of shares sold to satisfy tax withholding obligations that arise in connection with the vesting and settlement of such restricted stock unit awards. As such, for purposes of this disclosure, the aggregate number of shares of common stock available for sale is approximately 120,021, which reflects the aggregate maximum number of shares underlying Lauren Merendino&#8217;s restricted stock units which may be sold, without excluding the shares that will be sold to satisfy the tax withholding obligations. The Merendino Rule 10b5-1 Plan expires on March 31, 2026.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">95</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="tx180355_19"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 6. Exhibits.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The exhibits filed or furnished as part of this Quarterly Report on Form 10-Q are set forth on the Exhibit Index below.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:9%;box-sizing:content-box;"/>
     <td style="width:41.28%;box-sizing:content-box;"/>
     <td style="width:6%;box-sizing:content-box;"/>
     <td style="width:12.8%;box-sizing:content-box;"/>
     <td style="width:12%;box-sizing:content-box;"/>
     <td style="width:12%;box-sizing:content-box;"/>
     <td style="width:6.92%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td colspan="4" style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Incorporated by Reference</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p><p style="border-top:1pt solid;padding-top:1pt;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
    <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exhibit<br/>Number</span></p><p style="border-top:1pt solid;padding-top:1pt;font-size:8pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Description</span></p><p style="border-top:1pt solid;padding-top:1pt;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Form</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p><p style="border-top:1pt solid;padding-top:1pt;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">File No.</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p><p style="border-top:1pt solid;padding-top:1pt;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Filing<br/>Date</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p><p style="border-top:1pt solid;padding-top:1pt;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exhibit</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p><p style="border-top:1pt solid;padding-top:1pt;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Filed/Furnished<br/>Herewith</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p><p style="border-top:1pt solid;padding-top:1pt;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;31.1</span></p></td>
     <td style="padding-top:0in;text-indent:6.4pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:1.187%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="dawn-ex31_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></a></p></td>
     <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
    </tr>
    <tr style="height:5.75pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;text-indent:6.4pt;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="margin-left:1.187%;text-indent:0;font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;31.2</span></p></td>
     <td style="padding-top:0in;text-indent:6.4pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:1.187%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="dawn-ex31_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
     <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
    </tr>
    <tr style="height:5.75pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;text-indent:6.4pt;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="margin-left:1.187%;text-indent:0;font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;32.1*</span></p></td>
     <td style="padding-top:0in;text-indent:6.4pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:1.187%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="dawn-ex32_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></a></p></td>
     <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
    </tr>
    <tr style="height:5.75pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;text-indent:6.4pt;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="margin-left:1.187%;text-indent:0;font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;32.2*</span></p></td>
     <td style="padding-top:0in;text-indent:6.4pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:1.187%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="dawn-ex32_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
     <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
    </tr>
    <tr style="height:5.75pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;text-indent:6.4pt;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="margin-left:1.187%;text-indent:0;font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101.INS</span></p></td>
     <td style="padding-top:0in;text-indent:6.4pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:1.187%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document).</span></p></td>
     <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
    </tr>
    <tr style="height:5.75pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;text-indent:6.4pt;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="margin-left:1.187%;text-indent:0;font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101.SCH</span></p></td>
     <td style="padding-top:0in;text-indent:6.4pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:1.187%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inline XBRL Taxonomy Extension Schema With Embedded Linkbase Documents.</span></p></td>
     <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
    </tr>
    <tr style="height:5.75pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;text-indent:6.4pt;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="margin-left:1.187%;text-indent:0;font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">104</span></p></td>
     <td style="padding-top:0in;text-indent:6.4pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:1.187%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></p></td>
     <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">* This certification is deemed not filed for purposes of section 18 of the Exchange Act or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act or the Exchange Act.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">96</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="tx180355_20"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SIGNATURES</span><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:42.76%;box-sizing:content-box;"/>
     <td style="width:3.24%;box-sizing:content-box;"/>
     <td style="width:54%;box-sizing:content-box;"/>
    </tr>
    <tr style="word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td colspan="2" style="padding-top:0in;text-indent:12pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">DAY ONE BIOPHARMACEUTICALS, INC.</span></p></td>
    </tr>
    <tr style="height:12.25pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;text-indent:12pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date: May 6, 2025</span></p></td>
     <td style="padding-top:0in;text-indent:12pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</span></p></td>
     <td style="padding-top:0in;text-indent:12pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.75pt solid #000000;padding-right:0in;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Jeremy Bender, Ph.D., M.B.A.</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;text-indent:12pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Jeremy Bender, Ph.D., M.B.A.</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;text-indent:12pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chief Executive Officer and President</span></p><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Principal Executive Officer</span></p></td>
    </tr>
    <tr style="height:12.25pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;text-indent:12pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date: May 6, 2025</span></p></td>
     <td style="padding-top:0in;text-indent:12pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</span></p></td>
     <td style="padding-top:0in;text-indent:12pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.75pt solid #000000;padding-right:0in;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Charles N. York II, M.B.A.</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;text-indent:12pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Charles N. York II, M.B.A.</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;text-indent:12pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chief Operating Officer and Chief Financial Officer</span></p><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Principal Financial and Accounting Officer</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">97</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>dawn-ex31_1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html>
 <head>
  <title>EX-31.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;position:relative;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 31.1</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CERTIFICATION PURSUANT TO RULE 13a-14(a) OR 15d-14(a) OF</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">THE SECURITIES EXCHANGE ACT OF 1934,</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I, Jeremy Bender, certify that:</font></p><p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1. 	I have reviewed this Quarterly Report on Form 10-Q of Day One Biopharmaceuticals, Inc.;</font></p><p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2. 	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></p><p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3. 	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></p><p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4. 	The registrant&#x2019;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></p><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a. 	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></p><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">b. 	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></p><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">c. 	Evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></p><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">d. 	Disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting; and</font></p><p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5. 	The registrant&#x2019;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions):</font></p><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a. 	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and</font></p><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">b. 	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting.</font></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:49%;box-sizing:content-box;"></td>
     <td style="width:2.94%;box-sizing:content-box;"></td>
     <td style="width:48.06%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date: May 6, 2025</font></p></td>
     <td colspan="2" style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/</font></p></td>
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.006in;border-bottom:0.75pt solid #000000;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;Jeremy Bender, Ph.D., M.B.A.</font></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Jeremy Bender, Ph.D., M.B.A.</font></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Chief Executive Officer and President</font></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">(Principal Executive Officer)</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>dawn-ex31_2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html>
 <head>
  <title>EX-31.2</title>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;position:relative;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 31.2</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CERTIFICATION PURSUANT TO RULE 13a-14(a) OR 15d-14(a) OF</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">THE SECURITIES EXCHANGE ACT OF 1934,</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I, Charles N. York II, certify that:</font></p><p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1. 	I have reviewed this Quarterly Report on Form 10-Q of Day One Biopharmaceuticals, Inc.;</font></p><p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2. 	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></p><p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3. 	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></p><p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4. 	The registrant&#x2019;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></p><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a. 	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></p><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">b.	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></p><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">c.	Evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></p><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">d. 	Disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting; and</font></p><p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5. 	The registrant&#x2019;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions):</font></p><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a. 	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and</font></p><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">b. 	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting.</font></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:45%;box-sizing:content-box;"></td>
     <td style="width:7.76%;box-sizing:content-box;"></td>
     <td style="width:47.24%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date: May 6, 2025</font></p></td>
     <td colspan="2" style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/</font></p></td>
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.006in;border-bottom:0.75pt solid #000000;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Charles N. York II, M.B.A.</font></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Charles N. York II, M.B.A.</font></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Chief Operating Officer and Chief Financial Officer</font></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">(Principal Financial Officer and Principal Accounting Officer)</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>dawn-ex32_1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html>
 <head>
  <title>EX-32.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;position:relative;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 32.1</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CERTIFICATION PURSUANT TO</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I, Jeremy Bender, Chief Executive Officer of Day One Biopharmaceuticals, Inc. (the &#x201c;Company&#x201d;), do hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:</font></p><p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1. 	the Quarterly Report on Form 10-Q of the Company for the fiscal quarter ended March 31, 2025 (the &#x201c;Report&#x201d;) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and</font></p><p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2. 	the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></p>
   <table style="margin-left:0.046%;border-spacing:0;table-layout:auto;width:99.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:48.08%;box-sizing:content-box;"></td>
     <td style="width:3.84%;box-sizing:content-box;"></td>
     <td style="width:48.08%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Dated: May 6, 2025</font></p></td>
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/</font></p></td>
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.006in;border-bottom:0.75pt solid #000000;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Jeremy Bender, Ph.D., M.B.A.</font></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Jeremy Bender, Ph.D., M.B.A.</font></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Chief Executive Officer and President</font></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">(Principal Executive Officer)</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>dawn-ex32_2.htm
<DESCRIPTION>EX-32.2
<TEXT>
<html>
 <head>
  <title>EX-32.2</title>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;position:relative;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 32.2</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CERTIFICATION PURSUANT TO</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I, Charles N. York II, Chief</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Financial Officer of Day One Biopharmaceuticals, Inc. (the &#x201c;Company&#x201d;), do hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:</font></p><p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1. 	the Quarterly Report on Form 10-Q of the Company for the fiscal quarter ended March 31, 2025 (the &#x201c;Report&#x201d;) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and</font></p><p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2. 	the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></p>
   <table style="margin-left:0.046%;border-spacing:0;table-layout:auto;width:99.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:49.16%;box-sizing:content-box;"></td>
     <td style="width:2.5%;box-sizing:content-box;"></td>
     <td style="width:48.34%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Dated: May 6, 2025</font></p></td>
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/</font></p></td>
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.006in;border-bottom:0.75pt solid #000000;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Charles N. York II, M.B.A.</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:16pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Charles N. York II, M.B.A.</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:16pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Chief Operating Officer and Chief Financial Officer</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:16pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">(Principal Financial Officer and Principal Accounting Officer)</font></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:16pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>img14486971_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img14486971_0.jpg
M_]C_X  02D9)1@ ! @$ > !X  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" .:!E8# 2(  A$! Q$!_\0
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M 4444 %%%% !1110 4444 %%%% 'EGQQ^,7@G]GKX-?%3X[?$G4#I?@'X/\
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M/VX?V7?V!/AGH7QB_:U^)_\ PJ?X<>)?'>F?#31?$7_"%?$/QW]M\;:QX?\
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M[?VH_P#@IU\0?B=^S7\&?BE_PJ#X&-:>!?&G[3?BZ^NKBZT--+T&_P#$=O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MGBODNI(M0D>YFM9[AH[ED[7X1_\ !"[_ (+1?MX?$JV\1?%'X._%WPE>:_\
M8!XE^-G[:'B;Q#X6O=.T_P N V\NM6_CN;5_C!K;6L%P$33='\(ZU>VLB2VT
M\%F89_*Z:.18+#UH8BOFN%GA:<E42C*$95%%J48M^TDK-VYN3F<EI&SDFL*N
M;8JM2E1HY?B(XBI'DNXR<8.2LY)<B>B;MS<J6DI-I-/C_P#@WB_9E\0_M+?\
M%8/V85T_2&O_  O\"/$K?M'^/M3>U^TV?A[2/A*8M8\*7UR&1HXYK_XGS> ]
M!T^3*RP7^JP7L1S:,5_IU_X/+-/O)?V4_P!CW54AW6%E^T)XLT^YN/,B'E7F
MI_#B^N;&'RBXF?SX=(U!_,CC>*+[/MF>-Y8%E_<'_@DI_P $E/@C_P $I/@C
M?^"O!5^WQ"^,OQ";2]3^-?QKU/2X=,U+QAJ6F0RKIGA[P]IBRW<GAOX?^&Y+
MN_?0=!>_U"\EO-0U'5]7U&\O+R..RRO^"V__  3@U/\ X*=?L-^)/@AX*U'1
M=&^,G@GQ;H?Q>^"NI>(97M-$N/&_AFPUG1KOPQK>HPPS7%AI?B_PGXD\1Z"E
MX%:TT[7+G0M:U"&XM=)>(Y5\XH8C/<)BKN.$P\E2C.2:O&7.IUG%ZQCS3OM?
MDBFU>\2Z66U:.48C#M<V(K)U7"+3M*/(XTD]FTH6=M.:32;5F?C)_P &;&MZ
M7<?L>_M:^&X;R%];TG]I71];U#3U8&>UTOQ!\+_#5AH]Y*F<K#?7?AG7((&(
MP[Z=< $E#CVO_@[O\;^#]*_X)K^ / >I>)M#LO&OB_\ :;\ ZQX7\)W&I6L?
MB'7M(\*^$OB /$VK:7I#2?;KO2] ?6]%AU?4(H6L]/N-8TJWN9HY]1LXYOY"
M?@A^QO\ \%[_ -A'XL>(;/\ 9T_9N_;V^#GCO6[>/PSXHUGX0?#7Q[K_ ($\
M265M<7#VEOK'C'PCI?B/X3>);#3[EKFXTS4KG6M0M--DN)+O3[RW^V>;-]>?
MM;?\$3O^"P'Q$_9EU+]N3]KU_CY^T)^T[KOCOP5X%\(_L\Z#!XJ_:,^-.C?#
MS4H?$E[JWBWQ7;>"SXKM/!OAK1KFRTRWTCP5X1BO8-.?Q#-?>(?^$9NH&TJ]
M]&I@L+_;-/,9YCA52J5Z52E2C.,JLZBC&,8Z-Q5.Z4I5+V4=&E=2..&*KO+)
MX*."Q'M(4IPG4E!QIQAS-WU2DYV=E"UW+576A^G7_!E?_P Y*O\ NSC_ -^I
MKX5_X/$/^4F7P-_[,5^&?_J__P!IROU?_P"#1G]EW]IG]FS_ (>"_P##1?[.
MOQU^ 7_":?\ #*/_  AW_"ZOA'X_^%G_  EG_".?\-*?\)#_ ,(U_P )SX?T
M+^W?["_MW0_[9_LO[5_9?]LZ5]N\C^T;3SOC+_@ZN_8T_:__ &B/^"AGP;\:
M_L__ +*?[27QS\&Z7^QE\//"VI^+?@[\#/B?\3?#.G>)K+XW_M$ZM>>';[7O
M!7A?6]*M-=M-*UO1=3NM(N+N/4+?3]7TN]EMTMK^TDEBE5I+BK$U'4IJFZ$4
MI\\>1OZKAU92ORMW36CW3152G4_U?H0Y)\ZJMN'++F2^L5G=QM?9I[;-']-7
M_!OA_P H</V&_P#L0?&__JXOB/7[+5^3G_!#+X<_$+X2?\$HOV./AU\5O ?C
M/X9?$'POX)\86GB7P)\0O"^N>"_&7AVZNOBMX^U&VMM=\,>)+'3=;TFXN-/O
M+.^@AO[&WDEL[JVNHU:">)V_6.ODL<T\;C&FFGBL0TT[IIUIM--:--:IK<^B
MP::PF%3336'H)IJS35.-TT]4UU05_C<?&CQ!HWA/_@JU\6/%/B*_ATKP_P"&
MO^"A/COQ!KNJ7 D:#3=&T;]H_5=1U._G6%))3#9V5M/<2"*.20I&P1';"G_9
M'K_&>_:,\&6?Q'_X*<?'?X>:C>7.GZ?X\_;O^)_@R^O[)8FO+&S\4?M ZYH=
MU>6BSJ\#7-M!?/- LR/$9402*R$@_1\*6]IC^:ZC["G=K>W-.]O.QXO$%^7!
MV5W[:5D]F[1LG\S_ &3]&UG1_$>CZ5XA\/:KINNZ!KNFV.LZ'KFC7UKJFCZS
MH^J6L5]IFJZ5J=C+/9:CINHV4\%Y8WUG/-:W=K-%<6\LD4B.?\M3_@Z#^(?A
M7Q]_P5\^-%GX6U*#53\._A_\(/AYXCN+5UEMH/%6E^"[/7-6TV.=,QRSZ2OB
M*VTW4D1F:SU>UU#3I]EU9SQ1_5_Q+_9T_P"#F3_@EO9ZC^S)\ /%'[5GQ5_9
MTTRZU73OACXG_9J\*7?QU\-2>%K^6\6WE\/:+8^'/'?Q&^"4CK)-=W?A?R/#
M=MH>O3W5]HEYJ:7%IXBU+AO^";'_  ;=?MR_M;_';0?B;^W)X"\<_ 3X!+XJ
M3QK\4]2^+5_/8?&_XOR2ZK_:NN^&M&\,7]Q=^--+UOQ;<R3+K_C?QW::,MA;
MWU]J]@?$.M1QZ;-OE>%PF4U*V85<QPM:A[&<**I3O4FI2C+WJ;?,JEHJ/LH\
MS4I/F<>77',,1B<PA2P5/!5Z=7VD95G4C[D'%-:35TX7DVZDN562LG?3^O?]
MF;POKO@[_@W1\':'XD^V#5?^'5WBS67BO]@N[6P\3_L]>(_$VC64L:RS&$6&
MC:O86<=M*T=S;101V]U;6ES'+:P_PI_\&T__ "FP_8L_[N-_]9,^.]?Z:W[7
MG@RZO?V)OVG_ (>_#_PO=W][=_LL_&KP9X)\%^$]'N+Z_O;J?X2^)=$\-^%_
M#6@:5;S75Y=W,KV6E:-H^FVLMQ<3/;65G;R2/'&?\]C_ (-\OV#/VY?@O_P5
MZ_9'^)?QB_8Q_:P^$_PX\-?\+[_X2+X@?$O]G7XO^!/!.@?VQ^S%\:- TC^V
MO%?BGP?I6A:5_:NNZKI>BZ;]NOX/MVK:E8:;:^;>7EO#)AE>(A/+L_G.<(3K
MT\1.,)3BFW4H5W:*;3EK))66KLNIMF%&4<9DT(QE.-*=*,I*+:2A5HJ\K7Y5
M:+>K[]C^@_\ X/$/^49OP-_[/J^&?_J@/VG*^)_^#,;QWX-M]&_;J^&EQXET
MBW\?ZKJ_P3\::7X1GO(H==U/PIHUC\0=%UG7].L9"LM]IND:KK.CV&JW%J)5
MTZXU?2DO/(_M&R,_VQ_P>(?\HS?@;_V?5\,__5 ?M.5_(W_P2R_X)Y_MO?M,
M?#7XT?M;?\$\/B)K?A?]IC]DKQWX%M-.\*>&?%L?@'Q=XJ\+?$#PUXSFU2;P
M3XKN+W3M)DUNR/AUM.U/P=XCOK31/&7AW6M0L6N7NK6/1/$&^ HTJ_#=6C5K
MQP\9XAI59_!&?MJ3ASOI"4THREM%/F>UGCBZE2EGD*E*E*O*-%-TH_'*'LYJ
M?)WE&+<E'[35EJS_ $0_^"Y?Q \+?#C_ ()+_MU:OXLU2VTNTU[X%>(_A_I!
MGE1)-0\4_$>6S\$>%]+M(V(>XN;S6]=LU,4*N\=JES=.%M[::1/X6?\ @U*\
M,ZWKW_!7#PEJFE27J6'@OX$?&SQ-XF6U ,$NB76CZ5X.MX]2)EC*V0\1^+/#
M\L95)S_:,=@OE*&,\/GW[0OP0_X..O\ @H?K7AKX/?M)_ _]N;XJ6OA#6KB]
M\/:/\0/A%>?"WX3V.O/#+9/KLGB>X\-> /A'J&H16EQ<V=CXDU+6[R6UL;N]
MMM/U&*TO+I)?[*?^" 7_  1AU/\ X)<?"SQUX_\ C;J6@>(?VJ?CI;Z+9>+D
M\-7)U+P[\+_ .C,VH:9\.-&UEH8O[:U>\UJXEUGQUKEF$T:_OK#P]I.C)=V?
MAI?$'B")+#Y/DV+PL\50Q&)QCDHPH34TE.$:=]N91C!2FYR44VU&.JNZ3K9G
MF6&KQP]:CA\+RMSJQY&W"3G;LW*7+'EBY-1O)V6B_DC_ .#KWP=XA\-_\%9_
M$&OZNFI?V3\0?@)\&O$_A26\4_8SI&FZ?K/@F^ATF3E3:Q>(O">M2W$>0Z:A
M<W;L@66-W^H_V&_^#5SPO^W#^R5\"/VJ_"/_  46M_#^F_&;P%IOB>_\*VW[
M*\?BE?!?BB.2?2?&7@B7Q%'^TKH8UFX\'>+-.UGPW/J;Z'HLE])IK74FD::T
MQLX?Z>O^"Z'_  1KTK_@JW\&_"6H^ O$>B> /VG_ ()+KLWPJ\3^(HKA?"GB
M[0M>6UFUSX:^.;S3K:[U/3]*U"_T[3]4\/\ B.VL=7E\,:M%>A-)N;+7]6*_
MQP_![X7_ /!S/_P2AA\1_"3]GOX4?M<^&/!^IZS<W=QX>^%OP:\-?M<?"R74
MYV!N/$7AFRM?!?QL\(>&[O68[&W?4-6T>UT'5;^*.TMM;/G+%;+T8+'5,5E>
M&H8''X?!8W#*-.I#$>RY:E."<4X^TIU'9KDES0@VI)PE:ZD8XK"0P^85ZV+P
ME;%86NW.$J//S0G)J3NH3AL^:-I25TU*/5'UE^T)_P &PO[)/[)U]X8TW]I?
M_@MG\)/@;?\ C6TU.^\)6GQ,_9JTCPK/XBL]%FL[?5KG2(]3_:PA-[#ITVHV
M,5X\.X0/=VZO@RKG^LG_ ((<_LY?!?\ 99_8+\.?"?X!_M5^#/VR_AW:_$OX
MD:[9_&_P%X<L_"_AS4M3UK5+675/#]OIEAXX^(=K]H\/7$(M+NYC\2S&:9B'
MM;1XVCK^'A_^"7'_  7R_P""OWQTT'X@_M6^ _B_HMT\5KH-]\6/VK-*L_@E
MX8^'/A22^EO[B#PW\*&TGPQK=KIR7-[=WH\.?#?X9^5<:E.\E]%9AKB^@_T1
M_P!@K]CGP!^P)^R7\&OV4?AQ>W6LZ'\+/#US;ZGXHU"WAM=2\8^,?$.K:AXH
M\;^+KZ"$R"V.O>*M9U6]T_36N+S^Q-';3=!BO;JVTN"5O/SNO46$HX>OFD<;
MB744ZM&C3PWL*?+&:YO:4J4*B:YE&,927->4G%))';E5*#Q-6M1P$L+14'"G
M5JSK>UGS.#Y>2I4E"SLVY132M&*DVV?Y37_!(N)O#O\ P5>_8(L==,>DW=A^
MU_\ !O1;R&_EBMS!JS^/M,TF/3F:1PAO)M4DBT^W@5F>XO)8K> 22RQJW^MC
M^U!_R;3^T/\ ]D,^+7_J ^(*_P W[_@I'_P0,_X*,_LK?M<?$7XJ_LK?!CXE
M?&OX/7?Q-UCXO?!3XA? &TO/%/CSP.D_B2Y\7Z#X?U3P?X=DE\?Z5XU\ W8M
MK2RU?1]%O-,UI[+3M5T341J-S<Z/I?\ 3C_P1M\?_P#!43XV_L)?M]67_!1;
MPW^TI)\45T7Q+X:^#6C?'+X):U\+O%^M:'J7P=UZ*:R\(Z#<^!/!VH^*Q>^(
MI8+4W-M8ZM=S:G+%9"X:=UA/3GJHXZ&$S&ABL/.%.%.$Z2FO:WJ58M6@KM./
M._:1FXN-MGTPRAU,++$8&M0K1G.=2<:CA^[M"G;XG:_,HIQ<;IW/XQO^#?+_
M )3'?L-_]E \:?\ JG_B+7]NO_!UE_RB-\9_]ES^"7_I]U"OY0?^"&G[ '[>
M'PD_X*N?L;_$7XK?L3_M<?#+X?>%_''BZ[\2^._B%^S?\8_!?@WP[:7/PK\>
M:=;7.N^)_$G@S3=$TFWN-0O+2Q@FU"^MXY;RZMK:-FGGB1O[!_\ @Y<^#7Q?
M^/'_  2[\6_#_P"!WPI^)/QE\>7/QE^$&J6_@GX4^!O$_P 1/%UQIFF:S?2Z
MEJ,/AOPAI>L:S+8Z?$Z27UW'9-;VD;*\\D:L";S6K2EG^53C4IRA%8?FE&<7
M&/\ M%1ZR3LM&GJ]FF1@*=19-F$7":E*5:T7&2D_W-+9-7?R1^"O_!F!_P E
M4_;X_P"R?_ /_P!2/XH5_0I_P<L?\H3_ -M/_NW+_P!:S^!%?C1_P:4?LI?M
M1_LW_$G]MF__ &B/V;/C[\!;'Q7X'^"=IX7O/C1\'?B)\+;7Q)=Z3KWQ&FU2
MVT"X\<>'-"AUBXTV&^LI=0ATY[F2SCO+5[A8UN(B_P"Z7_!P;\+OB9\:/^"0
MO[7'PT^#OPZ\=_%CXC^)?^%"?\([\/\ X:>$?$'COQMK_P#8_P"T[\%]?U?^
MQ?"GA;3]5UW5?[*T+2M4UK4OL-A/]ATG3;_4KKRK.SN)H^',*D)<349QG!P^
MM9<^=23A9>PN^9.UE9W=]+:G9@X3615(.,E/ZOC5RN+4KMUK+EM>[NK*VMU8
M_E$_X,WO^3X?VH_^S4W_ /5N_#FOEK_@Z]\'>(?#?_!6?Q!K^KIJ7]D_$'X"
M?!KQ/X4EO%/V,Z1INGZSX)OH=)DY4VL7B+PGK4MQ'D.FH7-V[(%EC=_TP_X-
M0OV/_P!K7]G3]L7]H[Q/^T'^RY^T7\"?#6N?LT/H.B>(?C)\$OB7\,-#UC7#
M\4? 6H#1M+U;QMX9T.PU#5C86=W??V=:7$UY]CM;FY\GR8)77][?^"Z'_!&O
M2O\ @JW\&_"6H^ O$>B> /VG_@DNNS?"KQ/XBBN%\*>+M"UY;6;7/AKXYO-.
MMKO4]/TK4+_3M/U3P_XCMK'5Y?#&K17H32;FRU_5BO;5Q]#"<23KSG%T*E"G
M1E5BU.,.>G3:DW&^BG&*DUJHMOI9\=+!UL1D:I0A)585I58PDN5RY9237O6U
M<9-QONTEUN?S"_L-_P#!JYX7_;A_9*^!'[5?A'_@HM;^']-^,W@+3?$]_P"%
M;;]E>/Q2O@OQ1')/I/C+P1+XBC_:5T,:S<>#O%FG:SX;GU-]#T62^DTUKJ32
M--:8V<-[]H3_ (-A?V2?V3K[PQIO[2__  6S^$GP-O\ QK::G?>$K3XF?LU:
M1X5G\16>BS6=OJUSI$>I_M80F]ATZ;4;&*\>'<('N[=7P95S\F_![X7_ /!S
M/_P2AA\1_"3]GOX4?M<^&/!^IZS<W=QX>^%OP:\-?M<?"R74YV!N/$7AFRM?
M!?QL\(>&[O68[&W?4-6T>UT'5;^*.TMM;/G+%;+3?_@EQ_P7R_X*_?'30?B#
M^U;X#^+^BW3Q6N@WWQ8_:LTJS^"7ACX<^%)+Z6_N(/#?PH;2?#&MVNG)<WMW
M>CPY\-_AGY5QJ4[R7T5F&N+Z#N=3'*M4K5,^P<,O;G.G*FL)*MR.[A"TJ$H-
MQ32<E.<I6TC>6G*H81TH4X91B9XRT(S4WB8TG)64Y7C64DGNDXQC&^KLM?[A
M_P#@AS^SE\%_V6?V"_#GPG^ ?[5?@S]LOX=VOQ+^)&NV?QO\!>'+/POX<U+4
M]:U2UEU3P_;Z98>./B':_:/#UQ"+2[N8_$LQFF8A[6T>-HZ_7^OD#]@K]CGP
M!^P)^R7\&OV4?AQ>W6LZ'\+/#US;ZGXHU"WAM=2\8^,?$.K:AXH\;^+KZ"$R
M"V.O>*M9U6]T_36N+S^Q-';3=!BO;JVTN"5OK^OA<745;$XBJIRJJI6J252<
M8PG43DVIRA!1C%R6KC&*2;LEH?6X>'LZ%&FX*FX4H1<(R<HP:BDXJ4G*4E%Z
M*3;;2NWJ%%%%<YL%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M-/D]E[/?W)0O[3GT^*]N3I:_4****\D]$**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M[*\NQG+&?]GULWS'"Y?4Q\834H.MA</7K5<+SQG!8M8>52$Z:E%X?PD\"?\
M!6+]MS2F^+^A_'SQ/\./!FO75^VA:M>_$WQ1\*?#.J+8W$EE/%X<\+?#'3KN
M^;3;2XAEL8M1NM#CM;NXM;@G4;V[BNIJH:9^U[^WO_P3V^,&C^!_VGM3UWXF
M^#M5CLM0N]+\6Z]'XQ?6_#;7/V:[USP)X_FDGU>/5++%Q$;#5+Q[472)%K&C
MQ-+:W:?T4_LW6.E:;^SS\"K+0X+2WTB#X/\ PV&GQ6.PVOV9_!VCR1R0NA99
M5F#F8S[W:X>1IWDD>1G;\C_^"[-CH<GPB^!6I7#J/$EI\1_$%CI,9@C9VT/4
M/#!G\0NMR;I)852_TSPPKP)97$=P9$DENK-K6&&^_1LAXMPG$W%W^J.8\+<.
MQX=Q^(QN78;#8;*Z=#%X"&'I8B6&K4\32:FJR5&*K5*:I\CE*K0]BH<K_F[C
M[PCS;PQ\(5XO<.^*GB-/Q%X?R_(^(\RS/,^*,1C\GSZOF.)RZGF>"Q.5XI.C
M+!2>-JRP6'KSQ+KQA#"XU8QUO:0_8>X^-OPBT[X>^%_BMKWQ(\%^$_AWXSL-
M$U#PYXN\9>)-(\(Z)J47B/3#K&CP17_B&\TZV6_O=.26YCTYY%O0MO<AH ;:
M8)V?A?Q7X7\;Z#I_BGP7XDT#Q?X8U9)I-*\1^%]8T[7]!U..WN9K.XDT_5])
MN;O3[U(+RVN+29[:XE6*Y@F@<K+$Z+_-E^T#<7ES_P $6/V6Y+Z2:29?B9IM
MNC3Y#BSM=1^,]KI\:[@#Y,5A#;16_8VZ1%25P3^NO_!,#_DQ']G[_L#>+_\
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MR?#*O$/CA\/=7^+7_!5WXA?##1?%U[X$NOB#\3-1\'7?BG3K<W=YIVA>(?
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MFJ:5?:-H?AY[*8&[N5N8VBG#2+:36KVABE6?T/\ B%O#4<ZRS)I\58WV_$6
MCF&0PAE%VL.\+4Q'M<QJRKQIQYW1JJE1I*,VH?O94G*-_G5]*GQ+J<$<2\:4
M?"C(_P"S_#G/ZG#W'U>MQ@H0EF,,TPV >%X=PM/ U<34]C'&826)Q>+E4HJ=
M=?5:>+C2JJ/]9-075U;6-M<7M[<06=G9P375W=W4T=O;6MM;QM+/<7$\K)%!
M!!$CRS32NL<<:L[LJJ2/&OV:?$>L^,?V<O@!XN\17TVI^(/%7P3^%7B/7=2N
M'>6XU#6=<\"Z#J>J7T\DC/))-=WMU//*\CN[O(S,S,23\5_\%6/ VO\ Q ^
MFB:''\<_AO\  [P''XI%_P"/+[XB:QKFE1>+DMK-_P#A'_#>EV_AW1=<U77G
M2]>ZU:YT*ULY9+A]/LKX6\PTYG@_*LKR6..XAH9%B<9'!QJ8^I@JV,C0K8E4
M_93G&<Z6'HKVU><W3<:%**BZE24(RE!-RC_5_%'&U3(_#O'\>9;D]7.)T,@P
M^=X+)ZF/P>5RQ'URC0JT:6*S'&36#P%"C'$1JX[%U)3C0P]*O4A"M.,*<_L=
M?VI_V87U :2G[1WP&;53*81IB_%_X?-J!F"EC"+(>(3<F4*"QC\O>%!.,<UO
M?%SXR^ /A'X'OO%GBOQ]X \(_:M(U:?PA/XU\4Z+H.F>)=:M=(N-2T_3=,DU
M+5--_MB6Z\N)Q9Z9<M=SV[[H2NY9!_*M\4])_P""9'A[]FZX\+?#SQ-XV\<_
MM,Z;H>B3Q_$?3+'XAZ=X3U_Q:QTR7Q#81:9XLL=#TNV\)1'^U;33)'\*V.ML
MOV:634;C)FK[4_8H^"OA;]L#_@G=KNC?&O4_%>KV/P"^*_Q.D^'":;KKV3Z;
M:6/PQ\(>(+32+F6XM[YYM(M]1\1:J\%C";9+>&=88&C2-0/TO,/#?)LLP6&S
MNOC.),+E='.J668^AFV24\%CJ]&M%^QQV7T98B\\-5K.G3Y,3"E5]G*JY*G4
MH^SJ?S)P[])3C3BC.\RX'P&3^&V:<48S@G%<49#C>$^-\1G>18#%X2M%8W(^
M(<;2R]JCF6%P2Q.)]KEU7%X7V]+"PI2Q.'Q?UBA[_P#L&?\ !4S5_CWXI\>Z
M/^TMK_[/7PATS1=&T2Z\(7<>JW/@"37]7O\ 4;FUO=/CG\??$+6;?57@MXX)
M$M=,BBN8FE#RLZ.BC]L:_D._X):?LG_"C]JKQW\3=.^*:^)#!X#T+POX@T%O
M#FLIH\JW]UK%Y!,+QI+*^2Y@9+:$B/8C*RDB3#,#_7C7C^+.4</9)Q-/!9%3
MJ86<:5&6-P$:,:>"PO-A<)/#2PE3VDZE9XB,ZM3$>TC'V=2RAS)MGV7T2.,/
M$3C;PPHYWQWB<-FE"KB\7#(\^GC:F(SO-%1S7-J&90SC#/#T</A(X"I1PF&R
MYX>=5XC#<TZW).*3_#S]L+_@JOKGP@^//@'P)\ -=_9W^*/PPU[PGX6U7Q1X
MR_M.\\;?V+KFJ>,O$^C:WIO_  D7@OXB:9X>T[^SO#VF:-JOV/4;.:\L_P"T
M/MUW))8W=K%']F_MC?&W0==_8D^/_P 1O@+\7=(UBX\.:+!86GCOX1>/K+4)
MM!UZ+6O#,UU96WBCP9JTSZ7J\6F:K:RSVT5]!>I8ZE;O(@M[R,R?ST?\% OV
M4?A3^S3^U'\*_A'\-U\2'PCXO\#>!_$6L+X@UE-4U)M0U_XB>,_#.H"VO8K*
MR$%N=,T&Q$,?DNT5QYTWF-Y@1/VG_:-_9C^&7[*'_!.3]I[X=_"D>(1X>UF,
M^-+W_A)=6CUB^_MK4=0\!:'<>5<QV=BL=I]A\.:=Y<!B8K-Y\GF$2A4^MS3(
M>#,#2\+\3E2Q3Q.9YE@'2G6P=*"S?#+-<OAB*N:+VU2-*M2C-1I4J<9TZD:M
M13:LC\EX5X]\:,\Q?TH<LXMEE4<MX9X:SZ&*I8+.L96EPCF<N%,^KY?@^%G]
M4H3Q6"Q52C*KB\5B:E&OAZF&H.C&3DVN8_X)/_'Z^OOV2_'WQ!_:(^-=W>)I
M_P ??$?A^'QO\:/B1-<)8V*?#SX::C9Z)%XE\<:RXMK1+BZU6^MM-2]2%9KC
M4+J*$/+<NWZK>!_B;\-_B=8W6I_#7X@^"/B%IME*D%YJ'@?Q9H/BRQM)Y/,\
MN&ZN]!O]0@MY9/)FV1RR([>5)M!V-C^9K_@FS_P3]\&?M>_"7Q1XT^+/Q!\>
M6G@;PI\1]?\ #/AKP#X.U&RTN*'Q7+X7\":GX@\6WEWJVFZY9JVI:3=^'M)^
MSV.FVUY<'1H)+S46M[2VM'@_80\/:E^SI_P57O\ X$^&?$.I7WA===^,/PZU
M26XD\A]?\/>&_!GBKQ9H3ZM:V_EVDU[;ZAX<TBY=EB$45U'.]L(TDVF.+."N
M'\US7CS$9;G56GG.18?%9WB<KAEGL,MHX7#48U*F%I8CGBYUE3C[TX4XTHUJ
MD81A4C&=0U\)O&SQ"X4X4\!,NXEX*PM;@SCS,,JX(R[BFMQ.\;Q)B\US+%SP
M^'S;%9?["I&A@JF(JOV="OB*N)GA<-.M5K8>I5HX<_J'\1^*/#7@_2I]=\6^
M(M"\+:':E1=:SXCU:PT32K8OG8)]1U.XM;.$MM;:))EW8.,X-<%X-^/?P+^(
MVJ)H?P]^-/PF\=ZW(DLB:/X-^(W@_P 4:HZ6\+W$[II^B:S?7;)#!&\\K"$B
M.%'D<JBEA_,1_P %'OC]I?Q4_;COO ?Q<UCQY_PSU\&O$NF^%;KPSX%.FR:[
MY=GI]I/XVU30]/UJ]T[06\3ZSK,MYI,&L:G.3::-;6  G2T%G-\T_M >+OV(
MFTKPKK7[(.A?M'?#CXCZ#X@@N[RZ\?W/AMM'N=+2WFECU#3M6T7QYKVN:3XC
MTS4X;&2Q:SMH[*>VGO3,\$\%HS891X.?7<ORBKC<;FU+&YW@88ZE5P65TL5E
M660Q%/VN&I9EB)XNC7E5G!P=14*25*4W&4N2/M9=G%_TS/[%XBXPPV2Y+PEB
MLDX)SROD>)PN=<58K+.+.**N7XE87,\5PWE]#*,9@886C5C66&ECL4YXJG25
M6$/:SEA*?]LU4-3U33-$T^[U;6=1L-(TJPA:XOM2U.\M[#3[*!<!I[N\NY(K
M:WA4D!I)I$09&6&:^9OV(_BMXD^-O[*?P4^)GC"1)_%'B#PF]MKMZ@(.IZEX
M;UC5/"MSK$P+,%NM9?1#JMXL>V%;N\F$$4,(2)/R<_X+H^)_B/96?P(\*0W&
MH:=\(=<D\57^MRZ9/.T.M>,=,FT9+:RURR6X@MIAHFC7+W_AR"Z>%+VYU+6W
M1W;3?,M/SO(.$*^<<80X1KXNC@J\,=C\'BL3;VL82RV.(EB50IN5-UZD_JTX
MT8<T>9M2ERP4FOZ,X_\ &# <'>#M7Q>P.48O.\#6R/(,YRS+>?ZI4K4^)IY=
M3RYX[$*GB(X&A2_M.A4QE5PJ<BA*E34ZLZ:?ZX^)/VS?V4O#&@>(_$-S^T+\
M'M6@\+:;>:GJFF>%_B+X0\4>(FCL@WF6MCX>T+6+[5KZ_EE46\-G;VKRO.P1
M@BAV7F/V2OVT/AW^V/;?$35/AOX=\7Z)HOP_UG1=':[\86^DV5[K+ZQ875VM
MU;V&DZKK"6<$4EE/&BW%ZT\L+03R16TKRVL'X._MU_"/_@G9X+_9D^''B']F
MGQ1X9U+XH7NJ^'X+5]"\?ZAXG\2>)M"ETJ8^(]2\=>&[O6=33PY=17,5K<NA
MTWP\;+5IY=*L[1+4R6=O^E7A[2?BSXU_X)*^#M(N/B#X5^!WBC7OAO80>(?B
M#\0[V^\$:3I'P]G\7W++>W.H:79RSV]WXU\$C3+(7LEI(^OP^))YV9[_ %2*
M8_88_@OAS#</8#'89YU3Q&=\1T<@HXG/Z/\ 9U7*HTZBEB,:LIPL,3/,:,Z=
M.K2?^T0E2E4A"-)UXM/\>X?\:O$C-/$//\CS*/!6(RW@CPVQG'^-RS@#&/B/
M"<5U,1AW3R[)9\6YK5RVAP[BZ%?$X7%1O@*]+$T:%:O4Q,<#44X_H1J_[3G[
M-GA_59M#U[]H7X':)K=M,UM<:/J_Q9\!:;JL%PLK0-!-I][K\-W%,LZ/"T3P
MJXE1HRN]2!Z]HNMZ+XCTNRUSP]J^EZ]HNI1>?IVL:+?VFJ:7?P;VC\ZRU"QE
MGM+J+>CIYD$TB;T9=V5('\EOA#PC_P $O/ /P8\1^&/BK\2-=^,'QYU*QU^6
MR\;?"_3?BMIWA3PGJ,,UZGAK3_#BZ[H_A'2=92XMTT^XUN^U[0-:M#-<7=MI
M\D"6T=S-]??\$)O'WBF>]^/'PSN=3N+KP?8:?X2\8Z5I5Q-<RPZ/KEW>:KI.
MJ7&EPM/]FM%UJT2P_M8+;F2ZDTG3'$D?DRB=\0>&6$R[A_.<ZP&*SU?V'6PT
M*JSO)7E=#-*->M##RQ.5RG6==TJ=2HI?[11A*4%HK3I3GGX??2=S;B/Q!X+X
M)X@RK@.2XZP69XC"2X'XU7%./X5QN P5?,:>6<5PI8..!ABZ]"A*G_PGXNK"
MG5D^:7/1Q-"C^ZGA_P".GP2\6:SKWAWPK\8OA9XF\0>%K#5-5\3Z%X?^(/A+
M6=9\.:7HEU#8ZUJ6O:9IVKW-[I%AI%[<V]GJEYJ$%O;Z?=7$-O=R132HC,\)
M?'?X'^/]:;PWX$^,OPI\:^(D^T!] \)?$3PAXDUI#:I+)=!M*T;6+V^7[-'#
M-)<9@'DI%*\FU8W(_E _9M^!,G[2?[<WQ8^#UWXY\2^!O"'B?Q#\6)OB'+X5
MNC:ZKXF\&Z'XZCUV?PD&D$E@T.I:YIV@W>_5+/4K"SN--M]1;3;ZYLK:!O7?
M^"CG[&O@_P#85USX(_$_]GSQ;XVT.76M5UF.,ZEK2W&N>'?%/A-M*U72M?T+
M7;&UTZXB6YAU!XIK62,M:3Z=#-%/-'?RP6WH5?##AN&>8/AI\3XZGG>;9;#'
M9;1EE<:F%A*6%JU^7&XF-6"7M)4*_LX4H7C3IISJ.I5A3/G\+]*3Q*K\#9QX
MFQ\+\BK\$<)\25LCXEQD.**E#-*\(YK@\O53)<MJ82M)O#0S#!/$5L954*E?
M$2C1H*AAJU<_JKU'4M.T>PN]4U:_LM+TS3[>2ZO]1U&Z@L;"RM85+S7-W>7,
MD5O;6\2 M)--(D:*"S, ,UX[I7[37[-VNZM%H&B?M!_!#6==N)EMH-%TKXK^
M ]0U::X>5(5MXM.M-?FO))FFD2)8DA:0RND84NP!_%/_ (*:^+?BQ\<?V&OV
M3_BWX=76]0\&>(=#TSQ;\:8M M[R+2[7Q-J?A+0&L+K7+&WMX0NC:3XA7Q?8
MP7DT*Z/!>S63Q,WVK3I3^=FDK_P3K^)GP:\(^#B/B+^SI\?;%='@U[XH^)5\
M0?$CX=>(;T)8QZY<:EIVA:G<WFFZ==LE]-I*:1X/TB729[B"+4[K5+))+N#C
MX?\ "[#9CDU/,\PQV:RK3S/'97B,/D>6TLS>3U,#7JX>=;,Z/UF&-G"<J7M%
M3PF%J5HTJE&;A:IS1]GQ!^E/F/#O&>(X9X>R+A.&#H<,9'Q1EV8<<<3XGAB/
M&.'SS X3,:.#X9Q?]FU\DH5Z-+%?5Y8C.,UPV$GB\/BZ<:JE0Y*G]EU?&7[;
M/[5VB_LP_!KQMXAT+Q;\+5^,NG:+HVL^!_AQXZUZT&I>*+6^\5Z;H=[=VGA"
MS\1^'_%6M6-O8OK,RSZ1.D<5QID\DLKPV=W">X_8\\/ZAX5_9H^$7A[4/BII
M/QK;2O#D]MI_Q-T.:2XTKQ+X?_MG4Y/# M)IKB[GD71?#DFE>'I#/<23B;29
M!/LE#QK\+_\ !6[]F/X9>-O@AX[_ &D];'B$_$CX6^"?#?AWPM]DU9+?0!I]
M[\0[&*8ZCI9LY)+RXV^*=4*2+>0JI%L2A$3"3XWAG*\GGQK@<HS;$5<1EZSN
MG@85*&%DHX^I''PP^'IUL/B'2K4,+C9)1KJ:5>A2J2O#VD7$_:/$WBCC&CX)
MY[Q?PE@,)EW$,^":^>U</C\TI2GD&'JY%5S#,J^$S#+8XO!X_-<DI.=3 2H2
MG@,?B\/3<:_U>HJAZA^P%^WKIO[3GP[6Y^,'C'X)>#OC'J'C_6O#7A[X;^'/
M$,'A[7-;T2RT?0[_ $^_T[P?XH\8Z_XIU*>ZN;O6(_M5BSVD\>GND$"26ET[
M?G9_PO+XV?\ #X+_ (5G_P +A^*7_"M_^%R?V7_PK[_A8/BW_A"/[,_X0O[5
M_9W_  BG]K_V#]A^U?Z3]D^P?9_/_?>7YGS5T'_!'[]D3X1^._ ^C?M/:Z/$
M_P#PLWX??%WQ'I7A\V6M1V_A[[+IGAKP]+;&^TEK&5[F7=XAU 2.MY"' @&T
M&,E_C7XZ?#?4?C!_P5=\>?"_2_%E_P"!KGQU\5I/#DWBG3(I)]0TK3-0\&6\
M6M-:0QW5DTLMYH_VZP$;74,;BZ*S,82ZM^PY9D?"^'XR\0<MP'[G!4.%,W6*
M6+P,*F'R?$JO2C.>!IQE5JUZ.&H.-:%1<F(E)SA%)V;_ (WXHXX\4\P\&?H\
M\29__MF=9AXL<'3RIY3GM:AC^,<LE@<56HT<]Q%:&%PF"QN9XZ-3"5J$W5R^
ME!4:]63CSJ/]1=A^T+\ M5\3Q>"-,^.'P?U'QG<7JZ;!X1L/B7X+O/$\VHM*
M(5T^+0+?6I-5DO6F98EM4M&G,K",1ER!7K]?RA?\%+?V OA3^QWX2^%?C'X3
M^(_'5\/$WB+5?#FM6WC+5=(U2X%U9Z9%JFFZGIUSHV@>'UM7 @O([R)HI%:1
M[62V$ CD5OUZ\0ZU\2_CE_P2]\*ZM%\6/"?PM\5^-?@_X&B\<?%?X@^(M6T/
M2[71HI--L?%VH:AXAM(KZ]BU7QE:6<VF7;R13"^E\07MI%MN+FV9?S?-N",H
MIY=PQG&29[7Q.5<09K+**M?,, \/5P5>%9TI5WAZ%2M4JTDH5I^R@G4M"FH3
MJ2JVA_27"7CEQAB.(_$_@SCC@/ 99Q7X?\*T^,,)@.'<_AF.#SK 5L)'$T\!
M]?QU#!T,)BG+$8*E]<K.&&O6Q$ZU+#T\)SU_M+5_VG/V;/#^JS:'KW[0OP.T
M36[:9K:XT?5_BSX"TW58+A96@:";3[W7X;N*99T>%HGA5Q*C1E=ZD#O-2^)7
MPYT;P8_Q'UCQ_P""=*^'D<5K/)X]U+Q5H5CX,2"^U"#2;*9_%%U?Q:&L5YJE
MS;:;:R-?!+C4+B"SA9[F6.-OY3_"'A'_ ()>> ?@QXC\,?%7XD:[\8/CSJ5C
MK\MEXV^%^F_%;3O"GA/489KU/#6G^'%UW1_".DZREQ;II]QK=]KV@:U:&:XN
M[;3Y($MH[F;V3_@DSX4M/VC?AS^U!^RG\2]3UV[^$'B#3_AOXQ;2M+U6:QOM
M'US2O%ZZE+<:#<2K=V>G+K5SH.A_VX!I\LE]'I%DJR0%96E][-/##*L!E6/S
MB..XCHX+)<?E]+,:F:9$LO\ [0R_$XNCAL5C<DA5KJI5="-252G#%4Z?M'&,
M7:-2G4G\'PK]*'BK/N*\@X.J9%X<8W.N-L@X@Q?#F&X7X[EQ!_J_Q#EN48O,
M\LR3CBMA<!+#858ZIAZ>&Q-;*Z^)>&52I42G5P^(PU+Z^^#G_!5?7/&/[9/C
M7X.?$'7?V=_"W[/>B^+/BQI7ASXJ?VG>:'_:VA^%-1UFW\#:E_PG&M_$2Z\$
M7_\ PDEI9Z?/]LL=+BL]8^U>;H\=M%/ J_MEH^L:3XATG2]?T#5-.US0M<TZ
MRUC1=:T>]MM3TG6-)U.VBO=.U32]2LI9[/4-.U"SGAN[*]M)IK:[MIHIX)9(
MI$<_R!_L\_LH_"GXF?\ !0WXD?LR>)E\2'X:>&/'/QU\.Z5]@UE+3Q"NG_#S
M6/$%GX>,^JFRECFN/(TNV6^D-DJW+&5ECA++L_K@\ ^"]%^&_@3P5\._#GVO
M_A'O 7A+PYX+T'[?.+J^_L7PMH]GH>E_;;E8X5N;O[#8P?:9Q%$)IM\@C0-M
M'F^*>3<,9/B\EIY'"OA\1B,FP&)KX;ZO"GAJF'JQK>RQLJBJ3F\;B)Q:Q%+E
M5."A!QDVV?2?13XT\3^,\IXTQ/'-; YCEV7\99]EN"S)YA6Q&9X?,<)/ _6<
MCAAWA:-%9)E]&K&> Q;J2Q%:I6JQJTXJ,6?@)_P6:^-OQG^%WQD^$>E_#+XN
M_$_X=:9J7PSO+_4=.\">/O%?A&QO[Y?%.J6ZWM[:>']6T^WNKM;>..!;F>.2
M80HD0<(JJ/W1\6_'GX&^ -<3PQX[^,_PH\%>)9! 4\/>+?B+X0\-ZXXNEB>U
M*:3K.L65^PN4GA> BW(F6:)H]PD0G^=__@NK_P ER^"W_9*+[_U+]7KT+]K3
M_@E;\/\ X2?LN_$7XXZI\4OB+XX^.?AJSL_%OB[Q'KE]ITWAKQ7JVJ>(;&W\
M0!-+DTM]=M_.75)9[:_O?$6H7DUW;B>[ 2[>"V^EJ9!PUFW"OA=A\VS&IE%?
M,8YM@L-]1RV.(Q&88K%9C@J-.IB:Z<(4Z&%E[.$I5?:5&\3#V45"%64?S/#^
M('B9PGXL_2EQ_"'#>&XPP'#U3A+.LR_MWB6IEV7\/Y5E7#N=8S$X?+, XUJN
M(Q^;4WB*U*GA?J^'@LKJ_69SK5L)3G_1;:7=IJ%I:W]A=6][8WMO#=V5[:31
MW-I=VES&LUO=6MQ"SPW%O<0NDL,T3O'+&ZR1LRL"?,O&GQV^"'PWU'^Q_B)\
M9/A5X"U;9%)_9?C3XA^$?"VH^7/'YL,GV+7-8L;G9-$1+$WE;9(_G0E>:_,?
M_@C]XM\;^*OV&O&FF6^N0+K'@CXC?$3P?X OO$$TUQI>@Q-X*\'^*=(CO-Z7
M+1Z-I_B/Q3?W<UO'#*D5J\JQ0,,1G\O/A_\ #7]A3X;>//B1K/[;?[1&A?M&
M^+-2U)4L=,^#=[\7=>LWUF]EU:7Q1XD\2^---\/>&;+5[R*\_L[^S$TGQ9>6
M\DTEW)>6E[ $6+Y7 >'N%EG/%&68['9IB7P[B:>'HX7(,GJYCF>9JM5<85H4
MN=87!TX4^6=7ZSB%'FE*,:C5)RE^KY_](?-*7!OA;Q-D61<*Y9'Q&RVOF.,S
M7C[C'"\.<,<+O"8>G.M@ZV+5">9YO7KXEUJ.%_L[+W4Y*5*I4PZEB8TZ7]3W
MA#XB_#[X@Z5/KO@+QUX-\;Z);$+<ZSX0\3Z)XETJW8Q"<+/J.C7U[:1$P$3
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MHIJ3E-4O=\%OI&?\1*XSS;@+-L)PR\WP>1+B/+\ZX*SO&9WP]C\%#$X?"8S
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M\5^"-(\4ZCXJBDLM,CNO#]OX>U*XGU>SO#)>1Z<EI"UPLT,4C'\H_A#\/O\
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M;3YM;U.>]%KXW\0^(1I\_B6U_L6*ZDNKZVU*31].T*VTE?*\16-DK2V'6_\
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M7JPPN?)U)U*U2O6_MS$5<37@JBI2P-2-.,C\+O\ @NO_ ,D8^"'_ &4_5_\
MU%+RO,/VB/AA\4OB7_P2+_9:'PUT[6?$5KX/M?!_BOQMX8T#3I=0U*]\-6N@
M^*K'^VQ%:>9?W-IX<O[ZVN;^PM[:>+[+=2:W=&&+0/,']$%%>;E?B#5RK*.%
M\MH972J5>&L\KYS'$U\3ST\8L0L3&6&>&6&3H.,,3+DQ"Q%64)PC4C3322^C
MXI^CUA.+.+_%+B;'<58K#87Q-X&P/!E3+<%EBHXC)G@'EDZ>90S-YE*./A4J
MY9!ULOGE^%A5H5:F'J8F4')R_EY_93_:S\)V'P'T#]FWX*_L8W7CS]I+4+#7
M/#%[XIBTC0VT^;6]3GO1:^-_$/B$:?/XEM?[%BNI+J^MM2DT?3M"MM)7RO$5
MC9*TMAUO_!"+_DI?[0'_ &(W@[_T_P"IU_2S17HYIXD8/&Y7Q1EF$X:E@7Q1
M4PV(Q6+JY[B\PKT\31QDL74DUB<*J<\/*ZIX?#48X7ZNG4E.KB%*G"E\[PM]
M&O.<DXJ\+.)LW\2Z>=P\+,/F67Y7E&$X#RGA[ XG+,9DU/*</3C/+LUG7I9A
M!QEB<PS+&SS:68N.'ITL/E\J=>MBOY-O%GC?QE^P3_P4K^*OQK^(/PO\0ZWX
M?USXA?&+Q+H$222Z':>)?"_Q1U/Q#?:-J^@Z]<Z?>Z;?"T&IQ0WL40D$5[9Z
MCITSVUY;2+'_ %%_"GQY;_%/X7?#;XG6FG3:1:?$?P#X.\>6VDW,Z75QI=OX
MO\/:=X@ATZ>ZBCBCN9K*/45MI9XXHTF>)I$C16"COJ*^>XKXMP_%.'R>57)H
M8/-LMP.&R[$9E2Q]:K3QN%PM.4:,%@)T8T\+)5)SJ2G&M6G+FY'+EC&WZ%X3
M>$>8>%.8<84\+QG5SKA+B7/<QXCR_AK$Y!@\)B<DS7-:]*>,KSSZCC*N)S2$
M\/0H8:%">$PE&FJ7MHP]K.HY?S$?\%U?^2Y?!;_LE%]_ZE^KU^S'_!2/_DQ[
M]HC_ +$ZQ_\ 4HT"OM^BMZO&OM<)P'A?[,Y?]2,56Q//]=O_ &G[;'X+&\G+
M]47U+E^I^RYN;%W]IS\JY.27+@_!/ZKF_CUFO^LWM/\ B-^68'+O8?V-R?ZL
M?4LASK)/;>U_M:7]M>U_MCZU[/V>4\GU?V///VWM:7\[W_!._P '>.?B#_P2
MT_:R\%_#6XFA\;^(_B'\3M.T&*WE>"YU*:3X5?"9[O0;69"OEW7B/3DO- MG
M=XX5GU*,SRQ0>9(OQI^PU^TA\-_V2S\1_!'Q8_90\0?$GXRZOK5N?#?G>%],
MF\6:<;2V&FR>#;K3O$VF3ZSX=M6NVOKNXNM%L+V[OKF=+2_TRX6TM);?^NRB
MO=7B=1K2XIHX_AUXG+^)LRHYI/#4,ZQ& Q.&K4848*E/'X;"*IBL-+V$&Z7L
ML/9NHT[SNO@9?1@QV#I^%>,R#Q&65\0^&/#6+X7I9GCN"LNS_+<TP>+K8NK+
M%T,AS/-Y8?*LQA]>KQCBOK.8-J.'YHM45&7\HW['VH>,=8_X*[^%-:\?^"X/
MASXMUSQ+\5M=U;P%;;A'X/.M_ OQUJMCX>=&"/#<:5IMW9VEW;20VTMM=1S6
M\MG921-:0_9?_!;OX0WL>B_!K]I?PT'M=9\$ZV/ &O:A;N/M5O9WT]QXG\$:
M@@*%4BT;7;/7X6E+$F[U^R7RRNYE_>ZBL,1XF5:G%?#_ !/A\GIX2.29-A\E
MJY9#'3JT,;A:?UV-:*K5,,YT*=6GC7"G3JPQDJ,J-.I*K7EMW9=]&/"87PF\
M0_"_,.,<1FT^..,\PXVPO$U7(J.%QV29IB?[#J8.I+!8;,XT<=B,+B,DC5Q.
M(PM?)Z>,IXS$8>EA<#2^+^<[_@D%X.U[XX_M%_M ?MB>/H8KK5(KO5+'3K@0
MSPVH\<?$O4+C6O$,^D^65MTC\/\ ARW.C"RD9TMM.\56@CA!2&6*W_P4X_9\
M^-/PM_:B\(?MR_"/PW?^,-'TV^\ Z_XC32].N=5F\+>+/A[]@L;%]?T^QBEN
M?^$2UW1M(TBUDU8*8+>[^WV-])9FXTI[W^B:BLI>)6,7%U7B:CEF'A@JN60R
M-Y#5KRJX:.2JA2I3P$<1&C1E%2JTWB8U(T$H596=*=/FA+KI?1FR>7@_A?#+
M&<3YC5SK"<35N.8<>X7!0PF9SXUGCL5BJ.?U,NJ8S&0J2IX;$K+JE"ICYSK8
M:FIPQ5#$<E6E_.5\6/\ @L3\5/C!X8TGP!^RO\(O'7@CXR:OK6DQ3ZE#:Z!\
M2KVU"R21W?A_0?#%SX0U:/6+C5+IH+5+^^TFQN+>))A!8+<RI)!^U7[*-K\>
MK?X$>")_VF-?_M_XRZI;WVK^*F_LCPUHQT=-0U"YGT?P_+:>$M/TO16N]*T<
MV,.H306@<ZBUW$\LXA69_HNBO#SWB+)<?EN'RO(^$\!D%&GBI8NOBY8F6;9K
MB)N$J<:']IXC#4,12P45+F>%BY0E4C"=TU/G^YX#\.N-\@XDS#BGCGQ;S[C_
M !N)RFGD^"RFGE=+A/A3+Z,:U.O4Q_\ JSEV98[+L3G525+V:S62I5H4*U>A
MRRA*E['\@_\ @LU\'O&WQ-_9P\(^(/ ^AZMXFNOAO\0X=;U_1]%TVXU._C\,
M:IH&L:;?:XMO:"6[DATC4!I2WB0VTJQ6-]=:C<26]KITS-X;^Q+\4;/]M?\
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M$FTCPIH7B34-"T#1;/4M'%]?WD^F:E<ZL#&;^_TV>:Q_7FBJSKC/(\RPN;K
M\%9;E^:9Y65?'YKB,;4S6I1J.K*M7GE5#$X6G'*ZF(J3FZDZ%23Y)N-GR472
MSX)\%^.N&\TX0EGOC;Q+Q%PMP+@YX'(>%,OR7#\*8?&8>&%IX+ 4>*\=EF:8
MB?%-#+\-0H1P]+'X:'[VBJO-'VV,ABOYB/V./^4R?QJ_[*O^U?\ ^I%XQKU?
M_@O;_P VI?\ ==/_ 'CM?T045VKQ(MQAP_Q7_8W_ "(LFAE/U#^T?]ZY,#C\
M%]8^M?4?W%_KWM/9?5JUO9<GM'S\\/$E]&KF\'/$+PF_UTM_KYQG6XN_M_\
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MX6_L3^R.7^ROJF"RS"?7_P"TO[4E]>]I_9WM/JO]GX/D]MR?6)>SYI_SO_\
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MUC^R_## >&_]B?V/['V_U'%4L3_;/]I?VI5]E[7V7)_9WU"IR<W-]>G;E?\
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MZF*Q5>4*49XC$UZ\JE691117EGU(4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MV2Q<L/BE0:]OS\[P]7X>7EUNOVAHK_/G_P"$X\:?]#?XH_\ !_JW_P ET?\
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M_P ^?_A./&G_ $-_BC_P?ZM_\ET?\)QXT_Z&_P 4?^#_ %;_ .2Z/^)>J_\
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MJO\ ]%71_P##-/\ ^>?K_3T^<_XJ(X'_ *-/B_\ Q-*/_P!"Y_H,45_GS_\
M"<>-/^AO\4?^#_5O_DNC_A./&G_0W^*/_!_JW_R71_Q+U7_Z*NC_ .&:?_SS
M]?Z>A_Q41P/_ $:?%_\ B:4?_H7/]!BBO\^?_A./&G_0W^*/_!_JW_R71_PG
M'C3_ *&_Q1_X/]6_^2Z/^)>J_P#T5='_ ,,T_P#YY^O]/0_XJ(X'_HT^+_\
M$TH__0N?Z#%%?Y\__"<>-/\ H;_%'_@_U;_Y+H_X3CQI_P!#?XH_\'^K?_)=
M'_$O5?\ Z*NC_P"&:?\ \\_7^GH?\5$<#_T:?%_^)I1_^A<_T&**_P ^?_A.
M/&G_ $-_BC_P?ZM_\ET?\)QXT_Z&_P 4?^#_ %;_ .2Z/^)>J_\ T5='_P ,
MT_\ YY^O]/0_XJ(X'_HT^+_\32C_ /0N?Z#%%?Y\_P#PG'C3_H;_ !1_X/\
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MJO\ ]%71_P##-/\ ^>?K_3T^<_XJ(X'_ *-/B_\ Q-*/_P!"Y_H,45_GS_\
M"<>-/^AO\4?^#_5O_DNC_A./&G_0W^*/_!_JW_R71_Q+U7_Z*NC_ .&:?_SS
M]?Z>A_Q41P/_ $:?%_\ B:4?_H7/]!BBO\^?_A./&G_0W^*/_!_JW_R71_PG
M'C3_ *&_Q1_X/]6_^2Z/^)>J_P#T5='_ ,,T_P#YY^O]/0_XJ(X'_HT^+_\
M$TH__0N?Z#%%?Y\__"<>-/\ H;_%'_@_U;_Y+H_X3CQI_P!#?XH_\'^K?_)=
M'_$O5?\ Z*NC_P"&:?\ \\_7^GH?\5$<#_T:?%_^)I1_^A<_T&**_P ^?_A.
M/&G_ $-_BC_P?ZM_\ET?\)QXT_Z&_P 4?^#_ %;_ .2Z/^)>J_\ T5='_P ,
MT_\ YY^O]/0_XJ(X'_HT^+_\32C_ /0N?Z#%%?Y\_P#PG'C3_H;_ !1_X/\
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M .A<_P!!BBO\^?\ X3CQI_T-_BC_ ,'^K?\ R71_PG'C3_H;_%'_ (/]6_\
MDNC_ (EZK_\ 15T?_#-/_P">?K_3T/\ BHC@?^C3XO\ \32C_P#0N?Z#%%?Y
M\_\ PG'C3_H;_%'_ (/]6_\ DNC_ (3CQI_T-_BC_P '^K?_ "71_P 2]5_^
MBKH_^&:?_P \_7^GH?\ %1' _P#1I\7_ .)I1_\ H7/]!BBO\^?_ (3CQI_T
M-_BC_P '^K?_ "71_P )QXT_Z&_Q1_X/]6_^2Z/^)>J__15T?_#-/_YY^O\
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M !+U7_Z*NC_X9I__ #S]?Z>A_P 5$<#_ -&GQ?\ XFE'_P"A<_T&**_SY_\
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MZ#%%?Y\__"<>-/\ H;_%'_@_U;_Y+H_X3CQI_P!#?XH_\'^K?_)='_$O5?\
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M@Q17^?/_ ,)QXT_Z&_Q1_P"#_5O_ )+H_P"$X\:?]#?XH_\ !_JW_P ET?\
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M7^?/_P )QXT_Z&_Q1_X/]6_^2Z/^$X\:?]#?XH_\'^K?_)='_$O5?_HJZ/\
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M5T?_  S3_P#GGZ_T]#_BHC@?^C3XO_Q-*/\ ]"Y_H,45_GS_ /"<>-/^AO\
M%'_@_P!6_P#DNC_A./&G_0W^*/\ P?ZM_P#)='_$O5?_ **NC_X9I_\ SS]?
MZ>A_Q41P/_1I\7_XFE'_ .A<_P!!BBO\^?\ X3CQI_T-_BC_ ,'^K?\ R71_
MPG'C3_H;_%'_ (/]6_\ DNC_ (EZK_\ 15T?_#-/_P">?K_3T/\ BHC@?^C3
MXO\ \32C_P#0N?Z#%%?Y\_\ PG'C3_H;_%'_ (/]6_\ DNC_ (3CQI_T-_BC
M_P '^K?_ "71_P 2]5_^BKH_^&:?_P \_7^GH?\ %1' _P#1I\7_ .)I1_\
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M -"Y_H,45_GS_P#"<>-/^AO\4?\ @_U;_P"2Z/\ A./&G_0W^*/_  ?ZM_\
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M/A-_R63_ .R0\2?_ %W'%A^?=%%%?1GYL%%%% !1110 4444 %%%% !1110
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M@^#****^C/S8**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M^X/^";?_ "?#^SO_ -CA?_\ J*^(*^1/&?\ R.'BS_L9==_].EU7UW_P3;_Y
M/A_9W_['"_\ _45\05\B>,_^1P\6?]C+KO\ Z=+JOG*'_)79I_V3F0_^K/B,
M_2<?_P F?X5_[.3Q]_ZR_AJ<U1117T9^;!1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% 'Z"?L+?\BA^W5_V9/\ $[_U(?!U?GW7Z"?L+?\
M(H?MU?\ 9D_Q._\ 4A\'5^?=?-Y5_P C[BK_ +",H_\ 550/TGBO_D@?"O\
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M+$9ECL5^[Q$Y.CAL#A,1B:DTFO9TIVO*R?Q#1117U)^5A1110 4444 %%%%
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MJ/\ RBU\,_\ 9]7B'_U16EU^?=?H)J/_ "BU\,_]GU>(?_5%:77SG$/Q\/\
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M6?$9^DX__DS_  K_ -G)X^_]9?PU.:HHHKZ,_-@HHHH **** "BBB@ HHHH
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M1/ /CR[U+3/#_C[X1>+IO&/A*;6-):07NCS:A=:1HDZ7\8@NBOE6DUH[6-]
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M;G4;'5-.O+!]4O(94N(OGOP1_P % OCY\/OCC\5/CKX;7P5#JGQINI;GXC^
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M9[N2WU2&)UCEEL)+=IFA\&^''_!/;X:QZQ_P4L^%=UX9U7XN>.O@'X:\&'X
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M3KXF$\1.CAZ]6-)3E3HU9I0E\9T5_03\.OV?_P#@GC^U%\7OCA^ROX ^ /Q
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MABN]/N9#^&/QH_;?^+?QB\)_#_X?VN@?#/X.?#_X8^)U\;^#_!/P/\(S>!M
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MX11IX+-L7DV:X7*ZU+$UJF*KX&K!48<]%U?B^BONJ?\ X)H?MR6^G^(]3?\
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M>\? !1110!^@G["W_(H?MU?]F3_$[_U(?!U?GW7Z"?L+?\BA^W5_V9/\3O\
MU(?!U?GW7S>5?\C[BK_L(RC_ -55 _2>*_\ D@?"O_L XN_]:K&!1117TA^;
M!1110 4444 ?MQ_P2?T[P5J_P"_X*)Z5\2/$%[X3^'VH_#+X?V7C7Q/IME<:
MEJ&@>%KG0/CA%KFKV-A:6.IW-Y=Z?IS7%S;VUOIU_+-+&J1V=PQ$3^H_$/1/
MAI\)O^"7OQ@L/V+?&NI?'/X6^-OBA;#XK^//$<QT;Q%X#2XG\#Z5?6EOX)O_
M  9H5[Y%_'I'AS3KEM0M[/4;.P\2'Q+9376G&SGT_P#(CX+?M1>/_@3\./CW
M\,/".C^#M1T#]HGPG8^#O&UYXCT_6KO6-+TRPTWQ;I<,_A:XTSQ!I%E97[6_
MC+5'EEU;3];MVF@L&2U1(KB.ZT/@]^UM\2_@O\'OC7\#- TKP9K_ (#^.FDR
MZ;XDMO%FF:S?7WA^XGT?4-%FUSPC<:3X@T2WLM:DM[NQN#-K-IKUDEYH&BRQ
MV*)%?17_ .4YIP=G&*S_ #7.J-=U</4XEX7S7#Y/5Q%".79AALKP.687%U\2
ME06)I8W"U,/5K81/%+#5/8057#5HU'%_UCPKXS<&Y7X?\*<$XS QPN88?PS\
M4^%,PXQPN7XVKQ#P_F?%.><2YIE."RV<L<\LQ.29IAL?A,'G$EE<LRPZQM:>
M#S'!SP_.OVZM/AI^Q;^RA\)/V8-)\=6W[/7]L?%?P?HWBWQ3K?QC_9H^('[0
M?BWXE7&HV/AB[UR#P!KOA"ZEM?A^(&UO[#HUM/9:[#$M]I-U#I-]<6U_-JO
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MTWXAVFK07TL'G1+)#JZ01FX>Y2V6]BM+FV^+/V=_VAO$G[-'Q;L?C+X&\)>
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M!7[/'[3'_!/CQMXGUWQ%\+FT^?Q-#XM^ 'B[XMZM\5?"GP#L_$?A.'0M-O\
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MX)M]=^N_7_\ 5VA6H?VG?ZIA/JOUSVW-]2MB/J_+R_6Z][HHHHKW3X0****
M"OT&_;9_Y)9^P5_V:;H/_J6^)*_/FOT&_;9_Y)9^P5_V:;H/_J6^)*^;S;_D
M>\*?]AF:_P#JFQA^D\(_\D-XL?\ 8DX6_P#6UR0_/FBBBOI#\V"BBB@ K]$/
M^"47_)_?P$_[JE_ZI?XBU^=]%>;G67?VOD^;93[;ZO\ VIEF/R[ZQ[/VWL/K
MN%JX;VWLN>E[7V7M>?V?M*?/R\O/"_,OIN"N(O\ 4_C+A+BWZG_:/^J_$V0\
M1?V?]8^J?7O[$S7"9G]3^M^PQ7U7ZU]5]A]8^K8CV//[3V%7E]G+]DOVBO\
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M\$J*^MP' <,-B\)C<7F,<77IU^*L7BU3P"PU*KBN*)X"52I@H2Q>)EE\,%'
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M9]K3JJT5A<+BZDE)TFE_5/!GT;Z/&G GA]QG@^*:6"_MW,LZJ\;83&0H4_\
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M"-[%<6EK-:7MJ\;%_BG1[5K'_@DY^VU9/=W>H/9_MF36KW]^\4E]>M;Z_P#
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M3P4I1>(G2Q.7UX8S"X.IB<;E\'1K9AA<+0K4ZC^4:***^E/S(**** "BBB@
MHHHH **** "BBB@ K_0&^%W_ "3/X=_]B+X1_P#4?T^O\_FO] ;X7?\ ),_A
MW_V(OA'_ -1_3Z_G/Z0G^Z<+?]A&;?\ IO+S_2#]GA_R-?%3_L7\(_\ J3Q"
M=U1117\QG^H 5^)W_!<[_DV[X4_]EOL/_4#\<5^V-?B=_P %SO\ DV[X4_\
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M@ HHHH **** "BBB@#2T;_D,:5_V$K'_ -*HJ^X?^"G?_)]G[0?_ &'?"O\
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M110 4444 %%%% !1110 5^@W[;/_ "2S]@K_ +--T'_U+?$E?GS7Z#?ML_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ K_ $!OA=_R3/X=_P#8B^$?_4?T^O\ /YK_ $!O
MA=_R3/X=_P#8B^$?_4?T^OYS^D)_NG"W_81FW_IO+S_2#]GA_P C7Q4_[%_"
M/_J3Q"=U1117\QG^H 5^)W_!<[_DV[X4_P#9;[#_ -0/QQ7[8UX%^T-^S/\
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ML-_]"!XK_P##C>,/_EG1_P 1WX+_ .@7/_\ PAP?_P \@_XD*\:O^AIX?_\
MA\SK_P"AH_CZHK^P7_AT#^PW_P!"!XK_ /#C>,/_ )9T?\.@?V&_^A \5_\
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MLZ/^'0/[#?\ T('BO_PXWC#_ .6='_$=^"_^@7/_ /PAP?\ \\@_XD*\:O\
MH:>'_P#X?,Z_^AH_CZHK^P7_ (= _L-_]"!XK_\ #C>,/_EG1_PZ!_8;_P"A
M \5_^'&\8?\ RSH_XCOP7_T"Y_\ ^$.#_P#GD'_$A7C5_P!#3P__ /#YG7_T
M-'\?5%?V"_\ #H']AO\ Z$#Q7_X<;QA_\LZ/^'0/[#?_ $('BO\ \.-XP_\
MEG1_Q'?@O_H%S_\ \(<'_P#/(/\ B0KQJ_Z&GA__ .'S.O\ Z&C^/JBO[!?^
M'0/[#?\ T('BO_PXWC#_ .6='_#H']AO_H0/%?\ X<;QA_\ +.C_ (COP7_T
M"Y__ .$.#_\ GD'_ !(5XU?]#3P__P##YG7_ -#1_'U17]@O_#H']AO_ *$#
MQ7_X<;QA_P#+.C_AT#^PW_T('BO_ ,.-XP_^6='_ !'?@O\ Z!<__P#"'!__
M #R#_B0KQJ_Z&GA__P"'S.O_ *&C^/JBO[!?^'0/[#?_ $('BO\ \.-XP_\
MEG1_PZ!_8;_Z$#Q7_P"'&\8?_+.C_B._!?\ T"Y__P"$.#_^>0?\2%>-7_0T
M\/\ _P /F=?_ $-'\?5%?V"_\.@?V&_^A \5_P#AQO&'_P LZ/\ AT#^PW_T
M('BO_P .-XP_^6='_$=^"_\ H%S_ /\ "'!__/(/^)"O&K_H:>'_ /X?,Z_^
MAH_CZHK^P7_AT#^PW_T('BO_ ,.-XP_^6='_  Z!_8;_ .A \5_^'&\8?_+.
MC_B._!?_ $"Y_P#^$.#_ /GD'_$A7C5_T-/#_P#\/F=?_0T?Q]45_8+_ ,.@
M?V&_^A \5_\ AQO&'_RSH_X= _L-_P#0@>*__#C>,/\ Y9T?\1WX+_Z!<_\
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M'_$=^"_^@7/_ /PAP?\ \\@_XD*\:O\ H:>'_P#X?,Z_^AH_CZHK^P7_ (=
M_L-_]"!XK_\ #C>,/_EG1_PZ!_8;_P"A \5_^'&\8?\ RSH_XCOP7_T"Y_\
M^$.#_P#GD'_$A7C5_P!#3P__ /#YG7_T-'\?5%?V"_\ #H']AO\ Z$#Q7_X<
M;QA_\LZ/^'0/[#?_ $('BO\ \.-XP_\ EG1_Q'?@O_H%S_\ \(<'_P#/(/\
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M?^'0/[#?_0@>*_\ PXWC#_Y9T?\ #H']AO\ Z$#Q7_X<;QA_\LZ/^([\%_\
M0+G_ /X0X/\ ^>0?\2%>-7_0T\/_ /P^9U_]#1_'U17]@O\ PZ!_8;_Z$#Q7
M_P"'&\8?_+.C_AT#^PW_ -"!XK_\.-XP_P#EG1_Q'?@O_H%S_P#\(<'_ //(
M/^)"O&K_ *&GA_\ ^'S.O_H:/X^J*_L%_P"'0/[#?_0@>*__  XWC#_Y9T?\
M.@?V&_\ H0/%?_AQO&'_ ,LZ/^([\%_] N?_ /A#@_\ YY!_Q(5XU?\ 0T\/
M_P#P^9U_]#1_'U17]@O_  Z!_8;_ .A \5_^'&\8?_+.C_AT#^PW_P!"!XK_
M /#C>,/_ )9T?\1WX+_Z!<__ /"'!_\ SR#_ (D*\:O^AIX?_P#A\SK_ .AH
M_CZHK^P7_AT#^PW_ -"!XK_\.-XP_P#EG1_PZ!_8;_Z$#Q7_ .'&\8?_ "SH
M_P"([\%_] N?_P#A#@__ )Y!_P 2%>-7_0T\/_\ P^9U_P#0T?Q]45_8+_PZ
M!_8;_P"A \5_^'&\8?\ RSH_X= _L-_]"!XK_P##C>,/_EG1_P 1WX+_ .@7
M/_\ PAP?_P \@_XD*\:O^AIX?_\ A\SK_P"AH_CZHK^P7_AT#^PW_P!"!XK_
M /#C>,/_ )9T?\.@?V&_^A \5_\ AQO&'_RSH_XCOP7_ - N?_\ A#@__GD'
M_$A7C5_T-/#_ /\ #YG7_P!#1_'U7Z":C_RBU\,_]GU>(?\ U16EU_0#_P .
M@?V&_P#H0/%?_AQO&'_RSKOI/^"<_P"RI/\ #&W_ &?)/!'B0_#>P\;3?%ZW
MM?\ A,_%BW(\9W^B#PA/.=8\X2R0?V+:1)_9PU%TC<BY>SC,D<\OD9MXT\(X
MV65.CAL[2P6;X7'5N?!X2-Z-&GB(34+9A+FJ7JQY8OE32=Y)I)_7\)?0G\7<
MCI\5QQF9<#R>=\(9ID6#]AG.;S4<;C<3E]:C*OS\/T^3#J&%J<\X>TG&3@E3
MDFW'^+RBO[!?^'0/[#?_ $('BO\ \.-XP_\ EG1_PZ!_8;_Z$#Q7_P"'&\8?
M_+.O7_XCOP7_ - N?_\ A#@__GD?(?\ $A7C5_T-/#__ ,/F=?\ T-'\?5%?
MV"_\.@?V&_\ H0/%?_AQO&'_ ,LZ/^'0/[#?_0@>*_\ PXWC#_Y9T?\ $=^"
M_P#H%S__ ,(<'_\ /(/^)"O&K_H:>'__ (?,Z_\ H:/X^J*_L%_X= _L-_\
M0@>*_P#PXWC#_P"6='_#H']AO_H0/%?_ (<;QA_\LZ/^([\%_P#0+G__ (0X
M/_YY!_Q(5XU?]#3P_P#_  ^9U_\ 0T?Q]45_8+_PZ!_8;_Z$#Q7_ .'&\8?_
M "SH_P"'0/[#?_0@>*__  XWC#_Y9T?\1WX+_P"@7/\ _P (<'_\\@_XD*\:
MO^AIX?\ _A\SK_Z&C^/JBO[!?^'0/[#?_0@>*_\ PXWC#_Y9T?\ #H']AO\
MZ$#Q7_X<;QA_\LZ/^([\%_\ 0+G_ /X0X/\ ^>0?\2%>-7_0T\/_ /P^9U_]
M#1_'U17]@O\ PZ!_8;_Z$#Q7_P"'&\8?_+.C_AT#^PW_ -"!XK_\.-XP_P#E
MG1_Q'?@O_H%S_P#\(<'_ //(/^)"O&K_ *&GA_\ ^'S.O_H:/X^J*_L%_P"'
M0/[#?_0@>*__  XWC#_Y9T?\.@?V&_\ H0/%?_AQO&'_ ,LZ/^([\%_] N?_
M /A#@_\ YY!_Q(5XU?\ 0T\/_P#P^9U_]#1_'U17]@O_  Z!_8;_ .A \5_^
M'&\8?_+.C_AT#^PW_P!"!XK_ /#C>,/_ )9T?\1WX+_Z!<__ /"'!_\ SR#_
M (D*\:O^AIX?_P#A\SK_ .AH_CZHK^P7_AT#^PW_ -"!XK_\.-XP_P#EG1_P
MZ!_8;_Z$#Q7_ .'&\8?_ "SH_P"([\%_] N?_P#A#@__ )Y!_P 2%>-7_0T\
M/_\ P^9U_P#0T?Q]45_8+_PZ!_8;_P"A \5_^'&\8?\ RSH_X= _L-_]"!XK
M_P##C>,/_EG1_P 1WX+_ .@7/_\ PAP?_P \@_XD*\:O^AIX?_\ A\SK_P"A
MH_CZK]!OVV?^26?L%?\ 9IN@_P#J6^)*_?\ _P"'0/[#?_0@>*__  XWC#_Y
M9UWWC/\ X)T_LJ?%;3?!7AWQ?X(\23Z;\&O#-K\-/!*P^,_%FGM#X8M0FN0I
M-,DUH=3D6[UBYC:^:2^W-&T7VPR1R6\'D8[QIX2Q.9Y'C*>&SM4LNQ&-JXA2
MP>$4W'$9?B,+3]DEF#4FJE6+DI2@E"[3;23^OR'Z$_B[EG#7'&48C,N!Y8KB
M/+<EPF E2SG-I485<NXBRW-:[Q,Y</PG3A+#82K&FZ=.JY5G"$HPBW./\7E%
M?V"_\.@?V&_^A \5_P#AQO&'_P LZ/\ AT#^PW_T('BO_P .-XP_^6=>O_Q'
M?@O_ *!<_P#_  AP?_SR/D/^)"O&K_H:>'__ (?,Z_\ H:/X^J*_L%_X= _L
M-_\ 0@>*_P#PXWC#_P"6='_#H']AO_H0/%?_ (<;QA_\LZ/^([\%_P#0+G__
M (0X/_YY!_Q(5XU?]#3P_P#_  ^9U_\ 0T?Q]45_8+_PZ!_8;_Z$#Q7_ .'&
M\8?_ "SH_P"'0/[#?_0@>*__  XWC#_Y9T?\1WX+_P"@7/\ _P (<'_\\@_X
MD*\:O^AIX?\ _A\SK_Z&C^/JBO[!?^'0/[#?_0@>*_\ PXWC#_Y9T?\ #H']
MAO\ Z$#Q7_X<;QA_\LZ/^([\%_\ 0+G_ /X0X/\ ^>0?\2%>-7_0T\/_ /P^
M9U_]#1_'U17]@O\ PZ!_8;_Z$#Q7_P"'&\8?_+.C_AT#^PW_ -"!XK_\.-XP
M_P#EG1_Q'?@O_H%S_P#\(<'_ //(/^)"O&K_ *&GA_\ ^'S.O_H:/X^J*_L%
M_P"'0/[#?_0@>*__  XWC#_Y9T?\.@?V&_\ H0/%?_AQO&'_ ,LZ/^([\%_]
M N?_ /A#@_\ YY!_Q(5XU?\ 0T\/_P#P^9U_]#1_'U17]@O_  Z!_8;_ .A
M\5_^'&\8?_+.C_AT#^PW_P!"!XK_ /#C>,/_ )9T?\1WX+_Z!<__ /"'!_\
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M7@'Q4);>6.:,GXB^+V DB=9$)4ZG@@,H)!X/0UVGQ*_X)P_LH?'WQMKGQ?\
MB+X(\27/C3QL]C?:[/;>-/%FD0O/8Z99:/;A--CGT];398Z=:QM&;*UD+JSR
MPI*[BO(K>-/",\^R_,HX;._J^%RC.,#4B\'A/:NMC\9D>(HN,?[0<734,NQ"
MJ2<TXR=-*,E*3C]?A/H3^+M#@'B#AB>9<#O,<TXOX/S[#3CG.;/"QP60Y-QQ
ME^-A5J/A]5(XB=?B/ /#PC1G"=.&)E.K2E3IQK?Q@T5_8+_PZ!_8;_Z$#Q7_
M .'&\8?_ "SH_P"'0/[#?_0@>*__  XWC#_Y9UZ__$=^"_\ H%S_ /\ "'!_
M_/(^0_XD*\:O^AIX?_\ A\SK_P"AH_CZHK^P7_AT#^PW_P!"!XK_ /#C>,/_
M )9T?\.@?V&_^A \5_\ AQO&'_RSH_XCOP7_ - N?_\ A#@__GD'_$A7C5_T
M-/#_ /\ #YG7_P!#1_'U17]@O_#H']AO_H0/%?\ X<;QA_\ +.C_ (= _L-_
M]"!XK_\ #C>,/_EG1_Q'?@O_ *!<_P#_  AP?_SR#_B0KQJ_Z&GA_P#^'S.O
M_H:/X^J*_L%_X= _L-_]"!XK_P##C>,/_EG1_P .@?V&_P#H0/%?_AQO&'_R
MSH_XCOP7_P! N?\ _A#@_P#YY!_Q(5XU?]#3P_\ _#YG7_T-'\?5%?V"_P##
MH']AO_H0/%?_ (<;QA_\LZ/^'0/[#?\ T('BO_PXWC#_ .6='_$=^"_^@7/_
M /PAP?\ \\@_XD*\:O\ H:>'_P#X?,Z_^AH_CZHK^P7_ (= _L-_]"!XK_\
M#C>,/_EG1_PZ!_8;_P"A \5_^'&\8?\ RSH_XCOP7_T"Y_\ ^$.#_P#GD'_$
MA7C5_P!#3P__ /#YG7_T-'\?5%?V"_\ #H']AO\ Z$#Q7_X<;QA_\LZ/^'0/
M[#?_ $('BO\ \.-XP_\ EG1_Q'?@O_H%S_\ \(<'_P#/(/\ B0KQJ_Z&GA__
M .'S.O\ Z&C^/JBO[!?^'0/[#?\ T('BO_PXWC#_ .6='_#H']AO_H0/%?\
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MPZ!_8;_Z$#Q7_P"'&\8?_+.C_B._!?\ T"Y__P"$.#_^>0?\2%>-7_0T\/\
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M $-/#_\ \/F=?_0T?Q]45_8+_P .@?V&_P#H0/%?_AQO&'_RSH_X= _L-_\
M0@>*_P#PXWC#_P"6='_$=^"_^@7/_P#PAP?_ ,\@_P")"O&K_H:>'_\ X?,Z
M_P#H:/X^J*_L%_X= _L-_P#0@>*__#C>,/\ Y9T?\.@?V&_^A \5_P#AQO&'
M_P LZ/\ B._!?_0+G_\ X0X/_P">0?\ $A7C5_T-/#__ ,/F=?\ T-'\?5%?
MV"_\.@?V&_\ H0/%?_AQO&'_ ,LZ/^'0/[#?_0@>*_\ PXWC#_Y9T?\ $=^"
M_P#H%S__ ,(<'_\ /(/^)"O&K_H:>'__ (?,Z_\ H:/X^J*_L%_X= _L-_\
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MJKG3I.-1.,5.*4W_ !]45_8+_P .@?V&_P#H0/%?_AQO&'_RSH_X= _L-_\
M0@>*_P#PXWC#_P"6=>O_ ,1WX+_Z!<__ /"'!_\ SR/D/^)"O&K_ *&GA_\
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M?V&_^A \5_\ AQO&'_RSH_XCOP7_ - N?_\ A#@__GD'_$A7C5_T-/#_ /\
M#YG7_P!#1_'U17]@O_#H']AO_H0/%?\ X<;QA_\ +.C_ (= _L-_]"!XK_\
M#C>,/_EG1_Q'?@O_ *!<_P#_  AP?_SR#_B0KQJ_Z&GA_P#^'S.O_H:/X^J*
M_L%_X= _L-_]"!XK_P##C>,/_EG1_P .@?V&_P#H0/%?_AQO&'_RSH_XCOP7
M_P! N?\ _A#@_P#YY!_Q(5XU?]#3P_\ _#YG7_T-'\?5%?V"_P##H']AO_H0
M/%?_ (<;QA_\LZ/^'0/[#?\ T('BO_PXWC#_ .6='_$=^"_^@7/_ /PAP?\
M\\@_XD*\:O\ H:>'_P#X?,Z_^AH_CZHK^P7_ (= _L-_]"!XK_\ #C>,/_EG
M1_PZ!_8;_P"A \5_^'&\8?\ RSH_XCOP7_T"Y_\ ^$.#_P#GD'_$A7C5_P!#
M3P__ /#YG7_T-'\?5%?V"_\ #H']AO\ Z$#Q7_X<;QA_\LZ/^'0/[#?_ $('
MBO\ \.-XP_\ EG1_Q'?@O_H%S_\ \(<'_P#/(/\ B0KQJ_Z&GA__ .'S.O\
MZ&C^/JBO[!?^'0/[#?\ T('BO_PXWC#_ .6='_#H']AO_H0/%?\ X<;QA_\
M+.C_ (COP7_T"Y__ .$.#_\ GD'_ !(5XU?]#3P__P##YG7_ -#1_'U17]@O
M_#H']AO_ *$#Q7_X<;QA_P#+.C_AT#^PW_T('BO_ ,.-XP_^6='_ !'?@O\
MZ!<__P#"'!__ #R#_B0KQJ_Z&GA__P"'S.O_ *&C^/JBO[!?^'0/[#?_ $('
MBO\ \.-XP_\ EG1_PZ!_8;_Z$#Q7_P"'&\8?_+.C_B._!?\ T"Y__P"$.#_^
M>0?\2%>-7_0T\/\ _P /F=?_ $-'\?5%?V"_\.@?V&_^A \5_P#AQO&'_P L
MZ/\ AT#^PW_T('BO_P .-XP_^6='_$=^"_\ H%S_ /\ "'!__/(/^)"O&K_H
M:>'_ /X?,Z_^AH_CZHK^P7_AT#^PW_T('BO_ ,.-XP_^6='_  Z!_8;_ .A
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MET>/PY=?V58V5G>W4UYJ[ZC>1PQ6!D:US<!(N.?CWX4TLIEG-;B7$T,+#B#
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M#BC7^ZL6DV40&/+B*;9'WZP/"H4>'M)"*JI]D7:%$:KM+.5($4-O& 1@_+$
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M==N[1I;*/2UO[R/2K"]DM/M.ES:2NGS2( ;CP](8I;>X6&9=7XP?LK>+[?\
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M?2+'1[3Q,^C7RZ!#H[:W'K7GZJ+JQB_L+64$;:?+::S<:?':R@:D)PGDP/\
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MW\7FN0OA_29!#Y\K)'YFHZTIE%L=6>&)Y?+"M.FAVLMP(5CDU:^2VBL].WZ
M"BOR8_;4_P""B/Q]_9]_:S^!7['?[-?[&.F?M8?$[XW?"3Q_\7;4:O\ M+Z!
M^SU9Z#HWP]UBUTO5[5KCQ)\+_'&F:G(\5W'=QR-J^ES9S;PV5P<RKH_LJ_\
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MX%^!OP0_X*"?\%N?V5/!OPJ^'_P3_;H^)&J_&RZ_X)F6<7P&;P_J7A?PI/\
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M^"$_PW\;^%/BO\>7_:^^(7QP\-?M$_#CP=\7M&^#?Q _:<\(?LNR>/M-\%^
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M^3K7G_V9#]*_M1?&K_AFS]F;]HK]HO\ X1K_ (33_A07P*^+GQJ_X0[^V?\
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ME)2E"2G7<X<R@K)TZD:?-&G;ENN5I6?\Z?P?_9X^-_[-_P"VK^QC\0?V8?\
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MQ6_^5_U=^5OUH_X;Q^$/_0N?$C_P4>&/_FPH_P"&\?A#_P!"Y\2/_!1X8_\
MFPK\EZ*/^*F/TH_^AKP7_P"(?@__ )H_J[\K'_$M'A?_ - F=?\ AXK?_*_Z
MN_*WZT?\-X_"'_H7/B1_X*/#'_S84?\ #>/PA_Z%SXD?^"CPQ_\ -A7Y+T4?
M\5,?I1_]#7@O_P 0_!__ #1_5WY6/^):/"__ *!,Z_\ #Q6_^5_U=^5OUH_X
M;Q^$/_0N?$C_ ,%'AC_YL*/^&\?A#_T+GQ(_\%'AC_YL*_)>BC_BIC]*/_H:
M\%_^(?@__FC^KORL?\2T>%__ $"9U_X>*W_RO^KORM^M'_#>/PA_Z%SXD?\
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M $+GQ(_\%'AC_P";"OR7HH_XJ8_2C_Z&O!?_ (A^#_\ FC^KORL?\2T>%_\
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M/_FPK\EZ*/\ BIC]*/\ Z&O!?_B'X/\ ^:/ZN_*Q_P 2T>%__0)G7_AXK?\
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M,?\ S84?\-X_"'_H7/B1_P""CPQ_\V%?DO11_P 5,?I1_P#0UX+_ /$/P?\
M\T?U=^5C_B6CPO\ ^@3.O_#Q6_\ E?\ 5WY6_6C_ (;Q^$/_ $+GQ(_\%'AC
M_P";"C_AO'X0_P#0N?$C_P %'AC_ .;"OR7HH_XJ8_2C_P"AKP7_ .(?@_\
MYH_J[\K'_$M'A?\ ] F=?^'BM_\ *_ZN_*WZT?\ #>/PA_Z%SXD?^"CPQ_\
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M_A?4;+]H^V?P[XLU^#PI;>-Y_A;\;;/X<>'/%-WKO_".67AGXD_$N]^&UOX
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M:]XB\!>"? >F_#JS'BJ\T73M!TZ[U?5_#VF1_P!N7.DZ1HME<7EQ=2V&G:=
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M5&HHR:3=-RU<5U5_U<HK^8G]N;]HK]J3XC?%#_@DMX"_:G_8FU?]EKQ!>?\
M!63]ESQWX0UWPQ\;/"W[1GPSUC3M(\ _&O1]?\*>(_'?AGPKX';P7\2].N_%
M6DW6G^%;W0-1TCQ5HL'B'5O"GBS68_"VO0V7].U*OAI4(492E&3JJ;M"4*D4
MH3Y-*E.<X3OK>S]UIQ>J95*O&M*HHQDE3<5><9PD^:"EK"<82C:_5:K5:,**
M**YC8**** "BBB@ KR'XT>.]-^&GA:W\;:E#'<#1+Z\?3K=X8I&N=8N_#NO6
M6EVL4CZ9?2VWVJ[N([>XN;6]T2>*RDNBVH7%M]HT?5/7J_.?]OKQ3*EKX!\%
M19$-Q-J7B>^Y&&>U1=*TP =3M%WJI?.!DQ%<D$K^"?2>\5J_@KX%>(7B%@'3
M6<Y5E%/ \/>UA[6$>(,]QF&R3)Z\Z35JU/ XW,*>85Z4FHU*&$JPE))W/O?#
M'A6GQIQUP]P]74OJ>*Q<J^8<LN5O+\#1J8[&4U-:PE7HX>6'A-7<:E6+2;1^
M>7B3Q%K'BW7=4\2:_>RZAK&LW<E[?W<I^:2:3 "HHPL4$,:I!;01A8K>WCB@
MB58XT48E%%?\I>-QN,S+&8O,<PQ6(QV88_%8C&X[&XNM4Q&+QF,Q56=?$XK$
MXBK*=6OB,16J3K5JU24JE6I.4YR<I-O_ %6H4*.&HT<-AZ5.AA\/2IT*%"C"
M-.E1HTH*G2I4J<$H4Z=.$8PA"*48Q2C%))(***\:^(G[1O[/?PAUNU\-?%GX
M[_!KX7^([[2X-<LM ^(GQ0\$>"M;O-$N;N^L+;6+72O$NN:9?7&EW%]IFI64
M&H10/:2W>GWUM',TUI.D?3E639QGV,CE^1Y5F6<X^5.=6.!RK XK,<9*E22=
M2I'#8.E6K.G333G-0Y8)IR:3,\7C<'E]%XC'XO"X+#J48.OB\12PU%3F[0BZ
MM:<(*4GI&/->3T29[+17A=E^U#^S/J7A6;QUIW[1/P+U#P3;^([/P=/XQLOB
MWX NO"L/B[4;;[;I_A:;Q#!X@DTB/Q'?6?\ I=GH;WBZG=6W[^"U>+YZO_$3
M]HW]GOX0ZW:^&OBS\=_@U\+_ !'?:7!KEEH'Q$^*'@CP5K=YHES=WUA;:Q:Z
M5XEUS3+ZXTNXOM,U*R@U"*![26[T^^MHYFFM)TC]6/!/&<\=#+(<(\3SS*I/
M%TZ>7QR#-98Z<\!##U,="&$6$>(E/!4\7A9XN,:;>'AB</*LH1K4W+D>>9)&
M@\4\XRM86*HREB7F&$5",<1*I'#R=9UO9I5Y4JL:+<K594JBAS.$K>RT5YWX
M8^+_ ,)O&WA+4O'W@SXH?#OQ;X%T:WO;S6/&OACQMX:U[PEI5IIMHU_J-UJ7
MB/2M3N]'L;>PL4>]O9[J\BBM;16N)VCA4N/)K?\ ;9_8RNIX;6U_:X_9BN;F
MYECM[>WM_CW\*IIYYYG6.&&&&/Q6TDLLLC*D<:*SN[*JJ6(%/!\#\:9A6S##
MX#A#BC'5\IK+#YI0P?#^;8FMEM=QE-4,PIT<).>#K.$925/$1IS<8RDHV38J
MV>Y'AX8>IB,YRJA3QD/:82I6S'"4H8JG=1]IAY3K1C7A>45STG*-VE>[1].T
M5X7XX_:A_9G^&/B.[\'_ !)_:)^!?P]\6V$5I<7WA;QQ\6_ 'A/Q'907]M'>
M6,UWHFO>(-/U.VBO;2:*ZM))K5$N+:6.>%GB=6-_3OVC/V>]8TSPCK6D?'?X
M-:IHWQ \4CP/X#U;3OB?X(OM,\;>-6N(+1?!_A&_MM<EM?$GBEKJZM;8>']&
MEO=6-Q<P0BT\R:-67^I/&?U+!YE_JCQ/_9V8PA4R_'_V!FOU+'0J8:KC83P>
M*^J>PQ4)X.A6Q<)4*DU+#4:M=-TJ<YI_VYDGMZV&_MC*_K.&;CB,/_:&$]OA
MY1JPH2C6I>V]I2<:U2G1:J1BU5G"F_?E%/V6BN%^('Q1^&?PGTJRU[XI_$7P
M)\--#U+5(-#T[6?B!XN\/^#=*O\ 6KJ"YNK;1[+4?$6H:;9W6J7%M9WEQ!I\
M$TEW-!:W,L<+1P2LAXZ^*/PS^%UMI%[\3/B+X%^'5GXAU>'0- N_'7B[P_X1
MMM<UZYCDEM]$TB?Q!J&GQ:EJ\\44LD.FV3SWDL<<CI"RHQ'FX;(L[QBR]X/)
MLUQ2S:IBZ.5/#9=BZZS.M@(PECJ67NE1E]=J8*-2G+%PPWM98:-2#K*"E%OI
MJ8_ T7B%6QN$I/!QHSQ:J8FC3>%AB')4)XCFFO81KN,E1E5Y54<9*#E9G=44
M5PUU\3_AI9>/=.^%5[\0_ UI\4-8TJ77M(^&]UXMT"W\>ZIH<"WCS:SIW@^7
M4$\0WVE0IIVH/+J-MITMG&MC>,\P%K.4Y,)@<;CW7C@<'BL9+"X7$8[%+"8>
MMB'AL%A(>TQ6,KJC";HX7#4_WF(Q%3EHT8>]4G&.IM6Q%##JFZ]:E056K3P]
M)UJD*:J5ZTN2E1IN<H\]6K+W:=.-YSEI&+>AW-%8'BKQ3X>\#^&/$7C/Q;JU
MIH/A;PGHFJ>)/$>MW[,EEI&AZ)93ZEJNI73(KN(+*RMI[B7RT>0I&1&CN54X
MWPU^(_@_XO> O"GQ.^'VIW.M>"/'&C6OB'PMK%WHFO>'9=5T2_4O8ZDFC^)]
M,T;7+6VOH0MU9/?:;:F[LY8+VW62TN()I-5E.:2RNIGD<MS"624LPI935SA8
M/$/*Z>:5\/6QE#+:F8*G]4AF%;"8;$8JE@Y5EB*F'H5J\*<J5*<HP\7A%BXX
M!XK#K'3P\\7#!.M36+EA*=2%&IBHX?F]M+#PK5:=*=90=.-2I"G*2E.*?<45
MS_BSQ7X:\">&=>\9^,M=TSPSX4\+Z5>ZYXA\0:U=PV&E:/I&FP/<WVH7]W.R
M106]O!&\CNS9. JAG95+?"/B[POX^\,:%XT\%:_I7BGPEXGTRUUGP]XBT.]@
MU'2=7TN]B$UK>V-Y;N\,\,J-U5MR.&CD5)$=%C^SLP_L_P#M;ZCC/[+^N?V=
M_:7U:M_9_P#:#HO$K _7.3ZO]<>'3Q'U;VGMO8IU>3V?O%?6</\ 6/JGMZ/U
MOV/UGZK[6'UCZOS^R]O['F]I['VC5/VO+R<_N<W-H=%1117&;!15&PU33-5C
MFFTO4;'4HK>XDM)Y;"[M[R.&ZB5&EMIGMY)%CN(UDC:2%RLB+(A90&4F]53I
MSI3E3J0G3G%VE"<7"<7:]I1DDT[-/5;,491DE*,E*+VE%II^C5TPHKC?#/Q%
M^'WC35O%F@>#O'?@WQ9KO@+5%T/QSHOAGQ/HFO:MX+UMS<A-'\6:;I=]=7GA
MS5'-G=A=/UB&SNV-K<@0DP2[>1^(O[0OP"^#^J6.B?%OXX_!_P"%NLZI8?VK
MIND?$7XE^"_!&J:CIGVB:T_M*QL/$VMZ9=W=A]KM[BU^V6\4EO\ :()H?,\R
M)U7V,+PWQ%C<SCDN"R#.L7G,J,,3'*<+E>.Q&9RP]3#4\93KQP%*A/%.C4P=
M6EBH552Y)8:I3KQDZ4XS?%5S/+:&%>.KYA@:."4W2>,JXNA3PJJ1JRH2IO$3
MJ*DIQK0E1<.?F56,J;7.FE[!17E^G?&_X+ZQX#U'XIZ3\7OA?JGPPT>*:?5_
MB/IWC_PI?> ]+AMV1)YM1\7VVK2^'K&*!Y8EFDN=1B2-I$5RI=0>\T/7-$\3
MZ)H_B7PUK&E^(?#GB'2]/US0-?T/4+35M$US1-6M(;_2M8T?5;":XL=3TO4[
M&X@O=/U"RGGM+VTGAN;::2&1';GQF39OET:T\PRK,L!'#XZIEF(EC,#BL+&A
MF5&G&M6R^LZ]*"I8ZE2G"K4PDW&O3ISC.5-1DF]:&-P>)<%AL7A<0ZE"&*IJ
MAB*55U,+.3A#$P5.<G.A.<90A6C>G*47%2;31J4445YITA1110 45RGC7QYX
M'^&WA^Z\6?$7QGX4\ ^%;%XH[WQ+XU\1:1X6\/V;SML@2ZUG7+RPTZW>9P5B
M6:Y0R,-J GBO,_%'[3OP#\)_!S7/V@;WXH^&M<^#/AO[*=9^(/@"6[^*.A6:
MW>I:?I*2!OAK:>++NYA@O=4L1J$UG:W$.EVLQU#4GM-/AGNHO=RSA?B;.HX"
M63\.Y[FT<TS?"\/Y9++,HS#'QS'/L=.G3P628!X7#U5B\WQE2M2IX7+<.ZF-
MQ$ZM.%*C.4XI\&*S7*\$\0L;F6 PCPF#JYCBEBL9A\.\-E]",I5\=B%5J0='
M!T8QE*KBJG+0IQC)SG%)V]WHKXL_:7_:I\>?!G3],U?X4_L^ZY\>?#\?PP\9
M_&CQCXVA\8VWP]^'/A?X=^"[33K^X:V\>:AX;\1Z%KOC77K"^GU+PSX+273;
MG5-*TV_U0ZC;V%O).GTS\+O'^D_%CX9_#KXI:!!>6NA?$KP)X1\?Z+:ZA&(;
M^VTGQEX?T_Q%IT%]$"1%>0V>HPQW,8)"3*Z@D"O3S3@+BK)N%LFXSS'+J%'A
M[/L9B\OP&+I9MDV+Q<,=@Y5HU<+FF3X/,,1G.15JJP^(JX*&>9?ESS'#T:N*
MR_ZUAX2JKEPG$&4XW-L;DF&Q-2>99?0I8G$498/&T:,J%94W"KA<;6P]/!8^
M$?:TXUW@,1B?JU2I"EB/95)*#[JBBBOCSV0HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MN8[@;K>2WU6XNH[&9)U(:%XYV64'*%A7XS? []ECX1?M#_MA_MW:Q\8]'O\
MQGH_@OXL:/:Z%X+N=:U?3_"HU77M/UDW?B34+#2+ZQDU'6;2RTY=-TMYYOLU
MG:WNI-);W-Q+9S6',?LP?L5_ KQA^U#^UY\*/'.CZ]XS^%?[.WB?P:GPB^'&
MN^+?$]QX2\*?\+;L=?U[7YXK)=66ZN[RV3PYIFF6US>7LQO($DO-834=4%K>
MVM8SP!\(\GPW%;SCQ2XY68>'G ?A]XB\983+?#;*,3AJF4^(&&X,HX+)N&\;
MBN/\%/&9O@<YX[X?PV+Q6983+LO^H5\;BZ+K5LN6&QRH\?<78NKE2P?"V1_5
M^(<^X@X=R:MB>),73J1Q7#]7.9UL9F5&ED%94<)7P619C4I4L-5Q.(^L4Z%*
M?)#$NI0_=JQO['5+.VU'3+RTU'3[V&.YL[ZQN(;NSN[>50T4]M=6[R03PR*0
MT<L3NCJ058@YK%U7QEX0T+4M/T?7/%?AO1M7U9TCTK2M5US2].U+4Y)'$:1Z
M?8WEU#=7KO(0B);12,SD* 6(%?D=^SMK-S^R]XF_X*;_  R^'S:A=?#C]G7P
M_I7Q6^%7@S5;Z]UBW\.:CK?PT\7>-M5T/3Y[Z>XU&72[N^TS2[1(;B[FN)%L
MA=7$\^I7U_>W.C^R1^PY^S[\=O@-X8^.'Q^T*[^-WQ4^-]A=^,_&/C+Q)XI\
M5Q7-O/JE_=1Q:+HW]BZQH_\ 9,>BV\$5@\EO_I<5Y#<PVEW#IL=C96OS^<^!
M'!?!JXFXBXSX[XCAP#@<5X>X3A7'<-<&8#-.*N(JGB;P#A_$G))X_(\SXMR;
M*<BCE'#&*H//(3XBQTJF;267Y5+%X=ULRPW?@N.\YSG^S,NR7(LNEGU>EQ#6
MS6AF6<XC"Y5ET>&<^J<-XY4,=ALIQF+QSQF9TJBP+674%'")XC%*E4Y,-5^J
M_P!F3XU_$#XF_'+]LCP-XNU*SO?#OP<^)GAOPSX$MK;2[*QFT_2-2T_7+B[A
MN[JUBCGU*1Y;&W99[UY94"LJL Y%?6FH^-/!VD:O8^']6\6>&M+U[4VB33=$
MU'7=+LM7U!YV*PI8Z;<W45[=M,RLL2P0R&1E(0$@BOQ=_9FGNOV9++_@JM>^
M#+O6O$MU\&[^/4/"=SXKOYM>U63_ (1OP;XZO-"&M7]PCS:E!H\<5K%<23(#
M+IUAMD*#++ZC^RQ^P/\ LX_%S]G[P3\6/C;X=O?C+\3_ (U>%[+QWXS\>>)O
M%GBIM6%_XHA.H_V=I<FF:SI\>F'1([E-/>>!#>R7EM.TMRT M[6W^P\5?"/P
MRRGB'BKB[.^(,VX9\/<MI^$/"?#F'X&X)RS,LXS[B#/?!KA?BK,\XQ&2YCQ-
MPUEN38)TIU,YS-ULVQ./S#-<W>&H1J26.S##^1PKQ;Q-B\ORK*,%E^$S/B'$
MRXNS;,:F>9WB<-@\!E^!XRS/*L-@Z>-P^69EB<;64E'!X;DPE.AA\+A%5J.*
M=##U/U8E\5>&(#,)O$>@PFWU)-&G$NL:?&8-7D61H]*F#W \O4G6&5DL7VW3
M+%(5B(1L;44T4ZEX98YD62:%GB=9%$MO*]O<1%D) D@GBDAF0G=%+&\;A71E
M'X\_L _!GP9-K/[<7PJ\0#5_%WAWPE^TKJ&BZ=>^)-6N[KQ%<PZ5IFNZ!;7V
MIZU:-97-WJTFDW-Q;7>H 0R7#W$T^V.5U9/U@\%>"/"WPZ\.6?A'P7HUMX?\
M-Z=<ZO=V.D69E-K:3:YK.H:_J9@$TDKHEQJVJ7UT(@_EQ&<Q0JD2(B_@_BYP
M%PQX;\2YIPIE?$F<\0YEET^'\33Q>)R#"95EN.R?/^%LMXBIXR,EG>-QN$QM
M&>9X?"K+ZF$KTZE+VV(GCJ%2E##U_N^$<^S/B3+,+FV*RW!Y?AL3',*<J-/,
M*N+Q-#&8#-,1ETJ+3P-"C5HS6&JU?K$:T)1ER4U0G&;J0ZJO;_@!\6[WX0_$
M#3=9:XF_X1O4Y8-,\6V*;I([C2)9"OVQ8 1YE[I#R&^LF7$IV3V@<0WDZOXA
M17QG!7&/$'A]Q;P]QMPKCJF6\0<,9KA,WRO%TY22CB,+44G1KQA*'M\'BZ7M
M,)CL+.7LL7@J]?"UE*C6G%^SG63Y?Q!E.89)FM".)R_,\+5PF*HR2=Z=6-E.
M#:?)6I2Y:M"JEST:T*=6#4X1:_H9U>2VO?\ A%KJ#R+V"77;.[M+B.."ZB,<
MFEZD\5W;S-IFJ+&K0N3'=0/ISF.0JFJP)*T=QT]?+'[.WBN7Q;\%_A9/=L'N
M]%UL^&)I)6B<NN@VVJ6VGLAERQD.E+8*=J/.) [(5 ^T1_4]?];WAWQE@O$/
M@'@SCS+X>RP?&'"^1\24*#;E+#+.,NP^.EA)MI-U,).M+#5&TOWE*1_DIQ%D
MU;A[/LYR'$2YZV3YICLMG42255X/$U*"JQ2;7+5C!5(Z_#)!1117V1XQY3\$
M?@C\+_V<OAAX8^#/P9\,?\(;\-O!O]M?\(WX;_MKQ#XA_L[_ (2'Q#JWBK6/
M^)QXJU;7->O/MFO:YJE__I^J77V?[5]EM?(LH+>WA]6HHIRE*4G*3<I2;E*4
MFW*4F[MMO5MO5MZMZL22BE&*2BDDDDDDDK))+1)+1):)!1112&%%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !6!X:18]-F58EA']M^)W*+!%; M)XEU:1Y#'%I6C(6F=F
MF>8V3RW+R-<3:CK,TLFL7^_6!X:P--F V ?VWXGX01!0?^$EU?.1"J('SGS
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M*FC_ !L^*WQ.O/AEKGB+6+^^\+>#_"=QJF@ZBUA8VM[XFMX[*YT6\CT_C_\
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MLMR:CG&5XK-:&'HT)SHUL0L)@)1A7E'ZS5C.>'A*$*M15/C[_@M)XMUOPO\
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M:9%JNH26DLWAJX$]Q<>?JJ:D\4'E:GQ1_P""=_P+^+G[*_PP_9(\4ZQ\18/
MGP@'@Y_ WC#1]9\-6GQ+TR\\%:==:1INH_VY<>$+W01>WNF7U]9:J]OX6MH9
MHKJ1[6"RGCMY8?5QWC+]&3'5,1P]6X7RY</\0\1X3+^*\ZR_PQR'*9T,)C_
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MV<<7AS4?A9X7T/4K/[/.][H9N-<>U@:Y\(OVZOVN=#^./[&-MXQ^-/B;XT>
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MO#^SI\$(O@3IGPFTC1(/!7@SQ)X2\ :)X7\0/\2;FYU'QMXC\91>'M7@U77
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MOVFOBKXY^'UMX.^%T<]SHDEJ+SP;XJURWTW3[RZ2]CM-7\/W45_U7Q>_:_\
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M5P?/*\NQ.78^OEW%_%69YI2KYLOK;PN,QM;+ZN682IC:N IYBL!E6499+$+
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M6*XKQ6*R#(,)QGG69XCB#'8+,,'PCP5E'!N!RS),LXEX@XJS#(>%L#D>1P>
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M?$#0]+L/$NCZ[X4FNIK\^&/&O@W5I8--\1:9#>SW%Q8_:)UBMKBX,]]9:O\
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M\MHR:I8JGS-.-2,55='VCA^[]HI\G*Y)OEO.T4Y)1<FE>[2?[0T5^-/_  6
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M/^&M/_M/6M0@NH(+R/4&T?2];\ _X-\O^3*/BS_V?5^V7_ZMW4:Y*;Q?X?\
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MLG^)_P!DS3/B#\0/BC\4-;N]!\,1^#/"_P 2V^-&DZQK6I>(M9O[GQ (-/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MZ=XYTF&2^N_'%EK O;?48UT)X(;:YN_S:^(G_!$?]JSQ=^R?_P %K_@3IOQ
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MM)4O=N^6KA\17]HY*C!SIJ@HQG.2A!RYZE1R=*#G.ZBHT^6$59MU-;+\AO\
M@HE\!KO]H_\ X+;_ +!GPSL_CK\?_P!G6>Y_8O\ VE-9'Q)_9I\;Z-\/OBA;
M+I/BS1I6T>U\1:]X3\::?'HNK"3RM7M&T.26ZBCB6*YMRI9OUK_9._8EU/\
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M'?\ P67_ &Q?B5\*_"'BGXH_"3_@K[_P4&TK2/B7KOAG3_%?C#P)\/OA]?\
MAGXB2Z=\.IM8BNG\(W4^J^*/$FIZC/X6;1]0\173Z9%K%W>1Z1I"V/P%XJ^%
MLFM_\$1_VA/B_P" /V2OV)?AI^R?X_\ @7\=?B[X8^+?[5OQAN?BC^W)\2M:
M\:?\))XC\,_$[Q3XP\(?!#0_!%I\?O$7C>71=/\ AWX8N/'WB"_AUZ/PGX%O
M=6LVTN/[5_71\$_V8_@;^SK#\9[?X.^!8O"=O^T)\</B+^TA\88)O$'BKQ1#
MXR^,WQ8328_B#XOFB\7Z[KZ:-%XB30],23PQX=72/"&G);%=(T#3Q<7(F^,=
M-_X(K_\ !,72K/QGI-I^ROH;>'/'&B^-=!U#P9??$7XR:KX \.6/Q"T;7O#_
M (KG^&'P^U3XBWG@GX-:U>:1XGUZST[Q)\(M \$>(?#O]I33^&]4TFY6&:/>
M&8T?;U*LWB+.KA)TTES6AAX-2AR_6*<8-R;=.=JJBF[0BVV92P-3V4*<51NJ
M>(C-_#>5:47&7,Z,Y25HVG']VY:>^TC\D_C]\.O!/[37[5?_  :S>#OV@/#M
MA\6_"WC_ /9Q_:Y\3>.]!\:^?JVF^--8TG]A_P"!?CVWE\5VTDRIXAL[OQ7H
M]CJ6MZ3JWVO2?$<2W.E^(+'4](O]0L+KZML?AWX!^"'_  <0_#'0?@WX)\*?
M"O0/BA_P2Q\<7WQ"\/?#[P_I7A#P]XPU+PC^T!IEEX8U?7-"T*TL=)O=:T/3
MK2VTO3M:>S_M6WTB"+25O/[-1;4?K._[&7[-;^-/V3?B&WPWSXP_8;\*>,_!
M'[+>K_\ "8>/1_PJ_P +_$+X=Z/\*/%^F?V>/%(TOQK_ &OX T#2= ^V_$2R
M\6ZC8?9/[5TN[LM:GN=1FZO4?V:/@EJW[1OAW]K74/!7VC]H/PG\*=7^"/A_
MX@?\)'XMB_L_X8:[XB3Q9JOAC_A%(->C\$W7VK7XTO\ ^VKWPW<^(8,?9;;5
MH;(FV.$L?!PA3_>\D<%BL.X:<GM:^*Q->$U'GMRJ-6DI2MS*4-(M1BWI'"23
ME-^S<WB</54]>;DI4*%*<>9QO=RIU+*]G&>K3E)+\$O^"-7P%_9:^/W[#G[3
M7Q5_:S^&WPC^(?Q@^(?[4G[7!_;#\=_%O3= O_&F@ZSX7^(FNP+IWBOQ=KI_
MM[X9VW@;P/::%K6A6^GZOX=A\$Q/%XIT1])O9CJ9^MO^#=\:</\ @D'^RV-'
MNVO])'BC]JP:7?O>2Z@][IW_  V3^T%]ANWOYY)9KYKFV\J9KR:626Y+F:21
MW<L?IOQ]_P $G?\ @GI\3_C1KO[0'C;]FCPQJOQ*\6ZYIOB?QO+:^*/B)H7@
M7XA^(])GCNK+7?B7\(?#WC'2OA%\2=7^UQ)>7>H>.O WB"ZU*\+W>I2W=S+)
M*_U3^SY^SU\'OV5OA)X:^!?P$\'KX"^%7@^]\7:CX<\*)KOB;Q(FF7GCKQIX
MB^(?BJ5-8\8:SX@\07"ZGXP\5Z_JZPWFK7$&GB_&G:9%9:5:65C;+%XRE7I5
MHPE7<J^)HXCV<XQ5*@J=*O"5.FU5FY)>UA&#]G3_ '<$G%62'A\-4I5*,I1H
MI4</5HN<&W4JN=2A*,YITXI-JE*4USS]^=TW=L]HHHHKS#O"BBB@ HHHH **
M** .>A0?\)7J$FQ 3X>T=#*(HA(P&I:XP1IQ8+,40DLL1U.>)6D=UL+5V:XO
M.AKG82G_  EFH#<I<>'=')7=%O5&U+70&*B4SA7*L%:2 1,4812LZS(O14 ?
MAU^U9_P3EG_:S_X*P_"KXN?&?X&Z5\2_V/\ 1OV#/&'PG\1^*-1\5Z+I%WX?
M^-3?'&T\<^$8?#MMH_BS1?BWX?\ $EEI4+ZKI?CWP99V,6DEIK)?$MI=7$UI
M+^B?[+7[#'[*7[%EIXRM_P!FOX0:7\/;[XBZE;:O\0/%-WX@\9>/O'_CB_LC
M=M82^+OB1\2O$?C#Q_XCBTYK^_?3;36/$MY9Z<]]>O900/=W#2?65%=-3%UZ
ME.%%U)1I0IQI^RC*:IR4).2E.#DXRG=[V6T;)-7,(X>C"I.JH1=2<W/GE&+G
M%N*BU&7*I*-EM=[O74_'/4O^"!'_  2BU76_$/B&X_9L\5V^J>*_$6M^+->?
M2/VI?VO]!L[[Q#XCU&XU;6M272M#^/FG:39R7^H74]Q)#8V5M;1EQ'!!%"D<
M:_8/BO\ X)[?L9^/OV;?!_[(OQ ^ OA7XA?L^_#^SM[+P3X'^(%_XG\<WOAC
M[+]K%OJ&C^.O%>NZO\1+/7HDO[V!?$D?BS_A(#;74]JVIFVD:(_9=%*6+Q<^
M1SQ6(FZ;4H<U:I+DDE92A>3Y6EHFK-+38(X;#0YE'#T(J:<9J-*FN:+:;C*T
M5S)M)M.Z;2['YN_L]?\ !(G_ ()T_LM_$32_BW\&_P!FK1=/^)N@"8^&O'/C
MSQW\5_C3XD\*23Q^5-<>$-2^-7CSXA3^$;N2(O&UYX;;2[O9+.HF N)Q)]8_
MM"_LT? +]K#X<7_PC_:/^$W@OXQ?#K4+JVU"3PUXTTF/4(+/5+,2+::SHM\C
M0ZKX>URUCFGAMM;T&^TW5H+>YNK:*\2"ZN(Y?<:*B6(KSJ1JSK59U8VY:DJD
MY5(V=URS<G)6>JLU9[%QHT80=.-*G&G*_-"-.*A*ZL[Q247=:.ZU6A^:/P$_
MX(\_\$W?V:/B/H/Q=^$O[,>AV?Q)\)W#7G@_Q=X\\>_%KXS:IX+O63RQ?^"C
M\9O'WC^W\'ZA&@ @O_#4&EWEN0K03QLH(_2ZBBE5K5:TE*M5J59)64JLY5))
M=DY-NWE>PZ=.G27+2IPIQO?EIPC!7VO:*2O9)7\@HHHK,L**** "BBB@ HHH
MH **** "L#5T#:EX58QHYCUNZ<,T,4C1$^&M?CWQR2:?>/;NP<QF6"ZTF5HW
MDA-[-!+-IM_OUS^L;/[3\*;F0-_;=V4#&(,Q_P"$:U\$1^8Z.6"DL1!YLFP,
MS0&%99[< Z"FNB2*R.JNCJR.CJ&5T8$,K*00RL"0RD$$$@C%.HI-)III----
M-733T::>C36Z!-IW3LUJFMT^YY#KOP#^#7B2YEO-7^'7AJ2ZGYGN+.R.DS3-
MSF26329+%I)6S\TS$RMQN<X&../[)'[/3$L?A\,DDG'BKQLHR3GA5\2!5'H%
M  '  %?1]%?E>:>!/@AGF*J8[._!OPJSC&U9SJ5<9FGAYPCF&*JU*CYJE2IB
M,7E%:K.<Y>].4IN4GK)MGU6%XZXWP-*-#!<8\58.A!*,*.%XAS?#THQBK1C&
MG1QD(145HDDDEHCYO_X9&_9Z_P"B??\ EU^-_P#YI:/^&1OV>O\ HGW_ )=?
MC?\ ^:6OI"BO-_XEP^CQ_P!&&\&/_%7<#_\ SC.G_B(_B'_T7G&?_B49Y_\
M-Q\W_P##(W[/7_1/O_+K\;__ #2T?\,C?L]?]$^_\NOQO_\ -+7TA11_Q+A]
M'C_HPW@Q_P"*NX'_ /G&'_$1_$/_ *+SC/\ \2C//_FX^;_^&1OV>O\ HGW_
M )=?C?\ ^:6C_AD;]GK_ *)]_P"77XW_ /FEKZ0HH_XEP^CQ_P!&&\&/_%7<
M#_\ SC#_ (B/XA_]%YQG_P")1GG_ ,W'S?\ \,C?L]?]$^_\NOQO_P#-+1_P
MR-^SU_T3[_RZ_&__ ,TM?2%%'_$N'T>/^C#>#'_BKN!__G&'_$1_$/\ Z+SC
M/_Q*,\_^;CYO_P"&1OV>O^B??^77XW_^:6C_ (9&_9Z_Z)]_Y=?C?_YI:^D*
M*/\ B7#Z/'_1AO!C_P 5=P/_ /.,/^(C^(?_ $7G&?\ XE&>?_-Q\W_\,C?L
M]?\ 1/O_ "Z_&_\ \TM'_#(W[/7_ $3[_P NOQO_ /-+7TA11_Q+A]'C_HPW
M@Q_XJ[@?_P"<8?\ $1_$/_HO.,__ !*,\_\ FX^;_P#AD;]GK_HGW_EU^-__
M )I:/^&1OV>O^B??^77XW_\ FEKZ0HH_XEP^CQ_T8;P8_P#%7<#_ /SC#_B(
M_B'_ -%YQG_XE&>?_-Q\W_\ #(W[/7_1/O\ RZ_&_P#\TM'_  R-^SU_T3[_
M ,NOQO\ _-+7TA11_P 2X?1X_P"C#>#'_BKN!_\ YQA_Q$?Q#_Z+SC/_ ,2C
M//\ YN/F_P#X9&_9Z_Z)]_Y=?C?_ .:6L@?LF_ (Z_);?\(%)]D71XIQ#_PE
M7C7RC</>S1M)G^UM_F")%4C^TRNT@_8 ?](/U/6 NS_A*91N0N/#]O\ +F+>
MJ'4;GYBN_P X(Q&%)C\HE& ?>"M'_$N'T>/^C#>#'_BKN!__ )QA_P 1'\0_
M^B\XS_\ $HSS_P";CP[_ (9&_9Z_Z)]_Y=?C?_YI:/\ AD;]GK_HGW_EU^-_
M_FEKZ0HH_P")</H\?]&&\&/_ !5W _\ \XP_XB/XA_\ 1><9_P#B49Y_\W'S
M?_PR-^SU_P!$^_\ +K\;_P#S2T?\,C?L]?\ 1/O_ "Z_&_\ \TM?2%%'_$N'
MT>/^C#>#'_BKN!__ )QA_P 1'\0_^B\XS_\ $HSS_P";CYO_ .&1OV>O^B??
M^77XW_\ FEH_X9&_9Z_Z)]_Y=?C?_P":6OI"BC_B7#Z/'_1AO!C_ ,5=P/\
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MI:/^&1OV>O\ HGW_ )=?C?\ ^:6OI"BC_B7#Z/'_ $8;P8_\5=P/_P#.,/\
MB(_B'_T7G&?_ (E&>?\ S<?-_P#PR-^SU_T3[_RZ_&__ ,TM'_#(W[/7_1/O
M_+K\;_\ S2U](44?\2X?1X_Z,-X,?^*NX'_^<8?\1'\0_P#HO.,__$HSS_YN
M/F__ (9&_9Z_Z)]_Y=?C?_YI:/\ AD;]GK_HGW_EU^-__FEKZ0HH_P")</H\
M?]&&\&/_ !5W _\ \XP_XB/XA_\ 1><9_P#B49Y_\W'S?_PR-^SU_P!$^_\
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MGK_HGW_EU^-__FEH_P"&1OV>O^B??^77XW_^:6OI"BC_ (EP^CQ_T8;P8_\
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M9Z_Z)]_Y=?C?_P":6C_AD;]GK_HGW_EU^-__ )I:^D**/^)</H\?]&&\&/\
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M)1R>)J*4H.C%33IJ*]K=?O9N,55DJ;5.2BG-QC[7W6M?>5_WJHK^<O\ 9?\
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M73?$7A'XG>)?&7B#PYXN\.>*;>VAB>W\4:CI^LZ?=3SQVUA]BCDO_C;XK?\
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M*DVT]''HFYJ=%1:Y93E&:Y;MKV5246I7M%*45?1WNDFM5+[[HHHK$U"BBB@
MHHHH **** "BBB@#GXI ?%=_%O!*^'M(D,?GH2H;4M;4/]F_M>650Q0J9_[
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M%XF6WD(D2:.\TZ2)D(#+)'J%B\9 9;RU8"=-V@ HHHH **** "BBB@ HHHH
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M)?RZ)Q>IK4P].JHQDY)0IU*:Y6OAJ0]G*[:E=J.S[ZM/8_$C_@I?^R)^T/\
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M-S>OI<DEZMM8_2/[#7[*W[87P8O/^"B?[='QO\,_"J[_ &X?VW;CPQXK\-_
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MO$Y\OS-.T%<B'SMFLZA)M++I/G^6&T*/>(WEUTP[C&9ELM)#_9SJEX=(WJ*
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M;6*2\%F\397=IVA;2Z;]NLZ@2L9EMA(5!T(!G6 WCH"45Y5MHV,:22RQ[M%
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M#-Y._6=01G DU7[.9=NA.(S)%%HGG!?-$,E[JNPSKI=I_:X9O$V3C3M"(W$
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M(S%ITJF+R2=9\2/L\EX,B3Q%JLBR>6^CZ&Q\Y7$OFBQD2??Y\>J:['(NN:B
M;M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M5G>V5%:\M #H**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M>UYD6?PX&* OXB@5 SQ)N?\ LW5&PJR75NTKA59PD,=Y*H4S?91'%)<VW0T
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MLG=%O(OC'^S)>2VC,JW,=I?_  @\0&QNI("1*EM>BWG-I.R"*Y$$QA9Q&^T
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M2WNK2ZMY(Y[>X@DDAGAD26)V1E8_@K\0-=_X*5?L<_ ?6/#_ .TS\$/V8O\
M@I#^R)\// S6'Q"O_"4%QX%^,5U\*?"6D11W^M>/?A1X]T[Q'\,_&@T?3-.C
MUK4](\/QW\E];V5X]W-;E#JD7[/? CQ_\.OBK\$_A)\2OA%;VUE\+?'7PW\%
M^*?A[IUIIUEHT.D^#]:\/:??>']%_L33F>QT*;1=-FM]*NM"MCY6B7-G-I05
M#:%% +WQF^*7A_X&_!_XK_&OQ99ZSJ/A7X/?#7QU\4O$VG^';>RN_$%]X?\
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M.X5KJ< _IXHK\Y=2^%?QS_:L_9W_ &/?$_@O]N2X\#>(?#M[\,_BA\1_BQ\
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M_P#;I_X)F_\ !53_ (9@^(NO^/O^%6_L*_M&_P#"<?VY\(/C5\*?[)_X3?X
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M6C_AO'X0_P#0N?$C_P %'AC_ .;"C_AO'X0_]"Y\2/\ P4>&/_FPK\EZ*/\
MBIC]*/\ Z&O!?_B'X/\ ^:/ZN_*Q_P 2T>%__0)G7_AXK?\ RO\ J[\K?K1_
MPWC\(?\ H7/B1_X*/#'_ ,V%'_#>/PA_Z%SXD?\ @H\,?_-A7Y+T4?\ %3'Z
M4?\ T->"_P#Q#\'_ /-']7?E8_XEH\+_ /H$SK_P\5O_ )7_ %=^5OUH_P"&
M\?A#_P!"Y\2/_!1X8_\ FPH_X;Q^$/\ T+GQ(_\ !1X8_P#FPK\EZ*/^*F/T
MH_\ H:\%_P#B'X/_ .:/ZN_*Q_Q+1X7_ /0)G7_AXK?_ "O^KORM^M'_  WC
M\(?^A<^)'_@H\,?_ #84?\-X_"'_ *%SXD?^"CPQ_P#-A7Y+T4?\5,?I1_\
M0UX+_P#$/P?_ ,T?U=^5C_B6CPO_ .@3.O\ P\5O_E?]7?E;]:/^&\?A#_T+
MGQ(_\%'AC_YL*/\ AO'X0_\ 0N?$C_P4>&/_ )L*_)>BC_BIC]*/_H:\%_\
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M,?\ S84?\-X_"'_H7/B1_P""CPQ_\V%?DO11_P 5,?I1_P#0UX+_ /$/P?\
M\T?U=^5C_B6CPO\ ^@3.O_#Q6_\ E?\ 5WY6_6C_ (;Q^$/_ $+GQ(_\%'AC
M_P";"C_AO'X0_P#0N?$C_P %'AC_ .;"OR7HH_XJ8_2C_P"AKP7_ .(?@_\
MYH_J[\K'_$M'A?\ ] F=?^'BM_\ *_ZN_*WZT?\ #>/PA_Z%SXD?^"CPQ_\
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MW?C^\B+&6SEN/] @TRR G"_8&NUN]0O_ ,J**/\ BIC]*/\ Z&O!?_B'X/\
M^:/ZN_*Q_P 2T>%__0)G7_AXK?\ RO\ J[\K?K1_PWC\(?\ H7/B1_X*/#'_
M ,V%'_#>/PA_Z%SXD?\ @H\,?_-A7Y+T4?\ %3'Z4?\ T->"_P#Q#\'_ /-'
M]7?E8_XEH\+_ /H$SK_P\5O_ )7_ %=^5OUH_P"&\?A#_P!"Y\2/_!1X8_\
MFPH_X;Q^$/\ T+GQ(_\ !1X8_P#FPK\EZ*/^*F/TH_\ H:\%_P#B'X/_ .:/
MZN_*Q_Q+1X7_ /0)G7_AXK?_ "O^KORM^M'_  WC\(?^A<^)'_@H\,?_ #84
M?\-X_"'_ *%SXD?^"CPQ_P#-A7Y+T4?\5,?I1_\ 0UX+_P#$/P?_ ,T?U=^5
MC_B6CPO_ .@3.O\ P\5O_E?]7?E;]:/^&\?A#_T+GQ(_\%'AC_YL*/\ AO'X
M0_\ 0N?$C_P4>&/_ )L*_)>BC_BIC]*/_H:\%_\ B'X/_P":/ZN_*Q_Q+1X7
M_P#0)G7_ (>*W_RO^KORM^M'_#>/PA_Z%SXD?^"CPQ_\V%'_  WC\(?^A<^)
M'_@H\,?_ #85^2]%'_%3'Z4?_0UX+_\ $/P?_P T?U=^5C_B6CPO_P"@3.O_
M  \5O_E?]7?E;]:/^&\?A#_T+GQ(_P#!1X8_^;"C_AO'X0_]"Y\2/_!1X8_^
M;"OR7HH_XJ8_2C_Z&O!?_B'X/_YH_J[\K'_$M'A?_P! F=?^'BM_\K_J[\K?
MK1_PWC\(?^A<^)'_ (*/#'_S84?\-X_"'_H7/B1_X*/#'_S85^2]%'_%3'Z4
M?_0UX+_\0_!__-']7?E8_P"):/"__H$SK_P\5O\ Y7_5WY6_6C_AO'X0_P#0
MN?$C_P %'AC_ .;"C_AO'X0_]"Y\2/\ P4>&/_FPK\EZ*/\ BIC]*/\ Z&O!
M?_B'X/\ ^:/ZN_*Q_P 2T>%__0)G7_AXK?\ RO\ J[\K?K1_PWC\(?\ H7/B
M1_X*/#'_ ,V%'_#>/PA_Z%SXD?\ @H\,?_-A7Y+T4?\ %3'Z4?\ T->"_P#Q
M#\'_ /-']7?E8_XEH\+_ /H$SK_P\5O_ )7_ %=^5OUH_P"&\?A#_P!"Y\2/
M_!1X8_\ FPH_X;Q^$/\ T+GQ(_\ !1X8_P#FPK\EZ*/^*F/TH_\ H:\%_P#B
M'X/_ .:/ZN_*Q_Q+1X7_ /0)G7_AXK?_ "O^KORM^M'_  WC\(?^A<^)'_@H
M\,?_ #85GZ5^W-\)[#3K2SN-#^(US-!$$DG31]$VR-N9BR_VAX^U.](YP#<W
M]U,<9>5B<#\IZ*/^*F/TH_\ H:\%_P#B'X/_ .:/ZN_*Q_Q+1X7_ /0)G7_A
MXK?_ "O^KORM^M'_  WC\(?^A<^)'_@H\,?_ #84?\-X_"'_ *%SXD?^"CPQ
M_P#-A7Y+T4?\5,?I1_\ 0UX+_P#$/P?_ ,T?U=^5C_B6CPO_ .@3.O\ P\5O
M_E?]7?E;]:/^&\?A#_T+GQ(_\%'AC_YL*/\ AO'X0_\ 0N?$C_P4>&/_ )L*
M_)>BC_BIC]*/_H:\%_\ B'X/_P":/ZN_*Q_Q+1X7_P#0)G7_ (>*W_RO^KOR
MM^M'_#>/PA_Z%SXD?^"CPQ_\V%'_  WC\(?^A<^)'_@H\,?_ #85^2]%'_%3
M'Z4?_0UX+_\ $/P?_P T?U=^5C_B6CPO_P"@3.O_  \5O_E?]7?E;]:/^&\?
MA#_T+GQ(_P#!1X8_^;"I[?\ ;K^#L\@271OB#9J?^6UQHNA-&/7(M/$]U+P.
M3B(\5^2%%7#]IE]*&$XREF7!-6,6FZ=3A##J$TK>[)TL73J)/KR3A+5VDM+3
M+Z,_A>TTL-G<6U92CF]1R7FN:C*-_6+6NVUOW!\)?M/_  2\82K:V?C6STF]
M=PB6GB:&?0"[-@(([S4$BTR5G8[$BBOGF+@#RQN3?[Y')'-''-#(DL4J))%+
M&ZO')&ZADDC=25='4AD=2592""00:_G"KW[X/?M%>/?A'?6D%M?W&N^$5EQ>
M^$M2N'DLC Y D;2IY%EET>[49>)[4?99)<&\M+E3@?TMX,_M5,3B,TP63^.?
M!N6X/+L35IT)\8\#4\?!9;SU%!8K-.&<?B\RKXK"TXR]KC*^59BL52ITYO"9
M/C*DX4%^:\9_17I4\+6QG V<XFMB:495(Y/GDJ$OK-H\SI87,\/1PT*5637+
M1IXO#.E.4HJMC*,4YO\ <*BN ^&OQ*\+_%7PO:^*O"MTTMI*QM[VSN%6/4-)
MU"-4:?3M1@5G$5Q$'1U9'D@N(7BN+>66&5'/?U_L1D.?9+Q1DN6<1<.YG@LZ
MR+.L%0S'*LURZO#$X+'X+$P52AB,/7IMQG"<6NJE&2E"<8SC**_CW'X#&Y7C
M<5EV8X6M@L=@JU3#XO"8BG*E7H5Z4G&=.I"23C*+7HU:46XM-E%%%>L<@444
M4 %%%% !1110!A>*',7AO79!*(2FDW[^<93 (@MM(3(9AJ^@>4$ +>8=<T=$
MQN?4[% US'NUA>*&*>'-=8%E*Z5?,&1I$<$6\A!1X;FSE1AC*M%=VLBG!2Y@
M8"5=V@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
MY_79#'-X? E$0D\06T9!F,7F@V.HL(L?VQI*S%BH(A>+60Q7<FCSS)%=V705
M@:X2)O#^&=<Z_;@['E0,#8:B-KB.>W5T[E)C+$6"GR)I%C0[] !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MPT9\7OV/_BK_ ,+!_P"$._X91^,6H?%G^P?^$4_X2'_A/?MV@_V)_8']J?\
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MAEX6_9;\?_\ !4/XG^(_V-_"P\'Z-_P@6@? ?P;X%_:1\2?#[P#J^DZKX7\
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MV_BECFCCFAD26&5$EBEB=9(Y8Y%#))&ZDJZ.I#(ZDJRD$$@@U_.%7[@_LO\
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M0_!'_@D%\8_V./@3\)_%VK?\%)_B'XS^''B/X7_%W7O$5H_A_P 6^#/$>@>
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M#>'M7T6/6K'XC7>A^/M1UKP%K]U=Z5X@TJ31-2O[!+:PAFG_ $2^/?[4]O\
M'#_@C1^T+^V'\$/$NN>#[GQU_P $Y_CG\:_ 'B/PMKE_HOBSP#XI?]GGQ?XC
MLGTGQ%I$UCJFB>,/ /BFW>S35-,N;34-(\0Z(UQ9SP7-M'(OX_?\$]_V>?\
M@H'^V=JG[4/_  5&^!?[<WAC]D31?V^OC-K]]X6\$^+OV,/!O[0OB/5/V>_@
MCJ>M_"SX"27OBKQO\2O UYHUG'X6L=1A3P_9>&[:SOP%\2SW%S)K4=O8<C^S
MW:>,OV3?^"<__!=C_@DU\6O%]GXP\8?L9_LS?M4?$KX1>)K+PS;^!='\:_LZ
M_M)_LY?$+X@Z1JGA/P9;Z_XEM]#TW0?B+<^,O[;T:PUB_L?"]_XKT[P_]IEF
MMF=KEAZ/+0H0G0G5P%;#>UA"-15&JM2$,8JTI4HPJ>RQ4Z=.FH5*B5/F?NJZ
M:C6J\U6M*%6%+%TJWLYRE#DO3@Y89TU&HYP=2@JDY\T(7FEJ]#LOV0/@5^R5
M\8/V6?V7?B/\6/\ @NM^W?H'QE^*7P ^"?C?XE^$;?\ X*^7'AV?1?B=XW^'
M7AG7O&7AR'PIJGB"XUO0I=-\5:GJ6F1^'M1DGU33'A73;MY;N"1F_JH\.:*O
MAOP]H/AU=3UK6UT'1=+T5=9\1ZC)J_B'5UTNQ@L1J>O:M,J3:IK5^(!=ZIJ,
MJK)>WTL]RZAI2!^-/_!-C_@G=_P3^\4_\$_OV!?B'XG_ &%_V.O$?C_Q'^QU
M^RQXS\0^.=>_9D^"FK^,->\8:O\ !3P)KFK>+-9\3:AX)N-:U3Q+JFM7%QK&
MHZ[?7L^J7NJ3S:A<W4MW*\S?1GQP_99_;\^('QOU[Q_\'O\ @J5XL^ 'P?U&
M]\+7&B_ '3OV/_V9_B5IWAVTTCP_H.F^(["/XD^.M%N?'>J+XNUS3M:\23W.
MH7;3Z)+XAETK26CT_3-/1.'&3IXC$3A]9=.-.=:SQ,&H)\T8J%-86E5EJD_B
MC&*C%:INSZL-&=&C"?L%.4X4M*$DY-.%W*;KSIQT?\K;O)Z/5FY^T5_P48^'
M'P&^-%K^SEX5^"7[37[4_P =T\"VOQ-\3?#']EOX;Z#XWU;X?> =3U2;1M!\
M2_$#7O&_CCX;^"/#4'B34;/4(- TVX\52Z[J2Z=<SQ:4+=[26Z^5_P!J3]OC
MPK^T7_P26_X*$?'7]FSQ#\7?A!\1_@C\+OCQX \5:-X@L]:^$/Q\^ /QN^'_
M (76\U3PWK]MI.J'5/"7C+P]_:.F7]KJGA[7KRU*W,-QI6L3LDAC^1/VF?VE
M_#OAK_@I_P#M/_#+]J?]JWQ]_P $\/A9H/PX^ !_9ZU[X$_"GP1H7Q)_;8LM
M6\$W6M^.K_6_COJOP=^+?C[Q4?@_XYN[_P #>'OA7X(/A^:$2F^CAU">XNEG
M^3OV=/#7B?XE_P#!.?\ X.-/#G@?1OC_ .,O$?BOXL?'(>&-*^..B"+]HKQ6
MMQ^S%\/K[3)_&_ABQTK1[ZW\::[IRQ:@GAJ?0-*\3V_VJTT?5M L/$L=YI4/
M51P5&$,/6E!Q<)8"LZDG-TZBKUJ*G&3E"-%QC&IJJ;DZ;BX59.3:CA4Q524Z
MU)234EBZ:@E%2A[*G/E:49RJ)R<;IU%%334J<5&S?Z.?MK_\%(OCW^R#\%O^
M":4/P[^"OQY^*^K_ !O^(W[$F@?$WXD:)X.\#^._#WC?PK\27CTGQW\%]#UO
MQC\3?#6OO^TI\2(;3[7X&EU#3(/#LUW>PWFM>.=*EN)@GW9\4_\ @I-\,?@S
M\-?@1XH^('P2_:<TWXS?M*:GXDT7X._L:Z7\-O#WBC]K3Q1JG@^._O?%$3^
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M:_L_^%KOPS^SE\)=7\:_$+3M3T5O'_VC2]?U#PMX=TVYUJWU!WUZ6"RCM_\
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M4BT_2WP]_P $POV>O#5[^T%:67B?XUW'PT_:3TOQC:^/O@5??$=I?@SI^O\
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M 4444 %%%% !1110 4444 %%%% !7Z[_ +#/VC_A3-_Y_P#J_P#A.M<^R?\
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M= 'EBB+G^SM3?8@DO[-I7.S(BABU*5@K-]@\M)+VRZ&@#\NO^"LG_!./6O\
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MZB]WG]I[UIKFDI^^IRO.,[RC)2;9^3WP2_X)P?&2(_M.W7[<G[?'QL_;9?\
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M[^(>B0:YH.K6Q2.:!'4+>:1J]F)9)M,\0:+>>;IFN:3<8GTW4;>:WE)PC/\
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MCCF7#N,QE"HZ&8X6C%8BG%^]2JKEYY1B]>1\UDVF[IIO0_H=_9<^*FM?'/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH ***]^^#O[.OCWXNWMI/:V%QH7A%Y/]-\6ZE;/'9K"A!D
M72K>1H9=8NV&4B2U/V6.4@7EW:J":^MX(X$XQ\2.(L!PGP+P[FG$_$&8U(4\
M-EV58:=>I&,IPIRQ.+J^[A\!@*#G&6+S''5</@<'2O6Q6(HTHRFO)SO/<GX<
MRZOFV>9CA<LR_#1<JF)Q554XMJ+DJ5*.M2O7FHM4L/0A4KUI6A2ISDTF?LZ_
M!Z^^+GCVPMI[25O".A7%OJ7BV].4A%E&[20:4LA&&N]8EB^RI$A\V.U^UW@
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MO@OQKJW@#6_#VNZ[X!UA=0,GB#PE)JD.F:U)9V!OTE2U1#^9W_!([2-+\/\
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M4/@I#\6?B''K.O\ [3WQ@^)6E^%M&U+X8_!_X'"6'2?@ZUV(_$NNWWAOPSX
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M?ZN5_8Y5@,7EKPLJ]256=3&5,-RNK6I89<DKT$HQ<>=N[>CBE\W3X)<,JQ.
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MNH5<RQV)QDJ:=KQI?6*E14H:)<E-1BDDDK)!1117UYY 4444 %%%% !1110
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M?'+Q5\7/B'HNB06LU])##J-M<>/K'PW]MN;]8+FYLFO@-/M[CR+?Y?\ #'[
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M %%%% !1110 5@:QC^T_"I.S/]MW>"PBW9_X1KQ!_JS(I<.0#D0,LIC#[E:
M3%-^L#6'1-3\*JTJ1M+K=W&B--%$TY'AK7Y3$D<FI63W+!8C.88+35Y%6%KA
MK&&&"75-/ -^BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ K 7'_"4RGY ?[ @YQ%YA!U&X[[?/V*1TW&+<_W0YR=^N?5U_P"$JEC\
MU-__  C]N_D^=%O"_P!HW*F4V_\ :33A"<(LQTB*)BK(-2N'4VML =!1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5SVAX^W>*L;,
M_P#"0IG;Y6[/_"/:!_K/+^??C&//_>^7LV_N/)KH:Y[0Y$>]\5*LJ2&+Q$L;
MHL\4Q@<^'] E\ITCU/46MG*R+-Y$\&D2E9EG&F"&:+4-0 .AHHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *P/"V/^$?TK&P VJD",
M1!!EW.!Y*K%QG!*@Y.2SR,2[;]<_X5=)/#VDNDJSJUHN)4FBN4DPS@LL\.I:
MQ%*"0<.FJ7X/>ZF.7(!T%%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% &!XKQ_PC.O[MF/[(U#/F"(QX^RR9\P3J\!3'WA,C1%<^8K)
MD'?K \5ND?AG7Y'E2!(](OW:9YHK=(@EM(QD:XGU+1X853&XRRZII\:8W/=P
MJ"XWZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#
MGM>QY_AT'9SXAM\;_*ZC3]28;!+G+G;A?+1Y1DLGE[3-%T-<]KTB)/X<WRI%
MO\16\:AIXH3,YT_4RL2++J>G?:'.-_D10ZO*5C:5=,(B:_L.AH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MO TJ3Z*VKM&L:L4W?\(GK(;8&"->^&P=QB6382NN.H8.Q@8ABGF([*S0E)7
M.BK"5V_X2:6/>VT:% YC\Z79N.H7*AQ;_P!I^2&P"IF_L<2D;4.IE +41R:Q
MJJ([)X3UJ4JDS+&M[X;5Y#'%J,D<8+ZZJ*\[VEG A=U1)=5M3*\<-O?S6F.^
MJ:JGB6Y*^&M8E1-'9(Q'=Z,$F$.IZRL<R^;J\<"F[CL;.6!)#'<I'K.GK<I
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MFWULZ0IU;5 [+_PB^KD*[*)!>>'MC@2RQB10=:#A'2-)U#HKB*>(,BS":&$
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M!V,#$,4\Q'96:$I*ZR:QJJ([)X3UJ4JDS+&M[X;5Y#'%J,D<8+ZZJ*\[VEG
MA=U1)=5M3*\<-O?S6@!T-%8,FK:HCRJOA?5Y5C>=8W2\\/!9UBEU-(GC$NM1
MNHN4L+2:)9EB*)K>FK/Y4L.L)I2?VMJF<?\ "+:OC?M)^V>'ON>;Y9D _MK)
M'EYG53M8IA6"2DQ@ WZ*P8]6U1GB5_"^KQ"1X%DD:\\/,D EETR.620)K3.R
M6R7M[/((4D=XM&O! DLUSID-\R/6-6=$9_">LQ,R0LR->^&V,;21:=)(C&/7
M'4M;O>W,$I0LK2:1J+0--#+I,NJ '0T5SIUC5MFX>$]9+;2VS[;X;#!O*=PA
M/]N;,^8JPL0Y4,^\,T:EJ=)K&JIYNSPIK,NQ)V0+>^'%\XQ1:M)%&F_7%"O<
MO86$$1DV(DNN6)G>*&VU:;3P#H**P'U;5%+A?"VKR!'E52EYX> E6.6_C21/
M,UI"$G2TMYXA*(Y!%JE@)XX9X]3ATX&K:IO53X7U<*656?[9X>(0&6)"Y']M
M;BJQO)-A07(A*!-[H" ;]%8$>KZJY0-X6U>+<8 S27OAXK'YKZ0DA;RM:D8K
M;+J-_++L1V>/0=0$"S2W6CQ:FU=8U5DC8^$]:0ND;-&U[X;+Q%XK.1HY"FNN
MA>%[J>"0Q/(AETZ\,+RPOI\U\ =#17/'6-5 8CPIK#$(S*!>^' 698IW$?.M
M@!GDBAA4D[ URKNR1QRLJR:QJJ"4IX4UF7RS-L5;WPXK3B,:P4\KS-<15:X_
MLW3UB$S0A7\0::)VA2UUJ32@#H**P6U;5%=E'A?5W =U$BWGAX(P26ZC60!]
M:1]DJ6\4Z!D5Q%>VHD2.9+V&T1=6U1G"MX7U=%+HI<WGAXJJO+:HSD+K1<B)
M)KB9U"EBEG(L8DEF@20 WZ*Y^/5]5<1%O"NL1&0PAP][X=)@\P:/O+^7K<@9
M;=M2OQ-Y1D9E\/ZFT"SFYT1-60:QJI"D^%-94E$8AKWPWE6:*"0QMMUU@7C>
M:2!RI:,RVLY21X&M9KD Z&BN=;6-65)&'A/679%E946]\-@RLD5Y(B(7UQ5!
MF>WMH4,AC59+^)I&2&"ZEB?)J^J(7V^%M8E"F?:4O/#H,GE/JZQE1)K:8%RF
MG6,D6\J5_M_2TG$)M];.D !KDCQS>']CN@DU^WC?;-+"&0V.HDI)Y6HZ>)49
ME4"&5=0B=]A;3IV59(=^N$UO5-5-SH87PSK 6/Q!%F1;O12LB"VU6($&+5F=
M(Y0L<N;C[.AAGCCF/GF6SK<35M48QAO"VKQAGB5RUYX>81J\MA')(VS6F+)"
MEU=SN$#2/%ILXC1YY[.&X -^BN?CU?57\K=X5UB+S$@9]][X=;R6EBTEY4E\
MO6WRUM)J%[#*8?-5VT+4W@:5)]%;5VC6-6*;O^$3UD-L#!&O?#8.XQ+)L)77
M'4,'8P,0Q3S$=E9H2DK@'145STFL:JB.R>$]:E*I,RQK>^&U>0QQ:C)'&"^N
MJBO.]I9P(7=4275;4RO'#;W\UH^35M41Y57POJ\JQO.L;I>>'@LZQ2ZFD3QB
M76HW47*6%I-$LRQ%$UO35G\J6'6$TH WJ*P/[6U3./\ A%M7QOVD_;/#WW/-
M\LR ?VUDCR\SJIVL4PK!)28PL>K:HSQ*_A?5XA(\"R2->>'F2 2RZ9'+)($U
MIG9+9+V]GD$*2.\6C7@@26:YTR&^ -ZBN>CUC5G1&?PGK,3,D+,C7OAMC&TD
M6G22(QCUQU+6[WMS!*4+*TFD:BT#30RZ3+JB'6-6V;AX3UDMM+;/MOAL,&\I
MW"$_VYLSYBK"Q#E0S[PS1J6H Z*BN?DUC54\W9X4UF78D[(%O?#B^<8HM6DB
MC3?KBA7N7L+""(R;$277+$SO%#;:M-IZOJVJ*7"^%M7D"/*JE+SP\!*L<M_&
MDB>9K2$).EI;SQ"41R"+5+ 3QPSQZG#IP!OT5@#5M4WJI\+ZN%+*K/\ ;/#Q
M" RQ(7(_MK<56-Y)L*"Y$)0)O= 2/5]5<H&\+:O%N, 9I+WP\5C\U](20MY6
MM2,5MEU&_EEV([/'H.H"!9I;K1XM3 -^BN>76-59(V/A/6D+I&S1M>^&R\1>
M*SD:.0IKKH7A>ZG@D,3R(9=.O#"\L+Z?-?!UC50&(\*:PQ",R@7OAP%F6*=Q
M'SK8 9Y(H85).P-<J[LD<<K* =#17/R:QJJ"4IX4UF7RS-L5;WPXK3B,:P4\
MKS-<15:X_LW3UB$S0A7\0::)VA2UUJ32G-JVJ*[*/"^KN [J)%O/#P1@DMU&
ML@#ZTC[)4MXIT#(KB*]M1(D<R7L-H ;U%8"ZMJC.%;POJZ*712YO/#Q55>6U
M1G(76BY$237$SJ%+%+.18Q)+- DB1ZOJKB(MX5UB(R&$.'O?#I,'F#1]Y?R]
M;D#+;MJ5^)O*,C,OA_4V@6<W.B)JP!T%%<\-8U4A2?"FLJ2B,0U[X;RK-%!(
M8VVZZP+QO-) Y4M&9;6<I(\#6LURC:QJRI(P\)ZR[(LK*BWOAL&5DBO)$1"^
MN*H,SV]M"AD,:K)?Q-(R0P74L0!T5%8$FKZHA?;X6UB4*9]I2\\.@R>4^KK&
M5$FMI@7*:=8R1;RI7^W]+2<0FWULZ0IU;5 [+_PB^KD*[*)!>>'MC@2RQB10
M=:#A'2-)U#HKB*>(,BS":&$ WJ*P$U;5&,8;PMJ\89XE<M>>'F$:O+81R2-L
MUIBR0I=7<[A TCQ:;.(T>>>SAN$CU?57\K=X5UB+S$@9]][X=;R6EBTEY4E\
MO6WRUM)J%[#*8?-5VT+4W@:5)]%;5P#H**YT:QJQ3=_PB>LAM@8(U[X;!W&)
M9-A*ZXZA@[&!B&*>8CLK-"4E=9-8U5$=D\)ZU*529EC6]\-J\ACBU&2.,%]=
M5%>=[2S@0NZHDNJVIE>.&WOYK0 Z&BL&35M41Y57POJ\JQO.L;I>>'@LZQ2Z
MFD3QB76HW47*6%I-$LRQ%$UO35G\J6'6$TI/[6U3./\ A%M7QOVD_;/#WW/-
M\LR ?VUDCR\SJIVL4PK!)28P ;]%8,>K:HSQ*_A?5XA(\"R2->>'F2 2RZ9'
M+)($UIG9+9+V]GD$*2.\6C7@@26:YTR&^9'K&K.B,_A/68F9(69&O?#;&-I(
MM.DD1C'KCJ6MWO;F"4H65I-(U%H&FAETF75 #H:*YTZQJVS</">LEMI;9]M\
M-A@WE.X0G^W-F?,586(<J&?>&:-2U.DUC54\W9X4UF78D[(%O?#B^<8HM6DB
MC3?KBA7N7L+""(R;$277+$SO%#;:M-IX!T%%8#ZMJBEPOA;5Y CRJI2\\/ 2
MK'+?QI(GF:TA"3I:6\\0E$<@BU2P$\<,\>IPZ<#5M4WJI\+ZN%+*K/\ ;/#Q
M" RQ(7(_MK<56-Y)L*"Y$)0)O= 0#?HK CU?57*!O"VKQ;C &:2]\/%8_-?2
M$D+>5K4C%;9=1OY9=B.SQZ#J @6:6ZT>+4VKK&JLD;'PGK2%TC9HVO?#9>(O
M%9R-'(4UUT+PO=3P2&)Y$,NG7AA>6%]/FO@#H:*YXZQJH#$>%-88A&90+WPX
M"S+%.XCYUL ,\D4,*DG8&N5=V2..5E636-502E/"FLR^69MBK>^'%:<1C6"G
ME>9KB*K7']FZ>L0F:$*_B#31.T*6NM2:4 =!6'X=D>73I7>1Y"-9\1H&>>6X
M.R+Q%JD4:"2;4]6<)&B+''$+Q(K=%6""PTF&*/2K)K:MJBNRCPOJ[@.ZB1;S
MP\$8)+=1K( ^M(^R5+>*= R*XBO;42)',E[#:1>%9)Y=(,MQ!/:ROJ_B1F@N
M75YHE/B/53&K.DLT;*8]AC:*:: QE#!+)%L=@#HZ*** "BBB@ HHHH ****
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MA9!'X>TI!&L0%JN(TAC@5 7<X6*&RTZ-1SP4LX0WW_WA8RN ;]%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &%XH3S?#FN1B-YC)I5
MZ@BC@EN9)6>W=5CCMX-+UN:>1R0J10Z1J4KL0L=E<.5C;=K!\5()/#6O1E$D
M$FD7Z&.2%+A) UM(I1X);'4XIT8':T,FFZ@DH)1[&[5C;R;U !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!@:['OG\/'RGD\OQ!!
M)\D$LWE_\2_4D,K-%I.I_9T4.0T\D^C1 -Y3ZLOFC3]0WZY[7D#S^'<HC[?$
M-NXWQ12E"NGZG\\8EL+XQN!D>;$;*6-"["_@3>LO0T %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !6%X<C,6G2J8GA)UGQ(^R2"6W8B7Q%JLHD$<
MVEZ.Y28.)8YA9O%<1NMQ!J&L02QZO?;M8'AI!'ILRB-(A_;?B=]L<,4"DR>)
M=6D+F.'3]+0O(6,DDIM6EGD=II[W4YY)-2NP#?HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH YV$I_PEFH#<I<>'=')7=%O5&U+70&*B4SA7*L%:2 1,4812LZS(O15S\4
M@/BN_BW@E?#VD2&/ST)4-J6MJ'^S?VO+*H8H5,_]@6*/L$?]KZJT?V+1^@H
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M*AUM_P"UFE 8Y5IAH449*I&VK3LJV=L ;]%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MJOQ(_P#"Y\3_ /RTIG_"W_BUYOG?\+1^(OG&,1&7_A-O$OFF(,7$?F?VGO\
M+#DL$SM#$MC)S1_Q5G\//^C2<:?^'O(__D/7^GH?\2F\0_\ 16Y+_P"$6._S
M]?Z>G[]T5^ __"Y/B]_T57XD?^%SXG_^6E'_  N3XO?]%5^)'_A<^)__ ):4
M?\59_#S_ *-)QI_X>\C_ /D/7^GH?\2F\0_]%;DO_A%CO\_7^GI^_%%?@/\
M\+D^+W_15?B1_P"%SXG_ /EI1_PN3XO?]%5^)'_A<^)__EI1_P 59_#S_HTG
M&G_A[R/_ .0]?Z>A_P 2F\0_]%;DO_A%CO\ /U_IZ?OQ17X#_P#"Y/B]_P!%
M5^)'_A<^)_\ Y:4?\+D^+W_15?B1_P"%SXG_ /EI1_Q5G\//^C2<:?\ A[R/
M_P"0]?Z>A_Q*;Q#_ -%;DO\ X18[_/U_IZ?OQ17X#_\ "Y/B]_T57XD?^%SX
MG_\ EI5FU^-_QCLY/-B^*7C]VXXNO%FMWT?'_3*]O;B+Z_)SWS@5I3_:S>&[
MJ05;PGXWA2;7/.GF^0U:D8]7"G*5&,WVBZL$_P"9$R^B=Q&HMPXLR24K>ZI8
M/'QBWV<DIM+?51EZ:Z?O?17XU^#_ -LCXT>&'1-3U/3O&5B'R]MXBL(A<A#]
M]8=2TO\ L^\#GJCW;7J(?^63)\E?H/\ !W]IOP!\7&@TF)Y?#/B]XBS>&]6E
M1A=N@+2_V)J:K';ZHL:_.86CL]1V"23[!Y$3S#^HO!3Z<W@%XW9EA>'LISS'
M\(\68V4*6!X:XWPV&RC%9GB)OD6&RG,<-C<?DN88FI4:CA\##,:>9XI23HX"
M352-/\OXU\#>/N",-5S#%X&AFV4T$YU\RR2K4Q=+#4TKNIB\/5HX?&X>E%7=
M2O+#2PU.SYZZ3BY?1M%%%?V&?CP4444 %%%% !1110 4444 %8&BLS7GB8-(
MSA-?545I)9!$IT'0W,:+)>720J7=Y3'!!IT1>5YC9O-+-J%]OU@:*I%[XG)5
MUW:^K#>DJ C^P="7<GF00JR':</"]U$6W#SQ()+>W -^BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ K"\,L[Z#I;.[2.;8;G>5YF+
M!W!!DEN[^0[2-H#W4K( $(CV^4F[6%X9!&@:4"'4BU4$2+*D@(9@0Z3PV\R-
MZI)!"R'Y3&F-H -VBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@#"\3LR>'=<=9&B9-*OF65)'A>)EMY")$FCO-.DB9" RR1ZA8O&0&
M6\M6 G3=K"\4 GPYKH4.Q.E7P C65G.;>3[JP0W$Q(Z_NH)G'58G("G=H **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,#7&=9O#^
MV1XP=?MU?;)+%O0V.HCRV,=Y9JZ,^W,<WVN*0@+]CGD,93?K UQ29_#Y"NVW
M7X&)1)6"@Z?J2[I&B@F$:98#?*]M$SE(C.6D2WGWZ "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ K"\.NSZ=*SR-*?[9\1J'>668A4\1:HB('FOM
M1<+$BK$D8N1%"B+%!:V$*1V%MNUA>' 1ITH(<$ZSXD;$BRJ_S>(M58$B:&%\
M$'*G:Z,I#17%W$4NI@#=HHHH **** "ORB_;<\)Z7X\_:<_9Q\%ZV]VFD>*8
M+'0M2>PEC@O5LM2\6M;7#6LTL-Q'%.(Y&,4CP2JK8+1L!@_J[7YD_MCZ1\0;
M/]H/X$?$?PA\,O''Q$T_P);6NKZA;^$_#VMZI$\VG>)GU :;/J.F:7J<%A<W
M$* IY\;NJ.)?)=<9_G#Z5.#I8[PFJ4,5@:^98!<9\ ULTPF'P6*S&=3*:'%N
M55<S<\'@J-?$UZ,<#&O*M"C1J3=-248MM(_=OHYXJI@_$J%;#XRC@<8^%>,Z
M678FMB\/@8PS*KPUF-/+U'%8JK1H4:LL7*C&E.K5A%5'%N26IYS\>?@+=?L<
M:1H'QE^ _CWQ=ID5CXBTW2_$/AS7=3BO;+5EO?M$T#S16-EIUK?V,S6:6>H:
M;J%O-NCDCNK6YAF@ KWS]L;XMW-S^S?X0TS086@\2?M!)X4TK2M-C9I+B'3-
M9M-/UO5XHY 8PX<7&GZ!.QCD,D>LG;"I/F1>2_%;5?VB_P!L.UT#X8V'P)\3
M?![P;'KUEJ_BCQ'X]2^M6VV@EABD@35=&\/S3V]G%=RW LM,M]0O-0NUA0R6
MD$$[-)\3O@K\3OB]^T=X)\#>%CXQ^'7P^^!/@;1M/\*?%&_\'ZG<Z6-8T.VT
MRY&H:)<7\V@Z?J^KRZDVCZ8C:;J.470I]5MHI[:SDD/\VYE/%X#+_%G)_!'A
M?BVAX?\ B12X&X!X1RJEE6;Y'@JW%.=RS2EQSFW#.7\5++'D^ P_"L*F'Q^;
M8E93DL<Z^ISKXI0A&M#]WP$<-C,=X:YIXM<0\-5>,^!*O%_&?$V95,RRW-\9
M2X=RF.6U.$,MX@QO#KS#^U,;6XCG"M@\MH_VEFLLJ^M1I8=RE*E/H?V1M'@\
M/:I^T%^QU\0PFL6>BWEWJ6G6]S"L4>J^&-?M+:QU.>)92L\*W-I=^'-9LA'&
MXAEU2>[AEC=8WD\-T'XR^*/V.]"^/7[/>KO?7>MZ;,]_\&M6,#A9O^$GEALC
MJ*>7Q&@TZYMO$UM#',\,.M66K6#!YY7 ]#U+X,?&_P" O[1_PH^*LWB#QM\?
M;?7[J70_''B+1_ 6HRZCI&AM':Z+<1:S::9?^))&MH--OX]0TV]GGM0TND/;
MJ,6P+>D_M._#GQ'XK_:L_9LUVQ\":YXD\,:9=:#%XHUFS\,7^KZ%I]I:^,7O
M3%K^HP6-QI]I;6\,LUT8]1FCBCBEEF*A)'9N6IDW&V5\ TJ61Y7Q#P)XC>$G
M'6.\-\B^O8>EG6.?A5XL5Z<,HH8W&Y-C<;EV;+AC#YS@\;@\9@\PQV&RS'<,
M*H_9SKUU#IIYKPGF/&=2>;YCDG&' OB7P?@^/,X^IUZF4X./B/X;T9SS2MA<
M+FN$PF/RU\05\JQ6%Q6%Q>"PF(S#!\0N*]I"C1<]/X7?LE^)]-_9G'@.R\<7
M_P ,OB!\1[ZP\4_$7Q';Z.^K:PUI-;RM'X+F UC1+RV2SAFMX[Z6+40PO6UJ
M'RY;?4Y\_+_A[P_\/?!G[4GPN\"?LX^)_'D7B/PYX^O='^,\WBG7K32]%UBP
M\.:U8V/B2RL([IK%];O;VVM?$4<MA#!=)=LUA)I<3R))/!^C_P"TRWQTM/A_
M;ZQ\ +YT\6Z+K=K>ZKHT>F>'M3F\0>&Q;7:7]E:0^(+&\3[;#<FRN8H[!K>_
MN8$NH+5I;EX(F^)/B,WQB_:I^(GP8BL_V?/&OPDN/ GB.+5/$/CKQ?8WNG):
MV27FF7D\&FZG=Z1I$MW:64EA=7-C;VTMS/>WMQ;&*&S4SSR?4^+7!7!W"=;@
M_A3A#A#BA<7\%OPVPW#N*CP_Q#F53B_)<-Q)1Q./P? _%> QV.R+@K/*%?\
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MA%<M+"U8XBABL+2348.IB*%&$*&'IQ5VBBBO]"#^? HHHH **** "BBB@ K
MT2,I>>)V,0C$OB 2*PA,?G :%H<9EW_V/I:W!W1F,S)=Z^%,?D/K"302Z-H^
M_7.Z&J+?>*BJJ"_B)&D*QQ(6<>'?#Z!G:.UMWE8(J*))Y;Z4(J1"Z2&.&RM
M#HJ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L'PP
MAC\/Z5&8O)V6B*(A$8!&H9MJB)M(T'8 N  NCZ>A&#';JA4G>K \+*J>'M*5
M0B@6HX1$C3)=RQ5([6SC 9B6RELBL3N!D!\UP#?HHHH **** "BBB@ HHHH
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M=+E:DW::;]HFI2C%1:5U_</17^>KX;TK]C_X#_#'_@BK^T5_P39^.&K>+/\
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M045S3JQO9?Z?]?$'[%?[?7P>_;M_X:)_X5'X;^)?AW_AF?\ : \9_LX^//\
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M@ HHHH *PO#D9BTZ53%Y).L^)'V>2\&1)XBU619/+?1]#8^<KB7S18R)/O\
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M^'M7_!2O_AJW_ABO_ASQX0_X:"_X9Z_X:B_X1;_AY)\-?[+_ .%-_P#"R/\
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M45(PHKXQ^'7[7?\ PGW[<7[2?[&7_"O?[)_X9Z^$?P+^*?\ PLC_ (2S[?\
M\)?_ ,+IF\91?V%_PA__  C5G_8'_"-?\(CN_M3_ (2G6O[9_M#']G:5]DS<
M_4_C;QEX;^'7@SQ=\0?&>JV^A>#_  )X8U_QEXKUN\8K::-X;\,:5=ZWKNJW
M3 $K;Z?I=C=7<[ $B*%B :TG2G"48RBU*<*<XI-2;C5C&=-KE;UE&2=MU>S2
M=T3&<9)R3TC*<6W=).$G&:=[;2BU?9VNFUJ=/17Y2_\ !*C_ (*A:?\ \%,_
M 7Q4\0:C\#=?_9P\>_"_7_ 5Q=?"_P 4>+X?&>KZI\)/C+\/='^)GP-^+J:E
M#X6\():Z1\4/"]]JEWI>G1Z=?V\":)/+:Z]JT,ZO#Y_\=/\ @I5^U?H'[<?Q
M2_8D_91_X)^:)^U+X@^$7PC^&_Q>\6>,=;_:_P#"G[/\4&C?$>:]M+&T@T+Q
M7\(/%5O<R65[9M;M+:>);F:=7\][&T10&W^I8E5JN'E",*M&'/54ZU&$(0?)
M:3JSJ1I-/VD+-3=^96N8_6J#I4ZRE*5.K+DIN-.K.4I>][JA&#J)KDE>\5:S
MO8_9JBOR?_9Y_P""G6N>*?VC_#7[&O[9O[*7Q"_89_:=^(?AWQ!XJ^#F@>)_
M'?@OXR_!_P"..E>$[8W_ (HLOA1\;O 2V.D:YXJ\/:2KZ[K/A/6/#OA_5]-T
M=H)+N*+4KA-+&U^U-_P4GO\ X4?M":;^QK^RW^S3X\_;4_:[G\$0?$OQ1\,_
M"'C#PO\ "SX?_"7X?WUU'9:1XE^,GQG\:0WOA_P2FNSRH^BZ/:Z/X@UZ_M6@
MF33%EU7P];ZU/U/$>T5/D7,Z?M5)5*3I>RO9U?;J?L?9I^ZZGM.12]UOFT']
M9H\GM.=V4_9\KA-5/:.UJ?LG'VOM&FGR<G-ROFMRZGZC45^0_P +O^"G7Q.T
M+X_?"7]FG]OG]BGQI^Q#X_\ VA[_ %/1/V?O&=G\8? O[1WP*^)7BS2;-M0N
M/A]/\4O VE^&)O!?Q$OK4%M!\,>*O"=BNO2QO!IVI2RW&E+J?Z\5G5HU*#BJ
MB2YX\T)0G"I"<;N+<*E.4Z<TI)Q?+)\LDXNS31=.K"JFX-OE?+*,HSA.,K)V
ME"<8SBVFFE**NFFKIIA11161H<["R_\ "6:B@9-X\.Z,S*'B,@5M2UX(S1BZ
M:94)5PCR6443$2+#=3ND\5MT58$4A/BF_B\T$+X?TF00><25+ZCK2M+Y!UB1
M4#A%0S)X?LS+Y8276-2$,-EI._0!^%/[77QU_;LUC_@K5\$OV(OV8OCUX/\
M@S\,_B3^Q#XO^,'CK5/%OPN\)?$6X\)ZSH'QBD\/7?Q \%:?J.D0:OKWCP:'
M%9>%/#WASQ#XRL/AIIYUB[\8Z_X=\47>@P^'->Z#]GC]H_\ :C_9Q_X*"?$#
M]@3]L/X\V7[47A77/V1[O]L?X'_M 2?"?P5\*O']CI/A/X@3^ _B-\*/'WA7
MX566E^#-5O--3RO%'AGQ%I7A?0H[G28)+"\NK_6;M;*S^:/VS-+_ &CM1_X+
MZ_LXW/[+'BKX6>'/BSHG_!,GXD:Q::9\:M!U_6?ACXZT.+]H)[+6?!7BB_\
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M)#_$8^!/C#IG@73/AEXP\6>#[K]L?X-3/!\3_ _AA(_ FG^--%U_^V+#^UO
M-OI'AOQ!X?\ [$U >&_#^J_VG8U]2_M.?L*_M)7?QN_9-_;-_8[\=?!C1/VG
MOV<_@YK/[//C7P1\=X?&1^"OQI^#OBFWTN^U#0;[Q5X(TG5?&_@O6/"WBW3I
M?$7AC6M*\+ZE_:$]ZD6LVD=E8R:?J-#]G3]CG]N:V_X*1G]OC]K/XF?LZZ]9
M:G^Q#XM_9EA^%_P-M/'>G:7\,M<U3X[_  \^)>B:9X7N?&7AM-5\?^')]&\)
MZ[JWBKXA^*M?\/:_<^+M=MM"T+X;Z/X5TRVNH\XU*$:$E">&C%X.M"473BL1
M+$RJ2VG[/VCC*GR<J]I[%17+95$T7*%5UDY1KR:Q-*46IOV*H*$+WAS<B:GS
M<WN>UYO>NZ=F?L;7Y9?M\ZDTOCOP/HYD)6Q\)7&I"+<2J-JNLW=JT@7. 9!H
MR*S  L(E!)V#'ZFU^7O[?6D31>+? .O>2WD7WAS4=($^/D,VE:F;PPENS*FL
MJZJ<;@S%<[7V_P"?G[1ZGCZGT4>-7@U)T*6>\%5,S48RDOJ'^M&6P@Y\ND8K
M,9Y>^:?NW27Q.)_0WT<94(^*V2JLTIRP.=1PMVE^_P#[+Q+:5]V\.L0K+6U^
MESX!HHHK_FR/]) HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ K]R_V9M2;5?@1\-[II#(8M$FT
MT,S%B%T;5-0T=(\DG B6Q$2KT14"@   ?AI7[K?LYZ1-H?P0^&UC/"T$K^'8
MM2:)QM=1K5S<ZRA9>JLZ7ZN5;# MA@&! _U,_904\>_&GQ$JTU+^S(>%]>GC
M&HRY%CZO%G#4LN4I+W%)X>CFO)&7O22FX:1F?RW]*Z5!<%\.PE;ZU+BB$J.J
MYO81RK,EB;+=KVD\+=K1/E3U:/:J***_WL/X+"BBB@ HHHH **** "N=T-D:
M]\5!64E?$2K(%DB<J_\ PC^@$*XCNK@QML*-Y<L=G*%92;4JR75ST58&BR%[
MWQ.IE$GE>(%C"^<9?(']@:%((BK:QJA@)$GF^3]D\/@B43)H\B2KK>L@&_11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5S_A5D?P[
MI#(5*-9H5*/%(I4EB")(+B[ADR.?,BN;A')+++("&/05@^&',F@:6[2><S6P
M+2>:9]QWN#^];5]>=R#\I,FL7\F01).9 R* ;U%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% '/^*V5?#.OLY14&D7Y<R/$B!?LTFXL
MTUQ:1!0,D[[JW4CCSH\[AT%87BAS%X;UV02B$II-^_G&4P"(+;2$R&8:OH'E
M! "WF'7-'1,;GU.Q0-<Q[M !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110!SVO,BS^' Q0%_$4"H&>)-S_ -FZHV%62ZMVE<*K.$AC
MO)5"F;[*(XI+FVZ&N?UV0QS>'P)1$)/$%M&09C%YH-CJ+"+']L:2LQ8J"(7B
MUD,5W)H\\R17=ET% 'FWQ-^#7P@^->F>']%^,OPI^&WQ;T;PGXLTKQ[X5TGX
MF^!O#'CW3/#7CK0K>_M-#\:>'[#Q5I>JVNC>+-&M=5U2VTKQ'IT5MK&G6^I7
M\-G>0QWEPLG::]H.A^*=#UGPQXGT;2?$?AKQ'I.HZ#XA\/:]IUGJ^AZ]H>L6
M<VGZMHVLZ3J$-Q8:II.J6%Q<6.HZ=?6\]G>V<\UM<PRPRNC?/_[9'[0__#)7
M[*O[0/[37_"(?\+ _P"%%?"KQA\3?^$)_P"$@_X13_A*?^$4TF?5/[$_X23^
MQ/$G]B?;_(\C^TO[ U?[+N\W[!<[?+.GXW_:E_9_^#W@#P+\1/V@?C3\'?V?
M=#\?:5IE]HMY\8_BIX*^'>DWE]?:78ZI<:1I>M>-M5\.6>L7=A'?P+,MHHFV
M/%,]M"LR+6JIUI0IRBIRBZDX4U%\S]I%0G-1@FY)VE!MJ*3[MIVS<J<933<8
MR48RFVDERMRC%RDTDU>,DDWIV2:O/9_LJ?LO:?IOPCT>P_9N^ ECI'P U:ZU
M[X#Z59_![X>6VF_!/7+Z^CU.^UGX1V,/AU+7X;ZM>:E%%J%UJ/@V+1KRXOHX
M[N:9[A%D&K\8_P!G']GG]HG3]+TG]H'X#?!CXZ:5HD\USHNF?&/X7>!_B=I^
MD7-P(Q/<:79>-=#UNVL)YA#$)I;2.*2011AV;8N->7XW?!>#PAX-^(4_Q=^&
M$/@'XC:WX7\,_#WQQ+X^\*1^$/'?B/QQJ4>C>"_#_@WQ*^K+HOBC6_%^KS0Z
M5X7TK1+V^O\ Q!J4L=CI-O=W4BQ'&^%'[2/[._QXO?%&F_ [X]_!?XS:CX(O
M?[-\:6'PH^*7@?XB7OA'41++ ;#Q1:^$-=UB?0+T3P30_9=5CM)_-AEC\O?&
MZA_OU^\7MDZ;=Y^_[DG+WO>^RW)N^J;D]=6'[GX/W?OI>[[OO)+3W?M))*VC
M22TT1T,/P<^$5O\ #0_!>W^%?PX@^#K:1/X?;X3P^!_#$7PT;0+F:2XN=#/@
M1-+7PN=(N)Y99Y]-.E?8I9I9))(&=V8R_"[X1_"CX'>#;#X=?!7X8_#SX/\
MP^TJXO[O2_ GPN\%^&_A_P"#=-N]5O)M1U2YL/#'A/3=)T2SN-2U"XGOK^:W
ML8Y+R\GFN;AI)Y'=L.[_ &@O@)8?"6Y^/E]\;OA#9? JRMYKN\^--W\2O!EM
M\);2UMM=;PO<7-S\1IM:3P=!;P>)D?P[--+K*1Q:ZC:0[+J"FW%/XR_M*?LZ
M?LYV>CZC^T)\??@K\"-/\0SW%KH%_P#&7XJ>!?AA9ZY<VBQO=V^CW7C?7=#@
MU.>U2:%[B*R>>2%98VD50ZDI*M+W$JLN><O<2F^:I%>][NMYQ3][1R2>NX7I
M1]^]-6@O>O%6A)^[[W2#:TULVM-CA=6_8<_8IUZ[^(]_KG['W[+>LWWQB6S3
MXNWFK?L_?";4;OXIIIVOZ9XKT]/B/<7GA*:;QPMCXIT71O$EFOB9]4%KK^DZ
M9K$ 34;"UN8O0_BG^SQ\ /CIX7TOP/\ &WX&?!WXQ>"M#D@FT3P?\4_AEX*^
M(7A?1Y;:**"VETOP_P"+=$U?2=/DMX8((8'M+2%HHH8HXRJ1H!I:K\;?@QH?
MA7PCXZUOXN_##1_!'Q U32-#\!^,=5\?>%-/\*^-M:\06]W=Z!I'A'Q#=ZM#
MI'B35-<M;"^N=(T_1KR]N]2M[.[FLH9X[>9DS?A?^T-\ /C?<:E:?!;XY?![
MXO7>C:3H^O:O:_"_XF>"_']QI6A^(;S6=/T#6=2A\*:WJTECI.N7_ASQ#8Z/
MJ-TL5GJ=YH.LVUE-/-I=\D#<L1I-RK6IO2;<_<EI#27V7:,8[I^ZH]$A6HWY
M;4KS6L;0O-:RV^TKMRZ[M]3?TGX1_"C0?AXGPCT/X8_#S1?A1'I<NAQ_#'2?
M!?AO3OAY'HD^?.T=/!=GIL/AM=+FW-YNGKIHM)-QWPG)KC/@Y^R[^S-^SM+K
M4_[/W[.WP*^!<WB39_PD4WP<^$?@#X8RZ]Y;*\?]M2>"O#^B/JGENB,GVXS[
M&167!4$>E>$_'G@;Q['X@F\"^,_"GC2+PGXKU[P'XJE\)^(M'\1Q^&?'/A6Z
M%EXH\&>('T>\O%T;Q7X;O66TU[P[J)MM8T>Z(M]0L[>4A*_&'3O^"P_Q G^'
MWA+]K35OV)/$.B?\$Y_''Q&\*>!O#_[4]S\>_ TWQ&3P]X]^*UA\&?!?Q<UO
M]FQ/#":CI/PSUWQMJND@3I\3KWQE;:#JMAKC>#9;>9HX[I4L3652-/FLY052
M,JL:?/4GS.$.6I./M:L^63A"*E4DXOEB[$U*E"DX2GRI\LG"2IN?+"/*I2O"
M,N2G'FCS2;C"-U=H_3Z7]C[]DJ?XJ'XZS?LN?LZ3?&XZB^KGXQR_!+X:2?%0
MZL\CROJA^(3^&3XN_M%Y9))7O?[7^TM([N92S,3]"W-M;WEO/:7<$-U:74,M
MM=6MS$D]O<V\Z-%-!/#*K1S0S1LT<L4BLDB,R.I4D'\Q_C9^WK\:K#]H[XF?
MLQ?L=_L@O^UEX[^ 7@'P)X]_:"U?6_CQX;^ 'A'P#-\4+;6-5^'OPXT#5=<\
M$^/+KQI\4_%'AG1+CQ7!H;Z=X;\+:=H5WI<VL>-K"ZOXK1>:U#_@JOX7\7?L
MW_L>?&/]G#X'^-OCA\4?VY_$^M^!/@9\ ]2\1Z!\+]7L/&?@+0O&^N?&33/B
MGXUUJ'6]'\#Z?\&!\-_&VF^.=0L=,\47HU/16M]%T?55E,D5/#8N:I2DG)-0
M4.:M3;IQE3E5ASIU+T(2I0E5A*JJ<'3C*:?*FR57P\7.*:BTY.7+3FN>49QI
MRY6H6JR524*<E!SDIR4'[S2/NSX5_LM?LR? O7->\3_!']G/X$?!SQ+XJ##Q
M/XA^%?PB^'_P]USQ&'E\]QKVK>$O#VD7^L!I_P!\W]H7%QNE_>'+\U3\<_LD
M_LI_$[X@Z9\6_B5^S+^SY\0OBKHKV4NC_$WQS\&/AQXL^(.DR:9'#%ITFF>,
M]?\ #>H>([!]/BM[>.R>UU*)K2."%(#&L2!?C3X??\%(_$%QX+_;BL?CU^SN
MWP)_:)_8/^$$7QP^)?P<3XP^'?B+X+\5_#W7OAQXU^(7@7Q%X)^,NE^&-"CN
M=+UT_#_Q1X>\0RZK\/\ 3;_P5J5C#-J&EWUMJ&GM==)^R[^T_P#M^_&WQ%\+
M=4^*W[ 'PM^"OP,^(?AM?%=_\4]#_;@T_P"+/B7PYI&K>"KSQ-X1>+X7Q?LY
M>!+C6Y]<U=M!T"_@'BW2VT.WU>ZUIS?C2FTV\<J.+@YU)347"*4IRQ5)2E&5
M.-2*IMU;UE*FXRBJ7.FFDKMI JN&DH0C'F4FVHJA4:C*,W3;FE3:I.,TTW4Y
M.5IMV2;7W!XF^#'P>\:^// ?Q4\9?"?X:>+?B?\ "S^UO^%8_$?Q-X$\+Z]X
M\^'/]OVXM-=_X0/Q?JNE7?B'PA_;5JJVVK?\(_J.G_VC;J(;SSHP%H\,_!CX
M/>"O'GCSXJ>#?A/\-/"7Q/\ BG_9/_"SOB/X9\">%]!\>?$;^P+<VFA?\)YX
MOTK2K3Q#XO\ [%M6:VTG_A(-1U#^SK=C#9^3&2M>E45R\\[<O/*W+RVYG;EY
MN;EM>W+S>];;FUM?4WY8WORQO?FO97YK<O-?OR^[?>VFQ\^?#_\ 9)_93^$_
MCO4_BE\+/V9?V?/AI\3M;2ZBUGXC?#_X,?#CP;X[U>.^!6]CU/Q?X=\-Z;X@
MOTO Q%TEUJ$JW )$H<$UW/AGX,?![P5X\\>?%3P;\)_AIX2^)_Q3_LG_ (6=
M\1_#/@3POH/CSXC?V!;FTT+_ (3SQ?I6E6GB'Q?_ &+:LUMI/_"0:CJ']G6[
M&&S\F,E:]*HINI4E?FJ3E>*B[RD[Q3347=ZQ32:3T32:6@*$%:T(JS<E:*5I
M-6<E9:-IM-[M,\=O?V=_V?\ 4OB_H_[0FH_ OX.W_P ?/#UI<V&@?'"]^&7@
MJZ^+^AV-YHEYX9N[+1_B7/HDGC/3+2Z\-ZCJ'A^YMK+6H(9]$OKS294:PNI[
M=]?XJ_!?X._';PP?!/QO^$_PT^,G@PWD>H'PC\5? GA;XA^&#?PQ300WQT#Q
M=I6L:5]LBAN+B&.Y^R><D4\T:N$E<-Z712YYWB^>5X)*#YG>*5VE%WO%)MM)
M6M=ARQM)<L;2=Y*RM)NUW)6U;LM7V1YGH?P5^#?ACX;GX-^&_A+\,_#WP@.F
MW.BGX5:'X#\+:3\-SH][N^V:2? UAI5OX8.FW>YOM-@=+^RS[F\V)\G/&R_L
MH_LMS_![3?V>)OV:_@#-\ -%N;R\T?X&R_!SX=R?![2;O4-3U76K^ZTWX9OX
M</@JPN;[6->US5KR>UT2*6YU/6=5OYF>ZU&\EF]^HI^TJ7OSSOS*=^:5^=7M
M/?XE=VEOJ]0Y(?RQTCRKW5\.GN[?#HM-M%IH>.>$OV=?V?? 'PWU+X-^!/@5
M\'/!7P@UF"^M=8^%7A+X8^"?#?PWU6UU.,1:E;:EX&T;1++PQ?0:A$!'?0W6
MERQW<8"3K(HQ7'>#?V,OV/OAU>?#_4/A]^RC^S7X$O\ X3ZKXGU[X67W@WX%
M_"_PQ>?#37/&UI9V'C+6?A_<Z)X6L9O!NJ^+;'3M/L_$^H^'7TV\UZTL+.WU
M6:[AM8$3Z4HH]K4][]Y/WFW+WY>\VFFY:ZMIM-N]TVMF+V</=]R'NI*/NKW4
MFFE'31)I-6V:3Z'FW@+X-?"#X5:GX\UKX7_"GX;?#?6?BGXLU#Q[\3M6\!>!
MO#'@_4_B/XZU:XN;O5/&GCR_\/:7IUUXO\6:E=7EW<ZAXC\02ZCK%Y<75S-<
MWDDD\K-Y[JO['O[).N_%*+XY:Y^RW^SGK/QK@O8-2@^,&J_!'X9ZC\4H=1MB
MS6VH1?$"[\,3>+([VW9F,%TFKB>(LQCD4DU]%T4*I43<E4FI27+)J4DW&R7*
MW>[5DE9Z62[#Y(-).$6D[I<JLG>]TK63OK=:W/&/BS^SA^SS\?)O#5Q\=?@-
M\&/C3<>"[XZIX.G^+/PN\#_$:;PGJ;/'(=1\-2^,-#UE]"OB\,+F[TMK6X+Q
M1L9,HI'1> /@_P#"7X3S^-+KX6_"[X=?#6Y^)'C#5?B'\1+GP!X)\->#9_'O
MC_77$FN>.?&DWAW3-.D\4^,-9D DU7Q-KC7VM:BX#7=[,P!KT6BESS<5!SER
M+:/,^5:IZ1O;=)[;I,.6/-S<L>;^:RYMK;VOMIOMH%%%%24%%%% !1110 44
M44 %%%% !7/^&61M,E*%2O\ ;?B<'8\4BAE\2ZLLB[H;BYCRKAE91(C(P*/;
M63JUG!T%87AR3S--E;S1-C6O$J;Q,)\>7XCU6/R_,&L:[@P[/),?V^,P&/R3
MI6@F,Z'IP!NT444 %%%% !7\VW_!4.7]I:'_ (+&?\$II/V1['X&:C\<1\#_
M -MT>'+3]HW5/'VC?"E]-/A7PH/$;:WJ'PST?7O%\5\FAF]?1%L-,F@EU46L
M=^\-HTLJ_P!)-?)_Q$_8Z^&7Q,_:U_9S_;*U[7?'=I\3_P!F/PA\7?!7@+0M
M(U/P_!X#U?2OC1H]EHGBBX\7Z7>>&+_Q#?ZA86MC#)H$NC>*- MK6X:1]1M-
M5C*Q)UX.O##U95)I23P^)IJ+CS1E*KAZE."DDT^5RDE+565V<^)I2K4U"+L_
M;8>;:=FHTZ].<G%M-<RC%N-UND?G_P#"S]A_]N;XX?MN?L]?MK?\%&/'?[*5
MG/\ L=^%_BUI/[.?P1_9(TSXIZSX6/BSXX>';;PCX[^(7Q#\=?&2TT36[S4+
M?P]I]A:Z'X?TCPVNG6][9Z1JL%YIU_I%[-XCYO\ YV9/^\%?_O\ [7[J5\H?
M\,=_#/\ X;E_X> ?V[X[_P"%R?\ #)__  QW_P (U_:?A_\ X5G_ ,*S_P"%
MO_\ "ZO[=_L;_A&/^$I_X3O_ (2G_0/[3_X3/_A'_P#A'_\ 1?\ A&/[1_XF
MM:0QG,ZOM;1C]3J8:C"G!1A#FG[1126RE.52<I-MN4FV]=(EAK*FJ=Y/ZS3K
MU93DW*?+%0<FWNU",(I))*,4DC\ _P#@LK\+?VF_C3_P4S^ /PQ_8^^(]K\+
M/V@/%O\ P3=_:YT[P3XGF+65Y=+_ ,)5X=FUOPKH?B9;ZR'@3Q#XST2._P#"
MVB^/V%T?!U_JT6N10V\]I%J5A^KW_!'SXT?LU?$S]C'P-X#_ &=_A@_[/5Y^
MS^9?A%\9_P!F/78S:?$+X%_&#0Y)O^$VT+Q[;7OEZ[JFI>(M?&J^);;QSKMO
M%J?CQ;ZZUS5%M_$!US3=.^G_ !=^Q[\,_&G[87P@_;9U37/'5O\ %7X*_"?X
M@?!WPMX?L-3T"+X?7_AGXD7]IJ&N7WB#2KCPQ=>([K7;2:RB72;K3O%>E:?!
M$TBWFEWSE73D#^P3\'],_;57]N[P#XD^)/PH^+^O>!3\//C%X:^'6K>%=,^%
M?[1>A6;,_AJ^^-W@[6/!NNW.O^+/!;E%\+>-O#.M^$/%MI90PZ/?ZSJ6AQC3
M*TJ8JC5P=+"R<HNE14H3C%I.O&I6;IU4OCA*G->SG9NE-R2]RI4MG##U:>)J
MUXJ,E5J\LHM[4G3I)5(.WNSC.$N>.BJ04;^]""/BC_@KEXEU[]H+Q+^S1_P2
MC^&^HSV?B+]M_P 5W7B']HG6M.N'AO/ ?[%'P>O=.\1_&>]>>"6"YT_4/BA=
MQZ7\,/#$JSPKJ;7_ (CTT2(Q\Q/L3]I7]K"W_8JM/A?X%\&?L2?MF?M$^'+_
M ,-7.G:+;?L<?!KPA\0O#?PVT;P=%I&CZ1X>\3+K_P 2?A^OA\W-A<0Q^&K'
M3[?489;#2KT.]H+:))N_\"?L=?#+P-^UO\;_ -M5]=\=>,?C3\;/A_\ #_X3
M>;XRU+P]>^'/A5\+?A_)<:A%\/\ X1Z?H_A?0]3T'PWXL\47'_";>-(?$>M>
M+;W5_%D%MJ%K?:;;1FQ;ZQK"5:DHX>DH>TI4H.=2,G*'M,162=25XOF2A&-.
ME&SLU2YE\;OM&E4;K5'+DJ5)*,&DI\E&F_<C9^ZW-N<Y=G4Y=>1'\[__  7S
M^),WQ@_X-_\ ]I[XF7'PY^)GPCF\9:-^S=K$OPV^,GAZQ\)_%#P>TG[7/P.A
M.C^-?#FF:UXBT_2=9B\GS9;6TUO4H1#+"ZW+;R%]W_X+#7GPY\87/['/[.OC
M@?M _%.\^,7QC\4^(=._8O\ V=K2PT[Q!^V!HGPG\'C6/$?A3XA?$/6_B9\)
M?#OP]^#OP]NO$'AWQIXZU#7O%Z6&IF/2+-M,OC&6MOOK]N']COX9_M]_LN_$
M_P#9*^,6N^._#7PX^+'_  A7_"1:U\--3\/Z/XVLO^$$^(?A+XEZ1_8NI>*?
M#'C+0K;[3KO@W2[34OMWAO4O.TF>_@M?L=Y+;W]KRO[8'["'PM_;'U3X,>,O
M$GCKXQ_!KXO_ +/&O^*O$'P5^.?P \8:3X+^*GP_D\>:-9^'O'FE:7J/B/PO
MXU\-7N@^-=%T[3M-\1Z3K?A;5+>]MK&V5! R,S;T,31A##1DY0=+$X^L^5-\
MBKX?"PP]I?$TJM%\[@U5C!<U.2J<LEC6H592KM*,_:4,'2]YI<_LJ]>=;3X4
MW3J+D4DZ;D^6:<.9/\4_V'_!6I_LP_\ !8;P=\%_AS^R9KW[!'P=^,_["_Q1
M\;>+?V=;?XT>$/BG\/\ QEXU^'WQ8\#V?A_XLZ=H7@GQ9XKT#P9XNL],UV^\
M*:E/:RV3ZM8([>7=M)=7DW,_\$A?V2/A7X]\/?ML_M=^,M7U>_\ C7\!_P#@
MH1_P4 TO]G7Q!X]\=^+$^$/[.UW;:KK5UJ'C72/AOINJV/@J;4=8OO&^LWOC
MKQ/XHT3Q%JUWH5K9Z393Z?IUDUO<_L)\$_\ @ES\#?@E^U!H'[8UM\3?VC/B
MA^T'IGPH\7_"'Q%X\^,_Q/L_B#??$#P]XNUOP[K0O/%'VSPK9R:5<>%E\,V6
ME^#O#WP\F\"_#W0[&\UJZ'@JYUS6]3UFYVO G[%!_9'_ &6OVPOAM^R%XCU[
M5OBE\=?$G[3WQ]\$W_QGN_"^OZ/I7[0WQM\/7EUH]A-#I/A7PSIG_"M],\96
MNB>5I.M66K7Z:2;V'5M:U59-Z[U<=3DJD:524:E:GA:4ZEIQ4O9U*RJ\\ZDZ
MM1P=.<(.4YR<Z=XR2C>"SIX647!SIIPISKU(03@W'FA2]GRQA"G!24XR:4(I
M1G:2;=IO^5CP#\ ? _[67_!/CX':3\*OV%?VHO''_!4_Q_XP^%OC*7]N/XD?
M"KQ_XB^%GB#Q;H'QLT#Q9XE^.WC/]KCQG)<?"7XG?L]:MX<T:^UCPW\-$UKQ
M#_:6G_V!IFC>!HM3L;#7X/T;_P""A<'C;X]_\%7O#?[(^J_L;>-_VV?V:?@)
M^PQX9^+OA[]D7P1\</AA\ ? -YXW\<_%76O!+?%_QOI/Q%^(?PPT#XD:#X(T
M'PSIW@+PEX4@E\0:9X2U>_FU:*QL;BZD#?(&A_L9?L?Z7^QEI?PCT#_@CI^W
M5H?_  4IM/@Y+X5M/B-H'P*^)7@0Z1^U7=^&);"3XJVO[7'AWQ'X9_9\TOX?
M0_$R_F\3P:KH7BZ#0++P3&-,LO L5E:V_A9/Z$=0_P""= ^.7PC_ &/O%'Q[
M^+WQE^'/[<W[/_[/_@GX<>*/VLOV;_B):>#_ (JZOXBO? OAW3_C'I6H:YK?
MA?Q+X6\=^"?&7CC3K_Q.=(\:>"=8L8=5D&M:5::3?W-V\W;B,53I554<IN+G
MC(TO:\SG3E65.U6DZ.*=1X:*I^SI^SE2<%.<H>T;<5RT:$ZE/D48\W+AG4]G
MR\LXTG*].HJE!1]OS2<YJ<:BER1C+DLF_P N_P!DK]DSQ7J]O_P43_95_:1_
M8\NO@Y^PCKWP^^'/QH^ O[(WQB_:6^#'[0US\&_B/X<TK7I?&%KX/T;X6_%_
MX@>)O!?PTUO7=/\ "7C?PSH6M)I_A;1];L+B/PXL9O;VWF\+_9S\)>#/V$/^
M#;'Q9^VU^RC\/]#^&'[4WQ'_ &.O#5SXT^+OA2UN8_%^LZO?^.Y?"5KXPO)Y
M7O;?^U_!FG^+-7U_2+Z.SB73[VV6\=D2)I%_HB_97_8(^#W[*NH_&#Q?8^*?
MBW\=?BY^T#)X>C^-/QQ_:0\;0?$OXG_$'1_".E7NC>$O"FI7%IHGAKPAI'@_
MPWIVIZI;:5X8\+>$- TA(=1E@N;:YM[;3HK+@OV8_P#@F/\  _\ 9>^&'Q0_
M9^T3X@?'3XL_LP_$GPUKG@FP_9B^/'C/PW\1/@U\,/ _B?4/$NH>)?!OPXLA
MX(T;QG!H&NCQ3J%A?P>,_&GC6Z&GPV4-I=VLD4LT_%+,*<G-.<I4_K&!K2I1
M52-+$QH4^3$1DIU*KYJDE"3E6;=7EYYN,U&)TQP<XJ#44I^PQ5)5).#J475G
M&5&2E"%-6IKGBHTDE3YN2%XMR/YRO%_[*O[0/P3^$OPH^.'[(O\ P2H^+O[,
MO[4GPM\3?!WQW=_MK^-O^"B/[)-Y%\9-/;Q+X=3XG6/[0NL:S^U'>V_Q$\+?
M&_0M2UJUGT?7!=Z>FN:SHFGZ+!8Z,O\ 9DGZ5_&'X,^ /^"@_P#P6C^*?[,W
M[6NG7_Q+_9O_ &5?V-/AA\3?AC^S_J.O:WI7PS\1?$[XK^-K^U\1_%7QEX>T
M?4--/C/7-"TNQM_"V@C4YKO1-&@9I([%=2EDGD^G=-_X(L_ 7[-X \$^-_VD
M/VX/B]^SK\+O$'A+Q#X$_9*^*?Q^LO$7[/NCR_#_ %&SUCP%HVHZ?9>!-'^)
MOC'POX-U33]/N]!\,^.OB=XGT:W6PL;">TN=*L[:PB^A/VI_^"<OPD_:?^+?
M@/\ :'M/B=^T!^S7^T;\/?"6H_#O2?CS^R_\0=)^'_Q"U;X9ZIJ9UN[^&WBY
M/%'A'Q[X.\6^#/[<+:W:Z9KOA*]GT_5'>[T^\MG=@:GCZ4YI^U<9^RQ$(8F%
M/$.I1=5T73]^MB*U710J0<:34:/MINFZG,R8X.<8->SO'GH2G0G*CR5%24U-
M<M*C3IZN4))U%*51TXJ:A9'Y[_\ !/7X$>#/V;O^"P7_  4B^$_PYU7QA=^
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M3UV/VM_^":W[/?[7GCKP;\9M;UKXP? S]HSX>:/<^'/!7[2_[,GQ(O\ X/\
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MR;E9RE=\J5K]=+VKYY580A>2Y(Q?-)144O?GHG)RYK**M&-ES2;T****P-3
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M?QM?#_POX;\<_P#!-WX8_"[Q5IK^)OAOJ/\ P<<>&?AQ<>$_$W@*\^&UI=>
M->_X*#"UU;POJ'PFOT@N?AM8ZI;:WJPU3X;S0VTOA6XU/4-"N(8[FVFK]G+#
MP%X(^'W_  7 ^&=GX"\(>&O!-CK'_!)SXUP:KI_A+1-.\.:=J,7A+]K7]G&S
M\+K>:?H]O9V5P?#UGKVM6>C/) TFG6>IWMI:M%;SO&?V)HJJN/=1S_=N,9O%
M-Q]I=7Q*@KM*$4W!P3O9<S_EL13P:@H^^FX_5TI<EG:A?1/F;2DI-;^ZF_BN
M?PZ?'7]L/X >&?\ @WE^/'["FK>+M6B_:[^'6G^-_!GQ(^ T'@?QU=>-OAOJ
M%O\ MC:EXJDU;Q^MOX<DTCP?X1?P\UGJ-IXRU[5;'PSJ+ZOH&E:;J=WK>OZ-
MIE]^K_[:/QG^'_A?_@I]KVG?$#Q/^S1^RCXCT']DOX:^'/AY\=?VC/@M\4?V
MC/&O[2F@>)O'OQ)\0ZY\)OV<OAY;_$OP)\+-&N/ 7B6&VE\?#0-!\9?&CX@:
MGK_@[0+2UN/#^EV,.C_T645H\PIMMQH3CS5,55FW7A)\^*^K\W*I8=PY(^P:
M4*D*MU4>JE",R8X.:23K0?+##TX_N9)<N'=;EYK5N;F?M4W*$J=G!:.,I1/X
MYOA)X,\+_$C_ ()H?\$_OA3\0=$3QC\.;S_@O'KGP_OO!7C+PB_AG2[[P.W[
M3_[2\4_@_6_AK>Q0P^&M$NX+J[M-7^'-W9II^FV]W?>&K[3VM%N+1OTM_P""
MCWB/3/\ @F/\9/@C_P %#_A7\-1+\/9?A!\3_P!B[XQ?"WX<^&((K76[KQ!I
M^O\ Q=_8^N=*\)>'DTBTAN(OVB-'U/X4SZBKH]K:_'AS ]I&MXUS^]E?(OQX
M_8X\$_M'_%?X,_$7XG_$7XP7_@_X(^*?#'Q"T']GO2O$GAO2?@3XK^)W@;6K
MWQ%X#^(_Q"T2#P>WCKQ5K_@S6[BQU70M(E^(-IX&&HZ#H-_J7A'4;VP-Q,?7
MXU*_/5@XT'/$SJTN9R52.(UE!6C%*:TY:C5E-1FTN6P?5)0H\M.2=51P\:=3
ME4>1T%&*D[RDW!I/F@FWRRE%7O<P/V'_ (%6_P"Q5^Q5\+_AW\0=:L_^$F\%
M^"=:^)'Q]\;7)MTAUCXL^-+S5OBE\=?&FHW=K)<QSV]SXZU_Q3?0W N+I8='
MAL[:"5[6UMU7\&/%7_!73_@GY_P4'^,>A2?&S]L'X2_ S]A3X!_%?0/''@_X
M3^)M3U*W^*?[9/Q,^&6OC6/!WCOXJZ))H8N_A?\ L_\ @CQEI.F>*/ _PRU(
M2>,/BEJNG:7XH\?6OAO0K;2_"\_]8%%84<53C4K5JU*I4KU9.4:M.M&DZ3FY
M.I*,94*RYW>T):>S5W%<_+*&M3#SE"E2IU(PI4XJ,H3IRJ>T45%0C*2JTWRI
M+WH_;=E)N/-&7X&+^U/\%?\ @G7_ ,%(O^"D.M?MB>)X_@OX$_:PM?V6/CA^
MS[\2=9\.^)+[PU\38?AO\ -'^!7Q"^&NBZYH>D:I:WOQ,\+^)OA_;ZK8?#Q'
M_P"$IU?1O%MKJNCZ5>6KRS5\V_ []N?PG_P2 _X)8_ #4_VD- G\*?M$_M9_
M%/\ :,^)OP1_9]^(^I2^ );%OBO\=O$'Q#L5^*GC"\TW4;'X;^%OAYX(^)7@
M3Q'\5=2O]/N-;T:ZUN;PYH'AOQ%XD-K877]0M%6L91DH1J8>4XOZM[=*OR*J
ML)0E0HQA^ZDZ2DI*5:[J.;C:FZ29/U:HI2E3K1C)>W]DW2YO9_6:T*U5R7M$
MJC3BU3T@HI^^JEC^;W]G'XG?L2?%3]EO_@HQK=U^T3??\%(_VB/VAO@WKWBG
M]NJQ_9$T5O\ A/-3^&%WX#U3X6Z-\%OV<_!'B*\\/PZ1X"^&W@[7/%&@?#&R
MU/Q WC37M5U;Q-XQU6^F\5>(VL;7PGPO!_P3UE_:M_X)W2_\$?9KO5_V@D_:
M#TL?M7:W\.+[XIW>J2?LC0?#[QT?C*?VV+[Q@6>;QA+KQ\*)X-M?C28?B)'X
M[S;>&$ANT>RE_JXHJECTG5<8U[5%)*#Q$?96E15%1J4H4(0J0II+V<(JDHQ2
MA=J*:7U1M4TY4KPY;S5%^T]VK[5RA.5:4H3F[\\I.I>3YK)MIE%%%>:=H444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6%X<
M8MITI+.Q_MGQ(,R/+(V%\1:JJ@--<W;[% "QJ)O*2,*D$-M"L=M%NUA>'59=
M.E#HT;'6?$;;7CEC)#^(M4=7"S6MG(5E5A(DAA<2HZRI=7R.M[< &[1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110!S\48'BN_EV %O#VD1^9Y"*6$>I:VVPW(TB.641F0L
ML$FOW:0>8TD.D:>UQ/>ZGT%<["$_X2S4"%7>?#NCAFVQ!R@U+72BEA$)V4%G
M*JT[Q1DL5BC>1WEZ*@#\%/\ @HA\8?A_^RE_P5-_X)O_ +4'[0&M2?#C]G>Q
M^"'[9/PDU[XRZMIFIW7@/PG\0/%EC\,M<\*>'_%VLZ7:7Z^&[CQ3::%J</AV
M358[>'6KRTNK;3WG:PU$V?G7QG_:R^"?["G_  64\8_M ?M2>(]2^&'[/O[4
M/[ 'P;\%_![XUW'A+QEXB\!^(_B'X!^+/CC7-6^'QO\ PEX>UZYL_%<WASQ)
M9>(K33[NUA+Z6]M*S"2_M(Y/Z,**[X8NFH4X3HSDEAIX6KRUE!SA*LZ\)0O1
MG[.<)NTG+VD9Q6D8.[.2>&FY3E"K&+E7AB(<U-R49QI1I2C*U2'/&48W5N1Q
MD[MR6A_,E^R[\:]"_:%_:N_X.%OBSX4\+?$/PKX1\3_LL_L6MX2C^)_@O5_A
MYXH\1>&[#]G#]J*PTKQK%X-\1Q6GB;1O#?C""W&O^$?^$DTS1M:U+PS>Z5K%
MWH^G#4([=,3P*JO_ ,&G5\&56 _X)O\ Q%8!@" R:=XG=&P<C<CJK*>JL PP
M0#7]1%%6\?'GA*-!QC3K8&K&+J\SM@L.J"BY>S6M6W.Y6]QNRC+<E81I/FJJ
M4I4L73;5/E5\56]LY)<[LH?#RW?-OS1V/YMO^"R'[C_@A9\)?)_<^3=_\$]O
M*\K]WY7E_$/X0^7Y>S&S9@;-N-N!C&!7H'[1?C[PQ^PK_P %H+?]M3]IJ36?
M"/[+/QT_X)_VG[-GA[X^GPSX@\0^!/A9\6/ WQL_X6+?^ OB/K.A:=JY^'ND
M^-- N;?6_#6LZL-/T3Q!KD%]81B2XTC4KVT_H)HJ(8U1IJE*DY0;Q7M+5.64
MH8GV#M"3IR4)4Y8>+YG&:DFXN"6]2PK<N=5+2BL/R7A=*6'=762YTY*<:K3B
MG%QM=2?3\!_V/?%>D?MF?\%B_CA^WY^SQ%KFK?L@^$?V!/!O['UO\79?#>N^
M%O!/Q\^.#?'BY^+NH^(_A[+KUAHESX[T?X;^$57P/?\ C&+3;W3DO+J.RT36
M)]'N;22[\K_X(CC3XO\ @V^^%9U'X+ZG^T/I-W\(?VT8?$/P&\/Q6TFN?&G0
M[K]H3]HFQU[X;:9;W&(]1U7QIH377ANQL&W3:C+=P:= &EFA6OZ3***F.4Z;
MIQI.,%4P4H7J-RC#!TL13492C&#E*HZ[DYQ]GR<MHQLURJ&%<9JHZEY.&*C*
MT$HN6)G1FY1C*4E&,/8I*$N?FYKREH^;^+KP;\;OA+\-#^RAX4_X)A_MF?'_
M ./>KZW\9/V?_#7B3_@DS^T[X-O?VC+#X0^#=:U[2+?QAI5GK/C_ .'NG?$O
M]FF+X Z)'J-]#XJO_&=[H&@3:*TMEJ']@7B"?^T6BBHQ>*CB7!JFX./.W.<H
M3J3<VG[\X4://RV=I3C*H^9\TY+E2O#T'04KS4E+E2C&,H0@HIKW(RJ5>6]]
M8QDH*RY8)W;****XSI"BBB@ HHHH **** "L'5XP^I>%V*;C%K5TX;R5D\LG
MPWKT>_S&T?4C;Y#F/S4OO#[-O\@ZI<+*VAZQO5S^L!#J?A0LJ,1KEWY;,L1*
M.?#/B %HVD@D='*;U)@EMY3&SJ7DA,T+@&^RJRE6 96!5E8 JRD8((/!!'!!
MX(X-?(7Q2_8W^'7CN>;5?#$C?#_79F>2<Z79I=:!>2N68O/H9FM4M)6;: ^E
M75E %WO+9W$K;Q]?45^=^)/A-X<>+^1_ZN>)/".4<5Y7&4YX:.84IT\;E]:H
MHJIB,IS7"5,-FN4XFI&$85,1EN-PM:I37LJDY4VX/Z+AOBWB/A#'?VCPWF^+
MRG%-*-5X><94,1"+;C3Q>$JQJ87%TXMN4:>)HU81E[T4I)-?D#KO[$7QETRY
ME32#X:\26J\P7%GK T^:1><"6VU:&S6&48^9%N)XAD;9WYQQQ_9&_:%!('@
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M_P":6C_AD;]H7_HGW_EU^"/_ )I:_;"BC_BE-]'C_HLO&?\ \2+@?_Z70?\
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M66VN(F!(D@E0F-M^@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MBH@_MSQ1E46)!O\ ^$FU<R,5A@MTWL^YI"8A*TA9IWFF,DS@'04444 %%%%
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MXB'F)&X5M*=73S8K.55D#2#8Z_;5CD#$"*6WO$D*FUEPK>(5 8_V+XA;:CN
MNE298+%/*%4&0'>YA6)$.#YMQ K;5,K1 '0T5STGB%8Q*?[&\0OY7G9$>DRN
M7\H:RV8@'S)YHT?]SMR7.J:,A DO@L;VUX*[(='U\[7="RZ8[(?+ENHF8,)#
MN0_96E1ER)(IK5H]QN(E8 WJ*P5UX,X3^Q]?7+HFYM,<(N^6UBW,PD/R)]I:
M5V&0L5K=,>5B69D?B%9!$1HOB%/-,(Q)I4B&,S#1CB7,F$$1UD+,^2B'2]9;
M>4L&=P#H:*YY?$*L%/\ 8OB$;D1P&TJ0$!XH)0K R95P;A8G0X*2QSJV%@E9
M1O$(5)'_ +$\1-Y:2-M72G+OY<5Y+MC!D&YW^R+'&"0'EO+- 09)?) .AHKG
MY/$"H7']C^('"&?YH]*E(<02:PA* L&(E&CM) " TL>I:/M7?J$:*XZ\ [)_
M8^O_ "NR;AICE#MEEBW*PD^9&\EI58<&)HF.#-$K@&]16 FOJY0?V/KZ;WB0
ME]+D 02RV$1=\.2$B-\SRD!BL5C?R*K+%%YS8_$*R>5_Q)?$*>:D#_O-*D7R
M_/BTF4++^\.QX3JRQ3J<F*73]64Y6PE8@'0T5SP\0@IO_L3Q%]P-M.E.'.8E
MEVX,GWQO6,@D#S=R DQ2[$D\1+&CO_8OB)PB3/MCTF5W?RHM1E"H@?<SS#3U
M2%< M+J&G1OL:>3R0#HJPM6+C4?# 7?M;6;H2;3*!L'AW72#((Y%0IY@0#SX
MY8@Y3 2?R6IKZ^J/,G]CZ^_DO.FY-,D9)/(EU2+="V_$B3?V6TL## DBOM+<
M[3?1"L35-::34?#;+HOB I!K5RTK?V1.ZQHVB:W:"8E+2[6-1)*,2O<:;F$D
M)=3&XAT_40#NJ*P$U\.\2'1]?0RO FY],<)&9Y=,BS*P=@B0G4S)/)DHD6FZ
MI(&9;9/.9'XB61$?^Q/$2;TA;;)I4B.OG1:=+M<&3Y7B&I+',"<)+9ZC'DFR
MEP =%17/'Q" F\:)XB.4+!1I3[S^Z:55P9!AVVK& Q 6614D*%9?+)/$*Q^:
M?[&\0OY:3N/+TJ5C*((M6E(B^<9>8:4$@1MK2RZGI,8 :[80@'0T5@/KZH9!
M_8^OMY;RH2FER,&$4M_$73#Y=)#8-)$0,R175A(J[;N+*C7@75#H^OC<ZH6.
MF/L7,L43,S"0_(GF-*S+N#10RM'O/E+( ;U%<^GB!7*#^QO$"%S!]_2Y%">?
M)H\>7;S"JB(ZONGY)CCTO6)""ED&E:OB(.D;C1/$0\Q(W"MI3JZ>;%9RJL@:
M0;'7[:L<@8@12V]XDA4VLN #HJ*YYO$*@,?[%\0MM1W 72I,L%BGE"J#(#O<
MPK$B'!\VX@5MJF5HB3Q"L8E/]C>(7\KSLB/297+^4-9;,0#YD\T:/^YVY+G5
M-&0@27P6, Z&BL%M>"NR'1]?.UW0LNF.R'RY;J)F#"0[D/V5I49<B2*:U:/<
M;B)6%UX,X3^Q]?7+HFYM,<(N^6UBW,PD/R)]I:5V&0L5K=,>5B68 WJ*YZ/Q
M"L@B(T7Q"GFF$8DTJ1#&9AHQQ+F3""(ZR%F?)1#I>LMO*6#.XOB%6"G^Q?$(
MW(C@-I4@(#Q02A6!DRK@W"Q.AP4ECG5L+!*R@'0T5SS>(0J2/_8GB)O+21MJ
MZ4Y=_+BO)=L8,@W._P!D6.,$@/+>6: @R2^2LGB!4+C^Q_$#A#/\T>E2D.()
M-80E 6#$2C1VD@! :6/4M'VKOU"-% .@HK!.O .R?V/K_P KLFX:8Y0[998M
MRL)/F1O):56'!B:)C@S1*Z)KZN4']CZ^F]XD)?2Y $$LMA$7?#DA(C?,\I 8
MK%8W\BJRQ1>< ;]%<]'XA63RO^)+XA3S4@?]YI4B^7Y\6DRA9?WAV/"=66*=
M3DQ2Z?JRG*V$K$'B$%-_]B>(ON!MITIPYS$LNW!D^^-ZQD$@>;N0$F*78 =#
M6&I?_A)90-^S^PK<GF787.H7(7Y?,\G> &R?)$N"!YA3Y1#)XB6-'?\ L7Q$
MX1)GVQZ3*[OY46HRA40/N9YAIZI"N 6EU#3HWV-/)Y.0VLM'XEN93HNOO$FC
MO;K+'I,SI+):ZIK*R>5*+18V69=/2:W U)VFBO\ 3)/L, NXIIP#N:*P/[?7
M./['U_[^PG^RY" /-\HOPY)0$,^0"3$OF*I5XO,$U\.\2'1]?0RO FY],<)&
M9Y=,BS*P=@B0G4S)/)DHD6FZI(&9;9/. -^BN=C\1+(B/_8GB)-Z0MMDTJ1'
M7SHM.EVN#)\KQ#4ECF!.$EL]1CR392X4^(0$WC1/$1RA8*-*?>?W32JN#(,.
MVU8P&("RR*DA0K+Y8!T-%<])XA6/S3_8WB%_+2=QY>E2L91!%JTI$7SC+S#2
M@D"-M:674])C #7;"%SZ^J&0?V/K[>6\J$II<C!A%+?Q%TP^720V#21$#,D5
MU82*NV[BR ;]%8(UX%U0Z/KXW.J%CIC[%S+%$S,PD/R)YC2LR[@T4,K1[SY2
MR-3Q KE!_8WB!"Y@^_I<BA//DT>/+MYA51$=7W3\DQQZ7K$A!2R#2@'045SJ
M^(@Z1N-$\1#S$C<*VE.KIYL5G*JR!I!L=?MJQR!B!%+;WB2%3:RX5O$*@,?[
M%\0MM1W 72I,L%BGE"J#(#O<PK$B'!\VX@5MJF5H@#H:*YZ3Q"L8E/\ 8WB%
M_*\[(CTF5R_E#66S$ ^9/-&C_N=N2YU31D($E\%C>VO!79#H^OG:[H673'9#
MY<MU$S!A(=R'[*TJ,N1)%-:M'N-Q$K &]16"NO!G"?V/KZY=$W-ICA%WRVL6
MYF$A^1/M+2NPR%BM;ICRL2S,C\0K((B-%\0IYIA&)-*D0QF8:,<2YDP@B.LA
M9GR40Z7K+;RE@SN =#17/+XA5@I_L7Q"-R(X#:5(" \4$H5@9,JX-PL3H<%)
M8YU;"P2LHWB$*DC_ -B>(F\M)&VKI3EW\N*\EVQ@R#<[_9%CC!(#RWEF@(,D
MOD@'0T5S\GB!4+C^Q_$#A#/\T>E2D.()-80E 6#$2C1VD@! :6/4M'VKOU"-
M%<=> =D_L?7_ )79-PTQRAVRRQ;E82?,C>2TJL.#$T3'!FB5P#>HK 37U<H/
M['U]-[Q(2^ER ()9;"(N^')"1&^9Y2 Q6*QOY%5EBB\YL?B%9/*_XDOB%/-2
M!_WFE2+Y?GQ:3*%E_>'8\)U98IU.3%+I^K*<K82L0#H:P-%+F\\3!M^T:^HC
MW&7&S^P=#)\OS'9 GF%\B )%OWDH9S,[M'B$%-_]B>(ON!MITIPYS$LNW!D^
M^-ZQD$@>;N0$F*79@Z5KAM[GQ1*^A>(RKZW)<1[-%N-\T</AZU(,>ZRL3<-,
MVEF"!HY=27S;W3K9]021I[+3 #OZ*P'U]4>9/['U]_)>=-R:9(R2>1+JD6Z%
MM^)$F_LMI8&&!)%?:6YVF^B%']OKG']CZ_\ ?V$_V7(0!YOE%^')* AGR 28
ME\Q5*O%Y@!OT5@)KX=XD.CZ^AE>!-SZ8X2,SRZ9%F5@[!$A.IF2>3)1(M-U2
M0,RVR><R/Q$LB(_]B>(DWI"VV32I$=?.BTZ7:X,GRO$-26.8$X26SU&/)-E+
M@ Z*BN>/B$!-XT3Q$<H6"C2GWG]TTJK@R##MM6,!B LLBI(4*R^62>(5C\T_
MV-XA?RTG<>7I4K&401:M*1%\XR\PTH) C;6EEU/28P UVPA .AHK ?7U0R#^
MQ]?;RWE0E-+D8,(I;^(NF'RZ2&P:2(@9DBNK"15VW<65&O NJ'1]?&YU0L=,
M?8N98HF9F$A^1/,:5F7<&BAE:/>?*60 WJ*Y]/$"N4']C>($+F#[^ER*$\^3
M1X\NWF%5$1U?=/R3''I>L2$%+(-*U?$0=(W&B>(AYB1N%;2G5T\V*SE59 T@
MV.OVU8Y Q BEM[Q)"IM9< '145SS>(5 8_V+XA;:CN NE298+%/*%4&0'>YA
M6)$.#YMQ K;5,K1$GB%8Q*?[&\0OY7G9$>DRN7\H:RV8@'S)YHT?]SMR7.J:
M,A DO@L8!T-%8+:\%=D.CZ^=KNA9=,=D/ERW43,&$AW(?LK2HRY$D4UJT>XW
M$2L+KP9PG]CZ^N71-S:8X1=\MK%N9A(?D3[2TKL,A8K6Z8\K$LP!O45ST?B%
M9!$1HOB%/-,(Q)I4B&,S#1CB7,F$$1UD+,^2B'2]9;>4L&=Q?$*L%/\ 8OB$
M;D1P&TJ0$!XH)0K R95P;A8G0X*2QSJV%@E90#H:*YYO$(5)'_L3Q$WEI(VU
M=*<N_EQ7DNV,&0;G?[(L<8) >6\LT!!DE\E9/$"H7']C^('"&?YH]*E(<02:
MPA* L&(E&CM) " TL>I:/M7?J$:* =!16"=> =D_L?7_ )79-PTQRAVRRQ;E
M82?,C>2TJL.#$T3'!FB5T37U<H/['U]-[Q(2^ER ()9;"(N^')"1&^9Y2 Q6
M*QOY%5EBB\X WZPO#.XZ!I9;<#]E7AS*6 W-M#&:267(7 (9^.@2-0(TCC\0
MK)Y7_$E\0IYJ0/\ O-*D7R_/BTF4++^\.QX3JRQ3J<F*73]64Y6PE8XGAS6V
M@T'38Y=#\1)+%:*)(SI$T;APGF/'LDM=,8.I<1D-860,N]5@C\N18P#O**YV
M3Q$L:._]B^(G"),^V/297=_*BU&4*B!]S/,-/5(5P"TNH:=&^QIY/)>^OJCS
M)_8^OOY+SIN33)&23R)=4BW0MOQ(DW]EM+ PP)(K[2W.TWT0H WZ*P/[?7./
M['U_[^PG^RY" /-\HOPY)0$,^0"3$OF*I5XO,$U\.\2'1]?0RO FY],<)&9Y
M=,BS*P=@B0G4S)/)DHD6FZI(&9;9/. -^BN=C\1+(B/_ &)XB3>D+;9-*D1U
M\Z+3I=K@R?*\0U)8Y@3A);/48\DV4N%/B$!-XT3Q$<H6"C2GWG]TTJK@R##M
MM6,!B LLBI(4*R^6 =#17/2>(5C\T_V-XA?RTG<>7I4K&401:M*1%\XR\PTH
M) C;6EEU/28P UVPA<^OJAD']CZ^WEO*A*:7(P812W\1=,/ETD-@TD1 S)%=
M6$BKMNXL@&_16"->!=4.CZ^-SJA8Z8^Q<RQ1,S,)#\B>8TK,NX-%#*T>\^4L
MC4\0*Y0?V-X@0N8/OZ7(H3SY-'CR[>8541'5]T_),<>EZQ(04L@TH!T%%<ZO
MB(.D;C1/$0\Q(W"MI3JZ>;%9RJL@:0;'7[:L<@8@12V]XDA4VLN%;Q"H#'^Q
M?$+;4=P%TJ3+!8IY0J@R [W,*Q(AP?-N(%;:IE:( Z&BN>D\0K&)3_8WB%_*
M\[(CTF5R_E#66S$ ^9/-&C_N=N2YU31D($E\%C>VO!79#H^OG:[H673'9#Y<
MMU$S!A(=R'[*TJ,N1)%-:M'N-Q$K &]16"NO!G"?V/KZY=$W-ICA%WRVL6YF
M$A^1/M+2NPR%BM;ICRL2S,C\0K((B-%\0IYIA&)-*D0QF8:,<2YDP@B.LA9G
MR40Z7K+;RE@SN =#17/+XA5@I_L7Q"-R(X#:5(" \4$H5@9,JX-PL3H<%)8Y
MU;"P2LHWB$*DC_V)XB;RTD;:NE.7?RXKR7;&#(-SO]D6.,$@/+>6: @R2^2
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M3Y#C&)7$18J&64E89-ZN$UK6&EN-$":+K[+;:_%)*XTF:1%1+;5;82*R6=\
MC2!665I=-01R1%M0!GAL-0W$U]7*#^Q]?3>\2$OI<@""66PB+OAR0D1OF>4@
M,5BL;^1598HO. -^BN>C\0K)Y7_$E\0IYJ0/^\TJ1?+\^+290LO[P['A.K+%
M.IR8I=/U93E;"5B#Q""F_P#L3Q%]P-M.E.'.8EEVX,GWQO6,@D#S=R DQ2[
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MXA3S4@?]YI4B^7Y\6DRA9?WAV/"=66*=3DQ2Z?JRG*V$K$ Z&BN>'B$%-_\
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M\0K'YI_L;Q"_EI.X\O2I6,H@BU:4B+YQEYAI02!&VM++J>DQ@!KMA" =#16
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M1=0N@#HJ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M Y$#+*8P^Y6@$Q0 WZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "N?6-?^$IEE$0WGP_;QM-Y$>[:-1N66+[1_97FD9+OY!ULQJ<R
M#2E9C=MT%8"X_P"$IE/R _V!!SB+S"#J-QWV^?L4CIN,6Y_NASD@&_1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5SVAQHE[XJ*Q)
M$9/$2R.RP10F=_\ A'] 3S7>/3+!KEPJ+#Y\]UK<H6);<:G%#!%HVD=#7/:'
MC[=XJQLS_P )"F=OE;L_\(]H'^L\OY]^,8\_][Y>S;^X\F@#H:*** "BBB@
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M[/PYX7THW>N:W=(UOIEC=3*4#2;=DFV]DE=OY(3:2NVDN[T1V=%%%(84444
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MZF.7/05A>&9&ET'2Y&=I&:V!+O-+<.WSN/GFFO\ 5)788PQ>_N"""N8P!%&
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M-Y12:EF$,1*C/#6E&I&,HRBN/'< \:994SNCF'#6;8.MPY4RFEG=&OA9TZN
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MHWVWB+6C?:VJ[AX;T%(M2UH ABK7,)G@M=.5L#:=2N[,R!@85D ./F_]J/\
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M4 %%%% !1110 4444 %%%% !1110!A>)]Q\.:X$+ASI5]L,?F^8&^SR;2GD
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MP_X0B36Y_%MTUQJ_C&ZA@DTVWMM/TO6-0U634=!CG.O0RZB]EJ)29M-C$$$
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MQ^$R+!5J5=X.GFE*M6Q.(IY=B:$/89=*K&=&$_HJBBBO[%/Y="BBB@ HHHH
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MM'UJ:9U\/ZFZZ)XG@#GRWTB]E0&\,994:;2K@1:C$Q^;9!/;J56YD)_<\$$
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M+F(( ;:0'<9WC@"\X/G21Q?\]'5<L.@H **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** .>UY \_AW*(^WQ#;N-\44I0KI^I_/&);"^
M,;@9'FQ&REC0NPOX$WK+T-<]KQ3S_#@=D&[Q%;A59H@7<:?J;JJ"66/>Z[?,
MVQ)/*%C9UB4(T\/0T ?B5_P70_:[_:'_ &.?@=^R#XP_9P^(7_"N?$?Q1_X*
M$_ #X'>.]1_X1/P/XO\ [=^%OC;PA\7-4\3^%_LGCOPUXGL=,_M.^\,:'/\
MVWH]KI_B*R^P^5I^KVD-S>1W'=?M)_\ !:#]G3]F?]J_Q;^Q9J_P1_; ^+_Q
M]\.?";1_BWHOA/\ 9W^!]M\8KKXB6.M7.GI!X2\#:5X<\9#Q3)XJM-,N[[Q!
MJ=SXJ\.>%?!&GZ/H6J_:/&:ZG)H^FZMPO_!=#]D3]H?]L;X'?L@^#_V</A[_
M ,+&\1_"[_@H3\ /CCX[T[_A+/ _A#^POA;X)\(?%S2_$_BC[7X[\2^&+'4_
M[,OO$^AP?V)H]UJ'B*]^W>;I^D7<-M>26Y\._P!D3]H?0O\ @OS\>/VV-5^'
MOV7]F/QG_P $]M'^!WAKXF?\)9X'G_M+XI6OQ-^#7B&?PO\ \(9;>)9OB#9^
M7H_A37[S^V[_ ,*6OAUOL'V=-7:ZNK*"Y]>C'!2PE*594W4ITL;4<(U84JM2
MHJN&5&$Y).;O%U7"+3;BIN%K-KS:DL4L145+G4)U<+!2<)5*<(.%7VLHJZBK
M24.:2:2DX\U[V?W+^P=^WE\"O^"BGP*/Q\^ 8\::=X?T[QIXA^&_B_P?\2/#
MUOX6^(/P^^(/A:WTJ^UOP;XRT2QU77M+M-:M-+U[0M5(TK7=8L6L=8LF6]^T
M?:+>#X:_X*0?M=_M#_ 3_@HM_P $:O@1\)OB%_PBGPI_:M^*W[0_AKX^^%?^
M$3\#Z[_PGNB>!=)^"USX5LO[<\2^&M9\1^%O[+G\6^('^T^"]8\.W=]_:&W4
M9[Q+2R6V^3_^">?_  1CT/QK^R%^U%^S;_P5$_9N_M/PWXM_X*A_&S]KSX5>
M#/\ A<-W9_VAH>O?#'P5X"\#?$+_ (2+]GGXI6E_:?:["[^(&E?\(GXCUVVN
MX/,^W:QX:AF31+Q9_P!O'_@F%\5O@1XB_P""2OCO_@EO^RYH7Q0^'/\ P35^
M)_[1'BA?V7K[X_1> ];US3OC[KW@CQ=?2:)\6?CQKWB7;"GBK2?%^J:K)KVM
MZS?6 UJQM=#TJYTZUCT^TNG2R^&.G"%93@UBH0C65!X9*>#K>QE]:E647..(
ME3C%RHPC&24W54HZS*IC)X2$Y4G"5\/*;INJJ]XXFE[6/U>-+F4724W)1J2E
M)7C[-J6GU!\#?VX_"NA?M[_\%<=)^+?[5'Q8N?A'^R%X1^#WC+Q1\/?B7\'_
M (:^$/@U^S[X=;P!=ZYKVK_#3XE>#?'7BSXF?%)_$$-G<:AJNG>(OAYX(OK?
M4I8M*TJR\9ZC-8WB/^!7_!>[]D3XW?%;X*_#6\^#O[9WP/T#]ICQ''X1_9H^
M.?Q__9WO?A_\!?V@O$EY<V]GHVD_"OQ[:^)_$$^M3:]=WNG6VF3W^AZ59BYU
M/3K;4+FPN+R")OC7Q#_P2A_:<^-W[2G_  7WMO%F@VOPM^%_[?WPP^"OA;]F
MWXM:AXQ\,:GI/B+Q-X#\*"2237?#O@KQ/JOQ!\.>';+Q78:;IWB)/$7AK39=
M2T2YO_[.TW7[=GLKGO?V/_#G_!<_3;3]@#]D_P 1? OX6_L8?L\?L<Z7\)O
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MP-<^(+O]L_1O#?[<=I\=OV9_VC4OM&AAN-.^#7[/4_B_XC>./ ]AK7B*WO\
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M_P"%$?;O^$>T#6-<_P"%&_\ "T/LWVS^R?CG<_!?[+_PLS_A7=Q]G^T?9_\
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M]D_]H7]D'5/%VB:)#8^'=.^)G@KXJ?%+XI:?;7M]8R^&? GA6QU7Q-J/B/\
MJJHKHIYG5C/GG"-TZTKT>6E/VF(]C[6HY.%6+E-45%IPY4I245%6MA/ TW#E
MC*5OW4;5'*I'DH^T]G"RE!\L74;34KMI.3>M_P"<OX+_  V_:D_:B_9T_8>^
M/G[-7PU_9=^"?Q*_X)^?M#_'+PK\$/ ^OZ=\8/A]^R5^T)\![CX9>./V<_\
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M1D"MJ6O!&:,733*A*N$>2RBB8B18;J=TGBMNBH _*7]J#]C3]I*W_;'\(?\
M!0']ASQE\$]+^.2? R\_9I^,GPI_:-M?&MM\)OB]\*8_&,?C_P )ZC:^,OAS
M8ZWXM^'_ (^\&>)6OE@UF#PIXKM->TB[LM+O+:PM=*EBUCRS5/\ @GS^V=^T
ME\"_V_O#O[9'[5>AV?Q$_;5^%.F_";P+\+_@7=?$;5OV8/V7-#\-Z+K%II]U
MX+T3X@:AI.N^,]?\=ZMJ<%W\7?$LFA>"+[Q5IMF-)L[;3K0V<>G?M;177'&U
MXQ@E[/FIJG&%5TX.JH4JD:M.',T[QC.,;.W,XI4W)T_=.>6%I2<F^?EFYRE3
M4Y*#E.#A.7*FM91;OK;F;FES^\?SB_'O_@GS_P %6/VF_P!AK3OV,?%GC3_@
MGS\$?"7@B3X#PZ5H7P0M?C'=Z+\7K'X0?$SX;^*A;>+]9\1?#?2X?@OHL5IX
M5U7QG;^'?A]X!\;W^N^/=/\ ".A3^,_#?@Z7Q.^I_HIXJ_8Z^)NN?\%8?A3^
MW;::[X$C^$?@7]BGQS^SAJ_AVYU/Q GQ'N/''B;XJP>.;#5=.TB+PQ-X9F\*
M0Z3$UO=WUSXOL]7CU$B&'0KBVS=C])J*<L=6DG%1I0BUB$U""5_K,:<:S;NW
M)R5.+4I-N.R?*HQ2CA::=VZDG^YUE-M_N)2E36R22<W=))/=ZMM_F+X3_8>\
M:6__  4E_:Z_:P\:WW@#6_@7^T?^RK\)OV?K+P;;:KXD;QT;[PA=ZR/%_P#P
MDNF-X<L-"LO#NK:9JK6NFW>D>,-1U69FE%QI^G;4E;XQ^'G[#/\ P5L_9O\
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M#(-3\*ABH9M;NQ'N>)69AX:U]BJ*]Q!)(=BNQ6&.[8*K.]LJ*UY: '04444
M8^J>'?#^N8&M:%H^L!4\M1JFF66H8CR3L'VN";"99CM'RY).,DUR+_![X1R,
MSO\ "SX<N['+,_@CPRS,3U+,=,))/J3FO1J*^=S+A#A/.:SQ.<<+\.YKB'J\
M1F629;CJS=DKNKBL-5J/1)?%LDNAZ.&S?-L%#V>#S3,<)36U/#8W$T(;W^"E
M5A'?7;?4\W_X4W\(?^B5?#?_ ,(;PQ_\JZ/^%-_"'_HE7PW_ /"&\,?_ "KK
MTBBO-_XAQX>?]$%P7_XBV1__ ##Y+[CI_P!8^(?^A]G7_ATQW_R_R7W'F_\
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M>^*@K*2OB)5D"R1.5?\ X1_0"%<1W5P8VV%&\N6.SE"LI-J59+JY .BHHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *P/"RJGA[2E4
M(H%J.$1(TR7<L52.ULXP&8ELI;(K$[@9 ?-??KG_  JR/X=TAD*E&LT*E'BD
M4J2Q!$D%Q=PR9'/F17-PCDEEED!#$ Z"BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@# \5*C^&=?215=&TC4%='1)$9&M9 RM'):7\
M<BD$ADDL;Q&!*M:7"DPOOUS_ (K95\,Z^SE%0:1?ES(\2(%^S2;BS37%I$%
MR3ONK=2./.CSN'04 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% '.Z^B--X<WA&V^(K9U#1Q/AQ8:EM*^9:W3(ZY+"2 6\J@$FZAB
M\TGHJY[7F19_#@8H"_B*!4#/$FY_[-U1L*LEU;M*X56<)#'>2J%,WV41Q27-
MMT- !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5S_AE433)E154?
MVYXH8A(XHAO?Q-J[R$I#9V*;F=F9W-N99'+23W%Y,\EY/T%<_P"&61M,E*%2
MO]M^)P=CQ2*&7Q+JRR+NAN+F/*N&5E$B,C H]M9.K6< !T%%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% &!%(3XIOXO-!"^'])D$'G$E2^HZTK2^0=8D5 X14,R>'[,R^6
M$EUC4A##9:3OU@1$_P#"4WZ[G*C0-(.W=*8U)U'6QN"&<P([@ %DM8Y9%0"2
M>9(HHX-^@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K"
MU:39J7A=?-$?FZU=)L\X1^?CPYKTGEB,ZQIOV@KL\[RQ8>(2HB,W]E6XB.N:
M/NUA:LQ&H^& &<!M9N@P5Y55@/#NNMB18[F%)$! 8+/#>1"01N(8YEAN80#=
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *P1(?\
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MA>*&*>'-=8%E*Z5?,&1I$<$6\A!1X;FSE1AC*M%=VLBG!2Y@8"5=V@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH Y_79#'-X? E$
M0D\06T9!F,7F@V.HL(L?VQI*S%BH(A>+60Q7<FCSS)%=V705@:X2)O#^&=<Z
M_;@['E0,#8:B-KB.>W5T[E)C+$6"GR)I%C0[] !1110 4444 %%%% !1110
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MN41LXO[DF,3&T$!=%(8QI?/*JNK2VD:-#-+N44 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !6#HR.EYXE+QO&)->5T9HI8UF3^P
MM#3S(VEL[43(&1HC+%+?Q>9&\2WFZ-K2TWJ* "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ K#\-*Z:#I:21O$ZVJ*T4D<L3QD%AL
M:*>TL9HRHXV2V=K(N,/!&V5&Y10 4444 %%%% !1110 4444 %%%% !1110
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MW^M^(-8N9?(A^V:A<"YE4QR^6:!^W-I4_A3X\^(_$?A3PO>R?!#0_A]K:/\
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M.O!=O\6EC\$:AK=E/>PZ#=6>IZAICGPYXBUZY@FU![8Z%J_R'\9;7Q[\(/\
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M/'?^$?&N@^+?$=G8:1I"^ O%.H3^(GTSPAJ,VFVEQ]GTF[*R)JNMZ!*+./4
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MF!+JW>+PK+J2Z[(L]K)'<PLE@PE@=)D+1L&(!X9JG[)]M=:O\1K[0OCU\?O
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M\-W6NIXBEMM1C\6^ ?&,DDIU.*WE#VLUHFVWA4Q%@SOJ_#C]H'PQXWT7XO\
MBC6Y=!\$^%/A+\4O$_P[NO%.J^+-/?P]J>F>'M-\.:C#XPN-9N[;2=-T:QU-
M?$421VTEU?6\*Q1RKJMR+I4BP_ G[5'PQ\??$GQYX,T?Q1X#N?#'ABR^$ \+
M?$33/B'X?U?0?B#XB^+5W\0["T\*: UJ%T^76M.OOA_<V=M9Z=K>LWVLW5Y/
M;Q6-E-ILB7(!T6M? '1/%&A?!G1_%OC;XA>*;WX)?$G0_BGH7BC6=1\-MXD\
M3>)O#^F^)])L8_&4]CX5LM+O=->S\5WR7$&B:5X?NG:TTXQWL0BN1=^\5Q%S
M\3?AM9+XP>\^(/@>T3X>R64/C][GQ9H,"^!Y=2@CN=.B\8-+?H/#,E_;2Q7%
MDFM&R:Z@DCE@$D;JQY33OC7X/AT?Q_XB\<:SX0^'7A[P%\0=;\!7NN^(OB+X
M$ET=Y=)CT^2"^U34[#7I['PI>ZB+]67PIXFN--\4Z?&(9-3TNT%W;*X!M/\
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MK^%=4NMMR_V;3O$*ZD=(OKC997C^3;7DLFVTN6VX@E* %?XL?##0/C%X)NO
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MVFJK=:CI]WK%UXKN+KQCJ8U#5]4U74(+Q(;.233_ +4MW<WEKPG\>O@YX_\
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M7/Z.#7-%.M-X;&L:6?$2:6FN/H U"T.M+HLEW)81ZPVE>=]N72Y+Z*6R34#
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M!\U?#GX<^(O#'[2?[1/CF;08-*\#^._!/[/FF>%M0M;G25AU;6? UI\3M/\
M$R'2[*Z;4+*72M/U7PG8BZU*PM(KRS%E;:=-=PZ9*EI\V:%^S)\.?BA<?$33
M?C-=6]A)KO[2?Q/^/WPU3PYX\\.0ZCX[^#.N>'_ ?A_Q$UV=(OM3N[SX6^,K
M=[?1/&^GL-.N3!+HS376DW4^D7<GZ45\X:Q^RG^S7=1>(;[6OA;X4$.KZ_\
M\)EKMY=3:A;1)<VZZG-J%HEP-1B31_!6JIK?BF7Q7X%T]['P'XH7QEX]?Q1X
M>U4>.O&)UODQ4L=%0^I4L)5=Y>T6*KUJ"25G'D=+#8CF<O>C+F4>2ZFO:<KI
MR]_(J7"]66)7$N/S_ P4:7U.6193EV:RG*3J1KO$PS#.LF5*-%.E6I*E.L\2
MX5,--X158XNE\<ZGX(\:2>!/B+IOA33O"OB*3XC_ +7<_P"T5X5TW0_$WP8U
M[Q+XB_9XL8O ,\GQ2^%5EX[UVX^&EWJ&G7\6C-H]QXY0Z%IQO+6YO+6"YO-#
MEEX6X^$_CGQ?\)?VD='M=*M/$VL?'KXC? #XT_#S0O&_Q0^"FL^(/B7\-/ O
MBSX*ZCX\\::W?>";JT\"#2[32].;^VI=(MM1T*&"YTS2M&U+Q2MYH]QJWW%X
M?_9T_9,^)GAF/QEX<^'?@WQ)X7^(6HV'CZSUK3VU1+/5(KA-0D%MI3)>6[Z7
MX)UY-=\3-XC^'^FI8>!_%/\ PF?CP>)O#6J'QWXQ&M]%>_LD?LWZC_;'VSX2
M>&)?[=\1P^)]1Q_:,6Z]C_M'[3I=GY-_'_97@[6/[<\3_P#"2_#_ $K[%X$\
M5?\ "9^._P#A)?#FJ_\ "=^,/[;Y.?/?^@;*7_W/8Q7M_P!TZ7+S<O\ >Y?:
M?;]C_M'T/U7PK?\ S//$"%_^J5X<J<G-_P!WE2]K[+VO_3KV_P!2_P"8?^T_
M^$CXI\8_"?6_VE=3^.7B*RLO#'P4MOBK^S_\(+?X4>%];\:?#7Q%=?$;4/@G
M\0#\4=-^+6M0_"KQ1XHTE? =C?:MX+\ 6>O:?XCUN>'PO=V][=P6B7&C:$OT
M+HWQO^.7Q)UKX1:-I7@#P_\ "6RU5[+XC>._%VM?%3X/>/M"\6?"O1-CZXGP
MEL?!_BC7_$OB/1M??5O"\7_">:KH7A"R\/6VL0.WG7%S8FY]1O?V2/V;]1_M
MC[9\)/#$O]N^(X?$^HX_M&+=>Q_VC]ITNS\F_C_LKP=K']N>)_\ A)?A_I7V
M+P)XJ_X3/QW_ ,)+X<U7_A._&']ME[^R1^S?J/\ ;'VSX2>&)?[=\1P^)]1Q
M_:,6Z]C_ +1^TZ79^3?Q_P!E>#M8_MSQ/_PDOP_TK[%X$\5?\)GX[_X27PYJ
MO_"=^,/[;.?/?^@;*7_W/8Q7M_W3I<O-R_WN7VGV_8_[0?5?"M_\SSQ A?\
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M%AINF6=UJ&H7UU(L-K96-E ]S=W=S,Y"106]O%)--(Y"I&C,Q !H ^2?V:?
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M#MS+%-<:!XNT'2O$FBSS0$F":;2]9M+VQEEA+,8I'@9XRQ*$$FH_!W@3P/\
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MB#1&NK2Q^U6SI>.NH-\Z?\*1^.O_  B/_#*__"O9?^%5?\-,?\++_P"%V?\
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M.=8KB7#1X.QWZ=P=PWEM>GEN?XRL\1@E6QV"S/+,;E4U2K5)1=)T\KQE2O\
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M_P"'.K_$W7-.^#MA\%=;UWP[XQ^+/[6OQ3^ 5WXA^*NJ_$'7[OQ*;CXJ^#O
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M)%EI]@8-'BBT6U:TM[PW]['))<&;4)U>-(@#X"^)5[XQFU'_ (*8^,8?B?\
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M!'B;0M=UN&Z^$=]\+M?>3XZWO@J2&]C@\/R:G\*CI.IB/3IM*:3Q#<7&L/\
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MEU;7$^WQ!K36NJ))JUO#!^Y=% 'Y#^/-7_:"^$MKXP\&:-X[^(?B;XA^$?\
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M=?O=&VNOU&HH _&;X2:9K'@+X5?L\?%#PWX_^)=IJWB[]N+QCX U?PT_COQ
MWPYD\%>*_P!HKXP>&-<\/I\.DNX_!\BW?D'7UUN\TF[\46WB">2XMM=BT]+;
M3+?Z]_:.\3_&JW^"'Q);Q9-X+^!-NVH>";'P]\3/A_\ $OXC>.KO3;>[^(&@
M1:E-XS%A\)OAEJ_P^\,ZEHJRZ1XA\8>']?UJ[\*:?K%_J\4D?]E1W<WVY10!
M^&?C#6+'XA_LL_'I=9\6^,-;T#X6_'GX 7MEXI\.?M)?$;XK?"W^QM1\>_"
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MZ8FF:8NH7LVHW\RF66YNKV_O9SNN+W4+ZXN;Z[=$AMQ<7$B6EM:VJPV\7=T
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M^!_'FL^ -9^$S?#K3?AOX43XX^.O EU9:+I'@W0-;O+WX8_LY^ M!/A/Q[X
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MWB,: @E35_%_@[4K^+XD>$'DN)YX;^Y:26>T\;^"+))!;'PYK5E?W.AQ[I+
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MC74-8\4+:ZI=I'9^%FW1VA]8MOV7O@C;^&?&WA.7PGJ6JZ;\2-5\.ZUX\O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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? 4444 %%%% !1110 4444 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>dawn-20250331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2025-05-06T14:07:58.8077+00:00 -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://www.dayonebio.com/20250331" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2024" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:srt="http://fasb.org/srt/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:dawn="http://www.dayonebio.com/20250331" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd" namespace="http://xbrl.sec.gov/ecd-sub/2024"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd" namespace="http://fasb.org/srt/2024"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" namespace="http://xbrl.sec.gov/dei/2024"/>
  <xsd:import schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd" namespace="http://www.xbrl.org/dtr/type/2024-01-31"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" namespace="http://fasb.org/us-gaap/2024"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd" namespace="http://xbrl.sec.gov/ecd/2024"/>
  <xsd:import schemaLocation="https://www.xbrl.org/2023/calculation-1.1.xsd" namespace="https://xbrl.org/2023/calculation-1.1"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.dayonebio.com/20250331/taxonomy/role/CoverPage" id="CoverPage">
        <link:definition>100000 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedBalanceSheetsUnaudited" id="StatementCondensedBalanceSheetsUnaudited">
        <link:definition>100010 - Statement - Condensed Balance Sheets (unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureLeaseObligationsDetail2" id="DisclosureCommitmentsAndContingenciesSummaryOfFutureLeaseObligationsDetail2">
        <link:definition>100020 - Disclosure - Commitments and Contingencies - Summary of Future Lease Obligations (Detail) 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureRecurringFairValueMeasurementScheduleOfMaturitiesForAvailableForSaleSecuritiesDetails2" id="DisclosureRecurringFairValueMeasurementScheduleOfMaturitiesForAvailableForSaleSecuritiesDetails2">
        <link:definition>100030 - Disclosure - Recurring Fair Value Measurement - Schedule Of Maturities For Available For Sale Securities (Details) 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedBalanceSheetsUnauditedParenthetical" id="StatementCondensedBalanceSheetsUnauditedParenthetical">
        <link:definition>100040 - Statement - Condensed Balance Sheets (unaudited) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfOperationsUnaudited" id="StatementCondensedStatementsOfOperationsUnaudited">
        <link:definition>100050 - Statement - Condensed Statements of Operations (unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfComprehensiveLossUnaudited" id="StatementCondensedStatementsOfComprehensiveLossUnaudited">
        <link:definition>100060 - Statement - Condensed Statements of Comprehensive Loss (unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfStockholdersEquityUnaudited" id="StatementCondensedStatementsOfStockholdersEquityUnaudited">
        <link:definition>100070 - Statement - Condensed Statements of Stockholders' Equity (unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfStockholdersEquityUnauditedParenthetical" id="StatementCondensedStatementsOfStockholdersEquityUnauditedParenthetical">
        <link:definition>100080 - Statement - Condensed Statements of Stockholders' Equity (unaudited) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited" id="StatementCondensedStatementsOfCashFlowsUnaudited">
        <link:definition>100090 - Statement - Condensed Statements of Cash Flows (unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureDescriptionOfBusinessAndOrganization1" id="DisclosureDescriptionOfBusinessAndOrganization1">
        <link:definition>995455 - Disclosure - Description of Business and Organization</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dayonebio.com/20250331/taxonomy/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
        <link:definition>995465 - Disclosure - Summary Of Significant  Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureRecurringFairValueMeasurements" id="DisclosureRecurringFairValueMeasurements">
        <link:definition>995475 - Disclosure - Recurring Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureBalanceSheetItems" id="DisclosureBalanceSheetItems">
        <link:definition>995485 - Disclosure - Balance Sheet Items</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureIntangibleAssets" id="DisclosureIntangibleAssets">
        <link:definition>995495 - Disclosure - Intangible Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dayonebio.com/20250331/taxonomy/role/SignificantAgreements" id="SignificantAgreements">
        <link:definition>995505 - Disclosure - Significant Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dayonebio.com/20250331/taxonomy/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
        <link:definition>995515 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dayonebio.com/20250331/taxonomy/role/RedeemableConvertiblePreferredShares" id="RedeemableConvertiblePreferredShares">
        <link:definition>995525 - Disclosure - Redeemable Convertible Preferred Shares</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureCommonStock" id="DisclosureCommonStock">
        <link:definition>995535 - Disclosure - Common Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensation" id="DisclosureSharebasedCompensation">
        <link:definition>995545 - Disclosure - Share-based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureIncomeTaxes" id="DisclosureIncomeTaxes">
        <link:definition>995555 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureNetIncomeLossPerShare" id="DisclosureNetIncomeLossPerShare">
        <link:definition>995565 - Disclosure - Net Income (Loss) Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dayonebio.com/20250331/taxonomy/role/RedeemableNoncontrollingInterest" id="RedeemableNoncontrollingInterest">
        <link:definition>995575 - Disclosure - Redeemable NonControlling Interest</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureDefinedContributionPlan" id="DisclosureDefinedContributionPlan">
        <link:definition>995585 - Disclosure - Defined Contribution Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSegmentReporting" id="DisclosureSegmentReporting">
        <link:definition>995595 - Disclosure - Segment Reporting</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSubsequentEvents" id="DisclosureSubsequentEvents">
        <link:definition>995605 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dayonebio.com/20250331/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies" id="SummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>995615 - Disclosure - Summary of Significant  Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureRecurringFairValueMeasurementTables" id="DisclosureRecurringFairValueMeasurementTables">
        <link:definition>995625 - Disclosure - Recurring Fair Value Measurement (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureBalanceSheetItemsTables" id="DisclosureBalanceSheetItemsTables">
        <link:definition>995635 - Disclosure - Balance Sheet Items (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureIntangibleAssetsTables" id="DisclosureIntangibleAssetsTables">
        <link:definition>995645 - Disclosure - Intangible Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dayonebio.com/20250331/taxonomy/role/CommitmentsAndContingenciesTables" id="CommitmentsAndContingenciesTables">
        <link:definition>995655 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureCommonStockTables" id="DisclosureCommonStockTables">
        <link:definition>995665 - Disclosure - Common Stock (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationTables" id="DisclosureSharebasedCompensationTables">
        <link:definition>995675 - Disclosure - Share-based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureNetIncomeLossPerShareTables" id="DisclosureNetIncomeLossPerShareTables">
        <link:definition>995685 - Disclosure - Net Income (Loss) Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSegmentReportingTables" id="DisclosureSegmentReportingTables">
        <link:definition>995695 - Disclosure - Segment Reporting (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dayonebio.com/20250331/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" id="SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail">
        <link:definition>995705 - Disclosure - Summary of Significant  Accounting Policies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummarizesOfBalancesAndActivityTheProductRevenueDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesSummarizesOfBalancesAndActivityTheProductRevenueDetails">
        <link:definition>995715 - Disclosure - Summary of Significant Accounting Policies - Summarizes of balances and activity the product revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureRecurringFairValueMeasurementScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail" id="DisclosureRecurringFairValueMeasurementScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail">
        <link:definition>995725 - Disclosure - Recurring Fair Value Measurement - Schedule of fair value, assets and liabilities measured on recurring basis (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureRecurringFairValueMeasurementScheduleOfCashEquivalentsMarketableSecuritiesAndUnrealizedGainsAndLossesDetails" id="DisclosureRecurringFairValueMeasurementScheduleOfCashEquivalentsMarketableSecuritiesAndUnrealizedGainsAndLossesDetails">
        <link:definition>995735 - Disclosure - Recurring Fair Value Measurement - Schedule of cash equivalents, marketable securities, and unrealized gains and losses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureRecurringFairValueMeasurementScheduleOfMaturitiesForAvailableForSaleSecuritiesDetails" id="DisclosureRecurringFairValueMeasurementScheduleOfMaturitiesForAvailableForSaleSecuritiesDetails">
        <link:definition>995745 - Disclosure - Recurring Fair Value Measurement - Schedule Of Maturities For Available For Sale Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureRecurringFairValueMeasurementScheduleOfAvailableforsaleMarketableSecuritiesWithGrossUnrealizedLossesDetails" id="DisclosureRecurringFairValueMeasurementScheduleOfAvailableforsaleMarketableSecuritiesWithGrossUnrealizedLossesDetails">
        <link:definition>995755 - Disclosure - Recurring Fair Value Measurement - Schedule of available-for-sale marketable securities with gross unrealized losses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureRecurringFairValueMeasurementAdditionalInformationDetail" id="DisclosureRecurringFairValueMeasurementAdditionalInformationDetail">
        <link:definition>995765 - Disclosure - Recurring Fair Value Measurement - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureBalanceSheetItemsSummaryOfPrepaidAndOtherCurrentAssetsDetail" id="DisclosureBalanceSheetItemsSummaryOfPrepaidAndOtherCurrentAssetsDetail">
        <link:definition>995775 - Disclosure - Balance Sheet Items - Summary of Prepaid and Other Current Assets (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureBalanceSheetItemsSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetail" id="DisclosureBalanceSheetItemsSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetail">
        <link:definition>995785 - Disclosure - Balance Sheet Items - Summary of Accrued expenses and other current liabilities (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureIntangibleAssetsScheduleOfIntangibleAssetsDetails" id="DisclosureIntangibleAssetsScheduleOfIntangibleAssetsDetails">
        <link:definition>995795 - Disclosure - Intangible Assets - Schedule Of Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetails" id="DisclosureIntangibleAssetsAdditionalInformationDetails">
        <link:definition>995805 - Disclosure - Intangible Assets (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureIntangibleAssetsScheduleOfAmortizationExpenseForAmortizableFinitelivedIntangibleAssetsDetails" id="DisclosureIntangibleAssetsScheduleOfAmortizationExpenseForAmortizableFinitelivedIntangibleAssetsDetails">
        <link:definition>995815 - Disclosure - Intangible Assets - Schedule Of Amortization Expense For Amortizable Finite-Lived Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dayonebio.com/20250331/taxonomy/role/SignificantAgreementsAdditionalInformationDetail" id="SignificantAgreementsAdditionalInformationDetail">
        <link:definition>995825 - Disclosure - Significant Agreements - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureLeaseObligationsDetail" id="DisclosureCommitmentsAndContingenciesSummaryOfFutureLeaseObligationsDetail">
        <link:definition>995835 - Disclosure - Commitments and Contingencies - Summary of Future Lease Obligations (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" id="DisclosureCommitmentsAndContingenciesAdditionalInformationDetail">
        <link:definition>995845 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dayonebio.com/20250331/taxonomy/role/RedeemableConvertiblePreferredSharesAdditionalInformationDetail" id="RedeemableConvertiblePreferredSharesAdditionalInformationDetail">
        <link:definition>995855 - Disclosure - Redeemable Convertible Preferred Shares - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dayonebio.com/20250331/taxonomy/role/RedeemableConvertiblePreferredSharesSummaryOfSeriesARedeemableConvertiblePreferredSharesDetail" id="RedeemableConvertiblePreferredSharesSummaryOfSeriesARedeemableConvertiblePreferredSharesDetail">
        <link:definition>995865 - Disclosure - Redeemable Convertible Preferred Shares - Summary of Series A Redeemable Convertible Preferred Shares (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureCommonStockAdditionalInformationDetail" id="DisclosureCommonStockAdditionalInformationDetail">
        <link:definition>995875 - Disclosure - Common Stock - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureCommonStockScheduleOfCommonStockSharesReservedForFutureIssuanceDetailsDetails" id="DisclosureCommonStockScheduleOfCommonStockSharesReservedForFutureIssuanceDetailsDetails">
        <link:definition>995885 - Disclosure - Common Stock - Schedule of Common Stock Shares Reserved for Future Issuance (Details) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfSharestockbasedCompensationExpenseRecordedInTheAccompanyingCondensedConsolidatedStatementsOfOperation" id="DisclosureSharebasedCompensationSummaryOfSharestockbasedCompensationExpenseRecordedInTheAccompanyingCondensedConsolidatedStatementsOfOperation">
        <link:definition>995895 - Disclosure - Share-based Compensation - Summary of Share/Stock-based Compensation Expense Recorded in The Accompanying Condensed Consolidated Statements of Operations and Comprehensive Loss (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetail" id="DisclosureSharebasedCompensationAdditionalInformationDetail">
        <link:definition>995905 - Disclosure - Share-based Compensation - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfStockOptionActivityDetail" id="DisclosureSharebasedCompensationSummaryOfStockOptionActivityDetail">
        <link:definition>995915 - Disclosure - Share-based Compensation - Summary of Stock Option Activity (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfTheBlackscholesOptionPricingModelToEstimateTheFairValueOfStockOptionGrantedDetail" id="DisclosureSharebasedCompensationSummaryOfTheBlackscholesOptionPricingModelToEstimateTheFairValueOfStockOptionGrantedDetail">
        <link:definition>995925 - Disclosure - Share-based Compensation - Summary of The Black-Scholes Option Pricing Model to Estimate The Fair Value of Stock Option Granted (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfRestrictedStockUnitsActivityDetail" id="DisclosureSharebasedCompensationSummaryOfRestrictedStockUnitsActivityDetail">
        <link:definition>995935 - Disclosure - Share-based Compensation - Summary of Restricted Stock Units Activity (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfTheUnvestedCommonStockDetail" id="DisclosureSharebasedCompensationSummaryOfTheUnvestedCommonStockDetail">
        <link:definition>995945 - Disclosure - Share-based Compensation - Summary of The Unvested Common Stock (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfFairValueOfTheIncentiveSharesEstimatedUsingAnOptionPricingModelDetail" id="DisclosureSharebasedCompensationSummaryOfFairValueOfTheIncentiveSharesEstimatedUsingAnOptionPricingModelDetail">
        <link:definition>995955 - Disclosure - Share-based Compensation - Summary of Fair Value of The Incentive Shares Estimated Using An Option Pricing Model (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfTheIncentiveSharesActivityDetail" id="DisclosureSharebasedCompensationSummaryOfTheIncentiveSharesActivityDetail">
        <link:definition>995965 - Disclosure - Share-based Compensation - Summary of The Incentive Shares Activity (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfPerformanceStockOptionsActivityDetails" id="DisclosureSharebasedCompensationSummaryOfPerformanceStockOptionsActivityDetails">
        <link:definition>995975 - Disclosure - Share-based Compensation - Summary of Performance Stock Options Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationFairValueOfOurCommonStockToBeIssuedUnderTheEsppDetails" id="DisclosureSharebasedCompensationFairValueOfOurCommonStockToBeIssuedUnderTheEsppDetails">
        <link:definition>995985 - Disclosure - Share-based Compensation - Fair value of our common stock to be issued under the ESPP (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfTheBlackscholesOptionPricingModelToEstimateTheFairValueOfPerformanceStockOpDetails" id="DisclosureSharebasedCompensationSummaryOfTheBlackscholesOptionPricingModelToEstimateTheFairValueOfPerformanceStockOpDetails">
        <link:definition>995995 - Disclosure - Share-based Compensation - Summary of The Black-Scholes Option Pricing Model to Estimate The Fair Value of Performance Stock Op (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfPerformanceStockUnitsActivityDetails" id="DisclosureSharebasedCompensationSummaryOfPerformanceStockUnitsActivityDetails">
        <link:definition>996005 - Disclosure - Share-based Compensation - Summary of Performance Stock Units Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" id="DisclosureIncomeTaxesAdditionalInformationDetails">
        <link:definition>996015 - Disclosure - Income Taxes (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureNetIncomeLossPerShareSummaryOfBasicAndDilutedNetLossPerShareAttributableToCommonShareholdersstockholdersDetail" id="DisclosureNetIncomeLossPerShareSummaryOfBasicAndDilutedNetLossPerShareAttributableToCommonShareholdersstockholdersDetail">
        <link:definition>996025 - Disclosure - Net Income (Loss) Per Share - Summary of Basic and Diluted Net Loss Per Share Attributable to Common Shareholders/Stockholders (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureNetIncomeLossPerShareSummaryOfOutstandingPotentiallyDilutiveSecuritiesHaveBeenExcludedFromCalculationOfDilutedNetLossPerShare" id="DisclosureNetIncomeLossPerShareSummaryOfOutstandingPotentiallyDilutiveSecuritiesHaveBeenExcludedFromCalculationOfDilutedNetLossPerShare">
        <link:definition>996035 - Disclosure - Net Income (Loss) Per Share - Summary of Outstanding Potentially Dilutive Securities Have Been Excluded From Calculation of Diluted Net Loss Per Share (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureDefinedContributionPlanAdditionalInformationDetails" id="DisclosureDefinedContributionPlanAdditionalInformationDetails">
        <link:definition>996045 - Disclosure - Defined Contribution Plan (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSegmentReportingAdditionalInformationDetails" id="DisclosureSegmentReportingAdditionalInformationDetails">
        <link:definition>996055 - Disclosure - Segment Reporting (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSegmentReportingScheduleOfSegmentInformationDetails" id="DisclosureSegmentReportingScheduleOfSegmentInformationDetails">
        <link:definition>996065 - Disclosure - Segment Reporting - Schedule of Segment Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails" id="DisclosureSubsequentEventAdditionalInformationDetails">
        <link:definition>996075 - Disclosure - Subsequent Event (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbase id="lnk">
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="https://xbrl.org/2023/arcrole/summation-item" xlink:href="https://www.xbrl.org/2023/calculation-1.1.xsd#summation-item" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedBalanceSheetsUnaudited" xlink:href="dawn-20250331.xsd#StatementCondensedBalanceSheetsUnaudited" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureLeaseObligationsDetail2" xlink:href="dawn-20250331.xsd#DisclosureCommitmentsAndContingenciesSummaryOfFutureLeaseObligationsDetail2" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureRecurringFairValueMeasurementScheduleOfMaturitiesForAvailableForSaleSecuritiesDetails2" xlink:href="dawn-20250331.xsd#DisclosureRecurringFairValueMeasurementScheduleOfMaturitiesForAvailableForSaleSecuritiesDetails2" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfOperationsUnaudited" xlink:href="dawn-20250331.xsd#StatementCondensedStatementsOfOperationsUnaudited" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfComprehensiveLossUnaudited" xlink:href="dawn-20250331.xsd#StatementCondensedStatementsOfComprehensiveLossUnaudited" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited" xlink:href="dawn-20250331.xsd#StatementCondensedStatementsOfCashFlowsUnaudited" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureRecurringFairValueMeasurementScheduleOfMaturitiesForAvailableForSaleSecuritiesDetails" xlink:href="dawn-20250331.xsd#DisclosureRecurringFairValueMeasurementScheduleOfMaturitiesForAvailableForSaleSecuritiesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureBalanceSheetItemsSummaryOfPrepaidAndOtherCurrentAssetsDetail" xlink:href="dawn-20250331.xsd#DisclosureBalanceSheetItemsSummaryOfPrepaidAndOtherCurrentAssetsDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureBalanceSheetItemsSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetail" xlink:href="dawn-20250331.xsd#DisclosureBalanceSheetItemsSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureIntangibleAssetsScheduleOfIntangibleAssetsDetails" xlink:href="dawn-20250331.xsd#DisclosureIntangibleAssetsScheduleOfIntangibleAssetsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureIntangibleAssetsScheduleOfAmortizationExpenseForAmortizableFinitelivedIntangibleAssetsDetails" xlink:href="dawn-20250331.xsd#DisclosureIntangibleAssetsScheduleOfAmortizationExpenseForAmortizableFinitelivedIntangibleAssetsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureLeaseObligationsDetail" xlink:href="dawn-20250331.xsd#DisclosureCommitmentsAndContingenciesSummaryOfFutureLeaseObligationsDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSegmentReportingScheduleOfSegmentInformationDetails" xlink:href="dawn-20250331.xsd#DisclosureSegmentReportingScheduleOfSegmentInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dayonebio.com/20250331/taxonomy/role/CoverPage" xlink:href="dawn-20250331.xsd#CoverPage" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedBalanceSheetsUnauditedParenthetical" xlink:href="dawn-20250331.xsd#StatementCondensedBalanceSheetsUnauditedParenthetical" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfStockholdersEquityUnaudited" xlink:href="dawn-20250331.xsd#StatementCondensedStatementsOfStockholdersEquityUnaudited" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfStockholdersEquityUnauditedParenthetical" xlink:href="dawn-20250331.xsd#StatementCondensedStatementsOfStockholdersEquityUnauditedParenthetical" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationTables" xlink:href="dawn-20250331.xsd#DisclosureSharebasedCompensationTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dayonebio.com/20250331/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:href="dawn-20250331.xsd#SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureRecurringFairValueMeasurementScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail" xlink:href="dawn-20250331.xsd#DisclosureRecurringFairValueMeasurementScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureRecurringFairValueMeasurementScheduleOfCashEquivalentsMarketableSecuritiesAndUnrealizedGainsAndLossesDetails" xlink:href="dawn-20250331.xsd#DisclosureRecurringFairValueMeasurementScheduleOfCashEquivalentsMarketableSecuritiesAndUnrealizedGainsAndLossesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureRecurringFairValueMeasurementScheduleOfAvailableforsaleMarketableSecuritiesWithGrossUnrealizedLossesDetails" xlink:href="dawn-20250331.xsd#DisclosureRecurringFairValueMeasurementScheduleOfAvailableforsaleMarketableSecuritiesWithGrossUnrealizedLossesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureRecurringFairValueMeasurementAdditionalInformationDetail" xlink:href="dawn-20250331.xsd#DisclosureRecurringFairValueMeasurementAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dayonebio.com/20250331/taxonomy/role/SignificantAgreementsAdditionalInformationDetail" xlink:href="dawn-20250331.xsd#SignificantAgreementsAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" xlink:href="dawn-20250331.xsd#DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dayonebio.com/20250331/taxonomy/role/RedeemableConvertiblePreferredSharesAdditionalInformationDetail" xlink:href="dawn-20250331.xsd#RedeemableConvertiblePreferredSharesAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dayonebio.com/20250331/taxonomy/role/RedeemableConvertiblePreferredSharesSummaryOfSeriesARedeemableConvertiblePreferredSharesDetail" xlink:href="dawn-20250331.xsd#RedeemableConvertiblePreferredSharesSummaryOfSeriesARedeemableConvertiblePreferredSharesDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureCommonStockAdditionalInformationDetail" xlink:href="dawn-20250331.xsd#DisclosureCommonStockAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureCommonStockScheduleOfCommonStockSharesReservedForFutureIssuanceDetailsDetails" xlink:href="dawn-20250331.xsd#DisclosureCommonStockScheduleOfCommonStockSharesReservedForFutureIssuanceDetailsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfSharestockbasedCompensationExpenseRecordedInTheAccompanyingCondensedConsolidatedStatementsOfOperation" xlink:href="dawn-20250331.xsd#DisclosureSharebasedCompensationSummaryOfSharestockbasedCompensationExpenseRecordedInTheAccompanyingCondensedConsolidatedStatementsOfOperation" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetail" xlink:href="dawn-20250331.xsd#DisclosureSharebasedCompensationAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfStockOptionActivityDetail" xlink:href="dawn-20250331.xsd#DisclosureSharebasedCompensationSummaryOfStockOptionActivityDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfTheBlackscholesOptionPricingModelToEstimateTheFairValueOfStockOptionGrantedDetail" xlink:href="dawn-20250331.xsd#DisclosureSharebasedCompensationSummaryOfTheBlackscholesOptionPricingModelToEstimateTheFairValueOfStockOptionGrantedDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfRestrictedStockUnitsActivityDetail" xlink:href="dawn-20250331.xsd#DisclosureSharebasedCompensationSummaryOfRestrictedStockUnitsActivityDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfTheUnvestedCommonStockDetail" xlink:href="dawn-20250331.xsd#DisclosureSharebasedCompensationSummaryOfTheUnvestedCommonStockDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfFairValueOfTheIncentiveSharesEstimatedUsingAnOptionPricingModelDetail" xlink:href="dawn-20250331.xsd#DisclosureSharebasedCompensationSummaryOfFairValueOfTheIncentiveSharesEstimatedUsingAnOptionPricingModelDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfTheIncentiveSharesActivityDetail" xlink:href="dawn-20250331.xsd#DisclosureSharebasedCompensationSummaryOfTheIncentiveSharesActivityDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfPerformanceStockOptionsActivityDetails" xlink:href="dawn-20250331.xsd#DisclosureSharebasedCompensationSummaryOfPerformanceStockOptionsActivityDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationFairValueOfOurCommonStockToBeIssuedUnderTheEsppDetails" xlink:href="dawn-20250331.xsd#DisclosureSharebasedCompensationFairValueOfOurCommonStockToBeIssuedUnderTheEsppDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfTheBlackscholesOptionPricingModelToEstimateTheFairValueOfPerformanceStockOpDetails" xlink:href="dawn-20250331.xsd#DisclosureSharebasedCompensationSummaryOfTheBlackscholesOptionPricingModelToEstimateTheFairValueOfPerformanceStockOpDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfPerformanceStockUnitsActivityDetails" xlink:href="dawn-20250331.xsd#DisclosureSharebasedCompensationSummaryOfPerformanceStockUnitsActivityDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureNetIncomeLossPerShareSummaryOfBasicAndDilutedNetLossPerShareAttributableToCommonShareholdersstockholdersDetail" xlink:href="dawn-20250331.xsd#DisclosureNetIncomeLossPerShareSummaryOfBasicAndDilutedNetLossPerShareAttributableToCommonShareholdersstockholdersDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureNetIncomeLossPerShareSummaryOfOutstandingPotentiallyDilutiveSecuritiesHaveBeenExcludedFromCalculationOfDilutedNetLossPerShare" xlink:href="dawn-20250331.xsd#DisclosureNetIncomeLossPerShareSummaryOfOutstandingPotentiallyDilutiveSecuritiesHaveBeenExcludedFromCalculationOfDilutedNetLossPerShare" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails" xlink:href="dawn-20250331.xsd#DisclosureSubsequentEventAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingArrangements" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureDescriptionOfBusinessAndOrganization1" xlink:href="dawn-20250331.xsd#DisclosureDescriptionOfBusinessAndOrganization1" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dayonebio.com/20250331/taxonomy/role/SummaryOfSignificantAccountingPolicies" xlink:href="dawn-20250331.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureRecurringFairValueMeasurements" xlink:href="dawn-20250331.xsd#DisclosureRecurringFairValueMeasurements" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureBalanceSheetItems" xlink:href="dawn-20250331.xsd#DisclosureBalanceSheetItems" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureIntangibleAssets" xlink:href="dawn-20250331.xsd#DisclosureIntangibleAssets" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dayonebio.com/20250331/taxonomy/role/SignificantAgreements" xlink:href="dawn-20250331.xsd#SignificantAgreements" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dayonebio.com/20250331/taxonomy/role/CommitmentsAndContingencies" xlink:href="dawn-20250331.xsd#CommitmentsAndContingencies" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dayonebio.com/20250331/taxonomy/role/RedeemableConvertiblePreferredShares" xlink:href="dawn-20250331.xsd#RedeemableConvertiblePreferredShares" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureCommonStock" xlink:href="dawn-20250331.xsd#DisclosureCommonStock" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensation" xlink:href="dawn-20250331.xsd#DisclosureSharebasedCompensation" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureIncomeTaxes" xlink:href="dawn-20250331.xsd#DisclosureIncomeTaxes" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureNetIncomeLossPerShare" xlink:href="dawn-20250331.xsd#DisclosureNetIncomeLossPerShare" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dayonebio.com/20250331/taxonomy/role/RedeemableNoncontrollingInterest" xlink:href="dawn-20250331.xsd#RedeemableNoncontrollingInterest" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureDefinedContributionPlan" xlink:href="dawn-20250331.xsd#DisclosureDefinedContributionPlan" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSegmentReporting" xlink:href="dawn-20250331.xsd#DisclosureSegmentReporting" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSubsequentEvents" xlink:href="dawn-20250331.xsd#DisclosureSubsequentEvents" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dayonebio.com/20250331/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="dawn-20250331.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureRecurringFairValueMeasurementTables" xlink:href="dawn-20250331.xsd#DisclosureRecurringFairValueMeasurementTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureBalanceSheetItemsTables" xlink:href="dawn-20250331.xsd#DisclosureBalanceSheetItemsTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureIntangibleAssetsTables" xlink:href="dawn-20250331.xsd#DisclosureIntangibleAssetsTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dayonebio.com/20250331/taxonomy/role/CommitmentsAndContingenciesTables" xlink:href="dawn-20250331.xsd#CommitmentsAndContingenciesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureCommonStockTables" xlink:href="dawn-20250331.xsd#DisclosureCommonStockTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureNetIncomeLossPerShareTables" xlink:href="dawn-20250331.xsd#DisclosureNetIncomeLossPerShareTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSegmentReportingTables" xlink:href="dawn-20250331.xsd#DisclosureSegmentReportingTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummarizesOfBalancesAndActivityTheProductRevenueDetails" xlink:href="dawn-20250331.xsd#DisclosureSummaryOfSignificantAccountingPoliciesSummarizesOfBalancesAndActivityTheProductRevenueDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetails" xlink:href="dawn-20250331.xsd#DisclosureIntangibleAssetsAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" xlink:href="dawn-20250331.xsd#DisclosureIncomeTaxesAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureDefinedContributionPlanAdditionalInformationDetails" xlink:href="dawn-20250331.xsd#DisclosureDefinedContributionPlanAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSegmentReportingAdditionalInformationDetails" xlink:href="dawn-20250331.xsd#DisclosureSegmentReportingAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
        <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember" xlink:label="dawn_TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:label="us-gaap_TemporaryEquityLiquidationPreference"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_PremiumReceivedOnLicenseAgreement" xlink:label="dawn_PremiumReceivedOnLicenseAgreement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_PurchasesUnderThePurchaseObligation" xlink:label="dawn_PurchasesUnderThePurchaseObligation"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_ShareBasedCompensationByShareBasedPaymentAwardConversionOfIncentiveSharesIntoRestrictedStock" xlink:label="dawn_ShareBasedCompensationByShareBasedPaymentAwardConversionOfIncentiveSharesIntoRestrictedStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_CurrentMember" xlink:label="dawn_CurrentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_CommonStockIssuedPursuantToFollowOnOfferingNetOfIssuanceCostsAmount" xlink:label="dawn_CommonStockIssuedPursuantToFollowOnOfferingNetOfIssuanceCostsAmount"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_NetProductRevenueAndAccountsReceivableMember" xlink:label="dawn_NetProductRevenueAndAccountsReceivableMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:label="us-gaap_LesseeOperatingLeaseDescription"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_MaketValueOfCommonStockHeldByNonAffiliateStockholders" xlink:label="dawn_MaketValueOfCommonStockHeldByNonAffiliateStockholders"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_MilestonePaymentsNotYetReceived" xlink:label="dawn_MilestonePaymentsNotYetReceived"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_AccountsReceivableCreditLosses" xlink:label="dawn_AccountsReceivableCreditLosses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_RedeemableNonControllingInterestTextBlock" xlink:label="dawn_RedeemableNonControllingInterestTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="us-gaap_DerivativeFairValueOfDerivativeLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_MilestoneAchievementMember" xlink:label="dawn_MilestoneAchievementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_UpfrontOfCashPayment" xlink:label="dawn_UpfrontOfCashPayment"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_LicenseAgreementRelatedPayments" xlink:label="dawn_LicenseAgreementRelatedPayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_AggregateOfUpfrontLicenseFeeReceived" xlink:label="dawn_AggregateOfUpfrontLicenseFeeReceived"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_LeaseForCorporateOfficeFacilityMember" xlink:label="dawn_LeaseForCorporateOfficeFacilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:label="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_TakedaAssetAgreementMember" xlink:label="dawn_TakedaAssetAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_FirstAnniversaryMember" xlink:label="dawn_FirstAnniversaryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentForManagementFee" xlink:label="us-gaap_PaymentForManagementFee"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIntangibleAssetsMember" xlink:label="us-gaap_OtherIntangibleAssetsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_ProductRevenueAllowanceAndReserve" xlink:label="dawn_ProductRevenueAllowanceAndReserve"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_ScheduleOfPerformanceStockOptionsAssumptionsTableTextBlock" xlink:label="dawn_ScheduleOfPerformanceStockOptionsAssumptionsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_StockIssuanceCosts" xlink:label="dawn_StockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_ShareBasedCompensationByShareBasedPaymentArrangementEquityInstrumentsOtherThanOptionsConvertedToUnvestedCommonStock" xlink:label="dawn_ShareBasedCompensationByShareBasedPaymentArrangementEquityInstrumentsOtherThanOptionsConvertedToUnvestedCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_FounderMember" xlink:label="dawn_FounderMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherExpenses" xlink:label="us-gaap_OtherExpenses"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_ShareBasedCompensationByShareBasedPaymentAwardConversionOfIncentiveShareIntoRestrictedStockWeightedAverageGrantDateFairValue" xlink:label="dawn_ShareBasedCompensationByShareBasedPaymentAwardConversionOfIncentiveShareIntoRestrictedStockWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionMoreThanTwelveMonthsFairValue" xlink:label="dawn_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionMoreThanTwelveMonthsFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_InvestmentAgreementMember" xlink:label="dawn_InvestmentAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_ScheduleOfMaturitiesForAvailableForSaleSecuritiesTableTextBlock" xlink:label="dawn_ScheduleOfMaturitiesForAvailableForSaleSecuritiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LicenseMember" xlink:label="us-gaap_LicenseMember"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_MerckLicenseAgreementMember" xlink:label="dawn_MerckLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_SummaryOfPerformanceStockOptions" xlink:label="dawn_SummaryOfPerformanceStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="us-gaap_ReceivablesNetCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForProceedsFromInvestments" xlink:label="us-gaap_PaymentsForProceedsFromInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_AccountingPoliciesTable" xlink:label="dawn_AccountingPoliciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_AvailableForSaleSecuritieContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue" xlink:label="dawn_AvailableForSaleSecuritieContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_ResearchAndDevelopmentAgreementsMember" xlink:label="dawn_ResearchAndDevelopmentAgreementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCompensationArrangementWithIndividualSharesIssued" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_UnamortizedStockBasedCompensationForStockOptions" xlink:label="dawn_UnamortizedStockBasedCompensationForStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_TemporaryEquityRelatedTrancheLiabilityMember" xlink:label="dawn_TemporaryEquityRelatedTrancheLiabilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_UnvestedCommonSharesMember" xlink:label="dawn_UnvestedCommonSharesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_CashEquivalentsUnrealizedGains" xlink:label="dawn_CashEquivalentsUnrealizedGains"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_CommonSharesPurchaseAgreementMember" xlink:label="dawn_CommonSharesPurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_TwoCustomerMember" xlink:label="dawn_TwoCustomerMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities" xlink:label="dawn_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndemnificationGuaranteeMember" xlink:label="us-gaap_IndemnificationGuaranteeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_AccruedFederalAndStateTaxPayments" xlink:label="dawn_AccruedFederalAndStateTaxPayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventoriesAndOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInInventoriesAndOtherOperatingAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_TemporaryEquityIssuePricePerShare" xlink:label="dawn_TemporaryEquityIssuePricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_TemporaryEquityStockIssuedDuringThePeriodSharesNewIssues" xlink:label="dawn_TemporaryEquityStockIssuedDuringThePeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xlink:label="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_EmployeeRelatedExpenses" xlink:label="dawn_EmployeeRelatedExpenses"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_IncentiveSharesMember" xlink:label="dawn_IncentiveSharesMember"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_SeriesBRedeemableConvertiblePreferredSharesMember" xlink:label="dawn_SeriesBRedeemableConvertiblePreferredSharesMember"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_ViractaLicenseAgreementMember" xlink:label="dawn_ViractaLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:label="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_AvailableForSaleSecuritieContinuousUnrealizedLossPositionFairValue" xlink:label="dawn_AvailableForSaleSecuritieContinuousUnrealizedLossPositionFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember" xlink:label="us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_Third-PartyCROCMOAndOtherThird-PartyClinicalTrialCosts" xlink:label="dawn_Third-PartyCROCMOAndOtherThird-PartyClinicalTrialCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:label="us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_ConcentrationOfCreditRiskAndOtherRisksAndUncertaintiesMember" xlink:label="dawn_ConcentrationOfCreditRiskAndOtherRisksAndUncertaintiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_ExternalCostsAbstract" xlink:label="dawn_ExternalCostsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_CommonStockToBeIssuedUnderTheEsppTableTextBlock" xlink:label="dawn_CommonStockToBeIssuedUnderTheEsppTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:label="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_CashEquivalentsUnrealizedLosses" xlink:label="dawn_CashEquivalentsUnrealizedLosses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_IssuanceOfCommonStockInPrivatePlacementShare" xlink:label="dawn_IssuanceOfCommonStockInPrivatePlacementShare"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_CommonStockSharesIssuedAsAResultOfConversionOfTemporaryEquityIntoPermanentEquity" xlink:label="dawn_CommonStockSharesIssuedAsAResultOfConversionOfTemporaryEquityIntoPermanentEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_LicenseAgreementMilestonePaymentMember" xlink:label="dawn_LicenseAgreementMilestonePaymentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_TwoThousandAndTwentyOneStockIncentivePlanMember" xlink:label="dawn_TwoThousandAndTwentyOneStockIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_IpsenLicenseAgreementMember" xlink:label="dawn_IpsenLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_VolumeWeightedAveragePrice" xlink:label="dawn_VolumeWeightedAveragePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_SprintBioscienceAgreementMember" xlink:label="dawn_SprintBioscienceAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RedeemableNoncontrollingInterestEquityPreferredCarryingAmount" xlink:label="us-gaap_RedeemableNoncontrollingInterestEquityPreferredCarryingAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForProceedsFromPreviousAcquisition" xlink:label="us-gaap_PaymentsForProceedsFromPreviousAcquisition"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_OtherIndividualCustomerMember" xlink:label="dawn_OtherIndividualCustomerMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_DeferredSharesParValuePerShares" xlink:label="dawn_DeferredSharesParValuePerShares"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_RedeemableNoncontrollingInterestMember" xlink:label="dawn_RedeemableNoncontrollingInterestMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:label="us-gaap_ProceedsFromSaleOfProductiveAssets"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_MilestoneAchievedMember" xlink:label="dawn_MilestoneAchievedMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_DeferredSharesOutstanding" xlink:label="dawn_DeferredSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RoyaltyIncomeNonoperating" xlink:label="us-gaap_RoyaltyIncomeNonoperating"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_ManufacturingAndSupplyAgreementMember" xlink:label="dawn_ManufacturingAndSupplyAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_TwoThousandTwentyOneEmployeeStockPurchasePlanMember" xlink:label="dawn_TwoThousandTwentyOneEmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsConvertedToUnvestedCommonStockWeightedAverageGrantDateFairValue" xlink:label="dawn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsConvertedToUnvestedCommonStockWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableMember" xlink:label="us-gaap_AccountsReceivableMember"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock" xlink:label="dawn_ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_WeightedAveragePriceOfCompanysCommonStock" xlink:label="dawn_WeightedAveragePriceOfCompanysCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_BasisOfIssueDomain" xlink:label="dawn_BasisOfIssueDomain"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_DepositsAndOtherLongtermAssetsNonCurrent" xlink:label="dawn_DepositsAndOtherLongtermAssetsNonCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_IncentiveSharePlanMember" xlink:label="dawn_IncentiveSharePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_UpfrontPayment" xlink:label="dawn_UpfrontPayment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_MilestonePaymentsNotYetPaid" xlink:label="dawn_MilestonePaymentsNotYetPaid"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_BrisbaneCaliforniaMember" xlink:label="dawn_BrisbaneCaliforniaMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_LicenseAgreementWithIpsenPharmaSasMember" xlink:label="dawn_LicenseAgreementWithIpsenPharmaSasMember"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_AvailableForSaleSecuritieContinuousUnrealizedLossPositionAccumulatedLoss" xlink:label="dawn_AvailableForSaleSecuritieContinuousUnrealizedLossPositionAccumulatedLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ObligationsMember" xlink:label="us-gaap_ObligationsMember"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_AvailableForSaleSecuritie" xlink:label="dawn_AvailableForSaleSecuritie"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeNet" xlink:label="us-gaap_InvestmentIncomeNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDepositOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInDepositOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_PreFundedWarrantMember" xlink:label="dawn_PreFundedWarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdministrativeFeesExpense" xlink:label="us-gaap_AdministrativeFeesExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRepurchaseOfPrivatePlacement" xlink:label="us-gaap_PaymentsForRepurchaseOfPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_FounderOneMember" xlink:label="dawn_FounderOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_CommonSharesMember" xlink:label="dawn_CommonSharesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_TemporaryEquityTextBlock" xlink:label="dawn_TemporaryEquityTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_DetailsDomain" xlink:label="dawn_DetailsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_RestrictedStockAwardsMember" xlink:label="dawn_RestrictedStockAwardsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_CostOfProductRevenue" xlink:label="dawn_CostOfProductRevenue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassBMember" xlink:label="us-gaap_CommonClassBMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_IncentiveSharePlanMemberMember" xlink:label="dawn_IncentiveSharePlanMemberMember"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_IndividualCustomerMember" xlink:label="dawn_IndividualCustomerMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_DetailsAxis" xlink:label="dawn_DetailsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyAccrualAtCarryingValue" xlink:label="us-gaap_LossContingencyAccrualAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_LicenseRevenue" xlink:label="dawn_LicenseRevenue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_MarketableSecuritiesMember" xlink:label="dawn_MarketableSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_IncrementalSharesReservedForFutureIssuanceMember" xlink:label="dawn_IncrementalSharesReservedForFutureIssuanceMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_ScheduleOfStockOptionsAssumptionsTableTextBlock" xlink:label="dawn_ScheduleOfStockOptionsAssumptionsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AreaOfLand" xlink:label="us-gaap_AreaOfLand"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:label="dawn_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_IssuanceOfCommonStockInPrivatePlacementValue" xlink:label="dawn_IssuanceOfCommonStockInPrivatePlacementValue"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_SharesCommittedUnderESPPMember" xlink:label="dawn_SharesCommittedUnderESPPMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_UnvestedPerformanceStockUnitsMember" xlink:label="dawn_UnvestedPerformanceStockUnitsMember"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_PaymentsOfCreditsRelatingToSalesInCurrentYear" xlink:label="dawn_PaymentsOfCreditsRelatingToSalesInCurrentYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_CurrentProvisionRelatingToCurrentPeriodSales" xlink:label="dawn_CurrentProvisionRelatingToCurrentPeriodSales"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_BasisOfIssueAxis" xlink:label="dawn_BasisOfIssueAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_AccruedMilestonePayment" xlink:label="dawn_AccruedMilestonePayment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsOwnshareLendingArrangementIssuanceCostsNet" xlink:label="us-gaap_DeferredFinanceCostsOwnshareLendingArrangementIssuanceCostsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RealizedInvestmentGainsLosses" xlink:label="us-gaap_RealizedInvestmentGainsLosses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_PaymentsOfCreditsRelatingToSalesInPriorYear" xlink:label="dawn_PaymentsOfCreditsRelatingToSalesInPriorYear"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_SalesAgreementMember" xlink:label="dawn_SalesAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_PrepaidResearchAndDevelopmentExpenses" xlink:label="dawn_PrepaidResearchAndDevelopmentExpenses"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageGrantDateFairValue" xlink:label="dawn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_OneCustomerMember" xlink:label="dawn_OneCustomerMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_ParticipatingThreshold" xlink:label="dawn_ParticipatingThreshold"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_GrossProceedsMember" xlink:label="dawn_GrossProceedsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_FrontlinePayment" xlink:label="dawn_FrontlinePayment"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_AgreementDomain" xlink:label="dawn_AgreementDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_PremiumPaidOnEquityStatementAsAdditionalConsideration" xlink:label="dawn_PremiumPaidOnEquityStatementAsAdditionalConsideration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossAttributableToNoncontrollingInterest" xlink:label="us-gaap_IncomeLossAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RoyaltyMember" xlink:label="us-gaap_RoyaltyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_PrvPressureReliefValveMember" xlink:label="dawn_PrvPressureReliefValveMember"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_AccountingPoliciesLineItems" xlink:label="dawn_AccountingPoliciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_ConditionsForIssueDomain" xlink:label="dawn_ConditionsForIssueDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_NoncurrentMember" xlink:label="dawn_NoncurrentMember"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_AccruedPayrollRelatedExpenses" xlink:label="dawn_AccruedPayrollRelatedExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_AccruedLicenseAgreementUpfrontPayment" xlink:label="dawn_AccruedLicenseAgreementUpfrontPayment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsLineItems" xlink:label="us-gaap_CashAndCashEquivalentsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_TwoThousandAndTwentyTwoEquityInducementPlanMember" xlink:label="dawn_TwoThousandAndTwentyTwoEquityInducementPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PurchaseCommitmentMember" xlink:label="us-gaap_PurchaseCommitmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_PercentageOfUpfrontLicenseFee" xlink:label="dawn_PercentageOfUpfrontLicenseFee"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_ScheduleOfPrepaidAndOtherCurrentAssetstableTextBlockTableTextBlock" xlink:label="dawn_ScheduleOfPrepaidAndOtherCurrentAssetstableTextBlockTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_UnvestedCommonStockMember" xlink:label="dawn_UnvestedCommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_AccruedRebates" xlink:label="dawn_AccruedRebates"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FeeIncome" xlink:label="us-gaap_FeeIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashEquivalentsMember" xlink:label="us-gaap_CashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfInvestments" xlink:label="us-gaap_GainLossOnSaleOfInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_SeriesARedeemableConvertiblePreferredStockMember" xlink:label="dawn_SeriesARedeemableConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_SeriesBRedeemableConvertiblePreferredStockMember" xlink:label="dawn_SeriesBRedeemableConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_PerformanceStockUnitsMember" xlink:label="dawn_PerformanceStockUnitsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_AvailableForSaleSecuritieAmortizedCost" xlink:label="dawn_AvailableForSaleSecuritieAmortizedCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesSubscribedButUnissued" xlink:label="us-gaap_TemporaryEquitySharesSubscribedButUnissued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_PaymentOfMilestones" xlink:label="dawn_PaymentOfMilestones"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_FounderTwoMember" xlink:label="dawn_FounderTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_IpsenPharmaSasAgreementMember" xlink:label="dawn_IpsenPharmaSasAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanTextBlock" xlink:label="us-gaap_DefinedContributionPlanTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_AustinTXMember" xlink:label="dawn_AustinTXMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" xlink:label="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_PreFundedWarrantsMember" xlink:label="dawn_PreFundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_AvailableForSaleSecuritieContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:label="dawn_AvailableForSaleSecuritieContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_MrkdgLicenseAgreementMember" xlink:label="dawn_MrkdgLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_ShareBasedCompensationByShareBasedPaymentArrangementEquityInstrumentsOtherThanOptionsOutstanding" xlink:label="dawn_ShareBasedCompensationByShareBasedPaymentArrangementEquityInstrumentsOtherThanOptionsOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_CommonStockSharesPurchased" xlink:label="dawn_CommonStockSharesPurchased"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmountOfDilutiveSecuritiesStockOptionsAndRestrictiveStockUnits" xlink:label="us-gaap_AmountOfDilutiveSecuritiesStockOptionsAndRestrictiveStockUnits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets" xlink:label="us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_PerformanceStockOptionsMember" xlink:label="dawn_PerformanceStockOptionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_UpfrontLicenseFee" xlink:label="dawn_UpfrontLicenseFee"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_ThreeCustomerMember" xlink:label="dawn_ThreeCustomerMember"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_PRV-RelatedObligationPaymentMember" xlink:label="dawn_PRV-RelatedObligationPaymentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="us-gaap_OtherPrepaidExpenseCurrent"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionMoreThan12MonthsAccumulatedLoss" xlink:label="dawn_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionMoreThan12MonthsAccumulatedLoss"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_WithinOneYearMember" xlink:label="dawn_WithinOneYearMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_TwoThousandTwentyFourPrivatePlacementMember" xlink:label="dawn_TwoThousandTwentyFourPrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_UnvestedRestrictedStockAndStockOptionsMember" xlink:label="dawn_UnvestedRestrictedStockAndStockOptionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_TransactionPrice" xlink:label="dawn_TransactionPrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_CommonStockIssuedPursuantToFollowOnOfferingNetOfIssuanceCostsShares" xlink:label="dawn_CommonStockIssuedPursuantToFollowOnOfferingNetOfIssuanceCostsShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_AdjustmentsRelatingToPriorYears" xlink:label="dawn_AdjustmentsRelatingToPriorYears"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_DefinedContributionPlanEmployerMatchingContribution" xlink:label="dawn_DefinedContributionPlanEmployerMatchingContribution"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_UnvestedPsosAndPsusMember" xlink:label="dawn_UnvestedPsosAndPsusMember"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_MabcareLicenseAgreementMember" xlink:label="dawn_MabcareLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_PaymentOfAccruedInterest" xlink:label="dawn_PaymentOfAccruedInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_SummaryOfPerformanceStockUnitsActivity" xlink:label="dawn_SummaryOfPerformanceStockUnitsActivity"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_PaymentToObligationOfLicenseAgreement" xlink:label="dawn_PaymentToObligationOfLicenseAgreement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_AgreementAxis" xlink:label="dawn_AgreementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_TwoThousandAndTwentyOneEquityIncentivePlanMember" xlink:label="dawn_TwoThousandAndTwentyOneEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_ConditionsForIssueAxis" xlink:label="dawn_ConditionsForIssueAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditConcentrationRiskMember" xlink:label="us-gaap_CreditConcentrationRiskMember"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_IssuanceOfCommonStockUponReleaseOfRestrictedStockUnits" xlink:label="dawn_IssuanceOfCommonStockUponReleaseOfRestrictedStockUnits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_AtTheMarketMember" xlink:label="dawn_AtTheMarketMember"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_EmployeeStockPurchasePlanMember" xlink:label="dawn_EmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:label="us-gaap_ProceedsFromSaleOfShortTermInvestments"/>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Statement [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">2021 employee stock purchase plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2021 Employee Stock Purchase Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand And Twenty One Employee Stock Purchase Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accounts receivable, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts Receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accounts Receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityLiquidationPreference_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liquidation Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityLiquidationPreference_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Liquidation Preference</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_PremiumReceivedOnLicenseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Premium Received On License Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_PremiumReceivedOnLicenseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Premium Received On License Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_PremiumReceivedOnLicenseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Premium Received On License Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_PurchasesUnderThePurchaseObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchases under the purchase obligation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_PurchasesUnderThePurchaseObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Purchases Under the Purchase Obligation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_PurchasesUnderThePurchaseObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Purchases Under the Purchase Obligation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_ShareBasedCompensationByShareBasedPaymentAwardConversionOfIncentiveSharesIntoRestrictedStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of incentive shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_ShareBasedCompensationByShareBasedPaymentAwardConversionOfIncentiveSharesIntoRestrictedStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation By Share Based Payment Award Conversion Of Incentive Shares Into Restricted Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_ShareBasedCompensationByShareBasedPaymentAwardConversionOfIncentiveSharesIntoRestrictedStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation by share based payment award conversion of incentive shares into restricted stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Recurring and Nonrecurring [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_CurrentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Current [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_CurrentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_CurrentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenuesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenuesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenues [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_CommonStockIssuedPursuantToFollowOnOfferingNetOfIssuanceCostsAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock pursuant to follow-on offering, net of issuance costs, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_CommonStockIssuedPursuantToFollowOnOfferingNetOfIssuanceCostsAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common stock issued pursuant to follow-on offering, net of issuance costs, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_CommonStockIssuedPursuantToFollowOnOfferingNetOfIssuanceCostsAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock issued pursuant to follow-on offering, net of issuance costs, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_NetProductRevenueAndAccountsReceivableMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Product Revenue and Accounts Receivable [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_NetProductRevenueAndAccountsReceivableMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Product Revenue and Accounts Receivable [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_NetProductRevenueAndAccountsReceivableMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Net Product Revenue and Accounts Receivable [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Operating Segments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of operating segment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Issued During Period, Shares, Employee Stock Ownership Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Employee Stock Ownership Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2028</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercisable at March 31, 2025</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning Balance (In shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending Balance (In shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Option Indexed to Issuer's Equity, Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Shares Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary Equity, Shares Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Shares Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Inputs, Level 2</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 2 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease expiration description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_MaketValueOfCommonStockHeldByNonAffiliateStockholders_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maket Value Of CommonStock Held By Non Affiliate Stockholders</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_MaketValueOfCommonStockHeldByNonAffiliateStockholders_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maket value of common stock held by non-affiliate stockholders</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_MaketValueOfCommonStockHeldByNonAffiliateStockholders_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maket value of common stock held by non-affiliate stockholders</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_MilestonePaymentsNotYetReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone payments not yet received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_MilestonePaymentsNotYetReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Payments not Yet Received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_MilestonePaymentsNotYetReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone Payments not Yet Received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_AccountsReceivableCreditLosses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts receivable, credit losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_AccountsReceivableCreditLosses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Receivable, Credit Losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_AccountsReceivableCreditLosses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accounts Receivable, Credit Losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025 (Remaining)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_RedeemableNonControllingInterestTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Redeemable NonControlling Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_RedeemableNonControllingInterestTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Redeemable Non Controlling Interest [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_RedeemableNonControllingInterestTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of redeemable non-controlling interest.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeFairValueOfDerivativeLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Derivative liability at fair value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeFairValueOfDerivativeLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Derivative Liability, Subject to Master Netting Arrangement, before Offset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeFairValueOfDerivativeLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Derivative Liability, Fair Value, Gross Liability, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock, Class of Stock [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product and Service [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible assets, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Indefinite-Lived Intangible Assets (Excluding Goodwill)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Indefinite-Lived Intangible Assets (Excluding Goodwill), Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Indefinite-Lived Intangible Assets (Excluding Goodwill), Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Indefinite-Lived Intangible Assets (Excluding Goodwill), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation, Depletion and Amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Depreciation, Depletion and Amortization, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_MilestoneAchievementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Achievement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_MilestoneAchievementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone Achievement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payment of PRV related obligations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Productive Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payments to Acquire Productive Assets, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_UpfrontOfCashPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront License Fee</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_UpfrontOfCashPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Upfront of cash payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_UpfrontOfCashPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">upfront of cash payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_UpfrontOfCashPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Upfront of Cash Payment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_LicenseAgreementRelatedPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License agreement related payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_LicenseAgreementRelatedPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License Agreement Related Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_LicenseAgreementRelatedPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">License Agreement Related Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentInformationTable_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Document Information [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentInformationTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Information [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Benchmark [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_AggregateOfUpfrontLicenseFeeReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Aggregate Of Upfront License Fee Received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_AggregateOfUpfrontLicenseFeeReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Aggregate Of Upfront License Fee Received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_AggregateOfUpfrontLicenseFeeReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Of Upfront License Fee Received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt securities, available-for-sale, unrealized loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Unrealized Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Debt securities, available-for-sale, unrealized loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_LeaseForCorporateOfficeFacilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease For Corporate Office Facility [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_LeaseForCorporateOfficeFacilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease For Corporate Office Facility</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_LeaseForCorporateOfficeFacilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease For Corporate Office Facility Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible asset useful life</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Asset, Useful Life</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Stock Option Activity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_TakedaAssetAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Takeda Asset Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_TakedaAssetAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Takeda Asset Agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_FirstAnniversaryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">First Anniversary [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_FirstAnniversaryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">First Anniversary [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_FirstAnniversaryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">First Anniversary</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Cash equivalents, at carrying value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Equivalents, at Carrying Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash Equivalents, at Carrying Value, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrant [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Forfeiture</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Forfeiture</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentForManagementFee_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment for Management Fee</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentForManagementFee_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payment for upfront license fee</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in operating assets and liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Operating Capital [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock, Shares Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Common Stock, Shares, Issued, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Share Purchased</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherIntangibleAssetsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Intangible Assets [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherIntangibleAssetsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Intangible Assets [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_ProductRevenueAllowanceAndReserve_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance as of June 30, 2024</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_ProductRevenueAllowanceAndReserve_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance as of December 31, 2023</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_ProductRevenueAllowanceAndReserve_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product Revenue Allowance and Reserve</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_ProductRevenueAllowanceAndReserve_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Product Revenue Allowance and Reserve</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_ScheduleOfPerformanceStockOptionsAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of The Black-Scholes Option Pricing Model to Estimate The Fair Value of Performance Stock Option Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_ScheduleOfPerformanceStockOptionsAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Performance Stock Options Assumptions [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_ScheduleOfPerformanceStockOptionsAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of Performance Stock Options Assumptions table text block</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_StockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_StockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issuance Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_StockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issuance costs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid expenses and other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Prepaid Expense and Other Assets, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock pursuant to Employee Stock Purchase Plan, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_ShareBasedCompensationByShareBasedPaymentArrangementEquityInstrumentsOtherThanOptionsConvertedToUnvestedCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Shares, Converted to unvested common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_ShareBasedCompensationByShareBasedPaymentArrangementEquityInstrumentsOtherThanOptionsConvertedToUnvestedCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation By Share Based Payment Arrangement Equity Instruments Other Than Options Converted To Unvested Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_ShareBasedCompensationByShareBasedPaymentArrangementEquityInstrumentsOtherThanOptionsConvertedToUnvestedCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation by share based payment arrangement equity instruments other than options converted to unvested common stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_FounderMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Founder [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_FounderMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Founder [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_FounderMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Founder Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_ShareBasedCompensationByShareBasedPaymentAwardConversionOfIncentiveShareIntoRestrictedStockWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of incentive shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_ShareBasedCompensationByShareBasedPaymentAwardConversionOfIncentiveShareIntoRestrictedStockWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation By Share Based Payment Award Conversion Of Incentive Share Into Restricted Stock Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_ShareBasedCompensationByShareBasedPaymentAwardConversionOfIncentiveShareIntoRestrictedStockWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation by share based payment award conversion of incentive share into restricted stock weighted average grant date fair value.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionMoreThanTwelveMonthsFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities Continuous Unrealized Loss Position More Than Twelve Months Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionMoreThanTwelveMonthsFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Available For Sale Securities Continuous Unrealized Loss Position More Than Twelve Months Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionMoreThanTwelveMonthsFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized losses 12 months or greater, Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Short-Term Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid for purchase of short-term investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Cash paid for purchase of short-term investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_InvestmentAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investment Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_InvestmentAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Investment Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_InvestmentAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_ScheduleOfMaturitiesForAvailableForSaleSecuritiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Maturities For Available For Sale Securities Table Text Block</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_ScheduleOfMaturitiesForAvailableForSaleSecuritiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule Of Maturities For Available For Sale Securities Table Text Block</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_ScheduleOfMaturitiesForAvailableForSaleSecuritiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Maturities For Available For Sale Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MajorCustomersAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Customer [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2027</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Exercisable at September 30, 2023, Aggregate Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercisable at March 31, 2024, Aggregate Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Exercisable at March 31, 2025</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByLiabilityClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liability Class [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Cover [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net (decrease) increase in cash and cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Basic, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net income (loss) per share - basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share, basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cost and operating expenses:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LicenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License Product [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LicenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LicenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">License revenue [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_MerckLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Merck License Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_MerckLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Merck License Agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_SummaryOfPerformanceStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary of Performance Stock Options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_SummaryOfPerformanceStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary of Performance Stock Options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_SummaryOfPerformanceStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Performance Stock Options Activity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Share-based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Allocated share based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ReceivablesNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts receivable, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ReceivablesNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Receivables, Net, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ReceivablesNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Receivables, Net, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForProceedsFromInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross proceeds from the investment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForProceedsFromInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments for (Proceeds from) Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForProceedsFromInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payments for (Proceeds from) Investments, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Retained Earnings (Accumulated Deficit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings (Accumulated Deficit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Retained Earnings (Accumulated Deficit), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Retained Earnings (Accumulated Deficit), Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Retained Earnings (Accumulated Deficit), Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Number of Shares, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Outstanding at March 31, 2025</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_AccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_AccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accounting Policies Table.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock shares reserved for future issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_AvailableForSaleSecuritieContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized Losses Less Than 12 Months, Fair value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_AvailableForSaleSecuritieContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securitie Continuous Unrealized Loss Position Less Than Twelve Months Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_AvailableForSaleSecuritieContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Available For Sale Securitie Continuous Unrealized Loss Position Less Than Twelve Months Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_ResearchAndDevelopmentAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Agreements [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_ResearchAndDevelopmentAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research And Development Agreements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_ResearchAndDevelopmentAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Research And Development Agreements Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Prepaid Expenses and Other Current Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in operating activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Grant Date Fair Value, Forfeited</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Forfeiture</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercisable at March 31, 2025</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product and Service [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated other comprehensive (loss) income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Other Comprehensive Income (Loss), Net of Tax, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Term of Contract</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred Compensation Arrangement with Individual, Shares Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Compensation Arrangement with Individual, Shares Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Property and equipment, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Property, Plant and Equipment, Net, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Property, Plant and Equipment, Net, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property and equipment, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2029</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from operating activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_UnamortizedStockBasedCompensationForStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Unamortized stock-based compensation for stock options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_UnamortizedStockBasedCompensationForStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unamortized stock-based compensation for stock options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_UnamortizedStockBasedCompensationForStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unamortized stock-based compensation for stock options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Recurring</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Recurring [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_TemporaryEquityRelatedTrancheLiabilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Related Tranche Liability [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_TemporaryEquityRelatedTrancheLiabilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary Equity Related Tranche Liability.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Schedule of fair value, assets and liabilities measured on recurring basis</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VestingAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Vesting [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock par value per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock, Par or Stated Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Par or Stated Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Share-based Payment Arrangement, Option</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Intangible Assets Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_UnvestedCommonSharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unvested Common Shares [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_UnvestedCommonSharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Unvested common shares.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_UnvestedCommonSharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unvested common shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other comprehensive loss:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_CashEquivalentsUnrealizedGains_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash equivalents, unrealized gains</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_CashEquivalentsUnrealizedGains_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Equivalents, Unrealized Gains</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_CashEquivalentsUnrealizedGains_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash equivalents, unrealized gains</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Cash Flows [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities, Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Selling, general and administrative expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Selling, General and Administrative Expenses [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized gain loss due to change in fair value of derivatives</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Derivative, Gain (Loss) on Derivative, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Derivative, Gain (Loss) on Derivative, Net, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_CommonSharesPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Shares Purchase Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_CommonSharesPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Shares Purchase Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_CommonSharesPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common Shares Purchase Agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Balance Sheet Related Disclosures [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Components [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Basic and Diluted Net Loss Per Share Attributable to Common Shareholders/Stockholders</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_TwoCustomerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Two Customer [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_TwoCustomerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Customer [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_TwoCustomerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two Customer [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Shares, Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses and other current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) In Accrued Expenses And Other Current Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase (decrease) in accrued expenses and other current liabilities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total non-operating income, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nonoperating Income (Expense)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Outstanding Potentially Dilutive Securities Have Been Excluded From Calculation of Diluted Net Loss Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt securities, available-for-sale, unrealized gain</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Unrealized Gain</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IndemnificationGuaranteeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Indemnification Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IndemnificationGuaranteeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Indemnification Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Unvested restricted stock, ending balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Number of Shares, Beginning balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unvested restricted stock at March 31, 2022</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2026</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_AccruedFederalAndStateTaxPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Federal And State Tax Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_AccruedFederalAndStateTaxPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued Federal And State Tax Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_AccruedFederalAndStateTaxPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued federal and state taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Operating Lease Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInInventoriesAndOtherOperatingAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Inventory</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInInventoriesAndOtherOperatingAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Inventory</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInInventoriesAndOtherOperatingAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Inventories and Other Operating Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Long-term portion of operating lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchase price per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock, Price Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net income (loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net income (loss) - basic and diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Lease, Description [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock upon exercise of stock options (share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_NameOfMajorCustomerDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Customer [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_TemporaryEquityIssuePricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary equity issue price per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_TemporaryEquityIssuePricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Issue Price Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_TemporaryEquityIssuePricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity issue price per share.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_TemporaryEquityStockIssuedDuringThePeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary equity stock issued during the period shares new issues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_TemporaryEquityStockIssuedDuringThePeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Stock Issued During The Period Shares New Issues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_TemporaryEquityStockIssuedDuringThePeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity stock issued during the period shares new issues.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Selling, general and administrative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">General and Administrative Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Balance Sheet Disclosures [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance Sheet Items</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Nonoperating Income (Expense), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Nonoperating Income (Expense)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income (expense), net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Purchase Commitment, Excluding Long-Term Commitment [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_EmployeeRelatedExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Related Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_EmployeeRelatedExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Employee Related Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_EmployeeRelatedExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee related expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_IncentiveSharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Incentive Shares [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_IncentiveSharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Incentive shares.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_IncentiveSharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Incentive Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_SeriesBRedeemableConvertiblePreferredSharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series B redeemable convertible preferred shares [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_SeriesBRedeemableConvertiblePreferredSharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series B Redeemable Convertible Preferred Shares.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_ViractaLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Viracta License Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_ViractaLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Viracta License Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_ViractaLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Viracta License Agreement Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Revenue, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Revenue, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current portion of deferred revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Deferred Revenue Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred Stock, Shares Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Preferred Stock, Shares Issued, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. government agency securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">US Government Corporations and Agencies Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Stock Options Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of common stock upon stock option exercises</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Unvested restricted stock, beginning balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unvested restricted stock, beginning balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of Shares, Ending balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payables and Accruals [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments to Additional Paid in Capital, Warrant Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of prefunded warrants to purchase common stock, net of issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Issuance of prefunded warrants to purchase common stock in connection with private placement, net of issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock pursuant to Employee Stock Purchase Plan, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Short-Term Investments, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short-Term Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenueNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term portion of deferred revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenueNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Revenue, Noncurrent, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenueNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Revenue, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenueNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Deferred revenue, noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Total prepaid expenses and other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses and other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense and Other Assets, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total prepaid expenses and other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price Per Share, Vested and expected to vest at March 31, 2025</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Forfeiture</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from redeemable convertible preferred stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Redeemable Convertible Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Class of Stock [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_AvailableForSaleSecuritieContinuousUnrealizedLossPositionFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_AvailableForSaleSecuritieContinuousUnrealizedLossPositionFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securitie Continuous Unrealized Loss Position Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_AvailableForSaleSecuritieContinuousUnrealizedLossPositionFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Available For Sale Securitie Continuous Unrealized Loss Position Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Product Revenue [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue from Contract with Customer, Product and Service Benchmark [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Significant Agreements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Intangible Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total comprehensive loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock, Shares, Outstanding, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock, Shares, Outstanding, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_Third-PartyCROCMOAndOtherThird-PartyClinicalTrialCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Third-Party CRO, CMO and Other Third-Party Clinical Trial Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_Third-PartyCROCMOAndOtherThird-PartyClinicalTrialCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Third-Party CRO, CMO and Other Third-Party Clinical Trial Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_Third-PartyCROCMOAndOtherThird-PartyClinicalTrialCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Third-party CRO, CMO and other third-party clinical trial costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate amount of future minimum purchase obligations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Purchase Commitment, Remaining Minimum Amount Committed</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_ConcentrationOfCreditRiskAndOtherRisksAndUncertaintiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration of Credit Risk and Other Risks and Uncertainties [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_ConcentrationOfCreditRiskAndOtherRisksAndUncertaintiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Concentration of Credit Risk and Other Risks and Uncertainties [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SalesRevenueNetMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Benchmark [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Summary of Restricted Stock Units Activity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of The Unvested Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Unvested Restricted Stock Units Roll Forward [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_ExternalCostsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">External Costs [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_ExternalCostsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">External Costs [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Cash_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Cash_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Cash_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Cash_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_CommonStockToBeIssuedUnderTheEsppTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of fair value of our common stock to be issued under the ESPP</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_CommonStockToBeIssuedUnderTheEsppTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">common stock to be issued under the ESPP Table text block</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_CommonStockToBeIssuedUnderTheEsppTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">common stock to be issued under the ESPP Table text block</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Entity Interactive Data Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value, mature in one year or less</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProductMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProductMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product revenue, net [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone payment, capitalized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Recognition, Milestone Method, Revenue Recognized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_CashEquivalentsUnrealizedLosses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash equivalents, unrealized losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_CashEquivalentsUnrealizedLosses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Equivalents, Unrealized Losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_CashEquivalentsUnrealizedLosses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash equivalents, unrealized losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentQuarterlyReport_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Document Quarterly Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentQuarterlyReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Quarterly Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of cash equivalents, marketable securities, and unrealized gains and losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Liabilities Measured on Recurring and Nonrecurring Basis [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Vested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash and cash equivalents, end of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash and cash equivalents, beginning of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2029</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Asset, Expected Amortization, Year Five</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_IssuanceOfCommonStockInPrivatePlacementShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock in connection with private placement, net of placement agent fees and offering costs(Share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_IssuanceOfCommonStockInPrivatePlacementShare_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of common stock in private placement(Share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_IssuanceOfCommonStockInPrivatePlacementShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance of common stock in private placement(Share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_CommonStockSharesIssuedAsAResultOfConversionOfTemporaryEquityIntoPermanentEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock shares issued as a result of conversion of temporary equity into permanent equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_CommonStockSharesIssuedAsAResultOfConversionOfTemporaryEquityIntoPermanentEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Issued As A Result Of Conversion Of Temporary Equity Into Permanent Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_CommonStockSharesIssuedAsAResultOfConversionOfTemporaryEquityIntoPermanentEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock shares issued as a result of conversion of temporary equity into permanent equity.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related and Nonrelated Parties [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_LicenseAgreementMilestonePaymentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License Agreement Milestone Payment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_LicenseAgreementMilestonePaymentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">License Agreement Milestone Payment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_LicenseAgreementMilestonePaymentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License agreement milestone payments [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Future Lease Obligations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_TwoThousandAndTwentyOneStockIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2021 Equity Incentive Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_TwoThousandAndTwentyOneStockIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand and twenty one stock incentive plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_TwoThousandAndTwentyOneStockIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">2021 Stock Incentive Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Finite-Lived Intangible Assets, Gross, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible assets, gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted Average Grant Date Fair Value, Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Grant date fair value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Private Placement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of common stock in connection with private placement, net of placement agent fees and offering costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Proceeds from issuance of private placement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_IpsenLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Ipsen License Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_IpsenLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Ipsen License Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_IpsenLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ipsen License Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_VolumeWeightedAveragePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Volume Weighted Average Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_VolumeWeightedAveragePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Volume Weighted Average Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_VolumeWeightedAveragePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Volume weighted average price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_OwnershipDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Ownership [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Income Location, Balance [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_SprintBioscienceAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sprint Bioscience Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_SprintBioscienceAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sprint Bioscience Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Expected term (in years)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Time to liquidity (in years)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RedeemableNoncontrollingInterestEquityPreferredCarryingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Carrying Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RedeemableNoncontrollingInterestEquityPreferredCarryingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Redeemable Noncontrolling Interest, Equity, Preferred, Carrying Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RedeemableNoncontrollingInterestEquityPreferredCarryingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Redeemable convertible preferred shares, no par value; no shares authorized, issued and outstanding at September 30, 2021; 22,851,257 shares authorized, issued and outstanding at December 31, 2020</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Vested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recently Issued Accounting Pronouncements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">AOCI Attributable to Parent [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Other Comprehensive Income (Loss) [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForProceedsFromPreviousAcquisition_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross proceeds from the Private Placement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForProceedsFromPreviousAcquisition_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments for (Proceeds from) Previous Acquisition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForProceedsFromPreviousAcquisition_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payments for (Proceeds from) Previous Acquisition, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payment of stock issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments of Stock Issuance Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_OtherIndividualCustomerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Individual Customer [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_OtherIndividualCustomerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Individual Customer [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_OtherIndividualCustomerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Other Individual Customer [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Shares, Forfeited</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">Forfeiture</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Forfeiture</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_DeferredSharesParValuePerShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred Shares Par Value Per Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_DeferredSharesParValuePerShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Shares Par Value Per Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_DeferredSharesParValuePerShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred Shares Par Value Per Shares.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_RedeemableNoncontrollingInterestMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock upon exercise of stock options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_RedeemableNoncontrollingInterestMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Redeemable Noncontrolling Interest [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_RedeemableNoncontrollingInterestMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Redeemable Noncontrolling Interest Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Fair value, measurement recurring basis, asset, transfers, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers, Net, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleOfProductiveAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds From sale of PRV</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleOfProductiveAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Sale of Productive Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleOfProductiveAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Proceeds from Sale of Productive Assets, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleOfProductiveAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Proceeds from sale of priority review voucher</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_MilestoneAchievedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Achieved [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_MilestoneAchievedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone Achieved.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchase Price of Common Stock Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortized cost, mature in one year or less</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based Compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense and Other Assets, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_DeferredSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_DeferredSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_DeferredSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred Shares Outstanding.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RoyaltyIncomeNonoperating_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Royalty Income, Nonoperating</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RoyaltyIncomeNonoperating_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Royalty revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average discount rate percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_ManufacturingAndSupplyAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Manufacturing And Supply Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_ManufacturingAndSupplyAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Manufacturing and Supply Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_ManufacturingAndSupplyAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Manufacturing and Supply Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_TwoThousandTwentyOneEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty One Employee Stock Purchase Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_TwoThousandTwentyOneEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2021 Employee Stock Purchase Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_TwoThousandTwentyOneEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two Thousand Twenty One Employee Stock Purchase Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock Issued During Period, Value, New Issues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, New Issues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock issued, share issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock upon exercise of stock options, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Stock Options Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Lease, Description [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseContractualTermAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Contractual Term [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsConvertedToUnvestedCommonStockWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Grant Date Fair Value, Converted to unvested common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsConvertedToUnvestedCommonStockWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Converted To Unvested Common Stock Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsConvertedToUnvestedCommonStockWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award equity instruments other than options converted to unvested common stock weighted average grant date fair value.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsReceivableMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts Receivable [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsReceivableMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Receivable [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule Of Common Stock Shares Reserved For Future Issuance Table Text Block</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Common Stock Shares Reserved For Future Issuance [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Common Stock Shares Reserved for Future Issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_WeightedAveragePriceOfCompanysCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Weighted Average Price of Company's common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_WeightedAveragePriceOfCompanysCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Price of Company's common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_WeightedAveragePriceOfCompanysCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Price of Company's common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash and cash equivalents, beginning of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash and cash equivalents, end of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, at Carrying Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash and Cash Equivalents, at Carrying Value, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Cash equivalents, amortized cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_BasisOfIssueDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Basis of Issue [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_BasisOfIssueDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Basis Of Issue Domain</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_DepositsAndOtherLongtermAssetsNonCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deposits and other long-term assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_DepositsAndOtherLongtermAssetsNonCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deposits and other longterm assets Non current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_DepositsAndOtherLongtermAssetsNonCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deposits and other long-term assets Non current.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Statement of Stockholders' Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Stockholders' Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_IncentiveSharePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Incentive Share Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_IncentiveSharePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Incentive Share Plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_UpfrontPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Upfront payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_UpfrontPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Upfront Payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_UpfrontPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Upfront payment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Document Fiscal Period Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total research and development expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total research and development expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Research and development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_MilestonePaymentsNotYetPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Milestone payments not yet paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_MilestonePaymentsNotYetPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone payments not yet paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_MilestonePaymentsNotYetPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone payments not yet paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Share based compensation by share based payment arrangement non vested options granted during the period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Indefinite-Lived Intangible Assets [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Class [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_BrisbaneCaliforniaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Brisbane, California [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_BrisbaneCaliforniaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Brisbane, California [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_BrisbaneCaliforniaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Brisbane, California</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Fair value, total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Fair Value of The Incentive Shares Estimated Using An Option Pricing Model</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_LicenseAgreementWithIpsenPharmaSasMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">License agreement with Ipsen Pharma SAS [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_LicenseAgreementWithIpsenPharmaSasMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License agreement with Ipsen Pharma SAS [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_AvailableForSaleSecuritieContinuousUnrealizedLossPositionAccumulatedLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securitie Continuous Unrealized Loss Position Accumulated Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_AvailableForSaleSecuritieContinuousUnrealizedLossPositionAccumulatedLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Available For Sale Securitie Continuous Unrealized Loss Position Accumulated Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_AvailableForSaleSecuritieContinuousUnrealizedLossPositionAccumulatedLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized Losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ObligationsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Obligations [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ObligationsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Obligations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_AvailableForSaleSecuritie_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_AvailableForSaleSecuritie_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securitie</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_AvailableForSaleSecuritie_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Available For Sale Securitie</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, by Class of Stock [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Excersise price of pre-funded warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instruments [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investment income, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Income, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Investment Income, Net, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from investing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInDepositOtherAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Deposits and other long-term assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInDepositOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Deposit Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInDepositOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Deposit Assets, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_PreFundedWarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Pre-Funded Warrant [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_PreFundedWarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-Funded Warrant [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdministrativeFeesExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront License Fee</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdministrativeFeesExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Administrative Fees Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForRepurchaseOfPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments for Repurchase of Private Placement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForRepurchaseOfPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payment to private placement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_FounderOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Founder One [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_FounderOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Founder One [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_FounderOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Founder One Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Comprehensive Income [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_CommonSharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common Shares [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_CommonSharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common shares [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_CommonSharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_OwnershipAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Ownership [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_TemporaryEquityTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Redeemable Convertible Preferred Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_TemporaryEquityTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_TemporaryEquityTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary Equity [Text Block].</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Finite-Lived Intangible Assets, Net, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Finite-Lived Intangible Assets, Net, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total future expected amortization expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unamortized finite-lived intangible asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_DetailsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Details [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_DetailsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Details Domain</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Accrued Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accounts Payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Accounts Payable, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Entity Address, Address Line Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities and stockholders' equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_RestrictedStockAwardsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Restricted Stock Awards Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_RestrictedStockAwardsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock Awards [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_RestrictedStockAwardsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted stock awards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash provided by financing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonClassAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Class A [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Effective income tax rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Effective income tax rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Effective Income Tax Rate Reconciliation, Percent, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Note [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_CostOfProductRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cost of product revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_CostOfProductRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">cost of product revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_CostOfProductRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cost of Product Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based compensation expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonClassBMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Class B [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Method Investment, Ownership Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ownership percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Research and Development Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other research and development costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Participating threshold</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income tax expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Income Tax Expense (Benefit), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Income tax benefit (expense)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Income tax benefit (expense)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_IncentiveSharePlanMemberMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Incentive Share Plan Member [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_IncentiveSharePlanMemberMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Incentive Share Plan Member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_IndividualCustomerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Individual Customer [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_IndividualCustomerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Individual Customer [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_IndividualCustomerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Individual Customer [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total stockholders' equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_DetailsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Details [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_DetailsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Details Axis</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingencyAccrualAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Litigation amount awarded from other party</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingencyAccrualAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Termination and cancellation charges payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingencyAccrualAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loss Contingency Accrual</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingencyAccrualAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Loss Contingency Accrual, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingencyAccrualAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Loss Contingency Accrual, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment of Intangible Assets, Finite-Lived</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unamortized finite lived intangible asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Pre-funded warrants purchased</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Liabilities, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other long-term liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeInstrumentRiskAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Derivative Instrument [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock Units (RSUs)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Stock Units</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Restricted Stock Units (RSUs)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConversionOfStockSharesIssued1_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of shares issued upon conversion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConversionOfStockSharesIssued1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Conversion of Stock, Shares Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Deferred Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary Equity, Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Option Indexed to Issuer's Equity, Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_LicenseRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_LicenseRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_LicenseRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">License Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Share/Stock-based Compensation Expense Recorded in The Accompanying Condensed Consolidated Statements of Operations and Comprehensive Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_MarketableSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_MarketableSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_MarketableSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Marketable securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_IncrementalSharesReservedForFutureIssuanceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Incremental Shares Reserved for Future Issuance [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_IncrementalSharesReservedForFutureIssuanceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Incremental Shares Reserved For Future Issuance [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_IncrementalSharesReservedForFutureIssuanceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Incremental Shares Reserved For Future Issuance.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SecurityDeposit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security deposit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SecurityDeposit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Deposit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recognized income tax benefit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Income Tax Expense (Benefit), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Income Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Geographical [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vested and expected to vest at March 31, 2025, Aggregate Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_ScheduleOfStockOptionsAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of Stock Options Assumptions.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_ScheduleOfStockOptionsAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Stock Options Assumptions [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_ScheduleOfStockOptionsAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Summary of The Black-Scholes Option Pricing Model to Estimate The Fair Value of Stock Option Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AreaOfLand_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Area of Land</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AreaOfLand_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sublease agreement area</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Use of Estimates</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Use of Estimates, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration risk percentage of net product revenue and accounts receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk, Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due after Year Four</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee Operating Lease Liability Payments Due after Year Four</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Thereafter</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected dividend yield</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Share based compensation by share based payment award fair value assumptions dividend yield</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_IssuanceOfCommonStockInPrivatePlacementValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of common stock in private placement(Value)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_IssuanceOfCommonStockInPrivatePlacementValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance of common stock in private placement(Value)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_IssuanceOfCommonStockInPrivatePlacementValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock in connection with private placement, net of placement agent fees and offering costs(Value)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_SharesCommittedUnderESPPMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Shares Committed Under E S P P.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_SharesCommittedUnderESPPMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Committed Under E S P P [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_SharesCommittedUnderESPPMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares committed under ESPP</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_UnvestedPerformanceStockUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Unvested Performance Stock Units</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_UnvestedPerformanceStockUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unvested Performance Stock Units [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_UnvestedPerformanceStockUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unvested PSUs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_PaymentsOfCreditsRelatingToSalesInCurrentYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payments / credits relating to sales in current year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_PaymentsOfCreditsRelatingToSalesInCurrentYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments of Credits Relating to Sales in Current Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_PaymentsOfCreditsRelatingToSalesInCurrentYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payments of Credits Relating to Sales in Current Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value by Liability Class [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total cost and operating expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_CurrentProvisionRelatingToCurrentPeriodSales_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current provision relating to current period sales</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_CurrentProvisionRelatingToCurrentPeriodSales_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Provision Relating to Current Period Sales</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_CurrentProvisionRelatingToCurrentPeriodSales_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Current Provision Relating to Current Period Sales</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Class of Stock [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_BasisOfIssueAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Basis of Issue [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_BasisOfIssueAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Basis Of Issue Axis</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recurring Fair Value Measurements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2028</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Share based compensation by share based payment arrangement non vested options granted during the period weighted average grant date fair value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ownership percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsidiary, Ownership Percentage, Noncontrolling Owner</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities and stockholders' equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_AccruedMilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued milestone payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_AccruedMilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Milestone Payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_AccruedMilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued Milestone Payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease&#160;right-of-use&#160;asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Right-of-Use Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Share-based compensation arrangement by share-based payment award, options, vested, number of shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vested and expected to vest at March 31, 2025</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retirement Benefits [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredFinanceCostsOwnshareLendingArrangementIssuanceCostsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Deferred finance costs, own-share lending arrangement, issuance costs, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredFinanceCostsOwnshareLendingArrangementIssuanceCostsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Finance Costs, Own-share Lending Arrangement, Issuance Costs, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredFinanceCostsOwnshareLendingArrangementIssuanceCostsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Finance Costs, Own-share Lending Arrangement, Issuance Costs, Net, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Diluted, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net income (loss) per share - diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share, diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Entity Ex Transition Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash (used in) provided by investing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, New Issues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock issued in IPO, net of issuance costs of $16,995 (In shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RealizedInvestmentGainsLosses_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Realized Investment Gains (Losses), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RealizedInvestmentGainsLosses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Realized Investment Gains (Losses)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RealizedInvestmentGainsLosses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Realized gains and losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Entity Filer Category</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary equity shares issued upon conversion of notes payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Conversion, Converted Instrument, Shares Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_PaymentsOfCreditsRelatingToSalesInPriorYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payments / credits relating to sales in prior year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_PaymentsOfCreditsRelatingToSalesInPriorYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments of Credits Relating to Sales in Prior Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_PaymentsOfCreditsRelatingToSalesInPriorYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payments of Credits Relating to Sales in Prior Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_SalesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sales Agreement with Piper Sandler and Jones Services LLC</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_SalesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sales Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_SalesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sales agreement member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_PrepaidResearchAndDevelopmentExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Prepaid research and development expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_PrepaidResearchAndDevelopmentExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid research and development expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_PrepaidResearchAndDevelopmentExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Prepaid Research and Development Expenses.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Grant Date Fair Value, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award equity instruments other than options outstanding weighted average grant date fair value.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Description of Business and Organization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nonoperating Income (Expense) [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-operating income:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_OneCustomerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">One Customer [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_OneCustomerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">One Customer [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Current Fiscal Year End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Less: Imputed interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: Imputed interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary Equity, Par or Stated Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Par or Stated Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_ParticipatingThreshold_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Participating threshold.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_ParticipatingThreshold_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Participating Threshold</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_ParticipatingThreshold_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Participating threshold</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Outstanding at March 31, 2022, Aggregate Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Outstanding at March 31, 2025 Aggregate Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related and Nonrelated Parties [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_GrossProceedsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gross Proceeds [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_GrossProceedsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Gross Proceeds.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Indefinite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Reportable Segments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of reportable segment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Income (Loss) Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_FrontlinePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Frontline Payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_FrontlinePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Frontline Payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_FrontlinePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Frontline Payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_AgreementDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Agreement [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_AgreementDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Agreement Domain</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Money market funds</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Money Market Funds [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Cash paid for acquired intangible assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid for acquired intangible asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Intangible Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Basic, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted average shares outstanding - basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average number of common shares used in net income (loss) per share - basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_PremiumPaidOnEquityStatementAsAdditionalConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Premium Paid On Equity Statement As Additional Consideration</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_PremiumPaidOnEquityStatementAsAdditionalConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Premium Paid On Equity Statement As Additional Consideration</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_PremiumPaidOnEquityStatementAsAdditionalConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Premium paid on equity statement as additional consideration</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VestingDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Vesting [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock shares authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock, Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Loss before income taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income (Loss) Attributable to Noncontrolling Interest, before Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Income (Loss) Attributable to Noncontrolling Interest, before Tax, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Loss before income taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RoyaltyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Royalty [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RoyaltyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Royalty</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from the issuance of common stock, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Proceeds from issuance of common stock, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Inputs, Level 1</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 1 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization of intangible assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Amortization Of Intangible Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amortization of Intangible Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instrument [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Remaining Contractual Term, Outstanding at March 31, 2025</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_PrvPressureReliefValveMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">PRV</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_PrvPressureReliefValveMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">PRV (Pressure Relief Valve) [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_PrvPressureReliefValveMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">PRV (Pressure relief valve) [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_AccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_AccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accounting Policies LineItems.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Nonvested Share Activity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of The Unvested Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_ConditionsForIssueDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Conditions For Issue [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_ConditionsForIssueDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Conditions For Issue Domain</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_NoncurrentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">NonCurrent [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_NoncurrentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">NonCurrent [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_NoncurrentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Noncurrent Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_AccruedPayrollRelatedExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued Payroll Related Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_AccruedPayrollRelatedExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Payroll Related Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_AccruedPayrollRelatedExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued payroll related expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of prefunded warrants to purchase common stock, net of issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_AccruedLicenseAgreementUpfrontPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued license agreement upfront payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_AccruedLicenseAgreementUpfrontPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued license agreement upfront payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_AccruedLicenseAgreementUpfrontPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued license agreement upfront payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt securities, available-for-sale, estimated fair value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Securities, Available-for-Sale, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Attributable to Parent [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders' equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental disclosures of noncash activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_TwoThousandAndTwentyTwoEquityInducementPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two Thousand And Twenty Two Equity Inducement Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_TwoThousandAndTwentyTwoEquityInducementPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand And Twenty Two Equity Inducement Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_TwoThousandAndTwentyTwoEquityInducementPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2022 Equity Inducement Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Statement [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Segmen tReporting Policy Policy TextBlock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Schedule of Property and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average period expected to be recognized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted-Average Remaining Contractual Term, Vested and expected to vest at March 31, 2025</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PurchaseCommitmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchase Commitments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PurchaseCommitmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Purchase Commitment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_PercentageOfUpfrontLicenseFee_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage Of Upfront License Fee</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_PercentageOfUpfrontLicenseFee_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Upfront License Fee</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_PercentageOfUpfrontLicenseFee_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage Of Upfront License Fee</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_ScheduleOfPrepaidAndOtherCurrentAssetstableTextBlockTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Prepaid And Other Current Assets [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_ScheduleOfPrepaidAndOtherCurrentAssetstableTextBlockTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule Of Prepaid And Other Current Assets.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_ScheduleOfPrepaidAndOtherCurrentAssetstableTextBlockTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Schedule of Prepaid Expenses and Other Current Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_UnvestedCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Unvested Common Stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_UnvestedCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unvested Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_AccruedRebates_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Rebates</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_AccruedRebates_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued Rebates</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_AccruedRebates_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued rebates</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Entity File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Securities Act File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segment Reporting</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FeeIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fee Income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FeeIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">License Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FeeIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront License Fee</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashEquivalentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashEquivalentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Equivalents [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Thereafter</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Asset, Expected Amortization, after Year Five</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnSaleOfInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gain on Sale Of License Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnSaleOfInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gain (Loss) on Sale of Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnSaleOfInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Gain (Loss) on Sale of Investments, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseContractualTermDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Contractual Term [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Financial Position [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_SeriesARedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series A Redeemable Convertible Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_SeriesARedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series A Redeemable Convertible Preferred Stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IPOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">IPO [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income (Loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss from operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Expected volatility</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Volatility</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Entity Shell Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_SeriesBRedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series B Redeemable Convertible Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_SeriesBRedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series B Redeemable Convertible Preferred Stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Accrued professional service expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Professional Fees, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_PerformanceStockUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">PSUs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_PerformanceStockUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Performance Stock Units [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_PerformanceStockUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Performance Stock Units Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Entity Current Reporting Status</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Remaining Contractual Term, Exercisable at March 31, 2025</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_AvailableForSaleSecuritieAmortizedCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortized Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_AvailableForSaleSecuritieAmortizedCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securitie Amortized Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_AvailableForSaleSecuritieAmortizedCost_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Available For Sale Securitie Amortized Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Schedule of Accrued expenses and other current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesSubscribedButUnissued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary equity shares subscribed but not issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesSubscribedButUnissued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Shares Subscribed but Unissued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Geographical [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Document Fiscal Year Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capital Expenditures Incurred but Not yet Paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Amortized cost, total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Amortized Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less accumulated amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_PaymentOfMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment of Milestones</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_PaymentOfMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Launch And Sales Milestones</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_PaymentOfMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Payment of Milestones</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_PaymentOfMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payment of Milestones.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">Unrealized (loss) gain on available-for-sale securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Unrealized gain on available-for-sale securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Unrealized loss on available-for-sale securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">OCI, Debt Securities, Available-for-Sale, Gain (Loss), before Adjustment, after Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">OCI, Debt Securities, Available-for-Sale, Gain (Loss), before Adjustment, after Tax, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized loss on available-for-sale securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeContractTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Derivative Contract [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses and other current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities and Other Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accrued Liabilities and Other Liabilities, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_FounderTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Founder Two [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_FounderTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Founder two [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_FounderTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Founder Two Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Inventory</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Inventory, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Inventory, Net, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_IpsenPharmaSasAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Ipsen Pharma SAS Agreement Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_IpsenPharmaSasAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Ipsen Pharma SAS Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal statutory rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Federal Statutory Income Tax Rate Reconciliation, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Defined Contribution Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Issuance of Series B redeemable convertible preferred shares for cash, net of issuance costs, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Preferred Stock, Shares Outstanding, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Preferred Stock, Shares Outstanding, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unvested common stock forfeiture</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued, Shares, Share-Based Payment Arrangement, Forfeited</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional&#160;paid-in-capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid in Capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Additional Paid in Capital, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Additional Paid in Capital, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Additional Paid in Capital, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_AustinTXMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Austin, TX [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_AustinTXMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Austin, TX [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Purchase Commitment, Excluding Long-Term Commitment [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_PreFundedWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Pre-Funded Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_PreFundedWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-Funded Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_PreFundedWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre-Funded Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt securities, available-for-sale, amortized cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Securities, Available-for-Sale, Amortized Cost, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_AvailableForSaleSecuritieContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized Losses Less Than 12 Months, Unrealized losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_AvailableForSaleSecuritieContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securitie Continuous Unrealized Loss Position Less Than 12 Months Accumulated Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_AvailableForSaleSecuritieContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Available For Sale Securitie Continuous Unrealized Loss Position Less Than 12 Months Accumulated Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Less: current portion of operating lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current portion of operating lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: current portion of operating lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentInformationLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Document Information [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentInformationLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Information [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Accumulated Deficit [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Property, Plant, and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payments to Acquire Property, Plant, and Equipment, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Cash paid for purchase of property and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_MrkdgLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">MRKDG License Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_MrkdgLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">MRKDG License Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_MrkdgLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">MRKDG License Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Document Transition Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_ShareBasedCompensationByShareBasedPaymentArrangementEquityInstrumentsOtherThanOptionsOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of Shares, Unvested Common Stock, Ending balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_ShareBasedCompensationByShareBasedPaymentArrangementEquityInstrumentsOtherThanOptionsOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Number of Shares, Unvested Common Stock, Beginning balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_ShareBasedCompensationByShareBasedPaymentArrangementEquityInstrumentsOtherThanOptionsOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation By Share Based Payment Arrangement Equity Instruments Other Than Options Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_ShareBasedCompensationByShareBasedPaymentArrangementEquityInstrumentsOtherThanOptionsOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation by share based payment arrangement equity instruments other than options outstanding.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2027</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_CommonStockSharesPurchased_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common Stock Shares Purchased</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_CommonStockSharesPurchased_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Purchased</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_CommonStockSharesPurchased_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Common Stock Shares Purchased</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Security, Excluded EPS Calculation [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AmountOfDilutiveSecuritiesStockOptionsAndRestrictiveStockUnits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Dilutive Securities, Effect on Basic Earnings Per Share, Options and Restrictive Stock Units</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration of credit risk and other risks and uncertainties</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Method Investment, Underlying Equity in Net Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Investment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_PerformanceStockOptionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">PSOs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_PerformanceStockOptionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Performance Stock Options [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_PerformanceStockOptionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Performance Stock Options Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total fair value of options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted Average Grant Date Fair Value Per Share, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted Average Grant Date Fair Value Per Share, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unvested restricted stock as of December 31, 2021</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Unvested restricted stock Grant fair value at March 31, 2022</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization of operating right-of-use asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Amortization of operating right-of-use assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Amortization of operating&#160;right-of-use&#160;assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Right-of-Use Asset, Periodic Reduction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Additional Paid-in Capital [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid-in Capital [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_UpfrontLicenseFee_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront license fee</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_UpfrontLicenseFee_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Upfront License Fee</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_UpfrontLicenseFee_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Upfront License Fee</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Income Location, Balance [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2026</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_ThreeCustomerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Three Customer [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_ThreeCustomerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Three Customer [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_ThreeCustomerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Three Customer [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_PRV-RelatedObligationPaymentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">PRV-Related Obligation Payment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_PRV-RelatedObligationPaymentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">PRV-Related Obligation Payment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_PRV-RelatedObligationPaymentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">PRV-related obligation payment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Other prepaid expenses and other assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Prepaid Expense, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionMoreThan12MonthsAccumulatedLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities Continuous Unrealized Loss Position More Than 12 Months Accumulated Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionMoreThan12MonthsAccumulatedLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Available For Sale Securities Continuous Unrealized Loss Position More Than 12 Months Accumulated Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionMoreThan12MonthsAccumulatedLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized losses 12 months or greater, Unrealized Losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_WithinOneYearMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Within 1 year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_WithinOneYearMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Within One Year [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_WithinOneYearMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Within One Year [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Entity Common Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Basis of Presentation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Basis of Accounting, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025 (Remaining)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Value, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Common Stock, Value, Issued, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock, Value, Issued, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock, Value, Issued, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common Stock Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, $0.0001 par value; 500,000,000 shares authorized as of March 31, 2025 and December 31, 2024; 101,353,781 and 101,116,162 shares issued and outstanding as of March 31, 2025 and December 31, 2024, respectively.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred Compensation Arrangement with Individual, Shares Authorized for Issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Compensation Arrangement with Individual, Shares Authorized for Issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Amortization Expense For Amortizable Finite-Lived Intangible Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidInsurance_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Prepaid insurance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidInsurance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Insurance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Money market funds, included in cash and cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents, fair value disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalent [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_TwoThousandTwentyFourPrivatePlacementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024 Private Placement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_TwoThousandTwentyFourPrivatePlacementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two Thousand Twenty Four Private Placement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_TwoThousandTwentyFourPrivatePlacementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Four Private Placement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Present value of operating lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Present value of operating lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Frequency [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_UnvestedRestrictedStockAndStockOptionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unvested Restricted Stock and Stock Options [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_UnvestedRestrictedStockAndStockOptionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unvested Restricted Stock And Stock Options [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_UnvestedRestrictedStockAndStockOptionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Unvested Restricted Stock And Stock Options.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and contingencies (Note 6)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_TransactionPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transaction Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_TransactionPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Transaction Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_TransactionPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Transaction Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized losses twelve months or greater</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Diluted, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted average shares outstanding - diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average number of common shares used in net income (loss) per share - diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Policies [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Summary of Significant Accounting Policies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Segment Reporting Information, by Segment [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Segment Information</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Redeemable Convertible Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preferred shares [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Redeemable convertible preferred shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total future minimum lease payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_CommonStockIssuedPursuantToFollowOnOfferingNetOfIssuanceCostsShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock pursuant to follow-on offering, net of issuance costs, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_CommonStockIssuedPursuantToFollowOnOfferingNetOfIssuanceCostsShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common stock issued pursuant to follow-on offering, net of issuance costs, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_CommonStockIssuedPursuantToFollowOnOfferingNetOfIssuanceCostsShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock issued pursuant to follow-on offering, net of issuance costs, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Benchmark [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Entity Small Business</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Intangible Asset, Indefinite-Lived [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Revenues_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total revenue, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Revenues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Revenues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Royalty Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Revenues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total revenues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. treasury securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">US Treasury Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_AdjustmentsRelatingToPriorYears_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments Relating to Prior Years</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_AdjustmentsRelatingToPriorYears_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments relating to prior years</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_AdjustmentsRelatingToPriorYears_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Adjustments Relating to Prior Years</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_DefinedContributionPlanEmployerMatchingContribution_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Defined Contribution Plan Employer Matching Contribution</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_DefinedContributionPlanEmployerMatchingContribution_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan Employer Matching Contribution</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_DefinedContributionPlanEmployerMatchingContribution_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Matching Contribution</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_UnvestedPsosAndPsusMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unvested PSOs and PSUs [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_UnvestedPsosAndPsusMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unvested PSOs and PSUs [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_UnvestedPsosAndPsusMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Unvested PSOs and PSUs [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_MabcareLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">MabCare License Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_MabcareLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">MabCare License Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_PaymentOfAccruedInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payment of accrued interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_PaymentOfAccruedInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment Of Accrued Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_PaymentOfAccruedInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payment of accrued interest.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accretion of discounts on short-term investments, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_SummaryOfPerformanceStockUnitsActivity_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary of Performance Stock Units activity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_SummaryOfPerformanceStockUnitsActivity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary of Performance Stock Units activity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_SummaryOfPerformanceStockUnitsActivity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Performance Stock Units Activity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_PaymentToObligationOfLicenseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment to Obligation of License Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_PaymentToObligationOfLicenseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payment to Obligation of License Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_PaymentToObligationOfLicenseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payment to obligation of license agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from financing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted Average Exercise Price Per Share, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted Average Exercise Price Per Share, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_AgreementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Agreement [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_AgreementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Agreement Axis</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Effect of dilutive securities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_TwoThousandAndTwentyOneEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand and twenty one equity incentive plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_TwoThousandAndTwentyOneEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand And Twenty One Equity Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_TwoThousandAndTwentyOneEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2021 Equity Incentive Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Class [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_ConditionsForIssueAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Conditions For Issue [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_ConditionsForIssueAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Conditions For Issue Axis</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right-of-use asset obtained in exchange for new operating lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Frequency [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CreditConcentrationRiskMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Credit Concentration Risk [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_IssuanceOfCommonStockUponReleaseOfRestrictedStockUnits_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock upon release of restricted stock units, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_IssuanceOfCommonStockUponReleaseOfRestrictedStockUnits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance of common stock upon release of restricted stock units</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_IssuanceOfCommonStockUponReleaseOfRestrictedStockUnits_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of common stock upon release of restricted stock units</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary Equity, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Inputs, Level 3</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 3 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average remaining lease term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Weighted Average Remaining Lease Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Events</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accounts Payable, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_AtTheMarketMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">At The Market [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_AtTheMarketMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">At The Market [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_EmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock Purchase Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dawn_EmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Employee Stock Purchase Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total accrued expenses and other current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable and Accrued Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleOfShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Sale of Short-Term Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleOfShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from maturity of short-term investments</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dawn_TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember" xlink:to="dawn_TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityLiquidationPreference" xlink:to="us-gaap_TemporaryEquityLiquidationPreference_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dawn_PremiumReceivedOnLicenseAgreement" xlink:to="dawn_PremiumReceivedOnLicenseAgreement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dawn_PurchasesUnderThePurchaseObligation" xlink:to="dawn_PurchasesUnderThePurchaseObligation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dawn_ShareBasedCompensationByShareBasedPaymentAwardConversionOfIncentiveSharesIntoRestrictedStock" xlink:to="dawn_ShareBasedCompensationByShareBasedPaymentAwardConversionOfIncentiveSharesIntoRestrictedStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dawn_CurrentMember" xlink:to="dawn_CurrentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenuesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dawn_CommonStockIssuedPursuantToFollowOnOfferingNetOfIssuanceCostsAmount" xlink:to="dawn_CommonStockIssuedPursuantToFollowOnOfferingNetOfIssuanceCostsAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dawn_NetProductRevenueAndAccountsReceivableMember" xlink:to="dawn_NetProductRevenueAndAccountsReceivableMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesIssued" xlink:to="us-gaap_TemporaryEquitySharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseDescription" xlink:to="us-gaap_LesseeOperatingLeaseDescription_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dawn_MaketValueOfCommonStockHeldByNonAffiliateStockholders" xlink:to="dawn_MaketValueOfCommonStockHeldByNonAffiliateStockholders_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dawn_MilestonePaymentsNotYetReceived" xlink:to="dawn_MilestonePaymentsNotYetReceived_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dawn_AccountsReceivableCreditLosses" xlink:to="dawn_AccountsReceivableCreditLosses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dawn_RedeemableNonControllingInterestTextBlock" xlink:to="dawn_RedeemableNonControllingInterestTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:to="us-gaap_DerivativeFairValueOfDerivativeLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dawn_MilestoneAchievementMember" xlink:to="dawn_MilestoneAchievementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireProductiveAssets" xlink:to="us-gaap_PaymentsToAcquireProductiveAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dawn_UpfrontOfCashPayment" xlink:to="dawn_UpfrontOfCashPayment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dawn_LicenseAgreementRelatedPayments" xlink:to="dawn_LicenseAgreementRelatedPayments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dawn_AggregateOfUpfrontLicenseFeeReceived" xlink:to="dawn_AggregateOfUpfrontLicenseFeeReceived_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dawn_LeaseForCorporateOfficeFacilityMember" xlink:to="dawn_LeaseForCorporateOfficeFacilityMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:to="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dawn_TakedaAssetAgreementMember" xlink:to="dawn_TakedaAssetAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dawn_FirstAnniversaryMember" xlink:to="dawn_FirstAnniversaryMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashEquivalentsAtCarryingValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentForManagementFee" xlink:to="us-gaap_PaymentForManagementFee_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIntangibleAssetsMember" xlink:to="us-gaap_OtherIntangibleAssetsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dawn_ProductRevenueAllowanceAndReserve" xlink:to="dawn_ProductRevenueAllowanceAndReserve_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dawn_ScheduleOfPerformanceStockOptionsAssumptionsTableTextBlock" xlink:to="dawn_ScheduleOfPerformanceStockOptionsAssumptionsTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dawn_StockIssuanceCosts" xlink:to="dawn_StockIssuanceCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dawn_ShareBasedCompensationByShareBasedPaymentArrangementEquityInstrumentsOtherThanOptionsConvertedToUnvestedCommonStock" xlink:to="dawn_ShareBasedCompensationByShareBasedPaymentArrangementEquityInstrumentsOtherThanOptionsConvertedToUnvestedCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dawn_FounderMember" xlink:to="dawn_FounderMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherExpenses" xlink:to="us-gaap_OtherExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dawn_ShareBasedCompensationByShareBasedPaymentAwardConversionOfIncentiveShareIntoRestrictedStockWeightedAverageGrantDateFairValue" xlink:to="dawn_ShareBasedCompensationByShareBasedPaymentAwardConversionOfIncentiveShareIntoRestrictedStockWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dawn_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionMoreThanTwelveMonthsFairValue" xlink:to="dawn_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionMoreThanTwelveMonthsFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireShortTermInvestments" xlink:to="us-gaap_PaymentsToAcquireShortTermInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_ConcentrationRiskTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dawn_InvestmentAgreementMember" xlink:to="dawn_InvestmentAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dawn_ScheduleOfMaturitiesForAvailableForSaleSecuritiesTableTextBlock" xlink:to="dawn_ScheduleOfMaturitiesForAvailableForSaleSecuritiesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_MajorCustomersAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueByLiabilityClassAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicenseMember" xlink:to="us-gaap_LicenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dawn_MerckLicenseAgreementMember" xlink:to="dawn_MerckLicenseAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dawn_SummaryOfPerformanceStockOptions" xlink:to="dawn_SummaryOfPerformanceStockOptions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesNetCurrent" xlink:to="us-gaap_ReceivablesNetCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForProceedsFromInvestments" xlink:to="us-gaap_PaymentsForProceedsFromInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dawn_AccountingPoliciesTable" xlink:to="dawn_AccountingPoliciesTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dawn_AvailableForSaleSecuritieContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue" xlink:to="dawn_AvailableForSaleSecuritieContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dawn_ResearchAndDevelopmentAgreementsMember" xlink:to="dawn_ResearchAndDevelopmentAgreementsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualSharesIssued" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualSharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dawn_UnamortizedStockBasedCompensationForStockOptions" xlink:to="dawn_UnamortizedStockBasedCompensationForStockOptions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dawn_TemporaryEquityRelatedTrancheLiabilityMember" xlink:to="dawn_TemporaryEquityRelatedTrancheLiabilityMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dawn_UnvestedCommonSharesMember" xlink:to="dawn_UnvestedCommonSharesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dawn_CashEquivalentsUnrealizedGains" xlink:to="dawn_CashEquivalentsUnrealizedGains_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeGainLossOnDerivativeNet" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dawn_CommonSharesPurchaseAgreementMember" xlink:to="dawn_CommonSharesPurchaseAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_BalanceSheetRelatedDisclosuresAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dawn_TwoCustomerMember" xlink:to="dawn_TwoCustomerMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dawn_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities" xlink:to="dawn_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndemnificationGuaranteeMember" xlink:to="us-gaap_IndemnificationGuaranteeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dawn_AccruedFederalAndStateTaxPayments" xlink:to="dawn_AccruedFederalAndStateTaxPayments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventoriesAndOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInInventoriesAndOtherOperatingAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="srt_NameOfMajorCustomerDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dawn_TemporaryEquityIssuePricePerShare" xlink:to="dawn_TemporaryEquityIssuePricePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dawn_TemporaryEquityStockIssuedDuringThePeriodSharesNewIssues" xlink:to="dawn_TemporaryEquityStockIssuedDuringThePeriodSharesNewIssues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xlink:to="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dawn_EmployeeRelatedExpenses" xlink:to="dawn_EmployeeRelatedExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dawn_IncentiveSharesMember" xlink:to="dawn_IncentiveSharesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dawn_SeriesBRedeemableConvertiblePreferredSharesMember" xlink:to="dawn_SeriesBRedeemableConvertiblePreferredSharesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dawn_ViractaLicenseAgreementMember" xlink:to="dawn_ViractaLicenseAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueCurrent" xlink:to="us-gaap_DeferredRevenueCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:to="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestments" xlink:to="us-gaap_ShortTermInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueNoncurrent" xlink:to="us-gaap_DeferredRevenueNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:to="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dawn_AvailableForSaleSecuritieContinuousUnrealizedLossPositionFairValue" xlink:to="dawn_AvailableForSaleSecuritieContinuousUnrealizedLossPositionFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember" xlink:to="us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dawn_Third-PartyCROCMOAndOtherThird-PartyClinicalTrialCosts" xlink:to="dawn_Third-PartyCROCMOAndOtherThird-PartyClinicalTrialCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:to="us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dawn_ConcentrationOfCreditRiskAndOtherRisksAndUncertaintiesMember" xlink:to="dawn_ConcentrationOfCreditRiskAndOtherRisksAndUncertaintiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNetMember" xlink:to="us-gaap_SalesRevenueNetMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dawn_ExternalCostsAbstract" xlink:to="dawn_ExternalCostsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dawn_CommonStockToBeIssuedUnderTheEsppTableTextBlock" xlink:to="dawn_CommonStockToBeIssuedUnderTheEsppTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductMember" xlink:to="us-gaap_ProductMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:to="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dawn_CashEquivalentsUnrealizedLosses" xlink:to="dawn_CashEquivalentsUnrealizedLosses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dawn_IssuanceOfCommonStockInPrivatePlacementShare" xlink:to="dawn_IssuanceOfCommonStockInPrivatePlacementShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dawn_CommonStockSharesIssuedAsAResultOfConversionOfTemporaryEquityIntoPermanentEquity" xlink:to="dawn_CommonStockSharesIssuedAsAResultOfConversionOfTemporaryEquityIntoPermanentEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dawn_LicenseAgreementMilestonePaymentMember" xlink:to="dawn_LicenseAgreementMilestonePaymentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dawn_TwoThousandAndTwentyOneStockIncentivePlanMember" xlink:to="dawn_TwoThousandAndTwentyOneStockIncentivePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dawn_IpsenLicenseAgreementMember" xlink:to="dawn_IpsenLicenseAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dawn_VolumeWeightedAveragePrice" xlink:to="dawn_VolumeWeightedAveragePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OwnershipDomain" xlink:to="srt_OwnershipDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dawn_SprintBioscienceAgreementMember" xlink:to="dawn_SprintBioscienceAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_CashAndCashEquivalentsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RedeemableNoncontrollingInterestEquityPreferredCarryingAmount" xlink:to="us-gaap_RedeemableNoncontrollingInterestEquityPreferredCarryingAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForProceedsFromPreviousAcquisition" xlink:to="us-gaap_PaymentsForProceedsFromPreviousAcquisition_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dawn_OtherIndividualCustomerMember" xlink:to="dawn_OtherIndividualCustomerMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dawn_DeferredSharesParValuePerShares" xlink:to="dawn_DeferredSharesParValuePerShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dawn_RedeemableNoncontrollingInterestMember" xlink:to="dawn_RedeemableNoncontrollingInterestMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:to="us-gaap_ProceedsFromSaleOfProductiveAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dawn_MilestoneAchievedMember" xlink:to="dawn_MilestoneAchievedMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dawn_DeferredSharesOutstanding" xlink:to="dawn_DeferredSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyIncomeNonoperating" xlink:to="us-gaap_RoyaltyIncomeNonoperating_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dawn_ManufacturingAndSupplyAgreementMember" xlink:to="dawn_ManufacturingAndSupplyAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dawn_TwoThousandTwentyOneEmployeeStockPurchasePlanMember" xlink:to="dawn_TwoThousandTwentyOneEmployeeStockPurchasePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dawn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsConvertedToUnvestedCommonStockWeightedAverageGrantDateFairValue" xlink:to="dawn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsConvertedToUnvestedCommonStockWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableMember" xlink:to="us-gaap_AccountsReceivableMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dawn_ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock" xlink:to="dawn_ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dawn_WeightedAveragePriceOfCompanysCommonStock" xlink:to="dawn_WeightedAveragePriceOfCompanysCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dawn_BasisOfIssueDomain" xlink:to="dawn_BasisOfIssueDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dawn_DepositsAndOtherLongtermAssetsNonCurrent" xlink:to="dawn_DepositsAndOtherLongtermAssetsNonCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dawn_IncentiveSharePlanMember" xlink:to="dawn_IncentiveSharePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dawn_UpfrontPayment" xlink:to="dawn_UpfrontPayment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dawn_MilestonePaymentsNotYetPaid" xlink:to="dawn_MilestonePaymentsNotYetPaid_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dawn_BrisbaneCaliforniaMember" xlink:to="dawn_BrisbaneCaliforniaMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dawn_LicenseAgreementWithIpsenPharmaSasMember" xlink:to="dawn_LicenseAgreementWithIpsenPharmaSasMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dawn_AvailableForSaleSecuritieContinuousUnrealizedLossPositionAccumulatedLoss" xlink:to="dawn_AvailableForSaleSecuritieContinuousUnrealizedLossPositionAccumulatedLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ObligationsMember" xlink:to="us-gaap_ObligationsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dawn_AvailableForSaleSecuritie" xlink:to="dawn_AvailableForSaleSecuritie_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeNet" xlink:to="us-gaap_InvestmentIncomeNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDepositOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInDepositOtherAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dawn_PreFundedWarrantMember" xlink:to="dawn_PreFundedWarrantMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdministrativeFeesExpense" xlink:to="us-gaap_AdministrativeFeesExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRepurchaseOfPrivatePlacement" xlink:to="us-gaap_PaymentsForRepurchaseOfPrivatePlacement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dawn_FounderOneMember" xlink:to="dawn_FounderOneMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dawn_CommonSharesMember" xlink:to="dawn_CommonSharesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dawn_TemporaryEquityTextBlock" xlink:to="dawn_TemporaryEquityTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dawn_DetailsDomain" xlink:to="dawn_DetailsDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dawn_RestrictedStockAwardsMember" xlink:to="dawn_RestrictedStockAwardsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonClassAMember" xlink:to="us-gaap_CommonClassAMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dawn_CostOfProductRevenue" xlink:to="dawn_CostOfProductRevenue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonClassBMember" xlink:to="us-gaap_CommonClassBMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherResearchAndDevelopmentExpense" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dawn_IncentiveSharePlanMemberMember" xlink:to="dawn_IncentiveSharePlanMemberMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dawn_IndividualCustomerMember" xlink:to="dawn_IndividualCustomerMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dawn_DetailsAxis" xlink:to="dawn_DetailsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingencyAccrualAtCarryingValue" xlink:to="us-gaap_LossContingencyAccrualAtCarryingValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeInstrumentRiskAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesIssued1" xlink:to="us-gaap_ConversionOfStockSharesIssued1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesAuthorized" xlink:to="us-gaap_TemporaryEquitySharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dawn_LicenseRevenue" xlink:to="dawn_LicenseRevenue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dawn_MarketableSecuritiesMember" xlink:to="dawn_MarketableSecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dawn_IncrementalSharesReservedForFutureIssuanceMember" xlink:to="dawn_IncrementalSharesReservedForFutureIssuanceMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecurityDeposit" xlink:to="us-gaap_SecurityDeposit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dawn_ScheduleOfStockOptionsAssumptionsTableTextBlock" xlink:to="dawn_ScheduleOfStockOptionsAssumptionsTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AreaOfLand" xlink:to="us-gaap_AreaOfLand_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dawn_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:to="dawn_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dawn_IssuanceOfCommonStockInPrivatePlacementValue" xlink:to="dawn_IssuanceOfCommonStockInPrivatePlacementValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dawn_SharesCommittedUnderESPPMember" xlink:to="dawn_SharesCommittedUnderESPPMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dawn_UnvestedPerformanceStockUnitsMember" xlink:to="dawn_UnvestedPerformanceStockUnitsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dawn_PaymentsOfCreditsRelatingToSalesInCurrentYear" xlink:to="dawn_PaymentsOfCreditsRelatingToSalesInCurrentYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dawn_CurrentProvisionRelatingToCurrentPeriodSales" xlink:to="dawn_CurrentProvisionRelatingToCurrentPeriodSales_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dawn_BasisOfIssueAxis" xlink:to="dawn_BasisOfIssueAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dawn_AccruedMilestonePayment" xlink:to="dawn_AccruedMilestonePayment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFinanceCostsOwnshareLendingArrangementIssuanceCostsNet" xlink:to="us-gaap_DeferredFinanceCostsOwnshareLendingArrangementIssuanceCostsNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RealizedInvestmentGainsLosses" xlink:to="us-gaap_RealizedInvestmentGainsLosses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dawn_PaymentsOfCreditsRelatingToSalesInPriorYear" xlink:to="dawn_PaymentsOfCreditsRelatingToSalesInPriorYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dawn_SalesAgreementMember" xlink:to="dawn_SalesAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dawn_PrepaidResearchAndDevelopmentExpenses" xlink:to="dawn_PrepaidResearchAndDevelopmentExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dawn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageGrantDateFairValue" xlink:to="dawn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dawn_OneCustomerMember" xlink:to="dawn_OneCustomerMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dawn_ParticipatingThreshold" xlink:to="dawn_ParticipatingThreshold_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dawn_GrossProceedsMember" xlink:to="dawn_GrossProceedsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfReportableSegments" xlink:to="us-gaap_NumberOfReportableSegments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dawn_FrontlinePayment" xlink:to="dawn_FrontlinePayment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dawn_AgreementDomain" xlink:to="dawn_AgreementDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dawn_PremiumPaidOnEquityStatementAsAdditionalConsideration" xlink:to="dawn_PremiumPaidOnEquityStatementAsAdditionalConsideration_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_VestingDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossAttributableToNoncontrollingInterest" xlink:to="us-gaap_IncomeLossAttributableToNoncontrollingInterest_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyMember" xlink:to="us-gaap_RoyaltyMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dawn_PrvPressureReliefValveMember" xlink:to="dawn_PrvPressureReliefValveMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dawn_AccountingPoliciesLineItems" xlink:to="dawn_AccountingPoliciesLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dawn_ConditionsForIssueDomain" xlink:to="dawn_ConditionsForIssueDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dawn_NoncurrentMember" xlink:to="dawn_NoncurrentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dawn_AccruedPayrollRelatedExpenses" xlink:to="dawn_AccruedPayrollRelatedExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dawn_AccruedLicenseAgreementUpfrontPayment" xlink:to="dawn_AccruedLicenseAgreementUpfrontPayment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="us-gaap_CashAndCashEquivalentsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dawn_TwoThousandAndTwentyTwoEquityInducementPlanMember" xlink:to="dawn_TwoThousandAndTwentyTwoEquityInducementPlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PurchaseCommitmentMember" xlink:to="us-gaap_PurchaseCommitmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dawn_PercentageOfUpfrontLicenseFee" xlink:to="dawn_PercentageOfUpfrontLicenseFee_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dawn_ScheduleOfPrepaidAndOtherCurrentAssetstableTextBlockTableTextBlock" xlink:to="dawn_ScheduleOfPrepaidAndOtherCurrentAssetstableTextBlockTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dawn_UnvestedCommonStockMember" xlink:to="dawn_UnvestedCommonStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dawn_AccruedRebates" xlink:to="dawn_AccruedRebates_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FeeIncome" xlink:to="us-gaap_FeeIncome_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashEquivalentsMember" xlink:to="us-gaap_CashEquivalentsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfInvestments" xlink:to="us-gaap_GainLossOnSaleOfInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="us-gaap_LeaseContractualTermDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dawn_SeriesARedeemableConvertiblePreferredStockMember" xlink:to="dawn_SeriesARedeemableConvertiblePreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dawn_SeriesBRedeemableConvertiblePreferredStockMember" xlink:to="dawn_SeriesBRedeemableConvertiblePreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dawn_PerformanceStockUnitsMember" xlink:to="dawn_PerformanceStockUnitsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dawn_AvailableForSaleSecuritieAmortizedCost" xlink:to="dawn_AvailableForSaleSecuritieAmortizedCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesSubscribedButUnissued" xlink:to="us-gaap_TemporaryEquitySharesSubscribedButUnissued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dawn_PaymentOfMilestones" xlink:to="dawn_PaymentOfMilestones_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="us-gaap_DerivativeContractTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dawn_FounderTwoMember" xlink:to="dawn_FounderTwoMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dawn_IpsenPharmaSasAgreementMember" xlink:to="dawn_IpsenPharmaSasAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanTextBlock" xlink:to="us-gaap_DefinedContributionPlanTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dawn_AustinTXMember" xlink:to="dawn_AustinTXMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" xlink:to="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dawn_PreFundedWarrantsMember" xlink:to="dawn_PreFundedWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dawn_AvailableForSaleSecuritieContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:to="dawn_AvailableForSaleSecuritieContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityDisclosureAbstract" xlink:to="us-gaap_TemporaryEquityDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dawn_MrkdgLicenseAgreementMember" xlink:to="dawn_MrkdgLicenseAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dawn_ShareBasedCompensationByShareBasedPaymentArrangementEquityInstrumentsOtherThanOptionsOutstanding" xlink:to="dawn_ShareBasedCompensationByShareBasedPaymentArrangementEquityInstrumentsOtherThanOptionsOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dawn_CommonStockSharesPurchased" xlink:to="dawn_CommonStockSharesPurchased_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmountOfDilutiveSecuritiesStockOptionsAndRestrictiveStockUnits" xlink:to="us-gaap_AmountOfDilutiveSecuritiesStockOptionsAndRestrictiveStockUnits_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets" xlink:to="us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dawn_PerformanceStockOptionsMember" xlink:to="dawn_PerformanceStockOptionsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dawn_UpfrontLicenseFee" xlink:to="dawn_UpfrontLicenseFee_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dawn_ThreeCustomerMember" xlink:to="dawn_ThreeCustomerMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dawn_PRV-RelatedObligationPaymentMember" xlink:to="dawn_PRV-RelatedObligationPaymentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherPrepaidExpenseCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dawn_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionMoreThan12MonthsAccumulatedLoss" xlink:to="dawn_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionMoreThan12MonthsAccumulatedLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dawn_WithinOneYearMember" xlink:to="dawn_WithinOneYearMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidInsurance" xlink:to="us-gaap_PrepaidInsurance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:to="us-gaap_ScheduleOfCashAndCashEquivalentsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dawn_TwoThousandTwentyFourPrivatePlacementMember" xlink:to="dawn_TwoThousandTwentyFourPrivatePlacementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dawn_UnvestedRestrictedStockAndStockOptionsMember" xlink:to="dawn_UnvestedRestrictedStockAndStockOptionsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dawn_TransactionPrice" xlink:to="dawn_TransactionPrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RedeemableConvertiblePreferredStockMember" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dawn_CommonStockIssuedPursuantToFollowOnOfferingNetOfIssuanceCostsShares" xlink:to="dawn_CommonStockIssuedPursuantToFollowOnOfferingNetOfIssuanceCostsShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USTreasurySecuritiesMember" xlink:to="us-gaap_USTreasurySecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dawn_AdjustmentsRelatingToPriorYears" xlink:to="dawn_AdjustmentsRelatingToPriorYears_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dawn_DefinedContributionPlanEmployerMatchingContribution" xlink:to="dawn_DefinedContributionPlanEmployerMatchingContribution_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dawn_UnvestedPsosAndPsusMember" xlink:to="dawn_UnvestedPsosAndPsusMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dawn_MabcareLicenseAgreementMember" xlink:to="dawn_MabcareLicenseAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dawn_PaymentOfAccruedInterest" xlink:to="dawn_PaymentOfAccruedInterest_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dawn_SummaryOfPerformanceStockUnitsActivity" xlink:to="dawn_SummaryOfPerformanceStockUnitsActivity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dawn_PaymentToObligationOfLicenseAgreement" xlink:to="dawn_PaymentToObligationOfLicenseAgreement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dawn_AgreementAxis" xlink:to="dawn_AgreementAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dawn_TwoThousandAndTwentyOneEquityIncentivePlanMember" xlink:to="dawn_TwoThousandAndTwentyOneEquityIncentivePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueByAssetClassAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dawn_ConditionsForIssueAxis" xlink:to="dawn_ConditionsForIssueAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditConcentrationRiskMember" xlink:to="us-gaap_CreditConcentrationRiskMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dawn_IssuanceOfCommonStockUponReleaseOfRestrictedStockUnits" xlink:to="dawn_IssuanceOfCommonStockUponReleaseOfRestrictedStockUnits_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesOutstanding" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dawn_AtTheMarketMember" xlink:to="dawn_AtTheMarketMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dawn_EmployeeStockPurchasePlanMember" xlink:to="dawn_EmployeeStockPurchasePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:to="us-gaap_ProceedsFromSaleOfShortTermInvestments_lbl"/>
        </link:labelLink>
        <link:presentationLink xlink:role="http://www.dayonebio.com/20250331/taxonomy/role/CoverPage" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentQuarterlyReport" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityExTransitionPeriod" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine2" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" order="28" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" order="29" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" order="30" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentInformationTable" order="49.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedBalanceSheetsUnaudited" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="us-gaap_ReceivablesNetCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_DepositsAndOtherLongtermAssetsNonCurrent" xlink:label="dawn_DepositsAndOtherLongtermAssetsNonCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_ShortTermInvestments" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DeferredRevenueNoncurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_ReceivablesNetCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DeferredRevenueCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_InventoryNet" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="dawn_DepositsAndOtherLongtermAssetsNonCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedBalanceSheetsUnauditedParenthetical" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassBMember" xlink:label="us-gaap_CommonClassBMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_DeferredSharesParValuePerShares" xlink:label="dawn_DeferredSharesParValuePerShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCompensationArrangementWithIndividualSharesIssued" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_DeferredSharesOutstanding" xlink:label="dawn_DeferredSharesOutstanding"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassBMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dawn_DeferredSharesParValuePerShares" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualSharesIssued" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dawn_DeferredSharesOutstanding" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfOperationsUnaudited" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_CostOfProductRevenue" xlink:label="dawn_CostOfProductRevenue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeNet" xlink:label="us-gaap_InvestmentIncomeNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LicenseMember" xlink:label="us-gaap_LicenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossAttributableToNoncontrollingInterest" xlink:label="us-gaap_IncomeLossAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenuesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_Revenues" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="dawn_CostOfProductRevenue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InvestmentIncomeNet" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_LicenseMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_IncomeLossAttributableToNoncontrollingInterest" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasic" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareDiluted" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfComprehensiveLossUnaudited" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfStockholdersEquityUnaudited" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_CommonSharesMember" xlink:label="dawn_CommonSharesMember"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_RedeemableNoncontrollingInterestMember" xlink:label="dawn_RedeemableNoncontrollingInterestMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_IssuanceOfCommonStockUponReleaseOfRestrictedStockUnits" xlink:label="dawn_IssuanceOfCommonStockUponReleaseOfRestrictedStockUnits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_IssuanceOfCommonStockInPrivatePlacementShare" xlink:label="dawn_IssuanceOfCommonStockInPrivatePlacementShare"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_IssuanceOfCommonStockInPrivatePlacementValue" xlink:label="dawn_IssuanceOfCommonStockInPrivatePlacementValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_CommonStockIssuedPursuantToFollowOnOfferingNetOfIssuanceCostsShares" xlink:label="dawn_CommonStockIssuedPursuantToFollowOnOfferingNetOfIssuanceCostsShares"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_CommonStockIssuedPursuantToFollowOnOfferingNetOfIssuanceCostsAmount" xlink:label="dawn_CommonStockIssuedPursuantToFollowOnOfferingNetOfIssuanceCostsAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_16"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_17"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="dawn_CommonSharesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="dawn_RedeemableNoncontrollingInterestMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dawn_IssuanceOfCommonStockUponReleaseOfRestrictedStockUnits" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dawn_IssuanceOfCommonStockInPrivatePlacementShare" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dawn_IssuanceOfCommonStockInPrivatePlacementValue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dawn_CommonStockIssuedPursuantToFollowOnOfferingNetOfIssuanceCostsShares" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dawn_CommonStockIssuedPursuantToFollowOnOfferingNetOfIssuanceCostsAmount" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_16" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_17" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfStockholdersEquityUnauditedParenthetical" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_StockIssuanceCosts" xlink:label="dawn_StockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_SeriesBRedeemableConvertiblePreferredSharesMember" xlink:label="dawn_SeriesBRedeemableConvertiblePreferredSharesMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dawn_StockIssuanceCosts" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="dawn_SeriesBRedeemableConvertiblePreferredSharesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventoriesAndOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInInventoriesAndOtherOperatingAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:label="us-gaap_ProceedsFromSaleOfShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDepositOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInDepositOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities" xlink:label="dawn_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireShortTermInvestments" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInInventoriesAndOtherOperatingAssets" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleOfShortTermInvestments" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDepositOtherAssets" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="dawn_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingArrLineItems" xlink:label="ecd_InsiderTradingArrLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:label="ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_InsiderTradingArrLineItems" xlink:to="ecd_InsiderTrdPoliciesProcAdoptedFlag" order="14.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureDescriptionOfBusinessAndOrganization1" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.dayonebio.com/20250331/taxonomy/role/SummaryOfSignificantAccountingPolicies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureRecurringFairValueMeasurements" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureBalanceSheetItems" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureIntangibleAssets" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.dayonebio.com/20250331/taxonomy/role/SignificantAgreements" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.dayonebio.com/20250331/taxonomy/role/CommitmentsAndContingencies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.dayonebio.com/20250331/taxonomy/role/RedeemableConvertiblePreferredShares" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_TemporaryEquityTextBlock" xlink:label="dawn_TemporaryEquityTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityDisclosureAbstract" xlink:to="dawn_TemporaryEquityTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureCommonStock" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureIncomeTaxes" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureNetIncomeLossPerShare" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.dayonebio.com/20250331/taxonomy/role/RedeemableNoncontrollingInterest" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_RedeemableNonControllingInterestTextBlock" xlink:label="dawn_RedeemableNonControllingInterestTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityDisclosureAbstract" xlink:to="dawn_RedeemableNonControllingInterestTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureDefinedContributionPlan" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanTextBlock" xlink:label="us-gaap_DefinedContributionPlanTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSegmentReporting" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSubsequentEvents" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.dayonebio.com/20250331/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureRecurringFairValueMeasurementTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_ScheduleOfMaturitiesForAvailableForSaleSecuritiesTableTextBlock" xlink:label="dawn_ScheduleOfMaturitiesForAvailableForSaleSecuritiesTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="dawn_ScheduleOfMaturitiesForAvailableForSaleSecuritiesTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureBalanceSheetItemsTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_ScheduleOfPrepaidAndOtherCurrentAssetstableTextBlockTableTextBlock" xlink:label="dawn_ScheduleOfPrepaidAndOtherCurrentAssetstableTextBlockTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="dawn_ScheduleOfPrepaidAndOtherCurrentAssetstableTextBlockTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureIntangibleAssetsTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.dayonebio.com/20250331/taxonomy/role/CommitmentsAndContingenciesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureCommonStockTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock" xlink:label="dawn_ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="dawn_ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_TwoThousandAndTwentyTwoEquityInducementPlanMember" xlink:label="dawn_TwoThousandAndTwentyTwoEquityInducementPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_TwoThousandAndTwentyOneEquityIncentivePlanMember" xlink:label="dawn_TwoThousandAndTwentyOneEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:label="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_SummaryOfPerformanceStockOptions" xlink:label="dawn_SummaryOfPerformanceStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_ScheduleOfPerformanceStockOptionsAssumptionsTableTextBlock" xlink:label="dawn_ScheduleOfPerformanceStockOptionsAssumptionsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_SummaryOfPerformanceStockUnitsActivity" xlink:label="dawn_SummaryOfPerformanceStockUnitsActivity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_CommonStockToBeIssuedUnderTheEsppTableTextBlock" xlink:label="dawn_CommonStockToBeIssuedUnderTheEsppTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_ScheduleOfStockOptionsAssumptionsTableTextBlock" xlink:label="dawn_ScheduleOfStockOptionsAssumptionsTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="dawn_TwoThousandAndTwentyTwoEquityInducementPlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="dawn_TwoThousandAndTwentyOneEquityIncentivePlanMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="dawn_SummaryOfPerformanceStockOptions" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="dawn_ScheduleOfPerformanceStockOptionsAssumptionsTableTextBlock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="dawn_SummaryOfPerformanceStockUnitsActivity" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="dawn_CommonStockToBeIssuedUnderTheEsppTableTextBlock" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="dawn_ScheduleOfStockOptionsAssumptionsTableTextBlock" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureNetIncomeLossPerShareTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSegmentReportingTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.dayonebio.com/20250331/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_ViractaLicenseAgreementMember" xlink:label="dawn_ViractaLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditConcentrationRiskMember" xlink:label="us-gaap_CreditConcentrationRiskMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_AccountingPoliciesTable" xlink:label="dawn_AccountingPoliciesTable"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_OneCustomerMember" xlink:label="dawn_OneCustomerMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_SeriesBRedeemableConvertiblePreferredSharesMember" xlink:label="dawn_SeriesBRedeemableConvertiblePreferredSharesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_AccountingPoliciesLineItems" xlink:label="dawn_AccountingPoliciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_IpsenLicenseAgreementMember" xlink:label="dawn_IpsenLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_ConcentrationOfCreditRiskAndOtherRisksAndUncertaintiesMember" xlink:label="dawn_ConcentrationOfCreditRiskAndOtherRisksAndUncertaintiesMember"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_TwoCustomerMember" xlink:label="dawn_TwoCustomerMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember" xlink:label="us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_ThreeCustomerMember" xlink:label="dawn_ThreeCustomerMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsOwnshareLendingArrangementIssuanceCostsNet" xlink:label="us-gaap_DeferredFinanceCostsOwnshareLendingArrangementIssuanceCostsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableMember" xlink:label="us-gaap_AccountsReceivableMember"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_OtherIndividualCustomerMember" xlink:label="dawn_OtherIndividualCustomerMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_NetProductRevenueAndAccountsReceivableMember" xlink:label="dawn_NetProductRevenueAndAccountsReceivableMember"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_IndividualCustomerMember" xlink:label="dawn_IndividualCustomerMember"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_MaketValueOfCommonStockHeldByNonAffiliateStockholders" xlink:label="dawn_MaketValueOfCommonStockHeldByNonAffiliateStockholders"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_AccountsReceivableCreditLosses" xlink:label="dawn_AccountsReceivableCreditLosses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherExpenses" xlink:label="us-gaap_OtherExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:label="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FeeIncome" xlink:label="us-gaap_FeeIncome"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_PremiumReceivedOnLicenseAgreement" xlink:label="dawn_PremiumReceivedOnLicenseAgreement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdministrativeFeesExpense" xlink:label="us-gaap_AdministrativeFeesExpense"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_AggregateOfUpfrontLicenseFeeReceived" xlink:label="dawn_AggregateOfUpfrontLicenseFeeReceived"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_PremiumPaidOnEquityStatementAsAdditionalConsideration" xlink:label="dawn_PremiumPaidOnEquityStatementAsAdditionalConsideration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRepurchaseOfPrivatePlacement" xlink:label="us-gaap_PaymentsForRepurchaseOfPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_VolumeWeightedAveragePrice" xlink:label="dawn_VolumeWeightedAveragePrice"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_TransactionPrice" xlink:label="dawn_TransactionPrice"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_PercentageOfUpfrontLicenseFee" xlink:label="dawn_PercentageOfUpfrontLicenseFee"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="dawn_ViractaLicenseAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CreditConcentrationRiskMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dawn_AccountingPoliciesTable" xlink:to="srt_MajorCustomersAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="dawn_OneCustomerMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="dawn_SeriesBRedeemableConvertiblePreferredSharesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dawn_AccountingPoliciesLineItems" xlink:to="us-gaap_CashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="dawn_AccountingPoliciesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_SalesRevenueNetMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="dawn_IpsenLicenseAgreementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="dawn_ConcentrationOfCreditRiskAndOtherRisksAndUncertaintiesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dawn_AccountingPoliciesTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="dawn_TwoCustomerMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dawn_AccountingPoliciesLineItems" xlink:to="us-gaap_Cash" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dawn_AccountingPoliciesTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="dawn_ThreeCustomerMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dawn_AccountingPoliciesLineItems" xlink:to="us-gaap_DeferredFinanceCostsOwnshareLendingArrangementIssuanceCostsNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_AccountsReceivableMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dawn_AccountingPoliciesTable" xlink:to="srt_RangeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="dawn_OtherIndividualCustomerMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dawn_AccountingPoliciesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="dawn_NetProductRevenueAndAccountsReceivableMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dawn_AccountingPoliciesTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="dawn_IndividualCustomerMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dawn_AccountingPoliciesLineItems" xlink:to="dawn_MaketValueOfCommonStockHeldByNonAffiliateStockholders" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dawn_AccountingPoliciesTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dawn_AccountingPoliciesLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dawn_AccountingPoliciesTable" xlink:to="dawn_AccountingPoliciesLineItems" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dawn_AccountingPoliciesLineItems" xlink:to="dawn_AccountsReceivableCreditLosses" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dawn_AccountingPoliciesLineItems" xlink:to="us-gaap_OtherExpenses" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dawn_AccountingPoliciesLineItems" xlink:to="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dawn_AccountingPoliciesLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dawn_AccountingPoliciesLineItems" xlink:to="us-gaap_FeeIncome" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dawn_AccountingPoliciesLineItems" xlink:to="dawn_PremiumReceivedOnLicenseAgreement" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dawn_AccountingPoliciesLineItems" xlink:to="us-gaap_AdministrativeFeesExpense" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dawn_AccountingPoliciesLineItems" xlink:to="dawn_AggregateOfUpfrontLicenseFeeReceived" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dawn_AccountingPoliciesLineItems" xlink:to="dawn_PremiumPaidOnEquityStatementAsAdditionalConsideration" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dawn_AccountingPoliciesLineItems" xlink:to="us-gaap_PaymentsForRepurchaseOfPrivatePlacement" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dawn_AccountingPoliciesLineItems" xlink:to="dawn_VolumeWeightedAveragePrice" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dawn_AccountingPoliciesLineItems" xlink:to="dawn_TransactionPrice" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dawn_AccountingPoliciesLineItems" xlink:to="dawn_PercentageOfUpfrontLicenseFee" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummarizesOfBalancesAndActivityTheProductRevenueDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_ProductRevenueAllowanceAndReserve" xlink:label="dawn_ProductRevenueAllowanceAndReserve"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_CurrentProvisionRelatingToCurrentPeriodSales" xlink:label="dawn_CurrentProvisionRelatingToCurrentPeriodSales"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_AdjustmentsRelatingToPriorYears" xlink:label="dawn_AdjustmentsRelatingToPriorYears"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_PaymentsOfCreditsRelatingToSalesInCurrentYear" xlink:label="dawn_PaymentsOfCreditsRelatingToSalesInCurrentYear"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_PaymentsOfCreditsRelatingToSalesInPriorYear" xlink:label="dawn_PaymentsOfCreditsRelatingToSalesInPriorYear"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_ProductRevenueAllowanceAndReserve" xlink:label="dawn_ProductRevenueAllowanceAndReserve_5"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="dawn_ProductRevenueAllowanceAndReserve" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="dawn_CurrentProvisionRelatingToCurrentPeriodSales" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="dawn_AdjustmentsRelatingToPriorYears" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="dawn_PaymentsOfCreditsRelatingToSalesInCurrentYear" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="dawn_PaymentsOfCreditsRelatingToSalesInPriorYear" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="dawn_ProductRevenueAllowanceAndReserve_5" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureRecurringFairValueMeasurementScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:label="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_MoneyMarketFundsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureRecurringFairValueMeasurementScheduleOfCashEquivalentsMarketableSecuritiesAndUnrealizedGainsAndLossesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_MarketableSecuritiesMember" xlink:label="dawn_MarketableSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsLineItems" xlink:label="us-gaap_CashAndCashEquivalentsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashEquivalentsMember" xlink:label="us-gaap_CashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_CashEquivalentsUnrealizedGains" xlink:label="dawn_CashEquivalentsUnrealizedGains"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_CashEquivalentsUnrealizedLosses" xlink:label="dawn_CashEquivalentsUnrealizedLosses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:label="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:to="us-gaap_ScheduleOfCashAndCashEquivalentsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="dawn_MarketableSecuritiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CashEquivalentsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="dawn_CashEquivalentsUnrealizedGains" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:to="us-gaap_CashAndCashEquivalentsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_MoneyMarketFundsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="dawn_CashEquivalentsUnrealizedLosses" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureRecurringFairValueMeasurementScheduleOfMaturitiesForAvailableForSaleSecuritiesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_WithinOneYearMember" xlink:label="dawn_WithinOneYearMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsLineItems" xlink:label="us-gaap_CashAndCashEquivalentsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_AvailableForSaleSecuritieAmortizedCost" xlink:label="dawn_AvailableForSaleSecuritieAmortizedCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_AvailableForSaleSecuritie" xlink:label="dawn_AvailableForSaleSecuritie"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="dawn_WithinOneYearMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="dawn_AvailableForSaleSecuritieAmortizedCost" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_CashAndCashEquivalentsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="dawn_AvailableForSaleSecuritie" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureRecurringFairValueMeasurementScheduleOfAvailableforsaleMarketableSecuritiesWithGrossUnrealizedLossesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsLineItems" xlink:label="us-gaap_CashAndCashEquivalentsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_AvailableForSaleSecuritieContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue" xlink:label="dawn_AvailableForSaleSecuritieContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:label="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_AvailableForSaleSecuritieContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:label="dawn_AvailableForSaleSecuritieContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionMoreThanTwelveMonthsFairValue" xlink:label="dawn_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionMoreThanTwelveMonthsFairValue"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionMoreThan12MonthsAccumulatedLoss" xlink:label="dawn_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionMoreThan12MonthsAccumulatedLoss"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_AvailableForSaleSecuritieContinuousUnrealizedLossPositionAccumulatedLoss" xlink:label="dawn_AvailableForSaleSecuritieContinuousUnrealizedLossPositionAccumulatedLoss"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_AvailableForSaleSecuritieContinuousUnrealizedLossPositionFairValue" xlink:label="dawn_AvailableForSaleSecuritieContinuousUnrealizedLossPositionFairValue"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="dawn_AvailableForSaleSecuritieContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_CashAndCashEquivalentsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="dawn_AvailableForSaleSecuritieContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="dawn_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionMoreThanTwelveMonthsFairValue" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="dawn_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionMoreThan12MonthsAccumulatedLoss" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="dawn_AvailableForSaleSecuritieContinuousUnrealizedLossPositionAccumulatedLoss" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="dawn_AvailableForSaleSecuritieContinuousUnrealizedLossPositionFairValue" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureRecurringFairValueMeasurementAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RealizedInvestmentGainsLosses" xlink:label="us-gaap_RealizedInvestmentGainsLosses"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_RealizedInvestmentGainsLosses" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureBalanceSheetItemsSummaryOfPrepaidAndOtherCurrentAssetsDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_PrepaidResearchAndDevelopmentExpenses" xlink:label="dawn_PrepaidResearchAndDevelopmentExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="us-gaap_OtherPrepaidExpenseCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="dawn_PrepaidResearchAndDevelopmentExpenses" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_PrepaidInsurance" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_OtherPrepaidExpenseCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureBalanceSheetItemsSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_AccruedLicenseAgreementUpfrontPayment" xlink:label="dawn_AccruedLicenseAgreementUpfrontPayment"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_AccruedRebates" xlink:label="dawn_AccruedRebates"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_AccruedFederalAndStateTaxPayments" xlink:label="dawn_AccruedFederalAndStateTaxPayments"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_AccruedMilestonePayment" xlink:label="dawn_AccruedMilestonePayment"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_AccruedPayrollRelatedExpenses" xlink:label="dawn_AccruedPayrollRelatedExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="dawn_AccruedLicenseAgreementUpfrontPayment" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="dawn_AccruedRebates" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="dawn_AccruedFederalAndStateTaxPayments" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="dawn_AccruedMilestonePayment" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="dawn_AccruedPayrollRelatedExpenses" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureIntangibleAssetsScheduleOfIntangibleAssetsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_LicenseAgreementMilestonePaymentMember" xlink:label="dawn_LicenseAgreementMilestonePaymentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_PRV-RelatedObligationPaymentMember" xlink:label="dawn_PRV-RelatedObligationPaymentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="dawn_LicenseAgreementMilestonePaymentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="dawn_PRV-RelatedObligationPaymentMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureIntangibleAssetsScheduleOfAmortizationExpenseForAmortizableFinitelivedIntangibleAssetsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.dayonebio.com/20250331/taxonomy/role/SignificantAgreementsAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_TakedaAssetAgreementMember" xlink:label="dawn_TakedaAssetAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LicenseMember" xlink:label="us-gaap_LicenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_SeriesARedeemableConvertiblePreferredStockMember" xlink:label="dawn_SeriesARedeemableConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_CurrentMember" xlink:label="dawn_CurrentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ObligationsMember" xlink:label="us-gaap_ObligationsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIntangibleAssetsMember" xlink:label="us-gaap_OtherIntangibleAssetsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_UpfrontPayment" xlink:label="dawn_UpfrontPayment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_MerckLicenseAgreementMember" xlink:label="dawn_MerckLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_PrvPressureReliefValveMember" xlink:label="dawn_PrvPressureReliefValveMember"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_NoncurrentMember" xlink:label="dawn_NoncurrentMember"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_PaymentOfMilestones" xlink:label="dawn_PaymentOfMilestones"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_ViractaLicenseAgreementMember" xlink:label="dawn_ViractaLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RoyaltyMember" xlink:label="us-gaap_RoyaltyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_SprintBioscienceAgreementMember" xlink:label="dawn_SprintBioscienceAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LicenseMember" xlink:label="us-gaap_LicenseMember_3"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_MabcareLicenseAgreementMember" xlink:label="dawn_MabcareLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_MilestonePaymentsNotYetPaid" xlink:label="dawn_MilestonePaymentsNotYetPaid"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_IpsenPharmaSasAgreementMember" xlink:label="dawn_IpsenPharmaSasAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_MilestonePaymentsNotYetReceived" xlink:label="dawn_MilestonePaymentsNotYetReceived"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_LicenseAgreementWithIpsenPharmaSasMember" xlink:label="dawn_LicenseAgreementWithIpsenPharmaSasMember"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_UpfrontOfCashPayment" xlink:label="dawn_UpfrontOfCashPayment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_VolumeWeightedAveragePrice" xlink:label="dawn_VolumeWeightedAveragePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:label="us-gaap_ProceedsFromSaleOfProductiveAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_PaymentToObligationOfLicenseAgreement" xlink:label="dawn_PaymentToObligationOfLicenseAgreement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RoyaltyIncomeNonoperating" xlink:label="us-gaap_RoyaltyIncomeNonoperating"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_TransactionPrice" xlink:label="dawn_TransactionPrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets" xlink:label="us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_PercentageOfUpfrontLicenseFee" xlink:label="dawn_PercentageOfUpfrontLicenseFee"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FeeIncome" xlink:label="us-gaap_FeeIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentForManagementFee" xlink:label="us-gaap_PaymentForManagementFee"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_AggregateOfUpfrontLicenseFeeReceived" xlink:label="dawn_AggregateOfUpfrontLicenseFeeReceived"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_FrontlinePayment" xlink:label="dawn_FrontlinePayment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_LicenseRevenue" xlink:label="dawn_LicenseRevenue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfInvestments" xlink:label="us-gaap_GainLossOnSaleOfInvestments"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="dawn_TakedaAssetAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_LicenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="dawn_SeriesARedeemableConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="dawn_CurrentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="us-gaap_ObligationsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_OtherIntangibleAssetsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="dawn_UpfrontPayment" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="dawn_MerckLicenseAgreementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="dawn_PrvPressureReliefValveMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="dawn_NoncurrentMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="dawn_PaymentOfMilestones" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="dawn_ViractaLicenseAgreementMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_RoyaltyMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="dawn_SprintBioscienceAgreementMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_LicenseMember_3" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="dawn_MabcareLicenseAgreementMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="dawn_MilestonePaymentsNotYetPaid" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="dawn_IpsenPharmaSasAgreementMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_ProductOrServiceAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="dawn_MilestonePaymentsNotYetReceived" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="dawn_LicenseAgreementWithIpsenPharmaSasMember" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="dawn_UpfrontOfCashPayment" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="dawn_VolumeWeightedAveragePrice" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ProceedsFromSaleOfProductiveAssets" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_PaymentsToAcquireProductiveAssets" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="dawn_PaymentToObligationOfLicenseAgreement" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RoyaltyIncomeNonoperating" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="dawn_TransactionPrice" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="dawn_PercentageOfUpfrontLicenseFee" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_FeeIncome" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_PaymentForManagementFee" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="dawn_AggregateOfUpfrontLicenseFeeReceived" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="dawn_FrontlinePayment" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DeferredRevenueCurrent" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DeferredRevenueNoncurrent" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="dawn_LicenseRevenue" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_GainLossOnSaleOfInvestments" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureLeaseObligationsDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:label="dawn_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="dawn_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xlink:label="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PurchaseCommitmentMember" xlink:label="us-gaap_PurchaseCommitmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_AgreementDomain" xlink:label="dawn_AgreementDomain"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_ResearchAndDevelopmentAgreementsMember" xlink:label="dawn_ResearchAndDevelopmentAgreementsMember"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_LeaseForCorporateOfficeFacilityMember" xlink:label="dawn_LeaseForCorporateOfficeFacilityMember"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_BrisbaneCaliforniaMember" xlink:label="dawn_BrisbaneCaliforniaMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" xlink:label="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_AgreementAxis" xlink:label="dawn_AgreementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AreaOfLand" xlink:label="us-gaap_AreaOfLand"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_ViractaLicenseAgreementMember" xlink:label="dawn_ViractaLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_AustinTXMember" xlink:label="dawn_AustinTXMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:label="us-gaap_LesseeOperatingLeaseDescription"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_MrkdgLicenseAgreementMember" xlink:label="dawn_MrkdgLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndemnificationGuaranteeMember" xlink:label="us-gaap_IndemnificationGuaranteeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_ManufacturingAndSupplyAgreementMember" xlink:label="dawn_ManufacturingAndSupplyAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyAccrualAtCarryingValue" xlink:label="us-gaap_LossContingencyAccrualAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:label="us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_PurchasesUnderThePurchaseObligation" xlink:label="dawn_PurchasesUnderThePurchaseObligation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LeaseContractualTermAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xlink:to="us-gaap_PurchaseCommitmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dawn_AgreementDomain" xlink:to="dawn_ResearchAndDevelopmentAgreementsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="dawn_LeaseForCorporateOfficeFacilityMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="dawn_BrisbaneCaliforniaMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeLeaseDescriptionTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" xlink:to="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dawn_AgreementAxis" xlink:to="dawn_AgreementDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_StatementGeographicalAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_AreaOfLand" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dawn_AgreementDomain" xlink:to="dawn_ViractaLicenseAgreementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="dawn_AustinTXMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseDescription" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dawn_AgreementDomain" xlink:to="dawn_MrkdgLicenseAgreementMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="dawn_AgreementAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dawn_AgreementDomain" xlink:to="us-gaap_IndemnificationGuaranteeMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeasePayments" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dawn_AgreementDomain" xlink:to="dawn_ManufacturingAndSupplyAgreementMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LossContingencyAccrualAtCarryingValue" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_SecurityDeposit" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="dawn_PurchasesUnderThePurchaseObligation" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.dayonebio.com/20250331/taxonomy/role/RedeemableConvertiblePreferredSharesAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_BasisOfIssueDomain" xlink:label="dawn_BasisOfIssueDomain"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_MilestoneAchievedMember" xlink:label="dawn_MilestoneAchievedMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_DetailsDomain" xlink:label="dawn_DetailsDomain"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_GrossProceedsMember" xlink:label="dawn_GrossProceedsMember"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_DetailsAxis" xlink:label="dawn_DetailsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_BasisOfIssueAxis" xlink:label="dawn_BasisOfIssueAxis"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_ConditionsForIssueDomain" xlink:label="dawn_ConditionsForIssueDomain"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_MilestoneAchievementMember" xlink:label="dawn_MilestoneAchievementMember"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_TemporaryEquityRelatedTrancheLiabilityMember" xlink:label="dawn_TemporaryEquityRelatedTrancheLiabilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_ConditionsForIssueAxis" xlink:label="dawn_ConditionsForIssueAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_CommonStockSharesIssuedAsAResultOfConversionOfTemporaryEquityIntoPermanentEquity" xlink:label="dawn_CommonStockSharesIssuedAsAResultOfConversionOfTemporaryEquityIntoPermanentEquity"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_SeriesARedeemableConvertiblePreferredStockMember" xlink:label="dawn_SeriesARedeemableConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_SeriesBRedeemableConvertiblePreferredStockMember" xlink:label="dawn_SeriesBRedeemableConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_TemporaryEquityStockIssuedDuringThePeriodSharesNewIssues" xlink:label="dawn_TemporaryEquityStockIssuedDuringThePeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_TemporaryEquityIssuePricePerShare" xlink:label="dawn_TemporaryEquityIssuePricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_PaymentOfAccruedInterest" xlink:label="dawn_PaymentOfAccruedInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesSubscribedButUnissued" xlink:label="us-gaap_TemporaryEquitySharesSubscribedButUnissued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="us-gaap_DerivativeFairValueOfDerivativeLiability"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dawn_BasisOfIssueDomain" xlink:to="dawn_MilestoneAchievedMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dawn_DetailsDomain" xlink:to="dawn_GrossProceedsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dawn_DetailsAxis" xlink:to="dawn_DetailsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dawn_BasisOfIssueAxis" xlink:to="dawn_BasisOfIssueDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dawn_ConditionsForIssueDomain" xlink:to="dawn_MilestoneAchievementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="dawn_TemporaryEquityRelatedTrancheLiabilityMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityDisclosureAbstract" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dawn_ConditionsForIssueAxis" xlink:to="dawn_ConditionsForIssueDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="dawn_DetailsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="dawn_CommonStockSharesIssuedAsAResultOfConversionOfTemporaryEquityIntoPermanentEquity" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="dawn_SeriesARedeemableConvertiblePreferredStockMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="dawn_ConditionsForIssueAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="dawn_SeriesBRedeemableConvertiblePreferredStockMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="dawn_TemporaryEquityStockIssuedDuringThePeriodSharesNewIssues" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="dawn_BasisOfIssueAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="dawn_TemporaryEquityIssuePricePerShare" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_TemporaryEquityLineItems" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="dawn_PaymentOfAccruedInterest" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquitySharesSubscribedButUnissued" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_DerivativeFairValueOfDerivativeLiability" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.dayonebio.com/20250331/taxonomy/role/RedeemableConvertiblePreferredSharesSummaryOfSeriesARedeemableConvertiblePreferredSharesDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_SeriesARedeemableConvertiblePreferredStockMember" xlink:label="dawn_SeriesARedeemableConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:label="us-gaap_TemporaryEquityLiquidationPreference"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RedeemableNoncontrollingInterestEquityPreferredCarryingAmount" xlink:label="us-gaap_RedeemableNoncontrollingInterestEquityPreferredCarryingAmount"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="dawn_SeriesARedeemableConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityDisclosureAbstract" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_TemporaryEquityLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityLiquidationPreference" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_RedeemableNoncontrollingInterestEquityPreferredCarryingAmount" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureCommonStockAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_FounderMember" xlink:label="dawn_FounderMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_PreFundedWarrantMember" xlink:label="dawn_PreFundedWarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_AgreementDomain" xlink:label="dawn_AgreementDomain"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_TwoThousandTwentyFourPrivatePlacementMember" xlink:label="dawn_TwoThousandTwentyFourPrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_PreFundedWarrantsMember" xlink:label="dawn_PreFundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_AgreementAxis" xlink:label="dawn_AgreementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassBMember" xlink:label="us-gaap_CommonClassBMember"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_FounderOneMember" xlink:label="dawn_FounderOneMember"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_AtTheMarketMember" xlink:label="dawn_AtTheMarketMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_InvestmentAgreementMember" xlink:label="dawn_InvestmentAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_FounderTwoMember" xlink:label="dawn_FounderTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_CommonSharesPurchaseAgreementMember" xlink:label="dawn_CommonSharesPurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_SalesAgreementMember" xlink:label="dawn_SalesAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_UpfrontLicenseFee" xlink:label="dawn_UpfrontLicenseFee"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_CommonStockSharesPurchased" xlink:label="dawn_CommonStockSharesPurchased"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_WeightedAveragePriceOfCompanysCommonStock" xlink:label="dawn_WeightedAveragePriceOfCompanysCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="dawn_FounderMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipDomain" xlink:to="dawn_PreFundedWarrantMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dawn_AgreementDomain" xlink:to="dawn_TwoThousandTwentyFourPrivatePlacementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="dawn_PreFundedWarrantsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dawn_AgreementAxis" xlink:to="dawn_AgreementDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassBMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="dawn_FounderOneMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipDomain" xlink:to="dawn_AtTheMarketMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dawn_AgreementDomain" xlink:to="dawn_InvestmentAgreementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="dawn_FounderTwoMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dawn_AgreementDomain" xlink:to="dawn_CommonSharesPurchaseAgreementMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dawn_AgreementDomain" xlink:to="dawn_SalesAgreementMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="dawn_AgreementAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_OwnershipAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharePrice" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="dawn_UpfrontLicenseFee" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="dawn_CommonStockSharesPurchased" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockValue" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="dawn_WeightedAveragePriceOfCompanysCommonStock" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureCommonStockScheduleOfCommonStockSharesReservedForFutureIssuanceDetailsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_PreFundedWarrantsMember" xlink:label="dawn_PreFundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_EmployeeStockPurchasePlanMember" xlink:label="dawn_EmployeeStockPurchasePlanMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_AwardTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="dawn_PreFundedWarrantsMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="dawn_EmployeeStockPurchasePlanMember" order="5.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfSharestockbasedCompensationExpenseRecordedInTheAccompanyingCondensedConsolidatedStatementsOfOperation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_IncentiveSharePlanMember" xlink:label="dawn_IncentiveSharePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_UnvestedCommonStockMember" xlink:label="dawn_UnvestedCommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_DetailsDomain" xlink:label="dawn_DetailsDomain"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_IncrementalSharesReservedForFutureIssuanceMember" xlink:label="dawn_IncrementalSharesReservedForFutureIssuanceMember"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_DetailsAxis" xlink:label="dawn_DetailsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_FirstAnniversaryMember" xlink:label="dawn_FirstAnniversaryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_TwoThousandAndTwentyOneStockIncentivePlanMember" xlink:label="dawn_TwoThousandAndTwentyOneStockIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_TwoThousandAndTwentyOneEquityIncentivePlanMember" xlink:label="dawn_TwoThousandAndTwentyOneEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember" xlink:label="dawn_TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_PerformanceStockOptionsMember" xlink:label="dawn_PerformanceStockOptionsMember"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_TwoThousandAndTwentyTwoEquityInducementPlanMember" xlink:label="dawn_TwoThousandAndTwentyTwoEquityInducementPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_PerformanceStockUnitsMember" xlink:label="dawn_PerformanceStockUnitsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_UnvestedRestrictedStockAndStockOptionsMember" xlink:label="dawn_UnvestedRestrictedStockAndStockOptionsMember"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_UnamortizedStockBasedCompensationForStockOptions" xlink:label="dawn_UnamortizedStockBasedCompensationForStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_UnvestedPsosAndPsusMember" xlink:label="dawn_UnvestedPsosAndPsusMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_UnvestedPerformanceStockUnitsMember" xlink:label="dawn_UnvestedPerformanceStockUnitsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="dawn_IncentiveSharePlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="dawn_UnvestedCommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dawn_DetailsDomain" xlink:to="dawn_IncrementalSharesReservedForFutureIssuanceMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dawn_DetailsAxis" xlink:to="dawn_DetailsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_VestingAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain" xlink:to="dawn_FirstAnniversaryMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="dawn_TwoThousandAndTwentyOneStockIncentivePlanMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="dawn_TwoThousandAndTwentyOneEquityIncentivePlanMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ConversionOfStockSharesIssued1" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="dawn_TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="dawn_PerformanceStockOptionsMember" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="dawn_DetailsAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="dawn_TwoThousandAndTwentyTwoEquityInducementPlanMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="dawn_PerformanceStockUnitsMember" order="5.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="dawn_UnvestedRestrictedStockAndStockOptionsMember" order="6.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="dawn_UnamortizedStockBasedCompensationForStockOptions" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="dawn_UnvestedPsosAndPsusMember" order="7.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="dawn_UnvestedPerformanceStockUnitsMember" order="8.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfStockOptionActivityDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_TwoThousandAndTwentyTwoEquityInducementPlanMember" xlink:label="dawn_TwoThousandAndTwentyTwoEquityInducementPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_TwoThousandAndTwentyOneEquityIncentivePlanMember" xlink:label="dawn_TwoThousandAndTwentyOneEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_11"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="dawn_TwoThousandAndTwentyTwoEquityInducementPlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="dawn_TwoThousandAndTwentyOneEquityIncentivePlanMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_11" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfTheBlackscholesOptionPricingModelToEstimateTheFairValueOfStockOptionGrantedDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_TwoThousandAndTwentyOneEquityIncentivePlanMember" xlink:label="dawn_TwoThousandAndTwentyOneEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_TwoThousandTwentyOneEmployeeStockPurchasePlanMember" xlink:label="dawn_TwoThousandTwentyOneEmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="dawn_TwoThousandAndTwentyOneEquityIncentivePlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharePrice" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="dawn_TwoThousandTwentyOneEmployeeStockPurchasePlanMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfRestrictedStockUnitsActivityDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_TwoThousandAndTwentyTwoEquityInducementPlanMember" xlink:label="dawn_TwoThousandAndTwentyTwoEquityInducementPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_TwoThousandAndTwentyOneStockIncentivePlanMember" xlink:label="dawn_TwoThousandAndTwentyOneStockIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="dawn_TwoThousandAndTwentyTwoEquityInducementPlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="dawn_TwoThousandAndTwentyOneStockIncentivePlanMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfTheUnvestedCommonStockDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_TwoThousandAndTwentyOneStockIncentivePlanMember" xlink:label="dawn_TwoThousandAndTwentyOneStockIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_ShareBasedCompensationByShareBasedPaymentArrangementEquityInstrumentsOtherThanOptionsOutstanding" xlink:label="dawn_ShareBasedCompensationByShareBasedPaymentArrangementEquityInstrumentsOtherThanOptionsOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_UnvestedCommonStockMember" xlink:label="dawn_UnvestedCommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_ShareBasedCompensationByShareBasedPaymentAwardConversionOfIncentiveSharesIntoRestrictedStock" xlink:label="dawn_ShareBasedCompensationByShareBasedPaymentAwardConversionOfIncentiveSharesIntoRestrictedStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_ShareBasedCompensationByShareBasedPaymentArrangementEquityInstrumentsOtherThanOptionsOutstanding" xlink:label="dawn_ShareBasedCompensationByShareBasedPaymentArrangementEquityInstrumentsOtherThanOptionsOutstanding_4"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_ShareBasedCompensationByShareBasedPaymentAwardConversionOfIncentiveShareIntoRestrictedStockWeightedAverageGrantDateFairValue" xlink:label="dawn_ShareBasedCompensationByShareBasedPaymentAwardConversionOfIncentiveShareIntoRestrictedStockWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="dawn_TwoThousandAndTwentyOneStockIncentivePlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="dawn_ShareBasedCompensationByShareBasedPaymentArrangementEquityInstrumentsOtherThanOptionsOutstanding" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="dawn_UnvestedCommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="dawn_ShareBasedCompensationByShareBasedPaymentAwardConversionOfIncentiveSharesIntoRestrictedStock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="dawn_ShareBasedCompensationByShareBasedPaymentArrangementEquityInstrumentsOtherThanOptionsOutstanding_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="dawn_ShareBasedCompensationByShareBasedPaymentAwardConversionOfIncentiveShareIntoRestrictedStockWeightedAverageGrantDateFairValue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfFairValueOfTheIncentiveSharesEstimatedUsingAnOptionPricingModelDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_IncentiveSharePlanMemberMember" xlink:label="dawn_IncentiveSharePlanMemberMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_ParticipatingThreshold" xlink:label="dawn_ParticipatingThreshold"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="dawn_IncentiveSharePlanMemberMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharePrice" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="dawn_ParticipatingThreshold" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfTheIncentiveSharesActivityDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_ShareBasedCompensationByShareBasedPaymentArrangementEquityInstrumentsOtherThanOptionsOutstanding" xlink:label="dawn_ShareBasedCompensationByShareBasedPaymentArrangementEquityInstrumentsOtherThanOptionsOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_ShareBasedCompensationByShareBasedPaymentArrangementEquityInstrumentsOtherThanOptionsConvertedToUnvestedCommonStock" xlink:label="dawn_ShareBasedCompensationByShareBasedPaymentArrangementEquityInstrumentsOtherThanOptionsConvertedToUnvestedCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_IncentiveSharesMember" xlink:label="dawn_IncentiveSharesMember"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_ShareBasedCompensationByShareBasedPaymentArrangementEquityInstrumentsOtherThanOptionsOutstanding" xlink:label="dawn_ShareBasedCompensationByShareBasedPaymentArrangementEquityInstrumentsOtherThanOptionsOutstanding_4"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageGrantDateFairValue" xlink:label="dawn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsConvertedToUnvestedCommonStockWeightedAverageGrantDateFairValue" xlink:label="dawn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsConvertedToUnvestedCommonStockWeightedAverageGrantDateFairValue"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="dawn_ShareBasedCompensationByShareBasedPaymentArrangementEquityInstrumentsOtherThanOptionsOutstanding" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="dawn_ShareBasedCompensationByShareBasedPaymentArrangementEquityInstrumentsOtherThanOptionsConvertedToUnvestedCommonStock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="dawn_IncentiveSharesMember" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="dawn_ShareBasedCompensationByShareBasedPaymentArrangementEquityInstrumentsOtherThanOptionsOutstanding_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="dawn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageGrantDateFairValue" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="dawn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsConvertedToUnvestedCommonStockWeightedAverageGrantDateFairValue" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfPerformanceStockOptionsActivityDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_PerformanceStockOptionsMember" xlink:label="dawn_PerformanceStockOptionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_9"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="dawn_PerformanceStockOptionsMember" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_9" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationFairValueOfOurCommonStockToBeIssuedUnderTheEsppDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_TwoThousandTwentyOneEmployeeStockPurchasePlanMember" xlink:label="dawn_TwoThousandTwentyOneEmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="dawn_TwoThousandTwentyOneEmployeeStockPurchasePlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfTheBlackscholesOptionPricingModelToEstimateTheFairValueOfPerformanceStockOpDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_PerformanceStockOptionsMember" xlink:label="dawn_PerformanceStockOptionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="dawn_PerformanceStockOptionsMember" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfPerformanceStockUnitsActivityDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_TwoThousandAndTwentyOneStockIncentivePlanMember" xlink:label="dawn_TwoThousandAndTwentyOneStockIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_PerformanceStockOptionsMember" xlink:label="dawn_PerformanceStockOptionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="dawn_TwoThousandAndTwentyOneStockIncentivePlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="dawn_PerformanceStockOptionsMember" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureNetIncomeLossPerShareSummaryOfBasicAndDilutedNetLossPerShareAttributableToCommonShareholdersstockholdersDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_RestrictedStockAwardsMember" xlink:label="dawn_RestrictedStockAwardsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmountOfDilutiveSecuritiesStockOptionsAndRestrictiveStockUnits" xlink:label="us-gaap_AmountOfDilutiveSecuritiesStockOptionsAndRestrictiveStockUnits"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_NetIncomeLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="dawn_RestrictedStockAwardsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_EarningsPerShareBasic" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_EarningsPerShareDiluted" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AmountOfDilutiveSecuritiesStockOptionsAndRestrictiveStockUnits" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureNetIncomeLossPerShareSummaryOfOutstandingPotentiallyDilutiveSecuritiesHaveBeenExcludedFromCalculationOfDilutedNetLossPerShare" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_UnvestedCommonSharesMember" xlink:label="dawn_UnvestedCommonSharesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_SharesCommittedUnderESPPMember" xlink:label="dawn_SharesCommittedUnderESPPMember"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_PerformanceStockUnitsMember" xlink:label="dawn_PerformanceStockUnitsMember"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_PerformanceStockOptionsMember" xlink:label="dawn_PerformanceStockOptionsMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="dawn_UnvestedCommonSharesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="dawn_SharesCommittedUnderESPPMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="dawn_PerformanceStockUnitsMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="dawn_PerformanceStockOptionsMember" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureDefinedContributionPlanAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_DefinedContributionPlanEmployerMatchingContribution" xlink:label="dawn_DefinedContributionPlanEmployerMatchingContribution"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="dawn_DefinedContributionPlanEmployerMatchingContribution" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSegmentReportingAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_NumberOfOperatingSegments" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_NumberOfReportableSegments" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSegmentReportingScheduleOfSegmentInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_ExternalCostsAbstract" xlink:label="dawn_ExternalCostsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_Third-PartyCROCMOAndOtherThird-PartyClinicalTrialCosts" xlink:label="dawn_Third-PartyCROCMOAndOtherThird-PartyClinicalTrialCosts"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_LicenseAgreementRelatedPayments" xlink:label="dawn_LicenseAgreementRelatedPayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_EmployeeRelatedExpenses" xlink:label="dawn_EmployeeRelatedExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dawn_ExternalCostsAbstract" xlink:to="dawn_Third-PartyCROCMOAndOtherThird-PartyClinicalTrialCosts" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dawn_ExternalCostsAbstract" xlink:to="dawn_LicenseAgreementRelatedPayments" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dawn_ExternalCostsAbstract" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dawn_ExternalCostsAbstract" xlink:to="dawn_EmployeeRelatedExpenses" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dawn_ExternalCostsAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_UpfrontOfCashPayment" xlink:label="dawn_UpfrontOfCashPayment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForProceedsFromPreviousAcquisition" xlink:label="us-gaap_PaymentsForProceedsFromPreviousAcquisition"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForProceedsFromInvestments" xlink:label="us-gaap_PaymentsForProceedsFromInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_VolumeWeightedAveragePrice" xlink:label="dawn_VolumeWeightedAveragePrice"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_PaymentOfMilestones" xlink:label="dawn_PaymentOfMilestones"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="dawn_UpfrontOfCashPayment" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_PaymentsForProceedsFromPreviousAcquisition" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_PaymentsForProceedsFromInvestments" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="dawn_VolumeWeightedAveragePrice" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="dawn_PaymentOfMilestones" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.dayonebio.com/20250331/taxonomy/role/CoverPage">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dei_DocumentInformationTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentQuarterlyReport" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityExTransitionPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine2" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="24" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="25" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="26" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="27" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="28" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="29" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="30" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedBalanceSheetsUnauditedParenthetical">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassBMember" xlink:label="us-gaap_CommonClassBMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_DeferredSharesParValuePerShares" xlink:label="dawn_DeferredSharesParValuePerShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCompensationArrangementWithIndividualSharesIssued" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_DeferredSharesOutstanding" xlink:label="dawn_DeferredSharesOutstanding"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassBMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dawn_DeferredSharesParValuePerShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualSharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dawn_DeferredSharesOutstanding" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfOperationsUnaudited">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_CostOfProductRevenue" xlink:label="dawn_CostOfProductRevenue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeNet" xlink:label="us-gaap_InvestmentIncomeNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LicenseMember" xlink:label="us-gaap_LicenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossAttributableToNoncontrollingInterest" xlink:label="us-gaap_IncomeLossAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenuesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_Revenues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="dawn_CostOfProductRevenue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InvestmentIncomeNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_LicenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_IncomeLossAttributableToNoncontrollingInterest" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasic" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareDiluted" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfComprehensiveLossUnaudited">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfStockholdersEquityUnaudited">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_CommonSharesMember" xlink:label="dawn_CommonSharesMember"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_RedeemableNoncontrollingInterestMember" xlink:label="dawn_RedeemableNoncontrollingInterestMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_IssuanceOfCommonStockUponReleaseOfRestrictedStockUnits" xlink:label="dawn_IssuanceOfCommonStockUponReleaseOfRestrictedStockUnits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_IssuanceOfCommonStockInPrivatePlacementShare" xlink:label="dawn_IssuanceOfCommonStockInPrivatePlacementShare"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_IssuanceOfCommonStockInPrivatePlacementValue" xlink:label="dawn_IssuanceOfCommonStockInPrivatePlacementValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_CommonStockIssuedPursuantToFollowOnOfferingNetOfIssuanceCostsShares" xlink:label="dawn_CommonStockIssuedPursuantToFollowOnOfferingNetOfIssuanceCostsShares"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_CommonStockIssuedPursuantToFollowOnOfferingNetOfIssuanceCostsAmount" xlink:label="dawn_CommonStockIssuedPursuantToFollowOnOfferingNetOfIssuanceCostsAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="dawn_CommonSharesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="dawn_RedeemableNoncontrollingInterestMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dawn_IssuanceOfCommonStockUponReleaseOfRestrictedStockUnits" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dawn_IssuanceOfCommonStockInPrivatePlacementShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dawn_IssuanceOfCommonStockInPrivatePlacementValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dawn_CommonStockIssuedPursuantToFollowOnOfferingNetOfIssuanceCostsShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dawn_CommonStockIssuedPursuantToFollowOnOfferingNetOfIssuanceCostsAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfStockholdersEquityUnauditedParenthetical">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_StockIssuanceCosts" xlink:label="dawn_StockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_SeriesBRedeemableConvertiblePreferredSharesMember" xlink:label="dawn_SeriesBRedeemableConvertiblePreferredSharesMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dawn_StockIssuanceCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="dawn_SeriesBRedeemableConvertiblePreferredSharesMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationTables">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_TwoThousandAndTwentyTwoEquityInducementPlanMember" xlink:label="dawn_TwoThousandAndTwentyTwoEquityInducementPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_TwoThousandAndTwentyOneEquityIncentivePlanMember" xlink:label="dawn_TwoThousandAndTwentyOneEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:label="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_SummaryOfPerformanceStockOptions" xlink:label="dawn_SummaryOfPerformanceStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_ScheduleOfPerformanceStockOptionsAssumptionsTableTextBlock" xlink:label="dawn_ScheduleOfPerformanceStockOptionsAssumptionsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_SummaryOfPerformanceStockUnitsActivity" xlink:label="dawn_SummaryOfPerformanceStockUnitsActivity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_CommonStockToBeIssuedUnderTheEsppTableTextBlock" xlink:label="dawn_CommonStockToBeIssuedUnderTheEsppTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_ScheduleOfStockOptionsAssumptionsTableTextBlock" xlink:label="dawn_ScheduleOfStockOptionsAssumptionsTableTextBlock"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="dawn_TwoThousandAndTwentyTwoEquityInducementPlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="dawn_TwoThousandAndTwentyOneEquityIncentivePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="dawn_SummaryOfPerformanceStockOptions" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="dawn_ScheduleOfPerformanceStockOptionsAssumptionsTableTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="dawn_SummaryOfPerformanceStockUnitsActivity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="dawn_CommonStockToBeIssuedUnderTheEsppTableTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="dawn_ScheduleOfStockOptionsAssumptionsTableTextBlock" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.dayonebio.com/20250331/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_AccountingPoliciesLineItems" xlink:label="dawn_AccountingPoliciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_AccountingPoliciesTable" xlink:label="dawn_AccountingPoliciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_ViractaLicenseAgreementMember" xlink:label="dawn_ViractaLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditConcentrationRiskMember" xlink:label="us-gaap_CreditConcentrationRiskMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_OneCustomerMember" xlink:label="dawn_OneCustomerMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_SeriesBRedeemableConvertiblePreferredSharesMember" xlink:label="dawn_SeriesBRedeemableConvertiblePreferredSharesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_IpsenLicenseAgreementMember" xlink:label="dawn_IpsenLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_ConcentrationOfCreditRiskAndOtherRisksAndUncertaintiesMember" xlink:label="dawn_ConcentrationOfCreditRiskAndOtherRisksAndUncertaintiesMember"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_TwoCustomerMember" xlink:label="dawn_TwoCustomerMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember" xlink:label="us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_ThreeCustomerMember" xlink:label="dawn_ThreeCustomerMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsOwnshareLendingArrangementIssuanceCostsNet" xlink:label="us-gaap_DeferredFinanceCostsOwnshareLendingArrangementIssuanceCostsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableMember" xlink:label="us-gaap_AccountsReceivableMember"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_OtherIndividualCustomerMember" xlink:label="dawn_OtherIndividualCustomerMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_NetProductRevenueAndAccountsReceivableMember" xlink:label="dawn_NetProductRevenueAndAccountsReceivableMember"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_IndividualCustomerMember" xlink:label="dawn_IndividualCustomerMember"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_MaketValueOfCommonStockHeldByNonAffiliateStockholders" xlink:label="dawn_MaketValueOfCommonStockHeldByNonAffiliateStockholders"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_AccountsReceivableCreditLosses" xlink:label="dawn_AccountsReceivableCreditLosses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherExpenses" xlink:label="us-gaap_OtherExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:label="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FeeIncome" xlink:label="us-gaap_FeeIncome"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_PremiumReceivedOnLicenseAgreement" xlink:label="dawn_PremiumReceivedOnLicenseAgreement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdministrativeFeesExpense" xlink:label="us-gaap_AdministrativeFeesExpense"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_AggregateOfUpfrontLicenseFeeReceived" xlink:label="dawn_AggregateOfUpfrontLicenseFeeReceived"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_PremiumPaidOnEquityStatementAsAdditionalConsideration" xlink:label="dawn_PremiumPaidOnEquityStatementAsAdditionalConsideration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRepurchaseOfPrivatePlacement" xlink:label="us-gaap_PaymentsForRepurchaseOfPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_VolumeWeightedAveragePrice" xlink:label="dawn_VolumeWeightedAveragePrice"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_TransactionPrice" xlink:label="dawn_TransactionPrice"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_PercentageOfUpfrontLicenseFee" xlink:label="dawn_PercentageOfUpfrontLicenseFee"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dawn_AccountingPoliciesLineItems" xlink:to="dawn_AccountingPoliciesTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="dawn_ViractaLicenseAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CreditConcentrationRiskMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dawn_AccountingPoliciesTable" xlink:to="srt_MajorCustomersAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="dawn_OneCustomerMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="dawn_SeriesBRedeemableConvertiblePreferredSharesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dawn_AccountingPoliciesLineItems" xlink:to="us-gaap_CashEquivalentsAtCarryingValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_SalesRevenueNetMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="dawn_IpsenLicenseAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="dawn_ConcentrationOfCreditRiskAndOtherRisksAndUncertaintiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dawn_AccountingPoliciesTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="dawn_TwoCustomerMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dawn_AccountingPoliciesLineItems" xlink:to="us-gaap_Cash" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dawn_AccountingPoliciesTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="dawn_ThreeCustomerMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dawn_AccountingPoliciesLineItems" xlink:to="us-gaap_DeferredFinanceCostsOwnshareLendingArrangementIssuanceCostsNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_AccountsReceivableMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dawn_AccountingPoliciesTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="dawn_OtherIndividualCustomerMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dawn_AccountingPoliciesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="dawn_NetProductRevenueAndAccountsReceivableMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dawn_AccountingPoliciesTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="dawn_IndividualCustomerMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dawn_AccountingPoliciesLineItems" xlink:to="dawn_MaketValueOfCommonStockHeldByNonAffiliateStockholders" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dawn_AccountingPoliciesTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dawn_AccountingPoliciesLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dawn_AccountingPoliciesLineItems" xlink:to="dawn_AccountsReceivableCreditLosses" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dawn_AccountingPoliciesLineItems" xlink:to="us-gaap_OtherExpenses" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dawn_AccountingPoliciesLineItems" xlink:to="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dawn_AccountingPoliciesLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dawn_AccountingPoliciesLineItems" xlink:to="us-gaap_FeeIncome" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dawn_AccountingPoliciesLineItems" xlink:to="dawn_PremiumReceivedOnLicenseAgreement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dawn_AccountingPoliciesLineItems" xlink:to="us-gaap_AdministrativeFeesExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dawn_AccountingPoliciesLineItems" xlink:to="dawn_AggregateOfUpfrontLicenseFeeReceived" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dawn_AccountingPoliciesLineItems" xlink:to="dawn_PremiumPaidOnEquityStatementAsAdditionalConsideration" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dawn_AccountingPoliciesLineItems" xlink:to="us-gaap_PaymentsForRepurchaseOfPrivatePlacement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dawn_AccountingPoliciesLineItems" xlink:to="dawn_VolumeWeightedAveragePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dawn_AccountingPoliciesLineItems" xlink:to="dawn_TransactionPrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dawn_AccountingPoliciesLineItems" xlink:to="dawn_PercentageOfUpfrontLicenseFee" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureRecurringFairValueMeasurementScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:label="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_MoneyMarketFundsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByAssetClassAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureRecurringFairValueMeasurementScheduleOfCashEquivalentsMarketableSecuritiesAndUnrealizedGainsAndLossesDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsLineItems" xlink:label="us-gaap_CashAndCashEquivalentsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_MarketableSecuritiesMember" xlink:label="dawn_MarketableSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashEquivalentsMember" xlink:label="us-gaap_CashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_CashEquivalentsUnrealizedGains" xlink:label="dawn_CashEquivalentsUnrealizedGains"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_CashEquivalentsUnrealizedLosses" xlink:label="dawn_CashEquivalentsUnrealizedLosses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:label="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="us-gaap_ScheduleOfCashAndCashEquivalentsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="dawn_MarketableSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CashEquivalentsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="dawn_CashEquivalentsUnrealizedGains" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_MoneyMarketFundsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="dawn_CashEquivalentsUnrealizedLosses" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureRecurringFairValueMeasurementScheduleOfMaturitiesForAvailableForSaleSecuritiesDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsLineItems" xlink:label="us-gaap_CashAndCashEquivalentsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_WithinOneYearMember" xlink:label="dawn_WithinOneYearMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_default"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_AvailableForSaleSecuritieAmortizedCost" xlink:label="dawn_AvailableForSaleSecuritieAmortizedCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_AvailableForSaleSecuritie" xlink:label="dawn_AvailableForSaleSecuritie"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="dawn_WithinOneYearMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="dawn_AvailableForSaleSecuritieAmortizedCost" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="dawn_AvailableForSaleSecuritie" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureRecurringFairValueMeasurementScheduleOfAvailableforsaleMarketableSecuritiesWithGrossUnrealizedLossesDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsLineItems" xlink:label="us-gaap_CashAndCashEquivalentsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_AvailableForSaleSecuritieContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue" xlink:label="dawn_AvailableForSaleSecuritieContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:label="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_AvailableForSaleSecuritieContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:label="dawn_AvailableForSaleSecuritieContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionMoreThanTwelveMonthsFairValue" xlink:label="dawn_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionMoreThanTwelveMonthsFairValue"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionMoreThan12MonthsAccumulatedLoss" xlink:label="dawn_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionMoreThan12MonthsAccumulatedLoss"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_AvailableForSaleSecuritieContinuousUnrealizedLossPositionAccumulatedLoss" xlink:label="dawn_AvailableForSaleSecuritieContinuousUnrealizedLossPositionAccumulatedLoss"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_AvailableForSaleSecuritieContinuousUnrealizedLossPositionFairValue" xlink:label="dawn_AvailableForSaleSecuritieContinuousUnrealizedLossPositionFairValue"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="dawn_AvailableForSaleSecuritieContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="dawn_AvailableForSaleSecuritieContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="dawn_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionMoreThanTwelveMonthsFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="dawn_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionMoreThan12MonthsAccumulatedLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="dawn_AvailableForSaleSecuritieContinuousUnrealizedLossPositionAccumulatedLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="dawn_AvailableForSaleSecuritieContinuousUnrealizedLossPositionFairValue" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureRecurringFairValueMeasurementAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RealizedInvestmentGainsLosses" xlink:label="us-gaap_RealizedInvestmentGainsLosses"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByAssetClassAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_RealizedInvestmentGainsLosses" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureIntangibleAssetsScheduleOfIntangibleAssetsDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_LicenseAgreementMilestonePaymentMember" xlink:label="dawn_LicenseAgreementMilestonePaymentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_PRV-RelatedObligationPaymentMember" xlink:label="dawn_PRV-RelatedObligationPaymentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="dawn_LicenseAgreementMilestonePaymentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="dawn_PRV-RelatedObligationPaymentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.dayonebio.com/20250331/taxonomy/role/SignificantAgreementsAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_TakedaAssetAgreementMember" xlink:label="dawn_TakedaAssetAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LicenseMember" xlink:label="us-gaap_LicenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_SeriesARedeemableConvertiblePreferredStockMember" xlink:label="dawn_SeriesARedeemableConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_CurrentMember" xlink:label="dawn_CurrentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ObligationsMember" xlink:label="us-gaap_ObligationsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIntangibleAssetsMember" xlink:label="us-gaap_OtherIntangibleAssetsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_UpfrontPayment" xlink:label="dawn_UpfrontPayment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_MerckLicenseAgreementMember" xlink:label="dawn_MerckLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_PrvPressureReliefValveMember" xlink:label="dawn_PrvPressureReliefValveMember"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_NoncurrentMember" xlink:label="dawn_NoncurrentMember"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_PaymentOfMilestones" xlink:label="dawn_PaymentOfMilestones"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_ViractaLicenseAgreementMember" xlink:label="dawn_ViractaLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RoyaltyMember" xlink:label="us-gaap_RoyaltyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_SprintBioscienceAgreementMember" xlink:label="dawn_SprintBioscienceAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_MabcareLicenseAgreementMember" xlink:label="dawn_MabcareLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_MilestonePaymentsNotYetPaid" xlink:label="dawn_MilestonePaymentsNotYetPaid"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_IpsenPharmaSasAgreementMember" xlink:label="dawn_IpsenPharmaSasAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_MilestonePaymentsNotYetReceived" xlink:label="dawn_MilestonePaymentsNotYetReceived"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_LicenseAgreementWithIpsenPharmaSasMember" xlink:label="dawn_LicenseAgreementWithIpsenPharmaSasMember"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_UpfrontOfCashPayment" xlink:label="dawn_UpfrontOfCashPayment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_VolumeWeightedAveragePrice" xlink:label="dawn_VolumeWeightedAveragePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:label="us-gaap_ProceedsFromSaleOfProductiveAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_PaymentToObligationOfLicenseAgreement" xlink:label="dawn_PaymentToObligationOfLicenseAgreement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RoyaltyIncomeNonoperating" xlink:label="us-gaap_RoyaltyIncomeNonoperating"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_TransactionPrice" xlink:label="dawn_TransactionPrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets" xlink:label="us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_PercentageOfUpfrontLicenseFee" xlink:label="dawn_PercentageOfUpfrontLicenseFee"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FeeIncome" xlink:label="us-gaap_FeeIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentForManagementFee" xlink:label="us-gaap_PaymentForManagementFee"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_AggregateOfUpfrontLicenseFeeReceived" xlink:label="dawn_AggregateOfUpfrontLicenseFeeReceived"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_FrontlinePayment" xlink:label="dawn_FrontlinePayment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_LicenseRevenue" xlink:label="dawn_LicenseRevenue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfInvestments" xlink:label="us-gaap_GainLossOnSaleOfInvestments"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="dawn_TakedaAssetAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_LicenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="dawn_SeriesARedeemableConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="dawn_CurrentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="us-gaap_ObligationsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_OtherIntangibleAssetsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="dawn_UpfrontPayment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="dawn_MerckLicenseAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="dawn_PrvPressureReliefValveMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="dawn_NoncurrentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="dawn_PaymentOfMilestones" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="dawn_ViractaLicenseAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_RoyaltyMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="dawn_SprintBioscienceAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="dawn_MabcareLicenseAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="dawn_MilestonePaymentsNotYetPaid" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="dawn_IpsenPharmaSasAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="dawn_MilestonePaymentsNotYetReceived" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="dawn_LicenseAgreementWithIpsenPharmaSasMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="dawn_UpfrontOfCashPayment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_FairValueByAssetClassAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="dawn_VolumeWeightedAveragePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ProceedsFromSaleOfProductiveAssets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_PaymentsToAcquireProductiveAssets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="dawn_PaymentToObligationOfLicenseAgreement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RoyaltyIncomeNonoperating" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="dawn_TransactionPrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="dawn_PercentageOfUpfrontLicenseFee" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_FeeIncome" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_PaymentForManagementFee" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="dawn_AggregateOfUpfrontLicenseFeeReceived" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="dawn_FrontlinePayment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DeferredRevenueCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="24" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DeferredRevenueNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="25" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="26" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="dawn_LicenseRevenue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="27" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_GainLossOnSaleOfInvestments" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xlink:label="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PurchaseCommitmentMember" xlink:label="us-gaap_PurchaseCommitmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_AgreementDomain" xlink:label="dawn_AgreementDomain"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_ResearchAndDevelopmentAgreementsMember" xlink:label="dawn_ResearchAndDevelopmentAgreementsMember"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_LeaseForCorporateOfficeFacilityMember" xlink:label="dawn_LeaseForCorporateOfficeFacilityMember"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_BrisbaneCaliforniaMember" xlink:label="dawn_BrisbaneCaliforniaMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" xlink:label="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xlink:label="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_AgreementAxis" xlink:label="dawn_AgreementAxis"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_AgreementDomain" xlink:label="dawn_AgreementDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AreaOfLand" xlink:label="us-gaap_AreaOfLand"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_ViractaLicenseAgreementMember" xlink:label="dawn_ViractaLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_AustinTXMember" xlink:label="dawn_AustinTXMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:label="us-gaap_LesseeOperatingLeaseDescription"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_MrkdgLicenseAgreementMember" xlink:label="dawn_MrkdgLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndemnificationGuaranteeMember" xlink:label="us-gaap_IndemnificationGuaranteeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_ManufacturingAndSupplyAgreementMember" xlink:label="dawn_ManufacturingAndSupplyAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyAccrualAtCarryingValue" xlink:label="us-gaap_LossContingencyAccrualAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:label="us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_PurchasesUnderThePurchaseObligation" xlink:label="dawn_PurchasesUnderThePurchaseObligation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LeaseContractualTermAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xlink:to="us-gaap_PurchaseCommitmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dawn_AgreementDomain" xlink:to="dawn_ResearchAndDevelopmentAgreementsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="dawn_LeaseForCorporateOfficeFacilityMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="dawn_BrisbaneCaliforniaMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" xlink:to="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" xlink:to="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dawn_AgreementAxis" xlink:to="dawn_AgreementDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dawn_AgreementAxis" xlink:to="dawn_AgreementDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_StatementGeographicalAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_AreaOfLand" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dawn_AgreementDomain" xlink:to="dawn_ViractaLicenseAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="dawn_AustinTXMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseDescription" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dawn_AgreementDomain" xlink:to="dawn_MrkdgLicenseAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="dawn_AgreementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dawn_AgreementDomain" xlink:to="us-gaap_IndemnificationGuaranteeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeasePayments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dawn_AgreementDomain" xlink:to="dawn_ManufacturingAndSupplyAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LossContingencyAccrualAtCarryingValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_SecurityDeposit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="dawn_PurchasesUnderThePurchaseObligation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.dayonebio.com/20250331/taxonomy/role/RedeemableConvertiblePreferredSharesAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_BasisOfIssueDomain" xlink:label="dawn_BasisOfIssueDomain"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_MilestoneAchievedMember" xlink:label="dawn_MilestoneAchievedMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_DetailsDomain" xlink:label="dawn_DetailsDomain"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_GrossProceedsMember" xlink:label="dawn_GrossProceedsMember"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_DetailsAxis" xlink:label="dawn_DetailsAxis"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_DetailsDomain" xlink:label="dawn_DetailsDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_BasisOfIssueAxis" xlink:label="dawn_BasisOfIssueAxis"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_BasisOfIssueDomain" xlink:label="dawn_BasisOfIssueDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_ConditionsForIssueDomain" xlink:label="dawn_ConditionsForIssueDomain"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_MilestoneAchievementMember" xlink:label="dawn_MilestoneAchievementMember"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_TemporaryEquityRelatedTrancheLiabilityMember" xlink:label="dawn_TemporaryEquityRelatedTrancheLiabilityMember"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_ConditionsForIssueAxis" xlink:label="dawn_ConditionsForIssueAxis"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_ConditionsForIssueDomain" xlink:label="dawn_ConditionsForIssueDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_CommonStockSharesIssuedAsAResultOfConversionOfTemporaryEquityIntoPermanentEquity" xlink:label="dawn_CommonStockSharesIssuedAsAResultOfConversionOfTemporaryEquityIntoPermanentEquity"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_SeriesARedeemableConvertiblePreferredStockMember" xlink:label="dawn_SeriesARedeemableConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_SeriesBRedeemableConvertiblePreferredStockMember" xlink:label="dawn_SeriesBRedeemableConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_TemporaryEquityStockIssuedDuringThePeriodSharesNewIssues" xlink:label="dawn_TemporaryEquityStockIssuedDuringThePeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_TemporaryEquityIssuePricePerShare" xlink:label="dawn_TemporaryEquityIssuePricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_PaymentOfAccruedInterest" xlink:label="dawn_PaymentOfAccruedInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesSubscribedButUnissued" xlink:label="us-gaap_TemporaryEquitySharesSubscribedButUnissued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="us-gaap_DerivativeFairValueOfDerivativeLiability"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dawn_BasisOfIssueDomain" xlink:to="dawn_MilestoneAchievedMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dawn_DetailsDomain" xlink:to="dawn_GrossProceedsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dawn_DetailsAxis" xlink:to="dawn_DetailsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dawn_DetailsAxis" xlink:to="dawn_DetailsDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dawn_BasisOfIssueAxis" xlink:to="dawn_BasisOfIssueDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dawn_BasisOfIssueAxis" xlink:to="dawn_BasisOfIssueDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dawn_ConditionsForIssueDomain" xlink:to="dawn_MilestoneAchievementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="dawn_TemporaryEquityRelatedTrancheLiabilityMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dawn_ConditionsForIssueAxis" xlink:to="dawn_ConditionsForIssueDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dawn_ConditionsForIssueAxis" xlink:to="dawn_ConditionsForIssueDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="dawn_DetailsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="dawn_CommonStockSharesIssuedAsAResultOfConversionOfTemporaryEquityIntoPermanentEquity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="dawn_SeriesARedeemableConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="dawn_ConditionsForIssueAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="dawn_SeriesBRedeemableConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="dawn_TemporaryEquityStockIssuedDuringThePeriodSharesNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="dawn_BasisOfIssueAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="dawn_TemporaryEquityIssuePricePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="dawn_PaymentOfAccruedInterest" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquitySharesSubscribedButUnissued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_DerivativeFairValueOfDerivativeLiability" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.dayonebio.com/20250331/taxonomy/role/RedeemableConvertiblePreferredSharesSummaryOfSeriesARedeemableConvertiblePreferredSharesDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_SeriesARedeemableConvertiblePreferredStockMember" xlink:label="dawn_SeriesARedeemableConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:label="us-gaap_TemporaryEquityLiquidationPreference"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RedeemableNoncontrollingInterestEquityPreferredCarryingAmount" xlink:label="us-gaap_RedeemableNoncontrollingInterestEquityPreferredCarryingAmount"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="dawn_SeriesARedeemableConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityLiquidationPreference" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_RedeemableNoncontrollingInterestEquityPreferredCarryingAmount" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureCommonStockAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_FounderMember" xlink:label="dawn_FounderMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_PreFundedWarrantMember" xlink:label="dawn_PreFundedWarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_AgreementDomain" xlink:label="dawn_AgreementDomain"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_TwoThousandTwentyFourPrivatePlacementMember" xlink:label="dawn_TwoThousandTwentyFourPrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_PreFundedWarrantsMember" xlink:label="dawn_PreFundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_AgreementAxis" xlink:label="dawn_AgreementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassBMember" xlink:label="us-gaap_CommonClassBMember"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_FounderOneMember" xlink:label="dawn_FounderOneMember"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_AtTheMarketMember" xlink:label="dawn_AtTheMarketMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_InvestmentAgreementMember" xlink:label="dawn_InvestmentAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_FounderTwoMember" xlink:label="dawn_FounderTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_CommonSharesPurchaseAgreementMember" xlink:label="dawn_CommonSharesPurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_SalesAgreementMember" xlink:label="dawn_SalesAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_UpfrontLicenseFee" xlink:label="dawn_UpfrontLicenseFee"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_CommonStockSharesPurchased" xlink:label="dawn_CommonStockSharesPurchased"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_WeightedAveragePriceOfCompanysCommonStock" xlink:label="dawn_WeightedAveragePriceOfCompanysCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="dawn_FounderMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="dawn_PreFundedWarrantMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dawn_AgreementDomain" xlink:to="dawn_TwoThousandTwentyFourPrivatePlacementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="dawn_PreFundedWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dawn_AgreementAxis" xlink:to="dawn_AgreementDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassBMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="dawn_FounderOneMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="dawn_AtTheMarketMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dawn_AgreementDomain" xlink:to="dawn_InvestmentAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="dawn_FounderTwoMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dawn_AgreementDomain" xlink:to="dawn_CommonSharesPurchaseAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dawn_AgreementDomain" xlink:to="dawn_SalesAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="dawn_AgreementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_OwnershipAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="dawn_UpfrontLicenseFee" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="dawn_CommonStockSharesPurchased" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="dawn_WeightedAveragePriceOfCompanysCommonStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureCommonStockScheduleOfCommonStockSharesReservedForFutureIssuanceDetailsDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_PreFundedWarrantsMember" xlink:label="dawn_PreFundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_EmployeeStockPurchasePlanMember" xlink:label="dawn_EmployeeStockPurchasePlanMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="dawn_PreFundedWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="dawn_EmployeeStockPurchasePlanMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfSharestockbasedCompensationExpenseRecordedInTheAccompanyingCondensedConsolidatedStatementsOfOperation">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_IncentiveSharePlanMember" xlink:label="dawn_IncentiveSharePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_PerformanceStockOptionsMember" xlink:label="dawn_PerformanceStockOptionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_UnvestedCommonStockMember" xlink:label="dawn_UnvestedCommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_DetailsDomain" xlink:label="dawn_DetailsDomain"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_IncrementalSharesReservedForFutureIssuanceMember" xlink:label="dawn_IncrementalSharesReservedForFutureIssuanceMember"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_DetailsAxis" xlink:label="dawn_DetailsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_FirstAnniversaryMember" xlink:label="dawn_FirstAnniversaryMember"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_TwoThousandAndTwentyOneStockIncentivePlanMember" xlink:label="dawn_TwoThousandAndTwentyOneStockIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_TwoThousandAndTwentyOneEquityIncentivePlanMember" xlink:label="dawn_TwoThousandAndTwentyOneEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_PerformanceStockUnitsMember" xlink:label="dawn_PerformanceStockUnitsMember"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember" xlink:label="dawn_TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_UnvestedRestrictedStockAndStockOptionsMember" xlink:label="dawn_UnvestedRestrictedStockAndStockOptionsMember"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_TwoThousandAndTwentyTwoEquityInducementPlanMember" xlink:label="dawn_TwoThousandAndTwentyTwoEquityInducementPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_UnvestedPsosAndPsusMember" xlink:label="dawn_UnvestedPsosAndPsusMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_UnvestedPerformanceStockUnitsMember" xlink:label="dawn_UnvestedPerformanceStockUnitsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_UnamortizedStockBasedCompensationForStockOptions" xlink:label="dawn_UnamortizedStockBasedCompensationForStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="dawn_IncentiveSharePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="dawn_PerformanceStockOptionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="dawn_UnvestedCommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dawn_DetailsDomain" xlink:to="dawn_IncrementalSharesReservedForFutureIssuanceMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dawn_DetailsAxis" xlink:to="dawn_DetailsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_VestingAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="dawn_FirstAnniversaryMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="dawn_TwoThousandAndTwentyOneStockIncentivePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="dawn_TwoThousandAndTwentyOneEquityIncentivePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ConversionOfStockSharesIssued1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="dawn_PerformanceStockUnitsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="dawn_TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="dawn_UnvestedRestrictedStockAndStockOptionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="dawn_DetailsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="dawn_TwoThousandAndTwentyTwoEquityInducementPlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="dawn_UnvestedPsosAndPsusMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="dawn_UnvestedPerformanceStockUnitsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="dawn_UnamortizedStockBasedCompensationForStockOptions" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfStockOptionActivityDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_TwoThousandAndTwentyTwoEquityInducementPlanMember" xlink:label="dawn_TwoThousandAndTwentyTwoEquityInducementPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_TwoThousandAndTwentyOneEquityIncentivePlanMember" xlink:label="dawn_TwoThousandAndTwentyOneEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="dawn_TwoThousandAndTwentyTwoEquityInducementPlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="dawn_TwoThousandAndTwentyOneEquityIncentivePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfTheBlackscholesOptionPricingModelToEstimateTheFairValueOfStockOptionGrantedDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_TwoThousandAndTwentyOneEquityIncentivePlanMember" xlink:label="dawn_TwoThousandAndTwentyOneEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_TwoThousandTwentyOneEmployeeStockPurchasePlanMember" xlink:label="dawn_TwoThousandTwentyOneEmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="dawn_TwoThousandAndTwentyOneEquityIncentivePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="dawn_TwoThousandTwentyOneEmployeeStockPurchasePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfRestrictedStockUnitsActivityDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_TwoThousandAndTwentyTwoEquityInducementPlanMember" xlink:label="dawn_TwoThousandAndTwentyTwoEquityInducementPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_TwoThousandAndTwentyOneStockIncentivePlanMember" xlink:label="dawn_TwoThousandAndTwentyOneStockIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="dawn_TwoThousandAndTwentyTwoEquityInducementPlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="dawn_TwoThousandAndTwentyOneStockIncentivePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfTheUnvestedCommonStockDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_TwoThousandAndTwentyOneStockIncentivePlanMember" xlink:label="dawn_TwoThousandAndTwentyOneStockIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_ShareBasedCompensationByShareBasedPaymentArrangementEquityInstrumentsOtherThanOptionsOutstanding" xlink:label="dawn_ShareBasedCompensationByShareBasedPaymentArrangementEquityInstrumentsOtherThanOptionsOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_UnvestedCommonStockMember" xlink:label="dawn_UnvestedCommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_ShareBasedCompensationByShareBasedPaymentAwardConversionOfIncentiveSharesIntoRestrictedStock" xlink:label="dawn_ShareBasedCompensationByShareBasedPaymentAwardConversionOfIncentiveSharesIntoRestrictedStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_ShareBasedCompensationByShareBasedPaymentAwardConversionOfIncentiveShareIntoRestrictedStockWeightedAverageGrantDateFairValue" xlink:label="dawn_ShareBasedCompensationByShareBasedPaymentAwardConversionOfIncentiveShareIntoRestrictedStockWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="dawn_TwoThousandAndTwentyOneStockIncentivePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="dawn_ShareBasedCompensationByShareBasedPaymentArrangementEquityInstrumentsOtherThanOptionsOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="dawn_UnvestedCommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="dawn_ShareBasedCompensationByShareBasedPaymentAwardConversionOfIncentiveSharesIntoRestrictedStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="dawn_ShareBasedCompensationByShareBasedPaymentAwardConversionOfIncentiveShareIntoRestrictedStockWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfFairValueOfTheIncentiveSharesEstimatedUsingAnOptionPricingModelDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_IncentiveSharePlanMemberMember" xlink:label="dawn_IncentiveSharePlanMemberMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_ParticipatingThreshold" xlink:label="dawn_ParticipatingThreshold"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="dawn_IncentiveSharePlanMemberMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="dawn_ParticipatingThreshold" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfTheIncentiveSharesActivityDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_ShareBasedCompensationByShareBasedPaymentArrangementEquityInstrumentsOtherThanOptionsOutstanding" xlink:label="dawn_ShareBasedCompensationByShareBasedPaymentArrangementEquityInstrumentsOtherThanOptionsOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_IncentiveSharesMember" xlink:label="dawn_IncentiveSharesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_ShareBasedCompensationByShareBasedPaymentArrangementEquityInstrumentsOtherThanOptionsConvertedToUnvestedCommonStock" xlink:label="dawn_ShareBasedCompensationByShareBasedPaymentArrangementEquityInstrumentsOtherThanOptionsConvertedToUnvestedCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageGrantDateFairValue" xlink:label="dawn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsConvertedToUnvestedCommonStockWeightedAverageGrantDateFairValue" xlink:label="dawn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsConvertedToUnvestedCommonStockWeightedAverageGrantDateFairValue"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="dawn_ShareBasedCompensationByShareBasedPaymentArrangementEquityInstrumentsOtherThanOptionsOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="dawn_IncentiveSharesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="dawn_ShareBasedCompensationByShareBasedPaymentArrangementEquityInstrumentsOtherThanOptionsConvertedToUnvestedCommonStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="dawn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="dawn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsConvertedToUnvestedCommonStockWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfPerformanceStockOptionsActivityDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_PerformanceStockOptionsMember" xlink:label="dawn_PerformanceStockOptionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="dawn_PerformanceStockOptionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationFairValueOfOurCommonStockToBeIssuedUnderTheEsppDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_TwoThousandTwentyOneEmployeeStockPurchasePlanMember" xlink:label="dawn_TwoThousandTwentyOneEmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="dawn_TwoThousandTwentyOneEmployeeStockPurchasePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfTheBlackscholesOptionPricingModelToEstimateTheFairValueOfPerformanceStockOpDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_PerformanceStockOptionsMember" xlink:label="dawn_PerformanceStockOptionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="dawn_PerformanceStockOptionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfPerformanceStockUnitsActivityDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_TwoThousandAndTwentyOneStockIncentivePlanMember" xlink:label="dawn_TwoThousandAndTwentyOneStockIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_PerformanceStockOptionsMember" xlink:label="dawn_PerformanceStockOptionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="dawn_TwoThousandAndTwentyOneStockIncentivePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="dawn_PerformanceStockOptionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureNetIncomeLossPerShareSummaryOfBasicAndDilutedNetLossPerShareAttributableToCommonShareholdersstockholdersDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_RestrictedStockAwardsMember" xlink:label="dawn_RestrictedStockAwardsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmountOfDilutiveSecuritiesStockOptionsAndRestrictiveStockUnits" xlink:label="us-gaap_AmountOfDilutiveSecuritiesStockOptionsAndRestrictiveStockUnits"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="dawn_RestrictedStockAwardsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_EarningsPerShareBasic" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_EarningsPerShareDiluted" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AmountOfDilutiveSecuritiesStockOptionsAndRestrictiveStockUnits" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureNetIncomeLossPerShareSummaryOfOutstandingPotentiallyDilutiveSecuritiesHaveBeenExcludedFromCalculationOfDilutedNetLossPerShare">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_UnvestedCommonSharesMember" xlink:label="dawn_UnvestedCommonSharesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_SharesCommittedUnderESPPMember" xlink:label="dawn_SharesCommittedUnderESPPMember"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_PerformanceStockUnitsMember" xlink:label="dawn_PerformanceStockUnitsMember"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_PerformanceStockOptionsMember" xlink:label="dawn_PerformanceStockOptionsMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="dawn_UnvestedCommonSharesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="dawn_SharesCommittedUnderESPPMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="dawn_PerformanceStockUnitsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="dawn_PerformanceStockOptionsMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_UpfrontOfCashPayment" xlink:label="dawn_UpfrontOfCashPayment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForProceedsFromPreviousAcquisition" xlink:label="us-gaap_PaymentsForProceedsFromPreviousAcquisition"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForProceedsFromInvestments" xlink:label="us-gaap_PaymentsForProceedsFromInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_VolumeWeightedAveragePrice" xlink:label="dawn_VolumeWeightedAveragePrice"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_PaymentOfMilestones" xlink:label="dawn_PaymentOfMilestones"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="dawn_UpfrontOfCashPayment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_PaymentsForProceedsFromPreviousAcquisition" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_PaymentsForProceedsFromInvestments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="dawn_VolumeWeightedAveragePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="dawn_PaymentOfMilestones" priority="2" use="optional"/>
        </link:definitionLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedBalanceSheetsUnaudited">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_ShortTermInvestments" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_DeferredRevenueNoncurrent" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_ReceivablesNetCurrent" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_DeferredRevenueCurrent" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_InventoryNet" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="dawn_DepositsAndOtherLongtermAssetsNonCurrent" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="5" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="us-gaap_ReceivablesNetCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_DepositsAndOtherLongtermAssetsNonCurrent" xlink:label="dawn_DepositsAndOtherLongtermAssetsNonCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureLeaseObligationsDetail2">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiability" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureRecurringFairValueMeasurementScheduleOfMaturitiesForAvailableForSaleSecuritiesDetails2">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" order="0" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfOperationsUnaudited">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InvestmentIncomeNet" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="dawn_CostOfProductRevenue" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeLossAttributableToNoncontrollingInterest" xlink:to="us-gaap_OperatingIncomeLoss" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_Revenues" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossAttributableToNoncontrollingInterest" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeLossAttributableToNoncontrollingInterest" xlink:to="us-gaap_NonoperatingIncomeExpense" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="2" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeNet" xlink:label="us-gaap_InvestmentIncomeNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_CostOfProductRevenue" xlink:label="dawn_CostOfProductRevenue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossAttributableToNoncontrollingInterest" xlink:label="us-gaap_IncomeLossAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfComprehensiveLossUnaudited">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" order="2" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetIncomeLoss" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireShortTermInvestments" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleOfShortTermInvestments" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets" order="3" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="4" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" order="6" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="8" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="8" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInInventoriesAndOtherOperatingAssets" order="9" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="10" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInDepositOtherAssets" order="11" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="12" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="dawn_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities" order="13" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" order="14" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="15" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:label="us-gaap_ProceedsFromSaleOfShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventoriesAndOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInInventoriesAndOtherOperatingAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDepositOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInDepositOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities" xlink:label="dawn_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureRecurringFairValueMeasurementScheduleOfMaturitiesForAvailableForSaleSecuritiesDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" order="0" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureBalanceSheetItemsSummaryOfPrepaidAndOtherCurrentAssetsDetail">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidInsurance" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="dawn_PrepaidResearchAndDevelopmentExpenses" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent" order="2" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_PrepaidResearchAndDevelopmentExpenses" xlink:label="dawn_PrepaidResearchAndDevelopmentExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="us-gaap_OtherPrepaidExpenseCurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureBalanceSheetItemsSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetail">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="dawn_AccruedLicenseAgreementUpfrontPayment" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="dawn_AccruedRebates" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="dawn_AccruedFederalAndStateTaxPayments" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="dawn_AccruedMilestonePayment" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="dawn_AccruedPayrollRelatedExpenses" order="6" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="8" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="10" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_AccruedLicenseAgreementUpfrontPayment" xlink:label="dawn_AccruedLicenseAgreementUpfrontPayment"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_AccruedRebates" xlink:label="dawn_AccruedRebates"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_AccruedFederalAndStateTaxPayments" xlink:label="dawn_AccruedFederalAndStateTaxPayments"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_AccruedMilestonePayment" xlink:label="dawn_AccruedMilestonePayment"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_AccruedPayrollRelatedExpenses" xlink:label="dawn_AccruedPayrollRelatedExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureIntangibleAssetsScheduleOfIntangibleAssetsDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" order="1" weight="-1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureIntangibleAssetsScheduleOfAmortizationExpenseForAmortizableFinitelivedIntangibleAssetsDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" order="5" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureLeaseObligationsDetail">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="dawn_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="6" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:label="dawn_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSegmentReportingScheduleOfSegmentInformationDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="dawn_Third-PartyCROCMOAndOtherThird-PartyClinicalTrialCosts" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="dawn_LicenseAgreementRelatedPayments" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="dawn_EmployeeRelatedExpenses" order="3" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_Third-PartyCROCMOAndOtherThird-PartyClinicalTrialCosts" xlink:label="dawn_Third-PartyCROCMOAndOtherThird-PartyClinicalTrialCosts"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_LicenseAgreementRelatedPayments" xlink:label="dawn_LicenseAgreementRelatedPayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="dawn-20250331.xsd#dawn_EmployeeRelatedExpenses" xlink:label="dawn_EmployeeRelatedExpenses"/>
        </link:calculationLink>
      </link:linkbase>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="dawn_PaymentOfAccruedInterest" name="PaymentOfAccruedInterest" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="dawn_PaymentsOfCreditsRelatingToSalesInPriorYear" name="PaymentsOfCreditsRelatingToSalesInPriorYear" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="dawn_ScheduleOfPerformanceStockOptionsAssumptionsTableTextBlock" name="ScheduleOfPerformanceStockOptionsAssumptionsTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="dawn_TemporaryEquityRelatedTrancheLiabilityMember" name="TemporaryEquityRelatedTrancheLiabilityMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dawn_IncentiveSharePlanMemberMember" name="IncentiveSharePlanMemberMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dawn_FounderTwoMember" name="FounderTwoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dawn_LicenseAgreementRelatedPayments" name="LicenseAgreementRelatedPayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="dawn_IssuanceOfCommonStockInPrivatePlacementShare" name="IssuanceOfCommonStockInPrivatePlacementShare" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="dawn_TwoThousandTwentyOneEmployeeStockPurchasePlanMember" name="TwoThousandTwentyOneEmployeeStockPurchasePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dawn_ShareBasedCompensationByShareBasedPaymentAwardConversionOfIncentiveShareIntoRestrictedStockWeightedAverageGrantDateFairValue" name="ShareBasedCompensationByShareBasedPaymentAwardConversionOfIncentiveShareIntoRestrictedStockWeightedAverageGrantDateFairValue" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="dawn_ProductRevenueAllowanceAndReserve" name="ProductRevenueAllowanceAndReserve" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="dawn_CommonSharesPurchaseAgreementMember" name="CommonSharesPurchaseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dawn_PerformanceStockUnitsMember" name="PerformanceStockUnitsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dawn_LicenseAgreementMilestonePaymentMember" name="LicenseAgreementMilestonePaymentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dawn_AgreementAxis" name="AgreementAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dawn_DeferredSharesParValuePerShares" name="DeferredSharesParValuePerShares" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="dawn_IpsenPharmaSasAgreementMember" name="IpsenPharmaSasAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dawn_DefinedContributionPlanEmployerMatchingContribution" name="DefinedContributionPlanEmployerMatchingContribution" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="dawn_MilestoneAchievementMember" name="MilestoneAchievementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dawn_DetailsAxis" name="DetailsAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dawn_CurrentMember" name="CurrentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dawn_MerckLicenseAgreementMember" name="MerckLicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dawn_PaymentToObligationOfLicenseAgreement" name="PaymentToObligationOfLicenseAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="dawn_TakedaAssetAgreementMember" name="TakedaAssetAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dawn_TemporaryEquityIssuePricePerShare" name="TemporaryEquityIssuePricePerShare" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="dawn_AustinTXMember" name="AustinTXMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dawn_IncrementalSharesReservedForFutureIssuanceMember" name="IncrementalSharesReservedForFutureIssuanceMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dawn_TwoThousandAndTwentyTwoEquityInducementPlanMember" name="TwoThousandAndTwentyTwoEquityInducementPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dawn_CommonStockToBeIssuedUnderTheEsppTableTextBlock" name="CommonStockToBeIssuedUnderTheEsppTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="dawn_UpfrontLicenseFee" name="UpfrontLicenseFee" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="dawn_UpfrontPayment" name="UpfrontPayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="dawn_MilestonePaymentsNotYetReceived" name="MilestonePaymentsNotYetReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="dawn_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities" name="IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="dawn_MarketableSecuritiesMember" name="MarketableSecuritiesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dawn_PerformanceStockOptionsMember" name="PerformanceStockOptionsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dawn_UnvestedCommonStockMember" name="UnvestedCommonStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dawn_FounderMember" name="FounderMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dawn_SeriesBRedeemableConvertiblePreferredStockMember" name="SeriesBRedeemableConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dawn_AvailableForSaleSecuritieContinuousUnrealizedLossPositionFairValue" name="AvailableForSaleSecuritieContinuousUnrealizedLossPositionFairValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="dawn_LicenseRevenue" name="LicenseRevenue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="dawn_ConditionsForIssueAxis" name="ConditionsForIssueAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dawn_MabcareLicenseAgreementMember" name="MabcareLicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dawn_CashEquivalentsUnrealizedLosses" name="CashEquivalentsUnrealizedLosses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="dawn_AvailableForSaleSecuritieContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" name="AvailableForSaleSecuritieContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="dawn_ConcentrationOfCreditRiskAndOtherRisksAndUncertaintiesMember" name="ConcentrationOfCreditRiskAndOtherRisksAndUncertaintiesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dawn_ViractaLicenseAgreementMember" name="ViractaLicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dawn_GrossProceedsMember" name="GrossProceedsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dawn_LicenseAgreementWithIpsenPharmaSasMember" name="LicenseAgreementWithIpsenPharmaSasMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dawn_AccountsReceivableCreditLosses" name="AccountsReceivableCreditLosses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="dawn_Third-PartyCROCMOAndOtherThird-PartyClinicalTrialCosts" name="Third-PartyCROCMOAndOtherThird-PartyClinicalTrialCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="dawn_SummaryOfPerformanceStockUnitsActivity" name="SummaryOfPerformanceStockUnitsActivity" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="dawn_AdjustmentsRelatingToPriorYears" name="AdjustmentsRelatingToPriorYears" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="dawn_SharesCommittedUnderESPPMember" name="SharesCommittedUnderESPPMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dawn_DepositsAndOtherLongtermAssetsNonCurrent" name="DepositsAndOtherLongtermAssetsNonCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="dawn_PRV-RelatedObligationPaymentMember" name="PRV-RelatedObligationPaymentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dawn_CommonStockIssuedPursuantToFollowOnOfferingNetOfIssuanceCostsShares" name="CommonStockIssuedPursuantToFollowOnOfferingNetOfIssuanceCostsShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="dawn_TransactionPrice" name="TransactionPrice" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="dawn_MrkdgLicenseAgreementMember" name="MrkdgLicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dawn_TwoThousandAndTwentyOneEquityIncentivePlanMember" name="TwoThousandAndTwentyOneEquityIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dawn_ShareBasedCompensationByShareBasedPaymentArrangementEquityInstrumentsOtherThanOptionsOutstanding" name="ShareBasedCompensationByShareBasedPaymentArrangementEquityInstrumentsOtherThanOptionsOutstanding" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="dawn_AgreementDomain" name="AgreementDomain" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dawn_UnvestedCommonSharesMember" name="UnvestedCommonSharesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dawn_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionMoreThan12MonthsAccumulatedLoss" name="AvailableForSaleSecuritiesContinuousUnrealizedLossPositionMoreThan12MonthsAccumulatedLoss" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="dawn_IncentiveSharePlanMember" name="IncentiveSharePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dawn_EmployeeStockPurchasePlanMember" name="EmployeeStockPurchasePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dawn_UnvestedPsosAndPsusMember" name="UnvestedPsosAndPsusMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dawn_PaymentOfMilestones" name="PaymentOfMilestones" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="dawn_PaymentsOfCreditsRelatingToSalesInCurrentYear" name="PaymentsOfCreditsRelatingToSalesInCurrentYear" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="dawn_ShareBasedCompensationByShareBasedPaymentAwardConversionOfIncentiveSharesIntoRestrictedStock" name="ShareBasedCompensationByShareBasedPaymentAwardConversionOfIncentiveSharesIntoRestrictedStock" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="dawn_AggregateOfUpfrontLicenseFeeReceived" name="AggregateOfUpfrontLicenseFeeReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="dawn_PurchasesUnderThePurchaseObligation" name="PurchasesUnderThePurchaseObligation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="dawn_MilestonePaymentsNotYetPaid" name="MilestonePaymentsNotYetPaid" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="dawn_SalesAgreementMember" name="SalesAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dawn_OneCustomerMember" name="OneCustomerMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dawn_AccruedMilestonePayment" name="AccruedMilestonePayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="dawn_StockIssuanceCosts" name="StockIssuanceCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="dawn_AvailableForSaleSecuritie" name="AvailableForSaleSecuritie" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="dawn_UpfrontOfCashPayment" name="UpfrontOfCashPayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="dawn_BrisbaneCaliforniaMember" name="BrisbaneCaliforniaMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dawn_MilestoneAchievedMember" name="MilestoneAchievedMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dawn_PercentageOfUpfrontLicenseFee" name="PercentageOfUpfrontLicenseFee" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="dawn_PremiumPaidOnEquityStatementAsAdditionalConsideration" name="PremiumPaidOnEquityStatementAsAdditionalConsideration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="dawn_TwoThousandAndTwentyOneStockIncentivePlanMember" name="TwoThousandAndTwentyOneStockIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dawn_DeferredSharesOutstanding" name="DeferredSharesOutstanding" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="dawn_SummaryOfPerformanceStockOptions" name="SummaryOfPerformanceStockOptions" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="dawn_FrontlinePayment" name="FrontlinePayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="dawn_UnamortizedStockBasedCompensationForStockOptions" name="UnamortizedStockBasedCompensationForStockOptions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="dawn_AtTheMarketMember" name="AtTheMarketMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dawn_IndividualCustomerMember" name="IndividualCustomerMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dawn_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" name="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="dawn_SeriesARedeemableConvertiblePreferredStockMember" name="SeriesARedeemableConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dawn_PrvPressureReliefValveMember" name="PrvPressureReliefValveMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dawn_AccountingPoliciesLineItems" name="AccountingPoliciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dawn_IssuanceOfCommonStockUponReleaseOfRestrictedStockUnits" name="IssuanceOfCommonStockUponReleaseOfRestrictedStockUnits" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="dawn_ShareBasedCompensationByShareBasedPaymentArrangementEquityInstrumentsOtherThanOptionsConvertedToUnvestedCommonStock" name="ShareBasedCompensationByShareBasedPaymentArrangementEquityInstrumentsOtherThanOptionsConvertedToUnvestedCommonStock" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="dawn_BasisOfIssueDomain" name="BasisOfIssueDomain" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dawn_TwoThousandTwentyFourPrivatePlacementMember" name="TwoThousandTwentyFourPrivatePlacementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dawn_IssuanceOfCommonStockInPrivatePlacementValue" name="IssuanceOfCommonStockInPrivatePlacementValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="dawn_LeaseForCorporateOfficeFacilityMember" name="LeaseForCorporateOfficeFacilityMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dawn_NetProductRevenueAndAccountsReceivableMember" name="NetProductRevenueAndAccountsReceivableMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dawn_InvestmentAgreementMember" name="InvestmentAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dawn_CostOfProductRevenue" name="CostOfProductRevenue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="dawn_VolumeWeightedAveragePrice" name="VolumeWeightedAveragePrice" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="dawn_AccruedRebates" name="AccruedRebates" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="dawn_AccountingPoliciesTable" name="AccountingPoliciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dawn_SprintBioscienceAgreementMember" name="SprintBioscienceAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dawn_AccruedFederalAndStateTaxPayments" name="AccruedFederalAndStateTaxPayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="dawn_BasisOfIssueAxis" name="BasisOfIssueAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dawn_CommonStockSharesIssuedAsAResultOfConversionOfTemporaryEquityIntoPermanentEquity" name="CommonStockSharesIssuedAsAResultOfConversionOfTemporaryEquityIntoPermanentEquity" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="dawn_CommonStockSharesPurchased" name="CommonStockSharesPurchased" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="dawn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageGrantDateFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageGrantDateFairValue" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="dawn_ScheduleOfMaturitiesForAvailableForSaleSecuritiesTableTextBlock" name="ScheduleOfMaturitiesForAvailableForSaleSecuritiesTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="dawn_PreFundedWarrantMember" name="PreFundedWarrantMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dawn_AvailableForSaleSecuritieContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue" name="AvailableForSaleSecuritieContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="dawn_CommonSharesMember" name="CommonSharesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dawn_IncentiveSharesMember" name="IncentiveSharesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dawn_ParticipatingThreshold" name="ParticipatingThreshold" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="dawn_ExternalCostsAbstract" name="ExternalCostsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dawn_TwoCustomerMember" name="TwoCustomerMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dawn_PreFundedWarrantsMember" name="PreFundedWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dawn_CurrentProvisionRelatingToCurrentPeriodSales" name="CurrentProvisionRelatingToCurrentPeriodSales" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="dawn_WithinOneYearMember" name="WithinOneYearMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dawn_RedeemableNonControllingInterestTextBlock" name="RedeemableNonControllingInterestTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="dawn_AvailableForSaleSecuritieAmortizedCost" name="AvailableForSaleSecuritieAmortizedCost" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="dawn_ThreeCustomerMember" name="ThreeCustomerMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dawn_PremiumReceivedOnLicenseAgreement" name="PremiumReceivedOnLicenseAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="dawn_WeightedAveragePriceOfCompanysCommonStock" name="WeightedAveragePriceOfCompanysCommonStock" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="dawn_RedeemableNoncontrollingInterestMember" name="RedeemableNoncontrollingInterestMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dawn_NoncurrentMember" name="NoncurrentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dawn_OtherIndividualCustomerMember" name="OtherIndividualCustomerMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dawn_ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock" name="ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="dawn_MaketValueOfCommonStockHeldByNonAffiliateStockholders" name="MaketValueOfCommonStockHeldByNonAffiliateStockholders" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="dawn_IpsenLicenseAgreementMember" name="IpsenLicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dawn_DetailsDomain" name="DetailsDomain" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dawn_EmployeeRelatedExpenses" name="EmployeeRelatedExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="dawn_ConditionsForIssueDomain" name="ConditionsForIssueDomain" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dawn_FounderOneMember" name="FounderOneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dawn_AvailableForSaleSecuritieContinuousUnrealizedLossPositionAccumulatedLoss" name="AvailableForSaleSecuritieContinuousUnrealizedLossPositionAccumulatedLoss" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="dawn_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionMoreThanTwelveMonthsFairValue" name="AvailableForSaleSecuritiesContinuousUnrealizedLossPositionMoreThanTwelveMonthsFairValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="dawn_TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember" name="TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dawn_TemporaryEquityTextBlock" name="TemporaryEquityTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="dawn_ManufacturingAndSupplyAgreementMember" name="ManufacturingAndSupplyAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dawn_CommonStockIssuedPursuantToFollowOnOfferingNetOfIssuanceCostsAmount" name="CommonStockIssuedPursuantToFollowOnOfferingNetOfIssuanceCostsAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="dawn_ScheduleOfPrepaidAndOtherCurrentAssetstableTextBlockTableTextBlock" name="ScheduleOfPrepaidAndOtherCurrentAssetstableTextBlockTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="dawn_AccruedPayrollRelatedExpenses" name="AccruedPayrollRelatedExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="dawn_TemporaryEquityStockIssuedDuringThePeriodSharesNewIssues" name="TemporaryEquityStockIssuedDuringThePeriodSharesNewIssues" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="dawn_RestrictedStockAwardsMember" name="RestrictedStockAwardsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dawn_AccruedLicenseAgreementUpfrontPayment" name="AccruedLicenseAgreementUpfrontPayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="dawn_CashEquivalentsUnrealizedGains" name="CashEquivalentsUnrealizedGains" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="dawn_PrepaidResearchAndDevelopmentExpenses" name="PrepaidResearchAndDevelopmentExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="dawn_SeriesBRedeemableConvertiblePreferredSharesMember" name="SeriesBRedeemableConvertiblePreferredSharesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dawn_UnvestedPerformanceStockUnitsMember" name="UnvestedPerformanceStockUnitsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dawn_ResearchAndDevelopmentAgreementsMember" name="ResearchAndDevelopmentAgreementsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dawn_UnvestedRestrictedStockAndStockOptionsMember" name="UnvestedRestrictedStockAndStockOptionsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dawn_FirstAnniversaryMember" name="FirstAnniversaryMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dawn_ScheduleOfStockOptionsAssumptionsTableTextBlock" name="ScheduleOfStockOptionsAssumptionsTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="dawn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsConvertedToUnvestedCommonStockWeightedAverageGrantDateFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsConvertedToUnvestedCommonStockWeightedAverageGrantDateFairValue" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>May 01, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">DAY ONE BIOPHARMACEUTICALS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001845337<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Securities Act File Number</a></td>
<td class="text">001-40431<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">83-2415215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1800 Sierra Point Parkway<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Brisbane<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94005<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">484-0899<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.0001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">DAWN<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101,362,468<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Balance Sheets (unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 33,358<span></span>
</td>
<td class="nump">$ 124,968<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">439,662<span></span>
</td>
<td class="nump">406,752<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">18,054<span></span>
</td>
<td class="nump">13,876<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">3,565<span></span>
</td>
<td class="nump">3,321<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">14,012<span></span>
</td>
<td class="nump">13,413<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">508,651<span></span>
</td>
<td class="nump">562,330<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">2,508<span></span>
</td>
<td class="nump">2,285<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease&#160;right-of-use&#160;asset</a></td>
<td class="nump">2,577<span></span>
</td>
<td class="nump">2,422<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">20,405<span></span>
</td>
<td class="nump">15,630<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dawn_DepositsAndOtherLongtermAssetsNonCurrent', window );">Deposits and other long-term assets</a></td>
<td class="nump">215<span></span>
</td>
<td class="nump">121<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">534,356<span></span>
</td>
<td class="nump">582,788<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">2,540<span></span>
</td>
<td class="nump">3,262<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">43,641<span></span>
</td>
<td class="nump">68,625<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Current portion of deferred revenue</a></td>
<td class="nump">1,636<span></span>
</td>
<td class="nump">1,554<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of operating lease liabilities</a></td>
<td class="nump">62<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">47,879<span></span>
</td>
<td class="nump">73,451<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Long-term portion of deferred revenue</a></td>
<td class="nump">3,350<span></span>
</td>
<td class="nump">3,233<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term portion of operating lease liabilities</a></td>
<td class="nump">2,854<span></span>
</td>
<td class="nump">2,592<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liability</a></td>
<td class="nump">761<span></span>
</td>
<td class="nump">761<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">54,844<span></span>
</td>
<td class="nump">80,037<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 6)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value; 500,000,000 shares authorized as of March 31, 2025 and December 31, 2024; 101,353,781 and 101,116,162 shares issued and outstanding as of March 31, 2025 and December 31, 2024, respectively.</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional&#160;paid-in-capital</a></td>
<td class="nump">1,069,631<span></span>
</td>
<td class="nump">1,056,738<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive (loss) income</a></td>
<td class="num">(52)<span></span>
</td>
<td class="nump">84<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(590,077)<span></span>
</td>
<td class="num">(554,081)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">479,512<span></span>
</td>
<td class="nump">502,751<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 534,356<span></span>
</td>
<td class="nump">$ 582,788<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dawn_DepositsAndOtherLongtermAssetsNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deposits and other long-term assets Non current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dawn_DepositsAndOtherLongtermAssetsNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dawn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Balance Sheets (unaudited) (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, Shares Authorized</a></td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, Shares Issued</a></td>
<td class="nump">101,353,781<span></span>
</td>
<td class="nump">101,116,162<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, Shares Outstanding</a></td>
<td class="nump">101,353,781<span></span>
</td>
<td class="nump">101,116,162<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Statements of Operations (unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">$ 30,761<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Cost and operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dawn_CostOfProductRevenue', window );">Cost of product revenue</a></td>
<td class="nump">2,884<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">39,619<span></span>
</td>
<td class="nump">40,210<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">29,325<span></span>
</td>
<td class="nump">26,557<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total cost and operating expenses</a></td>
<td class="nump">71,828<span></span>
</td>
<td class="nump">66,767<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(41,067)<span></span>
</td>
<td class="num">(66,767)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Non-operating income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNet', window );">Investment income, net</a></td>
<td class="nump">5,094<span></span>
</td>
<td class="nump">4,365<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="num">(23)<span></span>
</td>
<td class="num">(10)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total non-operating income, net</a></td>
<td class="nump">5,071<span></span>
</td>
<td class="nump">4,355<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossAttributableToNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">(35,996)<span></span>
</td>
<td class="num">(62,412)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit (expense)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">$ (35,996)<span></span>
</td>
<td class="num">$ (62,412)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income (loss) per share - basic</a></td>
<td class="num">$ (0.35)<span></span>
</td>
<td class="num">$ (0.72)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net income (loss) per share - diluted</a></td>
<td class="num">$ (0.35)<span></span>
</td>
<td class="num">$ (0.72)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average number of common shares used in net income (loss) per share - basic</a></td>
<td class="nump">102,710,382<span></span>
</td>
<td class="nump">86,679,282<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average number of common shares used in net income (loss) per share - diluted</a></td>
<td class="nump">102,710,382<span></span>
</td>
<td class="nump">86,679,282<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product revenue, net [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">$ 30,503<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">License revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">$ 258<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dawn_CostOfProductRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cost of Product Revenue</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dawn_CostOfProductRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dawn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of income (loss) attributable to noncontrolling interest. Includes, but is not limited to, income (loss) from continuing operations, discontinued operations and equity method investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Statements of Comprehensive Loss (unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (35,996)<span></span>
</td>
<td class="num">$ (62,412)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract', window );"><strong>Other comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax', window );">Unrealized loss on available-for-sale securities</a></td>
<td class="num">(136)<span></span>
</td>
<td class="num">(14)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Total comprehensive loss</a></td>
<td class="num">$ (36,132)<span></span>
</td>
<td class="num">$ (62,426)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Statements of Stockholders' Equity (unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Shares [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss) [Member]</div></th>
<th class="th"><div>Accumulated Deficit [Member]</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Dec. 31, 2023</a></td>
<td class="nump">$ 346,540<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">$ 805,107<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="num">$ (458,585)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning Balance (In shares) at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87,227,132<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options (share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,862<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options, Amount</a></td>
<td class="nump">48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dawn_IssuanceOfCommonStockUponReleaseOfRestrictedStockUnits', window );">Issuance of common stock upon release of restricted stock units, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">157,724<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited', window );">Unvested common stock forfeiture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12,555)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation expenses</a></td>
<td class="nump">12,644<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,644<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax', window );">Unrealized loss on available-for-sale securities</a></td>
<td class="num">(14)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">(62,412)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(62,412)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Mar. 31, 2024</a></td>
<td class="nump">296,806<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">817,799<span></span>
</td>
<td class="num">(5)<span></span>
</td>
<td class="num">(520,997)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance (In shares) at Mar. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87,377,163<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Dec. 31, 2024</a></td>
<td class="nump">502,751<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">1,056,738<span></span>
</td>
<td class="nump">84<span></span>
</td>
<td class="num">(554,081)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning Balance (In shares) at Dec. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101,116,162<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options, Amount</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dawn_IssuanceOfCommonStockUponReleaseOfRestrictedStockUnits', window );">Issuance of common stock upon release of restricted stock units, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">238,354<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited', window );">Unvested common stock forfeiture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(735)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation expenses</a></td>
<td class="nump">12,893<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,893<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax', window );">Unrealized loss on available-for-sale securities</a></td>
<td class="num">(136)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(136)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">(35,996)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(35,996)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Mar. 31, 2025</a></td>
<td class="nump">$ 479,512<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">$ 1,069,631<span></span>
</td>
<td class="num">$ (52)<span></span>
</td>
<td class="num">$ (590,077)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance (In shares) at Mar. 31, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101,353,781<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dawn_IssuanceOfCommonStockUponReleaseOfRestrictedStockUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock upon release of restricted stock units</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dawn_IssuanceOfCommonStockUponReleaseOfRestrictedStockUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dawn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares (or other type of equity) forfeited during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Statements of Cash Flows (unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (35,996)<span></span>
</td>
<td class="num">$ (62,412)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">12,861<span></span>
</td>
<td class="nump">12,644<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation expense</a></td>
<td class="nump">94<span></span>
</td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Accretion of discounts on short-term investments, net</a></td>
<td class="num">(4,250)<span></span>
</td>
<td class="num">(1,292)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">725<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Amortization of operating right-of-use asset</a></td>
<td class="nump">75<span></span>
</td>
<td class="nump">93<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable, net</a></td>
<td class="num">(4,178)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventoriesAndOtherOperatingAssets', window );">Inventory</a></td>
<td class="num">(212)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(606)<span></span>
</td>
<td class="nump">837<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDepositOtherAssets', window );">Deposits and other long-term assets</a></td>
<td class="num">(94)<span></span>
</td>
<td class="nump">47<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(722)<span></span>
</td>
<td class="nump">2,204<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dawn_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="num">(26,984)<span></span>
</td>
<td class="num">(1,765)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Deferred revenue</a></td>
<td class="nump">199<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="nump">91<span></span>
</td>
<td class="num">(108)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(58,997)<span></span>
</td>
<td class="num">(49,729)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireShortTermInvestments', window );">Cash paid for purchase of short-term investments</a></td>
<td class="num">(189,796)<span></span>
</td>
<td class="num">(47,162)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfShortTermInvestments', window );">Proceeds from maturity of short-term investments</a></td>
<td class="nump">161,000<span></span>
</td>
<td class="nump">136,450<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Cash paid for acquired intangible assets</a></td>
<td class="num">(3,500)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Cash paid for purchase of property and equipment</a></td>
<td class="num">(317)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash (used in) provided by investing activities</a></td>
<td class="num">(32,613)<span></span>
</td>
<td class="nump">89,288<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from issuance of common stock upon stock option exercises</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">48<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Cash provided by financing activities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">48<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Net (decrease) increase in cash and cash equivalents</a></td>
<td class="num">(91,610)<span></span>
</td>
<td class="nump">39,607<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, beginning of period</a></td>
<td class="nump">124,968<span></span>
</td>
<td class="nump">230,784<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, end of period</a></td>
<td class="nump">33,358<span></span>
</td>
<td class="nump">270,391<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosures of noncash activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Capital Expenditures Incurred but Not yet Paid</a></td>
<td class="nump">2,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use asset obtained in exchange for new operating lease liabilities</a></td>
<td class="nump">$ 230<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dawn_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) in accrued expenses and other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dawn_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dawn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDepositOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in moneys or securities given as security including, but not limited to, contract, escrow, or earnest money deposits, retainage (if applicable), deposits with clearing organizations and others, collateral, or margin deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDepositOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventoriesAndOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in inventory, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventoriesAndOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sales of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (35,996)<span></span>
</td>
<td class="num">$ (62,412)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business and Organization<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Description of Business and Organization</a></td>
<td class="text"><div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Description of Business and Organization </span></div></div><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Organization and Business</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Day One Biopharmaceuticals, Inc. is a commercial-stage company focused on advancing medicines for childhood and adult diseases with equal intensity. The Company was founded in November 2018 and is headquartered in Brisbane, CA.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary Of Significant  Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><div class="item-list-element-wrapper" style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Summary of Significant Accounting Policies </span></div></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Basis of Presentation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States, or U.S. GAAP, for interim financial information and Article 10 of Regulation S-X of the Securities and Exchange Commission, or SEC, and should be read in conjunction with the Company's financial statements and notes thereto contained in the Company's Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on February 25, 2025. The condensed financial statements presented in this Quarterly Report on Form 10-Q are unaudited; however, in the opinion of management, such financial statements reflect all adjustments, consisting solely of normal recurring adjustments, necessary for a fair presentation of the results for the interim periods presented.</span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in Accounting Standards Codification, or ASC, and Accounting Standards Updates, or ASU, of the Financial Accounting Standards Board, or FASB.</span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Certain prior period amounts in the Notes to the Condensed Financial Statements have been reclassified to conform to the current period's presentation. These reclassifications did not affect the prior period's total assets, liabilities, stockholders' equity, net loss or cash flows. Specifically, the reclassifications separately present accrued rebates and accrued federal and state taxes within Note 4.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Use of Estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The preparation of condensed financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and disclosure of contingent assets and liabilities at the date of the condensed financial statements, and the reported amounts of expenses during the reporting period. Estimates and assumptions made in the accompanying condensed financial statements include, but are not limited to, accruals for research and development expenses, variable consideration and other relevant inputs impacting the gross and net revenue recognition, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the valuation of share-based awards, and the valuation of deferred tax assets. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable. Actual results may differ from those estimates or assumptions.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Segments</span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Operating segments are defined as components of an entity about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business in one operating segment.</span></p></div><div><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Concentration of Credit Risk and Other Risks and Uncertainties</span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Financial instruments that subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents, short-term investments, and accounts receivable. Amounts on deposit may at times exceed federally insured limits. The Company is exposed to credit risk in the event of default by the financial institutions holding its cash, cash equivalents and short-term investments that are recorded on its balance sheet. Per policy, the Company mitigates its risk by investing in high-grade instruments and limiting the concentration in any one non-United States government or government backed issuer, which limits its exposure. The Company has not experienced any losses on its cash, cash equivalents and short-term investments.
</span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the three months ended March 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, two individual customers accounted for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">98.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of total net product revenue, with these individual customers representing </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">64.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">34.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the Company's total net product revenue. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, two customers accounted for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">96.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the accounts receivable balance, with these individual customers representing </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">72.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the accounts receivable balance. No other individual customers account for more than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of net product revenue or accounts receivable. The Company monitors the financial condition of its customers so that it can appropriately respond to changes in their creditworthiness. To date, the Company has not experienced any losses with respect to the collection of its accounts receivable.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is subject to certain risks and uncertainties and believes that changes in any of the following areas could have a material adverse effect on the Company's future financial position or results of its operations: ability to obtain future financing; regulatory requirements for approval and market acceptance of, and reimbursement for, product candidates; performance of third-party clinical research organizations and manufacturers upon which the Company relies; development of sales channels; protection of the Company&#8217;s intellectual property; litigation or claims against the Company based on intellectual property, patent, product, regulatory or other factors; changes to the market landscape; and the Company&#8217;s ability to attract and retain employees necessary to support its growth.
</span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is dependent on third-party manufacturers to supply products for commercial and research and development activities in its programs. In particular, the Company relies and expects to continue to rely on a small number of manufacturers to supply it with its requirements for the active pharmaceutical ingredients and formulated drugs related to these programs. These programs could be adversely affected by a significant interruption in the supply of active pharmaceutical ingredients and formulated drugs.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Recently Issued Accounting Pronouncements</span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740) &#8211; Improvements to Income Tax Disclosures, which enhances the transparency and decision usefulness of income tax disclosures by requiring disclosure of disaggregated income taxes paid, prescribes standard categories for the components of the effective tax rate reconciliation, and modifies other income tax-related disclosures. The ASU is effective for fiscal years beginning after December 15, 2024 and allows for adoption on a prospective basis, with a retrospective option. The Company is currently evaluating the effect of this update on its financial statement disclosures.</span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2024, the FASB issued ASU No. 2024-03, Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures, which requires disclosure, in the notes to financial statements, of specified information about certain costs and expenses at each interim and annual reporting period. The ASU is effective for fiscal years beginning after December 15, 2026 and allows for adoption on a prospective basis, with a retrospective option. Early adoption is permitted. The Company is currently evaluating the effect of this update on its financial statement disclosures.</span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Recurring Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Recurring Fair Value Measurements</a></td>
<td class="text"><div class="item-list-element-wrapper" style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Recurring Fair Value Measurements </span></div></div><div style="font-size:12pt;font-family:Times New Roman;"><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table sets forth the Company&#8217;s financial instruments as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 31, 2025 and December 31, 2024, which are measured at fair value on a recurring basis by level within the fair value hierarchy (in thousands):</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:36.214%;box-sizing:content-box;"></td>
         <td style="width:1.2%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.745000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.2%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.745000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.2%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.745000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.2%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.745000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">March 31, 2025</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 1</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 3</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Financial assets:</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,146</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,146</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. treasury securities</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">345,377</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">345,377</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. government agency securities</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">94,285</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">94,285</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total assets measured at fair value</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,146</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">439,662</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">451,808</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:36.295%;box-sizing:content-box;"></td>
         <td style="width:1.2%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.725%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.2%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.725%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.2%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.725%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.2%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.725%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 1</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 3</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Financial assets:</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,728</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,728</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. treasury securities</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">311,487</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">311,487</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. government agency securities</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">183,375</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">183,375</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total assets measured at fair value</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,728</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">494,862</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">511,590</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company's money market funds are classified as Level 1 because they are measured using observable inputs from active markets for identical assets.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company's U.S. treasury securities and U.S. government agency securities are classified as Level 2 because they are measured with inputs that are either directly or indirectly observable for the asset which include quoted prices for similar assets in active markets and quoted prices for identical or similar assets in markets that are not active.</span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There were no assets or liabilities classified as Level 3 as of March 31, 2025 and December 31, 2024.</span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> transfers between Level 1, Level 2 or Level 3 categories during the periods presented.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following tables summarize the estimated fair value of the Company's cash equivalents, available-for-sale securities classified as short-term investments, and associated unrealized gains and losses (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:41.6%;box-sizing:content-box;"></td>
         <td style="width:1.1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:11.5%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:11.5%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:11.5%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:11.5%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">March 31, 2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortized Cost</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized Gains</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized Losses</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Estimated Fair Value</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash equivalents:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,146</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,146</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total cash equivalents</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,146</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,146</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Short-term investments</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. government agency securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">94,297</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">94,285</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. treasury securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">345,418</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">48</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">345,377</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total short-term investments</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">439,715</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">60</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">439,662</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:41.6%;box-sizing:content-box;"></td>
         <td style="width:1.1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:11.5%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:11.5%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:11.5%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:11.5%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortized Cost</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized Gains</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized Losses</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Estimated Fair Value</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash equivalents:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,728</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,728</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. government agency securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">75,163</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">75,163</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. treasury securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,947</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,947</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total cash equivalents</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">104,838</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">104,838</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;text-indent:5pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Short-term investments</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. government agency securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">108,210</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">108,212</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. treasury securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">298,457</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">85</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">298,540</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total short-term investments</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">406,667</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">98</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">406,752</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><div style="font-size:11pt;font-family:'Calibri',sans-serif;"><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the maturities of our cash equivalents and available-for-sale securities (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:53.261%;box-sizing:content-box;"></td>
         <td style="width:1.761%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:19.607999999999997%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.761%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:19.607999999999997%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">March 31, 2025</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortized Cost</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Mature in one year or less</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">451,861</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">451,808</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">451,861</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">451,808</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:53.261%;box-sizing:content-box;"></td>
         <td style="width:1.761%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:19.607999999999997%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.761%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:19.607999999999997%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortized Cost</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Mature in one year or less</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">511,505</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">511,590</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">511,505</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">511,590</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company regularly reviews the changes to the rating of its securities and monitors the surrounding economic conditions to assess the risk of expected credit losses. As of March 31, 2025 and December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, there were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> securities that were in an unrealized loss position for more than 12 months. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the unrealized losses on the Company&#8217;s short-term investments were primarily caused by interest rate increases. The Company does not expect the issuers to settle any security at a price less than the amortized cost basis of the investment with the contractual cash flows of these investments guaranteed by the issuer. No allowance for credit losses has been recorded since it is not more-likely-than-not that the Company will be required to sell the investments before recovery of their amortized cost basis.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 107<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 940<br> -SubTopic 820<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Items<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Balance Sheet Items</a></td>
<td class="text"><div class="item-list-element-wrapper" style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">4.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Balance Sheet Items </span></div></div><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Prepaid Expenses and Other Current Assets</span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prepaid expenses and other current assets consisted of the following (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:76.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:66.967%;box-sizing:content-box;"></td>
         <td style="width:1.62%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.897%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.62%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.897%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">March 31,<br/>2025</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,<br/>2024</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid research and development expenses</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,733</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,216</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid insurance</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">305</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">830</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other prepaid expenses and other assets</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,974</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,367</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total prepaid expenses and other current assets</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,012</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,413</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Accrued Expenses and Other Current Liabilities</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accrued expenses and other current liabilities consisted of the following (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:76.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:68.84%;box-sizing:content-box;"></td>
         <td style="width:1.26%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.32%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.26%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.32%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">March 31,<br/>2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,<br/>2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued research and development expenses</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,457</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,760</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued rebates</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,008</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,518</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued federal and state taxes</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,966</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,966</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued professional service expenses</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,943</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,758</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued payroll related expenses</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,202</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,943</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued milestone payment</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,000</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,000</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,065</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,680</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total accrued expenses and other current liabilities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">43,641</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">68,625</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/210/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">Intangible Assets</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5. Intangible Assets</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Intangible assets, net consisted of the following:</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:68.84%;box-sizing:content-box;"></td>
         <td style="width:1.26%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.32%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.26%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.32%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">March 31,<br/>2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,<br/>2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Intangible assets with finite lives:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">License agreement milestone payments</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,500</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,000</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">PRV-related obligation payment</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,100</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,100</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Intangible assets, gross</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22,600</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,100</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less accumulated amortization</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,195</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,470</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Intangible assets, net</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,405</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,630</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company incurred amortization expense of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three months ended March 31, 2025.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The estimated aggregate amortization expense for amortizable, finite-lived intangible assets as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 31, 2025 is as follows:</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:70.56%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:27.439999999999998%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ending December 31,</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Estimated<br/>Amortization<br/>Expense</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2025 (Remaining)</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,385</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2026</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,180</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2027</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,180</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2028</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,180</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2029</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,180</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Thereafter</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,300</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total future expected amortization expense</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,405</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/985-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Agreements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Significant Agreements</a></td>
<td class="text"><div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">6.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Significant Agreements</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Takeda asset purchase agreement</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On December 16, 2019, a subsidiary of the Company entered into an asset purchase agreement, or the Takeda Asset Agreement, with Millennium Pharmaceuticals, Inc., a related party and an affiliate of Takeda Pharmaceutical Company Limited, or Takeda. Effective December 31, 2021, the subsidiary was merged with and into the Company, with the Company being the surviving corporation and assuming the subsidiary&#8217;s obligations under the Takeda Asset Agreement. Pursuant to the Takeda Asset Agreement, the Company purchased certain technology rights and know-how related to TAK-580 (which is now OJEMDA&#153; (tovorafenib)) that provides a new approach for treating patients with primary brain tumors or brain metastases of solid tumors. The Company also received clinical inventory supplies to use in the Company's research and development activities of such RAF-inhibitor and an assigned investigator clinical trial agreement. Takeda also assigned to the Company its exclusive license agreement, or the Viracta License Agreement, with Viracta. Takeda also granted the Company a worldwide, sublicensable exclusive license under specified patents and know-how and non-exclusive license under other patents and know-how generated by Takeda under the Takeda Asset Agreement. The Company also granted Takeda a grant back license, as defined in the Takeda Asset Agreement, which is terminable either automatically or by the Company in the event Takeda does not achieve specified development milestones within the applicable timeframes set forth under the Takeda Asset Agreement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This grant back license to Takeda was terminated at the time of conversion of the Company from an LLC to a corporation in connection with the Millennium Stock Exchange Agreement.</span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The term of the Takeda Asset Agreement will expire on a country-by-country basis upon expiration of all assigned patent rights and all licensed patent rights in such country. Takeda can terminate the Takeda Asset Agreement in the event of the Company's bankruptcy. In the event of termination of the Takeda Asset Agreement by Takeda as a result of the Company's cessation of development or bankruptcy, all assigned patents, know-how and contracts (other than the Viracta License Agreement) will be assigned back to Takeda and Takeda will obtain a reversion license under patents and know-how generated to exploit all such terminated products.</span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In consideration for the sale and assignment of assets and the grant of the license under the Takeda Asset Agreement, the Company made an upfront payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in cash and issued </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,857,143</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Series A redeemable convertible preferred stock in the Company&#8217;s subsidiary in December 2019. The fair value of issued shares was estimated as $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, based on the price paid by other investors for issued shares in the Series A financing of the Company&#8217;s subsidiary. Based on the terms of the Millennium Stock Exchange Agreement, Takeda exchanged the </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,857,143</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Series A redeemable convertible preferred stock of the Company&#8217;s subsidiary for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,470,382</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of the Company's common stock upon the effectiveness of the conversion of the Company from an LLC to a corporation, on May 26, 2021.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">License agreement with Viracta</span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On December 16, 2019, a subsidiary of the Company amended and restated the Viracta License Agreement that was assigned pursuant to the Takeda Asset Agreement. Effective December 31, 2021, the subsidiary was merged with and into the Company, with the Company being the surviving corporation and assuming the subsidiary&#8217;s obligations under Viracta License Agreement. Under the Viracta License Agreement, the Company received a worldwide exclusive license under specified patent rights and know-how to develop, use, manufacture, and commercialize products containing compounds binding the RAF protein family.</span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The term of the Viracta License Agreement will expire on a licensed product-by-licensed product and country-by-country basis upon the expiration of the Company&#8217;s obligation to pay royalties to Viracta with respect to such product in such country. The Company has the right to terminate the Viracta License Agreement with respect to any or all of the licensed products at will upon a specified notice period.</span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company paid $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million upfront in cash to Viracta in December 2019, which was recorded as research and development expenses as the technology does not have an alternative future use.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On March 4, 2024, the Company entered into an amendment to the Viracta License Agreement. As part of the amendment, the Company made a one-time payment in March 2024 to Viracta of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, which was recorded as research and development expenses during the year ended December 31, 2024, in exchange for reduced future payment obligations ranging from the mid-teens to the high single-digit percentage related to the future sale or use of the rare pediatric disease priority review voucher, or PRV, received.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On April 23, 2024, the FDA approved OJEMDA (a tablet formulation and powder solution formulation of tovorafenib) for the treatment of patients 6 months of age and older with relapsed or refractory pLGG harboring a BRAF fusion or rearrangement, or BRAF V600 mutation. The indication was approved under accelerated approval based on response rate and duration of response. With the approval, the Company received a rare pediatric disease PRV from the FDA. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company made a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million milestone payment to Viracta in May 2024 for the achievement of this milestone. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million milestone was accounted for as a </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">finite-lived intangible asset and will be amortized over the life of the underlying asset. Related amortization expense will be recorded as cost of product revenue in the Company&#8217;s statements of operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On May 29, 2024, the Company sold its rare pediatric disease PRV for $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">108.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million to an undisclosed buyer. As part of the transaction, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of the total consideration received from the sale of the rare pediatric disease PRV was paid to Viracta to fully satisfy PRV-related obligations under the Viracta License Agreement and was capitalized as a finite-lived intangible asset, which will be amortized on a straight-line basis over its estimated useful life. The gross proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">108.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million were recorded as a gain from sale of priority review voucher in the accompanying statements of operations during the year ended December 31, 2024. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the unamortized finite-lived intangible asset was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. Related amortization expense will be recorded as cost of product revenue in the Company&#8217;s statements of operations.</span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On December 3, 2024, Viracta assigned the Viracta License Agreement to XOMA (US) LLC, or XOMA, pursuant to a Royalty Purchase Agreement dated March 22, 2021, between Viracta and XOMA, whereby Viracta sold its right, title, and interest in and to the Viracta License Agreement to XOMA. The Company has agreed to the assignment and novation of the Viracta License Agreement to XOMA as successor party, now referred to as the XOMA License Agreement. In connection with such assignment, the parties also agreed to assign all rights, title and interest in related intellectual property. No material terms of the XOMA License Agreement have been amended or modified in relation to the same.</span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On March 27, 2025, Ipsen Pharma SAS received validation of its completed submission of the Marketing Authorization Application to the European Medicines Agency, or EMA, for tovorafenib for the treatment of patients with relapsed or refractory pLGG. As a result, the Company paid $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million to XOMA for the achievement of this milestone in March 2025.</span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of March 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company could be required to make additional milestone payments of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">36.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million upon achievement of specified development and regulatory milestones for each licensed product in two indications, with milestones payable for the second indication upon achievement of a specified milestone event being lower than milestones payable for the first indication. Commencing with the first commercial sale of OJEMDA in a country, the Company is obligated to pay tiered royalties ranging in the mid-single-digit percentages on net sales of licensed products. The obligation to pay royalties will end on a country-by-country and licensed product-by-licensed product basis commencing on the first commercial sale in a country and continuing until the later of: (i) the expiration of the last valid claim of the XOMA licensed patents, jointly owned collaboration patents or specified patents owned by the Company covering the use or sale of such product in such country, (ii) the expiration of the last statutory exclusivity pertaining to such product in such country or (iii) the tenth anniversary of the first commercial sale of such product in such country.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">License agreement with Merck KGaA, Darmstadt, Germany</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On February 10, 2021, a subsidiary of the Company entered into a license agreement, or the MRKDG License Agreement, with Merck KGaA, Darmstadt, Germany, a pharmaceutical corporation located in Darmstadt, Germany. Effective December 31, 2021, the subsidiary was merged with and into the Company, with the Company being the surviving corporation and assuming the subsidiary&#8217;s obligations under the MRKDG License Agreement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the MRKDG License Agreement, Merck KGaA, Darmstadt, Germany granted to the Company an exclusive worldwide license, with the right to grant sublicenses through multiple tiers, under specified patent rights and know-how for the Company to research, develop, manufacture and commercialize products containing and comprising the pimasertib and MSC2015103B compounds. The Company also received clinical inventory supplies to use in its research and development activities. The Company's exclusive license grant is subject to a non-exclusive license granted by Merck KGaA, Darmstadt, Germany&#8217;s affiliate to a cancer research organization and Merck KGaA, Darmstadt, Germany retains the right to conduct, directly or indirectly, certain ongoing clinical studies relating to pimasertib. Under the MRKDG License Agreement, the Company has obligations to use commercially reasonable efforts to develop and commercialize at least two licensed products in at least two specified major market countries by the year 2029.</span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The term of the MRKDG License Agreement will expire on a licensed product-by-licensed product and country-by-country basis upon the expiration of the Company's obligation to pay royalties to the licensor with respect to such licensed product in such country and will expire in its entirety upon the expiration of all of the Company's payment obligations with respect to all licensed products and all countries under the MRKDG License Agreement.</span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In consideration for the rights granted under the MRKDG License Agreement and clinical supplies, the Company made an upfront payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in March 2021, which was recorded as research and development expenses, as the technology does not have an alternative future use and supplies are used for research activities. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company could be required to make additional payments of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">364.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million based upon the achievement of specified development, regulatory, and commercial milestones, as well a high, single-digit royalty percentage on future net sales of licensed products, if any. Milestones and royalties are contingent upon future events and will be recorded when the milestones are achieved and when payments are due.</span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2023, the Company discontinued its monotherapy substudy due to a limited duration of response in this rare patient population despite observing responses with a generally well tolerated therapy. In July 2024, the Company decided to close the program as the Company determined that the benefit/risk profile, as well as the market opportunity, did not justify the significant investment required to continue the trial despite observing some clinical responses.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research collaboration and license agreement with Sprint Bioscience AB</span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On August 15, 2023, the Company entered into a research collaboration and license agreement, or the Sprint License Agreement, with Sprint Bioscience AB, or Sprint, a Swedish corporation located in Huddinge, Sweden. Under the Sprint License Agreement, Sprint granted to the Company an exclusive, worldwide license, with the right to grant sublicenses through multiple tiers, to research, develop, and commercialize pharmaceutical products and to engage in research aimed at discovery, optimization and development of an inhibitor targeting Vaccinia Related Kinase 1, or VRK1.</span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The term of the Sprint License Agreement will expire on a licensed product and country basis upon the expiration of the royalty term with respect to such licensed product and such country, unless terminated earlier. The Company has the right to terminate the Sprint License Agreement in its entirety, or on a licensed product-by-licensed product basis, at will upon a specified notice period.</span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company paid $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million upfront in cash to Sprint in September 2023, which was recorded as research and development expenses as the technology does not have an alternative future use. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the Company could be</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">required </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to make milestone payments of up to </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">309.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million based upon achievement of specified development, regulatory, and commercial milestones for each licensed product, as well as tiered royalties ranging in the single-digit percentages on future net sales of licensed products, if any. Milestones and royalties are contingent upon future events and will be recorded when the milestones are achieved and when payments are due.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">License agreement with MabCare Therapeutics</span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On June 17, 2024, the Company entered into a license agreement, or the MabCare License Agreement, with MabCare Therapeutics, or MabCare, a pharmaceutical corporation located in Shanghai, China. Under the MabCare License Agreement, MabCare granted to the Company an exclusive worldwide license, excluding Greater China, with the right to grant sublicenses through multiple tiers, under specified patent rights and know-how for the Company to develop, manufacture and commercialize DAY301 (formerly MTX-13), a novel Antibody Drug Conjugate, or ADC, targeting protein-tyrosine kinase 7, or PTK7. The Company will also receive clinical inventory supplies to use in its research and development activities. Under the MabCare License Agreement, the Company has obligations to use commercially reasonable efforts to develop, obtain regulatory approval for, and commercialize at least one licensed product in one indication in each of the United States, Japan, and three European countries.</span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The term of the MabCare License Agreement will expire in its entirety upon the expiration of the last to expire royalty term with respect to all licensed products in the Company's territory, unless terminated earlier. Following the expiration of the royalty term for a licensed product in a country, the license granted to the Company shall become non-exclusive, fully paid-up, royalty-free, perpetual, and irrevocable for such licensed product in such country. Upon the expiration of the term, the license granted to the Company shall become non-exclusive, transferable, sublicensable, fully paid, royalty free, perpetual, and irrevocable in its entirety.</span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In consideration for the rights granted under the MabCare License Agreement, the Company made a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">55.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million upfront payment in July 2024. The upfront payment was recorded as research and development expenses, as the technology and supplies licensed do not have an alternative future use. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company could be required to make additional payments of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,132.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million based upon the achievement of specified development, regulatory, and commercial success-based milestones plus low-to-mid single-digit royalties on net sales outside of Greater China. Milestones and royalties are contingent upon future events and will be recorded when the milestones are achieved and when payments are due. In January 2025, the Company cleared the first cohort (a single-patient accelerated titration cohort) in the Phase 1a portion of the DAY301 Phase 1a/b clinical trial. The Company made a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million milestone payment to MabCare in January 2025 for the achievement of this milestone.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">License agreement with Ipsen Pharma SAS</span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On July 23, 2024, the Company entered into the Ipsen License Agreement, pursuant to which, the Company licensed to Ipsen, on an exclusive basis, the right to commercialize tovorafenib in all territories outside the United States and agreed to provide certain research and development and manufacturing services. Ipsen shall have the right to grant sublicenses to third-parties.</span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the terms of the Ipsen License Agreement, (i) Ipsen paid the Company an upfront license fee in the amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">70.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in August 2024 and (ii) the Investor, a fully-owned United States affiliate of Ipsen, purchased </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,341,495</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">shares of the Company&#8217;s common stock in a private placement for $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">40.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, at a price per share representing a </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% premium to the VWAP of the Company&#8217;s common stock as traded on The Nasdaq Stock Market LLC for the ten consecutive trading days prior to and including the date of the Revenue Release, and the ten consecutive trading days following the Revenue Release, in accordance with the terms set forth in an investment agreement by and between the Company and the Investor dated July 23, 2024.</span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of March 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company is also eligible to receive up to approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">350.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in additional commercial launch and sales-based milestone payments based on exchange rates as of the reporting date. The Company is also entitled to tiered, double-digit royalty payments starting at mid-teens percentage of annual net sales of tovorafenib, subject to customary adjustments specified in the Ipsen License Agreement. The royalty payment obligations under the Ipsen License Agreement expire on a country-by-country basis no earlier than ten years following the first commercial sale of tovorafenib in the applicable country.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, the Ipsen License Agreement provides that the Company will supply to Ipsen, and Ipsen will purchase from the Company, all required quantities of tovorafenib for all territories outside the United States in accordance with a supply agreement to be entered into by and between the Company and Ipsen, or the Ipsen Supply Agreement. The Company determined that the cost-plus rate to be charged for the supply of tovorafenib does not represent a material right. Ipsen has the right to request a manufacturing technology transfer of the then-current manufacturing process of tovorafenib under the Ipsen License Agreement, and such consent shall not be unreasonably withheld, such that upon completion of the manufacturing technology transfer, Ipsen or a third-party would be solely responsible for the manufacture of tovorafenib for all territories outside the United States.</span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Following the two-year anniversary of July 23, 2024, the effective date of the Ipsen License Agreement, Ipsen may terminate the Ipsen License Agreement for convenience with six months&#8217; prior written notice or for certain other specified reasons. The Company may terminate the Ipsen License Agreement if Ipsen or any of its affiliates challenge the validity of any patents controlled by the Company that are licensed under the Ipsen License Agreement. Both Ipsen and the Company may terminate the Ipsen License Agreement (i) for material breach by the other party and a failure to cure such breach within the time period specified in the Ipsen License Agreement or (ii) the other party&#8217;s bankruptcy event.</span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company evaluated the Ipsen License Agreement under Accounting Standards Codification, or ASC, 606 and concluded that Ipsen represents a customer in the transaction. The Company identified two distinct performance obligations for licenses to intellectual property in the form of the exclusive license to </span><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">commercialize tovorafenib outside the United States for both (i) relapsed or </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">refractory and (ii) front-line pLGG;</span><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and three distinct research and development performance obligations related to tovorafenib for completion of (i) the pivotal Phase 2 relapsed or refractory pLGG trial, or FIREFLY-1, (ii) the pivotal Phase 3 front-line pLGG trial, or FIREFLY-2, and (iii) the European Union, or EU, companion diagnostic for pLGG. Both the FIREFLY-1 and FIREFLY-2 trials related to pLGG pertain to later-stage intellectual property and only involve validating the efficacy of tovorafenib with respect to each distinct designation and are not expected to significantly modify or customize the licensed intellectual property. The FIREFLY-1 and FIREFLY-2 trials, and EU companion diagnostic research and development services related to pLGG could be performed by a third-party. The Company determined that the promise of the manufacturing technology transfer is a customer option that does not represent a material right given the value of the services is not material and fulfillment of this promise is ancillary to the main transaction. Accordingly, the manufacturing technology transfer is not a performance obligation at the outset of the arrangement.</span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Upon execution of the Ipsen License Agreement, the transaction price was determined to be $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">78.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, representing the aggregate of the upfront license fee of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">70.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and the premium paid by Ipsen on its equity investment in the Company of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(the excess of the value of the shares of the Company issued to Ipsen), representing additional consideration from Ipsen for the rights under the Ipsen License Agreement. Commercial launch milestones related to first commercial sale(s) in certain territories, sales-based milestones and royalties on net sales upon commercialization by Ipsen were excluded from the transaction price and will be recognized when the related sales occur as they were determined to predominantly relate to the intellectual property and, therefore, have been excluded from the transaction price in accordance with the sales-based royalty exception.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company allocated the transaction price to the performance obligations based on their relative standalone selling price. The Company developed the estimated stand-alone selling price for each license using discounted cash flow models. In developing this estimate, the Company applied judgment in the determination of the assumptions relating to forecasted future revenues, the discount rate, and the probability of success. The stand-alone selling price for each of the research and development services was estimated based on the Company&#8217;s forecasted costs to be incurred to fulfill the obligations plus a reasonable margin. The portion of the transaction price allocable to the</span><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> relapsed or </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">refractory and front-line pLGG</span><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">licenses to intellectual property was recognized as license revenue at the point in time in which Ipsen had the right to use the license/know-how, which occurred during the year ended December 31, 2024. The portion of the transaction price allocable to the </span><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">relapsed or </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">refractory, front-line and companion diagnostic research and development services performance obligations will be recognized over time as the services are delivered based on costs incurred relative to the total estimated cost to deliver the services. During the three months ended March 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of license revenue was recognized with $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of the undelivered services included in current and non-current deferred revenue, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/808/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><div class="item-list-element-wrapper" style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">7.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Commitments and Contingencies </span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Leases</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In April 2022, the Company entered into a lease agreement for approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> square feet of general use office space in Brisbane, California. The agreement was determined to be a lease since the right to control the use of the identified asset was conveyed to the Company for a period of time in exchange for consideration. The lease commenced in May 2022 and expired in November 2024. The Company was obligated to pay monthly rent expense and its pro rata share of the landlord's operating expenses which include utilities, common area maintenance expenses, and property taxes. Such expenses were a non-lease component and a variable consideration and included in the Company's operating expenses as incurred. The Company concluded that this lease was an operating lease.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In June 2024, the Company entered into a lease agreement for approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> square feet of general use office space in Brisbane, California. The agreement was determined to be a lease since the right to control the use of the identified asset was conveyed to the Company for a period of time in exchange for consideration. The term of the lease is approximately </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7.4</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years and commenced in August 2024. There is no option to extend the lease term nor is there an option to terminate the lease term prior to its expiration. The Company is obligated to pay monthly rent expense and its pro rata share of the landlord's operating expenses which include utilities, common area maintenance expenses, and property taxes. Such expenses are a non-lease component and a variable consideration and included in the Company's operating expenses as incurred. The Company concluded that this lease is an operating lease. The total payments for base rent over the term of the lease is approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. Upon execution of the agreement, the Company paid a security deposit of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">86,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> classified as deposits and other long-term assets on the condensed balance sheet.</span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company determined the lease incremental borrowing rate, or IBR, based on the information available at the applicable lease commencement date as the Company&#8217;s leases do not provide an implicit rate. The IBR is determined by using the rate of interest that the Company would pay to borrow on a collateralized basis an amount equal to the lease payments for a similar term and in a similar economic environment where the asset is located. As of March 31, 2025, the weighted-average remaining lease term and weighted-average discount rate were </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6.5</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively.</span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s leases do not require any contingent rental payments, impose financial restrictions, or contain any residual value guarantees.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Lease expense of right-of-use assets is recognized on a straight-line basis over the applicable lease term. Lease expense was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for the three months ended March 31, 2025 and 2024. There was no cash paid for amounts included in the measurement of operating lease liabilities for the three months ended March 31, 2025. Cash paid for amounts included in the measurement of operating lease liabilities was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for the three months ended March 31, 2024. Variable payments expensed during the three months ended March 31, 2025 and 2024 were immaterial.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 31, 2025, the future lease obligations were as follows (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:81.82%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:16.18%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ending December 31,</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2025 (Remaining)</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">404</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2026</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">527</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2027</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">543</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2028</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">492</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2029</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">711</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Thereafter</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,981</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total future minimum lease payments</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,658</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: imputed interest</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,742</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Present value of operating lease liabilities</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,916</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: current portion of operating lease liabilities</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">62</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Long-term portion of operating lease liabilities</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,854</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and Development Agreements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company enters into contracts in the normal course of business with clinical research organizations, contract manufacturing organizations, and other third-party vendors for clinical trial, manufacturing, testing, and other research and development activities. These contracts generally provide for termination on notice, with the exception of one vendor where certain costs are non-cancellable after the approval of the project. As of March 31, 2025 and December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, there were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> amounts accrued related to termination and cancellation charges as these are not probable.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">License Agreements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company entered into license agreements, as disclosed in Note 6, with various parties under which it is obligated to make contingent and non-contingent payments.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Purchase Commitments</span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To support product needs for OJEMDA, the Company entered into a manufacturing and supply agreement with Quotient Sciences - Philadelphia, LLC in July 2023 that requires the Company to meet minimum purchase obligations on an annual basis. The remaining amount of future minimum purchase obligations under the manufacturing and supply agreement over the next five years is approximately </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, in aggregate, as of March 31, 2025. For the three months ended March 31, 2025 and 2024, the Company made purchases of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively, under the purchase obligation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Legal Proceedings</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company, from time to time, may be party to litigation, claims and assessments arising in the ordinary course of business. The Company accrues liabilities for such matters when it is probable that future expenditures will be made and such</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">expenditures can be reasonably estimated. The Company is not subject to any material legal proceedings, and to the best of its knowledge, no material legal proceedings are currently pending or threatened.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Indemnification Agreements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and provide for indemnification for certain liabilities. The exposure under these agreements is unknown because it involves claims that may be made against it in the future but have not yet been made. To date, the Company has not paid any claims or been required to defend any action related to its indemnification obligations. However, the Company may record charges in the future as a result of these indemnification obligations. The Company also has indemnification obligations to its directors and executive officers for specified events or occurrences, subject to some limits, while they are serving at its request in such capacities. There have been no claims to date, and the Company believes the fair value of these indemnification agreements is minimal. Accordingly, the Company had </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t recorded any liabilities for these agreements as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 31, 2025 and December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Common Stock</a></td>
<td class="text"><div class="item-list-element-wrapper" style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">8.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Common Stock </span></div></div><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to its certificate of incorporation, the Company is authorized to issue </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">500.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million shares of common stock at a par value of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.0001</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 31, 2025, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101,353,781</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock were issued and outstanding.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has reserved shares of common stock for future issuances as follows:</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:69.66%;box-sizing:content-box;"></td>
         <td style="width:2.62%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:25.72%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">March 31,<br/>2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common stock options issued and outstanding</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,055,674</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common stock available for future grants</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,393,445</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common stock available for ESPP</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,448,112</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restricted stock units issued and outstanding</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,856,820</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Pre-funded warrants</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,517,241</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27,271,292</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">2024 Private Placement</span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In July 2024, the Company entered into a securities purchase agreement with certain institutional and accredited investors, or the PIPE Investors, pursuant to which the Company agreed to sell and issue to the PIPE Investors in a private placement, or the Private Placement, an </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">aggregate of (i) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,551,718</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of the Company&#8217;s common stock, par value $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.0001</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, at a purchase price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14.50</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share and (ii) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,517,241</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> pre-funded warrants, or the Pre-Funded Warrants, to purchase up to an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,517,241</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of the Company's common stock</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, or the Warrant Shares,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> at a purchase price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14.4999</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per Pre-Funded Warrant. Each Pre-Funded Warrant has an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.0001</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per Warrant Share.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Pre-Funded Warrants are exercisable at any time after their original issuance at the option of each holder, in such holder&#8217;s discretion, by (i) payment in full in immediately available funds for the number of shares of common stock purchased upon such exercise or (ii) a cashless exercise, in which case the holder would receive upon such exercise the net number of shares of common stock determined according to the formula set forth in the Pre-Funded Warrant. A holder will not be entitled to exercise any portion of any Pre-Funded Warrant if the holder&#8217;s ownership of the Company&#8217;s common stock would exceed </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.99</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% following such exercise.</span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the event of certain fundamental transactions, the holders of the Pre-Funded Warrants will be entitled to receive upon exercise of the Pre-Funded Warrants the kind of amounts of securities, cash or other property that the holders would have received had they exercised the Pre-Funded Warrants immediately prior to such fundamental transaction without regard to any limitations on exercise contained in the Pre-Funded Warrants.</span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Pre-Funded Warrants were classified as a component of permanent stockholders&#8217; equity within additional paid-in capital and were recorded at the issuance date using a relative fair value allocation method. The Pre-Funded Warrants are equity classified because they (i) are freestanding financial instruments that are legally detachable and separately exercisable from the equity instruments, (ii) are immediately exercisable, (iii) do not embody an obligation for the Company to repurchase its shares, (iv) permit the holders to receive a fixed number of shares of common stock upon exercise, (v) are indexed to the Company&#8217;s common stock and (vi) meet the equity classification criteria. In addition, such Pre-Funded Warrants do not provide any guarantee of value or return. The Company valued the Pre-Funded Warrants at issuance, concluding that their sales price approximated their fair value, and allocated net proceeds from the Private Placement proportionately to the Company's common stock and Pre-Funded Warrants.</span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Private Placement closed on August 1, 2024 and the Company received net proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">166.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, after deducting placement agent fees, offering costs, and other expenses, of which $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">145.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million was allocated to the common stock and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million was allocated to the Pre-Funded Warrants. The net proceeds were recorded as a component of additional paid-in capital.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Investment agreement with Ipsen Biopharmaceuticals, Inc.</span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In July 2024, the Company entered into the Ipsen License Agreement, pursuant to which, the Company licensed to Ipsen, on an exclusive basis, the right to commercialize tovorafenib in all territories outside the United States and agreed to provide certain research and development and manufacturing services. Under the terms of the Ipsen License Agreement, (i)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Ipsen paid the Company an upfront license fee in the amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">70.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in August 2024 and (ii) the Investor, a fully-owned United States affiliate of Ipsen, purchased </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,341,495</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of the Company&#8217;s common stock in a private placement for $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">40.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, at a price per share representing a </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% premium to the VWAP of the Company&#8217;s common stock as traded on The Nasdaq Stock Market LLC for the ten consecutive trading days prior to and including the date of the Revenue Release, and the ten consecutive trading days following the Revenue Release, in accordance with the terms set forth in an investment agreement by and between the Company and the Investor dated July 23, 2024. The Company valued the shares at issuance at $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, concluding that the Company's common stock price as traded on The Nasdaq Stock Market LLC on the closing date of the transaction approximated fair value, which was recorded as a component of additional paid-in capital.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">At-The-Market Offering</span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has entered into an equity distribution agreement, or the Equity Distribution Agreement, with Piper Sandler &amp; Co. and JonesTrading Institutional Services LLC, as sales agents, relating to the issuance and sale of shares of the Company&#8217;s common stock for an aggregate offering price of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">250.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million under an at-the-market offering program, or the ATM. The Company has no obligation to sell any shares and could at any time suspend solicitations and offers under the ATM. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of the Company&#8217;s common stock have been sold under the ATM as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Compensation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-based Compensation</a></td>
<td class="text"><div class="item-list-element-wrapper" style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">9.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Share-based Compensation</span></div></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Share-based compensation expense recorded in the accompanying condensed statements of operations is as follows (in thousands):</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:65.92%;box-sizing:content-box;"></td>
         <td style="width:1.6%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.64%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.6%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.64%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.6%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended<br/>March 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development expense</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,251</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,653</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Selling, general and administrative expense</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,610</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,991</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total share-based compensation expense</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,861</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,644</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">2022 Equity Inducement Plan</span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In October 2022, the Company's board of directors approved the 2022 Equity Inducement Plan, or the 2022 Plan. The 2022 Plan provides for the grant of non-statutory stock options and restricted stock units. The number of shares of common stock reserved for issuance under the 2022 Plan is </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,000,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">2021 Equity Incentive Plan</span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In May 2021, in connection with the IPO, the board of directors and stockholders approved the 2021 Equity Incentive Plan, or the 2021 Plan, which became effective on the day before the date of the effectiveness of the IPO. The 2021 Plan provides for the grant of incentive stock options, non-statutory stock options, stock appreciation rights, awards of restricted stock, restricted stock units and other share-based awards. The number of shares of common stock reserved for issuance under the 2021 Plan is equal to the sum of: (x) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,369,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock; plus (y) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,719,605</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock issued in respect of the conversion of incentive shares that were subject to vesting immediately prior to the effectiveness of the registration statement for the IPO that expire, terminate or are otherwise surrendered, canceled, forfeited or repurchased by us at their original issuance price pursuant to a contractual repurchase right. The number of shares available for grant and issuance under the 2021 Plan will be automatically increased on the first day of each fiscal year, beginning with the fiscal year commencing on January 1, 2021 and continuing for each fiscal year until, and including, the fiscal year commencing on January 1, 2031, by the lesser of (a) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the number of shares of all classes of the Company&#8217;s common stock, plus the total number of shares of Company common stock issuable upon conversion of any preferred stock or exercise of any warrants to acquire shares of Company common stock for a nominal exercise price issued and outstanding on each December 31 immediately prior to the date of increase or (b) such number of shares determined by the board of directors.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stock Options</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table provides a summary of stock option activity during the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three months ended March 31, 2025.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:39.088%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.322%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.34%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:11.722000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.322%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.34%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:11.862%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Options</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-Average<br/>Exercise Price<br/>Per Share</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-Average<br/>Remaining <br/>Contractual Term</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Aggregate <br/>Intrinsic Value<br/>(in thousands)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding at December 31, 2024</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,127,435</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16.50</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,132,000</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11.86</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercised</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forfeiture</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">203,761</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15.87</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding at March 31, 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,055,674</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15.81</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.6</span></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27.0</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Vested and expected to vest at March 31, 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,055,674</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15.81</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.6</span></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27.0</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercisable at March 31, 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,362,276</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16.58</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.8</span></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18.6</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Aggregate intrinsic value represents the difference between the estimated fair value of the underlying common stock and the exercise price of outstanding, in-the-money options. There were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> options exercised during the three months ended March 31, 2025. The total intrinsic value of options exercised during the three months ended March 31, 2024 was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The total fair value of options that vested during the three months ended March 31, 2025 and 2024 was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively. The weighted-average grant date fair value of options granted during the three months ended March 31, 2025 and 2024 was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.73</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.31</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, respectively.</span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Unrecognized share-based compensation for stock options as of March 31, 2025 was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">52.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, which is expected to be recognized over a weighted-average period of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.5</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years.</span></p><div style="font-size:11pt;font-family:'Calibri',sans-serif;"><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company used the Black-Scholes option pricing model to estimate the fair value of stock option awards granted with the following assumptions:</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:41.608%;box-sizing:content-box;"></td>
         <td style="width:3.001%;box-sizing:content-box;"></td>
         <td style="width:26.565%;box-sizing:content-box;"></td>
         <td style="width:2.26%;box-sizing:content-box;"></td>
         <td style="width:26.565%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended<br/>March 31,</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected term (in years)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.69 </span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">- </span><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.70</span></span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.77</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;- </span><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.74</span></span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected volatility</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">68.30</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">69.13</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">68.27</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">70.57</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Risk-free interest rate</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.99</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.48</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.90</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.31</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected dividend yield</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        </tr>
       </table></div><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Restricted Stock Units</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table provides a summary of restricted stock units activity under the 2021 Plan during the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three months ended March 31, 2025:</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:66.98%;box-sizing:content-box;"></td>
         <td style="width:1.16%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.36%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.62%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.88%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of<br/>Shares</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted Average<br/>Grant Date Fair Value<br/>Per Share</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unvested restricted stock units at December 31, 2024</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,774,287</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15.58</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,393,000</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11.86</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Vested</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">247,041</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14.73</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forfeiture</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">63,426</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14.14</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unvested restricted stock units at March 31, 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,856,820</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13.88</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Unamortized share-based compensation for restricted stock units as of March 31, 2025 was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">37.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, which is expected to be recognized over a weighted-average period of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.9</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Restricted Stock Awards</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table provides a summary of the unvested common stock awards activity during the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three months ended March 31, 2025.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:66.98%;box-sizing:content-box;"></td>
         <td style="width:1.16%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.36%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.62%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.88%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of<br/>Shares</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted Average<br/>Grant Date Fair Value<br/>Per Share</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unvested common stock as of December 31, 2024</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">82,281</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16.00</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Vested</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">66,752</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16.00</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forfeiture</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">735</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16.00</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unvested common stock as of March 31, 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,794</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16.00</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Unamortized share-based compensation for restricted stock awards as of March 31, 2025 was approximately </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, which is expected to be recognized over a weighted-average period of less than one year.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">2021 Employee Stock Purchase Plan</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In May 2021, the board of directors adopted and the stockholders approved the 2021 Employee Stock Purchase Plan, or the ESPP, which became effective on May 26, 2021. A total of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">603,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock were initially reserved for issuance under the ESPP. The number of shares of the common stock reserved for issuance under the ESPP will automatically increase on the first day of each fiscal year, beginning with the fiscal year commencing on January 1, 2021 and continuing for each fiscal year until, and including, the fiscal year commencing on January 1, 2031, by the lesser of: (a) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the total number of outstanding shares of common stock of the Company (on an as converted basis outstanding on the immediately preceding December 31 (rounded down to the nearest whole share)) and (b) an amount determined by the board of directors. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">407,629</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares have been issued under the ESPP as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 31, 2025. The Company recognized compensation expense related to the ESPP of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for each of the three months ended March 31, 2025 and 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><div class="item-list-element-wrapper" style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">10.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Income Taxes</span></div></div><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t record an income tax provision for the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three months ended March 31, 2025 and 2024 as it generated tax losses during each of the periods.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A valuation allowance is established when it is more likely than not that some portion or all of a deferred tax asset will not be realized. The realization of deferred tax assets depends on the generation of future taxable income during the period in which related temporary differences become deductible. The Company continues to establish a valuation allowance against the full amount of its net deferred tax assets since it is more likely than not that benefits will not be realized, including those benefits created in the current year. This assessment is based on the Company's historical cumulative losses, which provide strong objective evidence that cannot be overcome with projections of income, as well as the fact the Company expects continuing losses in the future.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income (Loss) Per Share<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Income (Loss) Per Share</a></td>
<td class="text"><div class="item-list-element-wrapper" style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">11.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Net Loss Per Share </span></div></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basic and diluted net loss per share attributable to common stockholders is calculated as follows (in thousands except share and per share amounts):</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:55.28%;box-sizing:content-box;"></td>
         <td style="width:1.92%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:18.439999999999998%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.92%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:18.439999999999998%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended<br/>March 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="border-top:0.5pt solid #000000;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="border-top:0.5pt solid #000000;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss - basic and diluted</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">35,996</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">62,412</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss per share, basic and diluted</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.35</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.72</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average number of common shares used in computing net loss per share, basic and diluted</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">102,710,382</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">86,679,282</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following outstanding potentially dilutive securities have been excluded from the calculation of diluted net loss per share, as their effect is anti-dilutive:</span></span></p><div style="font-size:10pt;font-family:Times New Roman;">
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:66.967%;box-sizing:content-box;"></td>
         <td style="width:1.16%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.357%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.16%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.357%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of March 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="border-top:0.5pt solid #000000;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="border-top:0.5pt solid #000000;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock options</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,055,674</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,404,090</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unvested common shares</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,794</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">543,239</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restricted stock units</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,856,820</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,243,998</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Shares committed under ESPP</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">108,717</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100,753</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,036,005</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,292,080</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Defined Contribution Plan<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanTextBlock', window );">Defined Contribution Plan</a></td>
<td class="text"><div class="item-list-element-wrapper" style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">12.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Defined Contribution Plan</span></div></div><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company maintains an employee savings plan pursuant to Section 401(k) of the Internal Revenue Code. All employees are eligible to participate provided that they meet the requirements of the plan. For each of the three months ended March 31, 2025 and 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company made matching contributions of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 70<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480794/715-70-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 70<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/715-70/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Reporting</a></td>
<td class="text"><div class="item-list-element-wrapper" style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">13.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Segment Reporting</span></div></div><p style="text-indent:4.173%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company views its operations and manages its business in </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">one</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> operating and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">one</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> reportable segment, which includes all activities related to the identification, development and commercialization of medicines for childhood and adult diseases with equal intensity. The determination of a single operating segment is consistent with the consolidated financial information regularly provided to the Company&#8217;s chief operating decision maker, or CODM. The Company&#8217;s CODM is its Chief Executive Officer, who reviews and evaluates net loss for purposes of assessing performance, making operating decisions, allocating resources, and planning and forecasting for future periods. Our CODM does not evaluate the operating segment using asset or liability information. The operating segment derives all net product revenues from the sales of OJEMDA in the United States through contractual arrangements with its specialty pharmacy and specialty distributor customers. All the Company&#8217;s assets are located in the United States.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to the significant expense categories included within net loss presented on the Company's condensed statements of operations, see below for disaggregated amounts that comprise research and development expenses:</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:66.993%;box-sizing:content-box;"></td>
         <td style="width:1.62%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.62%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended<br/>March 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">External costs:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Third-party CRO, CMO and other third-party clinical trial costs (1)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,821</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,546</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">License agreement related payments</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,000</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,000</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other research and development costs</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,021</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,167</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Internal costs:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Employee related expenses</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,777</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,497</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total research and development expenses</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">39,619</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">40,210</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1) </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Costs incurred under agreements with third-party CROs, CMOs, and other third parties that conduct clinical activities on the Company's behalf.</span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant  Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Basis of Presentation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States, or U.S. GAAP, for interim financial information and Article 10 of Regulation S-X of the Securities and Exchange Commission, or SEC, and should be read in conjunction with the Company's financial statements and notes thereto contained in the Company's Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on February 25, 2025. The condensed financial statements presented in this Quarterly Report on Form 10-Q are unaudited; however, in the opinion of management, such financial statements reflect all adjustments, consisting solely of normal recurring adjustments, necessary for a fair presentation of the results for the interim periods presented.</span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in Accounting Standards Codification, or ASC, and Accounting Standards Updates, or ASU, of the Financial Accounting Standards Board, or FASB.</span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Certain prior period amounts in the Notes to the Condensed Financial Statements have been reclassified to conform to the current period's presentation. These reclassifications did not affect the prior period's total assets, liabilities, stockholders' equity, net loss or cash flows. Specifically, the reclassifications separately present accrued rebates and accrued federal and state taxes within Note 4.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Use of Estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The preparation of condensed financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and disclosure of contingent assets and liabilities at the date of the condensed financial statements, and the reported amounts of expenses during the reporting period. Estimates and assumptions made in the accompanying condensed financial statements include, but are not limited to, accruals for research and development expenses, variable consideration and other relevant inputs impacting the gross and net revenue recognition, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the valuation of share-based awards, and the valuation of deferred tax assets. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable. Actual results may differ from those estimates or assumptions.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segments</a></td>
<td class="text"><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Segments</span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Operating segments are defined as components of an entity about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business in one operating segment.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of credit risk and other risks and uncertainties</a></td>
<td class="text"><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Concentration of Credit Risk and Other Risks and Uncertainties</span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Financial instruments that subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents, short-term investments, and accounts receivable. Amounts on deposit may at times exceed federally insured limits. The Company is exposed to credit risk in the event of default by the financial institutions holding its cash, cash equivalents and short-term investments that are recorded on its balance sheet. Per policy, the Company mitigates its risk by investing in high-grade instruments and limiting the concentration in any one non-United States government or government backed issuer, which limits its exposure. The Company has not experienced any losses on its cash, cash equivalents and short-term investments.
</span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the three months ended March 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, two individual customers accounted for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">98.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of total net product revenue, with these individual customers representing </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">64.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">34.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the Company's total net product revenue. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, two customers accounted for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">96.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the accounts receivable balance, with these individual customers representing </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">72.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the accounts receivable balance. No other individual customers account for more than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of net product revenue or accounts receivable. The Company monitors the financial condition of its customers so that it can appropriately respond to changes in their creditworthiness. To date, the Company has not experienced any losses with respect to the collection of its accounts receivable.</span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is subject to certain risks and uncertainties and believes that changes in any of the following areas could have a material adverse effect on the Company's future financial position or results of its operations: ability to obtain future financing; regulatory requirements for approval and market acceptance of, and reimbursement for, product candidates; performance of third-party clinical research organizations and manufacturers upon which the Company relies; development of sales channels; protection of the Company&#8217;s intellectual property; litigation or claims against the Company based on intellectual property, patent, product, regulatory or other factors; changes to the market landscape; and the Company&#8217;s ability to attract and retain employees necessary to support its growth.
</span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is dependent on third-party manufacturers to supply products for commercial and research and development activities in its programs. In particular, the Company relies and expects to continue to rely on a small number of manufacturers to supply it with its requirements for the active pharmaceutical ingredients and formulated drugs related to these programs. These programs could be adversely affected by a significant interruption in the supply of active pharmaceutical ingredients and formulated drugs.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Issued Accounting Pronouncements</a></td>
<td class="text"><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Recently Issued Accounting Pronouncements</span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740) &#8211; Improvements to Income Tax Disclosures, which enhances the transparency and decision usefulness of income tax disclosures by requiring disclosure of disaggregated income taxes paid, prescribes standard categories for the components of the effective tax rate reconciliation, and modifies other income tax-related disclosures. The ASU is effective for fiscal years beginning after December 15, 2024 and allows for adoption on a prospective basis, with a retrospective option. The Company is currently evaluating the effect of this update on its financial statement disclosures.</span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2024, the FASB issued ASU No. 2024-03, Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures, which requires disclosure, in the notes to financial statements, of specified information about certain costs and expenses at each interim and annual reporting period. The ASU is effective for fiscal years beginning after December 15, 2026 and allows for adoption on a prospective basis, with a retrospective option. Early adoption is permitted. The Company is currently evaluating the effect of this update on its financial statement disclosures.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478898/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 36<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-36<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Recurring Fair Value Measurement (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of fair value, assets and liabilities measured on recurring basis</a></td>
<td class="text"><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table sets forth the Company&#8217;s financial instruments as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 31, 2025 and December 31, 2024, which are measured at fair value on a recurring basis by level within the fair value hierarchy (in thousands):</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:36.214%;box-sizing:content-box;"></td>
         <td style="width:1.2%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.745000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.2%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.745000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.2%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.745000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.2%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.745000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">March 31, 2025</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 1</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 3</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Financial assets:</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,146</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,146</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. treasury securities</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">345,377</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">345,377</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. government agency securities</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">94,285</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">94,285</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total assets measured at fair value</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,146</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">439,662</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">451,808</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:36.295%;box-sizing:content-box;"></td>
         <td style="width:1.2%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.725%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.2%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.725%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.2%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.725%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.2%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.725%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 1</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 3</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Financial assets:</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,728</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,728</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. treasury securities</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">311,487</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">311,487</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. government agency securities</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">183,375</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">183,375</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total assets measured at fair value</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,728</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">494,862</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">511,590</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Schedule of cash equivalents, marketable securities, and unrealized gains and losses</a></td>
<td class="text"><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following tables summarize the estimated fair value of the Company's cash equivalents, available-for-sale securities classified as short-term investments, and associated unrealized gains and losses (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:41.6%;box-sizing:content-box;"></td>
         <td style="width:1.1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:11.5%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:11.5%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:11.5%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:11.5%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">March 31, 2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortized Cost</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized Gains</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized Losses</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Estimated Fair Value</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash equivalents:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,146</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,146</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total cash equivalents</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,146</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,146</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Short-term investments</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. government agency securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">94,297</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">94,285</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. treasury securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">345,418</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">48</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">345,377</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total short-term investments</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">439,715</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">60</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">439,662</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:41.6%;box-sizing:content-box;"></td>
         <td style="width:1.1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:11.5%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:11.5%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:11.5%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:11.5%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortized Cost</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized Gains</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized Losses</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Estimated Fair Value</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash equivalents:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,728</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,728</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. government agency securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">75,163</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">75,163</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. treasury securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,947</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,947</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total cash equivalents</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">104,838</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">104,838</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;text-indent:5pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Short-term investments</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. government agency securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">108,210</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">108,212</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. treasury securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">298,457</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">85</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">298,540</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total short-term investments</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">406,667</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">98</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">406,752</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dawn_ScheduleOfMaturitiesForAvailableForSaleSecuritiesTableTextBlock', window );">Schedule Of Maturities For Available For Sale Securities</a></td>
<td class="text"><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the maturities of our cash equivalents and available-for-sale securities (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:53.261%;box-sizing:content-box;"></td>
         <td style="width:1.761%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:19.607999999999997%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.761%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:19.607999999999997%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">March 31, 2025</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortized Cost</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Mature in one year or less</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">451,861</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">451,808</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">451,861</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">451,808</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:53.261%;box-sizing:content-box;"></td>
         <td style="width:1.761%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:19.607999999999997%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.761%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:19.607999999999997%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortized Cost</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Mature in one year or less</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">511,505</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">511,590</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">511,505</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">511,590</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dawn_ScheduleOfMaturitiesForAvailableForSaleSecuritiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Maturities For Available For Sale Securities Table Text Block</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dawn_ScheduleOfMaturitiesForAvailableForSaleSecuritiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dawn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of liabilities measured at fair value measured on a recurring or nonrecurring basis. Includes, but is not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Items (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dawn_ScheduleOfPrepaidAndOtherCurrentAssetstableTextBlockTableTextBlock', window );">Schedule of Prepaid Expenses and Other Current Assets</a></td>
<td class="text"><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prepaid expenses and other current assets consisted of the following (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:76.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:66.967%;box-sizing:content-box;"></td>
         <td style="width:1.62%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.897%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.62%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.897%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">March 31,<br/>2025</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,<br/>2024</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid research and development expenses</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,733</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,216</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid insurance</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">305</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">830</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other prepaid expenses and other assets</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,974</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,367</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total prepaid expenses and other current assets</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,012</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,413</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued expenses and other current liabilities</a></td>
<td class="text"><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accrued expenses and other current liabilities consisted of the following (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:76.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:68.84%;box-sizing:content-box;"></td>
         <td style="width:1.26%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.32%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.26%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.32%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">March 31,<br/>2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,<br/>2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued research and development expenses</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,457</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,760</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued rebates</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,008</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,518</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued federal and state taxes</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,966</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,966</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued professional service expenses</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,943</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,758</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued payroll related expenses</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,202</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,943</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued milestone payment</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,000</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,000</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,065</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,680</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total accrued expenses and other current liabilities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">43,641</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">68,625</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dawn_ScheduleOfPrepaidAndOtherCurrentAssetstableTextBlockTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Prepaid And Other Current Assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dawn_ScheduleOfPrepaidAndOtherCurrentAssetstableTextBlockTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dawn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule Of Intangible Assets</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Intangible assets, net consisted of the following:</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:68.84%;box-sizing:content-box;"></td>
         <td style="width:1.26%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.32%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.26%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.32%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">March 31,<br/>2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,<br/>2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Intangible assets with finite lives:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">License agreement milestone payments</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,500</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,000</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">PRV-related obligation payment</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,100</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,100</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Intangible assets, gross</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22,600</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,100</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less accumulated amortization</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,195</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,470</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Intangible assets, net</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,405</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,630</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule Of Amortization Expense For Amortizable Finite-Lived Intangible Assets</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The estimated aggregate amortization expense for amortizable, finite-lived intangible assets as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 31, 2025 is as follows:</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:70.56%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:27.439999999999998%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ending December 31,</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Estimated<br/>Amortization<br/>Expense</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2025 (Remaining)</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,385</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2026</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,180</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2027</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,180</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2028</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,180</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2029</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,180</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Thereafter</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,300</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total future expected amortization expense</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,405</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Summary of Future Lease Obligations</a></td>
<td class="text"><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 31, 2025, the future lease obligations were as follows (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:81.82%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:16.18%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ending December 31,</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2025 (Remaining)</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">404</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2026</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">527</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2027</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">543</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2028</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">492</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2029</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">711</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Thereafter</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,981</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total future minimum lease payments</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,658</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: imputed interest</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,742</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Present value of operating lease liabilities</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,916</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: current portion of operating lease liabilities</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">62</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Long-term portion of operating lease liabilities</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,854</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dawn_ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock', window );">Schedule of Common Stock Shares Reserved for Future Issuance</a></td>
<td class="text"><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has reserved shares of common stock for future issuances as follows:</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:69.66%;box-sizing:content-box;"></td>
         <td style="width:2.62%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:25.72%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">March 31,<br/>2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common stock options issued and outstanding</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,055,674</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common stock available for future grants</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,393,445</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common stock available for ESPP</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,448,112</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restricted stock units issued and outstanding</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,856,820</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Pre-funded warrants</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,517,241</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27,271,292</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dawn_ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Common Stock Shares Reserved For Future Issuance Table Text Block</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dawn_ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dawn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Summary of Share/Stock-based Compensation Expense Recorded in The Accompanying Condensed Consolidated Statements of Operations and Comprehensive Loss</a></td>
<td class="text"><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Share-based compensation expense recorded in the accompanying condensed statements of operations is as follows (in thousands):</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:65.92%;box-sizing:content-box;"></td>
         <td style="width:1.6%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.64%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.6%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.64%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.6%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended<br/>March 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development expense</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,251</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,653</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Selling, general and administrative expense</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,610</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,991</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total share-based compensation expense</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,861</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,644</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock', window );">Summary of The Unvested Common Stock</a></td>
<td class="text"><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table provides a summary of the unvested common stock awards activity during the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three months ended March 31, 2025.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:66.98%;box-sizing:content-box;"></td>
         <td style="width:1.16%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.36%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.62%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.88%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of<br/>Shares</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted Average<br/>Grant Date Fair Value<br/>Per Share</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unvested common stock as of December 31, 2024</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">82,281</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16.00</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Vested</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">66,752</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16.00</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forfeiture</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">735</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16.00</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unvested common stock as of March 31, 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,794</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16.00</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dawn_ScheduleOfStockOptionsAssumptionsTableTextBlock', window );">Summary of The Black-Scholes Option Pricing Model to Estimate The Fair Value of Stock Option Granted</a></td>
<td class="text"><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company used the Black-Scholes option pricing model to estimate the fair value of stock option awards granted with the following assumptions:</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:41.608%;box-sizing:content-box;"></td>
         <td style="width:3.001%;box-sizing:content-box;"></td>
         <td style="width:26.565%;box-sizing:content-box;"></td>
         <td style="width:2.26%;box-sizing:content-box;"></td>
         <td style="width:26.565%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended<br/>March 31,</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected term (in years)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.69 </span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">- </span><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.70</span></span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.77</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;- </span><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.74</span></span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected volatility</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">68.30</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">69.13</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">68.27</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">70.57</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Risk-free interest rate</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.99</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.48</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.90</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.31</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected dividend yield</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=dawn_TwoThousandAndTwentyOneEquityIncentivePlanMember', window );">2021 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock', window );">Summary of Stock Option Activity</a></td>
<td class="text"><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table provides a summary of stock option activity during the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three months ended March 31, 2025.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:39.088%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.322%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.34%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:11.722000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.322%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.34%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:11.862%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Options</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-Average<br/>Exercise Price<br/>Per Share</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-Average<br/>Remaining <br/>Contractual Term</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Aggregate <br/>Intrinsic Value<br/>(in thousands)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding at December 31, 2024</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,127,435</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16.50</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,132,000</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11.86</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercised</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forfeiture</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">203,761</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15.87</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding at March 31, 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,055,674</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15.81</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.6</span></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27.0</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Vested and expected to vest at March 31, 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,055,674</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15.81</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.6</span></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27.0</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercisable at March 31, 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,362,276</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16.58</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.8</span></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18.6</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock', window );">Summary of Restricted Stock Units Activity</a></td>
<td class="text"><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table provides a summary of restricted stock units activity under the 2021 Plan during the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three months ended March 31, 2025:</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:66.98%;box-sizing:content-box;"></td>
         <td style="width:1.16%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.36%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.62%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.88%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of<br/>Shares</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted Average<br/>Grant Date Fair Value<br/>Per Share</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unvested restricted stock units at December 31, 2024</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,774,287</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15.58</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,393,000</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11.86</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Vested</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">247,041</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14.73</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forfeiture</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">63,426</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14.14</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unvested restricted stock units at March 31, 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,856,820</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13.88</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dawn_ScheduleOfStockOptionsAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Stock Options Assumptions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dawn_ScheduleOfStockOptionsAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dawn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in restricted stock units (RSUs).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=dawn_TwoThousandAndTwentyOneEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=dawn_TwoThousandAndTwentyOneEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income (Loss) Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Summary of Basic and Diluted Net Loss Per Share Attributable to Common Shareholders/Stockholders</a></td>
<td class="text"><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basic and diluted net loss per share attributable to common stockholders is calculated as follows (in thousands except share and per share amounts):</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:55.28%;box-sizing:content-box;"></td>
         <td style="width:1.92%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:18.439999999999998%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.92%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:18.439999999999998%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended<br/>March 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="border-top:0.5pt solid #000000;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="border-top:0.5pt solid #000000;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss - basic and diluted</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">35,996</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">62,412</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss per share, basic and diluted</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.35</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.72</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average number of common shares used in computing net loss per share, basic and diluted</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">102,710,382</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">86,679,282</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Summary of Outstanding Potentially Dilutive Securities Have Been Excluded From Calculation of Diluted Net Loss Per Share</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following outstanding potentially dilutive securities have been excluded from the calculation of diluted net loss per share, as their effect is anti-dilutive:</span>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:66.967%;box-sizing:content-box;"></td>
         <td style="width:1.16%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.357%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.16%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.357%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of March 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="border-top:0.5pt solid #000000;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="border-top:0.5pt solid #000000;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock options</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,055,674</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,404,090</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unvested common shares</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,794</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">543,239</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restricted stock units</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,856,820</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,243,998</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Shares committed under ESPP</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">108,717</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100,753</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,036,005</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,292,080</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of Segment Information</a></td>
<td class="text"><p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to the significant expense categories included within net loss presented on the Company's condensed statements of operations, see below for disaggregated amounts that comprise research and development expenses:</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:66.993%;box-sizing:content-box;"></td>
         <td style="width:1.62%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.62%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended<br/>March 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">External costs:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Third-party CRO, CMO and other third-party clinical trial costs (1)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,821</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,546</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">License agreement related payments</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,000</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,000</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other research and development costs</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,021</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,167</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Internal costs:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Employee related expenses</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,777</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,497</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total research and development expenses</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">39,619</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">40,210</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1) </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Costs incurred under agreements with third-party CROs, CMOs, and other third parties that conduct clinical activities on the Company's behalf.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant  Accounting Policies - Additional Information (Detail) - Concentration of Credit Risk and Other Risks and Uncertainties [Member]<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=dawn_OneCustomerMember', window );">One Customer [Member] | Revenue Benchmark [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dawn_AccountingPoliciesLineItems', window );"><strong>Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage of net product revenue and accounts receivable</a></td>
<td class="nump">64.40%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=dawn_OneCustomerMember', window );">One Customer [Member] | Accounts Receivable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dawn_AccountingPoliciesLineItems', window );"><strong>Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage of net product revenue and accounts receivable</a></td>
<td class="nump">72.40%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=dawn_TwoCustomerMember', window );">Two Customer [Member] | Revenue Benchmark [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dawn_AccountingPoliciesLineItems', window );"><strong>Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage of net product revenue and accounts receivable</a></td>
<td class="nump">34.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=dawn_TwoCustomerMember', window );">Two Customer [Member] | Accounts Receivable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dawn_AccountingPoliciesLineItems', window );"><strong>Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage of net product revenue and accounts receivable</a></td>
<td class="nump">23.80%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=dawn_OtherIndividualCustomerMember', window );">Other Individual Customer [Member] | Net Product Revenue and Accounts Receivable [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dawn_AccountingPoliciesLineItems', window );"><strong>Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage of net product revenue and accounts receivable</a></td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=dawn_IndividualCustomerMember', window );">Individual Customer [Member] | Revenue Benchmark [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dawn_AccountingPoliciesLineItems', window );"><strong>Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage of net product revenue and accounts receivable</a></td>
<td class="nump">98.40%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=dawn_IndividualCustomerMember', window );">Individual Customer [Member] | Accounts Receivable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dawn_AccountingPoliciesLineItems', window );"><strong>Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage of net product revenue and accounts receivable</a></td>
<td class="nump">96.20%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dawn_AccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounting Policies LineItems.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dawn_AccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dawn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-20<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=dawn_OneCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=dawn_OneCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=dawn_ConcentrationOfCreditRiskAndOtherRisksAndUncertaintiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=dawn_ConcentrationOfCreditRiskAndOtherRisksAndUncertaintiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=dawn_TwoCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=dawn_TwoCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=dawn_OtherIndividualCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=dawn_OtherIndividualCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=dawn_NetProductRevenueAndAccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=dawn_NetProductRevenueAndAccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=dawn_IndividualCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=dawn_IndividualCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Recurring Fair Value Measurement - Schedule of fair value, assets and liabilities measured on recurring basis (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents, fair value disclosure</a></td>
<td class="nump">$ 12,146<span></span>
</td>
<td class="nump">$ 16,728<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents, fair value disclosure</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,947<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember', window );">U.S. government agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents, fair value disclosure</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,163<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents, fair value disclosure</a></td>
<td class="nump">451,808<span></span>
</td>
<td class="nump">511,590<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Fair Value, Inputs, Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents, fair value disclosure</a></td>
<td class="nump">12,146<span></span>
</td>
<td class="nump">16,728<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Fair Value, Inputs, Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents, fair value disclosure</a></td>
<td class="nump">439,662<span></span>
</td>
<td class="nump">494,862<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Fair Value, Inputs, Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents, fair value disclosure</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents, fair value disclosure</a></td>
<td class="nump">12,146<span></span>
</td>
<td class="nump">16,728<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Money market funds | Fair Value, Inputs, Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents, fair value disclosure</a></td>
<td class="nump">12,146<span></span>
</td>
<td class="nump">16,728<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Money market funds | Fair Value, Inputs, Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents, fair value disclosure</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Money market funds | Fair Value, Inputs, Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents, fair value disclosure</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents, fair value disclosure</a></td>
<td class="nump">345,377<span></span>
</td>
<td class="nump">311,487<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | U.S. treasury securities | Fair Value, Inputs, Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents, fair value disclosure</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | U.S. treasury securities | Fair Value, Inputs, Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents, fair value disclosure</a></td>
<td class="nump">345,377<span></span>
</td>
<td class="nump">311,487<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | U.S. treasury securities | Fair Value, Inputs, Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents, fair value disclosure</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | U.S. government agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents, fair value disclosure</a></td>
<td class="nump">94,285<span></span>
</td>
<td class="nump">183,375<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | U.S. government agency securities | Fair Value, Inputs, Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents, fair value disclosure</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | U.S. government agency securities | Fair Value, Inputs, Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents, fair value disclosure</a></td>
<td class="nump">94,285<span></span>
</td>
<td class="nump">183,375<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | U.S. government agency securities | Fair Value, Inputs, Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents, fair value disclosure</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Recurring Fair Value Measurement - Schedule of cash equivalents, marketable securities, and unrealized gains and losses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash equivalents, amortized cost</a></td>
<td class="nump">$ 33,358<span></span>
</td>
<td class="nump">$ 124,968<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=dawn_MarketableSecuritiesMember', window );">Marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Debt securities, available-for-sale, amortized cost</a></td>
<td class="nump">439,715<span></span>
</td>
<td class="nump">406,667<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain', window );">Debt securities, available-for-sale, unrealized gain</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">98<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss', window );">Debt securities, available-for-sale, unrealized loss</a></td>
<td class="num">(60)<span></span>
</td>
<td class="num">(13)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available-for-sale, estimated fair value</a></td>
<td class="nump">439,662<span></span>
</td>
<td class="nump">406,752<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CashEquivalentsMember', window );">Cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash equivalents, amortized cost</a></td>
<td class="nump">12,146<span></span>
</td>
<td class="nump">104,838<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dawn_CashEquivalentsUnrealizedGains', window );">Cash equivalents, unrealized gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dawn_CashEquivalentsUnrealizedLosses', window );">Cash equivalents, unrealized losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents, fair value disclosure</a></td>
<td class="nump">12,146<span></span>
</td>
<td class="nump">104,838<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash equivalents, amortized cost</a></td>
<td class="nump">12,146<span></span>
</td>
<td class="nump">16,728<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dawn_CashEquivalentsUnrealizedGains', window );">Cash equivalents, unrealized gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dawn_CashEquivalentsUnrealizedLosses', window );">Cash equivalents, unrealized losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents, fair value disclosure</a></td>
<td class="nump">12,146<span></span>
</td>
<td class="nump">16,728<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember', window );">U.S. government agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash equivalents, amortized cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,163<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dawn_CashEquivalentsUnrealizedGains', window );">Cash equivalents, unrealized gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dawn_CashEquivalentsUnrealizedLosses', window );">Cash equivalents, unrealized losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents, fair value disclosure</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,163<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Debt securities, available-for-sale, amortized cost</a></td>
<td class="nump">94,297<span></span>
</td>
<td class="nump">108,210<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain', window );">Debt securities, available-for-sale, unrealized gain</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss', window );">Debt securities, available-for-sale, unrealized loss</a></td>
<td class="num">(12)<span></span>
</td>
<td class="num">(11)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available-for-sale, estimated fair value</a></td>
<td class="nump">94,285<span></span>
</td>
<td class="nump">108,212<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash equivalents, amortized cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,947<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dawn_CashEquivalentsUnrealizedGains', window );">Cash equivalents, unrealized gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dawn_CashEquivalentsUnrealizedLosses', window );">Cash equivalents, unrealized losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents, fair value disclosure</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,947<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Debt securities, available-for-sale, amortized cost</a></td>
<td class="nump">345,418<span></span>
</td>
<td class="nump">298,457<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain', window );">Debt securities, available-for-sale, unrealized gain</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">85<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss', window );">Debt securities, available-for-sale, unrealized loss</a></td>
<td class="num">(48)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available-for-sale, estimated fair value</a></td>
<td class="nump">$ 345,377<span></span>
</td>
<td class="nump">$ 298,540<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dawn_CashEquivalentsUnrealizedGains">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash equivalents, unrealized gains</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dawn_CashEquivalentsUnrealizedGains</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dawn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dawn_CashEquivalentsUnrealizedLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash equivalents, unrealized losses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dawn_CashEquivalentsUnrealizedLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dawn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=dawn_MarketableSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=dawn_MarketableSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Recurring Fair Value Measurement - Schedule Of Maturities For Available For Sale Securities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost', window );">Amortized cost, mature in one year or less</a></td>
<td class="nump">$ 451,861<span></span>
</td>
<td class="nump">$ 511,505<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis', window );">Amortized cost, total</a></td>
<td class="nump">451,861<span></span>
</td>
<td class="nump">511,505<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Fair value, mature in one year or less</a></td>
<td class="nump">451,808<span></span>
</td>
<td class="nump">511,590<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate', window );">Fair value, total</a></td>
<td class="nump">$ 451,808<span></span>
</td>
<td class="nump">$ 511,590<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-3A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-3A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Recurring Fair Value Measurement - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet', window );">Fair value, measurement recurring basis, asset, transfers, net</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">Unrealized losses twelve months or greater</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-7<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transfer of financial instrument classified as an asset into (out of) level 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Items - Summary of Prepaid and Other Current Assets (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract', window );"><strong>Prepaid Expense and Other Assets, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dawn_PrepaidResearchAndDevelopmentExpenses', window );">Prepaid research and development expenses</a></td>
<td class="nump">$ 9,733<span></span>
</td>
<td class="nump">$ 8,216<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Prepaid insurance</a></td>
<td class="nump">305<span></span>
</td>
<td class="nump">830<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Other prepaid expenses and other assets</a></td>
<td class="nump">3,974<span></span>
</td>
<td class="nump">4,367<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Total prepaid expenses and other current assets</a></td>
<td class="nump">$ 14,012<span></span>
</td>
<td class="nump">$ 13,413<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dawn_PrepaidResearchAndDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid Research and Development Expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dawn_PrepaidResearchAndDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dawn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Items - Summary of Accrued expenses and other current liabilities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dawn_AccruedLicenseAgreementUpfrontPayment', window );">Accrued license agreement upfront payment</a></td>
<td class="nump">$ 18,457<span></span>
</td>
<td class="nump">$ 18,760<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dawn_AccruedRebates', window );">Accrued rebates</a></td>
<td class="nump">6,008<span></span>
</td>
<td class="nump">4,518<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dawn_AccruedFederalAndStateTaxPayments', window );">Accrued federal and state taxes</a></td>
<td class="nump">4,966<span></span>
</td>
<td class="nump">4,966<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dawn_AccruedMilestonePayment', window );">Accrued milestone payment</a></td>
<td class="nump">2,000<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dawn_AccruedPayrollRelatedExpenses', window );">Accrued payroll related expenses</a></td>
<td class="nump">4,202<span></span>
</td>
<td class="nump">13,943<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional service expenses</a></td>
<td class="nump">4,943<span></span>
</td>
<td class="nump">3,758<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">3,065<span></span>
</td>
<td class="nump">2,680<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Total accrued expenses and other current liabilities</a></td>
<td class="nump">$ 43,641<span></span>
</td>
<td class="nump">$ 68,625<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dawn_AccruedFederalAndStateTaxPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Federal And State Tax Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dawn_AccruedFederalAndStateTaxPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dawn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dawn_AccruedLicenseAgreementUpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued license agreement upfront payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dawn_AccruedLicenseAgreementUpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dawn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dawn_AccruedMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Milestone Payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dawn_AccruedMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dawn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dawn_AccruedPayrollRelatedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Payroll Related Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dawn_AccruedPayrollRelatedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dawn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dawn_AccruedRebates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Rebates</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dawn_AccruedRebates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dawn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Intangible Assets - Schedule Of Intangible Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible assets, gross</a></td>
<td class="nump">$ 22,600<span></span>
</td>
<td class="nump">$ 17,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Less accumulated amortization</a></td>
<td class="num">(2,195)<span></span>
</td>
<td class="num">(1,470)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total future expected amortization expense</a></td>
<td class="nump">20,405<span></span>
</td>
<td class="nump">15,630<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=dawn_LicenseAgreementMilestonePaymentMember', window );">License agreement milestone payments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible assets, gross</a></td>
<td class="nump">14,500<span></span>
</td>
<td class="nump">9,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=dawn_PRV-RelatedObligationPaymentMember', window );">PRV-related obligation payment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible assets, gross</a></td>
<td class="nump">$ 8,100<span></span>
</td>
<td class="nump">$ 8,100<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 928<br> -SubTopic 340<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478859/928-340-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=dawn_LicenseAgreementMilestonePaymentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=dawn_LicenseAgreementMilestonePaymentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=dawn_PRV-RelatedObligationPaymentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=dawn_PRV-RelatedObligationPaymentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets (Additional Information) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">$ 725<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Intangible Assets - Schedule Of Amortization Expense For Amortizable Finite-Lived Intangible Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2025 (Remaining)</a></td>
<td class="nump">$ 2,385<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2026</a></td>
<td class="nump">3,180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2027</a></td>
<td class="nump">3,180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2028</a></td>
<td class="nump">3,180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2029</a></td>
<td class="nump">3,180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive', window );">Thereafter</a></td>
<td class="nump">5,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total future expected amortization expense</a></td>
<td class="nump">$ 20,405<span></span>
</td>
<td class="nump">$ 15,630<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Agreements - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 23, 2024</div></th>
<th class="th"><div>May 29, 2024</div></th>
<th class="th"><div>Apr. 23, 2024</div></th>
<th class="th"><div>Mar. 04, 2024</div></th>
<th class="th"><div>May 26, 2021</div></th>
<th class="th"><div>Dec. 16, 2019</div></th>
<th class="th"><div>Jul. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Unamortized finite-lived intangible asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,405<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,630<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Current portion of deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,636<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,554<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred revenue, noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,233<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">199<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=dawn_TakedaAssetAgreementMember', window );">Takeda Asset Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dawn_UpfrontOfCashPayment', window );">Upfront of cash payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=dawn_TakedaAssetAgreementMember', window );">Takeda Asset Agreement [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of Series B redeemable convertible preferred shares for cash, net of issuance costs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,470,382<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=dawn_TakedaAssetAgreementMember', window );">Takeda Asset Agreement [Member] | Series A Redeemable Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Share Issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,857,143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Common stock issued, share issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of Series B redeemable convertible preferred shares for cash, net of issuance costs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,857,143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=dawn_MerckLicenseAgreementMember', window );">Merck License Agreement [Member] | Research And Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dawn_UpfrontPayment', window );">Upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dawn_MilestonePaymentsNotYetPaid', window );">Milestone payments not yet paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">364,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=dawn_ViractaLicenseAgreementMember', window );">Viracta License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dawn_PaymentOfMilestones', window );">Payment of Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=dawn_ViractaLicenseAgreementMember', window );">Viracta License Agreement [Member] | Other Intangible Assets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dawn_PaymentOfMilestones', window );">Payment of Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=dawn_ViractaLicenseAgreementMember', window );">Viracta License Agreement [Member] | PRV</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Unamortized finite-lived intangible asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfProductiveAssets', window );">Proceeds From sale of PRV</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 108,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 108,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dawn_PaymentToObligationOfLicenseAgreement', window );">Payment to obligation of license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=dawn_ViractaLicenseAgreementMember', window );">Viracta License Agreement [Member] | Research And Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dawn_UpfrontPayment', window );">Upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dawn_PaymentOfMilestones', window );">Payment of Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dawn_UpfrontOfCashPayment', window );">Upfront of cash payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=dawn_SprintBioscienceAgreementMember', window );">Sprint Bioscience Agreement [Member] | Research And Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dawn_UpfrontPayment', window );">Upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=dawn_SprintBioscienceAgreementMember', window );">Sprint Bioscience Agreement [Member] | Research And Development Expense | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dawn_MilestonePaymentsNotYetPaid', window );">Milestone payments not yet paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">309,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=dawn_MabcareLicenseAgreementMember', window );">MabCare License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dawn_UpfrontPayment', window );">Upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=dawn_MabcareLicenseAgreementMember', window );">MabCare License Agreement [Member] | Research And Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dawn_PaymentOfMilestones', window );">Payment of Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dawn_MilestonePaymentsNotYetPaid', window );">Milestone payments not yet paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,132,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=dawn_LicenseAgreementWithIpsenPharmaSasMember', window );">License agreement with Ipsen Pharma SAS [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dawn_MilestonePaymentsNotYetReceived', window );">Milestone payments not yet received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from issuance of private placement</a></td>
<td class="nump">$ 40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dawn_TransactionPrice', window );">Transaction Price</a></td>
<td class="nump">78,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets', window );">Equity Investment</a></td>
<td class="nump">7,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dawn_LicenseRevenue', window );">License revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=dawn_LicenseAgreementWithIpsenPharmaSasMember', window );">License agreement with Ipsen Pharma SAS [Member] | Current Member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Current portion of deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=dawn_LicenseAgreementWithIpsenPharmaSasMember', window );">License agreement with Ipsen Pharma SAS [Member] | Noncurrent Member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred revenue, noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=dawn_LicenseAgreementWithIpsenPharmaSasMember', window );">License agreement with Ipsen Pharma SAS [Member] | License revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dawn_UpfrontPayment', window );">Upfront payment</a></td>
<td class="nump">$ 70,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=dawn_LicenseAgreementWithIpsenPharmaSasMember', window );">License agreement with Ipsen Pharma SAS [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Share Issuance</a></td>
<td class="nump">2,341,495<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dawn_VolumeWeightedAveragePrice', window );">Volume weighted average price</a></td>
<td class="nump">17.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=dawn_LicenseAgreementWithIpsenPharmaSasMember', window );">License agreement with Ipsen Pharma SAS [Member] | Research And Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dawn_PaymentOfMilestones', window );">Payment of Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dawn_LicenseRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License Revenue</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dawn_LicenseRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dawn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dawn_MilestonePaymentsNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone payments not yet paid</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dawn_MilestonePaymentsNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dawn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dawn_MilestonePaymentsNotYetReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone Payments not Yet Received</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dawn_MilestonePaymentsNotYetReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dawn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dawn_PaymentOfMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment of Milestones.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dawn_PaymentOfMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dawn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dawn_PaymentToObligationOfLicenseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment to Obligation of License Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dawn_PaymentToObligationOfLicenseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dawn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dawn_TransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Transaction Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dawn_TransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dawn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dawn_UpfrontOfCashPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront of Cash Payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dawn_UpfrontOfCashPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dawn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dawn_UpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dawn_UpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dawn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dawn_VolumeWeightedAveragePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Volume Weighted Average Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dawn_VolumeWeightedAveragePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dawn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This item represents the entity's ownership percentage in the investee multiplied by the investee's total equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=dawn_TakedaAssetAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=dawn_TakedaAssetAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=dawn_SeriesARedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=dawn_SeriesARedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=dawn_MerckLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=dawn_MerckLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=dawn_ViractaLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=dawn_ViractaLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=dawn_PrvPressureReliefValveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=dawn_PrvPressureReliefValveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=dawn_SprintBioscienceAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=dawn_SprintBioscienceAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=dawn_MabcareLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=dawn_MabcareLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=dawn_LicenseAgreementWithIpsenPharmaSasMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=dawn_LicenseAgreementWithIpsenPharmaSasMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=dawn_CurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=dawn_CurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=dawn_NoncurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=dawn_NoncurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Summary of Future Lease Obligations (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2025 (Remaining)</a></td>
<td class="nump">$ 404<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2026</a></td>
<td class="nump">527<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2027</a></td>
<td class="nump">543<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2028</a></td>
<td class="nump">492<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2029</a></td>
<td class="nump">711<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dawn_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour', window );">Thereafter</a></td>
<td class="nump">1,981<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total future minimum lease payments</a></td>
<td class="nump">4,658<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Imputed interest</a></td>
<td class="num">(1,742)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of operating lease liabilities</a></td>
<td class="nump">2,916<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less: current portion of operating lease liabilities</a></td>
<td class="num">(62)<span></span>
</td>
<td class="num">$ (10)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities</a></td>
<td class="nump">$ 2,854<span></span>
</td>
<td class="nump">$ 2,592<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dawn_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee Operating Lease Liability Payments Due after Year Four</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dawn_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dawn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Aug. 31, 2024</div></th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Apr. 30, 2022 </div>
<div>ft&#178;</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Operating lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Amortization of operating&#160;right-of-use&#160;assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="nump">$ 93,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating lease payments</a></td>
<td class="nump">$ 4,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term</a></td>
<td class="text">6 years 6 months<span></span>
</td>
<td class="text">6 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate percent</a></td>
<td class="nump">12.90%<span></span>
</td>
<td class="nump">12.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dawn_AgreementAxis=dawn_ResearchAndDevelopmentAgreementsMember', window );">Research And Development Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Termination and cancellation charges payable</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dawn_AgreementAxis=us-gaap_IndemnificationGuaranteeMember', window );">Indemnification Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Termination and cancellation charges payable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis=us-gaap_PurchaseCommitmentMember', window );">Purchase Commitments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted', window );">Aggregate amount of future minimum purchase obligations</a></td>
<td class="nump">$ 12,600,000<span></span>
</td>
<td class="nump">12,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dawn_PurchasesUnderThePurchaseObligation', window );">Purchases under the purchase obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=dawn_BrisbaneCaliforniaMember', window );">Brisbane, California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfLand', window );">Sublease agreement area | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,000<span></span>
</td>
<td class="nump">12,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Security deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 86,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=dawn_LeaseForCorporateOfficeFacilityMember', window );">Lease For Corporate Office Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Amortization of operating&#160;right-of-use&#160;assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating lease payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dawn_PurchasesUnderThePurchaseObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchases Under the Purchase Obligation</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dawn_PurchasesUnderThePurchaseObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dawn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfLand">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of land held.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfLand</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum amount to be expended to satisfy the terms of arrangements in which the entity has agreed to expend funds to procure goods or services, excluding long-term purchase commitments or unconditional purchase obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecurityDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecurityDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dawn_AgreementAxis=dawn_ResearchAndDevelopmentAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dawn_AgreementAxis=dawn_ResearchAndDevelopmentAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dawn_AgreementAxis=us-gaap_IndemnificationGuaranteeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dawn_AgreementAxis=us-gaap_IndemnificationGuaranteeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis=us-gaap_PurchaseCommitmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis=us-gaap_PurchaseCommitmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=dawn_BrisbaneCaliforniaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=dawn_BrisbaneCaliforniaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=dawn_LeaseForCorporateOfficeFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=dawn_LeaseForCorporateOfficeFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock - Additional Information (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 01, 2024</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Jul. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, Shares Authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, Shares Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101,353,781<span></span>
</td>
<td class="nump">101,116,162<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101,353,781<span></span>
</td>
<td class="nump">101,116,162<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock shares reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,271,292<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common Stock Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=dawn_AtTheMarketMember', window );">At The Market [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, Shares Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dawn_AgreementAxis=dawn_TwoThousandTwentyFourPrivatePlacementMember', window );">2024 Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, Shares Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,551,718<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from issuance of private placement</a></td>
<td class="nump">$ 166,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dawn_AgreementAxis=dawn_TwoThousandTwentyFourPrivatePlacementMember', window );">2024 Private Placement [Member] | Pre-Funded Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dawn_AgreementAxis=dawn_InvestmentAgreementMember', window );">Investment Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dawn_UpfrontLicenseFee', window );">Upfront license fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dawn_CommonStockSharesPurchased', window );">Number of Common Stock Shares Purchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,341,495<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common Stock Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dawn_WeightedAveragePriceOfCompanysCommonStock', window );">Weighted Average Price of Company's common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dawn_AgreementAxis=dawn_CommonSharesPurchaseAgreementMember', window );">Common Shares Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, Shares Authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dawn_AgreementAxis=dawn_SalesAgreementMember', window );">Sales Agreement with Piper Sandler and Jones Services LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the issuance of common stock, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=dawn_PreFundedWarrantsMember', window );">Pre-Funded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Purchase Price of Common Stock Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.4999<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Pre-funded warrants purchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,517,241<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Excersise price of pre-funded warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=dawn_PreFundedWarrantsMember', window );">Pre-Funded Warrants [Member] | 2024 Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from issuance of prefunded warrants to purchase common stock, net of issuance costs</a></td>
<td class="nump">20,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock shares reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,055,674<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Purchase Price of Common Stock Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Pre-funded warrants purchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,517,241<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | 2024 Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the issuance of common stock, net</a></td>
<td class="nump">$ 145,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Investment Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common Stock Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dawn_CommonStockSharesPurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock Shares Purchased</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dawn_CommonStockSharesPurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dawn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dawn_UpfrontLicenseFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront License Fee</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dawn_UpfrontLicenseFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dawn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dawn_WeightedAveragePriceOfCompanysCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Price of Company's common Stock</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dawn_WeightedAveragePriceOfCompanysCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dawn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=dawn_AtTheMarketMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=dawn_AtTheMarketMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dawn_AgreementAxis=dawn_TwoThousandTwentyFourPrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dawn_AgreementAxis=dawn_TwoThousandTwentyFourPrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=dawn_PreFundedWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=dawn_PreFundedWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dawn_AgreementAxis=dawn_InvestmentAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dawn_AgreementAxis=dawn_InvestmentAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dawn_AgreementAxis=dawn_CommonSharesPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dawn_AgreementAxis=dawn_CommonSharesPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dawn_AgreementAxis=dawn_SalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dawn_AgreementAxis=dawn_SalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=dawn_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=dawn_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Common Stock - Schedule of Common Stock Shares Reserved for Future Issuance (Details) (Details)<br></strong></div></th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock shares reserved for future issuance</a></td>
<td class="nump">27,271,292<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock shares reserved for future issuance</a></td>
<td class="nump">5,393,445<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock shares reserved for future issuance</a></td>
<td class="nump">2,856,820<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=dawn_PreFundedWarrantsMember', window );">Pre-Funded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock shares reserved for future issuance</a></td>
<td class="nump">1,517,241<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=dawn_EmployeeStockPurchasePlanMember', window );">Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock shares reserved for future issuance</a></td>
<td class="nump">3,448,112<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock shares reserved for future issuance</a></td>
<td class="nump">14,055,674<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=dawn_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=dawn_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=dawn_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=dawn_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Compensation - Summary of Share/Stock-based Compensation Expense Recorded in The Accompanying Condensed Consolidated Statements of Operations and Comprehensive Loss (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 12,861<span></span>
</td>
<td class="nump">$ 12,644<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">4,251<span></span>
</td>
<td class="nump">4,653<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 8,610<span></span>
</td>
<td class="nump">$ 7,991<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Compensation - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Oct. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 48,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock shares reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,271,292<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated share based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,861,000<span></span>
</td>
<td class="nump">12,644,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dawn_UnamortizedStockBasedCompensationForStockOptions', window );">Unamortized stock-based compensation for stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted-average period expected to be recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=dawn_TwoThousandAndTwentyOneEquityIncentivePlanMember', window );">2021 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Total fair value of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,400,000<span></span>
</td>
<td class="nump">$ 7,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Number of shares issued upon conversion</a></td>
<td class="nump">4,719,605<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock shares reserved for future issuance</a></td>
<td class="nump">6,369,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted-average period expected to be recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=dawn_TwoThousandAndTwentyOneEquityIncentivePlanMember', window );">2021 Equity Incentive Plan | PSOs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Share based compensation by share based payment arrangement non vested options granted during the period weighted average grant date fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.73<span></span>
</td>
<td class="nump">$ 9.31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dawn_UnamortizedStockBasedCompensationForStockOptions', window );">Unamortized stock-based compensation for stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 52,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted-average period expected to be recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=dawn_TwoThousandAndTwentyOneEquityIncentivePlanMember', window );">2021 Equity Incentive Plan | Incremental Shares Reserved for Future Issuance [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=dawn_TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember', window );">2021 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock shares reserved for future issuance</a></td>
<td class="nump">603,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated share based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan', window );">Stock Issued During Period, Shares, Employee Stock Ownership Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">407,629<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=dawn_TwoThousandAndTwentyTwoEquityInducementPlanMember', window );">2022 Equity Inducement Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock shares reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=dawn_UnvestedCommonStockMember', window );">Unvested Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dawn_UnamortizedStockBasedCompensationForStockOptions', window );">Unamortized stock-based compensation for stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dawn_UnamortizedStockBasedCompensationForStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unamortized stock-based compensation for stock options</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dawn_UnamortizedStockBasedCompensationForStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dawn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of capital stock issued (purchased by employees) in connection with an employee stock ownership plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 40<br> -Section 25<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480637/718-40-25-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=dawn_TwoThousandAndTwentyOneEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=dawn_TwoThousandAndTwentyOneEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=dawn_PerformanceStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=dawn_PerformanceStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dawn_DetailsAxis=dawn_IncrementalSharesReservedForFutureIssuanceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dawn_DetailsAxis=dawn_IncrementalSharesReservedForFutureIssuanceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=dawn_TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=dawn_TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=dawn_TwoThousandAndTwentyTwoEquityInducementPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=dawn_TwoThousandAndTwentyTwoEquityInducementPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=dawn_UnvestedCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=dawn_UnvestedCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Compensation - Summary of Stock Option Activity (Detail) - 2021 Equity Incentive Plan<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Shares, Beginning Balance | shares</a></td>
<td class="nump">12,127,435<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted | shares</a></td>
<td class="nump">2,132,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeiture | shares</a></td>
<td class="num">(203,761)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at March 31, 2025 | shares</a></td>
<td class="nump">14,055,674<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Vested and expected to vest at March 31, 2025 | shares</a></td>
<td class="nump">14,055,674<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Exercisable at March 31, 2025 | shares</a></td>
<td class="nump">8,362,276<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per Share, Beginning Balance | $ / shares</a></td>
<td class="nump">$ 16.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted | $ / shares</a></td>
<td class="nump">11.86<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeiture | $ / shares</a></td>
<td class="nump">15.87<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per Share, Ending Balance | $ / shares</a></td>
<td class="nump">15.81<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per Share, Vested and expected to vest at March 31, 2025 | $ / shares</a></td>
<td class="nump">15.81<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable at March 31, 2025 | $ / shares</a></td>
<td class="nump">$ 16.58<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted-Average Remaining Contractual Term, Outstanding at March 31, 2025</a></td>
<td class="text">7 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted-Average Remaining Contractual Term, Vested and expected to vest at March 31, 2025</a></td>
<td class="text">7 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted-Average Remaining Contractual Term, Exercisable at March 31, 2025</a></td>
<td class="text">6 years 9 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested', window );">Exercised | $</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding at March 31, 2025 Aggregate Intrinsic Value | $</a></td>
<td class="nump">27,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Vested and expected to vest at March 31, 2025, Aggregate Intrinsic Value | $</a></td>
<td class="nump">27,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Exercisable at March 31, 2025 | $</a></td>
<td class="nump">$ 18,600<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of vested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=dawn_TwoThousandAndTwentyOneEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=dawn_TwoThousandAndTwentyOneEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Compensation - Summary of The Black-Scholes Option Pricing Model to Estimate The Fair Value of Stock Option Granted (Detail) - Two Thousand And Twenty One Equity Incentive Plan [Member]<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=dawn_TwoThousandAndTwentyOneEquityIncentivePlanMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years 8 months 12 days<span></span>
</td>
<td class="text">6 years 8 months 26 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility</a></td>
<td class="nump">69.13%<span></span>
</td>
<td class="nump">70.57%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate</a></td>
<td class="nump">4.48%<span></span>
</td>
<td class="nump">4.31%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=dawn_TwoThousandAndTwentyOneEquityIncentivePlanMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">5 years 8 months 8 days<span></span>
</td>
<td class="text">5 years 9 months 7 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility</a></td>
<td class="nump">68.30%<span></span>
</td>
<td class="nump">68.27%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate</a></td>
<td class="nump">3.99%<span></span>
</td>
<td class="nump">3.90%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=dawn_TwoThousandAndTwentyOneEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=dawn_TwoThousandAndTwentyOneEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Compensation - Summary of Restricted Stock Units Activity (Detail) - Restricted Stock Units - 2021 Equity Incentive Plan<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2025 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Unvested restricted stock, beginning balance | shares</a></td>
<td class="nump">1,774,287<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted | shares</a></td>
<td class="nump">1,393,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested | shares</a></td>
<td class="num">(247,041)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeiture | shares</a></td>
<td class="num">(63,426)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested restricted stock, ending balance | shares</a></td>
<td class="nump">2,856,820<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value Per Share, Beginning Balance | $ / shares</a></td>
<td class="nump">$ 15.58<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Grant date fair value | $ / shares</a></td>
<td class="nump">11.86<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested | $ / shares</a></td>
<td class="nump">14.73<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Forfeited | $ / shares</a></td>
<td class="nump">14.14<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value Per Share, Ending Balance | $ / shares</a></td>
<td class="nump">$ 13.88<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=dawn_TwoThousandAndTwentyOneStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=dawn_TwoThousandAndTwentyOneStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Compensation - Summary of The Unvested Common Stock (Detail) - Unvested Common Stock [Member]<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2025 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dawn_ShareBasedCompensationByShareBasedPaymentArrangementEquityInstrumentsOtherThanOptionsOutstanding', window );">Number of Shares, Unvested Common Stock, Beginning balance | shares</a></td>
<td class="nump">82,281<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested | shares</a></td>
<td class="num">(66,752)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Number of Shares, Forfeited | shares</a></td>
<td class="num">(735)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dawn_ShareBasedCompensationByShareBasedPaymentArrangementEquityInstrumentsOtherThanOptionsOutstanding', window );">Number of Shares, Unvested Common Stock, Ending balance | shares</a></td>
<td class="nump">14,794<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value Per Share, Beginning Balance | $ / shares</a></td>
<td class="nump">$ 16<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested | $ / shares</a></td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeiture | $ / shares</a></td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value Per Share, Ending Balance | $ / shares</a></td>
<td class="nump">$ 16<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dawn_ShareBasedCompensationByShareBasedPaymentArrangementEquityInstrumentsOtherThanOptionsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation by share based payment arrangement equity instruments other than options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dawn_ShareBasedCompensationByShareBasedPaymentArrangementEquityInstrumentsOtherThanOptionsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dawn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=dawn_UnvestedCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=dawn_UnvestedCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Additional Information) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income (Loss) Per Share - Summary of Basic and Diluted Net Loss Per Share Attributable to Common Shareholders/Stockholders (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss) - basic and diluted</a></td>
<td class="num">$ (35,996)<span></span>
</td>
<td class="num">$ (62,412)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares outstanding - basic</a></td>
<td class="nump">102,710,382<span></span>
</td>
<td class="nump">86,679,282<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares outstanding - diluted</a></td>
<td class="nump">102,710,382<span></span>
</td>
<td class="nump">86,679,282<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic</a></td>
<td class="num">$ (0.35)<span></span>
</td>
<td class="num">$ (0.72)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted</a></td>
<td class="num">$ (0.35)<span></span>
</td>
<td class="num">$ (0.72)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income (Loss) Per Share - Summary of Outstanding Potentially Dilutive Securities Have Been Excluded From Calculation of Diluted Net Loss Per Share (Detail) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Stock options</a></td>
<td class="nump">17,036,005<span></span>
</td>
<td class="nump">15,292,080<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Stock options</a></td>
<td class="nump">14,055,674<span></span>
</td>
<td class="nump">12,404,090<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=dawn_UnvestedCommonSharesMember', window );">Unvested common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Stock options</a></td>
<td class="nump">14,794<span></span>
</td>
<td class="nump">543,239<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Stock options</a></td>
<td class="nump">2,856,820<span></span>
</td>
<td class="nump">2,243,998<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=dawn_SharesCommittedUnderESPPMember', window );">Shares committed under ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Stock options</a></td>
<td class="nump">108,717<span></span>
</td>
<td class="nump">100,753<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=dawn_UnvestedCommonSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=dawn_UnvestedCommonSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=dawn_SharesCommittedUnderESPPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=dawn_SharesCommittedUnderESPPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Defined Contribution Plan (Additional Information) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dawn_DefinedContributionPlanEmployerMatchingContribution', window );">Matching Contribution</a></td>
<td class="nump">$ 0.7<span></span>
</td>
<td class="nump">$ 0.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dawn_DefinedContributionPlanEmployerMatchingContribution">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Defined Contribution Plan Employer Matching Contribution</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dawn_DefinedContributionPlanEmployerMatchingContribution</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dawn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting (Additional Information) (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2025 </div>
<div>Segment</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segment</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segment</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting - Schedule of Segment Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dawn_ExternalCostsAbstract', window );"><strong>External Costs [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dawn_Third-PartyCROCMOAndOtherThird-PartyClinicalTrialCosts', window );">Third-party CRO, CMO and other third-party clinical trial costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 20,821<span></span>
</td>
<td class="nump">$ 19,546<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dawn_LicenseAgreementRelatedPayments', window );">License agreement related payments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,000<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherResearchAndDevelopmentExpense', window );">Other research and development costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,021<span></span>
</td>
<td class="nump">2,167<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dawn_EmployeeRelatedExpenses', window );">Employee related expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">12,777<span></span>
</td>
<td class="nump">13,497<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total research and development expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 39,619<span></span>
</td>
<td class="nump">$ 40,210<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Costs incurred under agreements with third-party CROs, CMOs, and other third parties that conduct clinical activities on the Company's behalf.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dawn_EmployeeRelatedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Employee Related Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dawn_EmployeeRelatedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dawn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dawn_ExternalCostsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>External Costs [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dawn_ExternalCostsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dawn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dawn_LicenseAgreementRelatedPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License Agreement Related Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dawn_LicenseAgreementRelatedPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dawn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dawn_Third-PartyCROCMOAndOtherThird-PartyClinicalTrialCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Third-Party CRO, CMO and Other Third-Party Clinical Trial Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dawn_Third-PartyCROCMOAndOtherThird-PartyClinicalTrialCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dawn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other research and development expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Subsequent Event (Additional Information) (Details) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Jul. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock par value per share</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock par value per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>68
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( *R IEI&QTU(E0   ,T    0    9&]C4')O<',O87!P+GAM
M;$W/30O", P&X+]2=K>9BAZD#D0]BIZ\SRYUA;8I;83Z[^T$/VYY><@;HBZ)
M(B:VF$7Q+N1M,S+'#4#6(_H^R\JABJ'D>ZXQW8&,L1H/I!\> \.B;=> A3$,
M.,SBM[#IU"Y&9W7/ED)WLCI1)L/B6#0ZL2<?J]P<"A#G>B4^BQ-+.9<K!?^+
M4\L54Y[FRF_\9 6_![H74$L#!!0    ( *R IEIXCT<X\@   "L"   1
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MNIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X8-DOV]:[MR_>X%<R)!%!,!FGK_#
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M"CS<_N\-L,+$CN'MB[\!4$L#!!0    ( *R IEJ)1RZ!!@8  .@?   8
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M.U"@HE1X7ZIK;#1\(/P<.?89PA;N:<KCULG?D*55ORN-4[PC)[5S*NQNF)=
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MLY5E6?:@VW.<"RVG4=R4LXP]MC%7C&;42SB,M%2@L:=:<TC18Q(M*->2FLT
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M(PFC< 3+840P<J.*>U2Q%]5US3:49X#]V)CN(]N%*53.:MWT]FO2A3JVQRF
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MT-_?"<USNQMS@M__8K/^%U!+ P04    " "L@*9:6T\"858"  !)!@  &
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M'%VCB6XOKK9CU<Z?_96R>)/X9H5W/6A7@/-KI>Q;QUTG_;]'_@=02P,$%
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M"_:UK6.!J.""9;6S1) EM/J/7^M$'#G(.'H'5#N@OH,WXN#6#FY)M$)6TOJ
M!5[,<[8'N;*6T=1#F9O26[))J"KCL\CEKXGT$XLEH[$L"HG!L\""R ()#M@*
M?-J2'*M$<W!14%S$B2#Q>W %OCQ_ !?OWH-W(*'@\X85'-.8SVTAP:B0=E0/
M?%<-C$8&=L$#HV+#P:\20-SUMR6)A@DZ,+E#QH /.+\&+KP$R$&^!L_R='?/
M ,=M$NN6\=R1>$]D1VA!9KK,5)Z>WE--W!G?XHC<6')F<I+OB+7X^2<8.+_H
M:)TI6(>DUY#T3-$7GYG J9S-)55M$U3^0>FOEI3=PG7" ,[MW3&'H9736'2
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M^Y?O<>M4'<;UQ,B5R[.Y-)B.;EC@]PN4+<#G"RG-=F)?T'X1TS]02P,$%
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MI<T]7:]!]+$/[AU:M]&U/0^ZMEI<DW%#HVB1*;0NHWOI H[5+A2]0D]D7V/
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MLC:0]Y>,B>>3^D6F]EVZ^;]02P,$%     @ K("F6A_@YF;D!@  J1T  !@
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MWMP+-@^25>9J[9Y)R0HSW!"<$:X%U.]KQN3+@_Y =SN[^@]02P,$%     @
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MBL3[X*$<-J0IU3UOOT"G9VSX,EY*^XM:%SL>>RAKI.)5!]855)2Y+WGJ^G
M&!T#!!T@> V(C@#"#A!:H:XR*VM!%$ECP5LD3+1F,P?;&XO6:B@S_^)*"7U+
M-4ZE2_*,=A(M0=@7P3) "RJSDLM& +I$#ZL%.C^[0&>(,O2]X(TD+)<Q5CJW
M8<!9EV?F\@1'\H3HCC-52/2)Y9"_Q&-=<U]XL"]\%IPDO"/B"H6C=RCP@_%
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M["W>P&M&>^(1!/$6V$\;'#/E,;74YYJV CX-LTF_CLL:0V<V\/=#TRN9MYS
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MVPZ3BR<QN3@Z.>LPV4TF&8KS\]MNZ$-:.U70NT[8$Y>G1>_CN(6PV2*$''0
MJMT@K5>WFY!WD^/#XRJJ;7' R.@;O #AB4';QF36AYX0>8:%ED5)'-X.LSF@
M\57#ES.MWP<U+WY?U+R7]-:ADP'=H"XN5#R(_[] ZM"KP>/!*UT4N0V_N&;V
M-B&^W>V>=N_&+^,KX7YY?+&.NPL<ZD6IUMAZ,GOY?(*&E%]6QR_!UOR">&4#
M>G'^6"A<9QTMP.]K"_2D+W1 ]S\&+OX+4$L#!!0    ( *R IEKGFN"UZ08
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M*;HC>(I_UIF&]XD@?G(JGB\6BNQ-NWPKR_!_I#I@P%I6(E/E$D@@FI$"6GW
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M)C0+T?3I?=:]2+P"N)+;RJ"XN;IIS2\X?E=?QB03A8=9 ? *$R?-/--5F+^
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MH.[D.Y/@X2%4X3,A:#*'HGZNN_GB$O:_H6VSOO=]3B$ G7H%L?E)PDHB>VH
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MD0K%/'S"#0]D_!"D8_U21\.[,1Z$IY![QJ]KBUT7>J%OZ;PA)P%.=Y[6I:0
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M!K^P*G:C6/M5AZD,6@38J\#,S7SD.@@ZW@3EFF,_JG_B$C?T+2@;(3_IRJ*
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M+^=*PHJT >O3HJC:&V+0?;&]_B]02P,$%     @ K("F6N[%8:*E P  /@@
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M>H91.P/Z?ZNH 0X;YZ![V!?_ E!+ P04    " "L@*9:UXNY@L "   :!@
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M'Z!K:IJ0,8OVL>+()SBKWR50K2YI/D@N,JHD41RZVJP_E7DZL*2I#&.(HHX
M#>=O+T49LTHR/3IO74&ZE:3\L2=([ LX70QL! /!)C2<2H8:]_V G6/@D[H(
MQ<L.7 G>R17@B=QGLE:77>/Q5(T> F3@673R&*-!575IMPH;[Z975-TT-<_>
M"$ZH53>AF'SU)%10;5"V, FL.T_N>REMQI,(UC/B"H4YF(.1'*5YIK_C=RZQ
M\=4QU6$;).P*5/'!"#I19[":&P^ @'<CSJ!3TU!4$POR8(P*,42J\!4-_TS#
M4\XX.!R4'^3&1,/%Q-,XB53.<[4:76$E,X4:*..":$4DU^5C"@!R,["1NV9%
M>\5OT;->]33\N/<]40<:N<06-.9FOL!J5#9RKRCEH:)KZK9B(0F3)M0*_2Y9
M#W4&%UUG<'&P4K]75$E!B@]4".V-$>^<-998]MG&\ _:FJ#3#;91%9Q&]-#L
M,=9G.0TOD7XG?/=H^MT82X!9)3[R9.R;C[;6F7AU-OU6<*2=7(H/%5%E.@#.
MW"T0WW<S'M\6?LH41(,QR2(LC:=7'2;;IA!(+63CU;(IN5TC=H];TA1A-S;R
MY/L(2.X^]^9)^"97<.I*QAE[NQZK:JGS,<\',Z<7N.#3.%90_[FRCB*HQ?9^
M(\VM "./0$3BN-BR4IT,NDG38N9LGA\KWQ4RK01'+>Y[FL1\3*:G3J0[@(18
MXBD@E-Y,0&&UTL9P3ET"Y3M?GL1W#V>Q7Z+$F])8;F,@<,3#3UPKT-X+>H&5
MBCE)K-B[%]=\5B2D&3%PULX"4I?0)N]E?)/1U'%(%WEK8 JVK_H'FK2N.TR>
M'<3DV='TM,-D-^AF*,XN[[OY'4GM5$&OP*%/?#P]]"Y.S@B;+4+(0 -0[6:B
M.W&[%R[=BXCAR2,EWCBO9O3UWJ?Q *:ML3+KPXZM>1R)>DI)'-Z^&V&'QC=7
MGX\G_QC4G/^QJ'DGZ256MP=D@[CH]OB]SO\%4D-L?=Q[TX\,O.+?,W!J,2&^
M].^N=C^9N(Z_%-@]'G]O@<8*!O6B5$LLG4Y>O1RA6N;?,,0OP=;\NX&%#6@4
M^&.AT&L[>@#WEQ;H25_H@.Z')%?_ U!+ P04    " "L@*9:-R /=1 %  #C
M#P  &0   'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6R]5UMOVS84?O>O(-RA
M2P EUEUR+@9R:;L!+1;$:?<P[(&6CRVBDNB2E%WOU^^0NMAQ9,?=ACTDYNU<
MOG/Y*%ZMN/@J4P!%ON=9(:_[J5*+B\% )BGD5)[S!12X,^,BIPJG8CZ0"P%T
M:H3R;.#:=CC(*2OZHRNS]B!&5[Q4&2O@01!9YCD5ZUO(^.JZ[_2;A4<V3Y5>
M&(RN%G0.8U"?%P\"9X-6RY3E4$C&"R)@=MV_<2YN0WW>'/C"8"6WQD0CF7#^
M54]^G5[W;>T09) HK8'BSQ+N(,NT(G3C6ZVSWYK4@MOC1OM[@QVQ3*B$.Y[]
MSJ8JO>['?3*%&2TS]<A7OT"-)]#Z$IY)\Y^LZK-VGR2E5#ROA=&#G!75+_U>
MQ^$8 ;<6<(W?E2'CY3U5='0E^(H(?1JUZ8&!:J31.5;HI(R5P%V&<FKT"$DI
M!"OFY#UE@GRA60GD$U!9"L#8*W+R1"<9R-.K@4)S6FB0U*IO*]7N'M4>^<0+
ME4KRKIC"]+G\ -UL?74;7V_=@PH_47%./,<BKNT&!_1Y+7;/Z//VZ-M"?,]D
MDG$-6I(_;B92"2R7/[LP5RK];I6ZA2[D@B9PW<<>D2"6T!^]?>.$]N4!A_W6
M8?^0]M$86W):9D#XC,RT\TOMO$6HE* DH<649(Q.6,840R!YE<8I,?W3Y!EK
MF,DN9 =M=R-[2H',>(:=K34K72G$N()LH5*B</N.YPM:K-^^B5TGNL0=5M B
M830CK, PE[K(T'6I,6&"D[3-L,%S#PGD$Q#-JF^15<KP%!6P 4C55CPT7+H+
MF$S6)(,EZ/Y2*2N,;ULR*0.AK:_)B=GDI43S\O2B]]RIWD>CQ"'5KUO_>N2)
M*YKUWK?HJIR@."]@C1TKOB+#SDK427XBCFLY?H@#$Q;W\MFHVNQ]/A^?$R4,
MQ#5&%>%4:6U.>GY@>5&T.Z\$YWP)HC =C-Q:))T:AK[EQL'.M&>0-#6U)\1;
M$'QO:(6A^PR"'SA6;,>]%]G[C\(76I$;[PN?V3PB?(YC^7&T._^!\#FQAP$/
M=N?'!K !X6/<XYT !NA,,+3) =((6M((CB:-A,J4P+>2H1.Z[ZPZLG7C-@@M
MTWIE@='+V%_H^QQO]YI?.,+JI(^#7AQ-'[+^/$"SID5!*H9W+_JPW>"S;6KY
M67;@HDO*,JWP#*GH3-)G^$B287;8C.FTH,44V>I,@<B1DY9H,:]U%'I;<BQ(
M[<"!>+Q&&C<Y6C"2=UPJ\GFCZ8/1M+7PL5+XKL6]N:5Z=SLP_P6[5#6Z&[=&
MM#G>5G8E-.X,U!$=HYEEN&FU$U1(3AN^V=NIFM!\)R81"O@Q"C0,5SG?G;::
MD2(GP%&$?R<DM%&V):H.4OJ?TW,L>QT,:1183NB]R%2UO#^FF,FA'W4E&)?W
M5H6-#.7%+Z6J]7]>%XX=6ZYC$\?3->%@FJH5=S\ =QA;?A 1O+=.B*XBO1#X
M]JM%88>8?5T0P]A4!=H\K=>CP#W$M&'+M.%Q3/N;_I11C<?X>B W#1V9V5C3
MT;C%U,6F!RW]P,=80Z;2,&:^\0HYE)?B9:X-Z1TDSQ_CNJW^,#$!S M^H0%9
M Q4$@X&<+YM/AM#9^GBH$MJU\VH''VO47+-VL+EP6Z,O=CH+9+#U\,I!S,WS
M$J\77A:J>H.UJ^T+]J9ZN&V.5\]?C.)<<TT&,Q2USR.\3T7UI*PFBB_,,V["
M%3X*S3#%5S@(?0#W9YRK9J(-M._ZT=]02P,$%     @ K("F6A<P$F%L P
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MYET+I9LJ>:-!8$&NX>45)51U;:F;&+EQK6 M#346-ZRHDZ.R!K1?2&EV$WO
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MJ4#'!VB_L#8<%AR@__ALO@%02P,$%     @ K("F6@*;9$73 @  +@8  !D
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MZ2A!JCC7*09&;MU9RE(:))R[W !+0=D%>'\EI3D.;(#J=&WR/U!+ P04
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M%T6VJ5XZOLV*(DNJCVL1+D5>&JC?5UE6/%R4[S$W[ZW/_P=02P,$%     @
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M\?A1@HZJ>^J!A[\?T#\4SBMG;JE@EUG\=[24FXO19 26;$7S6'[)[CZRTJ%
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MLO(6CV6'S<R1':8[(W=W_GI^<P[6V8[QM%@HHFN6+NX?>4MU8_9]I(="JT?
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M51CY?L/1_D!FVV+/SFTF9984/S>,+AG7!NKZ*LODPX&^0;7M:_X_4$L#!!0
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M],LU75.H70"]7RIE]QN7H+[XDC]02P,$%     @ K("F6K/&-K6Y @  90<
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MVCG0][52=F>X /TV3_\ 4$L#!!0    ( *R IEKNTC>5\ (  .4)   9
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MOP_5]@DYC3?/E^7FG];]]K&C(VM^6U;Y:CNX/H)5FCW\._EM^X-X-F \?6'
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M!V<.+7R@FH]J M4"5 M13;H]A0^WL_I$YXPI3<]2V_9PV;9'O?K\>Y[-7UV
MFJ<='#:T 8)J/JH)5 M0+40UB6H1JL64IH>R;8"X!V^ N&@#!-4\5/-13:!:
M@&HAJDE4BU MIC0]GVT#Q#4W0+R=U>8;*WMZ3^P-&UK]0#4/U7Q4$Z@6H%J(
M:M+MJ7YT;BA%Z)PQI>DA:HL?KKGX\0,KSYT[#,8*LGGVP9E#^R.HYJ.:0+4
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M]=]?Y7GU^$4SP7U>?-L<]ME_ 5!+ P04    " "L@*9:HP)W#G8#   "#0
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M GR^$T(_3$P;W'[V)/\ 4$L#!!0    ( *R IEID5 OQ]@8  .0_   9
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M970T-BYX;6RU5]%NFS 4_16+25,GK043"*1+D-9NU2JM6I2HZT.U!P=N$E3
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MSN<0;9<X%!+5!5\PAI;1G)JKD1^<A?[ 76U'56<5=KN5U8Z[O<K=7J.[=R@
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MMR"-AVEP)B=7+;FK7G)?;;/6C"8[%/KR 5L?H#LHPB="!3R2<JN;$XKZ/%[
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M.L5F6&SLX=XXMF"J/*75L^4+A*EY@6!.P2?S5][EE3U.NP>8\JV$/H-M").
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MUT1)>=)XZ[ Q@F%5ZX=NI2R-L#_6M&11NP#ZOE;*'@QW0;^VBS]02P,$%
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M%^:+R.;NT%2TJ-QINA3:G,VN6)CK%D@;8/I70NB7BCV@NPM<\A=02P,$%
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M>,"0*++OP9WW4;AZ3X7K_V(.?P-02P,$%     @ K("F6I>*NQS     $P(
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M4$L! A0#%     @ K("F6EM/ F%6 @  208  !@              ("!SA0
M 'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    ( *R IEK>SR@_
M&P4  "$7   8              " @5H7  !X;"]W;W)K<VAE971S+W-H965T
M-"YX;6Q02P$"% ,4    " "L@*9:\::5+[P"   =!P  &
M@(&K'   >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @ K("F
M6ON2@<,)!@  5R<  !@              ("!G1\  'AL+W=O<FMS:&5E=',O
M<VAE970V+GAM;%!+ 0(4 Q0    ( *R IEH?X.9FY 8  *D=   8
M      " @=PE  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4
M" "L@*9:J#-/)TT"  "C!0  &               @('V+   >&PO=V]R:W-H
M965T<R]S:&5E=#@N>&UL4$L! A0#%     @ K("F6A.MA^M$ @  B@8  !@
M             ("!>2\  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4
M Q0    ( *R IEJV(B+IM@(  !8&   9              " @?,Q  !X;"]W
M;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @ K("F6@03JWME#
M/2   !D              ("!X#0  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX
M;6Q02P$"% ,4    " "L@*9:YYK@M>D&   N%   &0              @(%\
M00  >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( *R IEI<
MR9S+50,  # (   9              " @9Q(  !X;"]W;W)K<VAE971S+W-H
M965T,3,N>&UL4$L! A0#%     @ K("F6HU3/)]O P  M <  !D
M     ("!*$P  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( *R IEKNQ6&BI0,  #X(   9              "
M@<6*  !X;"]W;W)K<VAE971S+W-H965T,3DN>&UL4$L! A0#%     @ K("F
M6E(8#LBH P  Y <  !D              ("!H8X  'AL+W=O<FMS:&5E=',O
M<VAE970R,"YX;6Q02P$"% ,4    " "L@*9:UXNY@L "   :!@  &0
M        @(& D@  >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0
M   ( *R IEJ_%(PW-P4  (,+   9              " @7>5  !X;"]W;W)K
M<VAE971S+W-H965T,C(N>&UL4$L! A0#%     @ K("F6BT9<J6L#   5"(
M !D              ("!Y9H  'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q0
M2P$"% ,4    " "L@*9:-R /=1 %  #C#P  &0              @('(IP
M>&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    ( *R IEH7,!)A
M; ,  *\(   9              " @0^M  !X;"]W;W)K<VAE971S+W-H965T
M,C4N>&UL4$L! A0#%     @ K("F6JK_$W%V P  )P@  !D
M ("!LK   'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"% ,4    " "L
M@*9:KIEC+?\"  "(!@  &0              @(%?M   >&PO=V]R:W-H965T
M<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( *R IEH"FV1%TP(  "X&   9
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M970S,BYX;6Q02P$"% ,4    " "L@*9:&#"D::(&  ##/@  &0
M    @(&4S   >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    (
M *R IEKLT?&4] 4   (F   9              " @6W3  !X;"]W;W)K<VAE
M971S+W-H965T,S0N>&UL4$L! A0#%     @ K("F6M08='2X @  : <  !D
M             ("!F-D  'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q02P$"
M% ,4    " "L@*9:5 *79\$"   $!P  &0              @(&'W   >&PO
M=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    ( *R IEJSQC:UN0(
M &4'   9              " @7_?  !X;"]W;W)K<VAE971S+W-H965T,S<N
M>&UL4$L! A0#%     @ K("F6LK$:7$] P  _ D  !D              ("!
M;^(  'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q02P$"% ,4    " "L@*9:
MT)I3^2\#   '#   &0              @('CY0  >&PO=V]R:W-H965T<R]S
M:&5E=#,Y+GAM;%!+ 0(4 Q0    ( *R IEKUO@.6=0(  -D%   9
M      " @4GI  !X;"]W;W)K<VAE971S+W-H965T-# N>&UL4$L! A0#%
M  @ K("F6N[2-Y7P @  Y0D  !D              ("!]>L  'AL+W=O<FMS
M:&5E=',O<VAE970T,2YX;6Q02P$"% ,4    " "L@*9:$-*Y<%80  #)_@
M&0              @($<[P  >&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+
M 0(4 Q0    ( *R IEJC G<.=@,   (-   9              " @:G_  !X
M;"]W;W)K<VAE971S+W-H965T-#,N>&UL4$L! A0#%     @ K("F6F14"_'V
M!@  Y#\  !D              ("!5@,! 'AL+W=O<FMS:&5E=',O<VAE970T
M-"YX;6Q02P$"% ,4    " "L@*9:-CKZ[;<(  !W40  &0
M@(&#"@$ >&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+ 0(4 Q0    ( *R
MIEJ5;,1;/0,  "L.   9              " @7$3 0!X;"]W;W)K<VAE971S
M+W-H965T-#8N>&UL4$L! A0#%     @ K("F6E;L>G]C P  -PP  !D
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M=#4Q+GAM;%!+ 0(4 Q0    ( *R IEH8^8ZR&@,  &()   9
M  " @>8N 0!X;"]W;W)K<VAE971S+W-H965T-3(N>&UL4$L! A0#%     @
MK("F6BS@KN9; @  KP4  !D              ("!-S(! 'AL+W=O<FMS:&5E
M=',O<VAE970U,RYX;6Q02P$"% ,4    " "L@*9:4#O[]TX#  !#"0  &0
M            @(')- $ >&PO=V]R:W-H965T<R]S:&5E=#4T+GAM;%!+ 0(4
M Q0    ( *R IEH8=?W@X@,  'H1   9              " @4XX 0!X;"]W
M;W)K<VAE971S+W-H965T-34N>&UL4$L! A0#%     @ K("F6A:MJ,!F @
MP@4  !D              ("!9SP! 'AL+W=O<FMS:&5E=',O<VAE970U-BYX
M;6Q02P$"% ,4    " "L@*9:I/:9:#4"   R!0  &0              @($$
M/P$ >&PO=V]R:W-H965T<R]S:&5E=#4W+GAM;%!+ 0(4 Q0    ( *R IEJ8
MS)DYE@,  "H*   9              " @7!! 0!X;"]W;W)K<VAE971S+W-H
M965T-3@N>&UL4$L! A0#%     @ K("F6E/?S?^' @  S D  !D
M     ("!/44! 'AL+W=O<FMS:&5E=',O<VAE970U.2YX;6Q02P$"% ,4
M" "L@*9:'13AUD<#  #2%   #0              @ '[1P$ >&PO<W1Y;&5S
M+GAM;%!+ 0(4 Q0    ( *R IEJ7BKL<P    !,"   +              "
M 6U+ 0!?<F5L<R\N<F5L<U!+ 0(4 Q0    ( *R IEJ.7VLFP 0  &<G   /
M              "  59, 0!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " "L
M@*9:678!^/4!   X(P  &@              @ %#40$ >&PO7W)E;',O=V]R
M:V)O;VLN>&UL+G)E;'-02P$"% ,4    " "L@*9:%\C,&]L!  #1(@  $P
M            @ %P4P$ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     0P!#
+ $P2  !\50$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>189</ContextCount>
  <ElementCount>274</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>69</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="dawn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dayonebio.com/20250331/taxonomy/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="dawn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - Condensed Balance Sheets (unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedBalanceSheetsUnaudited</Role>
      <ShortName>Condensed Balance Sheets (unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="dawn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100040 - Statement - Condensed Balance Sheets (unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedBalanceSheetsUnauditedParenthetical</Role>
      <ShortName>Condensed Balance Sheets (unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="dawn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100050 - Statement - Condensed Statements of Operations (unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfOperationsUnaudited</Role>
      <ShortName>Condensed Statements of Operations (unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="dawn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100060 - Statement - Condensed Statements of Comprehensive Loss (unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfComprehensiveLossUnaudited</Role>
      <ShortName>Condensed Statements of Comprehensive Loss (unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="dawn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100070 - Statement - Condensed Statements of Stockholders' Equity (unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfStockholdersEquityUnaudited</Role>
      <ShortName>Condensed Statements of Stockholders' Equity (unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="dawn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>100090 - Statement - Condensed Statements of Cash Flows (unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited</Role>
      <ShortName>Condensed Statements of Cash Flows (unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="dawn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="dawn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="dawn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>995455 - Disclosure - Description of Business and Organization</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dayonebio.com/20250331/taxonomy/role/DisclosureDescriptionOfBusinessAndOrganization1</Role>
      <ShortName>Description of Business and Organization</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="dawn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>995465 - Disclosure - Summary Of Significant  Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dayonebio.com/20250331/taxonomy/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary Of Significant  Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="dawn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>995475 - Disclosure - Recurring Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dayonebio.com/20250331/taxonomy/role/DisclosureRecurringFairValueMeasurements</Role>
      <ShortName>Recurring Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="dawn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>995485 - Disclosure - Balance Sheet Items</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dayonebio.com/20250331/taxonomy/role/DisclosureBalanceSheetItems</Role>
      <ShortName>Balance Sheet Items</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="dawn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>995495 - Disclosure - Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dayonebio.com/20250331/taxonomy/role/DisclosureIntangibleAssets</Role>
      <ShortName>Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="dawn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>995505 - Disclosure - Significant Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dayonebio.com/20250331/taxonomy/role/SignificantAgreements</Role>
      <ShortName>Significant Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="dawn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>995515 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dayonebio.com/20250331/taxonomy/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="dawn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>995535 - Disclosure - Common Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dayonebio.com/20250331/taxonomy/role/DisclosureCommonStock</Role>
      <ShortName>Common Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="dawn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>995545 - Disclosure - Share-based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensation</Role>
      <ShortName>Share-based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="dawn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>995555 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dayonebio.com/20250331/taxonomy/role/DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="dawn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>995565 - Disclosure - Net Income (Loss) Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dayonebio.com/20250331/taxonomy/role/DisclosureNetIncomeLossPerShare</Role>
      <ShortName>Net Income (Loss) Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="dawn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>995585 - Disclosure - Defined Contribution Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dayonebio.com/20250331/taxonomy/role/DisclosureDefinedContributionPlan</Role>
      <ShortName>Defined Contribution Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="dawn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>995595 - Disclosure - Segment Reporting</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSegmentReporting</Role>
      <ShortName>Segment Reporting</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="dawn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>995615 - Disclosure - Summary of Significant  Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dayonebio.com/20250331/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant  Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.dayonebio.com/20250331/taxonomy/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="dawn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>995625 - Disclosure - Recurring Fair Value Measurement (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dayonebio.com/20250331/taxonomy/role/DisclosureRecurringFairValueMeasurementTables</Role>
      <ShortName>Recurring Fair Value Measurement (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.dayonebio.com/20250331/taxonomy/role/DisclosureRecurringFairValueMeasurements</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="dawn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>995635 - Disclosure - Balance Sheet Items (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dayonebio.com/20250331/taxonomy/role/DisclosureBalanceSheetItemsTables</Role>
      <ShortName>Balance Sheet Items (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.dayonebio.com/20250331/taxonomy/role/DisclosureBalanceSheetItems</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="dawn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>995645 - Disclosure - Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dayonebio.com/20250331/taxonomy/role/DisclosureIntangibleAssetsTables</Role>
      <ShortName>Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.dayonebio.com/20250331/taxonomy/role/DisclosureIntangibleAssets</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="dawn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>995655 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dayonebio.com/20250331/taxonomy/role/CommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.dayonebio.com/20250331/taxonomy/role/CommitmentsAndContingencies</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="dawn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>995665 - Disclosure - Common Stock (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dayonebio.com/20250331/taxonomy/role/DisclosureCommonStockTables</Role>
      <ShortName>Common Stock (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.dayonebio.com/20250331/taxonomy/role/DisclosureCommonStock</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="dawn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>995675 - Disclosure - Share-based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationTables</Role>
      <ShortName>Share-based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensation</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="dawn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>995685 - Disclosure - Net Income (Loss) Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dayonebio.com/20250331/taxonomy/role/DisclosureNetIncomeLossPerShareTables</Role>
      <ShortName>Net Income (Loss) Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.dayonebio.com/20250331/taxonomy/role/DisclosureNetIncomeLossPerShare</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="dawn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>995695 - Disclosure - Segment Reporting (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSegmentReportingTables</Role>
      <ShortName>Segment Reporting (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSegmentReporting</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="dawn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>995705 - Disclosure - Summary of Significant  Accounting Policies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dayonebio.com/20250331/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail</Role>
      <ShortName>Summary of Significant  Accounting Policies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="dawn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>995725 - Disclosure - Recurring Fair Value Measurement - Schedule of fair value, assets and liabilities measured on recurring basis (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dayonebio.com/20250331/taxonomy/role/DisclosureRecurringFairValueMeasurementScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail</Role>
      <ShortName>Recurring Fair Value Measurement - Schedule of fair value, assets and liabilities measured on recurring basis (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="dawn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>995735 - Disclosure - Recurring Fair Value Measurement - Schedule of cash equivalents, marketable securities, and unrealized gains and losses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dayonebio.com/20250331/taxonomy/role/DisclosureRecurringFairValueMeasurementScheduleOfCashEquivalentsMarketableSecuritiesAndUnrealizedGainsAndLossesDetails</Role>
      <ShortName>Recurring Fair Value Measurement - Schedule of cash equivalents, marketable securities, and unrealized gains and losses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="dawn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>995745 - Disclosure - Recurring Fair Value Measurement - Schedule Of Maturities For Available For Sale Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dayonebio.com/20250331/taxonomy/role/DisclosureRecurringFairValueMeasurementScheduleOfMaturitiesForAvailableForSaleSecuritiesDetails</Role>
      <ShortName>Recurring Fair Value Measurement - Schedule Of Maturities For Available For Sale Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="dawn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>995765 - Disclosure - Recurring Fair Value Measurement - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dayonebio.com/20250331/taxonomy/role/DisclosureRecurringFairValueMeasurementAdditionalInformationDetail</Role>
      <ShortName>Recurring Fair Value Measurement - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="dawn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>995775 - Disclosure - Balance Sheet Items - Summary of Prepaid and Other Current Assets (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dayonebio.com/20250331/taxonomy/role/DisclosureBalanceSheetItemsSummaryOfPrepaidAndOtherCurrentAssetsDetail</Role>
      <ShortName>Balance Sheet Items - Summary of Prepaid and Other Current Assets (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="dawn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>995785 - Disclosure - Balance Sheet Items - Summary of Accrued expenses and other current liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dayonebio.com/20250331/taxonomy/role/DisclosureBalanceSheetItemsSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetail</Role>
      <ShortName>Balance Sheet Items - Summary of Accrued expenses and other current liabilities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="dawn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>995795 - Disclosure - Intangible Assets - Schedule Of Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dayonebio.com/20250331/taxonomy/role/DisclosureIntangibleAssetsScheduleOfIntangibleAssetsDetails</Role>
      <ShortName>Intangible Assets - Schedule Of Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="dawn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>995805 - Disclosure - Intangible Assets (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dayonebio.com/20250331/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetails</Role>
      <ShortName>Intangible Assets (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.dayonebio.com/20250331/taxonomy/role/DisclosureIntangibleAssetsTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="dawn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>995815 - Disclosure - Intangible Assets - Schedule Of Amortization Expense For Amortizable Finite-Lived Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dayonebio.com/20250331/taxonomy/role/DisclosureIntangibleAssetsScheduleOfAmortizationExpenseForAmortizableFinitelivedIntangibleAssetsDetails</Role>
      <ShortName>Intangible Assets - Schedule Of Amortization Expense For Amortizable Finite-Lived Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="dawn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>995825 - Disclosure - Significant Agreements - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dayonebio.com/20250331/taxonomy/role/SignificantAgreementsAdditionalInformationDetail</Role>
      <ShortName>Significant Agreements - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="dawn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>995835 - Disclosure - Commitments and Contingencies - Summary of Future Lease Obligations (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dayonebio.com/20250331/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureLeaseObligationsDetail</Role>
      <ShortName>Commitments and Contingencies - Summary of Future Lease Obligations (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="dawn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>995845 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dayonebio.com/20250331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="dawn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>995875 - Disclosure - Common Stock - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dayonebio.com/20250331/taxonomy/role/DisclosureCommonStockAdditionalInformationDetail</Role>
      <ShortName>Common Stock - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="dawn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>995885 - Disclosure - Common Stock - Schedule of Common Stock Shares Reserved for Future Issuance (Details) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dayonebio.com/20250331/taxonomy/role/DisclosureCommonStockScheduleOfCommonStockSharesReservedForFutureIssuanceDetailsDetails</Role>
      <ShortName>Common Stock - Schedule of Common Stock Shares Reserved for Future Issuance (Details) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="dawn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>995895 - Disclosure - Share-based Compensation - Summary of Share/Stock-based Compensation Expense Recorded in The Accompanying Condensed Consolidated Statements of Operations and Comprehensive Loss (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfSharestockbasedCompensationExpenseRecordedInTheAccompanyingCondensedConsolidatedStatementsOfOperation</Role>
      <ShortName>Share-based Compensation - Summary of Share/Stock-based Compensation Expense Recorded in The Accompanying Condensed Consolidated Statements of Operations and Comprehensive Loss (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="dawn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>995905 - Disclosure - Share-based Compensation - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetail</Role>
      <ShortName>Share-based Compensation - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="dawn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>995915 - Disclosure - Share-based Compensation - Summary of Stock Option Activity (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfStockOptionActivityDetail</Role>
      <ShortName>Share-based Compensation - Summary of Stock Option Activity (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="dawn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>995925 - Disclosure - Share-based Compensation - Summary of The Black-Scholes Option Pricing Model to Estimate The Fair Value of Stock Option Granted (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfTheBlackscholesOptionPricingModelToEstimateTheFairValueOfStockOptionGrantedDetail</Role>
      <ShortName>Share-based Compensation - Summary of The Black-Scholes Option Pricing Model to Estimate The Fair Value of Stock Option Granted (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="dawn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>995935 - Disclosure - Share-based Compensation - Summary of Restricted Stock Units Activity (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfRestrictedStockUnitsActivityDetail</Role>
      <ShortName>Share-based Compensation - Summary of Restricted Stock Units Activity (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="dawn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>995945 - Disclosure - Share-based Compensation - Summary of The Unvested Common Stock (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfTheUnvestedCommonStockDetail</Role>
      <ShortName>Share-based Compensation - Summary of The Unvested Common Stock (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="dawn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>996015 - Disclosure - Income Taxes (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dayonebio.com/20250331/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>Income Taxes (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.dayonebio.com/20250331/taxonomy/role/DisclosureIncomeTaxes</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="dawn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>996025 - Disclosure - Net Income (Loss) Per Share - Summary of Basic and Diluted Net Loss Per Share Attributable to Common Shareholders/Stockholders (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dayonebio.com/20250331/taxonomy/role/DisclosureNetIncomeLossPerShareSummaryOfBasicAndDilutedNetLossPerShareAttributableToCommonShareholdersstockholdersDetail</Role>
      <ShortName>Net Income (Loss) Per Share - Summary of Basic and Diluted Net Loss Per Share Attributable to Common Shareholders/Stockholders (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.dayonebio.com/20250331/taxonomy/role/DisclosureNetIncomeLossPerShareTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="dawn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>996035 - Disclosure - Net Income (Loss) Per Share - Summary of Outstanding Potentially Dilutive Securities Have Been Excluded From Calculation of Diluted Net Loss Per Share (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dayonebio.com/20250331/taxonomy/role/DisclosureNetIncomeLossPerShareSummaryOfOutstandingPotentiallyDilutiveSecuritiesHaveBeenExcludedFromCalculationOfDilutedNetLossPerShare</Role>
      <ShortName>Net Income (Loss) Per Share - Summary of Outstanding Potentially Dilutive Securities Have Been Excluded From Calculation of Diluted Net Loss Per Share (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.dayonebio.com/20250331/taxonomy/role/DisclosureNetIncomeLossPerShareTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="dawn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>996045 - Disclosure - Defined Contribution Plan (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dayonebio.com/20250331/taxonomy/role/DisclosureDefinedContributionPlanAdditionalInformationDetails</Role>
      <ShortName>Defined Contribution Plan (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.dayonebio.com/20250331/taxonomy/role/DisclosureDefinedContributionPlan</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="dawn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>996055 - Disclosure - Segment Reporting (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSegmentReportingAdditionalInformationDetails</Role>
      <ShortName>Segment Reporting (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSegmentReportingTables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="dawn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>996065 - Disclosure - Segment Reporting - Schedule of Segment Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSegmentReportingScheduleOfSegmentInformationDetails</Role>
      <ShortName>Segment Reporting - Schedule of Segment Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="dawn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>996075 - Disclosure - Subsequent Event (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails</Role>
      <ShortName>Subsequent Event (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" isDefinitelyFs="true" isUsgaap="true" original="dawn-20250331.htm">dawn-20250331.htm</File>
    <File>dawn-20250331.xsd</File>
  </InputFiles>
  <SupplementalFiles>
    <File>img14486971_0.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="505">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="30">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/ecd/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>false</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>74
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "dawn-20250331.htm": {
   "nsprefix": "dawn",
   "nsuri": "http://www.dayonebio.com/20250331",
   "dts": {
    "inline": {
     "local": [
      "dawn-20250331.htm"
     ]
    },
    "schema": {
     "local": [
      "dawn-20250331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/2023/calculation-1.1.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    }
   },
   "keyStandard": 238,
   "keyCustom": 36,
   "axisStandard": 23,
   "axisCustom": 2,
   "memberStandard": 26,
   "memberCustom": 40,
   "hidden": {
    "total": 6,
    "http://fasb.org/us-gaap/2024": 2,
    "http://xbrl.sec.gov/dei/2024": 4
   },
   "contextCount": 189,
   "entityCount": 1,
   "segmentCount": 69,
   "elementCount": 709,
   "unitCount": 6,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 505,
    "http://xbrl.sec.gov/dei/2024": 30,
    "http://xbrl.sec.gov/ecd/2024": 4
   },
   "report": {
    "R1": {
     "role": "http://www.dayonebio.com/20250331/taxonomy/role/CoverPage",
     "longName": "100000 - Document - Cover Page",
     "shortName": "Cover Page",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "C_f6829778-ed0c-4d65-9007-5a3564f7ad3b",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dawn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f6829778-ed0c-4d65-9007-5a3564f7ad3b",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dawn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedBalanceSheetsUnaudited",
     "longName": "100010 - Statement - Condensed Balance Sheets (unaudited)",
     "shortName": "Condensed Balance Sheets (unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "C_b103f351-0eb2-495b-85c1-5630e54c751c",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dawn-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_b103f351-0eb2-495b-85c1-5630e54c751c",
      "name": "us-gaap:ShortTermInvestments",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dawn-20250331.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedBalanceSheetsUnauditedParenthetical",
     "longName": "100040 - Statement - Condensed Balance Sheets (unaudited) (Parenthetical)",
     "shortName": "Condensed Balance Sheets (unaudited) (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "C_b103f351-0eb2-495b-85c1-5630e54c751c",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dawn-20250331.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R4": {
     "role": "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfOperationsUnaudited",
     "longName": "100050 - Statement - Condensed Statements of Operations (unaudited)",
     "shortName": "Condensed Statements of Operations (unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "C_f6829778-ed0c-4d65-9007-5a3564f7ad3b",
      "name": "us-gaap:Revenues",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dawn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f6829778-ed0c-4d65-9007-5a3564f7ad3b",
      "name": "us-gaap:Revenues",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dawn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfComprehensiveLossUnaudited",
     "longName": "100060 - Statement - Condensed Statements of Comprehensive Loss (unaudited)",
     "shortName": "Condensed Statements of Comprehensive Loss (unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "C_f6829778-ed0c-4d65-9007-5a3564f7ad3b",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dawn-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f6829778-ed0c-4d65-9007-5a3564f7ad3b",
      "name": "us-gaap:ComprehensiveIncomeNetOfTax",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dawn-20250331.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfStockholdersEquityUnaudited",
     "longName": "100070 - Statement - Condensed Statements of Stockholders' Equity (unaudited)",
     "shortName": "Condensed Statements of Stockholders' Equity (unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "C_ba36f1f4-7ce5-434c-b80f-2bcb5a767c07",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dawn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_ba36f1f4-7ce5-434c-b80f-2bcb5a767c07",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dawn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited",
     "longName": "100090 - Statement - Condensed Statements of Cash Flows (unaudited)",
     "shortName": "Condensed Statements of Cash Flows (unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "C_f6829778-ed0c-4d65-9007-5a3564f7ad3b",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dawn-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f6829778-ed0c-4d65-9007-5a3564f7ad3b",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dawn-20250331.htm",
      "unique": true
     }
    },
    "R8": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "C_f6829778-ed0c-4d65-9007-5a3564f7ad3b",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dawn-20250331.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R9": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "C_f6829778-ed0c-4d65-9007-5a3564f7ad3b",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dawn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f6829778-ed0c-4d65-9007-5a3564f7ad3b",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dawn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureDescriptionOfBusinessAndOrganization1",
     "longName": "995455 - Disclosure - Description of Business and Organization",
     "shortName": "Description of Business and Organization",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "C_f6829778-ed0c-4d65-9007-5a3564f7ad3b",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dawn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f6829778-ed0c-4d65-9007-5a3564f7ad3b",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dawn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.dayonebio.com/20250331/taxonomy/role/SummaryOfSignificantAccountingPolicies",
     "longName": "995465 - Disclosure - Summary Of Significant  Accounting Policies",
     "shortName": "Summary Of Significant  Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "C_f6829778-ed0c-4d65-9007-5a3564f7ad3b",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dawn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f6829778-ed0c-4d65-9007-5a3564f7ad3b",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dawn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureRecurringFairValueMeasurements",
     "longName": "995475 - Disclosure - Recurring Fair Value Measurements",
     "shortName": "Recurring Fair Value Measurements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "C_f6829778-ed0c-4d65-9007-5a3564f7ad3b",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dawn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f6829778-ed0c-4d65-9007-5a3564f7ad3b",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dawn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureBalanceSheetItems",
     "longName": "995485 - Disclosure - Balance Sheet Items",
     "shortName": "Balance Sheet Items",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "C_f6829778-ed0c-4d65-9007-5a3564f7ad3b",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dawn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f6829778-ed0c-4d65-9007-5a3564f7ad3b",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dawn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureIntangibleAssets",
     "longName": "995495 - Disclosure - Intangible Assets",
     "shortName": "Intangible Assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "C_f6829778-ed0c-4d65-9007-5a3564f7ad3b",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dawn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f6829778-ed0c-4d65-9007-5a3564f7ad3b",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dawn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.dayonebio.com/20250331/taxonomy/role/SignificantAgreements",
     "longName": "995505 - Disclosure - Significant Agreements",
     "shortName": "Significant Agreements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "C_f6829778-ed0c-4d65-9007-5a3564f7ad3b",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dawn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f6829778-ed0c-4d65-9007-5a3564f7ad3b",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dawn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.dayonebio.com/20250331/taxonomy/role/CommitmentsAndContingencies",
     "longName": "995515 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "C_f6829778-ed0c-4d65-9007-5a3564f7ad3b",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dawn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f6829778-ed0c-4d65-9007-5a3564f7ad3b",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dawn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureCommonStock",
     "longName": "995535 - Disclosure - Common Stock",
     "shortName": "Common Stock",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "C_f6829778-ed0c-4d65-9007-5a3564f7ad3b",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dawn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f6829778-ed0c-4d65-9007-5a3564f7ad3b",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dawn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensation",
     "longName": "995545 - Disclosure - Share-based Compensation",
     "shortName": "Share-based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "C_f6829778-ed0c-4d65-9007-5a3564f7ad3b",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dawn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f6829778-ed0c-4d65-9007-5a3564f7ad3b",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dawn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureIncomeTaxes",
     "longName": "995555 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "C_f6829778-ed0c-4d65-9007-5a3564f7ad3b",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dawn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f6829778-ed0c-4d65-9007-5a3564f7ad3b",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dawn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureNetIncomeLossPerShare",
     "longName": "995565 - Disclosure - Net Income (Loss) Per Share",
     "shortName": "Net Income (Loss) Per Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "C_f6829778-ed0c-4d65-9007-5a3564f7ad3b",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dawn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f6829778-ed0c-4d65-9007-5a3564f7ad3b",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dawn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureDefinedContributionPlan",
     "longName": "995585 - Disclosure - Defined Contribution Plan",
     "shortName": "Defined Contribution Plan",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "C_f6829778-ed0c-4d65-9007-5a3564f7ad3b",
      "name": "us-gaap:DefinedContributionPlanTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dawn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f6829778-ed0c-4d65-9007-5a3564f7ad3b",
      "name": "us-gaap:DefinedContributionPlanTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dawn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSegmentReporting",
     "longName": "995595 - Disclosure - Segment Reporting",
     "shortName": "Segment Reporting",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "C_f6829778-ed0c-4d65-9007-5a3564f7ad3b",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dawn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f6829778-ed0c-4d65-9007-5a3564f7ad3b",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dawn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.dayonebio.com/20250331/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "995615 - Disclosure - Summary of Significant  Accounting Policies (Policies)",
     "shortName": "Summary of Significant  Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "23",
     "firstAnchor": {
      "contextRef": "C_f6829778-ed0c-4d65-9007-5a3564f7ad3b",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dawn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f6829778-ed0c-4d65-9007-5a3564f7ad3b",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dawn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureRecurringFairValueMeasurementTables",
     "longName": "995625 - Disclosure - Recurring Fair Value Measurement (Tables)",
     "shortName": "Recurring Fair Value Measurement (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "C_f6829778-ed0c-4d65-9007-5a3564f7ad3b",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dawn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f6829778-ed0c-4d65-9007-5a3564f7ad3b",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dawn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureBalanceSheetItemsTables",
     "longName": "995635 - Disclosure - Balance Sheet Items (Tables)",
     "shortName": "Balance Sheet Items (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "C_f6829778-ed0c-4d65-9007-5a3564f7ad3b",
      "name": "dawn:ScheduleOfPrepaidAndOtherCurrentAssetstableTextBlockTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dawn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f6829778-ed0c-4d65-9007-5a3564f7ad3b",
      "name": "dawn:ScheduleOfPrepaidAndOtherCurrentAssetstableTextBlockTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dawn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureIntangibleAssetsTables",
     "longName": "995645 - Disclosure - Intangible Assets (Tables)",
     "shortName": "Intangible Assets (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "C_f6829778-ed0c-4d65-9007-5a3564f7ad3b",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dawn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f6829778-ed0c-4d65-9007-5a3564f7ad3b",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dawn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.dayonebio.com/20250331/taxonomy/role/CommitmentsAndContingenciesTables",
     "longName": "995655 - Disclosure - Commitments and Contingencies (Tables)",
     "shortName": "Commitments and Contingencies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "C_f6829778-ed0c-4d65-9007-5a3564f7ad3b",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dawn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f6829778-ed0c-4d65-9007-5a3564f7ad3b",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dawn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureCommonStockTables",
     "longName": "995665 - Disclosure - Common Stock (Tables)",
     "shortName": "Common Stock (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "C_f6829778-ed0c-4d65-9007-5a3564f7ad3b",
      "name": "dawn:ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dawn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f6829778-ed0c-4d65-9007-5a3564f7ad3b",
      "name": "dawn:ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dawn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationTables",
     "longName": "995675 - Disclosure - Share-based Compensation (Tables)",
     "shortName": "Share-based Compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "C_f6829778-ed0c-4d65-9007-5a3564f7ad3b",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dawn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f6829778-ed0c-4d65-9007-5a3564f7ad3b",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dawn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureNetIncomeLossPerShareTables",
     "longName": "995685 - Disclosure - Net Income (Loss) Per Share (Tables)",
     "shortName": "Net Income (Loss) Per Share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "C_f6829778-ed0c-4d65-9007-5a3564f7ad3b",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dawn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f6829778-ed0c-4d65-9007-5a3564f7ad3b",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dawn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSegmentReportingTables",
     "longName": "995695 - Disclosure - Segment Reporting (Tables)",
     "shortName": "Segment Reporting (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "C_f6829778-ed0c-4d65-9007-5a3564f7ad3b",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dawn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f6829778-ed0c-4d65-9007-5a3564f7ad3b",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dawn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.dayonebio.com/20250331/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
     "longName": "995705 - Disclosure - Summary of Significant  Accounting Policies - Additional Information (Detail)",
     "shortName": "Summary of Significant  Accounting Policies - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "C_8a694c05-0437-4c75-8ae6-45e4b83604d0",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:ConcentrationRiskCreditRisk",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dawn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_8a694c05-0437-4c75-8ae6-45e4b83604d0",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:ConcentrationRiskCreditRisk",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dawn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureRecurringFairValueMeasurementScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail",
     "longName": "995725 - Disclosure - Recurring Fair Value Measurement - Schedule of fair value, assets and liabilities measured on recurring basis (Detail)",
     "shortName": "Recurring Fair Value Measurement - Schedule of fair value, assets and liabilities measured on recurring basis (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "C_b77b4a90-bf68-4a05-8f01-62a9520247e8",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dawn-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3e17f855-9bc9-4474-9b6f-1728c5807a4b",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dawn-20250331.htm",
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureRecurringFairValueMeasurementScheduleOfCashEquivalentsMarketableSecuritiesAndUnrealizedGainsAndLossesDetails",
     "longName": "995735 - Disclosure - Recurring Fair Value Measurement - Schedule of cash equivalents, marketable securities, and unrealized gains and losses (Details)",
     "shortName": "Recurring Fair Value Measurement - Schedule of cash equivalents, marketable securities, and unrealized gains and losses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "C_b103f351-0eb2-495b-85c1-5630e54c751c",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dawn-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7a2a1b79-4a52-4f59-8224-b2b1f9654b55",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dawn-20250331.htm",
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureRecurringFairValueMeasurementScheduleOfMaturitiesForAvailableForSaleSecuritiesDetails",
     "longName": "995745 - Disclosure - Recurring Fair Value Measurement - Schedule Of Maturities For Available For Sale Securities (Details)",
     "shortName": "Recurring Fair Value Measurement - Schedule Of Maturities For Available For Sale Securities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "C_b103f351-0eb2-495b-85c1-5630e54c751c",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "dawn:ScheduleOfMaturitiesForAvailableForSaleSecuritiesTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dawn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_b103f351-0eb2-495b-85c1-5630e54c751c",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "dawn:ScheduleOfMaturitiesForAvailableForSaleSecuritiesTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dawn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureRecurringFairValueMeasurementAdditionalInformationDetail",
     "longName": "995765 - Disclosure - Recurring Fair Value Measurement - Additional Information (Detail)",
     "shortName": "Recurring Fair Value Measurement - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "C_f6829778-ed0c-4d65-9007-5a3564f7ad3b",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dawn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f6829778-ed0c-4d65-9007-5a3564f7ad3b",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dawn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureBalanceSheetItemsSummaryOfPrepaidAndOtherCurrentAssetsDetail",
     "longName": "995775 - Disclosure - Balance Sheet Items - Summary of Prepaid and Other Current Assets (Detail)",
     "shortName": "Balance Sheet Items - Summary of Prepaid and Other Current Assets (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "C_b103f351-0eb2-495b-85c1-5630e54c751c",
      "name": "dawn:PrepaidResearchAndDevelopmentExpenses",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "dawn:ScheduleOfPrepaidAndOtherCurrentAssetstableTextBlockTableTextBlock",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dawn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_b103f351-0eb2-495b-85c1-5630e54c751c",
      "name": "dawn:PrepaidResearchAndDevelopmentExpenses",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "dawn:ScheduleOfPrepaidAndOtherCurrentAssetstableTextBlockTableTextBlock",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dawn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureBalanceSheetItemsSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetail",
     "longName": "995785 - Disclosure - Balance Sheet Items - Summary of Accrued expenses and other current liabilities (Detail)",
     "shortName": "Balance Sheet Items - Summary of Accrued expenses and other current liabilities (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "C_b103f351-0eb2-495b-85c1-5630e54c751c",
      "name": "dawn:AccruedLicenseAgreementUpfrontPayment",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dawn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_b103f351-0eb2-495b-85c1-5630e54c751c",
      "name": "dawn:AccruedLicenseAgreementUpfrontPayment",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dawn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureIntangibleAssetsScheduleOfIntangibleAssetsDetails",
     "longName": "995795 - Disclosure - Intangible Assets - Schedule Of Intangible Assets (Details)",
     "shortName": "Intangible Assets - Schedule Of Intangible Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "C_b103f351-0eb2-495b-85c1-5630e54c751c",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "div",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dawn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_b103f351-0eb2-495b-85c1-5630e54c751c",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "div",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dawn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetails",
     "longName": "995805 - Disclosure - Intangible Assets (Additional Information) (Details)",
     "shortName": "Intangible Assets (Additional Information) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "C_f6829778-ed0c-4d65-9007-5a3564f7ad3b",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dawn-20250331.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R41": {
     "role": "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureIntangibleAssetsScheduleOfAmortizationExpenseForAmortizableFinitelivedIntangibleAssetsDetails",
     "longName": "995815 - Disclosure - Intangible Assets - Schedule Of Amortization Expense For Amortizable Finite-Lived Intangible Assets (Details)",
     "shortName": "Intangible Assets - Schedule Of Amortization Expense For Amortizable Finite-Lived Intangible Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "C_b103f351-0eb2-495b-85c1-5630e54c751c",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "div",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dawn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_b103f351-0eb2-495b-85c1-5630e54c751c",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "div",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dawn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.dayonebio.com/20250331/taxonomy/role/SignificantAgreementsAdditionalInformationDetail",
     "longName": "995825 - Disclosure - Significant Agreements - Additional Information (Detail)",
     "shortName": "Significant Agreements - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "C_b103f351-0eb2-495b-85c1-5630e54c751c",
      "name": "us-gaap:FiniteLivedIntangibleAssetsNet",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "div",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dawn-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e9b4d1c1-00d7-4c4a-8ead-1b510859ed98",
      "name": "dawn:UpfrontOfCashPayment",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dawn-20250331.htm",
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureLeaseObligationsDetail",
     "longName": "995835 - Disclosure - Commitments and Contingencies - Summary of Future Lease Obligations (Detail)",
     "shortName": "Commitments and Contingencies - Summary of Future Lease Obligations (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "C_b103f351-0eb2-495b-85c1-5630e54c751c",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dawn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_b103f351-0eb2-495b-85c1-5630e54c751c",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dawn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
     "longName": "995845 - Disclosure - Commitments and Contingencies - Additional Information (Detail)",
     "shortName": "Commitments and Contingencies - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "C_2f4d68d5-969e-46de-b564-f0c6755d1515",
      "name": "us-gaap:LesseeOperatingLeaseTermOfContract",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dawn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2f4d68d5-969e-46de-b564-f0c6755d1515",
      "name": "us-gaap:LesseeOperatingLeaseTermOfContract",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dawn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureCommonStockAdditionalInformationDetail",
     "longName": "995875 - Disclosure - Common Stock - Additional Information (Detail)",
     "shortName": "Common Stock - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "C_b103f351-0eb2-495b-85c1-5630e54c751c",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dawn-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_388de2bd-eeb7-4fa1-87a1-3cdac91fa91d",
      "name": "us-gaap:CommonStockSharesIssued",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dawn-20250331.htm",
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureCommonStockScheduleOfCommonStockSharesReservedForFutureIssuanceDetailsDetails",
     "longName": "995885 - Disclosure - Common Stock - Schedule of Common Stock Shares Reserved for Future Issuance (Details) (Details)",
     "shortName": "Common Stock - Schedule of Common Stock Shares Reserved for Future Issuance (Details) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "C_b103f351-0eb2-495b-85c1-5630e54c751c",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "dawn:ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dawn-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0ddc2569-0696-4885-b32d-8451ee567481",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "dawn:ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dawn-20250331.htm",
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfSharestockbasedCompensationExpenseRecordedInTheAccompanyingCondensedConsolidatedStatementsOfOperation",
     "longName": "995895 - Disclosure - Share-based Compensation - Summary of Share/Stock-based Compensation Expense Recorded in The Accompanying Condensed Consolidated Statements of Operations and Comprehensive Loss (Detail)",
     "shortName": "Share-based Compensation - Summary of Share/Stock-based Compensation Expense Recorded in The Accompanying Condensed Consolidated Statements of Operations and Comprehensive Loss (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "C_f6829778-ed0c-4d65-9007-5a3564f7ad3b",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dawn-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7d91f4bf-04a0-434b-a91a-e1fd4c41cbe1",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dawn-20250331.htm",
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetail",
     "longName": "995905 - Disclosure - Share-based Compensation - Additional Information (Detail)",
     "shortName": "Share-based Compensation - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "C_f6829778-ed0c-4d65-9007-5a3564f7ad3b",
      "name": "us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dawn-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_fd702879-0dc1-44c9-85ec-00d54500225b",
      "name": "dawn:UnamortizedStockBasedCompensationForStockOptions",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dawn-20250331.htm",
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfStockOptionActivityDetail",
     "longName": "995915 - Disclosure - Share-based Compensation - Summary of Stock Option Activity (Detail)",
     "shortName": "Share-based Compensation - Summary of Stock Option Activity (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "C_dcf6712c-475d-4506-9554-ded223b0331a",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dawn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_dcf6712c-475d-4506-9554-ded223b0331a",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dawn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfTheBlackscholesOptionPricingModelToEstimateTheFairValueOfStockOptionGrantedDetail",
     "longName": "995925 - Disclosure - Share-based Compensation - Summary of The Black-Scholes Option Pricing Model to Estimate The Fair Value of Stock Option Granted (Detail)",
     "shortName": "Share-based Compensation - Summary of The Black-Scholes Option Pricing Model to Estimate The Fair Value of Stock Option Granted (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "C_910c0420-f57a-418a-8295-ee1ffb7bd08a",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "dawn:ScheduleOfStockOptionsAssumptionsTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dawn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_910c0420-f57a-418a-8295-ee1ffb7bd08a",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "dawn:ScheduleOfStockOptionsAssumptionsTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dawn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfRestrictedStockUnitsActivityDetail",
     "longName": "995935 - Disclosure - Share-based Compensation - Summary of Restricted Stock Units Activity (Detail)",
     "shortName": "Share-based Compensation - Summary of Restricted Stock Units Activity (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "C_27899ba1-a824-4fc6-ac6a-83ca5fb4f9b5",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dawn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_27899ba1-a824-4fc6-ac6a-83ca5fb4f9b5",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dawn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfTheUnvestedCommonStockDetail",
     "longName": "995945 - Disclosure - Share-based Compensation - Summary of The Unvested Common Stock (Detail)",
     "shortName": "Share-based Compensation - Summary of The Unvested Common Stock (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "C_3ef9f2ba-6c3d-4611-94f4-9657c80e0ee2",
      "name": "dawn:ShareBasedCompensationByShareBasedPaymentArrangementEquityInstrumentsOtherThanOptionsOutstanding",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dawn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3ef9f2ba-6c3d-4611-94f4-9657c80e0ee2",
      "name": "dawn:ShareBasedCompensationByShareBasedPaymentArrangementEquityInstrumentsOtherThanOptionsOutstanding",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dawn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails",
     "longName": "996015 - Disclosure - Income Taxes (Additional Information) (Details)",
     "shortName": "Income Taxes (Additional Information) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "C_f6829778-ed0c-4d65-9007-5a3564f7ad3b",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dawn-20250331.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R54": {
     "role": "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureNetIncomeLossPerShareSummaryOfBasicAndDilutedNetLossPerShareAttributableToCommonShareholdersstockholdersDetail",
     "longName": "996025 - Disclosure - Net Income (Loss) Per Share - Summary of Basic and Diluted Net Loss Per Share Attributable to Common Shareholders/Stockholders (Detail)",
     "shortName": "Net Income (Loss) Per Share - Summary of Basic and Diluted Net Loss Per Share Attributable to Common Shareholders/Stockholders (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "C_f6829778-ed0c-4d65-9007-5a3564f7ad3b",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dawn-20250331.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R55": {
     "role": "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureNetIncomeLossPerShareSummaryOfOutstandingPotentiallyDilutiveSecuritiesHaveBeenExcludedFromCalculationOfDilutedNetLossPerShare",
     "longName": "996035 - Disclosure - Net Income (Loss) Per Share - Summary of Outstanding Potentially Dilutive Securities Have Been Excluded From Calculation of Diluted Net Loss Per Share (Detail)",
     "shortName": "Net Income (Loss) Per Share - Summary of Outstanding Potentially Dilutive Securities Have Been Excluded From Calculation of Diluted Net Loss Per Share (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "C_f6829778-ed0c-4d65-9007-5a3564f7ad3b",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dawn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f6829778-ed0c-4d65-9007-5a3564f7ad3b",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dawn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureDefinedContributionPlanAdditionalInformationDetails",
     "longName": "996045 - Disclosure - Defined Contribution Plan (Additional Information) (Details)",
     "shortName": "Defined Contribution Plan (Additional Information) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "C_f6829778-ed0c-4d65-9007-5a3564f7ad3b",
      "name": "dawn:DefinedContributionPlanEmployerMatchingContribution",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:DefinedContributionPlanTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dawn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f6829778-ed0c-4d65-9007-5a3564f7ad3b",
      "name": "dawn:DefinedContributionPlanEmployerMatchingContribution",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:DefinedContributionPlanTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dawn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSegmentReportingAdditionalInformationDetails",
     "longName": "996055 - Disclosure - Segment Reporting (Additional Information) (Details)",
     "shortName": "Segment Reporting (Additional Information) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "C_f6829778-ed0c-4d65-9007-5a3564f7ad3b",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "U_Segment",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dawn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f6829778-ed0c-4d65-9007-5a3564f7ad3b",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "U_Segment",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dawn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R58": {
     "role": "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSegmentReportingScheduleOfSegmentInformationDetails",
     "longName": "996065 - Disclosure - Segment Reporting - Schedule of Segment Information (Details)",
     "shortName": "Segment Reporting - Schedule of Segment Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "C_f6829778-ed0c-4d65-9007-5a3564f7ad3b",
      "name": "dawn:Third-PartyCROCMOAndOtherThird-PartyClinicalTrialCosts",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "div",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dawn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f6829778-ed0c-4d65-9007-5a3564f7ad3b",
      "name": "dawn:Third-PartyCROCMOAndOtherThird-PartyClinicalTrialCosts",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "div",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dawn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R59": {
     "role": "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails",
     "longName": "996075 - Disclosure - Subsequent Event (Additional Information) (Details)",
     "shortName": "Subsequent Event (Additional Information) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "C_b103f351-0eb2-495b-85c1-5630e54c751c",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dawn-20250331.htm",
      "first": true
     },
     "uniqueAnchor": null
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dawn_AccountingPoliciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.dayonebio.com/20250331",
     "localname": "AccountingPoliciesLineItems",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Line Items]",
        "documentation": "Accounting Policies LineItems."
       }
      }
     },
     "auth_ref": []
    },
    "dawn_AccountingPoliciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.dayonebio.com/20250331",
     "localname": "AccountingPoliciesTable",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Table]",
        "documentation": "Accounting Policies Table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureBalanceSheetItemsSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureBalanceSheetItemsSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total accrued expenses and other current liabilities",
        "label": "Accounts Payable and Accrued Liabilities, Current",
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r63"
     ]
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Accounts Payable, Current",
        "totalLabel": "Accounts Payable, Current, Total",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r753"
     ]
    },
    "dawn_AccountsReceivableCreditLosses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dayonebio.com/20250331",
     "localname": "AccountsReceivableCreditLosses",
     "crdr": "credit",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts receivable, credit losses",
        "label": "Accounts Receivable, Credit Losses",
        "documentation": "Accounts Receivable, Credit Losses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsReceivableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivableMember",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts Receivable [Member]",
        "label": "Accounts Receivable [Member]",
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold."
       }
      }
     },
     "auth_ref": [
      "r689"
     ]
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "negatedLabel": "Accretion of discounts on short-term investments, net",
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r94"
     ]
    },
    "dawn_AccruedFederalAndStateTaxPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dayonebio.com/20250331",
     "localname": "AccruedFederalAndStateTaxPayments",
     "crdr": "credit",
     "calculation": {
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureBalanceSheetItemsSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetail": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureBalanceSheetItemsSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Federal And State Tax Payments",
        "documentation": "Accrued Federal And State Tax Payments",
        "terseLabel": "Accrued federal and state taxes"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesAndOtherLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesAndOtherLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses and other current liabilities",
        "label": "Accrued Liabilities and Other Liabilities",
        "totalLabel": "Accrued Liabilities and Other Liabilities, Total",
        "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "dawn_AccruedLicenseAgreementUpfrontPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dayonebio.com/20250331",
     "localname": "AccruedLicenseAgreementUpfrontPayment",
     "crdr": "credit",
     "calculation": {
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureBalanceSheetItemsSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetail": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureBalanceSheetItemsSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued license agreement upfront payment",
        "label": "Accrued license agreement upfront payment",
        "documentation": "Accrued license agreement upfront payment"
       }
      }
     },
     "auth_ref": []
    },
    "dawn_AccruedMilestonePayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dayonebio.com/20250331",
     "localname": "AccruedMilestonePayment",
     "crdr": "credit",
     "calculation": {
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureBalanceSheetItemsSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetail": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureBalanceSheetItemsSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued milestone payment",
        "label": "Accrued Milestone Payment",
        "documentation": "Accrued Milestone Payment"
       }
      }
     },
     "auth_ref": []
    },
    "dawn_AccruedPayrollRelatedExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dayonebio.com/20250331",
     "localname": "AccruedPayrollRelatedExpenses",
     "crdr": "credit",
     "calculation": {
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureBalanceSheetItemsSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetail": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureBalanceSheetItemsSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Payroll Related Expenses",
        "label": "Accrued Payroll Related Expenses",
        "terseLabel": "Accrued payroll related expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedProfessionalFeesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureBalanceSheetItemsSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetail": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureBalanceSheetItemsSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accrued professional service expenses",
        "label": "Accrued Professional Fees, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "dawn_AccruedRebates": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dayonebio.com/20250331",
     "localname": "AccruedRebates",
     "crdr": "credit",
     "calculation": {
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureBalanceSheetItemsSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetail": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureBalanceSheetItemsSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Rebates",
        "documentation": "Accrued Rebates",
        "terseLabel": "Accrued rebates"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated other comprehensive (loss) income",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "totalLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax, Total",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r14",
      "r78",
      "r149",
      "r555",
      "r583",
      "r584"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r7",
      "r14",
      "r416",
      "r419",
      "r471",
      "r579",
      "r580",
      "r891",
      "r892",
      "r893",
      "r901",
      "r902",
      "r903",
      "r904"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure [Text Block]",
        "terseLabel": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r818"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional\u00a0paid-in-capital",
        "label": "Additional Paid in Capital",
        "totalLabel": "Additional Paid in Capital, Total",
        "periodStartLabel": "Additional Paid in Capital, Beginning Balance",
        "periodEndLabel": "Additional Paid in Capital, Ending Balance",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r753",
      "r1048"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Additional Paid-in Capital [Member]",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r596",
      "r901",
      "r902",
      "r903",
      "r904",
      "r982",
      "r1051"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation Amount",
        "terseLabel": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r831"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]",
        "terseLabel": "Adjustment to Compensation:"
       }
      }
     },
     "auth_ref": [
      "r831"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]",
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r831"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]",
        "terseLabel": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r831"
     ]
    },
    "dawn_AdjustmentsRelatingToPriorYears": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dayonebio.com/20250331",
     "localname": "AdjustmentsRelatingToPriorYears",
     "crdr": "credit",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummarizesOfBalancesAndActivityTheProductRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments Relating to Prior Years",
        "terseLabel": "Adjustments relating to prior years",
        "documentation": "Adjustments Relating to Prior Years"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation expenses",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "totalLabel": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r49",
      "r350"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
     "crdr": "credit",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Additional Paid in Capital, Warrant Issued",
        "terseLabel": "Issuance of prefunded warrants to purchase common stock, net of issuance costs",
        "verboseLabel": "Issuance of prefunded warrants to purchase common stock in connection with private placement, net of issuance costs",
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r31",
      "r104"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:",
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdministrativeFeesExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdministrativeFeesExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Upfront License Fee",
        "label": "Administrative Fees Expense",
        "documentation": "Amount of expense for administrative fee from service provided, including, but not limited to, salary, rent, or overhead cost."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r643",
      "r1050"
     ]
    },
    "dawn_AggregateOfUpfrontLicenseFeeReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dayonebio.com/20250331",
     "localname": "AggregateOfUpfrontLicenseFeeReceived",
     "crdr": "debit",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/SignificantAgreementsAdditionalInformationDetail",
      "http://www.dayonebio.com/20250331/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate Of Upfront License Fee Received",
        "label": "Aggregate Of Upfront License Fee Received",
        "terseLabel": "Aggregate Of Upfront License Fee Received"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r864"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount",
        "terseLabel": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r790",
      "r800",
      "r810",
      "r842"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]",
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r793",
      "r803",
      "r813",
      "r845"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Pension Adjustments Service Cost [Member]",
        "terseLabel": "Aggregate Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r865"
     ]
    },
    "dawn_AgreementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.dayonebio.com/20250331",
     "localname": "AgreementAxis",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureCommonStockAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Agreement [Axis]",
        "documentation": "Agreement Axis"
       }
      }
     },
     "auth_ref": []
    },
    "dawn_AgreementDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dayonebio.com/20250331",
     "localname": "AgreementDomain",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureCommonStockAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Agreement [Domain]",
        "documentation": "Agreement Domain"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Adjustments to Compensation [Member]",
        "terseLabel": "All Adjustments to Compensation"
       }
      }
     },
     "auth_ref": [
      "r831"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Executive Categories [Member]",
        "terseLabel": "All Executive Categories"
       }
      }
     },
     "auth_ref": [
      "r838"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Individuals [Member]",
        "terseLabel": "All Individuals"
       }
      }
     },
     "auth_ref": [
      "r794",
      "r804",
      "r814",
      "r838",
      "r846",
      "r850",
      "r858"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Trading Arrangements [Member]",
        "terseLabel": "All Trading Arrangements"
       }
      }
     },
     "auth_ref": [
      "r856"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetail",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfSharestockbasedCompensationExpenseRecordedInTheAccompanyingCondensedConsolidatedStatementsOfOperation",
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Share-based compensation expense",
        "terseLabel": "Allocated share based compensation expense",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r380",
      "r384"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AmortizationOfIntangibleAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetails",
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of intangible assets",
        "verboseLabel": "Amortization Of Intangible Assets",
        "label": "Amortization of Intangible Assets",
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r285",
      "r288",
      "r729"
     ]
    },
    "us-gaap_AmountOfDilutiveSecuritiesStockOptionsAndRestrictiveStockUnits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AmountOfDilutiveSecuritiesStockOptionsAndRestrictiveStockUnits",
     "crdr": "credit",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureNetIncomeLossPerShareSummaryOfBasicAndDilutedNetLossPerShareAttributableToCommonShareholdersstockholdersDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dilutive Securities, Effect on Basic Earnings Per Share, Options and Restrictive Stock Units",
        "documentation": "Amount of increase (decrease) to net income used for calculating diluted earnings per share (EPS), resulting from the assumed exercise of stock options or restrictive stock units (RSUs)."
       }
      }
     },
     "auth_ref": [
      "r906"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureNetIncomeLossPerShareSummaryOfOutstandingPotentiallyDilutiveSecuritiesHaveBeenExcludedFromCalculationOfDilutedNetLossPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Stock options",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r197"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureNetIncomeLossPerShareSummaryOfBasicAndDilutedNetLossPerShareAttributableToCommonShareholdersstockholdersDetail",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureNetIncomeLossPerShareSummaryOfOutstandingPotentiallyDilutiveSecuritiesHaveBeenExcludedFromCalculationOfDilutedNetLossPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureNetIncomeLossPerShareSummaryOfBasicAndDilutedNetLossPerShareAttributableToCommonShareholdersstockholdersDetail",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureNetIncomeLossPerShareSummaryOfOutstandingPotentiallyDilutiveSecuritiesHaveBeenExcludedFromCalculationOfDilutedNetLossPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureNetIncomeLossPerShareSummaryOfBasicAndDilutedNetLossPerShareAttributableToCommonShareholdersstockholdersDetail",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureNetIncomeLossPerShareSummaryOfOutstandingPotentiallyDilutiveSecuritiesHaveBeenExcludedFromCalculationOfDilutedNetLossPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "us-gaap_AreaOfLand": {
     "xbrltype": "areaItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AreaOfLand",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Area of Land",
        "terseLabel": "Sublease agreement area",
        "documentation": "Area of land held."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureIntangibleAssetsScheduleOfIntangibleAssetsDetails",
      "http://www.dayonebio.com/20250331/taxonomy/role/SignificantAgreementsAdditionalInformationDetail",
      "http://www.dayonebio.com/20250331/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r410"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedBalanceSheetsUnaudited": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r123",
      "r145",
      "r169",
      "r201",
      "r209",
      "r225",
      "r228",
      "r269",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r411",
      "r413",
      "r449",
      "r550",
      "r636",
      "r720",
      "r721",
      "r753",
      "r781",
      "r945",
      "r946",
      "r1004"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current",
        "totalLabel": "Total current assets",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r141",
      "r151",
      "r169",
      "r269",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r411",
      "r413",
      "r449",
      "r753",
      "r945",
      "r946",
      "r1004"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "auth_ref": []
    },
    "dawn_AtTheMarketMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dayonebio.com/20250331",
     "localname": "AtTheMarketMember",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureCommonStockAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "At The Market [Member]",
        "documentation": "At The Market [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dawn_AustinTXMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dayonebio.com/20250331",
     "localname": "AustinTXMember",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Austin, TX [Member]",
        "documentation": "Austin, TX [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "crdr": "debit",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureRecurringFairValueMeasurementScheduleOfCashEquivalentsMarketableSecuritiesAndUnrealizedGainsAndLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt securities, available-for-sale, amortized cost",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "totalLabel": "Debt Securities, Available-for-Sale, Amortized Cost, Total",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r239",
      "r277",
      "r549"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleDebtSecuritiesGrossUnrealizedGain",
     "crdr": "credit",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureRecurringFairValueMeasurementScheduleOfCashEquivalentsMarketableSecuritiesAndUnrealizedGainsAndLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt securities, available-for-sale, unrealized gain",
        "label": "Debt Securities, Available-for-Sale, Unrealized Gain",
        "documentation": "Amount of unrealized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r914"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleDebtSecuritiesGrossUnrealizedLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureRecurringFairValueMeasurementScheduleOfCashEquivalentsMarketableSecuritiesAndUnrealizedGainsAndLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt securities, available-for-sale, unrealized loss",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss",
        "negatedLabel": "Debt securities, available-for-sale, unrealized loss",
        "documentation": "Amount of unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r915"
     ]
    },
    "dawn_AvailableForSaleSecuritie": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dayonebio.com/20250331",
     "localname": "AvailableForSaleSecuritie",
     "crdr": "debit",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureRecurringFairValueMeasurementScheduleOfMaturitiesForAvailableForSaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value",
        "label": "Available For Sale Securitie",
        "documentation": "Available For Sale Securitie"
       }
      }
     },
     "auth_ref": []
    },
    "dawn_AvailableForSaleSecuritieAmortizedCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dayonebio.com/20250331",
     "localname": "AvailableForSaleSecuritieAmortizedCost",
     "crdr": "debit",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureRecurringFairValueMeasurementScheduleOfMaturitiesForAvailableForSaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortized Cost",
        "label": "Available For Sale Securitie Amortized Cost",
        "documentation": "Available For Sale Securitie Amortized Cost"
       }
      }
     },
     "auth_ref": []
    },
    "dawn_AvailableForSaleSecuritieContinuousUnrealizedLossPositionAccumulatedLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dayonebio.com/20250331",
     "localname": "AvailableForSaleSecuritieContinuousUnrealizedLossPositionAccumulatedLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureRecurringFairValueMeasurementScheduleOfAvailableforsaleMarketableSecuritiesWithGrossUnrealizedLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Available For Sale Securitie Continuous Unrealized Loss Position Accumulated Loss",
        "documentation": "Available For Sale Securitie Continuous Unrealized Loss Position Accumulated Loss",
        "terseLabel": "Unrealized Losses"
       }
      }
     },
     "auth_ref": []
    },
    "dawn_AvailableForSaleSecuritieContinuousUnrealizedLossPositionFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dayonebio.com/20250331",
     "localname": "AvailableForSaleSecuritieContinuousUnrealizedLossPositionFairValue",
     "crdr": "debit",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureRecurringFairValueMeasurementScheduleOfAvailableforsaleMarketableSecuritiesWithGrossUnrealizedLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value",
        "label": "Available For Sale Securitie Continuous Unrealized Loss Position Fair Value",
        "documentation": "Available For Sale Securitie Continuous Unrealized Loss Position Fair Value"
       }
      }
     },
     "auth_ref": []
    },
    "dawn_AvailableForSaleSecuritieContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dayonebio.com/20250331",
     "localname": "AvailableForSaleSecuritieContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureRecurringFairValueMeasurementScheduleOfAvailableforsaleMarketableSecuritiesWithGrossUnrealizedLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized Losses Less Than 12 Months, Unrealized losses",
        "label": "Available For Sale Securitie Continuous Unrealized Loss Position Less Than 12 Months Accumulated Loss",
        "documentation": "Available For Sale Securitie Continuous Unrealized Loss Position Less Than 12 Months Accumulated Loss"
       }
      }
     },
     "auth_ref": []
    },
    "dawn_AvailableForSaleSecuritieContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dayonebio.com/20250331",
     "localname": "AvailableForSaleSecuritieContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue",
     "crdr": "debit",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureRecurringFairValueMeasurementScheduleOfAvailableforsaleMarketableSecuritiesWithGrossUnrealizedLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized Losses Less Than 12 Months, Fair value",
        "label": "Available For Sale Securitie Continuous Unrealized Loss Position Less Than Twelve Months Fair Value",
        "documentation": "Available For Sale Securitie Continuous Unrealized Loss Position Less Than Twelve Months Fair Value"
       }
      }
     },
     "auth_ref": []
    },
    "dawn_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionMoreThan12MonthsAccumulatedLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dayonebio.com/20250331",
     "localname": "AvailableForSaleSecuritiesContinuousUnrealizedLossPositionMoreThan12MonthsAccumulatedLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureRecurringFairValueMeasurementScheduleOfAvailableforsaleMarketableSecuritiesWithGrossUnrealizedLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Available For Sale Securities Continuous Unrealized Loss Position More Than 12 Months Accumulated Loss",
        "documentation": "Available For Sale Securities Continuous Unrealized Loss Position More Than 12 Months Accumulated Loss",
        "terseLabel": "Unrealized losses 12 months or greater, Unrealized Losses"
       }
      }
     },
     "auth_ref": []
    },
    "dawn_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionMoreThanTwelveMonthsFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dayonebio.com/20250331",
     "localname": "AvailableForSaleSecuritiesContinuousUnrealizedLossPositionMoreThanTwelveMonthsFairValue",
     "crdr": "debit",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureRecurringFairValueMeasurementScheduleOfAvailableforsaleMarketableSecuritiesWithGrossUnrealizedLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Available For Sale Securities Continuous Unrealized Loss Position More Than Twelve Months Fair Value",
        "documentation": "Available For Sale Securities Continuous Unrealized Loss Position More Than Twelve Months Fair Value",
        "terseLabel": "Unrealized losses 12 months or greater, Fair Value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate",
     "crdr": "debit",
     "calculation": {
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureRecurringFairValueMeasurementScheduleOfMaturitiesForAvailableForSaleSecuritiesDetails2": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureRecurringFairValueMeasurementScheduleOfMaturitiesForAvailableForSaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Fair value, total",
        "label": "Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Fair Value",
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date."
       }
      }
     },
     "auth_ref": [
      "r916",
      "r917",
      "r1015"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis",
     "crdr": "debit",
     "calculation": {
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureRecurringFairValueMeasurementScheduleOfMaturitiesForAvailableForSaleSecuritiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureRecurringFairValueMeasurementScheduleOfMaturitiesForAvailableForSaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Amortized cost, total",
        "label": "Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Amortized Cost",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date."
       }
      }
     },
     "auth_ref": [
      "r916",
      "r917",
      "r1014"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
     "crdr": "debit",
     "calculation": {
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureRecurringFairValueMeasurementScheduleOfMaturitiesForAvailableForSaleSecuritiesDetails": {
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureRecurringFairValueMeasurementScheduleOfMaturitiesForAvailableForSaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortized cost, mature in one year or less",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r918"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
     "crdr": "debit",
     "calculation": {
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureRecurringFairValueMeasurementScheduleOfMaturitiesForAvailableForSaleSecuritiesDetails2": {
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureRecurringFairValueMeasurementScheduleOfMaturitiesForAvailableForSaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value, mature in one year or less",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One",
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r246",
      "r547"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "crdr": "debit",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureRecurringFairValueMeasurementScheduleOfCashEquivalentsMarketableSecuritiesAndUnrealizedGainsAndLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt securities, available-for-sale, estimated fair value",
        "label": "Debt Securities, Available-for-Sale",
        "totalLabel": "Debt Securities, Available-for-Sale, Total",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r240",
      "r277",
      "r427",
      "r543",
      "r742",
      "r745",
      "r913",
      "r986",
      "r987",
      "r988"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Exercise Price",
        "terseLabel": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r853"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Grant Date Fair Value",
        "terseLabel": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r854"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]",
        "terseLabel": "Award Timing Disclosures"
       }
      }
     },
     "auth_ref": [
      "r849"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered [Text Block]",
        "terseLabel": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r849"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method [Text Block]",
        "terseLabel": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r849"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered [Flag]",
        "terseLabel": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r849"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure [Text Block]",
        "terseLabel": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r849"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined [Flag]",
        "terseLabel": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r849"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureCommonStockScheduleOfCommonStockSharesReservedForFutureIssuanceDetailsDetails",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetail",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfPerformanceStockOptionsActivityDetails",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfPerformanceStockUnitsActivityDetails",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfRestrictedStockUnitsActivityDetail",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfTheBlackscholesOptionPricingModelToEstimateTheFairValueOfPerformanceStockOpDetails",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfTheBlackscholesOptionPricingModelToEstimateTheFairValueOfStockOptionGrantedDetail",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfTheIncentiveSharesActivityDetail",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Underlying Securities Amount",
        "terseLabel": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r852"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r851"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures"
       }
      }
     },
     "auth_ref": [
      "r850"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r850"
     ]
    },
    "us-gaap_BalanceSheetRelatedDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BalanceSheetRelatedDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Balance Sheet Related Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Basis of Presentation",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "dawn_BasisOfIssueAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.dayonebio.com/20250331",
     "localname": "BasisOfIssueAxis",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/RedeemableConvertiblePreferredSharesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Issue [Axis]",
        "documentation": "Basis Of Issue Axis"
       }
      }
     },
     "auth_ref": []
    },
    "dawn_BasisOfIssueDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dayonebio.com/20250331",
     "localname": "BasisOfIssueDomain",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/RedeemableConvertiblePreferredSharesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Issue [Domain]",
        "documentation": "Basis Of Issue Domain"
       }
      }
     },
     "auth_ref": []
    },
    "dawn_BrisbaneCaliforniaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dayonebio.com/20250331",
     "localname": "BrisbaneCaliforniaMember",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Brisbane, California [Member]",
        "label": "Brisbane, California [Member]",
        "terseLabel": "Brisbane, California"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r20",
      "r21"
     ]
    },
    "us-gaap_Cash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Cash",
     "crdr": "debit",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash",
        "label": "Cash",
        "periodStartLabel": "Cash, Beginning Balance",
        "periodEndLabel": "Cash, Ending Balance",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r127",
      "r553",
      "r607",
      "r631",
      "r753",
      "r781",
      "r884"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureRecurringFairValueMeasurementScheduleOfCashEquivalentsMarketableSecuritiesAndUnrealizedGainsAndLossesDetails",
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "periodStartLabel": "Cash and cash equivalents, beginning of period",
        "periodEndLabel": "Cash and cash equivalents, end of period",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total",
        "verboseLabel": "Cash equivalents, amortized cost",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r143",
      "r707"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAxis",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureRecurringFairValueMeasurementScheduleOfMaturitiesForAvailableForSaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Axis]",
        "documentation": "Information by type of cash and cash equivalent balance."
       }
      }
     },
     "auth_ref": [
      "r143"
     ]
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureRecurringFairValueMeasurementScheduleOfCashEquivalentsMarketableSecuritiesAndUnrealizedGainsAndLossesDetails",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureRecurringFairValueMeasurementScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Money market funds, included in cash and cash equivalents",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash and cash equivalents, fair value disclosure",
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r984",
      "r985"
     ]
    },
    "us-gaap_CashAndCashEquivalentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsLineItems",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureRecurringFairValueMeasurementScheduleOfAvailableforsaleMarketableSecuritiesWithGrossUnrealizedLossesDetails",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureRecurringFairValueMeasurementScheduleOfCashEquivalentsMarketableSecuritiesAndUnrealizedGainsAndLossesDetails",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureRecurringFairValueMeasurementScheduleOfMaturitiesForAvailableForSaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Cash and cash equivalents, end of period",
        "periodStartLabel": "Cash and cash equivalents, beginning of period",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "totalLabel": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Total",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r92",
      "r166"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect",
        "totalLabel": "Net (decrease) increase in cash and cash equivalents",
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r92"
     ]
    },
    "us-gaap_CashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cash equivalents, at carrying value",
        "label": "Cash Equivalents, at Carrying Value",
        "totalLabel": "Cash Equivalents, at Carrying Value, Total",
        "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r884",
      "r1016"
     ]
    },
    "us-gaap_CashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashEquivalentsMember",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureRecurringFairValueMeasurementScheduleOfCashEquivalentsMarketableSecuritiesAndUnrealizedGainsAndLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash equivalents",
        "label": "Cash Equivalents [Member]",
        "documentation": "Short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r143"
     ]
    },
    "dawn_CashEquivalentsUnrealizedGains": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dayonebio.com/20250331",
     "localname": "CashEquivalentsUnrealizedGains",
     "crdr": "credit",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureRecurringFairValueMeasurementScheduleOfCashEquivalentsMarketableSecuritiesAndUnrealizedGainsAndLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash equivalents, unrealized gains",
        "label": "Cash Equivalents, Unrealized Gains",
        "terseLabel": "Cash equivalents, unrealized gains"
       }
      }
     },
     "auth_ref": []
    },
    "dawn_CashEquivalentsUnrealizedLosses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dayonebio.com/20250331",
     "localname": "CashEquivalentsUnrealizedLosses",
     "crdr": "debit",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureRecurringFairValueMeasurementScheduleOfCashEquivalentsMarketableSecuritiesAndUnrealizedGainsAndLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash equivalents, unrealized losses",
        "label": "Cash Equivalents, Unrealized Losses",
        "terseLabel": "Cash equivalents, unrealized losses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Supplemental disclosures of noncash activities:"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote [Text Block]",
        "terseLabel": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r829"
     ]
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]",
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r826"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]",
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r824"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/CoverPage",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureCommonStockAdditionalInformationDetail",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetail",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfTheUnvestedCommonStockDetail",
      "http://www.dayonebio.com/20250331/taxonomy/role/RedeemableConvertiblePreferredSharesSummaryOfSeriesARedeemableConvertiblePreferredSharesDetail",
      "http://www.dayonebio.com/20250331/taxonomy/role/SignificantAgreementsAdditionalInformationDetail",
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedBalanceSheetsUnauditedParenthetical",
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfStockholdersEquityUnaudited",
      "http://www.dayonebio.com/20250331/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Class of Stock [Domain]",
        "label": "Class of Stock [Domain]",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r138",
      "r146",
      "r147",
      "r148",
      "r169",
      "r188",
      "r192",
      "r194",
      "r196",
      "r203",
      "r204",
      "r269",
      "r307",
      "r309",
      "r310",
      "r311",
      "r314",
      "r315",
      "r320",
      "r321",
      "r324",
      "r327",
      "r334",
      "r449",
      "r590",
      "r591",
      "r592",
      "r593",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r608",
      "r623",
      "r645",
      "r663",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r869",
      "r897",
      "r905"
     ]
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureCommonStockAdditionalInformationDetail",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureCommonStockScheduleOfCommonStockSharesReservedForFutureIssuanceDetailsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r146",
      "r147",
      "r148",
      "r203",
      "r320",
      "r321",
      "r322",
      "r324",
      "r327",
      "r332",
      "r334",
      "r590",
      "r591",
      "r592",
      "r593",
      "r732",
      "r869",
      "r897"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureCommonStockAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureCommonStockAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Domain]",
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureCommonStockAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Excersise price of pre-funded warrants",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r335"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureCommonStockAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Outstanding",
        "terseLabel": "Number of Pre-funded warrants purchased",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount",
        "terseLabel": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r830"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name",
        "terseLabel": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r830"
     ]
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/SignificantAgreements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Significant Agreements",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants."
       }
      }
     },
     "auth_ref": [
      "r128",
      "r130",
      "r137"
     ]
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/SignificantAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r410"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 6)",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r115",
      "r552",
      "r622"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/CommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r300",
      "r301",
      "r690",
      "r939",
      "r941"
     ]
    },
    "us-gaap_CommonClassAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonClassAMember",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedBalanceSheetsUnauditedParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Class A [Member]",
        "documentation": "Classification of common stock representing ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r1051"
     ]
    },
    "us-gaap_CommonClassBMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonClassBMember",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureCommonStockAdditionalInformationDetail",
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedBalanceSheetsUnauditedParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Class B [Member]",
        "documentation": "Classification of common stock that has different rights than Common Class A, representing ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r1051"
     ]
    },
    "dawn_CommonSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dayonebio.com/20250331",
     "localname": "CommonSharesMember",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common Shares [Member]",
        "label": "Common shares [Member]",
        "documentation": "Common shares"
       }
      }
     },
     "auth_ref": []
    },
    "dawn_CommonSharesPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dayonebio.com/20250331",
     "localname": "CommonSharesPurchaseAgreementMember",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureCommonStockAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Shares Purchase Agreement",
        "label": "Common Shares Purchase Agreement [Member]",
        "documentation": "Common Shares Purchase Agreement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureCommonStockAdditionalInformationDetail",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureCommonStockScheduleOfCommonStockSharesReservedForFutureIssuanceDetailsDetails",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock shares reserved for future issuance",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "dawn_CommonStockIssuedPursuantToFollowOnOfferingNetOfIssuanceCostsAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dayonebio.com/20250331",
     "localname": "CommonStockIssuedPursuantToFollowOnOfferingNetOfIssuanceCostsAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock pursuant to follow-on offering, net of issuance costs, Amount",
        "label": "Common stock issued pursuant to follow-on offering, net of issuance costs, Amount",
        "documentation": "Common stock issued pursuant to follow-on offering, net of issuance costs, Amount"
       }
      }
     },
     "auth_ref": []
    },
    "dawn_CommonStockIssuedPursuantToFollowOnOfferingNetOfIssuanceCostsShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.dayonebio.com/20250331",
     "localname": "CommonStockIssuedPursuantToFollowOnOfferingNetOfIssuanceCostsShares",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock pursuant to follow-on offering, net of issuance costs, Shares",
        "label": "Common stock issued pursuant to follow-on offering, net of issuance costs, Shares",
        "documentation": "Common stock issued pursuant to follow-on offering, net of issuance costs, Shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureCommonStockAdditionalInformationDetail",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureCommonStockScheduleOfCommonStockSharesReservedForFutureIssuanceDetailsDetails",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails",
      "http://www.dayonebio.com/20250331/taxonomy/role/SignificantAgreementsAdditionalInformationDetail",
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfStockholdersEquityUnaudited",
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfStockholdersEquityUnauditedParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock",
        "verboseLabel": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r771",
      "r772",
      "r773",
      "r775",
      "r776",
      "r777",
      "r778",
      "r901",
      "r902",
      "r904",
      "r982",
      "r1047",
      "r1051"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureCommonStockAdditionalInformationDetail",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails",
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedBalanceSheetsUnauditedParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common stock par value per share",
        "terseLabel": "Common Stock, Par or Stated Value Per Share",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureCommonStockAdditionalInformationDetail",
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedBalanceSheetsUnauditedParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common stock shares authorized",
        "terseLabel": "Common Stock, Shares Authorized",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r623"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureCommonStockAdditionalInformationDetail",
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedBalanceSheetsUnauditedParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock, Shares Issued",
        "label": "Common Stock, Shares, Issued",
        "totalLabel": "Common Stock, Shares, Issued, Total",
        "verboseLabel": "Share Purchased",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "dawn_CommonStockSharesIssuedAsAResultOfConversionOfTemporaryEquityIntoPermanentEquity": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.dayonebio.com/20250331",
     "localname": "CommonStockSharesIssuedAsAResultOfConversionOfTemporaryEquityIntoPermanentEquity",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/RedeemableConvertiblePreferredSharesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock shares issued as a result of conversion of temporary equity into permanent equity",
        "label": "Common Stock Shares Issued As A Result Of Conversion Of Temporary Equity Into Permanent Equity",
        "documentation": "Common stock shares issued as a result of conversion of temporary equity into permanent equity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureCommonStockAdditionalInformationDetail",
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedBalanceSheetsUnauditedParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock, Shares Outstanding",
        "label": "Common Stock, Shares, Outstanding",
        "periodStartLabel": "Common Stock, Shares, Outstanding, Beginning Balance",
        "periodEndLabel": "Common Stock, Shares, Outstanding, Ending Balance",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r71",
      "r623",
      "r642",
      "r1051",
      "r1052"
     ]
    },
    "dawn_CommonStockSharesPurchased": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.dayonebio.com/20250331",
     "localname": "CommonStockSharesPurchased",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureCommonStockAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock Shares Purchased",
        "label": "Common Stock Shares Purchased",
        "terseLabel": "Number of Common Stock Shares Purchased"
       }
      }
     },
     "auth_ref": []
    },
    "dawn_CommonStockToBeIssuedUnderTheEsppTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.dayonebio.com/20250331",
     "localname": "CommonStockToBeIssuedUnderTheEsppTableTextBlock",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of fair value of our common stock to be issued under the ESPP",
        "label": "common stock to be issued under the ESPP Table text block",
        "documentation": "common stock to be issued under the ESPP Table text block"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureCommonStockAdditionalInformationDetail",
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Value, Issued",
        "totalLabel": "Common Stock, Value, Issued, Total",
        "periodStartLabel": "Common Stock, Value, Issued, Beginning Balance",
        "periodEndLabel": "Common Stock, Value, Issued, Ending Balance",
        "verboseLabel": "Common Stock Value",
        "terseLabel": "Common stock, $0.0001 par value; 500,000,000 shares authorized as of March 31, 2025 and December 31, 2024; 101,353,781 and 101,116,162 shares issued and outstanding as of March 31, 2025 and December 31, 2024, respectively.",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r554",
      "r753"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r835"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r834"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r836"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r833"
     ]
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfComprehensiveLossUnaudited": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfComprehensiveLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Total comprehensive loss",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r156",
      "r158",
      "r163",
      "r544",
      "r563",
      "r564"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomeNetOfTaxAbstract",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfComprehensiveLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]",
        "terseLabel": "Other comprehensive loss:"
       }
      }
     },
     "auth_ref": []
    },
    "dawn_ConcentrationOfCreditRiskAndOtherRisksAndUncertaintiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dayonebio.com/20250331",
     "localname": "ConcentrationOfCreditRiskAndOtherRisksAndUncertaintiesMember",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration of Credit Risk and Other Risks and Uncertainties [Member]",
        "documentation": "Concentration of Credit Risk and Other Risks and Uncertainties [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskBenchmarkDomain",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Benchmark [Domain]",
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r24",
      "r56",
      "r57",
      "r236",
      "r689"
     ]
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Benchmark [Axis]",
        "documentation": "Information by benchmark of concentration risk."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r24",
      "r56",
      "r57",
      "r236",
      "r586",
      "r689"
     ]
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskByTypeAxis",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Type [Axis]",
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r24",
      "r56",
      "r57",
      "r236",
      "r689",
      "r873"
     ]
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration of credit risk and other risks and uncertainties",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r132"
     ]
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskPercentage1",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration risk percentage of net product revenue and accounts receivable",
        "label": "Concentration Risk, Percentage",
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r24",
      "r56",
      "r57",
      "r236"
     ]
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskTypeDomain",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Type [Domain]",
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r24",
      "r56",
      "r57",
      "r236",
      "r689"
     ]
    },
    "dawn_ConditionsForIssueAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.dayonebio.com/20250331",
     "localname": "ConditionsForIssueAxis",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/RedeemableConvertiblePreferredSharesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conditions For Issue [Axis]",
        "documentation": "Conditions For Issue Axis"
       }
      }
     },
     "auth_ref": []
    },
    "dawn_ConditionsForIssueDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dayonebio.com/20250331",
     "localname": "ConditionsForIssueDomain",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/RedeemableConvertiblePreferredSharesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conditions For Issue [Domain]",
        "documentation": "Conditions For Issue Domain"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConversionOfStockSharesIssued1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConversionOfStockSharesIssued1",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Number of shares issued upon conversion",
        "label": "Conversion of Stock, Shares Issued",
        "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r20",
      "r21"
     ]
    },
    "dawn_CostOfProductRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dayonebio.com/20250331",
     "localname": "CostOfProductRevenue",
     "crdr": "debit",
     "calculation": {
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfOperationsUnaudited": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of product revenue",
        "label": "cost of product revenue",
        "documentation": "Cost of Product Revenue"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cover [Abstract]",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CreditConcentrationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CreditConcentrationRiskMember",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Credit Concentration Risk [Member]",
        "documentation": "Reflects the percentage that a specified receivable or amount at risk from a counterparty under a contractual arrangement is to a specified benchmark, such as total receivables, net revenues, pretax results. Risk is the materially adverse effects of loss attributable to (a) the failure to collect a significant receivable from a major customer or group of homogeneous accounts, or (b) a failure by a counterparty to perform under terms of a contractual arrangement."
       }
      }
     },
     "auth_ref": [
      "r113"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Current Fiscal Year End Date",
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dawn_CurrentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dayonebio.com/20250331",
     "localname": "CurrentMember",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/SignificantAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Current [Member]",
        "label": "Current [Member]",
        "terseLabel": "Current Member"
       }
      }
     },
     "auth_ref": []
    },
    "dawn_CurrentProvisionRelatingToCurrentPeriodSales": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dayonebio.com/20250331",
     "localname": "CurrentProvisionRelatingToCurrentPeriodSales",
     "crdr": "credit",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummarizesOfBalancesAndActivityTheProductRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current provision relating to current period sales",
        "label": "Current Provision Relating to Current Period Sales",
        "documentation": "Current Provision Relating to Current Period Sales"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtConversionConvertedInstrumentSharesIssued1",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/RedeemableConvertiblePreferredSharesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Temporary equity shares issued upon conversion of notes payable",
        "label": "Debt Conversion, Converted Instrument, Shares Issued",
        "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r21"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureRecurringFairValueMeasurementAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized losses twelve months or greater",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss",
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r279"
     ]
    },
    "us-gaap_DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedBalanceSheetsUnauditedParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred Compensation Arrangement with Individual, Shares Authorized for Issuance",
        "label": "Deferred Compensation Arrangement with Individual, Shares Authorized for Issuance",
        "documentation": "The maximum number of shares authorized for issuance under the deferred compensation arrangement as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "us-gaap_DeferredCompensationArrangementWithIndividualSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredCompensationArrangementWithIndividualSharesIssued",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedBalanceSheetsUnauditedParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred Compensation Arrangement with Individual, Shares Issued",
        "label": "Deferred Compensation Arrangement with Individual, Shares Issued",
        "documentation": "Number of shares issued pursuant to the terms of a deferred compensation arrangement."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureBalanceSheetItemsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]",
        "terseLabel": "Schedule of Prepaid Expenses and Other Current Assets",
        "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredFinanceCostsOwnshareLendingArrangementIssuanceCostsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredFinanceCostsOwnshareLendingArrangementIssuanceCostsNet",
     "crdr": "debit",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Deferred finance costs, own-share lending arrangement, issuance costs, net",
        "label": "Deferred Finance Costs, Own-share Lending Arrangement, Issuance Costs, Net",
        "totalLabel": "Deferred Finance Costs, Own-share Lending Arrangement, Issuance Costs, Net, Total",
        "documentation": "Amount of issuance costs recognized in a share-lending arrangement entered into by the entity, in contemplation of a convertible debt offering or other financing, after deduction of accumulated amortization or the effects of subsequent adjustments."
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recognized income tax benefit",
        "totalLabel": "Deferred Income Tax Expense (Benefit), Total",
        "label": "Deferred Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r135",
      "r899"
     ]
    },
    "us-gaap_DeferredRevenueCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredRevenueCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/SignificantAgreementsAdditionalInformationDetail",
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Deferred Revenue, Current, Total",
        "label": "Deferred Revenue, Current",
        "terseLabel": "Current portion of deferred revenue",
        "verboseLabel": "Deferred Revenue Current",
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r886"
     ]
    },
    "us-gaap_DeferredRevenueNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredRevenueNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/SignificantAgreementsAdditionalInformationDetail",
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term portion of deferred revenue",
        "totalLabel": "Deferred Revenue, Noncurrent, Total",
        "label": "Deferred Revenue, Noncurrent",
        "verboseLabel": "Deferred revenue, noncurrent",
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r887"
     ]
    },
    "dawn_DeferredSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.dayonebio.com/20250331",
     "localname": "DeferredSharesOutstanding",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedBalanceSheetsUnauditedParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred Shares Outstanding",
        "label": "Deferred Shares Outstanding",
        "documentation": "Deferred Shares Outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "dawn_DeferredSharesParValuePerShares": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.dayonebio.com/20250331",
     "localname": "DeferredSharesParValuePerShares",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedBalanceSheetsUnauditedParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred Shares Par Value Per Shares",
        "label": "Deferred Shares Par Value Per Shares",
        "documentation": "Deferred Shares Par Value Per Shares."
       }
      }
     },
     "auth_ref": []
    },
    "dawn_DefinedContributionPlanEmployerMatchingContribution": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dayonebio.com/20250331",
     "localname": "DefinedContributionPlanEmployerMatchingContribution",
     "crdr": "debit",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureDefinedContributionPlanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined Contribution Plan Employer Matching Contribution",
        "label": "Defined Contribution Plan Employer Matching Contribution",
        "terseLabel": "Matching Contribution"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedContributionPlanTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedContributionPlanTextBlock",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureDefinedContributionPlan"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Contribution Plan [Text Block]",
        "terseLabel": "Defined Contribution Plan",
        "documentation": "The entire disclosure for defined contribution plan."
       }
      }
     },
     "auth_ref": [
      "r345",
      "r346"
     ]
    },
    "dawn_DepositsAndOtherLongtermAssetsNonCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dayonebio.com/20250331",
     "localname": "DepositsAndOtherLongtermAssetsNonCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deposits and other long-term assets",
        "label": "Deposits and other longterm assets Non current",
        "documentation": "Deposits and other long-term assets Non current."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepreciationDepletionAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation, Depletion and Amortization",
        "totalLabel": "Depreciation, Depletion and Amortization, Total",
        "terseLabel": "Depreciation expense",
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r201",
      "r212",
      "r228",
      "r720",
      "r721"
     ]
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeContractTypeDomain",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/RedeemableConvertiblePreferredSharesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Contract [Domain]",
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset."
       }
      }
     },
     "auth_ref": [
      "r612",
      "r614",
      "r628",
      "r629",
      "r630",
      "r632",
      "r633",
      "r634",
      "r635",
      "r637",
      "r638",
      "r639",
      "r640",
      "r651",
      "r652",
      "r653",
      "r654",
      "r657",
      "r658",
      "r659",
      "r660",
      "r676",
      "r677",
      "r678",
      "r679",
      "r771",
      "r773",
      "r989",
      "r990",
      "r991",
      "r992",
      "r993",
      "r994",
      "r996",
      "r997"
     ]
    },
    "us-gaap_DerivativeFairValueOfDerivativeLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeFairValueOfDerivativeLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/RedeemableConvertiblePreferredSharesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative liability at fair value",
        "label": "Derivative Liability, Subject to Master Netting Arrangement, before Offset",
        "totalLabel": "Derivative Liability, Fair Value, Gross Liability, Total",
        "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r77",
      "r109",
      "r110",
      "r152",
      "r710"
     ]
    },
    "us-gaap_DerivativeGainLossOnDerivativeNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeGainLossOnDerivativeNet",
     "crdr": "credit",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/RedeemableConvertiblePreferredSharesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized gain loss due to change in fair value of derivatives",
        "label": "Derivative, Gain (Loss) on Derivative, Net",
        "totalLabel": "Derivative, Gain (Loss) on Derivative, Net, Total",
        "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement."
       }
      }
     },
     "auth_ref": [
      "r981"
     ]
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeInstrumentRiskAxis",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/RedeemableConvertiblePreferredSharesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Instrument [Axis]",
        "documentation": "Information by type of derivative contract."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r52",
      "r53",
      "r111",
      "r612",
      "r614",
      "r628",
      "r629",
      "r630",
      "r632",
      "r633",
      "r634",
      "r635",
      "r637",
      "r638",
      "r639",
      "r640",
      "r651",
      "r652",
      "r653",
      "r654",
      "r657",
      "r658",
      "r659",
      "r660",
      "r676",
      "r677",
      "r678",
      "r679",
      "r710",
      "r771",
      "r773",
      "r989",
      "r990",
      "r991",
      "r992",
      "r993",
      "r994",
      "r996",
      "r997"
     ]
    },
    "dawn_DetailsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.dayonebio.com/20250331",
     "localname": "DetailsAxis",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetail",
      "http://www.dayonebio.com/20250331/taxonomy/role/RedeemableConvertiblePreferredSharesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Details [Axis]",
        "documentation": "Details Axis"
       }
      }
     },
     "auth_ref": []
    },
    "dawn_DetailsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dayonebio.com/20250331",
     "localname": "DetailsDomain",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetail",
      "http://www.dayonebio.com/20250331/taxonomy/role/RedeemableConvertiblePreferredSharesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Details [Domain]",
        "documentation": "Details Domain"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "Share-based Compensation",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r348",
      "r353",
      "r381",
      "r382",
      "r383",
      "r740"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Stock Option Activity",
        "label": "Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block]",
        "documentation": "Tabular disclosure of share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r44"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Document Fiscal Period Focus",
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Document Fiscal Year Focus",
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Document Information [Line Items]",
        "label": "Document Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationTable",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Document Information [Table]",
        "label": "Document Information [Table]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Document Quarterly Report",
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r785"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Document Transition Report",
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r817"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "verboseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]",
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year"
       }
      }
     },
     "auth_ref": [
      "r828"
     ]
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureNetIncomeLossPerShareSummaryOfBasicAndDilutedNetLossPerShareAttributableToCommonShareholdersstockholdersDetail",
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic",
        "totalLabel": "Earnings Per Share, Basic, Total",
        "verboseLabel": "Net income (loss) per share - basic",
        "terseLabel": "Net loss per share, basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r164",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r186",
      "r188",
      "r194",
      "r195",
      "r196",
      "r200",
      "r406",
      "r409",
      "r424",
      "r425",
      "r545",
      "r565",
      "r712"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureNetIncomeLossPerShareSummaryOfBasicAndDilutedNetLossPerShareAttributableToCommonShareholdersstockholdersDetail",
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Diluted",
        "totalLabel": "Earnings Per Share, Diluted, Total",
        "verboseLabel": "Net income (loss) per share - diluted",
        "terseLabel": "Net loss per share, diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r164",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r188",
      "r194",
      "r195",
      "r196",
      "r200",
      "r406",
      "r409",
      "r424",
      "r425",
      "r545",
      "r565",
      "r712"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureNetIncomeLossPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Income (Loss) Per Share",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r185",
      "r197",
      "r198",
      "r199"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Effective income tax rate",
        "terseLabel": "Effective income tax rate",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Effective Income Tax Rate Reconciliation, Percent, Total",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r389",
      "r741"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal statutory rate",
        "negatedLabel": "Federal Statutory Income Tax Rate Reconciliation, Percent",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r170",
      "r389",
      "r397",
      "r741"
     ]
    },
    "dawn_EmployeeRelatedExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dayonebio.com/20250331",
     "localname": "EmployeeRelatedExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSegmentReportingScheduleOfSegmentInformationDetails": {
       "parentTag": "us-gaap_ResearchAndDevelopmentExpense",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSegmentReportingScheduleOfSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Related Expenses",
        "documentation": "Employee Related Expenses",
        "terseLabel": "Employee related expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfSharestockbasedCompensationExpenseRecordedInTheAccompanyingCondensedConsolidatedStatementsOfOperation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureCommonStockScheduleOfCommonStockSharesReservedForFutureIssuanceDetailsDetails",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureNetIncomeLossPerShareSummaryOfBasicAndDilutedNetLossPerShareAttributableToCommonShareholdersstockholdersDetail",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureNetIncomeLossPerShareSummaryOfOutstandingPotentiallyDilutiveSecuritiesHaveBeenExcludedFromCalculationOfDilutedNetLossPerShare",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfTheBlackscholesOptionPricingModelToEstimateTheFairValueOfStockOptionGrantedDetail",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Employee Stock Option",
        "verboseLabel": "Share-based Payment Arrangement, Option",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "dawn_EmployeeStockPurchasePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dayonebio.com/20250331",
     "localname": "EmployeeStockPurchasePlanMember",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureCommonStockScheduleOfCommonStockSharesReservedForFutureIssuanceDetailsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock Purchase Plan",
        "documentation": "Employee Stock Purchase Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Entity Address, Address Line Two",
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r783"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Entity Common Stock, Shares Outstanding",
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Entity Current Reporting Status",
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r783"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Entity Ex Transition Period",
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r868"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Entity File Number",
        "label": "Securities Act File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Entity Filer Category",
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r783"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Entity Interactive Data Current",
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r867"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r783"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Entity Shell Company",
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r783"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Entity Small Business",
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r783"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r783"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Footnote [Text Block]",
        "terseLabel": "Equity Awards Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r822"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]",
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r863"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments [Member]",
        "terseLabel": "Equity Awards Adjustments"
       }
      }
     },
     "auth_ref": [
      "r863"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r863"
     ]
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureCommonStockAdditionalInformationDetail",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureCommonStockScheduleOfCommonStockSharesReservedForFutureIssuanceDetailsDetails",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails",
      "http://www.dayonebio.com/20250331/taxonomy/role/SignificantAgreementsAdditionalInformationDetail",
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfStockholdersEquityUnaudited",
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfStockholdersEquityUnauditedParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r139",
      "r159",
      "r160",
      "r161",
      "r171",
      "r172",
      "r173",
      "r175",
      "r180",
      "r182",
      "r184",
      "r202",
      "r270",
      "r271",
      "r296",
      "r336",
      "r395",
      "r396",
      "r403",
      "r404",
      "r405",
      "r407",
      "r408",
      "r409",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r423",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r457",
      "r458",
      "r471",
      "r561",
      "r579",
      "r580",
      "r581",
      "r596",
      "r663"
     ]
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureCommonStockAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Method Investment, Ownership Percentage",
        "terseLabel": "Ownership percentage",
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting."
       }
      }
     },
     "auth_ref": [
      "r268"
     ]
    },
    "us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityMethodInvestmentUnderlyingEquityInNetAssets",
     "crdr": "credit",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/SignificantAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Method Investment, Underlying Equity in Net Assets",
        "terseLabel": "Equity Investment",
        "documentation": "This item represents the entity's ownership percentage in the investee multiplied by the investee's total equity."
       }
      }
     },
     "auth_ref": [
      "r923"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]",
        "terseLabel": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r832"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis [Text Block]",
        "terseLabel": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r790",
      "r800",
      "r810",
      "r842"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]",
        "terseLabel": "Erroneously Awarded Compensation Recovery"
       }
      }
     },
     "auth_ref": [
      "r787",
      "r797",
      "r807",
      "r839"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]",
        "terseLabel": "Executive Category:"
       }
      }
     },
     "auth_ref": [
      "r838"
     ]
    },
    "dawn_ExternalCostsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.dayonebio.com/20250331",
     "localname": "ExternalCostsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "External Costs [Abstract]",
        "documentation": "External Costs [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureRecurringFairValueMeasurementAdditionalInformationDetail",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureRecurringFairValueMeasurementScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r427",
      "r428",
      "r441",
      "r742"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureRecurringFairValueMeasurementAdditionalInformationDetail",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureRecurringFairValueMeasurementScheduleOfAvailableforsaleMarketableSecuritiesWithGrossUnrealizedLossesDetails",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureRecurringFairValueMeasurementScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureRecurringFairValueMeasurementScheduleOfMaturitiesForAvailableForSaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r427",
      "r428",
      "r441",
      "r742"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureRecurringFairValueMeasurementAdditionalInformationDetail",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureRecurringFairValueMeasurementScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail",
      "http://www.dayonebio.com/20250331/taxonomy/role/SignificantAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Class [Domain]",
        "documentation": "Class of asset."
       }
      }
     },
     "auth_ref": [
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r442",
      "r743"
     ]
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByAssetClassAxis",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureRecurringFairValueMeasurementAdditionalInformationDetail",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureRecurringFairValueMeasurementScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail",
      "http://www.dayonebio.com/20250331/taxonomy/role/SignificantAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Class [Axis]",
        "documentation": "Information by class of asset."
       }
      }
     },
     "auth_ref": [
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r442",
      "r743"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureRecurringFairValueMeasurementScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r316",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r426",
      "r428",
      "r429",
      "r430",
      "r431",
      "r440",
      "r441",
      "r443",
      "r480",
      "r481",
      "r482",
      "r730",
      "r731",
      "r736",
      "r737",
      "r738",
      "r742",
      "r745"
     ]
    },
    "us-gaap_FairValueByLiabilityClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByLiabilityClassAxis",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/SignificantAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liability Class [Axis]",
        "documentation": "Information by class of liability."
       }
      }
     },
     "auth_ref": [
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r442"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureRecurringFairValueMeasurementScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r427",
      "r428",
      "r429",
      "r431",
      "r742",
      "r987",
      "r998"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureRecurringFairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recurring Fair Value Measurements",
        "label": "Fair Value Disclosures [Text Block]",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r436",
      "r438",
      "r439",
      "r440",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r542",
      "r742",
      "r746"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureRecurringFairValueMeasurementScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Inputs, Level 1",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r316",
      "r338",
      "r343",
      "r428",
      "r441",
      "r480",
      "r736",
      "r737",
      "r738",
      "r742"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureRecurringFairValueMeasurementScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Inputs, Level 2",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r316",
      "r338",
      "r343",
      "r428",
      "r429",
      "r441",
      "r481",
      "r730",
      "r731",
      "r736",
      "r737",
      "r738",
      "r742"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureRecurringFairValueMeasurementScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Inputs, Level 3",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r316",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r428",
      "r429",
      "r430",
      "r431",
      "r441",
      "r482",
      "r730",
      "r731",
      "r736",
      "r737",
      "r738",
      "r742",
      "r745"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureRecurringFairValueMeasurementTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of cash equivalents, marketable securities, and unrealized gains and losses",
        "label": "Fair Value, Liabilities Measured on Recurring and Nonrecurring Basis [Table Text Block]",
        "documentation": "Tabular disclosure of liabilities measured at fair value measured on a recurring or nonrecurring basis. Includes, but is not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2."
       }
      }
     },
     "auth_ref": [
      "r427",
      "r428"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/SignificantAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value by Liability Class [Domain]",
        "documentation": "Represents classes of liabilities measured and disclosed at fair value."
       }
      }
     },
     "auth_ref": [
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r442"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureRecurringFairValueMeasurementScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Domain]",
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r427",
      "r428",
      "r429",
      "r431",
      "r742",
      "r987",
      "r998"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet",
     "crdr": "debit",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureRecurringFairValueMeasurementAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Fair value, measurement recurring basis, asset, transfers, net",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers, Net",
        "totalLabel": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers, Net, Total",
        "documentation": "Amount of transfer of financial instrument classified as an asset into (out of) level 3 of the fair value hierarchy."
       }
      }
     },
     "auth_ref": [
      "r993",
      "r997"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureRecurringFairValueMeasurementScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r316",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r426",
      "r428",
      "r429",
      "r430",
      "r431",
      "r440",
      "r441",
      "r443",
      "r480",
      "r481",
      "r482",
      "r730",
      "r731",
      "r736",
      "r737",
      "r738",
      "r742",
      "r745"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureRecurringFairValueMeasurementScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Recurring",
        "label": "Fair Value, Recurring [Member]",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r742",
      "r984",
      "r985",
      "r986",
      "r987",
      "r988",
      "r998"
     ]
    },
    "us-gaap_FeeIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FeeIncome",
     "crdr": "credit",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/SignificantAgreementsAdditionalInformationDetail",
      "http://www.dayonebio.com/20250331/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Income",
        "verboseLabel": "License Revenue",
        "terseLabel": "Upfront License Fee",
        "documentation": "Amount of fee income including, but not limited to, managerial assistance, servicing of investment, and origination and commitment fees."
       }
      }
     },
     "auth_ref": [
      "r1049"
     ]
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureRecurringFairValueMeasurementScheduleOfAvailableforsaleMarketableSecuritiesWithGrossUnrealizedLossesDetails",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureRecurringFairValueMeasurementScheduleOfCashEquivalentsMarketableSecuritiesAndUnrealizedGainsAndLossesDetails",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureRecurringFairValueMeasurementScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r278",
      "r280",
      "r281",
      "r318",
      "r332",
      "r421",
      "r448",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r562",
      "r727",
      "r742",
      "r743",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r754",
      "r876",
      "r877",
      "r878",
      "r879",
      "r880",
      "r881",
      "r882",
      "r919",
      "r920",
      "r921",
      "r922",
      "r983",
      "r986",
      "r987",
      "r988",
      "r995",
      "r998"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible asset useful life",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "crdr": "credit",
     "calculation": {
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureIntangibleAssetsScheduleOfIntangibleAssetsDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureIntangibleAssetsScheduleOfIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "negatedLabel": "Less accumulated amortization",
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r144",
      "r282",
      "r287",
      "r729"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive",
     "crdr": "debit",
     "calculation": {
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureIntangibleAssetsScheduleOfAmortizationExpenseForAmortizableFinitelivedIntangibleAssetsDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureIntangibleAssetsScheduleOfAmortizationExpenseForAmortizableFinitelivedIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Thereafter",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, after Year Five",
        "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r934",
      "r1053"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "crdr": "debit",
     "calculation": {
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureIntangibleAssetsScheduleOfAmortizationExpenseForAmortizableFinitelivedIntangibleAssetsDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureIntangibleAssetsScheduleOfAmortizationExpenseForAmortizableFinitelivedIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025 (Remaining)",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r289",
      "r703",
      "r729"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "crdr": "debit",
     "calculation": {
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureIntangibleAssetsScheduleOfAmortizationExpenseForAmortizableFinitelivedIntangibleAssetsDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureIntangibleAssetsScheduleOfAmortizationExpenseForAmortizableFinitelivedIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2029",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r289",
      "r703",
      "r729"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "crdr": "debit",
     "calculation": {
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureIntangibleAssetsScheduleOfAmortizationExpenseForAmortizableFinitelivedIntangibleAssetsDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureIntangibleAssetsScheduleOfAmortizationExpenseForAmortizableFinitelivedIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r289",
      "r703",
      "r729"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "crdr": "debit",
     "calculation": {
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureIntangibleAssetsScheduleOfAmortizationExpenseForAmortizableFinitelivedIntangibleAssetsDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureIntangibleAssetsScheduleOfAmortizationExpenseForAmortizableFinitelivedIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r289",
      "r703",
      "r729"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "crdr": "debit",
     "calculation": {
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureIntangibleAssetsScheduleOfAmortizationExpenseForAmortizableFinitelivedIntangibleAssetsDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureIntangibleAssetsScheduleOfAmortizationExpenseForAmortizableFinitelivedIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r289",
      "r703",
      "r729"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureIntangibleAssetsScheduleOfIntangibleAssetsDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureIntangibleAssetsScheduleOfIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Gross",
        "totalLabel": "Finite-Lived Intangible Assets, Gross, Total",
        "terseLabel": "Intangible assets, gross",
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r282",
      "r287",
      "r511",
      "r729"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureIntangibleAssetsScheduleOfIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r284",
      "r287",
      "r291",
      "r292",
      "r294",
      "r510",
      "r703",
      "r729"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureIntangibleAssetsScheduleOfIntangibleAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureIntangibleAssetsScheduleOfAmortizationExpenseForAmortizableFinitelivedIntangibleAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureIntangibleAssetsScheduleOfAmortizationExpenseForAmortizableFinitelivedIntangibleAssetsDetails",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureIntangibleAssetsScheduleOfIntangibleAssetsDetails",
      "http://www.dayonebio.com/20250331/taxonomy/role/SignificantAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Net",
        "periodEndLabel": "Finite-Lived Intangible Assets, Net, Ending Balance",
        "periodStartLabel": "Finite-Lived Intangible Assets, Net, Beginning Balance",
        "totalLabel": "Total future expected amortization expense",
        "terseLabel": "Unamortized finite-lived intangible asset",
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r510",
      "r933"
     ]
    },
    "dawn_FirstAnniversaryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dayonebio.com/20250331",
     "localname": "FirstAnniversaryMember",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First Anniversary [Member]",
        "label": "First Anniversary [Member]",
        "terseLabel": "First Anniversary"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r794",
      "r804",
      "r814",
      "r846"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount",
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r794",
      "r804",
      "r814",
      "r846"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r794",
      "r804",
      "r814",
      "r846"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]",
        "terseLabel": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r794",
      "r804",
      "r814",
      "r846"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r794",
      "r804",
      "r814",
      "r846"
     ]
    },
    "dawn_FounderMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dayonebio.com/20250331",
     "localname": "FounderMember",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureCommonStockAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Founder [Member]",
        "label": "Founder [Member]",
        "documentation": "Founder Member"
       }
      }
     },
     "auth_ref": []
    },
    "dawn_FounderOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dayonebio.com/20250331",
     "localname": "FounderOneMember",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureCommonStockAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Founder One [Member]",
        "label": "Founder One [Member]",
        "documentation": "Founder One Member"
       }
      }
     },
     "auth_ref": []
    },
    "dawn_FounderTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dayonebio.com/20250331",
     "localname": "FounderTwoMember",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureCommonStockAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Founder Two [Member]",
        "label": "Founder two [Member]",
        "documentation": "Founder Two Member"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]",
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year"
       }
      }
     },
     "auth_ref": [
      "r827"
     ]
    },
    "dawn_FrontlinePayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dayonebio.com/20250331",
     "localname": "FrontlinePayment",
     "crdr": "debit",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/SignificantAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frontline Payment",
        "label": "Frontline Payment",
        "terseLabel": "Frontline Payment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainLossOnSaleOfInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GainLossOnSaleOfInvestments",
     "crdr": "credit",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/SignificantAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gain on Sale Of License Agreement",
        "label": "Gain (Loss) on Sale of Investments",
        "totalLabel": "Gain (Loss) on Sale of Investments, Total",
        "documentation": "The net realized gain (loss) on investments sold during the period, not including gains (losses) on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, which, for cash flow reporting, is a component of proceeds from investing activities."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfOperationsUnaudited": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Selling, general and administrative",
        "label": "General and Administrative Expense",
        "totalLabel": "General and Administrative Expense, Total",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r647"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dawn_GrossProceedsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dayonebio.com/20250331",
     "localname": "GrossProceedsMember",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/RedeemableConvertiblePreferredSharesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gross Proceeds [Member]",
        "documentation": "Gross Proceeds."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IPOMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IPOMember",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/RedeemableConvertiblePreferredSharesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "IPO [Member]",
        "documentation": "First sale of stock by a private company to the public."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ImpairmentOfIntangibleAssetsFinitelived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOfIntangibleAssetsFinitelived",
     "crdr": "debit",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/SignificantAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment of Intangible Assets, Finite-Lived",
        "terseLabel": "Unamortized finite lived intangible asset",
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value."
       }
      }
     },
     "auth_ref": [
      "r285",
      "r896",
      "r938"
     ]
    },
    "dawn_IncentiveSharePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dayonebio.com/20250331",
     "localname": "IncentiveSharePlanMember",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Incentive Share Plan",
        "documentation": "Incentive Share Plan."
       }
      }
     },
     "auth_ref": []
    },
    "dawn_IncentiveSharePlanMemberMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dayonebio.com/20250331",
     "localname": "IncentiveSharePlanMemberMember",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfFairValueOfTheIncentiveSharesEstimatedUsingAnOptionPricingModelDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Incentive Share Plan Member [Member]",
        "documentation": "Incentive Share Plan Member."
       }
      }
     },
     "auth_ref": []
    },
    "dawn_IncentiveSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dayonebio.com/20250331",
     "localname": "IncentiveSharesMember",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfTheIncentiveSharesActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Incentive Shares [Member]",
        "documentation": "Incentive shares.",
        "verboseLabel": "Incentive Shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeLossAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossAttributableToNoncontrollingInterest",
     "crdr": "debit",
     "calculation": {
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfOperationsUnaudited": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Loss before income taxes",
        "label": "Income (Loss) Attributable to Noncontrolling Interest, before Tax",
        "totalLabel": "Income (Loss) Attributable to Noncontrolling Interest, before Tax, Total",
        "negatedTotalLabel": "Loss before income taxes",
        "documentation": "Amount, before tax, of income (loss) attributable to noncontrolling interest. Includes, but is not limited to, income (loss) from continuing operations, discontinued operations and equity method investments."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r893"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfSharestockbasedCompensationExpenseRecordedInTheAccompanyingCondensedConsolidatedStatementsOfOperation",
      "http://www.dayonebio.com/20250331/taxonomy/role/SignificantAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r297",
      "r298",
      "r299",
      "r433",
      "r437",
      "r442",
      "r576",
      "r578",
      "r648",
      "r703",
      "r744",
      "r1018"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfSharestockbasedCompensationExpenseRecordedInTheAccompanyingCondensedConsolidatedStatementsOfOperation",
      "http://www.dayonebio.com/20250331/taxonomy/role/SignificantAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Domain]",
        "documentation": "Location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r298",
      "r299",
      "r433",
      "r437",
      "r442",
      "r576",
      "r578",
      "r648",
      "r703",
      "r744",
      "r1018"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureIncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r170",
      "r387",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r398",
      "r400",
      "r401",
      "r402",
      "r595",
      "r741"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfOperationsUnaudited": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income tax expense",
        "label": "Income Tax Expense (Benefit)",
        "totalLabel": "Income Tax Expense (Benefit), Total",
        "negatedLabel": "Income tax benefit (expense)",
        "verboseLabel": "Income tax benefit (expense)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r126",
      "r136",
      "r183",
      "r184",
      "r201",
      "r213",
      "r228",
      "r388",
      "r389",
      "r399",
      "r567",
      "r741"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Increase (Decrease) in Accounts Payable",
        "totalLabel": "Increase (Decrease) in Accounts Payable, Total",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accounts receivable, net",
        "terseLabel": "Accounts Receivable",
        "label": "Increase (Decrease) in Accounts Receivable",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dawn_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dayonebio.com/20250331",
     "localname": "IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses and other current liabilities",
        "label": "Increase (Decrease) In Accrued Expenses And Other Current Liabilities",
        "documentation": "Increase (decrease) in accrued expenses and other current liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInDeferredRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInDeferredRevenue",
     "crdr": "debit",
     "calculation": {
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/SignificantAgreementsAdditionalInformationDetail",
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Deferred Revenue",
        "terseLabel": "Deferred revenue",
        "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r704"
     ]
    },
    "us-gaap_IncreaseDecreaseInDepositOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInDepositOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Deposits and other long-term assets",
        "label": "Increase (Decrease) in Deposit Assets",
        "totalLabel": "Increase (Decrease) in Deposit Assets, Total",
        "documentation": "The increase (decrease) during the reporting period in moneys or securities given as security including, but not limited to, contract, escrow, or earnest money deposits, retainage (if applicable), deposits with clearing organizations and others, collateral, or margin deposits."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInInventoriesAndOtherOperatingAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInInventoriesAndOtherOperatingAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Inventory",
        "terseLabel": "Inventory",
        "label": "Increase (Decrease) in Inventories and Other Operating Assets",
        "documentation": "Amount of increase (decrease) in inventory, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r895"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in operating assets and liabilities:",
        "label": "Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liability",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r875",
      "r895"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses and other current assets",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "totalLabel": "Increase (Decrease) in Prepaid Expense and Other Assets, Total",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureNetIncomeLossPerShareSummaryOfBasicAndDilutedNetLossPerShareAttributableToCommonShareholdersstockholdersDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of dilutive securities:",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements",
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method."
       }
      }
     },
     "auth_ref": [
      "r189",
      "r190",
      "r191",
      "r196",
      "r352"
     ]
    },
    "dawn_IncrementalSharesReservedForFutureIssuanceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dayonebio.com/20250331",
     "localname": "IncrementalSharesReservedForFutureIssuanceMember",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Incremental Shares Reserved for Future Issuance [Member]",
        "label": "Incremental Shares Reserved For Future Issuance [Member]",
        "documentation": "Incremental Shares Reserved For Future Issuance."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/SignificantAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Indefinite-Lived Intangible Assets [Axis]",
        "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit."
       }
      }
     },
     "auth_ref": [
      "r284",
      "r286",
      "r290",
      "r729"
     ]
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible assets, net",
        "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill)",
        "periodEndLabel": "Indefinite-Lived Intangible Assets (Excluding Goodwill), Ending Balance",
        "periodStartLabel": "Indefinite-Lived Intangible Assets (Excluding Goodwill), Beginning Balance",
        "totalLabel": "Indefinite-Lived Intangible Assets (Excluding Goodwill), Total",
        "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit."
       }
      }
     },
     "auth_ref": [
      "r282",
      "r290",
      "r729"
     ]
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/SignificantAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]",
        "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company."
       }
      }
     },
     "auth_ref": [
      "r284",
      "r286",
      "r290",
      "r729"
     ]
    },
    "us-gaap_IndemnificationGuaranteeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IndemnificationGuaranteeMember",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Indemnification Agreement [Member]",
        "terseLabel": "Indemnification Agreement",
        "documentation": "An agreement (contract) that contingently requires the guarantor to make payments to the guaranteed party in compensation for that party's or parties' loss or injury attributable to specified events or actions, such as a patent infringement action against an entity that relied on certain representations as to ownership rights made by a software vendor."
       }
      }
     },
     "auth_ref": [
      "r944"
     ]
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]",
        "terseLabel": "Individual:"
       }
      }
     },
     "auth_ref": [
      "r794",
      "r804",
      "r814",
      "r838",
      "r846",
      "r850",
      "r858"
     ]
    },
    "dawn_IndividualCustomerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dayonebio.com/20250331",
     "localname": "IndividualCustomerMember",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Individual Customer [Member]",
        "label": "Individual Customer [Member]",
        "documentation": "Individual Customer [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]",
        "terseLabel": "Insider Trading Arrangements:"
       }
      }
     },
     "auth_ref": [
      "r856"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]",
        "terseLabel": "Insider Trading Policies and Procedures:"
       }
      }
     },
     "auth_ref": [
      "r786",
      "r862"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted [Flag]",
        "terseLabel": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r786",
      "r862"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]",
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r786",
      "r862"
     ]
    },
    "us-gaap_IntangibleAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IntangibleAssetsDisclosureTextBlock",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureIntangibleAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible Assets",
        "label": "Intangible Assets Disclosure [Text Block]",
        "documentation": "The entire disclosure for all or part of the information related to intangible assets."
       }
      }
     },
     "auth_ref": [
      "r283",
      "r293",
      "r295",
      "r702",
      "r703"
     ]
    },
    "us-gaap_InventoryNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryNet",
     "crdr": "debit",
     "calculation": {
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory",
        "label": "Inventory, Net",
        "totalLabel": "Inventory, Net, Total",
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r150",
      "r708",
      "r753"
     ]
    },
    "dawn_InvestmentAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dayonebio.com/20250331",
     "localname": "InvestmentAgreementMember",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureCommonStockAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment Agreement [Member]",
        "documentation": "Investment Agreement [Member]",
        "label": "Investment Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentIncomeNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentIncomeNet",
     "crdr": "credit",
     "calculation": {
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfOperationsUnaudited": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment income, net",
        "label": "Investment Income, Net",
        "totalLabel": "Investment Income, Net, Total",
        "documentation": "Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r84",
      "r86"
     ]
    },
    "dawn_IpsenLicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dayonebio.com/20250331",
     "localname": "IpsenLicenseAgreementMember",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ipsen License Agreement [Member]",
        "label": "Ipsen License Agreement [Member]",
        "terseLabel": "Ipsen License Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "dawn_IpsenPharmaSasAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dayonebio.com/20250331",
     "localname": "IpsenPharmaSasAgreementMember",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/SignificantAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ipsen Pharma SAS Agreement Member",
        "label": "Ipsen Pharma SAS Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dawn_IssuanceOfCommonStockInPrivatePlacementShare": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.dayonebio.com/20250331",
     "localname": "IssuanceOfCommonStockInPrivatePlacementShare",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock in connection with private placement, net of placement agent fees and offering costs(Share)",
        "documentation": "Issuance of common stock in private placement(Share)",
        "label": "Issuance of common stock in private placement(Share)"
       }
      }
     },
     "auth_ref": []
    },
    "dawn_IssuanceOfCommonStockInPrivatePlacementValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dayonebio.com/20250331",
     "localname": "IssuanceOfCommonStockInPrivatePlacementValue",
     "crdr": "credit",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of common stock in private placement(Value)",
        "label": "Issuance of common stock in private placement(Value)",
        "terseLabel": "Issuance of common stock in connection with private placement, net of placement agent fees and offering costs(Value)"
       }
      }
     },
     "auth_ref": []
    },
    "dawn_IssuanceOfCommonStockUponReleaseOfRestrictedStockUnits": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.dayonebio.com/20250331",
     "localname": "IssuanceOfCommonStockUponReleaseOfRestrictedStockUnits",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock upon release of restricted stock units, shares",
        "label": "Issuance of common stock upon release of restricted stock units",
        "documentation": "Issuance of common stock upon release of restricted stock units"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseContractualTermAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseContractualTermAxis",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Contractual Term [Axis]",
        "documentation": "Information by contractual term of lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r470",
      "r874"
     ]
    },
    "us-gaap_LeaseContractualTermDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseContractualTermDomain",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Contractual Term [Domain]",
        "documentation": "Contractual term of lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r470",
      "r874"
     ]
    },
    "dawn_LeaseForCorporateOfficeFacilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dayonebio.com/20250331",
     "localname": "LeaseForCorporateOfficeFacilityMember",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease For Corporate Office Facility [Member]",
        "terseLabel": "Lease For Corporate Office Facility",
        "documentation": "Lease For Corporate Office Facility Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeaseDescriptionLineItems",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Lease, Description [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r462",
      "r470"
     ]
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeaseDescriptionTable",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Lease, Description [Table]",
        "documentation": "Disclosure of information about lessee's leases."
       }
      }
     },
     "auth_ref": [
      "r462",
      "r470"
     ]
    },
    "us-gaap_LesseeOperatingLeaseDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseDescription",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease expiration description",
        "label": "Lessee, Operating Lease, Description",
        "documentation": "Description of lessee's operating lease."
       }
      }
     },
     "auth_ref": [
      "r463"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/CommitmentsAndContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Future Lease Obligations",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r1001"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureLeaseObligationsDetail2": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureLeaseObligationsDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureLeaseObligationsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total future minimum lease payments",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r468"
     ]
    },
    "dawn_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dayonebio.com/20250331",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour",
     "crdr": "credit",
     "calculation": {
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureLeaseObligationsDetail": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureLeaseObligationsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee Operating Lease Liability Payments Due after Year Four",
        "documentation": "Lessee Operating Lease Liability Payments Due after Year Four",
        "terseLabel": "Thereafter"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureLeaseObligationsDetail": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureLeaseObligationsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2026",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r468"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "calculation": {
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureLeaseObligationsDetail": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureLeaseObligationsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2029",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r468"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureLeaseObligationsDetail": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureLeaseObligationsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2028",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r468"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureLeaseObligationsDetail": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureLeaseObligationsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2027",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r468"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "crdr": "credit",
     "calculation": {
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureLeaseObligationsDetail": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureLeaseObligationsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "terseLabel": "2025 (Remaining)",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r1001"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureLeaseObligationsDetail2": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureLeaseObligationsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Less: Imputed interest",
        "negatedLabel": "Less: Imputed interest",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r468"
     ]
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseTermOfContract",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease term",
        "label": "Lessee, Operating Lease, Term of Contract",
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1000"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r62",
      "r63",
      "r64",
      "r65",
      "r66",
      "r67",
      "r68",
      "r169",
      "r269",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r412",
      "r413",
      "r414",
      "r449",
      "r621",
      "r713",
      "r781",
      "r945",
      "r1004",
      "r1005"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedBalanceSheetsUnaudited": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r116",
      "r557",
      "r753",
      "r898",
      "r924",
      "r999"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and stockholders' equity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r142",
      "r169",
      "r269",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r412",
      "r413",
      "r414",
      "r449",
      "r753",
      "r945",
      "r1004",
      "r1005"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current Liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "dawn_LicenseAgreementMilestonePaymentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dayonebio.com/20250331",
     "localname": "LicenseAgreementMilestonePaymentMember",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureIntangibleAssetsScheduleOfIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "License Agreement Milestone Payment [Member]",
        "documentation": "License Agreement Milestone Payment [Member]",
        "terseLabel": "License agreement milestone payments [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dawn_LicenseAgreementRelatedPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dayonebio.com/20250331",
     "localname": "LicenseAgreementRelatedPayments",
     "crdr": "debit",
     "calculation": {
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSegmentReportingScheduleOfSegmentInformationDetails": {
       "parentTag": "us-gaap_ResearchAndDevelopmentExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSegmentReportingScheduleOfSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License agreement related payments",
        "label": "License Agreement Related Payments",
        "documentation": "License Agreement Related Payments"
       }
      }
     },
     "auth_ref": []
    },
    "dawn_LicenseAgreementWithIpsenPharmaSasMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dayonebio.com/20250331",
     "localname": "LicenseAgreementWithIpsenPharmaSasMember",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/SignificantAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License agreement with Ipsen Pharma SAS [Member]",
        "label": "License agreement with Ipsen Pharma SAS [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LicenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LicenseMember",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/SignificantAgreementsAdditionalInformationDetail",
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License Product [Member]",
        "label": "License [Member]",
        "verboseLabel": "License revenue [Member]",
        "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark."
       }
      }
     },
     "auth_ref": [
      "r949"
     ]
    },
    "dawn_LicenseRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dayonebio.com/20250331",
     "localname": "LicenseRevenue",
     "crdr": "credit",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/SignificantAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License revenue",
        "label": "License Revenue",
        "documentation": "License Revenue"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LossContingencyAccrualAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LossContingencyAccrualAtCarryingValue",
     "crdr": "credit",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Litigation amount awarded from other party",
        "terseLabel": "Termination and cancellation charges payable",
        "label": "Loss Contingency Accrual",
        "periodStartLabel": "Loss Contingency Accrual, Beginning Balance",
        "periodEndLabel": "Loss Contingency Accrual, Ending Balance",
        "documentation": "Amount of loss contingency liability."
       }
      }
     },
     "auth_ref": [
      "r302",
      "r870"
     ]
    },
    "dawn_MabcareLicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dayonebio.com/20250331",
     "localname": "MabcareLicenseAgreementMember",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/SignificantAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MabCare License Agreement [Member]",
        "documentation": "MabCare License Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MajorCustomersAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MajorCustomersAxis",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]"
       }
      }
     },
     "auth_ref": [
      "r236",
      "r735",
      "r764",
      "r768",
      "r948",
      "r1017",
      "r1019",
      "r1020",
      "r1022",
      "r1023",
      "r1024",
      "r1025",
      "r1026",
      "r1027",
      "r1028",
      "r1029",
      "r1030",
      "r1031",
      "r1032",
      "r1033",
      "r1034",
      "r1035",
      "r1036",
      "r1037",
      "r1038",
      "r1039",
      "r1040",
      "r1041",
      "r1042",
      "r1043",
      "r1044",
      "r1045",
      "r1046"
     ]
    },
    "dawn_MaketValueOfCommonStockHeldByNonAffiliateStockholders": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dayonebio.com/20250331",
     "localname": "MaketValueOfCommonStockHeldByNonAffiliateStockholders",
     "crdr": "debit",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maket Value Of CommonStock Held By Non Affiliate Stockholders",
        "label": "Maket value of common stock held by non-affiliate stockholders",
        "documentation": "Maket value of common stock held by non-affiliate stockholders"
       }
      }
     },
     "auth_ref": []
    },
    "dawn_ManufacturingAndSupplyAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dayonebio.com/20250331",
     "localname": "ManufacturingAndSupplyAgreementMember",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Manufacturing And Supply Agreement",
        "label": "Manufacturing and Supply Agreement [Member]",
        "documentation": "Manufacturing and Supply Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dawn_MarketableSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dayonebio.com/20250331",
     "localname": "MarketableSecuritiesMember",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureRecurringFairValueMeasurementScheduleOfCashEquivalentsMarketableSecuritiesAndUnrealizedGainsAndLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable securities",
        "label": "Marketable securities [Member]",
        "documentation": "Marketable securities [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfFairValueOfTheIncentiveSharesEstimatedUsingAnOptionPricingModelDetail",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfTheBlackscholesOptionPricingModelToEstimateTheFairValueOfPerformanceStockOpDetails",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfTheBlackscholesOptionPricingModelToEstimateTheFairValueOfStockOptionGrantedDetail",
      "http://www.dayonebio.com/20250331/taxonomy/role/SignificantAgreementsAdditionalInformationDetail",
      "http://www.dayonebio.com/20250331/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum [Member]",
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r303",
      "r304",
      "r305",
      "r306",
      "r347",
      "r385",
      "r431",
      "r508",
      "r575",
      "r577",
      "r585",
      "r613",
      "r614",
      "r669",
      "r671",
      "r673",
      "r674",
      "r680",
      "r700",
      "r701",
      "r726",
      "r732",
      "r739",
      "r745",
      "r746",
      "r750",
      "r751",
      "r765",
      "r947",
      "r1006",
      "r1007",
      "r1008",
      "r1009",
      "r1010",
      "r1011"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]",
        "terseLabel": "Measure:"
       }
      }
     },
     "auth_ref": [
      "r830"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r830"
     ]
    },
    "dawn_MerckLicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dayonebio.com/20250331",
     "localname": "MerckLicenseAgreementMember",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/SignificantAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Merck License Agreement [Member]",
        "documentation": "Merck License Agreement."
       }
      }
     },
     "auth_ref": []
    },
    "dawn_MilestoneAchievedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dayonebio.com/20250331",
     "localname": "MilestoneAchievedMember",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/RedeemableConvertiblePreferredSharesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Milestone Achieved [Member]",
        "documentation": "Milestone Achieved."
       }
      }
     },
     "auth_ref": []
    },
    "dawn_MilestoneAchievementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dayonebio.com/20250331",
     "localname": "MilestoneAchievementMember",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/RedeemableConvertiblePreferredSharesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Milestone Achievement [Member]",
        "documentation": "Milestone Achievement."
       }
      }
     },
     "auth_ref": []
    },
    "dawn_MilestonePaymentsNotYetPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dayonebio.com/20250331",
     "localname": "MilestonePaymentsNotYetPaid",
     "crdr": "debit",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/SignificantAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Milestone payments not yet paid",
        "documentation": "Milestone payments not yet paid",
        "terseLabel": "Milestone payments not yet paid"
       }
      }
     },
     "auth_ref": []
    },
    "dawn_MilestonePaymentsNotYetReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dayonebio.com/20250331",
     "localname": "MilestonePaymentsNotYetReceived",
     "crdr": "debit",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/SignificantAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone payments not yet received",
        "label": "Milestone Payments not Yet Received",
        "documentation": "Milestone Payments not Yet Received"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfFairValueOfTheIncentiveSharesEstimatedUsingAnOptionPricingModelDetail",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfTheBlackscholesOptionPricingModelToEstimateTheFairValueOfPerformanceStockOpDetails",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfTheBlackscholesOptionPricingModelToEstimateTheFairValueOfStockOptionGrantedDetail",
      "http://www.dayonebio.com/20250331/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum [Member]",
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r303",
      "r304",
      "r305",
      "r306",
      "r347",
      "r385",
      "r431",
      "r508",
      "r575",
      "r577",
      "r585",
      "r613",
      "r614",
      "r669",
      "r671",
      "r673",
      "r674",
      "r680",
      "r700",
      "r701",
      "r726",
      "r732",
      "r739",
      "r745",
      "r746",
      "r750",
      "r765",
      "r947",
      "r1006",
      "r1007",
      "r1008",
      "r1009",
      "r1010",
      "r1011"
     ]
    },
    "us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MinorityInterestOwnershipPercentageByNoncontrollingOwners",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureCommonStockAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ownership percentage",
        "label": "Subsidiary, Ownership Percentage, Noncontrolling Owner",
        "documentation": "The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]",
        "terseLabel": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r849"
     ]
    },
    "us-gaap_MoneyMarketFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MoneyMarketFundsMember",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureRecurringFairValueMeasurementScheduleOfCashEquivalentsMarketableSecuritiesAndUnrealizedGainsAndLossesDetails",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureRecurringFairValueMeasurementScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Money market funds",
        "label": "Money Market Funds [Member]",
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities."
       }
      }
     },
     "auth_ref": [
      "r950"
     ]
    },
    "dawn_MrkdgLicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dayonebio.com/20250331",
     "localname": "MrkdgLicenseAgreementMember",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "MRKDG License Agreement [Member]",
        "label": "MRKDG License Agreement [Member]",
        "terseLabel": "MRKDG License Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement [Text Block]",
        "terseLabel": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r857"
     ]
    },
    "srt_NameOfMajorCustomerDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "NameOfMajorCustomerDomain",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]"
       }
      }
     },
     "auth_ref": [
      "r236",
      "r735",
      "r764",
      "r768",
      "r948",
      "r1017",
      "r1019",
      "r1020",
      "r1022",
      "r1023",
      "r1024",
      "r1025",
      "r1026",
      "r1027",
      "r1028",
      "r1029",
      "r1030",
      "r1031",
      "r1032",
      "r1033",
      "r1034",
      "r1035",
      "r1036",
      "r1037",
      "r1038",
      "r1039",
      "r1040",
      "r1041",
      "r1042",
      "r1043",
      "r1044",
      "r1045",
      "r1046"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote [Text Block]",
        "terseLabel": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r831"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Cash provided by financing activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r165"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash (used in) provided by investing activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r165"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r93",
      "r94"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfComprehensiveLossUnaudited": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 0.0
      },
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 0.0
      },
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfOperationsUnaudited": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureNetIncomeLossPerShareSummaryOfBasicAndDilutedNetLossPerShareAttributableToCommonShareholdersstockholdersDetail",
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited",
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfComprehensiveLossUnaudited",
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfOperationsUnaudited",
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfStockholdersEquityUnaudited",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss)",
        "terseLabel": "Net Income (Loss)",
        "totalLabel": "Net income (loss)",
        "verboseLabel": "Net income (loss) - basic and diluted",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r94",
      "r119",
      "r140",
      "r155",
      "r157",
      "r161",
      "r169",
      "r174",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r183",
      "r184",
      "r193",
      "r269",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r406",
      "r409",
      "r425",
      "r449",
      "r560",
      "r644",
      "r661",
      "r662",
      "r779",
      "r945"
     ]
    },
    "dawn_NetProductRevenueAndAccountsReceivableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dayonebio.com/20250331",
     "localname": "NetProductRevenueAndAccountsReceivableMember",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Product Revenue and Accounts Receivable [Member]",
        "label": "Net Product Revenue and Accounts Receivable [Member]",
        "documentation": "Net Product Revenue and Accounts Receivable [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recently Issued Accounting Pronouncements",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description [Text Block]",
        "terseLabel": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r830"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-NEOs [Member]",
        "terseLabel": "Non-NEOs"
       }
      }
     },
     "auth_ref": [
      "r794",
      "r804",
      "r814",
      "r838",
      "r846"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r821"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount",
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r820"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO [Member]",
        "terseLabel": "Non-PEO NEO"
       }
      }
     },
     "auth_ref": [
      "r838"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r857"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r857"
     ]
    },
    "dawn_NoncurrentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dayonebio.com/20250331",
     "localname": "NoncurrentMember",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/SignificantAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "NonCurrent [Member]",
        "label": "NonCurrent [Member]",
        "terseLabel": "Noncurrent Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfOperationsUnaudited": {
       "parentTag": "us-gaap_IncomeLossAttributableToNoncontrollingInterest",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total non-operating income, net",
        "label": "Nonoperating Income (Expense)",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r85"
     ]
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Non-operating income:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSegmentReportingAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segment",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r721",
      "r908"
     ]
    },
    "us-gaap_NumberOfReportableSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NumberOfReportableSegments",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSegmentReportingAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Reportable Segments",
        "terseLabel": "Number of reportable segment",
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements."
       }
      }
     },
     "auth_ref": [
      "r715",
      "r725",
      "r908"
     ]
    },
    "us-gaap_ObligationsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ObligationsMember",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/SignificantAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Obligations [Member]",
        "terseLabel": "Obligations",
        "documentation": "Obligation, including, but not limited to, short-term and long-term debt and finance lease obligation."
       }
      }
     },
     "auth_ref": [
      "r900"
     ]
    },
    "dawn_OneCustomerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dayonebio.com/20250331",
     "localname": "OneCustomerMember",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "One Customer [Member]",
        "documentation": "One Customer [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfOperationsUnaudited": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total cost and operating expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost and operating expenses:",
        "label": "Operating Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfOperationsUnaudited": {
       "parentTag": "us-gaap_IncomeLossAttributableToNoncontrollingInterest",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r714",
      "r907",
      "r909",
      "r910",
      "r911",
      "r912"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureLeaseObligationsDetail2": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureLeaseObligationsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Present value of operating lease liabilities",
        "label": "Operating Lease, Liability",
        "totalLabel": "Present value of operating lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r460"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureLeaseObligationsDetail",
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Less: current portion of operating lease liabilities",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Current portion of operating lease liabilities",
        "negatedLabel": "Less: current portion of operating lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r460"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureLeaseObligationsDetail",
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities",
        "verboseLabel": "Long-term portion of operating lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r460"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease payments",
        "label": "Operating Lease, Payments",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r461",
      "r464"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease\u00a0right-of-use\u00a0asset",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r459"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of operating right-of-use asset",
        "negatedLabel": "Amortization of operating right-of-use assets",
        "verboseLabel": "Amortization of operating\u00a0right-of-use\u00a0assets",
        "label": "Operating Lease, Right-of-Use Asset, Periodic Reduction",
        "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease."
       }
      }
     },
     "auth_ref": [
      "r896"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average discount rate percent",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r467",
      "r752"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average remaining lease term",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r466",
      "r752"
     ]
    },
    "us-gaap_OptionIndexedToIssuersEquityTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OptionIndexedToIssuersEquityTypeAxis",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureCommonStockScheduleOfCommonStockSharesReservedForFutureIssuanceDetailsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option Indexed to Issuer's Equity, Type [Axis]",
        "documentation": "Information by type of freestanding contracts issued by an entity that are indexed to, and potentially settled in, an entity's own stock."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r54",
      "r55",
      "r112"
     ]
    },
    "us-gaap_OptionIndexedToIssuersEquityTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OptionIndexedToIssuersEquityTypeDomain",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureCommonStockScheduleOfCommonStockSharesReservedForFutureIssuanceDetailsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option Indexed to Issuer's Equity, Type [Domain]",
        "documentation": "Description of the type of freestanding contract issued by a Company that is indexed to, and potentially settled in, a Company's own stock. Specifically, the pertinent rights and privileges of the securities outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureDescriptionOfBusinessAndOrganization1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "verboseLabel": "Description of Business and Organization",
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r108",
      "r587",
      "r588"
     ]
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureBalanceSheetItemsSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetail": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureBalanceSheetItemsSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other",
        "label": "Other Accrued Liabilities, Current",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfComprehensiveLossUnaudited": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfComprehensiveLossUnaudited",
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Unrealized (loss) gain on available-for-sale securities",
        "negatedLabel": "Unrealized gain on available-for-sale securities",
        "verboseLabel": "Unrealized loss on available-for-sale securities",
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), before Adjustment, after Tax",
        "totalLabel": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), before Adjustment, after Tax, Total",
        "terseLabel": "Unrealized loss on available-for-sale securities",
        "documentation": "Amount, after tax and before adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale."
       }
      }
     },
     "auth_ref": [
      "r153",
      "r154"
     ]
    },
    "us-gaap_OtherExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherExpenses",
     "crdr": "debit",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other expenses",
        "label": "Other Expenses",
        "documentation": "Amount of expense classified as other."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r82"
     ]
    },
    "dawn_OtherIndividualCustomerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dayonebio.com/20250331",
     "localname": "OtherIndividualCustomerMember",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Individual Customer [Member]",
        "label": "Other Individual Customer [Member]",
        "documentation": "Other Individual Customer [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherIntangibleAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherIntangibleAssetsMember",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/SignificantAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Intangible Assets [Member]",
        "label": "Other Intangible Assets [Member]",
        "documentation": "Intangible assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r729",
      "r926",
      "r927",
      "r928",
      "r929",
      "r930",
      "r931",
      "r933",
      "r935",
      "r936",
      "r937"
     ]
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term liability",
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r66"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfOperationsUnaudited": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Other Nonoperating Income (Expense), Total",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other income (expense), net",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r87"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount",
        "terseLabel": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r830"
     ]
    },
    "us-gaap_OtherPrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherPrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureBalanceSheetItemsSummaryOfPrepaidAndOtherCurrentAssetsDetail": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureBalanceSheetItemsSummaryOfPrepaidAndOtherCurrentAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other prepaid expenses and other assets",
        "label": "Other Prepaid Expense, Current",
        "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r888",
      "r925"
     ]
    },
    "us-gaap_OtherResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSegmentReportingScheduleOfSegmentInformationDetails": {
       "parentTag": "us-gaap_ResearchAndDevelopmentExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSegmentReportingScheduleOfSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Research and Development Expense",
        "terseLabel": "Other research and development costs",
        "documentation": "Amount of other research and development expense."
       }
      }
     },
     "auth_ref": [
      "r977"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount",
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r792",
      "r802",
      "r812",
      "r844"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery Compensation Amount",
        "terseLabel": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r795",
      "r805",
      "r815",
      "r847"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r795",
      "r805",
      "r815",
      "r847"
     ]
    },
    "srt_OwnershipAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "OwnershipAxis",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureCommonStockAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_OwnershipDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "OwnershipDomain",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureCommonStockAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "dawn_PRV-RelatedObligationPaymentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dayonebio.com/20250331",
     "localname": "PRV-RelatedObligationPaymentMember",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureIntangibleAssetsScheduleOfIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PRV-Related Obligation Payment [Member]",
        "documentation": "PRV-Related Obligation Payment [Member]",
        "terseLabel": "PRV-related obligation payment [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dawn_ParticipatingThreshold": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.dayonebio.com/20250331",
     "localname": "ParticipatingThreshold",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfFairValueOfTheIncentiveSharesEstimatedUsingAnOptionPricingModelDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Participating threshold.",
        "label": "Participating Threshold",
        "terseLabel": "Participating threshold"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r819"
     ]
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PayablesAndAccrualsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentForManagementFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentForManagementFee",
     "crdr": "credit",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/SignificantAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payment for Management Fee",
        "terseLabel": "Payment for upfront license fee",
        "documentation": "Amount paid to managing member or general partner for management of the day-to-day business functions of the limited liability company (LLC) or limited partnership (LP)."
       }
      }
     },
     "auth_ref": [
      "r894",
      "r1002"
     ]
    },
    "dawn_PaymentOfAccruedInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dayonebio.com/20250331",
     "localname": "PaymentOfAccruedInterest",
     "crdr": "credit",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/RedeemableConvertiblePreferredSharesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payment of accrued interest",
        "label": "Payment Of Accrued Interest",
        "documentation": "Payment of accrued interest."
       }
      }
     },
     "auth_ref": []
    },
    "dawn_PaymentOfMilestones": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dayonebio.com/20250331",
     "localname": "PaymentOfMilestones",
     "crdr": "debit",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails",
      "http://www.dayonebio.com/20250331/taxonomy/role/SignificantAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payment of Milestones",
        "terseLabel": "Launch And Sales Milestones",
        "verboseLabel": "Payment of Milestones",
        "documentation": "Payment of Milestones."
       }
      }
     },
     "auth_ref": []
    },
    "dawn_PaymentToObligationOfLicenseAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dayonebio.com/20250331",
     "localname": "PaymentToObligationOfLicenseAgreement",
     "crdr": "credit",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/SignificantAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payment to Obligation of License Agreement",
        "documentation": "Payment to Obligation of License Agreement",
        "terseLabel": "Payment to obligation of license agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForProceedsFromInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsForProceedsFromInvestments",
     "crdr": "credit",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross proceeds from the investment",
        "label": "Payments for (Proceeds from) Investments",
        "totalLabel": "Payments for (Proceeds from) Investments, Total",
        "documentation": "The net cash paid (received) associated with the acquisition or disposal of all investments, including securities and other assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForProceedsFromPreviousAcquisition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsForProceedsFromPreviousAcquisition",
     "crdr": "credit",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross proceeds from the Private Placement",
        "label": "Payments for (Proceeds from) Previous Acquisition",
        "totalLabel": "Payments for (Proceeds from) Previous Acquisition, Total",
        "documentation": "The net cash inflow or outflow associated with the aggregate amount of adjustment to the purchase price of a previous acquisition."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForRepurchaseOfPrivatePlacement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsForRepurchaseOfPrivatePlacement",
     "crdr": "credit",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments for Repurchase of Private Placement",
        "terseLabel": "Payment to private placement",
        "documentation": "The cash outflow associated with the repurchase of amount received from entity's raising of capital via private rather than public placement."
       }
      }
     },
     "auth_ref": [
      "r91"
     ]
    },
    "dawn_PaymentsOfCreditsRelatingToSalesInCurrentYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dayonebio.com/20250331",
     "localname": "PaymentsOfCreditsRelatingToSalesInCurrentYear",
     "crdr": "debit",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummarizesOfBalancesAndActivityTheProductRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payments / credits relating to sales in current year",
        "label": "Payments of Credits Relating to Sales in Current Year",
        "documentation": "Payments of Credits Relating to Sales in Current Year"
       }
      }
     },
     "auth_ref": []
    },
    "dawn_PaymentsOfCreditsRelatingToSalesInPriorYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dayonebio.com/20250331",
     "localname": "PaymentsOfCreditsRelatingToSalesInPriorYear",
     "crdr": "credit",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummarizesOfBalancesAndActivityTheProductRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payments / credits relating to sales in prior year",
        "label": "Payments of Credits Relating to Sales in Prior Year",
        "documentation": "Payments of Credits Relating to Sales in Prior Year"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/RedeemableConvertiblePreferredSharesAdditionalInformationDetail",
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfStockholdersEquityUnauditedParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payment of stock issuance costs",
        "label": "Payments of Stock Issuance Costs",
        "verboseLabel": "Stock issuance costs",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireIntangibleAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Cash paid for acquired intangible assets",
        "terseLabel": "Cash paid for acquired intangible asset",
        "label": "Payments to Acquire Intangible Assets",
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill."
       }
      }
     },
     "auth_ref": [
      "r90"
     ]
    },
    "us-gaap_PaymentsToAcquireProductiveAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireProductiveAssets",
     "crdr": "credit",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/SignificantAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payment of PRV related obligations",
        "label": "Payments to Acquire Productive Assets",
        "totalLabel": "Payments to Acquire Productive Assets, Total",
        "documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r978",
      "r979",
      "r980"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "totalLabel": "Payments to Acquire Property, Plant, and Equipment, Total",
        "negatedLabel": "Cash paid for purchase of property and equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r90"
     ]
    },
    "us-gaap_PaymentsToAcquireShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireShortTermInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to Acquire Short-Term Investments",
        "terseLabel": "Cash paid for purchase of short-term investments",
        "negatedLabel": "Cash paid for purchase of short-term investments",
        "documentation": "The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term."
       }
      }
     },
     "auth_ref": [
      "r89"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote [Text Block]",
        "terseLabel": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r829"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount",
        "terseLabel": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r829"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount",
        "terseLabel": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r821"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO [Member]",
        "terseLabel": "PEO"
       }
      }
     },
     "auth_ref": [
      "r838"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name",
        "terseLabel": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r831"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount",
        "terseLabel": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r820"
     ]
    },
    "dawn_PercentageOfUpfrontLicenseFee": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.dayonebio.com/20250331",
     "localname": "PercentageOfUpfrontLicenseFee",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/SignificantAgreementsAdditionalInformationDetail",
      "http://www.dayonebio.com/20250331/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage Of Upfront License Fee",
        "label": "Percentage Of Upfront License Fee",
        "terseLabel": "Percentage Of Upfront License Fee"
       }
      }
     },
     "auth_ref": []
    },
    "dawn_PerformanceStockOptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dayonebio.com/20250331",
     "localname": "PerformanceStockOptionsMember",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureNetIncomeLossPerShareSummaryOfOutstandingPotentiallyDilutiveSecuritiesHaveBeenExcludedFromCalculationOfDilutedNetLossPerShare",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetail",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfPerformanceStockOptionsActivityDetails",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfPerformanceStockUnitsActivityDetails",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfTheBlackscholesOptionPricingModelToEstimateTheFairValueOfPerformanceStockOpDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PSOs",
        "label": "Performance Stock Options [Member]",
        "documentation": "Performance Stock Options Member"
       }
      }
     },
     "auth_ref": []
    },
    "dawn_PerformanceStockUnitsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dayonebio.com/20250331",
     "localname": "PerformanceStockUnitsMember",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureNetIncomeLossPerShareSummaryOfOutstandingPotentiallyDilutiveSecuritiesHaveBeenExcludedFromCalculationOfDilutedNetLossPerShare",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PSUs",
        "label": "Performance Stock Units [Member]",
        "documentation": "Performance Stock Units Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetail",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationFairValueOfOurCommonStockToBeIssuedUnderTheEsppDetails",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfFairValueOfTheIncentiveSharesEstimatedUsingAnOptionPricingModelDetail",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfPerformanceStockUnitsActivityDetails",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfRestrictedStockUnitsActivityDetail",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfStockOptionActivityDetail",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfTheBlackscholesOptionPricingModelToEstimateTheFairValueOfStockOptionGrantedDetail",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfTheUnvestedCommonStockDetail",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r951",
      "r952",
      "r953",
      "r954",
      "r955",
      "r956",
      "r957",
      "r958",
      "r959",
      "r960",
      "r961",
      "r962",
      "r963",
      "r964",
      "r965",
      "r966",
      "r967",
      "r968",
      "r969",
      "r970",
      "r971",
      "r972",
      "r973",
      "r974",
      "r975",
      "r976"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetail",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationFairValueOfOurCommonStockToBeIssuedUnderTheEsppDetails",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfFairValueOfTheIncentiveSharesEstimatedUsingAnOptionPricingModelDetail",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfPerformanceStockUnitsActivityDetails",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfRestrictedStockUnitsActivityDetail",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfStockOptionActivityDetail",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfTheBlackscholesOptionPricingModelToEstimateTheFairValueOfStockOptionGrantedDetail",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfTheUnvestedCommonStockDetail",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r951",
      "r952",
      "r953",
      "r954",
      "r955",
      "r956",
      "r957",
      "r958",
      "r959",
      "r960",
      "r961",
      "r962",
      "r963",
      "r964",
      "r965",
      "r966",
      "r967",
      "r968",
      "r969",
      "r970",
      "r971",
      "r972",
      "r973",
      "r974",
      "r975",
      "r976"
     ]
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Prior Service Cost [Member]",
        "terseLabel": "Pension Adjustments Prior Service Cost"
       }
      }
     },
     "auth_ref": [
      "r822"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Service Cost [Member]",
        "terseLabel": "Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r866"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Benefits Adjustments, Footnote [Text Block]",
        "terseLabel": "Pension Benefits Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r821"
     ]
    },
    "dawn_PreFundedWarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dayonebio.com/20250331",
     "localname": "PreFundedWarrantMember",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureCommonStockAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pre-Funded Warrant [Member]",
        "label": "Pre-Funded Warrant [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dawn_PreFundedWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dayonebio.com/20250331",
     "localname": "PreFundedWarrantsMember",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureCommonStockAdditionalInformationDetail",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureCommonStockScheduleOfCommonStockSharesReservedForFutureIssuanceDetailsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pre-Funded Warrants [Member]",
        "label": "Pre-Funded Warrants [Member]",
        "terseLabel": "Pre-Funded Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedBalanceSheetsUnauditedParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred Stock, Shares Issued",
        "label": "Preferred Stock, Shares Issued",
        "totalLabel": "Preferred Stock, Shares Issued, Total",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r320"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedBalanceSheetsUnauditedParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred Stock, Shares Outstanding",
        "label": "Preferred Stock, Shares Outstanding",
        "periodStartLabel": "Preferred Stock, Shares Outstanding, Beginning Balance",
        "periodEndLabel": "Preferred Stock, Shares Outstanding, Ending Balance",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r623",
      "r642",
      "r1051",
      "r1052"
     ]
    },
    "dawn_PremiumPaidOnEquityStatementAsAdditionalConsideration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dayonebio.com/20250331",
     "localname": "PremiumPaidOnEquityStatementAsAdditionalConsideration",
     "crdr": "debit",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Premium Paid On Equity Statement As Additional Consideration",
        "label": "Premium Paid On Equity Statement As Additional Consideration",
        "terseLabel": "Premium paid on equity statement as additional consideration"
       }
      }
     },
     "auth_ref": []
    },
    "dawn_PremiumReceivedOnLicenseAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dayonebio.com/20250331",
     "localname": "PremiumReceivedOnLicenseAgreement",
     "crdr": "credit",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Premium Received On License Agreement",
        "label": "Premium Received On License Agreement",
        "terseLabel": "Premium Received On License Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      },
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureBalanceSheetItemsSummaryOfPrepaidAndOtherCurrentAssetsDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureBalanceSheetItemsSummaryOfPrepaidAndOtherCurrentAssetsDetail",
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Total prepaid expenses and other current assets",
        "terseLabel": "Prepaid expenses and other current assets",
        "label": "Prepaid Expense and Other Assets, Current",
        "totalLabel": "Total prepaid expenses and other current assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r890"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseAndOtherAssetsCurrentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expense and Other Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidInsurance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidInsurance",
     "crdr": "debit",
     "calculation": {
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureBalanceSheetItemsSummaryOfPrepaidAndOtherCurrentAssetsDetail": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureBalanceSheetItemsSummaryOfPrepaidAndOtherCurrentAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Prepaid insurance",
        "label": "Prepaid Insurance",
        "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r709",
      "r728",
      "r925"
     ]
    },
    "dawn_PrepaidResearchAndDevelopmentExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dayonebio.com/20250331",
     "localname": "PrepaidResearchAndDevelopmentExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureBalanceSheetItemsSummaryOfPrepaidAndOtherCurrentAssetsDetail": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureBalanceSheetItemsSummaryOfPrepaidAndOtherCurrentAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Prepaid research and development expenses",
        "label": "Prepaid research and development expenses",
        "documentation": "Prepaid Research and Development Expenses."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureCommonStockAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from the issuance of common stock, net",
        "verboseLabel": "Proceeds from issuance of common stock, net",
        "label": "Proceeds from Issuance of Common Stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfPrivatePlacement",
     "crdr": "debit",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureCommonStockAdditionalInformationDetail",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails",
      "http://www.dayonebio.com/20250331/taxonomy/role/SignificantAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Private Placement",
        "terseLabel": "Proceeds from issuance of common stock in connection with private placement, net of placement agent fees and offering costs",
        "verboseLabel": "Proceeds from issuance of private placement",
        "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock",
     "crdr": "debit",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/RedeemableConvertiblePreferredSharesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from redeemable convertible preferred stock",
        "label": "Proceeds from Issuance of Redeemable Convertible Preferred Stock",
        "documentation": "The cash inflow from issuance of callable preferred stock which is identified as being convertible to another type of financial security at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfWarrants",
     "crdr": "debit",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureCommonStockAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Warrants",
        "terseLabel": "Proceeds from issuance of prefunded warrants to purchase common stock, net of issuance costs",
        "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ProceedsFromSaleOfProductiveAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromSaleOfProductiveAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/SignificantAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds From sale of PRV",
        "label": "Proceeds from Sale of Productive Assets",
        "totalLabel": "Proceeds from Sale of Productive Assets, Total",
        "verboseLabel": "Proceeds from sale of priority review voucher",
        "documentation": "The cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets."
       }
      }
     },
     "auth_ref": [
      "r88"
     ]
    },
    "us-gaap_ProceedsFromSaleOfShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromSaleOfShortTermInvestments",
     "crdr": "debit",
     "calculation": {
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Sale of Short-Term Investments",
        "terseLabel": "Proceeds from maturity of short-term investments",
        "documentation": "The cash inflow from sales of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "calculation": {
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from issuance of common stock upon stock option exercises",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r9"
     ]
    },
    "us-gaap_ProductMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProductMember",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product [Member]",
        "terseLabel": "Product revenue, net [Member]",
        "documentation": "Article or substance produced by nature, labor or machinery."
       }
      }
     },
     "auth_ref": [
      "r733"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/SignificantAgreementsAdditionalInformationDetail",
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r232",
      "r509",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r705",
      "r733",
      "r763",
      "r765",
      "r766",
      "r769",
      "r770",
      "r942",
      "r943",
      "r948",
      "r1017",
      "r1019",
      "r1020",
      "r1021",
      "r1022",
      "r1023",
      "r1024",
      "r1025",
      "r1026",
      "r1027",
      "r1028",
      "r1029",
      "r1030",
      "r1031",
      "r1032",
      "r1033",
      "r1034",
      "r1035",
      "r1036",
      "r1037",
      "r1038",
      "r1039",
      "r1040",
      "r1041",
      "r1042",
      "r1043",
      "r1044",
      "r1045",
      "r1046"
     ]
    },
    "dawn_ProductRevenueAllowanceAndReserve": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dayonebio.com/20250331",
     "localname": "ProductRevenueAllowanceAndReserve",
     "crdr": "credit",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummarizesOfBalancesAndActivityTheProductRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Balance as of June 30, 2024",
        "periodStartLabel": "Balance as of December 31, 2023",
        "label": "Product Revenue Allowance and Reserve",
        "documentation": "Product Revenue Allowance and Reserve"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/SignificantAgreementsAdditionalInformationDetail",
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]"
       }
      }
     },
     "auth_ref": [
      "r232",
      "r509",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r705",
      "r733",
      "r763",
      "r765",
      "r766",
      "r769",
      "r770",
      "r942",
      "r943",
      "r948",
      "r1017",
      "r1019",
      "r1020",
      "r1021",
      "r1022",
      "r1023",
      "r1024",
      "r1025",
      "r1026",
      "r1027",
      "r1028",
      "r1029",
      "r1030",
      "r1031",
      "r1032",
      "r1033",
      "r1034",
      "r1035",
      "r1036",
      "r1037",
      "r1038",
      "r1039",
      "r1040",
      "r1041",
      "r1042",
      "r1043",
      "r1044",
      "r1045",
      "r1046"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Property and equipment, net",
        "terseLabel": "Property and equipment, net",
        "label": "Property, Plant and Equipment, Net",
        "periodStartLabel": "Property, Plant and Equipment, Net, Beginning Balance",
        "periodEndLabel": "Property, Plant and Equipment, Net, Ending Balance",
        "totalLabel": "Property and equipment, net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r469",
      "r548",
      "r559",
      "r753"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureBalanceSheetItemsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Schedule of Property and Equipment",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dawn_PrvPressureReliefValveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dayonebio.com/20250331",
     "localname": "PrvPressureReliefValveMember",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/SignificantAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PRV",
        "label": "PRV (Pressure Relief Valve) [Member]",
        "documentation": "PRV (Pressure relief valve) [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PurchaseCommitmentExcludingLongtermCommitmentAxis",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase Commitment, Excluding Long-Term Commitment [Axis]",
        "documentation": "Information by arrangement, in which the entity has agreed to expend funds to procure goods or services from one or more suppliers."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r115"
     ]
    },
    "us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PurchaseCommitmentExcludingLongtermCommitmentDomain",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase Commitment, Excluding Long-Term Commitment [Domain]",
        "documentation": "This item is intended to be populated, by the entity, with Members identifying each purchase commitment about which information required or determined to be disclosed is being provided. If only one such commitment exists, this item may be used to capture such information; if multiple commitments exist, this item is the dimensional default, which will aggregate such information, as appropriate."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r115"
     ]
    },
    "us-gaap_PurchaseCommitmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PurchaseCommitmentMember",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase Commitments",
        "label": "Purchase Commitment [Member]",
        "documentation": "Purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier. Excludes long-term commitments."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r115"
     ]
    },
    "us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PurchaseCommitmentRemainingMinimumAmountCommitted",
     "crdr": "credit",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate amount of future minimum purchase obligations",
        "label": "Purchase Commitment, Remaining Minimum Amount Committed",
        "documentation": "Minimum amount to be expended to satisfy the terms of arrangements in which the entity has agreed to expend funds to procure goods or services, excluding long-term purchase commitments or unconditional purchase obligations."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r115"
     ]
    },
    "dawn_PurchasesUnderThePurchaseObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dayonebio.com/20250331",
     "localname": "PurchasesUnderThePurchaseObligation",
     "crdr": "credit",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchases under the purchase obligation",
        "label": "Purchases Under the Purchase Obligation",
        "documentation": "Purchases Under the Purchase Obligation"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r819"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance [Table Text Block]",
        "terseLabel": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r819"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfFairValueOfTheIncentiveSharesEstimatedUsingAnOptionPricingModelDetail",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfTheBlackscholesOptionPricingModelToEstimateTheFairValueOfPerformanceStockOpDetails",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfTheBlackscholesOptionPricingModelToEstimateTheFairValueOfStockOptionGrantedDetail",
      "http://www.dayonebio.com/20250331/taxonomy/role/SignificantAgreementsAdditionalInformationDetail",
      "http://www.dayonebio.com/20250331/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r303",
      "r304",
      "r305",
      "r306",
      "r337",
      "r347",
      "r376",
      "r377",
      "r378",
      "r385",
      "r431",
      "r483",
      "r492",
      "r508",
      "r575",
      "r577",
      "r585",
      "r613",
      "r614",
      "r669",
      "r671",
      "r673",
      "r674",
      "r680",
      "r700",
      "r701",
      "r726",
      "r732",
      "r739",
      "r745",
      "r746",
      "r750",
      "r751",
      "r765",
      "r773",
      "r940",
      "r947",
      "r987",
      "r1007",
      "r1008",
      "r1009",
      "r1010",
      "r1011"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeMember",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfFairValueOfTheIncentiveSharesEstimatedUsingAnOptionPricingModelDetail",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfTheBlackscholesOptionPricingModelToEstimateTheFairValueOfPerformanceStockOpDetails",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfTheBlackscholesOptionPricingModelToEstimateTheFairValueOfStockOptionGrantedDetail",
      "http://www.dayonebio.com/20250331/taxonomy/role/SignificantAgreementsAdditionalInformationDetail",
      "http://www.dayonebio.com/20250331/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r303",
      "r304",
      "r305",
      "r306",
      "r337",
      "r347",
      "r376",
      "r377",
      "r378",
      "r385",
      "r431",
      "r483",
      "r492",
      "r508",
      "r575",
      "r577",
      "r585",
      "r613",
      "r614",
      "r669",
      "r671",
      "r673",
      "r674",
      "r680",
      "r700",
      "r701",
      "r726",
      "r732",
      "r739",
      "r745",
      "r746",
      "r750",
      "r751",
      "r765",
      "r773",
      "r940",
      "r947",
      "r987",
      "r1007",
      "r1008",
      "r1009",
      "r1010",
      "r1011"
     ]
    },
    "us-gaap_RealizedInvestmentGainsLosses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RealizedInvestmentGainsLosses",
     "crdr": "credit",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureRecurringFairValueMeasurementAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Realized Investment Gains (Losses), Total",
        "label": "Realized Investment Gains (Losses)",
        "terseLabel": "Realized gains and losses",
        "documentation": "Amount of realized gain (loss) on investment."
       }
      }
     },
     "auth_ref": [
      "r566"
     ]
    },
    "us-gaap_ReceivablesNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReceivablesNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts receivable, net",
        "label": "Receivables, Net, Current",
        "totalLabel": "Receivables, Net, Current, Total",
        "documentation": "The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value."
       }
      }
     },
     "auth_ref": [
      "r753"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]",
        "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure"
       }
      }
     },
     "auth_ref": [
      "r787",
      "r797",
      "r807",
      "r839"
     ]
    },
    "us-gaap_RedeemableConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RedeemableConvertiblePreferredStockMember",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureCommonStockAdditionalInformationDetail",
      "http://www.dayonebio.com/20250331/taxonomy/role/RedeemableConvertiblePreferredSharesAdditionalInformationDetail",
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedBalanceSheetsUnauditedParenthetical",
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Redeemable Convertible Preferred Stock [Member]",
        "terseLabel": "Convertible preferred shares [Member]",
        "verboseLabel": "Redeemable convertible preferred shares",
        "documentation": "Description of type or class of redeemable convertible preferred stock. Convertible redeemable preferred stock possess conversion and redemption features. The stock has redemption features that are outside the control of the issuer."
       }
      }
     },
     "auth_ref": []
    },
    "dawn_RedeemableNonControllingInterestTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.dayonebio.com/20250331",
     "localname": "RedeemableNonControllingInterestTextBlock",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/RedeemableNoncontrollingInterest"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Redeemable NonControlling Interest",
        "label": "Redeemable Non Controlling Interest [Text Block]",
        "documentation": "Disclosure of redeemable non-controlling interest."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RedeemableNoncontrollingInterestEquityPreferredCarryingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RedeemableNoncontrollingInterestEquityPreferredCarryingAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/RedeemableConvertiblePreferredSharesSummaryOfSeriesARedeemableConvertiblePreferredSharesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Carrying Value",
        "label": "Redeemable Noncontrolling Interest, Equity, Preferred, Carrying Amount",
        "terseLabel": "Redeemable convertible preferred shares, no par value; no shares authorized, issued and outstanding at September 30, 2021; 22,851,257 shares authorized, issued and outstanding at December 31, 2020",
        "documentation": "As of the reporting date, the carrying amount of noncontrolling interests which are redeemable by the (parent) entity (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the (parent) entity. The noncontrolling interest holder's ownership (or holders' ownership) may be in the form of preferred shares (regardless of class), preferred partnership units (regardless of class), preferential membership interests, or any other form of preferred equity regardless of investee entity legal form."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r36",
      "r99",
      "r100"
     ]
    },
    "dawn_RedeemableNoncontrollingInterestMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dayonebio.com/20250331",
     "localname": "RedeemableNoncontrollingInterestMember",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock upon exercise of stock options",
        "label": "Redeemable Noncontrolling Interest [Member]",
        "documentation": "Redeemable Noncontrolling Interest Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureCommonStockAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Domain]",
        "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r237",
      "r344",
      "r472",
      "r473",
      "r551",
      "r558",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r641",
      "r643",
      "r668"
     ]
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureCommonStockAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Axis]",
        "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r237",
      "r344",
      "r472",
      "r473",
      "r551",
      "r558",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r641",
      "r643",
      "r668",
      "r1003"
     ]
    },
    "dawn_ResearchAndDevelopmentAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dayonebio.com/20250331",
     "localname": "ResearchAndDevelopmentAgreementsMember",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research And Development Agreements [Member]",
        "terseLabel": "Research And Development Agreements",
        "documentation": "Research And Development Agreements Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfOperationsUnaudited": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSegmentReportingScheduleOfSegmentInformationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSegmentReportingScheduleOfSegmentInformationDetails",
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense",
        "terseLabel": "Total research and development expenses",
        "totalLabel": "Total research and development expenses",
        "verboseLabel": "Research and development",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r386",
      "r703",
      "r720",
      "r1012"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfSharestockbasedCompensationExpenseRecordedInTheAccompanyingCondensedConsolidatedStatementsOfOperation",
      "http://www.dayonebio.com/20250331/taxonomy/role/SignificantAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development expense",
        "label": "Research And Development Expense",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]",
        "terseLabel": "Restatement Determination Date:"
       }
      }
     },
     "auth_ref": [
      "r788",
      "r798",
      "r808",
      "r840"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date",
        "terseLabel": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r789",
      "r799",
      "r809",
      "r841"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Does Not Require Recovery [Text Block]",
        "terseLabel": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r796",
      "r806",
      "r816",
      "r848"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureRecurringFairValueMeasurementScheduleOfMaturitiesForAvailableForSaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Domain]",
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r143"
     ]
    },
    "dawn_RestrictedStockAwardsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dayonebio.com/20250331",
     "localname": "RestrictedStockAwardsMember",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureNetIncomeLossPerShareSummaryOfBasicAndDilutedNetLossPerShareAttributableToCommonShareholdersstockholdersDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted Stock Awards Member",
        "label": "Restricted Stock Awards [Member]",
        "terseLabel": "Restricted stock awards"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestrictedStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedStockMember",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetail",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfRestrictedStockUnitsActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted Stock",
        "label": "Restricted Stock [Member]",
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureCommonStockScheduleOfCommonStockSharesReservedForFutureIssuanceDetailsDetails",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureNetIncomeLossPerShareSummaryOfBasicAndDilutedNetLossPerShareAttributableToCommonShareholdersstockholdersDetail",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureNetIncomeLossPerShareSummaryOfOutstandingPotentiallyDilutiveSecuritiesHaveBeenExcludedFromCalculationOfDilutedNetLossPerShare",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfRestrictedStockUnitsActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock Units (RSUs)",
        "terseLabel": "Restricted Stock Units",
        "verboseLabel": "Restricted Stock Units (RSUs)",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit",
        "label": "Retained Earnings (Accumulated Deficit)",
        "totalLabel": "Retained Earnings (Accumulated Deficit), Total",
        "periodStartLabel": "Retained Earnings (Accumulated Deficit), Beginning Balance",
        "periodEndLabel": "Retained Earnings (Accumulated Deficit), Ending Balance",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r104",
      "r556",
      "r582",
      "r584",
      "r594",
      "r624",
      "r753"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accumulated Deficit [Member]",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r139",
      "r171",
      "r172",
      "r173",
      "r175",
      "r180",
      "r182",
      "r184",
      "r270",
      "r271",
      "r296",
      "r395",
      "r396",
      "r403",
      "r404",
      "r405",
      "r407",
      "r408",
      "r409",
      "r415",
      "r417",
      "r418",
      "r420",
      "r423",
      "r457",
      "r458",
      "r579",
      "r581",
      "r596",
      "r1051"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerProductAndServiceBenchmarkMember",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Product Revenue [Member]",
        "label": "Revenue from Contract with Customer, Product and Service Benchmark [Member]",
        "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer for specified product or service, when it serves as benchmark in concentration of risk calculation."
       }
      }
     },
     "auth_ref": [
      "r872"
     ]
    },
    "us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueRecognitionMilestoneMethodRevenueRecognized",
     "crdr": "credit",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone payment, capitalized",
        "label": "Revenue Recognition, Milestone Method, Revenue Recognized",
        "documentation": "The amount of consideration recognized during the period for the milestone or milestones."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Revenues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Revenues",
     "crdr": "credit",
     "calculation": {
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfOperationsUnaudited": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total revenue, net",
        "label": "Revenues",
        "verboseLabel": "Royalty Revenue",
        "terseLabel": "Total revenues",
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r120",
      "r121",
      "r162",
      "r169",
      "r201",
      "r210",
      "r211",
      "r224",
      "r228",
      "r232",
      "r234",
      "r236",
      "r269",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r449",
      "r546",
      "r720",
      "r945"
     ]
    },
    "us-gaap_RevenuesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenuesAbstract",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue:",
        "label": "Revenues [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Right-of-use asset obtained in exchange for new operating lease liabilities",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r465",
      "r752"
     ]
    },
    "us-gaap_RoyaltyIncomeNonoperating": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RoyaltyIncomeNonoperating",
     "crdr": "credit",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/SignificantAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Royalty Income, Nonoperating",
        "terseLabel": "Royalty revenue",
        "documentation": "Ancillary revenue earned during the period from the consideration paid to the entity for the use of its rights and property by another party. Examples include licensing the use of copyrighted materials and leasing the extraction of natural resources."
       }
      }
     },
     "auth_ref": [
      "r85"
     ]
    },
    "us-gaap_RoyaltyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RoyaltyMember",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/SignificantAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Royalty [Member]",
        "terseLabel": "Royalty",
        "documentation": "Money for usage-based right to asset."
       }
      }
     },
     "auth_ref": [
      "r949"
     ]
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r857"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r857"
     ]
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/RedeemableConvertiblePreferredSharesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase price per share",
        "label": "Sale of Stock, Price Per Share",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "dawn_SalesAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dayonebio.com/20250331",
     "localname": "SalesAgreementMember",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureCommonStockAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales Agreement with Piper Sandler and Jones Services LLC",
        "label": "Sales Agreement [Member]",
        "documentation": "Sales agreement member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SalesRevenueNetMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SalesRevenueNetMember",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue Benchmark [Member]",
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation."
       }
      }
     },
     "auth_ref": [
      "r236",
      "r871"
     ]
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureBalanceSheetItemsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Schedule of Accrued expenses and other current liabilities",
        "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureNetIncomeLossPerShareSummaryOfBasicAndDilutedNetLossPerShareAttributableToCommonShareholdersstockholdersDetail",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureNetIncomeLossPerShareSummaryOfOutstandingPotentiallyDilutiveSecuritiesHaveBeenExcludedFromCalculationOfDilutedNetLossPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureNetIncomeLossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Outstanding Potentially Dilutive Securities Have Been Excluded From Calculation of Diluted Net Loss Per Share",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfCashAndCashEquivalentsTable",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureRecurringFairValueMeasurementScheduleOfCashEquivalentsMarketableSecuritiesAndUnrealizedGainsAndLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalent [Table]",
        "documentation": "Disclosure of information about cash and cash equivalent by type. Excludes restricted cash and cash equivalent."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/SignificantAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r410"
     ]
    },
    "dawn_ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.dayonebio.com/20250331",
     "localname": "ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureCommonStockTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Common Stock Shares Reserved For Future Issuance Table Text Block",
        "label": "Schedule Of Common Stock Shares Reserved For Future Issuance [Table Text Block]",
        "terseLabel": "Schedule of Common Stock Shares Reserved for Future Issuance"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureNetIncomeLossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Basic and Diluted Net Loss Per Share Attributable to Common Shareholders/Stockholders",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r906"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfSharestockbasedCompensationExpenseRecordedInTheAccompanyingCondensedConsolidatedStatementsOfOperation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Share/Stock-based Compensation Expense Recorded in The Accompanying Condensed Consolidated Statements of Operations and Comprehensive Loss",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureRecurringFairValueMeasurementTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Schedule of fair value, assets and liabilities measured on recurring basis",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r984",
      "r985"
     ]
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureIntangibleAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Intangible Assets",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment."
       }
      }
     },
     "auth_ref": [
      "r729",
      "r932"
     ]
    },
    "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTable",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureIntangibleAssetsScheduleOfIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Asset, Indefinite-Lived [Table]",
        "documentation": "Disclosure of information about indefinite-lived intangible asset. Excludes finite-lived intangible asset."
       }
      }
     },
     "auth_ref": [
      "r284",
      "r290",
      "r294",
      "r729"
     ]
    },
    "dawn_ScheduleOfMaturitiesForAvailableForSaleSecuritiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.dayonebio.com/20250331",
     "localname": "ScheduleOfMaturitiesForAvailableForSaleSecuritiesTableTextBlock",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureRecurringFairValueMeasurementTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Maturities For Available For Sale Securities Table Text Block",
        "documentation": "Schedule Of Maturities For Available For Sale Securities Table Text Block",
        "terseLabel": "Schedule Of Maturities For Available For Sale Securities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfNonvestedShareActivityTableTextBlock",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Nonvested Share Activity [Table Text Block]",
        "terseLabel": "Summary of The Unvested Common Stock",
        "documentation": "Tabular disclosure of the changes in outstanding nonvested shares."
       }
      }
     },
     "auth_ref": [
      "r105"
     ]
    },
    "dawn_ScheduleOfPerformanceStockOptionsAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.dayonebio.com/20250331",
     "localname": "ScheduleOfPerformanceStockOptionsAssumptionsTableTextBlock",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of The Black-Scholes Option Pricing Model to Estimate The Fair Value of Performance Stock Option Granted",
        "label": "Schedule of Performance Stock Options Assumptions [Table Text Block]",
        "documentation": "Schedule of Performance Stock Options Assumptions table text block"
       }
      }
     },
     "auth_ref": []
    },
    "dawn_ScheduleOfPrepaidAndOtherCurrentAssetstableTextBlockTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.dayonebio.com/20250331",
     "localname": "ScheduleOfPrepaidAndOtherCurrentAssetstableTextBlockTableTextBlock",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureBalanceSheetItemsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Prepaid And Other Current Assets [Table Text Block]",
        "documentation": "Schedule Of Prepaid And Other Current Assets.",
        "verboseLabel": "Schedule of Prepaid Expenses and Other Current Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSegmentReportingTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "terseLabel": "Schedule of Segment Information",
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r29",
      "r30"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetail",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationFairValueOfOurCommonStockToBeIssuedUnderTheEsppDetails",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfFairValueOfTheIncentiveSharesEstimatedUsingAnOptionPricingModelDetail",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfPerformanceStockOptionsActivityDetails",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfPerformanceStockUnitsActivityDetails",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfRestrictedStockUnitsActivityDetail",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfStockOptionActivityDetail",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfTheBlackscholesOptionPricingModelToEstimateTheFairValueOfPerformanceStockOpDetails",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfTheBlackscholesOptionPricingModelToEstimateTheFairValueOfStockOptionGrantedDetail",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfTheIncentiveSharesActivityDetail",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfTheUnvestedCommonStockDetail",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r349",
      "r351",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Fair Value of The Incentive Shares Estimated Using An Option Pricing Model",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r107"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureCommonStockAdditionalInformationDetail",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureCommonStockScheduleOfCommonStockSharesReservedForFutureIssuanceDetailsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock, Class of Stock [Table]",
        "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r38",
      "r39",
      "r40",
      "r41",
      "r42",
      "r98",
      "r102",
      "r103",
      "r104",
      "r146",
      "r147",
      "r148",
      "r203",
      "r320",
      "r321",
      "r322",
      "r324",
      "r327",
      "r332",
      "r334",
      "r590",
      "r591",
      "r592",
      "r593",
      "r732",
      "r869",
      "r897"
     ]
    },
    "dawn_ScheduleOfStockOptionsAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.dayonebio.com/20250331",
     "localname": "ScheduleOfStockOptionsAssumptionsTableTextBlock",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Stock Options Assumptions.",
        "label": "Schedule of Stock Options Assumptions [Table Text Block]",
        "verboseLabel": "Summary of The Black-Scholes Option Pricing Model to Estimate The Fair Value of Stock Option Granted"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Summary of Restricted Stock Units Activity",
        "terseLabel": "Summary of The Unvested Common Stock",
        "label": "Schedule of Unvested Restricted Stock Units Roll Forward [Table Text Block]",
        "documentation": "Tabular disclosure of the change in restricted stock units (RSUs)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureIntangibleAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Amortization Expense For Amortizable Finite-Lived Intangible Assets",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r729",
      "r934"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r782"
     ]
    },
    "us-gaap_SecurityDeposit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SecurityDeposit",
     "crdr": "debit",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security deposit",
        "label": "Security Deposit",
        "documentation": "The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease."
       }
      }
     },
     "auth_ref": [
      "r885"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r784"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]"
       }
      }
     },
     "auth_ref": [
      "r234",
      "r235",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r609",
      "r610",
      "r611",
      "r670",
      "r672",
      "r675",
      "r681",
      "r688",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r706",
      "r734",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761",
      "r762",
      "r767",
      "r773",
      "r948",
      "r1017",
      "r1019",
      "r1020",
      "r1022",
      "r1023",
      "r1024",
      "r1025",
      "r1026",
      "r1027",
      "r1028",
      "r1029",
      "r1030",
      "r1031",
      "r1032",
      "r1033",
      "r1034",
      "r1035",
      "r1036",
      "r1037",
      "r1038",
      "r1039",
      "r1040",
      "r1041",
      "r1042",
      "r1043",
      "r1044",
      "r1045",
      "r1046"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSegmentReporting"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting Disclosure [Text Block]",
        "terseLabel": "Segment Reporting",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r123",
      "r201",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r214",
      "r215",
      "r216",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r232",
      "r233",
      "r236",
      "r715",
      "r718",
      "r719",
      "r720",
      "r722",
      "r724",
      "r725"
     ]
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Segmen tReporting Policy Policy TextBlock",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segments",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r231",
      "r234",
      "r716",
      "r717",
      "r723"
     ]
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfSharestockbasedCompensationExpenseRecordedInTheAccompanyingCondensedConsolidatedStatementsOfOperation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Selling, general and administrative expense",
        "label": "Selling, General and Administrative Expenses [Member]",
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "dawn_SeriesARedeemableConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dayonebio.com/20250331",
     "localname": "SeriesARedeemableConvertiblePreferredStockMember",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/RedeemableConvertiblePreferredSharesAdditionalInformationDetail",
      "http://www.dayonebio.com/20250331/taxonomy/role/RedeemableConvertiblePreferredSharesSummaryOfSeriesARedeemableConvertiblePreferredSharesDetail",
      "http://www.dayonebio.com/20250331/taxonomy/role/SignificantAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series A Redeemable Convertible Preferred Stock [Member]",
        "documentation": "Series A Redeemable Convertible Preferred Stock."
       }
      }
     },
     "auth_ref": []
    },
    "dawn_SeriesBRedeemableConvertiblePreferredSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dayonebio.com/20250331",
     "localname": "SeriesBRedeemableConvertiblePreferredSharesMember",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfStockholdersEquityUnauditedParenthetical",
      "http://www.dayonebio.com/20250331/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series B redeemable convertible preferred shares [Member]",
        "documentation": "Series B Redeemable Convertible Preferred Shares."
       }
      }
     },
     "auth_ref": []
    },
    "dawn_SeriesBRedeemableConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dayonebio.com/20250331",
     "localname": "SeriesBRedeemableConvertiblePreferredStockMember",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/RedeemableConvertiblePreferredSharesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series B Redeemable Convertible Preferred Stock [Member]",
        "documentation": "Series B Redeemable Convertible Preferred Stock."
       }
      }
     },
     "auth_ref": []
    },
    "dawn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsConvertedToUnvestedCommonStockWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.dayonebio.com/20250331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsConvertedToUnvestedCommonStockWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfTheIncentiveSharesActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Grant Date Fair Value, Converted to unvested common stock",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Converted To Unvested Common Stock Weighted Average Grant Date Fair Value",
        "documentation": "Share based compensation arrangement by share based payment award equity instruments other than options converted to unvested common stock weighted average grant date fair value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfPerformanceStockUnitsActivityDetails",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfRestrictedStockUnitsActivityDetail",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfTheIncentiveSharesActivityDetail",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfTheUnvestedCommonStockDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of Shares, Forfeited",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedTerseLabel": "Forfeiture",
        "terseLabel": "Forfeiture",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r370"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfPerformanceStockUnitsActivityDetails",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfRestrictedStockUnitsActivityDetail",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfTheIncentiveSharesActivityDetail",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfTheUnvestedCommonStockDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Grant Date Fair Value, Forfeited",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "verboseLabel": "Forfeiture",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r370"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfPerformanceStockUnitsActivityDetails",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfRestrictedStockUnitsActivityDetail",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfTheIncentiveSharesActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Shares, Granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "verboseLabel": "Granted",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r368"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfFairValueOfTheIncentiveSharesEstimatedUsingAnOptionPricingModelDetail",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfPerformanceStockUnitsActivityDetails",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfRestrictedStockUnitsActivityDetail",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfTheIncentiveSharesActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted Average Grant Date Fair Value, Granted",
        "terseLabel": "Grant date fair value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r368"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfPerformanceStockUnitsActivityDetails",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfRestrictedStockUnitsActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Unvested restricted stock, ending balance",
        "periodStartLabel": "Number of Shares, Beginning balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "terseLabel": "Unvested restricted stock at March 31, 2022",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r365",
      "r366"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfPerformanceStockUnitsActivityDetails",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfRestrictedStockUnitsActivityDetail",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfTheUnvestedCommonStockDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Weighted Average Grant Date Fair Value Per Share, Ending Balance",
        "periodStartLabel": "Weighted Average Grant Date Fair Value Per Share, Beginning Balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "terseLabel": "Unvested restricted stock as of December 31, 2021",
        "verboseLabel": "Unvested restricted stock Grant fair value at March 31, 2022",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r365",
      "r366"
     ]
    },
    "dawn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.dayonebio.com/20250331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfTheIncentiveSharesActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Grant Date Fair Value, Outstanding",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Grant Date Fair Value",
        "documentation": "Share based compensation arrangement by share based payment award equity instruments other than options outstanding weighted average grant date fair value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfPerformanceStockUnitsActivityDetails",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfRestrictedStockUnitsActivityDetail",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfTheUnvestedCommonStockDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Vested",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r369"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfPerformanceStockUnitsActivityDetails",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfRestrictedStockUnitsActivityDetail",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfTheUnvestedCommonStockDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "verboseLabel": "Vested",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r369"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfFairValueOfTheIncentiveSharesEstimatedUsingAnOptionPricingModelDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Participating threshold",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price",
        "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments",
     "crdr": "debit",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend payments",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Payments",
        "documentation": "The estimated amount of dividends to be paid to holders of the underlying shares (expected dividends) over the option's term. Dividends are taken into account because payment of dividends to shareholders reduces the fair value of the underlying shares, and option holders generally do not receive dividends."
       }
      }
     },
     "auth_ref": [
      "r377"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationFairValueOfOurCommonStockToBeIssuedUnderTheEsppDetails",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfTheBlackscholesOptionPricingModelToEstimateTheFairValueOfPerformanceStockOpDetails",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfTheBlackscholesOptionPricingModelToEstimateTheFairValueOfStockOptionGrantedDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected dividend yield",
        "verboseLabel": "Share based compensation by share based payment award fair value assumptions dividend yield",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r377"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationFairValueOfOurCommonStockToBeIssuedUnderTheEsppDetails",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfFairValueOfTheIncentiveSharesEstimatedUsingAnOptionPricingModelDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Expected volatility",
        "terseLabel": "Volatility",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r376"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfTheBlackscholesOptionPricingModelToEstimateTheFairValueOfPerformanceStockOpDetails",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfTheBlackscholesOptionPricingModelToEstimateTheFairValueOfStockOptionGrantedDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum",
        "terseLabel": "Expected volatility",
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfTheBlackscholesOptionPricingModelToEstimateTheFairValueOfPerformanceStockOpDetails",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfTheBlackscholesOptionPricingModelToEstimateTheFairValueOfStockOptionGrantedDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
        "terseLabel": "Expected volatility",
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationFairValueOfOurCommonStockToBeIssuedUnderTheEsppDetails",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfFairValueOfTheIncentiveSharesEstimatedUsingAnOptionPricingModelDetail",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfTheBlackscholesOptionPricingModelToEstimateTheFairValueOfPerformanceStockOpDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r378"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfTheBlackscholesOptionPricingModelToEstimateTheFairValueOfStockOptionGrantedDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "terseLabel": "Risk-free interest rate",
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfTheBlackscholesOptionPricingModelToEstimateTheFairValueOfStockOptionGrantedDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "terseLabel": "Risk-free interest rate",
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetail",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationFairValueOfOurCommonStockToBeIssuedUnderTheEsppDetails",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfFairValueOfTheIncentiveSharesEstimatedUsingAnOptionPricingModelDetail",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfPerformanceStockOptionsActivityDetails",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfPerformanceStockUnitsActivityDetails",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfRestrictedStockUnitsActivityDetail",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfStockOptionActivityDetail",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfTheBlackscholesOptionPricingModelToEstimateTheFairValueOfPerformanceStockOpDetails",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfTheBlackscholesOptionPricingModelToEstimateTheFairValueOfStockOptionGrantedDetail",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfTheIncentiveSharesActivityDetail",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfTheUnvestedCommonStockDetail",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r349",
      "r351",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Exercisable at March 31, 2025",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r359"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfPerformanceStockOptionsActivityDetails",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "terseLabel": "Forfeiture",
        "negatedLabel": "Forfeiture",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r363"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfPerformanceStockOptionsActivityDetails",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Share based compensation by share based payment arrangement non vested options granted during the period",
        "terseLabel": "Granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r361"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Share based compensation by share based payment arrangement non vested options granted during the period weighted average grant date fair value",
        "terseLabel": "Granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r371"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfPerformanceStockOptionsActivityDetails",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Outstanding at March 31, 2022, Aggregate Intrinsic Value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Outstanding at March 31, 2025 Aggregate Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfPerformanceStockOptionsActivityDetails",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodStartLabel": "Number of Shares, Beginning Balance",
        "periodEndLabel": "Outstanding at March 31, 2025",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r357",
      "r358"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfPerformanceStockOptionsActivityDetails",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Weighted Average Exercise Price Per Share, Ending Balance",
        "periodStartLabel": "Weighted Average Exercise Price Per Share, Beginning Balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r357",
      "r358"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfPerformanceStockOptionsActivityDetails",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value",
        "terseLabel": "Vested and expected to vest at March 31, 2025, Aggregate Intrinsic Value",
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r374"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfPerformanceStockOptionsActivityDetails",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number",
        "terseLabel": "Exercisable at March 31, 2025",
        "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r374"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price Per Share, Vested and expected to vest at March 31, 2025",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r374"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Total fair value of options",
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r373"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum",
        "documentation": "Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureCommonStockScheduleOfCommonStockSharesReservedForFutureIssuanceDetailsDetails",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetail",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfPerformanceStockOptionsActivityDetails",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfPerformanceStockUnitsActivityDetails",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfRestrictedStockUnitsActivityDetail",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfTheBlackscholesOptionPricingModelToEstimateTheFairValueOfPerformanceStockOpDetails",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfTheBlackscholesOptionPricingModelToEstimateTheFairValueOfStockOptionGrantedDetail",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfTheIncentiveSharesActivityDetail",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Award Types",
        "terseLabel": "All Award Types",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfPerformanceStockOptionsActivityDetails",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r362"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfPerformanceStockOptionsActivityDetails",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Forfeiture",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r363"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r361"
     ]
    },
    "dawn_ShareBasedCompensationByShareBasedPaymentArrangementEquityInstrumentsOtherThanOptionsConvertedToUnvestedCommonStock": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.dayonebio.com/20250331",
     "localname": "ShareBasedCompensationByShareBasedPaymentArrangementEquityInstrumentsOtherThanOptionsConvertedToUnvestedCommonStock",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfTheIncentiveSharesActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Shares, Converted to unvested common stock",
        "label": "Share Based Compensation By Share Based Payment Arrangement Equity Instruments Other Than Options Converted To Unvested Common Stock",
        "documentation": "Share based compensation by share based payment arrangement equity instruments other than options converted to unvested common stock."
       }
      }
     },
     "auth_ref": []
    },
    "dawn_ShareBasedCompensationByShareBasedPaymentArrangementEquityInstrumentsOtherThanOptionsOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.dayonebio.com/20250331",
     "localname": "ShareBasedCompensationByShareBasedPaymentArrangementEquityInstrumentsOtherThanOptionsOutstanding",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfTheIncentiveSharesActivityDetail",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfTheUnvestedCommonStockDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Number of Shares, Unvested Common Stock, Ending balance",
        "periodStartLabel": "Number of Shares, Unvested Common Stock, Beginning balance",
        "label": "Share Based Compensation By Share Based Payment Arrangement Equity Instruments Other Than Options Outstanding",
        "documentation": "Share based compensation by share based payment arrangement equity instruments other than options outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "dawn_ShareBasedCompensationByShareBasedPaymentAwardConversionOfIncentiveShareIntoRestrictedStockWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.dayonebio.com/20250331",
     "localname": "ShareBasedCompensationByShareBasedPaymentAwardConversionOfIncentiveShareIntoRestrictedStockWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfTheUnvestedCommonStockDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion of incentive shares",
        "label": "Share Based Compensation By Share Based Payment Award Conversion Of Incentive Share Into Restricted Stock Weighted Average Grant Date Fair Value",
        "documentation": "Share based compensation by share based payment award conversion of incentive share into restricted stock weighted average grant date fair value."
       }
      }
     },
     "auth_ref": []
    },
    "dawn_ShareBasedCompensationByShareBasedPaymentAwardConversionOfIncentiveSharesIntoRestrictedStock": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.dayonebio.com/20250331",
     "localname": "ShareBasedCompensationByShareBasedPaymentAwardConversionOfIncentiveSharesIntoRestrictedStock",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfTheUnvestedCommonStockDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion of incentive shares",
        "label": "Share Based Compensation By Share Based Payment Award Conversion Of Incentive Shares Into Restricted Stock",
        "documentation": "Share based compensation by share based payment award conversion of incentive shares into restricted stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharePrice",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureCommonStockAdditionalInformationDetail",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfFairValueOfTheIncentiveSharesEstimatedUsingAnOptionPricingModelDetail",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfTheBlackscholesOptionPricingModelToEstimateTheFairValueOfStockOptionGrantedDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Price",
        "terseLabel": "Purchase Price of Common Stock Per Share",
        "documentation": "Price of a single share of a number of saleable stocks of a company."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested",
     "crdr": "debit",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfPerformanceStockOptionsActivityDetails",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercised",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested",
        "documentation": "Intrinsic value of vested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationFairValueOfOurCommonStockToBeIssuedUnderTheEsppDetails",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfFairValueOfTheIncentiveSharesEstimatedUsingAnOptionPricingModelDetail",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfTheBlackscholesOptionPricingModelToEstimateTheFairValueOfPerformanceStockOpDetails",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfTheBlackscholesOptionPricingModelToEstimateTheFairValueOfStockOptionGrantedDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Expected term (in years)",
        "terseLabel": "Time to liquidity (in years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r375"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfPerformanceStockOptionsActivityDetails",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Exercisable at September 30, 2023, Aggregate Intrinsic Value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Exercisable at March 31, 2024, Aggregate Intrinsic Value",
        "verboseLabel": "Exercisable at March 31, 2025",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfPerformanceStockOptionsActivityDetails",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-Average Remaining Contractual Term, Exercisable at March 31, 2025",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfPerformanceStockUnitsActivityDetails",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfRestrictedStockUnitsActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Unvested restricted stock, beginning balance",
        "terseLabel": "Unvested restricted stock, beginning balance",
        "periodEndLabel": "Number of Shares, Ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares",
        "documentation": "Number of non-vested options outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfPerformanceStockOptionsActivityDetails",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-Average Remaining Contractual Term, Outstanding at March 31, 2025",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r106"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetail",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfPerformanceStockOptionsActivityDetails",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-average period expected to be recognized",
        "verboseLabel": "Weighted-Average Remaining Contractual Term, Vested and expected to vest at March 31, 2025",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r373"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfPerformanceStockOptionsActivityDetails",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Share-based compensation arrangement by share-based payment award, options, vested, number of shares",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares",
        "terseLabel": "Vested and expected to vest at March 31, 2025",
        "documentation": "Number of options vested."
       }
      }
     },
     "auth_ref": []
    },
    "dawn_SharesCommittedUnderESPPMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dayonebio.com/20250331",
     "localname": "SharesCommittedUnderESPPMember",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureNetIncomeLossPerShareSummaryOfOutstandingPotentiallyDilutiveSecuritiesHaveBeenExcludedFromCalculationOfDilutedNetLossPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares Committed Under E S P P.",
        "label": "Shares Committed Under E S P P [Member]",
        "terseLabel": "Shares committed under ESPP"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning Balance (In shares)",
        "periodEndLabel": "Ending Balance (In shares)",
        "label": "Shares, Outstanding",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermInvestments",
     "crdr": "debit",
     "calculation": {
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Short-Term Investments, Total",
        "label": "Short-Term Investments",
        "terseLabel": "Short-term investments",
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current."
       }
      }
     },
     "auth_ref": [
      "r117",
      "r118",
      "r889"
     ]
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/SummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies [Text Block]",
        "verboseLabel": "Summary of Significant Accounting Policies",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r167"
     ]
    },
    "dawn_SprintBioscienceAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dayonebio.com/20250331",
     "localname": "SprintBioscienceAgreementMember",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/SignificantAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sprint Bioscience Agreement [Member]",
        "documentation": "Sprint Bioscience Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/CoverPage",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureCommonStockAdditionalInformationDetail",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetail",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfTheUnvestedCommonStockDetail",
      "http://www.dayonebio.com/20250331/taxonomy/role/RedeemableConvertiblePreferredSharesSummaryOfSeriesARedeemableConvertiblePreferredSharesDetail",
      "http://www.dayonebio.com/20250331/taxonomy/role/SignificantAgreementsAdditionalInformationDetail",
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedBalanceSheetsUnauditedParenthetical",
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfStockholdersEquityUnaudited",
      "http://www.dayonebio.com/20250331/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Class of Stock [Axis]",
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r138",
      "r146",
      "r147",
      "r148",
      "r169",
      "r188",
      "r192",
      "r194",
      "r196",
      "r203",
      "r204",
      "r269",
      "r307",
      "r309",
      "r310",
      "r311",
      "r314",
      "r315",
      "r320",
      "r321",
      "r324",
      "r327",
      "r334",
      "r449",
      "r590",
      "r591",
      "r592",
      "r593",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r608",
      "r623",
      "r645",
      "r663",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r869",
      "r897",
      "r905"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureCommonStockAdditionalInformationDetail",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureCommonStockScheduleOfCommonStockSharesReservedForFutureIssuanceDetailsDetails",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails",
      "http://www.dayonebio.com/20250331/taxonomy/role/SignificantAgreementsAdditionalInformationDetail",
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfStockholdersEquityUnaudited",
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfStockholdersEquityUnauditedParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r71",
      "r74",
      "r75",
      "r139",
      "r159",
      "r160",
      "r161",
      "r171",
      "r172",
      "r173",
      "r175",
      "r180",
      "r182",
      "r184",
      "r202",
      "r270",
      "r271",
      "r296",
      "r336",
      "r395",
      "r396",
      "r403",
      "r404",
      "r405",
      "r407",
      "r408",
      "r409",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r423",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r457",
      "r458",
      "r471",
      "r561",
      "r579",
      "r580",
      "r581",
      "r596",
      "r663"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]"
       }
      }
     },
     "auth_ref": [
      "r234",
      "r235",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r609",
      "r610",
      "r611",
      "r670",
      "r672",
      "r675",
      "r681",
      "r688",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r706",
      "r734",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761",
      "r762",
      "r767",
      "r773",
      "r948",
      "r1017",
      "r1019",
      "r1020",
      "r1022",
      "r1023",
      "r1024",
      "r1025",
      "r1026",
      "r1027",
      "r1028",
      "r1029",
      "r1030",
      "r1031",
      "r1032",
      "r1033",
      "r1034",
      "r1035",
      "r1036",
      "r1037",
      "r1038",
      "r1039",
      "r1040",
      "r1041",
      "r1042",
      "r1043",
      "r1044",
      "r1045",
      "r1046"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedBalanceSheetsUnauditedParenthetical",
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfComprehensiveLossUnaudited",
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfOperationsUnaudited",
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfStockholdersEquityUnaudited",
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfStockholdersEquityUnauditedParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Statement [Line Items]",
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r171",
      "r172",
      "r173",
      "r202",
      "r458",
      "r509",
      "r589",
      "r608",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r623",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r632",
      "r633",
      "r634",
      "r635",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r643",
      "r646",
      "r647",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r663",
      "r774"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Statement of Stockholders' Equity [Abstract]",
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedBalanceSheetsUnauditedParenthetical",
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfComprehensiveLossUnaudited",
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfOperationsUnaudited",
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfStockholdersEquityUnaudited",
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfStockholdersEquityUnauditedParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Statement [Table]",
        "label": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r171",
      "r172",
      "r173",
      "r202",
      "r237",
      "r458",
      "r509",
      "r589",
      "r608",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r623",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r632",
      "r633",
      "r634",
      "r635",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r643",
      "r646",
      "r647",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r663",
      "r774"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method [Text Block]",
        "terseLabel": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r791",
      "r801",
      "r811",
      "r843"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "dawn_StockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dayonebio.com/20250331",
     "localname": "StockIssuanceCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfStockholdersEquityUnauditedParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock issuance costs",
        "label": "Stock Issuance Costs",
        "documentation": "Stock issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/SignificantAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Issuance of Series B redeemable convertible preferred shares for cash, net of issuance costs, shares",
        "terseLabel": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r39",
      "r71",
      "r74",
      "r104",
      "r317"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Issued During Period, Shares, Employee Stock Ownership Plan",
        "label": "Stock Issued During Period, Shares, Employee Stock Ownership Plan",
        "documentation": "Number of shares of capital stock issued (purchased by employees) in connection with an employee stock ownership plan."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r50",
      "r70",
      "r71",
      "r104"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Issuance of common stock pursuant to Employee Stock Purchase Plan, Shares",
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r70",
      "r71",
      "r104"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails",
      "http://www.dayonebio.com/20250331/taxonomy/role/RedeemableConvertiblePreferredSharesAdditionalInformationDetail",
      "http://www.dayonebio.com/20250331/taxonomy/role/SignificantAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Issuance",
        "label": "Stock Issued During Period, Shares, New Issues",
        "verboseLabel": "Common stock issued in IPO, net of issuance costs of $16,995 (In shares)",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r70",
      "r71",
      "r104",
      "r590",
      "r663",
      "r683"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensationForfeited",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unvested common stock forfeiture",
        "label": "Shares Issued, Shares, Share-Based Payment Arrangement, Forfeited",
        "documentation": "Number of shares (or other type of equity) forfeited during the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfStockOptionActivityDetail",
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Exercised",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "terseLabel": "Issuance of common stock upon exercise of stock options (share)",
        "negatedLabel": "Exercised",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r70",
      "r71",
      "r104",
      "r362"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "crdr": "credit",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "terseLabel": "Issuance of common stock pursuant to Employee Stock Purchase Plan, Amount",
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r70",
      "r71",
      "r104"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails",
      "http://www.dayonebio.com/20250331/taxonomy/role/SignificantAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock Issued During Period, Value, New Issues",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Common stock issued, share issuance costs",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r70",
      "r71",
      "r104",
      "r596",
      "r663",
      "r683",
      "r780"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetail",
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock upon exercise of stock options, Amount",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r71",
      "r74",
      "r75",
      "r104"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedBalanceSheetsUnaudited",
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Attributable to Parent",
        "periodStartLabel": "Beginning Balance",
        "periodEndLabel": "Ending Balance",
        "totalLabel": "Total stockholders' equity",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r74",
      "r75",
      "r96",
      "r625",
      "r642",
      "r664",
      "r665",
      "r753",
      "r781",
      "r898",
      "r924",
      "r999",
      "r1051"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' equity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureCommonStock"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Text Block]",
        "terseLabel": "Common Stock",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r168",
      "r319",
      "r321",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r333",
      "r336",
      "r422",
      "r666",
      "r667",
      "r687"
     ]
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r456",
      "r475"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event [Member]",
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r456",
      "r475"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Table]",
        "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued."
       }
      }
     },
     "auth_ref": [
      "r456",
      "r475"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r456",
      "r475"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r456",
      "r475"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Events",
        "label": "Subsequent Events [Text Block]",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r474",
      "r476"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/RedeemableConvertiblePreferredSharesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "dawn_SummaryOfPerformanceStockOptions": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.dayonebio.com/20250331",
     "localname": "SummaryOfPerformanceStockOptions",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of Performance Stock Options",
        "label": "Summary of Performance Stock Options",
        "terseLabel": "Summary of Performance Stock Options Activity"
       }
      }
     },
     "auth_ref": []
    },
    "dawn_SummaryOfPerformanceStockUnitsActivity": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.dayonebio.com/20250331",
     "localname": "SummaryOfPerformanceStockUnitsActivity",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of Performance Stock Units activity",
        "label": "Summary of Performance Stock Units activity",
        "terseLabel": "Summary of Performance Stock Units Activity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureBalanceSheetItems"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "terseLabel": "Balance Sheet Items",
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity."
       }
      }
     },
     "auth_ref": [
      "r883"
     ]
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List [Table Text Block]",
        "terseLabel": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r837"
     ]
    },
    "dawn_TakedaAssetAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dayonebio.com/20250331",
     "localname": "TakedaAssetAgreementMember",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/SignificantAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Takeda Asset Agreement [Member]",
        "documentation": "Takeda Asset Agreement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquityByClassOfStockTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TemporaryEquityByClassOfStockTable",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/RedeemableConvertiblePreferredSharesAdditionalInformationDetail",
      "http://www.dayonebio.com/20250331/taxonomy/role/RedeemableConvertiblePreferredSharesSummaryOfSeriesARedeemableConvertiblePreferredSharesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity, by Class of Stock [Table]",
        "documentation": "Disclosure of information about equity instrument classified as temporary equity. Includes, but not is limited to, description of share, value, share authorized, issued, and outstanding, redemption price per share, and subscription receivable."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r34"
     ]
    },
    "us-gaap_TemporaryEquityDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TemporaryEquityDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dawn_TemporaryEquityIssuePricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.dayonebio.com/20250331",
     "localname": "TemporaryEquityIssuePricePerShare",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/RedeemableConvertiblePreferredSharesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Temporary equity issue price per share",
        "label": "Temporary Equity Issue Price Per Share",
        "documentation": "Temporary equity issue price per share."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquityLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TemporaryEquityLineItems",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/RedeemableConvertiblePreferredSharesAdditionalInformationDetail",
      "http://www.dayonebio.com/20250331/taxonomy/role/RedeemableConvertiblePreferredSharesSummaryOfSeriesARedeemableConvertiblePreferredSharesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquityLiquidationPreference": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TemporaryEquityLiquidationPreference",
     "crdr": "credit",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/RedeemableConvertiblePreferredSharesSummaryOfSeriesARedeemableConvertiblePreferredSharesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liquidation Value",
        "label": "Temporary Equity, Liquidation Preference",
        "documentation": "The aggregate liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquityParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TemporaryEquityParOrStatedValuePerShare",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedBalanceSheetsUnauditedParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Temporary Equity, Par or Stated Value Per Share",
        "label": "Temporary Equity, Par or Stated Value Per Share",
        "documentation": "Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r34"
     ]
    },
    "dawn_TemporaryEquityRelatedTrancheLiabilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dayonebio.com/20250331",
     "localname": "TemporaryEquityRelatedTrancheLiabilityMember",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/RedeemableConvertiblePreferredSharesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity Related Tranche Liability [Member]",
        "documentation": "Temporary Equity Related Tranche Liability."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquitySharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TemporaryEquitySharesAuthorized",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/RedeemableConvertiblePreferredSharesSummaryOfSeriesARedeemableConvertiblePreferredSharesDetail",
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedBalanceSheetsUnauditedParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Shares Authorized",
        "terseLabel": "Temporary Equity, Shares Authorized",
        "label": "Temporary Equity, Shares Authorized",
        "documentation": "The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r69"
     ]
    },
    "us-gaap_TemporaryEquitySharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TemporaryEquitySharesIssued",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/RedeemableConvertiblePreferredSharesSummaryOfSeriesARedeemableConvertiblePreferredSharesDetail",
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedBalanceSheetsUnauditedParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Shares Issued",
        "terseLabel": "Temporary Equity, Shares Issued",
        "label": "Temporary Equity, Shares Issued",
        "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r69"
     ]
    },
    "us-gaap_TemporaryEquitySharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TemporaryEquitySharesOutstanding",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/RedeemableConvertiblePreferredSharesAdditionalInformationDetail",
      "http://www.dayonebio.com/20250331/taxonomy/role/RedeemableConvertiblePreferredSharesSummaryOfSeriesARedeemableConvertiblePreferredSharesDetail",
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedBalanceSheetsUnauditedParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Shares Outstanding",
        "terseLabel": "Temporary Equity, Shares Outstanding",
        "label": "Temporary Equity, Shares Outstanding",
        "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r69"
     ]
    },
    "us-gaap_TemporaryEquitySharesSubscribedButUnissued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TemporaryEquitySharesSubscribedButUnissued",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/RedeemableConvertiblePreferredSharesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Temporary equity shares subscribed but not issued",
        "label": "Temporary Equity, Shares Subscribed but Unissued",
        "documentation": "Amount of a new issue of securities classified as temporary equity that are allocated to investors for them to buy. When securities are sold on a subscription basis, the issuer does not initially receive the total proceeds. In general, the issuer does not issue the securities to the investor until it receives the entire proceeds. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r69"
     ]
    },
    "dawn_TemporaryEquityStockIssuedDuringThePeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.dayonebio.com/20250331",
     "localname": "TemporaryEquityStockIssuedDuringThePeriodSharesNewIssues",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/RedeemableConvertiblePreferredSharesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Temporary equity stock issued during the period shares new issues",
        "label": "Temporary Equity Stock Issued During The Period Shares New Issues",
        "documentation": "Temporary equity stock issued during the period shares new issues."
       }
      }
     },
     "auth_ref": []
    },
    "dawn_TemporaryEquityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.dayonebio.com/20250331",
     "localname": "TemporaryEquityTextBlock",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/RedeemableConvertiblePreferredShares"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Redeemable Convertible Preferred Shares",
        "label": "Temporary Equity [Text Block]",
        "documentation": "Temporary Equity [Text Block]."
       }
      }
     },
     "auth_ref": []
    },
    "dawn_Third-PartyCROCMOAndOtherThird-PartyClinicalTrialCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dayonebio.com/20250331",
     "localname": "Third-PartyCROCMOAndOtherThird-PartyClinicalTrialCosts",
     "crdr": "debit",
     "calculation": {
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSegmentReportingScheduleOfSegmentInformationDetails": {
       "parentTag": "us-gaap_ResearchAndDevelopmentExpense",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSegmentReportingScheduleOfSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Third-Party CRO, CMO and Other Third-Party Clinical Trial Costs",
        "documentation": "Third-Party CRO, CMO and Other Third-Party Clinical Trial Costs",
        "terseLabel": "Third-party CRO, CMO and other third-party clinical trial costs"
       }
      }
     },
     "auth_ref": []
    },
    "dawn_ThreeCustomerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dayonebio.com/20250331",
     "localname": "ThreeCustomerMember",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Three Customer [Member]",
        "label": "Three Customer [Member]",
        "terseLabel": "Three Customer [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount",
        "terseLabel": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r829"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group [Text Block]",
        "terseLabel": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r836"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement [Axis]",
        "terseLabel": "Trading Arrangement:"
       }
      }
     },
     "auth_ref": [
      "r856"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]",
        "terseLabel": "Trading Arrangements, by Individual"
       }
      }
     },
     "auth_ref": [
      "r858"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dawn_TransactionPrice": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dayonebio.com/20250331",
     "localname": "TransactionPrice",
     "crdr": "debit",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/SignificantAgreementsAdditionalInformationDetail",
      "http://www.dayonebio.com/20250331/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Transaction Price",
        "documentation": "Transaction Price",
        "label": "Transaction Price"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureRecurringFairValueMeasurementScheduleOfAvailableforsaleMarketableSecuritiesWithGrossUnrealizedLossesDetails",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureRecurringFairValueMeasurementScheduleOfCashEquivalentsMarketableSecuritiesAndUnrealizedGainsAndLossesDetails",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureRecurringFairValueMeasurementScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r318",
      "r332",
      "r421",
      "r448",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r562",
      "r742",
      "r743",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r754",
      "r876",
      "r877",
      "r878",
      "r879",
      "r880",
      "r881",
      "r882",
      "r919",
      "r920",
      "r921",
      "r922",
      "r983",
      "r986",
      "r987",
      "r988",
      "r995",
      "r998"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Adoption Date",
        "terseLabel": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r859"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Duration",
        "terseLabel": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r860"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Expiration Date",
        "terseLabel": "Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r860"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r858"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Title",
        "terseLabel": "Title"
       }
      }
     },
     "auth_ref": [
      "r858"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Securities Aggregate Available Amount",
        "terseLabel": "Aggregate Available"
       }
      }
     },
     "auth_ref": [
      "r861"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Termination Date",
        "terseLabel": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r859"
     ]
    },
    "dawn_TwoCustomerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dayonebio.com/20250331",
     "localname": "TwoCustomerMember",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Two Customer [Member]",
        "label": "Two Customer [Member]",
        "documentation": "Two Customer [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dawn_TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dayonebio.com/20250331",
     "localname": "TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2021 employee stock purchase plan.",
        "terseLabel": "2021 Employee Stock Purchase Plan",
        "label": "Two Thousand And Twenty One Employee Stock Purchase Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dawn_TwoThousandAndTwentyOneEquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dayonebio.com/20250331",
     "localname": "TwoThousandAndTwentyOneEquityIncentivePlanMember",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetail",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfStockOptionActivityDetail",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfTheBlackscholesOptionPricingModelToEstimateTheFairValueOfStockOptionGrantedDetail",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand and twenty one equity incentive plan.",
        "label": "Two Thousand And Twenty One Equity Incentive Plan [Member]",
        "terseLabel": "2021 Equity Incentive Plan"
       }
      }
     },
     "auth_ref": []
    },
    "dawn_TwoThousandAndTwentyOneStockIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dayonebio.com/20250331",
     "localname": "TwoThousandAndTwentyOneStockIncentivePlanMember",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetail",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfPerformanceStockUnitsActivityDetails",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfRestrictedStockUnitsActivityDetail",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfTheUnvestedCommonStockDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2021 Equity Incentive Plan",
        "documentation": "Two thousand and twenty one stock incentive plan.",
        "label": "2021 Stock Incentive Plan"
       }
      }
     },
     "auth_ref": []
    },
    "dawn_TwoThousandAndTwentyTwoEquityInducementPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dayonebio.com/20250331",
     "localname": "TwoThousandAndTwentyTwoEquityInducementPlanMember",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetail",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfRestrictedStockUnitsActivityDetail",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfStockOptionActivityDetail",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Thousand And Twenty Two Equity Inducement Plan [Member]",
        "label": "Two Thousand And Twenty Two Equity Inducement Plan [Member]",
        "terseLabel": "2022 Equity Inducement Plan"
       }
      }
     },
     "auth_ref": []
    },
    "dawn_TwoThousandTwentyFourPrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dayonebio.com/20250331",
     "localname": "TwoThousandTwentyFourPrivatePlacementMember",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureCommonStockAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024 Private Placement [Member]",
        "documentation": "Two Thousand Twenty Four Private Placement [Member]",
        "label": "Two Thousand Twenty Four Private Placement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dawn_TwoThousandTwentyOneEmployeeStockPurchasePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dayonebio.com/20250331",
     "localname": "TwoThousandTwentyOneEmployeeStockPurchasePlanMember",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationFairValueOfOurCommonStockToBeIssuedUnderTheEsppDetails",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfTheBlackscholesOptionPricingModelToEstimateTheFairValueOfStockOptionGrantedDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Two Thousand Twenty One Employee Stock Purchase Plan",
        "terseLabel": "2021 Employee Stock Purchase Plan [Member]",
        "documentation": "Two Thousand Twenty One Employee Stock Purchase Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureIntangibleAssetsScheduleOfIntangibleAssetsDetails",
      "http://www.dayonebio.com/20250331/taxonomy/role/SignificantAgreementsAdditionalInformationDetail",
      "http://www.dayonebio.com/20250331/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r410"
     ]
    },
    "us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "USGovernmentCorporationsAndAgenciesSecuritiesMember",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureRecurringFairValueMeasurementScheduleOfAvailableforsaleMarketableSecuritiesWithGrossUnrealizedLossesDetails",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureRecurringFairValueMeasurementScheduleOfCashEquivalentsMarketableSecuritiesAndUnrealizedGainsAndLossesDetails",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureRecurringFairValueMeasurementScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. government agency securities",
        "label": "US Government Corporations and Agencies Securities [Member]",
        "documentation": "This category includes information about debt issued by US Government Corporations and Agencies. Investments in such US Government Corporations may include debt securities issued by the Government National Mortgage Association (Ginnie Mae) and by the Federal National Mortgage Association (Fannie Mae) and the Federal Home Loan Mortgage Corporation (Freddie Mac)."
       }
      }
     },
     "auth_ref": [
      "r1013"
     ]
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "USTreasurySecuritiesMember",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureRecurringFairValueMeasurementScheduleOfAvailableforsaleMarketableSecuritiesWithGrossUnrealizedLossesDetails",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureRecurringFairValueMeasurementScheduleOfCashEquivalentsMarketableSecuritiesAndUnrealizedGainsAndLossesDetails",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureRecurringFairValueMeasurementScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. treasury securities",
        "label": "US Treasury Securities [Member]",
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years)."
       }
      }
     },
     "auth_ref": [
      "r711",
      "r736",
      "r738",
      "r742",
      "r1013"
     ]
    },
    "dawn_UnamortizedStockBasedCompensationForStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dayonebio.com/20250331",
     "localname": "UnamortizedStockBasedCompensationForStockOptions",
     "crdr": "credit",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unamortized stock-based compensation for stock options",
        "label": "Unamortized stock-based compensation for stock options",
        "terseLabel": "Unamortized stock-based compensation for stock options"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change, Percent",
        "terseLabel": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r855"
     ]
    },
    "dawn_UnvestedCommonSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dayonebio.com/20250331",
     "localname": "UnvestedCommonSharesMember",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureNetIncomeLossPerShareSummaryOfOutstandingPotentiallyDilutiveSecuritiesHaveBeenExcludedFromCalculationOfDilutedNetLossPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unvested Common Shares [Member]",
        "documentation": "Unvested common shares.",
        "terseLabel": "Unvested common shares"
       }
      }
     },
     "auth_ref": []
    },
    "dawn_UnvestedCommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dayonebio.com/20250331",
     "localname": "UnvestedCommonStockMember",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetail",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationSummaryOfTheUnvestedCommonStockDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unvested Common Stock.",
        "label": "Unvested Common Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dawn_UnvestedPerformanceStockUnitsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dayonebio.com/20250331",
     "localname": "UnvestedPerformanceStockUnitsMember",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unvested Performance Stock Units",
        "label": "Unvested Performance Stock Units [Member]",
        "terseLabel": "Unvested PSUs"
       }
      }
     },
     "auth_ref": []
    },
    "dawn_UnvestedPsosAndPsusMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dayonebio.com/20250331",
     "localname": "UnvestedPsosAndPsusMember",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unvested PSOs and PSUs [Member]",
        "label": "Unvested PSOs and PSUs [Member]",
        "documentation": "Unvested PSOs and PSUs [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dawn_UnvestedRestrictedStockAndStockOptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dayonebio.com/20250331",
     "localname": "UnvestedRestrictedStockAndStockOptionsMember",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unvested Restricted Stock and Stock Options [Member]",
        "label": "Unvested Restricted Stock And Stock Options [Member]",
        "documentation": "Unvested Restricted Stock And Stock Options."
       }
      }
     },
     "auth_ref": []
    },
    "dawn_UpfrontLicenseFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dayonebio.com/20250331",
     "localname": "UpfrontLicenseFee",
     "crdr": "debit",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureCommonStockAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Upfront license fee",
        "documentation": "Upfront License Fee",
        "label": "Upfront License Fee"
       }
      }
     },
     "auth_ref": []
    },
    "dawn_UpfrontOfCashPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dayonebio.com/20250331",
     "localname": "UpfrontOfCashPayment",
     "crdr": "credit",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails",
      "http://www.dayonebio.com/20250331/taxonomy/role/SignificantAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Upfront License Fee",
        "verboseLabel": "Upfront of cash payment",
        "label": "upfront of cash payment",
        "documentation": "Upfront of Cash Payment."
       }
      }
     },
     "auth_ref": []
    },
    "dawn_UpfrontPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dayonebio.com/20250331",
     "localname": "UpfrontPayment",
     "crdr": "debit",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/SignificantAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Upfront payment",
        "label": "Upfront Payment",
        "documentation": "Upfront payment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Use of Estimates",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r26",
      "r27",
      "r129",
      "r131",
      "r133",
      "r134"
     ]
    },
    "us-gaap_VestingAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VestingAxis",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting [Axis]",
        "documentation": "Information by vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r951",
      "r952",
      "r953",
      "r954",
      "r955",
      "r956",
      "r957",
      "r958",
      "r959",
      "r960",
      "r961",
      "r962",
      "r963",
      "r964",
      "r965",
      "r966",
      "r967",
      "r968",
      "r969",
      "r970",
      "r971",
      "r972",
      "r973",
      "r974",
      "r975",
      "r976"
     ]
    },
    "us-gaap_VestingDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VestingDomain",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting [Domain]",
        "documentation": "Vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r951",
      "r952",
      "r953",
      "r954",
      "r955",
      "r956",
      "r957",
      "r958",
      "r959",
      "r960",
      "r961",
      "r962",
      "r963",
      "r964",
      "r965",
      "r966",
      "r967",
      "r968",
      "r969",
      "r970",
      "r971",
      "r972",
      "r973",
      "r974",
      "r975",
      "r976"
     ]
    },
    "dawn_ViractaLicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dayonebio.com/20250331",
     "localname": "ViractaLicenseAgreementMember",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.dayonebio.com/20250331/taxonomy/role/SignificantAgreementsAdditionalInformationDetail",
      "http://www.dayonebio.com/20250331/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Viracta License Agreement [Member]",
        "terseLabel": "Viracta License Agreement",
        "documentation": "Viracta License Agreement Member"
       }
      }
     },
     "auth_ref": []
    },
    "dawn_VolumeWeightedAveragePrice": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.dayonebio.com/20250331",
     "localname": "VolumeWeightedAveragePrice",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails",
      "http://www.dayonebio.com/20250331/taxonomy/role/SignificantAgreementsAdditionalInformationDetail",
      "http://www.dayonebio.com/20250331/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Volume Weighted Average Price",
        "documentation": "Volume Weighted Average Price",
        "terseLabel": "Volume weighted average price"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]",
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r825"
     ]
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantMember",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureNetIncomeLossPerShareSummaryOfOutstandingPotentiallyDilutiveSecuritiesHaveBeenExcludedFromCalculationOfDilutedNetLossPerShare",
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant [Member]",
        "terseLabel": "Warrants",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r771",
      "r772",
      "r775",
      "r776",
      "r777",
      "r778"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureNetIncomeLossPerShareSummaryOfBasicAndDilutedNetLossPerShareAttributableToCommonShareholdersstockholdersDetail",
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "totalLabel": "Weighted Average Number of Shares Outstanding, Diluted, Total",
        "verboseLabel": "Weighted average shares outstanding - diluted",
        "terseLabel": "Weighted-average number of common shares used in net income (loss) per share - diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r187",
      "r196"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureNetIncomeLossPerShareSummaryOfBasicAndDilutedNetLossPerShareAttributableToCommonShareholdersstockholdersDetail",
      "http://www.dayonebio.com/20250331/taxonomy/role/StatementCondensedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "totalLabel": "Weighted Average Number of Shares Outstanding, Basic, Total",
        "verboseLabel": "Weighted average shares outstanding - basic",
        "terseLabel": "Weighted-average number of common shares used in net income (loss) per share - basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r186",
      "r196"
     ]
    },
    "dawn_WeightedAveragePriceOfCompanysCommonStock": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.dayonebio.com/20250331",
     "localname": "WeightedAveragePriceOfCompanysCommonStock",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureCommonStockAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted Average Price of Company's common Stock",
        "label": "Weighted Average Price of Company's common Stock",
        "terseLabel": "Weighted Average Price of Company's common Stock"
       }
      }
     },
     "auth_ref": []
    },
    "dawn_WithinOneYearMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dayonebio.com/20250331",
     "localname": "WithinOneYearMember",
     "presentation": [
      "http://www.dayonebio.com/20250331/taxonomy/role/DisclosureRecurringFairValueMeasurementScheduleOfMaturitiesForAvailableForSaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Within 1 year",
        "label": "Within One Year [Member]",
        "documentation": "Within One Year [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]",
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r823"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(c)(2)",
   "SubTopic": "20",
   "Topic": "860",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4D"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "20",
   "Section": "25",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481284/470-20-25-2"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-2A"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "63",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481620/480-10-55-63"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Subparagraph": "(12)(c)",
   "Section": "S99",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Subparagraph": "(16)(c)",
   "Paragraph": "3A",
   "Section": "S99",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "40",
   "Section": "25",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480637/718-40-25-10"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "40",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-4"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "40",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-20"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-7"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3A",
   "Subparagraph": "(14)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3A",
   "Subparagraph": "(15)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/810/tableOfContent"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-3"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r120": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r121": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r122": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r123": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r124": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-7"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "210",
   "Topic": "946",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-20"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/808/tableOfContent"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/260/tableOfContent"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-22"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-23"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-28A"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "36",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479130/326-30-45-1"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-5"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480265/350-10-S45-1"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-30/tableOfContent"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-2"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-4"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "70",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/715-70/tableOfContent"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "70",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480794/715-70-50-1"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480454/718-10-45-1"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.1.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "928",
   "SubTopic": "340",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "280",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "940",
   "SubTopic": "820",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3A"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-1"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-2"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-21"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478785/954-310-50-2"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/985-20/tableOfContent"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "101",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r857": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r858": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r859": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r860": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r861": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r862": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r863": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r864": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r865": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r866": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r867": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r868": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r869": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r870": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10"
  },
  "r871": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r872": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r873": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "SubTopic": "825",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B"
  },
  "r874": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r875": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r876": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r877": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r878": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r879": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r880": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r881": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r882": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r883": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/210/tableOfContent"
  },
  "r884": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r885": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r886": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r887": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r888": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r889": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r890": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r891": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r892": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r893": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r894": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r895": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r896": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r897": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r898": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r899": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r900": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r901": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r902": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r903": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r904": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r905": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55"
  },
  "r906": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r907": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r908": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r909": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r910": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r911": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r912": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r913": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-1"
  },
  "r914": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r915": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r916": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r917": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r918": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r919": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r920": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r921": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r922": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r923": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r924": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r925": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1"
  },
  "r926": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r927": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r928": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r929": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r930": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r931": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r932": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r933": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r934": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r935": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r936": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r937": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r938": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r939": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r940": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r941": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r942": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r943": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r944": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-3"
  },
  "r945": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r946": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r947": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r948": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r949": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r950": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r951": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r952": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r953": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r954": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r955": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r956": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r957": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r958": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r959": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r960": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r961": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r962": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r963": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r964": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r965": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r966": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r967": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r968": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r969": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r970": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r971": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r972": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r973": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r974": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r975": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r976": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r977": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r978": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480060/805-50-25-1"
  },
  "r979": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480027/805-50-30-1"
  },
  "r980": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480027/805-50-30-2"
  },
  "r981": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r982": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r983": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r984": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r985": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r986": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r987": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r988": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r989": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r990": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r991": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r992": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r993": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r994": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r995": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r996": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r997": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r998": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r999": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3A"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r1023": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r1024": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1025": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1026": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1027": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1028": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1029": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1030": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1031": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1032": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1033": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1034": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1035": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1036": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1037": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1038": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1039": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1040": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1041": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1042": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1043": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1044": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1045": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1046": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1047": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r1048": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1049": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1050": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1051": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1052": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1053": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>75
<FILENAME>0000950170-25-064436-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-25-064436-xbrl.zip
M4$L#!!0    ( *R IEK(JTK>7G,# ,#])@ 1    9&%W;BTR,#(U,#,S,2YH
M=&WLO6EW&TER-OK=OZ)>C>WI/I=)Y;Y0W?T>MI8>77>+&E*R/?>+3JYBN4&
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MTL.4)J,TIH8A#P #T,(T<LHY9%P*(EIM&7G<T/(28MS)48P=L.P<YD<]S&C
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M<S4]BP@\&H-D2A#W&4^"*=;;[R,/QX:,U\UMC4C2YTB1BB!R5 *1HJ$>)3#
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M.N0!=2$(BB@8Q1,5E#-97-YM:.QRRU7%G7&\YJKB>B:3J=+&.$MR7T'PYQ.
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MFRN8F*7D5"\ONSBR*8M64[=_9D-\+'!+"P;QW^S@\ +8@^2TN7%&ZYO:S5W
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MC]1FJ,A4]& SM',"<0XQI"$\GQAL);-,4^K4"NM85V SA"EPC\5#4M9AH;'
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M/_SU[^LC[1[7V>^=$S>&CAK32?# "2/H-N"$83B! B<\*B>44TP!]P%  $
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M&"1K\Q:QM"N-P^2$L!'FQ>Q5+4N83 ">!)X$G@2>7!U4($*TG@<DN"$HDYQ
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M\ U]5T9BE:;-Q[9*\^8T1]SGL;T6;A_?9X#LM]%WK$-RGY:W_OL%??$ $X+
M&] ?P9A@3!CR>VA8,.8PQGSR]1/RI.LGY$@+=@ +*)V@ZTX(S:%0=;:<^Y.2
M$-FDJCUIYHO^")1>Y9WF*V M!2:>8.())IZ><N()!Q&5$@0Q' CBSEIDHK!(
MND0IU5)9_*#Z..N)I]_L10=YOS>O_+^7]3R^+XCX>P;$-Y=X.-3F/VTFRL#)
MH+!\<ACJ\!FZ*+ 8L-BW9 0X18+6.13"2606"QZ91##2F1,"D9P$<Z/.^7V6
M3QZ3Q;B:$ E5SO=RP00"\*<)P'^;-S[&L%I/R6-K.:\7%Q" 0P .TF4_I<OC
M9V(D*:/B$@62:"\++)$>I4"LT5JD9 ?97;B&JE\R4KW/\N!MVF5$+,DD6PS$
M!(Q9"(3!,T?LF0?&)A%S$A-A2"7C$.?<(1.I0L%C$:V50=$X2&#ZJ&S"Y(0+
M8).1%<>!)>$11J17EX1M/VM4-M<M[.Q#[::QLMV9O1")@G88)0Z!=G@ND^@T
M2H>U(4@XXHKNL,A0Q4HAOVA<=,K@&WL0!ED*?K,!PV\]O_R+,H5-!(2\L @,
ML>^^NBCPUU['OB8YGH+Q2$0F$4\.(V<QS5%P(,1)Z>G-U*)!%F6'X1,H!SOZ
MB!?68$<?\6XG09_-2T&9Q45W:&C,0_6LC%N(? ](.4#%/:BX]SRCYUB.$BW'
MBZH@LW+14B/')$<JYG^4DP)KO9/H^;<5JOXVM;/%JUGX>0VL0X719(2%:)YM
MI;T]"F<@T :Z!+K<DV#=.J*E=!(1:R/B++A"7PHQ*R/SE-DH;]#7(,'ZP/2U
M%U'['K'78:QE0WG8 8!C4Q[VSZOZL-^7B+ZK(U6YBUNKUT!L?T!B923&W$,I
M,F*A<?!Q>5(F<,L\HE1HQ*.0R'%.D,7<6.N\#$SML%CLFS4J[JZR'J,32=CX
M5,Y(\ +B;XB_1^ZB0&E['3NG@ 77RJ$8D\IT$3VR"EL4.58ZL,P:>)#=Q[N@
MF"\RBS83JD=XSLHA#5LHU;J/I5I3/;,S7T.I5JC;>%CR"HP)QH12K0=H6# F
ME&J%+,5-#U^M%%.W[3+KN2Y+T3>GITWYTL;_JUJ>;7YMSKJ0+WZ*<U^WL+;Q
MU+ %B1A[,E4$B1C?5'_&F"2\3<AXK!'W/B)K8D32!,LTT0$G.7C]F0)P;SM\
M:W]>X5N _ L8[Z *@:N>E>\"5WW3PD=T,G*=V<9RCGAT'CD1*+):8L(-#3(.
MDS2X&ZZZ67)UA&L=SXVKGGP7(.0*#K8)<"L[\+8%$XB@097L*4J!*AFO*@E)
M$ANX1%J7(TULQ,CYE!6&-@0[24(29H<9?[^LD>ZAZ1@02C_[@0^A-)#6OOHN
MD-8WD9;7!G/#D& AA]+6.&1)2B@E&XF+S%I*=IA#.!AI04P]PH'_)&O6!QBI
M#;Z=[L]YF&2[MO'[JI[UO^5?^EUVI4A.]TNIE'.>1QZ<5W)8XF,DQMQ#:3%B
MX7#P^^EL$LKHQ)"7FB%NA$9&FAQB"RRH\T0).\A^NJ)2RO\_7Z+?N]@NYK5?
MQ%#>>#4+5U_8^N1O<5XW6=;TD/K3"F1__N2GR^(X^9<3._L0W]E%_#FEZ+^A
MV,#=]N09,I$$BL_"GCR(R??418$6]SJ>YD)S9RA!CC*::8I2Y+ PB&'F* DB
MNCA(/#U6FOKRCG$SD7B$5=T.:>A_+>:^<VC]V07OYQ'K#;\L?5M@/:E<S*TJ
M=^@JU78#\ZOCX9EWS>/HC?L:&18''MWDL&KPR"K'N*BC9@0IPQ/BG!BD(Q<H
M<$&X"5Y)<>-X.>*48BQ%1&G^P8ETR#(64=2.:2V%($(.JG*&.G6.\HF1]UA-
M&". '.0RPY>-OEI2>*(P"-@1V!'8\7FQ(_5>*\<I8I3R',]3AYP,&@5FL-:$
MB?S'=79TELE$$D?*1X$XXQXYC1.BSCMAE50>JS&R(V5XHC0'=APMA, B_'Y-
M",3\ZMVG IZ'[0]CA>$J\M C6J G-,MR&N_(Q,M]%\K^:P3+$?<V\S.5*SGN
M3LP&A;( <8A[E0-SIR(RRD:?!)9&WMCY[0AFB0F"<'1EF4,XI(4G2$B&H\CW
M$,2/4:XP-F%B])F!UWSV(&7)")8H@<> QX#'#H?'F"L'H;$R%6T1C]0BK4)$
M4A'%=2F(Z_AU'N/.9IKS*C->E(@3FY!.U"#'> B44T8\&R./484GS! @LJ<G
M,BBDNP^%=-\OS\ZFL9SO9*=5J%L_;=KE/+<WA]KYPC[S'4KJ[DR:0'U-J*\)
MQGQ6QH0A#UXZ:F-"2=V#**G;K:7,FD5U$1?5F:U#"9VRF.N.^2SG!2[L[$-=
M A#;MG$!2RH'-!4U$F,>RHSH,YTY,H([86) 2<B$./$1:1LD$L1YFZ1S'N-A
M]A:>U3G^_/G369R%>E'BSS<SOYQGF/IQN?BU6?Q_<?%;!K"A)HDFV6+CFR*"
M,0LB#=@$//-0V43PR*F*$6'G,IM(H9!SAJ*84HP\,D;4C9WJ]]L"N$LVV8LJ
M<(<T8)^\ "U$HT-@PKORL*A):-FN LZJ<0M;S[I0M(JKO;5=C#K++6[.XMQV
MQ]=/NS(\T]JZ>@IU:D%;C!>J0%L\E;;03#,3!$<JAZJ(4VN1E=8@&SDF(7CJ
MJ1TB4NU0[&WZHXVO"H2]72'8F]FZ-L OS?SM&KG^5H#K;RO<NAAN8P'H#1C$
M$+J"9X[8,P^,7I*1-)DHD&:6(XXY1TX8C)+$C@A,F5:#G"C_Z/0"T>Q31;/Y
M%^NF<;>CYW*,W@W9+[_]2U_X$$,\_M-^4P7(NSU[=^?C,LE4^V_)M8LY\O6^
M.<VMNRB1[:Q9Y)LOFFIQ$@MZY.B^S>'PZFP6.\V/8!==<EY[=%NQR?$\6O6-
M?4ST5QJSHZF*OC&#^?>5Q_XAU.=E:/\E_[MNUW^Z.9M/Q_1EFL9/*-3SV('J
M<6[P\G3V,M3MV=1>')=W;T#?D<@X5[YZ-=O5O_#/9;NHT\6Z%=VE*,["R[.F
MK;M[S^,T$\1Y?.F:3^6)RV-L\H\_[9JQ'VT4WJF'S*T]=+*92%P]2#V;9J+-
MWF_GBV.[7#0OK[Z1[=N_?&8_Q'Y2$=F4G_/83C_:B_;EBQ^N=_U55BP]=^D,
M-SIU)'WW;=-,NV>+*T/*3VW;EA[+EZ\NZOXM$FG^XOJ($[?8])$\OQ.-BT]$
M8R;$/_10^=Q#F_LG>U&]G<7JQ[HY.[%9$_JX[ 19.ZG>S/S1?M#VSLWTZS9)
MO]Z0]"\;DGZ_(>F'</3.G^,*5VWAU#=\V28\^G5Y&N>U7]?UP-'2Z'),I%TI
M0>TH<MQ*1")QG ;&%+M1V_,^DV]OYQ_LK/Z/+8,Z=T17G*+[X]4L_#:/;=G$
M4/Y\FS:=<]DW/VWV-OR>6_'CM/'_>E'%'".=Y6]8S)?QQ5^W429WTRF:UNT"
MQ7Y[1-=59UM <X6ZMZ4-S5:\E:0[=GG9.3TJ]V^/78[@"K_<&!Z7G<B/!%/?
M[6R3R,.];-7 K=6V?\5XEMLZW:B;%8EVEOJ"95[\E6Q 9\M!^Z\A&']W[88C
M,L(U9,U^-:^[,U'+/IH?EVUN;=MVA2VVG?AR2!:>6_V\=16P&)E]=[VU6UXG
MGT9//\24]PPUKABP6'1MWJ="WT%#IELZ?7OIEQ\I;D;H!X^M3:HZCZ9,*:>G
MY<1A.RT(\J'$T%UL7:7&+PM)%P\)YZN#3D]CJ'WQE&Z-V9_4TW#2-*'S(1N6
MTT79_U;FU-KJ8[WHJL]D=J]+D[*0O#BJ?N\$0/\-'VVYS7(6^N7K7YOS>.KB
MO**8Z.Z.N8$GT89\CWE6-_VG?IS7K;.S.*E>O[HBKWZX0JMK).A^W$:X7"3I
MC1:(.8<1Q\8AS45 S#.?@@X)WSSG^3Z$^SZ[19VRV6>+5][GIRW3CK]EVO5U
M;#]'H]WWUK-E#*\6=VWL/\A@[*N!?>_+OO0PV/?]\C1WZ$5AWBT'KBX]N%J[
M\*W\.Z@TU@+3@(-#EMJ01QU+R";A$$D>&Z:DE64?_<-'ZH^VK=NWZ=HHO>A_
M?E[P@M;XLBMU9BV.M!U>@,XX')VQ1>G=\I=ZV5;+F5V&W(#PE2GYZL2>Q\K%
M.*MR(\_LBN3+#/\\Y$_'7D;82]PYF]?Y)F?3W-@/<1;G&:4OROOQ;-%?6Z88
M_IAUW]U%KEGM9*GRQ]'[H^I_O7KUVZ13+D61S.O3K3;5LWY-;ZV(7Y6%M6FL
M""Z^^RY^6$[[-]^C_[>\4K[F??3+>9=.UUVR7F LUCBMVS9_NOON]S^_GG0?
M:$^:Y33DQZTRRW2-S=;YYW+6+Y-V3[JX-.:?VMM-5NZT6O4XR:IHT53K&;S-
M\U_>X=5L5A38NWC6S!=%R_V2GS(_%/J_.SN4#U]$.R^5 ?/E/T7?2S!&)EF&
M49ZM54_S&YNVY6?I[A+=?%D(@HKN@Z)7=E_I[+,> =;MS+#POWMIE[OP9@O_
M=Y7=X=*37E8GS<=X'N>3]5,V9_5L%1YFC\W:M7S+I&J7_N3V[Y_'S-5^466?
MR6JU\/AI7Q<QMSN#5.=?;3.-TXN^=$/VAVF^J.0]E[>N7#++IFK;8H)N1V"5
M;#U?/Z!=1ZVEE?FEK(O;C;G7KM<78=PRRNV3A0 R'<B\RO%"[K[L[P44>@=H
MX^7J7U:V&=++:G#U85GWT)']ZS06V9+?[ZY=ST#:Y>*DR0.WF]'N4*%:AR+E
MUELJ)R/(+-AY[J;73>A4T&(]JE^]7XWJ6S_^QUG88,^K]W],UMYP.>5YZV4_
M-OF?[J)?7KW_$3SB2UMSX[R 7B&$;*Y^-%7VM-BT72/$-\P[;S%1'O$EA,K=
MG3_;PVOAALTB<]D&D;VJ_\H_M5=&?8>#;=RZ1^\R;0Z,.]BN;'?J47>G[:;_
MJ;2S%)#I\KJSXVPE:V=,6V3I>9(53YRW?^IJNBXN"@8MJFG3ML5?NBHS:=I\
M;(^J]V?1=]^<N7&R J'KS6D+V^:'SUBW:G]AT2QI0_ZP*[[;!_6KUU(,A6M[
M&BM&JQ;VTRK*[V+W_ J_6SP^7&3 L%=.E5ERQ0CB.GKD++%9Y9L4@K/<T4$B
M@S_:^#;]G/GAM-@%(H!O5,_9? 7^-@8$\7\X*/Q[!V,]EJQ$SU=$8*]Z"Z!F
M#.N%Y4:<9^CI*BNT6X*NP.ZI_5?,HV[E/STPM>WR]*S'LL6)O8*K\TY+QDLZ
MR*VZ!5:[^US6ZUJUO3!RAX;=!=UGKES3?T5A]S6G?_F!>Y'PN6;%LL.N3)>&
M9:<Q+S_7!3L=-1Q=#IT;CWYJPUH.7<V+^FHOE /YXJ1RRT6GLPLU3>O3+FY:
M-),>^.VTUZV%(.S<]V7%0Q;AT^:LZYMU\R?5N9W7G?SJM'2(\\M0JBEQ2K['
M-)X7-5;/SI:E!;FI?K%^Y@_S9K6X4TAMGK]BMNQHJ_DPJWO-]4C96W=R^]+D
M<SM=;IR^/<E&1&4V-/?/QZ+E+OO]R@=#$:(ES,W\N?*QJ[/BKIL]K[.%+AT^
M7YJCI476K)G3.Z//ZTX(=^:==<9OENW*TC>'QKPHFVF=K=H)FCX ;9M9Z;"C
MK$07RR[0Z0.54WN11T4J>CG-FRQ[3IIV>_0U5[[AL3E?11&%T0HE[B3BB@2D
M73#($$\9\U1RY0>9MX\?BH>_6X]%F P<)GWSPY4L#Z#46Q9G-[LVVY6UN@&<
M@:.;XLF1:H'Y?(<UL\VJ_&LA4^N:C.:YI1FIU_J^([AY7,0K,UQEZ>_<UM,.
ML0O"QTN0<A<]JYW4,6UM(2T)\&5*JR/C>1>CKE]"^:7RD;*%^*R;GBGOE,R]
M,F?3A>?3/%Q*:S+(-,NY7S%9F>K+$)@#DY[LN@9F7+N*B.=U_-@CXJHU!=C*
MY;U(Z-]RZP2!?,]LFZV&KZSXD,5"QU0@1@D4K.>(,YD##6DC2H:4+!W&C;A1
M_O=>15R:6<GDZI_Q7=W^ZW5FBGI1?OO*"N%=6MBM$ )"?65:8;L+RO#JNZ J
M?= GGW0<6_[LG?"/_/EN)N+ZMFK M:N6_65KKKW-3MQ#6R=0VJ7[YUJ\KT=]
M1HUV:^G1;_=+AWN^[YAYZ9C5!&Z94<G6J/L)W#(E,KGE%)SV)%,Z6L3Y:6[)
M>=Q,Z:[F.WIMGJ5GS)?T FFMUPNP=2FQG4@JH4!GC?C)Q\LYDOSE^0&71>-U
M@OJ:OJO+Y_--5G-+6P^QDO%%^RY64M&6E(H5(*<K]JL7R]X295:HP%P!P=N?
M>+WV<,M#7^K#(K7GH<_WZ/#43KM)U/8DQL51]5OV^;-._$RN]%)^OOI#)PO+
M1=UCN(O5-W2M*LKUPPGZ,.\#E<N.[P.K<OTJ!+C2PQTUY/L7*,]>A:ZLZ%0?
MFO/L<5T$DFEHZZ]2R*(L+V1]6CBJI\*^%WI)72R?N^9JEYQD3BWQSZ6P#MV7
ME[FU7GW?R[A'_P? P1?@8+4>LCB9QUB=YM=/VM4RU-^[6'.U!B7&%/=EY__8
MY#[.2J$.)6CRRQR69:G0KI$C]B4B;VOT-[3H$?9C>LZ=9MXBGWC,^D1AE(<H
MS;)!:<*(9$;=F#QEUDE*LJS( B/E'RP@$Q)%VFOG(]5.F_A539.AI+R0E1NY
MLN'R+(_+S8Y+1+>W7'YM0[_11Y\_)G ,?O-=-U?4S>^7^8VS>1.6?C//,=FL
MK[;Q=N>:Q]4D?0'+\?N64&5FGCN$O:"(4Q^198$CD;RC1"E+=+KN6]I*PST6
M"'.FRE%1 FE;#LX0L3BJQ#S@I_ MR4?O6X6"QN\41CF%$RY;'*A!'%./-.4V
MARC*!\PDU<+=.-B;,VTMTXA$81&W&6L,I2E[4\)2&<ZII$_A%(P??;Z$R#B<
M8C4Y?9D*\EGXR0*W$]1C:O_8)<#^\KZSBF:LE4B5A&+.K4>6DX"8PC$+ !F#
MN('-2H:HE#1(>):OH8Z7*@X6&6\S9#LM]"TE!!^#]^41W8]A>$M<N0ZQ#H[]
MB1%9"H;L4MJSK!*-1MI@AC*'8QP22Y+=F*+/1&"I+M<DK#/[DRQ$C8@H&,43
M%30+3OT4'J8HL/\PU<64"Y0:DDF<E2T,6F6GL Y%P:(APG$;;N9J,&(UCQ%Y
M5TX"U<DBBS-H)6G*?SX829["*2@[^OPYG^-PBJ_#SE'U:[-:,/Q2/-NQVFDS
M+X&ZG>V!HP67,ALICU+".5!57A:NBDA82GP,UD5QH^"Z)!I;76;H@\K2E!!<
MRNHF1*0@F?(4R['R4S@:P?L@,V^1E-TB\6U3J=O3;J=--E(S;Z_-;I;,A7H]
M^]Y-O&U\LFWZ"<MZ4?G\\/8L?^W9O.[3V#)%GC6S?E:UR\->IP'6\]4TZ\=F
M7K+58ENF9)LNA^/J;.97)@([GBY?T\U5KTO.3*=]/9)U<V][[J^O/7WF5:B'
M,NJ:&E $9=-A95IZU&6SAB^$\I#$EM7ZK=UBKF_:Y3G@]PZR=OP<ES"N+>MM
M5C$S :V2T^>;9>+E]C)Q]\HJ(VNU!K=%6=VZ5Z_?4F:7YF.W^:1D;&6V*1N(
MNE1U6Y5TK'EA3!O.,SO&*O8ID,WU34!I62KX;U'LVINK/K>O2_M:L==EBL5Q
MM2J+6!ZHKS-^[4ZS#R_SY=W.J&9^L4[>[)?WNETQA9_/5UGCN4__%1>KK5K=
MTF*3^C77>:Q/W3(_0+>$ER^<;.1$9OE0=SLI7F[GA_3FJ><!G66<O<BCN9YU
MJ7&;1,5FJ\+!)EEDF;*$RNW/2F)Y5G9<=<N#VP)@7OHD?]=VCF/)[K-EOUGI
MHEF<EJ;,F\4EZ6_=8+,!KNSRZ81!$=5%I>3.OWA93?OETI7I,PC5I[EU'VQ9
M&+W2D#Z3L%L'O>5&V4!VT6UV6AEJLMT/^<Z]KB^/F_75RXUSK33+JBMR&!"Z
MG)*7FU3%ZX^QY0%VL2@*=-5CG3?$T[-I<Q'SC2]W0Y5E^^59MY>KN-.'>?-Q
M<0(KH=\ (R&60S<ZSYM=\?*K'KPR=+=_H_.!54V&33V'54]])G/W\D#B CEU
MMSNO^3"WIUD;OYE5Y1MKGSUJ/KEE@'1W*R*Y?.MJ V))1NIW6I7LBXQB57M:
M-MKEH*;L*.PWZ=W:_JSF.V7=91!<QY ^BNTV:EVM8I&;_:&H^LTB? &',@3R
MN GSY8=RK_ZOWNO;N/6$OU_Y>P6K+JZ1M&PI[; T7^TNRJ-L9:)T&_CFR[-U
MFD)IX>I)2C;>O=IZ(T#8INF=Y-$2+(1U7B.1?\LA+X]($R>02D$ZIVP6!8/D
MT>:&;.VHGS>SIC!AU[^04CM$PMJ[6*1V=KXW)>GERG;$J^8&"/Z\$3/B;?8^
M4TQ9#WIE#V:?2Q3*)L[JU^:H>Q=ATY70:4YC]7NW#>[/OS=G>6@ICK^O.O(D
M+ZLWIT7]K* L8]#E!=5E(;5VG:049R=%V?23(9EI9VW9#3_S%ROD7B7?+MN8
MEM,NT;4(MOZ692O!]KGS;JW%NKS=*QM<\E_V0\:B#[;?AKV^/E]5CC>==)L!
M_;QV^85VM2VU*IF['YIY'2\A^6H*<I>VU@%FP;[2G'F?[%MRNK*"6.V:[618
MMX\VMINIQW4+T!JNMYZDGR\JIB]9<YLO*(U(=9E1ZS:OYP>.V<EFG4PNL?1E
M7Y)^>SKO<_N*EEXIT]"L2HL5HLK]U,WIE'N[4JYBM21CB]#9>J^_YD8ZWVI#
M:!Z"ZRSJ54;;6H^G?K/[\JS?-=33[2W;<JX\.@S7+P[7K6I1I4S!%X8K1YAM
MANMFP^^J4OMF?T?7H?-X4@I5Y:[N/[[ZT,_]+J<R;->#I_C.+:-XLW_MLB<W
MY0HV>]5OWR56PHQ^WVXW,+>J4719_>N(TC?MXE)_=5O'<O08;?[R=66!SM?[
MN@\WMY(-,Z#DL /J9UM*0&SND=N6FWM:+TI5A,<?;9^?H/V,*KM=81G/DM+6
M(A]*0I.4!!51B8S'02;%599;0RBL7VP]_Y]LB;CECW<M+':7-D)AL?N"UI"%
MQ=AA%!9[MZFF4MRVZORV^GNTQ6M[I73W>F+T?I&/Y<1Q3R/"EC#$5;3(L"A0
M3):S9+2W8I!Q^=Z?Q+"<QK=I,T*[$TG:5[/PM\L=Q:N'#V]G&]MT);-^+PM'
M]PN+GJ,D^/W*;&EW+DC5;>!.9='OULFM=.N&%#OR7+B.>6\IU-0+D+*5XW3E
M4448=&6)SKM1UC'S936CCI=+J# MLT+K0A[=I//E-2=UG)=OOZC^W+W9+-LR
M:?C]\19?]F?9E--L>J/WQEJM-17[E ?,?E/>11FBLIKIE\ VZ'64\6OU^;*<
M:L_:>+S>O_CRQ>8+M@\O/<_A4#\W>;R^9/N3VT?K]%_#Y!$E_+OMY;#UND^W
M'O;#ERXF1_2^5][W.IK'K<"7_]W[1O#(\,C/]Y$O3S[N;W+]]..B2&^>?IRZ
M_SYS^O&MP/\9[+FR=K]U#->##_"Z>H[<FHAO6=+73W0,UH,/ZGM$2^[6<H]\
M[O#:;MF5R]O__8+P%\,;<9-*LDXK.EM4W6$2U5H?C=-A[QT(/6#7PB/Y]1>Z
MI,<SS$;:*;L=#0=, 0<)7&"W!P(^!;Q_)+S_6Q<Z$P#Z40 ]H >@Q_ZA!P7T
M /0 ] #TN!=Z,$ /0 ] #T"/;T2/WTLQ$,".46#'UR:HNJ7DFS-4/ALL^2>8
MH<J?>PA8[717Z* ;S"\K5O:%NH]'"O]/M,]V/_#_BXAR.=QW:=;NJP]3CX M
M87##X#Y0A_S_V7O3YD:.*UWXKU3HCJZE""2=^](]UQ%M+7X]EBR%6O*]\\F1
M:[,L$."@@.ZF?_U[L@HKP9T 6 #3,]$B"515ULF3YSG[*;0\7D7H]$[V:1*Q
M$*Z_A'LU\J^<Y.-@R),CW!-='W<FYSS0R[%>)"'@*3>^Z%XT@/6*#7QFZ&;!
M!KZC5J._KI(?X<.K16.1!%O5/.FP/&D37O4)>B@U1^-3H.4FSSZ<B/_13V[L
MAX)QB($ )(: (T/6IMQ FFBDH^:("*N#UI(Q*Z_7W%FN0S32(!V"1]PQAZRT
M"@E/'34V\HC%5E-.VYR_&X7\G^]6,UINJ)#=Z-#YV_MOEPTZV7I_3G1O@TXZ
M(%S>VJ+SE9_6@PNY AD%,@IDG 9DZ. 9#CR/&;(.((-Q9#S%2-% E%>,&&NN
M0P8W/%IN S),!,2%!< A*L\TPCZHJ)C0V^-"]@L9J?X< _IWG(SSN6S;B12X
M.#:X>.6.WE?#@04KCA,K C5:"<[;?AP &!2P@DJP%Z*5U/L@ "RN8X5@QDB.
M'=*6T'R-0,8Y^"=:JZS'AE%6L**O)[6_6'%\![0@2$&07C/H(1Q4-M'DF$8:
M$XW A(C(,641,T%'*P)U:JLI5 "#@MJDD!",(1ZC0-;:;*%00HS!U)+MJ6C%
M0=6CT_K2<:P[4WA+'.L%XEB_G;T_JZ:3MH/65=7D;EEME[9^BN=B;AXU+8L2
M>U0Z0B32\2 2\L(9Q+VE2.LD42):6"PLI]LM\[FG+F'X.@XB![$P0PY;E6?Z
M6"P-V*QF>ZIUL3++ 3UNPA64*$SX2E&"LR"-MWEHK4D@\5-"QJ> @F2$!,%X
MBEMC[BTWA"L7$>;8Y/G:&%D:)*("!Q4M]LK)E[8D&1<#IE2!BF,[I25X53BP
MX$3O<(+YP+Q5%*E$)>)2@,P/FB 9)0O8>ZQ3O(X3SB?.&?,H![P0#TPBJ^'"
MD)PE%AM*C"[61#F@IW] "W 4ONPC7QX .)R/22KND>!Y3+3@!!G-)6)$N,"4
M=D&GZ\"AL$G*6HXBH02 (V'D< #$8=+#+U:S##;%P'@-I[347)U2K.K#&,@S
MZD;Z?FCG19:@U:EJ"T]I97;,DNJ ;/K,+G&GK7%(+811)"'M.4=<4X6T%0DQ
MXRU)PEEMU76-0Q/#C6(87C-K'"9?XYQ&1&!G=%+.D%1,U<=QXAU=\LHQ+VC4
M'T8M:%30:&]H9$ $<A$B(@1'0!9LD*;.(&6L2B8J'R*_CD9,Y$FWSJ% \OQ.
M!3:SQLJ#X1P"DT0+$LU+V[^&#Z@6!9%.\:B7&%R!H[[S:(&C)\$1IF#A,*V0
M"3@@'G-K"\X%LL88)64@E&^Y8PGF1 8;D-<)KE$R(FT"7!.S*]89SK$OQE&!
MHI<VCOIQB M %<XM /7TA$02DTV8Y!P3AG@R!-FD&;(\$,&\P(KI+7O)214-
M8)/R.'O\$D5&&K"V$DE6.B$-.S1 %7NIOT?]!<O?3LX<VZE$:,>\S*=75!=M
M55L,E9U6"8YE]3&?RS[([UX0_B35#'I&L_@)XYD;QGXI&D==*O\T*K\:G<,(
M%9@ 32-*EWVT,B$CC(1?-0F.!*+95L10<&$<21$9FW)Y':9@%!.'+*.)2@E7
M^$,W[SJ><OH[^?%$M8X"4 6@"D 5@'H*0/FH)>'>HN ,1MQ9BS0E&+!'6N^Y
M(#IWBMP$*$J(DEY8Q*T!H]AKC4R4'$D67?(<S&+ZXE5ZG)F!E+0@U&DB5)\-
MUP)/!9X*/.T&GE2P',2AS>F2N8@<\$8;+9#AQC,79>!ARV=+?"3**H%P"@KQ
M7"$(L(11HDQ8KAB3Q)6@8D&FE[>=^G&,"UX5O"IXM1N\(D:J0(A%PG,#]I%.
MR&$**"2PB)1B8]26OX\!7"4M<MME#]=PQ>$GF1!15'NAL;+\T'BU;4X),M!8
M%]#J!6AMA!GA%PLOVR<[IWLVA6??];AGD&/Y[NVK+Q8T9X6\HGQ+>('\*1K:
MJ_%L^L;.IN.WW=T)QF?XRP7K@%@8VLLFOFGBI9W8:5P/N:[%<#_63>WJ83V]
M>K.XY+;@;/<8)L^H$?DYGS-)\IKF[P0T_OSVBS_>=3$YHT^]\JG7T3-%G[S<
M\IKE-4_S->]+ZM"/+Q._470^,-%C3P;(0L+?@")Z1R"R4OWZ87[L/PRV*\J]
MD)MQ.0Z9\#W,0WYFLN*+,>Q#S8A/G7APXV%XQ+Y\&WV\<'%2,3*H**;\P*S]
MM*2]/NS+RTYH/F(4.$G95>CV3)E/B\@_D,C_(7Z,PXH40=\+05^D1Y$>QR<]
M:)$>17H4Z5&DQY.D!RO2HTB/(CV*]'BD]&C+ZHKLZ(7LV$<[VWUZJ/J<PKO3
M3)'OZY$=^7I9?_JFI^+_V).B]RK_^YK3=!KZ2*%E.=SE<)\H0Q9:'J\B='HG
M^S2)6 C77\*]&OE73O)Q,.3)$>X%VVZ523Z[=)7\"!]>5;""W^.T2K!5973/
MRXN>TQLA=M05>'U5, Y071=I8(JF@ R1&G%.)7)*&N2<MRHPG;#;FGA@F9>2
M1X^H4"HW. %9;X5"06%G$HO"LA>?^$?D0-$^%M?UXK2>1JUW@8RCIF6!C..$
M#*,=<Y81))4"R-!:(NMU0BE)$Z/. PBVIA)@*SP3Q" N0D(\28SR9#>D.%-)
MD:1<*@U$>GM2^PL7K]S1^VHXL&#%<6*%ME$$Y23B6.=&',DARZE"GCC&0F+>
M6[:%%=X;9B/.\P0"X L8&C9ZC#SE*1+#N>.''JA6L.($L.+X#FA!D((@O6;0
M R (XT9PC#WRG%K$":-@;02*<*3"1D6U<^$Z@H1H*8".1D0[A;A7#!D/J..$
MU]3$A"DGQ4'5Y]/ZTG&L.U-X2QSK!>)8OYV]/ZNFDW;.S%751#^;U-,ZEFA6
M419Z+'Z*CG ('4$RZIQ,!%G)P6S$G"'KB$!"*J8PLWGHZ74=027I" -[5*O(
M0:_P!AE-$S*$DJB#%]@?.HA5K,Q7=D +2APU+4^#"5\-2C"M@K1@22;"!.)!
M>&2-)"@)2I-@F-#<%'@3):*44A"-D234(9Z<13;XB!0+E&-8GG(OWDB8$3+@
M6A6H.+936H)7A0,+3O0.)[#55%H-YH,.$G'*<S9<2LA3DS^PT0N_Y7'T48AL
M2!BJ %LP,7E "EP3I=%69P?FH>=W%6NB'- 2LRI\6?CR8(EQ*I(4HLE3L@CB
M3$3D+'<(2Y( .9BU=@LX>-*!!$H!+G .;SF/G-8,$:8D8Y*%8%Y\,G$Q,'H=
MJRHU5[V,57T8 WE&%_"7RGZ((U^"5J=K9CZEE=DQ2ZH7FX[VZ"YQIZUQ,*ZC
M<L&CX&T C2-2I!6S2%$M><+1."NWJK=,P,8[#.9M BW%$8T<5PFN4=(I+)04
MQ51])">>Z%"T@D8%C0J;%C1Z:!J&,TEYJE%T42-.J4>6"H-XD-$($<"NW4K#
M$$G"IS@B%@Q<DRQ'VG*"I+:4^6 MV,$O;?\2S09,B0))IWC62Q"NX%'?>;3@
MT=.*SWS@GDN/:#9WN)<468 9Q D1Q%GJL(A;Q6<N*66\1M98G7M;Y."?(T@;
MG0Q+C)G(BW54H.BEK:-^'.("4(5S"T ]&:"$-8%C0Y$1(2 N&4,F!8LX2\9X
MJX326P!E<8S<:XH"Q11Q(1FR,3K$-<=).!,5?OGF2\5@ZLU9?\$"N).SQW8J
M$MI!+_/Y%=5%6]<60V6G58)S67W,![,/ KP7A#])/8.>T2Q^PGCFAK%?FL91
M%\L_C<JO1NG@#CM,B4<B$E ; I/(\AP.5(%1):(V_(:.CQ0[:R7R03#$%<-(
M>V>1T$*#76T]9_;%E8Z^%M3?R8\GJG44@"H 50"J -23W+;&A BV+/(ZAQ$9
MV,<V,8,,PXYBCZT-ZCI $1.]\TH@I0E8T@HSY$CT2&NG=$HQL:1>&J"XX0,M
M:4&HTT2H/ANN!9X*/!5XV@T\I<0Q]5(C:HQ W!"!= P$_M&66$"K),QU>'(B
M<)((19)(B;AG$=E<5RA!L%)F/ E&E*AB0::7MYWZ<8P+7A6\*GBUHR!C)$I+
M3A#5,H(Y11@R6FGD/?5<&FZIVVK!S)/S@0:-),]5B1:02VOMD7#$P0\B&OOB
M_CY!R$ 87$"K%Z"U$6:$7RR\[)\6>_/WV46<U!Y^#_7'6VK_^)E@;+/XCY\I
M;KZ\HP)0PJ\O$-Y;K>6NAS\B$G@>JV_&%["2JS\TU<76P+;*3F+EA[9IZE3G
M&&%3_1 _QF%%*A>]G36QFI[#-?EKRT#BK('G5F/7Q,G'O!E5/;J<39LJ3<87
M53XJ'^/\(4T^9R L8#&9O><AR;/%5O>!0M4ZWQ7VN8M];NN36ME1J.XM3+V5
MU>@=K/:IGIXOV&MZ;J?MIQ'^&"=5J"?13X=756:QT>JW%5]FYH.O=FQ7 =E\
MOID?SD*L_F<VGL(#+D%XQ(Y-FQJH92>+N'D]NL[+^36W+UMQ]XWW6%R\7/UH
M/)W?^*RPWIVL!\3Z%%N*+>@)%![6UM7#CJ-NXB:6?QRGZD<[@=UF9%!13$6[
M=]]&'R\<<,[\K[QLP,,VX"9Y_8AG'D 3=<*[R+%'6LD<>28:6<TXBH$[C86*
MF&X-CDI24Y/G3,4 %_(@!3(8*R0L$Y(G90/;:L"WU#E_["14%G7_%\31;Z.5
MV/EK*ZY^B? T#YQJ\S)_R6)P B_W9]O4S;O,S;].[*A)<=+\/4Z?I+<BD*U9
M=\UY4TT<W4::0*/$&*BB@N:9- 9($R*2.B0I8BZ2VNIRKQU.+A"!,&8FMQOA
MR#B/4>1&4)Q$I-N%O+TFS6A\@S)_BW;?A\,',#LG 8#C]%.,HX5>-EBB)@C#
MA<CS=AH_C"=9)H99IF4+>Y>@&8]!QX.E-MD.#1OR[F8%NOT7E.W_A/\NB/#O
M5O1]?D/?IF'\C#JD!8J] >K,+D9O0]U<#NW5F_SIEM%R)L#\R*\Y3PKL_O"O
M63.MT]7BC=M+41R%MY?CIF[O/8E#FT$23)[/F;R99$OKY_.^#9J5W=X';B!D
M8^,66W0^N099]6A8CV!)4SN9OK&SZ?CMY@= X.[/EZ"==;F7R"9XT3=V^,E>
M-6^_^./UO=^P9MNM6W'#UJZ^W.9ES+UW^PZW83=8M.OGJM5;\J[!Y?.+VO_"
M[W'RQ?5C)VZ@*[S9VB8]XATZE,@/JT<SN]YARK.DM+7(!Z80EY( :Z2(C,=!
M)L45<>*?Y)G/7<F;Y5.=4@(;)$-..?>$(!VT11HG8HB1)"2Z4]S^8:4^SG$J
M_+2"H'>C\/?Q:+*!2+]FX/H5'O_GX=C__D45 7\NX=;3R2S>UFWH=:N-@,3#
MX?A3"T.9>$W5S"Y@^?"D%I<BR'Y :M#:5_G(666?;EB;WC;G55RY^P:5_6C!
MN((;(H!ZU,"?U\W+36.@.1]/I@B$P 4881_AB1?S>XSRQ\W8U^T"9K#90,-_
MPX\?X/1U-MYP#$I(4WT%UMOT?#QKX&_-UV]ZI1ZLB9:E9ZRE]6)E<VF;%Y/O
M!NS2$@Y@>CR;8T-W8X+Q&?YRX5B$%QK:RR:^:>*EG0")UA/RUS+\/]9-W9ZC
MJS>+2VY+W>\>P\F9_'(=#A9RK\6#/]YU*3DC3[WRJ=>1,W'H1Y:7+"_9UY>\
MK]!'/[[.YT99^9#BGS-,UJ++SXY+=[>[ 4MO4%#U7HV+%PI,[X6>^Z7?"Z6A
M 5OGC__/%X1_L1=2/KJ@M3_,^U!%Z%,G,-QX&!ZQ.YN^W,/S^!-*._NS-?L]
M&2</#2<IR@KU=@($M.# 07'@W048]:VQ_LVXF18<Z!$.%+%2Q,JQBI7?5D[
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MD@)@!< *@!4 VPV !2XDX=RB&!* $?42&2H9HA2PBT?,E=UV"B<9J80OZ6
M],#H1I8)@Y0DDEG,HM6/!+#]14C-4<S5*N!UNB9O0:Z"7 6YCC%@2AWE(DJ,
MC$L,<:$M<B%*),%:4U0;;[$^.#;NLJZSI\T'C@L;2\RTQ$P+=!;H["5TWA)
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M,(GMC*S?+M,$;ORSO;K88<!<#[C811;Y"1_9EY!W!4,*AA0,.4D,(9&&R$E
MV&' D!@\LLSI//7,ZX!QU.E965<O@2%*[J*%Q@D?V9<V-)]=:U0,S4<:FLY.
MBSE95(%CD2L]8,A7HP'08+0'R$0V68NXX!99#F8A8]R3J TE/.[*BORE$T0[
M@GHYP%@7I'\M)[) Q E0])08\M5 1%"$)L$3BC$P$/=$YM'8 @FAJ,>!!!GI
MKHS$W4($'PA2(*+7QF").A[6&$PQQ(D=MD''9@IGK9K:S\4X+,A_+'*F!PSY
M:I#?*T4%D0PI+B7BDFEDA:%(4!,2]49INC/C\/M.,+T;A?=9+/UJ/\\]P[M3
M!HS<Q>R<<DB/XI 6U#@!BIX20[X:U(@NQ006(XK<&\1I$& OD@3XH;2'IS*A
MGC]UK:#&Z1W2$D\\"A/R<C).L6G@'( =V<3)Q]K'DK1:5((CDS8]8,A7HQ(X
M[Z/!5"'L&1B2#DQ*PX/,@UB34%1:*9YE2"YZ%\Q%U,]K$NK[&'?<V E4 KZ+
MOD[ED![%(2VH<0(4/26&?#6H8:1(+A&&(C4M @!J$$E1D$EK+*T1V^['I_0$
M/ AJL($2)1;9:T.RQ"(/;$C:J\EX.*S:AF9KW8WZ+'R+-G "%"W:P!%J R19
MHC1-B/J$$1?&(<,L1UX3KSVW@9*M-*2G!B-_[B33+YU@6C3^VYG]2/$N6M:7
M WH4![0@Q@E0])08\M4@!L<*6^X,HE@;Q+F3R/$@D%3$8*-XB%KL*A"Y5\0@
MK+@<^VX\EBCD88U'6%ALIO#-;$;FB'^?16[1 4Z HD4'.$(=0">LO:(1$94$
MXLIZY))C*&*GL.(L4*]V937^N!!)N^UI0 = G0+^K^5H%JPX 8J>$D.^&JQ0
M/B@K.$&!B#PM0RMD')$H<B9IL)8FLC-[<5]8@0M8]-U2+&'&PUB*[8B>/@O6
M@O3/H.@3&W0?L[PY+,L^OP/Z:6L+- 2I<^^\X+$$*]$PY")1")/ .9:&!?&L
M>.0B.ZD;4+HU>&O7V4E8BGZJ#4_N]%Z.>D&G'C)M0:>"3@>HN' R<(T]<B0&
MQ#T8IR91CA3S46&L-65;TR*?DCM[$'2B ZE[:M2^2G0J(=)>&[Z_CJ>YP\^C
M9H;V1*SW93].51.A9S1+J#">Y;&J?=-%CKV9_)-I_6K4DB0Q<=)$1!SUB*?
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M_-U>7K7.,[ OKS*-J[G;L1TA>V.3D"Y65B]J7KMDF^IR?+GHJA+@BW4>5.O
M.FU==XM+YUJTG8_<R59FR[S3\:)SR7Q);;+O?\V&5S?4W&8)$#IYW!9+SMO:
MCT$5O%@@Z^J[7:/']L[SH5X.G@VD^^.D;G[/UX'9']?.47>#N34ZOKP$PS?+
MJZMLM+<M'*MY[F?G=UP;PMVUT6^/]3IH+.@^3U3*!WB;0LWX(J[4TR6]2IOF
M1YR 7Q8:T&:8<2VD>CT0\_YR4L//?Z['C0<N]F O_+G(F+L;,LT^ /M71 QN
MD#+7@A>31VS(,JXQWY/; ALW;5E[;?=!CFR\_Q1!W)W?%M+X_V9M1C"<^?S%
M.%IWGMW^\/DG#_ =#W;M/+[9 WR#UW<SHK/AD\B3S48?L@+0%APL3 7@A';8
M80L/'V/6-<:74Q#^:X[.C;EO62>H5E.>I\"W77;G/ZSW(+WLLO+I;_4H5[V0
M=G/^\<O?;FDY7T[6C?Z[VQCQ?@?>NK/N?@_=0D-LG_TPQUMG@JXG5\Q&PSRA
M8&U2'K 76*B31S5AOO65KWGR6H9ZN.^R)<&@-&5^G4V9.5:">DZ1"3(B'HA"
MU@2#"%%2\N2"TWAKFE[2QCJC$$NY#06-%%E-'?+4"F\(?$AOG*:W6Z<8.Q:G
MV WMF.='&?[R/EY.UVV2P[=C+CZP1_G ^K2:F_QQ?5K?1IY&*4@\IH)$L;%U
MI2"Q%"0^OR"1/:T@D=]3D'CR>N726=8GV;Z(]MQ5S=.G]1Z!+NY%I-)%C!+Q
M#G&A/++4,Q2=L]* GJW3UF1K3HW#/-<WAB@0CZ"&.^;S>&NA,9A=U+*#!Y[P
MT71Y70L\[3#H='O5T:8;_9Y:F[OJ;$X_1-4[J=ZC\@CKOLGD_+6-!;7NS*;X
M9>[TRO_7# "*J/OGV-Q54# G^ZTE!3=L2WOQ_(.'%Q6\SW-%SFT]J+XYKT=V
M(WOU]D4L/GIB^G;[83M(\"^Y60 \KWWX2^9U/S";^]MW_\TPJ;[*J)3;5U<_
M_OK_$&%?#]KL9[A%]0XDG!N'J^K;R>P#/&'TKUDN>VQWY]VWWPS6_/3SZ8EH
M>C4!'1BXYO?.3Z^Z02F__DUM.FU;V;B>]KWKK.\'[?U.<Y?A35V;9;U64[N<
MF %?OBFVLDQ=SIK@3;FH7=G_LG VS\_)"#EWL_\V:L/I[W/7-F";_[+P)MUC
M@+/B6NN+9=YH\40_)MOY-LYY2D;PLB8TQ\RZ*^^,DMR<"+S9M^\/;71D4G>:
MU1WQDN_'P^'XTZ) XYYX3=NL_T9NO%82?;TJXIKH;,YMJP#YG(2P44\QF'?W
MS>Y^-(.3,W\^2D#@0=;:+F-NCS9O/C>9Q(\@YA=5W@]*W 8)</L^Y-=\]BNT
M7;,3@);+B1Y+L=[]NGJ_Y<M5][[<-4XJ9W6W&=P/PX'CF=]C<^S#4(VPQA0,
M7RV0<5&CH 0A"F/+Z?9D4,>YI%0B1G5"7.69/U03)*U* 3-EI*$'F(AW+"/Q
MMG+VZ[7\L4ZCN?Z-G>1M;^1C+T5=&)?(5+^RLX] 2KADF.#1(LM40#Q(@9QG
M#C&L##.!2TFW!G!H'1,.0B+/N 4I ?)"P_<1QH9I';"W)!S8/48&A!W-*.%=
M9V;/6]RB[K[KS6] &<E]<0#9T44=;DK3KK=:S,RF&3;S2C9,UE[YN]I$73!?
M<[%_USEPXYR"T329]U1>]#XY!W,LSVN<DV"10+P^OW!:3^?*0O?UKQ?J],]M
M)V5BJYR6NZ8GSDWDQ<=_="LKM<VXW;1ICT=S$$XD[^!H&Y7'H1'LD XF($V\
MI8P;KX1\MDS87S,NBH]%$&R%>3*@+!31>I/%'SC^KWB"G^T)OMZ$M-A9]WB!
ML\++[O4"YP\ZTMY@8JUWL6^SM39OM-1QX>/V'H,V%W/=^3K/N+S6^6#=F[;>
MPK7N6K(OW"/U&O!M><ZZ\NIE1_?LLLO?6W1-N-W?. IK/M:VWB+77?CL?^P(
MT?D/6H7]/E=PIE\]"6C>9KX8_P]JUK+1*?]6YLM]Y[H/NT%3F_[]A06W\ 6E
MN)R/82^R-^E(-/TD:.ZZ"PA- B!TH 2Y5N?W5 H1HXUR:TJ3]-B[2#VRQ@A
M]<21U?\_>V^ZW,:1I@O_GZM ^!N?L2.0[-P7><Y$J+W,IXFVI6.[N^/\FLA5
MPA@$V"A $OOJSYM954"! +B"9(&JCAE:)%!569GOOCTJ(AD(\P&+0.@3Q ,4
M/M.GH= GZU:5@MB;)<!Z!N";TJA5 OUU_ _5TP:OR)KU0!B@JD;4731@'OMK
M5?I%91@'2XT$B]&""<A]TLARY1&1U 5.*8T^[I1;6!&=DPSI* WB40?P015%
M+ +Y&:(4CSN CK\MY_Z/-U6UBN&'(ES?E5+ZWT!KQPK>N'RT;5%6Y;,NY>&;
M+,DQXV3,3<\[?ONTF'J3KPPW68\[R@IYGM<(AU=G#"X6DX^9VB^FL+:B-D\$
MN90Y0C7U' F=0Z5&<62\!YGJC!>*)1;U3GB5N$"PH )1FC&C,="X=2!810J$
M!Y*,YO0ZT+M,U'E"5 :^*]OVKMVU8TU&/Q77J;36%.JINVA&A>[ %KO(YE@)
M11R D^X7%:F@E"=,HR!C1%Q0BAR6'D6*$U%&"*'L0\1E4<I_R_7=\>_%P8KA
M]<>XL._CN[QU6V0#:B:NZ0;1+N&PF\)OJN=T\S602CR?K,[7V%1_?_WN5E(J
M1]\7-M3 GCF>\XNM@OW'J"B@!F@B0W)M4"%BG7N*?E5B[_GJ3([!7E8U$F.-
MO)O=HK8X)%\7&J6?__UK@\/V:\SY_]@F[6^X>=I*X^[<(\M;GV-O681L"E!J
M&SF#"^:2A0\UAE>WK7SC'KLZ]=!BAFT;RF'+RFG@QK:<P\%I>3&8!),&Z"S"
M/A9XRN6F5*<N4RZU+9\+SBV0P DH],29E12$J?0IY+)YAQP1&$7O(Z-4:>=V
M04T"BZ"\&0*9"T: S$%2DU%L Z7><9%8NE4FY-=FN.6QBH7%J>CQ(FTVR;-.
M4F-J5[,FJ%(2$U>S&YND0/U!0;KTN<8OPTDOZ^Z]MGXEELA]D9/+N!V67U/R
MK.#RU34>I8AX/ KSE=L=:],^M_3G%$-C64;X+T$F5EM3;W*A\"SC^&V5%'?B
M4./N5%$/?B-L8ZX+"[FQJGG*.AW4!!T.A#'JM[JRR /CB _<8JO#^^#DQ=F\
M+1P:%;"%K)+RN,RK^N?@U/DK<;@22*EQF;(@.9WQ\X/B:DMM6@X>7TM=3>"T
MV@S%V2KW+ 4-EYT(;V;]^E[E\S8*LD&07T_R+NB:;4[^'SF./*D3F]O$5BK7
M;AWUW6,NV7:1&Y,(ENOB=J#[!BNIC5]W6?&W^K97F/FZ>4(9N1>5_.ZBF1X,
MRX#]*4//U] J]6VO;,.ZAWGM+<&+K<%%2Q"Z#5#O#$_(NYP!2^V5R':G.*4M
M?%M7TWV(,^17BT5^T/95!>>^VCFG&P75N#L.8E;>H ZEY[=R&4][78I[64[N
M0YR&<7U!V<&2HFX Y#H)W1O?J46H*R60FX \/*0M#:GFTUA*@<LLI4D7>J9;
M;_T0RMPRHX<&X%-J )9# _#0 +S; 'P/A^BK!S4-W]3]^R7:,=M%\,M/<U2&
MP%_!4]J3[8YK9))N".>@ZJH_.+>75R81'3*;LFZ 57X$11'7ED@U^9R'*2X_
M5$W4JHDL?0+UD0WR9KX0_*5<W@[XSX,..QY%K26KJW5*MUW9)'74X>RR!69=
MI["J;)!,IS&[9/D^!< K(UP5Q^ARC;J5SV !N[\+O564=0[LK@L ;K0-SD9_
MGJ^+.-JHU-W?+>>$4P$(:.RB+&7!?&@66.]DK?M+>< HV<DT:_;BR"UB;6PT
M%^4C:SR=)=!G,_;IUJY= _/U[=4GKP.6SL[^6*PNEOZR+K@; FVW'"@5@217
M[0C0@]M?T]QK7US3+"# #IL%NP@5W"B409RU]Y,;WW[[?CR26+9X=SG"V]KM
M]?W75G=& :Y]_KAH*: 8FG6\YDJ8(I]132P9QP),-5B)+RW,)124)4/7V<^T
MVZT> <\D H?YW%J2[>X,,G?9/C7?H95;NZ@FU\\<H(0*:I[P_ X7]1SVY?)N
MN"P6,EMWL9G[%&7HX$2O"P=*-07*1E_!COZN3P?1J\W;=#6N6>-@8=8AGEDT
M0R1S!/"*<[;M*[9 E1>3C_,E\%-= 4RO0_VN*X*+B/CIS:\__O27_XM(!R!R
M^T[LZKGON9J.6RII;K'NY@32;X31CW\=EY7;69F0/+'O9W/8'%]>J<8B+\HR
M7[Y>5;GM^BGUD[?VIBRH :G,OQ< S^RLE#F?^\2,+=BCTRQO/LZG'^,:S;WM
M.$Q9AOJ=2,75IL>B3-?G&V*>@]R!9LNS&^9UYXQOUMJ9E R//\_2NL ?U7*W
M") /'>MB[_)K07S]_M2'\>-?]V_W04IL"P)WMG?=:M+0:FT:;<4<;HX1P0N<
M3ZIXZ^A&B85O5%*>R5I:%/*HUIMC1J/WH#1FK:&W6C]V_8Z3^@[KJ_)FI-44
MC,7I5C%SN^R\FIF'3[/IW:1MSPO-=97DZQ*CRU7]3=OIK5XS+\0>$ 2C9ONR
M.HG+]C7L(D\2&;!S;BR^O"B9F)*@WD36#GI#5XR>IJ(C=\EU*;I$-T\@A\@U
MP4*$A+ 6%G%N$K)6<R0-9B#DM+%ZIW/B+D5!)8?X^V:[=HLX'E!EJ<_H2>0,
MQ]ME/H4YWP-%O>]XW_N*=D^C3->1((%<(E+44<1]22GS@+AVWE-&&,US8(<R
MW8<DG=NP0%L35,J^0;\VT8RFS_X?JTEQD=:%,-O3%4Z$GD+2D402$,%,9X N
MB4Q,!GDEJ"9 9$KMT)/PQN 4*6*)&<2%S+U?PB";.) @HZS3S-76*?Y8MNOG
MN/PP#V_6>U9*\:>7L/;Z\S>S7^+R=05Z]5C=7NJ,GP;1]6E1WS2>?IM\V['9
M]E7Q@MV4RZW7&=IOKPCBK3J.K=D+.6%;\]:5,0RWB.9]OU,2TFD7[9C->\L-
MOJE*$V<;_^RDU\;[JTJNMK9NM<:V6<-U^*%^O;7@^!073?PDAWS6:>I=\^9J
M.RSX*/_L-L2VK]64C'B_6C13 "[KAVS;1G &89YCFL7)J2]N#>:##EDQO<!)
MG><96J4%R>5L]6V6?Z"0L+NA;1U*IK'B1@SU'*=BP'>]2CMM!ZCMIX2&R X%
M5-:56?"ER6+49KURY=0LV&FNXJJ .NM2 +C?59>V.,K-PX$_2S%AJ*]&>R[?
M&1$Y6A74Z8(SLBKS7LJL^#2=?\JQ@#BM2B=Y\Z#:F 3GL'W4=LECJ5&"6_S/
M*KSOF@,M+VZ-$"HP\1>=L%*#GIS9#=:0E])TR"_J,MVF=;%=:JGJ&'<,E;FS
M;C)MDB=-PW^]7;?8CG49W$UAB.QW;3:Z>WP[1=*=-\FU*%7CI$UFI=2C%LFU
M<U\[TQVR*&4KMCLNK6:-^GVN--GOD9Z%*)NB4_A*KV*B)Q)<OA)?[-46]FG;
M;DZAM -]&AUNUP-Y6LYNPTD7\P:=HJ0 X;\U*D5;:!6V"ZU6U59H\D_M1,<6
MS*(8!8L:+*_U@DN^.LZR]OXA^AH HRDEY_?DK5YE?OK/6^,N8S536NX3#CZD
M4/<8C1E JR:IIE9O?9,R+"5.<_5"5YC7TGHMI]=*N3GP9<E#;)1 _GH]QK+<
M:>L19Z,?-M179U_JHH2&"OO<S7 "KCLA5))@'-*P>XAKG5N^K$*1*1YC8E%2
M_N".A,;E:KJ%CN24XS-V&D[Y9L+W6EQ?$>C%O3D!8HF<1\N)1483AW@( 3G*
M+5(Q4<4U(X'NA)YE3#X1G</5C"'.'<F#?BR2T44M&%86ZZMQGA]BBEEP- 3S
M?5W8>ZPQ7F?R-.@F2^Y3((JD&".>HF"\01Q[C)R(%&EF([4@"[@75XG",B$=
M?(ZB(1YQ:PW2-!4AA*5WE K,;B"*7^8S?U2Z8*<2Y&O3#[.-XMWD/]MBH!R1
M:NKA,QWEP;'M[Z'9R%8:C=OT-]QLVN.FF$-EZ'T-KCQG"7&+^ .7_;(ZCV!W
MMZ6[0BJ&06/; (S*"1/(* )\ZR3FG@#OD9T)+4EJ:I3*"A[[>GZCP5@AD=F8
M)V4#<U>Y-8=4)W5[V>M9^'[>3.[SDUC],*DRO/5J$7^'9_P9G($_O@)CT-L+
MN'ZY6,5=M*%;+/J_25/GW!1,P]Z?@XU<+5&<EC!OV?^+3LWT5BM"APR(AH/9
MVW10BN6_*R>.\OVK5]GBS8;X#FULCBI3HOJZ#R/,#M!2L\!/\T6HZ_Q?_1'C
M!:QUNN[6:'H"RDY=LS,Y4])28:?DO'X,P?CK*S?LT29L,U2'>HOXW*+?C5#:
M=,$,$.8WS<'+\P&JA^B69UCT$,._OB?S]<5B,LU^-[T>F26??:>?L72B;;7N
M]]_*Q5*1H)("-\804#S*(VVC1\1HA:.VEJ0=U\<ZX32XQPAS(4%O:H,LA1].
M">]QXE8I?U5OO@8!_#;]!83.]ERI?Z3E7:9*$3J&K>BW/5O]8Y7#1RG6!7 @
M7>/"3DM4<IZ+->.H+".;LG]>3"IG9V"J?@^, &\^F]@ZVMB9J[FOGJLEOFJ2
MPUQ;T<^F(Z2VI3<5C)TB>)MK",I]2V_,Y2XX0XU3T;1:Y!LT8=?UE("FL6:3
MJ*Y772^JI'EA7<5:_]F6&:RTZ)NZ2;[\_9?YQS7,,+^"8+/!BVF2M/:R#HZ5
M%.UFP'L]"699RAYSUL<VHXS6F""S #00_@UN=U'6.7N_ 2BN8\&-8S%:+7.&
MJ"2WFQ$V<"-;:B;A7$LPL3-5?A8V0>RE_9RC>;_EGI7-S7.FV1;W9+TG%T U
MC=MB1Q_M8M+T['?3_9O1-IO.E@TBR9ZWL)MPY/8F7NF?*,FY>BEY>X%--C<K
M?^ZW?[2Q]X<FW3XWZ:JA27=HTKT#2N_M'.![^<UTZ-/=9]L6X,&;00=?@&G+
MB<$,Y['ZWCC$M3)(<\$0<\Y2*S C<F?*I*'8R#)3T(--S!D%TS:"81PP]5Q;
MKV/ CV7:FL&T[;%IVT6OJQ>8>VR.R1)?[8]L6D.L8#RA**T',HX6&09NFB)4
MQ9@\MYDDM\F8)AZD#B 6I8F(RP!*5$B.$O92"1&((.(J&?\EPM[%MZU56 (;
MO\-+OTTY2I3)<8N 417]J[!:Y,*)GDBW4L[<:+*K-F./F*@>^+7&H6D=I<[P
MZT)QBU@W6ZU[R3*X(=PC=$BP$.5L7MJR2DEJ;=BWW]]NU^]<LAZE68KUUR!^
M.]/=3MP+L_UUPB9[?;!:TI0JDO6HO-)_;4N2/3?Z?>R,Y[]!'IU DC4P8U54
M+C=7:!!N4B%+0%N3F$BDV(44=SHL--$R"H51X@P$(@\:? .5$ \\@% 4@F)[
M5;AMB[5V@.2Q)C^?2(:U >[<:3"T^^$:2V</,#-\>Y&+9T,LYGV90')J=,:$
M,]@K@JC,I3VYD\<)T*0N$>%9H* M=V9%W\<6_*W9K!_JO=HEL-O;@UKVWQXL
M_F%K>;4$4NNV>M;*=)Y=\BRJBF56M171<(]0MXT[.RURO?H 1N70'7S+YH*M
MEO6U ICY1>'C/')GOEC4$YD6+:[XFS__.MZN2Y_,:@HL2N^CG4R+,FQJ;CMS
M1;?#NL5T+^.:FJK)J^7MY>M5BZG98O[DP=CG^9:3ND*_5G:PJ*RX.N_C+IO6
M@V+Z-WVID^*>YFK*G?F7I=L_VR;9?2AOW0YAG9;I"F7626@&L&9LSQIX)OXC
MER(WSD']@ELJ-\/=P8'91:UI:YN@\]<(!S,_!RL]SCY.%O-9[= 4&ZQI8@!'
M)*O[N@FDQ0[=+NNL!>ZG9KH\LO5X>=#TV>)9FP6;%>Q\<ZOGH8XZ/XX7 E:I
M\4$XY+G,'H6PV9G&R&+%!-5:N%VL2T<P2TP0A&-NQS5PM1:>("$9CH)[)<A.
MGFA;45^9N_]KNR]KYX3TW2>19^*T?)+^Z_)$L/+6"(3!+P9=[A0R)@44% -?
M6*LDM'ET4ORA8;Q?,Y)(/;;Z:( 0],ST6NU_W:?%'*CR&PR(:PV( [JZ&00]
M:GS7%I5V4=L4K7X<9T4^SY,A<M]L:1C.NAF$6NFT*,9&DR4H=X(/)R%KV[I/
M^OW*%@3YSC3>/NS.4!1S4YG3.N #=DR)R:)Y0CD.V]CVDZWB_V*$ 578\LW2
MU5/;8.L0QHZ%F>V<L]'VLW(LMT]D<@+.KN22)G!2$=>@\3@E!!DF%!("E&!(
MRFJ\4[F> K$6.XVR-8>X@Q^&&H9\TI(ES(C1Y'H%^6L^Y[?IKU4L,RI>G^=^
MN;K-_\?Z+(\4;MG_TE0Y'CF3R%*E<LB;PTM3B:+$6GDJN-HM9)+61F>B1\R6
MC6(>V: (8LER;5(BVMQ@%3S92^,SLL<FZ+&1T :=>K6F-<[43?UVQ13NAN*S
M&)K-ZQ[X$A@K/F)Q):N=8/$YD,9JL8:9OA+E'4TG=3_ZI)FN>:L5G8V^/_:S
M!]%Z9]'J<RS048<,QR FHP,_(H)H#=8K2APWFC^"E#ERO'J_+.D/'9RTZ ")
M\;<VK;0.*#7&S%;'^>UE4!W7F9RWTQ_[:S8_9![_3L@I::^2MAIA&CGB*0:4
MY_DA"=X^9YAQK782W_=IZ=F7^/Y+(R8O?[;+$M#_/1_HH;Z>P5_8C\C7)SK=
M%WAMQLC4FG%K5D!)I;>H7-7HFZ)<YZL*6++Z]E6?WJO+?_\RJO_W[\LB?IJ5
M-?6,>3'Y;D S^5,TM9?S55-]N>YD.L-??]=\O\3/+ZKXJHH7-H>7X6'M ^ )
MZY+.CY-J4O/*J_:2[C?AJV&[84J3,TV_[E9<MJ6%I>3R3]==2^Y[G3PC^E&?
M^>]_6B[V[D]3>%J.W%G_Q_L%&&X!-?22RO^Z36IUM6O^PWXJ.K"W6_6ON<2U
M^;U(HOP'\+J7X&U/&VE12Y"=*NC.E8NZ8'8R>^P:YJ.V?-V*:?YOGO;RXZS
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MB/("$X\"S4C,.=GD7$I(PIVX=H&'N(/$_ AC@YKI5+A+<?PEC0\:-Y.H6AT
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MZVZY=EN77.JU_W3=M>1,WO?*^UY'SR1_ZF<.;_FGVX^IUW>'QMDK&VX_NGZ
M?3WNZ.\G 8(ZUOX]TV1Z(.O\<8F:/,9./AR8Y=EH]]XVYBUCI(L81S_#[Q^J
MT8^Y<O3?W>)/&_?RZ8G^WF E?3BL0=#T5] ,FG9@@"^: ;8U+1TT[9-JVFZ<
M=M"F@S 9A,D@3!XB3/@@3 9A\D*$R8#5V&NLQE\/M9TU*8">@.+U9>]?#I)C
M7W9TFYIOOY7_VF?*_&*@&#WU5%.%40HAYWNI058(B9(C-& >K-_%1U#!D,1=
M0IA;C#CC#EE#+(HD!>XY\2[N##=YW;;#[\\)_U@+JX,%>VRK8.^FM@\^IJ*G
M<,]]X=KG$'F#&AG4R*!&7J0:<3IB@V5$GM"8T7DM,AK^Y1+UH"J(]'87@L'Y
MP#BCB!@-UVA0(X83 ;\F;XP!72)VAA4]L1J1@@UJ9% C)ZI&[NFY7YM5&SSW
MHTG2WV*9TS\>O8^SN&AQ? -\/;<SU=.A!R?^95M?]PRB#Y+^Z;(4+]MPD\Z0
MH#A&@@2-.#C\8+@%FOU_C5T4D>F=%B=J"588$^2Q"!G !"/K\I!!'#5C.OKD
M=["SGM1PTV-)#C?L]97AKT_3#"P_:*D>$NV@I08M]033B11E(E&-K.<*<6PH
M<M$+%$0,*48B--\9P>VH4\+A//XD3T#F$;R9D#A*AB;.*)66^V?54FIL3$^C
MU(.6&K344#S0R_,ZJK3]?9ZAJZH;N@@'CODB[#IZ1K.<#_-5;N'LFV5WZOFA
M>^_U%V/D<:Q]#$8BY:5!7&./'$D$8:>-\)SQ8'?'!MVC7?U)C3Q"QUJ>A)5W
MA20'.V_06H/6&K36H+6NUUH:<X-9,H@1(YL".J,#$B&(*+P7D9FK6@NGP&BB
M JE <@#=@]9B<$TP#D>X5TC6/K?6DIP/6FO06B]::VU%)^"7/)WF$&3L, +W
MQJXGVLYC?3,+JP8NX=W4SKK[/TQPV@%->NN7\XQ(G7=P?&6 M)MG\/AY&M5P
MQ/-%50]\_MA,*+]FU]<S/LMW\E_J29_K7UL$HVH](OY]1B7+3X,EYRELRQ4\
M\7)4#V&<7VP&>BYB'KCKEV5T5,',!JW3PIG=A*^=@1$6^07R8]=S<S=#'3<+
MG%0G,"34N.@*5(*+(>-KV #*W$LDO9=$>,*\"3L&0""1BI00<1GKQ4J)K$T.
M&14\QXX9HW<RZ)TAH=_7([KK6:&_-MOYTWSQTVJY6L1V%.X-XT/?_/+335;
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MCQ29HTP+I'P ^U5B@;1Q 3&JM.&,8;V;KKL/][Z>3N?>MJ@[._KPQ_I0CX0
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M/$?MLRHPEP"EF%9<ZOZ'?+N\;NUAT0COD)4M35A&6.N8WS*^I#3K#,AL@8'
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M5M(%:J#BX /7PI'82%84.9'D9V$YW7L$R,'*48#'9=9XW,6)5$E;G6-=UA"
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MMHZ!.TGJ!2.)IHP;P>B=B["4:8(<)7!#L3OZY7 B/B]!'J:"V\,. QKBMK1
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M$,14>\GHCN(]T@Q4]V*G RHH(UU4\EI/5B58I0CV@/J2T^$7[<*;TCE;"N/
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M-,%,0[3T!@4.Y3-EX%S6,[D$\P)%AS#<(L!9$,PU>"M?H^A<SHI,>#]4PW$
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MB6''WI?)F2^8O6GJJD87<P)X?SFN[:UA %%UM<)IKP8[6GG5S7R1T'Z77_*
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M)F)OQ!\H]HVO_8BX$^,9%<XQM_$)$9!;4;I.,4M-#ZD9ABQW=&6]J!P8V<&
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MMJWG,M(B#LIM'N(69&_5\LKM2G/N9KP956 NPY!@\+JCM2#]%!<N!)'I_O
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M6LBJFI.N,F$:/[WC$\7OG1JE/+8U)QL]84HR&P$QY%B^H:YF?Y83G[D);NZ
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M=C"UAS[393[@NC@N;];1#6ZY%,V\6[=,Y8N)1 T+_#73<Q_.=Z0Z/!).=.@
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MIJAN90*+H<U]SSM">(@]6\@;-:Y0M?9ZQSKP??[*.;=1';B>S/921E\<SY/
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MCXB(E65ZWC3?[3#*X-_Z@X@"CW'0"G22L?518,6&+%47I@A@?'UX33Y*XYU
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M5^Y4:)[G7H3AI#5A<2VZVAR)S+$'XP=#QB:#%/5Q0'2Z>EMH6P)05..9E"I
M&I< Z"2L!ZWL@-\PD26HKHH>(=D,[" C)0R)H_T\"=D3&?_V--'Q?7\$GI-J
M9 3?7RX(M5@#FVY4RGA*72*]&; .@-<*=6L>?_TJ/ST_38,"")Y,L=WF8<=F
M P;-;+ZSDJ"?'0R_'1A*NVOAI,52Y,=2?F%8F<"_OA8; #L*ZQ[9I2G8*OG*
M5W.D)5\(G$M>[=><.3QXA#\9/ 1_W??\)A#M(0[7XUFLE$" J98#*ILPG@C-
M>G^QC$Z#*6SFO0CX/.0UA\W("<?Z16Q-[_NE7"Y<0<AY^WM4=<79]"MB4:V7
M3.D")]&ONBLHJK9K>*156#8Q2("1U^8\JW0W"%6;AY<$V 44>J3WAU!EC19+
MJ \/^@^E_LB0PRV$BK:-6RRGR3M.^NHQC=WHSD-@\(U!W=L5[ZGHZEREX1MN
MBM'(:RK#SV-L7C*#46EOR<AD%%J@ED'/Q['<<J/)ZWY=Z9-TZH/?JXK6.'M:
M[#,FN!@W6+*JE?Y!BS\+P2*C=C1*M2;H9L<8;=.])6=..[FU@;$PC9->%D8X
M!>'8V 'UKFG'KN<%8RMM%+=H[,HV$CR U,'-JJ9'+2F.M?RR(7.-<=P\\>TW
M^I<,Q6[DD/(?A2/6]BR@;A7,L=;F0JB$ -Y>DP\LF6,TOB:FI=B:LP!?%&LD
M^@]D9)P.:8/;'+#&H6:PP(X;:1WCV#&6&N\:6F9$HGA$:71<2!W? L4Q7;4-
M+V9%^\R>45W:R^A2P78:4)_S1L=,3SY 9DN1"P_#]287VAWA"A"9#5P%.(*\
M!=Q:0/HT3GL;QVG_/(W33N.T=W:<-O;FJO"8S;=*^K1FQNZZ24VAT9+/-.3\
M'5<(\(!=SWVV)ZSZU*3TLS[\F]\<;H,A.+[9D)ZNJSPG":\/XX[IQ7:'LEL*
M[B@@*G>#D3,>F#,N3_I[T!-UM.Q">8,SK(N/PL\T^-9XR,VT8DNZ)EQ$SE';
MK*@<4TN+;YTX=A6+\))-C0Z ,7PDLZ;.T'%EYA^% $LNQ;D3%PQYW*<J^J2]
M7,YIM](>IH/R0 \8QV2D>R>$NT(AZ00":'&=*#.OJTR=)F^X+V%,O1="5X,#
M^*MM<L<YJ%E7&)'RQ)_G?[%2J-P='8I?E+W#(+#F=^U2E+KB>B9SP_<R-%O?
MS@Y I53E0TM1*J9%G6OLVR(%E0_U(4A,S4E-5K:UQ:'^V#TUV)Y @V02^E5K
M@<M[5T%9O*":MN9JC)58"(OQ*B4$GKN)>--&[[1/+E<5\&OQSVUTP0BV[&(5
M01X]-(3$&:=\_?74YO1?K$"02A9$!L6/BBU.RX57)ST!$719\"(PFRS9'.6M
MR10;,X$530M09"L9RY?DE6]0RJE-EOF"Z9IX_@^>(L@<VU#1VS-$6&T%*Y%Q
MIAITR+Z:9S#SJ#1AGW%ZQ\RA@QS74J,>K5*P8OILH7[$N5\40%M#?0<<AW@4
M5PL0C@C]+FKON59\]EJ4&9R,);LQL$#N1/;ZP-\;\:ZO**G^(2[N\"//6(>7
MGS"E0\K^M>FB-["H+ZO+K&'%+?$J6/)2<^<B/:N82*X9',^]L39FVQUT5PYM
M<GWJUN2KX&5\+?P:UO6QRE7@D.4)'GYZ4L1B)NRZV\1E(CG\N*#*%TWA\0=Q
M*2^J>0.2Q>J\'.UV*7LC]A?I\F"+%$%'C2W<?L.Z%D+K34O5$%X+(6+LL%:X
MT@70@<03&LHT>5"DFZ_ SE>=1RTEZ34;!\%8[76V8V9SX0T."0N$IL!JW63H
M17YIWV%G.,#X]$X3%:,DBC)^9H[1A%,PB$Q9=8E#/\]D?,7Z[$6A6D1\/WP9
M.#,7W/P145RS6-''/!57I^R >.0IL_E4J"!FOI7HYK60SW/88]! 5$&?/3D[
MB:]J*"'D&__,; @?&(HQJ)>K3\@W"+^EL90S#-"-JQ]X:7A-)X/7%&\P'MKH
ME!U.DU=D^'38DM4$C^#PC(D;I>5I]69^S9[S@O>6\+).DY<4? HQZH$D)%:[
MTF)]MZF#47WNR?B'1?]).X?2L])2XAX>%W)U']9;HHU1Q9%<+5.X@F4'9UL/
MVL+A0(DB$TIR!(M=6.)MA+9?&<ZMI>B^P"]\;/,_8.YNEW9GZ:GT.+KYN$I,
M1^(P8E"F#DK4ET;FZ, 3H^>>MIW/?]L1%:60I'+OH[$ESYL+@LT>K-?E.@=L
MS%(4V5ZXCZ-XEH,_6[*2CI02>L$9_656T*,ZCS:@T^0=^6(X0=NUQ*T=X_=3
MR7SFUB YZH0:.^.7+CCK/Z:VKPQ1>$:$P2/5K;L1VC6[%LV8>\42_A+EJQI>
M<T/-.GFI%RZ0[6EL:(@;6&.7X1 U>Z+;,/MH^P'M/JG9:95__MM^W6U;C0SC
M&IC50OH +Z>8H] ELC@?&@90%B[[<*,^ZIM*"9@GU>LRQ <XG95SH_3EO4N9
MOOEB"A<()_F:5B.S8U?#A+F N)QNF[1(GG9-O:&]YW%&*R,+3LDA+Y./KS*Y
M%%Z[.%2!7(N5;;=11FCQKJ6!70O7T7\FU@?>)TKR K5L7O!Z ;UBICQYNSAM
M<,MMD,7\M6*73&OLZ5]3:[4'T; %[DT$+;H@QRVL[,$+H%]#=J9H 3)K73_=
M@ :6Y2H.C2]<I9:"*]?',4#XQ2\^P)3@64!ZP8=PXM8*1"[H>@4D'0JI:/<6
M_Y/W^[VA>U,&DRV,)-Q?_J5+%MQ(3"A4UN-GLN").9I:EZ(<C'U#]<W::A<N
MMG)@77ZZNI32_LODL1VQ*P<*'-"F!Q(RX[)PKWMF+^UUGR:"2ZKXJ* )9")!
M:N>B6*!B*2=@#(P$ F)*<ACENMI&>QP+WI+GZZ]^IS4JVD>\6NV=>4>@)14#
ML\G&)<B!4/?(MD8Z5G,^T,.)UM_9?%XW"TVH76,)Z_6@,[RB:N/,B/XS7W@B
M+\<)/X3UZ$_0#@CA"PX ',G.PO?5$@&$U2![WG=S_W+8C:CW,DSOXG?7N%Q2
M5;<@2$2V"Q?D\2P>BWDHDJ6WV4G':*OU<+:,H-WA+"1J:EX)%D-2/'8-T9WN
MNR]8E87L08F>Y9._*%/Y8S9,7SA=!!_31P"GMFOCGM@A=%I?1%=3J2%LCUWG
MHM[X2 XZ'E'-1>;GS,'XBCWW,%$"XYU.ZOQDR:D!Z%/3F>M]LR\?83+ :%.5
M97P%?YSLX X!WU^'[-^(]0K$]5&]%0JM(0-6683HYF)D+9C:G=\6PY:Y+@D.
MARCTU6/-O0PYX_ZDZYZK[F$5TY0S-,5-QS@LZH22_R)V_=CF/FYJ2-*KHDM@
M=T-[@R4BS$230!A\>OIT*=>PN&U*E]1ABJ9K?'M_)!L.P+%PPK+%QC[5;_%Q
MIAAAV-\,+G9>9L7:1K:X9V$JH(*X8-TBO0H8=RA39J!D!@Y?*JF_! +^:GS1
M2@H_X?D$$<%4LQ7K:%NP?FO=\H20O84(V>_N30C9"2%[AQ&R Q+/G<X>%.=A
M0=68PKFU>+B1BO^*]R9%FFE*2)]C_U"9:?EVX/%U6P X,G3K8WRCO4NUK2'4
M?W8JJ,AG>2RGC^W3)+C-;626TI5Y[O1C.=-%0\+T"ZMX8F2<Q9>^LK,\5Y1F
M.67BV3 \TX:K+HLFNY3A>*L THV_S<^S9E$&?#RTIQ=RI;RS=OB)S,*FP]T8
M)V5DH=\@%SG7I=& =YCGP0C:/[MF9VC*)M^HHERJ,!SNM"]SG32S%A?>XKE^
M+TL6C"-5DY&9.SQ%Y?YIN7AA8"'50E>M.E<D1.$NEQ;>I;2L:ZUK2OVYH"4C
M3\*FNZ2!W#6-])<YNAZ&53XXMXJ<U>V-6EF%$NW)M%NMFT=RPDY?5XJPF@1@
M)HCU=C&]A/J@@%^9'I1+A7MF^8L*U< >O7X=KH;AM.#>5E6"^5Y_FW2'_"A,
MG-, Z@).</!.G[[X//X\ T0R8#VUQ\@UX$A"L5=[#B$18\\>$JKH_PO-G@<-
M^:')'MK5U[Z/R[Q0)0O+D()88#CK%DD6+6^[O;)F?S3/NM;P@WO"6ZVH?^;<
M;2H8?'K.>M2#>,L9UUN/_W_NIX_?NAK_YTJ[_TA)]F<H/[SOB;OO39('2%K+
MCN,FI6\:^_:/ (R#F=7#TT 2)<CH=GI@;CO1HFF<KT?^G^6+L*L"6)6I%C-\
M8%E.=:(O(OQ^'^I!1%6>*(!. Y9\NJH/V3G_LR5S46X:] O!,L6?\_:T+5KY
M?E.O:]7K_8BAC12-%_Y?9Z$I4(&TA\\Z-6C;WRZ$T =?YZ_%7"VT,-9%:Q%?
MD"#HK L:SWX5R#!09IPY>EC%Y[M?M 4V;@3>%Y(BA&1E1H]P)/&!#PNQ/?.T
MN9M<'T=OHK];9E4E 7M=G==%J,8I,5I$9,(AFLXW#;KI&FL*3E-X5:)&5WJ,
M?SE-7HY[$@Y/&5$[.B.F<(%VY%61X;^BU$H'H"C+0OC('ZV[5H&8&Q5E8EBT
M756$, UUZNE^L^BY^-^$[[WAW(83/07UEO7YCM[4*E_# G?C54UIQW.HCP?&
M(2R@X5O=LHTS,8" !N(I8P^GH]"V#$8WO::VH?PX]Y3\"P]&)IT\F=7M"N;N
ML/O$>\(":R@]E1U349&BL:ZFSZM+(O>BK4/^*S;]X<<R8DGW*"A@E(M,\1[9
M2A//#L@Z8)99[\V"X3GW$ZD.R Q!"P7UK.P<VD+3LI8O9V[-?(Y7JH4&#W[-
M8I4QKXJ?9@KO7%E?9D&IPO'K"LS9)29!M45).V8U?4^X5?+!)8@#&3ZRE*$W
MA>?Z4J!9__>821(6#P&<"P.[@[5_4=W_F[-E?J,!7:+Z:'TAYUU&*2X]9*5I
MD?<"*U*$LOXP& *E W@R(GGU.N_LOL6*))Z8!Y< I&%8D,'D39/+/N2L9' Z
M5W1BU%P+V6GZZR[/5!=:HE1DQVYD%,<Y= >:^'-;";;KZP(LU2E1<4CFA%1;
M85I*R4<WL5P*5DN%W_1J5/*3'^1N(Q#&<#>S^9)HYE4+-+*I*^S 0?)P5Z_"
M)W,A*@/P&5P",FAF;W>2#( >LG"_-XK8,^:AK8TCC&J"D:L@*]:I=73J M-P
M*-4>2)SW2#]Z,SCN:?)ZJ9I/0*EY<507:83YU-C>FDJDE27M&O56ULMAF1R3
MWHYI?- CS)U%[$F:G%4X$.RL-]VQH NODK--0]OZ@X=I\N#>@V]3[RK-!>IV
MWHX3/SG*J.]1B-RNQ-<IN(6RH5S*MAR3;K2J2[ZL82I#>JZ_/G]."ZB9U1*[
M)#^_/7M&IFHE7SI5T\!")<2G3_@+__/]O7L4>&TUVGL!4 V%H,(NR>=#]3?T
M#18';X/]#T%]&U/JI?T07,U5ID[K080NGES^V@/C#T<ZA_1+FK!&T;"U=Y=9
M4=JX 9-OTEUA- SE:"Z\]"^M6*HA"RTHJ.74>;DUU[MZMV@;3Q[J'Y$4\*SH
M[IXF<IU8I*RB=U1?CM;WXQ': #XT(EW<:S/<T4TMFM'13(AC(1&]T#E'7AK_
MS&U<FCL5/- 6S#\'G( !\I:C==T+ROR\:/5SF&) &7B1NU9.'8%Y1WM*2FBQ
MZ!HW08K>T")$"$6Y>G^+Z&W0ZKM.DV?HX'S,X/(8EO:2G@;YJ0=BI:\KR8:2
MQ]QAQ=F>?ISG& J:R_"T>EMV:-Q<H.?TIJDY>7R]H2VVXVPZF"^0D6HFX>!]
M!AX"Z+JU^54>I\:GGL\6@T^+XGS-XZ=V33PH&'I^)*LRX_#O\,<2N/ I>&B]
MS6W1<#PM%]#P_SH?\Q&7HXP90@D7*!;S$>7TB"Y[G<AM7>9>SUBR3V6W:%?%
M,AC:DK8,K^H,J$"Y*#\9$@P;<\L-5]6M]01P4'(ODFG(^%A+)MHJ]5_+4YB!
MO<JP  ?PUNMB)63NGF -E&@ZCHA]NG893G@"KF,Z2^X48.BV-GPD::(R20&_
M^G7_/19<'50I#R?A82![H'OI-1XVNG!0A7L?.MGKS>Y90VO];4?;58,6(&9*
M ^MC-Y_1VI5M2^U']D;:-=?Y9=U\X*VX6'"JQ!,@/L;Q\\)RT'*T6&91".VN
M98&PSM:&<<W0"US9X 'O^Z-[/F@B^285^+Q \),WZ F+\4C\ZA!2VK_FG^0?
M5UG7PDR"P0E_ELWU&6[O:,_@QN'X<<<284FGX_B:7+#'R"@>*[?%%E/LR#:$
MJSK,^/]_]MZU26[CRA;]*Q43Q_=($>@^%.6W/E&49,O'&NJ2LAWW(ZJ0U043
M!=3@T<WRK[_[G3OQJ&X^QFI-(V+"(Y)5*""Q<^=^K+W6OLKON/!&%^)0/!OM
MP0RKB;NP;:13F)FF3JC;IJJ8F0@.'3A?\HR*:,2D>D/GD)L(!3O36QW-O$?\
MO;A%/&/4=Z+:*K;(OY/OSLFYH[O>[8961PRH\XV<DSIT([MKU"&!L&C @AVL
MEPUW8T\6ZQZAW^:[M_9-V8^ZX<9W4/ D&RP487"CXV^M#IVJU,-[@*,"?0N-
MM@MLY$CU;@L8X;?5'_#O7&^^CH&%QH<4:8(+Q-<J95?Z>A;+MCMP31F'*!(K
M=,DI@&>N'\B*1\!,:W\FR:2 /P9)9 /&7$3&. DOJ&;<(?5J*5F=#L\1#2_\
M2*\!*Y] R8TS0X-\CG&9^)MYG.60HQ2,.7NT+FL%4SY&,.47*YAR!5,^63!E
M9)#1.)\2W$QK*!$;OS@L_(J/3.GF<PUATGY,:QKCWX!(^IQ6DA?H2VG$F]%2
M*1%2(%24KR[]\=&> ZL>U:I']3"SP;BG".&X//J^Y4@SQ3BO$GRKV7V,V3F=
MTN5FCC'&&L*4E14PO!=)]BL:4I04:#7*U2@_C5%*CKY3Z6GN.G<A4%,>S5 +
MH!92F!WC)\UR%5,>\'\-:3]O[FU SAKF/D6J6+QAE&NC2@$C[V_G24B8Q W_
MB%5M*<@F$<^Z-=:M\0G]]:O7KPEHPRV$(W;U(3L]-24U?AI'8;$];]Z&,VP=
M+ 7YSV%PW4TX5"!%*JG64H!WKQVT3OS]5ZL9KV;\<=%N?M,&YX>IS ?W4S&1
M/M46'XIZ(0*C&)/0-)NW9B6$7\2:VAB?_]?6#?0LTLSHU)4!'!Q0@)A%8L5U
M[FF:20*]GA#KUOJ$)T0"EN\<O(''ROS<8EG/%71B.(2;9:C=/HLLM!#\KR?"
M:K:?.!$U6("X2R/B&DUV.E;KZ/=QZH@T5J@Y)B9LL!/1/I'6G8T]("(P_FI"
M.(9)1PSC5V-?C?TCPQ_RHYMD1D4 05)(9]-CB0Q5S\[=-U*F F([4VK*.Z+Q
MIW!'^-6IMYVS0I)G("A*[(J'NG>*Z#)8DN!FU[!D-?F/\N]EQP%_'+(BE\LZ
M#4)D(6.$BI G^Q7I!X8,K%:X6N%'.U[&3@N0<H$(9B2$/-^4$?J*<<0]NJJX
MZ?/%,CK5:DJBB6!*U-725TO_&$M79EX;7%+:6ZI)-!!Y(!K63>)\A?^RVMQJ
M<Q_G7;'_A]-5L8[&",H,2<=QU$SPW8+KD($RUKAL-SR+[;@>W86N9ZWSZ>!W
M_B&D2;C*Y]!'&&8R\WA)/.1!Q 37FW\<RBKB:WXYPVG2>1,-V)%DYUU0)5'F
M#>]$V"99.!D58UPK$= +7_QD#D>@Q\K,_T\XZKO"!MLBU,K-IQ4%*F'0!8T1
MH%BB??:,3<22@7$P]FIFF)MTD$-'T9H3]D0_9%CYETBC](&4+L+KBD6=OMD,
M?2DB7&=U/&#[-NR"5=.B%$5(8@!,IQO9\8FVY QQ!Z-WX%2[*540C(5 ]'*F
M_G5#<]3<1/;_KK^BA('[O.M#FPYZ.3.5V:ZF3:!V"X(.3W/60J?%::1<1L+G
MWG-$'GX':[[Y"3S6VVSS(\[<8%#_FE8ZVWR-QWY_:)OAYD JBOF)A\!>.)#"
M"YOKC+4=[2<%8S3X3N18OVL:,(1O<+@,+_2RZ8X!:8]?[-@#?O?-_Y,?3U^]
MY+\@+G#7\#T-;3?DW/_B:78W= V?O1G@]:/2,*D(BM5[DY,(,BDB[>EG7XP!
MG+/T5$2( H$..%WB;?%S(7Z&WR 9/%[AN#N9%-JG2>FHQ?W]N76HZ>=_['_P
MK(JZ6H+-H"N"X^Z6)]9&XN;W>]_1L.J=^X6X267J*9;RES745V_HN6KH#()M
MO;"41%=+(Z\46!%XI$?RF6(^,LR-O):F%/?A"MPD_'L0 4$?Q=0XZR3E;=\:
MI^*X<R ">3$24"(TI?AJ,]3@)9W0:B@T8BT[QW:Y\?Z?&T613"32UC2R&O1M
MMPK9IFNHIRKZ"TK8FE^DK\#%&D4!X\M&M7%I49V;(;;$\(;O!%>_(ZTEO<&R
MCX^$+]&X!!;>(MQVV>MM=PZ&X3]#@70%:1LA(QSG5FQ6)!WC&0K]U0/__(^M
MF2-QK<@V)15V_,MM ".6L'.S]5%,+U',V(_V#0[B[6'_;HF2SD:4:9Y:QYLQ
MHTO()UG4$R_PH%]9H*V37E=DM4ZUF3;))M!K!O58<2<28T]T(+.W)"P?HV\Z
MAP?/5\FI0NVWX[:4)^"JL3]P>.*&1L:;=G1-'M(4DIR+[M)Q\:2>\X2(/3
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MX)TQ=!-,E!OQGEW-D;REN4#ZAMW:9]IG32C7QY\BWDD$ G;]M/'P>4J.[M7
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M4XJZ:OG<+6:XAO@5H:RA!B:-_Q&CF::H?:9_E#W4AO*XQ2+E41G72L+LR:?
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M2A7KP*_!YUW?+RV>D/0*;S157DDP'51"2>IM-&-*GV^IZEHRCVM\T'3A/D.
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ML<8P8QWKGG1$P6F'PL<]J*_9B<?&\U<36M'TW8.[A>/K++/7'4M6LU.^ASI
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ML!]IXW..2DU&!]:&VQ(GU ZI?BDL:G_'P3,WIICVS"&Z%')K?!X\V$JYV#3
M&\D<1^"DXE.$I(P7%/+7/L'$5+"2E8Z!7TKI<.":&(MVB(G<"!@_>0I*#.A?
M]?U ZEAK%$#C=XVCFTXOP ^88GHX,M-;W7*:8!%Y%JM.K'\C[YWG^>#6$4[-
M!&G)K"7<^AN($SG:^X/2B%(B4M+$9)K*$ALF40/E$&H6X0K[.S1QB32>R-'&
M/Q@S!0S12%1D,KL@)N^?$CGQE:[3HAJX@N'!=9M(+1ZSJQI'A?\UPS0GC:2&
MN&VQP"^:[!K\4V$&GBS4-_"\-5/@TJATB=TIY.EKX!>W);A"<">Y+"GI?T/.
M$<<O#*[(-^ W@X9S[@5$%[$;*B&*4: C[4S5!\&_^+[>5TH4K"F.DI=__YHJ
M@99%/GO^7%T$9@KSFY:6E^?.D1'O&]22MU^4YC$^TY\'V(8IG>^?__PF2U^&
M$1#X6MET+$66^N4/;^+^[&8!\U_3][30A;DD/*3E>_K#HM-.&YYR(B/W.H!W
MOG+$A)A_WU1P9#1#NPL>V^PFZ+WB>8[)6 ZK^3L.QS>?0=[-_X7_;$_T>;JZ
M_LXZRGOQOQ0K@KF^!['"3CV>4H:=N4<K^3=SWBQRUSC3AFQ7\F3P7DY@SOP1
M]MBQYH0ST?IP]"VZ' MH"?VTZ'7MC*4.[833GEUS"D;-[B[-[V4RH:&FIPD1
MEY];HKC"J]"JA,+,HX9_P;Q,K9=]SY?\0K=8?@BQ*<$)]//?9OK/FQVVRPK2
MB+>5A2/_JH CLSU23WD7RLK<@ED3\S-2Q1EBAFZ66).)\?VFIEQ_V5;UJ?!N
MB&_LADHON!*Y* ?GG$*6NJ&G=5R:6C?R*"ZZ4A/KV5=%4P_P]ILJT%]\\=7\
MN E6&\JZ%O9C6+#?4&,]LD&!#9 SUJI*G)?! 8)W!*UN!BIBGYH=.4ND,N$S
ME^*)>H:%%"L990&KF=DQ18,+2*32(4$#GQC)N3X=(?KBV:]P@>1)!&H=#.J7
M'!]$FL@[TDT";8/ZMO09Y,GX/'B./Z-%N=G/Q6BO11 "UNK,>$YH7#V_FS?(
MPT*$L.@Z__R&T.)VGA\3RD+7"-$E0NI8[D/@ICYQ>$:U Z4OS&PS\?%1:8G@
MAZFY[O.RFF.UQ9N>TL7=YBTIQLRKK2_(=(VV$./FNX@$%C.02,OCYD6:+]($
M.RX#F\OB-HL<TE3"CVN%8R;T\&34>JC2"XD+RZ6VGL5RI#A&UH4Q,7'H4Y8:
M=P?6XUP#@UW!R!./VE?T]*V5_2OF[]6590Z6I/\RL\T3NR%U@#^_B4&!1>I]
MZ*0SA44BF@-JBB"U5PT4 _(.E1AI^#<(KXZMHL" MCEU4=>0(N+.3?K8"2$R
MA[L=>.J6'+O2L60B((0I1YY*"'WWS8N,.5=A-]-K["'GJDC[&TZ ([//]&TI
M[,M5B*?3D7[8<7(0!XP$:5V^#\*F1,^(#+I%WN?QIV\:5H2D6E@2,%IAVH9D
MXY%?-WIK>$)H]UL4CB VUKPO[ZWX%S0O<'VHCMEZZ)*Q#8BR)5BVYXHCQ=_<
M4?5YE3P[NXF0LL2ZG(OI.IMJW"_T@97C=Y@2+__1B';L$,S2_"B+0,+,+B2O
M@Q,QX<OYB@E#\#HQ<(],5TXOQJ0#YOA-OA+WR5N022MB&,21%-T.IJU?2:K*
M=D7)P5"]=:[D<14TGVB7[!^1WI0F!F.).M)OSY#2CIJI"5VX4I=42>3B+VT)
M7&/MUTGZG18"E%B6PE2)(+5%ISH1U 2^WKR4*SKJMW'K-RW+4P&D+6^:MB&:
M;CG.#"C.&:*__Z*YJU'VEF(:EEDRJO"=)J9W0:1W@X3MY^BJ9:_R@3R#6L!-
M*<4]\?K:M)YAL!6N'WHJI?<:I$&Q#;2>HKQ-F2^)D>BZP(<'.KFQULNN&?O8
M;!)&V]LK%H3HNAA'3S1+GO#NU5^^_>&;V J?\M8\KOW^-+?[7Y<9YF+%)Z;6
MI*="VHPG+D9YCK<$:,(7$UXX)O:7LN6QZ6,/43CA* (:(]NUIO>/X$AY:7?=
M'0(9O=N"<ZU\=0Q2'J6:AWY58IU4-$,C>,ZB8;>?,*YS?.];O;A>3*(*@7]H
M<JTW(%Y@@::NN\2I5Q)G=2:A_BCHC/U,*U.+\ 35@*R]+^$H/&=LL>O;$LI\
M^H$TH60>0(I)V7DLW'\BC*01,Q-DD@O%EP_+P"DA/6"5;T.E#MT%AQ052W0<
M6Y[>GJZ?YO:TZ!7<[5\&\,B0Y/PZBV_ZS7#"!8(W#A\D]TV2+)C0(LP3-0GH
M#*:WCEH8<;SDY2'<MAA/-SM\3T'+/:;0A7O2T([(58WQ7W )+3H).!CKW2C=
M%).[WKS <6XY5\D42PR(=Y2 $6?_PK;F%HUNN&CL*0@N",LKW\-Y+'6 L#"N
M4V/ V7=)89&T4OE&-%R@17]'-ZKF9T_)^K-<36N&7LR;R7QVT6M8\6_Z;D9%
M^F0IYL*/*&Q#31FA0.P&XNX7/D)U80F\+GGM^@NN=5 &[Q92LG<R#BRU3;V&
M:%6 0ZI"3MD,%ONH/JR(9 'V$2=AIO7\=CCUDZO5J(]2):3P_C8<EDYR3VDV
MB6R$>S%[*@BR=L1)U%2XF8,."3(3A;B0/<:#!-X,,K!*G!CQ>U,KE<C(-H*S
MP2V5,OKQ^Z"3@4K .7V5WGLO!7G7X8KVNHFB%FW9B1W-L!3C4Z:T_PS#>5_G
M^(2HH/]DZTU\/]C^4_-/:7I[@<8)D:8$+IP72^)N9DIO:DZG(@VC/R[ 76F;
M_XW 4!9ITDJ%/\Q>YG5>Y F@FB4;M6(DUO3MWS++^$I6.TD*W&ET2VHAKGR;
M0 _$W"CF$QAVO#.]OJMJRB#>HKC0CHNH#!E'L!JG?[!>&P+N2!,?4M-3SX/Y
M\PS0W+N*J:KQH*>IN2MF6K!93I<X2O:D@I8\TI+'4A[7&H6R&@==I)."2?%5
M.N6R&$_31 VG#"8&B7_,3U0&_WZ?/L.C34Q79-UC1-9]L2+K5F3=DT76I4ZW
MX]$<I[G;,LI:H&T,0F@1;#'4#'LI]W9@E R= U<_U!VL9;<G#>8S-VP0M>)E
MOSA=V :2.<.N[H\-COSLL,&%*MS-$;*S455+&F@4$8Z35NZ):-$5&W1-4F."
MC5ON]Z[H"F$XQ)/;O(4CK171U3VG[%'>,<R>V9F4PV9.<[P*+F^)I5@^H=,3
MUMK9?/[BD[^V_%PO.8@VJW:&O_U;&KC(#>0MYC,5/TK4I<O;;=E3V5L!?9!+
M7U$XS'TP N;(GT?7Q7A#5T$X^+D.3N5M(BBL62$-9:*E:\S=AOHL(<(YPF/2
M&)P'POQJ> S_A3JBY/^$EMKGMPU'0>FE_"M)F ZT8!^1F^4^5N\I^6U\G'8M
M[!U6P8\$'U2H&XOADJ&YD U-0!-M7<J%WL)T/6BK>.2/+BG&I/ZVVG&+;DTD
MEPOE<QJ@'')SU?*LLJ3B+)P6IH2ZTEMVS2EMT?#,DO9HQ$51\S=";+0VBLHH
M!.J($[ESFD)F]A>SWH@#4KTY^?&TJ4VQ=I7H)-L UIKC_A(.Z>_W(ERI[3AG
MGI<LA/,TQ/,5!,;H0SJUQ#C,B?QV/1P#=4]GI7-QU V+T5X)*<+IX0<)'13%
M/KDM^IWH)[UL6JHJ_FB:N(J?_>[ECR\(]W HMU@HU2U"Y5@/7V(@0A_UB!B@
MSQX9R\F];$7PSK0-B>2:_DM38NIL"P8'':E\ !T!(7--CALQ&9B156?%9O*?
M,F8L.9LN5$/('XQ=3AK&R!V1<*_L;D.0G8:6,><,01RP#B^.*-^)GI/4E[4M
M%<6/T5DQJISNHNM*J5\Z1$SC(JU28PT9L,:V&/_!/@)_>R-_AXA4Q *=J$6'
MTNFPIO(2X14QVDST8T/G:MUW=(J*IG8IRB8(1(]=_5'5+C4[8UC8T9$FQ%B*
M^(J 1SX4\5<)9(R1/BM(-,U;-=<=+(_2)N_@AN#W*H8O[?.RI:+TGN9A(:1@
MA$R^\]*B^@,^R$Q/"('7Y5P/$6@[^%\L 3-:1VX+Y0<*N'E\_:+@16]=5+#=
MTUJ4M&_:Q?/HB?;27HZ4>'LU1T@Z6$U5F^ F_I<)=0-XKI:@8#%4PF85]6G(
M&<DL;$YV<U/#G=,)#!'F<08O2+\J(O>=^PG?7!!S'P6SL;^R#:022YW!8XR;
MR92,88OVCSC10EO$L4XH79IF1^1';M94OK\)L&+-.<A&U/(A]P83GV5>E+ G
M(:JTZY[0%>]"ZHC;!,7J6B*Q48FK];B@(D\TAOB[9)+,3NP/=&;='D\KH9<W
M" B^R:'3_=5!KE+*8,/E\$-.NP[V@9'$J)N'N[VBLUV=''Z>CD-L,#*N'&LY
M++E"C#/F>_F,.>LQVB5@AE%L+=8==@>N2!-LE8L]>)@TDOTEB!6:WL85<.9-
M]SH;$<5$ CP13C;%EI.[+:MIF-HWK_QQ"P;4,-Y$;STZ*LH&X(6H%'H:![(;
MVH5[7D/9*UE!FBR\1TS8.TEL\19^+/X]TB"DJOB$65#:?:9R BV-Z 1&Z;5D
M- P_X8I)/,'PN/S4TW13&&;B\,3 DX;>!,G8XEY+ R2+9$^66*3 #(S7^IQ-
M@4<JJ"O8TGQ/Y7C3*4V/I!P4BF^Q1%GW;-H.!4 ;/2=(-T?(C!UQ(3!<[-MW
MC"AC[I6.D0GB&=]\^S)C3T-(+OI9DN^ 7X28I!LB.46;4Q3JXNM&DJ/P3B%K
MB9)]A(K &1S!('/1]2_:\I]0'>L;QN3PX1$Q1&0[.FQ%K>$Z(#P0AUKHX(0?
M-V?*.DD,RN%R\/]A  Z50VUDE=SI+$[":+&D(,S-<-M<$5IT=E+&> M^ZI:J
MT'S'X(Z/N)(>.D1('*P"3.'4DP FB]@H&@A60!<Y_+Z3X[,.%>Q,GAQ.[H3P
M(+@#MT&2?6IF$R*<(VJWX14Q-S=(G$@R9WH4J3*S/VU&70UKM%] E#[\K3S-
M<^.1[8R7QFA%MP&; W(M2O'QR_%4(MNP?-'#[. SIX:R6BW0(,T41K-1<EN0
M=026ZSK%3GHL7<:'R!A>&8<=$](#!+MA^+T+WCP39#@6-!38M\^[@R+;J))"
M$2JFLPD[Y3BWH!^M\E,G7*@, %4Z4X%PF>AS;T#L!-(8%P$R;IE7)-95\B1)
M_5OFO")>759;@(P(,,54/&E."KBE#BRU@N4#<DZA>*+[2STGOA>B2<,(2[:"
MI(IBTD2<<"N(R;QF%^I'A[K#T./,C88G.I 4W>P(;\OCH1XY[3SR76X& G]W
M$YA?S7Z#N3\Z<LN8_^(8$_P;#?T8%0C:L^0UD7=S!B7M^3?IA#I8DZ^BL56<
M,F+^WEA[(3:7YA3_+5HB[Q=T0 C\34ALW"IA_;+37OM-:&*!&7=RU6RC7O@.
M1ZG;NC/PO_I!"B$%GE6:"",_)'H6(K5EA\%.A7]P@J6.]TY9);NS= #!G>(V
M76209<JW$UBP)'HTS8!;T .WHU]+LSSJQ:'6&(UT5>J,=<J8RA+>&QL07QIW
M,\O<V4FM![F"BN%*SMOH>"S5\$GB@0%W4H%C2%T\8W8YU^)\P9YKZY7](XY;
M"2$THP;2#L\3=3A@+%=B"]0_H-)IL@L;VA9[))?U,2?EBAQX*G[<V52H;\NV
M$=<A8PIT":K4L"7"[\E%E'9['+SY63FACWB#"$DC&%#R7+)4>/!R'SJ.*XEP
MUQK).,B(C7T-41V!-$,F1Y#ZA3/P4+8Z 48&^#:<XS73O3.)/13BH]%!/39Y
M-NI'FR&NJ,K'B*I\OJ(J5U3EDT553H?*,/81USI3[29O'(\8C+PXDN#3"_(O
M6,XP5S.P;$8'YKDFP[3$G<R(+Q5E)!SR 2D^[31AFZ^VN$0RHCDIWRQXCJ Y
M#M6-<%X3'<$H9Q[H&LR+3>*Q-#PG;53I%0AXR9_;&$/!V3\$&05T"\? 3QX.
MH+:K9Q>LI&",^5PFC @W;L2(*D$]4C.S($U1M))Z(_-0+Z-ZE-?G,TR%TMZ*
M; @<9&,,[X?>VOP8[IKVK>32PD>IL@0:RN*YFX:!TOT1+JZ9S!1;Q), E[*$
M![Y$I=>T=WDQQ!ZZ9:+\M7([#^&:HX5REHWPH4,D_1/2G;F>(P_@RGLB@W"=
M2M3PHA<;FQI4/H(\4JBZ7'")$(5/IW:P8@+_C50ONOT\(ED[4H0)2?$9!NL3
M_$>F[DM](5ZO:JA\\6$VZ0'Y6,2+S;HJAV#*F"EVH: <QW0]X#\J:A43**:#
MS^6H(M+CR6!)%P;M2&E!\LOYO^ ,PX=1#\57N\L[Y";9O$I!DF5]VU2WP7 ,
MR14(%5;EQR-ARNUZ"0?; 8GU]4<<WY-]>O*3S&O(Y%/NQ^@&4["!G-%5?'G:
M<E? GY)LT''G5D&:)[,K$,>EC<.0HXFR>\NL-/!N(XP#_<,_!SJ?.&+Q%]9A
MQEC76_HV9Y<46Q")%*S)9+W="CLG!D9&_?M<535Y6%PO5^1', DITE&)6;6%
MY0HHL! **2$)B,&_0H)6VER+$=[Q0L4ZYLR-##43Z 2S?EJ&D1<]@;.E,H\O
M(Q/":N7*>0R/G0K(#"T1RQIEB>Y;9K#CP1/XN_XL?7E/CQ(MCZ+0G"-2+1S;
MMB07V;3>0UYO_D; ."._X/:]=[8+GE6)M837A9!<$%@&'C[AVV]8 B6]_00L
MS22$Y$ X1)<QF6+6N\0=*^U=!57H'F%P&,;2_T2)&0'82E&].OL]I"._C/ R
M$7O%(Q]#4>:&@8V.A5"2%-C.W R"N(19&C<D5L?A9\XF;/.V;H1UHF!^</Q+
M;:OY&]/KK-OTYW]L\\8<KOJ^$8>N%*3(#F0D[V52!Q._Q>Y':92/LN.)W!W/
M&#Y@%Y!'JH5[*>19T'PBI!$EN0(TXN"<87W&]FK;E8\YA_JCW@$=K;LJ+X]X
M25Z&KFMV3/A,MSB<;G &L-/$<9_O=(6:UB>E+JMD") &8W*(*S:1:L*R07/,
MG.F_YSL3C\%PGNA^,<D_&E.3D8-X0D5B7S)I%,'@!,#M)H;/!YMTXYTG"E-D
M?&4T'6ML"@U2_ '\*K/SL RO#3T8!Z-2[41,IMO(%(@5#5W"'B1>?4_8A.2@
M+!UY8=^\*W?POPB^I7T267FPCM%UL+L0TB%W,'3"H5L+-[QQ)4KNL6%9=SL+
M8\B?N:,(SZZ\*)N<6=%CO+QNC)_]L9-X+['L! E*N\!W9Y.)I!AU26'M@Q)C
MD[F;7&ZAM$-'&F;O5-MAL*LC-4[Y^7AP'8N 6&SD]&>F;=E8X1GM7?J3G+4N
MG'HNC!TCW@VQ.H^OI3,N2\M/@@-1[/LO>HL\H;JE#$.X,E(RETFU$QDGPI=_
M%4>J,OX+)*[';4$C010GI4,2V6@>PG,SS&\FKFQPU[X+/-62P))2%/1:S_Q%
M^.N?R9QLX'@A?K?IUCAH[$(@GC;.-B]?O\+__0'_5R0'F@$L$E5_&&^?T^>4
MM5__$$NU=JM8[ZL-]>\&EED""466DI%F#K?H/SOJZ?3\@5;XJJEXMC##+*LK
M(% >^35]3"[!\3ATJ+B(1S/1% JV?']PI?)4*C+4H:*81^R6AEX#/N/UYN_C
MP00]77 W+PQJ3+,FSJB\4@;<>=DU,A.)MU UPIY+;QUOHX27@I^U20[X8/X.
M2R40&7:=\,EL26!$RYM4B"6#;/.A<'+4I&X]]#IY0@V4^/Z\)R)?11 @7G._
M_C,3END\9H00ILR3"D>DSIW]]14"C"M."&V"%)5@2P+%VC *WV33WH!5_\MY
M5-$0.6G>;--Y#C=+Z8 .4)&>'NQV^K:2SB,.%,VLGBE>Q["$AL6$'Z[KAT+O
M+26-ZQ2 ;1 DAZL3X1=$V>\H><%AWUZ(.9TN7'SD)1IG.T]F*K]<M;(]PA<J
M*][A;F$4MQ\15T)#T,3]'(M4=Y;GP++1CL62A=P491YD,F"W\)]8Q*I"<1.U
MGURW_I<<0_T/.;9>U.>9B:O9DZ8@0LDMIJ';YC:\WWS:;-EHV?7)H<B.'?_K
MY_2"C]9,5^C@8X0.?KE"!U?HX/M#!Y]>4AYG["G\T/+2W/@@,](X9D)'%B:U
MJ%D="RR2'K?:CN,HM5>6?^+?3<?B\-SIE&# \PJ4W=LU$_]EA#3O:UWS5E)3
M),N(3E/G,]+%'1;UG17)/+S\(87#7F^^E<C9WT<LHLX;KN(^OGGQ_WWY[ N#
M&OW]]?_] OZ54GXNB;+<I8H[+=%G4[,\I"))W#8?: QX:9]8J]]OF""[Q>_&
M5!%2D3K2QS $<2LLVIJB4*7$PX(]<[C,>]PV;T,R8TRSL'0[9R8:G;M]T<M<
MFD=&%@^J>&<F"#A'],$:SH0)UAMBE01789XNT5@PAY"QX%BX;4\K,OT27Y*=
MT0+,FFA=O+[PT&F[&2YS[$*%<]Q[Y 1#H1!X?.(:)3X&A@D(FKG95*0G6S'2
M<A^1:ECK+^/:^Z'(.O!76<1\?[90.:Y\?!B\NX6GD']!7+&-+K,R6!N._&B*
M.A?U1KI_@N$A* FR2$RC]T/ES+DZ/]XP_4FY7J,C"%AL(YGBC_.^8F5CA^LU
M./O-.?0S\MO1&0K[V/OZ("JNT(R=* 6I=IT8IE*B>GI>QY:XY)>H#C+4RZ<)
M YVXR(( PB/S_TD9:<''KQO@YW_L[_<?=M;)NQ:+('4W,):BS>^D:#\Z_[HP
MC6-YP'IZJD4GR2*5=";=<]2EAYP_I'# I6EXPL.V^#T'\,-BGJC) 5M#]IE8
M?,(PTKH3 +O)NA7/ZC;H_!,:S ?\,A4T.5R[WKRPF!\;#*4&&XXRF^$AK=;*
M[H__EF.4AZX-'?QQ4125W0TBU]QO_@MAG%'-<%R)QHLWJ42FP44?_H+8P#P4
M<O[LS_G[%*-"3)I-V,IF1Y!MYOC.1K$($S!F+N'A^?J>H?EL#CF7&5@.G]MA
MW9%V1_C6VH:X!!YQU6^M)8Q"#K((E7G 5DY;$JD@*@EX[Z>DNYI+D3!H%H]3
MTXV#7;,=='^(DJP@^G7D<*2=VT77Y<)3'$T?1:QPLG-K>%=BPZ=8:PJ_B'/]
M'ZQ1146 +611=>*_M,:P+]O.8MQ,+">;)8\6?4JC:;X+1,92-](W<V8\_B6O
M@H56S,9EKGS1K^()X&21+UHSJA J#S$?.2Q9R.2"29IO(E@Z=QN/E4AJ6.7U
MO5CC7G0PL:)0C,=BC=.7^%/OW[B[_!0QUCIHYD@AZOR6",#9$3B4MJ%)J?U%
M)0R9OBIB/#0^S,"8\IN@]\HJO.X&GBH%BB=!NA,_30B]0&U^ID/'\ Y;>/A6
M, AE,,S(B%,><Y%TCJN>R=^T08BMF=(N-1'>)OE8S5V_*[\]M26=22<<V?M8
M2NAZ"-G*[F#0\[OZ?6W7/_C(A)$T)1/&%)DKPWT,_H.S1?@B%FINL2D/\6'%
M1,2. %O!-P[K3)1EPBL<=;-CPNDA HCQT+U/<3B^#21XN@&+.F#XB7+.97=B
M6>"YR_4A/W:)%KR+:8L ERS 4:*C$HBGT1&*3QUY"<Z,DKW/E2Q3E79SYS)E
MT;^/#YU,C(^5=<-\D"U^5S'FIG/"KK&6::88%GBQSX3U.'&=V!@IL#O+FE9A
M='.L9"&\P:-A%#7>)^J:1EP*DGH*&">2J&%XU1F9DF*$$L&Q9DGQ$1[-IH;5
M[2BV*(CJA?%\1NWW_4;5G-S7J0YEE;4NA+?NWRF%P?V*S+H7]-['65<8/<@%
MDFH_CINS#I23S'(W\EGWN5)U&S $[J&_@N4^4CS<8'\:_["%+;^/&LD2"2E-
M1"PRQ.O#!@LE,YH2:QP# AMB= QMBPV1\]7V?&5_V&QS6.5L;APYE@\%SL;N
MB<@C!;^FWCN,W#.+8'1V,]@I'&[8!7DGSQ>;NG?YOE!B5F48U.\\]*N947^-
M!$Q5R2WHW&2@J*E)]<3B3%BZ)BFI/.7P/&F9O&*) 0GA[R[*+.I8O.)F4,5D
MU@V\8A$\G0F:Y5=H]T@"#VN@-I!6/;9#616V3,FRI(=*XOX9?[<OZ9[E5B)$
MU3!R"W61A(+_0LT*]X4[PB(22L686;(- WWM;1RE*Z./)Z@E+&YU2BI/:T?G
M_1-UTW]"^EB>=LYW;P48MI0717F\B% 4ID6$@;T561V)T&,!4=(6/%3K97/(
MZTF:E-JI2_)%! @57USP1UF3D4<GOSJ3+/EBVW) <5]5HD!AAOF(PXQ7XPL?
M'CCH@U) $HC.:FJ.H\#M >%RB=L^D^EE]PFS>%R@T,>Q.NKV>*\;P>O"2Z "
M-(^W-K<B\AXC(N_7*R)O1>0]#43>@];W-14K7H=*T2 X10E_9'TR.&!^HKCP
M1XX+?ZX*]?^D>O3/TQAI*;GE D ?6.+/8[;XWR?3+OPI#LJ':3-1R!V(^[<3
MUF _M\L?L!GYF6D9"IRX5I/^LD1M3GR[))[I%O6#AUYZX8KK1YW(8N JV1PS
MG0@)L-+RO!P UI-D9C^$?F-$247(BXJG@,?-2]6>U8X/E9:X@.,JXSIH5,B(
M-G;TE_O;"SE[MM%1AE@-^F]J?WZ:ON?:D/HW-J1\BN/9ZLGZBH!*3-RPTLV<
MDY ;O66K=(Z! E@51Q2A]*?88#+-<NRJ]SJ-IKYIE)U*2YR3'P,GT* 6^C[4
MY383J&MV >=JC:N'CN U>Y\?W9/.<S^M+XFQ0,I@*I C50;I7D@2)BZ,?XKJ
M,;V)4&ZYSE!&8KRFJI@+:J;THOCV";NYE!OG'!#* =4$ YE<;O++6FFY::7,
M[6\]8]XIJR_2"&PGG2Y3&PQ*1Q\?F5N5YL8$282^E^"G@X,M[<G3XB>Z!FX<
MC)!2S4JJKS* R7/(SGKC"XVL6UI.=</(U*+$"G^>9+'PX$95;\8Y>FT&!ABV
M//'54[E+>%78WO+JW)6T;+@<4W4/S9:U</;C 4=,OQA9XZ8=:GS]W\ %-]_E
M[3:TFY>,_/L>\M^R'Q1)Y:MM=)+]^)^O7O*^>'DHJZ(-M;'HOZK1!=V<-W]J
MF^$$I_WF/W6F;7SQ*VEQS6S%&_RRK<5=TU:%_4(%'C%0CR$.W:)!-@RWV%5#
MQPT5XA>&VSLT3<$K5\ +Z':TIGPO<8@6.\P1H9_S':"K"^-E2]W$AL1-2'ZG
MV/P5ZX_M(:]1-1.VWP%!U<WNW$/$#_OCS\T=DKEE\L83$^*A=S]CGVY(X5L;
M<09)-6,.$JH[;>1E!;Z74%3#/<%?5W1.BV<=\[H%9 [B$BFBQ3$,&"T+H;3)
MIAE=AA6GMD@5AET$!/NP;W8-UW%H CA+P(A8(*6^&VX>)%2MB[PMY)$YO(OY
M 7O&AZ^FE:'P(O#XQ)RM4:.+S&0-/*62_CQ?OTWKW3[:^]/+'Y/8SO/0C.5B
ML=T2&/PN@E&%APCOFWM+O[11]84DPQZOYQ&>*DS%ICB^6?CKEFBPL+K9%/ &
MG*8- _3QG=/ZT'*/C6'J'=,/(/^Z<7!+U5#> *WL!#3(W[@OKIXNNAT:6@\O
MM'HW]CD6/R-](L3$9&!6,]1W,>F 6N[A:Y2C2V_Y#.;31PNP+LAV"F,SK:US
M,]"VRS;#J:G=F\CLKL@!% $;66!%O$GGGG%DH./)D-EEP7[N-KC-3=^^SQX%
M%%J(=O7N3S_\F-+.>*8DZ7O8'_>C_8KGSJ$YHJVTZMDGS$I^4TW?$FE&"0-"
M"\=YWH^?-(5U<H<^#GU,1YA$9>GQ%G^?3O;QDPIGU@WXTKR%8"NXEC!%I!S+
M7?13QDDQ8WUD&6)^LMLPXG!0%51#Y+:ZTWR>0(T=RT4;74?GBPB5V6XQVI]S
M-0IQ6R[7%^C\[D#\N=BFV/.^(*8/C+BC(A*K:DI0X&6Y#G0N.@@(ZXPI%;XD
M!A@G!1K=(@@V?',88U DH,CO\M;$Y"#HRYF" WE1#@.\;0S>CPPN-U9I/O?F
M,ZM<B1I5Z4$(0%1OU.N-*9S<6EJE2#_<$ F*25;.UU4\J;9;99*82U\NZ=XQ
MU:%@%<^6H9%FJ]*M:-AI H_-?/U)3[O%8E!>D.6+H=E":7!%-T-?7B@X96SP
M=SA=H<9(,AK2-,:82R4UT$G3^2(P1:1N(JU(U\4?Y,2-MJ*#=Y=*5N!4,+TJ
M#$[%_WEA[YC1D\ S?]QNKJ!EG9YE%$+$CW6.%CWO'*VAZ^EZ#I ]Y$'-W17D
M)27&3D?I?=9J%!A325)-_"/3$'FH"86@.T("==CV=;<GKX,0$[L:;D.1>XQP
MN9DG\M@LTMQ5G*RPE?"8YWI,_?R/G7)HCE!<_BBZDL :/1E'89Y^U2(Q-_J,
MWL_75HJ A0<>^IHM-$@=?F84.(DI\;JD*SE-6:<W2;J@0I\6#T8%T>[C-,_,
M/)".34F!!HTZ*/6-JU4-,MKDO&1F^]B/:?*>3O"JH=(J^WZT1@E2G/R7W9?P
MD)H2:(P16L$=8 4[8>W"19P"DF@Y%>"*%(L"ZO/.9 '@-TYO)RN?"#.(HF9C
M:8L[UW% FV,4<#CFX3 _\I=0GSV26DKT0T?*%/?>HJM^)$8K(&RV7&9!BT5/
MOE6T'E<"I6R.?O2>-:FQ^$<_A#GF73WZ]@-N>0[W!?>Z+QD\"+=&>9LH@2CQ
M^8,N+H :Q?_:MRE*HO)ELK^K\FV@60\4QR7[<P>EJ-/JI'I>W&*KA03)^+/S
ME0&3<2WWTT"XE"H=I5/"8<6'?K.MA+-JWE+G?BR%"%T@02C=.R;PD,J(PY$=
M";!QC-7JOSSF@IHWCMT-CW*2KB;[NJ'E9'GA>U\,S6W'OY72KN2^Y((HQIGH
M>HH[<9_WM?[%SH:1:H_H]C&,^6E<UZ(/RP^-K\@4R_J7$!:=FM)D5="LR"\F
M8S02YF>"_63'=D=U?HJJE9U0Z3-8$$XL=EQ-%@/V;V=\BW15B;+4^SJ8Y7^.
M-P.YQ]EW-2UL/%S(6,'S]_8[+[%&J',5?DZ(&'?A-(/53/HYZ32O+RD599=#
M*N5JI39YL+/*&!T/K$EB[ENAL98ES<Q2QQV9%L*XQ'C?L9[IEJ5YIQ,.>.AS
MOL_/.B&D^[UNUZ3+D]9R= J;A[\P@76UM_>XI\<;$Z^XO<>(V_O-BMM;<7M/
M5H17PD6,(I8KD=2PIV.8%PE\^Z$\*2$SQ1=!F"$R0VLE]0L9>#O!>4P1#Y[!
M5/Q/00$Q#Z89BVE"*?3?2*0*:X/:M5P8FQ3Z/"/SC(ZGW@O&)6H!]P+&/)[_
M(7"QA0)?DK_/]&9FVJP7D&6LQT(GOQ4(LZ7V,9^Q&:?F"; , T7%5V1+H9,?
M[WX0DB:='%@(N&9N=.D.DS@O&[V1Q:FSQQL1_ _%!W\@RNXGZLMI;$=.9'ZG
M)Z41QS:P*!S^GCR'I?14PSON:'IJ'G>#DKE!R([B!<%U"&2<)&K):#EW-"B,
M7I.:3X>\FFG82,]GX;'F.7AX"$QF=+(1(P\-_CW1,:\1F!']4II(1#4X@^!$
M4LY4=5;+?,N& ?_X\E#6.=40(T0Z:@ \ "*MDX.C/7&_P:>6$;I>13"F_;"A
MQ>E++'Y$8@2/V(D@AK12F&/'@T!(8Q,;W>U2UCR6GDI7)BXU >-X]]NH<E1+
M($U*SAE[VSC\P ]:*F&B3&%'_AUHM:2+Y1*M=]BY1?8TSY/U@ J9&^[NA'?L
MX"]![6XJ )]XLI1YL:1_A"QL$]>2:?%0ND4J>C62NKK,0$"RHI:OPWLQLCBU
M?B[V3'6MF_:$<[A%.]SXSTQ;R(*(H9X?-SSOF+:41"JX7N*ZWLJ0:GJG-Z$Y
M-;AE=]2'D_OJI0I#;;)2JQK8$<9P)-84(),#?YT4_U$*90N17<FT!PB"X4J0
M:)B%4UF@R'47]<0DB'->&R$D0YM8!#U&(E ]6T6]L*7)(1%<2&=\Y<>MAT16
M*,4P)VR9>^5>$Z!! 9"4\&0+H2R^#*6XPD(BW*8JF9#2GZ@,<9$H'FV3,03_
MSTX3!,](N81-6_H7_$0/IL03XK'D5CH)(KB@:X*.>P&<N6,'0F('>K9#*/.$
M?E9Q=SY&T0@D:A-"T<5.71X1^@ST@,T\M)CEE!VJJ+?Q!=/&),TFTJ:-?L=M
M#C;%,%( 1W!"D9_AK5X5N3 J<)3F#LJ)!WN0?T\2W*ZL#1V9GM=82J^:G4()
M9=FD3\2$[=::X,ZJO07]53%E]_:$%279'.5()#[ \S5'1,.J)%=F2K2J%D62
M5<%:G EK!BX_WBT^4E0Z0MH=YQE;AE;C #F?(?:K-K?C0Q:PR!>GMJPVSY\]
M_PT[4Y(Y0I@1$S-3&1X,VE2$-NC*T047[+X1K1T]; VWUA2=Z*QH2TL7F= N
M3AJ\N1ARNS=%P=56T+Y)N#8^DE_\^#T5J&N*:D812X)DU6:JDJ4:5HJV9AWR
MEIE%U/TR2(<)-9H4K4-PF"2XX>*"K(I7BNH=WR5>C^^7&V&4/*<X1D<PY,Z@
MBW-9BF*;CF:-8K$*M:&XR@/+*)VS$ENY#/U$,VEJGO$@H7<LU2=ZA]NRZ</N
M4//(0!RPIY<^D)X\%C$L#NE">UON/+R40R)LJO,L2ZAH<$/,?.'Z_C1CU(V3
M^[(.S$QX"HN=;?XQO"LW;WYZD45\>9<\*V<-Q:TX"3W)!Q9],ZIU01W 9[<H
MRGM(\-FV7GQ_^D"R )'V5<8BO.-D5!;>402\S5+^1:2Q\NE14*4B:A@J.+;G
M+=KCVU!/F[X4#%F]#S[8WZ$E3!T0KA=M97<28$+<BO!%WL?XEKFLY77/@1Q%
MNZMA4,;DSNUV!4@_^CF>V\"ZPTI6_4BBFQ<>" E&U^.^X@A!.[K5@BS]I_%G
M\3PF\T"%:MBI.TCZFL%ZOHC6PZ,IG_(Z2E[%5YG&K)L7=9$)]M1A#(?:"K_=
MJ7P;A*_Y2,Y%90'I;*"<LAUJGFP;[ B(P%+-'E9S_OD?&Q%AF,?004@Y4EI$
MXO8UV0>U_NF,(]_Z_PY-3[$(32EB;CSJ8R?A;+Z!AWF;W] UTPN].>3M"<ZE
M]B3C>U0MI[_-[%ARWV:7.\?L<[UY,\VO,_'"G1Q2;BY33_EX<=W"G _/AR4^
M-:8O2H %<1MNA ?4;_<B>(_<CPD?Y/7F!XCKFUO!.[EY(SN/'3Y1ZTII/*FT
M]"61=0DVVZ@'$I( 4EGQ)=Q1024MG$4R^4%>>%KT620$P\]V:5EG?F67)^V-
M.O+)[M()"X(GJHM%(-M;G2/PF\T[$CMA2H>NP=2&Y&_X5R QD"$H/V/AJXNY
M%5CJX8C#N<E8U/GJPF]R%MH)7(92 P*ODZ@-DJW\T;]LUPN'GSM>5; ?K@0L
M2RM_<NWP!&4R,H=9. G!(+ZB%W^%E^_^"#D[#0=,3"2^HU]?_^;+W_WJ\=B,
MW,]= V^< !M_?!O""6ZM,MB-@#MH72XL!*(2?O_\^6\-EN!0'OQ;7SQ[]JO1
M51_+9AG/W#ISE"J[>C66^I9/HYN1$C3/-.+??A7# @1ER/^NMKC:XJ>QQ9D>
M5N9;1-K[H0##X2*%-^%RAZM;K7>UWH^Q7A>$W5O&3(YV&T64-)/+7JXV2X/K
M&H:GM?/6Q7YI"0Q[6?5;O-Y.<_#D)OP]2,L,_+@R1,-R8N/O.PR#?_W[+S$$
MQQH55F5R6HM-%?JD_B_L X:_:NJ1)!I_;$:=ZKSNO'7G?<S.BVV9*CAQ]M3B
MTUQ:3-.=,/-&N**V'R-J^[<K:GM%;8]0V^MQL1X7'W!<',LN:MJDLU[P5Z''
M$KR;YQV+Y7"CK$.DC#2X<&#QZM#<K4'-:J6?S$J5X4)P0/#%%E+;NRA6?BFR
M(1 AD]DHLPJB#5C;!,RY06B$-2>&-1%>+?>C+'?'&,JD]\J6EF"A;(AY&\Z-
M]'^$-> K\J2K%:Y6^.%6J,QS-,;/S49KKPF#G< EL4O?-RVV)EW1A>%[XCA9
M? ZBT>M9JWPZO;6?+@[#S,BO**'?F"V0RD\EW$W>+@^X7=0+<T+H1I/819[$
MES^\BARK+(VMS0NZ(?Q>E=^I;IK=V!1(QL!*FDF$A^C2,7:OJ0ZOYS_AKX>Z
M+Y6R1^;]E>]UU[0MXT*8K1WI1G*A;$F*<P*0]A,8/!"1?DS/\^3Y?%^\B92,
MV0PGXSU@2X4S,"+^7NY[>J]<S73B;(IL!<L@;<TCPVGAB89DL0T\>6BJ@F$_
M#.O[YQ"QL>4M+.TIU'DE\Z:A_!=1WU&K"H'/'H&^,&B1:=$4>Z<!5;YV3K^N
M1:(:QG!VPB'498HN\&UYQP-=G86-> 1D,NC_2.UKA%*:JBKID)K'\O?RZS0U
M2^P?\6T5$^):S*894RL\Z>,-$)&Z:,O)QM-?3W?C7DJXNFW!89)E)X1,":FP
M=@B-N)B%;%U%CA@W"WJ#R,*#Y68T,W86\<>)*QZ1*5FZMQUZ4)#BK(B&]%8B
M(C'END4,0-=A^7R\)+2_1ZAQ8R4<27XYQ/J$ZVC:"L [OI^)>7P_;HO=YZKX
MUE>,V,_^V!/VW0?ZU[$]U\,QM,V %(2W9=L0L!^A5C*,1-]E(K/W/<700I%;
MJ:+!P*'#T0B.?\#'(_>GB4YC9-=TG&7>X;R'<Z$DUA9C+'\R$(1L[JZFAX.C
MTN>L '9FLW.H;?;X")A2OTSG@NQN.0=H%TU%"JXW7^=RU- X&7*5R=B&;T.I
M6W!\?%NBRNY-.&Z.&&"$T$^&^4=SMS+)NV<@&-UZ@M 3OZK0:&L(VM 4!PP"
M'DK!8<9J,$%]/8;=\$2=P,-&^EAF1$[\E$B+I12/^=DT#!W=QL+E[%)$GFB<
M@4MSSE/]%8UGE8S)+L'F[V(1PK*1-@?N)Y[8PA\E!1BO9CZ'>$N=( ?L,A@V
MSRPN\0AN3Z++VHH =Q72RRG1X;#N@4?PV"^(%A=^ [GCZ+T@AJ'%VL+-E#PO
M'TE'C\#*CM0DR"Q>_A9<>A].TUFJ#JX;QH.H#YH7?"5<X?F4*,[=!\5_N%'.
MH><?*S;#::;?+'SRD<UT:2+>U'GTZ?@1E.S1@9<$SBQ'"HUKWG_YZ\WEO#V!
MRB:\*LFZI@^'6W!7"C3K\M/Y.DK#Q.)7!N26RDKF'4@21&D6(1/@Q!?4(KUU
MP3=":X4DSJ/!/B>(DLKI@,\H=VVS)>@Z!%=\8.LT$8196FOGH RBH!T&3Y&&
M9CZ]E(!@R=_BO_/!O60#E-(503#XB]?Q=H*NL*)\FM]")-[FU(=J)U3Y]W3$
MRAA[#,59I@_=4Z_.\^=_;!R<DC$$2@>M9B-#P;"1+PP[I#O<SRS,,[DFRB6>
M\RG2K@O?/F7><PPC-G88]0^H)Q5%H$="\EKZ8B4'N"S$(R[5UL%>Y:^6>()B
M>"S.F/@C9 "PH+EZ$O?<=X?&9LWBV.?]G+5RO^#Z!J*,L(Z%#*X@F2H.S- L
M]/ZL03PSNLL?1:%"'I)6>0R^FRBSCR9]\")+#^>8?B^GF"/R^PEY)E*YD3Q6
MPEY4*#,-RUZ0#EK?YJ6PCHU8 <:< +"$1-9"Z>- 2VJCYW$NW:6U7)R;Y]J8
M6.#RLWZ4!4XS\SDQ35>O/7(0+*?:. 1>7>C/_MBOG-%PMA6'<L1/J@@@CFRB
M#I,,?E^F7EKF\J'(9&Z6-5+@P2UN>/TZ"T3=B%Q*8S?-#^\A-_86*0&U$1V2
MA?ZB[?()D>$);=C2S)@;6<2^1WYGHYBQL."[[Q@N&Z\_#3&C;.48@3Y1!EU0
M5=-8F21F+LYN7QC3?IH^Z:'OU1.I(OU_&]QKXS.9@C 9R;6WSV79R7>W5 8M
M*:D-2-'^3P@ ND+:7M<;&EKLCJ@K.6=DD#@TQ&N?NW]V8Y0T?^@KSO07?G98
MKQ631A=2\& 9+!LZ:E:**IG;[-3BT(&QL&7JVZ2A?_;?-$(TU][,-V_#.?XX
M'>!'5NA(;30O$ ;!U3(2+8E  /]<)KO%WC42]5"A%FEV6@XA?5W;0IY,T(+I
MK+ +Q"<3'"4FK%3X-R43H8\1E%?2$L^44R>6E!-.H)DX;5]BZ9KYP.!?$DHU
M[,>!UZ):ORJ-AK:%TZ8[PJN!'Q$R-$<!U<.%V^8$62YS''5>DD)4<O-.RG;J
ML9@.6-38A.\_<5 974QH%KS.DH9CI/B4>$&[I_A7$E3[F%JGW>/?=%)SA5?)
M[;_H%*OF#JYW+D-5= S"8[ #-B;+WM3-*#808L51(4/W)<<6>E]:^"7"/5^N
M#8_VL%ZG(A[C5,3OUJF(=2KBR7+9/Z#EU@9E=O814T)5/Q74(=E$$C>7OM:>
M82&?)L3FX"-&4@O27/$>_TWQ]A/*M5[Y&NI?(>"LX2!^D=;BOC]U&( HAR&&
M=:-17*I3\<<P *6FU'ZH]MBR*OLH!NNUME0>*\J%RA6F=P$_'<4PL\ME ]D)
M&&]!O%8*9;*"*:<4;B.J_41]S!7":BR](L@N4#6RK"#>17F^4WZV(IX4.MKF
M+, ,;NCB;TZ>Z8FF@! 1_F6 [?O\V?-?,SVD9Y2Z8 ,9AI4XH=TS5[($S!5_
MCM(L^B9QB5,G"%*)SDH_F7!88P-]8C)]@RPV^U"76VK65=4#;8?\%U59A666
MM! U+U517*F<.X&."1!0P2_7\OC= 6^"LH'DOF]0"1J=HSRWX!,0F'-EL)\7
MHP2L]9-=:J-HXD,0MNONX$2>;4.TY:W2E5Y\,99M1&BD$0O1:[6WQ9(!S$7D
MX$-/="_\S;S#XM(J"2_<>VE9'[L@;+DWC)U]IXR6_^O+WSR[?H;>J1(&97>Z
MNN9PE0_U3E%TX,FNN$0RX]6V"B&#_40)/^?XF/>)SXYREAAG).SX8(XM^NNB
M 8,-D!3=E+UXQW/\"0K%J9J+")?BJ@^P"JP_5ZNJ=EX3MK5&Q '3S>[]KLT2
M*"SD3? F$-M&=0V&T#YU$R-^KGO.V4S^@9 F3"/L' D" =J@U-PZ=*#%&D^?
M[P3CI7\I$O,YP3;8T9>^[>J_K?]6BQ*WWC1DOT2Q.P(OWD:N=Q-4\HVP?J+Q
MF7>F3'2]^4:Z= Y8H72OO!AXX4&>) :P/-\@4B;)?*+N"O;]V?W" R-PO(/J
MCQ 6HUN0*48L6-W8;&3>;DNEI:;/%U@J[#N_GDA$6GL>47Y9(^2W+28+VB:T
MW"5FU>@(;LK=9M_L6,38Z=Q#X$/P6@*>6/\5T1DM@5B)5=#1+9+*PW\-92>U
M(E:0Q#MWQD0PV*""J6PX@L+C<\_3K7(!3CBC'R:C^:&<JT_3M?QT(5Y7NF*+
MV;%B&TJ&;QJAE;T.)2UI'6G/J'C(OX37M8M>S!BH9".X9WR'>(*@/1&IK#H4
MPV#A%A-F=)D&UAF$KH1L&9[Y8+S49'&;.S Z6 C'#.0[$A(.V8"=:'<_44OY
M_KV2._@H,A=3;YI@&DXT8&5Y7(=A/X2;#-NXF.3@683^7":N2*I#(9[I/!LJ
MB)-I1BIJQE9C]') Y5X768?CJ6K.01/"BB4:N"W&=2V+AT11?!H$: XU%F^\
M"P2="+=E,W1P8Y 9MNQ/:3]]M8Z)KSOCPW<&PLIEW ;S]LH8-;B'S2@:!/^Y
M;C;G[:W@A<>&/*EUW&//=$1+\G8Y.UE-?37UCS!U#,O:@G$0F)]<LF&SV3@8
MI),)(;PEI0)2-"189PD'2P)5C:D1/*L(]U'B.6'9QO^M"8H06QS26%?RFZ_@
MKE?#7PW_HWS\##N%4;AS88CMC] E46T1/L8D!3IRB7%2:>G=7&BD$C\83_V+
M\J)N!ZDR9<PU_9EZC+'F04)1GB!'4/TN4&,5!]AW+N22"@/&08)T";E/L)XD
M/<G/70!Y#&NP67&U]TE#: >&^F +!]1$B'?<O[JOCID*WNYE#'_T>TI0$X?N
MDDE<3Z:3G^AQ_V5#0 )5C*,PR[__,?;Y,[RF)SJQ(-9)GMX'2=%FFO:3V"/C
MCT583[K#6HAF&C9GI!X!,=:)F_W-#VTFLW9*5;X-U=PS(TK"Q'S\_>5MBZ5Y
M;;<B@!;Y4EJ1&L*.&AW%(SEY)QUH %C\/+<Q<,9LX?.LL3,O0T@*?'N:*DJH
M+60.@SM'^(*IW6?$HR%]7E&1B0 /&1 C0JF:YSGBM!@MSOS24,^)*XG9)C\V
M6$V4$6>X 1S,.LG)QXPXOMLTN6#32@6X<_4<U34'7]EQST3B*39)HU.3B^(#
M-\P!F+Q"(1R:^6?WJ^$VKP8S,P]&EW;*TRTO,SF1.]=H>M I'?D]8N.%R4$7
M1^QE"U+(I$,*$XXCL*9!/$^/S"PW3*N2]#T=W"+=SP5J4U('HYGXL@>T"-.9
M_72KB.:' 3PZPV_@M$JZ#+8Y3#I[YF93.4[=_]JO'0_,NZ8KANA*+-:A.[#J
MT5&ZB*,[NMZ\G(E&9A>01S*4A7C&PW/4BYLI,@EQ2<MR&C]I8&)2?WQ4H>S:
M[5CS_0\@H$VVRG\WC&,FJ%<RCX>",%;MB5_.E,7OURF+=<IBU9Y8CZ9/<#0Q
MU]M5.$*JJ=5B.C00Z/V1&7[+E2Y*\?&:D2)5)E!KN/U[XVZK3QL,-IT&UWIH
M-L+')>'J_^[&8#D??H[81'+"MVZ$/D1V&_^#C;D,D /3)]SM:["=_?_LO5MW
MW,:Q/?Y5YB7_9:T%,9:<B\_QDR([CD[BG[0L.5[G$1Q@2%@SP!Q@0'KRZ?]=
MNRY=C<N0$F6;-/&26)P9H-&H[J[+KKTG@7B,PTO!=S/8NQ0U. &^ZR;1=XMJ
MPK(S?.J=(6%L.DB_FC995'77;YA?_&!FSKF@P1J510R:U_WX8_K)>=@YA-1Q
ML)50=FQ?YK(_U/B0MHX)5@@AUZ',3/@"N;W"X,C+=W3I22*I91TMZ^C3K2.%
MN"G3SV%KC N9.T$FZC[9@'I'>5@YY%+Q'/L7T[/.2M@/C\0N)3CS1#V1 [Z5
M?E3)QS'=7Y)MDN%SUUZX(_@ ?6=7H1UXR,F:Y HN2[#@9D=KC[I)#VA/K'A$
MR(8M1]JR%.^T%//$Y'F)..HJ)A@/Q\<Y1!:XQX\IBXF';K]U:T'3*63<%95+
M[>0;04M/W&'@+FL(AUY>SZS<+4B[Q? _J2]'P![*00ZZ7DT)0DL+4A\(+_Z*
M0P[VI5Y^]UH1<M="),"N%N_H]1'?FF2,)1+);JS% TY@TV;.ZX$ZLY&&KE&J
M;<SURVNGI<&-B:=O3GCP"+L)T^9$+CPS*2U=Z<H,5W6MF@,)WP.';7J#9:4N
M*_63KE3D7UK"=I&/![[%S,1TJ"UG@WJA"9[C1*%&ARVE6GH.MZ@>?M0#35(Q
MO2#[9I1%17!LZCH$&4"J8G5-+9I">'X5YFC0^\B+>&8P@E\')WE)P:(YMK0(
M?RJ;X/@6DH0*5P]&BACMXX;,;8]4?6149 0IW6G$BT>Z+/>[+'=E))[H=1Y'
M:+]RW_.OV^N\K*1E)7V:@Q/%['&_<TZ0LVJ3=+:R)ZPFG7-/"5*6CJ2#<:XX
M-+@,HFTJMUE/0"9%U;33E ++&EC6P"=; Y[S1_W(;9D7+$#[T2>!BHH0(VEI
M20^63(E\\XM@\F+-=VX/W$RAB)M6C+/CQE5.0@LCM"@D6UTV&/:YN$.9Z<I0
MQ;G@O;R2KD&N=W>*NE2SOVTU.@KD"6==\+4(@EIUEYP)CV?.8]=K9FAP;--,
MV+"2$WP@9SCJA.9D*8'DFJD7ELV*$DPC%XJR6[?5>7A?Q*E)#79XI\A5>72=
M;Y^6;!/G?R90L0O)Y4FNFFW3V1QR>P03A:GV5OCSFM)RVZT%&!+H )7A&?5"
M"'%)G8KG1^*Q'UQ+J4Z#B7#Z()*6D2V88&4BPDP@DD<*W_]16,^%UX[RI2"=
MS3EA,J O5-Y"H-JG1 3T10QES[1OZ' 9_!2A]%FQ5MAW(&G\XEE&K)1_#EOW
M=8/:YE554$;&KDBML83Z%Z_]O[X\^],?3$:\.0@_72RO8*29%E<)*3MYU;;<
M4]1<PQ;^\B>Z*!G*%W\Z^_P/W% T<VE(6(8O3(U_=M!_.7O^!PL5^*-.YAXQ
MPWF^I57P@</^ZW,=]O,OSKZ\S0T>K[6K4), 6="JTG5]2[,2^? !M&Y+II-R
M6C[Q!82W>=$V_;Y+S#X;@K5-"9TQV'H=9JPJUZ2%0$6('12-4W4?INA-1N1:
M,J5F+HD5UDQUYZN-,Z7ZI%Y0[6=C6BQ<6YPK$O,;TOMVQ"9)]U-"K34_-YPD
M\NT'SW^ME17'/)=NX-B<%0&O.PHI=,H1(:VEH-I)"T^1?[K:[7/AG[[S3OX0
M3^);6?OW\)V^C]PQWPA34MBS#@>5&J,6IM?63?Y;->O^GEIS?R,><5-G9>ED
M1AU9G),T=-J^5OY<KGO $!J*[]4F2+DFI=6*.TYFVPUUFC3AQU2I80'"BK4_
MP[92EULE6@:);+C791_^H2FVI2O\01R8@_Y&Q:')H7(97L/VF #(TM9D*(.G
MG<S!F^D)%5-&"XU]P/%.9FQF8>Z@D_M&FV,K:Z&IVR%+18=-^#%:/;>#,#":
M*#JF"9,F5S2DGM(<3/"&:VW#&H_IS/J?<(+NCJN_T:]#%/+F\NSKLVSUW=G?
MSEZ<,6/^R\NJW*R^L?7VFM=;RM@<[JA\*N11=^K?NML>2@+3\K?&RS2<D%6'
M)FYR==C9H.=JD!(T9X1^R), )"^<'WGDQ.$<Z*(B4B@]93S?G:<GIB -CSC>
M7K(5DXUNN!5U1"D:?"1W35RH[U:",R$%KOM%=[(($]WWEKG_6EKFEI:YQRM,
M!'P03ESB5.A<5$:I'CKV("F #;EO:S L("PC.U@=RWR"$.1F+R ]\[LXA%L=
M^5/^I=RD>Q_"8)&&\8\2G4[FC78^@/9X9(ZZ/DN!?5D4<'1>PN"\QZV[P9WO
M[VGT>&S\1R'<@0TR4-3E!5QYX0(==.WJ;1CSW\GGJ;IUL_I;<$%>A$\R= )>
M&)REZE:7I)D8\=FSE#S1@]LAG[3.(4^IH!>6H0F.%J2\6'R)<Q6LZ[D*/BPK
MG4>F'DK23,14\.LF"+HT&X1&**R>J8 LR06IT#JT/FDNN_$(IE*\DY$>V'WF
M)NAL]9U3F;II,B]RFJFH6J.[#9Q/?861(2_JC1J\*(.(6HE$&]6/6/M:2P#A
MF<)@P_<OJPXR%C(KMD>A!06<-KSSZ:0H2%-3A[0EE?)QW4GA433<F-^OV5/^
MG!I&A;GECT2R7U+N9? 9FM%"($(4U,45N>-0J4I9^(4@*U8\N>LU<^X\O0PU
MCVM5:VK:]_HV:9VTR2Z'XWY/:#21</!$Q)T7>]#.5;H^$TV.E,"DQ7<Z/8G#
M1C;:.%S-\''2L"XO<$JG$G,^'3G1@32J\I4WRZ5+3N.B;:['*G9NZPAS'L,H
M[#DA.N'BKI9.\J+9 W1DUKFE<8$:*OCFE0Q>,B[A9&W[2OIWJ;XHW2-^PL!P
M[A%YPEHF*VAN_^*)K#I>S@7G_(S8,[P%P>*=]PJ\%6)*G75+J]865@;[N) 3
M<+!IZ</:-]5_N%]GXD)(>>K@1%5!V96Q&(P\EK7)]I%Y2G(137L1=NK_R'[G
M-/I<PM]$+"M&$<&-8I*;8)YTG\/ED@%\*-[595ZLGGWYC"0EMT\I!^.33A,U
M4&R-3"^4%'[XO>MY&ST*9(K2;#,9H3$7)\Y<QCVRP;AR:I*0B^6TQZ$2I1W=
M"3S$_NJO,P@!O+#59I-7$$@BX$""+AET]9VMWC4^QTUE\W6U1\%%W"Q^:F96
M)9UW?TJ:QCIW,^S(M2A=QH\SFC9H<7>B\],=.P*^933;*CXKS4G*%>=O)V</
M3W$[*!E.>IM?\P\;<&.R)QCOGA(QHH=*ON.V@ND,9K(IY.+^28<8MYNXB12[
MP59#7Y!7"^7&FUX0M8RT) S?KQE;-$UP:V)$VZ.^3A8]"\/J' #">09-^Q'S
M^>Z&B\*W$N!F2N+9'2*WEVAS#>85S*#JQOC$==08NU<G\^/<3T7EC0OEYEFV
MP?#X,%6D#,$#NK(4'AGL)#BLT_5,OT*'EH/LY"T\.%7#2LE\50C8'>)A_6C9
M0'<,<O/RFONAA[JJ*I::TNAT/6@X_4!&_:7Z:!:EL_D/R3QT,XG[,W81=NFS
MU=<O_O>+SY\QQ//?W__S61C&9;C'H3%">P64R;1-\79&( C '^7JV/0&W;!'
MI-MB-[K3'(Y>&^T[QA$$1DSF1*:C-=@".)&#,T_Z9L$S@^1RQ($0T4+8@@NW
MO[1E"$G62N.9A(S51D5,^_K$7H==* 09V":*!/;8*H.$1FXTN>M@N?G:0GJ;
M+[$5""31-:]"&-(P6,;/2,4L1FVSJSIMPC! 2C9I%-+C031*-:;$*4;[+@^O
M&9UN\=Q..8L4#8_R"2S+V@JOJ3 HH?Q JWO>]B9@/M8-ZMZ4"8;/3&_3LH4T
M!\M/'%#3E#!2?S8T5 K[/"T'OP\>"5%X9!'SOYPDO_UCO[*U#5N:7]W.?W)^
M8AK'3:^9)-L2G54@.7,"%T41$NCZ)+U2LVF9V^SAO M(KK#:HZUC9KV=7I!H
M!2,D9$LGU?:8V7/FZTN0X'!69JIQ<AH]?M%08?PA+X!'E.-X[6/+;,@^5M57
M1/QUD;,>[LOO7]/_?D?_ZS;&+-DQ$RF ""D1+2F1^*"<&6(<2M&)MV,-YSO>
MU!.AJ^A+A<=YZF@J1/7 8E-RKXJ\+90D&%0<#+O@CGC:XEL*1^AJ2Y+E06SE
M@D)BU@*3^4/M@K+(;=X7T7Z<38F;-4R>> 49=2PH5EC!)51+^Q56P]GJNV2P
M7%+0H9D$*$0SD+3FV)F2,>OW6TG'4]&D+B_"2P,".RXGXM+>-IW$!\'!%8<N
M]6#9P<8T7%4-Y>Z[_UY]5CT!_8PL+ WH62:'*6#"*#GX"H$8D>?X_!#?:+AR
M^=?;_-KZ]I4GAZ8?K12L5'!HJ3,!B[P49!N[U"BJ&\5%%H89QIERT'Q6GEV<
M9:#1><('E+Y$+2?H5[Y]&;YAVP4N%JZV"1%%*XFD[H#2>IEOQ3T(1R91)597
MP;G/2+LYW).JXFR!&&?P8\/8+RC17^.0#%]?N^?+:.NIPZ()D>WZZ)Y[M%6Q
M-?/=J?;%,\>[6GPKDN!+Q%ID)&V3%_185^$QRY^I/^(RO#,1$HEWH/H7 B2W
M<N#*?A9^./VV3KV@Y$W&9)BG)B';##.)6"QF*S/G94SFK6(-*A65$987*4_F
M;93L!"[_&CY]3APIB,@FI]'8]WQM: _T_8%?;Y9,S_MJ_?X\7[_WKXK>/9,$
M2MWJ;/66HF.W(:UC(YVT:7)M58^\GI=7,EF(R[B=D[,#?2N+<,@^ZBN%L97?
M'XZYB5Z@>D&W"\$IB9URZY?D,L,[[ ^X_8/VXWX_I]^@D+IN"MF&A?@KLBJ0
MR6^WH[)!@J/-_=&@H;NS8\?1T&RIJYWM!5P_!8D>9JB1B@0UA0K ^)DJ*%+W
M!1!&1Y'<32JA?B%%=:$RV*-(JU#X])Z%(,,ON>I[;PUQP;7>0USK7S]?<*T+
MKO71XEK5<P&>0)S]H\]@61J,^:N@'[8E1ZNOW]?--7RTON8$62$L ]*#*%EO
M,#[0YHQ?B9)7]'N3>$GC!SE?UO8'\L7ZZD :!.4.%1)IG=[DU;9O2X73*CLF
M!TCPX)K6.W"+G_+;/W8LW0V4* ?<W6D K@G:H;N";"R)/:/^08%1@:\/*D-,
MH0UL@3789-:,HP7W 0J/Q/(&^E%&7A%'=U05NJOF8&5^\E/4[^X.?2%%H(F:
M#%>STX>-B0:M]G6N/ 3B.XH-A') ;/NRVFO/$-8/.58\DQT!<(.K%_79STL1
M"35,)I,+7%^RSMXQWN3<*HVT[HJVOTB3NUYFW@46@COD7B11T-+^*!1RRLM\
MNV%H:'B$*O9.#85[3]R2!;/3J@^_4!3OX4Z-90_-J1310\E/4Y J)2Q]8ZZ&
MJO" \"G">]4H+'@K@DW(S\Y6_R_8?_C=%C+4>)ET(L52+N=#PAOJ.!MA2HO)
MC:6.V]J(A:P'6?B8U4RYT@Y-6-=9F( +R4ZXN&Z4.X@ _YCA0+AM(3]E/)J3
MKZAH2O;N6V'#[PWCEMPZK6(/B"TB5\ M)DI;WZ8*G*B)GI@LABB[ X<R/MM<
MF16WY17(460>U0*2A=]6@K3>8JG25;]]^2:90)24I*8B Z4TH%&TI G#X(*0
MJ8<-:WB.N5=+M_#O3\B9#*>5VB22 )1&2^N^!>U\I"> UQDN2YM/Q1]SF'^(
MA-*Q[GFK%!XC*3CY(X2QHIOG"14&K^N\I(NRBJY)8;IT#C\_']TTK0X /[MC
M:GK2<G1-*RFZ0?X-%=XP"IK&O-IUTRF?)DFN25:/5X\D]O"[+$X9_U/=%YEZ
M[5N@4T:P^?T]<T<>J3\B9J7ORU2R^(#4/*=W.U1.UB71!] 63K>T,Z_=\!5C
MZ7B6LR1^:ED-CD8^^-22,:6]%<34F2QS'7R"1_?(MPA)]RB*H81L^)93ZTJ0
M<^'$#<?*NJ4C4TZ6O !A&]AK*9]9A@_8$2CR78Z6B@W=AAI)NHNF5?P[I3&K
MKJGY7\%[V_; \0U" P@B@5S,K3Z6,HM2Y]^A-9T0B?Q?5>$R5+H!3%ZAJG]2
M;=^,E_4ASN-Y2\W:*+8XWJ!KZG79EN?;YMIQPM3YSGH*XNBI!'Z>MTJ$UY:;
MOF-*U)QD>F6++*/:LWMPQ49QQ0C_V6./EUF->5=.UN\2\CRTZ<@!+S6E,L<Z
M +S*]F)*85]@_XJY>,P===V0=:52I^(*A2TO1-/;^%P*"I54_A!F+#MVXAH:
M_\QT<PK_/,7[K!1O(>PTN)7=YI'R,+VPETF ##)YWE)$)%IQ>+,GI7(PKBD^
M"&O4L'!BO"W]5]=W>RYU)* LK'84";D@^;%> [EW?&*KQKQS>F9\5X UQ:*H
M)T=1-]* (;@!H6##[FN8WP$R!Y4-1$>^7TL+>(2"X0?$=J-KD<6[P]_0>Q:A
MV9->RX(I.7'N(N11+RK$<E1IT(C'@(V9!LZ^W.78402]GQ2>U>/6PKO4VC/_
M#I-R?#1=?Y(;' 7..?F1/75$QC%3IG=]"4C,\;QLG^:' U7[,F'AHAZV_#T
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MHP&;",&-CO&3S*$$C8D\4O2X>%-3E.+M68)'YFQ>"5D2%*#39Q<V=\3Q"ZG
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M(20"/X]SX40$29BJX*,<*O@YX>U?-!*5D_A.=> (-A+75T1L34<=!<+K2[:
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MC.GPC3!0;Z0?;;9DIBU.F 5K\DV5 #E2S:6.7+9.ZU[IVM5SH["/3VN]R$)
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MTGU?)A/AMR!"2]0./+$#.18SF!L;2WP=+%E/!+"UJ9,-R.&2.M8YY?'+]V'
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M(-4@BT0SW#9>\J^W^9X'6V_"/43YE&-\_):S/#KXJ?P)K9,D8W*V>@-*U"B
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MF+F#:FKEE,"0T(P<Y84MNJU5<8PK[?%.+LTR ==EW;@NWY;*+;O+?TIJ>E*
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M'1WR(HSLV[!PPGW"Y_GY2^"FR?A?[;N2]V%8JIPRHD DS_G;/Q0&^)'/123
M$AYP.@S>,O^;,R6(:Y-M",39U\&=0)NNBN8)XPP+-EO(R&FS<,1=5GM)F RN
MM9$(9I)Q(QOTSDT3<(3M]M8[%O90AW>QIX7LLA^LX&*"N<?O:"M]\DO:>'F7
M&V_!5-)8NS:5!;.]U*H>>JUJ"W5K\R)FVB[36'E^02[PK\4:[VR-L5':$Q4.
M>V87DUQ,\M<PR5B72 IZ4F.1Y)+'>P^TT(=>S6*PB\'^H@:KR)%!18>\9/CS
MW@$^45U:<%"+)=Y5WJE>([2:@#X\>M!0@@#0ZBVHG&="SGG!0!_U^I!_#"H(
M9N)RC" \ MTD<:\,2'Y\05!RC0G'3QHR).P.TZ-,> \XH2G8 [I43)D;Z4H3
MGH13_@\[7_X[L=A7 !<X;RC"&D!P>-&@A&U4UH-:2LP&SU137$47JFZ"9%JS
MB42N:V^87%$[-CTX"RAV"#>B01U5*;9#I?_^VL_2=7(/NTZ^_'SI.EFZ3@9=
M)TME='P:L'?B$^@)FGWN+)@Y"6:YWGV^1XL"GY@@=BDM_KI^A%B.\R&<8\JP
M2>,Y,@PS,P;?AL4]>J8WFLW ,1T7ZK.(,82+82A/![L'CQNXCR;8E\Y6KUO!
M9JJ&$#!(1RZAT5>=KZLII9OGXR1'^?@Y4JB+<^2"/]'V>^$%2X<^5?*+J[UI
M/\'DW%O7[/$LR9EZ*S2_I^ N;:G)>*"_,J%1NYDY/S/X,^!0TQ+DZ^8I"4"#
MXEEAQEM?NF7;GJ_4KS[;_/']'_/5VSX86-5-U]F?G,V5F6<?FX9<[9&+LA\1
M@F]=[1&NUV7>/J7P/7Y-,/;;OAB 95)@T&1=WH#S7%8WH/UI<(!CO46_@RPY
MVE$$-;#ZETSC"]UA,N,I9298F72A3(T5P2SI(1GNO.7JZQ?_^\7GSU;73;LM
M@IV%L>): /]_*_#(EY<ATE\6_6__V#_@4 '7](3K-F[]N,K;BA0.W%'EFSN*
M*OP9QXD_RY15^N83.[GL%"3%FB?W^7%7IM)&/E6T>C5[TB:-&'Z8R<EX@U.;
M'']1@<7:)+#:-(?')SEO<)1DCT=W.,X;X4QD0-596,$U=>A00A"OI6%,/$9=
MCW"(L1% .5]\=E^;BO(UMX4-^!9G@?X&49U'L4Z"7I<5_=L_]K^LI1C]9U/'
M<,4(^+82@F+QRM;ER/&C-RW]>YU!YM'HEJ5?ZM95R5ROS!U+'8-5M^^5(39L
M&[2HRL-U">%Z.SKC(N(>$*;?GAJUVX7R\9ITN] "R%J*9@^]:)94622,@FJ1
M]1-.GMD#[:I8R;%.:EZ="[I@,<\[:<^J1H6P8H?74W*($<&T+IV2B!4XP;QZ
MKDJX<>:MO;7"CNV.@?B=A$%C,>[%N.]BW%;4YN9!+:5_H#S@D%%(MNWP4-O\
MO)&&/!\1)4FVQ887&[ZK#4\'XV.&BW+E.E(M)>5%%VHS3HT0;A'*CSHX9C4W
MD!Z.O"Q=N$"W.0JOQ>13+,MC61YW=:]-A8]Y6DJC".=]/ED"B[TM]G97>R-M
MYY8.]\3@.!-"BHA/+YOKJ;YX8K *FR9ESJ6K7[;K:??C_#C(J]#U7<)%&5^^
MPE\6LU[,^I<+ ]G*882.70B_[PY*/Q[>IE,HJSR@-#'DQPX6?@5B$$ZI K0[
MO?Z5#PGU"//FE" HE5A*9)U8V&VBNH#@NFUS(4":;!GPM).)>IMQL(#RB3GK
M?&MA\D%:2'3N(TQ%R .F.X 3OB$W4YQXSMF<_ YL4S,YC2,>!:&-HQ)LS<C4
MQ%M.Q<SD\7\JFSVEM/\#/D5/RQ5W9ZU0Y47Y?SU+<$E5G<+'[I:C2R<N$=Y2
M3D)2Z5KJ,[_]8P\$S#X>XG,S8BG699/F=D2 OSG%P<?Q-K2EEJ'XSR8WV397
M5:?(*2XXQWFU'HB.=JU*]J0=>5KA4H-4N1 \$H/3MO?L0W--$KZ?(BI<\<:3
MM$Y<R]:L6GT'B*=_PH:*+.FHF+[=S7T6KL 0M3ICG:VL^ >; 5W<AY$F3=25
M9YF44M8DQW=8?=B1:(F\#SH,YP_!&R@:/^@<3'?P&\Z[(5/?G:=^CL7J=T18
M]?LY/KI]=;#-XIP\:4%(CV I2&*'WPKT3):!:\;1QK(9G N3/W JG-CBJ,-G
M &N9 L?@N^?$7K<+N[(</S.*WJG=F]>2LBYZ.?4YLBS'I.7Y75+^%MX@.=.)
M76Y[K*+TJSEC.$V*4FCIPF=%&6&(%?E?GM7T.JY"H&O"B HZC!LP43LBRKP_
M7#9M3)#RSF8*]EE\?*;=HU.7HR#6-N\^%$@_TD_-EFW@][$-_'A)RM.1$#?J
M/1M1.!\B1BJ)XUR5!WP]H(PLQ$8W26L@!_L3:?K"&I0^6TR4>\1K0:GQ;:*C
M%2D2V)F*PX#[P9>:' V1<D4B+A!2IW5D?\3?6T-<&OKN8T/?LZ6A;VGH^_"&
MOM_)D6'AT#47?#EJ=NKLU^4MPQ/=^T77?@-F8\<]?\L@)QXE4Y%2\$L1M4*D
M0L*Q\(OP3.))/F@WY#$UB::@<WG7=<ENAA+31$;F2&2Q2>0WG!]@29:1/E*X
M8L_)Z#;54V NRR1B[^NQ>A+C$51^B9D%1$P%WG"9XJ-!ZP_"<-$Z3WH(U"\/
M,UB7@F*[SAG&YEJ&EI;5![%__EAR/$>R0C_O9T$ML>U+6CHH:+6(E/5:2I?C
M>U\>DZ8P=IC%1;YHFVMJMMRD9N>]9+W+F.O<]<JE9BG=(.DXW J\H3T6@XR"
M*>$0IJ&"?T..$26!UB69CF3F_O7Q%C>>[&@]58YZT*?$[V3EO$;">(WZ024]
ME/DZ+\H=M8M(R0#AGVDV(<6Q"3%NH9MYB(WJ6M2ZZ(/)QE%/76RYZU$C]M]A
M0Z1S).) &<1J6F2]!YHOLF#1>#Z2@O*>BX^=K5?]5'T&#V*R1>PD#5@#^;0I
M?ZXZ%3))H_"D!/KV$F$\$O[):.2(M7-5%MOTV>JK1D.9I.2JK@DT8T1*B*.H
M7>_60\[XX@E3U=R!?GO90]X_J]IMA([\SC_T2*C)I29'+\+Q2]_JX1)N(O8@
M\O/P:</CT'8,R]SZA'Y7HLER>QSWYGF]G:7A[EX\-IN;.]]Y>PLVQ>%F;#9-
M#C((K_@<;=CD<G9 \U7=[\ZYQL9J-!V=;55'F7JWC9*+2YLEL ET9R5IYT4^
M<>3>XH"-50)4/+L*XF4'5#[#,+&\NKDA62/LX-%(A.*04\L'5>G"<BB8<I\!
M/QUBRG7>73I1/YH(5=-9!W\*V?";8<?K?,\KOQK!0N(P\8QA$:U+&AVOSG,_
M: 2=$I"2,R/GSI#7@O:F@<#/5"C+V?P-;:85.RFW> ]4I9<*)%D&4K#-NK?6
M9GK[,W5%V>_B*#_@OMDM-;^L&O#[ 9@\HIC\1[-2Z>Y%'+'-K\E2.BF! 83D
M $^@J+FNS1L88ID(R/CLKU\YY\B=:>>E*'U"+A#.%^TN_4YWS+Z.-NSH*_2F
MZ%LL;GOO>---TW,/,^EP CQ;R_-@052;* LI*EOASDM$_B!.WI>N",L<*]I8
M.,N2RGMB.,0:0X$DDJHP$*W34J]M5\XY^0A"DA^K)*[8/>3BHM5SL3<\[%,S
M_)%.8CB"IH1>O3IDSB:*$17ENM+"OOWR&E!S1@)9V"W-DU@%&6O1^F4@\J#R
M+;VW1RTZ_S>VL#4J'(H8'_)MI>C@>E%=E>9+Y:,AS\P[BXU]1B@Z\EY,2GF"
M>GU3U@5%>^)W4[TQ'/!0I<;\,/;=- 4NH\+ 9@"; .J2]PN9E\&>,47;\4KW
M12]2)WP;/]0$F%N]/?!XD[':*#L*7LH+YC\PU>#Q #BJ$2#<KJE#7+P.7MFW
M;0,E.R()RE?V^ZAYJP1$)%%*-R+6H:@PNBO+@[[C+JP+T@@.'EZ(RYLH0ZB$
M?A8@AEN_IU_4P:W; I9Z?D61"[L.^BFY!A7X(5;7;74(DQ2FH%NWU9[-'J+T
M\&1T";K+/#T<]^'U-OVYA?Q8.,GSUA,3I#K,8A##QY=N-M4\)!,3@<6R8(0D
M>3CENG<NO*VP\/%E";59P^9%=41KW/CA[9MWK[E^40"O477$*L6.>KB2UW!V
M-WO0/M3OY&1YER1J+"O%ZI%=%:Z>MWZ9R@H^%X24?_FVRX0U0&'->=ODA93+
MFO[0*<X(-__YP-!TW4'.5F\I1;(K24B[ZG:=V7%X?.("$WWA;/4K&<U'.BA
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MB $[9MYA_!B-J:BNJB*\H@X/AUX9>RIV;]WF;=$O>;S7..SU3WHR,N+*B[\
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MI"'1=-/6"F$E]Z/5,\"#\[XB;8H<S5+09E21&[HC%[0Z[4H&\=@PM+U%@/I
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M-:%PAW,#4;VH\84'J0M2=_]AN2.+*J:KU$@VDTTU-8;S!8WXE[YOZD]#K8E
MY2*-]=3>\[A*M0UW>P4&!K>!O5X$P?#&2;'-EZ'GTF6>+X+8!['?-'4[CK.\
MY>A=!N7EHFZ[@&4(]:?*2G<M(Z?1X_Q+V;KV>0LQ?:%'^,U53Y1$Z=QS&K58
MRBAU/#=!G(,X;T3M.%.)@-FT_P WK(4$0/,ODMYMBZP)ZC/(VV;R-B%7E!H
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MJXJYI5E0?/"M!E^,-CYX8N":\)_$/HX^AJ!_7':P[3U-@4!G"PETGA\$ IU
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M(#L;:W<Q;AH4<WDK]*A_MZ!\"8;!TLV2I2J>M])/_CCPV#RF! 'BS&Q<]W"
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MY,M"[!@V+VQ>V+RP>6'S0K[L$>;+/I[],^3+'BA?]BF^*HMRNHA^OH)/:X2
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M+^7[\#!Y/*O5BUK-8O3$=";226E>9G7&KMT+_?6^?"5?_NEP__3D&]=2:I-
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M\(?O1V6Z^,?_^^'[23/-__'_ 5!+ P04    " "L@*9:!L_CMP:' 0#&3!D
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M:;4)DLCR(:QC]4+6=T]T&_Z)\TAXB,YJQ&3J16**5SM%R.A_B;-N;U#8RV-
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M+8^:D1P7JIU&ERS<#?;^)HC_@6-(JJPUPW7L/M'0J&OR7K-_W9,7Q</\WWM
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MEI&19V;&'=^S=FB9F?$E6W;:F=,$-'*?['8>_1@L3X84D'+]!T=I2T.@/+)
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M2G&_#0,;8R<"C!65L7&"+H-+8;Y13AIIBWU2SES^F9,Y=!O#V^20MC36;?S
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MOQ.B"./0V]]A !08F!S.B:*4*F)D9\")9XB%5)$0HLA55MF=EQ!SEOX=R!B
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M_<+4J23L)5JB_,?ALG"LWSBW.5!ESJJ5LKHM>DKU)2A<82(4XWS),&%7WHL
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M*P$ +JT5C5^7IX38G%!^4@L)/O*$+2K'S5EEBWKSU2QJ+F5.S\KJLH5)YC^
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MNF*<19@B4:+O\([#XD*I,/<9@. ]R\8#LAH$=0J+DM%G9='H""@=8J:<YNI
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M?@G94^0%.A36.1^M*$S(!A3SM<:-]A^98'X^VQ Z]?-^9-(KOH3" @7FI,O
M7?WV!<\ MTP8,T@Z'IB7'B(/TX7/QDV2^ELX O")D,U7X:+S#>(WQK=SSV+D
MSM?W^ 0?"E* .X#)0Q?V3K9L.,1; 'QV+I9&]!K!<M4=>_(O4&Z+KWYGO:&\
M\UYH$;&\-[OG'L@G?>$LHL!?X><%^^\$0D)P<T,J%C7F0B1,D;/?JW1UJ5\G
MQAT+V?M ?8C2*H(-N3Y=#G\<HQ7RWZ>(_1V2!X&,?.CS8D)8!K$,?=\W<+7J
M_(0OX('3UJE:]DL$ >80:P9 ;@]^Z&^SK8UI[$R++.9+D.<N'#;E\V5^"7*1
ML^D][WE<YR5*$H28]RM\NX?KDT='[GEER6M,^QK/\B_(C6]Q5X<Z9<E83CZ8
M0T;+ T'W3EY5\QID)XSHP) .C'G\7*AZ>L^;&Z5PEPW":AKT=I1"X!JR<E'H
M/1V XRP]^Q[KT-G[Z.C 5/KS1!+7Y4@PY/ ]E B_[=@]1+++G#5<0^_D&G*%
M1^N9<W;":YY/DUSRX_KDF/=KOF8%'T&ONPNK]8\/,HE5_7'<V8C5QQ4K!DFT
M2#^L%T;^@8PX,E3'B+1S/^PYT5QROFL(7T5A"$C*^-\^_'139\0%>0\"J"G_
M%P>_D_#_KQ$KUA&MURB&>Y_ ATW!..I!!J;Y*3ZB+U"5^>9YL1C$5<W<TWGO
M#NG>N7&>G86S&-DL.BAAHI!4$C1-N,&PA-6061.RKREUM$8W=#XF*@?WG]]\
M7VW@IGETMWW5 ^Z1YUTZT*?M-%3#"::9/&RI%X)J24(%UU&\!0%7I/(,(@GX
M"(XPQ!0Y2F.1QXV<#61-(Q%&H*^<-,R)?'X9=Z'X.Q+?XC'R((T,!>2YN8R>
MW0 E=R$K7P@/S'X0E>P9_0=G14=R8C84>&T2&(Q<Z70X9X_'.U[*@PK16 -A
MHSA/ M7/G&HV%+$L'"_5%0ED%?5Y)5S^IA.2CQ^0FV1X@O/P"6X"4 ?Q:\M/
M7L+H%<+\P%EP%^ZRM%R>XW*?FV.(-;M7RHKPDL-/OL+\1.WD8R>J%%DYS-K$
M@G]ZE3FA>$6DK #1M',3VU2P\[VI86M3& =O1IXY+8I CP.I<)40('=^1/DO
M%"L%CD\O7QH[=CL^4$DB<T%,84JH@#Y:LH,RQ?D8)7F4_THI?CYJBJM5,:RA
MO,!&8Q%_HE?QD(B_\D.DZE><)O1O*%H4SM'Q<=/(?3=?DS3)'A,GW1!@'^CH
M&"9>.2>4@#DG8 KPMUPCN?:351"!)C), E^NS(AF8J;K$,7LJ"BKZTE"K\Y_
M31C;TM8Q!^KL<A.C@[-GR3@75=_D1:$=7H#P?D4.5(.YH&Y),N#1<T#<QC_]
M^-._6.LB8@&0))@0/Y[H!?HK O@IY,WPU>2^(?(CE(/-S\/$KCC!G13B9LRV
MP$JL.6\T$-+QLIA6CT!<Y_M@=#@N)80V=2!Q5_#LG?G:B%MUHIA2RSDRG'LS
MSR^@,P9; 9WSA<-G[;!ITR:DZK)PW8V]$@]^&('E^ XO.VXJ*U%TN0=LLRA,
M,6\"*"%*FAQ;X:+)".6;)WM-?,]WX[V\ A7%JBL&HXU&/WAX5NB_,SR%FW?\
M?P/X?_(.'=+C9/7$!J$D,$0$)(P]N-\AR&\(: '2D?V3#J:=;Z[K%7;26>@-
MAHXO=$O3QD8%,A^+F+JY,ZC0-3E<.T$-1MZ#'V Q'86(7:E]C@CKTMGR/KEJ
M>0R$!&4:\NZXKG$,-%2,%)/34C.HDQ<?!=E=OR04,;F72I,_<4GFT/_\QZ]_
M^O'?8NC_2[3^DO%_F00H>5 B:QX$]H1_XK1!TLYL"K+D16+KCX97;?XK1=&<
MKVG@R@#O6%E98K?\0$B$=J7PT@O^AKU@;]H+)ZR@?)X#5T=X;_W"V%F ICZ?
M#3L/SK\>/Y],8$GH/:'4IX;<PA Z>TW2V%T=*J:*+AT&^@!%6UB?DR&3W/HA
M!-00_#3\K",'^1X1''=A)_"X4-+LL;MD+LNB' !C30>GX:!8P'R$7ZA-+: S
M$(73!<$0%IN'X\OQ:;D45-C#1B5EO!/R-&?L84-7*G]S]K#FCZ?&'BE*3&\>
M300E<^/&4$0E6:"82,IK/\C2@S%E>6]@I*&WQ87#>CP20L3%U%!S7*M3 4%'
M*8=F^@'?&,GOP(3(G 9?'.^XEDNLT8'I GH*<B[&I@9BD&_"E$0@+_%Y3GRX
MEZEYNM\BT5Z=F^].T2^S>Q\#,8$Q*B16GD$-.A;/NVY5F\RY+T84Y/_X[SY^
M\&+E>#]44&3>(5'&'V>_3!832<M!7?6JM<.+6UU-4UVGUY0E(9PL/(R87T;?
M6%B67[G)AD2J><B[W+\D '=W1V+B07U;I?Y[GT,"EP6,X/ AX%7\ XR"[\;?
M.?E 3C'2\=(LKB80O@+"?\@XL3N!!7Y.N#L9X31KD)0HN2;Q!RSDD;S<']$'
M^:G7$YY&2W M^SCIX18>$@U(>W=H][D_G(X SX</VN)(EZX2S5E*^*2$^Z%S
MMYCGF9WE)SC\R__X^J>+/__Y9^>'NY!9 2>H+T51U^F!)3B6^&I* +&^WY'E
M'3M%SP[IVOF!=CX5[NB@% 9MB3LJJLJQEXRT-T(/Z"P!Z71\#?[6#U!\Y:;H
M+8H[.S2E+Q'2H\.[M)R"P,#4"^/3:UK4XJ)_2F%W\?I]O8I]R4L349>ROJ@9
M 4:+TNG*'H_+B-PH^9HZQ2@73CZ.4#%QHCIH+9/K%OB&C*=*I=S!8#8D4AY,
M=5 AN"F1D QD0Q+EP10?FD(Y$>5DO!F']1P@_HW,/^^0HG@L?+#B/>,[$V0W
M7)W_)PIQ,U:))W'N[Z^LIS*0$S@-7L4 \Z_BBA Z"D#7+>ETW%,6HYWK>T\H
M06#XF87>-7I'0;2#"1R:T5G6;]@06'S2,<AF\XI11L]4'8_0X.0IK(I*1NF3
M2*DP3)Z[.P$(SB&Q^30 L5!<$E+,>KEQ0Q;;()0S'S6)H5UD_23EW8^8HUS^
M$^M30U#.)0O*<21!.;Q$C$"&0\N< R$Y)+Q BN'4B"->,QF6EBS/2A:?)H4_
M9&\S7UB[B*Q="FO'$[ B8>W:I5R-7F%J'K^YH?]W0FY1KI'&'2W@+F%,FJ]I
ML(/O!D4AQR(<J6^RISB-"Z<T$2+>Q:F BIQ/1BPK64QGTBQ1TRRLQC<EJ]C?
M<49=9HF/56IJF!)G.KJC(PIS'!!::XA=RSTCU\1^>1&C'UC7OYLPAFUP^DI1
M#E'XI:"2QG'\ZZAR?!ZBJRQ)\3AQKV<0[L?A'4WS!NH]\\IE,"T%R.?@(+=8
M$K@!/.QOL-;<&\:7(WW0;FG*^ THRF/"PPY(36".C%K@ _6R8W&NAY+"#?#!
MC4O(4O<]JR>(>CB=!I'D8E(5GXE#L%XX$@0)GA!FXU# BRG++VC! UZP&I20
M2AW(N_F^PDUI&>,^8A,&_%?G;KN#<# L-FD&ZW&3^6=*9DBJ?7DG3&AW2 QQ
M2(>.R6IA3UPF=.'&\YCH=!XYJCS><1B_#QWC K\68R>*J<+KL6"I/&CU2"D.
MK"*6V?SCU%_Y.VKGW^"FD-39V[PO=(H?A:S7<2U4PU"2NV9$"O+>CH" LD=-
MN@ZVXW@(MI #2TY*KQ'1EE1-<OKIB"MX]F?7> EWPMPNSI:OI8Q@S2;\V=P>
M),Y7X$*<[DE<NTO*#R27>_&7'@AZK)M"4:=_)1(*<,[&1]3[%D=)LHBC%4)>
M/ZQNTI/#NYKFW3_ ["N7=)F*\>[F//SI";WY8"P*T_ZX_"P,JNAR=%S^(6@(
M3$R>'_&[T$-K/_13_(IYAY@E+(;>?*CO3![:#^[?HI@ =,)D>J4W%"-](4,Y
MQ5@.SQ@@PS$4:!APLK0'GD3]A+ .GD+0V#-Z(\;I0TVT>2YYT:7#^SP>:DH&
MV9RDN" IH1V/?FL7E9B;[N]$=8&38LV':C]B>>H6FE"B5858'>O1=W4U]["O
MAZJ>)SJIDVDP<JK)E-R%<D^21,=_8A?YAUL4OV&2\*W[D6Y@,[GA,%',O&>'
M=NVPOH^$I, H+:!9W<91F.)_'0C$*.]N$B"FOI/G=O>CFK1XJ*>=>1Y\V$L_
M$L(F1U9ZAIAT%:0KGSSM;G2$SBA$>_Q,_@VEMUEXZ-NGA(P(/3I;TJ6SACZ/
M@X9 G#[MS2'=38:9R,.VE]%L]=^9'Z/J(Z*?@8XDKY)@QS5^&[AT".+PX:^'
M:3)UAR-35IVD'9%'1V-N.&>1_6GDL)[KS[^QB:M$T)5QLP0+'#B)5P<26HM&
MK&**E6V?9*BCIEM,WSR$^(D2.D?E05D!_[4:U,B2U<3 QR\00'GL*R^)HO["
M:2Z0"7D56\H$EHI/TIG5T#RC,H?'Z&_]; NE).8A];?F\8BS9.9Y!,'%#2"6
MT?>(^SWJJR.Q,4G]"F<>\ECG?%PL!IUB9*<T]/$S@]\$9\V$DAN6<8+<^OB$
M\-36G!-NXK@%)U93<((+CE\H-$:O]PSK8S(3[BB%[W^)(/T00FV@I#Q#(S?G
M014@@H3)7CA\NDXQ7P<F#!9U,N7S9;YXY'(VO><]3P!CRLO%TVMWEJ6;* :T
MA '!0MCMZN9]'Q%9I6<0)8KTF^>RSXZ1JL *@JAA&\S:LS2-_=>,.&V64;F<
M""]STC,>$QS'KPB_7Q%7[5+W^_C(/"/16'5>BAX"<2!XTE:JL_"Q+C@[EN[W
MX^:"^,KKS8J)GGR3[/VEP!A3!^ IVKM!NN]E/F1]3&8S[#7G$O00[6ATPQ@+
MB+F-HRU'5YNOA?NBWTN Q0RM<>^D)%T.\R4\H.D5,@'F]N"T5F$(1&I/B])
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MJFIJC1?5,E"].[."%1"R.U\+ZZT*]94VM(($ LC/O/J:TBNU5N9-4 >#_XV
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MIK",+A&UN[] ,>+E!MTDNUU#D<>.WUNQ(AI5]EY76:W-=\;3@RB< K';N0!
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MAT44?1%*77K\1RNF6HW?UCV25&VM(*1B3M"4?9<UM(*$6W62B.C5YFG">4$
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M:#<1CB^4R%KYZLND\4.#YT%;#>_F^RK(P+[Y+8J\#S]0:2V=NS&HSJ =5JP
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MCG2JO&H;)U5B5$-(TIF4K&T.9LK%DU)U.M5MU379H92$)8^O.G56]34.:*/
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MKT16F*WB(+#N%J(OVF3Q-[2]/A4O25Q.4N66H0\ 0$-P*7QW^=L7Q!*GQ?T
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MT[ND_3&D@#7AI;ND;0&A,IW17Q>T;]G0H>QJ@_\;P^&BVYB/GDX+RCX67%\
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M[O7^5_>*Q?VO)P 7Y)!N/%@=0RKR8!-U65$33'MC-H;Q7B3H4MYLOAI"J&_
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ML7 )O=;V_-7K\Z&V#%$O:\OYM-LA$GAV.3(D4H\4IHZ34YR\KO 1+P\$*XQ
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M7FUD\6#E088MW @(8,5"FGW=B$X(K'A(-=L;@0"L:$AU!C " 4"!D.EB8 0
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MDH6,#]332O<(@(PD@!.K)[F\&GQ_<>>@"L*K(:,#Y)CVS-.0$;,MS'.CY4T
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MW^K C$NN>)"S+VO(J,SQ*F_?]Z"QD/.F%TEE;3QHIVP!]GTI>2E87OVQO$X
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M/-I[3P,+,@1+\<&"Y/EGDBN/46U!QAL&?7)80' 8# Z#RX%_)H?!X+ 6'-9
M7Z3CU)3!02TXJ(7]"0YJ%P>U\_I*7[6>L/XI+^(C!F'[DL?)ZU4-&RD_A?_Y
MF&[1(7BR!4^VX,DVQE[9/6H7G3#;%4?0PZY!J:Y)QSY,50/K.V['44RF7#NS
MOG3[UWD+7W<+TPTFUOT]%+@W5O\599LX%Q\Q,Q_TL-8Z@R4_15F!19LWC%WR
MNL9-\WUZZ/LP\5KZ06^T6A)SD!WUNWY 2B]/,\]9IG[9O<3O$F7BV&B:^:![
MM!F20 9'GN#((^'((WJ=.;YZ@XJZ4)P<XHH749Q\ :6U87@C!&^9N<O+=30
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MJ-IU.KG0FMKD'S(Z<Q8[D>AK,]23HR:GKHC;Q=X>L93@]%UAM+8V?8Z2F[H
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ML0IH>S>2IUZ-:C<HCGL R&E\K;9XJ:]VVNQK.++6^C62G#CJL&W=[\NY@/>
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M3Q^*#,LP($2DEDX\SDY!%&K%@<J$H[DBC[CDG.DCD;U*TI'("UY1N6!A(1U
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M7Z4;J[F[ H+Y,R7U^AX='IGUP?+FD!(F5DV%]WBGFHJ6;YH7>O!&*N\^\<&
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M+,NSV>4. +5H3O&$%'<D"T>*2 ^S&<XS<T_JU/4;.:<O.G7S+L^_4$L#!!0
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MTSG%,8-ON=8XWWOGSI68A"5D(UZ@K,V3$-9V*F!\@&\<!UX^IX_*B5N(FNC
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M=K9ILLR^G.Y%>VG=B+47HSL0=WFON'ERYZE37605\!\<!9\)=V,AE*9G!4Z
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MR2(?5Y6BZ">OO H;$AG;/X3WQ: $;$#94<[M#+9;DZP/J!G$'@IET]Z;K-^
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M4MI_<T1]IX.RIX4%(@A*K-!YO4)"NQO_%#B(IR!?XV51^,8S7ZSU,K$G, I
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MH$,,-T00CFN!,D#H$T'J<:\WE0!&CWA/<P1NM1%V^D5>7&BV>9X#<HIJ92S
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MLMZ7[P#Q#9X@CA<=5)"/6%*QI_$.51O+DK1:DEI,@3S &E.E969'W!>.8UX
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M%4.WMJ@<4!&&/@@_N(9&C2LSE(+?&=>B!DC2YQC!Q<M^1L1LW>62]XO@<SL
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M%';XN2*!OGA@!<91OOT6R_ OD*49,2YD+8M.JOZZW&YV ZWABZ$NJ3O]4 Z
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M:<^G6.[P%D'>E!5#@GP:M=I?E%!+1E4F&HX6JS([887+6@-56B66E'%\[CV
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MB5LN2JW=%=R;/2U+U2=KG$&/G;A(ED4M>A[#8P+9Z%A+IWE\-*42_^%H##+
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MBZTK>[V2/?/!G.$W2"1!TQ[IKE.6$A$EE$C:8XF^X6[#685W]0%CBR9XZH[
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MH3CFX9CCQ"+L',(Q(@I:M$U.$R^2UX7*ANTY8S,#!&"K ] Z")4/@\<,8!/
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M$BM^=VT5$[>-M;WL48!W;I"WK!,2NZ.3C?MU0#.!-(\*F=E(/\8R]9&' 2A
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MPF;1K3*,)Q'FX3 #,L,Q'5#M*P^..;NW);YA3^[-V;6G:4M.^H4>J$;,-.%
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MG%!^9<5Q"_A#:MR3/!="LM+H.XN>3S$JW)A$LTK];*U[;(];DJE_[LT>!/M
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M66Y"1GS.N\[U5AML9L42O(X=U5:O]/AL<J(>F.GQ ?YI_],;0@G9'1#F9V-
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M\^NN&W,Y=.AB(UZCJ66DQOO'(V-/ZH7RCF='#LDOU#ZF&9<_W-1P?BPMI4$
M_C\'T+'<\K%Z(44EQ,'$*'TF1.R9X]2PAV[XRSZCZ.H24HJVE:EC&+NN\=&Q
M<<@V.7<']Q*W>&;""G-)8BZ>-V'S?I^L&7[7,BHF9+0]S4E, A(O2S&(L\J6
MLM62K07M9JN?V?R]U7#,_<MRE&C_@Y1_A.G_3&&:6X4V(),ZS$(HFHC5%D'=
M&W.U4@UDS356W\J2Q].2^9,VY$PGT1&?&[D<I".0:QGH8<H?1ADV2<>-D!]1
M;GD0=-?-"MNH ,4>BD;6>'%;G$O,R/19L<L=&9!-<]#&]VEM)4%%3QJ0+0JD
M[&!6"'JK*X2O,W$3,\BG1 2%R=]KX0K\YM/'4[H_=]DLO']0#F9E43S]Q,VV
MI_KM#H0B_G>@V G\#UC4#?F'(_]PY']R\89&[8K+$O_% +Q\2@XP$[\Q-_":
MR=\$^46RCTA"AX\>^>K;A^_18:1TT))\W_ O2ANLK($?$C6VW,4O6G\$=>K>
MK+#96TCEZ+27*;R3B6%K)-6>I;1-1V4Z%!]\*U%M3B_#'5;&L8/CKYC^25GL
M/$@['2\LU3^-BO+6$B'K*%W*QPTC^F?.%S-J9O2X/ +<%'T&*5?_(>P_A/V'
ML/^9L C$HJXL4:^RAP&8-S6&\/C,-CC2AY_SCWW-.1\H9?^R7"( 2S7I'QD,
M1(,VK"Q'9"+8?F5_RG8<A+AHW;/>4,.+][:(*/*UDC1S4TLJ._6]ZF"?F4Y*
M)A72AZ:,\P4V-S^TR)V#*IG6=BQ85W8\-TZKFCU.V=91]7%X_W0UR'NTL5#
MM&J@&O>'[.64^N0K7W=F24D%E2,LBC &P"7K[Z[-7,5?%Z=R_!_X_*-6__/4
MBNI)UR2^FCFI@S_!!U\N<[ZD0Z^^^_/F+W=_/OR)NYL%'=7( %Q4(D*30AF
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MSROL[#OT=7XZ]<U<+Y@4Y7B- 9CAKY@;#^(:9,X]R6P-?#*@3)/J+5DCQS,
M[DL)X-/;-\&ZVV^2SM6.G[Y)D@;\=PWS*6#)@V[HL<_/[%_PF@'8M<<;4<_^
MX\MG'4MT@PX9!L#I%89>51^_ Y)@ &YH)@-)-W !-+_@^\>;2=*8<O M-NDW
MO_YW3;TIX(S#"TKBJ6< )M^AO@'),JO4$H\#%N;'K[(Q#]A)B(7?*4/^X6+$
M -1EI].S]:"!3*TQ9<XW!>P)IEPF,Z7*ZC!&;DL%?&3#G'.2:9 2O8;\B":E
MP(0H> !*"H9K, "ST/[HM6'I-UTIU'GI-TF _ZY1HNFL3+&0ZJ7<9@(:AV0
MWF$2Y+Y"A!F /W#X"8IPV"I-YXG-'))@@CW3!2ZLT@?9&0":'OPN]#IL@F[
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M[Y;6CSCDUM;1\KW,RYU8I9Y/"JWT&1ZBWF>ZG>F2[-C_8F1L7N^LLB$D=AF
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M7HPE.Y \U^U)-'IK-;71T=5"\1/9@V,VE.PX8])>H\JX5>)%MGY+M;%6A=Z
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M^KT!*=&;EU4L!<6DSJH+NQ?Q!;G>5.9WSY$I,QW#F_GKR/XRV>%G_HD>X!0
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MKOZ+YW-3T=2*.U7KTV?-!P,DSP6KEG<7P#J8_&_POON)<?UPFL+.'H-)4Z!
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M8!0#$0>'5K?P>%.W>&?FIBV\4$/\']X=UEAPO$$K>]S^B;[V+[88($:#)4)
M]"_]\2V85+8L$*3ZBY+"K[9S1<Q3\((A3=)"U?V[>71TS3HV=E_Z[K=S]<';
MW[S/%* PYT.-_"?]H?LLE1_NJF2K]YA@+\WVNTYM:MFNF9J.J2K>BD?&J4J]
MF_@%$M/=_T)AX<LEZC&7*$JUAQH2?G5:<#4+Z4"2(HKC""<^=%1Y(>@Y5HFD
MT'Y^\#OM(OUP3'MH=LA,QLZ?T7FE)"8XQEE[V=*:M0?DEFTX@\C!H/5.@10:
MGG\]RB2MRZYL?4&:,9FP[Y#V4UH9-AV\H[TCUJ</QX4=%=#JU(8O!Z(,/?8+
M,AHWZ>XN!]\/T%ZA.C7U6_G$I+TA7W+Q;Q-J$4'19/WZTOJ J+IMK,L0S&&R
M?I4XT<K[]L^SY@6?!Y/J??_^R]W)K7'(VV$K7%;O?NGYEZM5YVV7K5W'<-K+
MIRO4$'**[J:$?]]WY&=9">DU=PFWQ>'\L%F/&L]&D9"?W86*T?HBRI;A54PE
M2]N-[S:A&<T5BG=%5V)#3>/1S]$?0-^#0/3[&.95#G%@]GP0>_\N\\4UF; *
M3%B70.Q_B+V+1T[Y,4BPPS'754X<>*$EC[FF,I0@QURDX ,5W-%+F6O'7%L=
MM-X?W_['*@KE_>C]2. 6$P0$LWD.*M$3QUPRZ%.;(%'6G3<H"P*]; R!N=@5
ML\3\G ;9=1S]6:1Q-=:089G[^NJ,*7KLGS682]*RRK6BV?L..DP[] ?,*; 5
M77(_\*@,^A#.#;2_WR>"(+(SJ*L-@!&M^W',700+5OL%>&<QNJNJ0[RT=9C:
M&5E0A[Q]?_Q-,1..,R*.[ZE*VJ=;2.C5LZ<9ML"62@X"W%G/K=-KC0U+_D<T
M*+'LN9-M\SUY&63GJPCK8DB]6G[V^<=5EG6!TDH6"B-ZSO9'G<2_6%8"8B5D
MY+T?\5KWW![Q#2"/Z.GPE.$U2GB'@]Y'OQ6]0 HU]-99,46R63&D&VR DN>^
M1?&<6!$Q3GL4A3KF^GO"80HD1/0@SN&I@@F[8!N&X!(;_Y_U)^[*8^"+^__L
MC9S;LH8#I>Z.PYEEZT\@((9 324R<<%4:4YN]1FBRM&DLG;NX;35Y@58$,B.
M!@,4%';P5/4S"ZS?IPDG@/3I7OU'N?+-E:9!=8"6W=1VRXRGUKSK%Z2Y*4/U
M5\H#ILKY'VZ]\MAVT;_[K[5K&$D]UF2:)R%#2?%&9'%9K%)-"39_*$3@<C[#
M=D5)6VYGQ[G:KDK7LB!KK,:B8RZ42(;RL?ZT:P0BJ;\DJP_<A?18P['4>P?V
M@PU:.5<O]"UO'!GBN.,*Z:\J^R\FINEKYDA>%+FY/F$%Y"0?:BW!MS.91NBQ
MA@!=W!G(9?\%[?$6WL3MO2 XT[QW0>K33G!9_",Q2[<P2F=?[!LW?T0@?7ZD
M?,Y])"8X*!01&AI\2??)B/H8M(FX'5/MS/Z".0_UA<V]H_K456PLR+8P""6U
M@+G-9/#/?UKKH): ]W):M/&$-E$84'=IUYVZL-4IW8(+HK.)<K6YSC'#!1$J
MR;EMV#"!:Q\>;SZMJ<H@35,>'CQ1U^I;>>5J+U2/X%,3Y%>QLV^PQI]_D55E
M%*WK,&OSN/!6M;'FJC9UEU]O.I$!5I2""JYV\-6D=J0H4E-SD[7NU=PDT5M=
M1VY]1*P@'0=O8T\2),KTD7F#6[P\>[5_>!@3FWLGJRS&,86V#IOJ)/QL,S4C
MA2W/7F"+9B[EDC,2)7Q[-MBRLZR;$"[&8EP7-)C^03M8"*#UFDRB3-3)ZM+(
MZ/L,D;2RXB3/%SJ=R,7[&HCI_ON?(F[7;#DE#$'Y_UVQ/E=!^Q7;);U\S(5=
M/-<*%04,^SN+&]\@?9W'N^XLK=.*?_Q>8-<VB;-MZV*(U/W"MFR9=XL>#C*]
MR%.=QB\,?LW4UN'+.R>U.X(U*RBWE)&XVN4;!^$W:DZ,.&A0EFZTK*CT<_U0
M,=#[X;ER?<+1<:*PQ%F[3,ZXS@PRE:9KNTE&VO4U8NV_?\S5H)G-UHP<8<42
M-%%,;;)-66\>"QD 2JPLR1HO<^!7&:N72%,"]#LZ0XJU>!+ZP/(WNT(2!BXY
MS!,%B _Q,@#W?A, HQON_PTH+%N8P41<"25A]"W2@A+=+><=[4B0J>N2(TM=
M%/NP+*W>4^9%&/OZ\E=DZL]R/Y7Z6GOVP'ZT;WTP^9BK"4_&R:#'B2*$\ZA3
M@,$R]AV]/5FG)V I)MB97E]1B]2Z@]V**,.G@#V\\&Y(^?G/US[-]D>QE;K:
MBNVQ0SHQ]D KI6\P\7MD8GC.;9YM43NI-:;A5H=8;M?I1BT2T]O-\VUW?A5W
MU+>7I-G*6L.JH3.#ZOS( 7&4QN-_PKPS<*)V2ZV]>+D1APO]D+*<3T/N0HYB
MV=7N"X[^C*_O^X55IO,UJU0(>I'G?P"'R8=BRQ7;9<R[Z*&@4EP:CF\/<_IS
MP*Z*/J3\$!M+XQ<Z7#U''ILUP2,=[*>U;2>$A->*]%V W53E:Z3Y_DNIA![$
M,=?IZ:/V792.6(HJ^P2'&F;#$(8NR5/!0DBA:7)=Q671)2CK2JZ[4D+?R:]]
MF\39G1)^PY&KG[>)B*-)!.0J]1 9>%.S/#ISG.3EK?> 8?.1;M7KN69IIH65
MZ*JIMEOAT1'ORRI?EL\T;<[/2(!<\0R3&E'HI2N(T[10.442LWT.)O$_.M^F
MVYA?Y+'MG?Q(UZ9KDI<4IRO$+5,9ME7&M;**=P84FZG5RC]SJ9'O!>-E?N.@
M@3]Z' >*V#W7.M('2H"+HA2H&!Z@:F]$V!F24KH)^0VXY5&)V*4R@SP7>QWJ
M5(G)K8!SC(-15U?<HF@R<J6U.2!XJ'I<=:AAMNS>5(Z,2(E*J595%LW-;SS5
MWU.1>@/YP3(VWBS=5EHEZ'J5K6VU_HO*(AT1<5A!$M)$D^H*/>\9)C&C]&E9
M0+0W])&+E/0](]-/@Z%.]:&9XR49=O29"'-I*4O3E,(-CY7D_U3:]@[HY=D6
MF=DF7W_=;;CRG'A'!W1@A,=BM@^[#(^YJI7-\2.=1Z<G,"NB!/%CKN9-AB"[
MLDZ-$):(AH X,9EQXIBK7"-A R)US,5-AC)OSM\YYJJ:U3CX973)8117\/\L
MU2U%27\*QXF@7 $G:EK4^,XA*)&#2K)WIFI1S )X&T*_/ZFE&VK5PK3(FOJ5
M<\SEU]R1#X*,T7A?11[\;7&I.OWM5(W$)?_I_,QX"3NE#T8*"A*A82^3@Q3D
M,YN"E+^-36R^IRKY7)Z7.9E:(C$S;P_B,;-S+;74T= I,2ZLUC-^?-\Z/RPT
M[NOK JO,)G28$<;$7?_?@\]/3]/Q.Z&OT?UBBTW$U""4.8UI(6H@2Q.(9030
MW%9R<#$T57DWRZ&*,1V8C*5G\N1O>;[O7B[:8A4<5W)(YD_R2NC!"2 Z+!C;
MN 6B6X_$1[J+3Z+5D%M+(&S79327?ZB_^]7QB'4=HA12EP9*TKY\;92E5;,1
M!4V,>"O71J^+GW>N+WA:[KJI'SCFC&B[F3M],^A@3U!8T^R5;S+9^V *SO-
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M&ETZA50/E=R3E>!'P>(./38I _0 82RR-@ICVUMKQ&U?*^*,6KAB%",<S51
M?VJ3X.XYYA*RH,^Q8Z#+7P<%2;Q!MYWH?7B:H.2W-NQ>Q7B70EE 9+%B2Q-V
MF#;W;>O^9'@0A#0\MSD67?/*L[,=<3LC&=>@OO.4[M 3B;O OH82F6J!<B,^
MG.XL;_7"(W4I/&]Z0OYY\<5_'RW$D']7N7$SX-J+?H/54M^@H "5).F/C;>K
M7ZP="-4DO/Y16V9/F:PRY#5===1Q$'9/0WA4C_:.1[RML2M+C*NTK; P"ZD3
MMWYI8WD](X'U%'S3(RWA-".\X:FEF&#Z4&@HIZ<= YO/I/38?&QX]9'4V:/O
MJ**FK%9G#DH@>_I:IJ%$G)'5-MD\?:7_SA6V4Z';!DP[5"C]&DX8(LJ2GF+9
M+,7G6CWG#XW \/H-5IN^^8?N+WMGG'4'C]#')^;,;2IN._U4EC8"6;5UCGOY
M$EL[VC/F,$MEQUPGT&+L$>AEM"C2A J+P_5TFB1"?1=/(\?)$@\[1Y(BJM3
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MI_<^=G$J7J4&N,4XR<R+&PX%.F(W=32U19[>77CZ%6Z6ICV\UMV6;ZH73Y<
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M30K3HT$CF2*4RY@+=,*5-[3$A)=I[6&*[Y^%ROV6L]@F)FLVW7MWRE&EH-!
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M4N\H7+T+V3B<J"V>7BBU,.6S2:B5S#@X^@]R^[,]0<O>8.X@Y27Z_@Q2M*<
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MP%_VMH7??J%J^+8R"<A7!@8/$D^V@&27G;ICO/(J%38H-2!MX 3=FY:(.2
M(66<2O0BH1) 2-> <\%))>F:R_61U1:WZ5C#V=D-9DQ,-!%NHE">5Q'  =<Z
M6F)LO[VS%__CX\:S--WXI?E?>MX/^_^17;8;K3ETU#>A,JZK*U)MW>59D&.5
MHKW7(.SC\E#G>9\!N6<+3PL0F7F!&9_#@4\#BL87G>/9'JN6?[N=O!(?.VGE
M6ONY5_SRRYQA(>OPRW[_?][#O?OEK;GVJ/]L/"X)'WA6[/HYC3!;WRMK(J3H
M[&/E6K:GGX;)UA]+D>"OD,TZDBP\I&%865K/PCMQ!O_T12FL]BGTS?)ZS3SO
MXYZ,E/F-+OQ2&77@GQ,>W\9P.51M,U/T@X/:&_Z<T5V11\F\6#X6$PI]"&^@
MK4YP%9:PS4G=ZQDT,0B&?6\T9%<$3WS(-?/\;F)$GKD^83NVYC77C17GA;\,
MN0-Q#Y_I4PW9\9GZ3#!T%SWW.FNU3E@O5( ,M@6G?)QT'4&E</YDPU?#N';6
MK$1X%OK %QEF7QPI2"H1?L1<EHHL09VH#551!JKH]:KD>QPJ)[=^0-9(H#@.
M,?*/.@2+-*+:5&*G=]!5R1R;5IUCQXU<U;S2ZE;SGODZ7*^-N6VIT3XP-75J
M>MAG<><S*&CIKFV)G7/82&W9VC&743.<>N-">$[PW9G9 5^IL1!M5JZ%\'HK
M!3-8!:*!8!QTB!3@ *C1$HDF@(4P+\H(_EQ39!93KY6+!.09>W>V4R"G"@HQ
M5&GD^1[X'@/QSR;'+6Q'=1"HM+! [Y;F:"J%Z[3@<2.$"Q>(\;FQWTFMX$3B
M&4^AR0[P@KD0%)+_C*CAAP+QGZ-_0_TYBL^(@@.8N0,ZUT;QW'IH]\[^&>6>
M4FFV1-T,5A(HZ!=7V+HY$JE9OYI9I+]FX1AYQB/U2J2ZPIT>Y[Q1[2\UQE:U
M]L4U]B4PEY<5E<H7>C4O:+3#*@[W.-:H'>AWSRW*,M!ZD_X5/%AVH>M,<49Q
MR+G[ISEVN"\VVNR=3<'!)7J[ Z!EU\J321/(J=2H)\S<(DA$<Z_@TD5Y)\9!
M>'05JVU79,ZMF'40(9YUP"PW9)LD\0H](]F^*R*VXXOILM-DY2)]X)>V1<=(
M] I0*RYK5^3:M-14KCW@RC6F"BCP(] 0!ZJR!;^$("U,M/0VS'NN+>((D$6F
M_FBN#)$WUQM#[9E;TR<;C*<713R&>RZY?:EG=!0ZN[8:;H*<N[DV^B6F#M(P
MMXI*DW"G2HU^F]M.1?'R.MXA=])@OI6145M%Q_)O5B&'JY=<0F1R7652PQT=
M[^02<GQ28:WE]P*7?.5^/629<DJ$/GX&S#%;XU#:;+) +%"HDA]"#S:GK;R%
M^+-#[?@DM"+*JX/EF^[ERQ^KY)/(]3+"79(,X#+-LS7[$O/&"^Z/Q1<,TXC/
M1V#'BSO!2WQ_M[SJCU:WB\-\8[1&0WLG0CT=2RY75751\U^MW2P>*;D\:N_H
M##-%;^3;V',<+H_%GQIOKQC[@8L8T7A!/,NOA8:2@)N(%'A#%7D(<">QBC%D
M'_0PA]2TS>GCJ6%90D[21>0Z/.!=F\, MIBF71&&T@2)H3TEC"0L)Y C-8TR
M:!?2T3 !%=[(SYF_]&S9-D>\R"VO/@(?[_/M!]7+2G<]*E2[_<1@^*.%W$:"
MZ^IL8TZZ6TK'C9&-CMFDJ5'W![9<6Q0XB?/R#3]S=L4+I!0)?J#4NJ8;>ET_
M.BNIF(%.8\M; KZ8B!T@]X-=,,0=M_2EK_P)84G'SWLL]\;?S>L_*Q6MO@Z'
M+Z3FW:Y'ME-MV^[=0ULXI>-N8K7#[\7 O)8X]^LA7:D:-0K_D6MP)70?K;F/
M9X NY_IZ8+K^55#B D5OS@" XZK^(K'RA1?M+ PN&D];2AQU@0WFZ8#  FF<
M)*8+S'\G_$-8B4D,61H3O#JTBL4+][:MCB5]:.3JO:Z\0,F-G]#)20M96M*H
ML7:ACI]SB 4'OH[O"J^1,S;MF1W\?(MZ7[]TJ?[1&X,H\1K 1=[R7*A[D%QE
MJN'C+(F5D; ,/\XX;'*OWK5$"<M'JO:<[+X]\"G$^-'ZTY]MNU86SD6WC8W<
MDOEXN%CEV$3%Y/!+7)5N/ZYP(3F@86+.*N/V_J<(G;,K]_^6O3W\7\R7]Q_I
M^OO;?Y]L!FV_M'IX2P OEG\:5SVCMWF@X_QJ_]H18LDQ[\;LV7[!K</KXP=R
M!5K1)S<]'CXG_Q$W=">MY%+DN33_NB=CV-\.K91IOTFWHK9KJ16)(/Z;\_YG
MOCZSLK>A--D'WP7P9-<#L.N/>S%O].6G3EIBD%=1Q@@M#_R2S3G[6X:?"@M+
M)*X&-2(ZV":_<.KYS'U9H0XZL_81$@<=CU04M;QH^9@"Z=QK6"3K^7B(GZN3
M"ZM?$?FO'TK*/60$2C'6U,@5#^NE6_M..:L&/)F_\6C;,:'O5@\&65+ O&)4
MLM/)(C_5E]"S4/W;:U)&>TAWX$,4T;<*ZS+^,J_A(UBO)NJ$0-WBR>,]]__+
MJ2 /2<F=<9 ('1S,CA]!3!)R>G[7.#IRQ"\8%_']A>.L.PGOT3?$26YXBQB7
M3P7ULV;;U9^P?MVWX_ZJ@;0,J4P'*[1]M:@-RNER.?0K>\7+XOFO0N<&U37'
MVU_^JT?OPB9JAC.&\8S%7T27GFC]4\7CA1ZFJ=EH\I$MUS!_\%-R69I3_J.F
MV+@!&/A6F]+BUA3D'<$<,I$.8XH'];_:Z%+[G/F"J>ZQ%:9[6T;CU,9I.[>3
MPZ](4T9'+(]Q9O:)8,[#61$O_WW/PV$U@7L$&<@-]&.M\T[!62[0J=9+PI"+
MZZ)F<:Q3?H+7,(E0O J6W\3X[/WQK>#3!'X(']MZ>10]!)UL/J#[ _4459^Q
M#8\GT;$D5N^NR!Y2*.G(K@@Y[-\U%W9%0G# WT)!O"N2X@7BB*X]Y<(P76S6
M4 *TB7>"J;TKLI:U;PG.2D3"N>*^'3,<78LKFS^(E*K:Z6C-C,6MY=2UG37+
MQ/*$5+RF?<7"#VSS8LF%GE!Q<C9E!K8)=ZD/'-BZ#+'TL8@JN=QU=OBU_>5!
MW25MV^+B5Z[U$U6L\EV1O:U"7&>@A1UK O&DR8RLU=LM4#DT6#!Y7_X1-&CH
MT'>2B#F(I\DN[8"F\ES9T#EH+U@.J7TYK?M+T"82[6NX;<E^^3"V_JN'0RW<
MP_-S3%A8Q;)7<RO'AY#5+?40V@Q:712>)H#_ $K/N*1KU$EK ?-D*9RLL74#
MVEYDKM?HJS7!4=XQ<\-&-J<F=(Z+D_!:)O[!VBJI_X25! O^H$X&4>M[7CY&
MGT9&"^61T\CKU4K!ML;KQ>*1C.#QRKAPSMO6S#JE)UFAGY-3:[]O-%\J2M!R
MU>HOCTNO--5H2PFYH]-67JD4>5;+;^C0F[RO&EQ3Q]R*VDV_5U]K71+4)&\'
M*/A^O-@A-6=$7RCF1F ZSY/HC=#&P&[<=-<<YS*%("'D7I) "*WA5"&H@8NR
MP0-WJT*%)01/VC^)VI?;ZQ78O7X(>6>!TNOOV,:2)T/%9SUG?3K#Z4\C\U*.
MS%FUIUWAI@DDC=GK"2A-!GC2U HH9M4Q7C:PBCWYM3K-)'G!,.@83Y?=Q'00
MTOJI)!=6<VE>J1(;GDF41BFSMQ]> \JCF D3S76ZJEV8(]8I:)40ZLTT9AC(
M]TM%EKN\VZ[(2(+<X*;>+7MY.1,QES+82%&EXXCK$5=5&T=\P.J\O4SZ+7[%
MZ9H>&TF]*S&QL%JY[U9-X?6.+FDU^QP[N9GA0OD0>:'7J>U;7C1->\'&^C^1
ML?;%_"02QWDN#)"?2 N."SNRI95)2MD583D,B3NPSO>@?^,_VX)/4KJ(4""A
M&G6\\$\6)D, $@RUFA24[HI(^H\1 JI#T^A@V:'H.VUY;:T\G>IOHZ]XMI$(
M#!G=3=07'OD:IBM1^(% #_@I"C]OK4#Q4CPY\'N0"D0,P<[MNA\8AS80]).4
MS?<B<7^S<2FW#3!9&$5H$$("*2EAW8.68+E^*C)L#F5QN]':8P3=X)<&N2OC
M*I+F,JV-38)?WU^G!!Z\'57FJ*DE:3XDIW7N;EGB3B-GI-Q&LO(".)92M1H=
M4''S!179ISM_I=G#2-Z+]U/NKW(O?"@T4"G_=)EQOY96!;]^_#7DXWD@#NA@
M@B9)'']A3\LPG;X\:V%H% ![S?6$"?WG$N;@*?XC'"J&)=]+DL-CD\U%FUE)
M&3^+:4G0/;QKE<B8WGM8*4)DM-P0.4MT"FBR);$Z%I-0,$;L'=NPF"YW3F/P
M]K$LGNP>QE ZA6,D/(D2RA[:%)@LI(3KD^4,>);Y62!W3KT3FBR0^,\BPR*L
MB=4&(4IADW]."^G8K#&P1B>!EOUDV$D]<-'/C 9FR1VI0T ;^1)((HSG68TR
M=9UPBQ7OFH#/N,J=_?PUX!*Z][9+^8%!L+2Z9:\"["JE_"(EHOISEWWYLSG?
MVK09O)HQ;$!W(2,HQJ-Z]$Z>5YF<ZP6F?TI(?8"!4X5+^8=R,4>_SU.SX>ES
M/%4AXDG\E$JAB9+H[:5Z_!R!%G*%\X3EW@.?Q+I^V;+%/H*S'#Y ;TA-*3-%
M>S"'D/8[NB<Q#]K4L'V(8Z&E8""W*O@,<L"6[9[TDQ2'5A2,C1L<M_6.\QK]
M8= !$AR!&PBUA!L-M"M"S\&P_@(?0^[Q'6W&3.5RH$!E&4J7_PX<*375)X2R
MXQ!-%H+9^@@E03]N>ID-ZG%XZ+Z-/@22X8FR-K37%9>*?CJ:K2=$+D%\0QD#
M8&G;ZA#RGQ.8+Y*IE<^:C8>6?]C+E3D=&].$%QC#:VW..Y(O/:M<7=.P<WX4
MGT,XG?]POBZ;/'VJTOY*SI6:4,*E;G5YK8VBK'/ASWR^+52L&9O!6?E<TR#:
M(<)%!@G0J^J%3BW.<6K8<XS %"@]EX1W2"">0#;1A:IASHZ?NBMR'7,8!1LF
M2B_? 6PV.XW*YVBID;H(YE 2_L1<['G?D:N ;EEPVS,E7#+!5CV=>BVD5&<G
MB4[KI#W"-B7QE#5K>!C DWL4 ,_!>[+2:8V+\90Y*^RUL#E?[1[:T9_PPR@'
M"C[V'B998 X$,+/$4+=&S8\C5?]Z]XZM5\X BR*GK? M7_0O_&R_]AR(W#*[
M1.;*OGCQ,DSS+3A 38%Y9JRBHS&MYI"!,27C0IMLM7:KG)IQ+Z0@-1TA=X*L
M=Z6=D[T0H3WB,/5.PY[P:^9R[9BVF1PEOE(O]..[D&%!#+8Q;+VKQ%MP4,A-
M]SJ-H<4!H0NKNA%[5M *P 1KVW,,&HB=;!(ZKA%+5E;0ISUL6IK] S"J!=;[
MJ*_;F6!JG ]K)K,Q#!7)1,B$FKS&!0IC_I MLULPR@[XAN#(KYK2X0])>Z'T
MYUB6-W;*N9-TD CBR?#;S$^%D)3U2/2G!>&H_0BI93]Y5H40NM&&OI:Q+.^^
M(G#\SR%)G@[+PG/9[S"AV)[""Z6;&747A3<WC,QR;#7G&@23075USV)<C;EB
ME9!S9?7(F4&%FNME3B\250X_0ZC;5)I?;GM\9YOY;;5FGOBYL[;AML$,G&'S
MM9'<%<]0"1G)"_@1<]FAU.;(_/:I%[F[(F>QCV;W @'5Z,_8)M'5^7 VR1<(
MYMY%RG,2A\&WA%0 \PC+NGQT D-_#I<R/X.,ZE/JX;>F$ARX?R%;.1F .CB5
M((?0;_,=;Z@.55$=,>^IVA6Y$2S!B(F&R!EQU%<+>XX[<RP 72$\"$7FH\<D
MGAR6GK'=>UR>DPX$LY(N\1-U>-9<,^0TYT$+^T<**!Y?K^T.1++.__U%'ZH,
MDN!=(HZ:DY][A-Y3[R)-H=5'>-9W!*=9-XIF/SMS75[4OHQ8'KSM$J(Q6N5U
MY!O.OL2CO]E+KKC2J_2HY%FG,KD!)X.;<YI5SD4^W93^,>-.K3=Y929./C^K
MC&%.54XYKII#TFJ:QF-Y[\JTPM-'O1(*-7D,3&>=F_M]!.](:-?.O;(P@Q)^
M4A\ML\6]I5 :[WZT]1[Q9..C!2KRR?[,H-,9S +#W[+'\AY<Q"W2.#_80V1X
M,OPHB=[BY9"&$F6Y<^X!*Y(=;/-I& !E@B>WYW!KMEQ'P7"I. !_@8P/PN E
MB]F4WEDH&T'&3L6\#_]>4,-\RG-FY9+1"BR'))3NR^"H"=O(L!< QF>,-'PT
MM;<@=)7]A!#X)A=95#I\R2 O6M?+X)UWOF97A7>J_<_17/Q2OPRL:/3]!<8;
M(,!5[=*Q3*>*^2%NE<-3C='X,K5[8R^96^FC+ZC0(<H<L95U+QA*GS"+X=2R
M I/19WG2%*$#H7)PGANKGA2/LF5[;3JS[CUD;;X_9_:C@9[QNZYMM_D95E+<
MVD\N^#"RE<SQNM?2JB+*$N "P4E;G\W4AL&QY70\2<Q<!UDLD#3GO]P5N;K^
MVV<Z%E!7SR#1G]!D>""&A#5Y5T3" !>W*W(0$LG&_<5_UCQ<OXR5@DC4 7?)
MFD'Z,26F3 AUOKXEJ\)W*0JMF71E+"+-G1V0"^-?1]WE/T1+H;^ FG&KQ=P
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M"&R.]H!X!G@E, (<:K\+3+_\^WK.%*WGJ DX+0RE.%>O0G,$8A@IS1W*SJR
MM=+6%T,G5XJ\@"BGIF$=6Y8X)Y?_!$-/I[%@#M/;S,4$GF\E#RD$P)NH&#Q0
M7H=T\&WL<$@^BFW ]&#3W94,FUB+W891O],<1[J)8F]9XM[!)NE11L1#+-VQ
M\6Q]+UD.-:&@A-\_;,N]1DWEZ&X,QM4KNMVI,G8DVXIKN9Q8%3)UAE?ZM]H5
MMXWPD'[(:U*3ZS)Z2R]HS(5:D3=GDL](SK!I6N3_K'&ID@JL-+74WT(- *Z$
M9K8LB67I &A@>+*Y3*-5X7% !$=A5%WDOZI'JP%)7>;J1 #[(LA\+_\)1)D=
M$JM*_X&;VP*4YZ1^YSEAA0I! O$S(]2UE8*'*WEYAGCY-3/$#)H)K)]>W6W/
MA!0KS):Q-L23=^;(3J /\&P!=S:4T2?DD#>R,@0*&"$]AS8DI9"N8^)43IH?
M9V5E&7BB%)]_%YP8-9"PG?-!BP5#SAZM8<N[CD::CH^N172HNQ68W26/>'M@
M(G]>V4RC=%,B0.N"!H5*SSO.55X)$#.-.S;IQ1$G;,1LGM7$_)7SS/<YD]04
M9G+$M?!';'S)$C%X,#_8K48O:#35CWHW-R2\YL/T/R%KT 5E@40&D,# 2?(.
M\>M)-^!'2J+(4'Q@9Q9UDTG+,E=#G6&#XGFN92&SBJS";D6\':ASIWNGH*K<
M"T"O198X=!)/-V<Y4+9B.KS&(D@M< ^OI9W$W"@,'S)L&3U)N-1S78LI>QP:
M,EHI:AYCFZ_IY?-XVR<WW,Y(=M2G8N+\&MD1>5_V^[L:KO%&S9T-/TVB]^O@
MD/(;,VNGBVTTIV0=+>\J)_SO"R5<10:3EW(>+_VA-)&2&W&G1VL!>B1D.']&
M8HT7\L&EO$O=JC4RZ!2>\BWCE6[KBC@Y)[KM5OV"_MMQ@DTQ-5KOP ;!NK:O
MZ5.A^_BDCC>D,AYN?;SM>6O:WU^8*?IVD#WW_F?1XJ/"''DAU%E.T&EWS@&*
MN1'*1U@CZ,5$%6" JXY2HA!4:S^RV:0PS#Z4R03D8@!3V^' 9,@=J3@GE"*[
M*O7GRR^$**8WZ< I?^>Q4V-A^'RVCFVH?[5:?>N:&EHHNSH[=T4VDJ2F<P7=
MH+V89280[HO<9X\DF)G@R[Q*0D:K^\_G>TRYU!UX9SE28^.SK%L9I;$\G78O
M%'MT\9A9,*5&R[G*OM)20^M.>_RI4:^:@]GS8=I3FL$5!:T[&(Z0I^^*A$$S
M)[PZ%M>,N <!#,>.=:M49AAB38?*?M\5:<YZ1 J*Y@5&O8(=PU7X(C%DJ"1*
M*H9Q+;32[N@+ _&E]2.,J5?$H4,?"?QU>+S0$JY0$62A!3^=%$";;F6@LPWK
MV'$"L08F)@'4?+KPVK5C%BYL]\XTW3TPUO::+FM)K^)L<9AZ#UP,'&D']_18
M;,U9@!Z8MI =MK^>?0MIT5UZE$_"T''H \!3^HP7K6=7I&F=)Y/&\?R"NL8(
MNSD. UF.DX+AT^WDPZ%MDN7!BCG:=E>0_AQ_BOZ,DW*<9+EA4C7OSQ91KLK&
MY2*NY[5RMR/=%CD9"GW2:ZKV!J=J7)XS%"RVFVOM_69=J]4NV&O:5/RZ/F98
M&D*H^7BET, KT\5%S6B?UN.Z3XO0.WE_=*0'C]T^F]86CSBU?)H4H8&;FQ8<
MP GK#HZ?10IU %35W\-3,'@TEIDECZ1TFX/X96$$<?:>;HPT#_[2@GLV6*#,
M+S,W"&Z[7<ZZ-&#-EDK"@Y/F[-C',RO9%C[CA\XM$T^R[9OK^IBQ@5=8>"6K
MN(I?=A-KGEQGP:C0O'8DX 24C%$&G)FDOD(^CG@"]0]K8DV&-==)D\<CXC"'
MH<%#!] #C4BN'0O^  5C%_:B-5B2)2^#:7+Z&/&EV7/LF@XV,:$.234['2-A
MR'4=CQ3W^-%:X"D5YI4/L2T<8[N>&5MTR@O6V'#N'EN,RX]25#^D&UK3G^>O
M]]?B@%Y 3M_ U$B-"80X&Z\]DJYE4X[:++.S"G:R-^><+'GF:C7W:12AXL['
M3?1B65<PU#F!@@7'&)CG>OU[DU_(.6J$M,;_SV&#(>!/*$-[5R1>J!@=UK *
MP-TN3(!PLTX@C5/ ^/.+!4>DUJ2@ ND.]T&N^A3J"7&8\P1S%.H/>@17(06"
M (W%]S#B(6&.F/.$L+QWB9]O?@9E %#HZU1UAI001T-Q4U5,T ->-),D!MP$
M*:(T@6+6-'WBH> "0.G&LDJ1,9Y-;UG8]*VA?8"7YQ\L4NJM=0-<8S!VFIJ.
MO8WY_R:?1Y^8O<)7.7DGN27WFJ2%^3SP1Z?6II(+;7(AO>>W UBNN?/A^7/J
M >7=]AX^=JYB3C56<F&?%:>+]/,O#VK5F]S)BYUG4[((%:]&VG?.,Y/6YH3&
MH'%>"ZM?F. 3E%5+:L$P&,*HJ8BD ?90Q@7!H-!BEKLBAWZQG,DD!?2_ZVI.
M\$YLTUA83)<OOT.XN8[ED^BX5:E&3.@ODPDL_ZG4"*E9OA<'W!R:*N:D\E_\
M^S1%:%>*0%;^/2X-JT1B2 JFA#_<%1P9 EQ+1=BBF9C_[)'$U?85= EFA&U
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M3O5*7F>?80JDD+:#V:?*/#W +L1TPW9W:*VW!\H5>^PY\OB[-T,8-\K6)ZH
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M;;V(P/M9O?H561^F]MMK@V8<MX\EW^0NQ^GJE>]#E=:=C&KEC6'MGOWM]"S
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M:V$?,4*\P5T^6)<:VPYGQ:V[O>'=[X SARH7-/<QYI-ONWTVO9#5:W!?+>E
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M'SK->UVSO5J3^*?=(8^L_<;LO\Y4S-=?[:MC.FQ'H2W5'W!K>TX4_Y'GD/H
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MJ;_.6Y.O0[[R]Z]>0'>9\M5%4ZPE3M)X6\9V2*&;41?2'8"YX\]=]  3.C%
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MAL-ERB?=;SUUC..OP=3.<,/NSE$,7XS:]JN<^$0PL%END&90>>E4@_8MH0S
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M<[M;0Z9KVC.JEZ)V?U&7O+*VV9%R<"4GA)^?&F<JQ2*:SP!A(03WTR02R$V
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MC(;LG6^33@P5_46T\J:ZAY)/M[N]+_DA;4B'#NM?8<_%^X*4!$Q@TJV6;%[
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M9F H&6W&'"F_%583L,44A/-J+IYT S$C9,6(Q_<N2LT$PW:A]X> &\6!P'(
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M!LMQVH><'(_;N04-XK[OQ-5MM\-NL,&COM*<=I0^M[[3DM<C8"J_W9^WY[6
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M^+ UF&TE3&?\R+Q\*2_$F;4PEIL9G/>UR?EX< W5@?TC#3UT_A;ID*4FYR0
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MS>_=JSL]IZ)OAH;]G?A8;>XMYSRW!/T'"CRI&PE-QQQ&BW'TIJ+LQ>B^QA>
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M-Z[FE2.Z^WO;FJ3*UZP-EZPE[D4N[ZN+?=7CDN?Z;.IEF?,@O>+6D+Q:.C+
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MX9WW:66=^O81H3 VY$9^^5B",V;42)K3_WL_2Z? 5EVP, $6L$T%]RUU47*
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MPE*O\?IENKU4D2H@BN+^ID6K_75^=C%4HQ-N)+L"Y'I[A&_=O447Y7-^MV9
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MU+.J-,L2]2X4X#_@+&2H$;=TZE.VXMI.@7'+C\LFI\U)!-C". K6:1 <>;V
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M0RCF^+"VFS@9WD-1,[G"?624?P68Y<*P^)#]O8!&.@):76UZ:W'%O366YS7
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ME)5<%_ +/.](O-/8&40#OH>0 ),>784=@GDC9$V!#9I 1\788[1#/T6L=KJ
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M+'J:RN7^.-M[W"<Y,CB_-$)%,JW"?J8$GG'JRX)R6H:I>86E[;V,G)9&[;3
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M@X(A\L5^.@YM;3GWJ32W6.-@U[6</H[QM0,T"^UQ,<3F6O5O<AD7G2#:%"_
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M[ZL_[S:;T#2 BU66B<:JV1 ]Q8>8&=EG/%H^H3SE$NX8C&2X.XL)?,+46Q5
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M).8/6A<L-8MX*-U\;Y=H7(:J"6>5"N:E!'$UVGL*[_[UJ0Y/H+5;N=U] P'
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MV'@ S)Y$U;8(W51[W#H:*N'_%)(/>273V"EYL_$5GV58F%U"<:Y^7E;WD=+
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M$]3"SF;U'4# _XD-%F?\#BE.A!.!W2*[\N==1,G[4P!C%AKTQ^1G!U']S2D
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M8'I+[\GS6G&RKC$O51F?@RL72F\F4E)5%2&SB^^[UM\Z/W5EOPY=F/8&<SG
M\>-*Z857^,FNZC 2-<$_'H58V HGG<?GQJM(6+N8SC/#W;'5EXE!J@1_=-8\
M-60'PL.!(NQ'R;4I39H3XB8C?"IBXF15/Q!8?A<H))8,RZ?E[.V-HA[FR!/U
M\<TXD_<+<98XQ6Y/ /$48$1TQK7R\L!OCZ.@"UM7B16/B8C%[)O6<O,<1/X=
MZ['JWT Q7-M=P41)N'I>_]-*"XF6S@!V.[H7ZJ9RU4-#T@Y)!JTM6MY%07,#
M*FO6#=^M:AL_&E<'F5OLMVTV;E57M>:PX/2F_/><".D]W *+$3&G &?/$!MQ
MX@1VOR;Y/K$#IQ<:#)A4$5V)+Q+T6HTOA-\;/P;YXH;D_WS'14ER#IJ$3A5Z
M(3_&Z=];1RGBGV/97@=S@[KH+A]+$+VP>J%U,\3H4;VP.2X\*%Q.)L+ @MAM
M-"$_S#H#>N73)CW9K>>)BX-:81KC&52GG\9;3LC'&3X>QZQM/6[-] 3G1]QI
M2'Z7&??1,!GB/9\VL&?2VMC4VK2A3:_;R%XB,5M:T3J][X?9,VW?,_U^4-%Y
M"JB-V C [ZN/P147>*?4]ESQH @?3UZ8):XI,8\(6C#MVJ)U:3'MX;V@=W?R
M5;#@:HM-#!8JP<7+"U-97EM;[)J[V?A*AIX8')2Q/.K+I26<F#4*-,<;+LS'
MPYT7$)&D.T0=_&!O+CV)PWH0@9_IRY'$\X;!U1=!$9-CE3'ROT*.]2LAIIF_
M0G\OFSN:>\AQK5,6F@M>_:GLS(:V;1#IHJ,\]B*Z'RG"7O>< J9. 9PJ,C!P
MGXTRT7]A>(..V1K1I8:U#:\N "^ZFY(8):18?W5EZNU)$%]K\CZ=E)^5-1@/
MGLP6_GIL.<ON'4P5/)9+@7"Q1BPBPE6889E':,[YC54"U(+(1_ 8W>^:$\?C
MB/XX4,2FY):\+L_7=72F0BH$IZSYI"TD'W-\1Z4B?_:\Q33);%HQ&;P;G@W>
M1 Y^65,)\G[T*%=1]D@VZ5G;IO [7T@^6ZW>5+5C,-1;6F='7:QH\'@DQK"Q
M*ME@1&[H .$\_#+YV*;I)&^9R(</]XSW"W3(E,KM/0CF)-[2B\%DRK4X9$JV
MZ#:C2T;T8A?&!$>6TK62NJ0@4K8/DW0H(J=;'P3R1B&HVMF.7?#A!?BC1;9N
MQ#FX&9ZU"K-5 1/ V;X^OKO8<<4U'B*:.;'+2PLK>#3A \4T93QHVGSN*!;^
M6#"VXB6TK=(>!Z*CHR\)?=26'\^JE=^/D\-W3DB"(VV[1VS5BW6JA:.=2:/N
MK%+:+CX'\O?=W P.S9"<7E[\O<]_92]*0VPH1=N=8:(;^5NPTC^-22NVDFZ3
MDN["!ZFIA7/[UI;K+X;%\(B-P2-%.# =^X,$.,E5N0+C1(32$YOFL7)S=$3]
M!1#-(+Y]O@\3Z)&]6*K"W9^_PJJW\!8.*5F95H^(L<./C#&A_0)-LJ"54C]9
M%<K8( O#81TT[=?FB9-&Q"#\^J><B^,D06+53A^"P9>7 @;N)K%U$/;?R+,_
M;1X'.BY:#C'IU7X@F$9O;6XB%U $UE8A4K4O+>JF'FR5V;5M%G:Y>W@ZZ&P^
M:UP'-SF/$1>)F:< 0V+CD;SB2[9%N@AI,E8,"8]UV^/\(Y8(H%<YP^C IBA'
M;#5#%;*@T^M9=W=F4^F>%'5?<-J7D8/4H^EH=Z5D_7AY<("6QE6(C:=1_IJN
MZY]?24=ZQJ[/O$Q"K;+SD,P_/MHD_C[@WYM,NYLX0P0OS'?1 6!@*_SEER06
MN")>[^6Q'@)G;8INI\3'AZ!N8CNN$",,">^2=19I=:SP<W%%4R[3C:> Z*4/
M']+1S>E[IFR<&\E?#@O3=272MK<H23VVM1TO*S=]3@'G2?V(>L57&Y*H%UA$
M=).?"A.1#E_?G>:7RPQD\/5ZL= 1Q=HT#0ISPS83]D-E/'Y7 V46KR0"U?*L
MK7Y8093B"NLU-_\,,;<5Z07M)^]G>N\O;<G7I[4TCK0]/KB^"0//FL2WM(WO
MZ^BR)9&K1UY>?C2Q98M$17<D-$/JFQ[>_'49/3.KLV?^#8&]SAF!=@=A]]$9
MGBS'4@354\#"U_8$(J/ME4X"A>?&5A2GS7OL 3=0:DF'I6(];5L7NQQCG(1]
M5+C93_EU)TQ^D$UBO&QH YL??'S@V,^]-"@AX@Q)P5+O/+K9X*@X)-CVV3(G
ML",<.+*<-K)LZKIRI!']=637'60[*H?TU\JN\FF#ZM9.-,RDO<)-5,F=:&,D
M!N],3_\6E=Z<MH04)'3Z7E1D8-U>CK[#D@BOTINFQM* &J1R-RI$8IJ.@\95
M:-9L&UA*7IX":H"/X%NA2N"X/[D12O$Q'5A1:V;B+5 ]<=AJ](_G!B7\08Y(
MUJ;M] V7NM7'5K:J*0Z_4QQ^&*8DZ6[W*C<[YEM;COARI1A7C;9J61?Y[6D?
M-8](V:I-07,Q ^ @[&"4JJ1"9N,F>I^Q]Z%?0G7X[E)0E CI\[A @SIM[6_A
M#OP?2ZLN7\N(5#E=V[SJ-PAW6\XAK&=XBTUVB=5)EBE!H?%YB3I_(87/R->8
M,@OHT,6D;LD:CDU?]H;^PL:D.7O/,ATF[:=I9H7'6SWQ#-ZYE'#%11F&G0_:
M3;9==WADY--8F>*4WAY;&;G\-\;>,ZJ)K8T?C5U$1$"*H$0%1&H40922'$5
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M?922=#O3VPAW(<^+T%QU+LW/3L**L63P4'P4,=DAE5E2PUXZ)2DI+U=\MBO
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MD&M/Y-(@CMG.7DA.7W\(WTW&I[/&T-P,:!P(X>*@LPP9X2Y2=YIG-ON_E&S
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M1Z#4(CR(B:%53:9R#M9OX]D2_#G13[1%R1YM!>5D[< Y8@#SGKB5Q9L@/-J
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MOW#/O&[9@[;3F?D&:T;W\KLTWJ\XG*$4?^;TS5H54!^96(DDM0'T%1"W@21
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M(KL<\K=[:.:*)@1U(6,@=?<[R*<0@@"6S$BQ(#8G(#T<D8E"K$ 9S87Z7%2
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MEB0H_3'(;9<3$0)T$+-PV)UA,H2*I3( C_#)LT,D&!#G]>< AU9T+ K!B%N
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M" #';OJWP1BZ IBFLSO2@PR'#X;#[H9A(01C:#CR9.<5.)*41N-NN[/YI$Z
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MXA/R#%2$ C]*TN0@&U!L@<M$'CP2 WW!0V4!1/'Y3 CM$:1'ARPF3V L[!2
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M .XL[;K@?*]E//6-=P/^C9-O@.0X 4RZ1G1)(=]'=MVE7@U;RJ_'.*Q5DR\
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MM,D!HIJ*/C"6&&4R<NY%W;I'%_+*1DSG^=K\]>K&F]5LDK$VBM+4/B+C;Y=
MW:<W:Z"#_$/W+X"5@HL,CK[,9ZF7OHAD4(CH.S$R:B>'.AVH4[2U[M/*[:PX
MPY(E-W&S*S+F,;BNX=U0BIB50T-((L:X>ZOKC21)J[/%WW2X]*K>DER5X^O(
MF&_F#0TU/<)W&UO=!C'U()B%T\\P8?M3NIZ=PN;*W8H2&2*\GWOTKV8IN9XR
ML&>\_*U04,'>=_4BWSR4M?(TY&NGL$#*^3-CQ:?HXAFTWRNY.PE$Q8TL%]=^
MJ8Z*L+E%,\9Z#D;8TH"*(7($>XGZ.DL/H;.XOK6YG;G1LK2=</[.2R''(>53
M?.)[-N:L,CS@K]0+#Z.1V==D+,_?D'@?^?8B;YQ^TMAU>N:+3S.3&X,VV0J?
M^7/:,$P_"Z2Y-'(UT+3GYN.8!W6]+79&^Z+!<C+OES&CBEW9XOZFH4YOJ?W3
MXR&8R,ZL"_3BF=TBNS%B8OJ_\RQ/<L7W4?5L[ KWGZE^KWD*8:W*LZ48(;3S
MO*\?@]K'BJ$*V 2C](OH=@TACLJ+5N4#\<X0&ZN,]QFQFMIG8;21\,PS-VR8
MG5\3S_)CRD? [#Z)L:@^_N>FY3;HNV=-X-^",ZNS\]W^'WM03;[DI-U,2347
M<;:4&VFB&*8AW1O>7_J8*KLC]V4\E/4M\Z'L27+HDV3:B'>W)<GRVJ!]1"%%
M3?P$TV]0&OOO^!(7A4NF" U,C,'TR"!!8GW\O-C]8/]/];)T=^(8)CZG#:3&
M<>=4&/)ESF@N_R/R[T[(Y'P/TIE4_9MMJKD&#E]&VS^"03!A;DO-]U^^<QJ@
MG4XWM4(Q65F0KRZB26KMD(**AE8YC$>(\_R\IKY-71)WZD* I\T:YV3-XJQ)
M"$X^_ZXPCWHFD4C/T.Z9)Z*FW:6?3L;^R+9VXCLCV%1U1_&$>XJE=I3[WD=U
M?MF\-(PL.!M9VZY-=3!;&1HK<9.*D'.P%/G=Y^):<BI<P,=$OJRX#^33Q-IR
M<*!S@6;#N:'@6^ECW^YT2\/P\J\0K88/^ UC^5)E*QFX A=Z7])FYY3/Q]:"
MT0-BRR2CH"))WCU>XKZK\&^.SU[V60\]"S**%A$E*>7XTX^?DP4P]$Y=OWZV
M<$KF2R0+.;=W5XBH=V[\EKCZL^.N]EG[,^DGWQ:V3!)9_1/[XO#":V)^7 UE
MMN979-6L[S%?^+I%FDRZCJ$O:6XW.IMC_[ :SW4BF:00Z^BM\:SU]NL[M>92
MUF>N![5$W=6]JN6+.3MW>W 4Y*]L>^TOD4R:CF@3'CW8;UQ@E'^U'3.4N2EQ
MIUNGA67&X;;[IU3I:H=K?7CQ.\R;LJ<#EK]PD,%0IU:)M?'S(KN94W*?NW7V
M)&<=;%U?UCHL**[>M7\-CK6YP<:O$&LU?.F%48EA].5+HTGBGU_=8)O2_OQ;
M*L9DRC'8Y$S0'Y<-1FA7<?X)1Y%^N@\%C%^R"DF)G_TXD/'0CUM2)R*U7[V)
MF\%>GTA_.^5/6M)==#"<LS5^O+O:&RS_M>NE7Q!9I)]7C"YS;_C$&2/$RS^8
M_T;\I^#143*>CM[C=]%8B3"&W8?>^)^NV'3/'3'0L['^<D^R;5@!OVQ2^\DZ
MI-O6,4BVSH_?+5W#/5-NL-O\M<" EW7,&8FX)*91V6<P"SL&5&4Z+34=PN O
ML\:^G3A5]U77F? M,G;I\N#UN[5V2Y\JACA=GK@1SPZL(C%9&.FU8A;RL(S>
M'@5H>*T]1.ZIQ:G7]:J_>54R?N"NYLA@]XQF%,W_%9B--'5KB] T\[X1N4EV
M&W,/0LK(Z=]Z%_[K\F?E T-;4$-K=*[ MM>WO>OJ,MV3"8D&/2>"=GSO?S=J
M&#S3A5OP?WXA24\[[\YU36 U5NWFJ?P!;Y^MS60EVG!WO[5OM"@/\(GMB4^*
M+##",'&J)$>3DTP,(IUC\SNJHV<QDRJE:1:$.?D$_#\O?6SE9)'WS+;XK\15
MSS+$F9@T)NJFOC#^Q>_G*B8^T8<7A%B ?KRK.C7=TV[H'QK*A/K'+U2Q6]\C
MZV:"TOM ^I>Y-P<T7TNE>+46A[_V3?MR+TS$G@U,YL 8=0C[UGE9BJ)RN7/E
MI\^89^#Y4_LO23+(Y14)&=5E@02YN+!@UF<Y-""(IE_D]#)OIVZ46'>]=)WS
M[CO)RFW/)29E [WXUVBFS;G-R:W-Z!M'R:CFS+T"Z9)/79&62QCG2[_]7WY5
M3F&]+&9KPRZSTY8@H[+L?.O[(3"_&97TBLRCU,MQ^=)+2MR:<M70!^5;@Z.[
M6I:?3G3H/=GX*T1G5.(O; @D<F!T/AO.RWJ9U>0]L'E<\8G_1NWT3N7Y\%@V
M$Q@\E>M*W;]$9(UX]ED_F0<CURCXT5GFYGN[LG29YQ<TYKMK1<Z#K^!/^U:X
M>\9I:M?&_4M%!O?K1,?<'U-O33DJ@GZG#?-#?@1^:YE4OG?!",%]B8:#+E^X
M;!V-8F@XC]1M)'U"M/@5WF<2TWAYE%&B[Q0GDCU9-.\G8L/CPH2CL96#H4(_
M7\5N^=^^=^<_BT%$0DM* OD8N:K'A6S$7YU\&K]>1#S[2414CW@VN)0M3KF<
MM>\^OR*F)8U>1/V3?;XXZ\;3(9CTG2]X(,I.FMI+I)^/7;Z2<>&"YBUCKO T
MF>7YBV8QI\63 AY<9*_[U_\7A<^F0DB2L3E#1@+>&V;.E \H\3E>)>8OQZ![
M=BNGGNTMVK^],*"06@</O_6!VD\\&7F9,KIA^1+/H!(I?N(.QE@Y,!5TW<MM
MHB&T$GTKD9,6.=^;_:_Q7.BSN4I'RWHYBV+B/UM -RXVL?$@U(1%5#_OO>2M
MLE'=DZGKY7E#TUA/1H&H>WMHO F><]^2[F@M0^1W&,+A9H'[$>XK(=?^;J[9
M3<N-P[HWU9%5-_"L5DC:4#J7?<N,'ZXK7FQ[>(^\\K3OQH7@MI?L=[/NT.G8
M>4.I[/;7E^K)9^?SW+\Z;?((AT$O#RR"'N2+F430O;):91W BR<*TB(<0A?'
M[C$GE";;]MO"6RE*EZ4ES[6L0OO#Z9()Y>]+;N:2:2]GAPSPCJ_-$E#M1D4=
MK4-":9>+ZQPVLP<'5HWEN*_89YD;57^<R"V-/P;=3-N^Q/BA],W)EL+WD.;I
MJ[1\1J5V(^N^76!1'53H2;W%BGW)H*CPJL(:O_^W$ 8M%;9\I>C6B?PQ7]I3
M[;E[8\4&4'4Y=><:IGQ9C(IXTATS=L=K^III[O*<0.2I165SMO,%=XJ,0]=_
MF<K4,#T_-V=SB?=9W:=R8>VZWW<$F;FP1GBNY&'(UT5AI)SDH]4-R]KT&]S5
MTFR(%85+8Q'7$QM+LJS&W$ J<_1.AX<%+VDFWEEM?V?L]?B2*V<SD>>FEK/8
M%68Q7:8!KLG(^#8__">:5(CX"QA/$/]IN7&4B#\E?X=\Z!3/@4TS2)9?=+5F
M$X3Z4]+./W6I%3Y]\;GQB1$+ITT@5EU_19?(NL^N>G;6JK(LA^M-1=V9EP\"
MR-[]%^Z>LIQ;%(LRK?I@\Q<0?O9_\1#>]&.0&SR*@M(0N29AJ[#*[%[/RO):
M<[2(NNYGDFNEKWTJJ\LMQ*?+^>7WP]^S/Z*R;@;JK X%<%QR%9Z/V:Z64?IF
MQ#E5+;3RB/W]F0.NB%:"!P,MNM4X<SSQ2F(+&O+A7OM#0W;D9-]_LJOV>[57
M>Y&FBV0OQ";RT'+4*WVQL6(=OE>>_>QK-R_$;@G?1Z3KE&S)M9<\U_@7H)W"
M-F>1M0AM59&KS"6&]"R<[%%W[@U^4&7D*.@R<LMU9#Q5502/E#$\!GW-$X')
MB?E6EJ@%[>';LQ[<^:2J<93B]H+]Y%#P_6?/Q3H-Z73TGNS]'9"Y^EU.S-#B
MT3$H8T:567%0L&Z(>]55\G/BMX:*GN<<NOUG/#,^JOY).).#+#1=J=IN:++Q
M&!1A_T!$'GBLK0M[O7I!T:X*]LW:/5Y!K?:O07Q=G?_CJ$D.EN/,4H//INB\
M>Q]V6Y I7^%SX/4\5T3L/WKH8"F/RQH-\$C.I:,XO,(' :^Q-VJ?3>3G^;2
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M57&-/$.VCX8I\1CY"'A)OVXI2AW;:L)] 2KZ.%JA''S79:[] RUUUINDOUE
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M;$)5Z^_@:WL_EBX7OUB)7W.G]Q'<GU_R4;.)]CL%!?3)I;X9%'NJ61!:NF"
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MV>#$GQNM!R2M2*QYO<NL$%?&2$@3==\I:)X7>V>95U,:OGKD?U)U*# O_EZ
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M/IEK._VC*;I$LB;$[+0&XRMZG3A#G5;HJ4SQLIFCO=#YK++@BDV\;K'LSLE
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M8X.T,.AS,# 5M 2*HB.@(\#0P!7_"C!*<LJ%<*-@/:G.J>6S35G94=JX4;N
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M,B@2>M1-BX[EL2()(81G?>I6#C07:^!>W.EW>FQ.03 !0(RS'_:"7X@R;_K
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M]$9/?U8-C3-=/M=".=GDZG8YW$S%(]7,8$TF^$>@[O*99S;S#AL/N0A;M)Y
MZ/T*:%U>B-#2">@!:IO+H$P&=+^5%&WR?H4,NVMSANO?-31Y "P9S$-6#R28
M4D!1&G20?. ="+_\%'L58&62M,H^__J&;\F^.A-<H05TO%U9";%([3VNA9-
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MZN+@V%B0#??E=CK=6<[[Z6N+]@5E!)+JP#:G'3S,C?Q$V@7@QC"++.;"Q@#
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MM+P\MYINZ'2ACRW$$:SU:;9RJLP]GB>=I0I&.@+0+%0@V]Z/#;]G=2*<@9
M@RZ3 4PRL5QFL/1;@M+#^K"?I^MK*;;7R;;H:<33DHTFKB]80I_,(5GQC# *
M2"K]6&D>F,C$[D.R&/!!JJHPOE_)GPZ'7W11YNFRL?=X]@W(>-?2%RMADWL_
MJU94TC]G>#EHS:BL/@L)1?Z4<[T?-_U^U"Y.T:2&U*8**\O6SGSRX:5%)*ZT
M';U5&N%<:2_A934=6H!Z&V)G%(Y_]P*U-G[Y/M;D^O.[(;XPKWPX5,-:1O :
ML0MMB1G 0&EU/UFCN%0-<1 ?!PS1(C=L&I'[7C*4[@4P^*)#"2M] -.=0&(K
M8A_$O8WLM4(Y2U=4%/NXI*_.Z,P3#"PG_)=L24_3?.;<MK*F4/9L92%^=.Z(
M\-1C&*P4N=#+/!^@:Z./JR ,#K$4DTBC-N5A/WF!Q&=VHCMPJ=3#M7U<IZ9"
MFSBC.FJ^Z/<EQ3'[P'THAJ?)-4') <9CN"PR@9J*4N07L<E,<AI/E([)7#G]
M*R]^I(L*% 4C]IIP<XS[YZ% SKK%]]646.B&I51/NO4<O4_4OG>6-VEVY=FL
MSH4\%Q'!!'2W0)EW"]P1X=J":@.(MQB57P3JB0#Z>@-_A=BL."@(P] =D(Y;
M_=2]4$;%O.FFS>"*BO!I08.4U)62'1&%.VGT'9%-O.7FRF'!_&Q@YN;)G[RS
MW-$:!F!N96H1TW&_0J/U]UK?UIO5CO5SC=XC9QQ>6+V!%^3B/$J>!^T9O\8V
M735?=A@E6OF9>W]M#1E:&EPCY&?G%[2[ &:TH(U?IM@[3Z;=@XCVWF!3+P+&
M0XB4G]B-)J"$B1AUH:3U:ZB_N0G2:;B<@A"-@POH0[Q+P.1PDN6 OPF;@%..
MA68%P0'B8\(TR@EOPMD1 5J9TW&&4(%6](Z('75?*Z&'E;8BUC=E=:X%[+#M
M!>(?&!&P"N##FRYRR!*G9U/';LSPSC%V/Y^)#4N=_UYFG^4ZY\6\.%WGRRV[
M9U06>"CL"OGLK]61D[\R]W786RB;$LXE((P*S1X;M@<<V/;#9-!UDHFQN@J1
M(V^\M[H%#=J>TW#ECI?1'WIK&NY.?]-AAW$QV.N7$$=,O>0,"YUK,O4[?Z)^
M\^[9MT=?5Q?V+<$B+KLY*M4JE270G[S.)U2>/TAH<(,5%!3.64<FQ*<H>'5E
MRY5E1??9Q_[/]31$$;2+^"B#K3;0];XM<W7 Z>9?_"GMW)ZF"8/?^!_]SN\?
MCO[C*F#PW8>DP._I/<QOH$5*(;LI,B>WAWR61U(';-5V1-KCFFRTOEJKH3+"
M$VL7_[P5)7GUG7.WR9:3D*CY4*3-<:9,U5CZ;'3WJ>% \Z3KO;X;AU5>N/<#
M@JCDD2!%P]W+3Y\;O#K1WAWU8<CR*R^*7])_C"I3 -8.=8PXNU?_DQ2OMUK@
MH/_CP3[BL8-QG<2H)IESWO4)W8B@'YZV"G#>.&[MG_^S/",&AYC)7OBBO/$\
M2!O;[Y)V_(7WPV_+CH"2%L[8=>%[^'G92: 9?O2)A9C(/@.V_84I(F3_9U7_
MY)JEOI7Z9@0EI%/IWP.$A?@.[5Z)5*_#EW)[EG8?B8@9+!4D]QK0N5!A]!H2
M''@JX@UB[&9B$Z.5(\!OGR^V7&@^H^.0;>?MG1&4M[S\\)\" 5$P3MK_ZH3&
M(63MV,IHU(OVBGT#M^\/.SB:?+YYT*:<UM'@6JWS7']2Z@$]?5*NZMT3>^64
M:-<KZ3$8;?ZQ4ZBSUA Z*KG<RLO8'%_6'5)_-.#KAB)*[M'"B*)773#3@5!D
M;]?2NM83Z6JK*/B(&PKX'^N@4D=V1 ;=C_F.LC:D[NZ]&;PM)IAZ?OES)+]Y
M^J\Q_1EIR:/C'CG$D$6OUTOHIW-4@9SW_G^YT*>/HY3+C 97+S^3ULWCL'21
MOWDX\4NU!_0X#-PGFFCT?[PKAB_WQS9)[[>A [SS;4^WIMU_A03,N=O964WK
MV%N.W?\^=0ZO/&/OE#*]5WZH*;1/[,_@YHF[C#^G3Z4LS+GZ.%R7U7L3:W:B
M:OQN[-\-\7<OW3Y7?\$?_L]B[_3$$X1(Y']8I5/$2SSUG0.=KS>4(>IS_Z"S
M^NB&9<YH\/?P.*U ;/F#MB>=O+3NO"%9\A5_E: D<:>@.WD33]^Q#%Z-)#\[
M-&ZXS$L+4?LCL<%;9,^%1%3-_\X\_?_:GR(^ M,$YOL.1ZG6Y:%??;S>M:>*
M<O[5@MPZ1>'RD>R24K\PQTQ3L0]D8K;)>-\5?]V;+OL^Y[:;7"KUW#K6H#G(
M/KGT[X4,D_C2V+R3^U6N8R^W(?_=VU7<O'NMY_]17>W_]CLHZ#ODT'NV1((\
M?'KJKZ"+%U*;38_LSS!-.@I#OGMZS&*FH[$[1,[DVHZ(RR<#T:M!WKW03OML
M=?0RXE;^2)]T;I55YXD5[Z9JZW=C9A3&WW^1 RML5)Q_BAS%9__7JB]A9&$C
MAPL13@[4QY2Q1M[Y*9ZI<BII'S*8V/",'3\JQ.?2\I*_2#)(_]<4MDXFQ]F7
M 4GOA:HO/^]Z=N4;8=;8Z/#I.UU&N /"L*CW?4<DARR&\N1>$/ZS@H:Z9&N<
M!5?999R[:72S4<1NGA]8R>@+&M4X#N( .'/UWD9$G%H''IG+<IO_GHA((T.L
M#-G) ^?#RF'KZ@9V&,G@8E>?M<[B7?[_!-1;G;UT/M]1KOU![W2VG_EL_EIH
M=(NM:0\GI^6P08 ^.R?8-60EE$>)'G5V'C1N656-\^E\EP'-@'1XP-_;9PI[
MVX@#LC$#.BAA3!.S%6H.60X+M"=(!UX57@M#H)3-!O668!Q<C0$0&V2@ TKW
M>Y>$VX0$"4V^9%)X3Q*TB,R%C!=$<IH2QT:A2Z*,SA*N0RBUO7YCC M%(ICX
M$9?=*/DWZ+,\V',0RQYU^:M""IA,L0IB()1 ]WZT^AO3'ID4842-PRJA_F#?
M:: A%(BM)68/>BWIZAJOIP>9P_X6TQ@"XR*V\9JQP8"1]WR]KGXA\\#KM Y/
MCUJ])[7*7J5NX7:PD'/CR[K?,T\[.Y""9QZYI2P5AL5P3U=5O7]7=*9'>T)1
MZ7W^+%>0R0OBYPO[74V5M]8&W042RPT\=Z K&67;\JL:!5H+/>5SIY0DT3E'
M@JQ1._SS '>Z\G!D>C0*.GO+M-R%83HV.H%Q8HL/YB0.6)"Q+::3#TJM>Z(:
ML8K!%:H=T[=N?7.V6>;Y"8=3=AHES5[B;('V>)[._!>"\5LXQQ4(VG1O038-
M^6LZQPQCY @X>60@PR63"!$#,?W1R$1GK-/\MY?0-'>?$+@;LL?+93]B_<UY
M3H+%4LFSZ &&YAGW]VZ%U][_N*$6/4J>*X.'],#YRRWQ;"TZ2]*\]&1F?H&C
MLZV_H<D'VVMR=YPQ8@TK'(04:F7MIXTM&H9^204NX[$[(H04#;FY3>AUX]V3
M-%P63LK*C\E*)LNC]Z+G567&6&E*Z*-O>&;UR)(AQ-X=D>!?ZV2)=)D'D_V0
M_<@7ZA=#O!**'P:RPRYV+'R;B+SH0%3K,?"8/4&FY6$(K,U*KC/O!%C.@%*J
M^\DRFP2R#"^>7\U3I$>FKQP *X4\_&%B0:A!L6ASP)%WH@],JD))@MXU;S]!
MI GEJC+2GR!R6@O$I$2&86Y1) ,B^TE5J:W1;VG01=SGD?YK] OK40^F.3?4
MK6C]3.V+ZC-Z)FOC#KJO>DS*',U+W8O,A\JYMGIV_B^J<AX_7GY7U1+G9F38
MZM6]B5EX8? 5SWG"?RC00KF!0VP7IO*F.#<,Y<U_"+V&%=J@.$HS"=BRX9>1
M@R$*@DG5Y9)LDS5>8(LP$M1R_T".77Q#B.^>,LG1-Q8+J?CMS<QHZ7;JC:=I
MPUVDP\!''+JXI5& !,V8DYME[$D.]-?."\&DX!A(9%O2R5AR)"07HO -HBYX
M4[J[>$44Y.(%_Y+%>D^QZYE0(>374:7E7: R:'U4)*A+BWQ0\K,^VV3":OV-
M;RAEM"DR** %F=,<F_5 AG+^5&I"N)]^E[MC:6PHO,"MBZ5N$5N[&:@>J'N@
M-2*LH4(W'W:RUF2#7]'62VF"93HCWKDW>%E/]&EKA%CZC'T;L44KH+1[^#70
M(-R2 6="V- $U%&0S<1EG_I,?FKV@!S&6A0=IA*[AB$*O"NS@OT\CP4>@FU#
MRQE+Z8UC0WUF>IW9XB/0O2S2$63DH/6I?&D?F0.A*QI3K]L":VS0!3K_H%8P
M#S!JT$ \I4,@,0:P!LB=8YOVW(N"&8P&[VZ,[F8JD,58&%U&,-(&U7TYB6\$
M"N @EPD=,Y9!F<Y^<_)3H\'NT79$LBZ#9@Z@9Q)=7;._TX<O(,K<^U+BV^-4
MAH3,+IA4;]+C';QJG@>Q9CA&/84_W5PS;T? G"C!9:GK4I]AXUP];P^.I^%1
MDC?7UN'H]R?O2O,=;+^&3I<\P]A\@V]U";T4"LA@K7]#6C)7-W69DY0=$8'D
MV1;4178AZ4PWOYB 6#1"I./V8FYB%O.'+@ KJ8' 9R?^8Y/)O:$)DP.!=%^H
MTHIZ/ ,S)D.!>TT3A,9JYO,UF**;)C]D((K^Q).:XSDQ9.XCQ.-8JLBR09(I
M.[<+P-._X!F3*DBY;9?97ED&56[=7V[:V)0JCS1SG=ZU!A<H+A =6HD(&?^U
MS.ZD^;SXH+-_*TU?,-!_%B=ITF17]2C4\3)X Y)P(KOVY:L2DVL?7GP(YHXO
MFE-<'.,>K<,*DE,>%Y*.OEPNR(=_B"R&O9OOV?8)KZ]<CW6UC5'[?ZMC^G_]
M_0F&#Y?>>M7:_NOX YT/%9;W_N$Y--F]_&C;%.:H>MHM1Z(OU^F.>^3ILBIG
M^4^=:G.I](6@F=J@O%KHDK7F9=:QCOT-#$-76=&)I"?/KN1Y:65?3:^\<.4Q
M\6FJYM/._U;O8I0*&ID-4A76=T3:1LNYKBC#F=H^</G7-DRP#_C,>0L&%]]^
ML>!3A!W@!T2@]9 WUY%*WIBGIOC4^)5C??.WM(CDI[/4"S,T<GMP7D0XYOJ3
MEB=>L09NS?DE':4%65,PL^U*0_[B*%",=3AE,3OGXUZW_)PQG;]BC!P/;[X1
M8FR"'82 1WH7H,3?.[C"^6W R\JV=KU87O".K%8#D/M[G!,66[ZKRW"<^66:
M/2 "J!(CKA@2FEAR85X5AO-6KB$!$4]7UN>+*:FCE<T7IU:,^S$ # ]JXS=L
MN-%(JD!RDZW)*0'A#*P:N.0H=+I7 BI"FK <= '\P-ZF$XGU*<?B,+O#YN_(
MT/$/H/(\"-W0[J.T[TCW]YG0!-*])Z'Q4<LC 9CX^+HK(1PO\OR<XOR6:EN%
M3NS=3Q93E;"R>B_7(LDKZ"LS=;6*RB8-@\<CW_4]+YT?,YMM>/8FQ]_Q14&#
M7L-,=K57B^_SV:B"_*R8Z%+_[_BPM9@?CB"4X9=(A_+D P52:\)1GV7?J?V]
M-E%XQ0;/<KV1"+KM4C!%/.U[(GXQC(G9&&"+,N#]$E;V0?1-39NGLSQ;I6*K
M\]VX]("9QWXPB=BII^ERB;DV--W!R S<K^IV-AQ589>K!>/6"G.] 8 Q [(!
MY:K[_=K<=,-%\EQ$_8B_1@?X&RW >!,#=#C]N);&F!SZ%!$1!TGO]LR6-1Z6
M5@JW]YDWNA4AD\ZSAWP?M_5]13+=.$+W:0Z]%O*<6X2WV]]<>AFKV>!U$@^+
MVGXR,5;R<,#A1?]2'A<^X5B6JO*$.[OIYE[WY?V/0CVB8U2"Y_T2T\)2_R@@
MF<$:PF Q>ZVDV&5T\2P"5@-U"BR@3UB.H/>R;Z;>-C+9#+2;9<C9'/K7>],X
M_(;<V_5NOPVOGQ4YC925-8N6VHK:&W%A,LPTGEK)CLC102">7\*B=.R(^(B/
M$;DMME'Z+TP,WF1##$,)H7IG=&A/&M=L*7H.XU[S3GFZD+25[00_G?7IQO=X
M6)%/^-%%A[G8Z^_Q.HR"VAJ$Z0^2<3QB$ <:XWA_X]]&"J9;N/LPZPB&8SQO
M8WQ'!&FP(T+EXY<=#4*1KQTETSKZ&A@A6S%+?/I4_(</&/%VBF#[-+OS^:3T
MA.?<*G']<L/+EQA:0Q/B(>HJ=VFY\_5/S&F*/:_VE$!J>T?DICKW!&;]'IA\
M5>:O'9$/[CTLKMWV,(9_&EE%?I)@X(+_;,LUIGOTSPIT1[[K:XQ2?Z]88)!Z
MRWP2\[X[W^37C[DHRR1'MGAY1K+#-C9?AI_IZKT#+:&FX[["H;0Y#%<!!=\1
M:;:AZ==SS=!+N [<AO"_V!]"NY@7^CUA.^,[+@7].WM[S&5Q4%V4(>B@X91"
M,9*^?D#:QHY(T.E*6E+,F+_:U/<6RR%KXXJ7P_,6N#0"0FY'Y(9QQJ'B+S+[
MWH7ZU"@K2?'M79T#:6LOBASE"K7/>VB/>Y_WYYQA>A3$WBPJ;_CZ;-SD46O9
M!Z?U_.Q"NI=^5(MJPXN"PJ1W1P;-"8WG>FI6X[1F4)UW>@1_I))ZV/8<T1V1
MY!Q,^/*I0?_C@$L_=DEI892RNK%U@XF06:^0G>V-I&%2,:*X 1_L:#AT\&=?
M'0X3\)AW>3XH?]NQE_R4,/M=85H[\5O>X\P0ZWQ^DY5K'4^+GX>A4?$4R[$3
MH0F1 RY_892@UQ'RO! VOZ+@29BJ_1!D#XCEN"SP#M]@&A^PKUE:\5^SENM<
M((9;C'FP]W;6.\_<[&V_OX[\@O_&322OM69&GH"Y1J0]5\U'-=;BVI&.2%.7
MLD5RDGM=S?I7PD?6QO14UN[I.TTL<^V)C6\<W)5B[<DBY\36Z!#WOMG8U4CW
M'R] .GN5#A^ @OKDC3GAJW%BCZ6WQKF\E6%.\N3=_?D/4;K<BY\TU-F03)(*
MSPQ\"!WK0>0(--AFN9'?P@W<N@'H X$V4H<ID*7N SLNSS3?BL2'?VG!XRNG
M-^)4-GH@B_@Q:S7^<RBMPP*_V<,]:=W&@"RZTQ8V1*$;DPP(-@\,0P#49&M3
ME!\[:$P,3+M!P_RV;K&"JQ(2QY"_", GCN*;P=+Q.&<9>_8IRIK7TR8J)70&
M\T>A5Z2*S,WI:FWX.DM"I;MAP#4ZW,S9S7GN,NK1>LV?5/+&;-:5D)CEN:RZ
MS\<N5#40=3UM#77631J>:QOYVVOU48.G0-<=D=\_Z.-Y\C*#8I[G,!113E/0
M(1&_M+$=$8U#-S6+_TQO*B@@>B:(B'_I4X!;ZW3-GU!L^OHU,;2C81P=X7_W
MC&_I5!\^;!'1?KK2Z>U4K7U9V:)[JG58]%:TK1VGA[B9Z+?4(WFTZJGI?\]R
M.7Y$7"!7QJ%P8?=J1$9N?!U7S>UT;/IGMUB_OE]@]]WS_[QZ<R%G=SYK?K=K
M'J/L!^JQ*!)S$3OY]:*1N^O\6]O5' WM@ /1#"6VV!IVPJC4NE@K?_O*KY)7
MO.O\.DRP#*6#&<13<!^B C"717NF=0[7*(0DP2^9W/1E;W'N%=#C4P1&R)^,
ML:M@ZHZ()+6?*DDZ /HR=)=0XO5^RZ^[_'789IE6-G2<[)!BR=MPDZFP^*#X
M@.:?:?T300))/R#(EM]AI<B]<(X62;FV1->]+Y[[*].$XO\5D8K8#>&DS+;V
M2N'7MZE2Z).@_"#E>VL6, 8'X-F$%C7;6;2F3AH=(O:Y6X,<U>*[M/:R^IUA
MG)56->QDD8_LHTK)QNSZHW.QZXXG4@H*%771-ZQM/6<]6*X#=B?#RJ\=63W:
M&'<U4._<7+9'0\.@U=>L#P5/6IKO/E(XN'"DH" 3TQ +9V^QQ062][A_H">%
M6DB4:R,4KF+1H 07SD,\9:\.E$%S$6WB0]C[T-UQD/LG%GGGP%2ZBP3O$A@#
MX)CX(2EII]' 88A4,\_A-@6>1:1F61MT++C;]"U$?--K,0TW=NSDG^*W6EN@
MEQ,F>8HE-*IPQC_.0P/V RX/A-H)$X!7YOW)KFA@0E/0*B NANZ7> Y\8V49
MQV2)7O%;6O-I;6*^?W.$"+Q.KD16CPS1DQZIUE4S_&(&T4?F3'K4+79$[MX@
M5FO5NF5FI=[MSO>D*SQEIS0NPU)"':<:E%7.RZ6P@AT(TR_,UZ.=GWA$N]5J
M7%AS=)Z/,/F> Q=CV3DZNF=7A[W0,Z%^*5<$D[B:@ED$H62 *J1=SA8_%Q,V
MF1O)=0N&=KCTXQ] B,I_H<WQ@^0TH2WTHE'BC#[CX0+P93_I&( 9.FLY)-@S
M'Z>NP;K8B=D;2H&5U4S$ARLNSGE_F#7<_(;[#91@D,%CB,URKMJB$*+.H_<+
MYG=$9%"_,1$9W<J9 @/>+G[R+7(0-25A>V#"=U#U-+'9EH9(U8""RTSO#6O]
M"28DW<<Z)S*R =R"L;ON65G2)V(0J53']FG"9Z&,J31YOXJ0@95R#A+KUAOC
M-'3*FASL9OULD7IG'&L.'_"9*?3-^?PY*N3H=,L9<OB$HS[.2E&B,>X@WO4<
MQ2TS,V55SY_MK!OY29 IN/LKI09PQV3LB(A:>7(ET*]7C,$!8%4@T<-TH<#I
M1CWL$B&Q+;/E+P+X42$6!:7S#.GE$L;6^W@FTQ^3 NG87-*A,*@<L6Q'1&*$
MJ>[::TN7/G416%Y(OQ6+DUNB+MG#A+/;3>% 7#*V-A8LX>3(URSQ2R[T29Z"
MP8 QU]H7/065V!$)B91 60(+@RS5X/B?QCG?=D1V\2Z !FRGH0H1H:H0">TN
MK_I,4F?7)_?:T"?W(F^W)D<]60QS;J2^#.V.$;P>3O)C&"J+2<RU>VHGW'ZR
MYAA:$])[MK!:]\5GO6=&<4J/KF);IS@O<AMAKJE+]PD?Q$R5G2>\^FH5/FP\
M5\ 9Y(<L_52N(C^"@MKDL4E0'[+IS#V)$"R29:'!,K^C[-Z@U4>XWJ#[ *0#
M^H D 4I=8-MO&C*-?P-QC-PRX">+$3EB8!"^BTKGSQ?@Q^BXW6"84.%+]1I6
MOUTOE4GYQD\<I7SL: 5+_([S6%P#S, Y<A@TLYO<W]0# ?6,!ZD'T L)VUAK
MC34J(8@GQ^04\\O1ZH)Q>:3;V+#R>!#;AKX]@%5 )ML "Z/.D:,XF9:(]\\
M(WP4@YK1B3[3/:V4.*%SE%7_IKGE0Y%'T]#2Y8*AE_E-V,[\;/Z.2!SQ_!O_
M+T3]:%>8:]:3VHD#+\;<HZJ-@SSUV1_K)S8*HE"E->LK+E3_]V<:3<HNAQ6]
M_#E<E6DP87G^OR_\/F,=".[&I-.GOQGZ+VQV>[7$-X;\S.G0RE'H+*E09HL1
MQC6U3FG==7 IT6JY)>?WP"#//).RVM9LZ'/R)_;! =M>V^9E2VC^UQ^'P'@_
M[*LM9?O98FK,Q2-;UTG 3[.'[Z7=& X%-G/ 2,#3M^].:XIG5]HKIHR\:7HP
M$M"F0/=YH"GM_Z@!7NE?9'O4L]JG\ .L]LS(X.W":JV9X.DBGT+]F1:[FC6O
M:C?%$,]Z7<G"=??\1_KGHT)='VG]NB<[/Z0..X3/0>PAXI/1)Y\#7ZJN]TRW
M7BBI.#C_RO;PW+=VT,M<XVH\YT8QU8WHI:/"^;>L)<+P1LF_83\EV=M#9 G4
M)8 G4&.C2Y2J W76#.L.9.Z(7.HY^F_)3S^:5_[TET-C^RJKBLQL8A0X+"WC
M'[YL=\Y9L( 6$F',,XPTQO9:]E'T8A/A%OSFNW<NL@A'7W6\?O&7WK/IG'5+
MZ:\V(<\#(5L+WY[^W,6FIC[GA(\(%*Y[EZB ?KG#UT[,MO,JBC5/,8PDZ]U"
M:[Z^&C).ZWP58U4M/6EZ[_73OT=>%^_+RHW_'CI;F2V<JQ\+%) __F;;B4H4
M1OE;2A=$V4K&?G*1S2ZW.NU7[FA0=.TVF!$= +SM[L1V#7@6:5O,D*0H@[ <
MF;Q/36;%\-*D5YUP3LEIL[]/CV]&'BJ>_ZC<;ZE]/\XA\-;^.T*P>*U/Q#PB
MAGA4N]6JSJXZMNB]*/?Q#-"/TYM->10$J]$JK#1W,']QTM$U/Z1FBJ^B8A>5
M33_Z6BZS\(92K8J=([OP>NLCGY"Z,F?+%J%=/3GP7ROZ?D&IO1),J-JR87T*
MRK@%O!]X*&?ITLP7(\/'UWZ;6&:,<2Q-5/RFER?WAAZ(B,K#O:'>1[1=5S5=
MKL] &XX'-%T=5 I#_.YC1HG]-^*W%]8]J#U9;E^[RT_.J;G<%>':+O-)W#N"
MOP"G3R\9.R+8NZ/RH@-6QCD/'-SZS&]:!971V2H8B0_F\=8^Q,\?B7K1@6'N
MF06YOD7VZ@^]PMX-<DW=:JQ%<WHOT??M&IC#EW\LU#A]O&#H_5O'0K9*IU$5
M//MP2O:/)^=AXXPHV -5Y>W&+?-1;T@;MK_L'^TN<(21%2A)[!NVEIAI/3S<
MVB7YYS/VL?NVOYNO_%XZ<[%?!UG_C*QVC;NW78!UU\PU#[Q8=2'S:%Y@KOF<
MFSG35C(]_;'^D:.2C8_UGXB(B%F3U^S[H;N1B$]\>JLS?77OF6O%BI/')SL:
M9XL.PF6CE(S*#]ST?JV37^YYSHNC</NME5;H7*Z4T2 -0%-ZGSCV(;:"L,^6
M3-BB&5&/;!Y22HA.,G\-G(^(;=_HSJX#WEI$1V65I5FM>S4RE1&R7L2(BWI/
M+@BC 2>&^3^K@!9"0(=:<Y2ZI,B!YBJKG/.TOUNO?96BW7_1\:.Q4NJ"[-3K
MS3^;@P1R=V]\37=_O#0:]-5W+_QR]XVL3=&+'MJBIWX8XB\.W<TS23^7N/27
M]/I_G!,]Y9%%E<]O[2%^#^C3_L.>LR^EI^#5?<7KEC -Y>[T3OIJQNYB#O?[
MO2H[MZWAC6NR&:@_M+SV_\.CF1CN.V6T([*19!BQ[].KF]=[%@;_X:7-RP5K
M3Q%N2__\3QLP"/RK^<?TO7TU/D^.V!9I[3ZU2UWWP<KU2(_\/=XR+P(OA:L1
MD^DI)T",8_;(^PV"K>R>[%VF>Y<\+E#LDI^*]?\6FW1VST#N\N6&0__Q87@!
MR,?R](G8HW=T'4DB=NT=CY;&M[WV1.AHQ?%GY<W7V\[\!ML,0%;N)1U<T+R2
M,NJL_WVWG2;T'Y_E?I?#L3E)'X_!=KM^*NW-A^2?/?WU?.?7B/_X"+C??W]6
M,TG_JK@401:5RS 0$W>9+8G-49#?,W/L]Q_^%)WH/)67%XNW6/._]ZC<Y5E=
M.&\#23]4$)]_XSAV@^^@>AEN/U=Z1)%RZGB9K63[25*;PBT.G/OMMQ\/N1CT
M8 )KD\T6Y\  R+!AD&,:YS3HSA8=H:J0K)$&%]FKPXA=*#?P(5M^2"!?=@$4
MK0+#?  Q$C:^&G09%!Q9X-DRC95"_P:W_UC $ ADR;I[X9QG:IXSO,A!*."
MWX-^N2/2B=V@<SW0PRTQM'*#BV_0NJA#_&:4'CN>N;VIPG;<$6$@!B J:Z<3
MJ"G*_13LB(PL#_&LG0T?PF=V_Y[!\%7?Y6P_6*$\'[MLCS!; -:G0DJDN,:V
M<?8JZ:FF=J:J-0VS=6LZ_$=S_NB[,.4/12Z)RV57I][7OUC0"D]Y.GO#S.LR
MK/J13J/)(\;:UZ^C<D2F3/Q*)JK]8_G,:KP@D*0O9".A3=*>6!\5DA+RUY>3
M^P&@,4-WP^ &H/\%([>$.@GB&094K#AC-=M*KXEWNQ<<J0.#&.)IS5;R4;3)
M!]TMM:./BRW2LE&GXMAN!DMGE;D6"X.J20OIV'2>Z1!FP$T;&&WYE<6P@$<?
M0[_![")?CY1"VG!<P0#:Y"XDDU,O%+NAD <K:F WZ32;/"*=R#!.$\@C/W-<
M^)68Z^KN(Q2=#&EL6BPKHT(2;& [,8IQX8E)@<8/4!)T7W7X, 6;OB/2V&A0
M51'D=6KUD6;L9\=O=T-<*-?.8HE/WM.]C-P]/'QN?W!T<W7UZI3OG[G](;LV
M<MEN[F"C?3Z6P+G=7@@YYF<WX]83<L9,V-)'Y/N_#EX)=:%D<6+Y:21K] 1"
M&G.#>A\C1Z;A< 3HF+$D;S]@3:Y'_2GD>6WT&]QO7ZQ5A#V)V1%)S0/8FL!"
M.OHX#PK49_'.,++PLKRS!=[ CDCF37+/3-!L*]$PQF&.P+^S]0F?C&LSV^0'
M<,\+5C"$A6%\+K1C<@B1A2'"-R8!#!T^L",BC_H=F,RT0@0"F@S((!>:_G=(
M=UTUW3B;I/YLVOKP)Q]#5@;!V2.4TC+7 ;YF<B/FF?T"R;8LYWO"87W2_"'W
M";\JU<(U^T=5X>/&%R8?_*XEE17.K&([KTZ66F^;5/%'JPBY<K+OHQ^]JYK%
M'7NNJ==HE 8]AE;>:%$,"7FIU/?^_8[(/F@0'M1-VQ2M%"S^6K</)6= I'=$
M B87A]Q 5_IDAD70R-E(CEXWF!/(@"X9N+*I]^J!G/N\:*"X$NBB*R?')BD/
M^?"7>+#IA<O=8 _#$B*_5JI34(O,@DUOXHTB22W\^]";>(H4QZD/_ %4C\+)
M>ZS<N=9@%G-A#)$+W<V[09^418Z@C]=@U$G'D,F,I.W[:!VDKBMP&D=[>9BN
M8N60%!#&H.X%M[PQ<A8VQTC*P'N;<4BUAU=<5%&3G2M.UR#E4%7!MN>9U[>C
MPI_KE#MF^!&JS787!HJIUC^H=VZP+WOHZ!:Q%G-F5#8_1%O-%":]J//N;EF$
M6S3/E-]#ON$"ZJ5M&G!AP:JX!]_P;Q&,R T;8* 7RH"(H%\CU 3&@C<58LF,
MH.&73M+B'IB#@FE_-4"F'ZL1#)$UF=P%DI8\H=+6:B\93N0TAF429-3::,H4
M+V]86WSO,UD-<P.W!.=D@7Y<<Y0G^W0EUXBGR>\F7\=@9W@W0/MPFG,BHPL+
MO4F6!>]L#:FN#DW*H4S8KXEXT&  (ON-KSNV\AL;A@]K#B5!@,(N@=K<AHEW
M;.IL\P3/7= YY1RH?W3*-?4 5^SE[X^_,(\^FW7/*DCI:PSWC# KWUC.=TCR
MD9Z+B-/>]'O_J*C V7&?H:VC]<1(HNE$\.<;=U@_I  JYPK_^3<L1#!'[:3F
M?L<M>FUQ-L%:P&R VK&ZL0EL7YQ''UO'M&\/L-*H,G$(623Y8AL['FO<JU8E
M[%$VR4CX+J6#1JU/A!OT6VLX!7_C&U^8JMX1<>B9>PQ0WZ9QK@C#3S/ZM344
M<X#G Y3PY)<87;G6QT'6D&K))IP+"T5 A&H-JX!^XW\"2$D@9H8EN QM&GOR
M'_::TEA[P< !M+IJ"D)<(+F6@$M%JR*C&9:69^J[2K>\V&)CK!L*@A[7T1IU
M"R-3S3W0J-8K[IDY%E%1^:B\#VX?2DX6+EC]J"FPG_NS5D)O#K;/#2QP>_3^
MPYEQ<^*$ 3$NXDK7GJ\C!+0EN,6Y*VQG#=(-0<FB8P=DLJ@=B)')^U1"?"[I
M*/ARH.(TOXGGQQYD,5@;$[6\Z^VYQK(\4P"7*A334!4DE%$R!/TM%.XSQQJ$
M2JYK&((!(?1RG:\S@V8/N.>?$G,A;ZB+032-#*Z!8(*\BWR3*OVYM#[C&_0>
M6;)7%NB!L76("L=#NWD:T@ _-X-/3 J[-1E^P[I>NWJ%F-,Q'GE-1^FV@]9E
MS:Z^*6^/85B-@FH*_&3A\T-5J^9C^2?+">%V:][:\7HF'W16_J[>XS!^QBSH
MP);#^'E#(35R=:83.N?RG6VU,O_/A;+_@$QHFK#"_;3RH.&<#"5/3-FP3].N
M"V\&P4,?8 MV;JH&6<\R_9Q[KO@?S!ZI=ZPSUA+>B.T81Y[48BLU'1G_0,)6
MMFT5#9."V_)TJ:MCC6%M_W9_K/K/CP_^OQUE:RF'YVF7)F\ZKPYUG_^RN/_O
MQG6?1<IUI:93APS_QB8><W0(WOPSOMBW(O/Y6V\,_=CLY9.1&NI3#PNM[/YH
M:0@;4*E6=CY9J4_7<#I:=4WK2D1];(5!1.9?4#U,J,S;&4Y^%[_M5UE&L=_X
M:58W !<G\#U.U!AZ$Y>-D\0$+R%4EU Z8!]0!STPQMP1D5@_33H)Q@2V@%UT
MH13H56%XD:Z8_F.EQ^AQ3KS8TS[-,FPVC&VX-F_5\2LM#B58I!)*^LE+W"%R
MI_TFO'*1=X%/1"NLD25ZI0 RS6]A.-R7\R>_Q 0J_:E[I X71^N39_Q>6?.9
M=&J!%]\4>MM/:(K'2I7O&_=ZUBWFZ+Q>@A%.1ZU1B03XU2@B\X#VQH^&QJA4
M.&Q?8ZI^7A/LX(3EZ*GL6YNO&$5FNB[+9SZDUNKJ_/AQ<U7/W3T_N9!&/Q-=
M1RST)75^C B)X8YM9;%9 HDM8>^O_"IG%M!BR3G!#LJ!TG#0W2AM6H:UZ%!M
M,&*W(?K$\B>R<C-Z/^H2&,FH#&?P@X81TM^>H:4^M?D@X9[L<G(:&H(4'_U?
MM+U[5%+K]SY*V\K*#+74TI3*U$J-77DI1<C,S,Q,+:\IGRZF2,9NITF*4)GB
M)667I9]T*Y7WO-!%M!0A!;0R\RZ)*0+MO*)K[137%L1#W[_.;9RQ?^.<\\=B
M,/ACC9?YSOG,YWG77',N+,[28I9A:\;]H$XN>4,N;[9"E4ZLE#M"^364YD#R
M)M5P7=[L;3/(?13[I:P-\SJ%(1XJ\.:M!4VE;:864*5FUA6[4*?C&=R-Q,N$
M=:[%O(&%. $:^;I?VG<\Q62=9,CAXEQ>^N]M_@^N^92L8:9Z'5F+G=I79M31
M6&]I?LKFA->;:?J>>[Y9!GEQ5XOI,[$/ARAO'I9X77G@T3&\,WMX<HCR7_;&
M)2H+1U#_:?.E&@X>;B0B:H1 A@IWU4?.6D[$%'+U4!1[)\'$>'9-Z)09?QD&
M/)C(%+=KKVOG-M0]?LZLR8\K)G)]^B]??G@.MWBC[Q%['W13L5[-Q4(PEY=A
M@S7+,+GFSSH(VJ"!2![7:RO:3-00PV6NT@Q$IB-&=@W BS'W[$(O2'J$O>_(
MFKU/H' I)DT$MZV^*FEK#D-3)?!;LKS%MN/]#*6324?V6K4J3]\5*&P_5G%J
MCZU>\HEK?_IQ70>[\S(4/AE1 :S+^7[W'CTP-<AN/%5\:=C_K[5O/CSO\:LP
M$ P^?%:-/V&_<*E@2)D+S2HT2 3FP#+L0B>-\ZJSM<#,;ZER&781GIPKTMB+
M\E+XA$*-?/26I7(U>\MN81MW*<.+2== +#6K4EJ-:5WDI+)VEY)<7D&TXA"\
M\*ZI#6M@AMEDS+LF:JDC5RCVDZS5+I\4IHP'W=MH0^Y2S>8",ZZK.+.>BZ5R
M7M5/<Q)!>!B$*8F22;"R)3\I\I[R.NC@ A#227Z@P0S?/3E&ME_4$A^08IOX
M"VZS*Z62NZ$,^^SA&4]]WS-+?SXZ%+S_3L6>:[%F:[WZ'II91;[]RR+O7+?O
MM7L/0]RLG>W0Q+?\4(_F4R<V^*3?R4Z/9V[FVXJL7OU^*IC^$ .<ZOSB*L5,
M%RS#5@(@8IHJI:4':R:KK/ -'!DRME@9!)E3*J=>0ANPF>C]8!UG=!EF2+Q,
MV0)A6QP.0(SFWXBYI_K)[8E/2_/R5/ERX@QC^LBP)[C02H L<Y6;BN0M4#A
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M.#7>@G<;6:E=69.G[4:R4WA$Q0?PD,(D3VBLA-R/U6$9 O6\NK!]T#^EI#5
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ML7S1A\)5.K<V5OWS Q8C0W%+N</*2U!1(C K=>!:.25@3(A9-@&C"S)#R5\
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M9OG[QO/(E>JDJ]=Y\_F44<&C9=@75:=%<IDPK+V\IJD$1D[KQJXE75IB:K;
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M/2NSE4@]:-U^U+XZ#6I($UB#Z8URQN0MAD2[#3=[^P>/D&# W[ UT5$SVBW
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MU5O*S]>\  B]R,(2OAD:B8<; :GJ;J3A%+TIY%,':#7C _;VN /=M&SKT\"
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MZN490#=JQB*7BSZ? K#Y*1CSU^%1LTX+$>7]&[]J9085#SAW'/.<!X^_"7$
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MK:%O0V, ^MB*WL*? +U'GA/M#;4RIUI6]#:@3"<'<M/5MWX9T:0JO3'8?)5
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M$6'Q"\7]B)RD3TR-0P9"D F;E9IG9S]XEO-^1>\X,"JA-A/G,[V.+/#7DGP
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M]07D2CA;B5V?*+,%_&]J,A^10J Z0'086%>M6EZGZH'_P(825$&$SAEEIH-
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M@2QNK-U=H]++3WH56--XWLY,%WD$IV3&EWXB:.=7L$$Q.OMSY8? DK=^I0M
MGUMUX+9+??X!WS8WX,!+=9.&!LJ0ZVXLFX^$9#A[DFG?$VTSPHVH_C_-G $F
M*FO<FQ@=_Z>9L4/_IYGU#V _C*[H7< 8RL8T1D'ZO7QCC3&3/" SY@&8&Z2S
MBG+ZFLB9-/BV42Y&,6"HT\8ROX!DH*0;R@:>)/ LAF]+%CS7W<^,N\(Q3;"T
MBO_CX1!N++#+HG(;1*B.)Z.@Z@=XRD:TK<87HBM@B/&9:"L)"@]O!T/.@.]K
M5'CO"Q]ZHHU!] VEC4<P-K=LX8]_9Z+A'1+?LK#CTC=ESV33:3(YXYOYU-OG
MG!_F9DQV!*$2$AH2X4:9F&Y/FVGB,X&@SWIFD;<5CY]:UY%0]>@I^FER3?GC
ME.YB]P[BZCIT<@-Y2+Y!_H)NCCH'J'OE,/0/TXB-7&,E?XON:0"<$&8XXZ%K
M4>M["A\GTL>DCZ0VKUK1V0M3GPRIX\[S__'Z';-Y?;^"_QFM>C6]HO>,?CWU
MH+*\G; 9FCD$(G/)[B^7?DJ(=AER<_H.84*T5&Z3&0RA$0/(6[MXP*CVMQ0O
M^J9X^KF.0<WI1\2' R>B3I^Q5$Y;/,WIVH^)17Q7@3[RA6:F^0GTR$M%Z%J)
MD=83*NTMFZM1<$!" 2H.:#\U2-#8QC38[.LJBZ,Z<O?$$!3]'OXT 6\KH*;.
M.L[?N6Q4+$T:%992):0-H*U ZSZ,VO$C?VA>;@8Q%.H<WB[,S76ML1E*PWT"
MK2W[AI*?L=TIU;H";N,7UIS[15 ;/A85/1Y@DLLPO/0_-WH18BWI@&+"M%N[
M ^(#[8< >M[YYU1!Y?=B\G8B-A!0Y^YNOE/55G!8K&;'NTX$!R;<>_@\T* \
M)\<W_NW&%_EZ[U+E8XN'1MGTVW!;$>HRB.RLW $-60KVDPXV0@Y"STO4^OB]
M&L?BT]6P#3C*SQ.1"8+PELH/QT'/:61];34C*E(J=?ZCZ0!Z,=K[L28!R+FC
M7,HT/2M&V=823ZD5,CJX;KSW*TV(_2YT*LU"RL]OEF_\N%#R=?>K=D0N0\2.
MZ, =TPZ %].O 37O%JIK/UYM:_@ZNMQQ-RV<5:BQK,+AILKD!1ID]70XCFH/
MYC 8TVW:>PQY@LR$W8IWH)O)I5$3 F\&U4EMSK07S]G2CN6_"]_@7'+BA%[R
MBMYF])9XA/$76$Y92>NUAO !@*7TI@I7]&!V]R['K@DIT](5-'/HE+5W+,%U
MZ</SH?'CNENXMBRX)$B8&6MOYSW>91P9$64OQ&7+$% Y4C#%GNG_98AG33JB
M:]K=-NL3+"V"9]*4,,.QZ05W]_0_.T3J?[ZBGN)#@M((%RXBSQ=[)1M5??<H
MS[GW)F\'M%H9?,^N YCI1<- +=5\I,1E!KT1="]0,G_P>GTV/.* F\W&!6V_
M\\,0O^*)6I.';24_;3$-Q^CD;FCW%.AA6 HQJP-KH?'PNP+RIA%;\-+U!;0S
M:+9/)NU[0/QE-G7U.C[3-YF1:/%O0OB9TK27WMF?@O2*Q:FW5_\S1[E H9;*
M#='NI!_X;>!N=0X912Q5VA>@HAP7V^(6:DL;2$=2Z:?O"CR,X\&(T-Z',O^U
MBU1,<P/[6L/<K*)8FQ1D7GVQGC;V3 G;AJ=OYCJ 'U2X&]Q )6L]M+I3Z]@Z
MJ(#V,+N5>%R.6#K+IZ9&!9"W:[: S>*O(DY>:GO%*=41^K$F?BO/66S\R&)(
M,&.E[A[(AEL.IV9F"/FF/#@QS>=;A(OH\EQ@-T(B0;K?W8=$IE-5!V53XM>B
MJKJ(L2G>C@BO@HR6(<(%ZJF(!,4?X^MK_"]\&TL>5 .E^8-7&:"/0E:AP&P>
MGYCX"+?G@YR<!HU78_C4@BA:_N;CU]$>!KR\;GPL;/Q-U$1_;#+JJG@P"/7/
MG<-S#[:&([ML;(]"=^/ 7]1"\AX05O@S%%2MV<'CBQ&"WZ0SX7YW6)'$>US_
MQU-?]7/FO?:33C])E*29)B*KNQ]!EV/N_B5">=0*[SSYE6^F,^EV1![%.(6>
M'Y[6/7";LI&$JR'^H'J!N A%U4.VQZDG@0EQ6^7.DO&3M&[>*O!V\='4_<QW
M,+S;PR1.]C'?+*]IS?[E!Z2]JLQO@__SW5I3=.QV6H'LUL5FKS;P>+VRWUOC
M73=5"1>1#CP6J P*+\R-!XA2\#9!)%\3_Z3=HU^X#F97&NNO.-_;*0#L9T\"
MO;UR$]*UR7Y$-WQU*]";X\C;##,@'1:A=T"4D$'R=JA .2H7>AE@-\8;)EIB
M2\-%+![BS=AXV)14UI39,!&-)9@7_D]Z,>_*JB$\3B\%:Q:/6Y="L8#&E9;Y
M!/(&4L"@=L_'Z._%J0A#3AXJ2$F 3?'LAR_&@/];0)L_&U:G2)K J'\C#SY,
MB$:T76T6W4Y[NK[15\X-,4X&/13L8JA3C=X.P8?0\)>Q,)KL0W?9)H/):ZG?
MV[:*'H)9@>0L@0MN/-"\NQCO][+Q0?&!GTW\IGO_)^*Y06@;1*]V)]C3I(!1
MH^& I="&\"*D39W+VPF91-F\&XX1O;VY=&;DD]O4)]*>C,<%7V(!1EZCJ]QL
M"LP]/S+??C#M8N.J;SNSN>@5/<M):(3@1H..)FFM)S3.@:LNQ^H:SG_ \H>\
M3]PP)Y6T C5M'QKEU[4EYKG5DS$#NV)WD>P*9T\>:#E)O<6S)S($9$?04!>O
MF03-WDE"OLYO&AX,LN/G<^V&T#^^)L8=![W_D9P(:VE*:@@=AT*P!%BBIQ^S
M-J#V35#:Y1^BCR99B>X"EK/[=.70:\7IW;..,SGKH5!W%N([RWZ%'J%2'\J)
M'D(IH4 +)T;T^D19O2@2'1[ZE+)$,UG1^SG'2E9/2',KE6HE%Q<Q/V>-:7:H
M*&LUAX9^ >VODW *RC;BU83:%FHTD,-_!)7ZEBC?/'[.*3@S=$E]\7S9=Q_M
M\NQ=#H?Y/)G;JO<O)D?>U','6.QUT1P90>\@^4/W5$CHIUGTUM=X-*;\Q</,
M?9W!Z36\)J-[6P"/&RBC-G;GB-.YLJ1D8744N$9Q+#FQ\?8+$.V^7$0R5R7Y
M*_\9)OE"' 4+1DH:<62S<BLW CRVP@ +FT%O%S7;( 4M97\G6I7>8!.V2O_W
MYU#S0JE/03<=R)L8T/\:1VUT&F,.U$"]*K6.D(S&Y(;Z0MYZL++C$5YJ06LD
M7A(H"0*FT8K>3RTCVIT1))?1U*A$G FQ-)#SE'80#)1]-)EZU5^?&.WT%&T@
MNL@ M\U<*$,[0_\!^!>R[;1.V4ZH0/&8>]E;5AI+ )8"N 13DE_K<_%-].\M
M?!AI'YRE"OQ]KNK.I6ZAE5D)&#K'KPQMJ"Y.U>N24.((:XDW*/$C':.HTYN7
M&22G) 4"OERR&.#S*$%W\1QOFS_F%FK"A/ GSL9H+I!Q-\Q*HW_V3$52R3]N
M!1<A]23MEG:[!@U\$,R>6M$3EIU'&W*!RJ>3:O-XJWN\"N6WT1ZTSIW&"K5I
M@F?6ZZB$ZI#FT F[P GXYZ/<F]-S8O6Q,O'5F\\'LNEL2P$E-UV2A]I13Z1U
MP@W A3L@3LD0!)F^L*+1YJUI6XA/) I&H1M?GY4WSX)%-MYA!A :*XP^G(BP
M#O(Z03ONX/W[R!?8LY=7)"C]I1#2*J@@$T0+#D(5D\]K(7_F=#JN@'X2I-QB
M*FC'AAV;#<K55F%<JR]#E.]\KRD=DM9 #\&+%RV%P9ZU=^Q+DR\<O@[? 0H6
MSHXZ\]9J?AWBFM=#<B6C6WW;L[>KG;49XO2$J[/F6:8S5I0;I&1%^;@A^E64
M90"@?X/D70N=/D@56DK/UMY]..6\&!+2^&UB7AO'9VIVR99H$(;+%6E\08J0
M56 E$?+736%@7S#&D"IRD,E.TN^R,JIVYE0GH$UH+RHM@6#:0S1=J5\@#'Q2
M:/<A@BMQ<F+;!)[JJ(AU61KX_]VAZY584R*A4VI7I218$K,. RRJZ^_%F2%"
M^*[1BZ[>IL=R JHY14D^9T?FG"XZ*HN5\3\'.%^R]2L+59Z*]CVU2H%<VN_S
M! I1QMWB$L!J%46(1^0C#-UHV9ZW98X@+(LI$<BV2EP[3@?PN( X6X'XCAC2
MM4%9RAF-O0#&Y:(\E(;D*>;L=CZ/^ZPH,* ]"3DYD#U/RXV&07>3*"Q>^R3K
M5CJ]L^*'X0SF@>9RFL%TF_R6VTS!\J'U\\]9NR7#GSO3(W^=B,!)$_J2+C^V
MG;H2Z-0L;F_S[R9D?SM*_[[^ 2D ,.+H"N],N0]05/.(V"MHNT?-3ZW/B"B8
M*;05E):$WQ9_?5^W]E[-Z%LI^?[NT3?!+1)+V,;N347-;$HA0I^$4?Q'"F.1
M0J&$A\1@PRN+ E.H- 249S?+80)EE+L2'^0O&)[Q:&OP3$E_ESW:T<V>*UYT
MH. OKQD<(&R[X_EX+<9&8SO$35-AL^F;=TLT00J^J6:7F%V(%2SRMI4>-$XL
M2\N[R&P>,(,BA.Z\[8.H@X14Q8J>\93XMW"<^Q]EP1UQ[WHSJF;*_&K6=GQ"
M>RDPK]6=6N.[BOX:AI!?(*5EHTV([Y=ZY48:_3H\?"-V(Y01/"(7GI))!Y;O
M3#HY"-%V3XMQIM/%$4$J0XK0\U7I^RW-A=%=!A5^#FJ?4;3GQ\LZ^+&<I!OZ
MU!!UU:*JT1P=;>9O^TC>W<0==DPBPS]^=7_R[+53=F55G-(Z,X%]H26B/#.Z
MQVMU8BSBDLOO#^?QE%RR7OLPZ0 KG/BA<S'<\K9;J"MR_4RPUF[HPC#I-'/"
M31D1+]LV$M.!]R:<?9[I=>*(ZZP+OKZUK >,R2YL4.BA?P4^Z"":!0M41%A
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MNZ[+<67.4\=M_PL7O,K\+X9CL]E6?'K'<.![%/@QN'1.-K>$T.PJ$P"L)01
MI@GO+"%2W^E0;%$P1]?8XL '-*% MZ)2[7HF?$10K?M0B&Y+WBPA,@E:8P&,
MQW9]H8G;U9:3*-XCI!^J^NC]"&52># H:\%G\=> L@SL%ET1&5-<07K&C"%*
M:"'+BN37],XVOJN] .S4VHXU1&;66N+KX*>B!J38RD8DYW$3[K07/W.;/^5C
MUZ1&P_KBL-7PR+##(*'5Z-(2HD:?R5*BLRICX@PWN#CN"[GO"V+OQ5#V.?-1
M1=+VXV9#B*Z_#C[OGPBD)GTH:87;7%[<"".\T'YTKWOP@EQ-P*=,X-Z0EFDN
M5<&;E-.,O?"X0U*\'^2A2P,PK)XS0/F)+LQ+4S>';8)*."1@RC] M_K6@<#(
M'.6"[$"^5#XL8JO0<EI;T6KI; PA"-:O&%.LJ,$Q=+EQ) G2#X'BY\RSICD\
M7\XH?WT-Q$FCFH?!/S.--5C2A@FI15Q1[075A>?C\NN^E5$-ABT/FM[>TBO1
MX==D*4!+E[>E7W'1>8P-3T :@Q($T"QA%A!7604X</2B^=M!UMRF'E),I(RR
MX04\(@0_:*VZ/W_OL;0"EHF"D_[I\ML7_(P;CW>]M9CO7( VF;"0I?%W42+
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M,JK>X!."(K3]\82U)4B@NRQZ?HU\'1KLV_^EX;ZD5B(/5\HTVU%Z+S0;P'B
MFXYQ47L;,)BI^8IT_D]PA3"_(6I.L=8%E<F^JN(@SU$E6J<Z<%"<;_;@9L2&
MRE0E:F-YGX5T_Y5MM?G$BA"+)<14$BJ5X@6YO0F6W#JK5L8GQ^%3^4C0^S9O
MIU+$'J($P'0(_:9NR,E]9>KU<G*D2/(4CA=^ZW G\IW[+E/?A0,,2\Z&\80K
M#[8P#ORN-\;2N6PD!@T^?3-D <</M_M,\ER T/VQ4ZX.%?73TQ&&N[F!\;)Y
MV>Z>H6CW!XLMTJ=E@V^]SH<-XEU[UQE1DEMPU4[,2G)U*W\7J&C!9;'6,,7U
M-41!NMQ>N(0P)L>+%B(9M9YK6MM\JJ6LD[V4K6RX6IC_SP+V86F4>RX'G!</
M(06]DY<?A8R-% ;?^$QUIL3!BR!=))_/9@VC1-F$-WQC\(SU+@B?/HN2VY$,
M:U,_5^9PM3;=SHN.VK7CLN!740NW"HYW?NUBDW@_*[N&NRX[38?WW!^CZ1$3
M)!F4#<-+"".8*?*']XEUY<.ESS8E-L\'TD\V@"75S\=<\Q9*TRI)'45_D4H[
M.:4LWWQP;,[NB^_9/_OET_^NUVO6Q*EWPMZM"S*QWR&DM>84>((.I0V]5RCG
M[V",7I ))T"N^&K4LV#RC:!:>A\/54EF'6KLH^P/CP06;TR_X=N"#UJYSP;8
M_%+;=E[WNYY0[0?J#_7UL 3CYJXM0+8A4_EFL)?2#^=7WQTSLZ@O+$)V:F*
M*2N>C=YH=UUA625+U11P\;Y_7E#5WJ"QL*,LDJGYJ;!1N$>IAFU4^LU+B+3\
M4OJ3&*3*U-KM93?FDDM)^EB1,YAV5S]]BN*8^,3GZ6+1&<B>KI)..[./X];;
MM@TX.U3H/?,9$<6%F>L@>3JTDQ>BPAN0'8 K><I1B@O$U05M<@GQ#+X?!*<F
M 7CD!,N(;S<Z]6(BU\WM+&J=YH)K7A3XKX'"4,1^%TFJ' H]/W'MT.[+VWOF
MPA")5KHO3PT7'AT!XGH72C//XE,$!I2KX'W1'8=!V]/S(BJN4V/UB.C6\#')
M2#X24E<-GGC@]/#Z+_*8%#<WB^3!*&Z5;XSA8T#1/Z SWWESY%S1&>CG#K4S
M&7D*OCE\,#[QV=N&.D8Y["WB&[QN@"[1#W/=%IY$43>]?)V6M'G4E4%S^<2)
ML.7]+A_X[XABRO_[6:R7^O 8R@1K%!6V&9*](=UQ4U@[.C,--"<(F[ZWFEY_
M1]1Z+Z@M0MG(U".'!(&#LQ_8PP6+>Y6*8! G9V]]G7PF3;K0_\1'/:U'[6Q3
MXK.NS*!7P'N3B,(A(U#G!2#O-M>%KCP\V);M$FK='MS--R?[XVNZKHS MU66
M1-\,.^CRV7D+0T[*4_<8]C]YP7/E9JFK5D0)(G!Z=D5W1_F[X-L T_@<Y2+,
M@"0B*J9S%F6(9F!VJE"9P;F--.6$E8U:)T!+TZ8I.Y/TTVL=M_(\E*1UY#O2
M"5^U<\+3<;?<JK!*$?5#@Z,V;[@"94HY#)>KDKR:41MGEA Y9F$V4&1ZK.]B
M^$GH8D%$V<>0J$#7.>JF'HWG4_*>K;U?+5!K8+>#8%UA^ YDB2.S():[B898
M0EQ*\E:1,JEH\O73<)"2F=I-^;$/LS4J*DKE.Q  '>66P&VB::65VVDIQB7J
M2CM@F59M="S?LY5306 W_8TN,]P[@R\5/53B<G#F3EA'S0DX!*P8GKY#N8H6
M"E93W*$3532E("N_5#3E%4Q*5[7:_]Q-\2B64[9"_(>.':6:K0EW/GV:"+/K
MG KZ.GGG;;K,^, RMI+5G^<MP^@ >8..(UBM^%1OY7FYBT(<8P+0,C >P.*^
M%GE1:GCXL_X)?%DT=KU4$P3X74M"_=Q34^@;""<J2?J*\1NN)QUGOGU@>P1"
M;9./AY%6XTN(]3RO1"5J\^B"3EVC+"@[X92%NHPR<MQ%L)1!-1RK6R#H0'=M
M<+36O&^F_M2%NJ!:/UQ+KO7.'E)EZ*?@@^LS=\QA-VM[!*LQ\: *D(D]_5OX
MEG#B$L+ QJM6ZLQ:"T^TA%EVN?3FAE[ N%R-,#4/_LNW?!7OQ-CCD+!SJW\1
M-!6]WX$HFMN(?!)$.0^?*B=+1X"Z0IT$^?H8,GO[B2%!])-[1/%A+C6N_ZMM
M^5@/UEC\D?_/2NF*J*^'ZU;]DAKL<^/1;@3&]=O< ?!*>;'F0'*(+J-((9";
M&&]"<88J'T/Z)Z6:[9@+C\CM@%/I2O:PP)CL-8E=_0KDWXZ[$!]SQ?)GNF@O
M'!?SU#4WW[&8)S/J,,]90H1+5L&+FLCK910?N*)X'+6>$@+FM8;]V-1="L<X
M8[?T:@WA.&?TVH_C0RB9UF*";]R'P96'#HQI=^C0IQ:'#(MRIV<XL]U]?4,]
MO%-GHI(2OJEDS8WXC4$:#%/IECI+0PW!=W!K:4(#(/L@)53EB#M[Z;=ZECI>
MJ#4+#3\/?LDKD8MEP4,"SL>Q_'6WHT^/A/3.P+:9WJ\%EGP#?H'2\ (634''
MV C_%Q4?MK,OL$UK&N,F.BO_9[Y.[MB6CDY[$1-[R851Z':*V_VE-Z*.>;)(
M..=P--\W2/KC.I.0Q:("\4D8?;I/NU=SOA[.!N?]H0W3*50G+Y30#]<JOUBH
M;#?P\Q!C-Q8<ZZ&:]&M^[.-YE#=?*'WG4E<+3I_BAS0:.+RMW?@UYI>[GK@W
M0WI<D)#B+W0KLH5HXN7W8L*2_ GP73;2E+CP*7]PJF]J,CBE1-I^//G$P1M2
M5W?KN\_&$M85E!Q9D9J6%T.R;BV/@.B =3% I%E%*4SYFQ6PW;0__4@ME)V7
MK=D7!Q ++RI_XR;[<*&U%G_E_RS_:][8>[FKT6!M[WWWPW?WO2H?"5]\1HN\
M^6)FZBB:25OQN6<V.SA)WT? 5.;=+I*<D<7D#E;&AKJ/Q?6L^,J^PKV1C2V\
M_._08>[9+\?.X,V&D1:H*M0M.ITNN@NYJ>(U.Y=1G?3?A*NL5O.M:!$&DKHE
MA'!+G!V8 3^BF CF]86ERCW=?JR%3;<&- \F?J>L .6:B%=P#TU)L"1:L.@U
M#M\G)AHTNZ>5/FL!)X#:DNIG,.V(K!2\>+OX4G",QBW_,XONZ#>3_[6:X[4V
M+_]6]W#/</ZJF$9T!M4=M8[W(]\NR<GP+ H^1K%]C+=29&AV#JL=?N+Y*[-M
M1%ZG&J2:B!>7\@\Q?%S.#?7XIHW'A!-Z_7)3GYP;'$]X4!-@BC/7FIPGR_%I
MOW__GR%.?.EGAMNMK1 WK1BJ\3/%1?WA YSI'0CUVB"8_L?PES5>:JF0TKOL
M,TJ?=G%B"7$G 7>'9P\PY7JJL/)AU ]!!XM'M3] 5O0W(87&*I^ZG#/)?KUQ
M2?;#5[)5-Q]E%W\[TL)EQ+B8W7,V#N.%_88?9ZW6;KR$TJ>8$(=Q:X>(YG+/
MHB85:7W+]<I/0:'1?HDJB27,:&O@G?8K'5L(+:^MDV+\:#$E3_I?O!Q[*?>*
M\_S<>SWL/ &2B*?3%&LOLUW0&83U/"3X[42O?2+18 FQ&:X^"!8^F/H[FF/;
M5"P5T$J;KV,NC4I,]V+2*U^\U_LA7C]#XTSY:6B/]=9.28K_L3PQ4GFWXAQJ
MG=UMPZ>$CDK7^CGF9$OWMBKOIKS3;H?>>QPFYOYUJ/B-?@<+?#MD4M6)-;^D
MW0!G0][-P4R=]+#2G(93AQ4;1OTI[KUQ<"V'(>/_U #%5#Z-42'IUCO!)FWN
M%CA9QP_'4WEN5H,/[@<=F^>Z9W,'_LE$?9QO-B9?5Y;D56H.P(U*A1GE5Y"F
M<9C>2#D+X3)F/'1NJPHV;6KW 5#K!D/@L^W"HDV=D>8+O]>_ZM+81W.-H]W,
MK^]3>$?%$2>Y.@18&\7?W 2E/87B@306X.@61ELSCMW9!,VG.E+V7U"2AT/*
M,?L3V9(*[Y+@B:X!]_-8IF=OPITW$_M"TC_N*0B#V\%D(=^B2Q.I9&8J#'EN
MWUO?/+#0SYR=W@R'>X/2UZ%KTYV3XD_V.<XT_<R+[M[QJN&O5SLO/%C>N0*Y
MD6(!TK*VPH$&A;XB!5C"BP(D%K %P; ]/-(E2[NYN]9P&06W3S$FS_U^?H>U
MZD//6%T1?@H>#(WB;JSMW5T)<!L8MV'6L,!B#+61MQJ2 2-I6Z%"+0.<5Z)%
M! OX5!Q[GU=?G  9/59"[A$:C\;+/^7*#R>D,K,U.TE/W(<4_0=V4\)O)GGP
M@J_N26"E:]$4>S">/D,S(S<J:2*) 3E0C,7/Z6?PO%4$PTM4E S;LZJ>JVV3
MQGF>D)WHU:BOV=,G _?]]_+NKBN'+/):".984[+YX2Z-KXJ6H4!2K #)^C;3
MAI4")4?GS41RNWK3.2BTV8GY?'SA06%.Z69I=?-UDWZ\^SN2L__6/6^S>K9_
MWG3D^,DKCCO;'KQWK-AYY,2^Y#_"*O+W9LN:S"J+:J(//8@.B#Y5FI'J7C..
M1P9)LRW E-[BHR]>SEX*S'8O_\FODW/T559!\=F__KLH<'V!,7\N&NYP:+9&
MPFAU2%/:0]6$(A-7?8)=KJ#8@?'I5"N"XW0&AT+YK2^.L^+-$F+=O1&M,<<H
M:!1K#"^:YUR$Z:5$=\_L9W5FT$0%X.?+6A=&I@,ZKI<L9_:KYXJAM&IH1&R!
MSY[D[R1S T!D,M66S @$]W3^K1-0&S0+9MD Z5:#Y)8 ,._V%M)63Q09]\0J
MC,J[S7U[=M^;:&$ TUU^D=\?!%P7E7"T7HG*"$-TQN+71_T;+5]7]>)[X^VP
M//;859\2D5/QLVAS^1]F^;DLTX8/3-.\W.M^5^Y%-T0[W^:P#[^40,F +2?[
M5YAX'?(%^@3BJ'Q3^AL36"'Z$98&OD[W^^$($.3B(OLM"MAV+F#WZGO;MA]X
M>SV,T'M=GQ^7&:C(6YWG$/;I$^]CD/Q3GR?+#8>V,V?)U;OQ,NKT8M0PK,%N
M^NW:9]B3:W3UC__J<?2IQ9Q$^L@<*[!YD?0Q*42^2,0M<'JI37=ISY<0K'EY
MV.-$@):<H"]"]ROF'H)8-GC_6-*^.3+4RH@#IYNU.QM!GH5+40:T"Y61*UA?
M8TAK+M+C0VO= PIG2^C0/N&^4(UWWX!7[TQ>EQ-++ %*1A=V2_/QHBDW$:$Z
M?FI?91A,4QV9GD(.XXU@[CF03M=X0?@V@\=DCDCK*:.Z#<)WA$,]0-*G.NRN
M7F0J!?W\(QQ&VMA /F3X@]\ZX8!X+EB_3T<Q@FA\FM81(N50])5X([+-&^Q>
M4-:*,M&E2%NJBR3=8@W,:AL1S<FW_TZ4(^G3,N^^"/=B*=LE*_@L*^;%S4 S
MXVW1;GL]CNCWF"9Y_Y@X<JXXZ;__/;Q6.]71WI%:R.[P[_]V_=]_+]Q<Y+P2
M+\8N(8+)6!PR+6AS/149(SX?@;V"!]2T\"+@O\72/I 6,H<Z.R<(EF@K9E&<
MWPCC@G^8F13]Y]^?>SN<@&R>'C# @YPV_*9@C6\5N-E"IK/.>C"I)6Q+I\E1
MO"DYN55.S\2@KJM(*?%5K'7G? #F,GBZI0.8MF['YBQ0,TI84]/P8?5@@AG$
MTT'R;SI'>&[Q,<:+I#YU$%B]>S*NPU]$U;^C% &YMV,>?8J.YYIGE(S3]'A'
MB@W=!P+!M$+5U*%_EQ"M\IY1MV"/41!I%$P.GVG-Q#[]T_/;B]-\S>N?ZX/G
MOGS^(OP@_5(^^5_]?S=_Y&EE_;]2&VAL# I%%^W..2_0KU,Z[66YV8.+@BK)
M_S3:GG$8QU8C*Q()[,@E1, "4_8*/4OXEQ7218E33:^@' 7=TGDKU#&:DSW8
M?; =;CGL2D.1[P.DVW*T_FC/NZO*QJG PZ_ P%2,%<AH?0O<%^4M(4QY>U[
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M',*^,C?NX/8)!M3.%%]H<0DQ]3 2,+23'.ZA.I!-Y@(9;_*NCH=95M5"1ZM
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MTQM(J<[3:^!,?/H2HO;3$J(F,#5V$"E6K'29-H89<^0JQIM][R!?(" O9W:
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MIHX]I7HGW9#:E%L%3R_Y&[.N5M#RG9I*T?5NZ69! \@.5VE$8]/-QVQM-?%
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MGGOO*25+T\SA)/FG;(U]-34")-V/PV<NHTM!I"C,>DB*S]+MA6RK*,S0HI.
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M L)/0$^GVY<YF63X$109;S452_EK+J BA.@>^H'[2LS&7(IZC'A3C1]6*S]
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MX;2E>7WEE*I1!J<>X7Q>=M/8-IE$)T;>UGA^_9QO-D)H,<BKK2C:W*0K4J[
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M7P-NW1-L???ME[<W+KF<YOJ>Z(_[PHLXO0(+[!3KWG5TFYSD[EGD51_)7:L
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MYBZ)*7*HW/.<2?&,+/[H?^-_@UOG\8"S7-?K]7SQAO>5S5_7R_@E$W&/JS,
MY2F29*D?'^2*J1IO;:[SI9>031VTT;[?.6X*+]NS:\6_=IUGH8;">H:9_GE$
MT4*;H$TH\(P6/]K?F',+LA?GP-M1*0F"F0.5U+7?6C=23=6^&(?GQ)CQ!%[)
M"5Y_?8M7:%?^.]_:KODP3Z^>Z;FT%J'*JXMGHD!GL1L-4_-$_&TL8 MARWQU
MB+P5:PN7*ZOCS[ 5[1SPV^CG@4+E3= ]@Q9<$3JY(7R*0RF5T7SRCK[N+_K;
M@6 D!M#3H:'&>]!=4;M60+%B'0Z&%)TFFI]A1BG<"1Q\1Q?I]D$L2:=9N"]@
M''NJ&2X!6<$0ZXZ&#$Z]+7(>T,E5G$WG&6UE4AUZXL'Y<+\;)TM&K<T_$.OP
MO["0'*J7B.X)7:E6[R#)9N_SMP>/"^KE[0Q90'L^D[D=$F3&/6R "0#^+F%3
M SIEQ.S5FUY7?V>5Q$_OS,]@']&BNRI>15#A,VWSQ):8D)NO(EH(?2&[5H!L
MA1Z?-)L9ZA]U_X0;=F-B@0*R6?F,H)3* -P*+D)XD4R2J;.1LS=JXAM[IT=[
M*#.,"VQ%>.WS\3MD+M$RDDFQ#B1V9OA=(.VW>X7S$5RIK"9XP^GJ )H]6\1W
MA'Q2=!:TLV "=<^L)-P!0F1C3I<2;7Z"W4%UNXS)O (1,ERM \+ZXZ+18?T-
M/[GLJQR11]W,E;X*#8L*^O,W"WK3T]LXTSE66M$FT)A]SZ5S< $P&WF=K+SR
M?X8:TP5E^1V>*X?F#3J_B8<LAS&^[BFV/3UC>CY<+U"L;NYSIMU2%))#!S"^
M"FN/T#6<K=*=CVNB1Q!;-&??U.'JM5]R('WHH_?PD=H*9XV[&DO;V0@7 U#D
M"V+W%':].=:J6V<:XA_[E#K6ME@R&3)3GF8:!"YDN,RN#PD=<FJF4BXD<54C
M/+E"VC:+T.S/ ];)C+_4WI1OI.^D,H'L)M?$3(>4>L@PW7$NTVKJX,Y@HFJ5
ML<VN^M# >B[/?:'V+]O6@E.%X2YI*T;1Z4'\?06GEPSN_@&WH]*7##;-#>J,
M8*-00FK^>I9RF'$,%*1P7 4?OK6%;VWNKW*)]O@RC#S;*'TKG4M,_4/RA'KG
MZ_S,>FM<<+]KHM;+*J 1(H@0)O0>J66YF)-EZ8+2L_(OG-LZ=Y!>,#J;4;07
MS&9'*LDF5"O@?642T/QGO=/)]]'XTZ3.-<17^,N,&&QRE4L> CB("GGDN+-6
M&_Y]\T_=IH\P^;RV2K>*=@1.5SJ13D!L,>X#2X%.GROEPZ5*M/%5W0$X*Z8B
M,J1K#K7&/M/E^U2;&\:[LGY=4'QA/PL;Q\E,+\!_CPD[..'A4[$S]*Z$)8/D
M.=30_G_QF^D]\8PZ+/N6>MM@B!@@&<<K3B8S.'_2]\"UI=W3Y7") F6>7C-Z
M&UL<C;QWL9=VPNZ.38_VQB9=L=YJLW&K>,$04EADJD]SZ-$=%:'$EY-+!HU7
MDD>;?VP7*))V*(\R1^5KX/=J17PV)EB1A \L"BZ%4DNLV9D[6<%-35FNT8>5
M(;W/&C.^#N>4PILAPQF=O39'+SCA&B+,@MR!L4QEL[YG7H*(3.Q6:HG8C;ZI
M9TBQD.:*,X\*=X0955$'KLI_:&"MT?ASNS2XT1EW+W#A7E!H8V'<1]+-7JNA
MSH%\O4;$CR+%*)M#$/I0CPLZHZF\G;69FM,JMYJUL6+<QWI(G0%H?6;9I&5G
MRIP@>\F@CLWRUS+?&@=VGN4V=LVMX9F\&#>W?#9C]SBFK.,:O6_D/_5N?90(
M%"2"5T9U/2@D+Q127P!MY\?T*<M2*D)94"M/+AG<XXT_G6HW9VS@6T8-)#3>
M 2]J=M14:SGWJN.:<:DQDT:1D<0?1APR/OLO&4RXZA-7P%/->9C- -6J8WD
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MFNMV^;>6DW.#=SI^6O&O;K&SC;Y&^VS)@&RE4!),]<ACIT_?0OI>F/)LA$:
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MLFO^UM''MRJ)":G<8M?<G(CBR::;S-+!"1-ZL][<_A@QANS%GG)6@OOTXUN
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M-6671%\&T&D>XJI>WXU1^PBAH:W+DZ)_1OUF\T,?)J9,<U!;I'/UA4C*]1Q
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MQ^!!N9",I":&]%X?S(0?4DN.M( S[.2Y=\>*FYK[*7(+0M3-D<U=<?[8]^J
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MHFCK(!Q5R;"A')D6EI _OW1L06<:]DD9S;2S[-$2=):D#9$;A-?]D"S$CY!
M'+,Q)4CG?*ZM<0#WQB!.4%=<B(K -8.V2MPOJ .C5V0"]T'7>4?@;;5[GYG&
M#I%!PTS-6T'D4)V;%E>YV@T-7\G<S*VOA%J.7.B+O;%TKBY6^RH\>O0=UF3D
M:[@]WC"H:'1CFR(M:V<^+SE?Z+.)0UO3HJ88MG$%'>OI^V9M=W>5V$L_9<WM
M5L7>6FV].60Q8Y,!H2G$9=Y.WH(I%SQ?+E6>B*_&_%3X=\BO?+Y/<S<Y%VY%
MH^JVQDU:0E7 V)D&L*GU\TZ_;J]KS"ERAEQ@(TLD,R,8F3OS4Y)$R7(Q>@WE
MWHM:-])1;(N4;ZG*,HU*4LJS'=OX0SRTY9@(]KLBQO-].X Q6!1;"I]10D.D
M<TAO54YL=YO'\S**3N6:I=8A;*!,^^<,"\H=^CX"ZF ]E.?!49D2-46D&Q^G
M)?&8IY&-/\;YOG6F)MS1?.8TIB\0<N>2DA3JSU1.9^A/J!0F<6WF+-1.B"%I
M8]Q!ABWVJ7JCYWOLG#+?(V-KHRB5LZ$U*O+<'#6();:XX.;%3_JUVO<A_"@E
M55L#U5P$3U(=MLB["A6B"6]M+A#;V?L?$6;5/Y*""[!2)$;--J$=%\AY.-;N
M$"G*BE#B(J5A5)6WV>9SR..U?7$N16>'>*^P49*6CR1S%4NR8G3+#CZ7!Z:*
M7@#J("AV"C&J[K:=W >D<Q]3ZA=[! =X'63F*#ZCA\G'EFNT$9YIKHTZTSD/
M[";3#F/*E,;V\;^N8V=S2/GD-L?E^X)UO2IGEA5&Z1"(/:E6.3(E'<\Z6(+=
M<--1/5;*Q\:H-]#BGU#V0,V&S1.[Q06PG5+.O#L6=[;_ZK3L(;7W:!AQSCEP
MZ&IM]2R\'OU^Q:@:R@H&/4JGLL9>*393!A$9]-V#;T&Y^-34O"4T./G15(>E
M2F!&L(.P=:#+<,YPHWF%I!9*.M\H'72_]7)RPU$+(TBJ8F84"9/@0 !W\]X'
MA*>H8K!">^[*@FX.([$[_73P L542VG,]2?K[57PC5 FHKY=.-%C7=)*)"?M
M,8FM%E7.6"IFFDLXU70I>FLC+K<#2(>R_%;]B[;F)OC\!!2JS!\VP"FZ@#J0
MSN0\*2*M;RC7TX#IS$]X9K(?ZT.B]_.6JP8K2D7GZ-Z'<Y<3^J S?P]?.(4_
M"WV>Z>RM=L'W%"HR^"Y4*A7TD@KS2WS2S;=2%-\.TC"K(HAZ5!H7;=DNZ'?C
M;@E[AWGZK@ &'[S8*.<D:%*NSC1]?/=/W)89VV:9IWLMXS+YUB+]",JK2&17
M*;/OEJ&WE$EW@M-B9_P:'&B.O2>CHK>/ZX\V@=^A-[G2HLQZ<XI'0+.>M#W#
MY>U-Z5IBJ^NOV*_A)A1C%5[2ESJ:U*/(& V'XJE  7:Y'1FD)-M2KJVJ'.@^
M+8XZUZ."=Z--(=-@.?*XRIMA.0/;-O!AP9YM^6[1B_Y+%42^P(RX-198."V.
M<,LA7J9.X+5"J/FZ>C[C5PJB,W1R%] A8N18T/;G=;8AWB^O7MT^">R0-"$%
M=WJ01E#5(')*;)L8J9.;GTOM X;<HQ BN[</*I%+T?GLT5'9?=?RR[W:8'DG
M_O:BP!:,376E[7\+$7O@%KLAKBK'4Y<DKEJN4D/\R,?0?]U7C)K\GCHNYRNL
M(*K?,+J^45.#M5IFO?<[YY4H&2Z#4+N6?T=M@+CBT8HL=ZX)_E4E<53&4N&V
M$$)0'J V:ZK#FL+\FNHTZ-YG2_,>H 540&LDA>UY,VU4UU(5VBPNZ:<B9SR*
M0,O0_DRSUWVGQT*OP- I]-PE:CDK/0(M1*>O&%F40WZ>3.X"PSJ*=D:.%Z)V
M +]Y36>6@@FPW:FBY"/LS=%=>^\JJVBFU0Z8;_SMU.*VJQ_'QM&:%)I<C1LQ
MU5*AU&JH)A0,_86,V -*EG.YJF5740_> HE6DBTT;5</G;BH\HGL*G$ +]]7
MVG=81?B1S/-4-]U.<4L?_1:'(OXYKRDDBUCK9V ^H*=XSML_7]$]>7B@T6>-
M.+EUF%?U:,B-:U94^G@LQR[%-VKCRTA<T_AZOG3A5:2&EX@9*[J=;IV]IN7_
M;G;YW_I_U9J_4(?U>X#F'KB1@N8%9B\ME^0D<2%[R:$XF(VLEN:C<G 6,\ST
M24KN'929+"'G\E_;WI,3R%LIF)/#NQ)#_>E_?E]X?$?^-V1GH.]]%M#A"S+3
MD5153I*J1Z*PINS2DH*Z/-G;Z,Z07+7IKM+L/]38!H,"6$QUQP8@S2J@$E/_
M6I>GM!"!W>K%[(^*.G6Q9NST]0-H!JA3?HNWIUL35XS,KCGRTLV2@@#2^[GD
MQ;I(/LH6[&$B(P^:>13O">WWCX?=ELD6;08/YB]ND1P[EIW:-0MO,'"3B%<0
MR--*]+8+PN^C_'!0SE3,:M_4R(T[%:9Z1Z<[")I/#)>P>912@QM".?ASWC7_
MBG7GW&=G\-HWVE,)7)=/<]X3G:KJH,ZGR/@VR"[166W]K:-7<,3Y&J9P\'YP
MX/TS$S'?ES.Y6-VQCQ>K_GGYU,D1\T*B5"-#FVX&;[_P"&/V(J/X+*$UB!/]
M.#7MC'=*R#GW&6R\(%GZ]_D_@JHF]>&0.3"O]H8NKQA)FB9W2FD!4UD<W\5.
M@P_@E$T+!N95QK==W:GH9W$#5R8/ R'<QT3\FZ7>MLC:#F64[_1Y@'6'+JHP
MMWCG54_0$HR-@7^T)R%W8$QUC@T6G&T"61DHEU$*0Q*]50#EJ?M@J[(*.R1?
MP&_UGVI-=/".'.;[5^%?H HJ7DSY6.L//PKGL)C\O7(O'27^C#12[-7Z?#5X
MTX.SY@2[Y9$JV'-$YJ>Y(.7:%ZJ@,NBF.P9[5)G6T^7\JJG$0#HR_YTLD9,4
M *'W5I \VBMGDS=E):DBY^NAFW\MB4=?D'1'B?VKIM7A*?&)GIT6!M'.8S>9
MN'&.F&+/]:A#<VED%3RC2GWL_8[ZHLC"^3-RFH-KSJ;[J[*"P(&LGQO;;Y!0
MLT*5^@QI1N63;ZVLNNZZM\1AL,HW+-C/WN[:?1JR>OC1UJH6I,^WP>$!').?
M3F*')=3C@K"^_0.)AS>V?YN;K:&>"0Z>N'#P2<79QOW2FOW'_CG0+Y+F1 1=
M&,S,/C1['=OR5K\>\K:C]S,:%^<\5>BU&"7<1N\'AK"!9N&OBF^ 65N&&<IB
MIC V#9?C>O&?O]/(=">HP)<=N$JL.PI"H'@E^G;=^+\5_FG,D41@\HYN)\04
M:@UFJ2*T#=>-H'>ZJ.XPQU;/&&"-@P@>=Z/^VWH(4P:QL2W/@-X^)M_[25R$
MZX,ILY.X+^.6]F8]:<I3F:*_H+#%,L%AF5O']G':B=G&OI&\"X.<B[=Z5"4-
MEW="GD_T)AAG$LJM_R(0PIHBFB$P0RII3"LSF&%-,'@W#WW2D<XQ+,[446+$
M$8KTAY'4L0SWL4N_/]WD4<]!SEIJ*<E;(PXME1S-S[=?LRY5.)!5]$<KO>ID
MSAGOYOWGXJHKW,:S+25*@E? RVE8\O!UZ]A/?[C/ADI>:8YEU@><SS'4A3S=
M<Z\^>]=,:U=M9+33,@OE,+NT8G2'?WIJQ6@[[3IT.%Y-.DLB=MOAN\C9, 3@
ME):XG/R1X#3,/T.S)R=1E5A3"6I'H2];/+D?>,)Z2,D2%U 3S>*_ZQ@*<)6O
MXK%^*W0=( J32LP@QD/_"H)7$Z<&2A6'%M8VU%(JQ).NH%/&GB.:$D>P(!L9
M4$6$'0#)&8E!]=Z<6+%7=RF=M*-1JBIQ076_E"E>VFKIK<P>A1G_D@T+J)Z4
M=^4'S<@C]C*G)IQ/#'(V:D*29!%RYE7N L(Z:F;I#P]9R,?NPFB>\L4<^>I[
M"QY51ST6?N"4SO5-',QVD'9<C9DWA;IHWB0=&J*>- P 5X^&G5#B?Q8<8EB,
M\GIS.57$G7RL:AD=($\@Q9]OR']U+O?EQ]>#/D?"7+CV@<[_B4JV>@:5[!0/
MBR93[SOY<OPHP??7OFUOK^8[;N@NAQ/1-WZ;..@=_?':?7A,2&+E#T/[96?K
M@ZTC?@RY?RPXSGPDNE \G)>&NV2>7'9<XU0:K0-6C)33:8)M-$\ )V29C/22
MIKC,R0V 0M1G1E@LB)^UM3'8 "6IEY3M=J]GEV8F9[57&HM,KS@];[D[W9I(
M*+]Q=X25IS"\1*^;-]C0=D"^;HS-,Q'FG2[&HF@8Y*E"? 4INF$64!:@E0OI
M%JS.46P/4[ +BHP8T$>M_0>*/EQ*N67""U_HL"74C\^4')3RVET_S+XDKIE*
MN,.-)-9/4-!BF%\&+:6FIX+2([2DI$LQK.[)HTP)X::R:_EYS*8\SLA!3&PE
M'D.@+]6/$A@_%)W 8.JJXKUB.W';H-#NY ZQF66W=G+/L/XT:&ZPN=:L7#&R
M^CIA8BWE 6V_NH-Y_54Y_IW6-IG#WP\LBB<W 6W%P>XUOR_TI=%MZW+_>_%Y
MR[T^N^";3A&\[5K>P6^F#P;>R]W[FT9]LR8PJ_A2P+ZS"41YO#CXWG]S;@[&
MG2T;'2QWWS=8'K2_(C [9KO/'Y6OW7YL*O4HQ7:U[ALN]_?-MB0-Y& DW29+
M%<*.U.BMD-^FME'79M!48M>1Z7KUFOZT"G<';\&_!-I&#[V5?I\_VK6K!8RN
MJXJX$N)1ASO&/ /TYM\I+<O#')+J_X6=TJQ=OR[LR[+-)XQN;>A:"]NP^Y;Y
MVM \/0I*J:+X258_Y'\S_M$>&+)C@!=3?J7M:AU/P"7:E"]SJA3$B.P"+\$C
M]R4\8>GJC;TJETVO?8QU,7Z#;ACN%J)7<G+OS=]'[W%6@^GW!S&.QP9_XKJ[
M$CQ]BV=X3DYQZ,Y,7%Y^X=]GMU<E7;QHE[!SP_E<N\.)5E>Z99G!3H3)_<[#
M!N>VMV^+IOG_%DE63QK3#;UQYDXI)>E;WJ!;Y0?N_*YG#:<<&D/MBC]UER;W
M=X??#GAU,Q%Y9RWU^V;?,)?2],E]CT\V57(1ZVYU_;<%Z8HON'BHY:N.-<S2
MVUW?_QB6''8!9F["K+ +HWG8FIVT>J<$%O:?='LW4+HAJ/S<X=N[MY85D)(_
MU;E7JPY_+NO9<[SD3[/G.''#<?ZORR-X<<?/E?OWMIZ+S_NM;+QLC)1F%1#E
M>^+SXJW_K?^ORGAEY'\ 4$L! A0#%     @ K("F6LBK2MY><P, P/TF !$
M             ( !     &1A=VXM,C R-3 S,S$N:'1M4$L! A0#%     @
MK("F6@;/X[<&AP$ QDP9 !$              ( !C7,# &1A=VXM,C R-3 S
M,S$N>'-D4$L! A0#%     @ K("F6ET--UC+"   9#<   \
M ( !POH$ &1A=VXM97@S,5\Q+FAT;5!+ 0(4 Q0    ( *R IEI(02*6QP@
M * V   /              "  ;H#!0!D87=N+65X,S%?,BYH=&U02P$"% ,4
M    " "L@*9:ZPA*@48%  "T'P  #P              @ &N# 4 9&%W;BUE
M>#,R7S$N:'1M4$L! A0#%     @ K("F6L/"P?-Q!0  TB,   \
M     ( !(1(% &1A=VXM97@S,E\R+FAT;5!+ 0(4 Q0    ( *R IEH411\%
MMW,& /<^!P 1              "  ;\7!0!I;6<Q-#0X-CDW,5\P+FIP9U!+
4!08     !P ' +$!  "EBPL    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>dawn-20250331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dawn="http://www.dayonebio.com/20250331"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="dawn-20250331.xsd" xlink:type="simple"/>
    <context id="C_80830bed-79cc-4012-a094-ef9b93307718">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dawn:PRV-RelatedObligationPaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_80a0754a-565e-4050-8b95-677c6495d268">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_8186e570-f43c-44d8-af7f-4d4d7125520a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
        </entity>
        <period>
            <startDate>2025-03-31</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_81949730-fa21-4927-8bb8-150b98f7b91f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_827ac41e-d0d2-4df1-8321-6fb95701054e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_8387ea00-db0a-45ff-8cd7-7258098914d9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_88ef0d56-c34a-4726-8307-009388d0ca1d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dawn:MabcareLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_89780293-cea0-4538-b7bb-9bfd5ea8a319">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_8a694c05-0437-4c75-8ae6-45e4b83604d0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">dawn:OneCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">dawn:ConcentrationOfCreditRiskAndOtherRisksAndUncertaintiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_8b0fbd15-0039-4354-9bc0-e49520f5e256">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_8bbef5b6-cf7a-452a-9829-28292e282f79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_910c0420-f57a-418a-8295-ee1ffb7bd08a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dawn:TwoThousandAndTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_92096138-dcf7-4329-ae91-d02c48ac8ed0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">dawn:BrisbaneCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_94ce4acc-2f61-45fc-9674-ab4c0d8f85f3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_966510c1-eaf6-4a1c-9fae-2da70fcc6537">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dawn:ViractaLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_9be30ffd-c276-4ccc-8f21-4e37e3595dc7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dawn:AgreementAxis">dawn:TwoThousandTwentyFourPrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-01</startDate>
            <endDate>2024-08-01</endDate>
        </period>
    </context>
    <context id="C_9c3764ad-c7bb-4bf4-a68b-e200db91be51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dawn:PRV-RelatedObligationPaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_9cc6beef-2bd0-4841-8e97-5da5102095a3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_9cfff08d-a5d3-4ed4-8454-95741093c5c8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">dawn:CommonSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_9e37dcd2-0722-43fd-aedf-af23527c98ee">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dawn:TwoThousandAndTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_9ece43fe-da8e-4bfb-aa46-983f40858774">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dawn:TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-31</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="C_a0ee4c82-d202-4563-aeeb-4840f5b9e70e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_a308fa2a-9dd8-441a-aaa4-31aac0a1a5eb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_a320baa6-cd53-4730-8cba-58584c6ac43a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_a356b3ae-e91c-4aa9-82fb-80206cb22503">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">dawn:NoncurrentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dawn:LicenseAgreementWithIpsenPharmaSasMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_a3c664ec-2577-4bad-ba57-d70b9f3e5a3e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_a48de969-8ddc-4b3b-a6a7-5c2b29ae4e05">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_a49147be-0409-42b0-a2d6-250d7ea0c7b6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_a9d09cb0-58f1-4b18-b47f-7276b7057656">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_ab5b8469-0456-4d89-a289-b75cc0f4a77c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">dawn:BrisbaneCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-30</instant>
        </period>
    </context>
    <context id="C_ac5f563a-6d18-4f41-8866-bd417f95f7f7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">dawn:CommonSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_ac9ee8d9-bca6-4fd2-9709-df26868eb7bf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_af8109ab-99db-4170-9328-c13fd756a885">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">dawn:CommonSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_afbd7133-30d1-4e7e-80d8-66c0f4c8b5c1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dawn:UnvestedCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_afcca245-4cb7-422b-8748-147e3421ebb4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_b0966c50-b1d4-43dc-abb7-4c4d573ddf0b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_b103f351-0eb2-495b-85c1-5630e54c751c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_b18881d4-5741-464f-8b09-c6e20048b1ff">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dawn:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dawn:TakedaAssetAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-16</startDate>
            <endDate>2019-12-16</endDate>
        </period>
    </context>
    <context id="C_b2b75b00-4621-44ed-bdf4-f92f43226a4c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_b5d41f12-6166-4c3e-a249-6ff0239c1d95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_b5f6c9ab-25d5-4e70-992c-f10381920bf2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_b77b4a90-bf68-4a05-8f01-62a9520247e8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_ba36f1f4-7ce5-434c-b80f-2bcb5a767c07">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_ba5b769f-138e-4a96-8876-aa121d01b3cc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_ba809785-9e5e-4537-b8ed-aa9a95f5018c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">dawn:MarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_bcf4433c-d298-4d36-a850-dfba1a092198">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_bf59d3f6-5cf9-4cca-852c-63e292df8618">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dawn:TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-31</instant>
        </period>
    </context>
    <context id="C_c2dd807f-0b0a-4c78-a0c1-eae1f3ef85f9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dawn:TwoThousandAndTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_c5d9f2d2-fe53-4440-9bbe-b118d81d16cc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
        </entity>
        <period>
            <instant>2025-05-01</instant>
        </period>
    </context>
    <context id="C_c5ebd5f2-8017-4e7b-b087-5114b6fdabe3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">us-gaap:PurchaseCommitmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_ca787bd4-a367-40e2-8820-37c26a26c233">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dawn:ViractaLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-04</startDate>
            <endDate>2024-03-04</endDate>
        </period>
    </context>
    <context id="C_ca7ef576-0ffb-4b1b-9387-f848fc7d1ea5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dawn:LicenseAgreementWithIpsenPharmaSasMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_cb883bf9-9846-4518-bf47-5d7e85524d73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dawn:PerformanceStockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dawn:TwoThousandAndTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_cbc72dd7-8c81-4d68-9f7a-1b1c2d90b6a0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_cc903eab-f003-453f-ad1c-4dd61852d801">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dawn:TakedaAssetAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-26</startDate>
            <endDate>2021-05-26</endDate>
        </period>
    </context>
    <context id="C_cd3e5fd3-74ef-469d-8938-ed22cb45f3fd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dawn:LicenseAgreementWithIpsenPharmaSasMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_ce9b7ba8-66b0-4fb8-95da-9540fc395eeb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">dawn:UnvestedCommonSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_cfe0c0d8-2e22-409b-b482-35888c79dbfa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_d33c859c-b7aa-4b79-9a88-d16340c5fe28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dawn:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dawn:TakedaAssetAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-26</startDate>
            <endDate>2021-05-26</endDate>
        </period>
    </context>
    <context id="C_d9880916-1c46-4df1-82f9-7cfa90e42ed8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dawn:UnvestedCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_dce557e4-9275-4019-bfcf-ce698a8400c6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_dcf6712c-475d-4506-9554-ded223b0331a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dawn:TwoThousandAndTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_de732af7-5533-4ee5-aaa0-722119902a1a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_dea27b68-18b7-4c73-9c27-b5c829ef0241">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_e6665180-612b-4fba-adce-73d240ace7bb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_e9b4d1c1-00d7-4c4a-8ead-1b510859ed98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dawn:TakedaAssetAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-16</startDate>
            <endDate>2019-12-16</endDate>
        </period>
    </context>
    <context id="C_ebb60e12-8f30-4b8b-a830-3f64f4c2ba34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dawn:AgreementAxis">dawn:ResearchAndDevelopmentAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_ebe52b1a-a4be-4f4e-a3d1-d3bb26eaa194">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_ee47eb20-6b00-401a-8f3b-4c791e30712a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_ee6e19da-95ec-456c-abbd-e2850974503c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_ef0986cb-13e6-4f2b-818c-1d5b4469876d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">dawn:CommonSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_ef89ab97-3fce-42e2-a82b-c2a5c9189a28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dawn:SprintBioscienceAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_f17c501c-d230-47ae-bbff-603a48bd4de4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-31</instant>
        </period>
    </context>
    <context id="C_f1827e81-e977-406d-8a9b-6f880a33cdfe">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_f30f7047-2b1e-4315-95a7-8a873401a0b3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dawn:TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_f31a84ee-cbb2-48fa-a085-f699999cd961">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">dawn:TwoCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">dawn:ConcentrationOfCreditRiskAndOtherRisksAndUncertaintiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_f34d98de-c249-4523-b50b-c9af86c79722">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dawn:AgreementAxis">dawn:SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_fd1aa0b8-3528-4b28-9293-cf863f031981">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">dawn:LeaseForCorporateOfficeFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_fd702879-0dc1-44c9-85ec-00d54500225b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_ffb4c57e-cb92-46fd-9286-ea36197252e3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">dawn:PreFundedWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dawn:AgreementAxis">dawn:TwoThousandTwentyFourPrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_ffe0f1b7-fa8f-4028-beb7-7b994de8b4b7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dawn:TwoThousandAndTwentyOneStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_01058ddf-79d2-4e72-962f-17fe256a6f09">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dawn:TwoThousandAndTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-31</instant>
        </period>
    </context>
    <context id="C_01bb969c-6b26-4ada-840e-3e6660f4d113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_02cfe4b1-bd5d-4fbb-95f7-4ee6c0f9824a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_09d1a768-c6f7-4724-958d-e37516f230d8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dawn:AgreementAxis">dawn:ResearchAndDevelopmentAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_0a5c3519-45df-4f60-a8a7-7437f71f7bfb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_0bf779c8-a9a8-4ba9-bbb1-898f93f339e4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_0cc93ae0-4f9d-48ec-aec0-c24fe1944b49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_0d1e25ff-1b51-4a66-aafb-97dc40b3998f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dawn:TwoThousandAndTwentyTwoEquityInducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-31</instant>
        </period>
    </context>
    <context id="C_0ddc2569-0696-4885-b32d-8451ee567481">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_0eee3e9c-c51c-4e38-bfea-aebbe8a2a4a1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_0fd32f25-7d1d-46c5-938d-d9b0e3f9dfaa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_1012909a-67d0-4f8d-9538-ec497e5c24af">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dawn:PrvPressureReliefValveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dawn:ViractaLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_10416dad-c8fd-476e-89d5-ae0a83b9440c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_1129e786-4666-4dce-88b0-ece78eb6efc6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dawn:AgreementAxis">dawn:InvestmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-31</instant>
        </period>
    </context>
    <context id="C_13a2630f-ef56-4f08-840c-b986a80c28b9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dawn:TwoThousandAndTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_1438aa38-1e5a-4af2-922f-a3f067944262">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">dawn:TwoCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">dawn:ConcentrationOfCreditRiskAndOtherRisksAndUncertaintiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_145e429b-05a9-4c43-8d23-41fa26213179">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_14897498-6682-45a8-b5bc-6360e09cde1d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dawn:AgreementAxis">us-gaap:IndemnificationGuaranteeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_172d1f62-d597-4e9e-a3d0-7f8bd3d31541">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dawn:TwoThousandAndTwentyOneStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_18678d79-8e7d-4c54-8b85-ba5704b25f78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dawn:AgreementAxis">dawn:InvestmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-31</instant>
        </period>
    </context>
    <context id="C_190b79d3-0ec2-457e-b743-7f9aaa10d94b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">us-gaap:PurchaseCommitmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_19ecbc75-781d-4703-b1ec-88b78ffef3f7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_1b7733fe-22fe-416b-a33e-e8b388655156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_1bd10525-22f6-4072-ab95-5fd14d1f9842">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dawn:LicenseAgreementWithIpsenPharmaSasMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-23</startDate>
            <endDate>2024-07-23</endDate>
        </period>
    </context>
    <context id="C_1ce17a75-0fd7-4298-bfc0-f235a473361b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_21176c5a-4a94-4c88-9e64-63ebfc46b526">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_21c9ec3b-26c7-4a87-b2d1-3f695174dd3f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_22370d4f-2229-4fea-b11d-aaa9611c4ebe">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_22c0360b-da7f-497c-9e18-47a5bdec0579">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_23977cdf-3070-48c6-b19d-11d5afb96e9a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dawn:LicenseAgreementMilestonePaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_24aa28dd-3f08-4c12-b95e-d974f2524368">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">dawn:OneCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">dawn:ConcentrationOfCreditRiskAndOtherRisksAndUncertaintiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_27899ba1-a824-4fc6-ac6a-83ca5fb4f9b5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dawn:TwoThousandAndTwentyOneStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_2896a425-ea56-4272-8792-62ad898655c5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dawn:AgreementAxis">dawn:CommonSharesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_2a107001-c05d-46f0-ab44-70e8338ecfcf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_2a98f92e-aa86-4a5c-aad4-edb5374ed00b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dawn:PerformanceStockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dawn:TwoThousandAndTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_2d38634e-b453-46b0-9ce4-c47fae6625de">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dawn:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_2e6bdcde-a879-4a55-aaf6-c92b45ed690a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dawn:AgreementAxis">us-gaap:IndemnificationGuaranteeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_2f4d68d5-969e-46de-b564-f0c6755d1515">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
        </entity>
        <period>
            <instant>2024-08-31</instant>
        </period>
    </context>
    <context id="C_30fad386-55b9-45a7-8945-04e8a03f752e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dawn:TwoThousandAndTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_310c50ba-37a3-430e-bd89-9a82d7460226">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dawn:TwoThousandAndTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_342128b9-4127-453a-8974-3c82ca357e86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">dawn:SharesCommittedUnderESPPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_3488a8c4-e12f-41ec-89c7-dac4e84ea67e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dawn:MerckLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_359c3fbb-d10c-4741-807c-98dd361851e9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_3844ba24-08c1-421c-b49d-4740f7e0d572">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_388de2bd-eeb7-4fa1-87a1-3cdac91fa91d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">dawn:AtTheMarketMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_3aa48c9e-64e5-48ce-b002-f58764db64d0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">dawn:UnvestedCommonSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_3ab621ae-436f-433d-9df2-8c8bce28b89e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">dawn:IndividualCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">dawn:ConcentrationOfCreditRiskAndOtherRisksAndUncertaintiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_3b0aca41-c2bf-46f8-b765-42580bbf6433">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_3b446226-328f-479e-b281-6a7fd0379692">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dawn:MabcareLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-07-31</endDate>
        </period>
    </context>
    <context id="C_3b4a9bf0-9117-492a-a8d5-7f4450cbd994">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_3b67e9fd-7c04-48f2-969e-4f1fa6b5693c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_3c025e0b-f004-497c-8763-6a8406223ff4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_3c61836b-73ea-4fb6-bc25-ae73f9f94d9d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dawn:ViractaLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_3e17f855-9bc9-4474-9b6f-1728c5807a4b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_3ef9f2ba-6c3d-4611-94f4-9657c80e0ee2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dawn:UnvestedCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_414a2ccf-e2e3-4dea-882d-8f99a0bcc263">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_429b0413-0de5-4e2b-b3ca-8e5807492a3e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dawn:SprintBioscienceAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_43327af5-1891-4b55-b0a6-4f7ba631a198">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dawn:TwoThousandAndTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dawn:DetailsAxis">dawn:IncrementalSharesReservedForFutureIssuanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-31</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="C_451cb9d2-19ad-4b9a-87a0-770cffddb183">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_46800e87-c56c-4f8c-b6af-964b831f2ace">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dawn:TwoThousandAndTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-31</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="C_491e1be7-189f-4d71-b2f9-eac0bf60040c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dawn:PrvPressureReliefValveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dawn:ViractaLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_494cf197-0008-4f30-9715-0a6b5cf186d6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dawn:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_494ea4ad-935d-45a3-a172-b60cd7e73582">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_4a5ebb63-8e69-4e8d-bc72-3ec0c91774e6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dawn:LicenseAgreementWithIpsenPharmaSasMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-23</startDate>
            <endDate>2024-07-23</endDate>
        </period>
    </context>
    <context id="C_4a61c31c-c9f6-4c86-9285-1639c02fc666">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">dawn:SharesCommittedUnderESPPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_4b6fd4af-8d4f-4f7d-b960-b6ac6218c53a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">dawn:CommonSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_4ba97ac7-abe6-41af-8f29-b34dd24231c3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_4c2bf0b9-0d5c-4b03-b0a7-3c3a06954490">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_4f40a47c-f03a-48ad-8dc7-1d9331ced26a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">dawn:MarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_4f6e2663-8d98-4973-a359-76163a03ea8a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">dawn:MarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_4f8d1d22-bf0a-41bc-b883-13763363dd92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_4fbcd2d8-640a-4a12-888c-5b1b8885e9aa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_5399640b-8a12-4325-9bb5-9eaa7ac09323">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_5459b1fe-9af9-4c02-891b-a32f266837c2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_56ac395d-44a1-4679-8062-efee79181688">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">dawn:CommonSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_5a86561f-8ff9-4f61-acd4-e523f9c716bf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dawn:TwoThousandAndTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_5b86a378-9cda-47eb-8a66-30562f03c4e4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_5c990fe2-3f39-456d-8159-af4c23323a1d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dawn:LicenseAgreementWithIpsenPharmaSasMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-23</instant>
        </period>
    </context>
    <context id="C_5cceec90-fafe-4db7-b0a1-8211d20a03b7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dawn:LicenseAgreementMilestonePaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_5d08cb7b-c76a-4de6-8dca-2d248eef4467">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">us-gaap:PurchaseCommitmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_5f6d6e0e-3d98-4fa4-8a41-68a23cdaa376">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_60b37620-bd42-435a-8868-27168e7b2da5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_60b4b3d3-4a6b-45de-b852-487c0414710f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dawn:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-31</instant>
        </period>
    </context>
    <context id="C_6180a865-9d79-4110-bb9f-16515c37344b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">dawn:OtherIndividualCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">dawn:NetProductRevenueAndAccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">dawn:ConcentrationOfCreditRiskAndOtherRisksAndUncertaintiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_63138494-78aa-453f-87e2-d7692e2526f2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dawn:AgreementAxis">dawn:TwoThousandTwentyFourPrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-31</instant>
        </period>
    </context>
    <context id="C_6687375b-114a-46c2-aae2-63bb21248fa4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dawn:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dawn:AgreementAxis">dawn:TwoThousandTwentyFourPrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-01</startDate>
            <endDate>2024-08-01</endDate>
        </period>
    </context>
    <context id="C_68539f11-26b8-4c60-96db-44201518557b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_6aaeb9ec-3a51-423c-ad71-3fa489ff189c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">dawn:LeaseForCorporateOfficeFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_6ad97ba9-d866-451d-a09a-4e4e40d00691">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dawn:ViractaLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-23</startDate>
            <endDate>2024-04-23</endDate>
        </period>
    </context>
    <context id="C_6b43dd28-89c1-4746-bb60-edcdf09081e0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dawn:TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_6bcd3432-198e-484b-9415-19fc999fd457">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_6c0cbe2c-a995-47f4-a87e-6d13cd05d122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dawn:LicenseAgreementWithIpsenPharmaSasMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-23</startDate>
            <endDate>2024-07-23</endDate>
        </period>
    </context>
    <context id="C_6d1be359-db5b-4358-8204-bf1ab5d70c18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_6e1b373b-8302-46c1-aa4e-7f2da1ba09e1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_6efcf18f-0833-44b1-8d9a-6ebe85307a08">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">dawn:CurrentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dawn:LicenseAgreementWithIpsenPharmaSasMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_709f7aa4-e121-4df0-b0d0-a36cdf0a83fe">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_749941a2-d394-4f48-bd13-a62ecd76cd82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_74bf62ce-416a-4686-8cdc-9e58e09531b6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dawn:PrvPressureReliefValveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dawn:ViractaLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-29</startDate>
            <endDate>2024-05-29</endDate>
        </period>
    </context>
    <context id="C_76de7769-5c35-42b4-83aa-9ca4c0b858aa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">dawn:IndividualCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">dawn:ConcentrationOfCreditRiskAndOtherRisksAndUncertaintiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_78dfe459-4b7a-4e97-aa42-abf96dae2d9e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_7902fa1d-00a4-4ae2-802d-20016ff59f3d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_7a2a1b79-4a52-4f59-8224-b2b1f9654b55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">dawn:MarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_7a724b91-c619-4f16-b0fa-87eb52d80cd1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dawn:AgreementAxis">dawn:TwoThousandTwentyFourPrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-01</startDate>
            <endDate>2024-08-01</endDate>
        </period>
    </context>
    <context id="C_7aae3619-1673-4b07-91a5-706dabc13942">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dawn:PerformanceStockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dawn:TwoThousandAndTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_7d91f4bf-04a0-434b-a91a-e1fd4c41cbe1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_7f6b13fb-87e4-41c9-982f-9121e8dc50ce">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_7f944cae-458f-4eb0-b171-e53812c6128e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001845337</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dawn:TwoThousandAndTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <unit id="U_pure">
        <measure>pure</measure>
    </unit>
    <unit id="U_UnitedStatesOfAmericaDollarsShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U_sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="U_shares">
        <measure>shares</measure>
    </unit>
    <unit id="U_Segment">
        <measure>dawn:Segment</measure>
    </unit>
    <unit id="U_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <dei:CurrentFiscalYearEndDate
      contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b"
      id="F_48d683d5-1b1c-45ac-9f94-523d199d6b60">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalPeriodFocus
      contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b"
      id="F_e6f4cab5-8aec-450e-8766-eb81987b6f5f">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b"
      id="F_98157962-cc3f-4ca8-950f-f51468f6a1a6">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b"
      id="F_6832b236-bceb-42b9-ad8d-15689755f2d4">0001845337</dei:EntityCentralIndexKey>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_b103f351-0eb2-495b-85c1-5630e54c751c"
      id="F_2822a515-be27-4a7e-b4e8-a1d6dcb822ad"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_1b7733fe-22fe-416b-a33e-e8b388655156"
      id="F_e884c67c-98c2-4dc5-85ba-d3ff1ddf6d72"
      unitRef="U_USD"
      xsi:nil="true"/>
    <dei:DocumentType
      contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b"
      id="F_71359b49-12e7-4d1e-80fa-983392b1c335">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b"
      id="F_5960062d-fdb4-4a0e-abfc-50572638669d">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b"
      id="F_2f6e3da0-afc6-4f2c-8015-e4daa7fec05f">2025-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b"
      id="F_fd5082b4-5fd7-4bf0-8c80-8a9e27dffe0f">2025</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport
      contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b"
      id="F_7991f431-73f4-4a7c-b963-3c8fdb4252e9">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b"
      id="F_f9a69a21-7771-457d-88b0-17dfa1e7fde4">001-40431</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b"
      id="F_d2a72bcc-f368-456e-b4fe-ce0b5ff14b55">DAY ONE BIOPHARMACEUTICALS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b"
      id="F_f849259d-cfe0-4c03-9d07-e11847bd6d58">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b"
      id="F_ed1ac380-8598-4925-9ef0-26147011eb12">83-2415215</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b"
      id="F_0c7687a0-8a61-4463-888f-36e5d689497a">1800 Sierra Point Parkway</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b"
      id="F_65d4a2e9-af68-4244-ab82-10458b032fa7">Suite 200</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b"
      id="F_6931060f-7d07-4711-97f1-91a7de0be76b">Brisbane</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b"
      id="F_c5af7fa3-5e16-477f-bee9-fde1ebeef573">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b"
      id="F_57028f4d-7eaf-40cd-8daa-71293e271cf8">94005</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b"
      id="F_e4392354-914b-4cae-bf79-68a68caefa4a">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b"
      id="F_9a253445-9ef1-41c3-966f-766a4543cb7e">484-0899</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b"
      id="F_fa8740e2-b3d8-466b-8d86-f6a5d15eb16d">Common Stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b"
      id="F_cb410d86-a4aa-47b2-9fde-792d441a6d24">DAWN</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b"
      id="F_f68d4b7e-b816-4821-a9eb-bc7a8205f0d0">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b"
      id="F_9d9a2414-6df6-4458-8562-5f2ad2ce6423">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b"
      id="F_fe870b4a-7a00-4fbc-bc5f-91f8a43b0d45">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b"
      id="F_74dbe06c-4bc9-4800-b4f1-73d4a90704f6">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b"
      id="F_4e407aca-49b8-4d89-bd0b-539d3bc2c6ce">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b"
      id="F_82b2d1a9-0a34-4771-a937-a05363a5ae82">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b"
      id="F_051d15c2-244a-4f1e-9ea6-41b6e0582d59">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_c5d9f2d2-fe53-4440-9bbe-b118d81d16cc"
      decimals="0"
      id="F_fd7db2d7-ed5c-46ed-b4d7-d560d16b91ff"
      unitRef="U_shares">101362468</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_b103f351-0eb2-495b-85c1-5630e54c751c"
      decimals="-3"
      id="F_05892d23-f80f-4fee-845c-2a236580e192"
      unitRef="U_USD">33358000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_1b7733fe-22fe-416b-a33e-e8b388655156"
      decimals="-3"
      id="F_8b9704fc-af31-4285-ae31-719eced41ae9"
      unitRef="U_USD">124968000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments
      contextRef="C_b103f351-0eb2-495b-85c1-5630e54c751c"
      decimals="-3"
      id="F_eb07b6ad-8a26-434f-a2ca-3073b2403484"
      unitRef="U_USD">439662000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="C_1b7733fe-22fe-416b-a33e-e8b388655156"
      decimals="-3"
      id="F_ddae1e7e-6ca7-47f8-abee-acb363d880ff"
      unitRef="U_USD">406752000</us-gaap:ShortTermInvestments>
    <us-gaap:ReceivablesNetCurrent
      contextRef="C_b103f351-0eb2-495b-85c1-5630e54c751c"
      decimals="-3"
      id="F_75f6a68b-2927-4ea7-9182-4e19dfccc3b0"
      unitRef="U_USD">18054000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="C_1b7733fe-22fe-416b-a33e-e8b388655156"
      decimals="-3"
      id="F_03a547c2-3392-47a6-a8ed-ec6b14bfaa86"
      unitRef="U_USD">13876000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:InventoryNet
      contextRef="C_b103f351-0eb2-495b-85c1-5630e54c751c"
      decimals="-3"
      id="F_eae29e2d-0684-40ef-93fc-9882440bbc87"
      unitRef="U_USD">3565000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="C_1b7733fe-22fe-416b-a33e-e8b388655156"
      decimals="-3"
      id="F_c3cb119f-c020-4f27-8018-0b60e6194bb6"
      unitRef="U_USD">3321000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_b103f351-0eb2-495b-85c1-5630e54c751c"
      decimals="-3"
      id="F_9f2ec791-50b1-4625-ba3b-b8a8373b7a53"
      unitRef="U_USD">14012000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_1b7733fe-22fe-416b-a33e-e8b388655156"
      decimals="-3"
      id="F_8dd1bb82-1d8b-4c52-996c-d9e2374b14fc"
      unitRef="U_USD">13413000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_b103f351-0eb2-495b-85c1-5630e54c751c"
      decimals="-3"
      id="F_59a559b0-6510-45bd-ba48-a7416f2b1734"
      unitRef="U_USD">508651000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_1b7733fe-22fe-416b-a33e-e8b388655156"
      decimals="-3"
      id="F_0506ec50-8323-47cd-9547-8bad5401182a"
      unitRef="U_USD">562330000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_b103f351-0eb2-495b-85c1-5630e54c751c"
      decimals="-3"
      id="F_a646628b-3595-49a4-931a-124c1eac3b6b"
      unitRef="U_USD">2508000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_1b7733fe-22fe-416b-a33e-e8b388655156"
      decimals="-3"
      id="F_8c9ca39f-28fa-40f6-b422-f3ba66136e89"
      unitRef="U_USD">2285000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_b103f351-0eb2-495b-85c1-5630e54c751c"
      decimals="-3"
      id="F_e898ed53-4f5c-41fa-8b8c-be121b22e462"
      unitRef="U_USD">2577000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_1b7733fe-22fe-416b-a33e-e8b388655156"
      decimals="-3"
      id="F_2123452c-13b5-472d-b0e2-108ffb9f5c11"
      unitRef="U_USD">2422000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="C_b103f351-0eb2-495b-85c1-5630e54c751c"
      decimals="-3"
      id="F_866d7c67-5ac1-4cd5-b886-fe8787abf42c"
      unitRef="U_USD">20405000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="C_1b7733fe-22fe-416b-a33e-e8b388655156"
      decimals="-3"
      id="F_d6a45aeb-3351-4c2d-9f94-9ccb17ac12f1"
      unitRef="U_USD">15630000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <dawn:DepositsAndOtherLongtermAssetsNonCurrent
      contextRef="C_b103f351-0eb2-495b-85c1-5630e54c751c"
      decimals="-3"
      id="F_42aca274-19c5-4556-8274-43e9ffc07b3a"
      unitRef="U_USD">215000</dawn:DepositsAndOtherLongtermAssetsNonCurrent>
    <dawn:DepositsAndOtherLongtermAssetsNonCurrent
      contextRef="C_1b7733fe-22fe-416b-a33e-e8b388655156"
      decimals="-3"
      id="F_d1722279-3084-4a8e-80c3-2c65b7ddd4b1"
      unitRef="U_USD">121000</dawn:DepositsAndOtherLongtermAssetsNonCurrent>
    <us-gaap:Assets
      contextRef="C_b103f351-0eb2-495b-85c1-5630e54c751c"
      decimals="-3"
      id="F_954d8997-94ea-4fc4-ba39-0a68e8c58729"
      unitRef="U_USD">534356000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_1b7733fe-22fe-416b-a33e-e8b388655156"
      decimals="-3"
      id="F_9903decd-b640-435e-b291-dc111c78ba7a"
      unitRef="U_USD">582788000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_b103f351-0eb2-495b-85c1-5630e54c751c"
      decimals="-3"
      id="F_4a2abc04-a31a-4c04-a742-cac012d19356"
      unitRef="U_USD">2540000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_1b7733fe-22fe-416b-a33e-e8b388655156"
      decimals="-3"
      id="F_71039b44-e57b-4eae-a24e-9938a848ab79"
      unitRef="U_USD">3262000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="C_b103f351-0eb2-495b-85c1-5630e54c751c"
      decimals="-3"
      id="F_1a9a4e80-4bb8-4f32-bba5-7874440cb44e"
      unitRef="U_USD">43641000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="C_1b7733fe-22fe-416b-a33e-e8b388655156"
      decimals="-3"
      id="F_44fa4675-5efc-406c-96ba-5d6a735fb4f0"
      unitRef="U_USD">68625000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:DeferredRevenueCurrent
      contextRef="C_b103f351-0eb2-495b-85c1-5630e54c751c"
      decimals="-3"
      id="F_4a8cecbe-3229-4f38-8617-1e124a355248"
      unitRef="U_USD">1636000</us-gaap:DeferredRevenueCurrent>
    <us-gaap:DeferredRevenueCurrent
      contextRef="C_1b7733fe-22fe-416b-a33e-e8b388655156"
      decimals="-3"
      id="F_e9a492d2-38cc-49dd-9024-6f43f282d0e2"
      unitRef="U_USD">1554000</us-gaap:DeferredRevenueCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_b103f351-0eb2-495b-85c1-5630e54c751c"
      decimals="-3"
      id="F_6cca5915-ffb6-4676-83dd-46babde6c612"
      unitRef="U_USD">62000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_1b7733fe-22fe-416b-a33e-e8b388655156"
      decimals="-3"
      id="F_f00767bd-3abf-4fb2-9b85-1160588a8f40"
      unitRef="U_USD">10000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_b103f351-0eb2-495b-85c1-5630e54c751c"
      decimals="-3"
      id="F_ff91b70b-1035-4b7b-849a-124e5d34540e"
      unitRef="U_USD">47879000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_1b7733fe-22fe-416b-a33e-e8b388655156"
      decimals="-3"
      id="F_9644b5fd-4267-4ca7-a017-54bd0ee57655"
      unitRef="U_USD">73451000</us-gaap:LiabilitiesCurrent>
    <us-gaap:DeferredRevenueNoncurrent
      contextRef="C_b103f351-0eb2-495b-85c1-5630e54c751c"
      decimals="-3"
      id="F_13c9d680-c460-4331-91bb-e45a94e8b1a8"
      unitRef="U_USD">3350000</us-gaap:DeferredRevenueNoncurrent>
    <us-gaap:DeferredRevenueNoncurrent
      contextRef="C_1b7733fe-22fe-416b-a33e-e8b388655156"
      decimals="-3"
      id="F_5a687350-abc1-48d5-888b-52a4936ff645"
      unitRef="U_USD">3233000</us-gaap:DeferredRevenueNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_b103f351-0eb2-495b-85c1-5630e54c751c"
      decimals="-3"
      id="F_c7bde89e-e36b-493d-9d4e-e1043221e2fc"
      unitRef="U_USD">2854000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_1b7733fe-22fe-416b-a33e-e8b388655156"
      decimals="-3"
      id="F_7e37ec9e-8bb5-4450-914e-b2a63a3822b7"
      unitRef="U_USD">2592000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="C_b103f351-0eb2-495b-85c1-5630e54c751c"
      decimals="-3"
      id="F_f144e392-ce33-4abc-80a3-3dea69ddb750"
      unitRef="U_USD">761000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="C_1b7733fe-22fe-416b-a33e-e8b388655156"
      decimals="-3"
      id="F_99bb3812-658a-4787-b343-77ae0a0d53aa"
      unitRef="U_USD">761000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="C_b103f351-0eb2-495b-85c1-5630e54c751c"
      decimals="-3"
      id="F_d56f5e8a-1f32-41cb-a2e0-d2f4304e99c1"
      unitRef="U_USD">54844000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="C_1b7733fe-22fe-416b-a33e-e8b388655156"
      decimals="-3"
      id="F_06390701-f47a-4fbf-b4ef-d057d7610fb4"
      unitRef="U_USD">80037000</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_b103f351-0eb2-495b-85c1-5630e54c751c"
      decimals="4"
      id="F_07300589-19c5-4ab9-8b35-27e1cd6512a7"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_1b7733fe-22fe-416b-a33e-e8b388655156"
      decimals="4"
      id="F_bde21e23-5130-496d-a184-8ff984bb5b26"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_b103f351-0eb2-495b-85c1-5630e54c751c"
      decimals="0"
      id="F_e6204760-e1e2-4320-9e15-8544a8c2ca03"
      unitRef="U_shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_1b7733fe-22fe-416b-a33e-e8b388655156"
      decimals="0"
      id="F_b29f0c11-ff87-492f-81c3-932b4eb56345"
      unitRef="U_shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_b103f351-0eb2-495b-85c1-5630e54c751c"
      decimals="0"
      id="F_4d7f4d84-7180-4930-a696-b83e390d51d7"
      unitRef="U_shares">101353781</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_b103f351-0eb2-495b-85c1-5630e54c751c"
      decimals="0"
      id="F_b637289b-6d54-4500-9444-4e09668fcbe3"
      unitRef="U_shares">101353781</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_1b7733fe-22fe-416b-a33e-e8b388655156"
      decimals="0"
      id="F_79d656d4-b482-49a2-ac01-45bbc920d553"
      unitRef="U_shares">101116162</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_1b7733fe-22fe-416b-a33e-e8b388655156"
      decimals="0"
      id="F_3fd79347-ac49-4a26-8e15-e1abdfe222cd"
      unitRef="U_shares">101116162</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="C_b103f351-0eb2-495b-85c1-5630e54c751c"
      decimals="-3"
      id="F_2b50aaf5-d6a6-435e-a395-b65ffc7bae18"
      unitRef="U_USD">10000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_1b7733fe-22fe-416b-a33e-e8b388655156"
      decimals="-3"
      id="F_39388701-944e-42b3-b64d-d18e54631351"
      unitRef="U_USD">10000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="C_b103f351-0eb2-495b-85c1-5630e54c751c"
      decimals="-3"
      id="F_53ad2141-2e65-4305-b9ba-5507f92c9f2b"
      unitRef="U_USD">1069631000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="C_1b7733fe-22fe-416b-a33e-e8b388655156"
      decimals="-3"
      id="F_892c25aa-9b94-4510-a6cb-bef6839d441d"
      unitRef="U_USD">1056738000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_b103f351-0eb2-495b-85c1-5630e54c751c"
      decimals="-3"
      id="F_746494c7-dac3-4406-a76f-0ad3f1ecb512"
      unitRef="U_USD">-52000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_1b7733fe-22fe-416b-a33e-e8b388655156"
      decimals="-3"
      id="F_bbe71ebb-71cd-4762-b3c4-2188bcc4fd90"
      unitRef="U_USD">84000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_b103f351-0eb2-495b-85c1-5630e54c751c"
      decimals="-3"
      id="F_a5353292-5c12-47cd-97fd-d8567219864a"
      unitRef="U_USD">-590077000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_1b7733fe-22fe-416b-a33e-e8b388655156"
      decimals="-3"
      id="F_69931125-12e4-4033-8b6e-3557fd8afb3b"
      unitRef="U_USD">-554081000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="C_b103f351-0eb2-495b-85c1-5630e54c751c"
      decimals="-3"
      id="F_f8bcc9a3-c02b-4a90-aeca-9f33802b8aa8"
      unitRef="U_USD">479512000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_1b7733fe-22fe-416b-a33e-e8b388655156"
      decimals="-3"
      id="F_3494ac32-e41d-46a2-a156-62f683f4b054"
      unitRef="U_USD">502751000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_b103f351-0eb2-495b-85c1-5630e54c751c"
      decimals="-3"
      id="F_a183b31d-5806-4d15-9b48-189ab8203a71"
      unitRef="U_USD">534356000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_1b7733fe-22fe-416b-a33e-e8b388655156"
      decimals="-3"
      id="F_5c0f6927-dc0f-4706-86cd-7f21a53b625e"
      unitRef="U_USD">582788000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues
      contextRef="C_b5f6c9ab-25d5-4e70-992c-f10381920bf2"
      decimals="-3"
      id="F_85050965-7319-43f5-b18b-93c00134526f"
      unitRef="U_USD">30503000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_749941a2-d394-4f48-bd13-a62ecd76cd82"
      decimals="-3"
      id="F_9f5e2684-a34e-49a4-8d72-78e3ccf0f899"
      unitRef="U_USD">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_7902fa1d-00a4-4ae2-802d-20016ff59f3d"
      decimals="-3"
      id="F_12d40946-793c-427e-bb14-87478ff5b689"
      unitRef="U_USD">258000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_8bbef5b6-cf7a-452a-9829-28292e282f79"
      decimals="-3"
      id="F_b9618f86-7053-4ee2-b2b0-3ba4a49cf3d7"
      unitRef="U_USD">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b"
      decimals="-3"
      id="F_f85cfbe8-6ece-4879-83df-8c65c261f11a"
      unitRef="U_USD">30761000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_0fd32f25-7d1d-46c5-938d-d9b0e3f9dfaa"
      decimals="-3"
      id="F_7c165b2a-65b3-4812-ad6b-e90c128a315e"
      unitRef="U_USD">0</us-gaap:Revenues>
    <dawn:CostOfProductRevenue
      contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b"
      decimals="-3"
      id="F_b2dba719-411f-4052-8bfb-389c451ebf5a"
      unitRef="U_USD">2884000</dawn:CostOfProductRevenue>
    <dawn:CostOfProductRevenue
      contextRef="C_0fd32f25-7d1d-46c5-938d-d9b0e3f9dfaa"
      decimals="-3"
      id="F_24b7c733-3c58-4d9d-ac75-89b3daaf3b3f"
      unitRef="U_USD">0</dawn:CostOfProductRevenue>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b"
      decimals="-3"
      id="F_308c170b-6447-49e7-bed7-8d025d37eed2"
      unitRef="U_USD">39619000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_0fd32f25-7d1d-46c5-938d-d9b0e3f9dfaa"
      decimals="-3"
      id="F_f11f6130-1173-45c8-989e-2f91fd41f758"
      unitRef="U_USD">40210000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b"
      decimals="-3"
      id="F_2a2f9861-5eff-41e8-b5c3-a24dfb6bd29b"
      unitRef="U_USD">29325000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_0fd32f25-7d1d-46c5-938d-d9b0e3f9dfaa"
      decimals="-3"
      id="F_8c1dc444-d46f-41d1-ae82-0bfd6186e0c2"
      unitRef="U_USD">26557000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b"
      decimals="-3"
      id="F_1fc10f39-922d-4603-b593-b17937e2eaff"
      unitRef="U_USD">71828000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_0fd32f25-7d1d-46c5-938d-d9b0e3f9dfaa"
      decimals="-3"
      id="F_962c3746-6170-43ed-a879-a195517f2214"
      unitRef="U_USD">66767000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b"
      decimals="-3"
      id="F_2cf5f8e8-5717-4cf3-8201-826a3d041e0b"
      unitRef="U_USD">-41067000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_0fd32f25-7d1d-46c5-938d-d9b0e3f9dfaa"
      decimals="-3"
      id="F_8f73a89e-c86c-4954-8e65-1da805b42c71"
      unitRef="U_USD">-66767000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeNet
      contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b"
      decimals="-3"
      id="F_a51e496f-07bf-473f-bef6-1c6cb5d727a8"
      unitRef="U_USD">5094000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet
      contextRef="C_0fd32f25-7d1d-46c5-938d-d9b0e3f9dfaa"
      decimals="-3"
      id="F_066a4e3c-04ca-46b3-a55a-d0962f42854a"
      unitRef="U_USD">4365000</us-gaap:InvestmentIncomeNet>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b"
      decimals="-3"
      id="F_5a1e3662-3152-4820-bcde-94ce1d795623"
      unitRef="U_USD">-23000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_0fd32f25-7d1d-46c5-938d-d9b0e3f9dfaa"
      decimals="-3"
      id="F_30972918-5fd3-46c9-8725-508f97e5bca1"
      unitRef="U_USD">-10000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b"
      decimals="-3"
      id="F_7bb7ba68-d382-4d59-befd-c84669e95f99"
      unitRef="U_USD">5071000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_0fd32f25-7d1d-46c5-938d-d9b0e3f9dfaa"
      decimals="-3"
      id="F_19352ba3-e94d-403c-b14f-043dffcd90c0"
      unitRef="U_USD">4355000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossAttributableToNoncontrollingInterest
      contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b"
      decimals="-3"
      id="F_d0946080-f83f-4ec1-8103-d32d4f8129af"
      unitRef="U_USD">35996000</us-gaap:IncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossAttributableToNoncontrollingInterest
      contextRef="C_0fd32f25-7d1d-46c5-938d-d9b0e3f9dfaa"
      decimals="-3"
      id="F_5bf0d181-3951-469e-a6eb-cb797fee192b"
      unitRef="U_USD">62412000</us-gaap:IncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b"
      decimals="-3"
      id="F_d8fb95ed-ed4c-4ded-a726-5343fa46e8f4"
      unitRef="U_USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_0fd32f25-7d1d-46c5-938d-d9b0e3f9dfaa"
      decimals="-3"
      id="F_da9ef3dc-b8d9-4e1f-8036-838356a19507"
      unitRef="U_USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b"
      decimals="-3"
      id="F_b0dd88bd-0334-4306-8873-0d0f01c681c1"
      unitRef="U_USD">-35996000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0fd32f25-7d1d-46c5-938d-d9b0e3f9dfaa"
      decimals="-3"
      id="F_1fbba0f1-11cc-4c91-be85-7b8e3017efa7"
      unitRef="U_USD">-62412000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b"
      decimals="2"
      id="F_3ffe07c1-316b-4622-a79d-73d3d82ddb7c"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-0.35</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_0fd32f25-7d1d-46c5-938d-d9b0e3f9dfaa"
      decimals="2"
      id="F_09780e53-f1e2-40c1-b503-dcfba7e3daf4"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-0.72</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b"
      decimals="2"
      id="F_f25fb7e5-e7b1-46ac-8f26-a15d5da73f53"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-0.35</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_0fd32f25-7d1d-46c5-938d-d9b0e3f9dfaa"
      decimals="2"
      id="F_c261b4d6-b02e-4224-951a-38fefe85906b"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-0.72</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b"
      decimals="0"
      id="F_9a3f449a-0fcc-4de8-a354-c1b8e665a156"
      unitRef="U_shares">102710382</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_0fd32f25-7d1d-46c5-938d-d9b0e3f9dfaa"
      decimals="0"
      id="F_49c18272-e4c0-4357-8755-ccfbed6c613d"
      unitRef="U_shares">86679282</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b"
      decimals="0"
      id="F_99eb882e-688c-4974-88f9-1d5b690128c5"
      unitRef="U_shares">102710382</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_0fd32f25-7d1d-46c5-938d-d9b0e3f9dfaa"
      decimals="0"
      id="F_b16ddf80-df44-4164-b373-e81f046b7b53"
      unitRef="U_shares">86679282</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b"
      decimals="-3"
      id="F_35bb620a-13eb-489b-ba2e-e58420095b22"
      unitRef="U_USD">-35996000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0fd32f25-7d1d-46c5-938d-d9b0e3f9dfaa"
      decimals="-3"
      id="F_01e11454-bd8d-4511-9a83-a0dec3843427"
      unitRef="U_USD">-62412000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
      contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b"
      decimals="-3"
      id="F_b7353c95-dd99-479e-92b1-1486a9e5f0b8"
      unitRef="U_USD">-136000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
      contextRef="C_0fd32f25-7d1d-46c5-938d-d9b0e3f9dfaa"
      decimals="-3"
      id="F_5b90b3fd-8617-421a-95ba-40d1d9c9634c"
      unitRef="U_USD">-14000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b"
      decimals="-3"
      id="F_81dee589-5e66-4754-813c-a36a9c1ed5d2"
      unitRef="U_USD">-36132000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_0fd32f25-7d1d-46c5-938d-d9b0e3f9dfaa"
      decimals="-3"
      id="F_95deac4d-5491-4f75-aa5c-08c1c00e62c2"
      unitRef="U_USD">-62426000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="C_9cfff08d-a5d3-4ed4-8454-95741093c5c8"
      decimals="0"
      id="F_3b93e06c-aa6a-4db6-9281-7aed6c1eab45"
      unitRef="U_shares">101116162</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_9cfff08d-a5d3-4ed4-8454-95741093c5c8"
      decimals="-3"
      id="F_416edd78-5cc5-41ae-a17f-76c38ed64acb"
      unitRef="U_USD">10000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_3844ba24-08c1-421c-b49d-4740f7e0d572"
      decimals="-3"
      id="F_c69fe68b-f450-4955-a6da-0bd7587c9904"
      unitRef="U_USD">1056738000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_827ac41e-d0d2-4df1-8321-6fb95701054e"
      decimals="-3"
      id="F_7f8360d8-3811-468d-840e-3d000e7754a7"
      unitRef="U_USD">84000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_02cfe4b1-bd5d-4fbb-95f7-4ee6c0f9824a"
      decimals="-3"
      id="F_c4bb9d8d-e3e6-4d99-898b-10a50fa4b041"
      unitRef="U_USD">-554081000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_1b7733fe-22fe-416b-a33e-e8b388655156"
      decimals="-3"
      id="F_35901308-18ae-43be-b5de-96f8c64f71ea"
      unitRef="U_USD">502751000</us-gaap:StockholdersEquity>
    <dawn:IssuanceOfCommonStockUponReleaseOfRestrictedStockUnits
      contextRef="C_ef0986cb-13e6-4f2b-818c-1d5b4469876d"
      decimals="0"
      id="F_ab1c24c6-88e5-4ff1-82b5-7ffc9db4b00b"
      unitRef="U_shares">238354</dawn:IssuanceOfCommonStockUponReleaseOfRestrictedStockUnits>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited
      contextRef="C_ef0986cb-13e6-4f2b-818c-1d5b4469876d"
      decimals="0"
      id="F_98c36d37-856a-4bd6-9323-652a9a1bc6ef"
      unitRef="U_shares">-735</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_ee47eb20-6b00-401a-8f3b-4c791e30712a"
      decimals="-3"
      id="F_cff4609d-4765-4715-9017-725f56ccd567"
      unitRef="U_USD">12893000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b"
      decimals="-3"
      id="F_1db65d77-7d46-4ea4-bd7f-315046c66c25"
      unitRef="U_USD">12893000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
      contextRef="C_ee6e19da-95ec-456c-abbd-e2850974503c"
      decimals="-3"
      id="F_217e78af-522d-40d3-b8d1-da2e4d963618"
      unitRef="U_USD">-136000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
      contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b"
      decimals="-3"
      id="F_5532ed49-7b0a-4c23-bdae-afac514fbea9"
      unitRef="U_USD">-136000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="C_3b4a9bf0-9117-492a-a8d5-7f4450cbd994"
      decimals="-3"
      id="F_2e35e8a4-7580-4880-94dc-b3f3c203dd96"
      unitRef="U_USD">-35996000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b"
      decimals="-3"
      id="F_542159c7-7e63-4766-9533-7c237bc55a45"
      unitRef="U_USD">-35996000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_4b6fd4af-8d4f-4f7d-b960-b6ac6218c53a"
      decimals="0"
      id="F_eb9b7f8d-b8ff-44ca-854f-ebdbdc6397bc"
      unitRef="U_shares">101353781</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_4b6fd4af-8d4f-4f7d-b960-b6ac6218c53a"
      decimals="-3"
      id="F_ea6a85d4-31ad-4789-b9af-0c9ba499bad7"
      unitRef="U_USD">10000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_60b37620-bd42-435a-8868-27168e7b2da5"
      decimals="-3"
      id="F_ea484ccd-318d-4fff-9617-535bbf7137ac"
      unitRef="U_USD">1069631000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_94ce4acc-2f61-45fc-9674-ab4c0d8f85f3"
      decimals="-3"
      id="F_67548d1b-a65f-45b9-a698-9606406c38b4"
      unitRef="U_USD">-52000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_78dfe459-4b7a-4e97-aa42-abf96dae2d9e"
      decimals="-3"
      id="F_525d4254-a26c-4015-96c1-75c3f2683d44"
      unitRef="U_USD">-590077000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_b103f351-0eb2-495b-85c1-5630e54c751c"
      decimals="-3"
      id="F_5835950c-93ec-47fe-87d9-83868645829b"
      unitRef="U_USD">479512000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="C_ac5f563a-6d18-4f41-8866-bd417f95f7f7"
      decimals="0"
      id="F_10e08763-8e37-410a-b012-3ce67b0ef675"
      unitRef="U_shares">87227132</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_ac5f563a-6d18-4f41-8866-bd417f95f7f7"
      decimals="-3"
      id="F_ff7f54c0-8229-416f-b3e1-003c5237b8db"
      unitRef="U_USD">9000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_21c9ec3b-26c7-4a87-b2d1-3f695174dd3f"
      decimals="-3"
      id="F_4ae1528d-fc7f-4b68-a341-b72f72b32e0a"
      unitRef="U_USD">805107000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_01bb969c-6b26-4ada-840e-3e6660f4d113"
      decimals="-3"
      id="F_d4f3fa11-48f3-48e7-ba89-ac2c4533da5e"
      unitRef="U_USD">9000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_6e1b373b-8302-46c1-aa4e-7f2da1ba09e1"
      decimals="-3"
      id="F_3479542b-a1e9-491b-869d-8061c9614ba9"
      unitRef="U_USD">-458585000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_ba36f1f4-7ce5-434c-b80f-2bcb5a767c07"
      decimals="-3"
      id="F_ffc3b164-b7ae-4190-8bc9-0bcbb7585035"
      unitRef="U_USD">346540000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_56ac395d-44a1-4679-8062-efee79181688"
      decimals="0"
      id="F_4c68dbff-2838-41b4-8018-6b48a883cf59"
      unitRef="U_shares">4862</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_22370d4f-2229-4fea-b11d-aaa9611c4ebe"
      decimals="-3"
      id="F_69d52458-849a-4fe2-8fe6-4590d8b407c5"
      unitRef="U_USD">48000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_0fd32f25-7d1d-46c5-938d-d9b0e3f9dfaa"
      decimals="-3"
      id="F_b69611e9-fb21-475e-aea3-afe89421f24d"
      unitRef="U_USD">48000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <dawn:IssuanceOfCommonStockUponReleaseOfRestrictedStockUnits
      contextRef="C_56ac395d-44a1-4679-8062-efee79181688"
      decimals="0"
      id="F_a4f94902-c32f-4cf7-80ce-7938dfb7f38b"
      unitRef="U_shares">157724</dawn:IssuanceOfCommonStockUponReleaseOfRestrictedStockUnits>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited
      contextRef="C_56ac395d-44a1-4679-8062-efee79181688"
      decimals="0"
      id="F_8b8ddf3d-a6cc-4f13-ad4c-694f6a0c24a0"
      unitRef="U_shares">-12555</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_22370d4f-2229-4fea-b11d-aaa9611c4ebe"
      decimals="-3"
      id="F_fced9535-3784-4799-9592-35949343ce53"
      unitRef="U_USD">12644000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0fd32f25-7d1d-46c5-938d-d9b0e3f9dfaa"
      decimals="-3"
      id="F_ad607df5-8f9b-4c36-b48e-8ad7f7bcf767"
      unitRef="U_USD">12644000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
      contextRef="C_6d1be359-db5b-4358-8204-bf1ab5d70c18"
      decimals="-3"
      id="F_61d99163-9f1a-41ae-a52b-2e0d67443dec"
      unitRef="U_USD">-14000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
      contextRef="C_0fd32f25-7d1d-46c5-938d-d9b0e3f9dfaa"
      decimals="-3"
      id="F_3923c26c-9d10-4b24-a360-00f910dbcbc9"
      unitRef="U_USD">-14000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="C_80a0754a-565e-4050-8b95-677c6495d268"
      decimals="-3"
      id="F_728b41d4-5e94-4528-9b06-4ec6b27a9431"
      unitRef="U_USD">-62412000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0fd32f25-7d1d-46c5-938d-d9b0e3f9dfaa"
      decimals="-3"
      id="F_384317bf-d506-4c81-9114-18014a8cc71d"
      unitRef="U_USD">-62412000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_af8109ab-99db-4170-9328-c13fd756a885"
      decimals="0"
      id="F_e665be3b-5330-42e4-b9fa-b1201b0cea81"
      unitRef="U_shares">87377163</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_af8109ab-99db-4170-9328-c13fd756a885"
      decimals="-3"
      id="F_415e3d2f-4f3b-4183-b606-f66c3c3e696d"
      unitRef="U_USD">9000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_ac9ee8d9-bca6-4fd2-9709-df26868eb7bf"
      decimals="-3"
      id="F_acc32a59-7636-43b2-beae-7543e0e0d2c5"
      unitRef="U_USD">817799000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_22c0360b-da7f-497c-9e18-47a5bdec0579"
      decimals="-3"
      id="F_41e974b3-bac2-46b9-8e30-44e99c318c6b"
      unitRef="U_USD">-5000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_5b86a378-9cda-47eb-8a66-30562f03c4e4"
      decimals="-3"
      id="F_d4e3f64c-b221-46d8-bdd1-56cb3a8b9b76"
      unitRef="U_USD">-520997000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_4ba97ac7-abe6-41af-8f29-b34dd24231c3"
      decimals="-3"
      id="F_5c641216-3840-47c4-b9f3-565e67fca857"
      unitRef="U_USD">296806000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b"
      decimals="-3"
      id="F_267c33ce-7d9c-4487-b9b1-bc217470b99a"
      unitRef="U_USD">-35996000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0fd32f25-7d1d-46c5-938d-d9b0e3f9dfaa"
      decimals="-3"
      id="F_a8b672e7-ec09-4f41-8f8f-00f1a2eb0e46"
      unitRef="U_USD">-62412000</us-gaap:NetIncomeLoss>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b"
      decimals="-3"
      id="F_b6545f19-f4a1-4621-9528-30d22593e4ac"
      unitRef="U_USD">12861000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0fd32f25-7d1d-46c5-938d-d9b0e3f9dfaa"
      decimals="-3"
      id="F_2498ff81-3476-4f79-acd0-88f6477129c7"
      unitRef="U_USD">12644000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b"
      decimals="-3"
      id="F_967cd8b4-0729-4bea-97b1-f14390fc6518"
      unitRef="U_USD">94000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_0fd32f25-7d1d-46c5-938d-d9b0e3f9dfaa"
      decimals="-3"
      id="F_6121ee80-b591-4087-8346-098f16ee866a"
      unitRef="U_USD">23000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b"
      decimals="-3"
      id="F_d55fd735-e219-4f91-a588-3011fb0f865f"
      unitRef="U_USD">4250000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="C_0fd32f25-7d1d-46c5-938d-d9b0e3f9dfaa"
      decimals="-3"
      id="F_211c1ba9-32f1-497c-843f-0ba9f1a076b3"
      unitRef="U_USD">1292000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b"
      decimals="-3"
      id="F_5a7326ec-623f-4d33-9f26-069bf3b6c873"
      unitRef="U_USD">725000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_0fd32f25-7d1d-46c5-938d-d9b0e3f9dfaa"
      decimals="-3"
      id="F_26277fd1-0704-43e3-8120-84637128cde5"
      unitRef="U_USD">0</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b"
      decimals="-3"
      id="F_f45f00dd-c92a-4ab7-88d0-edc84988302f"
      unitRef="U_USD">75000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="C_0fd32f25-7d1d-46c5-938d-d9b0e3f9dfaa"
      decimals="-3"
      id="F_05b5050c-7ed1-490f-acc8-1413ed2ebff1"
      unitRef="U_USD">93000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b"
      decimals="-3"
      id="F_b77b23a9-2e49-4022-9397-be04ef0fa3b3"
      unitRef="U_USD">4178000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="C_0fd32f25-7d1d-46c5-938d-d9b0e3f9dfaa"
      decimals="-3"
      id="F_a9a520f0-bf85-46b7-9a7b-3aba71fc2866"
      unitRef="U_USD">0</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventoriesAndOtherOperatingAssets
      contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b"
      decimals="-3"
      id="F_aff03aa7-0f6e-4d84-b256-e495e7260959"
      unitRef="U_USD">212000</us-gaap:IncreaseDecreaseInInventoriesAndOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInInventoriesAndOtherOperatingAssets
      contextRef="C_0fd32f25-7d1d-46c5-938d-d9b0e3f9dfaa"
      decimals="-3"
      id="F_38265443-974a-4592-9f44-336d4484b2a8"
      unitRef="U_USD">0</us-gaap:IncreaseDecreaseInInventoriesAndOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b"
      decimals="-3"
      id="F_ebf2958e-09c7-4c2f-89a9-24d6bb9ae887"
      unitRef="U_USD">606000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_0fd32f25-7d1d-46c5-938d-d9b0e3f9dfaa"
      decimals="-3"
      id="F_f143a285-16d6-4965-9d60-7adbd85d6788"
      unitRef="U_USD">-837000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInDepositOtherAssets
      contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b"
      decimals="-3"
      id="F_6851b91d-b8c4-483a-a100-651ce701955a"
      unitRef="U_USD">94000</us-gaap:IncreaseDecreaseInDepositOtherAssets>
    <us-gaap:IncreaseDecreaseInDepositOtherAssets
      contextRef="C_0fd32f25-7d1d-46c5-938d-d9b0e3f9dfaa"
      decimals="-3"
      id="F_12232f1d-967c-47ad-a293-568daca3ff7b"
      unitRef="U_USD">-47000</us-gaap:IncreaseDecreaseInDepositOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b"
      decimals="-3"
      id="F_e12a6d4a-74d9-4271-998e-6e9dc0cf9ed2"
      unitRef="U_USD">-722000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_0fd32f25-7d1d-46c5-938d-d9b0e3f9dfaa"
      decimals="-3"
      id="F_a6878b11-c74b-4d3c-997e-b05bc729a415"
      unitRef="U_USD">2204000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <dawn:IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities
      contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b"
      decimals="-3"
      id="F_3710633f-9689-4346-b4ef-bee0dc570a3f"
      unitRef="U_USD">-26984000</dawn:IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities>
    <dawn:IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities
      contextRef="C_0fd32f25-7d1d-46c5-938d-d9b0e3f9dfaa"
      decimals="-3"
      id="F_a806cb74-f5a9-4782-897a-3bdaa1f1a2eb"
      unitRef="U_USD">-1765000</dawn:IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b"
      decimals="-3"
      id="F_e1975174-1f77-4b8f-8760-b185e9477d19"
      unitRef="U_USD">199000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="C_0fd32f25-7d1d-46c5-938d-d9b0e3f9dfaa"
      decimals="-3"
      id="F_65f7d098-f4f6-465d-a545-e6478098c441"
      unitRef="U_USD">0</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b"
      decimals="-3"
      id="F_2f06ace4-e289-4e77-ac92-0d636baccfdc"
      unitRef="U_USD">91000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="C_0fd32f25-7d1d-46c5-938d-d9b0e3f9dfaa"
      decimals="-3"
      id="F_b1d30144-5a67-4570-93ce-1a3000e72b11"
      unitRef="U_USD">-108000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b"
      decimals="-3"
      id="F_b7d4e41a-9bc0-4ca0-acbe-0f851f0fed55"
      unitRef="U_USD">-58997000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_0fd32f25-7d1d-46c5-938d-d9b0e3f9dfaa"
      decimals="-3"
      id="F_65fe17e6-5bdd-4e1e-a2a8-3c0fbac25733"
      unitRef="U_USD">-49729000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireShortTermInvestments
      contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b"
      decimals="-3"
      id="F_0d5e7751-30d1-4baa-9e5a-6bf222867a0f"
      unitRef="U_USD">189796000</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:PaymentsToAcquireShortTermInvestments
      contextRef="C_0fd32f25-7d1d-46c5-938d-d9b0e3f9dfaa"
      decimals="-3"
      id="F_bb71d88d-b0f5-4bdc-9f10-8decd1641d92"
      unitRef="U_USD">47162000</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:ProceedsFromSaleOfShortTermInvestments
      contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b"
      decimals="-3"
      id="F_6f66e746-d1f2-46c5-a16c-fd1a9885ffac"
      unitRef="U_USD">161000000</us-gaap:ProceedsFromSaleOfShortTermInvestments>
    <us-gaap:ProceedsFromSaleOfShortTermInvestments
      contextRef="C_0fd32f25-7d1d-46c5-938d-d9b0e3f9dfaa"
      decimals="-3"
      id="F_e041ef13-7f9b-444b-9e27-dc05eaa6d72e"
      unitRef="U_USD">136450000</us-gaap:ProceedsFromSaleOfShortTermInvestments>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b"
      decimals="-3"
      id="F_2e6b0891-5b1b-46ca-9273-465e9beb7903"
      unitRef="U_USD">3500000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="C_0fd32f25-7d1d-46c5-938d-d9b0e3f9dfaa"
      decimals="-3"
      id="F_9fb4fd9c-5e36-4fb0-ba02-44d11b66c20f"
      unitRef="U_USD">0</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b"
      decimals="-3"
      id="F_e70a3346-7d6d-4868-b364-7eb367b65088"
      unitRef="U_USD">317000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_0fd32f25-7d1d-46c5-938d-d9b0e3f9dfaa"
      decimals="-3"
      id="F_ab1866b6-1aae-43db-b367-3a6e3c23ae68"
      unitRef="U_USD">0</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b"
      decimals="-3"
      id="F_f79d4a3c-2258-4e56-b441-a049aabc6d37"
      unitRef="U_USD">-32613000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_0fd32f25-7d1d-46c5-938d-d9b0e3f9dfaa"
      decimals="-3"
      id="F_fd05487b-eef7-4dec-a70a-e4078d35a302"
      unitRef="U_USD">89288000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b"
      decimals="-3"
      id="F_699f5caf-9c08-4cce-a9ee-69da3818d0f6"
      unitRef="U_USD">0</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_0fd32f25-7d1d-46c5-938d-d9b0e3f9dfaa"
      decimals="-3"
      id="F_feb6e485-9a44-4ebc-b5d2-a8601492d6e8"
      unitRef="U_USD">48000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b"
      decimals="-3"
      id="F_df61ad46-88d1-4ae0-bcfd-d8910b61df59"
      unitRef="U_USD">0</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_0fd32f25-7d1d-46c5-938d-d9b0e3f9dfaa"
      decimals="-3"
      id="F_dc890493-53d4-4a9b-a1ff-ffae1be3aa21"
      unitRef="U_USD">48000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b"
      decimals="-3"
      id="F_af5798f3-c683-4958-9690-b5052bc175a7"
      unitRef="U_USD">-91610000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="C_0fd32f25-7d1d-46c5-938d-d9b0e3f9dfaa"
      decimals="-3"
      id="F_4584b921-b232-4922-b059-303b21d5ebe1"
      unitRef="U_USD">39607000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_1b7733fe-22fe-416b-a33e-e8b388655156"
      decimals="-3"
      id="F_9be8e831-794f-4419-8e45-d45149dc765e"
      unitRef="U_USD">124968000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_ba36f1f4-7ce5-434c-b80f-2bcb5a767c07"
      decimals="-3"
      id="F_2cc87b42-3224-462b-b6d8-d390881356d8"
      unitRef="U_USD">230784000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_b103f351-0eb2-495b-85c1-5630e54c751c"
      decimals="-3"
      id="F_156f3ad7-6f1b-4c7b-ab7e-97aecf506966"
      unitRef="U_USD">33358000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_4ba97ac7-abe6-41af-8f29-b34dd24231c3"
      decimals="-3"
      id="F_13b33463-8e4a-4e2a-87de-6717488d35b4"
      unitRef="U_USD">270391000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b"
      decimals="-3"
      id="F_954b59ed-f56f-41ce-8ad6-51bcaf6bbc00"
      unitRef="U_USD">2000000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="C_0fd32f25-7d1d-46c5-938d-d9b0e3f9dfaa"
      decimals="-3"
      id="F_54e427ee-0bbf-4657-bb92-effee4e33177"
      unitRef="U_USD">0</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b"
      decimals="-3"
      id="F_83839d54-7f56-42aa-a6a9-ae401ddc2c2a"
      unitRef="U_USD">230000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_0fd32f25-7d1d-46c5-938d-d9b0e3f9dfaa"
      decimals="-3"
      id="F_f962f9e5-83a4-4044-b590-f60b15023872"
      unitRef="U_USD">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b"
      id="F_20ea2eb4-b8b3-49b2-b4a6-1e1b42d33731">&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;1.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Description of Business and Organization &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Organization and Business&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Day One Biopharmaceuticals, Inc. is a commercial-stage company focused on advancing medicines for childhood and adult diseases with equal intensity. The Company was founded in November 2018 and is headquartered in Brisbane, CA.&lt;/span&gt;&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b"
      id="F_45f6c985-3bb0-409b-845d-3c3cfd8df0e8">&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;2.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Summary of Significant Accounting Policies &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Basis of Presentation&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company&#x2019;s unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States, or U.S. GAAP, for interim financial information and Article 10 of Regulation S-X of the Securities and Exchange Commission, or SEC, and should be read in conjunction with the Company's financial statements and notes thereto contained in the Company's Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on February 25, 2025. The condensed financial statements presented in this Quarterly Report on Form 10-Q are unaudited; however, in the opinion of management, such financial statements reflect all adjustments, consisting solely of normal recurring adjustments, necessary for a fair presentation of the results for the interim periods presented.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in Accounting Standards Codification, or ASC, and Accounting Standards Updates, or ASU, of the Financial Accounting Standards Board, or FASB.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Certain prior period amounts in the Notes to the Condensed Financial Statements have been reclassified to conform to the current period's presentation. These reclassifications did not affect the prior period's total assets, liabilities, stockholders' equity, net loss or cash flows. Specifically, the reclassifications separately present accrued rebates and accrued federal and state taxes within Note 4.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Use of Estimates&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The preparation of condensed financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and disclosure of contingent assets and liabilities at the date of the condensed financial statements, and the reported amounts of expenses during the reporting period. Estimates and assumptions made in the accompanying condensed financial statements include, but are not limited to, accruals for research and development expenses, variable consideration and other relevant inputs impacting the gross and net revenue recognition, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;the valuation of share-based awards, and the valuation of deferred tax assets. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable. Actual results may differ from those estimates or assumptions.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Segments&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Operating segments are defined as components of an entity about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business in one operating segment.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Concentration of Credit Risk and Other Risks and Uncertainties&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Financial instruments that subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents, short-term investments, and accounts receivable. Amounts on deposit may at times exceed federally insured limits. The Company is exposed to credit risk in the event of default by the financial institutions holding its cash, cash equivalents and short-term investments that are recorded on its balance sheet. Per policy, the Company mitigates its risk by investing in high-grade instruments and limiting the concentration in any one non-United States government or government backed issuer, which limits its exposure. The Company has not experienced any losses on its cash, cash equivalents and short-term investments.
&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;For the three months ended March 31, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, two individual customers accounted for &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;98.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of total net product revenue, with these individual customers representing &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;64.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;34.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the Company's total net product revenue. As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;March 31, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, two customers accounted for &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;96.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the accounts receivable balance, with these individual customers representing &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;72.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the accounts receivable balance. No other individual customers account for more than &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of net product revenue or accounts receivable. The Company monitors the financial condition of its customers so that it can appropriately respond to changes in their creditworthiness. To date, the Company has not experienced any losses with respect to the collection of its accounts receivable.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company is subject to certain risks and uncertainties and believes that changes in any of the following areas could have a material adverse effect on the Company's future financial position or results of its operations: ability to obtain future financing; regulatory requirements for approval and market acceptance of, and reimbursement for, product candidates; performance of third-party clinical research organizations and manufacturers upon which the Company relies; development of sales channels; protection of the Company&#x2019;s intellectual property; litigation or claims against the Company based on intellectual property, patent, product, regulatory or other factors; changes to the market landscape; and the Company&#x2019;s ability to attract and retain employees necessary to support its growth.
&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company is dependent on third-party manufacturers to supply products for commercial and research and development activities in its programs. In particular, the Company relies and expects to continue to rely on a small number of manufacturers to supply it with its requirements for the active pharmaceutical ingredients and formulated drugs related to these programs. These programs could be adversely affected by a significant interruption in the supply of active pharmaceutical ingredients and formulated drugs.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Recently Issued Accounting Pronouncements&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740) &#x2013; Improvements to Income Tax Disclosures, which enhances the transparency and decision usefulness of income tax disclosures by requiring disclosure of disaggregated income taxes paid, prescribes standard categories for the components of the effective tax rate reconciliation, and modifies other income tax-related disclosures. The ASU is effective for fiscal years beginning after December 15, 2024 and allows for adoption on a prospective basis, with a retrospective option. The Company is currently evaluating the effect of this update on its financial statement disclosures.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In November 2024, the FASB issued ASU No. 2024-03, Income Statement&#x2014;Reporting Comprehensive Income&#x2014;Expense Disaggregation Disclosures, which requires disclosure, in the notes to financial statements, of specified information about certain costs and expenses at each interim and annual reporting period. The ASU is effective for fiscal years beginning after December 15, 2026 and allows for adoption on a prospective basis, with a retrospective option. Early adoption is permitted. The Company is currently evaluating the effect of this update on its financial statement disclosures.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b"
      id="F_8502d0db-a2ad-4d3f-af5b-1fc09376a6c3">&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Basis of Presentation&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company&#x2019;s unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States, or U.S. GAAP, for interim financial information and Article 10 of Regulation S-X of the Securities and Exchange Commission, or SEC, and should be read in conjunction with the Company's financial statements and notes thereto contained in the Company's Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on February 25, 2025. The condensed financial statements presented in this Quarterly Report on Form 10-Q are unaudited; however, in the opinion of management, such financial statements reflect all adjustments, consisting solely of normal recurring adjustments, necessary for a fair presentation of the results for the interim periods presented.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in Accounting Standards Codification, or ASC, and Accounting Standards Updates, or ASU, of the Financial Accounting Standards Board, or FASB.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Certain prior period amounts in the Notes to the Condensed Financial Statements have been reclassified to conform to the current period's presentation. These reclassifications did not affect the prior period's total assets, liabilities, stockholders' equity, net loss or cash flows. Specifically, the reclassifications separately present accrued rebates and accrued federal and state taxes within Note 4.&lt;/span&gt;&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b"
      id="F_30c7b7a6-1731-48ec-ba1a-5a9fddba4b23">&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Use of Estimates&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The preparation of condensed financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and disclosure of contingent assets and liabilities at the date of the condensed financial statements, and the reported amounts of expenses during the reporting period. Estimates and assumptions made in the accompanying condensed financial statements include, but are not limited to, accruals for research and development expenses, variable consideration and other relevant inputs impacting the gross and net revenue recognition, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;the valuation of share-based awards, and the valuation of deferred tax assets. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable. Actual results may differ from those estimates or assumptions.&lt;/span&gt;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b"
      id="F_7e5e5987-f4b6-471d-8bd9-91c233c2647c">&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Segments&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Operating segments are defined as components of an entity about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business in one operating segment.&lt;/span&gt;&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b"
      id="F_b37d1975-dac4-436c-b6ae-f91b4a634954">&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Concentration of Credit Risk and Other Risks and Uncertainties&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Financial instruments that subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents, short-term investments, and accounts receivable. Amounts on deposit may at times exceed federally insured limits. The Company is exposed to credit risk in the event of default by the financial institutions holding its cash, cash equivalents and short-term investments that are recorded on its balance sheet. Per policy, the Company mitigates its risk by investing in high-grade instruments and limiting the concentration in any one non-United States government or government backed issuer, which limits its exposure. The Company has not experienced any losses on its cash, cash equivalents and short-term investments.
&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;For the three months ended March 31, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, two individual customers accounted for &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;98.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of total net product revenue, with these individual customers representing &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;64.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;34.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the Company's total net product revenue. As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;March 31, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, two customers accounted for &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;96.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the accounts receivable balance, with these individual customers representing &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;72.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the accounts receivable balance. No other individual customers account for more than &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of net product revenue or accounts receivable. The Company monitors the financial condition of its customers so that it can appropriately respond to changes in their creditworthiness. To date, the Company has not experienced any losses with respect to the collection of its accounts receivable.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company is subject to certain risks and uncertainties and believes that changes in any of the following areas could have a material adverse effect on the Company's future financial position or results of its operations: ability to obtain future financing; regulatory requirements for approval and market acceptance of, and reimbursement for, product candidates; performance of third-party clinical research organizations and manufacturers upon which the Company relies; development of sales channels; protection of the Company&#x2019;s intellectual property; litigation or claims against the Company based on intellectual property, patent, product, regulatory or other factors; changes to the market landscape; and the Company&#x2019;s ability to attract and retain employees necessary to support its growth.
&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company is dependent on third-party manufacturers to supply products for commercial and research and development activities in its programs. In particular, the Company relies and expects to continue to rely on a small number of manufacturers to supply it with its requirements for the active pharmaceutical ingredients and formulated drugs related to these programs. These programs could be adversely affected by a significant interruption in the supply of active pharmaceutical ingredients and formulated drugs.&lt;/span&gt;&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_3ab621ae-436f-433d-9df2-8c8bce28b89e"
      decimals="3"
      id="F_c44b83ca-cf4e-4d70-ade2-b67813163973"
      unitRef="U_pure">0.984</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_8a694c05-0437-4c75-8ae6-45e4b83604d0"
      decimals="3"
      id="F_570c7b4b-0c52-42ce-a3d4-5fcb2177a18f"
      unitRef="U_pure">0.644</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_1438aa38-1e5a-4af2-922f-a3f067944262"
      decimals="3"
      id="F_97b70f04-b829-402c-824a-f97cd036285b"
      unitRef="U_pure">0.34</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_76de7769-5c35-42b4-83aa-9ca4c0b858aa"
      decimals="3"
      id="F_ba728a66-7985-44ac-a41d-370eade6ed5f"
      unitRef="U_pure">0.962</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_24aa28dd-3f08-4c12-b95e-d974f2524368"
      decimals="3"
      id="F_19528bdd-38c3-4398-8903-36000df3f63c"
      unitRef="U_pure">0.724</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_f31a84ee-cbb2-48fa-a085-f699999cd961"
      decimals="3"
      id="F_87bd2291-4a30-4087-89ab-e53e915b4ad3"
      unitRef="U_pure">0.238</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_6180a865-9d79-4110-bb9f-16515c37344b"
      decimals="3"
      id="F_dbf8aa7c-ff0e-47c6-83ae-5a21cedabe50"
      unitRef="U_pure">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b"
      id="F_1055abc8-5105-414e-81b5-7fd6bb7ab37c">&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Recently Issued Accounting Pronouncements&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740) &#x2013; Improvements to Income Tax Disclosures, which enhances the transparency and decision usefulness of income tax disclosures by requiring disclosure of disaggregated income taxes paid, prescribes standard categories for the components of the effective tax rate reconciliation, and modifies other income tax-related disclosures. The ASU is effective for fiscal years beginning after December 15, 2024 and allows for adoption on a prospective basis, with a retrospective option. The Company is currently evaluating the effect of this update on its financial statement disclosures.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In November 2024, the FASB issued ASU No. 2024-03, Income Statement&#x2014;Reporting Comprehensive Income&#x2014;Expense Disaggregation Disclosures, which requires disclosure, in the notes to financial statements, of specified information about certain costs and expenses at each interim and annual reporting period. The ASU is effective for fiscal years beginning after December 15, 2026 and allows for adoption on a prospective basis, with a retrospective option. Early adoption is permitted. The Company is currently evaluating the effect of this update on its financial statement disclosures.&lt;/span&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b"
      id="F_9c3f78aa-cd37-4661-affe-9c0d6f7471b5">&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;3.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Recurring Fair Value Measurements &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table sets forth the Company&#x2019;s financial instruments as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;March 31, 2025 and December 31, 2024, which are measured at fair value on a recurring basis by level within the fair value hierarchy (in thousands):&lt;/span&gt;&lt;/p&gt;
       &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:36.214%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.2%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.745000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.2%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.745000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.2%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.745000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.2%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.745000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="14" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;March 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Financial assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,146&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,146&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;345,377&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;345,377&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. government agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;94,285&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;94,285&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total assets measured at fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,146&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;439,662&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;451,808&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:36.295%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.2%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.725%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.2%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.725%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.2%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.725%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.2%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.725%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="14" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Financial assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16,728&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16,728&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;311,487&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;311,487&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. government agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;183,375&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;183,375&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total assets measured at fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16,728&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;494,862&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;511,590&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company's money market funds are classified as Level 1 because they are measured using observable inputs from active markets for identical assets.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company's U.S. treasury securities and U.S. government agency securities are classified as Level 2 because they are measured with inputs that are either directly or indirectly observable for the asset which include quoted prices for similar assets in active markets and quoted prices for identical or similar assets in markets that are not active.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;There were no assets or liabilities classified as Level 3 as of March 31, 2025 and December 31, 2024.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;There were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; transfers between Level 1, Level 2 or Level 3 categories during the periods presented.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following tables summarize the estimated fair value of the Company's cash equivalents, available-for-sale securities classified as short-term investments, and associated unrealized gains and losses (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
       &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:41.6%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:11.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:11.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:11.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:11.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;March 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Amortized Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Unrealized Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Unrealized Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Estimated Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,146&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,146&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,146&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,146&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Short-term investments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. government agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;94,297&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;94,285&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;345,418&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;48&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;345,377&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total short-term investments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;439,715&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;60&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;439,662&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:41.6%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:11.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:11.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:11.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:11.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Amortized Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Unrealized Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Unrealized Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Estimated Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16,728&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16,728&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. government agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;75,163&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;75,163&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,947&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,947&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;104,838&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;104,838&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Short-term investments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. government agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;108,210&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;108,212&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;298,457&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;85&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;298,540&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total short-term investments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;406,667&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;98&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;406,752&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;div style="font-size:11pt;font-family:'Calibri',sans-serif;"&gt;&lt;p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table summarizes the maturities of our cash equivalents and available-for-sale securities (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
       &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:53.261%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.761%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:19.607999999999997%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.761%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:19.607999999999997%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;March 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Amortized Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Mature in one year or less&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;451,861&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;451,808&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;451,861&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;451,808&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:53.261%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.761%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:19.607999999999997%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.761%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:19.607999999999997%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Amortized Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Mature in one year or less&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;511,505&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;511,590&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;511,505&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;511,590&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company regularly reviews the changes to the rating of its securities and monitors the surrounding economic conditions to assess the risk of expected credit losses. As of March 31, 2025 and December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, there were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; securities that were in an unrealized loss position for more than 12 months. As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;March 31, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the unrealized losses on the Company&#x2019;s short-term investments were primarily caused by interest rate increases. The Company does not expect the issuers to settle any security at a price less than the amortized cost basis of the investment with the contractual cash flows of these investments guaranteed by the issuer. No allowance for credit losses has been recorded since it is not more-likely-than-not that the Company will be required to sell the investments before recovery of their amortized cost basis.&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b"
      id="F_a41b4c2e-0a13-47ea-93e5-efa43f98ca55">&lt;p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table sets forth the Company&#x2019;s financial instruments as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;March 31, 2025 and December 31, 2024, which are measured at fair value on a recurring basis by level within the fair value hierarchy (in thousands):&lt;/span&gt;&lt;/p&gt;
       &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:36.214%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.2%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.745000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.2%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.745000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.2%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.745000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.2%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.745000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="14" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;March 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Financial assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,146&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,146&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;345,377&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;345,377&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. government agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;94,285&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;94,285&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total assets measured at fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,146&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;439,662&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;451,808&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:36.295%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.2%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.725%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.2%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.725%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.2%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.725%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.2%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.725%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="14" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Financial assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16,728&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16,728&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;311,487&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;311,487&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. government agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;183,375&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;183,375&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total assets measured at fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16,728&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;494,862&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;511,590&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_a48de969-8ddc-4b3b-a6a7-5c2b29ae4e05"
      decimals="-3"
      id="F_51edd0e3-aaf5-4218-8e84-15a8d88633a6"
      unitRef="U_USD">12146000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_494ea4ad-935d-45a3-a172-b60cd7e73582"
      decimals="-3"
      id="F_8dc30d4f-43ab-4234-9c20-72d17c7319a9"
      unitRef="U_USD">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_5399640b-8a12-4325-9bb5-9eaa7ac09323"
      decimals="-3"
      id="F_d2987544-5a35-4324-926b-aea62ccd519a"
      unitRef="U_USD">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_de732af7-5533-4ee5-aaa0-722119902a1a"
      decimals="-3"
      id="F_5af2fb38-8018-4ade-b37a-39d8ea5d2b75"
      unitRef="U_USD">12146000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_4c2bf0b9-0d5c-4b03-b0a7-3c3a06954490"
      decimals="-3"
      id="F_e16b4d5f-c5b9-4ca2-88f6-f185a05a427c"
      unitRef="U_USD">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_a49147be-0409-42b0-a2d6-250d7ea0c7b6"
      decimals="-3"
      id="F_43d69cae-cb9f-4bff-9cfd-d6311d534feb"
      unitRef="U_USD">345377000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_bcf4433c-d298-4d36-a850-dfba1a092198"
      decimals="-3"
      id="F_3cd3ca72-7f26-4650-ad81-6e63d0cc08fe"
      unitRef="U_USD">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_709f7aa4-e121-4df0-b0d0-a36cdf0a83fe"
      decimals="-3"
      id="F_bcef674c-54b0-4541-9846-315bd378bd8f"
      unitRef="U_USD">345377000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_81949730-fa21-4927-8bb8-150b98f7b91f"
      decimals="-3"
      id="F_6855971f-8c44-4827-8a5f-39ca1f5ba8a7"
      unitRef="U_USD">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_359c3fbb-d10c-4741-807c-98dd361851e9"
      decimals="-3"
      id="F_9ff045de-110e-4909-82b9-79a7f9e7cde4"
      unitRef="U_USD">94285000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_10416dad-c8fd-476e-89d5-ae0a83b9440c"
      decimals="-3"
      id="F_02fa2387-9d0d-4e18-8445-a999766d124f"
      unitRef="U_USD">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_3b67e9fd-7c04-48f2-969e-4f1fa6b5693c"
      decimals="-3"
      id="F_41efaf01-4653-4f91-af83-a4d153c50738"
      unitRef="U_USD">94285000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_5459b1fe-9af9-4c02-891b-a32f266837c2"
      decimals="-3"
      id="F_957d3591-e6be-496f-9596-e681db1d1837"
      unitRef="U_USD">12146000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_21176c5a-4a94-4c88-9e64-63ebfc46b526"
      decimals="-3"
      id="F_ce8614ca-db90-4baa-8210-9a6acc451882"
      unitRef="U_USD">439662000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_1ce17a75-0fd7-4298-bfc0-f235a473361b"
      decimals="-3"
      id="F_7da4f03a-150f-4b94-8985-949c3be6d4d8"
      unitRef="U_USD">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_3e17f855-9bc9-4474-9b6f-1728c5807a4b"
      decimals="-3"
      id="F_1967d11a-5c49-4a8f-b027-4505e2209977"
      unitRef="U_USD">451808000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_a3c664ec-2577-4bad-ba57-d70b9f3e5a3e"
      decimals="-3"
      id="F_e2d372fd-9168-4426-b769-bbca7d38f0b4"
      unitRef="U_USD">16728000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_0a5c3519-45df-4f60-a8a7-7437f71f7bfb"
      decimals="-3"
      id="F_98b3ba31-6778-4886-ac8f-ff69ee81041f"
      unitRef="U_USD">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_0cc93ae0-4f9d-48ec-aec0-c24fe1944b49"
      decimals="-3"
      id="F_8ae5d7b6-4089-44fb-a427-c1b33df3cca3"
      unitRef="U_USD">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_dea27b68-18b7-4c73-9c27-b5c829ef0241"
      decimals="-3"
      id="F_3495400c-c42a-4132-acd2-0e25ae728bbd"
      unitRef="U_USD">16728000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_7f6b13fb-87e4-41c9-982f-9121e8dc50ce"
      decimals="-3"
      id="F_632bb6f1-a640-4043-ab15-5673703a9440"
      unitRef="U_USD">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_e6665180-612b-4fba-adce-73d240ace7bb"
      decimals="-3"
      id="F_387d6a0c-f135-4d5c-a961-f522f530124b"
      unitRef="U_USD">311487000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_dce557e4-9275-4019-bfcf-ce698a8400c6"
      decimals="-3"
      id="F_0a826a85-58d6-4249-bbff-c29826aaec5c"
      unitRef="U_USD">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_4f8d1d22-bf0a-41bc-b883-13763363dd92"
      decimals="-3"
      id="F_97e1fde9-0fd1-435e-ba4b-061f8263aaac"
      unitRef="U_USD">311487000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_a9d09cb0-58f1-4b18-b47f-7276b7057656"
      decimals="-3"
      id="F_348e7bdc-dcad-43e2-873a-72864f0e9ba6"
      unitRef="U_USD">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_5f6d6e0e-3d98-4fa4-8a41-68a23cdaa376"
      decimals="-3"
      id="F_6b9f7c28-ebe8-422c-a259-4d6e955d8830"
      unitRef="U_USD">183375000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_0bf779c8-a9a8-4ba9-bbb1-898f93f339e4"
      decimals="-3"
      id="F_8cd4c46c-2cb0-4c62-a3d9-41151ba2b05e"
      unitRef="U_USD">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_a0ee4c82-d202-4563-aeeb-4840f5b9e70e"
      decimals="-3"
      id="F_5a9d4092-95dd-4633-9fda-43f99ca7578e"
      unitRef="U_USD">183375000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_a320baa6-cd53-4730-8cba-58584c6ac43a"
      decimals="-3"
      id="F_4b0b021c-5e1b-4d36-a4b0-57d3275e8944"
      unitRef="U_USD">16728000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_19ecbc75-781d-4703-b1ec-88b78ffef3f7"
      decimals="-3"
      id="F_899de0f5-c8e8-4392-af39-930b20c0aad7"
      unitRef="U_USD">494862000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_b5d41f12-6166-4c3e-a249-6ff0239c1d95"
      decimals="-3"
      id="F_ff402c68-2995-4915-8ed1-8e8a1a392f59"
      unitRef="U_USD">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_4fbcd2d8-640a-4a12-888c-5b1b8885e9aa"
      decimals="-3"
      id="F_5e178641-286e-4313-9878-cc2c4694a2b3"
      unitRef="U_USD">511590000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
      contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b"
      decimals="-3"
      id="F_b5cbe40c-876b-4d18-a834-ed4b8057e02f"
      unitRef="U_USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
      contextRef="C_8b0fbd15-0039-4354-9bc0-e49520f5e256"
      decimals="-3"
      id="F_d2e6006b-7d84-4d19-a8de-68df65ef6d6d"
      unitRef="U_USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock
      contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b"
      id="F_9cb77509-6d02-4c11-8d8a-80f191961df2">&lt;p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following tables summarize the estimated fair value of the Company's cash equivalents, available-for-sale securities classified as short-term investments, and associated unrealized gains and losses (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
       &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:41.6%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:11.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:11.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:11.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:11.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;March 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Amortized Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Unrealized Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Unrealized Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Estimated Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,146&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,146&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,146&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,146&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Short-term investments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. government agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;94,297&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;94,285&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;345,418&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;48&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;345,377&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total short-term investments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;439,715&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;60&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;439,662&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:41.6%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:11.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:11.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:11.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:11.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Amortized Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Unrealized Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Unrealized Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Estimated Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16,728&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16,728&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. government agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;75,163&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;75,163&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,947&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,947&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;104,838&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;104,838&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Short-term investments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. government agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;108,210&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;108,212&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;298,457&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;85&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;298,540&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total short-term investments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;406,667&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;98&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;406,752&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_b77b4a90-bf68-4a05-8f01-62a9520247e8"
      decimals="-3"
      id="F_7c9b005a-31b1-4303-aa82-22d74d9b32b0"
      unitRef="U_USD">12146000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <dawn:CashEquivalentsUnrealizedGains
      contextRef="C_b77b4a90-bf68-4a05-8f01-62a9520247e8"
      decimals="-3"
      id="F_945d2381-3842-4315-a928-05559582f521"
      unitRef="U_USD">0</dawn:CashEquivalentsUnrealizedGains>
    <dawn:CashEquivalentsUnrealizedLosses
      contextRef="C_b77b4a90-bf68-4a05-8f01-62a9520247e8"
      decimals="-3"
      id="F_284bfba2-3839-43c7-8e50-e300f92b87b7"
      unitRef="U_USD">0</dawn:CashEquivalentsUnrealizedLosses>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_b77b4a90-bf68-4a05-8f01-62a9520247e8"
      decimals="-3"
      id="F_b17bdfe2-93e1-4fe5-9cbe-8abeccf9d98a"
      unitRef="U_USD">12146000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_a308fa2a-9dd8-441a-aaa4-31aac0a1a5eb"
      decimals="-3"
      id="F_a5a20148-abea-442a-9a9a-3e0f0e042057"
      unitRef="U_USD">12146000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <dawn:CashEquivalentsUnrealizedGains
      contextRef="C_a308fa2a-9dd8-441a-aaa4-31aac0a1a5eb"
      decimals="-3"
      id="F_9c44b5e3-dc50-474e-b715-4622276d6be2"
      unitRef="U_USD">0</dawn:CashEquivalentsUnrealizedGains>
    <dawn:CashEquivalentsUnrealizedLosses
      contextRef="C_a308fa2a-9dd8-441a-aaa4-31aac0a1a5eb"
      decimals="-3"
      id="F_b400c7f8-abd5-4de1-81c5-c7e778cb8173"
      unitRef="U_USD">0</dawn:CashEquivalentsUnrealizedLosses>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_a308fa2a-9dd8-441a-aaa4-31aac0a1a5eb"
      decimals="-3"
      id="F_47fbb381-d033-4040-aa65-09ccc9f90fd2"
      unitRef="U_USD">12146000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_cbc72dd7-8c81-4d68-9f7a-1b1c2d90b6a0"
      decimals="-3"
      id="F_329b405e-1244-45c5-b5c0-7550323eb01c"
      unitRef="U_USD">94297000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain
      contextRef="C_68539f11-26b8-4c60-96db-44201518557b"
      decimals="-3"
      id="F_9f57fbdd-0735-452e-9243-a03ef94c6928"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
      contextRef="C_68539f11-26b8-4c60-96db-44201518557b"
      decimals="-3"
      id="F_ec0bbf22-7d26-4c36-b5fe-abff913efcb5"
      unitRef="U_USD">12000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_cbc72dd7-8c81-4d68-9f7a-1b1c2d90b6a0"
      decimals="-3"
      id="F_b1f63ada-91c0-4f41-a849-61e18e1d67e0"
      unitRef="U_USD">94285000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_3c025e0b-f004-497c-8763-6a8406223ff4"
      decimals="-3"
      id="F_b5f192b6-aaa0-4b3f-953d-d3e353ddeba0"
      unitRef="U_USD">345418000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain
      contextRef="C_cfe0c0d8-2e22-409b-b482-35888c79dbfa"
      decimals="-3"
      id="F_4d834299-d6c7-4cac-8474-c98c28a8b337"
      unitRef="U_USD">7000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
      contextRef="C_cfe0c0d8-2e22-409b-b482-35888c79dbfa"
      decimals="-3"
      id="F_f59228b7-20a3-48ff-8b17-d8bfb6551e99"
      unitRef="U_USD">48000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_3c025e0b-f004-497c-8763-6a8406223ff4"
      decimals="-3"
      id="F_eb7403e2-a650-43a9-88bc-7bf0c8798984"
      unitRef="U_USD">345377000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_7a2a1b79-4a52-4f59-8224-b2b1f9654b55"
      decimals="-3"
      id="F_8a0cdc85-dc2a-4c76-8073-b67903b3738b"
      unitRef="U_USD">439715000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain
      contextRef="C_ba809785-9e5e-4537-b8ed-aa9a95f5018c"
      decimals="-3"
      id="F_0bd10917-0259-49ed-a2c7-0e16a3420363"
      unitRef="U_USD">7000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
      contextRef="C_ba809785-9e5e-4537-b8ed-aa9a95f5018c"
      decimals="-3"
      id="F_19d0f00d-808a-4855-bd0b-0e8c077544df"
      unitRef="U_USD">60000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_7a2a1b79-4a52-4f59-8224-b2b1f9654b55"
      decimals="-3"
      id="F_603b34f2-a841-4cb8-945b-c4139c5ac26e"
      unitRef="U_USD">439662000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_3b0aca41-c2bf-46f8-b765-42580bbf6433"
      decimals="-3"
      id="F_83b47e59-aa06-4158-982d-2d8249637a07"
      unitRef="U_USD">16728000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <dawn:CashEquivalentsUnrealizedGains
      contextRef="C_3b0aca41-c2bf-46f8-b765-42580bbf6433"
      decimals="-3"
      id="F_d63c3164-f879-46d4-a66a-c522f19fe585"
      unitRef="U_USD">0</dawn:CashEquivalentsUnrealizedGains>
    <dawn:CashEquivalentsUnrealizedLosses
      contextRef="C_3b0aca41-c2bf-46f8-b765-42580bbf6433"
      decimals="-3"
      id="F_067c2246-de42-4c19-b59c-d688a98e138d"
      unitRef="U_USD">0</dawn:CashEquivalentsUnrealizedLosses>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_3b0aca41-c2bf-46f8-b765-42580bbf6433"
      decimals="-3"
      id="F_55402a75-52e3-45cb-bfe9-fdb1e9b5f775"
      unitRef="U_USD">16728000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_ebe52b1a-a4be-4f4e-a3d1-d3bb26eaa194"
      decimals="-3"
      id="F_d29ce536-bfa2-4d7f-b3c1-14ff421e3ade"
      unitRef="U_USD">75163000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <dawn:CashEquivalentsUnrealizedGains
      contextRef="C_ebe52b1a-a4be-4f4e-a3d1-d3bb26eaa194"
      decimals="-3"
      id="F_bff94360-6c15-444b-a487-af9e348767dc"
      unitRef="U_USD">0</dawn:CashEquivalentsUnrealizedGains>
    <dawn:CashEquivalentsUnrealizedLosses
      contextRef="C_ebe52b1a-a4be-4f4e-a3d1-d3bb26eaa194"
      decimals="-3"
      id="F_a10122dc-cfaf-4801-a5e3-13eb7de02ec8"
      unitRef="U_USD">0</dawn:CashEquivalentsUnrealizedLosses>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_ebe52b1a-a4be-4f4e-a3d1-d3bb26eaa194"
      decimals="-3"
      id="F_361d6bc1-868a-46f0-9ce7-91a1e387e0f0"
      unitRef="U_USD">75163000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_451cb9d2-19ad-4b9a-87a0-770cffddb183"
      decimals="-3"
      id="F_fbd362d4-bbc0-488f-b7c3-33fda9be5a01"
      unitRef="U_USD">12947000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <dawn:CashEquivalentsUnrealizedGains
      contextRef="C_451cb9d2-19ad-4b9a-87a0-770cffddb183"
      decimals="-3"
      id="F_aa955f6b-33c6-49dd-8582-afed5fa7e6a9"
      unitRef="U_USD">0</dawn:CashEquivalentsUnrealizedGains>
    <dawn:CashEquivalentsUnrealizedLosses
      contextRef="C_451cb9d2-19ad-4b9a-87a0-770cffddb183"
      decimals="-3"
      id="F_91c29798-df3a-4314-b50e-3dadcb095236"
      unitRef="U_USD">0</dawn:CashEquivalentsUnrealizedLosses>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_451cb9d2-19ad-4b9a-87a0-770cffddb183"
      decimals="-3"
      id="F_32227377-01b7-4c0a-abc8-021f1c7f423d"
      unitRef="U_USD">12947000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_0eee3e9c-c51c-4e38-bfea-aebbe8a2a4a1"
      decimals="-3"
      id="F_bd7c3b5c-777e-4b68-bd87-7607e484cb74"
      unitRef="U_USD">104838000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <dawn:CashEquivalentsUnrealizedGains
      contextRef="C_0eee3e9c-c51c-4e38-bfea-aebbe8a2a4a1"
      decimals="-3"
      id="F_02ece62d-69af-4c2e-a634-6b9dc8c93379"
      unitRef="U_USD">0</dawn:CashEquivalentsUnrealizedGains>
    <dawn:CashEquivalentsUnrealizedLosses
      contextRef="C_0eee3e9c-c51c-4e38-bfea-aebbe8a2a4a1"
      decimals="-3"
      id="F_88cd65b3-032e-4d87-8555-41987a6acc7d"
      unitRef="U_USD">0</dawn:CashEquivalentsUnrealizedLosses>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_0eee3e9c-c51c-4e38-bfea-aebbe8a2a4a1"
      decimals="-3"
      id="F_368a7267-3194-4703-836c-00d72831cfe4"
      unitRef="U_USD">104838000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_ebe52b1a-a4be-4f4e-a3d1-d3bb26eaa194"
      decimals="-3"
      id="F_72122798-998d-4590-a17c-124f05e229e1"
      unitRef="U_USD">108210000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain
      contextRef="C_afcca245-4cb7-422b-8748-147e3421ebb4"
      decimals="-3"
      id="F_9a421caf-3312-4a1a-90d3-a981542e980e"
      unitRef="U_USD">13000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
      contextRef="C_afcca245-4cb7-422b-8748-147e3421ebb4"
      decimals="-3"
      id="F_6e4a95f6-e61b-4898-9357-ee8166b0b78a"
      unitRef="U_USD">11000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_ebe52b1a-a4be-4f4e-a3d1-d3bb26eaa194"
      decimals="-3"
      id="F_b2209374-f491-4e90-ac01-6e8137ac9ae9"
      unitRef="U_USD">108212000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_451cb9d2-19ad-4b9a-87a0-770cffddb183"
      decimals="-3"
      id="F_07877ad6-9596-4caa-a841-c3a4b974d0e5"
      unitRef="U_USD">298457000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain
      contextRef="C_414a2ccf-e2e3-4dea-882d-8f99a0bcc263"
      decimals="-3"
      id="F_e70cc5ce-bd55-496f-8bbf-bffb25000a4f"
      unitRef="U_USD">85000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
      contextRef="C_414a2ccf-e2e3-4dea-882d-8f99a0bcc263"
      decimals="-3"
      id="F_5ef6642a-0061-4003-b091-4134e38fe29d"
      unitRef="U_USD">2000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_451cb9d2-19ad-4b9a-87a0-770cffddb183"
      decimals="-3"
      id="F_5785368b-c09e-4694-8d50-f2973cae0722"
      unitRef="U_USD">298540000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_4f40a47c-f03a-48ad-8dc7-1d9331ced26a"
      decimals="-3"
      id="F_9df01d23-5a38-4ada-a6d3-f14a38a38d35"
      unitRef="U_USD">406667000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain
      contextRef="C_4f6e2663-8d98-4973-a359-76163a03ea8a"
      decimals="-3"
      id="F_d456144a-edfa-42c6-9263-2238d4e047ad"
      unitRef="U_USD">98000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
      contextRef="C_4f6e2663-8d98-4973-a359-76163a03ea8a"
      decimals="-3"
      id="F_2b245e60-9bf3-458a-bde6-6dc77289ca08"
      unitRef="U_USD">13000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_4f40a47c-f03a-48ad-8dc7-1d9331ced26a"
      decimals="-3"
      id="F_56793866-b642-4cd1-8e9a-b1cadbf56477"
      unitRef="U_USD">406752000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <dawn:ScheduleOfMaturitiesForAvailableForSaleSecuritiesTableTextBlock
      contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b"
      id="F_f42047de-cf1d-4eac-9939-ef4791e1b9b0">&lt;p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table summarizes the maturities of our cash equivalents and available-for-sale securities (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
       &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:53.261%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.761%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:19.607999999999997%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.761%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:19.607999999999997%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;March 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Amortized Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Mature in one year or less&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;451,861&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;451,808&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;451,861&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;451,808&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:53.261%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.761%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:19.607999999999997%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.761%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:19.607999999999997%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Amortized Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Mature in one year or less&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;511,505&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;511,590&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;511,505&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;511,590&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</dawn:ScheduleOfMaturitiesForAvailableForSaleSecuritiesTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
      contextRef="C_b103f351-0eb2-495b-85c1-5630e54c751c"
      decimals="-3"
      id="F_2e079bb6-b35b-48b3-8171-a0da2f932b30"
      unitRef="U_USD">451861000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="C_b103f351-0eb2-495b-85c1-5630e54c751c"
      decimals="-3"
      id="F_a2b0849b-89d7-4069-bb0c-5cf5d310d19c"
      unitRef="U_USD">451808000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis
      contextRef="C_b103f351-0eb2-495b-85c1-5630e54c751c"
      decimals="-3"
      id="F_022e1a4c-a3c6-4260-83a5-93fc4b5b0246"
      unitRef="U_USD">451861000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate
      contextRef="C_b103f351-0eb2-495b-85c1-5630e54c751c"
      decimals="-3"
      id="F_7f50af9a-2b60-460d-9b77-299cd5c18e27"
      unitRef="U_USD">451808000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
      contextRef="C_1b7733fe-22fe-416b-a33e-e8b388655156"
      decimals="-3"
      id="F_459a2599-1558-47bd-831a-7d9701c60dd5"
      unitRef="U_USD">511505000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="C_1b7733fe-22fe-416b-a33e-e8b388655156"
      decimals="-3"
      id="F_e34d38bb-03f5-47c6-9982-e0c4ce7500e8"
      unitRef="U_USD">511590000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis
      contextRef="C_1b7733fe-22fe-416b-a33e-e8b388655156"
      decimals="-3"
      id="F_7affcaa1-d0c4-42ba-b2e2-832f03af3ceb"
      unitRef="U_USD">511505000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate
      contextRef="C_1b7733fe-22fe-416b-a33e-e8b388655156"
      decimals="-3"
      id="F_032bd089-7adf-4458-bedf-e755b2c9cea3"
      unitRef="U_USD">511590000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="C_b103f351-0eb2-495b-85c1-5630e54c751c"
      decimals="-3"
      id="F_73777bf9-a0ca-4be0-95ea-151e7dd1d3f6"
      unitRef="U_USD">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="C_1b7733fe-22fe-416b-a33e-e8b388655156"
      decimals="-3"
      id="F_95663651-fbe2-4d5f-8e89-d834330e5c36"
      unitRef="U_USD">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock
      contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b"
      id="F_9ed4494a-75fb-49e3-b10b-aed2d3b1d0e4">&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;4.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Balance Sheet Items &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Prepaid Expenses and Other Current Assets&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Prepaid expenses and other current assets consisted of the following (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:76.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:66.967%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.897%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.897%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;March 31,&lt;br/&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Prepaid research and development expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,733&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,216&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Prepaid insurance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;305&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;830&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other prepaid expenses and other assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,974&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,367&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total prepaid expenses and other current assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,012&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,413&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Accrued Expenses and Other Current Liabilities&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Accrued expenses and other current liabilities consisted of the following (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:76.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:68.84%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.26%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.32%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.26%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.32%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;March 31,&lt;br/&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued research and development expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18,457&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18,760&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued rebates&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,008&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,518&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued federal and state taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,966&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,966&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued professional service expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,943&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,758&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued payroll related expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,202&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,943&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued milestone payment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,065&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,680&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total accrued expenses and other current liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;43,641&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;68,625&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <dawn:ScheduleOfPrepaidAndOtherCurrentAssetstableTextBlockTableTextBlock
      contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b"
      id="F_0eee9bc9-531b-41af-bc7a-4f75679411bb">&lt;p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Prepaid expenses and other current assets consisted of the following (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:76.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:66.967%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.897%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.897%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;March 31,&lt;br/&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Prepaid research and development expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,733&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,216&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Prepaid insurance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;305&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;830&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other prepaid expenses and other assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,974&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,367&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total prepaid expenses and other current assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,012&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,413&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</dawn:ScheduleOfPrepaidAndOtherCurrentAssetstableTextBlockTableTextBlock>
    <dawn:PrepaidResearchAndDevelopmentExpenses
      contextRef="C_b103f351-0eb2-495b-85c1-5630e54c751c"
      decimals="-3"
      id="F_d984e44b-c396-44d9-978a-a65d09b415db"
      unitRef="U_USD">9733000</dawn:PrepaidResearchAndDevelopmentExpenses>
    <dawn:PrepaidResearchAndDevelopmentExpenses
      contextRef="C_1b7733fe-22fe-416b-a33e-e8b388655156"
      decimals="-3"
      id="F_00972291-3c80-4282-9d4f-0c17eb990f33"
      unitRef="U_USD">8216000</dawn:PrepaidResearchAndDevelopmentExpenses>
    <us-gaap:PrepaidInsurance
      contextRef="C_b103f351-0eb2-495b-85c1-5630e54c751c"
      decimals="-3"
      id="F_e2a98ba2-82cc-44a5-817a-b0655e9c5a97"
      unitRef="U_USD">305000</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidInsurance
      contextRef="C_1b7733fe-22fe-416b-a33e-e8b388655156"
      decimals="-3"
      id="F_43dde408-dd3b-4fc2-845a-1787052e43b8"
      unitRef="U_USD">830000</us-gaap:PrepaidInsurance>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="C_b103f351-0eb2-495b-85c1-5630e54c751c"
      decimals="-3"
      id="F_61a06455-16c5-4f4d-9cf8-240df09fd384"
      unitRef="U_USD">3974000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="C_1b7733fe-22fe-416b-a33e-e8b388655156"
      decimals="-3"
      id="F_0f0756d1-75b6-4e92-8ce2-fd53bc78ab6c"
      unitRef="U_USD">4367000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_b103f351-0eb2-495b-85c1-5630e54c751c"
      decimals="-3"
      id="F_2d9b2a53-29dd-48a2-b333-b8e6ae68a08a"
      unitRef="U_USD">14012000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_1b7733fe-22fe-416b-a33e-e8b388655156"
      decimals="-3"
      id="F_4e2e0296-08fa-47d3-9d5b-1aa4b625f70c"
      unitRef="U_USD">13413000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock
      contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b"
      id="F_1be0e3e7-cc23-4ee7-979d-d596213428b0">&lt;p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Accrued expenses and other current liabilities consisted of the following (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:76.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:68.84%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.26%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.32%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.26%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.32%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;March 31,&lt;br/&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued research and development expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18,457&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18,760&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued rebates&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,008&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,518&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued federal and state taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,966&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,966&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued professional service expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,943&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,758&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued payroll related expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,202&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,943&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued milestone payment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,065&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,680&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total accrued expenses and other current liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;43,641&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;68,625&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <dawn:AccruedLicenseAgreementUpfrontPayment
      contextRef="C_b103f351-0eb2-495b-85c1-5630e54c751c"
      decimals="-3"
      id="F_fb20fe33-f2bb-4ab0-ad42-289f5e77c644"
      unitRef="U_USD">18457000</dawn:AccruedLicenseAgreementUpfrontPayment>
    <dawn:AccruedLicenseAgreementUpfrontPayment
      contextRef="C_1b7733fe-22fe-416b-a33e-e8b388655156"
      decimals="-3"
      id="F_1e2de41d-0b0b-4edc-a3b8-4f7c8d00e8fc"
      unitRef="U_USD">18760000</dawn:AccruedLicenseAgreementUpfrontPayment>
    <dawn:AccruedRebates
      contextRef="C_b103f351-0eb2-495b-85c1-5630e54c751c"
      decimals="-3"
      id="F_2d98c760-afaa-454a-a45b-334c1e89214e"
      unitRef="U_USD">6008000</dawn:AccruedRebates>
    <dawn:AccruedRebates
      contextRef="C_1b7733fe-22fe-416b-a33e-e8b388655156"
      decimals="-3"
      id="F_d712f54f-eed3-4916-bc75-5572c0d1d6e2"
      unitRef="U_USD">4518000</dawn:AccruedRebates>
    <dawn:AccruedFederalAndStateTaxPayments
      contextRef="C_b103f351-0eb2-495b-85c1-5630e54c751c"
      decimals="-3"
      id="F_c7725163-7466-4638-a592-529df2c9782e"
      unitRef="U_USD">4966000</dawn:AccruedFederalAndStateTaxPayments>
    <dawn:AccruedFederalAndStateTaxPayments
      contextRef="C_1b7733fe-22fe-416b-a33e-e8b388655156"
      decimals="-3"
      id="F_ebfef2f5-e4c9-42d5-bc1f-4678c0003573"
      unitRef="U_USD">4966000</dawn:AccruedFederalAndStateTaxPayments>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_b103f351-0eb2-495b-85c1-5630e54c751c"
      decimals="-3"
      id="F_bcce9027-0c36-4b63-94d6-0c1f5726a65e"
      unitRef="U_USD">4943000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_1b7733fe-22fe-416b-a33e-e8b388655156"
      decimals="-3"
      id="F_965fbf13-e292-4953-9162-d6f8806a952e"
      unitRef="U_USD">3758000</us-gaap:AccruedProfessionalFeesCurrent>
    <dawn:AccruedPayrollRelatedExpenses
      contextRef="C_b103f351-0eb2-495b-85c1-5630e54c751c"
      decimals="-3"
      id="F_1fa1782f-2cf0-459b-93a4-c81c8c4ad212"
      unitRef="U_USD">4202000</dawn:AccruedPayrollRelatedExpenses>
    <dawn:AccruedPayrollRelatedExpenses
      contextRef="C_1b7733fe-22fe-416b-a33e-e8b388655156"
      decimals="-3"
      id="F_4070a4b9-2089-44b6-b4d5-67190974de85"
      unitRef="U_USD">13943000</dawn:AccruedPayrollRelatedExpenses>
    <dawn:AccruedMilestonePayment
      contextRef="C_b103f351-0eb2-495b-85c1-5630e54c751c"
      decimals="-3"
      id="F_8f08c72e-17f5-47ac-bfb3-e0b70743d2c7"
      unitRef="U_USD">2000000</dawn:AccruedMilestonePayment>
    <dawn:AccruedMilestonePayment
      contextRef="C_1b7733fe-22fe-416b-a33e-e8b388655156"
      decimals="-3"
      id="F_7cd7a541-d15c-4d87-9b16-e4362daa2f15"
      unitRef="U_USD">20000000</dawn:AccruedMilestonePayment>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_b103f351-0eb2-495b-85c1-5630e54c751c"
      decimals="-3"
      id="F_2dd6841d-dc06-4993-be17-01d440693d52"
      unitRef="U_USD">3065000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_1b7733fe-22fe-416b-a33e-e8b388655156"
      decimals="-3"
      id="F_bb6d480c-b1ed-4cfe-9f24-73ce70088230"
      unitRef="U_USD">2680000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="C_b103f351-0eb2-495b-85c1-5630e54c751c"
      decimals="-3"
      id="F_f601b69e-1b2c-4fd3-90f0-c73df0e3346b"
      unitRef="U_USD">43641000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="C_1b7733fe-22fe-416b-a33e-e8b388655156"
      decimals="-3"
      id="F_80bbb80e-acae-49f5-bba1-6fae46ff49e1"
      unitRef="U_USD">68625000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:IntangibleAssetsDisclosureTextBlock
      contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b"
      id="F_e2f0cf4d-f16b-419c-b9f3-43cd01d2a047">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;5. Intangible Assets&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Intangible assets, net consisted of the following:&lt;/span&gt;&lt;/p&gt;
       &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:68.84%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.26%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.32%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.26%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.32%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;March 31,&lt;br/&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Intangible assets with finite lives:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;License agreement milestone payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;PRV-related obligation payment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Intangible assets, gross&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22,600&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less accumulated amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,195&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,470&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Intangible assets, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20,405&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15,630&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company incurred amortization expense of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million for the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;three months ended March 31, 2025.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The estimated aggregate amortization expense for amortizable, finite-lived intangible assets as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;March 31, 2025 is as follows:&lt;/span&gt;&lt;/p&gt;
       &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:70.56%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:27.439999999999998%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ending December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Estimated&lt;br/&gt;Amortization&lt;br/&gt;Expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2025 (Remaining)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,385&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,180&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,180&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,180&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2029&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,180&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,300&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total future expected amortization expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20,405&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock
      contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b"
      id="F_9ec26968-af5e-4f07-a60f-efa7e4a5e8b3">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Intangible assets, net consisted of the following:&lt;/span&gt;&lt;/p&gt;
       &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:68.84%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.26%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.32%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.26%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.32%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;March 31,&lt;br/&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Intangible assets with finite lives:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;License agreement milestone payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;PRV-related obligation payment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Intangible assets, gross&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22,600&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less accumulated amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,195&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,470&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Intangible assets, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20,405&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15,630&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="C_23977cdf-3070-48c6-b19d-11d5afb96e9a"
      decimals="-3"
      id="F_0db8151d-adda-41eb-86e7-1a299c172d17"
      unitRef="U_USD">14500000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="C_5cceec90-fafe-4db7-b0a1-8211d20a03b7"
      decimals="-3"
      id="F_2b5cdb4b-0ff5-41e2-83e3-5cd6834533fa"
      unitRef="U_USD">9000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="C_80830bed-79cc-4012-a094-ef9b93307718"
      decimals="-3"
      id="F_d93e8cf3-3872-47ad-8487-ba3cfa90261e"
      unitRef="U_USD">8100000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="C_9c3764ad-c7bb-4bf4-a68b-e200db91be51"
      decimals="-3"
      id="F_689659d5-a15c-4067-be6f-2e244ce865c7"
      unitRef="U_USD">8100000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="C_b103f351-0eb2-495b-85c1-5630e54c751c"
      decimals="-3"
      id="F_d0080482-9dcc-45e7-8031-97d72f0201f6"
      unitRef="U_USD">22600000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="C_1b7733fe-22fe-416b-a33e-e8b388655156"
      decimals="-3"
      id="F_1ab4dbd1-9573-4643-a1ed-db72f51f1aca"
      unitRef="U_USD">17100000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="C_b103f351-0eb2-495b-85c1-5630e54c751c"
      decimals="-3"
      id="F_702c533f-55b2-4f3b-94bb-d4609980eae3"
      unitRef="U_USD">2195000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="C_1b7733fe-22fe-416b-a33e-e8b388655156"
      decimals="-3"
      id="F_4d537071-d543-4827-af1c-8b408fdf9799"
      unitRef="U_USD">1470000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="C_b103f351-0eb2-495b-85c1-5630e54c751c"
      decimals="-3"
      id="F_7f104227-6cc9-4960-ac3b-1451c009bf10"
      unitRef="U_USD">20405000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="C_1b7733fe-22fe-416b-a33e-e8b388655156"
      decimals="-3"
      id="F_13846300-1835-49b3-9c0d-36f04ce3cb82"
      unitRef="U_USD">15630000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b"
      decimals="-5"
      id="F_40423762-5e75-4766-8965-4cc4f8da66a3"
      unitRef="U_USD">700000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock
      contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b"
      id="F_c69429e9-a946-4adf-a32d-e3897e5a74f1">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The estimated aggregate amortization expense for amortizable, finite-lived intangible assets as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;March 31, 2025 is as follows:&lt;/span&gt;&lt;/p&gt;
       &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:70.56%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:27.439999999999998%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ending December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Estimated&lt;br/&gt;Amortization&lt;br/&gt;Expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2025 (Remaining)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,385&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,180&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,180&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,180&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2029&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,180&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,300&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total future expected amortization expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20,405&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="C_b103f351-0eb2-495b-85c1-5630e54c751c"
      decimals="-3"
      id="F_89279f8e-7f2c-4930-9aaf-42b7c3aa9d4f"
      unitRef="U_USD">2385000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="C_b103f351-0eb2-495b-85c1-5630e54c751c"
      decimals="-3"
      id="F_ce3534ff-5904-4e75-b149-4841cc5e5914"
      unitRef="U_USD">3180000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="C_b103f351-0eb2-495b-85c1-5630e54c751c"
      decimals="-3"
      id="F_807763b5-37ad-4e21-a4bd-90c8d3ed6914"
      unitRef="U_USD">3180000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="C_b103f351-0eb2-495b-85c1-5630e54c751c"
      decimals="-3"
      id="F_38dc264a-7683-4830-8ad1-3eed6fdd5882"
      unitRef="U_USD">3180000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
      contextRef="C_b103f351-0eb2-495b-85c1-5630e54c751c"
      decimals="-3"
      id="F_b0ff28db-af69-41e7-ad99-8bd6c10f9728"
      unitRef="U_USD">3180000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
      contextRef="C_b103f351-0eb2-495b-85c1-5630e54c751c"
      decimals="-3"
      id="F_40040eb0-4ebb-4e34-9761-a88299ed7bb2"
      unitRef="U_USD">5300000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="C_b103f351-0eb2-495b-85c1-5630e54c751c"
      decimals="-3"
      id="F_03465e73-f62d-4925-b7cd-020ebd631764"
      unitRef="U_USD">20405000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b"
      id="F_79d29752-12c2-4b8d-9e41-21c880df84b8">&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;6.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Significant Agreements&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Takeda asset purchase agreement&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On December 16, 2019, a subsidiary of the Company entered into an asset purchase agreement, or the Takeda Asset Agreement, with Millennium Pharmaceuticals, Inc., a related party and an affiliate of Takeda Pharmaceutical Company Limited, or Takeda. Effective December 31, 2021, the subsidiary was merged with and into the Company, with the Company being the surviving corporation and assuming the subsidiary&#x2019;s obligations under the Takeda Asset Agreement. Pursuant to the Takeda Asset Agreement, the Company purchased certain technology rights and know-how related to TAK-580 (which is now OJEMDA&#x99; (tovorafenib)) that provides a new approach for treating patients with primary brain tumors or brain metastases of solid tumors. The Company also received clinical inventory supplies to use in the Company's research and development activities of such RAF-inhibitor and an assigned investigator clinical trial agreement. Takeda also assigned to the Company its exclusive license agreement, or the Viracta License Agreement, with Viracta. Takeda also granted the Company a worldwide, sublicensable exclusive license under specified patents and know-how and non-exclusive license under other patents and know-how generated by Takeda under the Takeda Asset Agreement. The Company also granted Takeda a grant back license, as defined in the Takeda Asset Agreement, which is terminable either automatically or by the Company in the event Takeda does not achieve specified development milestones within the applicable timeframes set forth under the Takeda Asset Agreement.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;This grant back license to Takeda was terminated at the time of conversion of the Company from an LLC to a corporation in connection with the Millennium Stock Exchange Agreement.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The term of the Takeda Asset Agreement will expire on a country-by-country basis upon expiration of all assigned patent rights and all licensed patent rights in such country. Takeda can terminate the Takeda Asset Agreement in the event of the Company's bankruptcy. In the event of termination of the Takeda Asset Agreement by Takeda as a result of the Company's cessation of development or bankruptcy, all assigned patents, know-how and contracts (other than the Viracta License Agreement) will be assigned back to Takeda and Takeda will obtain a reversion license under patents and know-how generated to exploit all such terminated products.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In consideration for the sale and assignment of assets and the grant of the license under the Takeda Asset Agreement, the Company made an upfront payment of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in cash and issued &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,857,143&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of Series A redeemable convertible preferred stock in the Company&#x2019;s subsidiary in December 2019. The fair value of issued shares was estimated as $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, based on the price paid by other investors for issued shares in the Series A financing of the Company&#x2019;s subsidiary. Based on the terms of the Millennium Stock Exchange Agreement, Takeda exchanged the &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,857,143&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of Series A redeemable convertible preferred stock of the Company&#x2019;s subsidiary for &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,470,382&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of the Company's common stock upon the effectiveness of the conversion of the Company from an LLC to a corporation, on May 26, 2021.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;License agreement with Viracta&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On December 16, 2019, a subsidiary of the Company amended and restated the Viracta License Agreement that was assigned pursuant to the Takeda Asset Agreement. Effective December 31, 2021, the subsidiary was merged with and into the Company, with the Company being the surviving corporation and assuming the subsidiary&#x2019;s obligations under Viracta License Agreement. Under the Viracta License Agreement, the Company received a worldwide exclusive license under specified patent rights and know-how to develop, use, manufacture, and commercialize products containing compounds binding the RAF protein family.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The term of the Viracta License Agreement will expire on a licensed product-by-licensed product and country-by-country basis upon the expiration of the Company&#x2019;s obligation to pay royalties to Viracta with respect to such product in such country. The Company has the right to terminate the Viracta License Agreement with respect to any or all of the licensed products at will upon a specified notice period.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company paid $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million upfront in cash to Viracta in December 2019, which was recorded as research and development expenses as the technology does not have an alternative future use.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On March 4, 2024, the Company entered into an amendment to the Viracta License Agreement. As part of the amendment, the Company made a one-time payment in March 2024 to Viracta of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, which was recorded as research and development expenses during the year ended December 31, 2024, in exchange for reduced future payment obligations ranging from the mid-teens to the high single-digit percentage related to the future sale or use of the rare pediatric disease priority review voucher, or PRV, received.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On April 23, 2024, the FDA approved OJEMDA (a tablet formulation and powder solution formulation of tovorafenib) for the treatment of patients 6 months of age and older with relapsed or refractory pLGG harboring a BRAF fusion or rearrangement, or BRAF V600 mutation. The indication was approved under accelerated approval based on response rate and duration of response. With the approval, the Company received a rare pediatric disease PRV from the FDA. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company made a $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million milestone payment to Viracta in May 2024 for the achievement of this milestone. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million milestone was accounted for as a &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;finite-lived intangible asset and will be amortized over the life of the underlying asset. Related amortization expense will be recorded as cost of product revenue in the Company&#x2019;s statements of operations.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On May 29, 2024, the Company sold its rare pediatric disease PRV for $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;108.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million to an undisclosed buyer. As part of the transaction, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of the total consideration received from the sale of the rare pediatric disease PRV was paid to Viracta to fully satisfy PRV-related obligations under the Viracta License Agreement and was capitalized as a finite-lived intangible asset, which will be amortized on a straight-line basis over its estimated useful life. The gross proceeds of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;108.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million were recorded as a gain from sale of priority review voucher in the accompanying statements of operations during the year ended December 31, 2024. As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;March 31, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the unamortized finite-lived intangible asset was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million. Related amortization expense will be recorded as cost of product revenue in the Company&#x2019;s statements of operations.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On December 3, 2024, Viracta assigned the Viracta License Agreement to XOMA (US) LLC, or XOMA, pursuant to a Royalty Purchase Agreement dated March 22, 2021, between Viracta and XOMA, whereby Viracta sold its right, title, and interest in and to the Viracta License Agreement to XOMA. The Company has agreed to the assignment and novation of the Viracta License Agreement to XOMA as successor party, now referred to as the XOMA License Agreement. In connection with such assignment, the parties also agreed to assign all rights, title and interest in related intellectual property. No material terms of the XOMA License Agreement have been amended or modified in relation to the same.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On March 27, 2025, Ipsen Pharma SAS received validation of its completed submission of the Marketing Authorization Application to the European Medicines Agency, or EMA, for tovorafenib for the treatment of patients with relapsed or refractory pLGG. As a result, the Company paid $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million to XOMA for the achievement of this milestone in March 2025.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of March 31, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company could be required to make additional milestone payments of up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;36.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million upon achievement of specified development and regulatory milestones for each licensed product in two indications, with milestones payable for the second indication upon achievement of a specified milestone event being lower than milestones payable for the first indication. Commencing with the first commercial sale of OJEMDA in a country, the Company is obligated to pay tiered royalties ranging in the mid-single-digit percentages on net sales of licensed products. The obligation to pay royalties will end on a country-by-country and licensed product-by-licensed product basis commencing on the first commercial sale in a country and continuing until the later of: (i) the expiration of the last valid claim of the XOMA licensed patents, jointly owned collaboration patents or specified patents owned by the Company covering the use or sale of such product in such country, (ii) the expiration of the last statutory exclusivity pertaining to such product in such country or (iii) the tenth anniversary of the first commercial sale of such product in such country.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;License agreement with Merck KGaA, Darmstadt, Germany&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On February 10, 2021, a subsidiary of the Company entered into a license agreement, or the MRKDG License Agreement, with Merck KGaA, Darmstadt, Germany, a pharmaceutical corporation located in Darmstadt, Germany. Effective December 31, 2021, the subsidiary was merged with and into the Company, with the Company being the surviving corporation and assuming the subsidiary&#x2019;s obligations under the MRKDG License Agreement.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Under the MRKDG License Agreement, Merck KGaA, Darmstadt, Germany granted to the Company an exclusive worldwide license, with the right to grant sublicenses through multiple tiers, under specified patent rights and know-how for the Company to research, develop, manufacture and commercialize products containing and comprising the pimasertib and MSC2015103B compounds. The Company also received clinical inventory supplies to use in its research and development activities. The Company's exclusive license grant is subject to a non-exclusive license granted by Merck KGaA, Darmstadt, Germany&#x2019;s affiliate to a cancer research organization and Merck KGaA, Darmstadt, Germany retains the right to conduct, directly or indirectly, certain ongoing clinical studies relating to pimasertib. Under the MRKDG License Agreement, the Company has obligations to use commercially reasonable efforts to develop and commercialize at least two licensed products in at least two specified major market countries by the year 2029.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The term of the MRKDG License Agreement will expire on a licensed product-by-licensed product and country-by-country basis upon the expiration of the Company's obligation to pay royalties to the licensor with respect to such licensed product in such country and will expire in its entirety upon the expiration of all of the Company's payment obligations with respect to all licensed products and all countries under the MRKDG License Agreement.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In consideration for the rights granted under the MRKDG License Agreement and clinical supplies, the Company made an upfront payment of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in March 2021, which was recorded as research and development expenses, as the technology does not have an alternative future use and supplies are used for research activities. As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;March 31, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company could be required to make additional payments of up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;364.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million based upon the achievement of specified development, regulatory, and commercial milestones, as well a high, single-digit royalty percentage on future net sales of licensed products, if any. Milestones and royalties are contingent upon future events and will be recorded when the milestones are achieved and when payments are due.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In November 2023, the Company discontinued its monotherapy substudy due to a limited duration of response in this rare patient population despite observing responses with a generally well tolerated therapy. In July 2024, the Company decided to close the program as the Company determined that the benefit/risk profile, as well as the market opportunity, did not justify the significant investment required to continue the trial despite observing some clinical responses.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Research collaboration and license agreement with Sprint Bioscience AB&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On August 15, 2023, the Company entered into a research collaboration and license agreement, or the Sprint License Agreement, with Sprint Bioscience AB, or Sprint, a Swedish corporation located in Huddinge, Sweden. Under the Sprint License Agreement, Sprint granted to the Company an exclusive, worldwide license, with the right to grant sublicenses through multiple tiers, to research, develop, and commercialize pharmaceutical products and to engage in research aimed at discovery, optimization and development of an inhibitor targeting Vaccinia Related Kinase 1, or VRK1.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The term of the Sprint License Agreement will expire on a licensed product and country basis upon the expiration of the royalty term with respect to such licensed product and such country, unless terminated earlier. The Company has the right to terminate the Sprint License Agreement in its entirety, or on a licensed product-by-licensed product basis, at will upon a specified notice period.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company paid $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million upfront in cash to Sprint in September 2023, which was recorded as research and development expenses as the technology does not have an alternative future use. As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;March 31, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;the Company could be&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;required &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;to make milestone payments of up to &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;309.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million based upon achievement of specified development, regulatory, and commercial milestones for each licensed product, as well as tiered royalties ranging in the single-digit percentages on future net sales of licensed products, if any. Milestones and royalties are contingent upon future events and will be recorded when the milestones are achieved and when payments are due.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;License agreement with MabCare Therapeutics&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On June 17, 2024, the Company entered into a license agreement, or the MabCare License Agreement, with MabCare Therapeutics, or MabCare, a pharmaceutical corporation located in Shanghai, China. Under the MabCare License Agreement, MabCare granted to the Company an exclusive worldwide license, excluding Greater China, with the right to grant sublicenses through multiple tiers, under specified patent rights and know-how for the Company to develop, manufacture and commercialize DAY301 (formerly MTX-13), a novel Antibody Drug Conjugate, or ADC, targeting protein-tyrosine kinase 7, or PTK7. The Company will also receive clinical inventory supplies to use in its research and development activities. Under the MabCare License Agreement, the Company has obligations to use commercially reasonable efforts to develop, obtain regulatory approval for, and commercialize at least one licensed product in one indication in each of the United States, Japan, and three European countries.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The term of the MabCare License Agreement will expire in its entirety upon the expiration of the last to expire royalty term with respect to all licensed products in the Company's territory, unless terminated earlier. Following the expiration of the royalty term for a licensed product in a country, the license granted to the Company shall become non-exclusive, fully paid-up, royalty-free, perpetual, and irrevocable for such licensed product in such country. Upon the expiration of the term, the license granted to the Company shall become non-exclusive, transferable, sublicensable, fully paid, royalty free, perpetual, and irrevocable in its entirety.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In consideration for the rights granted under the MabCare License Agreement, the Company made a $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;55.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million upfront payment in July 2024. The upfront payment was recorded as research and development expenses, as the technology and supplies licensed do not have an alternative future use. As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;March 31, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company could be required to make additional payments of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,132.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million based upon the achievement of specified development, regulatory, and commercial success-based milestones plus low-to-mid single-digit royalties on net sales outside of Greater China. Milestones and royalties are contingent upon future events and will be recorded when the milestones are achieved and when payments are due. In January 2025, the Company cleared the first cohort (a single-patient accelerated titration cohort) in the Phase 1a portion of the DAY301 Phase 1a/b clinical trial. The Company made a $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million milestone payment to MabCare in January 2025 for the achievement of this milestone.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;License agreement with Ipsen Pharma SAS&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On July 23, 2024, the Company entered into the Ipsen License Agreement, pursuant to which, the Company licensed to Ipsen, on an exclusive basis, the right to commercialize tovorafenib in all territories outside the United States and agreed to provide certain research and development and manufacturing services. Ipsen shall have the right to grant sublicenses to third-parties.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Under the terms of the Ipsen License Agreement, (i) Ipsen paid the Company an upfront license fee in the amount of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;70.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in August 2024 and (ii) the Investor, a fully-owned United States affiliate of Ipsen, purchased &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,341,495&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;shares of the Company&#x2019;s common stock in a private placement for $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;40.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, at a price per share representing a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% premium to the VWAP of the Company&#x2019;s common stock as traded on The Nasdaq Stock Market LLC for the ten consecutive trading days prior to and including the date of the Revenue Release, and the ten consecutive trading days following the Revenue Release, in accordance with the terms set forth in an investment agreement by and between the Company and the Investor dated July 23, 2024.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of March 31, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company is also eligible to receive up to approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;350.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in additional commercial launch and sales-based milestone payments based on exchange rates as of the reporting date. The Company is also entitled to tiered, double-digit royalty payments starting at mid-teens percentage of annual net sales of tovorafenib, subject to customary adjustments specified in the Ipsen License Agreement. The royalty payment obligations under the Ipsen License Agreement expire on a country-by-country basis no earlier than ten years following the first commercial sale of tovorafenib in the applicable country.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In addition, the Ipsen License Agreement provides that the Company will supply to Ipsen, and Ipsen will purchase from the Company, all required quantities of tovorafenib for all territories outside the United States in accordance with a supply agreement to be entered into by and between the Company and Ipsen, or the Ipsen Supply Agreement. The Company determined that the cost-plus rate to be charged for the supply of tovorafenib does not represent a material right. Ipsen has the right to request a manufacturing technology transfer of the then-current manufacturing process of tovorafenib under the Ipsen License Agreement, and such consent shall not be unreasonably withheld, such that upon completion of the manufacturing technology transfer, Ipsen or a third-party would be solely responsible for the manufacture of tovorafenib for all territories outside the United States.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Following the two-year anniversary of July 23, 2024, the effective date of the Ipsen License Agreement, Ipsen may terminate the Ipsen License Agreement for convenience with six months&#x2019; prior written notice or for certain other specified reasons. The Company may terminate the Ipsen License Agreement if Ipsen or any of its affiliates challenge the validity of any patents controlled by the Company that are licensed under the Ipsen License Agreement. Both Ipsen and the Company may terminate the Ipsen License Agreement (i) for material breach by the other party and a failure to cure such breach within the time period specified in the Ipsen License Agreement or (ii) the other party&#x2019;s bankruptcy event.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company evaluated the Ipsen License Agreement under Accounting Standards Codification, or ASC, 606 and concluded that Ipsen represents a customer in the transaction. The Company identified two distinct performance obligations for licenses to intellectual property in the form of the exclusive license to &lt;/span&gt;&lt;span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;commercialize tovorafenib outside the United States for both (i) relapsed or &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;refractory and (ii) front-line pLGG;&lt;/span&gt;&lt;span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;and three distinct research and development performance obligations related to tovorafenib for completion of (i) the pivotal Phase 2 relapsed or refractory pLGG trial, or FIREFLY-1, (ii) the pivotal Phase 3 front-line pLGG trial, or FIREFLY-2, and (iii) the European Union, or EU, companion diagnostic for pLGG. Both the FIREFLY-1 and FIREFLY-2 trials related to pLGG pertain to later-stage intellectual property and only involve validating the efficacy of tovorafenib with respect to each distinct designation and are not expected to significantly modify or customize the licensed intellectual property. The FIREFLY-1 and FIREFLY-2 trials, and EU companion diagnostic research and development services related to pLGG could be performed by a third-party. The Company determined that the promise of the manufacturing technology transfer is a customer option that does not represent a material right given the value of the services is not material and fulfillment of this promise is ancillary to the main transaction. Accordingly, the manufacturing technology transfer is not a performance obligation at the outset of the arrangement.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Upon execution of the Ipsen License Agreement, the transaction price was determined to be $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;78.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, representing the aggregate of the upfront license fee of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;70.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and the premium paid by Ipsen on its equity investment in the Company of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;(the excess of the value of the shares of the Company issued to Ipsen), representing additional consideration from Ipsen for the rights under the Ipsen License Agreement. Commercial launch milestones related to first commercial sale(s) in certain territories, sales-based milestones and royalties on net sales upon commercialization by Ipsen were excluded from the transaction price and will be recognized when the related sales occur as they were determined to predominantly relate to the intellectual property and, therefore, have been excluded from the transaction price in accordance with the sales-based royalty exception.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company allocated the transaction price to the performance obligations based on their relative standalone selling price. The Company developed the estimated stand-alone selling price for each license using discounted cash flow models. In developing this estimate, the Company applied judgment in the determination of the assumptions relating to forecasted future revenues, the discount rate, and the probability of success. The stand-alone selling price for each of the research and development services was estimated based on the Company&#x2019;s forecasted costs to be incurred to fulfill the obligations plus a reasonable margin. The portion of the transaction price allocable to the&lt;/span&gt;&lt;span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; relapsed or &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;refractory and front-line pLGG&lt;/span&gt;&lt;span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;licenses to intellectual property was recognized as license revenue at the point in time in which Ipsen had the right to use the license/know-how, which occurred during the year ended December 31, 2024. The portion of the transaction price allocable to the &lt;/span&gt;&lt;span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;relapsed or &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;refractory, front-line and companion diagnostic research and development services performance obligations will be recognized over time as the services are delivered based on costs incurred relative to the total estimated cost to deliver the services. During the three months ended March 31, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of license revenue was recognized with $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of the undelivered services included in current and non-current deferred revenue, respectively.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <dawn:UpfrontOfCashPayment
      contextRef="C_e9b4d1c1-00d7-4c4a-8ead-1b510859ed98"
      decimals="-5"
      id="F_0a7da810-9f23-4814-8318-3f4beb38cfd9"
      unitRef="U_USD">1000000</dawn:UpfrontOfCashPayment>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_b18881d4-5741-464f-8b09-c6e20048b1ff"
      decimals="0"
      id="F_bd5a1bc6-b37a-4fb8-8c56-5a1ca5ebf106"
      unitRef="U_shares">9857143</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_b18881d4-5741-464f-8b09-c6e20048b1ff"
      decimals="-5"
      id="F_111196fd-05d8-40bd-8733-e3d852307667"
      unitRef="U_USD">9900000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="C_d33c859c-b7aa-4b79-9a88-d16340c5fe28"
      decimals="0"
      id="F_a36fb902-95dd-4cee-ba9e-11c128f145fa"
      unitRef="U_shares">9857143</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="C_cc903eab-f003-453f-ad1c-4dd61852d801"
      decimals="0"
      id="F_0518ac3f-868c-4375-b875-904309f404c3"
      unitRef="U_shares">6470382</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <dawn:UpfrontOfCashPayment
      contextRef="C_3c61836b-73ea-4fb6-bc25-ae73f9f94d9d"
      decimals="-5"
      id="F_0d8d51a4-0c5e-4258-acfa-db4fa4e3b2a7"
      unitRef="U_USD">2000000</dawn:UpfrontOfCashPayment>
    <dawn:UpfrontPayment
      contextRef="C_ca787bd4-a367-40e2-8820-37c26a26c233"
      decimals="-5"
      id="F_c08d998e-3979-47bd-9d84-52db10bb19bc"
      unitRef="U_USD">5000000</dawn:UpfrontPayment>
    <dawn:PaymentOfMilestones
      contextRef="C_6ad97ba9-d866-451d-a09a-4e4e40d00691"
      decimals="-5"
      id="F_e6c3b2e3-ae19-419e-ba03-51f5d23fe7e7"
      unitRef="U_USD">9000000</dawn:PaymentOfMilestones>
    <dawn:PaymentOfMilestones
      contextRef="C_966510c1-eaf6-4a1c-9fae-2da70fcc6537"
      decimals="-5"
      id="F_52c76b70-49f2-4f37-b743-74aa909de48c"
      unitRef="U_USD">9000000</dawn:PaymentOfMilestones>
    <us-gaap:ProceedsFromSaleOfProductiveAssets
      contextRef="C_74bf62ce-416a-4686-8cdc-9e58e09531b6"
      decimals="-5"
      id="F_24db83aa-cb53-46b9-ad4a-77d1b690a651"
      unitRef="U_USD">108000000</us-gaap:ProceedsFromSaleOfProductiveAssets>
    <dawn:PaymentToObligationOfLicenseAgreement
      contextRef="C_74bf62ce-416a-4686-8cdc-9e58e09531b6"
      decimals="-5"
      id="F_ba46d8ba-f8a3-4c9f-87e8-3dd3fd764d24"
      unitRef="U_USD">8100000</dawn:PaymentToObligationOfLicenseAgreement>
    <us-gaap:ProceedsFromSaleOfProductiveAssets
      contextRef="C_1012909a-67d0-4f8d-9538-ec497e5c24af"
      decimals="-5"
      id="F_503e67f9-84b3-41b8-8dfd-6e3c7b6ed6b2"
      unitRef="U_USD">108000000</us-gaap:ProceedsFromSaleOfProductiveAssets>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="C_491e1be7-189f-4d71-b2f9-eac0bf60040c"
      decimals="-5"
      id="F_c1ae3286-648d-4f7b-9cb1-e9c38564e31f"
      unitRef="U_USD">7200000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <dawn:PaymentOfMilestones
      contextRef="C_ca7ef576-0ffb-4b1b-9387-f848fc7d1ea5"
      decimals="-5"
      id="F_62392313-0cc2-434d-a91f-e76f33605fad"
      unitRef="U_USD">4000000</dawn:PaymentOfMilestones>
    <dawn:PaymentOfMilestones
      contextRef="C_3c61836b-73ea-4fb6-bc25-ae73f9f94d9d"
      decimals="-5"
      id="F_87626e68-36a9-4d55-9444-a166c0dbb91d"
      unitRef="U_USD">36000000</dawn:PaymentOfMilestones>
    <dawn:UpfrontPayment
      contextRef="C_3488a8c4-e12f-41ec-89c7-dac4e84ea67e"
      decimals="-5"
      id="F_430e9dac-23a4-4ccc-86dd-533af793f825"
      unitRef="U_USD">8000000</dawn:UpfrontPayment>
    <dawn:MilestonePaymentsNotYetPaid
      contextRef="C_3488a8c4-e12f-41ec-89c7-dac4e84ea67e"
      decimals="-5"
      id="F_08b600b5-4a53-41df-929a-4bb6cd9caf6b"
      unitRef="U_USD">364500000</dawn:MilestonePaymentsNotYetPaid>
    <dawn:UpfrontPayment
      contextRef="C_ef89ab97-3fce-42e2-a82b-c2a5c9189a28"
      decimals="-5"
      id="F_40752c42-9d6e-4d17-a9d9-117664fbdb80"
      unitRef="U_USD">3000000</dawn:UpfrontPayment>
    <dawn:MilestonePaymentsNotYetPaid
      contextRef="C_429b0413-0de5-4e2b-b3ca-8e5807492a3e"
      decimals="-5"
      id="F_c5e26be0-f1cb-457c-a2c3-ebba6942e8f9"
      unitRef="U_USD">309000000</dawn:MilestonePaymentsNotYetPaid>
    <dawn:UpfrontPayment
      contextRef="C_3b446226-328f-479e-b281-6a7fd0379692"
      decimals="-5"
      id="F_a2023928-0802-4585-9be8-d7511700a427"
      unitRef="U_USD">55000000</dawn:UpfrontPayment>
    <dawn:MilestonePaymentsNotYetPaid
      contextRef="C_88ef0d56-c34a-4726-8307-009388d0ca1d"
      decimals="-5"
      id="F_bf9354ea-a37d-4d65-bc3b-307939d46621"
      unitRef="U_USD">1132000000</dawn:MilestonePaymentsNotYetPaid>
    <dawn:PaymentOfMilestones
      contextRef="C_88ef0d56-c34a-4726-8307-009388d0ca1d"
      decimals="-5"
      id="F_5b5fcb4a-97f2-410b-8d9d-81ca2349c756"
      unitRef="U_USD">20000000</dawn:PaymentOfMilestones>
    <dawn:UpfrontPayment
      contextRef="C_6c0cbe2c-a995-47f4-a87e-6d13cd05d122"
      decimals="-5"
      id="F_f524b1b6-c1da-4d21-b37d-4c2655eeae62"
      unitRef="U_USD">70800000</dawn:UpfrontPayment>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_4a5ebb63-8e69-4e8d-bc72-3ec0c91774e6"
      decimals="0"
      id="F_00da296b-8a26-4cf8-a47c-162bd4222ece"
      unitRef="U_shares">2341495</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="C_1bd10525-22f6-4072-ab95-5fd14d1f9842"
      decimals="-5"
      id="F_3b1282c4-588f-4974-9cc1-bb9c573f3e87"
      unitRef="U_USD">40000000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <dawn:VolumeWeightedAveragePrice
      contextRef="C_4a5ebb63-8e69-4e8d-bc72-3ec0c91774e6"
      decimals="3"
      id="F_7d77c138-d6ee-4522-b06c-e20f1795557a"
      unitRef="U_pure">0.17</dawn:VolumeWeightedAveragePrice>
    <dawn:MilestonePaymentsNotYetReceived
      contextRef="C_cd3e5fd3-74ef-469d-8938-ed22cb45f3fd"
      decimals="-5"
      id="F_f43a628d-6cfd-4b8b-b150-ecce32278bbd"
      unitRef="U_USD">350000000</dawn:MilestonePaymentsNotYetReceived>
    <dawn:TransactionPrice
      contextRef="C_1bd10525-22f6-4072-ab95-5fd14d1f9842"
      decimals="-5"
      id="F_481055df-085a-449f-aa84-6903eff89a86"
      unitRef="U_USD">78200000</dawn:TransactionPrice>
    <dawn:UpfrontPayment
      contextRef="C_6c0cbe2c-a995-47f4-a87e-6d13cd05d122"
      decimals="-5"
      id="F_b1d6690e-72b2-4c9d-894d-48bcc2313228"
      unitRef="U_USD">70800000</dawn:UpfrontPayment>
    <us-gaap:EquityMethodInvestmentUnderlyingEquityInNetAssets
      contextRef="C_5c990fe2-3f39-456d-8159-af4c23323a1d"
      decimals="-5"
      id="F_df8e1e1d-1038-4cc6-9ef9-c7528172b778"
      unitRef="U_USD">7400000</us-gaap:EquityMethodInvestmentUnderlyingEquityInNetAssets>
    <dawn:LicenseRevenue
      contextRef="C_cd3e5fd3-74ef-469d-8938-ed22cb45f3fd"
      decimals="-5"
      id="F_11261d9b-8025-4883-8ea7-e374eef3e624"
      unitRef="U_USD">300000</dawn:LicenseRevenue>
    <us-gaap:DeferredRevenueCurrent
      contextRef="C_6efcf18f-0833-44b1-8d9a-6ebe85307a08"
      decimals="-5"
      id="F_e44ea41a-981b-4ddd-b24a-7ef274831d26"
      unitRef="U_USD">1600000</us-gaap:DeferredRevenueCurrent>
    <us-gaap:DeferredRevenueNoncurrent
      contextRef="C_a356b3ae-e91c-4aa9-82fb-80206cb22503"
      decimals="-5"
      id="F_ef7331c2-d9c9-40c0-b5e2-83ae2af3f4c5"
      unitRef="U_USD">3400000</us-gaap:DeferredRevenueNoncurrent>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b"
      id="F_7567309d-adc0-4135-9719-4b604c1cb212">&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;7.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Commitments and Contingencies &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In April 2022, the Company entered into a lease agreement for approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; square feet of general use office space in Brisbane, California. The agreement was determined to be a lease since the right to control the use of the identified asset was conveyed to the Company for a period of time in exchange for consideration. The lease commenced in May 2022 and expired in November 2024. The Company was obligated to pay monthly rent expense and its pro rata share of the landlord's operating expenses which include utilities, common area maintenance expenses, and property taxes. Such expenses were a non-lease component and a variable consideration and included in the Company's operating expenses as incurred. The Company concluded that this lease was an operating lease.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In June 2024, the Company entered into a lease agreement for approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; square feet of general use office space in Brisbane, California. The agreement was determined to be a lease since the right to control the use of the identified asset was conveyed to the Company for a period of time in exchange for consideration. The term of the lease is approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;7.4&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; years and commenced in August 2024. There is no option to extend the lease term nor is there an option to terminate the lease term prior to its expiration. The Company is obligated to pay monthly rent expense and its pro rata share of the landlord's operating expenses which include utilities, common area maintenance expenses, and property taxes. Such expenses are a non-lease component and a variable consideration and included in the Company's operating expenses as incurred. The Company concluded that this lease is an operating lease. The total payments for base rent over the term of the lease is approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million. Upon execution of the agreement, the Company paid a security deposit of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;86,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; classified as deposits and other long-term assets on the condensed balance sheet.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company determined the lease incremental borrowing rate, or IBR, based on the information available at the applicable lease commencement date as the Company&#x2019;s leases do not provide an implicit rate. The IBR is determined by using the rate of interest that the Company would pay to borrow on a collateralized basis an amount equal to the lease payments for a similar term and in a similar economic environment where the asset is located. As of March 31, 2025, the weighted-average remaining lease term and weighted-average discount rate were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;6.5&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; years and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company&#x2019;s leases do not require any contingent rental payments, impose financial restrictions, or contain any residual value guarantees.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Lease expense of right-of-use assets is recognized on a straight-line basis over the applicable lease term. Lease expense was &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; for the three months ended March 31, 2025 and 2024. There was no cash paid for amounts included in the measurement of operating lease liabilities for the three months ended March 31, 2025. Cash paid for amounts included in the measurement of operating lease liabilities was &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; for the three months ended March 31, 2024. Variable payments expensed during the three months ended March 31, 2025 and 2024 were immaterial.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;March 31, 2025, the future lease obligations were as follows (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
       &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:81.82%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:16.18%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ending December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2025 (Remaining)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;404&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;527&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;543&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;492&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2029&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;711&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,981&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total future minimum lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,658&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less: imputed interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,742&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Present value of operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,916&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less: current portion of operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;62&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Long-term portion of operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,854&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Research and Development Agreements&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company enters into contracts in the normal course of business with clinical research organizations, contract manufacturing organizations, and other third-party vendors for clinical trial, manufacturing, testing, and other research and development activities. These contracts generally provide for termination on notice, with the exception of one vendor where certain costs are non-cancellable after the approval of the project. As of March 31, 2025 and December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, there were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; amounts accrued related to termination and cancellation charges as these are not probable.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;License Agreements&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company entered into license agreements, as disclosed in Note 6, with various parties under which it is obligated to make contingent and non-contingent payments.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Purchase Commitments&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;To support product needs for OJEMDA, the Company entered into a manufacturing and supply agreement with Quotient Sciences - Philadelphia, LLC in July 2023 that requires the Company to meet minimum purchase obligations on an annual basis. The remaining amount of future minimum purchase obligations under the manufacturing and supply agreement over the next five years is approximately &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, in aggregate, as of March 31, 2025. For the three months ended March 31, 2025 and 2024, the Company made purchases of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, respectively, under the purchase obligation.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Legal Proceedings&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company, from time to time, may be party to litigation, claims and assessments arising in the ordinary course of business. The Company accrues liabilities for such matters when it is probable that future expenditures will be made and such&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;expenditures can be reasonably estimated. The Company is not subject to any material legal proceedings, and to the best of its knowledge, no material legal proceedings are currently pending or threatened.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Indemnification Agreements&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and provide for indemnification for certain liabilities. The exposure under these agreements is unknown because it involves claims that may be made against it in the future but have not yet been made. To date, the Company has not paid any claims or been required to defend any action related to its indemnification obligations. However, the Company may record charges in the future as a result of these indemnification obligations. The Company also has indemnification obligations to its directors and executive officers for specified events or occurrences, subject to some limits, while they are serving at its request in such capacities. There have been no claims to date, and the Company believes the fair value of these indemnification agreements is minimal. Accordingly, the Company had &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;t recorded any liabilities for these agreements as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;March 31, 2025 and December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:AreaOfLand
      contextRef="C_ab5b8469-0456-4d89-a289-b75cc0f4a77c"
      decimals="0"
      id="F_0671d7f7-0891-4b7c-8aec-19870e8aa1f6"
      unitRef="U_sqft">12000</us-gaap:AreaOfLand>
    <us-gaap:AreaOfLand
      contextRef="C_92096138-dcf7-4329-ae91-d02c48ac8ed0"
      decimals="0"
      id="F_41903056-cc9b-4879-8453-3bba2a503167"
      unitRef="U_sqft">19000</us-gaap:AreaOfLand>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="C_2f4d68d5-969e-46de-b564-f0c6755d1515"
      id="F_a91a534f-e6ac-48ea-937c-7127eefc4ad0">P7Y4M24D</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:OperatingLeasePayments
      contextRef="C_8186e570-f43c-44d8-af7f-4d4d7125520a"
      decimals="-5"
      id="F_d39a7e7b-4cc8-4867-a19b-1ef1e20bdfe8"
      unitRef="U_USD">4400000</us-gaap:OperatingLeasePayments>
    <us-gaap:SecurityDeposit
      contextRef="C_92096138-dcf7-4329-ae91-d02c48ac8ed0"
      decimals="0"
      id="F_35b90c71-26ef-4cc6-b5ea-bf15c3d2d68a"
      unitRef="U_USD">86000</us-gaap:SecurityDeposit>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="C_b103f351-0eb2-495b-85c1-5630e54c751c"
      id="F_0249cd5b-c46e-465a-8450-a07352885b21">P6Y6M</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_b103f351-0eb2-495b-85c1-5630e54c751c"
      decimals="3"
      id="F_f107ca95-0a53-4cb7-99fd-d734ad87f589"
      unitRef="U_pure">0.129</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="C_fd1aa0b8-3528-4b28-9293-cf863f031981"
      decimals="-5"
      id="F_6462f02c-4851-4211-9357-5503fdf7a805"
      unitRef="U_USD">100000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="C_6aaeb9ec-3a51-423c-ad71-3fa489ff189c"
      decimals="-5"
      id="F_27b4e436-a277-46d4-9326-e6087c2547f6"
      unitRef="U_USD">100000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeasePayments
      contextRef="C_6aaeb9ec-3a51-423c-ad71-3fa489ff189c"
      decimals="-5"
      id="F_cdcf7b2b-9408-4ebb-8e57-dac721b49846"
      unitRef="U_USD">100000</us-gaap:OperatingLeasePayments>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b"
      id="F_f8c7f8a8-02e4-4fed-9842-699f43034870">&lt;p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;March 31, 2025, the future lease obligations were as follows (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
       &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:81.82%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:16.18%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ending December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2025 (Remaining)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;404&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;527&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;543&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;492&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2029&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;711&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,981&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total future minimum lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,658&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less: imputed interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,742&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Present value of operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,916&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less: current portion of operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;62&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Long-term portion of operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,854&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="C_b103f351-0eb2-495b-85c1-5630e54c751c"
      decimals="-3"
      id="F_b1d44225-c7ee-49ab-aeed-a1e2d1c37c94"
      unitRef="U_USD">404000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="C_b103f351-0eb2-495b-85c1-5630e54c751c"
      decimals="-3"
      id="F_dd90d6ce-e292-40d6-a811-c6c0b31769af"
      unitRef="U_USD">527000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="C_b103f351-0eb2-495b-85c1-5630e54c751c"
      decimals="-3"
      id="F_c5de17f6-3a57-4931-9d73-c18bdec2b486"
      unitRef="U_USD">543000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="C_b103f351-0eb2-495b-85c1-5630e54c751c"
      decimals="-3"
      id="F_15efd895-6b1d-4b37-b1af-619a0d250569"
      unitRef="U_USD">492000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="C_b103f351-0eb2-495b-85c1-5630e54c751c"
      decimals="-3"
      id="F_3107678d-4b88-4e86-a4de-5a1debf13060"
      unitRef="U_USD">711000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <dawn:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
      contextRef="C_b103f351-0eb2-495b-85c1-5630e54c751c"
      decimals="-3"
      id="F_62a577ab-cfd0-4f2a-a4cb-c642bdd18445"
      unitRef="U_USD">1981000</dawn:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="C_b103f351-0eb2-495b-85c1-5630e54c751c"
      decimals="-3"
      id="F_5b1c7cbb-3db4-4444-99f2-bbaf584ab47c"
      unitRef="U_USD">4658000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="C_b103f351-0eb2-495b-85c1-5630e54c751c"
      decimals="-3"
      id="F_8e4a4539-128e-48b5-9cf6-f5df8c1eb0b0"
      unitRef="U_USD">1742000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_b103f351-0eb2-495b-85c1-5630e54c751c"
      decimals="-3"
      id="F_64ac51b0-01fb-4353-a797-fbad50733f37"
      unitRef="U_USD">2916000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_b103f351-0eb2-495b-85c1-5630e54c751c"
      decimals="-3"
      id="F_9bcdcc05-1995-4e2d-b876-3abe4eab6912"
      unitRef="U_USD">62000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_b103f351-0eb2-495b-85c1-5630e54c751c"
      decimals="-3"
      id="F_8f73b4c1-20a3-4290-ba29-3a67e159c3b6"
      unitRef="U_USD">2854000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="C_09d1a768-c6f7-4724-958d-e37516f230d8"
      decimals="-3"
      id="F_8abe0082-ae9b-4829-a58b-e1e35b6abe27"
      unitRef="U_USD">0</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="C_ebb60e12-8f30-4b8b-a830-3f64f4c2ba34"
      decimals="-3"
      id="F_1751673a-f8a3-405e-bb88-fffc4fbc8f02"
      unitRef="U_USD">0</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted
      contextRef="C_190b79d3-0ec2-457e-b743-7f9aaa10d94b"
      decimals="-5"
      id="F_ef4d9a6d-017b-4a6b-8fad-167c853564fe"
      unitRef="U_USD">12600000</us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted>
    <dawn:PurchasesUnderThePurchaseObligation
      contextRef="C_5d08cb7b-c76a-4de6-8dca-2d248eef4467"
      decimals="-5"
      id="F_62d88a31-6d8f-40b4-8ffa-b9d6f05f1ea6"
      unitRef="U_USD">1500000</dawn:PurchasesUnderThePurchaseObligation>
    <dawn:PurchasesUnderThePurchaseObligation
      contextRef="C_c5ebd5f2-8017-4e7b-b087-5114b6fdabe3"
      decimals="-5"
      id="F_594d0f22-aa68-4f7f-8191-c2e8131f45f9"
      unitRef="U_USD">500000</dawn:PurchasesUnderThePurchaseObligation>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="C_2e6bdcde-a879-4a55-aaf6-c92b45ed690a"
      decimals="-3"
      id="F_c6bf0bc0-9b0c-4305-9917-2a45b5cc4761"
      unitRef="U_USD">0</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="C_14897498-6682-45a8-b5bc-6360e09cde1d"
      decimals="-3"
      id="F_e1329753-44dd-42e1-b08d-dba2adee4645"
      unitRef="U_USD">0</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b"
      id="F_f4375883-f708-4c9a-b463-7fd6df3b82f4">&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;8.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Common Stock &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Pursuant to its certificate of incorporation, the Company is authorized to issue &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;500.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million shares of common stock at a par value of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.0001&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share. As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;March 31, 2025, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;101,353,781&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of common stock were issued and outstanding.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company has reserved shares of common stock for future issuances as follows:&lt;/span&gt;&lt;/p&gt;
       &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:69.66%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:2.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:25.72%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;March 31,&lt;br/&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Common stock options issued and outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,055,674&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Common stock available for future grants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,393,445&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Common stock available for ESPP&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,448,112&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Restricted stock units issued and outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,856,820&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Pre-funded warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,517,241&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27,271,292&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;2024 Private Placement&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In July 2024, the Company entered into a securities purchase agreement with certain institutional and accredited investors, or the PIPE Investors, pursuant to which the Company agreed to sell and issue to the PIPE Investors in a private placement, or the Private Placement, an &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;aggregate of (i) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,551,718&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of the Company&#x2019;s common stock, par value $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.0001&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share, at a purchase price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14.50&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share and (ii) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,517,241&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; pre-funded warrants, or the Pre-Funded Warrants, to purchase up to an aggregate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,517,241&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of the Company's common stock&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, or the Warrant Shares,&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; at a purchase price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14.4999&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per Pre-Funded Warrant. Each Pre-Funded Warrant has an exercise price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.0001&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per Warrant Share.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Pre-Funded Warrants are exercisable at any time after their original issuance at the option of each holder, in such holder&#x2019;s discretion, by (i) payment in full in immediately available funds for the number of shares of common stock purchased upon such exercise or (ii) a cashless exercise, in which case the holder would receive upon such exercise the net number of shares of common stock determined according to the formula set forth in the Pre-Funded Warrant. A holder will not be entitled to exercise any portion of any Pre-Funded Warrant if the holder&#x2019;s ownership of the Company&#x2019;s common stock would exceed &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9.99&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% following such exercise.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In the event of certain fundamental transactions, the holders of the Pre-Funded Warrants will be entitled to receive upon exercise of the Pre-Funded Warrants the kind of amounts of securities, cash or other property that the holders would have received had they exercised the Pre-Funded Warrants immediately prior to such fundamental transaction without regard to any limitations on exercise contained in the Pre-Funded Warrants.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Pre-Funded Warrants were classified as a component of permanent stockholders&#x2019; equity within additional paid-in capital and were recorded at the issuance date using a relative fair value allocation method. The Pre-Funded Warrants are equity classified because they (i) are freestanding financial instruments that are legally detachable and separately exercisable from the equity instruments, (ii) are immediately exercisable, (iii) do not embody an obligation for the Company to repurchase its shares, (iv) permit the holders to receive a fixed number of shares of common stock upon exercise, (v) are indexed to the Company&#x2019;s common stock and (vi) meet the equity classification criteria. In addition, such Pre-Funded Warrants do not provide any guarantee of value or return. The Company valued the Pre-Funded Warrants at issuance, concluding that their sales price approximated their fair value, and allocated net proceeds from the Private Placement proportionately to the Company's common stock and Pre-Funded Warrants.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Private Placement closed on August 1, 2024 and the Company received net proceeds of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;166.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, after deducting placement agent fees, offering costs, and other expenses, of which $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;145.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million was allocated to the common stock and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million was allocated to the Pre-Funded Warrants. The net proceeds were recorded as a component of additional paid-in capital.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Investment agreement with Ipsen Biopharmaceuticals, Inc.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In July 2024, the Company entered into the Ipsen License Agreement, pursuant to which, the Company licensed to Ipsen, on an exclusive basis, the right to commercialize tovorafenib in all territories outside the United States and agreed to provide certain research and development and manufacturing services. Under the terms of the Ipsen License Agreement, (i)&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Ipsen paid the Company an upfront license fee in the amount of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;70.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in August 2024 and (ii) the Investor, a fully-owned United States affiliate of Ipsen, purchased &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,341,495&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of the Company&#x2019;s common stock in a private placement for $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;40.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, at a price per share representing a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% premium to the VWAP of the Company&#x2019;s common stock as traded on The Nasdaq Stock Market LLC for the ten consecutive trading days prior to and including the date of the Revenue Release, and the ten consecutive trading days following the Revenue Release, in accordance with the terms set forth in an investment agreement by and between the Company and the Investor dated July 23, 2024. The Company valued the shares at issuance at $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;32.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, concluding that the Company's common stock price as traded on The Nasdaq Stock Market LLC on the closing date of the transaction approximated fair value, which was recorded as a component of additional paid-in capital.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;At-The-Market Offering&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company has entered into an equity distribution agreement, or the Equity Distribution Agreement, with Piper Sandler &amp;amp; Co. and JonesTrading Institutional Services LLC, as sales agents, relating to the issuance and sale of shares of the Company&#x2019;s common stock for an aggregate offering price of up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;250.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million under an at-the-market offering program, or the ATM. The Company has no obligation to sell any shares and could at any time suspend solicitations and offers under the ATM. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;No&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of the Company&#x2019;s common stock have been sold under the ATM as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;March 31, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_2896a425-ea56-4272-8792-62ad898655c5"
      decimals="-5"
      id="F_23f10c48-6f13-472c-9755-31a17eb0715b"
      unitRef="U_shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_2896a425-ea56-4272-8792-62ad898655c5"
      decimals="INF"
      id="F_d3ef6aa7-2ef0-4d2e-b71f-99d43c9270ea"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_b103f351-0eb2-495b-85c1-5630e54c751c"
      decimals="0"
      id="F_26f00029-172d-4a28-b302-441612aa7370"
      unitRef="U_shares">101353781</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_b103f351-0eb2-495b-85c1-5630e54c751c"
      decimals="0"
      id="F_988188e4-a5ed-4842-b19f-3eed0542334e"
      unitRef="U_shares">101353781</us-gaap:CommonStockSharesOutstanding>
    <dawn:ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock
      contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b"
      id="F_df498bab-49a3-42f3-aa32-73387aea7fcd">&lt;p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company has reserved shares of common stock for future issuances as follows:&lt;/span&gt;&lt;/p&gt;
       &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:69.66%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:2.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:25.72%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;March 31,&lt;br/&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Common stock options issued and outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,055,674&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Common stock available for future grants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,393,445&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Common stock available for ESPP&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,448,112&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Restricted stock units issued and outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,856,820&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Pre-funded warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,517,241&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27,271,292&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</dawn:ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_145e429b-05a9-4c43-8d23-41fa26213179"
      decimals="0"
      id="F_306c7289-8074-45bb-b699-da34bac29beb"
      unitRef="U_shares">14055674</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_0ddc2569-0696-4885-b32d-8451ee567481"
      decimals="0"
      id="F_2d741296-38e1-44ca-bee8-85835f663e12"
      unitRef="U_shares">5393445</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_2d38634e-b453-46b0-9ce4-c47fae6625de"
      decimals="0"
      id="F_1f81d0b0-c4a2-4c03-82bb-b3058c8a0520"
      unitRef="U_shares">3448112</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_f1827e81-e977-406d-8a9b-6f880a33cdfe"
      decimals="0"
      id="F_656dd46c-f53f-46ca-a7ae-f50329a1e402"
      unitRef="U_shares">2856820</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_494cf197-0008-4f30-9715-0a6b5cf186d6"
      decimals="0"
      id="F_0f2be637-fc7a-492d-a474-4e7ae298c542"
      unitRef="U_shares">1517241</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_b103f351-0eb2-495b-85c1-5630e54c751c"
      decimals="0"
      id="F_ef098990-0822-4174-adb7-4aa4dc65e1a3"
      unitRef="U_shares">27271292</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_63138494-78aa-453f-87e2-d7692e2526f2"
      decimals="INF"
      id="F_47489efe-6523-480b-bf83-201f3fb6853a"
      unitRef="U_shares">10551718</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_f17c501c-d230-47ae-bbff-603a48bd4de4"
      decimals="4"
      id="F_6ba03abc-79d1-44cd-b4a6-25fee8a43f8d"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:SharePrice
      contextRef="C_f17c501c-d230-47ae-bbff-603a48bd4de4"
      decimals="2"
      id="F_763358c5-8e4d-4478-81b0-1b63d0142521"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">14.5</us-gaap:SharePrice>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_60b4b3d3-4a6b-45de-b852-487c0414710f"
      decimals="0"
      id="F_aa7c39a5-0497-49a2-8de3-7cb1017443bb"
      unitRef="U_shares">1517241</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_f17c501c-d230-47ae-bbff-603a48bd4de4"
      decimals="0"
      id="F_e6603764-18ad-49d8-82c5-0f57cc909e7e"
      unitRef="U_shares">1517241</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:SharePrice
      contextRef="C_60b4b3d3-4a6b-45de-b852-487c0414710f"
      decimals="4"
      id="F_5cf35e4b-72a6-4b26-9546-6ce0dc904d6c"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">14.4999</us-gaap:SharePrice>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_60b4b3d3-4a6b-45de-b852-487c0414710f"
      decimals="4"
      id="F_c23aaaa2-45f6-4520-be70-5005093ae588"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners
      contextRef="C_ffb4c57e-cb92-46fd-9286-ea36197252e3"
      decimals="4"
      id="F_2d135658-0136-4a89-8a61-92a440e72091"
      unitRef="U_pure">0.0999</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="C_7a724b91-c619-4f16-b0fa-87eb52d80cd1"
      decimals="-5"
      id="F_cf86c4b1-1382-4031-b9d5-5d6665a142a1"
      unitRef="U_USD">166500000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_9be30ffd-c276-4ccc-8f21-4e37e3595dc7"
      decimals="-5"
      id="F_ed9cb9f5-f525-41c7-b698-4e96538a6c4b"
      unitRef="U_USD">145600000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="C_6687375b-114a-46c2-aae2-63bb21248fa4"
      decimals="-5"
      id="F_60d86044-748f-47af-ae1f-e3304faa0db5"
      unitRef="U_USD">20900000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <dawn:UpfrontLicenseFee
      contextRef="C_18678d79-8e7d-4c54-8b85-ba5704b25f78"
      decimals="-5"
      id="F_0ee93ab3-570c-49a9-8cf4-09c1c103d0cb"
      unitRef="U_USD">70800000</dawn:UpfrontLicenseFee>
    <dawn:CommonStockSharesPurchased
      contextRef="C_18678d79-8e7d-4c54-8b85-ba5704b25f78"
      decimals="0"
      id="F_d8ce56f2-5851-4b52-9902-8b4fbf6bbd27"
      unitRef="U_shares">2341495</dawn:CommonStockSharesPurchased>
    <us-gaap:CommonStockValue
      contextRef="C_1129e786-4666-4dce-88b0-ece78eb6efc6"
      decimals="-5"
      id="F_aeae08e9-8dc5-4ab9-a3a1-4d41b821f0e6"
      unitRef="U_USD">40000000</us-gaap:CommonStockValue>
    <dawn:WeightedAveragePriceOfCompanysCommonStock
      contextRef="C_18678d79-8e7d-4c54-8b85-ba5704b25f78"
      decimals="3"
      id="F_0b418f0b-2483-4b77-bbbf-2643e3a11c2f"
      unitRef="U_pure">0.17</dawn:WeightedAveragePriceOfCompanysCommonStock>
    <us-gaap:CommonStockValue
      contextRef="C_18678d79-8e7d-4c54-8b85-ba5704b25f78"
      decimals="-5"
      id="F_a9fbb6b3-52d0-46bd-b20d-4a66c14518a4"
      unitRef="U_USD">32600000</us-gaap:CommonStockValue>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_f34d98de-c249-4523-b50b-c9af86c79722"
      decimals="-5"
      id="F_c94488ae-3af3-40c7-a485-94fc22363f42"
      unitRef="U_USD">250000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_388de2bd-eeb7-4fa1-87a1-3cdac91fa91d"
      decimals="0"
      id="F_13419e56-cc84-40a6-a583-503888385ce2"
      unitRef="U_shares">0</us-gaap:CommonStockSharesIssued>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b"
      id="F_ac184c94-590e-4277-b7e0-e314b9e5f5ba">&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;9.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Share-based Compensation&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Share-based compensation expense recorded in the accompanying condensed statements of operations is as follows (in thousands):&lt;/span&gt;&lt;/p&gt;
       &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:65.92%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.6%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.64%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.6%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.64%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.6%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,251&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,653&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Selling, general and administrative expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,610&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,991&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total share-based compensation expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,861&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,644&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;2022 Equity Inducement Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In October 2022, the Company's board of directors approved the 2022 Equity Inducement Plan, or the 2022 Plan. The 2022 Plan provides for the grant of non-statutory stock options and restricted stock units. The number of shares of common stock reserved for issuance under the 2022 Plan is &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,000,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;2021 Equity Incentive Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In May 2021, in connection with the IPO, the board of directors and stockholders approved the 2021 Equity Incentive Plan, or the 2021 Plan, which became effective on the day before the date of the effectiveness of the IPO. The 2021 Plan provides for the grant of incentive stock options, non-statutory stock options, stock appreciation rights, awards of restricted stock, restricted stock units and other share-based awards. The number of shares of common stock reserved for issuance under the 2021 Plan is equal to the sum of: (x) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,369,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of common stock; plus (y) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,719,605&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of common stock issued in respect of the conversion of incentive shares that were subject to vesting immediately prior to the effectiveness of the registration statement for the IPO that expire, terminate or are otherwise surrendered, canceled, forfeited or repurchased by us at their original issuance price pursuant to a contractual repurchase right. The number of shares available for grant and issuance under the 2021 Plan will be automatically increased on the first day of each fiscal year, beginning with the fiscal year commencing on January 1, 2021 and continuing for each fiscal year until, and including, the fiscal year commencing on January 1, 2031, by the lesser of (a) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the number of shares of all classes of the Company&#x2019;s common stock, plus the total number of shares of Company common stock issuable upon conversion of any preferred stock or exercise of any warrants to acquire shares of Company common stock for a nominal exercise price issued and outstanding on each December 31 immediately prior to the date of increase or (b) such number of shares determined by the board of directors.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Stock Options&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table provides a summary of stock option activity during the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;three months ended March 31, 2025.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
       &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:39.088%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.322%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.34%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:11.722000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.322%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.34%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:11.862%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted-Average&lt;br/&gt;Exercise Price&lt;br/&gt;Per Share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted-Average&lt;br/&gt;Remaining &lt;br/&gt;Contractual Term&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Aggregate &lt;br/&gt;Intrinsic Value&lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding at December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,127,435&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16.50&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,132,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11.86&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Forfeiture&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;203,761&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15.87&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding at March 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,055,674&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15.81&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.6&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Vested and expected to vest at March 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,055,674&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15.81&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.6&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Exercisable at March 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,362,276&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16.58&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.8&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Aggregate intrinsic value represents the difference between the estimated fair value of the underlying common stock and the exercise price of outstanding, in-the-money options. There were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; options exercised during the three months ended March 31, 2025. The total intrinsic value of options exercised during the three months ended March 31, 2024 was &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The total fair value of options that vested during the three months ended March 31, 2025 and 2024 was &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, respectively. The weighted-average grant date fair value of options granted during the three months ended March 31, 2025 and 2024 was &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.73&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9.31&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Unrecognized share-based compensation for stock options as of March 31, 2025 was &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;52.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, which is expected to be recognized over a weighted-average period of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2.5&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; years.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:11pt;font-family:'Calibri',sans-serif;"&gt;&lt;p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company used the Black-Scholes option pricing model to estimate the fair value of stock option awards granted with the following assumptions:&lt;/span&gt;&lt;/p&gt;
       &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:41.608%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:3.001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:26.565%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:2.26%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:26.565%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.69 &lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;- &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.70&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.77&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.74&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;68.30&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;69.13&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;68.27&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;70.57&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.99&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.48&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.90&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.31&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Restricted Stock Units&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table provides a summary of restricted stock units activity under the 2021 Plan during the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;three months ended March 31, 2025:&lt;/span&gt;&lt;/p&gt;
       &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:66.98%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.36%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.88%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Number of&lt;br/&gt;Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted Average&lt;br/&gt;Grant Date Fair Value&lt;br/&gt;Per Share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Unvested restricted stock units at December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,774,287&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15.58&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,393,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11.86&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Vested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;247,041&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14.73&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Forfeiture&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;63,426&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14.14&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Unvested restricted stock units at March 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,856,820&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13.88&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Unamortized share-based compensation for restricted stock units as of March 31, 2025 was &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;37.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, which is expected to be recognized over a weighted-average period of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2.9&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; years.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Restricted Stock Awards&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table provides a summary of the unvested common stock awards activity during the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;three months ended March 31, 2025.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:66.98%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.36%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.88%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Number of&lt;br/&gt;Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted Average&lt;br/&gt;Grant Date Fair Value&lt;br/&gt;Per Share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Unvested common stock as of December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;82,281&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Vested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;66,752&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Forfeiture&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;735&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Unvested common stock as of March 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,794&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Unamortized share-based compensation for restricted stock awards as of March 31, 2025 was approximately &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, which is expected to be recognized over a weighted-average period of less than one year.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;2021 Employee Stock Purchase Plan&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In May 2021, the board of directors adopted and the stockholders approved the 2021 Employee Stock Purchase Plan, or the ESPP, which became effective on May 26, 2021. A total of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;603,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of common stock were initially reserved for issuance under the ESPP. The number of shares of the common stock reserved for issuance under the ESPP will automatically increase on the first day of each fiscal year, beginning with the fiscal year commencing on January 1, 2021 and continuing for each fiscal year until, and including, the fiscal year commencing on January 1, 2031, by the lesser of: (a) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the total number of outstanding shares of common stock of the Company (on an as converted basis outstanding on the immediately preceding December 31 (rounded down to the nearest whole share)) and (b) an amount determined by the board of directors. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;407,629&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares have been issued under the ESPP as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;March 31, 2025. The Company recognized compensation expense related to the ESPP of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; for each of the three months ended March 31, 2025 and 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b"
      id="F_cd7e9c25-28a9-4d40-946c-03d929b26586">&lt;p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Share-based compensation expense recorded in the accompanying condensed statements of operations is as follows (in thousands):&lt;/span&gt;&lt;/p&gt;
       &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:65.92%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.6%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.64%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.6%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.64%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.6%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,251&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,653&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Selling, general and administrative expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,610&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,991&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total share-based compensation expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,861&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,644&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_7d91f4bf-04a0-434b-a91a-e1fd4c41cbe1"
      decimals="-3"
      id="F_c2c28270-fddc-4d29-a556-fb12d04dac7e"
      unitRef="U_USD">4251000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_6bcd3432-198e-484b-9415-19fc999fd457"
      decimals="-3"
      id="F_b8e0906e-c12e-495a-982e-bf2cf4b16ca8"
      unitRef="U_USD">4653000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_2a107001-c05d-46f0-ab44-70e8338ecfcf"
      decimals="-3"
      id="F_6b91d740-51d8-44da-98d2-fb180be5e382"
      unitRef="U_USD">8610000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_b2b75b00-4621-44ed-bdf4-f92f43226a4c"
      decimals="-3"
      id="F_07235f28-ac47-4092-bec5-d5edfee15841"
      unitRef="U_USD">7991000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b"
      decimals="-3"
      id="F_408ced96-7c69-480c-b1f1-0b895c434da2"
      unitRef="U_USD">12861000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0fd32f25-7d1d-46c5-938d-d9b0e3f9dfaa"
      decimals="-3"
      id="F_804903f9-3196-4d29-a98d-5dd5e5cc5e39"
      unitRef="U_USD">12644000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_0d1e25ff-1b51-4a66-aafb-97dc40b3998f"
      decimals="INF"
      id="F_9bebbbbf-bed1-4dad-93c6-6cc615c13c9d"
      unitRef="U_shares">1000000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_01058ddf-79d2-4e72-962f-17fe256a6f09"
      decimals="INF"
      id="F_6bd58c8b-a8fc-4167-a5ed-cbb47d2d06bc"
      unitRef="U_shares">6369000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="C_46800e87-c56c-4f8c-b6af-964b831f2ace"
      decimals="INF"
      id="F_261a4ab6-603b-4b43-8f4d-5f8ac7377c18"
      unitRef="U_shares">4719605</us-gaap:ConversionOfStockSharesIssued1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
      contextRef="C_43327af5-1891-4b55-b0a6-4f7ba631a198"
      decimals="2"
      id="F_eea0a91d-ea44-44e2-9bd5-3492fe3ecafb"
      unitRef="U_pure">0.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock
      contextRef="C_910c0420-f57a-418a-8295-ee1ffb7bd08a"
      id="F_edb97fe5-97b9-48aa-9b9e-641c4f93d97a">&lt;p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table provides a summary of stock option activity during the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;three months ended March 31, 2025.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
       &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:39.088%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.322%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.34%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:11.722000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.322%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.34%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:11.862%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted-Average&lt;br/&gt;Exercise Price&lt;br/&gt;Per Share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted-Average&lt;br/&gt;Remaining &lt;br/&gt;Contractual Term&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Aggregate &lt;br/&gt;Intrinsic Value&lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding at December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,127,435&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16.50&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,132,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11.86&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Forfeiture&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;203,761&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15.87&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding at March 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,055,674&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15.81&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.6&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Vested and expected to vest at March 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,055,674&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15.81&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.6&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Exercisable at March 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,362,276&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16.58&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.8&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_dcf6712c-475d-4506-9554-ded223b0331a"
      decimals="0"
      id="F_d96cf084-8d83-423a-8100-21862cbe63fc"
      unitRef="U_shares">12127435</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_dcf6712c-475d-4506-9554-ded223b0331a"
      decimals="2"
      id="F_9f278333-2080-40fb-ba1b-a4b09973168c"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">16.5</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_910c0420-f57a-418a-8295-ee1ffb7bd08a"
      decimals="0"
      id="F_05981031-2743-48ff-9ec1-b11b54b8b01a"
      unitRef="U_shares">2132000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_910c0420-f57a-418a-8295-ee1ffb7bd08a"
      decimals="2"
      id="F_7ce9a9d8-fa6e-410c-bf51-35a938a3b9c8"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">11.86</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_910c0420-f57a-418a-8295-ee1ffb7bd08a"
      decimals="0"
      id="F_11f1988c-13c3-44b1-a9cb-d5a3fab1afd3"
      unitRef="U_shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_910c0420-f57a-418a-8295-ee1ffb7bd08a"
      decimals="0"
      id="F_6aff3823-d0df-48b8-80b7-f28971a29da4"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested
      contextRef="C_910c0420-f57a-418a-8295-ee1ffb7bd08a"
      decimals="-3"
      id="F_436c447d-abfa-4a13-9aca-9a0ef82486cc"
      unitRef="U_USD">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_910c0420-f57a-418a-8295-ee1ffb7bd08a"
      decimals="0"
      id="F_edb08972-534b-4530-b462-b902ca381d52"
      unitRef="U_shares">203761</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="C_910c0420-f57a-418a-8295-ee1ffb7bd08a"
      decimals="2"
      id="F_6d3fcfef-0c60-4731-bc56-4832fb7f8a81"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">15.87</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_13a2630f-ef56-4f08-840c-b986a80c28b9"
      decimals="0"
      id="F_7d90d9ee-9a20-4639-b4a9-0e9564fd4431"
      unitRef="U_shares">14055674</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_13a2630f-ef56-4f08-840c-b986a80c28b9"
      decimals="2"
      id="F_b2c31ee6-9e2d-49eb-b726-fd9dd5546e65"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">15.81</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_910c0420-f57a-418a-8295-ee1ffb7bd08a"
      id="F_1b1476d8-1826-42a0-b8b8-24d6a034ac0c">P7Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_13a2630f-ef56-4f08-840c-b986a80c28b9"
      decimals="-2"
      id="F_3138fdba-3ecb-4c78-b7d6-bf23fd17b07a"
      unitRef="U_USD">27000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="C_910c0420-f57a-418a-8295-ee1ffb7bd08a"
      decimals="0"
      id="F_8be841a1-9738-416e-bcf5-fd07e153f374"
      unitRef="U_shares">14055674</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="C_13a2630f-ef56-4f08-840c-b986a80c28b9"
      decimals="2"
      id="F_3d0162aa-47b1-450a-ab7c-78b38a14ab41"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">15.81</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="C_910c0420-f57a-418a-8295-ee1ffb7bd08a"
      id="F_bdc99b59-8421-4382-9f27-21709f681eda">P7Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
      contextRef="C_13a2630f-ef56-4f08-840c-b986a80c28b9"
      decimals="-2"
      id="F_4a428053-fdfd-448a-9d82-f19c728f56c2"
      unitRef="U_USD">27000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
      contextRef="C_13a2630f-ef56-4f08-840c-b986a80c28b9"
      decimals="0"
      id="F_4face764-886c-461f-ab2c-8d60c48da6b7"
      unitRef="U_shares">8362276</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="C_13a2630f-ef56-4f08-840c-b986a80c28b9"
      decimals="2"
      id="F_3670ded4-3741-47a8-83bc-96841a57aba3"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">16.58</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="C_910c0420-f57a-418a-8295-ee1ffb7bd08a"
      id="F_decdfb17-f3d8-4201-aa44-6c03e0d8db3e">P6Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="C_13a2630f-ef56-4f08-840c-b986a80c28b9"
      decimals="-2"
      id="F_75f6322b-edf9-47a1-b66f-3ac4cdbee77d"
      unitRef="U_USD">18600</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b"
      decimals="-3"
      id="F_638a09cf-b1ed-4c18-89ac-a51ad2a04393"
      unitRef="U_USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_c2dd807f-0b0a-4c78-a0c1-eae1f3ef85f9"
      decimals="-5"
      id="F_683c9d1f-f88c-48c3-85b7-57ea6567a342"
      unitRef="U_USD">100000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="C_13a2630f-ef56-4f08-840c-b986a80c28b9"
      decimals="-5"
      id="F_32673d9f-aa0f-4222-8cf5-a21fd95e23d9"
      unitRef="U_USD">8400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="C_7f944cae-458f-4eb0-b171-e53812c6128e"
      decimals="-5"
      id="F_06e1fbd9-ce87-44ad-a4d2-1282213643ba"
      unitRef="U_USD">7900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_cb883bf9-9846-4518-bf47-5d7e85524d73"
      decimals="2"
      id="F_00cdbcbd-b417-4665-8c00-fb8c46caccb0"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">7.73</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_2a98f92e-aa86-4a5c-aad4-edb5374ed00b"
      decimals="2"
      id="F_9c42ce77-2328-4e09-bfc5-2f4219205ba7"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">9.31</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <dawn:UnamortizedStockBasedCompensationForStockOptions
      contextRef="C_7aae3619-1673-4b07-91a5-706dabc13942"
      decimals="-5"
      id="F_e496d29f-55e4-4f5a-b712-ecea69b901a1"
      unitRef="U_USD">52900000</dawn:UnamortizedStockBasedCompensationForStockOptions>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="C_cb883bf9-9846-4518-bf47-5d7e85524d73"
      id="F_24ea5e55-66d3-46b9-91f7-baa8fbdfe1c4">P2Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <dawn:ScheduleOfStockOptionsAssumptionsTableTextBlock
      contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b"
      id="F_9020f117-7ffa-4b07-93cf-1288c35921ce">&lt;p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company used the Black-Scholes option pricing model to estimate the fair value of stock option awards granted with the following assumptions:&lt;/span&gt;&lt;/p&gt;
       &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:41.608%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:3.001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:26.565%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:2.26%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:26.565%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.69 &lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;- &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.70&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.77&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.74&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;68.30&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;69.13&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;68.27&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;70.57&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.99&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.48&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.90&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.31&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</dawn:ScheduleOfStockOptionsAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_9e37dcd2-0722-43fd-aedf-af23527c98ee"
      id="F_81c3115d-376d-4731-82ba-d44a302bfcd4">P5Y8M8D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_30fad386-55b9-45a7-8945-04e8a03f752e"
      id="F_08722941-cfbc-4c32-bf37-a4e5dd22e1d9">P6Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_5a86561f-8ff9-4f61-acd4-e523f9c716bf"
      id="F_6dfb5887-8b67-4695-ba0a-194a7760c9ac">P5Y9M7D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_310c50ba-37a3-430e-bd89-9a82d7460226"
      id="F_d7a6dd76-a386-400f-a46f-e67d76f694fe">P6Y8M26D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_9e37dcd2-0722-43fd-aedf-af23527c98ee"
      decimals="4"
      id="F_5370be91-e5bd-4f1c-8e6a-b25aaffe9e03"
      unitRef="U_pure">0.683</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_30fad386-55b9-45a7-8945-04e8a03f752e"
      decimals="4"
      id="F_9a7461f2-a249-4902-a704-cf301ad8be9c"
      unitRef="U_pure">0.6913</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_5a86561f-8ff9-4f61-acd4-e523f9c716bf"
      decimals="4"
      id="F_ebfb3a65-7ed9-48e9-a0d4-a45069905975"
      unitRef="U_pure">0.6827</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_310c50ba-37a3-430e-bd89-9a82d7460226"
      decimals="4"
      id="F_5604a5b7-2ba8-4a4a-9e47-0691a919e564"
      unitRef="U_pure">0.7057</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_9e37dcd2-0722-43fd-aedf-af23527c98ee"
      decimals="4"
      id="F_0ed52d3b-aecc-4280-947a-c65144551fb2"
      unitRef="U_pure">0.0399</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_30fad386-55b9-45a7-8945-04e8a03f752e"
      decimals="4"
      id="F_d5f64d06-8d38-4594-8d42-6cefa31e6b4b"
      unitRef="U_pure">0.0448</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_5a86561f-8ff9-4f61-acd4-e523f9c716bf"
      decimals="4"
      id="F_f5c3d57a-6588-4746-a44a-ada289391dd5"
      unitRef="U_pure">0.039</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_310c50ba-37a3-430e-bd89-9a82d7460226"
      decimals="4"
      id="F_648e1f2d-0fa8-470a-af5c-efb439719970"
      unitRef="U_pure">0.0431</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_910c0420-f57a-418a-8295-ee1ffb7bd08a"
      decimals="2"
      id="F_01569e7f-2fcc-4e08-8e92-d30a9aa01c8e"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_c2dd807f-0b0a-4c78-a0c1-eae1f3ef85f9"
      decimals="2"
      id="F_57463d82-9c4c-4b74-83b3-f644c2abea48"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock
      contextRef="C_910c0420-f57a-418a-8295-ee1ffb7bd08a"
      id="F_febb0fd8-ec3f-448d-8a98-4b89457d66aa">&lt;p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table provides a summary of restricted stock units activity under the 2021 Plan during the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;three months ended March 31, 2025:&lt;/span&gt;&lt;/p&gt;
       &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:66.98%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.36%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.88%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Number of&lt;br/&gt;Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted Average&lt;br/&gt;Grant Date Fair Value&lt;br/&gt;Per Share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Unvested restricted stock units at December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,774,287&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15.58&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,393,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11.86&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Vested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;247,041&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14.73&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Forfeiture&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;63,426&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14.14&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Unvested restricted stock units at March 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,856,820&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13.88&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="C_27899ba1-a824-4fc6-ac6a-83ca5fb4f9b5"
      decimals="0"
      id="F_7df6d044-d70f-4ca7-907a-e1c3852b4f85"
      unitRef="U_shares">1774287</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_27899ba1-a824-4fc6-ac6a-83ca5fb4f9b5"
      decimals="2"
      id="F_86bceefa-34b5-449e-91db-b01ea0576780"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">15.58</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="C_172d1f62-d597-4e9e-a3d0-7f8bd3d31541"
      decimals="0"
      id="F_86aa0f62-67a8-45f3-8d6b-8754caaa1295"
      unitRef="U_shares">1393000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_172d1f62-d597-4e9e-a3d0-7f8bd3d31541"
      decimals="2"
      id="F_fea9aa74-a2de-4456-a5ad-22ca085cc940"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">11.86</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="C_172d1f62-d597-4e9e-a3d0-7f8bd3d31541"
      decimals="0"
      id="F_a31000c1-d8f3-4543-a39a-f62018d25e28"
      unitRef="U_shares">247041</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_172d1f62-d597-4e9e-a3d0-7f8bd3d31541"
      decimals="2"
      id="F_46d02cbd-03fe-4925-9242-95edfa27ad14"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">14.73</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="C_172d1f62-d597-4e9e-a3d0-7f8bd3d31541"
      decimals="0"
      id="F_b2ba6629-c338-4bc5-a534-3e99076a7a88"
      unitRef="U_shares">63426</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="C_172d1f62-d597-4e9e-a3d0-7f8bd3d31541"
      decimals="2"
      id="F_b7b1ec11-ed5f-4767-a6db-6e500adc82f5"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">14.14</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_ffe0f1b7-fa8f-4028-beb7-7b994de8b4b7"
      decimals="0"
      id="F_c073f266-65d9-4813-9051-2ed2cd8b6a63"
      unitRef="U_shares">2856820</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_ffe0f1b7-fa8f-4028-beb7-7b994de8b4b7"
      decimals="2"
      id="F_e0f27f00-99fc-4846-a2eb-e3d0ac4210f1"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">13.88</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <dawn:UnamortizedStockBasedCompensationForStockOptions
      contextRef="C_fd702879-0dc1-44c9-85ec-00d54500225b"
      decimals="-5"
      id="F_0fc7fe20-cd58-400d-9f82-1ac036cfa51d"
      unitRef="U_USD">37300000</dawn:UnamortizedStockBasedCompensationForStockOptions>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="C_b0966c50-b1d4-43dc-abb7-4c4d573ddf0b"
      id="F_be20a77a-46a6-4d83-9c5a-f5f692e70a03">P2Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock
      contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b"
      id="F_dc67d8fe-4c27-4d74-b1fa-881a03b34d57">&lt;p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table provides a summary of the unvested common stock awards activity during the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;three months ended March 31, 2025.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:66.98%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.36%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.88%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Number of&lt;br/&gt;Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted Average&lt;br/&gt;Grant Date Fair Value&lt;br/&gt;Per Share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Unvested common stock as of December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;82,281&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Vested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;66,752&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Forfeiture&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;735&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Unvested common stock as of March 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,794&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock>
    <dawn:ShareBasedCompensationByShareBasedPaymentArrangementEquityInstrumentsOtherThanOptionsOutstanding
      contextRef="C_3ef9f2ba-6c3d-4611-94f4-9657c80e0ee2"
      decimals="0"
      id="F_2600f399-79b9-4f09-9bf4-99b3821641d6"
      unitRef="U_shares">82281</dawn:ShareBasedCompensationByShareBasedPaymentArrangementEquityInstrumentsOtherThanOptionsOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_3ef9f2ba-6c3d-4611-94f4-9657c80e0ee2"
      decimals="2"
      id="F_45737355-b46b-4025-8e2c-5c21afc218d9"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">16</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="C_d9880916-1c46-4df1-82f9-7cfa90e42ed8"
      decimals="0"
      id="F_afadc249-e738-4274-b1e6-2d33b51da8cc"
      unitRef="U_shares">66752</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_d9880916-1c46-4df1-82f9-7cfa90e42ed8"
      decimals="2"
      id="F_580a9157-1d03-4977-b725-5fbd5fdefcc8"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">16</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="C_d9880916-1c46-4df1-82f9-7cfa90e42ed8"
      decimals="0"
      id="F_a46d2e8e-be76-4268-81fa-8ca08899b2e9"
      unitRef="U_shares">735</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="C_d9880916-1c46-4df1-82f9-7cfa90e42ed8"
      decimals="2"
      id="F_fed4643b-823e-4816-af1b-32a4287f14f2"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">16</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <dawn:ShareBasedCompensationByShareBasedPaymentArrangementEquityInstrumentsOtherThanOptionsOutstanding
      contextRef="C_afbd7133-30d1-4e7e-80d8-66c0f4c8b5c1"
      decimals="0"
      id="F_3f68ff4e-49c2-4d96-b4f2-94c38b7497d2"
      unitRef="U_shares">14794</dawn:ShareBasedCompensationByShareBasedPaymentArrangementEquityInstrumentsOtherThanOptionsOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_afbd7133-30d1-4e7e-80d8-66c0f4c8b5c1"
      decimals="2"
      id="F_55fdbda3-337d-41c2-8496-512f0962178e"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">16</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <dawn:UnamortizedStockBasedCompensationForStockOptions
      contextRef="C_afbd7133-30d1-4e7e-80d8-66c0f4c8b5c1"
      decimals="0"
      id="F_0f45d8bc-cbfd-4425-b5c5-d5dd77fadcad"
      unitRef="U_USD">15000</dawn:UnamortizedStockBasedCompensationForStockOptions>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_bf59d3f6-5cf9-4cca-852c-63e292df8618"
      decimals="INF"
      id="F_613f63be-d862-40f8-9a03-604e44dcfbfe"
      unitRef="U_shares">603000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
      contextRef="C_9ece43fe-da8e-4bfb-aa46-983f40858774"
      decimals="2"
      id="F_3eb74b7e-4886-48d7-be5d-72ad4985baf3"
      unitRef="U_pure">0.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan
      contextRef="C_f30f7047-2b1e-4315-95a7-8a873401a0b3"
      decimals="0"
      id="F_ae94f1dd-48dd-48d8-ae7a-8c231f52b31f"
      unitRef="U_shares">407629</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_f30f7047-2b1e-4315-95a7-8a873401a0b3"
      decimals="-5"
      id="F_fe3b2385-7cd2-4605-89bd-32789433088e"
      unitRef="U_USD">200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_6b43dd28-89c1-4746-bb60-edcdf09081e0"
      decimals="-5"
      id="F_a6d25e54-451d-4885-96c1-91f5ea629318"
      unitRef="U_USD">200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b"
      id="F_260d7941-4683-487c-afcd-cd7f71309700">&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;10.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company did &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;t record an income tax provision for the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;three months ended March 31, 2025 and 2024 as it generated tax losses during each of the periods.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;A valuation allowance is established when it is more likely than not that some portion or all of a deferred tax asset will not be realized. The realization of deferred tax assets depends on the generation of future taxable income during the period in which related temporary differences become deductible. The Company continues to establish a valuation allowance against the full amount of its net deferred tax assets since it is more likely than not that benefits will not be realized, including those benefits created in the current year. This assessment is based on the Company's historical cumulative losses, which provide strong objective evidence that cannot be overcome with projections of income, as well as the fact the Company expects continuing losses in the future.&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b"
      decimals="-3"
      id="F_01cf5331-c97a-4c45-bcad-83e83bb19bc6"
      unitRef="U_USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_0fd32f25-7d1d-46c5-938d-d9b0e3f9dfaa"
      decimals="-3"
      id="F_8cf50d33-db2d-45ec-a1c8-b18afd115e43"
      unitRef="U_USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b"
      id="F_cd190b48-44e3-4058-9cbf-10a1f1966382">&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;11.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Net Loss Per Share &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Basic and diluted net loss per share attributable to common stockholders is calculated as follows (in thousands except share and per share amounts):&lt;/span&gt;&lt;/p&gt;
       &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:55.28%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.92%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:18.439999999999998%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.92%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:18.439999999999998%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="border-top:0.5pt solid #000000;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="border-top:0.5pt solid #000000;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss - basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;35,996&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;62,412&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss per share, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.35&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.72&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted-average number of common shares used in computing net loss per share, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;102,710,382&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;86,679,282&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following outstanding potentially dilutive securities have been excluded from the calculation of diluted net loss per share, as their effect is anti-dilutive:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;
       &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:66.967%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.357%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.357%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;As of March 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="border-top:0.5pt solid #000000;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="border-top:0.5pt solid #000000;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,055,674&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,404,090&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Unvested common shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,794&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;543,239&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Restricted stock units&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,856,820&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,243,998&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Shares committed under ESPP&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;108,717&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;100,753&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,036,005&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15,292,080&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b"
      id="F_403c9985-20b1-49a6-977c-b58fcb322c81">&lt;p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Basic and diluted net loss per share attributable to common stockholders is calculated as follows (in thousands except share and per share amounts):&lt;/span&gt;&lt;/p&gt;
       &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:55.28%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.92%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:18.439999999999998%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.92%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:18.439999999999998%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="border-top:0.5pt solid #000000;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="border-top:0.5pt solid #000000;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss - basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;35,996&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;62,412&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss per share, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.35&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.72&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted-average number of common shares used in computing net loss per share, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;102,710,382&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;86,679,282&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b"
      decimals="-3"
      id="F_29c4c747-9eed-43b0-8b84-1aa72374cae1"
      unitRef="U_USD">-35996000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0fd32f25-7d1d-46c5-938d-d9b0e3f9dfaa"
      decimals="-3"
      id="F_89978c8e-0233-4727-853f-951ab97cb6eb"
      unitRef="U_USD">-62412000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b"
      decimals="2"
      id="F_f205c988-a611-4285-b1ba-c025213e5e4c"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-0.35</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b"
      decimals="2"
      id="F_4fcaf1b4-b13f-4c60-a7ee-6376a6b6edc3"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-0.35</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_0fd32f25-7d1d-46c5-938d-d9b0e3f9dfaa"
      decimals="2"
      id="F_162132c3-37f0-475e-a40a-5947f82536b1"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-0.72</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_0fd32f25-7d1d-46c5-938d-d9b0e3f9dfaa"
      decimals="2"
      id="F_b5de2b7c-9c7a-4d0f-8003-79729fcd6c64"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-0.72</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b"
      decimals="0"
      id="F_dae78655-b457-40b0-98ee-cf7f9b6ee18e"
      unitRef="U_shares">102710382</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b"
      decimals="0"
      id="F_d4d24c2c-0d2e-4196-9340-6b2efeff63c5"
      unitRef="U_shares">102710382</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_0fd32f25-7d1d-46c5-938d-d9b0e3f9dfaa"
      decimals="0"
      id="F_32d27fa8-d857-4da1-8c69-00a94f963fea"
      unitRef="U_shares">86679282</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_0fd32f25-7d1d-46c5-938d-d9b0e3f9dfaa"
      decimals="0"
      id="F_1b1c86c2-4863-4229-aba6-87a2b4a07489"
      unitRef="U_shares">86679282</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b"
      id="F_5ff50c6d-2e7c-4261-8783-6aa733283d75">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following outstanding potentially dilutive securities have been excluded from the calculation of diluted net loss per share, as their effect is anti-dilutive:&lt;/span&gt;
       &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:66.967%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.357%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.357%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;As of March 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="border-top:0.5pt solid #000000;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="border-top:0.5pt solid #000000;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,055,674&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,404,090&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Unvested common shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,794&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;543,239&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Restricted stock units&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,856,820&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,243,998&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Shares committed under ESPP&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;108,717&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;100,753&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,036,005&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15,292,080&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_ba5b769f-138e-4a96-8876-aa121d01b3cc"
      decimals="0"
      id="F_d7d69373-2668-4802-a673-27de76d0d73e"
      unitRef="U_shares">14055674</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_89780293-cea0-4538-b7bb-9bfd5ea8a319"
      decimals="0"
      id="F_e7129b53-b7a7-446f-b468-3b5928ff0b39"
      unitRef="U_shares">12404090</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_ce9b7ba8-66b0-4fb8-95da-9540fc395eeb"
      decimals="0"
      id="F_316bb835-8c61-4cec-97ec-46eb2d2578d1"
      unitRef="U_shares">14794</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_3aa48c9e-64e5-48ce-b002-f58764db64d0"
      decimals="0"
      id="F_94bb63a4-ca28-4c63-8c52-1d9f8aa24134"
      unitRef="U_shares">543239</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_8387ea00-db0a-45ff-8cd7-7258098914d9"
      decimals="0"
      id="F_2033911f-5777-4e4c-ae49-8a91dfc5388f"
      unitRef="U_shares">2856820</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_9cc6beef-2bd0-4841-8e97-5da5102095a3"
      decimals="0"
      id="F_1ba18590-5afa-4533-93ac-ed954d507a49"
      unitRef="U_shares">2243998</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_4a61c31c-c9f6-4c86-9285-1639c02fc666"
      decimals="0"
      id="F_da6e2763-bd93-4aac-9a5f-c358b0509868"
      unitRef="U_shares">108717</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_342128b9-4127-453a-8974-3c82ca357e86"
      decimals="0"
      id="F_ecc9a0fc-a1f0-4e55-86e5-2daa75db6fea"
      unitRef="U_shares">100753</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b"
      decimals="0"
      id="F_7c058de1-d167-4f1d-9420-50354337396f"
      unitRef="U_shares">17036005</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0fd32f25-7d1d-46c5-938d-d9b0e3f9dfaa"
      decimals="0"
      id="F_81a6a0d3-712d-4eba-b8c0-25ce49730fc8"
      unitRef="U_shares">15292080</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:DefinedContributionPlanTextBlock
      contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b"
      id="F_04560c55-8160-47f6-ac0f-db3a3da2fef9">&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;12.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Defined Contribution Plan&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company maintains an employee savings plan pursuant to Section 401(k) of the Internal Revenue Code. All employees are eligible to participate provided that they meet the requirements of the plan. For each of the three months ended March 31, 2025 and 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company made matching contributions of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, respectively.&lt;/span&gt;&lt;/p&gt;</us-gaap:DefinedContributionPlanTextBlock>
    <dawn:DefinedContributionPlanEmployerMatchingContribution
      contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b"
      decimals="-5"
      id="F_cbc92a61-a042-4108-bd24-50232f4cc343"
      unitRef="U_USD">700000</dawn:DefinedContributionPlanEmployerMatchingContribution>
    <dawn:DefinedContributionPlanEmployerMatchingContribution
      contextRef="C_0fd32f25-7d1d-46c5-938d-d9b0e3f9dfaa"
      decimals="-5"
      id="F_4c7a9e3d-efcb-4e2a-81aa-abe3fe0684ee"
      unitRef="U_USD">600000</dawn:DefinedContributionPlanEmployerMatchingContribution>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b"
      id="F_7953a92d-7f57-479f-9913-29fdfc1e934c">&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;13.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Segment Reporting&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:4.173%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company views its operations and manages its business in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; operating and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; reportable segment, which includes all activities related to the identification, development and commercialization of medicines for childhood and adult diseases with equal intensity. The determination of a single operating segment is consistent with the consolidated financial information regularly provided to the Company&#x2019;s chief operating decision maker, or CODM. The Company&#x2019;s CODM is its Chief Executive Officer, who reviews and evaluates net loss for purposes of assessing performance, making operating decisions, allocating resources, and planning and forecasting for future periods. Our CODM does not evaluate the operating segment using asset or liability information. The operating segment derives all net product revenues from the sales of OJEMDA in the United States through contractual arrangements with its specialty pharmacy and specialty distributor customers. All the Company&#x2019;s assets are located in the United States.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In addition to the significant expense categories included within net loss presented on the Company's condensed statements of operations, see below for disaggregated amounts that comprise research and development expenses:&lt;/span&gt;&lt;/p&gt;
       &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;External costs:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Third-party CRO, CMO and other third-party clinical trial costs (1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20,821&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19,546&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;License agreement related payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other research and development costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,167&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Internal costs:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Employee related expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,777&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,497&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total research and development expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;39,619&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;40,210&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Costs incurred under agreements with third-party CROs, CMOs, and other third parties that conduct clinical activities on the Company's behalf.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b"
      decimals="INF"
      id="F_5f1881aa-ec16-47f0-8431-0930fed21bb0"
      unitRef="U_Segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NumberOfReportableSegments
      contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b"
      decimals="INF"
      id="F_106641bf-392a-439f-a74f-3d69a9b04c97"
      unitRef="U_Segment">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock
      contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b"
      id="F_1570f557-5635-491a-acb0-89e798625859">&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In addition to the significant expense categories included within net loss presented on the Company's condensed statements of operations, see below for disaggregated amounts that comprise research and development expenses:&lt;/span&gt;&lt;/p&gt;
       &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;External costs:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Third-party CRO, CMO and other third-party clinical trial costs (1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20,821&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19,546&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;License agreement related payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other research and development costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,167&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Internal costs:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Employee related expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,777&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,497&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total research and development expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;39,619&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;40,210&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Costs incurred under agreements with third-party CROs, CMOs, and other third parties that conduct clinical activities on the Company's behalf.&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <dawn:Third-PartyCROCMOAndOtherThird-PartyClinicalTrialCosts
      contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b"
      decimals="-3"
      id="F_a38f27e3-eb4b-4eb4-814a-963ea523b1df"
      unitRef="U_USD">20821000</dawn:Third-PartyCROCMOAndOtherThird-PartyClinicalTrialCosts>
    <dawn:Third-PartyCROCMOAndOtherThird-PartyClinicalTrialCosts
      contextRef="C_0fd32f25-7d1d-46c5-938d-d9b0e3f9dfaa"
      decimals="-3"
      id="F_e7bc9a6d-21f3-4425-a0f4-b8ddd2c8a2f5"
      unitRef="U_USD">19546000</dawn:Third-PartyCROCMOAndOtherThird-PartyClinicalTrialCosts>
    <dawn:LicenseAgreementRelatedPayments
      contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b"
      decimals="-3"
      id="F_74fc83ab-f8dd-49ed-a6b3-359a7dc79fec"
      unitRef="U_USD">4000000</dawn:LicenseAgreementRelatedPayments>
    <dawn:LicenseAgreementRelatedPayments
      contextRef="C_0fd32f25-7d1d-46c5-938d-d9b0e3f9dfaa"
      decimals="-3"
      id="F_4df9da7b-c2b6-4fdf-bf84-4991ae86a62f"
      unitRef="U_USD">5000000</dawn:LicenseAgreementRelatedPayments>
    <us-gaap:OtherResearchAndDevelopmentExpense
      contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b"
      decimals="-3"
      id="F_45d09d44-4a94-430e-a610-feec2ba4e21c"
      unitRef="U_USD">2021000</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:OtherResearchAndDevelopmentExpense
      contextRef="C_0fd32f25-7d1d-46c5-938d-d9b0e3f9dfaa"
      decimals="-3"
      id="F_f88d3733-d976-4726-8508-ea1def957279"
      unitRef="U_USD">2167000</us-gaap:OtherResearchAndDevelopmentExpense>
    <dawn:EmployeeRelatedExpenses
      contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b"
      decimals="-3"
      id="F_b353f1cc-a14c-4910-b4c2-36ca758f9a68"
      unitRef="U_USD">12777000</dawn:EmployeeRelatedExpenses>
    <dawn:EmployeeRelatedExpenses
      contextRef="C_0fd32f25-7d1d-46c5-938d-d9b0e3f9dfaa"
      decimals="-3"
      id="F_77f46c6a-f712-4c4f-9e21-63c7be7825dd"
      unitRef="U_USD">13497000</dawn:EmployeeRelatedExpenses>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b"
      decimals="-3"
      id="F_c6586fc6-c034-4e77-aaf9-6227bb506b37"
      unitRef="U_USD">39619000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_0fd32f25-7d1d-46c5-938d-d9b0e3f9dfaa"
      decimals="-3"
      id="F_8fec429e-3f3c-4f94-ba4f-8409c33f43f1"
      unitRef="U_USD">40210000</us-gaap:ResearchAndDevelopmentExpense>
    <ecd:Rule10b51ArrAdoptedFlag
      contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b"
      id="F_a08815c4-c959-4bb7-a54c-dcaa0bf7c6cc">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrAdoptedFlag
      contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b"
      id="F_76229d00-facf-4577-9c80-7b4f0c32a399">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag
      contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b"
      id="F_6c5aae11-6941-4d7b-affb-106f426213be">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrTrmntdFlag
      contextRef="C_f6829778-ed0c-4d65-9007-5a3564f7ad3b"
      id="F_b2a71166-3338-4d09-8c8e-6ebd68f20322">false</ecd:NonRule10b51ArrTrmntdFlag>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#F_a38f27e3-eb4b-4eb4-814a-963ea523b1df"
          xlink:label="F_a38f27e3-eb4b-4eb4-814a-963ea523b1df"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_e7bc9a6d-21f3-4425-a0f4-b8ddd2c8a2f5"
          xlink:label="F_e7bc9a6d-21f3-4425-a0f4-b8ddd2c8a2f5"
          xlink:type="locator"/>
        <link:footnote id="FNT_60f2d66a-bd18-4379-ab25-550bcb317590" xlink:label="FNT_60f2d66a-bd18-4379-ab25-550bcb317590" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Costs incurred under agreements with third-party CROs, CMOs, and other third parties that conduct clinical activities on the Company's behalf.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_a38f27e3-eb4b-4eb4-814a-963ea523b1df"
          xlink:to="FNT_60f2d66a-bd18-4379-ab25-550bcb317590"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_e7bc9a6d-21f3-4425-a0f4-b8ddd2c8a2f5"
          xlink:to="FNT_60f2d66a-bd18-4379-ab25-550bcb317590"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
